Stimulation	O
of	O
ciliary	O
motility	O
mediated	O
by	O
atypical	O
beta-adrenoceptor	GENE-N
in	O
canine	O
bronchial	O
epithelium	O
.	O
Using	O
radioligand	O
binding	O
assays	O
,	O
we	O
determined	O
the	O
equilibrium	O
dissociation	O
constants	O
(	O
KD's	O
)	O
for	O
37	O
antidepressants	O
,	O
three	O
of	O
their	O
metabolites	O
(	O
desmethylcitalopram	CHEMICAL
,	O
desmethylsertraline	CHEMICAL
,	O
and	O
norfluoxetine	CHEMICAL
)	O
,	O
some	O
mood	O
stabilizers	O
,	O
and	O
assorted	O
other	O
compounds	O
(	O
some	O
antiepileptics	O
,	O
Ca2	CHEMICAL
+	CHEMICAL
channel	O
antagonists	O
,	O
benzodiazepines	CHEMICAL
,	O
psychostimulants	O
,	O
antihistamines	CHEMICAL
,	O
and	O
monoamines	CHEMICAL
)	O
for	O
the	O
human	GENE-N
serotonin	CHEMICAL
,	O
norepinephrine	CHEMICAL
,	O
and	O
dopamine	CHEMICAL
transporters	O
.	O

Among	O
the	O
compounds	O
that	O
we	O
tested	O
,	O
mazindol	CHEMICAL
was	O
the	O
most	O
potent	O
at	O
the	O
human	GENE-N
norepinephrine	CHEMICAL
and	O
dopamine	CHEMICAL
transporters	O
with	O
KD's	O
of	O
0	O
.	O
45	O
+	O
/	O
-	O
0	O
.	O
03	O
nM	O
and	O
8	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
4	O
nM	O
,	O
respectively	O
.	O

Sertraline	CHEMICAL
(	O
KD	O
=	O
25	O
+	O
/	O
-	O
2	O
nM	O
)	O
and	O
nomifensine	CHEMICAL
(	O
56	O
+	O
/	O
-	O
3	O
nM	O
)	O
were	O
the	O
two	O
most	O
potent	O
antidepressants	O
at	O
the	O
human	GENE-Y
dopamine	CHEMICAL
transporter	O
.	O

We	O
showed	O
significant	O
correlations	O
for	O
antidepressant	O
affinities	O
at	O
binding	O
to	O
serotonin	CHEMICAL
(	O
R	O
=	O
0	O
.	O
93	O
)	O
,	O
norepinephrine	CHEMICAL
(	O
R	O
=	O
0	O
.	O
97	O
)	O
,	O
and	O
dopamine	CHEMICAL
(	O
R	O
=	O
0	O
.	O
87	O
)	O
transporters	O
in	O
comparison	O
to	O
their	O
respective	O
values	O
for	O
inhibiting	O
uptake	O
of	O
monoamines	CHEMICAL
into	O
rat	O
brain	O
synaptosomes	O
.	O

These	O
data	O
are	O
useful	O
in	O
predicting	O
some	O
possible	O
adverse	O
effects	O
and	O
drug-drug	O
interactions	O
of	O
antidepressants	O
and	O
related	O
compounds	O
.	O
Role	O
of	O
quercetin	CHEMICAL
in	O
cadmium-induced	O
oxidative	O
stress	O
,	O
neuronal	O
damage	O
,	O
and	O
apoptosis	O
in	O
rats	O
.	O
Pyridoxal-5'-phosphate	CHEMICAL
(	O
PLP	CHEMICAL
)	O
,	O
the	O
bioactive	O
form	O
of	O
vitamin	CHEMICAL
B6	CHEMICAL
,	O
reportedly	O
functions	O
as	O
a	O
prosthetic	O
group	O
for	O
>4%	O
of	O
classified	O
enzymatic	O
activities	O
of	O
the	O
cell	O
.	O

It	O
is	O
therefore	O
not	O
surprising	O
that	O
alterations	O
of	O
vitamin	CHEMICAL
B6	CHEMICAL
metabolism	O
have	O
been	O
associated	O
with	O
multiple	O
human	O
diseases	O
.	O

As	O
a	O
striking	O
example	O
,	O
mutations	O
in	O
the	O
gene	O
coding	O
for	O
antiquitin	GENE-Y
,	O
an	O
evolutionary	O
old	O
aldehyde	GENE-N
dehydrogenase	O
,	O
result	O
in	O
pyridoxine-dependent	O
seizures	O
,	O
owing	O
to	O
the	O
accumulation	O
of	O
a	O
metabolic	O
intermediate	O
that	O
inactivates	O
PLP	CHEMICAL
.	O

In	O
addition	O
,	O
PLP	CHEMICAL
is	O
required	O
for	O
the	O
catabolism	O
of	O
homocysteine	CHEMICAL
by	O
transsulfuration	O
.	O

Hence	O
,	O
reduced	O
circulating	O
levels	O
of	O
B6	CHEMICAL
vitamers	O
(	O
including	O
PLP	CHEMICAL
as	O
well	O
as	O
its	O
major	O
precursor	O
pyridoxine	CHEMICAL
)	O
are	O
frequently	O
paralleled	O
by	O
hyperhomocysteinemia	O
,	O
a	O
condition	O
that	O
has	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
multiple	O
cardiovascular	O
diseases	O
.	O

During	O
the	O
past	O
30	O
years	O
,	O
an	O
intense	O
wave	O
of	O
clinical	O
investigation	O
has	O
attempted	O
to	O
dissect	O
the	O
putative	O
links	O
between	O
vitamin	CHEMICAL
B6	CHEMICAL
and	O
cancer	O
.	O

Thus	O
,	O
high	O
circulating	O
levels	O
of	O
vitamin	CHEMICAL
B6	CHEMICAL
,	O
as	O
such	O
or	O
as	O
they	O
reflected	O
reduced	O
amounts	O
of	O
circulating	O
homocysteine	CHEMICAL
,	O
have	O
been	O
associated	O
with	O
improved	O
disease	O
outcome	O
in	O
patients	O
bearing	O
a	O
wide	O
range	O
of	O
hematological	O
and	O
solid	O
neoplasms	O
.	O

More	O
recently	O
,	O
the	O
proficiency	O
of	O
vitamin	CHEMICAL
B6	CHEMICAL
metabolism	O
has	O
been	O
shown	O
to	O
modulate	O
the	O
adaptive	O
response	O
of	O
tumor	O
cells	O
to	O
a	O
plethora	O
of	O
physical	O
and	O
chemical	O
stress	O
conditions	O
.	O

Moreover	O
,	O
elevated	O
levels	O
of	O
pyridoxal	CHEMICAL
kinase	O
(	O
PDXK	GENE-Y
)	O
,	O
the	O
enzyme	O
that	O
converts	O
pyridoxine	CHEMICAL
and	O
other	O
vitamin	CHEMICAL
B6	CHEMICAL
precursors	O
into	O
PLP	CHEMICAL
,	O
have	O
been	O
shown	O
to	O
constitute	O
a	O
good	O
,	O
therapy-independent	O
prognostic	O
marker	O
in	O
patients	O
affected	O
by	O
non-small	O
cell	O
lung	O
carcinoma	O
(	O
NSCLC	O
)	O
.	O

Here	O
,	O
we	O
will	O
discuss	O
the	O
clinical	O
relevance	O
of	O
vitamin	CHEMICAL
B6	CHEMICAL
metabolism	O
as	O
a	O
prognostic	O
factor	O
in	O
cancer	O
patients	O
.	O

Oncogene	O
advance	O
online	O
publication	O
,	O
21	O
January	O
2013;	O
doi	O
:	O
10	O
.	O
1038	O
/	O
onc	O
.	O
2012	O
.	O
623	O
.	O
The	O
mechanisms	O
of	O
progression	O
from	O
Barrett's	O
esophagus	O
(	O
BE	O
)	O
to	O
esophageal	O
adenocarcinoma	O
(	O
EA	O
)	O
are	O
not	O
known	O
.	O

Cycloxygenase-2	GENE-Y
(	O
COX-2	GENE-Y
)	O
-derived	O
prostaglandin	CHEMICAL
E2	CHEMICAL
(	O
PGE2	CHEMICAL
)	O
has	O
been	O
shown	O
to	O
be	O
important	O
in	O
esophageal	O
tumorigenesis	O
.	O

We	O
have	O
shown	O
that	O
COX-2	GENE-Y
mediates	O
acid-induced	O
PGE2	CHEMICAL
production	O
.	O

The	O
prostaglandin	GENE-Y
E	GENE-Y
synthase	O
(	O
PGES	GENE-Y
)	O
responsible	O
for	O
acid-induced	O
PGE2	CHEMICAL
production	O
in	O
BE	O
,	O
however	O
,	O
is	O
not	O
known	O
.	O

We	O
found	O
that	O
microsomal	GENE-Y
PGES1	GENE-Y
(	O
mPGES1	GENE-Y
)	O
,	O
mPGES2	GENE-Y
,	O
and	O
cytosolic	GENE-Y
PGES	GENE-Y
(	O
cPGES	GENE-Y
)	O
were	O
present	O
in	O
FLO	O
EA	O
cells	O
.	O

Pulsed	O
acid	O
treatment	O
significantly	O
increased	O
mPGES1	GENE-Y
mRNA	O
and	O
protein	O
levels	O
but	O
had	O
little	O
or	O
no	O
effect	O
on	O
mPGES2	GENE-Y
or	O
cPGES	GENE-Y
mRNA	O
.	O

Knockdown	O
of	O
mPGES1	GENE-Y
by	O
mPGES1	GENE-Y
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
blocked	O
acid-induced	O
increase	O
in	O
PGE2	CHEMICAL
production	O
and	O
thymidine	CHEMICAL
incorporation	O
.	O

Knockdown	O
of	O
NADPH	GENE-N
oxidase	O
,	O
NOX5-S	GENE-Y
,	O
a	O
variant	O
lacking	O
calcium-binding	O
domains	O
,	O
by	O
NOX5	GENE-Y
siRNA	O
significantly	O
inhibited	O
acid-induced	O
increase	O
in	O
mPGES1	GENE-Y
expression	O
,	O
thymidine	CHEMICAL
incorporation	O
,	O
and	O
PGE2	CHEMICAL
production	O
.	O

Overexpression	O
of	O
NOX5-S	GENE-Y
significantly	O
increased	O
the	O
luciferase	O
activity	O
in	O
FLO	O
cells	O
transfected	O
with	O
a	O
nuclear	GENE-N
factor	GENE-N
κB	GENE-N
(	O
NF-κB	GENE-N
)	O
in	O
vivo	O
activation	O
reporter	O
plasmid	O
pNF-κB-Luc	O
.	O

Knockdown	O
of	O
NF-κB1	GENE-Y
p50	GENE-Y
by	O
p50	GENE-Y
siRNA	O
significantly	O
decreased	O
acid-induced	O
increase	O
in	O
mPGES1	GENE-Y
expression	O
,	O
thymidine	CHEMICAL
incorporation	O
,	O
and	O
PGE2	CHEMICAL
production	O
.	O

Two	O
novel	O
NF-κB	GENE-N
binding	GENE-N
elements	GENE-N
,	O
GGAGTCTCCC	GENE-N
and	O
CGGGACACCC	GENE-N
,	O
were	O
identified	O
in	O
the	O
mPGES1	GENE-N
gene	GENE-N
promoter	GENE-N
.	O

We	O
conclude	O
that	O
mPGES1	GENE-Y
mediates	O
acid-induced	O
increase	O
in	O
PGE2	CHEMICAL
production	O
and	O
cell	O
proliferation	O
.	O

Acid-induced	O
mPGES1	GENE-Y
expression	O
depends	O
on	O
activation	O
of	O
NOX5-S	GENE-Y
and	O
NF-κB1	GENE-Y
p50	GENE-Y
.	O

Microsomal	GENE-Y
PGES1	GENE-Y
may	O
be	O
a	O
potential	O
target	O
to	O
prevent	O
or	O
treat	O
EA	O
.	O
Probing	O
for	O
a	O
hydrophobic	O
a	O
binding	O
register	O
in	O
prostate-specific	GENE-Y
membrane	GENE-Y
antigen	GENE-Y
with	O
phenylalkylphosphonamidates	CHEMICAL
.	O
PURPOSE	O
:	O
Activating	O
mutations	O
in	O
FGFR2	GENE-Y
have	O
been	O
identified	O
as	O
potential	O
therapeutic	O
targets	O
in	O
endometrial	O
cancer	O
,	O
typically	O
occurring	O
alongside	O
genetic	O
alterations	O
that	O
disrupt	O
the	O
mTOR	GENE-Y
pathway	O
,	O
such	O
as	O
PTEN	GENE-Y
loss	O
.	O

These	O
observations	O
suggest	O
that	O
the	O
mTOR	GENE-Y
pathway	O
may	O
act	O
in	O
concert	O
with	O
oncogenic	O
FGFR2	GENE-Y
to	O
drive	O
endometrial	O
cancer	O
growth	O
in	O
a	O
subset	O
of	O
patients	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
therapeutic	O
potential	O
of	O
a	O
rational	O
drug	O
combination	O
based	O
on	O
the	O
simultaneous	O
targeting	O
of	O
mutant-FGFR2	GENE-Y
and	O
mTOR-driven	O
signaling	O
pathways	O
in	O
endometrial	O
cancer	O
cells	O
.	O

METHODS	O
:	O
Ponatinib	CHEMICAL
is	O
an	O
oral	O
multitargeted	O
kinase	GENE-N
inhibitor	O
that	O
potently	O
inhibits	O
all	O
4	O
members	O
of	O
the	O
FGFR	GENE-N
family	O
.	O

Ridaforolimus	CHEMICAL
is	O
a	O
selective	O
inhibitor	O
of	O
mTOR	GENE-Y
that	O
has	O
demonstrated	O
positive	O
clinical	O
activity	O
in	O
endometrial	O
cancer	O
.	O

The	O
combinatorial	O
effects	O
of	O
ponatinib	CHEMICAL
and	O
ridaforolimus	CHEMICAL
on	O
growth	O
of	O
endometrial	O
cancer	O
models	O
,	O
and	O
their	O
modes	O
of	O
action	O
,	O
were	O
evaluated	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

RESULTS	O
:	O
The	O
combination	O
of	O
ponatinib	CHEMICAL
and	O
ridaforolimus	CHEMICAL
had	O
a	O
synergistic	O
effect	O
on	O
the	O
in	O
vitro	O
growth	O
of	O
endometrial	O
lines	O
bearing	O
an	O
activating	O
FGFR2	GENE-Y
mutation	O
,	O
irrespective	O
of	O
PTEN	GENE-Y
status	O
.	O

Concomitant	O
inhibition	O
of	O
both	O
FGFR2	GENE-Y
and	O
mTOR	GENE-Y
signaling	O
pathways	O
was	O
observed	O
,	O
with	O
simultaneous	O
blockade	O
resulting	O
in	O
enhanced	O
cell	O
cycle	O
arrest	O
.	O

Ponatinib	CHEMICAL
and	O
ridaforolimus	CHEMICAL
each	O
demonstrated	O
inhibition	O
of	O
tumor	O
growth	O
in	O
vivo	O
,	O
but	O
dual	O
inhibition	O
by	O
the	O
combination	O
of	O
agents	O
resulted	O
in	O
superior	O
efficacy	O
and	O
induced	O
tumor	O
regression	O
in	O
an	O
endometrial	O
xenograft	O
.	O

CONCLUSIONS	O
:	O
These	O
encouraging	O
preclinical	O
findings	O
suggest	O
the	O
inhibition	O
of	O
both	O
FGFR2	GENE-Y
and	O
mTOR	GENE-Y
by	O
the	O
ponatinib-ridaforolimus	CHEMICAL
combination	O
may	O
provide	O
a	O
new	O
therapeutic	O
strategy	O
to	O
treat	O
advanced	O
endometrial	O
cancers	O
with	O
dual	O
pathway	O
dysregulation	O
.	O
In	O
the	O
present	O
paper	O
,	O
the	O
cloning	O
and	O
expression	O
of	O
the	O
guinea	GENE-Y
pig	GENE-Y
alpha	GENE-Y
(	GENE-Y
1A	GENE-Y
)	GENE-Y
-adrenoceptor	GENE-Y
is	O
presented	O
.	O

The	O
nucleotide	CHEMICAL
sequence	O
had	O
an	O
open	O
reading	O
frame	O
of	O
1401	O
bp	O
that	O
encoded	O
a	O
466	O
amino-acid	CHEMICAL
protein	O
with	O
an	O
estimated	O
molecular	O
mass	O
of	O
approximately	O
51	O
.	O
5	O
kDa	O
.	O

When	O
the	O
clone	O
was	O
expressed	O
in	O
Cos-1	O
cells	O
,	O
specific	O
high-affinity	O
binding	O
of	O
[	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
H	CHEMICAL
]	CHEMICAL
prazosin	CHEMICAL
and	O
[	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
H	CHEMICAL
]	CHEMICAL
tamsulosin	CHEMICAL
was	O
observed	O
.	O

Chloroethylclonidine	CHEMICAL
treatment	O
of	O
membranes	O
slightly	O
decreased	O
the	O
total	O
binding	O
with	O
both	O
radioligands	O
.	O

Binding	O
competition	O
experiments	O
using	O
[	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
H	CHEMICAL
]	CHEMICAL
tamsulosin	CHEMICAL
showed	O
the	O
following	O
potency	O
order	O
:	O
(	O
a	O
)	O
for	O
agonists	O
:	O
oxymetazoline	CHEMICAL
>>epinephrine>norepinephrine>methoxamine	CHEMICAL
,	O
and	O
(	O
b	O
)	O
for	O
antagonists	O
:	O
prazosin>	O
or	O
5-methyl-urapidil	CHEMICAL
=	O
benoxathian>phentolamine>>BMY	CHEMICAL
7378	CHEMICAL
(	O
8-	CHEMICAL
[	CHEMICAL
2-	CHEMICAL
[	CHEMICAL
4-	CHEMICAL
(	CHEMICAL
2-methoxyphenyl	CHEMICAL
)	CHEMICAL
-1-piperazinyl	CHEMICAL
]	CHEMICAL
ethyl	CHEMICAL
]	CHEMICAL
-8-azaspiro	CHEMICAL
[	CHEMICAL
4	CHEMICAL
,	CHEMICAL
5	CHEMICAL
]	CHEMICAL
decane-7	CHEMICAL
,	CHEMICAL
9-dione	CHEMICAL
)	O
.	O

Photoaffinity	O
labeling	O
using	O
[	CHEMICAL
(	CHEMICAL
125	CHEMICAL
)	CHEMICAL
I-aryl	CHEMICAL
]	CHEMICAL
azido-prazosin	CHEMICAL
revealed	O
a	O
major	O
broad	O
band	O
with	O
a	O
molecular	O
mass	O
between	O
70	O
and	O
80	O
kDa	O
.	O

The	O
receptor	O
was	O
functional	O
,	O
as	O
evidenced	O
by	O
an	O
epinephrine-increased	O
production	O
of	O
[	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
H	CHEMICAL
]	CHEMICAL
inositol	CHEMICAL
phosphates	CHEMICAL
that	O
was	O
blocked	O
by	O
prazosin	CHEMICAL
.	O
Pharmacodynamic	O
profile	O
of	O
the	O
direct	O
thrombin	GENE-Y
antagonist	O
bivalirudin	O
given	O
in	O
combination	O
with	O
the	O
glycoprotein	GENE-N
IIb	GENE-N
/	GENE-N
IIIa	GENE-N
antagonist	O
eptifibatide	O
.	O
Increased	O
expression	O
of	O
tissue	GENE-Y
factor	GENE-Y
procoagulant	O
by	O
peripheral	O
blood	O
monocytes	O
has	O
been	O
implicated	O
in	O
a	O
number	O
of	O
thrombotic	O
disorders	O
.	O

The	O
present	O
studies	O
were	O
undertaken	O
to	O
determine	O
whether	O
stable	O
analogues	O
of	O
prostacyclin	CHEMICAL
,	O
a	O
potent	O
endothelium-derived	O
platelet	O
inhibitor	O
and	O
vasodilator	O
,	O
could	O
inhibit	O
tissue	GENE-Y
factor	GENE-Y
expression	O
by	O
human	O
monocytic	O
cells	O
.	O

Exposure	O
of	O
monocytic	O
tumor	O
THP-1	O
cells	O
to	O
100	O
ng	O
/	O
ml	O
endotoxin	O
,	O
2	O
units	O
/	O
ml	O
interleukin-1	GENE-Y
beta	GENE-Y
,	O
or	O
5	O
ng	O
/	O
ml	O
tumor	GENE-Y
necrosis	GENE-Y
factor-alpha	GENE-Y
for	O
4	O
hours	O
led	O
to	O
increased	O
tissue	GENE-Y
factor	GENE-Y
procoagulant	O
activity	O
.	O

Preincubation	O
for	O
30	O
minutes	O
with	O
iloprost	CHEMICAL
,	O
ciprostene	CHEMICAL
,	O
and	O
carbacyclin	CHEMICAL
led	O
to	O
a	O
dose-dependent	O
inhibition	O
of	O
tissue	GENE-Y
factor	GENE-Y
expression	O
induced	O
by	O
all	O
three	O
challenging	O
agents	O
.	O

Iloprost	CHEMICAL
was	O
the	O
most	O
potent	O
:	O
50%	O
inhibition	O
occurred	O
at	O
5	O
nM	O
,	O
a	O
concentration	O
close	O
to	O
the	O
reported	O
dissociation	O
constant	O
for	O
iloprost	CHEMICAL
binding	O
to	O
the	O
platelet	O
prostacyclin	GENE-Y
receptor	O
.	O

An	O
orally	O
active	O
analogue	O
,	O
cicaprost	CHEMICAL
,	O
was	O
equally	O
effective	O
against	O
endotoxin-induced	O
tissue	GENE-Y
factor	GENE-Y
expression	O
.	O

Carbacyclin	CHEMICAL
and	O
ciprostene	CHEMICAL
were	O
100	O
times	O
less	O
potent	O
.	O

Iloprost	O
prevented	O
the	O
endotoxin-induced	O
expression	O
of	O
tissue	GENE-Y
factor	GENE-Y
antigen	O
on	O
the	O
surface	O
of	O
THP-1	O
cells	O
,	O
as	O
determined	O
by	O
flow	O
cytometry	O
.	O

Iloprost	CHEMICAL
(	O
500	O
pM-50	O
nM	O
)	O
increased	O
intracellular	O
levels	O
of	O
cyclic	CHEMICAL
AMP	CHEMICAL
.	O

This	O
effect	O
was	O
potentiated	O
by	O
isobutylmethylxanthine	CHEMICAL
,	O
an	O
inhibitor	O
of	O
phosphodiesterase	GENE-N
.	O

The	O
inhibitory	O
effects	O
of	O
iloprost	O
on	O
tissue	GENE-Y
factor	GENE-Y
expression	O
were	O
also	O
potentiated	O
by	O
isobutylmethylxanthine	CHEMICAL
and	O
mimicked	O
by	O
forskolin	CHEMICAL
and	O
dibutyryl	CHEMICAL
cyclic	CHEMICAL
AMP	CHEMICAL
but	O
not	O
dibutyryl	CHEMICAL
cyclic	CHEMICAL
GMP	CHEMICAL
.	O

These	O
results	O
suggest	O
that	O
prostacyclin	CHEMICAL
may	O
play	O
a	O
role	O
in	O
downregulating	O
tissue	GENE-Y
factor	GENE-Y
expression	O
in	O
monocytes	O
,	O
at	O
least	O
in	O
part	O
via	O
elevation	O
of	O
intracellular	O
levels	O
of	O
cyclic	CHEMICAL
AMP	CHEMICAL
.	O
Sodium	CHEMICAL
fluoride	CHEMICAL
induces	O
apoptosis	O
in	O
odontoblasts	O
via	O
a	O
JNK-dependent	O
mechanism	O
.	O
Selective	O
and	O
potent	O
adenosine	CHEMICAL
A3	O
receptor	O
antagonists	O
by	O
methoxyaryl	CHEMICAL
substitution	O
on	O
the	O
N-	CHEMICAL
(	CHEMICAL
2	CHEMICAL
,	CHEMICAL
6-diarylpyrimidin-4-yl	CHEMICAL
)	CHEMICAL
acetamide	CHEMICAL
scaffold	O
.	O
Alcohol	CHEMICAL
is	O
one	O
of	O
the	O
most	O
commonly	O
abused	O
substances	O
,	O
and	O
its	O
chronic	O
intake	O
leads	O
to	O
the	O
development	O
of	O
ethanol	CHEMICAL
dependence	O
in	O
both	O
humans	O
and	O
laboratory	O
animals	O
.	O

In	O
many	O
countries	O
,	O
a	O
mu-opioid	GENE-Y
receptor	GENE-Y
antagonist	O
naltrexone	CHEMICAL
has	O
been	O
used	O
in	O
the	O
treatment	O
of	O
alcohol	CHEMICAL
dependence	O
.	O

The	O
introduction	O
of	O
naltrexone	CHEMICAL
for	O
the	O
treatment	O
of	O
alcohol	CHEMICAL
dependence	O
has	O
been	O
mainly	O
based	O
on	O
behavioral	O
animal	O
models	O
that	O
provide	O
evidence	O
of	O
the	O
involvement	O
of	O
the	O
endogenous	O
opioid	O
system	O
in	O
alcohol	CHEMICAL
drinking	O
and	O
dependence	O
.	O

It	O
has	O
been	O
well	O
known	O
that	O
alcohol	CHEMICAL
leads	O
to	O
the	O
activation	O
of	O
the	O
endogenous	O
opioid	O
system	O
.	O

The	O
endogenous	O
opioid	O
agonists	O
,	O
such	O
as	O
beta-endorphin	GENE-Y
,	O
increase	O
the	O
activity	O
of	O
the	O
mesolimbic	O
dopaminergic	O
system	O
through	O
the	O
inhibition	O
of	O
the	O
gamma-aminobutyric	CHEMICAL
acid	CHEMICAL
(	O
GABA	CHEMICAL
)	O
-containing	O
inhibitory	O
interneurons	O
in	O
the	O
ventral	O
tegmental	O
area	O
,	O
resulting	O
in	O
the	O
expression	O
of	O
alcohol	CHEMICAL
reinforcement	O
and	O
/	O
or	O
rewarding	O
effect	O
.	O

Therefore	O
,	O
naltrexone	CHEMICAL
,	O
which	O
is	O
useful	O
for	O
alcohol	CHEMICAL
dependence	O
therapy	O
,	O
may	O
attenuate	O
the	O
rewarding	O
effect	O
of	O
ethanol	CHEMICAL
by	O
interfering	O
with	O
the	O
ethanol-induced	O
stimulation	O
of	O
the	O
mesolimbic	O
dopaminergic	O
system	O
.	O

The	O
following	O
review	O
provides	O
a	O
summary	O
of	O
the	O
interactions	O
between	O
endogenous	O
opioid	O
system	O
and	O
mesolimbic	O
dopaminergic	O
system	O
in	O
alcohol	CHEMICAL
dependence	O
.	O
Aldo-keto	GENE-N
reductases	GENE-N
in	O
retinoid	CHEMICAL
metabolism	O
:	O
search	O
for	O
substrate	O
specificity	O
and	O
inhibitor	O
selectivity	O
.	O
The	O
cAMP	CHEMICAL
signaling	O
system	O
can	O
trigger	O
precise	O
physiological	O
cellular	O
responses	O
that	O
depend	O
on	O
the	O
fidelity	O
of	O
many	O
protein-protein	O
interactions	O
,	O
which	O
act	O
to	O
bring	O
together	O
signaling	O
intermediates	O
at	O
defined	O
locations	O
within	O
cells	O
.	O

In	O
the	O
heart	O
,	O
cAMP	CHEMICAL
participates	O
in	O
the	O
fine	O
control	O
of	O
excitation-contraction	O
coupling	O
,	O
hence	O
,	O
any	O
disregulation	O
of	O
this	O
signaling	O
cascade	O
can	O
lead	O
to	O
cardiac	O
disease	O
.	O

Due	O
to	O
the	O
ubiquitous	O
nature	O
of	O
the	O
cAMP	CHEMICAL
pathway	O
,	O
general	O
inhibitors	O
of	O
cAMP	CHEMICAL
signaling	O
proteins	O
such	O
as	O
PKA	GENE-N
,	O
EPAC	GENE-Y
and	O
PDEs	GENE-N
would	O
act	O
non-specifically	O
and	O
universally	O
,	O
increasing	O
the	O
likelihood	O
of	O
serious	O
'off	O
target'	O
effects	O
.	O

Recent	O
advances	O
in	O
the	O
discovery	O
of	O
peptides	O
and	O
small	O
molecules	O
that	O
disrupt	O
the	O
protein-protein	O
interactions	O
that	O
underpin	O
cellular	O
targeting	O
of	O
cAMP	CHEMICAL
signaling	O
proteins	O
are	O
described	O
and	O
discussed	O
.	O
Arsenic	CHEMICAL
trioxide	CHEMICAL
induces	O
cardiac	O
fibroblast	O
apoptosis	O
in	O
vitro	O
and	O
in	O
vivo	O
by	O
up-regulating	O
TGF-β1	GENE-N
expression	O
.	O
Substituted	O
imidazopyridazines	CHEMICAL
are	O
potent	O
and	O
selective	O
inhibitors	O
of	O
Plasmodium	GENE-Y
falciparum	GENE-Y
calcium-dependent	O
protein	O
kinase	O
1	O
(	O
PfCDPK1	GENE-Y
)	O
.	O
SNAIL	GENE-Y
Induces	O
Epithelial-to-Mesenchymal	O
Transition	O
and	O
Cancer	O
Stem	O
Cell-like	O
Properties	O
in	O
Aldehyde	CHEMICAL
Dehydroghenase-Negative	O
Thyroid	O
Cancer	O
Cells	O
.	O
Glucocorticoid	GENE-N
receptor	GENE-N
binding	O
:	O
a	O
biphasic	O
dependence	O
on	O
molecular	O
size	O
as	O
revealed	O
by	O
the	O
bilinear	O
LinBiExp	O
model	O
.	O
Osteoporosis	O
is	O
a	O
common	O
disease	O
characterized	O
by	O
an	O
increased	O
susceptibility	O
to	O
fracture	O
.	O

It	O
is	O
a	O
complex	O
disorder	O
resulting	O
from	O
the	O
interaction	O
of	O
several	O
polymorphisms	O
in	O
different	O
genes	O
and	O
environmental	O
factors	O
.	O

Since	O
we	O
recently	O
reported	O
a	O
role	O
for	O
low	GENE-Y
density	GENE-Y
lipoprotein-related	GENE-Y
protein	GENE-Y
(	GENE-Y
LRP	GENE-Y
)	GENE-Y
-4	GENE-Y
in	O
monogenic	O
disorders	O
with	O
bone	O
overgrowth	O
,	O
we	O
now	O
wanted	O
to	O
evaluate	O
whether	O
genetic	O
variation	O
in	O
the	O
LRP4	GENE-Y
gene	O
has	O
an	O
effect	O
on	O
the	O
susceptibility	O
to	O
osteoporosis	O
in	O
a	O
population	O
based	O
cohort	O
from	O
the	O
Odense	O
Androgen	CHEMICAL
Study	O
.	O

We	O
chose	O
to	O
genotype	O
four	O
common	O
(	O
minor	O
allele	O
frequency	O
(	O
MAF	O
)	O
≥0	O
.	O
05	O
)	O
and	O
non-synonymous	O
coding	O
polymorphisms	O
located	O
in	O
the	O
extracellular	O
region	O
of	O
the	O
LRP4	GENE-Y
protein	O
:	O
rs3816614	O
(	O
A	O
/	O
g	O
)	O
,	O
rs2306029	O
(	O
G	O
/	O
a	O
)	O
,	O
rs2306033	O
(	O
C	O
/	O
t	O
)	O
and	O
rs6485702	O
(	O
G	O
/	O
a	O
)	O
(	O
large	O
and	O
small	O
characters	O
indicate	O
major	O
and	O
minor	O
alleles	O
,	O
respectively	O
)	O
.	O

Bone	O
mineral	O
density	O
(	O
BMD	O
)	O
measurements	O
of	O
the	O
hip	O
,	O
the	O
spine	O
and	O
whole	O
body	O
as	O
well	O
as	O
different	O
hip	O
geometry	O
parameters	O
were	O
available	O
for	O
a	O
total	O
of	O
1404	O
Danish	O
men	O
from	O
two	O
age	O
groups	O
(	O
[	O
20-29	O
years	O
]	O
:	O
n	O
=	O
804;	O
[	O
60-74	O
years	O
]	O
:	O
n	O
=	O
600	O
)	O
.	O

Using	O
linear	O
regression	O
analysis	O
adjusted	O
for	O
age	O
,	O
height	O
and	O
weight	O
,	O
we	O
found	O
significant	O
associations	O
between	O
both	O
rs2306029	O
and	O
rs6485702	O
and	O
BMD	O
at	O
all	O
sites	O
except	O
the	O
lumbar	O
spine	O
.	O

The	O
most	O
significant	O
association	O
was	O
found	O
with	O
whole	O
body	O
BMD	O
(	O
p	O
=	O
4	O
.	O
7×10	O
(	O
-5	O
)	O
)	O
.	O

In	O
addition	O
,	O
we	O
found	O
these	O
two	O
polymorphisms	O
to	O
be	O
associated	O
with	O
different	O
geometry	O
parameters	O
especially	O
of	O
the	O
femoral	O
shaft	O
.	O

Analysis	O
of	O
the	O
two	O
associated	O
SNPs	O
in	O
the	O
separate	O
age	O
groups	O
demonstrated	O
that	O
most	O
associations	O
are	O
only	O
present	O
in	O
the	O
youngest	O
group	O
of	O
Danish	O
men	O
.	O

In	O
the	O
group	O
of	O
elderly	O
men	O
,	O
one	O
Bonferroni	O
corrected	O
association	O
between	O
whole	O
body	O
BMD	O
and	O
rs6485702	O
was	O
found	O
to	O
be	O
significant	O
.	O

Subsequently	O
,	O
all	O
polymorphisms	O
were	O
included	O
in	O
haplotype	O
analyses	O
using	O
the	O
PLINK	O
software	O
(	O
v1	O
.	O
07	O
)	O
.	O

After	O
adjusting	O
for	O
age	O
,	O
height	O
and	O
weight	O
,	O
two	O
out	O
of	O
five	O
common	O
haplotypes	O
(	O
MAF≥0	O
.	O
01	O
)	O
were	O
found	O
to	O
be	O
of	O
particular	O
interest	O
in	O
the	O
regulation	O
of	O
hip	O
and	O
whole	O
body	O
BMD	O
(	O
AGCG	O
,	O
AACA	O
)	O
.	O

Additional	O
analysis	O
suggested	O
that	O
these	O
latter	O
associations	O
are	O
driven	O
by	O
the	O
association	O
of	O
rs6485702	O
.	O

We	O
suggest	O
,	O
based	O
on	O
these	O
results	O
and	O
the	O
localisation	O
of	O
the	O
variant	O
in	O
the	O
third	O
β-propeller	GENE-N
domain	GENE-N
of	O
LRP4	GENE-Y
,	O
that	O
the	O
variant	O
has	O
possibly	O
a	O
functional	O
effect	O
.	O

Hereby	O
,	O
we	O
conclude	O
that	O
common	O
variation	O
in	O
the	O
LRP4	GENE-Y
gene	O
determines	O
hip	O
and	O
whole	O
body	O
BMD	O
and	O
thus	O
confirm	O
previous	O
results	O
from	O
different	O
GWAs	O
.	O

In	O
addition	O
,	O
our	O
data	O
proves	O
an	O
additional	O
role	O
for	O
LRP4	GENE-Y
in	O
regulating	O
hip	O
structure	O
.	O

Finally	O
,	O
interaction	O
analysis	O
for	O
LRP4	GENE-Y
with	O
SOST	GENE-Y
and	O
LRP5	GENE-Y
showed	O
interaction	O
with	O
LRP5	GENE-Y
for	O
femoral	O
shaft	O
geometry	O
.	O
The	O
present	O
study	O
describes	O
the	O
characterization	O
of	O
the	O
binding	O
properties	O
and	O
autoradiographic	O
distribution	O
of	O
a	O
new	O
nonpeptide	O
antagonist	O
of	O
neurotensin	CHEMICAL
receptors	O
,	O
[	CHEMICAL
3H	CHEMICAL
]	CHEMICAL
SR	CHEMICAL
142948A	CHEMICAL
(	O
2-	CHEMICAL
[	CHEMICAL
[	CHEMICAL
5-	CHEMICAL
(	CHEMICAL
2	CHEMICAL
,	CHEMICAL
6-dimethoxyphenyl	CHEMICAL
)	CHEMICAL
-1-	CHEMICAL
(	CHEMICAL
4-	CHEMICAL
(	CHEMICAL
N-	CHEMICAL
(	CHEMICAL
3-dimethylaminopropyl	CHEMICAL
)	CHEMICAL
-N-methyl	CHEMICAL
carbamoyl	CHEMICAL
)	CHEMICAL
-2-isopropylphenyl	CHEMICAL
)	CHEMICAL
-1H-pyrazole-3-carbonyl	CHEMICAL
]	CHEMICAL
-amino	CHEMICAL
]	CHEMICAL
-ad	CHEMICAL
amantane-2-carboxylic	CHEMICAL
acid	CHEMICAL
,	CHEMICAL
hydrochloride	CHEMICAL
)	O
,	O
in	O
the	O
rat	O
brain	O
.	O

The	O
binding	O
of	O
[	CHEMICAL
3H	CHEMICAL
]	CHEMICAL
SR	CHEMICAL
142948A	CHEMICAL
in	O
brain	O
membrane	O
homogenates	O
was	O
specific	O
,	O
time-dependent	O
,	O
reversible	O
and	O
saturable	O
.	O

[	CHEMICAL
3H	CHEMICAL
]	CHEMICAL
SR	CHEMICAL
142948A	CHEMICAL
bound	O
to	O
an	O
apparently	O
homogeneous	O
population	O
of	O
sites	O
,	O
with	O
a	O
Kd	O
of	O
3	O
.	O
5	O
nM	O
and	O
a	O
Bmax	O
value	O
of	O
508	O
fmol	O
/	O
mg	O
of	O
protein	O
,	O
which	O
was	O
80%	O
higher	O
than	O
that	O
observed	O
in	O
saturation	O
experiments	O
with	O
[	CHEMICAL
3H	CHEMICAL
]	CHEMICAL
neurotensin	CHEMICAL
.	O

[	CHEMICAL
3H	CHEMICAL
]	CHEMICAL
SR	CHEMICAL
142948A	CHEMICAL
binding	O
was	O
inhibited	O
by	O
SR	CHEMICAL
142948A	CHEMICAL
,	O
the	O
related	O
nonpeptide	O
receptor	O
antagonist	O
,	O
SR	CHEMICAL
48692	CHEMICAL
(	O
2-	CHEMICAL
[	CHEMICAL
[	CHEMICAL
1-	CHEMICAL
(	CHEMICAL
7-chloroquinolin-4-yl	CHEMICAL
)	CHEMICAL
-5-	CHEMICAL
(	CHEMICAL
2	CHEMICAL
,	CHEMICAL
6-dimethoxyphenyl	CHEMICAL
)	CHEMICAL
-1H-pyrazole	CHEMICAL
-3-carbonyl	CHEMICAL
]	CHEMICAL
amino	CHEMICAL
]	CHEMICAL
-adamantane-2-carboxylic	CHEMICAL
acid	CHEMICAL
)	O
and	O
neurotensin	GENE-Y
.	O

Saturation	O
and	O
competition	O
studies	O
in	O
the	O
presence	O
or	O
absence	O
of	O
the	O
histamine	GENE-Y
H1	O
receptor	O
antagonist	O
,	O
levocabastine	CHEMICAL
,	O
revealed	O
that	O
[	CHEMICAL
3H	CHEMICAL
]	CHEMICAL
SR	CHEMICAL
142948A	CHEMICAL
bound	O
with	O
similar	O
affinities	O
to	O
both	O
the	O
levocabastine-insensitive	O
neurotensin	CHEMICAL
NT1	O
receptors	O
(	O
20%	O
of	O
the	O
total	O
binding	O
population	O
)	O
and	O
the	O
recently	O
cloned	O
levocabastine-sensitive	O
neurotensin	GENE-Y
NT2	GENE-Y
receptors	GENE-Y
(	O
80%	O
of	O
the	O
receptors	O
)	O
(	O
Kd	O
=	O
6	O
.	O
8	O
and	O
4	O
.	O
8	O
nM	O
,	O
respectively	O
)	O
.	O

The	O
regional	O
distribution	O
of	O
[	CHEMICAL
3H	CHEMICAL
]	CHEMICAL
SR	CHEMICAL
142948A	CHEMICAL
binding	O
in	O
the	O
rat	O
brain	O
closely	O
matched	O
the	O
distribution	O
of	O
[	CHEMICAL
125I	CHEMICAL
]	CHEMICAL
neurotensin	CHEMICAL
binding	O
.	O

In	O
conclusion	O
,	O
these	O
findings	O
indicate	O
that	O
[	CHEMICAL
3H	CHEMICAL
]	CHEMICAL
SR	CHEMICAL
142948A	CHEMICAL
is	O
a	O
new	O
potent	O
antagonist	O
radioligand	O
which	O
recognizes	O
with	O
high	O
affinity	O
both	O
neurotensin	GENE-Y
NT1	O
and	O
NT2	GENE-Y
receptors	GENE-Y
and	O
represents	O
thus	O
an	O
excellent	O
tool	O
to	O
study	O
neurotensin	GENE-N
receptors	O
in	O
the	O
rat	O
brain	O
.	O
Anti-inflammatory	O
activity	O
of	O
Cymbopogon	O
citratus	O
leaves	O
infusion	O
via	O
proteasome	GENE-N
and	O
nuclear	GENE-N
factor-κB	GENE-N
pathway	O
inhibition	O
:	O
Contribution	O
of	O
chlorogenic	CHEMICAL
acid	CHEMICAL
.	O
TCDD	CHEMICAL
inhibition	O
of	O
canonical	O
wnt	GENE-N
signaling	O
disrupts	O
prostatic	O
bud	O
formation	O
in	O
mouse	O
urogenital	O
sinus	O
.	O
Incoherent	O
neutron	O
scattering	O
is	O
one	O
of	O
the	O
most	O
powerful	O
tools	O
for	O
studying	O
dynamics	O
in	O
biological	O
matter	O
.	O

Using	O
the	O
cold	O
neutron	O
backscattering	O
spectrometer	O
IN16	O
at	O
the	O
Institut	O
Laue	O
Langevin	O
(	O
ILL	O
,	O
Grenoble	O
,	O
France	O
)	O
,	O
temperature	O
dependence	O
of	O
cholinesterases'	O
dynamics	O
(	O
human	GENE-Y
butyrylcholinesterase	GENE-Y
from	O
plasma	O
:	O
hBChE;	O
recombinant	O
human	GENE-Y
acetylcholinesterase	GENE-Y
:	O
hAChE	GENE-Y
and	O
recombinant	O
mouse	GENE-Y
acetylcholinesterase	GENE-Y
:	O
mAChE	GENE-Y
)	O
was	O
examined	O
using	O
elastic	O
incoherent	O
neutron	O
scattering	O
(	O
EINS	O
)	O
.	O

The	O
dynamics	O
was	O
characterized	O
by	O
the	O
averaged	O
atomic	O
mean	O
square	O
displacement	O
(	O
MSD	O
)	O
,	O
associated	O
with	O
the	O
sample	O
flexibility	O
at	O
a	O
given	O
temperature	O
.	O

We	O
found	O
MSD	O
values	O
of	O
hAChE	GENE-Y
above	O
the	O
dynamical	O
transition	O
temperature	O
(	O
around	O
200K	O
)	O
larger	O
than	O
for	O
mAChE	GENE-Y
and	O
hBChE	GENE-Y
,	O
implying	O
that	O
hAChE	GENE-Y
is	O
more	O
flexible	O
than	O
the	O
other	O
ChEs	GENE-N
.	O

Activation	O
energies	O
for	O
thermodynamical	O
transition	O
were	O
extracted	O
through	O
the	O
frequency	O
window	O
model	O
(	O
FWM	O
)	O
(	O
Becker	O
et	O
al	O
.	O

2004	O
)	O
[	O
1	O
]	O
and	O
turned	O
out	O
to	O
increase	O
from	O
hBChE	GENE-Y
to	O
mAChE	GENE-Y
and	O
finally	O
to	O
hAChE	GENE-Y
,	O
inversely	O
to	O
the	O
MSDs	O
relations	O
.	O

Between	O
280	O
and	O
316K	O
,	O
catalytic	O
studies	O
of	O
these	O
enzymes	O
were	O
carried	O
out	O
using	O
thiocholine	CHEMICAL
esters	CHEMICAL
:	O
at	O
the	O
same	O
temperature	O
,	O
the	O
hAChE	GENE-Y
activity	O
was	O
systematically	O
higher	O
than	O
the	O
mAChE	GENE-Y
or	O
hBChE	GENE-Y
ones	O
.	O

Our	O
results	O
thus	O
suggest	O
a	O
strong	O
correlation	O
between	O
dynamics	O
and	O
activity	O
within	O
the	O
ChE	GENE-N
family	O
.	O

We	O
also	O
studied	O
and	O
compared	O
the	O
ChEs	GENE-N
thermal	O
inactivation	O
kinetics	O
.	O

Here	O
,	O
no	O
direct	O
correlation	O
with	O
the	O
dynamics	O
was	O
observed	O
,	O
thus	O
suggesting	O
that	O
relations	O
between	O
enzyme	O
dynamics	O
and	O
catalytic	O
stability	O
are	O
more	O
complex	O
.	O

Finally	O
,	O
the	O
possible	O
relation	O
between	O
flexibility	O
and	O
protein	O
ability	O
to	O
grow	O
in	O
crystals	O
is	O
discussed	O
.	O
The	O
pharmacological	O
dosage	O
of	O
dehydroepiandrosterone	CHEMICAL
(	O
DHEA	CHEMICAL
)	O
protects	O
against	O
chemically	O
induced	O
carcinogenesis	O
.	O

The	O
chemoprotective	O
activity	O
of	O
DHEA	CHEMICAL
is	O
attributed	O
to	O
its	O
inhibitory	O
potential	O
for	O
the	O
expression	O
of	O
CYP1A	GENE-N
enzymes	O
,	O
which	O
are	O
highly	O
responsible	O
for	O
metabolic	O
activation	O
of	O
several	O
mutagenic	O
and	O
carcinogenic	O
chemicals	O
.	O

The	O
present	O
work	O
investigated	O
whether	O
the	O
chemoprevention	O
by	O
DHEA	CHEMICAL
was	O
due	O
to	O
diminished	O
transcriptional	O
activation	O
of	O
CYP1A	GENE-N
genes	O
or	O
to	O
the	O
post-transcriptional	O
modulation	O
of	O
CYP1A	GENE-N
expression	O
.	O

In	O
primary	O
human	O
hepatocytes	O
,	O
DHEA	CHEMICAL
diminished	O
the	O
increase	O
in	O
CYP1A	GENE-N
activities	O
(	O
7-ethoxyresorufin	CHEMICAL
O-dealkylation	O
and	O
phenacetin	CHEMICAL
O-dealkylation	O
)	O
and	O
in	O
CYP1A2	GENE-Y
mRNA	O
level	O
induced	O
by	O
3-methylcholanthrene	CHEMICAL
,	O
but	O
did	O
not	O
alter	O
the	O
amount	O
of	O
CYP1A1	GENE-Y
and	O
CYP1B1	GENE-Y
mRNA	O
.	O

The	O
androgen	GENE-Y
receptor	O
seemed	O
to	O
be	O
involved	O
in	O
DHEA-mediated	O
diminishment	O
of	O
CYP1A2	GENE-Y
induction	O
,	O
which	O
was	O
attenuated	O
in	O
the	O
presence	O
of	O
bicalutamide	CHEMICAL
,	O
the	O
androgen	GENE-Y
receptor	O
antagonist	O
.	O

The	O
potential	O
role	O
of	O
the	O
glucocorticoid	GENE-Y
receptor	GENE-Y
and	O
estrogen	GENE-Y
receptor	O
in	O
DHEA-mediated	O
decrease	O
in	O
CYP1A2	GENE-Y
induction	O
was	O
excluded	O
.	O

The	O
developed	O
computational	O
model	O
of	O
CYP1A2	GENE-Y
induction	O
kinetics	O
and	O
CYP1A2	GENE-Y
mRNA	O
degradation	O
proposed	O
that	O
a	O
post-transcriptional	O
mechanism	O
was	O
likely	O
to	O
be	O
the	O
primary	O
mechanism	O
of	O
the	O
DHEA-mediated	O
diminishment	O
of	O
CYP1A2	GENE-Y
induction	O
.	O

The	O
hypothesis	O
was	O
confirmed	O
by	O
the	O
results	O
of	O
actinomycin	CHEMICAL
D-chase	O
experiments	O
in	O
MCF-7	O
and	O
LNCaP	O
cells	O
,	O
displaying	O
that	O
the	O
degradation	O
rates	O
of	O
CYP1A2	GENE-Y
mRNA	O
were	O
significantly	O
higher	O
in	O
the	O
cells	O
exposed	O
to	O
DHEA	CHEMICAL
.	O

The	O
novel	O
findings	O
on	O
DHEA-mediated	O
modulation	O
of	O
CYP1A2	GENE-Y
mRNA	O
stability	O
may	O
account	O
for	O
the	O
beneficial	O
effects	O
of	O
DHEA	CHEMICAL
by	O
decreasing	O
the	O
metabolic	O
activation	O
of	O
pro-carcinogenic	O
compounds	O
.	O
Metabolism	O
of	O
nomifensine	CHEMICAL
to	O
a	O
dihydroisoquinolinium	CHEMICAL
ion	O
metabolite	O
by	O
human	GENE-Y
myeloperoxidase	GENE-Y
,	O
hemoglobin	GENE-N
,	O
monoamine	GENE-Y
oxidase	O
A	O
,	O
and	O
cytochrome	GENE-N
P450	GENE-N
enzymes	O
.	O
Hydroxysafflor	CHEMICAL
yellow	CHEMICAL
a	CHEMICAL
inhibits	O
lipopolysaccharide-induced	O
inflammatory	O
signal	O
transduction	O
in	O
human	O
alveolar	O
epithelial	O
A549	O
cells	O
.	O
A	O
general	O
two-process	O
model	O
describes	O
the	O
hydrogen	CHEMICAL
exchange	O
behavior	O
of	O
RNase	GENE-Y
A	GENE-Y
in	O
unfolding	O
conditions	O
.	O
Selective	O
histamine-H1	O
receptor	O
antagonists	O
inhibit	O
adenosine	CHEMICAL
5'-monophosphate	CHEMICAL
(	O
AMP	CHEMICAL
)	O
-induced	O
bronchoconstriction	O
by	O
greater	O
than	O
80%	O
when	O
expressed	O
as	O
a	O
percentage	O
inhibition	O
of	O
the	O
FEV1	O
time-response	O
curve	O
following	O
inhalation	O
of	O
the	O
provocation	O
concentration	O
of	O
AMP	CHEMICAL
required	O
to	O
produce	O
a	O
20%	O
decrease	O
in	O
FEV1	O
from	O
baseline	O
(	O
PC20	O
)	O
.	O

To	O
investigate	O
this	O
further	O
we	O
have	O
determined	O
that	O
,	O
in	O
eight	O
mild	O
atopic	O
asthmatic	O
subjects	O
,	O
terfenadine	CHEMICAL
(	O
180	O
mg	O
)	O
,	O
administered	O
3	O
hr	O
pre-challenge	O
,	O
increases	O
the	O
geometric	O
mean	O
PC20	O
for	O
histamine	CHEMICAL
from	O
0	O
.	O
4	O
(	O
range	O
0	O
.	O
03-3	O
)	O
mg	O
/	O
ml	O
after	O
placebo	O
,	O
to	O
20	O
.	O
2	O
(	O
range	O
0	O
.	O
6-64	O
)	O
mg	O
/	O
ml	O
following	O
active	O
treatment	O
(	O
P	O
less	O
than	O
0	O
.	O
0001	O
)	O
.	O

For	O
AMP	CHEMICAL
,	O
the	O
PC20	O
increased	O
from	O
9	O
.	O
3	O
(	O
range	O
1	O
.	O
0-113	O
.	O
3	O
)	O
mg	O
/	O
ml	O
after	O
placebo	O
,	O
to	O
150	O
.	O
2	O
(	O
range	O
32	O
.	O
1-1177	O
.	O
7	O
)	O
mg	O
/	O
ml	O
with	O
terfenadine	CHEMICAL
(	O
P	O
less	O
than	O
0	O
.	O
0001	O
)	O
.	O

This	O
16	O
.	O
2-fold	O
(	O
range	O
,	O
5	O
.	O
5-47	O
.	O
9	O
)	O
displacement	O
to	O
the	O
right	O
of	O
the	O
AMP	CHEMICAL
concentration-response	O
curve	O
by	O
a	O
selective	O
histamine-H1	O
receptor	O
antagonist	O
emphasizes	O
the	O
central	O
role	O
of	O
histamine	CHEMICAL
in	O
the	O
airways	O
response	O
to	O
this	O
nucleotide	O
.	O
This	O
study	O
determined	O
the	O
nutritional	O
potential	O
of	O
Thai	O
indigenous	O
fruits	O
in	O
terms	O
of	O
nutrients	O
,	O
bioactive	O
compounds	O
,	O
and	O
antioxidant	O
activities	O
.	O

Three	O
indigenous	O
fruits	O
were	O
collected	O
at	O
two	O
conservation	O
areas	O
in	O
Kanchanaburi	O
province	O
,	O
Thailand	O
.	O

The	O
results	O
showed	O
that	O
Phyllanthus	O
emblica	O
L	O
.	O

exhibited	O
the	O
highest	O
levels	O
of	O
vitamin	CHEMICAL
C	CHEMICAL
(	O
575±452mg	O
/	O
100g	O
)	O
,	O
total	O
phenolics	CHEMICAL
(	O
TP	O
)	O
(	O
3703±1244mGAE	O
/	O
100g	O
)	O
,	O
and	O
antioxidant	O
activities	O
,	O
as	O
measured	O
by	O
DPPH	CHEMICAL
,	O
FRAP	O
and	O
ORAC	O
assays	O
.	O

Compared	O
to	O
the	O
other	O
two	O
fruits	O
,	O
Antidesma	O
velutinosum	O
Blume	O
contained	O
higher	O
levels	O
of	O
most	O
nutrients	O
and	O
dietary	O
fibre	O
(	O
15	O
.	O
6±5	O
.	O
9g	O
/	O
100g	O
)	O
,	O
as	O
well	O
as	O
carotenoids	O
(	O
335±98μg	O
/	O
100g	O
)	O
and	O
phytosterols	CHEMICAL
(	O
22	O
.	O
1±3	O
.	O
9mg	O
/	O
100g	O
)	O
.	O

Spondias	O
pinnata	O
(	O
L	O
.	O

f	O
.	O

)	O
Kurz	O
was	O
high	O
in	O
total	O
phenolics	CHEMICAL
(	O
3178±887mGAE	O
/	O
100g	O
)	O
and	O
antioxidant	O
activity	O
.	O

Moreover	O
,	O
high	O
correlations	O
were	O
found	O
between	O
TP	O
and	O
antioxidant	O
activities	O
(	O
r>0	O
.	O
9	O
)	O
.	O

These	O
Thai	O
indigenous	O
fruits	O
are	O
potentially	O
good	O
sources	O
of	O
nutrients	O
,	O
bioactive	O
compounds	O
,	O
and	O
antioxidant	O
activities	O
.	O

Conservation	O
and	O
utilisation	O
should	O
be	O
promoted	O
for	O
food	O
security	O
and	O
consumption	O
as	O
part	O
of	O
a	O
healthy	O
diet	O
.	O
We	O
report	O
the	O
cloning	O
and	O
characterization	O
of	O
a	O
novel	O
serotonin	GENE-N
receptor	O
,	O
designated	O
as	O
5-HT7	GENE-Y
,	O
which	O
is	O
coupled	O
to	O
the	O
stimulation	O
of	O
adenylyl	GENE-N
cyclase	O
.	O

5-HT7	GENE-Y
mRNA	O
is	O
expressed	O
discretely	O
throughout	O
the	O
CNS	O
,	O
predominantly	O
in	O
the	O
thalamus	O
and	O
hypothalamus	O
.	O

5-HT7	GENE-Y
has	O
a	O
unique	O
pharmacological	O
profile	O
that	O
redefines	O
agonist	O
and	O
antagonist	O
classification	O
of	O
ligands	O
previously	O
thought	O
to	O
be	O
"selective	O
.	O

"	O
The	O
circadian	O
phase	O
of	O
spontaneous	O
neuronal	O
activity	O
of	O
the	O
rat	O
suprachiasmatic	O
nucleus	O
of	O
the	O
hypothalamus	O
advances	O
in	O
response	O
to	O
serotonin	CHEMICAL
ligands	O
with	O
a	O
pharmacological	O
profile	O
consistent	O
exclusively	O
with	O
that	O
of	O
5-HT7	GENE-Y
.	O

These	O
findings	O
suggest	O
a	O
physiological	O
role	O
in	O
the	O
regulation	O
of	O
circadian	O
rhythms	O
for	O
one	O
subtype	O
of	O
serotonin	GENE-N
receptor	GENE-N
,	O
5-HT7	GENE-Y
,	O
and	O
provide	O
a	O
pharmacological	O
test	O
to	O
evaluate	O
its	O
role	O
in	O
other	O
neuronal	O
systems	O
.	O
Axitinib	CHEMICAL
in	O
metastatic	O
renal	O
cell	O
carcinoma	O
:	O
results	O
of	O
a	O
pharmacokinetic	O
and	O
pharmacodynamic	O
analysis	O
.	O
Reconstitution	O
into	O
liposomes	O
of	O
the	O
glutamine	GENE-Y
/	O
amino	CHEMICAL
acid	CHEMICAL
transporter	O
from	O
renal	O
cell	O
plasma	O
membrane	O
:	O
functional	O
characterization	O
,	O
kinetics	O
and	O
activation	O
by	O
nucleotides	O
.	O
Concentration-effect	O
relationship	O
of	O
the	O
positive	O
chronotropic	O
and	O
hypokalaemic	O
effects	O
of	O
fenoterol	CHEMICAL
in	O
healthy	O
women	O
of	O
childbearing	O
age	O
.	O
Non-enzymatic	O
interactions	O
of	O
glyoxylate	CHEMICAL
with	O
lysine	CHEMICAL
,	O
arginine	CHEMICAL
,	O
and	O
glucosamine	CHEMICAL
:	O
a	O
study	O
of	O
advanced	O
non-enzymatic	O
glycation	O
like	O
compounds	O
.	O
Osteoblasts	O
survive	O
the	O
arsenic	CHEMICAL
trioxide	CHEMICAL
treatment	O
by	O
activation	O
of	O
ATM-mediated	O
pathway	O
.	O
Cloning	O
of	O
another	O
human	GENE-Y
serotonin	CHEMICAL
receptor	O
(	O
5-HT1F	O
)	O
:	O
a	O
fifth	O
5-HT1	GENE-N
receptor	O
subtype	O
coupled	O
to	O
the	O
inhibition	O
of	O
adenylate	CHEMICAL
cyclase	O
.	O
Organic	O
Solvent-Based	O
Graphene	CHEMICAL
Oxide	CHEMICAL
Liquid	O
Crystals	O
:	O
A	O
Facile	O
Route	O
toward	O
the	O
Next	O
Generation	O
of	O
Self-Assembled	O
Layer-by-Layer	O
Multifunctional	O
3D	O
Architectures	O
.	O
RATIONALE	O
:	O
A	O
common	O
polymorphism	O
(	O
5HTTLPR	GENE-Y
)	O
within	O
the	O
promoter	O
region	O
of	O
the	O
serotonin	GENE-Y
transporter	O
gene	O
(	O
LSC6A4	GENE-Y
)	O
has	O
been	O
shown	O
to	O
influence	O
response	O
time	O
as	O
well	O
as	O
overall	O
response	O
to	O
selective	O
serotonin	CHEMICAL
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
in	O
subjects	O
with	O
major	O
depressive	O
disorder	O
.	O

We	O
hypothesized	O
that	O
a	O
similar	O
effect	O
in	O
response	O
time	O
to	O
sertraline	CHEMICAL
would	O
be	O
observed	O
and	O
that	O
no	O
effect	O
on	O
response	O
time	O
would	O
be	O
seen	O
in	O
a	O
placebo	O
arm	O
.	O

OBJECTIVES	O
:	O
We	O
tested	O
the	O
hypothesis	O
that	O
subjects	O
homozygous	O
for	O
the	O
long	O
allele	O
at	O
the	O
5HTTLPR	GENE-Y
polymorphism	O
would	O
respond	O
more	O
rapidly	O
to	O
sertraline	CHEMICAL
than	O
subjects	O
carrying	O
one	O
or	O
two	O
copies	O
of	O
the	O
short	O
allele	O
.	O

METHODS	O
:	O
HAM-D	O
and	O
CGI-I	O
responses	O
to	O
sertraline	CHEMICAL
and	O
placebo	O
were	O
measured	O
weekly	O
in	O
the	O
context	O
of	O
an	O
8-week	O
,	O
placebo-controlled	O
study	O
in	O
elderly	O
depressed	O
subjects	O
.	O

Genotyping	O
of	O
the	O
5HTTLPR	GENE-Y
polymorphism	O
was	O
performed	O
to	O
test	O
for	O
correlations	O
with	O
response	O
at	O
each	O
week	O
in	O
the	O
sertraline	CHEMICAL
and	O
placebo	O
groups	O
(	O
n	O
=	O
206	O
)	O
.	O

RESULTS	O
:	O
Subjects	O
homozygous	O
for	O
the	O
long	O
allele	O
of	O
5HTTLPR	GENE-Y
showed	O
a	O
significant	O
increase	O
in	O
response	O
at	O
week	O
1	O
and	O
week	O
2	O
,	O
as	O
assessed	O
by	O
the	O
CGI-I	O
scale	O
compared	O
with	O
subjects	O
carrying	O
one	O
or	O
two	O
copies	O
of	O
the	O
short	O
allele	O
(	O
P	O
=	O
0	O
.	O
01	O
at	O
both	O
weeks	O
)	O
.	O

No	O
significant	O
difference	O
was	O
observed	O
in	O
the	O
placebo	O
group	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
genetic	O
variation	O
in	O
the	O
serotonin	GENE-Y
transporter	O
gene	O
effects	O
the	O
response	O
time	O
to	O
sertraline	CHEMICAL
and	O
provides	O
complementing	O
evidence	O
to	O
previous	O
reports	O
that	O
this	O
polymorphism	O
affects	O
response	O
time	O
to	O
other	O
SSRIs	O
.	O
A	O
large	O
amount	O
of	O
the	O
data	O
gathered	O
in	O
the	O
last	O
50	O
years	O
support	O
the	O
hypothesis	O
that	O
alterations	O
of	O
the	O
serotonin	CHEMICAL
(	O
5-HT	CHEMICAL
)	O
neurotransmission	O
play	O
a	O
crucial	O
role	O
in	O
the	O
pathophysiology	O
of	O
not	O
only	O
major	O
depression	O
(	O
MD	O
)	O
,	O
but	O
also	O
of	O
different	O
neuropsychiatric	O
disorders	O
.	O

Research	O
in	O
this	O
field	O
has	O
been	O
substantially	O
promoted	O
by	O
the	O
evidence	O
that	O
the	O
reuptake	O
protein	O
(	O
SERT	GENE-Y
)	O
,	O
present	O
in	O
presynaptic	O
neurons	O
,	O
is	O
a	O
key	O
element	O
in	O
terminating	O
the	O
activity	O
of	O
the	O
neurotransmitter	O
in	O
the	O
synaptic	O
cleft	O
.	O

For	O
this	O
reason	O
,	O
it	O
was	O
specifically	O
targeted	O
for	O
the	O
development	O
of	O
second-generation	O
antidepressants	O
,	O
in	O
particular	O
of	O
selective	O
5-HT	CHEMICAL
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
,	O
with	O
the	O
aim	O
of	O
increasing	O
the	O
intrasynaptic	O
5-HT	CHEMICAL
concentrations	O
.	O

Moreover	O
,	O
since	O
a	O
lot	O
of	O
studies	O
showed	O
that	O
circulating	O
platelets	O
and	O
,	O
more	O
recently	O
,	O
lymphocytes	O
possess	O
functional	O
SERT	GENE-Y
proteins	O
,	O
they	O
have	O
been	O
widely	O
used	O
as	O
peripheral	O
mirrors	O
of	O
the	O
same	O
structures	O
located	O
in	O
the	O
central	O
nervous	O
system	O
.	O

The	O
presence	O
of	O
functional	O
SERT	GENE-Y
in	O
blood	O
cells	O
suggests	O
strict	O
relationships	O
between	O
the	O
nervous	O
and	O
the	O
immune	O
system	O
that	O
need	O
to	O
be	O
better	O
clarified	O
in	O
MD	O
,	O
as	O
well	O
as	O
the	O
possibility	O
of	O
reciprocal	O
modulation	O
of	O
the	O
two	O
systems	O
by	O
different	O
drugs	O
.	O

This	O
paper	O
aims	O
to	O
review	O
briefly	O
the	O
literature	O
on	O
the	O
5-HT	CHEMICAL
hypothesis	O
of	O
depression	O
with	O
a	O
major	O
focus	O
on	O
the	O
possible	O
role	O
of	O
SERT	GENE-Y
in	O
this	O
disorder	O
,	O
while	O
highlighting	O
how	O
recent	O
data	O
are	O
more	O
oriented	O
on	O
dimensional	O
rather	O
than	O
nosological	O
involvement	O
of	O
this	O
structure	O
in	O
different	O
conditions	O
spanning	O
from	O
normality	O
to	O
pathology	O
.	O
Beta-adrenoceptor	GENE-N
antagonists	O
(	O
"beta-blockers"	O
)	O
are	O
one	O
of	O
the	O
most	O
widely	O
used	O
classes	O
of	O
drugs	O
in	O
cardiovascular	O
medicine	O
(	O
hypertension	O
,	O
ischaemic	O
heart	O
disease	O
and	O
increasingly	O
in	O
heart	O
failure	O
)	O
as	O
well	O
as	O
in	O
the	O
management	O
of	O
anxiety	O
,	O
migraine	O
and	O
glaucoma	O
.	O

Where	O
known	O
,	O
the	O
mode	O
of	O
action	O
in	O
cardiovascular	O
disease	O
is	O
from	O
antagonism	O
of	O
endogenous	O
catecholamine	CHEMICAL
responses	O
in	O
the	O
heart	O
(	O
mainly	O
at	O
beta1-adrenoceptors	GENE-Y
)	O
,	O
while	O
the	O
worrisome	O
side	O
effects	O
of	O
bronchospasm	O
result	O
from	O
airway	O
beta2-adrenoceptor	GENE-Y
blockade	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
selectivity	O
of	O
beta-antagonists	O
for	O
the	O
human	GENE-N
beta-adrenoceptor	GENE-N
subtypes	O
.	O

(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
H-CGP	CHEMICAL
12177	CHEMICAL
whole	O
cell-binding	O
studies	O
were	O
undertaken	O
in	O
CHO	O
cell	O
lines	O
stably	O
expressing	O
either	O
the	O
human	GENE-N
beta1-	GENE-N
,	GENE-N
beta2-	GENE-N
or	GENE-N
the	GENE-N
beta3-adrenoceptor	GENE-N
in	O
order	O
to	O
determine	O
the	O
affinity	O
of	O
ligands	O
for	O
each	O
receptor	O
subtype	O
in	O
the	O
same	O
cell	O
background	O
.	O

In	O
this	O
study	O
,	O
the	O
selectivity	O
of	O
well-known	O
subtype-selective	O
ligands	O
was	O
clearly	O
demonstrated	O
:	O
thus	O
,	O
the	O
selective	O
beta1	O
antagonist	O
CGP	CHEMICAL
20712A	CHEMICAL
was	O
501-fold	O
selective	O
over	O
beta2	O
and	O
4169-fold	O
selective	O
over	O
beta3;	O
the	O
beta2-selective	O
antagonist	O
ICI	CHEMICAL
118551	CHEMICAL
was	O
550-	O
and	O
661-fold	O
selective	O
over	O
beta1	O
and	O
beta3	O
,	O
respectively	O
,	O
and	O
the	O
selective	O
beta3	O
compound	O
CL	CHEMICAL
316243	CHEMICAL
was	O
10-fold	O
selective	O
over	O
beta2	O
and	O
more	O
than	O
129-fold	O
selective	O
over	O
beta1	O
.	O

Those	O
beta2-adrenoceptor	GENE-Y
agonists	O
used	O
clinically	O
for	O
the	O
treatment	O
of	O
asthma	O
and	O
COPD	O
were	O
beta2	O
selective	O
:	O
29-	O
,	O
61-	O
and	O
2818-fold	O
for	O
salbutamol	CHEMICAL
,	O
terbutaline	CHEMICAL
and	O
salmeterol	CHEMICAL
over	O
beta1	O
,	O
respectively	O
.	O

There	O
was	O
little	O
difference	O
in	O
the	O
affinity	O
of	O
these	O
ligands	O
between	O
beta1	GENE-N
and	GENE-N
beta3	GENE-N
adrenoceptors	GENE-N
.	O

The	O
clinically	O
used	O
beta-antagonists	O
studied	O
ranged	O
from	O
bisoprolol	CHEMICAL
(	O
14-fold	O
beta1-selective	O
)	O
to	O
timolol	CHEMICAL
(	O
26-fold	O
beta2-selective	O
)	O
.	O

However	O
,	O
the	O
majority	O
showed	O
little	O
selectivity	O
for	O
the	O
beta1-	O
over	O
the	O
beta2-adrenoceptor	GENE-Y
,	O
with	O
many	O
actually	O
being	O
more	O
beta2-selective	O
.	O

This	O
study	O
shows	O
that	O
the	O
beta1	O
/	O
beta2	O
selectivity	O
of	O
most	O
clinically	O
used	O
beta-blockers	O
is	O
poor	O
in	O
intact	O
cells	O
,	O
and	O
that	O
some	O
compounds	O
that	O
are	O
traditionally	O
classed	O
as	O
"beta1-selective"	O
actually	O
have	O
higher	O
affinity	O
for	O
the	O
beta2-adrenoceptor	GENE-Y
.	O

There	O
is	O
therefore	O
considerable	O
potential	O
for	O
developing	O
more	O
selective	O
beta-antagonists	O
for	O
clinical	O
use	O
and	O
thereby	O
reducing	O
the	O
side-effect	O
profile	O
of	O
beta-blockers	O
.	O
Impact	O
of	O
glucose	CHEMICAL
infusion	O
on	O
the	O
structural	O
and	O
functional	O
characteristics	O
of	O
adipose	O
tissue	O
and	O
on	O
hypothalamic	O
gene	O
expression	O
for	O
appetite	GENE-N
regulatory	GENE-N
neuropeptides	GENE-N
in	O
the	O
sheep	O
fetus	O
during	O
late	O
gestation	O
.	O
Buckwheat	O
(	O
Fagopyrum	O
esculentum	O
Moench	O
)	O
groats	O
contain	O
the	O
iminosugar	O
D-fagomine	CHEMICAL
as	O
a	O
minor	O
component	O
that	O
might	O
contribute	O
to	O
the	O
alleged	O
health	O
benefits	O
of	O
this	O
pseudo-cereal	O
.	O

This	O
study	O
presents	O
analysis	O
of	O
D-fagomine	CHEMICAL
in	O
buckwheat-based	O
foodstuffs	O
by	O
liquid	O
chromatography	O
coupled	O
to	O
mass	O
spectrometry	O
and	O
an	O
estimation	O
of	O
its	O
presence	O
in	O
the	O
human	O
diet	O
based	O
on	O
a	O
published	O
population-based	O
cross-sectional	O
nutrition	O
survey	O
.	O

D-fagomine	CHEMICAL
is	O
present	O
in	O
common	O
buckwheat-based	O
foodstuffs	O
in	O
amounts	O
ranging	O
from	O
1	O
to	O
25	O
mg	O
/	O
kg	O
or	O
mg	O
/	O
L	O
,	O
it	O
is	O
stable	O
during	O
boiling	O
,	O
baking	O
,	O
frying	O
and	O
fermentation	O
,	O
and	O
it	O
is	O
biosynthesised	O
upon	O
sprouting	O
.	O

The	O
estimated	O
total	O
intake	O
of	O
D-fagomine	CHEMICAL
resulting	O
from	O
a	O
diet	O
that	O
includes	O
such	O
foodstuffs	O
would	O
be	O
between	O
3	O
and	O
17	O
mg	O
per	O
day	O
(	O
mean	O
for	O
both	O
genders;	O
range	O
from	O
P5	O
to	O
P95	O
)	O
.	O

A	O
diet	O
rich	O
in	O
buckwheat	O
products	O
would	O
provide	O
a	O
daily	O
amount	O
of	O
D-fagomine	CHEMICAL
that	O
may	O
in	O
part	O
explain	O
the	O
beneficial	O
properties	O
traditionally	O
attributed	O
to	O
buckwheat	O
consumption	O
.	O
Predictive	O
modeling	O
of	O
insulin	GENE-Y
release	O
profile	O
from	O
cross-linked	O
chitosan	O
microspheres	O
.	O
The	O
effects	O
of	O
pentoxifylline	CHEMICAL
on	O
the	O
myocardial	O
inflammation	O
and	O
ischemia-reperfusion	O
injury	O
during	O
cardiopulmonary	O
bypass	O
.	O
Serine	GENE-N
hydroxymethyltransferase	O
isoforms	O
are	O
differentially	O
inhibited	O
by	O
leucovorin	CHEMICAL
:	O
characterization	O
and	O
comparison	O
of	O
recombinant	O
zebrafish	GENE-N
serine	CHEMICAL
hydroxymethyltransferases	O
.	O
Receptors	O
for	O
prostaglandin	CHEMICAL
E	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
that	O
regulate	O
cellular	O
immune	O
responses	O
in	O
the	O
mouse	O
.	O
Quercetin	CHEMICAL
ameliorate	O
insulin	GENE-Y
resistance	O
and	O
up-regulates	O
cellular	O
antioxidants	O
during	O
oleic	CHEMICAL
acid	CHEMICAL
induced	O
hepatic	O
steatosis	O
in	O
HepG2	O
cells	O
.	O
Polyamines	CHEMICAL
,	O
androgens	CHEMICAL
,	O
and	O
skeletal	O
muscle	O
hypertrophy	O
.	O
Effect	O
of	O
miR-21	GENE-Y
on	O
Renal	O
Fibrosis	O
by	O
Regulating	O
MMP-9	GENE-Y
and	O
TIMP1	GENE-Y
in	O
kk-ay	O
Diabetic	O
Nephropathy	O
Mice	O
.	O
Pharmacodynamics	O
,	O
chiral	O
pharmacokinetics	O
,	O
and	O
pharmacokinetic-pharmacodynamic	O
modeling	O
of	O
fenoprofen	CHEMICAL
in	O
patients	O
with	O
diabetes	O
mellitus	O
.	O
Pharmacodynamic	O
characteristics	O
of	O
lixisenatide	O
once	O
daily	O
versus	O
liraglutide	O
once	O
daily	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
insufficiently	O
controlled	O
on	O
metformin	CHEMICAL
.	O
OBJECTIVE	O
:	O
Angiotensin	CHEMICAL
II-receptor	O
blockers	O
are	O
an	O
established	O
class	O
of	O
antihypertensive	O
agents	O
,	O
but	O
the	O
differences	O
between	O
individual	O
members	O
of	O
the	O
class	O
are	O
largely	O
unknown	O
.	O

The	O
present	O
study	O
employed	O
an	O
animal	O
model	O
to	O
demonstrate	O
angiotensin	GENE-N
II-receptor	O
blocker-specific	O
effects	O
and	O
to	O
quantify	O
these	O
differences	O
by	O
comparing	O
two	O
common	O
agents	O
,	O
losartan	CHEMICAL
and	O
valsartan	CHEMICAL
.	O

METHODS	O
:	O
We	O
measured	O
the	O
effects	O
on	O
angiotensin	GENE-Y
II	GENE-Y
AT2-receptor-mediated	O
renal	O
cGMP	CHEMICAL
by	O
microdialysis	O
in	O
the	O
outer	O
renal	O
cortex	O
in	O
conscious	O
normotensive	O
,	O
sodium-depleted	O
,	O
4-week-old	O
Sprague-Dawley	O
rats	O
.	O

Rats	O
(	O
n	O
=	O
8	O
)	O
were	O
given	O
equimolar	O
and	O
equidepressor	O
doses	O
of	O
losartan	CHEMICAL
(	O
0	O
.	O
02	O
mmol	O
/	O
kg	O
)	O
or	O
valsartan	CHEMICAL
(	O
0	O
.	O
02	O
mmol	O
/	O
kg	O
)	O
either	O
intravenously	O
or	O
orally	O
.	O

Time	O
was	O
allowed	O
for	O
the	O
conversion	O
of	O
losartan	CHEMICAL
into	O
its	O
active	O
metabolite	O
,	O
EXP	CHEMICAL
3174	CHEMICAL
.	O

RESULTS	O
:	O
Both	O
drugs	O
had	O
equal	O
effects	O
on	O
blood	O
pressure	O
.	O

There	O
were	O
significantly	O
greater	O
increases	O
in	O
cGMP	CHEMICAL
levels	O
after	O
administration	O
of	O
valsartan	CHEMICAL
than	O
of	O
losartan	CHEMICAL
with	O
both	O
routes	O
of	O
administration	O
.	O

Intravenous	O
administration	O
of	O
valsartan	CHEMICAL
led	O
to	O
a	O
69	O
.	O
1%	O
increase	O
in	O
cGMP	CHEMICAL
,	O
versus	O
a	O
10	O
.	O
3%	O
increase	O
with	O
losartan	CHEMICAL
.	O

Five	O
hours	O
after	O
oral	O
administration	O
of	O
valsartan	CHEMICAL
,	O
a	O
48%	O
increase	O
in	O
cGMP	CHEMICAL
was	O
observed	O
versus	O
a	O
10	O
.	O
9%	O
increase	O
with	O
losartan	CHEMICAL
.	O

The	O
increase	O
after	O
oral	O
administration	O
of	O
valsartan	CHEMICAL
was	O
sustained	O
8	O
h	O
after	O
administration	O
,	O
whereas	O
the	O
effect	O
of	O
losartan	CHEMICAL
was	O
not	O
sustained	O
.	O

The	O
effects	O
of	O
losartan	CHEMICAL
and	O
valsartan	CHEMICAL
on	O
cGMP	CHEMICAL
were	O
completely	O
inhibited	O
by	O
AT2-receptor	O
blockade	O
.	O

CONCLUSION	O
:	O
The	O
results	O
indicate	O
that	O
AT1-receptor	O
blockade	O
with	O
valsartan	CHEMICAL
influences	O
AT2-receptor-mediated	O
angiotensin	GENE-Y
II	GENE-Y
responses	O
to	O
a	O
greater	O
extent	O
than	O
with	O
losartan	CHEMICAL
,	O
as	O
quantified	O
by	O
renal	O
interstitial	O
fluid	O
cGMP	CHEMICAL
.	O
The	O
lymphocyte	GENE-Y
function-associated	GENE-Y
antigen	GENE-Y
(	O
LFA-1	GENE-Y
)	O
belongs	O
to	O
the	O
family	O
of	O
beta2-integrins	GENE-Y
and	O
plays	O
an	O
important	O
role	O
in	O
T-cell	O
activation	O
and	O
leukocyte	O
migration	O
to	O
sites	O
of	O
inflammation	O
.	O

We	O
report	O
here	O
that	O
lovastatin	CHEMICAL
,	O
a	O
drug	O
clinically	O
used	O
for	O
lowering	O
cholesterol	CHEMICAL
levels	O
,	O
inhibits	O
the	O
interaction	O
of	O
human	GENE-Y
LFA-1	GENE-Y
with	O
its	O
counter-receptor	O
intercellular	GENE-Y
adhesion	GENE-Y
molecule-1	GENE-Y
.	O

Using	O
nuclear	O
magnetic	O
resonance	O
spectroscopy	O
and	O
X-ray	O
crystallography	O
we	O
show	O
that	O
the	O
inhibitor	O
binds	O
to	O
a	O
highly	O
conserved	O
domain	O
of	O
the	O
LFA-1	GENE-Y
alpha-chain	GENE-Y
called	O
the	O
I-domain	GENE-N
.	O

The	O
first	O
three-dimensional	O
structure	O
of	O
an	O
integrin	GENE-N
inhibitor	O
bound	O
to	O
its	O
receptor	O
reveals	O
atomic	O
details	O
for	O
a	O
hitherto	O
unknown	O
mode	O
of	O
LFA-1	GENE-Y
inhibition	O
.	O

It	O
also	O
sheds	O
light	O
into	O
possible	O
mechanisms	O
of	O
LFA-1	GENE-Y
mediated	O
signalling	O
and	O
will	O
support	O
the	O
design	O
of	O
novel	O
anti-adhesive	O
and	O
immunosuppressive	O
drugs	O
.	O
Antidepressants	O
suppress	O
production	O
of	O
the	O
Th1	O
cytokine	GENE-N
interferon-gamma	GENE-Y
,	O
independent	O
of	O
monoamine	GENE-N
transporter	O
blockade	O
.	O
GluR5	GENE-Y
kainate	GENE-N
receptors	O
,	O
seizures	O
,	O
and	O
the	O
amygdala	O
.	O
INTRODUCTION	O
:	O
The	O
recently	O
approved	O
angiotensin	GENE-Y
II	GENE-Y
(	O
Ang	CHEMICAL
II	CHEMICAL
)	O
type	O
1	O
(	O
AT1	GENE-Y
)	O
receptor	O
blocker	O
(	O
ARB	O
)	O
azilsartan	O
strongly	O
reduces	O
blood	O
pressure	O
(	O
BP	O
)	O
in	O
patients	O
with	O
hypertension	O
.	O

We	O
previously	O
reported	O
that	O
azilsartan	CHEMICAL
showed	O
unique	O
binding	O
behavior	O
to	O
the	O
AT1	GENE-Y
receptor	O
because	O
of	O
its	O
5-oxo-1	CHEMICAL
,	CHEMICAL
2	CHEMICAL
,	CHEMICAL
4-oxadiazole	CHEMICAL
moiety	O
.	O

However	O
,	O
the	O
ability	O
of	O
azilsartan	CHEMICAL
to	O
block	O
Ang	GENE-Y
II-dependent	O
AT1	GENE-Y
receptor	O
activation	O
is	O
not	O
yet	O
clear	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Azilsartan	CHEMICAL
and	O
a	O
derivative	O
of	O
azilsartan	CHEMICAL
(	O
azilsartan-7H	CHEMICAL
)	O
that	O
lacks	O
a	O
carboxyl	O
group	O
at	O
the	O
benzimidazole	CHEMICAL
ring	O
were	O
used	O
.	O

Ang	GENE-Y
II-induced	O
inositol	CHEMICAL
phosphate	CHEMICAL
(	O
IP	CHEMICAL
)	O
production	O
and	O
extracellular	GENE-N
signal-regulated	GENE-N
kinase	GENE-N
(	O
ERK	GENE-N
)	O
activation	O
were	O
analyzed	O
in	O
a	O
cell-based	O
wash-out	O
assay	O
.	O

RESULTS	O
:	O
Azilsartan	CHEMICAL
,	O
but	O
not	O
azilsartan-7H	CHEMICAL
,	O
completely	O
blocked	O
Ang	GENE-Y
II-induced	O
IP	O
production	O
and	O
ERK	GENE-N
activation	O
.	O

Our	O
previous	O
report	O
demonstrated	O
that	O
azilsartan	CHEMICAL
mainly	O
interacts	O
with	O
Tyr	CHEMICAL
(	O
113	O
)	O
,	O
Lys	CHEMICAL
(	O
199	O
)	O
,	O
and	O
Gln	CHEMICAL
(	O
257	O
)	O
in	O
the	O
AT1	GENE-Y
receptor	O
.	O

The	O
interactions	O
between	O
azilsartan	CHEMICAL
and	O
Tyr	CHEMICAL
(	O
113	O
)	O
and	O
Gln	CHEMICAL
(	O
257	O
)	O
,	O
but	O
not	O
Lys	CHEMICAL
(	O
199	O
)	O
,	O
were	O
critical	O
for	O
blocking	O
Ang	CHEMICAL
II-induced	O
IP	CHEMICAL
production	O
and	O
ERK	GENE-N
activation	O
after	O
wash-out	O
.	O

CONCLUSIONS	O
:	O
Although	O
our	O
findings	O
regarding	O
the	O
molecule-specific	O
effects	O
of	O
azilsartan	CHEMICAL
are	O
based	O
on	O
basic	O
research	O
,	O
they	O
may	O
lead	O
to	O
an	O
exciting	O
insight	O
into	O
the	O
mechanism	O
of	O
azilsartan	CHEMICAL
.	O
There	O
is	O
an	O
increasing	O
body	O
of	O
evidence	O
demonstrating	O
that	O
growth	O
factor	O
networks	O
are	O
highly	O
interactive	O
with	O
oestrogen	GENE-Y
receptor	O
(	O
ER	GENE-Y
)	O
signalling	O
in	O
the	O
control	O
of	O
breast	O
cancer	O
growth	O
.	O

As	O
such	O
,	O
tumour	O
responses	O
to	O
anti-	O
hormones	O
are	O
likely	O
to	O
be	O
a	O
composite	O
of	O
the	O
ER	GENE-Y
and	O
growth	O
factor	O
inhibitory	O
activity	O
of	O
these	O
agents	O
.	O

The	O
current	O
article	O
examines	O
the	O
modulation	O
of	O
growth	O
factor	O
networks	O
during	O
endocrine	O
response	O
,	O
and	O
presents	O
in	O
vitro	O
and	O
clinical	O
evidence	O
that	O
epidermal	GENE-Y
growth	GENE-Y
factor	GENE-Y
receptor	GENE-Y
signalling	O
,	O
maintained	O
in	O
either	O
an	O
ER-dependent	O
or	O
-independent	O
manner	O
,	O
is	O
critical	O
to	O
anti-	O
hormonal-resistant	O
breast	O
cancer	O
cell	O
growth	O
.	O

The	O
considerable	O
potential	O
of	O
the	O
epidermal	GENE-Y
growth	GENE-Y
factor	GENE-Y
receptor-selective	O
tyrosine	CHEMICAL
kinase	O
inhibitor	O
,	O
ZD	CHEMICAL
1839	CHEMICAL
(	O
Iressa;	O
AstraZeneca	O
)	O
to	O
efficiently	O
treat	O
,	O
and	O
perhaps	O
even	O
prevent	O
,	O
endocrine-resistant	O
breast	O
cancer	O
is	O
highlighted	O
.	O
The	O
long	O
QT-related	O
arrhythmia	O
torsades	O
de	O
pointes	O
(	O
TdP	O
)	O
can	O
arise	O
with	O
mutations	O
in	O
HERG	GENE-Y
and	O
during	O
treatment	O
with	O
drugs	O
that	O
block	O
cardiac	O
I	GENE-Y
Kr	GENE-Y
,	O
the	O
current	O
encoded	O
by	O
HERG	GENE-Y
.	O

Multiple	O
test	O
systems	O
have	O
been	O
used	O
to	O
assess	O
drug	O
block	O
of	O
I	GENE-Y
Kr	GENE-Y
.	O

This	O
study	O
evaluated	O
the	O
I	GENE-Y
Kr	GENE-Y
blocking	O
potency	O
of	O
a	O
series	O
of	O
antiarrhythmics	O
associated	O
with	O
a	O
range	O
of	O
clinical	O
risks	O
of	O
TdP	O
in	O
two	O
such	O
systems	O
:	O
mouse	O
AT-1	O
cells	O
(	O
in	O
which	O
I	GENE-Y
Kr	GENE-Y
is	O
the	O
major	O
repolarizing	O
current	O
)	O
and	O
Ltk	O
cells	O
transiently	O
transfected	O
with	O
HERG	GENE-Y
(	O
n	O
=	O
4-10	O
cells	O
per	O
drug	O
)	O
.	O

For	O
each	O
compound	O
,	O
the	O
concentration	O
required	O
to	O
produce	O
50%	O
block	O
of	O
I	GENE-Y
Kr	GENE-Y
or	O
HERG	GENE-Y
tail	O
currents	O
(	O
IC	O
50	O
)	O
was	O
determined	O
.	O

There	O
was	O
an	O
excellent	O
correlation	O
(	O
r	O
=	O
0	O
.	O
98	O
,	O
p	O
<	O
10	O
-5	O
)	O
between	O
values	O
obtained	O
in	O
the	O
two	O
systems	O
.	O

However	O
,	O
the	O
relation	O
between	O
the	O
liability	O
of	O
a	O
drug	O
to	O
cause	O
TdP	O
appeared	O
dissociated	O
from	O
I	GENE-Y
Kr	GENE-Y
blocking	O
potency	O
.	O

Quinidine	CHEMICAL
,	O
dofetilide	CHEMICAL
,	O
ibutilide	CHEMICAL
,	O
procainamide	CHEMICAL
,	O
and	O
disopyramide	CHEMICAL
are	O
all	O
associated	O
with	O
TdP	O
,	O
but	O
only	O
the	O
first	O
three	O
were	O
potent	O
blockers	O
(	O
IC	O
50	O
<	O
or	O
=	O
1	O
microM	O
)	O
,	O
whereas	O
procainamide	CHEMICAL
and	O
disopyramide	CHEMICAL
were	O
not	O
(	O
IC	O
50	O
>	O
50	O
microM	O
)	O
.	O

Conversely	O
,	O
verapamil	CHEMICAL
and	O
amiodarone	CHEMICAL
,	O
drugs	O
not	O
associated	O
with	O
TdP	O
,	O
were	O
also	O
blockers	O
(	O
IC	O
50	O
<	O
or	O
=	O
1	O
microM	O
)	O
.	O

We	O
conclude	O
that	O
I	GENE-Y
Kr	GENE-Y
blocking	O
potency	O
can	O
be	O
readily	O
assessed	O
in	O
either	O
AT-1	O
cells	O
or	O
systems	O
in	O
which	O
HERG	GENE-Y
is	O
heterologously	O
expressed	O
.	O

However	O
,	O
not	O
all	O
drugs	O
causing	O
TdP	O
are	O
potent	O
I	GENE-Y
Kr	GENE-Y
blockers	O
,	O
and	O
I	GENE-Y
Kr	GENE-Y
block	O
is	O
not	O
necessarily	O
associated	O
with	O
TdP	O
.	O

Other	O
properties	O
of	O
these	O
drugs	O
,	O
therefore	O
,	O
contribute	O
to	O
their	O
propensity	O
to	O
cause	O
TdP	O
.	O
Limited	O
availability	O
of	O
L-arginine	CHEMICAL
increases	O
DNA-binding	O
activity	O
of	O
NF-kappaB	GENE-N
and	O
contributes	O
to	O
regulation	O
of	O
iNOS	GENE-Y
expression	O
.	O
Androgen	CHEMICAL
/	O
androgen	GENE-Y
receptor	O
pathway	O
regulates	O
expression	O
of	O
the	O
genes	O
for	O
cyclooxygenase-2	GENE-Y
and	O
amphiregulin	GENE-Y
in	O
periovulatory	O
granulosa	O
cells	O
.	O
A	O
series	O
of	O
phosphorylated	CHEMICAL
flavonoids	CHEMICAL
were	O
synthesized	O
and	O
investigated	O
in	O
vitro	O
as	O
inhibitors	O
of	O
pancreatic	O
cholesterol	GENE-Y
esterase	O
(	O
CEase	GENE-Y
)	O
and	O
acetylcholinesterase	GENE-Y
(	O
AChE	GENE-Y
)	O
.	O

The	O
results	O
showed	O
that	O
most	O
of	O
the	O
synthesized	O
compounds	O
exhibited	O
nanomolar	O
potency	O
against	O
CEase	GENE-Y
,	O
much	O
better	O
than	O
the	O
parent	O
flavonoids	CHEMICAL
.	O

Furthermore	O
,	O
these	O
phosphorylated	CHEMICAL
flavonoids	CHEMICAL
demonstrated	O
good	O
to	O
high	O
selectivity	O
for	O
CEase	GENE-Y
over	O
AChE	GENE-Y
,	O
which	O
only	O
showed	O
micromolar	O
potency	O
inhibition	O
of	O
AChE	GENE-Y
.	O

The	O
most	O
selective	O
and	O
potent	O
inhibitor	O
of	O
CEase	GENE-Y
(	O
3e	O
)	O
had	O
IC50	O
value	O
of	O
0	O
.	O
72	O
nM	O
and	O
11800-fold	O
selectivity	O
for	O
CEase	GENE-Y
over	O
AChE	GENE-Y
.	O

The	O
structure-activity	O
relationships	O
revealed	O
that	O
the	O
free	O
hydroxyl	CHEMICAL
group	O
at	O
position	O
5	O
and	O
phosphate	CHEMICAL
group	O
at	O
position	O
7	O
of	O
the	O
phosphorylated	CHEMICAL
flavonoids	CHEMICAL
are	O
favorable	O
to	O
the	O
inhibition	O
of	O
CEase	GENE-Y
.	O

The	O
inhibition	O
mechanism	O
and	O
kinetic	O
characterization	O
studies	O
indicated	O
that	O
they	O
are	O
irreversible	O
competitive	O
inhibitors	O
of	O
CEase	GENE-Y
.	O
In	O
this	O
study	O
seven	O
published	O
methods	O
of	O
extraction	O
of	O
skin	O
free	O
and	O
bound	O
volatile	O
compounds	O
have	O
been	O
compared	O
.	O

The	O
free	O
and	O
bound	O
volatiles	O
were	O
separated	O
by	O
solid	O
phase	O
extraction	O
(	O
SPE	O
)	O
and	O
then	O
analysed	O
by	O
gas	O
chromatography	O
coupled	O
with	O
mass	O
spectrometry	O
(	O
GC-MS	O
)	O
.	O

The	O
results	O
showed	O
that	O
the	O
extraction	O
of	O
volatile	O
compounds	O
from	O
grapes	O
is	O
highly	O
affected	O
by	O
extraction	O
solution	O
features	O
.	O

The	O
solution	O
at	O
pH	O
3	O
.	O
2	O
and	O
0%	O
ethanol	CHEMICAL
resulted	O
the	O
most	O
effective	O
as	O
it	O
led	O
to	O
the	O
extraction	O
of	O
a	O
higher	O
number	O
and	O
amount	O
of	O
free	O
and	O
glycosilated	O
volatile	O
compounds	O
.	O

The	O
selected	O
extraction	O
method	O
of	O
grape	O
skin	O
and	O
the	O
process	O
of	O
pulp	O
juice	O
were	O
validated	O
for	O
quantitative	O
determination	O
of	O
a	O
wide	O
range	O
of	O
grape	O
aroma	O
compounds	O
.	O

A	O
total	O
of	O
37	O
free	O
and	O
bound	O
grape	O
aroma	O
compounds	O
were	O
quantified	O
by	O
GC-MS	O
in	O
selective	O
ion	O
monitoring	O
modality	O
(	O
SIM	O
)	O
.	O

Among	O
them	O
,	O
26	O
volatile	O
compounds	O
resulted	O
validated	O
in	O
grape	O
skin	O
and	O
pulp	O
juice	O
.	O
Monoacylglycerol	GENE-Y
lipase	O
inhibition-induced	O
changes	O
in	O
plasma	O
corticosterone	CHEMICAL
levels	O
,	O
anxiety	O
and	O
locomotor	O
activity	O
in	O
male	O
CD1	O
mice	O
.	O
Suppression	O
by	O
cetirizine	CHEMICAL
of	O
pleurisy	O
triggered	O
by	O
antigen	O
in	O
actively	O
sensitized	O
rats	O
.	O
Similar	O
pyruvate	CHEMICAL
kinase	O
modifications	O
in	O
glioblastoma	O
cells	O
by	O
7β-hydroxycholesterol	CHEMICAL
and	O
glutamine	CHEMICAL
withdrawal	O
.	O
A	O
novel	O
mechanism	O
of	O
action	O
of	O
tetracyclines	CHEMICAL
:	O
effects	O
on	O
nitric	GENE-N
oxide	GENE-N
synthases	O
.	O
The	O
cDNA	O
encoding	O
PH-20	GENE-Y
hyaluronidase	GENE-Y
from	O
human	O
sperm	O
has	O
been	O
mutated	O
at	O
five	O
positions	O
by	O
in	O
vitro	O
mutagenesis	O
.	O

We	O
have	O
changed	O
three	O
acidic	CHEMICAL
amino	CHEMICAL
acids	CHEMICAL
and	O
two	O
arginine	CHEMICAL
residues	O
that	O
are	O
conserved	O
in	O
the	O
sequence	O
of	O
mammalian	O
PH-20	GENE-N
polypeptides	O
as	O
well	O
as	O
in	O
the	O
hyaluronidases	GENE-N
from	O
bee	O
and	O
hornet	O
venom	O
.	O

Of	O
the	O
former	O
,	O
the	O
mutants	O
[	O
Gln113	O
]	O
PH-20	GENE-Y
and	O
[	O
Gln249	O
]	O
PH-20	GENE-Y
had	O
no	O
detectable	O
enzymatic	O
activity;	O
the	O
mutant	O
[	O
Asn111	O
]	O
PH-20	GENE-Y
had	O
about	O
3%	O
activity	O
.	O

The	O
mutant	O
[	O
Thr252	O
]	O
PH-20	GENE-Y
was	O
also	O
inactive	O
,	O
while	O
[	O
Gly176	O
]	O
PH-20	GENE-Y
had	O
only	O
about	O
1%	O
activity	O
.	O

This	O
indicates	O
that	O
the	O
PH-20	GENE-Y
hyaluronidases	GENE-Y
,	O
like	O
numerous	O
enzymes	O
that	O
hydrolyze	O
glycosidic	O
bonds	O
,	O
have	O
acidic	CHEMICAL
amino	CHEMICAL
acids	CHEMICAL
in	O
their	O
active	O
site	O
.	O

Moreover	O
,	O
for	O
the	O
binding	O
of	O
the	O
substrate	O
,	O
the	O
polyanion	O
hyaluronan	O
,	O
arginine	CHEMICAL
residues	O
appear	O
to	O
be	O
essential	O
.	O
The	O
Interaction	O
of	O
Adrenomedullin	GENE-Y
and	O
Macrophages	O
Induces	O
Ovarian	O
Cancer	O
Cell	O
Migration	O
via	O
Activation	O
of	O
RhoA	GENE-Y
Signaling	O
Pathway	O
.	O
Increased	O
levels	O
of	O
free	CHEMICAL
fatty	CHEMICAL
acids	CHEMICAL
(	O
FFAs	CHEMICAL
)	O
,	O
specifically	O
saturated	CHEMICAL
free	CHEMICAL
fatty	CHEMICAL
acids	CHEMICAL
such	O
as	O
palmitate	CHEMICAL
are	O
associated	O
with	O
insulin	GENE-Y
resistance	O
of	O
muscle	O
,	O
fat	O
and	O
liver	O
.	O

Skeletal	O
muscle	O
,	O
responsible	O
for	O
up	O
to	O
80%	O
of	O
the	O
glucose	CHEMICAL
disposal	O
from	O
the	O
peripheral	O
circulation	O
,	O
is	O
particularly	O
vulnerable	O
to	O
increased	O
levels	O
of	O
saturated	O
FFAs	CHEMICAL
.	O

Rooibos	O
(	O
Aspalathus	O
linearis	O
)	O
and	O
its	O
unique	O
dihydrochalcone	CHEMICAL
C-glucoside	CHEMICAL
,	O
aspalathin	CHEMICAL
,	O
shown	O
to	O
reduce	O
hyperglycemia	O
in	O
diabetic	O
rats	O
,	O
could	O
play	O
a	O
role	O
in	O
preventing	O
or	O
ameliorating	O
the	O
development	O
of	O
insulin	GENE-N
resistance	O
.	O

This	O
study	O
aims	O
to	O
establish	O
whether	O
rooibos	O
can	O
ameliorate	O
experimentally-induced	O
insulin-resistance	O
in	O
C2C12	O
skeletal	O
muscle	O
cells	O
.	O

Palmitate-induced	O
insulin	O
resistant	O
C2C12	O
cells	O
were	O
treated	O
with	O
an	O
aspalathin-enriched	O
green	O
(	O
unfermented	O
)	O
rooibos	O
extract	O
(	O
GRE	O
)	O
,	O
previously	O
shown	O
for	O
its	O
blood	O
glucose	CHEMICAL
lowering	O
effect	O
in	O
vitro	O
and	O
in	O
vivo	O
or	O
an	O
aqueous	O
extract	O
of	O
fermented	O
rooibos	O
(	O
FRE	O
)	O
.	O

Glucose	CHEMICAL
uptake	O
and	O
mitochondrial	O
activity	O
were	O
measured	O
using	O
2-deoxy-	CHEMICAL
[	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
H	CHEMICAL
]	CHEMICAL
-d-glucose	CHEMICAL
,	O
MTT	CHEMICAL
and	O
ATP	CHEMICAL
assays	O
,	O
respectively	O
.	O

Expression	O
of	O
proteins	O
relevant	O
to	O
glucose	CHEMICAL
metabolism	O
was	O
analysed	O
by	O
Western	O
blot	O
.	O

GRE	O
contained	O
higher	O
levels	O
of	O
all	O
compounds	O
,	O
except	O
the	O
enolic	O
phenylpyruvic	CHEMICAL
acid-2-O-glucoside	CHEMICAL
and	O
luteolin-7-O-glucoside	CHEMICAL
.	O

Both	O
rooibos	O
extracts	O
increased	O
glucose	CHEMICAL
uptake	O
,	O
mitochondrial	O
activity	O
and	O
ATP	CHEMICAL
production	O
.	O

Compared	O
to	O
FRE	O
,	O
GRE	O
was	O
more	O
effective	O
at	O
increasing	O
glucose	CHEMICAL
uptake	O
and	O
ATP	CHEMICAL
production	O
.	O

At	O
a	O
mechanistic	O
level	O
both	O
extracts	O
down-regulated	O
PKC	GENE-Y
θ	GENE-Y
activation	O
,	O
which	O
is	O
associated	O
with	O
palmitate-induced	O
insulin	GENE-N
resistance	O
.	O

Furthermore	O
,	O
the	O
extracts	O
increased	O
activation	O
of	O
key	O
regulatory	O
proteins	O
(	O
AKT	GENE-Y
and	O
AMPK	GENE-Y
)	O
involved	O
in	O
insulin-dependent	O
and	O
non-insulin	GENE-N
regulated	O
signalling	O
pathways	O
.	O

Protein	O
levels	O
of	O
the	O
glucose	GENE-N
transporter	O
(	O
GLUT4	GENE-Y
)	O
involved	O
in	O
glucose	CHEMICAL
transport	O
via	O
these	O
two	O
pathways	O
were	O
also	O
increased	O
.	O

This	O
in	O
vitro	O
study	O
therefore	O
confirms	O
that	O
rooibos	O
can	O
ameliorate	O
palmitate-induced	O
insulin	GENE-N
resistance	O
in	O
C2C12	O
skeletal	O
muscle	O
cells	O
.	O

Inhibition	O
of	O
PKC	GENE-Y
θ	GENE-Y
activation	O
and	O
increased	O
activation	O
of	O
AMPK	GENE-Y
and	O
AKT	GENE-Y
offer	O
a	O
plausible	O
mechanistic	O
explanation	O
for	O
this	O
ameliorative	O
effect	O
.	O
Inborn	O
errors	O
in	O
the	O
metabolism	O
of	O
glutathione	CHEMICAL
.	O
Suppression	O
of	O
adrenal	O
function	O
by	O
low-dose	O
prednisone	CHEMICAL
:	O
assessment	O
with	O
24-hour	O
urinary	O
steroid	CHEMICAL
hormone	O
profiles--a	O
review	O
of	O
five	O
cases	O
.	O
ACTH	GENE-Y
has	O
been	O
shown	O
to	O
stimulate	O
androgen	CHEMICAL
production	O
by	O
the	O
fetal	O
/	O
neonatal	O
mouse	O
testis	O
through	O
the	O
melanocortin	GENE-Y
type	GENE-Y
2	GENE-Y
receptor	GENE-Y
(	O
MC2R	GENE-Y
)	O
.	O

This	O
study	O
was	O
designed	O
to	O
localize	O
the	O
expression	O
of	O
MC2R	GENE-Y
in	O
the	O
neonatal	O
mouse	O
testis	O
and	O
characterize	O
the	O
effects	O
of	O
ACTH	GENE-Y
on	O
testicular	O
androgen	CHEMICAL
production	O
.	O

Using	O
immunohistochemistry	O
,	O
MC2R	GENE-Y
was	O
localized	O
to	O
the	O
fetal-type	O
Leydig	O
cell	O
population	O
of	O
the	O
neonatal	O
testis	O
.	O

ACTH	GENE-Y
caused	O
a	O
time-dependent	O
increase	O
in	O
cyclic	CHEMICAL
AMP	CHEMICAL
(	O
cAMP	CHEMICAL
)	O
and	O
testosterone	CHEMICAL
production	O
by	O
isolated	O
cells	O
with	O
an	O
increase	O
in	O
cAMP	CHEMICAL
apparent	O
in	O
<	O
3	O
min	O
.	O

There	O
was	O
no	O
additive	O
effect	O
of	O
maximally	O
stimulating	O
doses	O
of	O
ACTH	GENE-Y
and	O
human	GENE-N
chorionic	GENE-N
gonadotropin	GENE-N
(	O
hCG	GENE-N
)	O
.	O

Androgen	O
production	O
in	O
response	O
to	O
ACTH	GENE-Y
and	O
hCG	GENE-N
was	O
reduced	O
by	O
UO126	CHEMICAL
and	O
dexamethasone	CHEMICAL
,	O
which	O
are	O
the	O
inhibitors	O
of	O
ERK1	GENE-N
/	GENE-N
2	GENE-N
and	O
phospholipase	GENE-N
A2	GENE-N
respectively	O
.	O

Expression	O
of	O
mRNA	O
encoding	O
StAR	GENE-Y
was	O
increased	O
fourfold	O
by	O
both	O
ACTH	GENE-Y
and	O
hCG	O
,	O
although	O
expression	O
of	O
mRNA	O
encoding	O
for	O
steroidogenic	O
enzymes	O
was	O
not	O
markedly	O
affected	O
.	O

The	O
potency	O
of	O
N-terminal	O
fragments	O
of	O
ACTH	GENE-Y
to	O
stimulate	O
androgen	CHEMICAL
production	O
was	O
similar	O
to	O
that	O
seen	O
previously	O
in	O
the	O
adrenal	O
.	O

Data	O
indicate	O
that	O
both	O
LH	GENE-N
and	O
ACTH	GENE-Y
,	O
acting	O
through	O
their	O
respective	O
receptors	O
,	O
stimulate	O
steroidogenesis	O
by	O
fetal-type	O
Leydig	O
cells	O
via	O
arachidonic	O
acid	O
,	O
protein	GENE-N
kinase	GENE-N
A	GENE-N
,	O
and	O
ERK1	GENE-N
/	GENE-N
2	GENE-N
activation	O
of	O
StAR	GENE-Y
.	O
As	O
a	O
treatment	O
for	O
dyslipidemia	O
,	O
oral	O
doses	O
of	O
1-3	O
grams	O
of	O
nicotinic	CHEMICAL
acid	CHEMICAL
per	O
day	O
lower	O
serum	O
triglycerides	CHEMICAL
,	O
raise	O
high	O
density	O
lipoprotein	O
cholesterol	CHEMICAL
,	O
and	O
reduce	O
mortality	O
from	O
coronary	O
heart	O
disease	O
(	O
Tavintharan	O
,	O
S	O
.	O

,	O
and	O
Kashyap	O
,	O
M	O
.	O

L	O
.	O

(	O
2001	O
)	O
Curr	O
.	O

Atheroscler	O
.	O

Rep	O
.	O

3	O
,	O
74-82	O
)	O
.	O

These	O
benefits	O
likely	O
result	O
from	O
the	O
ability	O
of	O
nicotinic	CHEMICAL
acid	CHEMICAL
to	O
inhibit	O
lipolysis	O
in	O
adipocytes	O
and	O
thereby	O
reduce	O
serum	O
non-esterified	CHEMICAL
fatty	CHEMICAL
acid	CHEMICAL
levels	O
(	O
Carlson	O
,	O
L	O
.	O

A	O
.	O

(	O
1963	O
)	O
Acta	O
Med	O
.	O

Scand	O
.	O

173	O
,	O
719-722	O
)	O
.	O

In	O
mice	O
,	O
nicotinic	CHEMICAL
acid	CHEMICAL
inhibits	O
lipolysis	O
via	O
PUMA-G	GENE-Y
,	O
a	O
Gi	GENE-N
/	GENE-N
o-coupled	GENE-N
seven-transmembrane	GENE-N
receptor	GENE-N
expressed	O
in	O
adipocytes	O
and	O
activated	O
macrophages	O
(	O
Tunaru	O
,	O
S	O
.	O

,	O
Kero	O
,	O
J	O
.	O

,	O
Schaub	O
,	O
A	O
.	O

,	O
Wufka	O
,	O
C	O
.	O

,	O
Blaukat	O
,	O
A	O
.	O

,	O
Pfeffer	O
,	O
K	O
.	O

,	O
and	O
Offermanns	O
,	O
S	O
.	O

(	O
2003	O
)	O
Nat	O
.	O

Med	O
.	O

9	O
,	O
352-355	O
)	O
.	O

The	O
human	O
ortholog	O
HM74a	GENE-Y
is	O
also	O
a	O
nicotinic	GENE-Y
acid	GENE-Y
receptor	O
and	O
likely	O
has	O
a	O
similar	O
role	O
in	O
anti-lipolysis	O
.	O

Endogenous	O
levels	O
of	O
nicotinic	CHEMICAL
acid	CHEMICAL
are	O
too	O
low	O
to	O
significantly	O
impact	O
receptor	O
activity	O
,	O
hence	O
the	O
natural	O
ligands	O
(	O
s	O
)	O
of	O
HM74a	GENE-Y
/	O
PUMA-G	GENE-Y
remain	O
to	O
be	O
elucidated	O
.	O

Here	O
we	O
show	O
that	O
the	O
fatty	CHEMICAL
acid-derived	O
ketone	CHEMICAL
body	O
(	CHEMICAL
D	CHEMICAL
)	CHEMICAL
-beta-hydroxybutyrate	CHEMICAL
(	O
(	CHEMICAL
D	CHEMICAL
)	CHEMICAL
-beta-OHB	CHEMICAL
)	O
specifically	O
activates	O
PUMA-G	GENE-Y
/	O
HM74a	GENE-Y
at	O
concentrations	O
observed	O
in	O
serum	O
during	O
fasting	O
.	O

Like	O
nicotinic	CHEMICAL
acid	CHEMICAL
,	O
(	CHEMICAL
D	CHEMICAL
)	CHEMICAL
-beta-OHB	CHEMICAL
inhibits	O
mouse	O
adipocyte	O
lipolysis	O
in	O
a	O
PUMA-G-dependent	O
manner	O
and	O
is	O
thus	O
the	O
first	O
endogenous	O
ligand	O
described	O
for	O
this	O
orphan	O
receptor	O
.	O

These	O
findings	O
suggests	O
a	O
homeostatic	O
mechanism	O
for	O
surviving	O
starvation	O
in	O
which	O
(	CHEMICAL
D	CHEMICAL
)	CHEMICAL
-beta-OHB	CHEMICAL
negatively	O
regulates	O
its	O
own	O
production	O
,	O
thereby	O
preventing	O
ketoacidosis	O
and	O
promoting	O
efficient	O
use	O
of	O
fat	O
stores	O
.	O
The	O
mechanisms	O
that	O
can	O
account	O
for	O
the	O
remarkable	O
mammary	O
carcinogenicity	O
of	O
the	O
environmental	O
pollutant	O
6-nitrochrysene	CHEMICAL
(	O
6-NC	CHEMICAL
)	O
in	O
the	O
rat	O
remain	O
elusive	O
.	O

In	O
our	O
previous	O
studies	O
,	O
we	O
identified	O
several	O
6-NC-derived	O
DNA	O
adducts	O
in	O
the	O
rat	O
mammary	O
gland;	O
one	O
major	O
adduct	O
was	O
derived	O
from	O
(	CHEMICAL
±	CHEMICAL
)	CHEMICAL
-trans-1	CHEMICAL
,	CHEMICAL
2-dihydroxy-1	CHEMICAL
,	CHEMICAL
2-dihydro-6-nitrochrysene	CHEMICAL
(	O
1	CHEMICAL
,	CHEMICAL
2-DHD-6-NC	CHEMICAL
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
resolved	O
the	O
racemic	O
(	CHEMICAL
±	CHEMICAL
)	CHEMICAL
-1	CHEMICAL
,	CHEMICAL
2-DHD-6-NC	CHEMICAL
into	O
(	CHEMICAL
-	CHEMICAL
)	CHEMICAL
-	CHEMICAL
[	CHEMICAL
R	CHEMICAL
,	CHEMICAL
R	CHEMICAL
]	CHEMICAL
-	CHEMICAL
and	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-	CHEMICAL
[	CHEMICAL
S	CHEMICAL
,	CHEMICAL
S	CHEMICAL
]	CHEMICAL
-1	CHEMICAL
,	CHEMICAL
2-DHD-6-NC	CHEMICAL
and	O
compared	O
their	O
in	O
vivo	O
mutagenicity	O
and	O
carcinogenicity	O
in	O
the	O
mammary	O
glands	O
of	O
female	O
transgenic	O
(	O
BigBlue	O
F344	O
×	O
Sprague-Dawley	O
)	O
F1	O
rats	O
harboring	O
lacI	O
/	O
cII	O
and	O
Sprague-Dawley	O
rats	O
,	O
respectively	O
.	O

Both	O
[	O
R	O
,	O
R	O
]	O
-	O
and	O
[	O
S	O
,	O
S	O
]	O
-isomers	O
exerted	O
similar	O
mutagenicity	O
and	O
carcinogenicity	O
but	O
were	O
less	O
potent	O
than	O
6-NC	CHEMICAL
.	O

Additional	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
were	O
then	O
performed	O
to	O
explore	O
possible	O
mechanisms	O
that	O
can	O
explain	O
the	O
higher	O
potency	O
of	O
6-NC	CHEMICAL
than	O
1	CHEMICAL
,	CHEMICAL
2-DHD-6-NC	CHEMICAL
.	O

Using	O
ELISA	O
,	O
we	O
found	O
that	O
neither	O
6-NC	CHEMICAL
nor	O
1	CHEMICAL
,	CHEMICAL
2-DHD-6-NC	CHEMICAL
increased	O
the	O
levels	O
of	O
several	O
inflammatory	O
cytokines	GENE-N
in	O
plasma	O
obtained	O
from	O
rats	O
24	O
h	O
after	O
treatment	O
.	O

In	O
MCF-7	O
cells	O
,	O
as	O
determined	O
by	O
immunoblotting	O
,	O
the	O
effects	O
of	O
6-NC	CHEMICAL
and	O
1	CHEMICAL
,	CHEMICAL
2-DHD-6-NC	CHEMICAL
on	O
protein	O
expression	O
(	O
p53	GENE-Y
,	O
Akt	GENE-Y
,	O
p38	GENE-N
,	O
JNK	GENE-N
,	O
c-myc	GENE-Y
,	O
bcl-2	GENE-Y
,	O
PCNA	GENE-Y
,	O
and	O
ERβ	GENE-Y
)	O
were	O
comparable;	O
however	O
,	O
the	O
expressions	O
of	O
AhR	GENE-Y
and	O
ERα	GENE-Y
proteins	O
were	O
decreased	O
by	O
6-NC	CHEMICAL
but	O
not	O
1	CHEMICAL
,	CHEMICAL
2-DHD-6-NC	CHEMICAL
.	O

The	O
expression	O
of	O
both	O
receptors	O
was	O
decreased	O
in	O
mammary	O
tissues	O
of	O
rats	O
treated	O
with	O
6-NC	CHEMICAL
.	O

Our	O
findings	O
suggest	O
that	O
the	O
differential	O
effects	O
of	O
6-NC	CHEMICAL
and	O
1	CHEMICAL
,	CHEMICAL
2-DHD-6-NC	CHEMICAL
on	O
AhR	GENE-Y
and	O
ERα	GENE-Y
could	O
potentially	O
account	O
for	O
the	O
higher	O
carcinogenicity	O
of	O
6-NC	CHEMICAL
in	O
the	O
rat	O
mammary	O
gland	O
.	O
Evidence	O
for	O
a	O
role	O
of	O
dopamine	CHEMICAL
and	O
serotonin	CHEMICAL
in	O
the	O
control	O
of	O
ethanol	CHEMICAL
intake	O
in	O
animals	O
suggests	O
that	O
monoamine	CHEMICAL
oxidase	O
(	O
MAO	GENE-N
)	O
inhibitors	O
,	O
which	O
increase	O
the	O
synaptic	O
availability	O
of	O
serotonin	CHEMICAL
and	O
dopamine	CHEMICAL
by	O
blocking	O
their	O
metabolism	O
,	O
might	O
have	O
efficacy	O
in	O
the	O
treatment	O
of	O
alcohol	CHEMICAL
dependence	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
,	O
therefore	O
,	O
to	O
evaluate	O
several	O
MAO	GENE-N
inhibitors	O
for	O
their	O
capacity	O
to	O
affect	O
ethanol	CHEMICAL
self-administration	O
in	O
rats	O
trained	O
to	O
self-administer	O
ethanol	CHEMICAL
(	O
10%	O
v	O
/	O
v	O
)	O
orally	O
in	O
a	O
free-choice	O
two-lever	O
operant	O
task	O
.	O

The	O
nonselective	O
and	O
irreversible	O
MAO	GENE-N
inhibitors	O
,	O
phenelzine	CHEMICAL
(	O
3-10	O
mg	O
/	O
kg	O
)	O
,	O
tranylcypromine	CHEMICAL
(	O
1-3	O
mg	O
/	O
kg	O
)	O
,	O
and	O
nialamide	CHEMICAL
(	O
30	O
mg	O
/	O
kg	O
)	O
,	O
decreased	O
rates	O
of	O
responding	O
maintained	O
by	O
ethanol	CHEMICAL
reinforcement	O
.	O

The	O
reversible	O
MAO-A	GENE-Y
inhibitor	O
,	O
befloxatone	CHEMICAL
(	O
0	O
.	O
3-3	O
mg	O
/	O
kg	O
)	O
,	O
and	O
the	O
irreversible	O
MAO-A	GENE-Y
inhibitor	O
,	O
clorgyline	CHEMICAL
(	O
10-30	O
mg	O
/	O
kg	O
)	O
,	O
also	O
reduced	O
ethanol	CHEMICAL
self-administration	O
.	O

However	O
,	O
befloxatone-induced	O
effects	O
leveled	O
off	O
at	O
a	O
50%	O
decrease	O
.	O

The	O
irreversible	O
MAO-B	GENE-Y
inhibitors	O
,	O
pargyline	CHEMICAL
(	O
30	O
mg	O
/	O
kg	O
)	O
and	O
l-deprenyl	CHEMICAL
(	O
3-10	O
mg	O
/	O
kg	O
)	O
also	O
decreased	O
responding	O
maintained	O
by	O
ethanol	CHEMICAL
reinforcement;	O
these	O
results	O
are	O
consistent	O
with	O
previous	O
findings	O
that	O
both	O
drugs	O
decreased	O
ethanol	CHEMICAL
intake	O
in	O
mice	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
results	O
showing	O
that	O
several	O
MAO	GENE-N
inhibitors	O
decreased	O
ethanol	CHEMICAL
self-administration	O
in	O
rats	O
are	O
consistent	O
with	O
previous	O
findings	O
that	O
synaptic	O
levels	O
of	O
serotonin	CHEMICAL
and	O
dopamine	CHEMICAL
play	O
a	O
critical	O
role	O
in	O
the	O
control	O
of	O
ethanol	CHEMICAL
self-administration	O
.	O
MLL	GENE-N
histone	GENE-N
methylases	GENE-N
regulate	O
expression	O
of	O
HDLR-SR-B1	GENE-Y
in	O
presence	O
of	O
estrogen	CHEMICAL
and	O
control	O
plasma	O
cholesterol	CHEMICAL
in	O
vivo	O
.	O
Apomorphine	CHEMICAL
induces	O
trophic	O
factors	O
that	O
support	O
fetal	O
rat	O
mesencephalic	O
dopaminergic	O
neurons	O
in	O
cultures	O
.	O
A	O
series	O
of	O
5-	CHEMICAL
and	CHEMICAL
8-methoxypsoralen	CHEMICAL
(	O
MOP	CHEMICAL
)	O
analogs	O
,	O
suitable	O
for	O
structure-antioxidative	O
/	O
anti-inflammatory	O
activity	O
relationship	O
studies	O
,	O
were	O
synthesized	O
using	O
as	O
key-reactions	O
the	O
selective	O
monobromination	O
of	O
MOPs	CHEMICAL
with	O
N-bromosaccharin	CHEMICAL
and	O
either	O
a	O
Heck	O
reaction	O
or	O
a	O
Suzuki	O
coupling	O
or	O
a	O
Suzuki	O
coupling	O
followed	O
by	O
a	O
Wittig	O
reaction	O
to	O
install	O
side-chains	O
of	O
the	O
acrylate-	O
or	O
benzoate-	O
or	O
cinnamate-type	O
,	O
respectively	O
.	O

The	O
8-MOP	CHEMICAL
analogs	O
19	O
and	O
24	O
,	O
incorporating	O
at	O
position	O
5	O
of	O
the	O
psoralen	CHEMICAL
nucleus	O
a	O
butyl	CHEMICAL
acrylate	CHEMICAL
or	O
a	O
tert-butyl	CHEMICAL
cinnamate	CHEMICAL
moiety	O
,	O
were	O
the	O
most	O
powerful	O
inhibitors	O
of	O
soybean	GENE-N
LOX	GENE-N
and	O
inhibited	O
effectively	O
lipid	O
peroxidation	O
.	O

Analog	O
19	O
was	O
a	O
more	O
potent	O
anti-inflammatory	O
agent	O
than	O
the	O
reference	O
compound	O
indomethacin	CHEMICAL
and	O
of	O
comparable	O
cytocompatibility	O
to	O
8-MOP	CHEMICAL
whereas	O
analog	O
24	O
was	O
a	O
weaker	O
inhibitor	O
of	O
inflammation	O
than	O
indomethacin	CHEMICAL
and	O
significantly	O
more	O
cytotoxic	O
than	O
8-MOP	CHEMICAL
.	O

The	O
results	O
of	O
the	O
biological	O
tests	O
are	O
discussed	O
in	O
terms	O
of	O
structural	O
characteristics	O
.	O
1	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
effects	O
of	O
chronic	O
infusion	O
of	O
the	O
long-acting	O
agonist	O
salmeterol	CHEMICAL
on	O
pulmonary	O
beta	GENE-Y
(	GENE-Y
2	GENE-Y
)	GENE-Y
-adrenoceptor	GENE-Y
function	O
in	O
Sprague-Dawley	O
rats	O
in	O
vivo	O
and	O
to	O
elucidate	O
the	O
molecular	O
basis	O
of	O
any	O
altered	O
state	O
.	O

2	O
.	O

Systemic	O
administration	O
of	O
rats	O
with	O
salmeterol	CHEMICAL
for	O
7	O
days	O
compromised	O
the	O
ability	O
of	O
salmeterol	CHEMICAL
and	O
prostaglandin	CHEMICAL
E	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
(	O
PGE	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
)	O
,	O
given	O
acutely	O
by	O
the	O
intravenous	O
route	O
,	O
to	O
protect	O
against	O
ACh-induced	O
bronchoconstriction	O
when	O
compared	O
to	O
rats	O
treated	O
identically	O
with	O
vehicle	O
.	O

3	O
.	O

beta	GENE-N
(	GENE-N
1	GENE-N
)	GENE-N
-	GENE-N
and	GENE-N
beta	GENE-N
(	GENE-N
2	GENE-N
)	GENE-N
-adrenoceptor	GENE-N
density	O
was	O
significantly	O
reduced	O
in	O
lung	O
membranes	O
harvested	O
from	O
salmeterol-treated	O
animals	O
,	O
which	O
was	O
associated	O
with	O
impaired	O
salmeterol-	O
and	O
PGE	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
-induced	O
cyclic	O
AMP	O
accumulation	O
ex	O
vivo	O
.	O

4	O
.	O

Three	O
variants	O
of	O
G	GENE-N
(	GENE-N
s	GENE-N
alpha	GENE-N
)	GENE-N
that	O
migrated	O
as	O
42	O
,	O
44	O
and	O
52	O
kDa	O
peptides	O
on	O
SDS	O
polyacrylamide	O
gels	O
were	O
detected	O
in	O
lung	O
membranes	O
prepared	O
from	O
both	O
groups	O
of	O
rats	O
but	O
the	O
intensity	O
of	O
each	O
isoform	O
was	O
markedly	O
reduced	O
in	O
rats	O
that	O
received	O
salmeterol	CHEMICAL
.	O

5	O
.	O

The	O
activity	O
of	O
cytosolic	O
,	O
but	O
not	O
membrane-associated	O
,	O
G-protein	GENE-N
receptor-coupled	GENE-N
kinase	GENE-N
was	O
elevated	O
in	O
the	O
lung	O
of	O
salmeterol-treated	O
rats	O
when	O
compared	O
to	O
vehicle-treated	O
animals	O
.	O

6	O
.	O

The	O
ability	O
of	O
salmeterol	CHEMICAL
,	O
administered	O
systemically	O
,	O
to	O
protect	O
the	O
airways	O
of	O
untreated	O
rats	O
against	O
ACh-induced	O
bronchoconstriction	O
was	O
short-acting	O
(	O
t	O
(	O
off	O
)	O
approximately	O
45	O
min	O
)	O
,	O
which	O
contrasts	O
with	O
its	O
long-acting	O
nature	O
when	O
given	O
to	O
asthmatic	O
subjects	O
by	O
inhalation	O
.	O

7	O
.	O

These	O
results	O
indicate	O
that	O
chronic	O
treatment	O
of	O
rats	O
with	O
salmeterol	CHEMICAL
results	O
in	O
heterologous	O
desensitization	O
of	O
pulmonary	O
G	GENE-N
(	GENE-N
s	GENE-N
)	GENE-N
-coupled	GENE-N
receptors	GENE-N
.	O

In	O
light	O
of	O
previous	O
data	O
obtained	O
in	O
rats	O
treated	O
chronically	O
with	O
salbutamol	CHEMICAL
,	O
we	O
propose	O
that	O
a	O
primary	O
mechanism	O
responsible	O
for	O
this	O
effect	O
is	O
a	O
reduction	O
in	O
membrane-associated	O
G	GENE-N
(	GENE-N
s	GENE-N
alpha	GENE-N
)	GENE-N
.	O

The	O
short-acting	O
nature	O
of	O
salmeterol	CHEMICAL
,	O
when	O
administered	O
systemically	O
,	O
and	O
the	O
reduction	O
in	O
beta-adrenoceptor	GENE-N
number	O
may	O
be	O
due	O
to	O
metabolism	O
to	O
a	O
biologically-active	O
,	O
short-acting	O
and	O
non-selective	O
beta-adrenoceptor	GENE-N
agonist	O
.	O
Novel	O
locus	O
including	O
FGF21	GENE-Y
is	O
associated	O
with	O
dietary	O
macronutrient	O
intake	O
.	O
Few	O
studies	O
have	O
addressed	O
the	O
delivery	O
of	O
lipoprotein-derived	O
cholesterol	CHEMICAL
to	O
the	O
adrenals	O
for	O
steroid	CHEMICAL
production	O
in	O
humans	O
.	O

While	O
there	O
is	O
evidence	O
against	O
a	O
role	O
for	O
low-density	GENE-N
lipoprotein	GENE-N
(	O
LDL	GENE-N
)	O
,	O
it	O
is	O
unresolved	O
whether	O
high	GENE-N
density	GENE-N
lipoprotein	GENE-N
(	O
HDL	GENE-N
)	O
contributes	O
to	O
adrenal	O
steroidogenesis	O
.	O

To	O
study	O
this	O
,	O
steroid	CHEMICAL
hormone	CHEMICAL
profiles	O
in	O
urine	O
were	O
assessed	O
in	O
male	O
subjects	O
suffering	O
from	O
functional	O
mutations	O
in	O
ATP	GENE-Y
binding	O
cassette	O
transporter	O
A1	O
(	O
ABCA1	GENE-Y
)	O
(	O
n	O
=	O
24	O
)	O
,	O
lecithin	GENE-Y
:	GENE-Y
cholesterol	CHEMICAL
acyltransferase	O
(	O
LCAT	GENE-Y
)	O
(	O
n	O
=	O
40	O
)	O
,	O
as	O
well	O
as	O
in	O
11	O
subjects	O
with	O
low	O
HDL	GENE-N
cholesterol	CHEMICAL
(	O
HDL-C	O
)	O
without	O
ABCA1	GENE-Y
/	O
LCAT	GENE-Y
mutations	O
.	O

HDL-C	O
levels	O
were	O
39%	O
lower	O
in	O
the	O
ABCA1	GENE-Y
,	O
LCAT	GENE-Y
,	O
and	O
low	O
HDL-C	O
groups	O
compared	O
with	O
controls	O
(	O
all	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
all	O
groups	O
with	O
low	O
HDL-C	O
levels	O
,	O
urinary	O
excretion	O
of	O
17-ketogenic	CHEMICAL
steroids	CHEMICAL
was	O
reduced	O
by	O
33%	O
,	O
27%	O
,	O
and	O
32%	O
compared	O
with	O
controls	O
(	O
all	O
P	O
<	O
0	O
.	O
04	O
)	O
.	O

In	O
seven	O
carriers	O
of	O
either	O
type	O
of	O
mutation	O
,	O
adrenocorticotropic	GENE-Y
hormone	GENE-Y
(	O
ACTH	GENE-Y
)	O
stimulation	O
did	O
not	O
reveal	O
differences	O
from	O
normolipidemic	O
controls	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
shows	O
that	O
basal	O
but	O
not	O
stimulated	O
corticosteroid	O
metabolism	O
is	O
attenuated	O
in	O
subjects	O
with	O
low	O
HDL-C	O
,	O
irrespective	O
of	O
its	O
molecular	O
origin	O
.	O

These	O
findings	O
lend	O
support	O
to	O
a	O
role	O
for	O
HDL	GENE-N
as	O
a	O
cholesterol	CHEMICAL
donor	O
for	O
basal	O
adrenal	O
steroidogenesis	O
in	O
humans	O
.	O
Sepracor	O
in	O
the	O
US	O
is	O
developing	O
arformoterol	CHEMICAL
[	O
R	CHEMICAL
,	CHEMICAL
R-formoterol	CHEMICAL
]	O
,	O
a	O
single	O
isomer	O
form	O
of	O
the	O
beta	GENE-Y
(	GENE-Y
2	GENE-Y
)	GENE-Y
-adrenoceptor	GENE-Y
agonist	O
formoterol	CHEMICAL
[	O
eformoterol	CHEMICAL
]	O
.	O

This	O
isomer	O
contains	O
two	O
chiral	O
centres	O
and	O
is	O
being	O
developed	O
as	O
an	O
inhaled	O
preparation	O
for	O
the	O
treatment	O
of	O
respiratory	O
disorders	O
.	O

Sepracor	O
believes	O
that	O
arformoterol	CHEMICAL
has	O
the	O
potential	O
to	O
be	O
a	O
once-daily	O
therapy	O
with	O
a	O
rapid	O
onset	O
of	O
action	O
and	O
a	O
duration	O
of	O
effect	O
exceeding	O
12	O
hours	O
.	O

In	O
1995	O
,	O
Sepracor	O
acquired	O
New	O
England	O
Pharmaceuticals	O
,	O
a	O
manufacturer	O
of	O
metered-dose	O
and	O
dry	O
powder	O
inhalers	O
,	O
for	O
the	O
purpose	O
of	O
preparing	O
formulations	O
of	O
levosalbutamol	CHEMICAL
and	O
arformoterol	CHEMICAL
.	O

Phase	O
II	O
dose-ranging	O
clinical	O
studies	O
of	O
arformoterol	CHEMICAL
as	O
a	O
longer-acting	O
,	O
complementary	O
bronchodilator	O
were	O
completed	O
successfully	O
in	O
the	O
fourth	O
quarter	O
of	O
2000	O
.	O

Phase	O
III	O
trials	O
of	O
arformoterol	CHEMICAL
began	O
in	O
September	O
2001	O
.	O

The	O
indications	O
for	O
the	O
drug	O
appeared	O
to	O
be	O
asthma	O
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
.	O

However	O
,	O
an	O
update	O
of	O
the	O
pharmaceutical	O
product	O
information	O
on	O
the	O
Sepracor	O
website	O
in	O
September	O
2003	O
listed	O
COPD	O
maintenance	O
therapy	O
as	O
the	O
only	O
indication	O
for	O
arformoterol	CHEMICAL
.	O

In	O
October	O
2002	O
,	O
Sepracor	O
stated	O
that	O
two	O
pivotal	O
phase	O
III	O
studies	O
were	O
ongoing	O
in	O
1600	O
patients	O
.	O

Sepracor	O
estimates	O
that	O
its	O
NDA	O
submission	O
for	O
arformoterol	CHEMICAL
,	O
which	O
is	O
projected	O
for	O
the	O
first	O
half	O
of	O
2004	O
,	O
will	O
include	O
approximately	O
3000	O
adult	O
subjects	O
.	O

Sepracor	O
stated	O
in	O
July	O
2003	O
that	O
it	O
had	O
completed	O
more	O
than	O
100	O
preclinical	O
studies	O
and	O
initiated	O
or	O
completed	O
15	O
clinical	O
studies	O
for	O
arformoterol	CHEMICAL
inhalation	O
solution	O
for	O
the	O
treatment	O
of	O
bronchospasm	O
in	O
patients	O
with	O
COPD	O
.	O

In	O
addition	O
,	O
Sepracor	O
stated	O
that	O
the	O
two	O
pivotal	O
phase	O
III	O
studies	O
in	O
1600	O
patients	O
were	O
still	O
progressing	O
.	O

In	O
1995	O
,	O
European	O
patents	O
were	O
granted	O
to	O
Sepracor	O
for	O
the	O
use	O
of	O
arformoterol	CHEMICAL
in	O
the	O
treatment	O
of	O
asthma	O
,	O
and	O
the	O
US	O
patent	O
application	O
was	O
pending	O
.	O
Salicylate	CHEMICAL
regulates	O
COX-2	GENE-Y
expression	O
through	O
ERK	GENE-N
and	O
subsequent	O
NF-kappaB	GENE-N
activation	O
in	O
osteoblasts	O
.	O
High	O
resolution	O
(	CHEMICAL
1	CHEMICAL
)	CHEMICAL
H	CHEMICAL
NMR	O
spectroscopy	O
was	O
proposed	O
for	O
the	O
determination	O
of	O
the	O
fatty	CHEMICAL
acid	CHEMICAL
chain	O
profile	O
of	O
lipids	O
in	O
pork	O
meat	O
products	O
during	O
ripening	O
.	O

Two	O
typical	O
Mediterranean	O
PDO	O
salami	O
produced	O
in	O
Calabria	O
,	O
a	O
region	O
in	O
the	O
Southern	O
Italy	O
,	O
were	O
chosen	O
as	O
a	O
case	O
of	O
study	O
.	O

Quantitative	O
NMR	O
analysis	O
provided	O
the	O
fatty	CHEMICAL
acid	CHEMICAL
chain	O
profiles	O
of	O
total	O
lipid	O
extracts	O
.	O

The	O
transesterification	O
of	O
total	O
lipid	O
extracts	O
furnished	O
FAME	CHEMICAL
mixtures	O
that	O
enabled	O
quantitation	O
of	O
fatty	CHEMICAL
acid	CHEMICAL
acyl	CHEMICAL
chains	O
in	O
the	O
acylglycerol	CHEMICAL
and	O
FFA	O
portions	O
.	O

In	O
all	O
cases	O
,	O
oleyl	CHEMICAL
chains	O
were	O
predominant	O
,	O
and	O
high	O
amounts	O
of	O
polyunsaturated	CHEMICAL
fatty	CHEMICAL
acid	CHEMICAL
chains	O
were	O
observed	O
.	O

The	O
proposed	O
spectroscopic	O
method	O
allowed	O
also	O
the	O
estimation	O
of	O
the	O
most	O
important	O
nutritional	O
parameters	O
of	O
dry	O
fermented	O
meat	O
products	O
.	O
Dofetilide	CHEMICAL
,	O
a	O
methanesulfonanilide	CHEMICAL
derivative	O
,	O
is	O
a	O
potent	O
class	O
III	O
antiarrhythmic	O
drug	O
.	O

Like	O
other	O
members	O
of	O
this	O
class	O
of	O
K	CHEMICAL
+	CHEMICAL
channel	O
blockers	O
,	O
the	O
sites	O
in	O
the	O
channel	O
to	O
which	O
the	O
drug	O
binds	O
are	O
unknown	O
,	O
although	O
high	O
and	O
low	O
affinity	O
binding	O
has	O
been	O
reported	O
in	O
cardiomyocytes	O
.	O

The	O
most	O
sensitive	O
K	CHEMICAL
+	CHEMICAL
channel	O
target	O
for	O
dofetilide	CHEMICAL
seems	O
to	O
be	O
IKr	GENE-N
,	O
the	O
rapid	O
component	O
of	O
the	O
repolarizing	O
delayed	O
rectifier	O
K	CHEMICAL
+	CHEMICAL
current	O
.	O

However	O
,	O
block	O
of	O
other	O
K	GENE-N
+	GENE-N
channels	O
occurs	O
at	O
higher	O
concentrations	O
and	O
is	O
of	O
special	O
interest	O
in	O
regard	O
to	O
toxicity	O
.	O

Recently	O
,	O
we	O
have	O
demonstrated	O
that	O
hIRK	GENE-N
,	O
a	O
cloned	O
inward	GENE-N
rectifier	GENE-N
K	CHEMICAL
+	CHEMICAL
channel	O
(	O
IRK	GENE-N
)	O
isolated	O
from	O
human	O
atrium	O
and	O
expressed	O
heterologously	O
in	O
Xenopus	O
oocytes	O
,	O
is	O
blocked	O
by	O
dofetilide	CHEMICAL
.	O

We	O
report	O
the	O
localization	O
of	O
a	O
site	O
that	O
is	O
critical	O
for	O
dofetilide	CHEMICAL
block	O
in	O
hIRK	GENE-N
.	O

We	O
used	O
chimeric	O
constructs	O
between	O
hIRK	GENE-N
and	O
ROMK1	GENE-Y
,	O
a	O
related	O
inward	O
rectifier	O
that	O
is	O
drug	O
resistant	O
.	O

Substitution	O
of	O
hIRK-M2	O
,	O
the	O
second	O
putative	O
transmembrane	O
spanning	O
segment	O
of	O
IRKs	GENE-N
,	O
with	O
ROMK1-M2	O
increased	O
unblocking	O
of	O
dofetilide	CHEMICAL
by	O
10-20-fold	O
in	O
hIRK	GENE-N
.	O

Site-directed	O
mutagenesis	O
further	O
pinpointed	O
the	O
effects	O
to	O
a	O
single	O
hydrophobic	O
residue	O
(	O
I177	O
)	O
in	O
M2	O
.	O

A	O
reduction	O
in	O
hydrophobicity	O
by	O
the	O
point	O
mutation	O
I177C	GENE-N
increased	O
recovery	O
from	O
block	O
>	O
10-fold	O
(	O
1	O
.	O
17	O
sec	O
in	O
wild-type	O
to	O
0	O
.	O
112	O
sec	O
at	O
-80	O
mV	O
at	O
physiological	O
K	CHEMICAL
+	CHEMICAL
concentrations	O
)	O
,	O
leading	O
us	O
to	O
suggest	O
that	O
hydrophobic	O
interactions	O
are	O
essential	O
for	O
dofetilide	CHEMICAL
block	O
in	O
hIRK	GENE-N
.	O

A	O
similar	O
mechanism	O
may	O
explain	O
dofetilide	CHEMICAL
block	O
in	O
other	O
ion	GENE-N
channels	GENE-N
,	O
including	O
IKr	GENE-N
.	O
Jaceosidin	CHEMICAL
,	O
isolated	O
from	O
dietary	O
mugwort	O
(	O
Artemisia	O
princeps	O
)	O
,	O
induces	O
G2	O
/	O
M	O
cell	O
cycle	O
arrest	O
by	O
inactivating	O
cdc25C-cdc2	GENE-Y
via	O
ATM-Chk1	GENE-N
/	GENE-N
2	GENE-N
activation	O
.	O
The	O
role	O
of	O
cytochrome	GENE-N
P450-dependent	O
metabolism	O
in	O
the	O
regulation	O
of	O
mouse	GENE-Y
hepatic	GENE-Y
growth	GENE-Y
hormone	GENE-Y
signaling	O
components	O
and	O
target	O
genes	O
by	O
3-methylcholanthrene	CHEMICAL
.	O
The	O
glutamine	CHEMICAL
/	O
amino	CHEMICAL
acid	CHEMICAL
transporter	O
was	O
solubilized	O
from	O
rat	O
renal	O
apical	O
plasma	O
membrane	O
(	O
brush-border	O
membrane	O
)	O
with	O
C12E8	O
and	O
reconstituted	O
into	O
liposomes	O
by	O
removing	O
the	O
detergent	O
from	O
mixed	O
micelles	O
by	O
hydrophobic	O
chromatography	O
on	O
Amberlite	O
XAD-4	O
.	O

The	O
reconstitution	O
was	O
optimised	O
with	O
respect	O
to	O
the	O
protein	O
concentration	O
,	O
the	O
detergent	O
/	O
phospholipid	O
ratio	O
and	O
the	O
number	O
of	O
passages	O
through	O
a	O
single	O
Amberlite	O
column	O
.	O

The	O
reconstituted	O
glutamine	GENE-Y
/	O
amino	CHEMICAL
acid	CHEMICAL
transporter	O
catalysed	O
a	O
first-order	O
antiport	O
reaction	O
stimulated	O
by	O
external	O
,	O
not	O
internal	O
,	O
Na	CHEMICAL
+	CHEMICAL
.	O

Optimal	O
activity	O
was	O
found	O
at	O
pH	O
7	O
.	O
0	O
.	O

The	O
sulfhydryl	CHEMICAL
reagents	CHEMICAL
HgCl2	CHEMICAL
,	O
mersalyl	CHEMICAL
and	O
p-hydroxymercuribenzoate	CHEMICAL
and	O
the	O
amino	CHEMICAL
acids	CHEMICAL
alanine	CHEMICAL
,	O
serine	CHEMICAL
,	O
threonine	CHEMICAL
,	O
cysteine	CHEMICAL
,	O
asparagine	CHEMICAL
,	O
methionine	CHEMICAL
and	O
valine	CHEMICAL
strongly	O
inhibited	O
the	O
transport	O
,	O
whereas	O
the	O
amino	CHEMICAL
acid	CHEMICAL
analogue	O
methylaminoisobutyrate	CHEMICAL
had	O
no	O
effect	O
.	O

Glutamine	CHEMICAL
,	O
alanine	CHEMICAL
,	O
serine	CHEMICAL
,	O
asparagine	CHEMICAL
,	O
threonine	CHEMICAL
were	O
efficiently	O
translocated	O
from	O
outside	O
to	O
inside	O
and	O
from	O
inside	O
to	O
outside	O
the	O
proteoliposomes	O
as	O
well	O
.	O

Cysteine	O
and	O
valine	O
were	O
translocated	O
preferentially	O
from	O
outside	O
to	O
inside	O
.	O

The	O
Km	O
for	O
glutamine	CHEMICAL
on	O
the	O
external	O
and	O
internal	O
side	O
of	O
the	O
transporter	O
was	O
0	O
.	O
47	O
and	O
11	O
mM	O
,	O
respectively;	O
the	O
values	O
were	O
not	O
influenced	O
by	O
the	O
type	O
of	O
the	O
counter	O
substrate	O
.	O

The	O
transporter	O
is	O
functionally	O
asymmetrical	O
and	O
it	O
is	O
unidirectionally	O
inserted	O
into	O
the	O
proteoliposomal	O
membrane	O
with	O
an	O
orientation	O
corresponding	O
to	O
that	O
of	O
the	O
native	O
membrane	O
.	O

By	O
a	O
bisubstrate	O
kinetic	O
analysis	O
of	O
the	O
glutamine	CHEMICAL
antiport	O
,	O
a	O
random	O
simultaneous	O
mechanism	O
was	O
found	O
.	O

The	O
glutamine	CHEMICAL
antiport	O
was	O
strongly	O
stimulated	O
by	O
internal	O
nucleoside	CHEMICAL
triphosphates	CHEMICAL
and	O
,	O
to	O
a	O
lower	O
extent	O
,	O
by	O
pyrophoshate	CHEMICAL
.	O

The	O
reconstituted	O
glutamine	CHEMICAL
/	O
amino	CHEMICAL
acid	CHEMICAL
transporter	O
functionally	O
corresponds	O
to	O
the	O
ASCT2	GENE-Y
protein	O
.	O
Arsenic	CHEMICAL
can	O
induce	O
reactive	O
oxygen	CHEMICAL
species	O
(	O
ROS	O
)	O
leading	O
to	O
oxidative	O
stress	O
and	O
carcinogenesis	O
.	O

Bladder	O
is	O
one	O
of	O
the	O
major	O
target	O
organs	O
of	O
arsenic	CHEMICAL
,	O
and	O
cyclooxygenase-2	GENE-Y
(	O
COX-2	GENE-Y
)	O
may	O
play	O
an	O
important	O
role	O
in	O
arsenic-induced	O
bladder	O
cancer	O
.	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
arsenic	CHEMICAL
induces	O
COX-2	GENE-Y
in	O
bladder	O
cells	O
remains	O
unclear	O
.	O

This	O
study	O
aimed	O
at	O
investigating	O
arsenic-mediated	O
intracellular	O
redox	O
status	O
and	O
signaling	O
cascades	O
leading	O
to	O
COX-2	GENE-Y
induction	O
in	O
human	O
uroepithelial	O
cells	O
(	O
SV-HUC-1	O
)	O
.	O

SV-HUC-1	O
cells	O
were	O
exposed	O
to	O
sodium	CHEMICAL
arsenite	CHEMICAL
and	O
COX-2	GENE-Y
expression	O
,	O
mitogen-activated	GENE-N
protein	GENE-N
kinase	GENE-N
(	O
MAPK	GENE-N
)	O
phosphorylation	O
,	O
glutathione	CHEMICAL
(	O
GSH	CHEMICAL
)	O
levels	O
,	O
ROS	O
induction	O
and	O
Nrf2	GENE-Y
expression	O
were	O
quantified	O
.	O

Our	O
results	O
demonstrate	O
that	O
arsenite	CHEMICAL
(	O
1-10	O
μM	O
)	O
elevates	O
COX-2	GENE-Y
expression	O
,	O
GSH	CHEMICAL
levels	O
,	O
ROS	O
and	O
Nrf2	GENE-Y
expression	O
.	O

Arsenite	CHEMICAL
treatment	O
for	O
24h	O
stimulates	O
phosphorylation	O
of	O
ERK	GENE-N
and	O
p38	GENE-N
,	O
but	O
not	O
JNK	GENE-N
in	O
SV-HUC-1	O
cells	O
.	O

Induction	O
of	O
Cox-2	GENE-Y
mRNA	O
levels	O
by	O
arsenite	CHEMICAL
was	O
attenuated	O
by	O
inhibitors	O
of	O
ERK	GENE-N
,	O
p38	GENE-N
and	O
JNK	GENE-N
.	O

Arsenite-induced	O
ROS	O
generation	O
and	O
COX-2	GENE-Y
expression	O
were	O
significantly	O
attenuated	O
by	O
treatment	O
with	O
melatonin	CHEMICAL
(	O
a	O
ROS	O
scavenger	O
)	O
,	O
but	O
enhanced	O
by	O
DL-buthionine-	CHEMICAL
(	CHEMICAL
S	CHEMICAL
,	CHEMICAL
R	CHEMICAL
)	CHEMICAL
-sulfoximine	CHEMICAL
(	O
BSO	CHEMICAL
,	O
an	O
inhibitor	O
of	O
gamma-glutamylcysteine	CHEMICAL
synthetase	O
(	O
γ-GCS	GENE-Y
)	O
resulting	O
in	O
lower	O
GSH	CHEMICAL
and	O
increased	O
ROS	O
levels	O
)	O
.	O

These	O
data	O
indicate	O
that	O
arsenite	CHEMICAL
promotes	O
an	O
induction	O
of	O
ROS	O
,	O
which	O
results	O
in	O
an	O
induction	O
of	O
COX-2	GENE-Y
expression	O
through	O
activation	O
of	O
the	O
MAPK	GENE-N
pathway	O
.	O
Due	O
to	O
the	O
increased	O
prevalence	O
of	O
bacterial	O
strains	O
that	O
are	O
resistant	O
to	O
existing	O
antibiotics	O
,	O
there	O
is	O
an	O
urgent	O
need	O
for	O
new	O
antibacterial	O
strategies	O
.	O

Bacterial	O
glycans	O
are	O
an	O
attractive	O
target	O
for	O
new	O
treatments	O
,	O
as	O
they	O
are	O
frequently	O
linked	O
to	O
pathogenesis	O
and	O
contain	O
distinctive	O
structures	O
that	O
are	O
absent	O
in	O
humans	O
.	O

We	O
set	O
out	O
to	O
develop	O
a	O
novel	O
targeting	O
strategy	O
based	O
on	O
surface	O
glycans	O
present	O
on	O
the	O
gastric	O
pathogen	O
Helicobacter	O
pylori	O
(	O
Hp	O
)	O
.	O

In	O
this	O
study	O
,	O
metabolic	O
labeling	O
of	O
bacterial	O
glycans	O
with	O
an	O
azide-containing	O
sugar	O
allowed	O
selective	O
delivery	O
of	O
immune	O
stimulants	O
to	O
azide-covered	O
Hp	O
.	O

We	O
established	O
that	O
Hp's	O
surface	O
glycans	O
are	O
labeled	O
by	O
treatment	O
with	O
the	O
metabolic	O
substrate	O
peracetylated	CHEMICAL
N-azidoacetylglucosamine	CHEMICAL
(	O
Ac4	CHEMICAL
GlcNAz	CHEMICAL
)	O
.	O

By	O
contrast	O
,	O
mammalian	O
cells	O
treated	O
with	O
Ac4	CHEMICAL
GlcNAz	CHEMICAL
exhibited	O
no	O
incorporation	O
of	O
the	O
chemical	O
label	O
within	O
extracellular	O
glycans	O
.	O

We	O
further	O
demonstrated	O
that	O
the	O
Staudinger	O
ligation	O
between	O
azides	CHEMICAL
and	O
phosphines	CHEMICAL
proceeds	O
under	O
acidic	O
conditions	O
with	O
only	O
a	O
small	O
loss	O
of	O
efficiency	O
.	O

We	O
then	O
targeted	O
azide-covered	O
Hp	O
with	O
phosphines	CHEMICAL
conjugated	O
to	O
the	O
immune	O
stimulant	O
2	CHEMICAL
,	CHEMICAL
4-dinitrophenyl	CHEMICAL
(	O
DNP	CHEMICAL
)	O
,	O
a	O
compound	O
capable	O
of	O
directing	O
a	O
host	O
immune	O
response	O
against	O
these	O
cells	O
.	O

Finally	O
,	O
we	O
report	O
that	O
immune	O
effector	O
cells	O
catalyze	O
selective	O
damage	O
in	O
vitro	O
to	O
DNP-covered	O
Hp	O
in	O
the	O
presence	O
of	O
anti-DNP	CHEMICAL
antibodies	O
.	O

The	O
technology	O
reported	O
herein	O
represents	O
a	O
novel	O
strategy	O
to	O
target	O
Hp	O
based	O
on	O
its	O
glycans	O
.	O
Extracellular	GENE-N
loop	GENE-N
3	GENE-N
(	O
EL3	GENE-N
)	O
and	O
EL3-proximal	GENE-N
transmembrane	GENE-N
helix	GENE-N
7	GENE-N
of	O
the	O
mammalian	GENE-N
type	GENE-N
I	GENE-N
and	GENE-N
type	GENE-N
II	GENE-N
gonadotropin-releasing	GENE-N
hormone	GENE-N
(	GENE-N
GnRH	GENE-N
)	GENE-N
receptors	GENE-N
determine	O
differential	O
ligand	O
selectivity	O
to	O
GnRH-I	GENE-Y
and	O
GnRH-II	GENE-Y
.	O
Lanthanum	CHEMICAL
(	CHEMICAL
III	CHEMICAL
)	CHEMICAL
regulates	O
the	O
nitrogen	CHEMICAL
assimilation	O
in	O
soybean	O
seedlings	O
under	O
ultraviolet-B	O
radiation	O
.	O
The	O
enzyme	O
,	O
10-formyltetrahydrofolate	CHEMICAL
dehydrogenase	O
(	O
FDH	GENE-Y
)	O
,	O
converts	O
10-formyltetrahydrofolate	CHEMICAL
(	O
10-formyl-THF	CHEMICAL
)	O
to	O
tetrahydrofolate	CHEMICAL
in	O
an	O
NADP	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-dependent	O
dehydrogenase	O
reaction	O
or	O
an	O
NADP	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-independent	O
hydrolase	O
reaction	O
.	O

The	O
hydrolase	GENE-N
reaction	O
occurs	O
in	O
a	O
310-amino	CHEMICAL
acid	CHEMICAL
long	O
amino-terminal	O
domain	O
of	O
FDH	GENE-Y
(	O
N	O
(	O
t	O
)	O
-FDH	GENE-Y
)	O
,	O
whereas	O
the	O
dehydrogenase	GENE-N
reaction	O
requires	O
the	O
full-length	O
enzyme	O
.	O

The	O
amino-terminal	O
domain	O
of	O
FDH	GENE-Y
shares	O
some	O
sequence	O
identity	O
with	O
several	O
other	O
enzymes	O
utilizing	O
10-formyl-THF	CHEMICAL
as	O
a	O
substrate	O
.	O

These	O
enzymes	O
have	O
two	O
strictly	O
conserved	O
residues	O
,	O
aspartate	CHEMICAL
and	O
histidine	CHEMICAL
,	O
in	O
the	O
putative	O
catalytic	O
center	O
.	O

We	O
have	O
shown	O
recently	O
that	O
the	O
conserved	O
aspartate	CHEMICAL
is	O
involved	O
in	O
FDH	GENE-Y
catalysis	O
.	O

In	O
the	O
present	O
work	O
we	O
studied	O
the	O
role	O
of	O
the	O
conserved	O
histidine	CHEMICAL
,	O
His	O
(	O
106	O
)	O
,	O
in	O
FDH	GENE-Y
function	O
.	O

Site-directed	O
mutagenesis	O
experiments	O
showed	O
that	O
replacement	O
of	O
the	O
histidine	CHEMICAL
with	O
alanine	CHEMICAL
,	O
asparagine	CHEMICAL
,	O
aspartate	CHEMICAL
,	O
glutamate	CHEMICAL
,	O
glutamine	CHEMICAL
,	O
or	O
arginine	CHEMICAL
in	O
N	O
(	O
t	O
)	O
-FDH	GENE-Y
resulted	O
in	O
expression	O
of	O
insoluble	O
proteins	O
.	O

Replacement	O
of	O
the	O
histidine	CHEMICAL
with	O
another	O
positively	O
charged	O
residue	O
,	O
lysine	CHEMICAL
,	O
produced	O
a	O
soluble	O
mutant	O
with	O
no	O
hydrolase	GENE-N
activity	O
.	O

The	O
insoluble	O
mutants	O
refolded	O
from	O
inclusion	O
bodies	O
adopted	O
a	O
conformation	O
inherent	O
to	O
the	O
wild-type	O
N	O
(	O
t	O
)	O
-FDH	GENE-Y
,	O
but	O
they	O
did	O
not	O
exhibit	O
any	O
hydrolase	GENE-N
activity	O
.	O

Substitution	O
of	O
alanine	CHEMICAL
for	O
three	O
non-conserved	O
histidines	CHEMICAL
located	O
close	O
to	O
the	O
conserved	O
one	O
did	O
not	O
reveal	O
any	O
significant	O
changes	O
in	O
the	O
hydrolase	O
activity	O
of	O
N	O
(	O
t	O
)	O
-FDH	GENE-Y
.	O

Expressed	O
full-length	O
FDH	GENE-Y
with	O
the	O
substitution	O
of	O
lysine	CHEMICAL
for	O
the	O
His	O
(	O
106	O
)	O
completely	O
lost	O
both	O
the	O
hydrolase	GENE-N
and	O
dehydrogenase	GENE-N
activities	O
.	O

Thus	O
,	O
our	O
study	O
showed	O
that	O
His	O
(	O
106	O
)	O
,	O
besides	O
being	O
an	O
important	O
structural	O
residue	O
,	O
is	O
also	O
directly	O
involved	O
in	O
both	O
the	O
hydrolase	GENE-N
and	O
dehydrogenase	GENE-N
mechanisms	O
of	O
FDH	GENE-Y
.	O

Modeling	O
of	O
the	O
putative	O
hydrolase	GENE-N
catalytic	O
center	O
/	O
folate-binding	O
site	O
suggested	O
that	O
the	O
catalytic	O
residues	O
,	O
aspartate	CHEMICAL
and	O
histidine	CHEMICAL
,	O
are	O
unlikely	O
to	O
be	O
adjacent	O
to	O
the	O
catalytic	O
cysteine	CHEMICAL
in	O
the	O
aldehyde	GENE-N
dehydrogenase	O
catalytic	O
center	O
.	O

We	O
hypothesize	O
that	O
10-formyl-THF	GENE-Y
dehydrogenase	O
reaction	O
is	O
not	O
an	O
independent	O
reaction	O
but	O
is	O
a	O
combination	O
of	O
hydrolase	GENE-N
and	O
aldehyde	GENE-N
dehydrogenase	O
reactions	O
.	O
Serine	CHEMICAL
(	O
Ser	CHEMICAL
)	O
biosynthesis	O
in	O
C	O
(	O
3	O
)	O
plants	O
can	O
occur	O
via	O
several	O
pathways	O
.	O

One	O
major	O
route	O
involves	O
the	O
tetrahydrofolate	CHEMICAL
(	O
THF	CHEMICAL
)	O
-dependent	O
activities	O
of	O
the	O
glycine	GENE-N
decarboxylase	O
complex	O
(	O
GDC	GENE-N
,	O
EC	GENE-Y
2	GENE-Y
.	GENE-Y
1	GENE-Y
.	GENE-Y
1	GENE-Y
.	GENE-Y
10	GENE-Y
)	O
and	O
serine	GENE-N
hydroxymethyltransferase	O
(	O
SHMT	GENE-N
,	O
EC	GENE-Y
2	GENE-Y
.	GENE-Y
1	GENE-Y
.	GENE-Y
2	GENE-Y
.	GENE-Y
1	GENE-Y
)	O
with	O
glycine	CHEMICAL
(	O
Gly	CHEMICAL
)	O
as	O
one-carbon	CHEMICAL
(	O
1-C	CHEMICAL
)	O
source	O
.	O

An	O
alternative	O
THF-dependent	O
pathway	O
involves	O
the	O
C1-THF	CHEMICAL
synthase	O
/	O
SHMT	GENE-N
activities	O
with	O
formate	CHEMICAL
as	O
1-C	CHEMICAL
source	O
.	O

Here	O
,	O
we	O
have	O
investigated	O
aspects	O
of	O
the	O
regulation	O
of	O
these	O
two	O
folate-mediated	O
pathways	O
in	O
Arabidopsis	O
thaliana	O
(	O
L	O
.	O

)	O
Heynh	O
.	O

Columbia	O
using	O
two	O
approaches	O
.	O

Firstly	O
,	O
transgenic	O
plants	O
overexpressing	O
formate	GENE-Y
dehydrogenase	O
(	O
FDH	GENE-Y
,	O
EC	GENE-Y
1	GENE-Y
.	GENE-Y
2	GENE-Y
.	GENE-Y
1	GENE-Y
.	GENE-Y
2	GENE-Y
)	O
were	O
used	O
to	O
continue	O
our	O
previous	O
studies	O
on	O
the	O
function	O
of	O
FDH	GENE-Y
in	O
formate	CHEMICAL
metabolism	O
.	O

The	O
formate	CHEMICAL
pool	O
size	O
was	O
approximately	O
73	O
nmol	O
(	O
g	O
FW	O
)	O
(	O
-1	O
)	O
in	O
wild	O
type	O
(	O
WT	O
)	O
Arabidopsis	O
plants;	O
three	O
independent	O
transgenic	O
lines	O
had	O
similar-sized	O
pools	O
of	O
formate	CHEMICAL
.	O

Transgenic	O
plants	O
produced	O
more	O
(	CHEMICAL
13	CHEMICAL
)	CHEMICAL
CO	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
from	O
supplied	O
[	CHEMICAL
(	CHEMICAL
13	CHEMICAL
)	CHEMICAL
C	CHEMICAL
]	CHEMICAL
formate	CHEMICAL
than	O
did	O
WT	O
plants	O
but	O
were	O
not	O
significantly	O
different	O
from	O
WT	O
plants	O
in	O
their	O
synthesis	O
of	O
Ser	CHEMICAL
.	O

We	O
concluded	O
that	O
FDH	GENE-Y
has	O
no	O
direct	O
role	O
in	O
the	O
regulation	O
of	O
the	O
above	O
two	O
pathways	O
of	O
Ser	CHEMICAL
synthesis;	O
the	O
breakdown	O
of	O
formate	CHEMICAL
to	O
CO	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
by	O
the	O
FDH	GENE-Y
reaction	O
is	O
the	O
primary	O
and	O
preferred	O
fate	O
of	O
the	O
organic	O
acid	O
in	O
Arabidopsis	O
.	O

The	O
ratio	O
between	O
the	O
GDC	GENE-N
/	O
SHMT	GENE-N
and	O
C1-THF	CHEMICAL
synthase	O
/	O
SHMT	GENE-N
pathways	O
of	O
Ser	CHEMICAL
synthesis	O
from	O
[	CHEMICAL
alpha-	CHEMICAL
(	CHEMICAL
13	CHEMICAL
)	CHEMICAL
C	CHEMICAL
]	CHEMICAL
Gly	CHEMICAL
and	O
[	CHEMICAL
(	CHEMICAL
13	CHEMICAL
)	CHEMICAL
C	CHEMICAL
]	CHEMICAL
formate	CHEMICAL
,	O
respectively	O
,	O
in	O
Arabidopsis	O
shoots	O
was	O
21	O
:	O
1;	O
in	O
roots	O
,	O
9	O
:	O
1	O
.	O

In	O
shoots	O
,	O
therefore	O
,	O
the	O
pathway	O
from	O
formate	CHEMICAL
plays	O
only	O
a	O
small	O
role	O
in	O
Ser	CHEMICAL
synthesis;	O
in	O
the	O
case	O
of	O
roots	O
,	O
results	O
indicated	O
that	O
the	O
9	O
:	O
1	O
ratio	O
was	O
as	O
a	O
result	O
of	O
greater	O
fluxes	O
of	O
(	CHEMICAL
13	CHEMICAL
)	CHEMICAL
C	CHEMICAL
through	O
both	O
pathways	O
together	O
with	O
a	O
relatively	O
higher	O
contribution	O
from	O
the	O
C1-THF	CHEMICAL
synthase	O
/	O
SHMT	GENE-N
route	O
than	O
in	O
shoots	O
.	O

We	O
also	O
examined	O
the	O
synthesis	O
of	O
Ser	CHEMICAL
in	O
a	O
GDC-deficient	O
mutant	O
of	O
Arabidopsis	O
(	O
glyD	CHEMICAL
)	O
where	O
the	O
GDC	GENE-N
/	O
SHMT	GENE-N
pathway	O
was	O
impaired	O
.	O

Compared	O
with	O
WT	O
,	O
glyD	CHEMICAL
plants	O
accumulated	O
5-fold	O
more	O
Gly	CHEMICAL
than	O
WT	O
after	O
supplying	O
[	CHEMICAL
alpha-	CHEMICAL
(	CHEMICAL
13	CHEMICAL
)	CHEMICAL
C	CHEMICAL
]	CHEMICAL
Gly	CHEMICAL
for	O
24	O
h;	O
the	O
accumulation	O
of	O
Ser	CHEMICAL
from	O
[	CHEMICAL
alpha-	CHEMICAL
(	CHEMICAL
13	CHEMICAL
)	CHEMICAL
C	CHEMICAL
]	CHEMICAL
Gly	CHEMICAL
was	O
reduced	O
by	O
25%	O
in	O
the	O
same	O
time	O
period	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
accumulation	O
of	O
Ser	CHEMICAL
through	O
the	O
C1-THF	CHEMICAL
synthase	O
/	O
SHMT	GENE-N
pathway	O
in	O
glyD	CHEMICAL
plants	O
was	O
2	O
.	O
5-fold	O
greater	O
than	O
that	O
in	O
WT	O
plants	O
.	O

Our	O
experiments	O
confirmed	O
that	O
the	O
GDC	GENE-N
/	O
SHMT	GENE-N
and	O
C1-THF	CHEMICAL
synthase	O
/	O
SHMT	GENE-N
pathways	O
normally	O
operate	O
independently	O
in	O
Arabidopsis	O
plants	O
but	O
that	O
when	O
the	O
primary	O
GDC	GENE-N
/	O
SHMT	GENE-N
pathway	O
is	O
impaired	O
the	O
alternative	O
C1-THF	CHEMICAL
synthase	O
/	O
SHMT	GENE-N
pathway	O
can	O
partially	O
compensate	O
for	O
deficiencies	O
in	O
the	O
synthesis	O
of	O
Ser	CHEMICAL
.	O
Strontium	CHEMICAL
stimulates	O
cartilage	O
matrix	O
formation	O
in	O
vitro	O
.	O

However	O
,	O
the	O
mechanisms	O
governing	O
these	O
effects	O
have	O
not	O
yet	O
been	O
extensively	O
reported	O
.	O

In	O
this	O
study	O
,	O
chondrocytes	O
were	O
isolated	O
from	O
rat	O
articular	O
cartilage	O
by	O
enzymatic	O
digestion	O
and	O
cultured	O
for	O
24-72	O
h	O
with	O
1-5	O
mM	O
strontium	CHEMICAL
.	O

We	O
investigated	O
the	O
effects	O
of	O
different	O
concentrations	O
of	O
strontium	CHEMICAL
on	O
collagen	GENE-N
content	O
,	O
type	GENE-N
II	GENE-N
collagen	GENE-N
,	O
insulin-like	GENE-Y
growth	GENE-Y
factor	GENE-Y
(	O
IGF-1	GENE-Y
)	O
and	O
matrix	GENE-Y
metalloproteinase	GENE-Y
(	GENE-Y
MMP	GENE-Y
)	GENE-Y
-13	GENE-Y
expression	O
in	O
rat	O
cultured	O
articular	O
chondrocytes	O
in	O
vitro	O
.	O

The	O
collagen	GENE-N
content	O
of	O
the	O
chondrocytes	O
,	O
determined	O
as	O
hydroxyproline	CHEMICAL
,	O
was	O
measured	O
by	O
a	O
colorimetry	O
method	O
.	O

Type	GENE-N
II	GENE-N
collagen	GENE-N
,	O
IGF-1	GENE-Y
,	O
and	O
MMP-13	GENE-Y
mRNA	O
abundance	O
and	O
protein	O
expression	O
levels	O
were	O
determined	O
by	O
real-time	O
polymerase	O
chain	O
reaction	O
(	O
real-time	O
PCR	O
)	O
and	O
western	O
blot	O
,	O
respectively	O
.	O

The	O
results	O
showed	O
that	O
collagen	GENE-N
content	O
from	O
the	O
chondrocytes	O
extracellular	O
matrix	O
increased	O
with	O
increasing	O
strontium	CHEMICAL
concentration	O
.	O

Moreover	O
,	O
3	O
and	O
5	O
mM	O
strontium	CHEMICAL
strongly	O
stimulated	O
protein	O
expression	O
and	O
mRNA	O
levels	O
of	O
type	GENE-N
II	GENE-N
collagen	GENE-N
and	O
IGF-1	GENE-Y
.	O

Conversely	O
,	O
MMP-13	GENE-Y
expression	O
in	O
chondrocytes	O
decreased	O
dose-dependently	O
with	O
increasing	O
strontium	CHEMICAL
concentration	O
.	O

These	O
results	O
should	O
provide	O
insight	O
into	O
the	O
ability	O
of	O
strontium	CHEMICAL
to	O
promote	O
chondrocyte	O
extracellular	O
matrix	O
synthesis	O
.	O

Strontium	CHEMICAL
could	O
promote	O
collagen	O
synthesis	O
and	O
suppress	O
collagen	GENE-N
degradation	O
via	O
the	O
repression	O
of	O
MMP-13	GENE-Y
expression	O
.	O
Hepatocytes	O
display	O
a	O
compensatory	O
survival	O
response	O
against	O
cadmium	CHEMICAL
toxicity	O
by	O
a	O
mechanism	O
mediated	O
by	O
EGFR	GENE-Y
and	O
Src	GENE-Y
.	O
Chronic	O
treatment	O
with	O
myo-inositol	CHEMICAL
reduces	O
white	O
adipose	O
tissue	O
accretion	O
and	O
improves	O
insulin	GENE-N
sensitivity	O
in	O
female	O
mice	O
.	O
Three	O
anatase	O
titanium	CHEMICAL
dioxide	CHEMICAL
(	O
TiO	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
)	O
nanoparticles	O
(	O
NPs	O
)	O
were	O
prepared;	O
nanospheres	O
(	O
NSs	O
)	O
,	O
short	O
nanobelts	O
(	O
NB1	O
)	O
,	O
and	O
long	O
nanobelts	O
(	O
NB2	O
)	O
.	O

These	O
NPs	O
were	O
used	O
to	O
investigate	O
the	O
effect	O
of	O
NP	O
shape	O
and	O
length	O
on	O
lung	O
toxicity	O
.	O

Mice	O
were	O
exposed	O
(	O
0-30	O
µg	O
per	O
mouse	O
)	O
by	O
pharyngeal	O
aspiration	O
and	O
pulmonary	O
toxicity	O
was	O
assessed	O
over	O
a	O
112-day	O
time	O
course	O
.	O

Whole	O
lung	O
lavage	O
data	O
indicated	O
that	O
NB1-	O
and	O
NB2-exposed	O
mice	O
,	O
but	O
not	O
NS-exposed	O
mice	O
,	O
had	O
significant	O
dose-	O
and	O
time-dependent	O
pulmonary	O
inflammation	O
and	O
damage	O
.	O

Histopathological	O
analyses	O
at	O
112	O
days	O
postexposure	O
determined	O
no	O
interstitial	O
fibrosis	O
in	O
any	O
NS-exposed	O
mice	O
,	O
an	O
increased	O
incidence	O
in	O
30	O
µg	O
NB1-exposed	O
mice	O
,	O
and	O
significant	O
interstitial	O
fibrosis	O
in	O
30	O
µg	O
NB2-exposed	O
mice	O
.	O

At	O
112	O
days	O
postexposure	O
,	O
lung	O
burden	O
of	O
NS	O
was	O
decreased	O
by	O
96	O
.	O
4%	O
and	O
NB2	O
by	O
80	O
.	O
5%	O
from	O
initial	O
deposition	O
levels	O
.	O

At	O
112	O
days	O
postexposure	O
,	O
enhanced	O
dark	O
field	O
microscopy	O
determined	O
that	O
alveolar	O
macro-	O
phages	O
were	O
the	O
dominant	O
deposition	O
site	O
,	O
but	O
a	O
fraction	O
of	O
NB1	O
and	O
NB2	O
was	O
observed	O
in	O
the	O
alveolar	O
interstitial	O
spaces	O
.	O

For	O
the	O
30	O
µg	O
exposure	O
groups	O
at	O
112	O
days	O
postexposure	O
,	O
confocal	O
micro-	O
scopy	O
and	O
immunofluorescent	O
staining	O
demonstrated	O
that	O
retained	O
NB2	O
but	O
not	O
NS	O
were	O
present	O
in	O
the	O
interstitium	O
subjacent	O
to	O
the	O
terminal	O
bronchiole	O
near	O
the	O
normal	O
location	O
of	O
the	O
smallest	O
lymphatic	O
capillaries	O
in	O
the	O
lung	O
.	O

These	O
lymphatic	O
capillaries	O
play	O
a	O
critical	O
role	O
in	O
particle	O
clearance	O
,	O
and	O
the	O
accumulation	O
of	O
NB2	O
,	O
but	O
not	O
NS	O
,	O
suggests	O
possible	O
impaired	O
lymphatic	O
clearance	O
by	O
the	O
high	O
aspect	O
ratio	O
particles	O
.	O

In	O
summary	O
,	O
our	O
data	O
indicate	O
that	O
TiO	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
NP	O
shape	O
alters	O
pulmonary	O
responses	O
,	O
with	O
severity	O
of	O
responses	O
being	O
ranked	O
as	O
NS	O
<	O
NB1	O
<	O
NB2	O
.	O
The	O
L1	GENE-N
stalk	GENE-N
is	O
a	O
prominent	O
mobile	O
element	O
of	O
the	O
large	O
ribosomal	O
subunit	O
.	O

We	O
explore	O
the	O
structure	O
and	O
dynamics	O
of	O
its	O
non-canonical	O
rRNA	O
elements	O
,	O
which	O
include	O
two	O
kink-turns	GENE-N
,	O
an	O
internal	GENE-N
loop	GENE-N
,	O
and	O
a	O
tetraloop	GENE-N
.	O

We	O
use	O
bioinformatics	O
to	O
identify	O
the	O
L1	GENE-N
stalk	GENE-N
RNA	O
conservation	O
patterns	O
and	O
carry	O
out	O
over	O
11	O
.	O
5	O
μs	O
of	O
MD	O
simulations	O
for	O
a	O
set	O
of	O
systems	O
ranging	O
from	O
isolated	O
RNA	O
building	O
blocks	O
up	O
to	O
complexes	O
of	O
L1	GENE-N
stalk	GENE-N
rRNA	O
with	O
the	O
L1	GENE-Y
protein	GENE-Y
and	O
tRNA	O
fragment	O
.	O

We	O
show	O
that	O
the	O
L1	GENE-N
stalk	GENE-N
tetraloop	GENE-N
has	O
an	O
unusual	O
GNNA	GENE-N
or	O
UNNG	GENE-N
conservation	O
pattern	O
deviating	O
from	O
major	O
GNRA	GENE-N
and	O
YNMG	GENE-N
RNA	GENE-N
tetraloop	GENE-N
families	O
.	O

We	O
suggest	O
that	O
this	O
deviation	O
is	O
related	O
to	O
a	O
highly	O
conserved	O
tertiary	O
contact	O
within	O
the	O
L1	GENE-N
stalk	GENE-N
.	O

The	O
available	O
X-ray	O
structures	O
contain	O
only	O
UCCG	GENE-N
tetraloops	GENE-N
which	O
in	O
addition	O
differ	O
in	O
orientation	O
(	O
anti	O
vs	O
syn	O
)	O
of	O
the	O
guanine	CHEMICAL
.	O

Our	O
analysis	O
suggests	O
that	O
the	O
anti	O
orientation	O
might	O
be	O
a	O
mis-refinement	O
,	O
although	O
even	O
the	O
anti	O
interaction	O
would	O
be	O
compatible	O
with	O
the	O
sequence	O
pattern	O
and	O
observed	O
tertiary	O
interaction	O
.	O

Alternatively	O
,	O
the	O
anti	O
conformation	O
may	O
be	O
a	O
real	O
substate	O
whose	O
population	O
could	O
be	O
pH-dependent	O
,	O
since	O
the	O
guanine	CHEMICAL
syn	O
orientation	O
requires	O
protonation	O
of	O
cytosine	CHEMICAL
in	O
the	O
tertiary	O
contact	O
.	O

In	O
absence	O
of	O
structural	O
data	O
,	O
we	O
use	O
molecular	O
modeling	O
to	O
explore	O
the	O
GCCA	GENE-N
tetraloop	GENE-N
that	O
is	O
dominant	O
in	O
bacteria	O
and	O
suggest	O
that	O
the	O
GCCA	GENE-N
tetraloop	GENE-N
is	O
structurally	O
similar	O
to	O
the	O
YNMG	GENE-N
tetraloop	GENE-N
.	O

Kink-turn	GENE-N
Kt-77	GENE-N
is	O
unusual	O
due	O
to	O
its	O
11-nucleotide	CHEMICAL
bulge	O
.	O

The	O
simulations	O
indicate	O
that	O
the	O
long	O
bulge	O
is	O
a	O
stalk-specific	O
eight-nucleotide	CHEMICAL
insertion	O
into	O
consensual	O
kink-turn	GENE-N
only	O
subtly	O
modifying	O
its	O
structural	O
dynamics	O
.	O

We	O
discuss	O
a	O
possible	O
evolutionary	O
role	O
of	O
helix	GENE-N
H78	GENE-N
and	O
a	O
mechanism	O
of	O
L1	GENE-N
stalk	GENE-N
interaction	O
with	O
tRNA	O
.	O

We	O
also	O
assess	O
the	O
simulation	O
methodology	O
.	O

The	O
simulations	O
provide	O
a	O
good	O
description	O
of	O
the	O
studied	O
systems	O
with	O
the	O
latest	O
bsc0χOL3	O
force	O
field	O
showing	O
improved	O
performance	O
.	O

Still	O
,	O
even	O
bsc0χOL3	O
is	O
unable	O
to	O
fully	O
stabilize	O
an	O
essential	O
sugar-edge	O
H-bond	O
between	O
the	O
bulge	O
and	O
non-canonical	O
stem	O
of	O
the	O
kink-turn	GENE-N
.	O

Inclusion	O
of	O
Mg	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
ions	O
may	O
deteriorate	O
the	O
simulations	O
.	O

On	O
the	O
other	O
hand	O
,	O
monovalent	O
ions	O
can	O
in	O
simulations	O
readily	O
occupy	O
experimental	O
Mg	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
binding	O
sites	O
.	O
RATIONALE	O
:	O
Recent	O
studies	O
provide	O
evidence	O
for	O
reduced	O
phosphodiesterase-4B	GENE-Y
(	O
PDE4B	GENE-Y
)	O
as	O
a	O
genetic	O
susceptibility	O
factor	O
as	O
well	O
as	O
suggesting	O
an	O
association	O
of	O
several	O
single	O
nucleotide	CHEMICAL
polymorphisms	O
(	O
SNPs	O
)	O
in	O
PDE4B	GENE-Y
that	O
are	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
schizophrenia	O
.	O

OBJECTIVES	O
:	O
The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
assess	O
the	O
activity	O
of	O
rolipram	CHEMICAL
,	O
a	O
nonsubtype-selective	O
PDE4	GENE-N
inhibitor	O
,	O
in	O
several	O
animal	O
models	O
predictive	O
of	O
antipsychotic-like	O
efficacy	O
and	O
side-effect	O
liability	O
and	O
to	O
use	O
PDE4B	GENE-Y
wild-type	O
and	O
knockout	O
mice	O
to	O
begin	O
to	O
understand	O
the	O
subtypes	O
involved	O
in	O
the	O
activity	O
of	O
rolipram	CHEMICAL
.	O

RESULTS	O
:	O
In	O
rats	O
,	O
rolipram	CHEMICAL
antagonized	O
both	O
phencyclidine	CHEMICAL
hydrochloride-	O
and	O
D-amphetamine-induced	O
hyperactivity	O
and	O
inhibited	O
conditioned	O
avoidance	O
responding	O
(	O
CAR	O
)	O
.	O

In	O
PDE4B	GENE-Y
wild-type	O
mice	O
,	O
rolipram	CHEMICAL
dose-dependently	O
suppressed	O
CAR	O
(	O
ED	O
(	O
50	O
)	O
=	O
2	O
.	O
4	O
mg	O
/	O
kg	O
)	O
;	O
however	O
,	O
in	O
knockout	O
mice	O
,	O
their	O
sensitivity	O
to	O
rolipram	CHEMICAL
at	O
the	O
higher	O
doses	O
(	O
1	O
.	O
0	O
and	O
3	O
.	O
2	O
mg	O
/	O
kg	O
)	O
was	O
reduced	O
,	O
resulting	O
in	O
a	O
threefold	O
shift	O
in	O
the	O
ED	O
(	O
50	O
)	O
(	O
7	O
.	O
3	O
mg	O
/	O
kg	O
)	O
,	O
suggesting	O
PDE4B	GENE-Y
is	O
involved	O
,	O
at	O
least	O
in	O
part	O
,	O
with	O
the	O
activity	O
of	O
rolipram	CHEMICAL
.	O

Only	O
the	O
highest	O
dose	O
of	O
rolipram	CHEMICAL
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
)	O
produced	O
a	O
modest	O
but	O
significant	O
degree	O
of	O
catalepsy	O
.	O

CONCLUSIONS	O
:	O
Rolipram	CHEMICAL
has	O
a	O
pharmacologic	O
profile	O
similar	O
to	O
that	O
of	O
the	O
atypical	O
antipsychotics	O
and	O
has	O
low	O
extrapyramidal	O
symptom	O
liability	O
.	O

These	O
results	O
suggest	O
that	O
PDE4B	GENE-Y
mediates	O
the	O
antipsychotic	O
effects	O
of	O
rolipram	CHEMICAL
in	O
CAR	O
and	O
that	O
the	O
PDE4B-regulated	O
cyclic	CHEMICAL
adenosine	CHEMICAL
monophosphate	CHEMICAL
signaling	O
pathway	O
may	O
play	O
a	O
role	O
in	O
the	O
pathophysiology	O
and	O
pharmacotherapy	O
of	O
psychosis	O
.	O
Effect	O
of	O
JTH-601	O
,	O
a	O
novel	O
alpha	GENE-N
(	GENE-N
1	GENE-N
)	GENE-N
-adrenoceptor	GENE-N
antagonist	O
,	O
on	O
prostate	O
function	O
in	O
dogs	O
.	O
Storage	O
protocols	O
of	O
vascular	O
grafts	O
need	O
further	O
improvement	O
against	O
ischemia-reperfusion	O
(	O
IR	O
)	O
injury	O
.	O

Hypoxia	O
elicits	O
a	O
variety	O
of	O
complex	O
cellular	O
responses	O
by	O
altering	O
the	O
activity	O
of	O
many	O
signaling	O
pathways	O
,	O
such	O
as	O
the	O
oxygen-dependent	O
prolyl-hyroxylase	O
domain-containing	O
enzyme	O
(	O
PHD	GENE-N
)	O
.	O

Reduction	O
of	O
PHD	GENE-N
activity	O
during	O
hypoxia	O
leads	O
to	O
stabilization	O
and	O
accumulation	O
of	O
hypoxia	GENE-Y
inducible	GENE-Y
factor	GENE-Y
(	GENE-Y
HIF	GENE-Y
)	GENE-Y
1α	GENE-Y
.	O

We	O
examined	O
the	O
effects	O
of	O
PHD	GENE-N
inhibiton	O
by	O
dimethyloxalylglycine	CHEMICAL
on	O
the	O
vasomotor	O
responses	O
of	O
isolated	O
rat	O
aorta	O
and	O
aortic	O
vascular	O
smooth	O
muscle	O
cells	O
(	O
VSMCs	O
)	O
in	O
a	O
model	O
of	O
cold	O
ischemia	O
/	O
warm	O
reperfusion	O
.	O

Aortic	O
segments	O
underwent	O
24	O
hours	O
of	O
cold	O
ischemic	O
preservation	O
in	O
saline	O
or	O
DMOG	CHEMICAL
(	O
dimethyloxalylglycine	CHEMICAL
)	O
-supplemented	O
saline	O
solution	O
.	O

We	O
investigated	O
endothelium-dependent	O
and	O
-independent	O
vasorelaxations	O
.	O

To	O
simulate	O
IR	O
injury	O
,	O
hypochlorite	CHEMICAL
(	O
NaOCl	CHEMICAL
)	O
was	O
added	O
during	O
warm	O
reperfusion	O
.	O

VSMCs	O
were	O
incubated	O
in	O
NaCl	CHEMICAL
or	O
DMOG	CHEMICAL
solution	O
at	O
4°C	O
for	O
24	O
hours	O
after	O
the	O
medium	O
was	O
changed	O
for	O
a	O
supplied	O
standard	O
medium	O
at	O
37°C	O
for	O
6	O
hours	O
.	O

Apoptosis	O
was	O
assessed	O
using	O
the	O
TUNEL	O
method	O
.	O

Gene	O
expression	O
analysis	O
was	O
performed	O
using	O
quantitative	O
real-time	O
polymerase	O
chain	O
reaction	O
.	O

Cold	O
ischemic	O
preservation	O
and	O
NaOCl	CHEMICAL
induced	O
severe	O
endothelial	O
dysfunction	O
,	O
which	O
was	O
significantly	O
improved	O
by	O
DMOG	CHEMICAL
supplementation	O
(	O
maximal	O
relaxation	O
of	O
aortic	O
segments	O
to	O
acetylcholine	CHEMICAL
:	O
control	O
95%	O
±	O
1%	O
versus	O
NaOCl	CHEMICAL
44%	O
±	O
4%	O
versus	O
DMOG	CHEMICAL
68%	O
±	O
5%	O
)	O
.	O

Number	O
of	O
TUNEL-positive	O
cell	O
nuclei	O
was	O
significantly	O
higher	O
in	O
the	O
NaOCl	CHEMICAL
group	O
,	O
and	O
DMOG	CHEMICAL
treatment	O
significantly	O
decreased	O
apoptosis	O
.	O

Inducible	O
heme-oxygenase	O
1	O
mRNA	O
expressions	O
were	O
significantly	O
higher	O
in	O
the	O
DMOG	CHEMICAL
group	O
.	O

Pharmacological	O
modulation	O
of	O
oxygen	CHEMICAL
sensing	O
system	O
by	O
DMOG	CHEMICAL
in	O
an	O
in	O
vitro	O
model	O
of	O
vascular	O
IR	O
effectively	O
preserved	O
endothelial	O
function	O
.	O

Inhibition	O
of	O
PHDs	GENE-N
could	O
therefore	O
be	O
a	O
new	O
therapeutic	O
avenue	O
for	O
protecting	O
endothelium	O
and	O
vascular	O
muscle	O
cells	O
against	O
IR	O
injury	O
.	O
Using	O
a	O
fragment-based	O
approach	O
to	O
target	O
protein-protein	O
interactions	O
.	O
Salicylic	CHEMICAL
acid	CHEMICAL
(	O
SA	CHEMICAL
)	O
,	O
an	O
endogenous	O
signaling	O
molecule	O
of	O
plants	O
,	O
possesses	O
anti-inflammatory	O
and	O
anti-neoplastic	O
actions	O
in	O
human	O
.	O

Its	O
derivative	O
,	O
aspirin	O
,	O
is	O
the	O
most	O
commonly	O
used	O
anti-inflammatory	O
and	O
analgesic	O
drug	O
.	O

Aspirin	CHEMICAL
and	O
sodium	CHEMICAL
salicylate	CHEMICAL
(	O
salicylates	CHEMICAL
)	O
have	O
been	O
reported	O
to	O
have	O
multiple	O
pharmacological	O
actions	O
.	O

However	O
,	O
it	O
is	O
unclear	O
whether	O
they	O
bind	O
to	O
a	O
cellular	O
protein	O
.	O

Here	O
,	O
we	O
report	O
for	O
the	O
first	O
time	O
the	O
purification	O
from	O
human	O
fibroblasts	O
of	O
a	O
approximately	O
78	O
kDa	O
salicylate	GENE-N
binding	GENE-N
protein	GENE-N
with	O
sequence	O
identity	O
to	O
immunoglobulin	GENE-Y
heavy	GENE-Y
chain	GENE-Y
binding	GENE-Y
protein	GENE-Y
(	O
BiP	GENE-Y
)	O
.	O

The	O
Kd	O
values	O
of	O
SA	CHEMICAL
binding	O
to	O
crude	O
extract	O
and	O
to	O
recombinant	O
BiP	GENE-Y
were	O
45	O
.	O
2	O
and	O
54	O
.	O
6	O
microM	O
,	O
respectively	O
.	O

BiP	GENE-Y
is	O
a	O
chaperone	GENE-N
protein	GENE-N
containing	O
a	O
polypeptide	O
binding	O
site	O
recognizing	O
specific	O
heptapeptide	GENE-N
sequence	GENE-N
and	O
an	O
ATP	CHEMICAL
binding	O
site	O
.	O

A	O
heptapeptide	O
with	O
the	O
specific	O
sequence	O
displaced	O
SA	CHEMICAL
binding	O
in	O
a	O
concentration-dependent	O
manner	O
whereas	O
a	O
control	O
heptapeptide	O
did	O
not	O
.	O

Salicylates	CHEMICAL
inhibited	O
ATPase	GENE-N
activity	O
stimulated	O
by	O
this	O
specific	O
heptapeptide	O
but	O
did	O
not	O
block	O
ATP	CHEMICAL
binding	O
or	O
induce	O
BiP	GENE-Y
expression	O
.	O

These	O
results	O
indicate	O
that	O
salicylates	CHEMICAL
bind	O
specifically	O
to	O
the	O
polypeptide	O
binding	O
site	O
of	O
BiP	GENE-Y
in	O
human	O
cells	O
that	O
may	O
interfere	O
with	O
folding	O
and	O
transport	O
of	O
proteins	O
important	O
in	O
inflammation	O
.	O
The	O
activity	O
of	O
penicillins	CHEMICAL
against	O
bacteria	O
is	O
in	O
large	O
part	O
related	O
to	O
binding	O
to	O
specific	O
receptor	O
proteins	O
involved	O
in	O
cell	O
wall	O
biosynthesis	O
.	O

These	O
proteins	O
have	O
been	O
designated	O
penicillin-binding	O
proteins	O
.	O

They	O
can	O
be	O
separated	O
into	O
distinct	O
entities	O
through	O
the	O
use	O
of	O
acrylamide	CHEMICAL
gel	O
electrophoresis	O
and	O
binding	O
of	O
radioactive	O
14C-labeled	CHEMICAL
penicillin	CHEMICAL
G	CHEMICAL
.	O

Six	O
major	O
proteins	O
have	O
been	O
defined	O
in	O
the	O
Enterobacteriaceae	O
,	O
penicillin-binding	O
proteins	O
1	O
to	O
6	O
.	O

Selection	O
of	O
mutants	O
has	O
shown	O
that	O
there	O
are	O
three	O
essential	O
proteins	O
:	O
penicillin-binding	O
protein	O
1	O
,	O
which	O
is	O
divided	O
into	O
penicillin-binding	O
protein	O
1Bs	O
,	O
a	O
peptidoglycan	GENE-N
transpeptidase	GENE-N
,	O
and	O
penicillin-binding	O
protein	O
1A	O
,	O
which	O
acts	O
as	O
a	O
replacement	O
for	O
penicillin-binding	O
protein	O
1Bs	O
.	O

Penicillin-binding	O
protein	O
2	O
is	O
a	O
murein-elongation	O
initiating	O
enzyme	O
and	O
penicillin-binding	O
protein	O
3	O
is	O
a	O
septal	O
murein-synthesizing	O
enzyme	O
.	O

Penicillin-binding	O
proteins	O
4	O
,	O
5	O
,	O
and	O
6	O
are	O
not	O
essential	O
for	O
bacterial	O
survival	O
.	O

Binding	O
of	O
penicillins	CHEMICAL
to	O
penicillin-binding	O
protein	O
1Bs	O
produces	O
lysis	O
,	O
binding	O
to	O
penicillin-binding	O
protein	O
2	O
produces	O
round	O
cells	O
,	O
and	O
binding	O
to	O
penicillin-binding	O
protein	O
3	O
produces	O
long	O
filaments	O
.	O

Amdinocillin	CHEMICAL
is	O
a	O
beta-amidino	CHEMICAL
penicillanic	CHEMICAL
acid	CHEMICAL
derivative	O
that	O
binds	O
specifically	O
to	O
penicillin-binding	O
protein	O
2	O
.	O

The	O
compound	O
is	O
more	O
beta-lactamase	GENE-N
stable	O
than	O
ampicillin	CHEMICAL
and	O
has	O
no	O
major	O
delay	O
in	O
entry	O
into	O
the	O
periplasmic	O
space	O
as	O
do	O
some	O
penicillins	CHEMICAL
.	O

Amdinocillin	CHEMICAL
inhibits	O
most	O
of	O
the	O
Enterobacteriaceae	O
,	O
with	O
the	O
exception	O
of	O
some	O
indole-positive	O
Proteus	O
species	O
,	O
but	O
it	O
does	O
not	O
inhibit	O
gram-positive	O
cocci	O
or	O
Pseudomonas	O
aeruginosa	O
.	O

Amdinocillin	CHEMICAL
produces	O
spherical	O
bacterial	O
cells	O
that	O
eventually	O
lyse	O
.	O

Its	O
activity	O
in	O
vitro	O
is	O
markedly	O
affected	O
by	O
ionic	O
content	O
of	O
media	O
.	O

This	O
agent	O
acts	O
synergistically	O
with	O
many	O
penicillins	CHEMICAL
,	O
such	O
as	O
ampicillin	CHEMICAL
,	O
carbenicillin	CHEMICAL
,	O
and	O
the	O
like	O
,	O
and	O
with	O
cephalosporins	CHEMICAL
,	O
cefazolin	CHEMICAL
,	O
cefamandole	CHEMICAL
,	O
or	O
cefoxitin	CHEMICAL
to	O
inhibit	O
gram-negative	O
bacilli	O
,	O
probably	O
on	O
the	O
basis	O
of	O
binding	O
to	O
different	O
proteins	O
needed	O
for	O
the	O
production	O
of	O
the	O
peptidoglycan	GENE-N
of	O
the	O
bacterial	O
cell	O
wall	O
.	O

Amdinocillin	CHEMICAL
possesses	O
a	O
number	O
of	O
the	O
essentials	O
for	O
effective	O
antimicrobial	O
activity	O
and	O
,	O
by	O
virtue	O
of	O
its	O
enhancement	O
of	O
the	O
activity	O
of	O
other	O
beta-lactams	CHEMICAL
,	O
may	O
prove	O
to	O
be	O
a	O
useful	O
agent	O
in	O
the	O
chemotherapy	O
of	O
certain	O
infections	O
.	O
Relaxin	GENE-N
is	O
a	O
polypeptide	O
hormone	O
involved	O
in	O
remodeling	O
of	O
the	O
birth	O
canal	O
during	O
parturition	O
.	O

It	O
is	O
synthesized	O
as	O
a	O
preprohormone	O
precursor	O
,	O
which	O
undergoes	O
specific	O
processing	O
to	O
form	O
the	O
mature	O
two-chain	O
disulfide-linked	O
active	O
species	O
that	O
is	O
secreted	O
by	O
the	O
cell	O
.	O

A	O
major	O
part	O
of	O
this	O
processing	O
requires	O
endoproteolytic	O
cleavage	O
at	O
specific	O
pairs	O
of	O
basic	O
amino	CHEMICAL
acid	CHEMICAL
residues	O
,	O
an	O
event	O
necessary	O
for	O
the	O
maturation	O
of	O
a	O
variety	O
of	O
important	O
biologically	O
active	O
proteins	O
,	O
such	O
as	O
insulin	GENE-Y
and	O
nerve	GENE-Y
growth	GENE-Y
factor	GENE-Y
.	O

Human	GENE-Y
type	GENE-Y
2	GENE-Y
preprorelaxin	GENE-Y
was	O
coexpressed	O
in	O
human	O
kidney	O
293	O
cells	O
with	O
the	O
candidate	O
prohormone	GENE-N
convertase-processing	GENE-N
enzymes	GENE-N
mPC1	GENE-Y
or	O
mPC2	GENE-Y
,	O
both	O
cloned	O
from	O
the	O
mouse	O
pituitary	O
tumor	O
AtT-20	O
cell	O
line	O
,	O
or	O
with	O
the	O
yeast	GENE-Y
kex2	GENE-Y
alpha-mating	GENE-Y
factor-converting	GENE-Y
enzyme	GENE-Y
from	O
Saccharomyces	O
cerevisiae	O
.	O

Prorelaxin	GENE-N
expressed	O
alone	O
in	O
293	O
cells	O
was	O
secreted	O
into	O
the	O
culture	O
medium	O
unprocessed	O
.	O

Transient	O
coexpression	O
with	O
mPC1	GENE-Y
or	O
kex2	GENE-Y
,	O
but	O
not	O
with	O
mPC2	GENE-Y
,	O
resulted	O
in	O
the	O
secretion	O
of	O
a	O
low	O
mol	O
wt	O
species	O
with	O
an	O
electrophoretic	O
mobility	O
very	O
similar	O
,	O
if	O
not	O
identical	O
,	O
to	O
that	O
of	O
authentic	O
mature	O
relaxin	GENE-N
purified	O
from	O
human	O
placenta	O
.	O

This	O
species	O
was	O
precipitable	O
by	O
monoclonal	O
antibodies	O
specific	O
for	O
relaxin	GENE-N
and	O
had	O
a	O
retention	O
time	O
on	O
reverse	O
phase	O
HPLC	O
comparable	O
to	O
that	O
of	O
relaxin	GENE-N
.	O

Its	O
analysis	O
by	O
both	O
electrospray	O
and	O
fast	O
atom	O
bombardment	O
mass	O
spectrometry	O
generated	O
mass	O
data	O
that	O
were	O
consistent	O
only	O
with	O
mature	O
relaxin	GENE-N
.	O

The	O
basic	O
residues	O
required	O
for	O
mPC1-dependent	O
cleavage	O
of	O
prorelaxin	GENE-N
are	O
defined	O
by	O
site-directed	O
mutagenesis	O
.	O
BACKGROUND	O
:	O
The	O
risk	O
of	O
postoperative	O
immune	O
reaction	O
/	O
transplant	O
rejection	O
is	O
increased	O
in	O
the	O
presence	O
of	O
distinct	O
risk	O
factors	O
.	O

In	O
these	O
situations	O
,	O
the	O
use	O
of	O
established	O
immunosuppressive	O
agents	O
(	O
steroids	CHEMICAL
,	O
cyclosporin	CHEMICAL
)	O
is	O
indicated	O
.	O

However	O
,	O
immune	O
reactions	O
can	O
occur	O
despite	O
this	O
therapy	O
.	O

Basiliximab	O
is	O
a	O
monoclonal	O
antibody	O
with	O
a	O
high	O
specific	O
binding	O
affinity	O
to	O
the	O
IL-2	GENE-N
receptor	GENE-N
of	O
activated	O
T-cells	O
.	O

After	O
renal	O
transplantation	O
,	O
the	O
combination	O
therapy	O
with	O
basiliximab	O
and	O
cyclosporin	CHEMICAL
reduces	O
the	O
risk	O
of	O
acute	O
rejection	O
by	O
30%	O
against	O
placebo	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
complementary	O
immune	O
suppression	O
with	O
the	O
IL-2	GENE-Y
synthesis	O
inhibitor	O
cyclosporin	CHEMICAL
and	O
the	O
IL-2	GENE-N
receptor	GENE-N
antagonist	O
basiliximab	O
on	O
the	O
incidence	O
of	O
transplant	O
rejection	O
after	O
high-risk	O
keratoplasty	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
In	O
an	O
open	O
pilot	O
study	O
,	O
seven	O
patients	O
with	O
high-risk	O
keratoplasty	O
were	O
treated	O
with	O
basiliximab	O
perioperatively	O
and	O
cyclosporin	CHEMICAL
postoperatively	O
.	O

All	O
patients	O
had	O
penetrating	O
keratoplasty	O
with	O
a	O
non-HLA-matched	O
corneal	O
graft	O
.	O

RESULTS	O
:	O
Seven	O
patients	O
were	O
operated	O
on	O
from	O
12	O
/	O
98	O
through	O
12	O
/	O
99	O
with	O
a	O
corneal	O
transplant	O
diameter	O
between	O
7	O
.	O
1	O
and	O
9	O
.	O
5	O
mm	O
.	O

Risk	O
factors	O
included	O
extensive	O
corneal	O
neovascularization	O
in	O
all	O
patients	O
(	O
indications	O
for	O
surgery	O
:	O
4	O
cases	O
with	O
corneal	O
scars	O
after	O
herpetic	O
disease	O
,	O
2	O
cases	O
with	O
conditions	O
after	O
alkali	O
burns	O
,	O
1	O
case	O
with	O
corneal	O
ulceration	O
after	O
thermal	O
burn	O
)	O
.	O

During	O
the	O
follow-up	O
of	O
14-25	O
months	O
,	O
no	O
immune	O
reaction	O
has	O
occurred	O
,	O
and	O
all	O
transplants	O
are	O
clear	O
.	O

The	O
mean	O
visual	O
acuity	O
increased	O
from	O
0	O
.	O
04	O
to	O
0	O
.	O
41	O
postoperatively	O
.	O

DISCUSSION	O
:	O
The	O
preliminary	O
data	O
on	O
a	O
combination	O
therapy	O
with	O
basiliximab	O
and	O
cyclosporin	CHEMICAL
are	O
promising	O
.	O

For	O
further	O
evaluation	O
a	O
prospective	O
multicenter	O
study	O
is	O
planned	O
.	O
The	O
aromatic	GENE-N
amino	GENE-N
acid	GENE-N
hydroxylases	O
represent	O
a	O
superfamily	O
of	O
structurally	O
and	O
functionally	O
closely	O
related	O
enzymes	O
,	O
one	O
of	O
those	O
functions	O
being	O
reversible	O
inhibition	O
by	O
catechol	CHEMICAL
derivatives	O
.	O

Here	O
we	O
present	O
the	O
crystal	O
structure	O
of	O
the	O
dimeric	O
catalytic	O
domain	O
(	O
residues	O
117-424	O
)	O
of	O
human	GENE-Y
phenylalanine	CHEMICAL
hydroxylase	O
(	O
hPheOH	GENE-Y
)	O
,	O
cocrystallized	O
with	O
various	O
potent	O
and	O
well-known	O
catechol	CHEMICAL
inhibitors	O
and	O
refined	O
at	O
a	O
resolution	O
of	O
2	O
.	O
0	O
A	O
.	O

The	O
catechols	CHEMICAL
bind	O
by	O
bidentate	O
coordination	O
to	O
each	O
iron	CHEMICAL
in	O
both	O
subunits	O
of	O
the	O
dimer	O
through	O
the	O
catechol	CHEMICAL
hydroxyl	CHEMICAL
groups	O
,	O
forming	O
a	O
blue-green	O
colored	O
ligand-to-metal	O
charge-transfer	O
complex	O
.	O

In	O
addition	O
,	O
Glu330	O
and	O
Tyr325	O
are	O
identified	O
as	O
determinant	O
residues	O
in	O
the	O
recognition	O
of	O
the	O
inhibitors	O
.	O

In	O
particular	O
,	O
the	O
interaction	O
with	O
Glu330	O
conforms	O
to	O
the	O
structural	O
explanation	O
for	O
the	O
pH	O
dependence	O
of	O
catecholamine	CHEMICAL
binding	O
to	O
PheOH	CHEMICAL
,	O
with	O
a	O
pKa	O
value	O
of	O
5	O
.	O
1	O
(	O
20	O
degreesC	O
)	O
.	O

The	O
overall	O
structure	O
of	O
the	O
catechol-bound	O
enzyme	O
is	O
very	O
similar	O
to	O
that	O
of	O
the	O
uncomplexed	O
enzyme	O
(	O
rms	O
difference	O
of	O
0	O
.	O
2	O
A	O
for	O
the	O
Calpha	O
atoms	O
)	O
.	O

Most	O
striking	O
is	O
the	O
replacement	O
of	O
two	O
iron-bound	O
water	O
molecules	O
with	O
catechol	CHEMICAL
hydroxyl	CHEMICAL
groups	O
.	O

This	O
change	O
is	O
consistent	O
with	O
a	O
change	O
in	O
the	O
ligand	O
field	O
symmetry	O
of	O
the	O
high-spin	O
(	O
S	O
=	O
5	O
/	O
2	O
)	O
Fe	O
(	O
III	O
)	O
from	O
a	O
rhombic	O
to	O
a	O
nearly	O
axial	O
ligand	O
field	O
symmetry	O
as	O
seen	O
upon	O
noradrenaline	CHEMICAL
binding	O
using	O
EPR	O
spectroscopy	O
[	O
Martinez	O
,	O
A	O
.	O

,	O
Andersson	O
,	O
K	O
.	O

K	O
.	O

,	O
Haavik	O
,	O
J	O
.	O

,	O
and	O
Flatmark	O
,	O
T	O
.	O

(	O
1991	O
)	O
Eur	O
.	O

J	O
.	O

Biochem	O
.	O

198	O
,	O
675-682	O
]	O
.	O

Crystallographic	O
comparison	O
with	O
the	O
structurally	O
related	O
rat	GENE-Y
tyrosine	CHEMICAL
hydroxylase	O
binary	O
complex	O
with	O
the	O
oxidized	O
cofactor	O
7	CHEMICAL
,	CHEMICAL
8-dihydrobiopterin	CHEMICAL
revealed	O
overlapping	O
binding	O
sites	O
for	O
the	O
catechols	CHEMICAL
and	O
the	O
cofactor	O
,	O
compatible	O
with	O
a	O
competitive	O
type	O
of	O
inhibition	O
of	O
the	O
catechols	CHEMICAL
versus	O
BH4	O
.	O

The	O
comparison	O
demonstrates	O
some	O
structural	O
differences	O
at	O
the	O
active	O
site	O
as	O
the	O
potential	O
basis	O
for	O
the	O
different	O
substrate	O
specificity	O
of	O
the	O
two	O
enzymes	O
.	O
The	O
hypothalamus-pituitary-adrenal-axis	O
is	O
strongly	O
controlled	O
by	O
the	O
endocannabinoid	O
system	O
.	O

The	O
specific	O
impact	O
of	O
enhanced	O
2-arachidonoylglycerol	CHEMICAL
signaling	O
on	O
corticosterone	CHEMICAL
plasma	O
levels	O
,	O
however	O
,	O
was	O
not	O
investigated	O
so	O
far	O
.	O

Here	O
we	O
studied	O
the	O
effects	O
of	O
the	O
recently	O
developed	O
monoacylglycerol	GENE-Y
lipase	O
inhibitor	O
JZL184	CHEMICAL
on	O
basal	O
and	O
stress-induced	O
corticosterone	CHEMICAL
levels	O
in	O
male	O
CD1	O
mice	O
,	O
and	O
found	O
that	O
this	O
compound	O
dramatically	O
increased	O
basal	O
levels	O
without	O
affecting	O
stress	O
responses	O
.	O

Since	O
acute	O
changes	O
in	O
corticosterone	CHEMICAL
levels	O
can	O
affect	O
behavior	O
,	O
JZL184	CHEMICAL
was	O
administered	O
concurrently	O
with	O
the	O
corticosterone	CHEMICAL
synthesis	O
inhibitor	O
metyrapone	CHEMICAL
,	O
to	O
investigate	O
whether	O
the	O
previously	O
shown	O
behavioral	O
effects	O
of	O
JZL184	CHEMICAL
are	O
dependent	O
on	O
corticosterone	CHEMICAL
.	O

We	O
found	O
that	O
in	O
the	O
elevated	O
plus-maze	O
,	O
the	O
effects	O
of	O
JZL184	CHEMICAL
on	O
"classical"	O
anxiety-related	O
measures	O
were	O
abolished	O
by	O
corticosterone	CHEMICAL
synthesis	O
blockade	O
.	O

By	O
contrast	O
,	O
effects	O
on	O
the	O
"ethological"	O
measures	O
of	O
anxiety	O
(	O
i	O
.	O

e	O
.	O

risk	O
assessment	O
)	O
were	O
not	O
affected	O
by	O
metyrapone	CHEMICAL
.	O

In	O
the	O
open-field	O
,	O
the	O
locomotion-enhancing	O
effects	O
of	O
the	O
compound	O
were	O
not	O
changed	O
either	O
.	O

These	O
findings	O
show	O
that	O
monoacylglycerol	GENE-Y
lipase	O
inhibition	O
dramatically	O
increases	O
basal	O
levels	O
of	O
corticosterone	CHEMICAL
.	O

This	O
endocrine	O
effect	O
partly	O
affects	O
the	O
anxiolytic	O
,	O
but	O
not	O
the	O
locomotion-enhancing	O
effects	O
of	O
monoacylglycerol	GENE-Y
lipase	O
blockade	O
.	O
Selective	O
separation	O
of	O
similarly	O
sized	O
proteins	O
with	O
tunable	O
nanoporous	O
block	O
copolymer	O
membranes	O
.	O
Improvement	O
of	O
cardiac	O
output	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
by	O
use	O
of	O
ACE-inhibitors	O
combined	O
with	O
the	O
AT1-antagonist	O
eprosartan	CHEMICAL
.	O
Topical	O
vitamin	CHEMICAL
D3	CHEMICAL
and	O
low-calcemic	O
analogs	O
induce	O
thymic	O
stromal	O
lymphopoietin	O
in	O
mouse	O
keratinocytes	O
and	O
trigger	O
an	O
atopic	O
dermatitis	O
.	O
UNLABELLED	O
:	O
Escitalopram	CHEMICAL
is	O
the	O
therapeutically	O
active	O
S-enantiomer	CHEMICAL
of	CHEMICAL
RS-citalopram	CHEMICAL
,	O
a	O
commonly	O
prescribed	O
SSRI	O
.	O

The	O
R-enantiomer	O
is	O
essentially	O
pharmacologically	O
inactive	O
.	O

Escitalopram	CHEMICAL
10	O
or	O
20	O
mg	O
/	O
day	O
produced	O
significantly	O
greater	O
improvements	O
in	O
standard	O
measurements	O
of	O
antidepressant	O
effect	O
(	O
Montgomery-Asberg	O
Depression	O
Rating	O
Scale	O
[	O
MADRS	O
]	O
,	O
Clinical	O
Global	O
Impressions	O
Improvement	O
and	O
Severity	O
scales	O
[	O
CGI-I	O
and	O
CGI-S	O
]	O
and	O
Hamilton	O
Rating	O
Scale	O
for	O
Depression	O
[	O
HAM-D	O
]	O
)	O
in	O
patients	O
with	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
than	O
placebo	O
in	O
several	O
8-week	O
,	O
placebo-controlled	O
,	O
randomised	O
,	O
double-blind	O
,	O
multicentre	O
studies	O
.	O

Symptom	O
improvement	O
was	O
rapid	O
,	O
with	O
some	O
parameters	O
improving	O
within	O
1-2	O
weeks	O
of	O
starting	O
escitalopram	CHEMICAL
treatment	O
.	O

In	O
addition	O
,	O
escitalopram	CHEMICAL
showed	O
earlier	O
and	O
clearer	O
separation	O
from	O
placebo	O
than	O
RS-citalopram	CHEMICAL
,	O
at	O
one-quarter	O
to	O
half	O
the	O
dosage	O
,	O
in	O
8-week	O
,	O
placebo-controlled	O
trials;	O
had	O
significantly	O
better	O
efficacy	O
than	O
RS-citalopram	CHEMICAL
in	O
a	O
subgroup	O
of	O
patients	O
with	O
moderate	O
MDD	O
in	O
a	O
24-week	O
trial;	O
and	O
produced	O
sustained	O
response	O
and	O
remission	O
significantly	O
faster	O
than	O
venlafaxine	CHEMICAL
extended	O
release	O
in	O
patients	O
with	O
MDD	O
.	O

Escitalopram	CHEMICAL
reduced	O
relapse	O
rate	O
compared	O
with	O
placebo	O
and	O
increased	O
the	O
percentage	O
of	O
patients	O
in	O
remission	O
in	O
long-term	O
trials	O
(	O
up	O
to	O
52	O
weeks	O
)	O
.	O

Consistently	O
significant	O
improvements	O
for	O
all	O
efficacy	O
parameters	O
were	O
also	O
observed	O
in	O
patients	O
with	O
generalised	O
anxiety	O
disorder	O
,	O
social	O
anxiety	O
disorder	O
and	O
panic	O
disorder	O
treated	O
with	O
escitalopram	CHEMICAL
for	O
8-12	O
weeks	O
in	O
individual	O
,	O
randomised	O
,	O
placebo-controlled	O
,	O
double-blind	O
investigations	O
.	O

The	O
good	O
tolerability	O
profile	O
of	O
escitalopram	CHEMICAL
is	O
predictable	O
and	O
similar	O
to	O
that	O
of	O
RS-citalopram	CHEMICAL
.	O

Such	O
adverse	O
events	O
as	O
nausea	O
,	O
ejaculatory	O
problems	O
,	O
diarrhoea	O
and	O
insomnia	O
are	O
expected	O
but	O
,	O
with	O
the	O
exception	O
of	O
ejaculatory	O
problems	O
and	O
nausea	O
,	O
which	O
is	O
mild	O
and	O
transient	O
,	O
these	O
were	O
generally	O
no	O
more	O
frequent	O
than	O
with	O
placebo	O
in	O
fully	O
published	O
clinical	O
trials	O
.	O

No	O
adverse	O
events	O
not	O
previously	O
seen	O
in	O
acute	O
trials	O
were	O
reported	O
with	O
long-term	O
use	O
.	O

CONCLUSIONS	O
:	O
Escitalopram	CHEMICAL
,	O
the	O
S-enantiomer	O
of	O
RS-citalopram	CHEMICAL
,	O
is	O
a	O
highly	O
selective	O
inhibitor	O
for	O
the	O
serotonin	GENE-Y
transporter	O
,	O
ameliorates	O
depressive	O
symptoms	O
in	O
patients	O
with	O
MDD	O
at	O
half	O
the	O
RS-citalopram	CHEMICAL
dosage	O
,	O
has	O
a	O
rapid	O
onset	O
of	O
symptom	O
improvement	O
and	O
has	O
a	O
predictable	O
tolerability	O
profile	O
of	O
generally	O
mild	O
adverse	O
events	O
.	O

Like	O
RS-citalopram	CHEMICAL
,	O
escitalopram	CHEMICAL
is	O
expected	O
to	O
have	O
a	O
low	O
propensity	O
for	O
drug	O
interactions	O
,	O
a	O
potential	O
benefit	O
in	O
the	O
management	O
of	O
patients	O
with	O
comorbidities	O
.	O

In	O
combination	O
,	O
these	O
properties	O
place	O
escitalopram	CHEMICAL
,	O
like	O
other	O
SSRIs	O
,	O
as	O
first-line	O
therapy	O
in	O
patients	O
with	O
MDD	O
.	O

Escitalopram	CHEMICAL
is	O
indicated	O
for	O
use	O
in	O
patients	O
with	O
panic	O
disorder	O
in	O
Europe	O
and	O
,	O
should	O
further	O
evidence	O
confirm	O
early	O
findings	O
that	O
escitalopram	CHEMICAL
reduces	O
anxiety	O
,	O
the	O
drug	O
may	O
well	O
find	O
an	O
additional	O
role	O
in	O
the	O
management	O
of	O
anxiety	O
disorders	O
.	O
Cofactor	O
and	O
tryptophan	CHEMICAL
accessibility	O
and	O
unfolding	O
of	O
brain	O
glutamate	GENE-Y
decarboxylase	O
.	O
Association	O
of	O
enzyme	O
and	O
transporter	O
genotypes	O
with	O
the	O
pharmacokinetics	O
of	O
imatinib	CHEMICAL
.	O
Multiple	O
exposure	O
to	O
theophylline	CHEMICAL
,	O
a	O
phosphodiesterase	GENE-N
(	O
PDE	GENE-N
)	O
inhibitor	O
,	O
induces	O
acinar	O
hypertrophy	O
in	O
the	O
salivary	O
gland	O
.	O

This	O
study	O
examined	O
the	O
effect	O
of	O
theophylline	CHEMICAL
on	O
the	O
gene	O
expression	O
of	O
secretory	O
proteins	O
and	O
phosphodiesterases	GENE-N
in	O
the	O
submaxillary	O
gland	O
.	O

Male	O
F344	O
rats	O
received	O
saline	O
or	O
theophylline	CHEMICAL
(	O
50	O
mg	O
/	O
kg	O
)	O
intraperitoneally	O
for	O
4	O
days	O
.	O

The	O
gene	O
expressions	O
for	O
the	O
secretory	O
protein	O
,	O
cystatin	GENE-Y
S	CHEMICAL
(	O
CysS	GENE-Y
)	O
,	O
and	O
PDE	GENE-N
subfamilies	GENE-N
3A	GENE-N
and	GENE-N
4D	GENE-N
in	O
the	O
submaxillary	O
gland	O
were	O
quantified	O
using	O
RT-PCR	O
.	O

Theophylline	CHEMICAL
exposure	O
resulted	O
in	O
a	O
sustained	O
increase	O
in	O
mRNA	O
expression	O
for	O
CysS	GENE-Y
and	O
PDE3A	GENE-Y
,	O
but	O
PDE4D	GENE-Y
gene	O
expression	O
was	O
unchanged	O
.	O

Our	O
results	O
suggest	O
that	O
submaxillary	O
hypertrophy	O
is	O
primarily	O
caused	O
by	O
the	O
enhanced	O
transcription	O
of	O
CysS	GENE-Y
,	O
and	O
that	O
the	O
transcription	O
of	O
each	O
PDE	GENE-N
subfamily	O
gene	O
is	O
regulated	O
differently	O
.	O
Very	O
few	O
nonpeptide	O
oxytocin	GENE-Y
agonists	O
have	O
currently	O
been	O
reported	O
,	O
and	O
none	O
of	O
them	O
seem	O
suitable	O
for	O
the	O
in	O
vivo	O
investigation	O
of	O
the	O
oxytocin	GENE-Y
mediated	O
functions	O
.	O

In	O
an	O
attempt	O
to	O
rationalize	O
the	O
design	O
of	O
better	O
tools	O
,	O
we	O
have	O
systematically	O
studied	O
the	O
structural	O
determinants	O
of	O
the	O
affinity	O
and	O
efficacy	O
of	O
representative	O
ligands	O
of	O
the	O
V	GENE-Y
(	GENE-Y
1a	GENE-Y
)	GENE-Y
,	O
V	GENE-Y
(	GENE-Y
2	GENE-Y
)	GENE-Y
,	O
and	O
OT	GENE-Y
receptor	GENE-Y
subtypes	O
.	O

Despite	O
apparently	O
obvious	O
similarity	O
between	O
the	O
ligand	O
structures	O
on	O
one	O
hand	O
,	O
and	O
between	O
the	O
receptor	O
subtypes	O
on	O
the	O
other	O
hand	O
,	O
the	O
binding	O
affinity	O
and	O
the	O
functional	O
activity	O
profiles	O
of	O
truncated	O
and	O
hybrid	O
ligands	O
highlight	O
the	O
subtlety	O
of	O
ligand-receptor	O
interactions	O
for	O
obtaining	O
nonpeptide	O
OT	GENE-Y
receptor	GENE-Y
agonists	O
.	O
Several	O
signaling	O
pathways	O
are	O
believed	O
to	O
be	O
involved	O
in	O
the	O
epileptogenic	O
process	O
that	O
triggers	O
the	O
subsequent	O
changes	O
in	O
the	O
brain	O
causing	O
epilepsy	O
.	O

The	O
mammalian	GENE-Y
target	GENE-Y
of	GENE-Y
rapamycin	CHEMICAL
(	O
mTOR	GENE-Y
)	O
is	O
a	O
serine	CHEMICAL
/	O
threonine	CHEMICAL
kinase	O
that	O
in	O
the	O
brain	O
,	O
regulates	O
several	O
important	O
physiological	O
functions	O
such	O
as	O
neuronal	O
development	O
and	O
synaptic	O
plasticity	O
,	O
and	O
also	O
seems	O
to	O
be	O
involved	O
in	O
many	O
pathologies	O
,	O
including	O
epilepsy	O
and	O
psychiatric	O
disorders	O
.	O

Previous	O
work	O
in	O
animal	O
models	O
of	O
both	O
genetic	O
and	O
acquired	O
generalized	O
convulsive	O
epilepsies	O
,	O
has	O
suggested	O
that	O
modulators	O
of	O
the	O
mTOR	GENE-Y
signaling	O
pathway	O
may	O
have	O
beneficial	O
neuroprotective	O
and	O
antiepileptogenic	O
effects	O
.	O

Here	O
,	O
we	O
investigated	O
for	O
the	O
first	O
time	O
,	O
the	O
effect	O
of	O
some	O
treatment	O
schedules	O
(	O
i	O
.	O

e	O
.	O

early	O
chronic	O
,	O
sub-chronic	O
and	O
acute	O
)	O
with	O
the	O
specific	O
mTOR	GENE-Y
inhibitor	O
rapamycin	CHEMICAL
,	O
on	O
the	O
development	O
of	O
absence	O
seizures	O
and	O
seizure	O
parameters	O
as	O
well	O
as	O
depressive-like	O
behavior	O
in	O
WAG	O
/	O
Rij	O
rats	O
,	O
a	O
genetic	O
model	O
of	O
absence	O
epilepsy	O
,	O
epileptogenesis	O
and	O
mild-depression	O
comorbidity	O
.	O

In	O
addition	O
,	O
we	O
studied	O
the	O
possible	O
interaction	O
between	O
rapamycin	CHEMICAL
treatment	O
and	O
the	O
effects	O
of	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
endotoxin	O
administration	O
,	O
which	O
is	O
known	O
to	O
aggravate	O
absence	O
seizures	O
through	O
generation	O
of	O
increased	O
neuroinflammatory	O
responses	O
.	O

We	O
found	O
that	O
rapamycin	CHEMICAL
(	O
early	O
chronic	O
treatment	O
for	O
17	O
weeks	O
,	O
starting	O
at	O
P45	O
)	O
exhibited	O
clear	O
antiepileptogenic	O
properties	O
also	O
in	O
this	O
animal	O
epilepsy	O
model;	O
however	O
,	O
this	O
effect	O
was	O
accompanied	O
by	O
unexpected	O
prodepressant	O
effects	O
.	O

Both	O
acute	O
and	O
sub-chronic	O
(	O
7	O
day	O
)	O
treatments	O
also	O
had	O
anti-absence	O
properties	O
,	O
but	O
the	O
sub-chronic	O
treatment	O
produced	O
contrasting	O
antidepressant	O
properties	O
in	O
the	O
WAG	O
/	O
Rij	O
rats	O
that	O
were	O
not	O
seen	O
in	O
control	O
Wistar	O
rats	O
.	O

The	O
rapamycin	CHEMICAL
/	O
LPS	O
co-administration	O
studies	O
showed	O
that	O
rapamycin	CHEMICAL
blocked	O
or	O
prevented	O
the	O
LPS-dependent	O
increase	O
in	O
absence	O
seizures	O
,	O
suggesting	O
an	O
anti-inflammatory-like	O
protective	O
action	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
demonstrated	O
a	O
novel	O
antiepileptogenic	O
effect	O
of	O
rapamycin	CHEMICAL
in	O
a	O
well-established	O
animal	O
model	O
of	O
absence	O
epilepsy	O
,	O
and	O
we	O
suggest	O
that	O
this	O
effect	O
may	O
be	O
mediated	O
by	O
the	O
inhibition	O
of	O
inflammatory	O
processes	O
that	O
are	O
developed	O
in	O
the	O
brain	O
of	O
these	O
specific	O
animals	O
during	O
epileptogenesis	O
and	O
during	O
seizures	O
.	O

Our	O
experiments	O
here	O
suggest	O
new	O
insights	O
into	O
this	O
intriguing	O
field	O
,	O
which	O
deserves	O
to	O
be	O
further	O
explored	O
.	O

This	O
article	O
is	O
part	O
of	O
the	O
Special	O
Issue	O
entitled	O
'New	O
Targets	O
and	O
Approaches	O
to	O
the	O
Treatment	O
of	O
Epilepsy'	O
.	O
A	O
series	O
of	O
novel	O
hybrid	O
compounds	O
between	O
2-benzylbenzofuran	CHEMICAL
and	O
imidazole	CHEMICAL
has	O
been	O
prepared	O
and	O
evaluated	O
in	O
vitro	O
against	O
a	O
panel	O
of	O
human	O
tumor	O
cell	O
lines	O
.	O

The	O
results	O
suggest	O
that	O
the	O
existence	O
of	O
benzimidazole	CHEMICAL
ring	O
and	O
substitution	O
of	O
the	O
imidazolyl-3-position	O
with	O
a	O
naphthylacyl	CHEMICAL
or	O
4-methoxyphenacyl	CHEMICAL
group	O
were	O
vital	O
for	O
modulating	O
cytotoxic	O
activity	O
.	O

In	O
particular	O
,	O
hybrid	O
compounds	O
46	O
and	O
47	O
were	O
found	O
to	O
be	O
the	O
most	O
potent	O
derivatives	O
against	O
5	O
strains	O
human	O
tumor	O
cell	O
lines	O
and	O
more	O
active	O
than	O
cisplatin	CHEMICAL
(	O
DDP	CHEMICAL
)	O
,	O
and	O
exhibited	O
cytotoxic	O
activities	O
selectively	O
against	O
breast	O
carcinoma	O
(	O
MCF-7	O
)	O
and	O
myeloid	O
liver	O
carcinoma	O
(	O
SMMC-7721	O
)	O
,	O
respectively	O
.	O
RNAi	O
silencing	O
of	O
three	O
homologues	O
of	O
S-adenosylmethionine	CHEMICAL
decarboxylase	O
gene	O
in	O
tapetal	O
tissue	O
of	O
tomato	O
results	O
in	O
male	O
sterility	O
.	O
Synthesis	O
and	O
structure-activity	O
studies	O
of	O
benzyl	CHEMICAL
ester	CHEMICAL
meperidine	CHEMICAL
and	O
normeperidine	CHEMICAL
derivatives	O
as	O
selective	O
serotonin	GENE-Y
transporter	O
ligands	O
.	O
HIV	O
entry	O
is	O
mediated	O
by	O
the	O
envelope	GENE-Y
glycoproteins	GENE-Y
gp120	GENE-Y
and	O
gp41	GENE-Y
.	O

The	O
gp41	GENE-Y
subunit	O
contains	O
several	O
functional	O
domains	O
:	O
the	O
N-terminal	O
heptad	O
repeat	O
(	O
NHR	O
)	O
domains	O
fold	O
a	O
triple	O
stranded	O
coiled-coil	O
forming	O
a	O
meta-stable	O
prefusion	O
intermediate	O
.	O

C-terminal	O
heptad	O
repeat	O
(	O
CHR	O
)	O
subsequently	O
folds	O
onto	O
the	O
hydrophobic	O
grooves	O
of	O
the	O
NHR	O
coiled-coil	O
to	O
form	O
a	O
stable	O
6-helix	O
bundle	O
,	O
which	O
juxtaposes	O
the	O
viral	O
and	O
cellular	O
membranes	O
for	O
fusion	O
.	O

The	O
C34	O
which	O
has	O
34	O
amino	CHEMICAL
acid	CHEMICAL
residues	O
is	O
known	O
as	O
the	O
core	O
structure	O
in	O
CHR	O
.	O

A	O
highly	O
anti-HIV	O
peptide	O
inhibitor	O
derived	O
from	O
C34	O
was	O
designed	O
.	O

An	O
artificial	O
salt	O
bridge	O
was	O
added	O
in	O
the	O
6-helical	O
bundle	O
by	O
substitution	O
of	O
lysine	CHEMICAL
for	O
Ile646	O
.	O

With	O
a	O
cholesterol	CHEMICAL
modification	O
at	O
C-terminal	O
,	O
the	O
inhibitor	O
containing	O
I646K	GENE-N
mutation	O
represented	O
higher	O
anti-viral	O
activity	O
than	O
C34-cholesterol	CHEMICAL
combination	O
without	O
mutation	O
.	O
Cisapride	CHEMICAL
,	O
a	O
gastrointestinal	O
prokinetic	O
agent	O
,	O
is	O
known	O
to	O
cause	O
long	O
Q-T	O
syndrome	O
and	O
ventricular	O
arrhythmias	O
.	O

The	O
cellular	O
mechanism	O
is	O
not	O
known	O
.	O

The	O
human	GENE-Y
ether-a-go-go-related	GENE-Y
gene	GENE-Y
(	O
HERG	GENE-Y
)	O
,	O
which	O
encodes	O
the	O
rapidly	O
activating	O
delayed	O
rectifier	O
K	CHEMICAL
+	CHEMICAL
current	O
and	O
is	O
important	O
in	O
cardiac	O
repolarization	O
,	O
may	O
serve	O
as	O
a	O
target	O
for	O
the	O
action	O
of	O
cisapride	CHEMICAL
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
cisapride	CHEMICAL
blocks	O
HERG	GENE-Y
.	O

The	O
whole	O
cell	O
patch-clamp	O
recording	O
technique	O
was	O
used	O
to	O
study	O
HERG	GENE-Y
channels	O
stably	O
expressed	O
heterologously	O
in	O
HEK293	O
cells	O
.	O

Under	O
voltage-clamp	O
conditions	O
,	O
cisapride	CHEMICAL
block	O
of	O
HERG	GENE-Y
is	O
dose	O
dependent	O
with	O
a	O
half-maximal	O
inhibitory	O
concentration	O
of	O
6	O
.	O
5	O
nM	O
at	O
22	O
degrees	O
C	O
(	O
n	O
=	O
25	O
cells	O
)	O
.	O

Currents	O
rapidly	O
recovered	O
with	O
drug	O
washout	O
.	O

The	O
onset	O
of	O
block	O
by	O
cisapride	CHEMICAL
required	O
channel	O
activation	O
indicative	O
of	O
open	O
or	O
inactivated	O
state	O
blockage	O
.	O

Block	O
of	O
HERG	GENE-Y
with	O
cisapride	CHEMICAL
after	O
channel	O
activation	O
was	O
voltage	O
dependent	O
.	O

At	O
-20	O
mV	O
,	O
10	O
nM	O
cisapride	CHEMICAL
reduced	O
HERG	GENE-Y
tail-current	O
amplitude	O
by	O
5%	O
,	O
whereas	O
,	O
at	O
+	O
20	O
mV	O
,	O
the	O
tail-current	O
amplitude	O
was	O
reduced	O
by	O
45%	O
(	O
n	O
=	O
4	O
cells	O
)	O
.	O

At	O
-20	O
and	O
+	O
20	O
mV	O
,	O
100	O
nM	O
cisapride	CHEMICAL
reduced	O
tail-current	O
amplitude	O
by	O
66	O
and	O
90%	O
,	O
respectively	O
.	O

We	O
conclude	O
that	O
cisapride	CHEMICAL
is	O
a	O
potent	O
blocker	O
of	O
HERG	GENE-Y
channels	O
expressed	O
in	O
HEK293	O
cells	O
.	O

This	O
effect	O
may	O
account	O
for	O
the	O
clinical	O
occurrence	O
of	O
Q-T	O
prolongation	O
and	O
ventricular	O
arrhythmias	O
observed	O
with	O
cisapride	CHEMICAL
.	O
Dominant	O
expression	O
of	O
mRNA	O
for	O
prostaglandin	CHEMICAL
D	CHEMICAL
synthase	O
in	O
leptomeninges	O
,	O
choroid	O
plexus	O
,	O
and	O
oligodendrocytes	O
of	O
the	O
adult	O
rat	O
brain	O
.	O
Differential	O
regulation	O
of	O
T-cell	O
growth	O
by	O
IL-2	GENE-Y
and	O
IL-15	GENE-Y
.	O
Involvement	O
of	O
UDP-glucuronosyltransferases	O
UGT1A9	GENE-Y
and	O
UGT2B7	GENE-Y
in	O
ethanol	CHEMICAL
glucuronidation	O
,	O
and	O
interactions	O
with	O
common	O
drugs	O
of	O
abuse	O
.	O
Nonsteroidal	O
anti-inflammatory	O
agents	O
differ	O
in	O
their	O
ability	O
to	O
suppress	O
NF-kappaB	GENE-N
activation	O
,	O
inhibition	O
of	O
expression	O
of	O
cyclooxygenase-2	GENE-Y
and	O
cyclin	GENE-Y
D1	GENE-Y
,	O
and	O
abrogation	O
of	O
tumor	O
cell	O
proliferation	O
.	O
Minireview	O
:	O
the	O
AMP-activated	O
protein	O
kinase	O
cascade	O
:	O
the	O
key	O
sensor	O
of	O
cellular	O
energy	O
status	O
.	O
Vitamin	CHEMICAL
B-6	CHEMICAL
deficiency	O
suppresses	O
the	O
hepatic	O
transsulfuration	O
pathway	O
but	O
increases	O
glutathione	CHEMICAL
concentration	O
in	O
rats	O
fed	O
AIN-76A	O
or	O
AIN-93G	O
diets	O
.	O
Perfluorooctanoic	CHEMICAL
acid	CHEMICAL
(	O
PFOA	CHEMICAL
)	O
is	O
in	O
use	O
for	O
the	O
production	O
of	O
fluoropolymers	CHEMICAL
(	O
PFT	CHEMICAL
)	O
.	O

Due	O
to	O
its	O
toxic	O
properties	O
it	O
was	O
proposed	O
to	O
replace	O
the	O
substance	O
in	O
its	O
industrial	O
applications	O
by	O
homologous	O
compounds	O
with	O
shorter	O
carbon	CHEMICAL
chain	O
length	O
that	O
were	O
supposed	O
to	O
be	O
less	O
toxic	O
compared	O
to	O
PFOA	CHEMICAL
,	O
however	O
,	O
the	O
smaller	O
PFOA	CHEMICAL
homologs	O
are	O
poorly	O
characterized	O
so	O
far	O
.	O

In	O
this	O
study	O
we	O
have	O
conducted	O
a	O
comparative	O
analysis	O
of	O
the	O
toxicity	O
of	O
perfluorinated	CHEMICAL
carboxylic	CHEMICAL
acids	CHEMICAL
(	O
PFCA	CHEMICAL
)	O
with	O
a	O
carbon	CHEMICAL
chain	O
length	O
ranging	O
from	O
four	O
to	O
twelve	O
carbon	CHEMICAL
atoms	O
.	O

By	O
using	O
the	O
human	O
hepatocarcinoma	O
cell	O
line	O
HepG2	O
as	O
an	O
in	O
vitro	O
model	O
for	O
human	O
hepatocytes	O
we	O
could	O
show	O
a	O
positive	O
correlation	O
between	O
the	O
carbon	CHEMICAL
chain	O
length	O
of	O
the	O
respective	O
PFCA	CHEMICAL
and	O
its	O
cytotoxicity	O
.	O

There	O
was	O
,	O
however	O
,	O
no	O
indication	O
of	O
an	O
apoptotic	O
mechanism	O
for	O
cytotoxicity	O
.	O

All	O
PFCA	CHEMICAL
under	O
investigation	O
were	O
negative	O
in	O
two	O
independent	O
genotoxicity	O
assays	O
.	O

As	O
PFOA	CHEMICAL
,	O
being	O
a	O
well-known	O
peroxisome	O
proliferator	O
,	O
the	O
other	O
PFCA	CHEMICAL
tested	O
in	O
this	O
study	O
were	O
also	O
shown	O
to	O
activate	O
human	GENE-Y
peroxisome	GENE-Y
proliferator-activated	GENE-Y
receptor	GENE-Y
alpha	GENE-Y
(	O
PPARα	GENE-Y
)	O
with	O
PFOA	CHEMICAL
having	O
the	O
highest	O
potential	O
of	O
PPARα	GENE-Y
activation	O
.	O

Moreover	O
,	O
the	O
compounds	O
showed	O
weak	O
potential	O
to	O
activate	O
PPARγ	GENE-Y
and	O
hardly	O
activated	O
PPARδ	GENE-Y
.	O

Taken	O
together	O
,	O
the	O
in	O
vitro	O
study	O
revealed	O
that	O
PFCA	CHEMICAL
with	O
a	O
shorter	O
carbon	CHEMICAL
chain	O
length	O
seem	O
to	O
be	O
less	O
toxic	O
than	O
PFOA	CHEMICAL
.	O
Lithium	CHEMICAL
modulates	O
desensitization	O
of	O
the	O
glutamate	GENE-N
receptor	O
subtype	O
gluR3	GENE-Y
in	O
Xenopus	O
oocytes	O
.	O
In	O
response	O
to	O
intense	O
stress	O
,	O
the	O
tumor	GENE-Y
protein	GENE-Y
p53	GENE-Y
(	O
p53	GENE-Y
)	O
tumor	O
suppressor	O
rapidly	O
mounts	O
a	O
direct	O
mitochondrial	O
death	O
program	O
that	O
precedes	O
transcription-mediated	O
apoptosis	O
.	O

By	O
eliminating	O
severely	O
damaged	O
cells	O
,	O
this	O
pathway	O
contributes	O
to	O
tumor	O
suppression	O
as	O
well	O
as	O
to	O
cancer	O
cell	O
killing	O
induced	O
by	O
both	O
genotoxic	O
drugs	O
and	O
non-genotoxic	O
p53-reactivating	O
molecules	O
.	O

Here	O
we	O
have	O
explored	O
the	O
role	O
had	O
in	O
this	O
pathway	O
by	O
the	O
prolyl-isomerase	O
Pin1	O
(	O
peptidylprolyl	GENE-Y
cis	GENE-Y
/	GENE-Y
trans	GENE-Y
isomerase	GENE-Y
,	GENE-Y
NIMA-interacting	GENE-Y
1	GENE-Y
)	O
,	O
a	O
crucial	O
transducer	O
of	O
p53's	GENE-Y
phosphorylation	O
into	O
conformational	O
changes	O
unleashing	O
its	O
pro-apoptotic	O
activity	O
.	O

We	O
show	O
that	O
Pin1	GENE-Y
promotes	O
stress-induced	O
localization	O
of	O
p53	GENE-Y
to	O
mitochondria	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
particular	O
,	O
we	O
demonstrate	O
that	O
upon	O
stress-induced	O
phosphorylation	O
of	O
p53	GENE-Y
on	O
Ser46	O
by	O
homeodomain	GENE-Y
interacting	GENE-Y
protein	GENE-Y
kinase	GENE-Y
2	GENE-Y
,	O
Pin1	GENE-Y
stimulates	O
its	O
mitochondrial	O
trafficking	O
signal	O
,	O
that	O
is	O
,	O
monoubiquitination	O
.	O

This	O
pathway	O
is	O
induced	O
also	O
by	O
the	O
p53-activating	O
molecule	O
RITA	O
,	O
and	O
we	O
demonstrate	O
the	O
strong	O
requirement	O
of	O
Pin1	GENE-Y
for	O
the	O
induction	O
of	O
mitochondrial	O
apoptosis	O
by	O
this	O
compound	O
.	O

These	O
findings	O
have	O
significant	O
implications	O
for	O
treatment	O
of	O
p53-expressing	O
tumors	O
and	O
for	O
prospective	O
use	O
of	O
p53-activating	O
compounds	O
in	O
clinics	O
.	O
Bupropion	CHEMICAL
occupancy	O
of	O
the	O
dopamine	GENE-Y
transporter	O
is	O
low	O
during	O
clinical	O
treatment	O
.	O
Over	O
the	O
past	O
20	O
years	O
,	O
studies	O
of	O
transient	GENE-N
receptor	GENE-N
potential	GENE-N
(	GENE-N
TRP	GENE-N
)	GENE-N
channels	GENE-N
have	O
significantly	O
extended	O
our	O
knowledge	O
regarding	O
the	O
molecular	O
basis	O
of	O
Ca2	CHEMICAL
+	CHEMICAL
signals	O
in	O
cardiac	O
myocytes	O
.	O

The	O
functional	O
significance	O
of	O
cardiac	O
TRP	GENE-N
channels	GENE-N
is	O
likely	O
connected	O
to	O
the	O
alteration	O
of	O
membrane	O
potential	O
or	O
Ca2	CHEMICAL
+	CHEMICAL
entry	O
into	O
a	O
noncontractile	O
compartment	O
,	O
where	O
gene	O
expression	O
responsible	O
for	O
various	O
cardiac	O
diseases	O
is	O
induced	O
.	O

This	O
review	O
highlights	O
some	O
aspects	O
of	O
TRP	GENE-N
channels	GENE-N
with	O
anticipated	O
roles	O
in	O
cardiac	O
disease	O
.	O

Evidence	O
suggests	O
that	O
(	O
a	O
)	O
increased	O
activities	O
of	O
TRPC1	GENE-Y
,	O
TRPC3	GENE-Y
,	O
or	O
TRPC6	GENE-Y
are	O
involved	O
in	O
the	O
development	O
of	O
cardiac	O
hypertrophy	O
,	O
where	O
these	O
TRPC	GENE-N
channels	GENE-N
act	O
as	O
unique	O
sensors	O
for	O
a	O
wide	O
range	O
of	O
hypertrophic	O
stimuli	O
,	O
and	O
(	O
b	O
)	O
mutations	O
in	O
TRPM4	GENE-Y
are	O
now	O
recognized	O
as	O
causes	O
of	O
human	O
cardiac	O
conduction	O
disorders	O
.	O

Ultimately	O
,	O
TRP	GENE-N
channels	GENE-N
may	O
become	O
novel	O
pharmacological	O
targets	O
in	O
the	O
treatment	O
of	O
human	O
cardiac	O
disease	O
.	O
Study	O
on	O
medicinal	O
chemistry	O
of	O
k203	O
in	O
wistar	O
rats	O
and	O
beagle	O
dogs	O
.	O
The	O
voltage-dependent	O
M-type	O
potassium	CHEMICAL
current	O
(	O
M-current	O
)	O
plays	O
a	O
major	O
role	O
in	O
controlling	O
brain	O
excitability	O
by	O
stabilizing	O
the	O
membrane	O
potential	O
and	O
acting	O
as	O
a	O
brake	O
for	O
neuronal	O
firing	O
.	O

The	O
KCNQ2	GENE-N
/	GENE-N
Q3	GENE-N
heteromeric	O
channel	O
complex	O
was	O
identified	O
as	O
the	O
molecular	O
correlate	O
of	O
the	O
M-current	O
.	O

Furthermore	O
,	O
the	O
KCNQ2	GENE-Y
and	O
KCNQ3	GENE-Y
channel	GENE-Y
alpha	GENE-Y
subunits	GENE-Y
are	O
mutated	O
in	O
families	O
with	O
benign	O
familial	O
neonatal	O
convulsions	O
,	O
a	O
neonatal	O
form	O
of	O
epilepsy	O
.	O

Enhancement	O
of	O
KCNQ2	GENE-N
/	GENE-N
Q3	GENE-N
potassium	CHEMICAL
currents	O
may	O
provide	O
an	O
important	O
target	O
for	O
antiepileptic	O
drug	O
development	O
.	O

Here	O
,	O
we	O
show	O
that	O
meclofenamic	CHEMICAL
acid	CHEMICAL
(	O
meclofenamate	CHEMICAL
)	O
and	O
diclofenac	CHEMICAL
,	O
two	O
related	O
molecules	O
previously	O
used	O
as	O
anti-inflammatory	O
drugs	O
,	O
act	O
as	O
novel	O
KCNQ2	GENE-N
/	GENE-N
Q3	GENE-N
channel	O
openers	O
.	O

Extracellular	O
application	O
of	O
meclofenamate	CHEMICAL
(	O
EC	O
(	O
50	O
)	O
=	O
25	O
microM	O
)	O
and	O
diclofenac	CHEMICAL
(	O
EC	O
(	O
50	O
)	O
=	O
2	O
.	O
6	O
microM	O
)	O
resulted	O
in	O
the	O
activation	O
of	O
KCNQ2	GENE-N
/	GENE-N
Q3	GENE-N
K	O
(	O
+	O
)	O
currents	O
,	O
heterologously	O
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
.	O

Both	O
openers	O
activated	O
KCNQ2	GENE-N
/	GENE-N
Q3	GENE-N
channels	O
by	O
causing	O
a	O
hyperpolarizing	O
shift	O
of	O
the	O
voltage	O
activation	O
curve	O
(	O
-23	O
and	O
-15	O
mV	O
,	O
respectively	O
)	O
and	O
by	O
markedly	O
slowing	O
the	O
deactivation	O
kinetics	O
.	O

The	O
effects	O
of	O
the	O
drugs	O
were	O
stronger	O
on	O
KCNQ2	GENE-Y
than	O
on	O
KCNQ3	GENE-Y
channel	GENE-Y
alpha	GENE-Y
subunits	GENE-Y
.	O

In	O
contrast	O
,	O
they	O
did	O
not	O
enhance	O
KCNQ1	GENE-Y
K	O
(	O
+	O
)	O
currents	O
.	O

Both	O
openers	O
increased	O
KCNQ2	GENE-N
/	GENE-N
Q3	GENE-N
current	O
amplitude	O
at	O
physiologically	O
relevant	O
potentials	O
and	O
led	O
to	O
hyperpolarization	O
of	O
the	O
resting	O
membrane	O
potential	O
.	O

In	O
cultured	O
cortical	O
neurons	O
,	O
meclofenamate	CHEMICAL
and	O
diclofenac	CHEMICAL
enhanced	O
the	O
M-current	O
and	O
reduced	O
evoked	O
and	O
spontaneous	O
action	O
potentials	O
,	O
whereas	O
in	O
vivo	O
diclofenac	CHEMICAL
exhibited	O
an	O
anticonvulsant	O
activity	O
(	O
ED	O
(	O
50	O
)	O
=	O
43	O
mg	O
/	O
kg	O
)	O
.	O

These	O
compounds	O
potentially	O
constitute	O
novel	O
drug	O
templates	O
for	O
the	O
treatment	O
of	O
neuronal	O
hyperexcitability	O
including	O
epilepsy	O
,	O
migraine	O
,	O
or	O
neuropathic	O
pain	O
.	O
The	O
pharmacological	O
treatment	O
of	O
obesity	O
should	O
be	O
considered	O
when	O
cannot	O
be	O
achieved	O
a	O
10%	O
weight	O
loss	O
with	O
diet	O
therapy	O
and	O
physical	O
activity	O
.	O

The	O
drugs	O
effective	O
in	O
obesity	O
treatment	O
may	O
act	O
by	O
different	O
mechanisms	O
such	O
as	O
reduction	O
in	O
food	O
intake	O
,	O
inhibition	O
of	O
fat	O
absorption	O
,	O
increase	O
of	O
thermogenesis	O
and	O
stimulation	O
of	O
adipocyte	O
apoptosis	O
.	O

At	O
present	O
,	O
we	O
only	O
have	O
two	O
marketed	O
drugs	O
for	O
obesity	O
treatment	O
.	O

Sibutramine	CHEMICAL
is	O
an	O
inhibitor	O
of	O
norepinephrine	CHEMICAL
,	O
dopamine	CHEMICAL
and	O
serotonina	O
reuptake	O
which	O
inhibits	O
food	O
intake	O
and	O
increases	O
thermogenesis	O
.	O

Sibutramine	CHEMICAL
administration	O
for	O
a	O
year	O
can	O
induce	O
a	O
weight	O
loss	O
of	O
4-7%	O
.	O

Its	O
main	O
side	O
effects	O
are	O
hypertension	O
,	O
headache	O
,	O
insomnia	O
and	O
constipation	O
.	O

Orlistat	CHEMICAL
is	O
an	O
inhibitor	O
of	O
pancreatic	GENE-N
lipase	GENE-N
which	O
is	O
able	O
to	O
block	O
the	O
absorption	O
of	O
30%	O
of	O
ingested	O
fat	O
.	O

Its	O
administration	O
induces	O
weight	O
loss	O
and	O
reduction	O
of	O
ulterior	O
weight	O
regain	O
.	O

Also	O
,	O
this	O
drug	O
improves	O
hypertension	O
dyslipdaemia	O
and	O
helps	O
to	O
prevent	O
diabetes	O
in	O
52%	O
of	O
cases	O
when	O
administered	O
over	O
four	O
years	O
.	O

The	O
increase	O
in	O
frequency	O
of	O
stools	O
and	O
interference	O
with	O
vitamin	O
absorption	O
are	O
its	O
main	O
side	O
effects	O
.	O

Glucagon-like	GENE-Y
peptide	GENE-Y
1	GENE-Y
,	O
which	O
increases	O
insulin	GENE-Y
sensitivity	O
and	O
satiety	O
,	O
adiponectin	GENE-Y
and	O
PPAR-gamma	GENE-Y
agonists	O
which	O
reduce	O
insulin	GENE-Y
resistance	O
and	O
modulates	O
adipocyte	O
generation	O
are	O
the	O
basis	O
for	O
future	O
therapeutic	O
approaches	O
of	O
obesity	O
.	O

Phosphatase	GENE-N
inhibitors	O
induce	O
PPAR-gamma	GENE-Y
phosphorylation	O
and	O
UCP-1	GENE-Y
expression	O
leading	O
to	O
an	O
increase	O
in	O
thermogenesis	O
and	O
reduction	O
in	O
appetite	O
.	O
In	O
the	O
present	O
study	O
,	O
our	O
aim	O
was	O
to	O
determine	O
whether	O
intrafetal	O
glucose	CHEMICAL
infusion	O
increases	O
fetal	O
adiposity	O
,	O
synthesis	O
and	O
secretion	O
of	O
leptin	GENE-Y
and	O
regulates	O
gene	O
expression	O
of	O
the	O
'appetite	GENE-N
regulatory'	GENE-N
neuropeptides	GENE-N
neuropepetide	GENE-Y
Y	GENE-Y
(	O
NPY	GENE-Y
)	O
,	O
agouti-related	GENE-Y
peptide	GENE-Y
(	O
AGRP	GENE-Y
)	O
,	O
pro-opiomelanocortin	GENE-Y
(	O
POMC	GENE-Y
)	O
and	O
cocaine-	O
and	O
amphetamine-regulated	O
transcript	O
(	O
CART	GENE-Y
)	O
and	O
receptors	O
(	O
leptin	GENE-Y
receptor	GENE-Y
(	O
OB-Rb	GENE-Y
)	O
and	O
melancortin	GENE-Y
3	GENE-Y
receptor	GENE-Y
(	O
MC3R	GENE-Y
)	O
)	O
within	O
the	O
fetal	O
hypothalamus	O
.	O

Glucose	CHEMICAL
(	O
50%	O
dextrose	O
in	O
saline	O
)	O
or	O
saline	O
was	O
infused	O
(	O
7	O
.	O
5	O
ml	O
h	O
(	O
-1	O
)	O
)	O
into	O
fetal	O
sheep	O
between	O
130	O
and	O
140	O
days	O
gestation	O
(	O
term	O
=	O
150	O
+	O
/	O
-	O
3	O
days	O
gestation	O
)	O
.	O

Glucose	CHEMICAL
infusion	O
increased	O
circulating	O
glucose	CHEMICAL
and	O
insulin	GENE-Y
concentrations	O
,	O
mean	O
lipid	O
locule	O
size	O
(	O
532	O
.	O
8	O
+	O
/	O
-	O
3	O
.	O
3	O
microm2	O
versus	O
456	O
.	O
7	O
+	O
/	O
-	O
14	O
.	O
8	O
microm2	O
)	O
and	O
total	O
unilocular	O
fat	O
mass	O
(	O
11	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
6	O
g	O
versus	O
8	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
6	O
g	O
)	O
of	O
the	O
perirenal	O
fat	O
depot	O
.	O

The	O
expression	O
of	O
OB-Rb	GENE-Y
mRNA	O
was	O
higher	O
in	O
the	O
ventromedial	O
nucleus	O
compared	O
to	O
the	O
arcuate	O
nucleus	O
of	O
the	O
hypothalamus	O
in	O
both	O
glucose	CHEMICAL
and	O
saline	O
infused	O
fetuses	O
(	O
F	O
=	O
8	O
.	O
04;	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
there	O
was	O
a	O
positive	O
correlation	O
between	O
expression	O
of	O
OB-Rb	GENE-Y
and	O
MC3R	GENE-Y
mRNA	O
in	O
the	O
arcuate	O
nucleus	O
(	O
r	O
=	O
0	O
.	O
81;	O
P	O
<	O
0	O
.	O
005	O
)	O
.	O

Glucose	CHEMICAL
infusion	O
increased	O
mRNA	O
expression	O
for	O
POMC	GENE-Y
,	O
but	O
not	O
for	O
the	O
anorectic	GENE-N
neuropeptide	GENE-N
CART	GENE-Y
,	O
or	O
the	O
orexigenic	GENE-N
neuropeptides	GENE-N
NPY	GENE-Y
and	O
AGRP	GENE-Y
,	O
in	O
the	O
arcuate	O
nucleus	O
of	O
the	O
fetal	O
hypothalamus	O
.	O

These	O
findings	O
demonstrate	O
that	O
increased	O
circulating	O
glucose	CHEMICAL
and	O
insulin	GENE-Y
regulate	O
gene	O
expression	O
of	O
the	O
neuropeptides	O
within	O
the	O
fetal	O
hypothalamus	O
that	O
are	O
part	O
of	O
the	O
neural	O
network	O
regulating	O
energy	O
balance	O
in	O
adult	O
life	O
.	O
Pseudohypoaldosteronism	O
type	O
1	O
(	O
PHA1	O
)	O
is	O
characterized	O
by	O
neonatal	O
salt	O
wasting	O
resistant	O
to	O
mineralocorticoids	O
.	O

There	O
are	O
2	O
forms	O
of	O
PHA1	O
:	O
the	O
autosomal	O
recessive	O
form	O
with	O
symptoms	O
persisting	O
into	O
adulthood	O
,	O
caused	O
by	O
mutations	O
in	O
the	O
amiloride-sensitive	O
luminal	O
sodium	CHEMICAL
channel	O
,	O
and	O
the	O
autosomal	O
dominant	O
or	O
sporadic	O
form	O
,	O
which	O
shows	O
milder	O
symptoms	O
that	O
remit	O
with	O
age	O
.	O

Mutations	O
in	O
the	O
gene	O
encoding	O
the	O
human	GENE-Y
mineralocorticoid	GENE-Y
receptor	GENE-Y
(	O
hMR	GENE-Y
)	O
are	O
,	O
at	O
least	O
in	O
some	O
patients	O
,	O
responsible	O
for	O
the	O
latter	O
form	O
of	O
PHA1	O
.	O

We	O
here	O
report	O
the	O
results	O
of	O
a	O
genetic	O
study	O
in	O
a	O
sporadic	O
case	O
and	O
in	O
5	O
affected	O
patients	O
from	O
2	O
families	O
with	O
autosomal	O
dominant	O
PHA1	O
.	O

In	O
the	O
sporadic	O
case	O
we	O
identified	O
a	O
new	O
frameshift	O
mutation	O
,	O
Ins2871C	GENE-N
,	O
in	O
exon	O
9	O
of	O
the	O
hMR	GENE-Y
gene	O
.	O

Family	O
members	O
were	O
asymptomatic	O
and	O
had	O
no	O
mutation	O
.	O

This	O
mutation	O
is	O
the	O
first	O
described	O
in	O
exon	O
9	O
and	O
impairs	O
the	O
last	O
27	O
amino	CHEMICAL
acids	CHEMICAL
of	O
the	O
hormone-binding	GENE-N
domain	GENE-N
.	O

In	O
2	O
kindreds	O
with	O
autosomal	O
dominant	O
PHA1	O
we	O
found	O
no	O
mutation	O
of	O
the	O
hMR	GENE-Y
gene	O
.	O

Our	O
results	O
confirm	O
the	O
hypothesis	O
that	O
autosomal	O
dominant	O
or	O
sporadic	O
PHA1	O
is	O
a	O
genetically	O
heterogeneous	O
disease	O
involving	O
other	O
,	O
as	O
yet	O
unidentified	O
,	O
genes	O
.	O
Therapeutic	O
oral	O
anticoagulation	O
is	O
still	O
commonly	O
achieved	O
by	O
administration	O
of	O
warfarin	CHEMICAL
or	O
other	O
vitamin	CHEMICAL
K	CHEMICAL
antagonists	O
that	O
are	O
associated	O
with	O
an	O
untoward	O
pharmacokinetic	O
/	O
pharmacodynamic	O
(	O
PK	O
/	O
PD	O
)	O
profile	O
leading	O
to	O
a	O
high	O
incidence	O
of	O
bleeding	O
complications	O
or	O
therapeutic	O
failure	O
.	O

Hence	O
,	O
there	O
is	O
an	O
unmet	O
medical	O
need	O
of	O
novel	O
easy-to-use	O
oral	O
anticoagulants	O
with	O
improved	O
efficacy	O
and	O
safety	O
.	O

Recent	O
developments	O
include	O
the	O
identification	O
of	O
non-peptidic	O
small-molecules	O
that	O
selectively	O
inhibit	O
certain	O
serine	CHEMICAL
proteases	O
within	O
the	O
coagulation	O
cascade	O
.	O

Of	O
these	O
,	O
the	O
thrombin	GENE-Y
inhibitor	O
dabigatran	CHEMICAL
and	O
factor	GENE-Y
Xa	GENE-Y
inhibitor	O
rivaroxaban	CHEMICAL
have	O
recently	O
been	O
licensed	O
for	O
thromboprophylaxis	O
after	O
orthopaedic	O
surgery	O
mainly	O
in	O
Europe	O
.	O

In	O
addition	O
,	O
the	O
factor	GENE-Y
Xa	GENE-Y
inhibitor	O
apixaban	CHEMICAL
is	O
in	O
late-stage	O
clinical	O
development	O
.	O

Each	O
drug	O
is	O
prescribed	O
at	O
fixed	O
doses	O
without	O
the	O
need	O
of	O
anticoagulant	O
monitoring	O
.	O

Phase	O
III	O
trials	O
in	O
orthopaedic	O
patients	O
essentially	O
resulted	O
in	O
non-inferior	O
efficacy	O
of	O
dabigatran	CHEMICAL
and	O
superior	O
efficacy	O
of	O
rivaroxaban	CHEMICAL
over	O
enoxaparin	O
without	O
any	O
marked	O
differences	O
of	O
drug	O
safety	O
,	O
while	O
apixaban	CHEMICAL
data	O
is	O
still	O
controversial	O
.	O

However	O
,	O
alterations	O
of	O
rivaroxaban	CHEMICAL
and	O
apixaban	CHEMICAL
pharmacokinetics	O
upon	O
interactions	O
with	O
inhibitors	O
and	O
inducers	O
of	O
CYP3A4	GENE-Y
or	O
P-glycoprotein	GENE-N
may	O
complicate	O
the	O
use	O
of	O
these	O
compounds	O
in	O
daily	O
practice	O
,	O
whereas	O
dabigatran	CHEMICAL
elimination	O
largely	O
depends	O
on	O
renal	O
function	O
.	O

Hence	O
,	O
this	O
review	O
reports	O
PK	O
/	O
PD	O
,	O
efficacy	O
and	O
safety	O
data	O
of	O
dabigatran	CHEMICAL
,	O
rivaroxaban	CHEMICAL
and	O
apixaban	CHEMICAL
throughout	O
preclinical	O
and	O
clinical	O
development	O
.	O
Electrical	O
Stimuli	O
Release	O
ATP	CHEMICAL
to	O
Increase	O
GLUT4	GENE-Y
Translocation	O
and	O
Glucose	CHEMICAL
Uptake	O
via	O
PI3Kγ-Akt-AS160	GENE-Y
in	O
Skeletal	O
Muscle	O
Cells	O
.	O
Progress	O
and	O
Developments	O
in	O
Tau	GENE-Y
Aggregation	O
Inhibitors	O
for	O
Alzheimer	O
Disease	O
.	O
It	O
has	O
been	O
recognised	O
that	O
the	O
active	O
transport	O
of	O
L-phenylalanine	CHEMICAL
and	O
its	O
autocrine	O
turnover	O
to	O
L-tyrosine	CHEMICAL
via	O
phenylalanine	CHEMICAL
hydroxylase	O
in	O
the	O
cytosol	O
of	O
epidermal	O
melanocytes	O
provides	O
the	O
majority	O
of	O
the	O
L-tyrosine	CHEMICAL
pool	O
for	O
melanogenesis	O
.	O

In	O
this	O
context	O
,	O
it	O
has	O
been	O
shown	O
that	O
the	O
cofactor	O
6	CHEMICAL
(	CHEMICAL
R	CHEMICAL
)	CHEMICAL
-L-erythro	CHEMICAL
5	CHEMICAL
,	CHEMICAL
6	CHEMICAL
,	CHEMICAL
7	CHEMICAL
,	CHEMICAL
8	CHEMICAL
tetrahydrobiopterin	CHEMICAL
(	O
6BH4	CHEMICAL
)	O
is	O
produced	O
de	O
novo	O
,	O
recycled	O
and	O
regulated	O
in	O
both	O
epidermal	O
melanocytes	O
and	O
keratinocytes	O
to	O
control	O
tyrosine	CHEMICAL
hydroxylase	O
,	O
phenylalanine	CHEMICAL
hydroxylase	O
and	O
tyrosinase	GENE-Y
activity	O
.	O

Inhibition	O
of	O
the	O
enzymes	O
by	O
excessive	O
6BH4	O
levels	O
is	O
reversible	O
with	O
alpha-MSH	GENE-Y
by	O
specific	O
complex	O
formation	O
between	O
6BH4	CHEMICAL
and	O
the	O
hormone	O
.	O

This	O
direct	O
mechanism	O
of	O
alpha-MSH	GENE-Y
is	O
supported	O
by	O
the	O
presence	O
of	O
the	O
entire	O
POMC	GENE-Y
processing	O
system	O
in	O
the	O
melanosome	O
indicating	O
a	O
receptor	O
independent	O
control	O
of	O
eumelanogenesis	O
.	O

Finally	O
,	O
the	O
role	O
of	O
tyrosinase	GENE-Y
,	O
TRP-1	GENE-Y
and	O
TRP2	GENE-Y
is	O
discussed	O
in	O
association	O
with	O
oxidative	O
stress	O
specifically	O
related	O
to	O
hydrogen	CHEMICAL
peroxide	CHEMICAL
.	O

These	O
recent	O
findings	O
are	O
based	O
on	O
detailed	O
investigations	O
of	O
the	O
depigmentation	O
disorder	O
vitiligo	O
and	O
Hermansky-Pudlak	O
syndrome	O
.	O
We	O
report	O
the	O
SAR	O
around	O
a	O
series	O
of	O
2	CHEMICAL
,	CHEMICAL
4-diaminopyrimidine-5-carboxamide	CHEMICAL
inhibitors	O
of	O
Sky	GENE-Y
kinase	GENE-N
.	O

2-Aminophenethyl	CHEMICAL
analogs	O
demonstrate	O
excellent	O
potency	O
but	O
moderate	O
kinase	GENE-N
selectivity	O
,	O
while	O
2-aminobenzyl	CHEMICAL
analogs	O
that	O
fill	O
the	O
Ala571	O
subpocket	O
exhibit	O
good	O
inhibition	O
activity	O
and	O
excellent	O
kinase	GENE-N
selectivity	O
.	O
In	O
a	O
recent	O
study	O
it	O
has	O
been	O
shown	O
that	O
mitochondrial	GENE-N
creatine	CHEMICAL
kinase	O
from	O
chicken	O
brain	O
(	O
Mia-CK	GENE-Y
)	O
and	O
heart	O
(	O
Mib-CK	GENE-Y
)	O
are	O
two	O
distinct	O
isoenzymes	O
differing	O
in	O
ten	O
out	O
of	O
the	O
thirty	O
N-terminal	CHEMICAL
amino	CHEMICAL
acids	CHEMICAL
(	O
Hossle	O
,	O
J	O
.	O

P	O
.	O

,	O
Schlegel	O
,	O
J	O
.	O

,	O
Wegmann	O
,	O
G	O
.	O

,	O
Wyss	O
,	O
M	O
.	O

,	O
Bohlen	O
,	O
P	O
.	O

,	O
Eppenberger	O
,	O
H	O
.	O

M	O
.	O

,	O
Wallimann	O
,	O
T	O
.	O

,	O
and	O
Perriard	O
J	O
.	O

C	O
.	O

(	O
1988	O
)	O
Biochem	O
.	O

Biophys	O
.	O

Res	O
.	O

Commun	O
.	O

151	O
,	O
408-416	O
)	O
.	O

The	O
present	O
article	O
describes	O
the	O
purification	O
and	O
biophysical	O
characterization	O
of	O
the	O
mitochondrial	GENE-N
creatine	CHEMICAL
kinase	O
isoenzyme	O
from	O
chicken	O
brain	O
(	O
Mia-CK	GENE-Y
)	O
.	O

Gel	O
permeation	O
chromatography	O
,	O
direct	O
mass	O
measurements	O
of	O
individual	O
molecules	O
by	O
scanning	O
transmission	O
electron	O
microscopy	O
,	O
and	O
analytical	O
ultracentrifugation	O
confirmed	O
the	O
existence	O
of	O
two	O
different	O
oligomeric	O
forms	O
,	O
dimeric	O
and	O
octameric	O
Mia-CK	GENE-Y
,	O
with	O
molecular	O
masses	O
of	O
85	O
kDa	O
and	O
306-352	O
kDa	O
and	O
with	O
sedimentation	O
constants	O
of	O
4	O
.	O
9-5	O
.	O
3	O
and	O
11	O
.	O
6-12	O
.	O
0	O
S	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
it	O
was	O
tested	O
if	O
Mia-	O
and	O
Mib-CK	GENE-Y
can	O
form	O
heterodimeric	O
and	O
heterooctameric	O
molecules	O
with	O
subunits	O
of	O
other	O
CK	GENE-N
isoenzymes	O
.	O

By	O
denaturation	O
in	O
urea	CHEMICAL
or	O
guanidine	CHEMICAL
hydrochloride	CHEMICAL
and	O
subsequent	O
renaturation	O
,	O
MiaMib-CK	GENE-Y
and	O
surprisingly	O
also	O
MiaM-CK	GENE-Y
heterodimers	O
could	O
be	O
generated	O
.	O

In	O
contrast	O
,	O
no	O
heterodimers	O
were	O
obtained	O
between	O
Mib-	O
and	O
M-	O
or	O
B-CK	GENE-Y
.	O

Furthermore	O
,	O
reoctamerization	O
of	O
a	O
mixture	O
of	O
Mia-	O
and	O
Mib-CK	GENE-Y
homodimers	O
led	O
to	O
the	O
formation	O
of	O
MiaMib-CK	GENE-Y
heterooctamers	O
.	O

In	O
these	O
heterooctamers	O
,	O
the	O
Mia-	O
and	O
Mib-CK	GENE-Y
homodimers	O
remained	O
the	O
fundamental	O
building	O
blocks	O
.	O

No	O
subunit	O
exchange	O
between	O
adjacent	O
dimers	O
within	O
the	O
heterooctamer	O
could	O
be	O
observed	O
even	O
after	O
storage	O
for	O
3	O
months	O
at	O
4	O
degrees	O
C	O
.	O

The	O
relevance	O
of	O
these	O
data	O
on	O
the	O
structural	O
organization	O
of	O
the	O
Mi-CK	GENE-N
octamer	O
and	O
on	O
the	O
physiological	O
aspects	O
of	O
tissue-specific	O
isoenzyme	O
expression	O
are	O
discussed	O
.	O
To	O
characterize	O
neonatal	O
mesenteric	O
alpha-adrenoceptor	GENE-N
populations	O
,	O
an	O
extracorporeal	O
perfusion	O
circuit	O
was	O
established	O
to	O
control	O
intestinal	O
blood	O
flow	O
in	O
prematurely	O
delivered	O
(	O
by	O
cesarean	O
section	O
at	O
90%	O
of	O
gestational	O
age	O
)	O
piglets	O
.	O

Activation	O
of	O
alpha	GENE-N
1-adrenoceptors	GENE-N
was	O
documented	O
by	O
observing	O
dose-dependent	O
increases	O
in	O
mesenteric	O
perfusion	O
pressure	O
after	O
intramesenteric	O
arterial	O
injection	O
of	O
methoxamine;	O
alpha	GENE-N
2-adrenoceptor	GENE-N
activity	O
was	O
confirmed	O
by	O
finding	O
similar	O
increases	O
in	O
mesenteric	O
perfusion	O
pressure	O
after	O
intramesenteric	O
arterial	O
injections	O
of	O
BHT	CHEMICAL
933	CHEMICAL
.	O

Peripheral	O
intravenous	O
injections	O
of	O
WB	CHEMICAL
4101	CHEMICAL
(	O
a	O
competitive	O
alpha	GENE-Y
1A-adrenoceptor	GENE-Y
antagonist	O
)	O
,	O
but	O
not	O
clorethylclonidine	CHEMICAL
(	O
CEC	CHEMICAL
,	O
an	O
alpha	GENE-Y
1B-adrenoceptor	GENE-Y
antagonist	O
)	O
,	O
significantly	O
blunted	O
(	O
P	O
<	O
.	O
05	O
,	O
ANOVA	O
)	O
the	O
mesenteric	O
vasoconstrictor	O
responses	O
to	O
methoxamine	CHEMICAL
.	O

The	O
mesenteric	O
vasoconstrictor	O
response	O
to	O
BHT	CHEMICAL
933	CHEMICAL
(	O
an	O
alpha	GENE-N
2-adrenoceptor	GENE-N
agonist	O
)	O
also	O
was	O
blunted	O
by	O
WB	CHEMICAL
4101	CHEMICAL
,	O
but	O
not	O
by	O
CEC	CHEMICAL
.	O

These	O
data	O
suggest	O
that	O
alpha	O
1A-	O
and	O
alpha	GENE-N
2-adrenoceptors	GENE-N
can	O
be	O
activated	O
in	O
the	O
small	O
intestinal	O
mesentery	O
of	O
piglets	O
well	O
before	O
they	O
reach	O
full-term	O
maturation	O
,	O
although	O
receptor	O
specificity	O
has	O
not	O
been	O
fully	O
established	O
.	O
The	O
scientific	O
rationale	O
of	O
pharmacologically	O
inhibiting	O
phosphodiesterase	GENE-Y
type	GENE-Y
5	GENE-Y
(	O
PDE5	GENE-Y
)	O
in	O
the	O
treatment	O
of	O
erectile	O
dysfunction	O
(	O
ED	O
)	O
is	O
reviewed	O
.	O

Published	O
literature	O
on	O
the	O
nitric	CHEMICAL
oxide-cyclic	CHEMICAL
guanosine	CHEMICAL
monophosphate	CHEMICAL
(	O
cGMP	CHEMICAL
)	O
pathway	O
for	O
penile	O
erection	O
and	O
on	O
PDE5	GENE-Y
inhibition	O
using	O
sildenafil	O
as	O
the	O
model	O
for	O
pharmacologic	O
PDE5	GENE-Y
inhibition	O
are	O
assessed	O
.	O

The	O
key	O
second	O
messenger	O
in	O
the	O
mediation	O
of	O
penile	O
erection	O
is	O
cGMP	O
.	O

PDE5	GENE-Y
is	O
the	O
predominant	O
PDE	GENE-N
in	O
the	O
corpus	O
cavernosum	O
,	O
and	O
cGMP	CHEMICAL
is	O
its	O
primary	O
substrate	O
.	O

Therefore	O
,	O
in	O
men	O
with	O
ED	O
,	O
elevation	O
of	O
cGMP	CHEMICAL
in	O
corpus	O
cavernosal	O
tissue	O
via	O
selective	O
inhibition	O
of	O
cGMP-specific	O
PDE5	GENE-Y
is	O
a	O
means	O
of	O
improving	O
erectile	O
function	O
at	O
minimal	O
risk	O
of	O
adverse	O
events	O
.	O

This	O
approach	O
is	O
validated	O
by	O
the	O
clinical	O
efficacy	O
and	O
safety	O
of	O
sildenafil	CHEMICAL
,	O
the	O
pioneering	O
drug	O
for	O
selective	O
PDE5	GENE-Y
inhibitor	O
therapy	O
for	O
ED	O
.	O

Sildenafil	CHEMICAL
exhibits	O
inhibitory	O
potency	O
against	O
PDE5	GENE-Y
and	O
a	O
10-fold	O
lower	O
dose-related	O
inhibitory	O
potency	O
against	O
rod	O
outer	O
segment	O
PDE6	GENE-N
,	O
the	O
predominant	O
PDE	GENE-N
in	O
the	O
phototransduction	O
cascade	O
in	O
rods	O
.	O

Thus	O
,	O
its	O
pharmacologic	O
profile	O
is	O
predictable	O
,	O
with	O
close	O
correlation	O
between	O
pharmacodynamic	O
and	O
pharmacokinetic	O
properties	O
.	O

Clinically	O
,	O
sildenafil	CHEMICAL
improves	O
erectile	O
function	O
in	O
a	O
large	O
percentage	O
of	O
men	O
with	O
ED	O
.	O

The	O
most	O
common	O
adverse	O
events	O
are	O
due	O
to	O
PDE5	GENE-Y
inhibition	O
in	O
vascular	O
and	O
visceral	O
smooth	O
muscle;	O
similar	O
adverse	O
events	O
are	O
expected	O
during	O
therapeutic	O
use	O
of	O
all	O
PDE5	GENE-Y
inhibitors	O
.	O

As	O
free	O
sildenafil	CHEMICAL
plasma	O
concentrations	O
approach	O
concentrations	O
sufficient	O
to	O
inhibit	O
retinal	O
PDE6	GENE-N
,	O
usually	O
at	O
higher	O
therapeutic	O
doses	O
,	O
transient	O
,	O
reversible	O
visual	O
adverse	O
events	O
can	O
occur	O
,	O
albeit	O
infrequently	O
.	O

Selective	O
inhibition	O
of	O
PDE5	GENE-Y
is	O
a	O
rational	O
therapeutic	O
approach	O
in	O
ED	O
,	O
as	O
proved	O
by	O
the	O
clinical	O
success	O
of	O
sildenafil	CHEMICAL
.	O
Prostaglandins	CHEMICAL
are	O
key	O
regulators	O
of	O
ion	O
transport	O
in	O
the	O
kidney	O
.	O

In	O
MDCK	O
cells	O
,	O
which	O
model	O
distal	O
tubule	O
cells	O
,	O
the	O
transcription	O
of	O
the	O
Na	GENE-N
,	O
K-ATPase	O
beta1	O
subunit	O
is	O
regulated	O
by	O
PGE1	O
and	O
PGE2	O
.	O

To	O
identify	O
the	O
EP	GENE-N
receptors	GENE-N
that	O
mediate	O
transcriptional	O
regulation	O
,	O
transient	O
transfection	O
studies	O
are	O
conducted	O
using	O
the	O
human	O
beta1promoter	O
/	O
luciferase	O
construct	O
,	O
pHbeta1-1141	O
Luc	O
.	O

The	O
involvement	O
of	O
EP1	GENE-Y
and	O
EP2	GENE-Y
receptors	GENE-Y
is	O
indicated	O
by	O
studies	O
with	O
the	O
EP1	GENE-Y
selective	O
agonist	O
17-phenyl	CHEMICAL
trinor	CHEMICAL
PGE2	CHEMICAL
,	O
and	O
the	O
EP2	GENE-Y
selective	O
agonist	O
butaprost	CHEMICAL
(	O
which	O
stimulate	O
)	O
,	O
as	O
well	O
as	O
by	O
studies	O
with	O
the	O
antagonists	O
SC-51089	CHEMICAL
(	O
EP1	O
specific	O
)	O
and	O
AH	CHEMICAL
6809	CHEMICAL
(	O
EP1	GENE-Y
and	O
EP2	GENE-Y
specific	O
)	O
.	O

Consistent	O
with	O
the	O
involvement	O
of	O
Gs	GENE-N
coupled	O
EP2	GENE-Y
receptors	GENE-Y
,	O
is	O
that	O
the	O
PGE1	CHEMICAL
stimulation	O
is	O
inhibited	O
by	O
the	O
PKAI	GENE-N
expression	O
vector	O
(	O
encoding	O
the	O
protein	GENE-N
kinase	GENE-N
A	GENE-N
(	GENE-N
PKA	GENE-N
)	GENE-N
inhibitory	GENE-N
protein	GENE-N
)	O
,	O
as	O
well	O
as	O
by	O
the	O
myristolated	GENE-N
PKA	GENE-N
inhibitory	GENE-N
peptide	GENE-N
PKI	O
.	O

In	O
addition	O
to	O
this	O
evidence	O
(	O
for	O
the	O
involvement	O
of	O
EP2	GENE-Y
receptors	GENE-Y
)	O
,	O
evidence	O
for	O
the	O
involvement	O
of	O
EP1	GENE-Y
receptors	GENE-Y
in	O
the	O
PGE1	CHEMICAL
mediated	O
stimulation	O
of	O
Na	GENE-N
,	O
K-ATPase	O
beta	O
subunit	O
gene	O
transcription	O
includes	O
the	O
stimulatory	O
effect	O
of	O
17-phenyl	CHEMICAL
trinor	CHEMICAL
PGE2	CHEMICAL
,	O
as	O
well	O
as	O
the	O
inhibitory	O
effects	O
of	O
SC-51089	CHEMICAL
.	O

Also	O
consistent	O
with	O
the	O
involvement	O
of	O
Gq	GENE-N
coupled	O
EP1	GENE-Y
receptors	GENE-Y
,	O
the	O
PGE1	CHEMICAL
stimulation	O
is	O
inhibited	O
by	O
the	O
PKCI	GENE-N
vector	O
(	O
encoding	O
the	O
PKC	GENE-N
inhibitory	GENE-N
domain	GENE-N
)	O
,	O
the	O
PKC	GENE-N
inhibitor	O
Go	CHEMICAL
6976	CHEMICAL
,	O
thapsigargin	CHEMICAL
,	O
as	O
well	O
as	O
the	O
calmodulin	GENE-N
antagonists	O
W7	CHEMICAL
and	O
W13	CHEMICAL
.	O
Effect	O
of	O
developmental	O
dioxin	CHEMICAL
exposure	O
on	O
methylation	O
and	O
expression	O
of	O
specific	O
imprinted	O
genes	O
in	O
mice	O
.	O
Emerging	O
role	O
of	O
epidermal	GENE-Y
growth	GENE-Y
factor	GENE-Y
receptor	GENE-Y
inhibition	O
in	O
therapy	O
for	O
advanced	O
malignancy	O
:	O
focus	O
on	O
NSCLC	O
.	O
We	O
determined	O
the	O
effects	O
of	O
low-level	O
prenatal	O
MeHg	CHEMICAL
exposure	O
on	O
neuronal	O
migration	O
in	O
the	O
developing	O
rat	O
cerebral	O
cortex	O
using	O
in	O
utero	O
electroporation	O
.	O

We	O
used	O
offspring	O
rats	O
born	O
to	O
dams	O
that	O
had	O
been	O
exposed	O
to	O
saline	O
or	O
various	O
doses	O
of	O
MeHg	CHEMICAL
(	O
0	O
.	O
01	O
mg	O
/	O
kg	O
/	O
day	O
,	O
0	O
.	O
1	O
mg	O
/	O
kg	O
/	O
day	O
,	O
and	O
1	O
mg	O
/	O
kg	O
/	O
day	O
)	O
from	O
gestational	O
day	O
(	O
GD	O
)	O
11-21	O
.	O

Immunohistochemical	O
examination	O
of	O
the	O
brains	O
of	O
the	O
offspring	O
was	O
conducted	O
on	O
postnatal	O
day	O
(	O
PND	O
)	O
0	O
,	O
PND3	O
,	O
and	O
PND7	O
.	O

Our	O
results	O
showed	O
that	O
prenatal	O
exposure	O
to	O
low	O
levels	O
of	O
MeHg	CHEMICAL
(	O
0	O
.	O
1	O
mg	O
/	O
kg	O
/	O
day	O
or	O
1	O
mg	O
/	O
kg	O
/	O
day	O
)	O
during	O
the	O
critical	O
stage	O
in	O
neuronal	O
migration	O
resulted	O
in	O
migration	O
defects	O
of	O
the	O
cerebrocortical	O
neurons	O
in	O
offspring	O
rats	O
.	O

Importantly	O
,	O
our	O
data	O
revealed	O
that	O
the	O
abnormal	O
neuronal	O
distribution	O
induced	O
by	O
MeHg	CHEMICAL
was	O
not	O
caused	O
by	O
altered	O
proliferation	O
of	O
neural	O
progenitor	O
cells	O
(	O
NPCs	O
)	O
,	O
induction	O
of	O
apoptosis	O
of	O
NPCs	O
and	O
/	O
or	O
newborn	O
neurons	O
,	O
abnormal	O
differentiation	O
of	O
NPCs	O
,	O
and	O
the	O
morphological	O
changes	O
of	O
radial	O
glial	O
scaffold	O
,	O
indicating	O
that	O
the	O
defective	O
neuronal	O
positioning	O
triggered	O
by	O
exposure	O
to	O
low-dose	O
of	O
MeHg	CHEMICAL
is	O
due	O
to	O
the	O
impacts	O
of	O
MeHg	CHEMICAL
on	O
the	O
process	O
of	O
neuronal	O
migration	O
itself	O
.	O

Moreover	O
,	O
we	O
demonstrated	O
that	O
in	O
utero	O
exposure	O
to	O
low-level	O
MeHg	CHEMICAL
suppresses	O
the	O
expression	O
of	O
Rac1	GENE-Y
,	O
Cdc42	GENE-Y
,	O
and	O
RhoA	GENE-Y
,	O
which	O
play	O
key	O
roles	O
in	O
the	O
migration	O
of	O
cerebrocortical	O
neurons	O
during	O
the	O
early	O
stage	O
of	O
brain	O
development	O
,	O
suggesting	O
that	O
the	O
MeHg-induced	O
migratory	O
disturbance	O
of	O
cerebrocortical	O
neurons	O
is	O
likely	O
associated	O
with	O
the	O
Rho	GENE-N
GTPases	GENE-N
signal	O
pathway	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
provide	O
a	O
novel	O
perspective	O
on	O
clarifying	O
the	O
mechanisms	O
underlying	O
the	O
impairment	O
of	O
neuronal	O
migration	O
induced	O
by	O
MeHg	CHEMICAL
.	O
BACKGROUND	O
:	O
Because	O
of	O
the	O
adverse	O
characteristics	O
associated	O
with	O
heparin	O
,	O
direct	O
antagonists	O
of	O
thrombin	GENE-Y
have	O
been	O
investigated	O
as	O
anticoagulants	O
during	O
percutaneous	O
coronary	O
interventions	O
.	O

However	O
,	O
the	O
hematologic	O
and	O
clinical	O
interactions	O
between	O
direct	O
thrombin	GENE-Y
antagonists	O
and	O
inhibitors	O
of	O
platelet	GENE-N
glycoprotein	GENE-N
IIb-IIIa	GENE-N
are	O
incompletely	O
explored	O
.	O

METHODS	O
:	O
Forty-two	O
patients	O
who	O
underwent	O
elective	O
percutaneous	O
coronary	O
intervention	O
were	O
randomized	O
to	O
receive	O
a	O
bivalirudin	O
1	O
.	O
0	O
mg	O
/	O
kg	O
bolus	O
followed	O
by	O
a	O
4-hour	O
infusion	O
at	O
2	O
.	O
5	O
mg	O
/	O
kg	O
/	O
h;	O
a	O
bivalirudin	O
0	O
.	O
75	O
mg	O
/	O
kg	O
bolus	O
followed	O
by	O
a	O
4-hour	O
infusion	O
at	O
1	O
.	O
75	O
mg	O
/	O
kg;	O
or	O
a	O
heparin	O
60	O
U	O
/	O
kg	O
bolus	O
.	O

All	O
the	O
patients	O
also	O
received	O
eptifibatide	CHEMICAL
,	O
given	O
as	O
2	O
sequential	O
boluses	O
of	O
180	O
microg	O
/	O
kg	O
followed	O
by	O
a	O
2	O
microg	O
/	O
kg	O
/	O
min	O
infusion	O
for	O
18	O
to	O
24	O
hours	O
,	O
and	O
aspirin	CHEMICAL
.	O

RESULTS	O
:	O
After	O
the	O
bolus	O
dose	O
of	O
the	O
study	O
drug	O
,	O
turbidimetric	O
platelet	O
aggregation	O
in	O
response	O
to	O
5	O
micromol	O
/	O
L	O
adenosine	CHEMICAL
diphosphate	CHEMICAL
increased	O
in	O
patients	O
assigned	O
to	O
heparin	O
but	O
not	O
those	O
assigned	O
to	O
bivalirudin	O
.	O

After	O
eptifibatide	O
,	O
platelet	O
aggregation	O
was	O
eliminated	O
in	O
all	O
3	O
treatment	O
groups	O
.	O

The	O
effect	O
of	O
heparin	O
and	O
the	O
effects	O
of	O
both	O
bivalirudin	O
regimens	O
on	O
the	O
formation	O
of	O
thrombin	GENE-Y
antithrombin	O
complexes	O
and	O
prothrombin	GENE-Y
fragment	O
1	O
.	O
2	O
were	O
comparable	O
.	O

Neither	O
agent	O
affected	O
the	O
formation	O
of	O
platelet-monocyte	O
complexes	O
or	O
expression	O
of	O
CD	GENE-Y
63	GENE-Y
lysosomal	O
antigen	O
.	O

There	O
were	O
no	O
major	O
bleeding	O
events	O
,	O
and	O
a	O
single	O
non-Q-wave	O
myocardial	O
infarction	O
(	O
MI	O
)	O
occurred	O
in	O
a	O
patient	O
treated	O
with	O
bivalirudin	O
.	O

CONCLUSION	O
:	O
These	O
findings	O
show	O
the	O
feasibility	O
of	O
combining	O
the	O
direct	O
thrombin	O
antagonist	O
bivalirudin	O
with	O
a	O
potent	O
antagonist	O
of	O
platelet	GENE-N
glycoprotein	GENE-N
IIb-IIIa	GENE-N
.	O

Clinical	O
trials	O
are	O
needed	O
to	O
assess	O
the	O
safety	O
and	O
efficacy	O
of	O
this	O
combination	O
.	O
The	O
phytochemical	O
investigation	O
of	O
the	O
ethylacetate-soluble	O
fraction	O
of	O
Caryopteris	O
odorata	O
(	O
Ham	O
.	O

ex	O
Roxb	O
.	O

)	O
led	O
to	O
the	O
isolation	O
of	O
four	O
new	O
iridoid	CHEMICAL
glucosides	CHEMICAL
(	O
1-4	O
)	O
:	O
8-O-trans-cinnamoyl	CHEMICAL
caryoptoside	CHEMICAL
(	O
1	O
)	O
,	O
8-O-trans-cinnamoyl	CHEMICAL
shanzhiside	CHEMICAL
methylester	CHEMICAL
(	O
2	O
)	O
,	O
8-O-trans-cinnamoyl	CHEMICAL
mussaenoside	CHEMICAL
(	O
3	O
)	O
and	O
8-O-cafeoyl	CHEMICAL
massenoside	CHEMICAL
(	O
4	O
)	O
.	O

The	O
structures	O
of	O
these	O
compounds	O
were	O
determined	O
by	O
FAB-MS	O
,	O
IR	O
,	O
1D	O
and	O
2D-NMR	O
spectroscopy	O
and	O
by	O
comparing	O
with	O
the	O
published	O
data	O
of	O
the	O
closely	O
related	O
compounds	O
.	O

The	O
antioxidant	O
potential	O
of	O
the	O
isolated	O
iridoids	CHEMICAL
(	O
1-4	O
)	O
was	O
evaluated	O
relative	O
to	O
conventionally	O
used	O
standards	O
and	O
these	O
molecules	O
exhibited	O
good	O
antioxidant	O
potential	O
.	O

Moreover	O
,	O
their	O
inhibitory	O
potential	O
was	O
also	O
screened	O
against	O
three	O
enzymes	O
,	O
namely	O
acetyl	CHEMICAL
cholinesterase	O
,	O
butyrylcholinesterase	GENE-Y
and	O
lipoxygenase	GENE-N
.	O

These	O
iridoid	CHEMICAL
glucosides	CHEMICAL
were	O
found	O
to	O
be	O
inactive	O
against	O
acetyl	CHEMICAL
and	O
butyrylcholinesterases	GENE-Y
but	O
active	O
against	O
lipoxygenase	GENE-N
.	O
Reconstitution	O
of	O
homomeric	O
GluA2	GENE-Y
(	GENE-Y
flop	GENE-Y
)	GENE-Y
receptors	O
in	O
supported	O
lipid	O
membranes	O
:	O
functional	O
and	O
structural	O
properties	O
.	O
Dopamine	CHEMICAL
genes	O
and	O
pathological	O
gambling	O
in	O
discordant	O
sib-pairs	O
.	O
Novel	O
analgesic	O
/	O
anti-inflammatory	O
agents	O
:	O
1	CHEMICAL
,	CHEMICAL
5-diarylpyrrole	CHEMICAL
nitrooxyalkyl	CHEMICAL
ethers	CHEMICAL
and	O
related	O
compounds	O
as	O
cyclooxygenase-2	GENE-Y
inhibiting	O
nitric	CHEMICAL
oxide	CHEMICAL
donors	O
.	O
Minocycline	CHEMICAL
inhibits	O
the	O
production	O
of	O
inducible	GENE-Y
nitric	CHEMICAL
oxide	CHEMICAL
synthase	O
in	O
articular	O
chondrocytes	O
.	O
Interaction	O
of	O
silymarin	O
flavonolignans	CHEMICAL
with	O
organic	GENE-N
anion-transporting	GENE-N
polypeptides	GENE-N
.	O
DNA	GENE-N
polymerase	GENE-N
is	O
one	O
of	O
the	O
most	O
important	O
target	O
molecules	O
of	O
antitumor	O
agents	O
,	O
especially	O
for	O
antimetabolite	O
nucleosides	O
that	O
include	O
1-beta-D-arabinofuranosylcytosine	CHEMICAL
(	O
araC	CHEMICAL
)	O
and	O
2'-deoxy-2'	CHEMICAL
,	CHEMICAL
2'-difluorocytidine	CHEMICAL
(	O
gemcitabine	CHEMICAL
)	O
.	O

There	O
are	O
several	O
subtypes	O
of	O
mammalian	GENE-N
DNA	GENE-N
polymerases	GENE-N
and	O
their	O
localization	O
and	O
function	O
have	O
been	O
clarified	O
.	O

DNA	GENE-N
polymerase	GENE-N
alpha	GENE-N
,	GENE-N
delta	GENE-N
and	GENE-N
epsilon	GENE-N
have	O
been	O
implicated	O
to	O
be	O
responsible	O
for	O
DNA	O
replication	O
,	O
whereas	O
DNA	GENE-N
polymerase	GENE-N
beta	GENE-N
,	GENE-N
delta	GENE-N
and	GENE-N
epsilon	GENE-N
have	O
been	O
suggested	O
to	O
work	O
in	O
DNA	O
repair	O
.	O

DNA	GENE-Y
polymerase	GENE-Y
gamma	GENE-Y
is	O
encoded	O
in	O
the	O
nucleus	O
but	O
localizes	O
in	O
the	O
mitochondria	O
,	O
and	O
is	O
responsible	O
for	O
the	O
mitochondrial	O
DNA	O
replication	O
.	O

Recently	O
,	O
several	O
antiviral	O
nucleoside	O
analogs	O
were	O
reported	O
to	O
inhibit	O
DNA	GENE-Y
polymerase	GENE-Y
gamma	GENE-Y
after	O
intracellular	O
phosphorylation	O
and	O
cause	O
severe	O
chronic	O
toxicity	O
.	O

1-	CHEMICAL
(	CHEMICAL
2-Deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl	CHEMICAL
)	CHEMICAL
cytosine	CHEMICAL
(	O
4'-thio-FAC	CHEMICAL
)	O
,	O
an	O
antimetabolite	O
similar	O
to	O
araC	CHEMICAL
and	O
gemcitabine	CHEMICAL
,	O
is	O
recently	O
shown	O
by	O
us	O
to	O
be	O
a	O
very	O
promising	O
agent	O
because	O
of	O
its	O
potent	O
antitumor	O
activity	O
by	O
oral	O
administration	O
to	O
mice	O
.	O

We	O
tested	O
for	O
the	O
inhibitory	O
activities	O
of	O
the	O
triphosphates	CHEMICAL
of	CHEMICAL
4'-thio-FAC	CHEMICAL
and	O
gemcitabine	CHEMICAL
against	O
DNA	GENE-N
polymerase	GENE-N
alpha	GENE-N
,	GENE-N
beta	GENE-N
and	GENE-N
gamma	GENE-N
.	O

The	O
triphosphates	CHEMICAL
of	CHEMICAL
4'-thio-FAC	CHEMICAL
(	O
4'-thio-FACTP	CHEMICAL
)	O
exhibited	O
the	O
potent	O
inhibitory	O
action	O
against	O
DNA	GENE-Y
polymerase	GENE-Y
alpha	GENE-Y
,	O
whereas	O
it	O
showed	O
moderate	O
inhibition	O
against	O
DNA	GENE-Y
polymerase	GENE-Y
beta	GENE-Y
and	O
little	O
inhibition	O
against	O
DNA	GENE-Y
polymerase	GENE-Y
gamma	GENE-Y
.	O

The	O
triphosphate	CHEMICAL
of	CHEMICAL
gemcitabine	CHEMICAL
(	O
dFdCTP	CHEMICAL
)	O
did	O
not	O
show	O
potent	O
inhibition	O
against	O
these	O
three	O
DNA	GENE-N
polymerases	GENE-N
.	O

Thus	O
,	O
the	O
effect	O
on	O
ribonucleotide	O
reductase	O
was	O
suggested	O
to	O
be	O
more	O
responsible	O
for	O
the	O
antitumor	O
action	O
of	O
gemcitabine	CHEMICAL
.	O

The	O
differences	O
in	O
the	O
mechanisms	O
of	O
action	O
against	O
DNA	GENE-N
polymerases	GENE-N
between	O
these	O
drugs	O
and	O
other	O
nucleosides	O
were	O
also	O
discussed	O
.	O
OBJECTIVE	O
:	O
The	O
metabolic	O
syndrome	O
(	O
MetS	O
)	O
is	O
an	O
increasing	O
epidemiologic	O
challenge	O
and	O
cardiovascular	O
risk	O
factor	O
.	O

Interleukin-6	GENE-Y
(	O
IL-6	GENE-Y
)	O
is	O
a	O
cytokine	GENE-N
that	O
exerts	O
its	O
biological	O
function	O
via	O
a	O
complex	O
orchestration	O
of	O
soluble	O
and	O
membrane	O
bound	O
receptors	O
.	O

We	O
have	O
investigated	O
associations	O
between	O
IL-6	GENE-Y
and	O
its	O
soluble	O
receptors	O
,	O
soluble	GENE-Y
IL-6	GENE-Y
receptor	GENE-Y
(	O
sIL-6r	GENE-Y
)	O
and	O
soluble	GENE-Y
glycoprotein	GENE-Y
130	GENE-Y
(	O
sGP130	GENE-Y
)	O
and	O
the	O
metabolic	O
syndrome	O
.	O

Furthermore	O
,	O
we	O
have	O
investigated	O
possible	O
associations	O
with	O
endothelial	O
dysfunction	O
and	O
arterial	O
stiffness	O
.	O

METHODS	O
:	O
A	O
total	O
of	O
563	O
subjects	O
were	O
included	O
in	O
this	O
study	O
.	O

The	O
Adult	O
Treatment	O
Panel	O
III	O
criteria	O
of	O
the	O
National	O
Cholesterol	CHEMICAL
Education	O
Program	O
were	O
used	O
for	O
the	O
definition	O
of	O
MetS	O
.	O

We	O
used	O
commercially	O
available	O
ELISA	O
to	O
analyse	O
circulating	O
levels	O
of	O
the	O
markers	O
.	O

Pulse	O
wave	O
propagation	O
time	O
(	O
PWP	O
)	O
was	O
determined	O
to	O
assess	O
arterial	O
stiffness	O
.	O

RESULTS	O
:	O
The	O
criteria	O
for	O
having	O
MetS	O
were	O
filled	O
by	O
221	O
subjects	O
.	O

sGP130	GENE-Y
,	O
sIL-6r	GENE-Y
and	O
IL-6	GENE-Y
levels	O
were	O
elevated	O
in	O
subjects	O
with	O
MetS	O
(	O
p<0	O
.	O
05	O
for	O
all	O
markers	O
)	O
,	O
and	O
are	O
associated	O
with	O
increasing	O
components	O
of	O
MetS	O
.	O

Particularly	O
hypertriglyceridaemia	O
,	O
hypertension	O
and	O
fasting	O
plasma	O
glucose	CHEMICAL
(	O
FPG	O
)	O
seem	O
to	O
carry	O
this	O
association	O
.	O

sGP130	O
(	O
p<0	O
.	O
01	O
)	O
,	O
IL-6	GENE-Y
(	O
p<0	O
.	O
05	O
)	O
and	O
partially	O
sIL-6r	GENE-Y
(	O
p<0	O
.	O
05	O
)	O
correlated	O
with	O
markers	O
of	O
endothelial	O
function	O
(	O
E-selectin	GENE-Y
,	O
I-CAM-1	GENE-Y
,	O
V-CAM-1	GENE-Y
)	O
and	O
inversely	O
with	O
PWP	O
after	O
adjustment	O
for	O
relevant	O
covariates	O
.	O

CONCLUSION	O
:	O
sGP130	GENE-Y
,	O
sIL-6r	GENE-Y
and	O
IL-6	GENE-Y
were	O
significantly	O
elevated	O
in	O
subjects	O
with	O
MetS	O
.	O

In	O
addition	O
,	O
sGP130	GENE-Y
,	O
IL-6	GENE-Y
and	O
partially	O
sIL-6r	GENE-Y
were	O
associated	O
with	O
markers	O
of	O
endothelial	O
function	O
and	O
arterial	O
stiffness	O
.	O

This	O
finding	O
sheds	O
new	O
light	O
on	O
the	O
role	O
of	O
these	O
inflammatory	O
cytokines	O
in	O
subjects	O
with	O
MetS	O
and	O
the	O
development	O
and	O
progression	O
of	O
clinically	O
silent	O
atherosclerosis	O
.	O
Methylenetetrahydrofolate	GENE-Y
reductase	O
genotype	O
,	O
vitamin	CHEMICAL
B12	CHEMICAL
,	O
and	O
folate	CHEMICAL
influence	O
plasma	O
homocysteine	CHEMICAL
in	O
hemodialysis	O
patients	O
.	O
Direct	O
transcriptional	O
regulation	O
of	O
human	GENE-Y
hepatic	GENE-Y
cytochrome	GENE-Y
P450	GENE-Y
3A4	GENE-Y
(	O
CYP3A4	GENE-Y
)	O
by	O
peroxisome	GENE-Y
proliferator-activated	GENE-Y
receptor	GENE-Y
alpha	GENE-Y
(	O
PPARα	GENE-Y
)	O
.	O
The	O
YLR205c	GENE-Y
gene	O
of	O
Saccharomyces	O
cerevisiae	O
does	O
not	O
show	O
significant	O
sequence	O
identity	O
to	O
any	O
known	O
gene	O
,	O
except	O
for	O
heme	GENE-N
oxygenase	GENE-N
(	O
22%	O
to	O
human	GENE-Y
HO-1	GENE-Y
)	O
.	O

The	O
YLR205	GENE-N
ORF	GENE-N
was	O
cloned	O
and	O
overexpressed	O
in	O
both	O
Escherichia	O
coli	O
and	O
S	O
.	O

cerevisiae	O
.	O

Both	O
expression	O
systems	O
yielded	O
proteins	O
that	O
bound	O
heme	O
tightly	O
.	O

The	O
isolated	O
YLR205c	GENE-Y
protein	O
underwent	O
reduction	O
in	O
the	O
presence	O
of	O
either	O
NADPH-cytochrome	O
P450	O
reductase	O
or	O
NADH-putidaredoxin-putidaredoxin	O
reductase	O
but	O
did	O
not	O
exhibit	O
heme	GENE-N
oxygenase	GENE-N
activity	O
.	O

The	O
protein	O
exhibited	O
modest	O
H	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
O	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
-dependent	O
peroxidase	GENE-N
activities	O
with	O
guaiacol	CHEMICAL
,	O
potassium	CHEMICAL
iodide	CHEMICAL
,	O
and	O
2	CHEMICAL
,	CHEMICAL
2	CHEMICAL
(	CHEMICAL
'	CHEMICAL
)	CHEMICAL
-azino-bis	CHEMICAL
(	CHEMICAL
3-ethylbenzothiazoline-6-sulfonic	CHEMICAL
acid	CHEMICAL
(	O
ABTS	CHEMICAL
)	O
.	O

Thus	O
,	O
YLR205c	GENE-Y
codes	O
for	O
a	O
hemoprotein	GENE-N
of	O
unknown	O
physiological	O
function	O
that	O
exhibits	O
peroxidase	GENE-N
activity	O
.	O
Maqui	O
berry	O
(	O
Aristotelia	O
chilensis	O
)	O
and	O
the	O
constituent	O
delphinidin	CHEMICAL
glycoside	CHEMICAL
inhibit	O
photoreceptor	GENE-N
cell	O
death	O
induced	O
by	O
visible	O
light	O
.	O
A	O
low-affinity	O
Ca	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
/	O
H	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-antiport	O
was	O
described	O
in	O
the	O
membrane	O
of	O
mammalian	O
brain	O
synaptic	O
vesicles	O
.	O

Electrophysiological	O
studies	O
showed	O
that	O
this	O
antiport	O
contributes	O
to	O
the	O
extreme	O
brevity	O
of	O
excitation-release	O
coupling	O
in	O
rapid	O
synapses	O
.	O

Synaptotagmin-1	GENE-Y
,	O
a	O
vesicular	O
protein	O
interacting	O
with	O
membranes	O
upon	O
low-affinity	O
Ca	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-binding	O
,	O
plays	O
a	O
major	O
role	O
in	O
excitation-release	O
coupling	O
,	O
by	O
synchronizing	O
calcium	CHEMICAL
entry	O
with	O
fast	O
neurotransmitter	O
release	O
.	O

Here	O
,	O
we	O
report	O
that	O
synaptotagmin-1	GENE-Y
is	O
necessary	O
for	O
expression	O
of	O
the	O
vesicular	O
Ca	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
/	O
H	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-antiport	O
.	O

We	O
measured	O
Ca	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
/	O
H	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-antiport	O
activity	O
in	O
vesicles	O
and	O
granules	O
of	O
pheochromocytoma	O
PC12	O
cells	O
by	O
three	O
methods	O
:	O
(	O
1	O
)	O
Ca	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-induced	O
dissipation	O
of	O
the	O
vesicular	O
H	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-gradient;	O
(	O
2	O
)	O
bafilomycin-sensitive	O
calcium	CHEMICAL
accumulation	O
and	O
(	O
3	O
)	O
pH-jump-induced	O
calcium	CHEMICAL
accumulation	O
.	O

The	O
results	O
were	O
congruent	O
and	O
highly	O
significant	O
:	O
Ca	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
/	O
H	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-antiport	O
activity	O
is	O
detectable	O
only	O
in	O
acidic	O
organelles	O
expressing	O
functional	O
synaptotagmin-1	GENE-Y
.	O

In	O
contrast	O
,	O
synaptotagmin-1-deficient	O
cells	O
-	O
and	O
cells	O
where	O
transgenically	O
encoded	O
synaptotagmin-1	GENE-Y
was	O
acutely	O
photo-inactivated	O
-	O
were	O
devoid	O
of	O
any	O
Ca	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
/	O
H	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-antiport	O
activity	O
.	O

Therefore	O
,	O
in	O
addition	O
to	O
its	O
previously	O
described	O
functions	O
,	O
synaptotagmin-1	GENE-Y
is	O
involved	O
in	O
a	O
rapid	O
vesicular	O
Ca	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
sequestration	O
through	O
a	O
Ca	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
/	O
H	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
antiport	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O
The	O
human	GENE-Y
NADH	CHEMICAL
:	O
ubiquinone	CHEMICAL
oxidoreductase	O
NDUFS5	O
(	O
15	O
kDa	O
)	O
subunit	O
:	O
cDNA	O
cloning	O
,	O
chromosomal	O
localization	O
,	O
tissue	O
distribution	O
and	O
the	O
absence	O
of	O
mutations	O
in	O
isolated	O
complex	GENE-N
I-deficient	O
patients	O
.	O
Type	O
II	O
diabetes	O
is	O
a	O
heterogeneous	O
disease	O
where	O
environment	O
and	O
genetics	O
are	O
important	O
factors	O
for	O
the	O
expression	O
of	O
the	O
disease	O
.	O

The	O
high	O
cost	O
for	O
treating	O
complications	O
of	O
diabetes	O
is	O
a	O
burden	O
for	O
public	O
health	O
systems	O
and	O
governments	O
worldwide	O
.	O

Type	O
II	O
diabetes	O
has	O
been	O
causing	O
debilitation	O
worldwide	O
for	O
many	O
decades	O
,	O
and	O
a	O
single	O
drug	O
that	O
safely	O
treats	O
the	O
disease	O
has	O
yet	O
to	O
be	O
discovered	O
.	O

Sulfonylureas	CHEMICAL
,	O
biguanides	CHEMICAL
,	O
alpha-glucosidase	GENE-N
,	O
meglitinides	CHEMICAL
,	O
DPP-4	GENE-Y
inhibitors	O
and	O
thiazolidinediones	CHEMICAL
are	O
among	O
the	O
classes	O
of	O
oral	O
hypoglycemic	O
drugs	O
available	O
to	O
treat	O
Type	O
II	O
diabetes	O
,	O
but	O
concerns	O
exist	O
regarding	O
safety	O
and	O
efficacy	O
of	O
these	O
drugs	O
.	O

In	O
this	O
article	O
we	O
present	O
the	O
pros	O
and	O
cons	O
of	O
the	O
six	O
classes	O
and	O
discuss	O
some	O
of	O
the	O
latest	O
advances	O
towards	O
the	O
development	O
of	O
new	O
drugs	O
for	O
the	O
treatment	O
of	O
Type	O
II	O
diabetes	O
.	O
Distinct	O
pharmacologic	O
properties	O
of	O
neuromuscular	O
blocking	O
agents	O
on	O
human	GENE-N
neuronal	GENE-N
nicotinic	CHEMICAL
acetylcholine	CHEMICAL
receptors	O
:	O
a	O
possible	O
explanation	O
for	O
the	O
train-of-four	O
fade	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
role	O
of	O
intercellular	GENE-Y
adhesion	GENE-Y
molecule-2	GENE-Y
(	O
ICAM2	GENE-Y
)	O
in	O
the	O
testis	O
.	O

ICAM2	GENE-Y
is	O
a	O
cell	O
adhesion	O
protein	O
having	O
important	O
roles	O
in	O
cell	O
migration	O
,	O
especially	O
during	O
inflammation	O
when	O
leukocytes	O
cross	O
the	O
endothelium	O
.	O

Herein	O
,	O
we	O
showed	O
ICAM2	GENE-Y
to	O
be	O
expressed	O
by	O
germ	O
and	O
Sertoli	O
cells	O
in	O
the	O
rat	O
testis	O
.	O

When	O
a	O
monospecific	O
antibody	O
was	O
used	O
for	O
immunolocalization	O
experiments	O
,	O
ICAM2	GENE-Y
was	O
found	O
to	O
surround	O
the	O
heads	O
of	O
elongating	O
/	O
elongated	O
spermatids	O
in	O
all	O
stages	O
of	O
the	O
seminiferous	O
epithelial	O
cycle	O
.	O

To	O
determine	O
whether	O
ICAM2	GENE-Y
is	O
a	O
constituent	O
of	O
apical	O
ectoplasmic	O
specialization	O
(	O
ES	O
)	O
,	O
co-immunoprecipitation	O
and	O
dual	O
immunofluorescence	O
staining	O
were	O
performed	O
.	O

Interestingly	O
,	O
ICAM2	GENE-Y
was	O
found	O
to	O
associate	O
with	O
β1-integrin	GENE-Y
,	O
nectin-3	GENE-Y
,	O
afadin	GENE-Y
,	O
Src	GENE-Y
,	O
proline-rich	GENE-Y
tyrosine	CHEMICAL
kinase	O
2	O
,	O
annexin	GENE-Y
II	GENE-Y
,	O
and	O
actin	GENE-N
.	O

Following	O
CdCl₂	CHEMICAL
treatment	O
,	O
ICAM2	GENE-Y
was	O
found	O
to	O
be	O
upregulated	O
during	O
restructuring	O
of	O
the	O
seminiferous	O
epithelium	O
,	O
with	O
round	O
spermatids	O
becoming	O
increasingly	O
immunoreactive	O
for	O
ICAM2	GENE-Y
by	O
6-16	O
h	O
.	O

Interestingly	O
,	O
there	O
was	O
a	O
loss	O
in	O
the	O
binding	O
of	O
ICAM2	GENE-Y
to	O
actin	GENE-N
during	O
CdCl₂-induced	O
germ	O
cell	O
loss	O
,	O
suggesting	O
that	O
a	O
loss	O
of	O
ICAM2-actin	GENE-N
interactions	O
might	O
have	O
facilitated	O
junction	O
restructuring	O
.	O

Taken	O
collectively	O
,	O
these	O
results	O
illustrate	O
that	O
ICAM2	GENE-Y
plays	O
an	O
important	O
role	O
in	O
apical	O
ES	O
dynamics	O
during	O
spermatogenesis	O
.	O
Over-expression	O
of	O
cleaved	O
cyclin	GENE-Y
E	GENE-Y
in	O
breast	O
tumors	O
is	O
closely	O
associated	O
with	O
tumor	O
progression	O
and	O
resistance	O
to	O
antiestrogens	O
.	O

17β-Estradiol	CHEMICAL
(	O
E2	O
)	O
has	O
been	O
recently	O
shown	O
to	O
induce	O
cyclin	GENE-Y
E	GENE-Y
processing	O
in	O
breast	O
cancer	O
cells	O
.	O

Tamoxifen	CHEMICAL
has	O
been	O
used	O
in	O
patients	O
with	O
estrogen-sensitive	O
breast	O
cancer	O
,	O
yet	O
resistance	O
to	O
antiestrogens	O
and	O
recurrence	O
will	O
appear	O
in	O
some	O
of	O
the	O
patients	O
after	O
its	O
continued	O
use	O
.	O

We	O
therefore	O
addressed	O
possible	O
effects	O
of	O
tamoxifen	CHEMICAL
on	O
the	O
generation	O
of	O
cleaved	O
cyclin	GENE-Y
E	GENE-Y
and	O
its	O
signal	O
mechanism	O
(	O
s	O
)	O
in	O
estrogen-responsive	O
MCF-7	O
breast	O
cancer	O
cells	O
that	O
express	O
both	O
G	GENE-Y
protein-coupled	GENE-Y
protein	GENE-Y
(	GENE-Y
GPR	GENE-Y
)	GENE-Y
30	GENE-Y
and	O
estrogen	CHEMICAL
receptor	O
α	O
(	O
ERα	GENE-N
)	O
.	O

4-Hydroxytamoxifen	CHEMICAL
(	O
OHT	CHEMICAL
,	O
tamoxifen's	O
active	O
form	O
)	O
failed	O
to	O
prevent	O
E2-induced	O
proteolysis	O
of	O
cyclin	GENE-Y
E	GENE-Y
and	O
migration	O
,	O
but	O
rather	O
triggered	O
cyclin	GENE-Y
E	GENE-Y
cleavage	O
coincident	O
with	O
augmented	O
migration	O
.	O

OHT-induced	O
cyclin	GENE-Y
E	GENE-Y
truncation	O
also	O
occurred	O
in	O
SK-BR-3	O
cells	O
that	O
express	O
GPR30	GENE-Y
and	O
lack	O
ERα	GENE-Y
,	O
but	O
not	O
in	O
MDA-MB-231	O
cells	O
that	O
express	O
neither	O
GPR30	GENE-Y
nor	O
ERα	GENE-Y
.	O

G1	O
,	O
a	O
specific	O
GPR	GENE-Y
30	GENE-Y
agonist	O
,	O
caused	O
dramatic	O
proteolysis	O
of	O
cyclin	GENE-Y
E	GENE-Y
and	O
enhanced	O
migration	O
.	O

Furthermore	O
,	O
OHT-stimulated	O
cleavage	O
of	O
cyclin	GENE-Y
E	GENE-Y
and	O
migration	O
were	O
tremendously	O
attenuated	O
by	O
G15	O
,	O
a	O
GPR30	GENE-Y
antagonist	O
,	O
or	O
siRNA	O
against	O
GPR30	GENE-Y
.	O

In	O
addition	O
,	O
inhibitors	O
for	O
EGFR	GENE-Y
or	O
ERK1	GENE-N
/	GENE-N
2	GENE-N
remarkably	O
suppressed	O
OHT-induced	O
truncation	O
of	O
cyclin	GENE-Y
E	GENE-Y
,	O
suggesting	O
involvement	O
of	O
EGFR	GENE-Y
signaling	O
.	O

Collectively	O
,	O
our	O
data	O
indicate	O
that	O
OHT	CHEMICAL
contributes	O
to	O
the	O
production	O
of	O
proteolyzed	O
cyclin	GENE-Y
E	GENE-Y
via	O
GPR30	GENE-Y
with	O
augmented	O
migration	O
in	O
MCF-7	O
cells	O
.	O
The	O
effect	O
of	O
vitamin	CHEMICAL
B6	CHEMICAL
deficiency	O
on	O
alanine	GENE-N
:	O
glyoxylate	CHEMICAL
aminotransferase	O
isoenzymes	O
in	O
rat	O
liver	O
.	O
No	O
mutations	O
in	O
the	O
serotonin	CHEMICAL
related	O
TPH1	GENE-Y
and	O
HTR1B	GENE-Y
genes	O
in	O
patients	O
with	O
monogenic	O
sclerosing	O
bone	O
disorders	O
.	O
Nitric	CHEMICAL
oxide	CHEMICAL
(	O
NO	CHEMICAL
)	O
is	O
involved	O
in	O
many	O
physiological	O
and	O
pathological	O
processes	O
in	O
the	O
brain	O
.	O

NO	CHEMICAL
is	O
synthesized	O
from	O
arginine	CHEMICAL
by	O
nitric	CHEMICAL
oxide	CHEMICAL
synthase	O
(	O
NOS	GENE-N
)	O
,	O
and	O
the	O
citrulline	CHEMICAL
generated	O
as	O
a	O
by-product	O
can	O
be	O
recycled	O
to	O
arginine	CHEMICAL
by	O
argininosuccinate	GENE-Y
synthetase	O
(	O
AS	GENE-Y
)	O
and	O
argininosuccinate	GENE-Y
lyase	O
(	O
AL	GENE-Y
)	O
via	O
the	O
citrulline-NO	CHEMICAL
cycle	O
.	O

When	O
neuronal	O
PC12	O
cells	O
differentiated	O
with	O
nerve	GENE-Y
growth	GENE-Y
factor	GENE-Y
were	O
treated	O
with	O
interferon-gamma	GENE-Y
(	O
IFNgamma	GENE-Y
)	O
and	O
tumor	GENE-Y
necrosis	GENE-Y
factor-alpha	GENE-Y
(	O
TNFalpha	GENE-Y
)	O
,	O
iNOS	GENE-Y
and	O
AS	GENE-Y
mRNAs	O
and	O
proteins	O
were	O
markedly	O
induced	O
,	O
with	O
AL	GENE-Y
mRNA	O
and	O
protein	O
being	O
weakly	O
induced	O
.	O

Cationic	GENE-N
amino	CHEMICAL
acid	CHEMICAL
transporter-1	O
and	O
-2	O
were	O
not	O
induced	O
.	O

IFNgamma	GENE-Y
or	O
TNFalpha	GENE-Y
alone	O
was	O
ineffective	O
.	O

A	O
large	O
amount	O
of	O
NO	CHEMICAL
(	O
190	O
microM	O
NO	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
(	CHEMICAL
-	CHEMICAL
)	CHEMICAL
plus	O
NO	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
(	CHEMICAL
-	CHEMICAL
)	CHEMICAL
in	O
culture	O
medium	O
in	O
24	O
h	O
)	O
was	O
produced	O
from	O
arginine	CHEMICAL
by	O
cytokine-stimulated	O
cells	O
,	O
and	O
arginine	CHEMICAL
could	O
be	O
replaced	O
by	O
citrulline	CHEMICAL
.	O

iNOS	GENE-Y
induction	O
and	O
NO	CHEMICAL
production	O
were	O
attenuated	O
by	O
dexamethasone	CHEMICAL
and	O
dibutyryl	CHEMICAL
cAMP	CHEMICAL
and	O
even	O
more	O
strongly	O
so	O
when	O
combined	O
.	O

Therefore	O
,	O
a	O
large	O
amount	O
of	O
NO	CHEMICAL
is	O
produced	O
in	O
cytokine-stimulated	O
PC12	O
cells	O
following	O
to	O
induction	O
of	O
iNOS	GENE-Y
and	O
citrulline-arginine	CHEMICAL
recycling	O
is	O
important	O
for	O
NO	O
production	O
.	O
Hospitalized	O
osteoporotic	O
vertebral	O
fracture	O
increases	O
the	O
risk	O
of	O
stroke	O
:	O
a	O
population-based	O
cohort	O
study	O
.	O
The	O
mineralocorticoid	GENE-Y
receptor	GENE-Y
may	O
compensate	O
for	O
the	O
loss	O
of	O
the	O
glucocorticoid	GENE-Y
receptor	GENE-Y
at	O
specific	O
stages	O
of	O
mammary	O
gland	O
development	O
.	O
Platelet	O
activation	O
by	O
ADP	CHEMICAL
and	O
ATP	CHEMICAL
plays	O
a	O
crucial	O
role	O
in	O
haemostasis	O
and	O
thrombosis	O
,	O
and	O
their	O
so-called	O
P2	GENE-N
receptors	GENE-N
are	O
potential	O
targets	O
for	O
antithrombotic	O
drugs	O
.	O

The	O
ATP-gated	O
channel	O
P2X1	O
and	O
the	O
2	O
G	GENE-Y
protein-coupled	GENE-Y
P2Y1	GENE-Y
and	O
P2Y12	GENE-Y
ADP	GENE-N
receptors	GENE-N
selectively	O
contribute	O
to	O
platelet	O
aggregation	O
.	O

The	O
P2Y1	GENE-Y
receptor	O
is	O
responsible	O
for	O
ADP-induced	O
shape	O
change	O
and	O
weak	O
and	O
transient	O
aggregation	O
,	O
while	O
the	O
P2Y12	GENE-Y
receptor	O
is	O
responsible	O
for	O
the	O
completion	O
and	O
amplification	O
of	O
the	O
response	O
to	O
ADP	CHEMICAL
and	O
to	O
all	O
platelet	O
agonists	O
,	O
including	O
thromboxane	CHEMICAL
A2	CHEMICAL
(	O
TXA2	CHEMICAL
)	O
,	O
thrombin	GENE-Y
,	O
and	O
collagen	GENE-N
.	O

The	O
P2X1	GENE-Y
receptor	O
is	O
involved	O
in	O
platelet	O
shape	O
change	O
and	O
in	O
activation	O
by	O
collagen	GENE-N
under	O
shear	O
conditions	O
.	O

Due	O
to	O
its	O
central	O
role	O
in	O
the	O
formation	O
and	O
stabilization	O
of	O
a	O
thrombus	O
,	O
the	O
P2Y12	GENE-Y
receptor	O
is	O
a	O
well-established	O
target	O
of	O
antithrombotic	O
drugs	O
like	O
ticlopidine	CHEMICAL
or	O
clopidogrel	CHEMICAL
,	O
which	O
have	O
proved	O
efficacy	O
in	O
many	O
clinical	O
trials	O
and	O
experimental	O
models	O
of	O
thrombosis	O
.	O

Competitive	O
P2Y12	GENE-Y
antagonists	O
have	O
also	O
been	O
shown	O
to	O
be	O
effective	O
in	O
experimental	O
thrombosis	O
as	O
well	O
as	O
in	O
several	O
clinical	O
trials	O
.	O

Studies	O
in	O
P2Y1	GENE-Y
and	O
P2X1	GENE-Y
knockout	O
mice	O
and	O
experimental	O
thrombosis	O
models	O
using	O
selective	O
P2Y1	GENE-Y
and	O
P2X1	GENE-Y
antagonists	O
have	O
shown	O
that	O
,	O
depending	O
on	O
the	O
conditions	O
,	O
these	O
receptors	O
could	O
also	O
be	O
potential	O
targets	O
for	O
new	O
antithrombotic	O
drugs	O
.	O
Synaptotagmin	GENE-Y
1	GENE-Y
is	O
required	O
for	O
vesicular	O
Ca	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
/	O
H	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-antiport	O
activity	O
.	O
The	O
implementation	O
of	O
a	O
reactive	O
functional	O
group	O
onto	O
a	O
material	O
surface	O
is	O
of	O
great	O
importance	O
.	O

Reactive	O
functional	O
groups	O
(	O
e	O
.	O

g	O
.	O

,	O
an	O
amino	CHEMICAL
group	O
and	O
a	O
hydroxyl	CHEMICAL
group	O
)	O
are	O
usually	O
hydrophilic	O
,	O
which	O
makes	O
it	O
difficult	O
to	O
display	O
them	O
on	O
a	O
dry	O
polymer	O
surface	O
.	O

We	O
here	O
propose	O
a	O
novel	O
method	O
for	O
displaying	O
amino	CHEMICAL
groups	O
on	O
the	O
surfaces	O
of	O
polymeric	O
substrates	O
through	O
dip-coating	O
of	O
a	O
methacrylate-based	O
copolymer	O
.	O

We	O
synthesized	O
copolymers	O
composed	O
of	O
methyl	CHEMICAL
methacrylate	CHEMICAL
and	O
2-aminoethyl	CHEMICAL
methacrylate	CHEMICAL
with	O
different	O
protecting	O
groups	O
or	O
ion-complexes	O
on	O
their	O
amino	CHEMICAL
groups	O
,	O
then	O
dip-coated	O
the	O
copolymers	O
onto	O
a	O
poly	CHEMICAL
(	CHEMICAL
methyl	CHEMICAL
methacrylate	CHEMICAL
)	CHEMICAL
(	O
PMMA	CHEMICAL
)	O
substrate	O
.	O

Evaluation	O
using	O
a	O
cleavable	O
fluorescent	O
compound	O
,	O
which	O
was	O
synthesized	O
in	O
the	O
present	O
study	O
to	O
quantify	O
a	O
small	O
amount	O
(	O
pmol	O
/	O
cm	O
(	O
2	O
)	O
)	O
of	O
amino	CHEMICAL
groups	O
on	O
a	O
solid	O
surface	O
,	O
revealed	O
that	O
the	O
protection	O
of	O
amino	CHEMICAL
groups	O
affected	O
their	O
surface	O
segregation	O
in	O
the	O
copolymer	O
coating	O
.	O

p-Toluenesulfonate	CHEMICAL
ion-complex	O
and	O
tert-butoxycarbonyl	CHEMICAL
(	O
Boc	CHEMICAL
)	O
protection	O
of	O
amino	CHEMICAL
groups	O
were	O
found	O
to	O
effectively	O
display	O
amino	CHEMICAL
groups	O
on	O
the	O
surface	O
(	O
more	O
than	O
70	O
pmol	O
/	O
cm	O
(	O
2	O
)	O
)	O
.	O

The	O
density	O
of	O
amino	CHEMICAL
groups	O
displayed	O
on	O
a	O
surface	O
can	O
be	O
easily	O
controlled	O
by	O
mixing	O
the	O
copolymer	O
and	O
PMMA	CHEMICAL
before	O
dip-coating	O
.	O

Dip-coating	O
of	O
the	O
copolymer	O
with	O
Boc	CHEMICAL
protection	O
on	O
various	O
polymeric	O
substrates	O
also	O
successfully	O
displayed	O
amino	CHEMICAL
groups	O
on	O
their	O
surfaces	O
.	O

Finally	O
,	O
we	O
demonstrated	O
that	O
the	O
amino	CHEMICAL
groups	O
displayed	O
can	O
be	O
utilized	O
for	O
the	O
immobilization	O
of	O
a	O
DNA	O
oligonucleotide	O
on	O
a	O
substrate	O
surface	O
.	O
Injection	O
of	O
ropivacaine	CHEMICAL
into	O
the	O
subarachnoid	O
changes	O
the	O
ultrastructure	O
and	O
proteome	O
of	O
the	O
rat	O
spinal	O
cord	O
.	O
Role	O
of	O
dehydropeptidase-I	GENE-Y
in	O
the	O
metabolism	O
of	O
glutathione	CHEMICAL
and	O
its	O
conjugates	O
in	O
the	O
rat	O
kidney	O
.	O
Exendin-4	O
,	O
a	O
GLP-1	GENE-Y
receptor	GENE-Y
agonist	O
,	O
prevents	O
osteopnia	O
by	O
promoting	O
bone	O
formation	O
and	O
suppressing	O
bone	O
resorption	O
in	O
aged	O
ovariectomized	O
rats	O
.	O
Polycomb	GENE-N
repressive	GENE-N
complex	GENE-N
1	GENE-N
(	O
PRC1	GENE-N
)	O
catalyzes	O
lysine	CHEMICAL
119	O
monoubiquitylation	O
on	O
H2A	GENE-N
(	O
H2AK119ub1	O
)	O
and	O
regulates	O
pluripotency	O
in	O
embryonic	O
stem	O
cells	O
(	O
ESCs	O
)	O
.	O

However	O
,	O
the	O
mechanisms	O
controlling	O
the	O
binding	O
of	O
PRC1	GENE-N
to	O
genomic	O
sites	O
and	O
its	O
catalytic	O
activity	O
are	O
poorly	O
understood	O
.	O

Here	O
,	O
we	O
show	O
that	O
Fbxl10	GENE-Y
interacts	O
with	O
Ring1B	GENE-Y
and	O
Nspc1	GENE-Y
,	O
forming	O
a	O
noncanonical	O
PRC1	GENE-N
that	O
is	O
required	O
for	O
H2AK119ub1	O
in	O
mouse	O
ESCs	O
.	O

Genome-wide	O
analyses	O
reveal	O
that	O
Fbxl10	GENE-Y
preferentially	O
binds	O
to	O
CpG	CHEMICAL
islands	O
and	O
colocalizes	O
with	O
Ring1B	GENE-Y
on	O
Polycomb	GENE-N
target	O
genes	O
.	O

Notably	O
,	O
Fbxl10	GENE-Y
depletion	O
causes	O
a	O
decrease	O
in	O
Ring1B	GENE-Y
binding	O
to	O
target	O
genes	O
and	O
a	O
major	O
loss	O
of	O
H2AK119ub1	O
.	O

Furthermore	O
,	O
genetic	O
analyses	O
demonstrate	O
that	O
Fbxl10	GENE-Y
DNA	O
binding	O
capability	O
and	O
integration	O
into	O
PRC1	GENE-N
are	O
required	O
for	O
H2AK119	O
ubiquitylation	O
.	O

ESCs	O
lacking	O
Fbxl10	GENE-Y
,	O
like	O
previously	O
characterized	O
Polycomb	GENE-N
mutants	O
,	O
cannot	O
differentiate	O
properly	O
.	O

These	O
results	O
demonstrate	O
that	O
Fbxl10	GENE-Y
has	O
a	O
key	O
role	O
in	O
regulating	O
Ring1B	GENE-Y
recruitment	O
to	O
its	O
target	O
genes	O
and	O
H2AK119	O
ubiquitylation	O
in	O
ESCs	O
.	O
Considerable	O
evidence	O
indicates	O
that	O
serotonergic	O
mechanisms	O
,	O
particularly	O
the	O
serotonin	CHEMICAL
transporter	O
(	O
5HTT	GENE-Y
)	O
,	O
may	O
mediate	O
central	O
effects	O
of	O
cocaine	CHEMICAL
and	O
may	O
also	O
be	O
involved	O
in	O
impulsive	O
and	O
aggressive	O
behavior	O
.	O

We	O
investigated	O
whether	O
polymorphisms	O
in	O
the	O
5HTT	GENE-Y
gene	O
were	O
related	O
to	O
traits	O
of	O
impulsivity	O
,	O
sensation	O
seeking	O
,	O
and	O
aggression	O
among	O
cocaine	CHEMICAL
abusers	O
.	O

Standardized	O
measures	O
of	O
these	O
personality	O
traits	O
were	O
obtained	O
in	O
a	O
sample	O
of	O
105	O
severely	O
affected	O
cocaine-dependent	O
African-American	O
subjects	O
and	O
44	O
African-American	O
controls	O
.	O

Two	O
polymorphisms	O
of	O
the	O
5HTT	GENE-Y
gene	O
were	O
examined	O
involving	O
the	O
5'	O
promoter	O
(	O
5HTTLPR	GENE-N
)	O
region	O
and	O
a	O
17	O
base	O
pair	O
variable-number-tandem-repeat	GENE-N
(	O
VNTR	GENE-N
)	O
marker	O
among	O
cocaine	CHEMICAL
patients	O
.	O

No	O
significant	O
relationships	O
were	O
observed	O
between	O
polymorphic	O
variants	O
of	O
the	O
5HTTLPR	GENE-N
and	O
VNTR	GENE-N
regions	O
and	O
scores	O
on	O
any	O
of	O
the	O
trait	O
measures	O
.	O

Similarly	O
,	O
demographic	O
variables	O
and	O
measures	O
of	O
severity	O
of	O
substance	O
use	O
and	O
depression	O
were	O
unrelated	O
to	O
allele	O
frequencies	O
or	O
genotype	O
distributions	O
of	O
the	O
variants	O
among	O
cocaine	CHEMICAL
patients	O
.	O

As	O
expected	O
,	O
cocaine	CHEMICAL
patients	O
scored	O
significantly	O
higher	O
on	O
total	O
scores	O
of	O
impulsivity	O
,	O
aggression	O
,	O
and	O
sensation	O
seeking	O
compared	O
to	O
controls	O
.	O

The	O
findings	O
do	O
not	O
seem	O
to	O
support	O
an	O
association	O
between	O
these	O
polymorphisms	O
in	O
the	O
5HTT	GENE-Y
gene	O
and	O
impulsive-aggressive	O
traits	O
among	O
cocaine-dependent	O
African-American	O
individuals	O
.	O
Anti-diabetic	O
and	O
anti-lipidemic	O
effects	O
of	O
chlorogenic	CHEMICAL
acid	CHEMICAL
are	O
mediated	O
by	O
ampk	GENE-Y
activation	O
.	O
E7080	CHEMICAL
,	O
a	O
novel	O
inhibitor	O
that	O
targets	O
multiple	O
kinases	GENE-N
,	O
has	O
potent	O
antitumor	O
activities	O
against	O
stem	GENE-Y
cell	GENE-Y
factor	GENE-Y
producing	O
human	O
small	O
cell	O
lung	O
cancer	O
H146	O
,	O
based	O
on	O
angiogenesis	O
inhibition	O
.	O
Defective	O
DNA	O
damage	O
response	O
and	O
repair	O
in	O
liver	O
cells	O
expressing	O
hepatitis	GENE-Y
B	GENE-Y
virus	GENE-Y
surface	GENE-Y
antigen	GENE-Y
.	O
Recent	O
evidence	O
suggests	O
that	O
the	O
dopamine	CHEMICAL
D4	O
receptor	O
may	O
play	O
a	O
role	O
in	O
schizophrenia	O
,	O
and	O
that	O
the	O
atypical	O
properties	O
of	O
the	O
antipsychotic	O
clozapine	CHEMICAL
may	O
be	O
attributable	O
in	O
part	O
to	O
its	O
antagonistic	O
actions	O
at	O
this	O
receptor	O
.	O

In	O
the	O
present	O
study	O
,	O
clozapine	CHEMICAL
and	O
three	O
other	O
compounds	O
having	O
D4	GENE-Y
dopamine	CHEMICAL
receptor	O
antagonist	O
properties	O
were	O
examined	O
for	O
their	O
effectiveness	O
in	O
reducing	O
losses	O
in	O
prepulse	O
inhibition	O
(	O
PPI	O
)	O
induced	O
in	O
rats	O
by	O
the	O
dopamine	CHEMICAL
receptor	O
agonist	O
apomorphine	CHEMICAL
.	O

Previously	O
,	O
activity	O
in	O
the	O
PPI	O
model	O
has	O
been	O
shown	O
to	O
correlate	O
highly	O
with	O
the	O
antipsychotic	O
potency	O
of	O
a	O
number	O
of	O
neuroleptics	O
.	O

As	O
previously	O
reported	O
,	O
clozapine	CHEMICAL
(	O
1-5	O
.	O
6	O
mg	O
/	O
kg	O
)	O
significantly	O
reduced	O
apomorphine-induced	O
PPI	O
deficits	O
.	O

The	O
three	O
D4-selective	O
compounds	O
,	O
CP-293	CHEMICAL
,	CHEMICAL
019	CHEMICAL
(	O
5	O
.	O
6-17	O
.	O
8	O
mg	O
/	O
kg	O
)	O
,	O
U-101	CHEMICAL
,	CHEMICAL
387	CHEMICAL
(	O
3-30	O
mg	O
/	O
kg	O
)	O
and	O
L-745	CHEMICAL
,	CHEMICAL
870	CHEMICAL
(	O
1-10	O
mg	O
/	O
kg	O
)	O
,	O
also	O
significantly	O
blocked	O
the	O
losses	O
in	O
PPI	O
produced	O
by	O
apomorphine	CHEMICAL
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
dopamine	GENE-N
receptor	O
antagonists	O
with	O
selectivity	O
for	O
the	O
D4	GENE-Y
dopamine	CHEMICAL
receptor	O
subtype	O
may	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
schizophrenia	O
,	O
while	O
being	O
less	O
likely	O
to	O
produce	O
dyskinesias	O
associated	O
with	O
D2	GENE-Y
receptor	GENE-Y
antagonists	O
.	O
Bupropion	CHEMICAL
,	O
an	O
efficacious	O
antidepressant	O
and	O
smoking	O
cessation	O
agent	O
,	O
inhibits	O
dopamine	GENE-N
and	O
norepinephrine	CHEMICAL
transporters	O
(	O
DAT	GENE-Y
and	O
NET	GENE-Y
,	O
respectively	O
)	O
.	O

Recently	O
,	O
bupropion	CHEMICAL
has	O
been	O
reported	O
to	O
noncompetitively	O
inhibit	O
alpha3beta2	GENE-N
,	GENE-N
alpha3beta4	GENE-N
,	GENE-N
and	GENE-N
alpha4beta2	GENE-N
nicotinic	CHEMICAL
acetylcholine	CHEMICAL
receptors	O
(	O
nAChRs	O
)	O
expressed	O
in	O
Xenopus	O
oocytes	O
or	O
established	O
cell	O
lines	O
.	O

The	O
present	O
study	O
evaluated	O
bupropion-induced	O
inhibition	O
of	O
native	O
alpha3beta2*	GENE-N
and	GENE-N
alpha3beta4*	GENE-N
nAChRs	GENE-N
using	O
functional	O
neurotransmitter	O
release	O
assays	O
,	O
nicotine-evoked	O
[	O
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
H	CHEMICAL
]	O
overflow	O
from	O
superfused	O
rat	O
striatal	O
slices	O
preloaded	O
with	O
[	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
H	CHEMICAL
]	CHEMICAL
dopamine	CHEMICAL
(	O
[	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
H	CHEMICAL
]	CHEMICAL
DA	CHEMICAL
)	O
,	O
and	O
nicotine-evoked	O
[	O
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
H	CHEMICAL
]	O
overflow	O
from	O
hippocampal	O
slices	O
preloaded	O
with	O
[	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
H	CHEMICAL
]	CHEMICAL
norepinephrine	CHEMICAL
(	O
[	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
H	CHEMICAL
]	CHEMICAL
NE	CHEMICAL
)	O
.	O

The	O
mechanism	O
of	O
inhibition	O
was	O
evaluated	O
using	O
Schild	O
analysis	O
.	O

To	O
eliminate	O
the	O
interaction	O
of	O
bupropion	CHEMICAL
with	O
DAT	GENE-Y
or	O
NET	GENE-Y
,	O
nomifensine	CHEMICAL
or	O
desipramine	CHEMICAL
,	O
respectively	O
,	O
was	O
included	O
in	O
the	O
superfusion	O
buffer	O
.	O

A	O
high	O
bupropion	CHEMICAL
concentration	O
(	O
100	O
microM	O
)	O
elicited	O
intrinsic	O
activity	O
in	O
the	O
[	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
H	CHEMICAL
]	CHEMICAL
DA	CHEMICAL
release	O
assay	O
.	O

However	O
,	O
none	O
of	O
the	O
concentrations	O
(	O
1	O
nM-100	O
microM	O
)	O
examined	O
evoked	O
[	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
H	CHEMICAL
]	CHEMICAL
NE	CHEMICAL
overflow	O
and	O
,	O
thus	O
,	O
were	O
without	O
intrinsic	O
activity	O
in	O
this	O
assay	O
.	O

Moreover	O
,	O
bupropion	CHEMICAL
inhibited	O
both	O
nicotine-evoked	O
[	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
H	CHEMICAL
]	CHEMICAL
DA	CHEMICAL
overflow	O
(	O
IC	O
(	O
50	O
)	O
=	O
1	O
.	O
27	O
microM	O
)	O
and	O
nicotine-evoked	O
[	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
H	CHEMICAL
]	CHEMICAL
NE	CHEMICAL
overflow	O
(	O
IC	O
(	O
50	O
)	O
=	O
323	O
nM	O
)	O
at	O
bupropion	CHEMICAL
concentrations	O
well	O
below	O
those	O
eliciting	O
intrinsic	O
activity	O
.	O

Results	O
from	O
Schild	O
analyses	O
suggest	O
that	O
bupropion	CHEMICAL
competitively	O
inhibits	O
nicotine-evoked	O
[	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
H	CHEMICAL
]	CHEMICAL
DA	CHEMICAL
overflow	O
,	O
whereas	O
evidence	O
for	O
receptor	O
reserve	O
was	O
obtained	O
upon	O
assessment	O
of	O
bupropion	CHEMICAL
inhibition	O
of	O
nicotine-evoked	O
[	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
H	CHEMICAL
]	CHEMICAL
NE	CHEMICAL
overflow	O
.	O

Thus	O
,	O
bupropion	CHEMICAL
acts	O
as	O
an	O
antagonist	O
at	O
alpha3beta2*	GENE-N
and	GENE-N
alpha3beta4*	GENE-N
nAChRs	GENE-N
in	O
rat	O
striatum	O
and	O
hippocampus	O
,	O
respectively	O
,	O
across	O
the	O
same	O
concentration	O
range	O
that	O
inhibits	O
DAT	GENE-Y
and	O
NET	GENE-Y
function	O
.	O

The	O
combination	O
of	O
nAChR	GENE-N
and	O
transporter	O
inhibition	O
produced	O
by	O
bupropion	CHEMICAL
may	O
contribute	O
to	O
its	O
clinical	O
efficacy	O
as	O
a	O
smoking	O
cessation	O
agent	O
.	O
Effect	O
of	O
naloxone	CHEMICAL
on	O
ischemic	O
acute	O
kidney	O
injury	O
in	O
the	O
mouse	O
.	O
LPA1-induced	O
cytoskeleton	O
reorganization	O
drives	O
fibrosis	O
through	O
CTGF-dependent	O
fibroblast	O
proliferation	O
.	O
Determination	O
of	O
homocysteine	CHEMICAL
levels	O
in	O
cells	O
and	O
serum	O
is	O
important	O
because	O
high	O
homocysteine	CHEMICAL
is	O
a	O
risk	O
factor	O
for	O
cardiovascular	O
disease	O
.	O

The	O
currently	O
used	O
methods	O
for	O
homocysteine	CHEMICAL
analysis	O
either	O
are	O
time	O
consuming	O
or	O
rely	O
on	O
the	O
use	O
of	O
expensive	O
equipment	O
.	O

Described	O
in	O
this	O
study	O
is	O
an	O
enzymatic	O
assay	O
that	O
determines	O
levels	O
of	O
homocysteine	CHEMICAL
in	O
multiple	O
samples	O
in	O
less	O
than	O
30	O
min	O
at	O
levels	O
from	O
5	O
to	O
50	O
pmol	O
using	O
only	O
a	O
spectrophotometer	O
.	O

The	O
reproducibility	O
of	O
the	O
assay	O
is	O
consistent	O
with	O
the	O
other	O
methods	O
currently	O
used	O
.	O

A	O
second	O
assay	O
,	O
that	O
is	O
about	O
5-fold	O
more	O
sensitive	O
,	O
follows	O
the	O
enzymatic	O
catalyzed	O
solvent	O
exchange	O
of	O
protons	O
on	O
glycine	CHEMICAL
,	O
which	O
requires	O
a	O
scintillation	O
counter	O
.	O

Both	O
the	O
spectrophotometric	O
and	O
the	O
radiometric	O
methods	O
are	O
based	O
on	O
the	O
conversion	O
of	O
5-methyltetrahydrofolate	CHEMICAL
to	O
tetrahydrofolate	CHEMICAL
by	O
methionine	GENE-Y
synthase	O
.	O

The	O
tetrahydrofolate	CHEMICAL
is	O
formed	O
in	O
stoichiometric	O
amounts	O
to	O
the	O
homocysteine	CHEMICAL
in	O
the	O
sample	O
.	O

In	O
the	O
spectrophotometric	O
method	O
the	O
tetrahydrofolate	CHEMICAL
is	O
used	O
at	O
catalytic	O
levels	O
by	O
three	O
enzymes	O
to	O
form	O
a	O
metabolic	O
cycle	O
that	O
generates	O
NADPH	CHEMICAL
from	O
NADP	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
.	O

In	O
the	O
radiometric	O
assay	O
tetrahydrofolate	CHEMICAL
is	O
required	O
for	O
the	O
enzymatic	O
exchange	O
of	O
the	O
pro	O
2S	O
proton	O
of	O
glycine	CHEMICAL
with	O
solvent	O
.	O

L-Cysteine	CHEMICAL
,	O
at	O
levels	O
more	O
than	O
30-fold	O
higher	O
than	O
the	O
upper	O
level	O
of	O
homocysteine	CHEMICAL
used	O
in	O
these	O
assays	O
,	O
does	O
not	O
give	O
any	O
measurable	O
response	O
.	O
Drospirenone	CHEMICAL
(	O
ZK	CHEMICAL
30595;	O
6	CHEMICAL
beta	CHEMICAL
,	CHEMICAL
7	CHEMICAL
beta	CHEMICAL
,	CHEMICAL
15	CHEMICAL
beta	CHEMICAL
,	CHEMICAL
16	CHEMICAL
beta-dimethylen-3-oxo-17	CHEMICAL
alpha-pregn-4-ene-21	CHEMICAL
,	CHEMICAL
17-carbolactone	CHEMICAL
)	O
is	O
a	O
novel	O
progestogen	CHEMICAL
under	O
clinical	O
development	O
.	O

Drospirenone	CHEMICAL
is	O
characterized	O
by	O
an	O
innovative	O
pharmacodynamic	O
profile	O
which	O
is	O
very	O
closely	O
related	O
to	O
that	O
of	O
progesterone	CHEMICAL
.	O

Potential	O
applications	O
include	O
oral	O
contraception	O
,	O
hormone	O
replacement	O
therapy	O
and	O
treatment	O
of	O
hormonal	O
disorders	O
.	O

The	O
pharmacological	O
properties	O
of	O
drospirenone	CHEMICAL
were	O
investigated	O
in	O
vitro	O
by	O
receptor	O
binding	O
and	O
transactivation	O
experiments	O
and	O
in	O
vivo	O
in	O
appropriate	O
animal	O
models	O
.	O

In	O
qualitative	O
agreement	O
with	O
progesterone	CHEMICAL
,	O
the	O
compound	O
binds	O
strongly	O
to	O
the	O
progesterone	GENE-N
and	O
the	O
mineralocorticoid	O
receptor	O
and	O
with	O
lower	O
affinity	O
to	O
androgen	GENE-N
and	O
glucocorticoid	O
receptors	O
.	O

There	O
is	O
no	O
detectable	O
binding	O
to	O
the	O
estrogen	GENE-Y
receptor	O
.	O

Steroid	CHEMICAL
hormone	CHEMICAL
agonistic	O
and	O
antagonistic	O
activities	O
of	O
progesterone	CHEMICAL
and	O
drospirenone	CHEMICAL
were	O
compared	O
in	O
transactivation	O
experiments	O
.	O

Individual	O
steroid	GENE-N
hormone	GENE-N
receptors	O
were	O
artificially	O
expressed	O
together	O
with	O
a	O
reporter	O
gene	O
in	O
appropriate	O
cell	O
lines	O
.	O

Both	O
hormones	O
were	O
unable	O
to	O
induce	O
any	O
androgen	GENE-Y
receptor-mediated	O
agonistic	O
activity	O
.	O

Rather	O
,	O
both	O
progesterone	CHEMICAL
and	O
drospirenone	CHEMICAL
distinctly	O
antagonized	O
androgen-stimulated	O
transcriptional	O
activation	O
.	O

Likewise	O
,	O
both	O
compounds	O
only	O
very	O
weakly	O
activated	O
the	O
mineralocorticoid	GENE-Y
receptor	GENE-Y
but	O
showed	O
potent	O
aldosterone	CHEMICAL
antagonistic	O
activity	O
.	O

Drospirenone	CHEMICAL
did	O
not	O
induce	O
glucocorticoid	GENE-Y
receptor-driven	O
transactivation	O
.	O

Progesterone	CHEMICAL
was	O
a	O
weak	O
agonist	O
in	O
this	O
respect	O
.	O

Drospirenone	CHEMICAL
exerts	O
potent	O
progestogenic	O
and	O
antigonadotropic	O
activity	O
which	O
was	O
studied	O
in	O
various	O
animal	O
species	O
.	O

It	O
efficiently	O
promotes	O
the	O
maintenance	O
of	O
pregnancy	O
in	O
ovariectomized	O
rats	O
,	O
inhibits	O
ovulation	O
in	O
rats	O
and	O
mice	O
and	O
stimulates	O
endometrial	O
transformation	O
in	O
the	O
rabbit	O
.	O

Furthermore	O
,	O
drospirenone	CHEMICAL
shows	O
potent	O
antigonadotropic	O
,	O
i	O
.	O

e	O
.	O

,	O
testosterone-lowering	O
activity	O
in	O
male	O
cynomolgus	O
monkeys	O
.	O

The	O
progestogenic	O
potency	O
of	O
drospirenone	CHEMICAL
was	O
found	O
to	O
be	O
in	O
the	O
range	O
of	O
that	O
of	O
norethisterone	CHEMICAL
acetate	CHEMICAL
.	O

The	O
majority	O
of	O
clinically	O
used	O
progestogens	CHEMICAL
are	O
androgenic	O
.	O

Drospirenone	CHEMICAL
,	O
like	O
progesterone	CHEMICAL
,	O
has	O
no	O
androgenic	O
but	O
rather	O
an	O
antiandrogenic	O
effect	O
.	O

This	O
property	O
was	O
demonstrated	O
in	O
castrated	O
,	O
testosterone	CHEMICAL
propionate	CHEMICAL
substituted	O
male	O
rats	O
by	O
a	O
dose-dependent	O
inhibition	O
of	O
accessory	O
sex	O
organ	O
growth	O
(	O
seminal	O
vesicles	O
,	O
prostate	O
)	O
.	O

In	O
this	O
model	O
,	O
the	O
potency	O
of	O
drospirenone	CHEMICAL
was	O
about	O
a	O
third	O
that	O
of	O
cyproterone	CHEMICAL
acetate	CHEMICAL
.	O

Drospirenone	CHEMICAL
,	O
like	O
progesterone	CHEMICAL
,	O
shows	O
antimineralocorticoid	O
activity	O
,	O
which	O
causes	O
moderately	O
increased	O
sodium	CHEMICAL
and	O
water	O
excretion	O
.	O

This	O
is	O
an	O
outstanding	O
characteristic	O
which	O
has	O
not	O
been	O
described	O
for	O
any	O
other	O
synthetic	O
progestogen	CHEMICAL
before	O
.	O

Drospirenone	CHEMICAL
is	O
eight	O
to	O
ten	O
times	O
more	O
effective	O
in	O
this	O
respect	O
than	O
spironolactone	CHEMICAL
.	O

The	O
natriuretic	O
effect	O
was	O
demonstrable	O
for	O
at	O
least	O
three	O
weeks	O
upon	O
daily	O
treatment	O
of	O
rats	O
with	O
a	O
dose	O
of	O
10	O
mg	O
/	O
animal	O
.	O

Drospirenone	CHEMICAL
is	O
devoid	O
of	O
any	O
estrogenic	O
,	O
glucocorticoid	O
or	O
antiglucocorticoid	O
activity	O
.	O

In	O
summary	O
,	O
drospirenone	CHEMICAL
,	O
like	O
progesterone	CHEMICAL
,	O
combines	O
potent	O
progestogenic	O
with	O
antimineralocorticoid	O
and	O
antiandrogenic	O
activity	O
in	O
a	O
similar	O
dose	O
range	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O
Recently	O
,	O
we	O
described	O
the	O
aminothiazole	CHEMICAL
lead	O
(	CHEMICAL
4-biphenyl-4-ylthiazol-2-yl	CHEMICAL
)	CHEMICAL
-	CHEMICAL
(	CHEMICAL
6-methylpyridin-2-yl	CHEMICAL
)	CHEMICAL
-amine	CHEMICAL
(	O
1	O
)	O
,	O
which	O
exhibits	O
many	O
desirable	O
properties	O
,	O
including	O
excellent	O
stability	O
in	O
liver	O
microsomes	O
,	O
oral	O
bioavailability	O
of	O
∼40	O
%	O
,	O
and	O
high	O
exposure	O
in	O
the	O
brains	O
of	O
mice	O
.	O

Despite	O
its	O
good	O
pharmacokinetic	O
properties	O
,	O
compound	O
1	O
exhibited	O
only	O
modest	O
potency	O
in	O
mouse	O
neuroblastoma	O
cells	O
overexpressing	O
the	O
disease-causing	O
prion	GENE-Y
protein	GENE-Y
PrP	GENE-Y
(	GENE-Y
Sc	GENE-Y
)	GENE-Y
.	O

Accordingly	O
,	O
we	O
sought	O
to	O
identify	O
analogues	O
of	O
1	O
with	O
improved	O
antiprion	O
potency	O
in	O
ScN2a-cl3	O
cells	O
while	O
retaining	O
similar	O
or	O
superior	O
properties	O
.	O

Herein	O
we	O
report	O
the	O
discovery	O
of	O
improved	O
lead	O
compounds	O
such	O
as	O
(	CHEMICAL
6-methylpyridin-2-yl	CHEMICAL
)	CHEMICAL
-	CHEMICAL
[	CHEMICAL
4-	CHEMICAL
(	CHEMICAL
4-pyridin-3-yl-phenyl	CHEMICAL
)	CHEMICAL
thiazol-2-yl	CHEMICAL
]	CHEMICAL
amine	CHEMICAL
and	O
cyclopropanecarboxylic	CHEMICAL
acid	CHEMICAL
(	CHEMICAL
4-biphenylthiazol-2-yl	CHEMICAL
)	CHEMICAL
amide	CHEMICAL
,	O
which	O
exhibit	O
brain	O
exposure	O
/	O
EC50	O
ratios	O
at	O
least	O
tenfold	O
greater	O
than	O
that	O
of	O
compound	O
1	O
.	O
The	O
molecular	O
events	O
during	O
nongenotoxic	O
carcinogenesis	O
and	O
their	O
temporal	O
order	O
are	O
poorly	O
understood	O
but	O
thought	O
to	O
include	O
long-lasting	O
perturbations	O
of	O
gene	O
expression	O
.	O

Here	O
,	O
we	O
have	O
investigated	O
the	O
temporal	O
sequence	O
of	O
molecular	O
and	O
pathological	O
perturbations	O
at	O
early	O
stages	O
of	O
phenobarbital	CHEMICAL
(	O
PB	O
)	O
mediated	O
liver	O
tumor	O
promotion	O
in	O
vivo	O
.	O

Molecular	O
profiling	O
(	O
mRNA	O
,	O
microRNA	O
[	O
miRNA	O
]	O
,	O
DNA	O
methylation	O
,	O
and	O
proteins	O
)	O
of	O
mouse	O
liver	O
during	O
13	O
weeks	O
of	O
PB	O
treatment	O
revealed	O
progressive	O
increases	O
in	O
hepatic	O
expression	O
of	O
long	O
noncoding	O
RNAs	O
and	O
miRNAs	O
originating	O
from	O
the	O
Dlk1-Dio3	GENE-Y
imprinted	O
gene	O
cluster	O
,	O
a	O
locus	O
that	O
has	O
recently	O
been	O
associated	O
with	O
stem	O
cell	O
pluripotency	O
in	O
mice	O
and	O
various	O
neoplasms	O
in	O
humans	O
.	O

PB	O
induction	O
of	O
the	O
Dlk1-Dio3	GENE-Y
cluster	O
noncoding	O
RNA	O
(	O
ncRNA	O
)	O
Meg3	O
was	O
localized	O
to	O
glutamine	CHEMICAL
synthetase-positive	O
hypertrophic	O
perivenous	O
hepatocytes	O
,	O
suggesting	O
a	O
role	O
for	O
β-catenin	GENE-N
signaling	O
in	O
the	O
dysregulation	O
of	O
Dlk1-Dio3	GENE-Y
ncRNAs	O
.	O

The	O
carcinogenic	O
relevance	O
of	O
Dlk1-Dio3	GENE-Y
locus	O
ncRNA	O
induction	O
was	O
further	O
supported	O
by	O
in	O
vivo	O
genetic	O
dependence	O
on	O
constitutive	GENE-N
androstane	CHEMICAL
receptor	O
and	O
β-catenin	GENE-N
pathways	O
.	O

Our	O
data	O
identify	O
Dlk1-Dio3	GENE-Y
ncRNAs	O
as	O
novel	O
candidate	O
early	O
biomarkers	O
for	O
mouse	O
liver	O
tumor	O
promotion	O
and	O
provide	O
new	O
opportunities	O
for	O
assessing	O
the	O
carcinogenic	O
potential	O
of	O
novel	O
compounds	O
.	O
The	O
serotonin	GENE-Y
transporter	O
polymorphism	O
,	O
5HTTLPR	GENE-Y
,	O
is	O
associated	O
with	O
a	O
faster	O
response	O
time	O
to	O
sertraline	CHEMICAL
in	O
an	O
elderly	O
population	O
with	O
major	O
depressive	O
disorder	O
.	O
Minocycline	CHEMICAL
is	O
protective	O
in	O
models	O
of	O
transient	O
middle	O
cerebral	O
artery	O
occlusion	O
(	O
MCAO	O
)	O
.	O

We	O
studied	O
whether	O
minocycline	CHEMICAL
and	O
doxycycline	CHEMICAL
,	O
another	O
tetracycline	CHEMICAL
derivative	O
,	O
provide	O
protection	O
in	O
permanent	O
MCAO	O
.	O

Because	O
minocycline	CHEMICAL
inhibits	O
matrix	GENE-Y
metalloprotease-9	GENE-Y
(	O
MMP-9	GENE-Y
)	O
,	O
we	O
also	O
compared	O
minocycline's	O
protective	O
effect	O
in	O
wild	O
type	O
(	O
wt	O
)	O
and	O
MMP-9	GENE-Y
knock-out	O
(	O
ko	O
)	O
mice	O
.	O

Wt	O
FVB	O
/	O
N	O
,	O
Balb	O
/	O
C	O
,	O
and	O
two	O
lines	O
of	O
MMP-9	GENE-Y
ko	O
and	O
their	O
wt	O
C57Bl	O
/	O
6	O
control	O
mice	O
were	O
subjected	O
to	O
24-	O
or	O
72-hour	O
permanent	O
MCAO	O
.	O

Drug	O
administration	O
was	O
started	O
either	O
12	O
hours	O
before	O
or	O
2	O
hours	O
after	O
the	O
onset	O
of	O
MCAO	O
.	O

Infarct	O
size	O
was	O
determined	O
by	O
triphenyltetrazolium	CHEMICAL
staining	O
or	O
T2-weighted	O
MRI	O
.	O

Zymography	O
was	O
used	O
to	O
study	O
the	O
expression	O
of	O
MMPs	GENE-N
.	O

In	O
wt	O
strains	O
,	O
tetracycline	CHEMICAL
treatments	O
started	O
before	O
MCAO	O
reduced	O
the	O
infarct	O
size	O
by	O
25%	O
to	O
50%	O
,	O
whereas	O
the	O
treatment	O
started	O
after	O
MCAO	O
was	O
not	O
protective	O
.	O

Minocycline	CHEMICAL
inhibited	O
ischemia-provoked	O
pro-MMP-9	GENE-Y
induction	O
in	O
wt	O
mice	O
,	O
but	O
was	O
not	O
protective	O
in	O
MMP-9	GENE-Y
ko	O
mice	O
.	O

Pro-MMP-2	GENE-Y
was	O
induced	O
by	O
MCAO	O
in	O
wt	O
and	O
MMP-9	GENE-Y
ko	O
mice	O
.	O

MCAO-induced	O
pro-MMP-2	GENE-Y
was	O
downregulated	O
by	O
minocycline	CHEMICAL
treatment	O
in	O
wt	O
mice	O
but	O
remained	O
in	O
MMP-9	GENE-Y
ko	O
mice	O
at	O
the	O
same	O
level	O
as	O
in	O
saline-treated	O
wt	O
mice	O
.	O

Tetracyclines	CHEMICAL
are	O
protective	O
in	O
permanent	O
MCAO	O
when	O
the	O
treatment	O
is	O
started	O
before	O
the	O
insult	O
.	O

Minocycline	CHEMICAL
may	O
provide	O
protection	O
by	O
interfering	O
with	O
MMPs	GENE-N
.	O
Differential	O
phosphoproteome	O
of	O
the	O
striatum	O
from	O
pleiotrophin	GENE-Y
knockout	O
and	O
midkine	GENE-Y
knockout	O
mice	O
treated	O
with	O
amphetamine	CHEMICAL
:	O
Correlations	O
with	O
amphetamine-induced	O
neurotoxicity	O
.	O
Activation	O
of	O
β-cell	O
EphA5	GENE-Y
receptors	GENE-Y
by	O
its	O
ligand	O
ephrinA5	GENE-Y
from	O
adjacent	O
β-cells	O
has	O
been	O
reported	O
to	O
decrease	O
insulin	O
secretion	O
during	O
hypoglycemia	O
.	O

Given	O
the	O
similarities	O
between	O
islet	O
and	O
ventromedial	O
hypothalamus	O
(	O
VMH	O
)	O
glucose	CHEMICAL
sensing	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
the	O
EphA5	GENE-Y
/	O
ephrinA5	GENE-Y
system	O
might	O
function	O
within	O
the	O
VMH	O
during	O
hypoglycemia	O
to	O
stimulate	O
counterregulatory	O
hormone	O
release	O
as	O
well	O
.	O

Counterregulatory	O
responses	O
and	O
glutamine	CHEMICAL
/	O
glutamate	CHEMICAL
concentrations	O
in	O
the	O
VMH	O
were	O
assessed	O
during	O
a	O
hyperinsulinemic-hypoglycemic	O
glucose	CHEMICAL
clamp	O
study	O
in	O
chronically	O
catheterized	O
awake	O
male	O
Sprague-Dawley	O
rats	O
that	O
received	O
an	O
acute	O
VMH	O
microinjection	O
of	O
ephrinA5-Fc	O
,	O
chronic	O
VMH	O
knockdown	O
,	O
or	O
overexpression	O
of	O
ephrinA5	GENE-Y
using	O
an	O
adenoassociated	O
viral	O
construct	O
.	O

Local	O
stimulation	O
of	O
VMH	O
EphA5	GENE-Y
receptors	GENE-Y
by	O
ephrinA5-Fc	GENE-Y
or	O
ephrinA5	GENE-Y
overexpression	O
increased	O
,	O
whereas	O
knockdown	O
of	O
VMH	O
ephrinA5	GENE-Y
reduced	O
counterregulatory	O
responses	O
during	O
hypoglycemia	O
.	O

Overexpression	O
of	O
VMH	O
ephrinA5	GENE-Y
transiently	O
increased	O
local	O
glutamate	CHEMICAL
concentrations	O
,	O
whereas	O
ephrinA5	GENE-Y
knockdown	O
produced	O
profound	O
suppression	O
of	O
VMH	O
interstitial	O
fluid	O
glutamine	CHEMICAL
concentrations	O
in	O
the	O
basal	O
state	O
and	O
during	O
hypoglycemia	O
.	O

Changes	O
in	O
ephrinA5	GENE-Y
/	O
EphA5	GENE-Y
interactions	O
within	O
the	O
VMH	O
,	O
a	O
key	O
brain	O
glucose-sensing	O
region	O
,	O
act	O
in	O
concert	O
with	O
islets	O
to	O
restore	O
glucose	CHEMICAL
homeostasis	O
during	O
acute	O
hypoglycemia	O
,	O
and	O
its	O
effect	O
on	O
counterregulation	O
may	O
be	O
mediated	O
by	O
changes	O
in	O
glutamate	CHEMICAL
/	O
glutamine	CHEMICAL
cycling	O
.	O
Dual	O
antithrombotic	O
agents	O
acting	O
as	O
anticoagulants	O
and	O
aggregation	O
inhibitors	O
could	O
have	O
substantial	O
advantages	O
over	O
currently	O
prescribed	O
combinations	O
of	O
antithrombotic	O
drugs	O
.	O

Herein	O
,	O
we	O
report	O
compounds	O
with	O
moderate	O
inhibitory	O
activity	O
for	O
factor	GENE-Y
Xa	GENE-Y
and	O
fibrinogen	GENE-N
GPIIb	GENE-Y
/	GENE-Y
IIIa	GENE-Y
binding	O
(	O
both	O
in	O
the	O
micromolar	O
range	O
)	O
.	O

These	O
compounds	O
resulted	O
from	O
our	O
efforts	O
to	O
merge	O
the	O
pharmacophores	O
of	O
selective	O
factor	GENE-Y
Xa	GENE-Y
inhibitor	O
rivaroxaban	CHEMICAL
with	O
a	O
mimic	O
of	O
the	O
Arg-Gly-Asp	GENE-N
(	O
RGD	GENE-N
)	O
sequence	O
of	O
fibrinogen	GENE-N
to	O
obtain	O
designed	O
multiple	O
ligands	O
with	O
potential	O
antithrombotic	O
activity	O
.	O

Resulting	O
from	O
this	O
study	O
,	O
a	O
structurally	O
novel	O
class	O
of	O
submicromolar	O
fibrinogen	O
GPIIb	GENE-Y
/	GENE-Y
IIIa	GENE-Y
binding	O
inhibitor	O
bearing	O
1	CHEMICAL
,	CHEMICAL
2	CHEMICAL
,	CHEMICAL
4-oxadiazol-5	CHEMICAL
(	CHEMICAL
4H	CHEMICAL
)	CHEMICAL
-one	CHEMICAL
moiety	O
is	O
also	O
described	O
.	O
Intermittent	O
PTH	GENE-Y
is	O
the	O
major	O
anabolic	O
therapy	O
for	O
osteoporosis	O
while	O
continuous	O
PTH	GENE-Y
causes	O
bone	O
loss	O
.	O

PTH	GENE-Y
acts	O
on	O
the	O
osteoblast	O
(	O
OB	O
)	O
lineage	O
to	O
regulate	O
bone	O
resorption	O
and	O
formation	O
.	O

PTH	GENE-Y
also	O
induces	O
cyclooxygenase-2	GENE-Y
(	O
COX-2	GENE-Y
)	O
,	O
producing	O
prostaglandin	CHEMICAL
E2	CHEMICAL
(	O
PGE2	CHEMICAL
)	O
,	O
that	O
can	O
act	O
on	O
both	O
OBs	O
and	O
osteoclasts	O
(	O
OCs	O
)	O
.	O

Because	O
intermittent	O
PTH	GENE-Y
is	O
more	O
anabolic	O
in	O
Cox-2	GENE-Y
knockout	O
(	O
KO	O
)	O
than	O
wild	O
type	O
(	O
WT	O
)	O
mice	O
,	O
we	O
hypothesized	O
COX-2	GENE-Y
might	O
contribute	O
to	O
the	O
effects	O
of	O
continuous	O
PTH	GENE-Y
by	O
suppressing	O
PTH-stimulated	O
differentiation	O
of	O
mesenchymal	O
stem	O
cells	O
into	O
OBs	O
.	O

We	O
compared	O
effects	O
of	O
continuous	O
PTH	GENE-Y
on	O
bone	O
marrow	O
stromal	O
cells	O
(	O
BMSCs	O
)	O
and	O
primary	O
OBs	O
(	O
POBs	O
)	O
from	O
Cox-2	GENE-Y
KO	O
mice	O
,	O
mice	O
with	O
deletion	O
of	O
PGE2	CHEMICAL
receptors	O
(	O
Ptger4	GENE-Y
and	O
Ptger2	GENE-Y
KO	O
mice	O
)	O
,	O
and	O
WT	O
controls	O
.	O

PTH	GENE-Y
increased	O
OB	O
differentiation	O
in	O
BMSCs	O
only	O
in	O
the	O
absence	O
of	O
COX-2	GENE-Y
expression	O
or	O
activity	O
.	O

In	O
the	O
absence	O
of	O
COX-2	GENE-Y
,	O
PTH	GENE-Y
stimulated	O
differentiation	O
if	O
added	O
during	O
the	O
first	O
week	O
of	O
culture	O
.	O

In	O
Cox-2	GENE-Y
KO	O
BMSCs	O
,	O
PTH-stimulated	O
differentiation	O
was	O
prevented	O
by	O
adding	O
PGE2	CHEMICAL
to	O
cultures	O
.	O

Co-culture	O
of	O
POBs	O
with	O
M-CSF-expanded	O
bone	O
marrow	O
macrophages	O
(	O
BMMs	O
)	O
showed	O
that	O
the	O
inhibition	O
of	O
PTH-stimulated	O
OB	O
differentiation	O
required	O
not	O
only	O
COX-2	GENE-Y
or	O
PGE2	CHEMICAL
but	O
also	O
BMMs	O
.	O

Sufficient	O
PGE2	CHEMICAL
to	O
mediate	O
the	O
inhibitory	O
effect	O
was	O
made	O
by	O
either	O
WT	O
POBs	O
or	O
WT	O
BMMs	O
.	O

The	O
inhibitory	O
effect	O
mediated	O
by	O
COX-2	GENE-Y
/	O
PGE2	CHEMICAL
was	O
transferred	O
by	O
conditioned	O
media	O
from	O
RANKL-treated	O
BMMs	O
and	O
could	O
be	O
blocked	O
by	O
osteoprotegerin	GENE-Y
,	O
which	O
interferes	O
with	O
RANKL	GENE-Y
binding	O
to	O
its	O
receptor	O
on	O
OC	O
lineage	O
cells	O
.	O

Deletion	O
of	O
Ptger4	GENE-Y
,	O
but	O
not	O
Ptger2	GENE-Y
,	O
in	O
BMMs	O
prevented	O
the	O
inhibition	O
of	O
PTH-stimulated	O
OB	O
differentiation	O
.	O

As	O
expected	O
,	O
PGE2	CHEMICAL
also	O
stimulated	O
OB	O
differentiation	O
,	O
but	O
when	O
given	O
in	O
combination	O
with	O
PTH	GENE-Y
,	O
the	O
stimulatory	O
effects	O
of	O
both	O
were	O
abrogated	O
.	O

These	O
data	O
suggest	O
that	O
PGE2	CHEMICAL
,	O
acting	O
via	O
EP4R	O
on	O
BMMs	O
committed	O
to	O
the	O
OC	O
lineage	O
,	O
stimulated	O
secretion	O
of	O
a	O
factor	O
or	O
factors	O
that	O
acted	O
to	O
suppress	O
PTH-stimulated	O
OB	O
differentiation	O
.	O

This	O
suppression	O
of	O
OB	O
differentiation	O
could	O
contribute	O
to	O
the	O
bone	O
loss	O
seen	O
with	O
continuous	O
PTH	GENE-Y
in	O
vivo	O
.	O
OBJECTIVES	O
:	O
Significant	O
variability	O
in	O
the	O
efficacy	O
and	O
toxicity	O
of	O
an	O
anticancer	O
drug	O
is	O
observed	O
in	O
cancer	O
patients	O
.	O

Currently	O
,	O
there	O
are	O
no	O
standard	O
tools	O
for	O
prediction	O
of	O
a	O
patient's	O
tumor	O
response	O
or	O
his	O
risk	O
of	O
adverse	O
events	O
to	O
chemotherapy	O
.	O

METHODS	O
:	O
We	O
investigate	O
an	O
association	O
between	O
polymorphisms	O
of	O
gemcitabine	CHEMICAL
metabolism-related	O
genes	O
and	O
its	O
chemosensitivity	O
in	O
vitro	O
using	O
62	O
human	O
cancer	O
cell	O
lines	O
of	O
various	O
origins	O
.	O

Polymorphisms	O
of	O
gemcitabine	CHEMICAL
metabolism-related	O
genes	O
of	O
deoxycytidine	CHEMICAL
monophosphate	CHEMICAL
deaminase	O
(	O
DCTD	GENE-Y
)	O
,	O
deoxycytidine	CHEMICAL
kinase	O
(	O
DCK	GENE-Y
)	O
and	O
ribonucleotide	GENE-Y
reductase	GENE-Y
M1	GENE-Y
(	O
RRM1	GENE-Y
)	O
were	O
evaluated	O
using	O
the	O
CEQ8000	O
Genetic	O
analysis	O
system	O
and	O
GeneDoc	O
software	O
.	O

Chemosensitivity	O
of	O
gemcitabine	CHEMICAL
was	O
expressed	O
as	O
an	O
IC50	O
using	O
MTT	CHEMICAL
assay	O
.	O

RESULTS	O
:	O
The	O
frequency	O
of	O
the	O
polymorphisms	O
was	O
21%	O
in	O
DCTD	GENE-Y
315T>C	GENE-N
,	O
45	O
.	O
2%	O
in	O
RRM1	GENE-Y
1082C>A	GENE-N
,	O
59	O
.	O
7%	O
in	O
RRM1	GENE-Y
2455A>G	GENE-N
,	O
and	O
79%	O
in	O
RRM1	GENE-Y
2464G>A	GENE-N
.	O

When	O
examining	O
the	O
association	O
between	O
these	O
polymorphisms	O
and	O
IC50	O
,	O
only	O
the	O
RRM1	GENE-Y
2464G>A	GENE-N
showed	O
the	O
tendency	O
to	O
be	O
more	O
chemosensitive	O
to	O
gemcitabine	CHEMICAL
(	O
P	O
=	O
0	O
.	O
011	O
)	O
,	O
and	O
haplotypes	O
containing	O
2464G>A	GENE-N
polymorphism	O
also	O
showed	O
the	O
association	O
with	O
chemosensitivity	O
when	O
compared	O
to	O
wild-type	O
RRM1	GENE-Y
(	O
G2464G	GENE-N
)	O
.	O

We	O
could	O
not	O
see	O
the	O
significant	O
differences	O
of	O
mRNA	O
expression	O
level	O
with	O
real-time	O
PCR	O
between	O
cell	O
lines	O
according	O
to	O
G2464A	GENE-N
polymorphism	O
.	O

In	O
oligonucleotide	O
microarray	O
73	O
GenBank	O
Accession	O
Number	O
(	O
69	O
genes	O
)	O
were	O
selected	O
which	O
expressed	O
differently	O
between	O
RRM1	GENE-N
wild-type	O
and	O
the	O
G2464A	GENE-N
polymorphism	O
.	O

CONCLUSIONS	O
:	O
RRM1	GENE-N
2464G>A	GENE-N
polymorphism	O
demonstrated	O
an	O
association	O
with	O
gemcitabine	CHEMICAL
sensitivity	O
,	O
which	O
needs	O
functional	O
studies	O
with	O
co-expressing	O
genes	O
and	O
prospective	O
clinical	O
studies	O
for	O
the	O
clinical	O
application	O
as	O
a	O
predictive	O
bio-marker	O
.	O
Supernumerary	O
centrosomes	O
and	O
aneuploidy	O
are	O
associated	O
with	O
a	O
malignant	O
phenotype	O
of	O
tumor	O
cells	O
.	O

Centrosomal	O
clustering	O
is	O
a	O
mechanism	O
used	O
by	O
cancer	O
cells	O
with	O
supernumerary	O
centrosomes	O
to	O
solve	O
the	O
threatening	O
problem	O
of	O
multipolar	O
spindles	O
.	O

Griseofulvin	CHEMICAL
is	O
an	O
antifungal	O
substance	O
that	O
interferes	O
with	O
the	O
microtubule	O
apparatus	O
and	O
inhibits	O
centrosomal	O
clustering	O
.	O

It	O
has	O
also	O
been	O
demonstrated	O
that	O
griseofulvin	CHEMICAL
inhibits	O
the	O
growth	O
of	O
tumor	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

However	O
,	O
it	O
is	O
not	O
yet	O
known	O
whether	O
treatment	O
with	O
griseofulvin	CHEMICAL
inhibits	O
growth	O
of	O
adrenocortical	O
tumor	O
cells	O
.	O

We	O
studied	O
the	O
viability	O
and	O
antiproliferative	O
effects	O
of	O
griseofulvin	CHEMICAL
on	O
cultured	O
NCI-H295R	O
adrenocortical	O
carcinoma	O
cells	O
using	O
Wst-1-	O
,	O
BrdUrd-	O
,	O
and	O
[	CHEMICAL
3H	CHEMICAL
]	CHEMICAL
-thymidine	CHEMICAL
assays	O
.	O

For	O
the	O
detection	O
of	O
apoptosis	O
we	O
used	O
a	O
caspase	GENE-N
3	GENE-N
/	GENE-N
7	GENE-N
cleavage	O
assay	O
and	O
light	O
microscopy	O
techniques	O
.	O

We	O
observed	O
that	O
incubation	O
with	O
griseofulvin	CHEMICAL
for	O
24-48	O
h	O
leads	O
to	O
a	O
decrease	O
in	O
the	O
viability	O
and	O
proliferation	O
of	O
NCI-H295R	O
cells	O
in	O
a	O
dose-dependent	O
manner	O
.	O

Significant	O
effects	O
could	O
be	O
observed	O
after	O
incubation	O
with	O
griseofulvin	CHEMICAL
as	O
measured	O
by	O
Wst-1-	O
,	O
BrdUrd-	O
,	O
and	O
[	CHEMICAL
3H	CHEMICAL
]	CHEMICAL
dT-	O
uptake	O
assays	O
.	O

Apoptosis	O
of	O
NCI-H295R	O
cells	O
was	O
increased	O
in	O
a	O
dose-dependent	O
manner	O
up	O
to	O
4	O
.	O
5-fold	O
after	O
incubation	O
with	O
griseofulvin	CHEMICAL
40	O
μM	O
for	O
24	O
h	O
as	O
shown	O
by	O
caspase	GENE-N
3	GENE-N
/	GENE-N
7	GENE-N
cleavage	O
assay	O
and	O
light	O
microscopy	O
.	O

With	O
regard	O
to	O
new	O
treatment	O
strategies	O
for	O
adrenocortical	O
cancer	O
,	O
griseofulvin	CHEMICAL
,	O
and	O
possibly	O
other	O
agents	O
,	O
which	O
interfere	O
with	O
the	O
microtubule	O
apparatus	O
and	O
inhibit	O
centrosomal	O
clustering	O
,	O
may	O
turn	O
out	O
to	O
be	O
interesting	O
targets	O
for	O
further	O
research	O
.	O
Traumatic	O
brain	O
injury	O
(	O
TBI	O
)	O
evokes	O
an	O
intense	O
neuroinflammatory	O
reaction	O
that	O
is	O
essentially	O
mediated	O
by	O
activated	O
microglia	O
and	O
that	O
has	O
been	O
reported	O
to	O
act	O
as	O
a	O
secondary	O
injury	O
mechanism	O
that	O
further	O
promotes	O
neuronal	O
death	O
.	O

It	O
involves	O
the	O
excessive	O
production	O
of	O
inflammatory	O
cytokines	GENE-N
and	O
the	O
diminution	O
of	O
neuroprotective	GENE-N
and	GENE-N
neurotrophic	GENE-N
factors	GENE-N
,	O
such	O
as	O
the	O
soluble	GENE-Y
form	GENE-Y
alpha	GENE-Y
of	GENE-Y
the	GENE-Y
amyloid	GENE-Y
precursor	GENE-Y
protein	GENE-Y
(	O
sAPPα	GENE-Y
)	O
,	O
generated	O
by	O
the	O
activity	O
of	O
α-secretases	GENE-N
.	O

Hence	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effects	O
of	O
etazolate	CHEMICAL
,	O
an	O
α-secretase	GENE-N
activator	O
,	O
on	O
acute	O
and	O
belated	O
post-TBI	O
consequences	O
.	O

The	O
mouse	O
model	O
of	O
TBI	O
by	O
mechanical	O
percussion	O
was	O
used	O
and	O
injured	O
mice	O
received	O
either	O
the	O
vehicle	O
or	O
etazolate	CHEMICAL
at	O
the	O
dose	O
of	O
1	O
,	O
3	O
or	O
10	O
mg	O
/	O
kg	O
at	O
2	O
h	O
post-TBI	O
.	O

Neurological	O
score	O
,	O
cerebral	O
œdema	O
,	O
IL-1β	GENE-Y
and	O
sAPPα	GENE-Y
levels	O
,	O
microglial	O
activation	O
and	O
lesion	O
size	O
were	O
evaluated	O
from	O
6	O
to	O
24	O
h	O
post-TBI	O
.	O

Spontaneous	O
locomotor	O
activity	O
was	O
evaluated	O
from	O
48	O
h	O
to	O
12	O
weeks	O
post-TBI	O
,	O
memory	O
function	O
at	O
5	O
weeks	O
and	O
olfactory	O
bulb	O
lesions	O
at	O
13	O
weeks	O
post-TBI	O
.	O

A	O
single	O
administration	O
of	O
etazolate	CHEMICAL
exerted	O
a	O
dose-dependent	O
anti-inflammatory	O
and	O
anti-œdematous	O
effect	O
accompanied	O
by	O
lasting	O
memory	O
improvement	O
,	O
reduction	O
of	O
locomotor	O
hyperactivity	O
and	O
olfactory	O
bulb	O
tissue	O
protection	O
,	O
with	O
a	O
therapeutic	O
window	O
of	O
at	O
least	O
2	O
h	O
.	O

These	O
effects	O
were	O
associated	O
with	O
the	O
restoration	O
of	O
the	O
levels	O
of	O
the	O
sAPPα	GENE-Y
protein	O
post-TBI	O
.	O

Taken	O
together	O
,	O
these	O
results	O
highlight	O
for	O
the	O
first	O
time	O
the	O
therapeutic	O
interest	O
of	O
an	O
α-secretase	GENE-N
activator	O
in	O
TBI	O
.	O
Design	O
,	O
synthesis	O
,	O
and	O
structure-activity	O
relationship	O
studies	O
of	O
tryptanthrins	CHEMICAL
as	O
antitubercular	O
agents	O
.	O
Synthesis	O
,	O
crystal	O
structure	O
and	O
antidiabetic	O
activity	O
of	O
substituted	O
(	CHEMICAL
E	CHEMICAL
)	CHEMICAL
-3-	CHEMICAL
(	CHEMICAL
Benzo	CHEMICAL
[	CHEMICAL
d	CHEMICAL
]	CHEMICAL
thiazol-2-ylamino	CHEMICAL
)	CHEMICAL
phenylprop-2-en-1-one	CHEMICAL
.	O
DNA	O
damage	O
and	O
homologous	O
recombination	O
signaling	O
induced	O
by	O
thymidylate	CHEMICAL
deprivation	O
.	O
The	O
human	GENE-Y
multidrug	GENE-Y
and	GENE-Y
toxin	GENE-Y
extrusion	GENE-Y
(	GENE-Y
MATE	GENE-Y
)	GENE-Y
transporter	GENE-Y
1	GENE-Y
contributes	O
to	O
the	O
tissue	O
distribution	O
and	O
excretion	O
of	O
many	O
drugs	O
.	O

Inhibition	O
of	O
MATE1	GENE-Y
may	O
result	O
in	O
potential	O
drug-drug	O
interactions	O
(	O
DDIs	O
)	O
and	O
alterations	O
in	O
drug	O
exposure	O
and	O
accumulation	O
in	O
various	O
tissues	O
.	O

The	O
primary	O
goals	O
of	O
this	O
project	O
were	O
to	O
identify	O
MATE1	GENE-Y
inhibitors	O
with	O
clinical	O
importance	O
or	O
in	O
vitro	O
utility	O
and	O
to	O
elucidate	O
the	O
physicochemical	O
properties	O
that	O
differ	O
between	O
MATE1	GENE-Y
and	O
OCT2	GENE-Y
inhibitors	O
.	O

Using	O
a	O
fluorescence	O
assay	O
of	O
ASP	O
(	O
+	O
)	O
uptake	O
in	O
cells	O
stably	O
expressing	O
MATE1	GENE-Y
,	O
over	O
900	O
prescription	O
drugs	O
were	O
screened	O
and	O
84	O
potential	O
MATE1	GENE-Y
inhibitors	O
were	O
found	O
.	O

We	O
identified	O
several	O
MATE1	GENE-Y
selective	O
inhibitors	O
including	O
four	O
FDA-approved	O
medications	O
that	O
may	O
be	O
clinically	O
relevant	O
MATE1	GENE-Y
inhibitors	O
and	O
could	O
cause	O
a	O
clinical	O
DDI	O
.	O

In	O
parallel	O
,	O
a	O
QSAR	O
model	O
identified	O
distinct	O
molecular	O
properties	O
of	O
MATE1	GENE-Y
versus	O
OCT2	GENE-Y
inhibitors	O
and	O
was	O
used	O
to	O
screen	O
the	O
DrugBank	O
in	O
silico	O
library	O
for	O
new	O
hits	O
in	O
a	O
larger	O
chemical	O
space	O
.	O
Exposure	O
to	O
chronic	O
stress	O
during	O
developmental	O
periods	O
is	O
a	O
risk	O
factor	O
for	O
a	O
number	O
of	O
psychiatric	O
disorders	O
.	O

While	O
the	O
direct	O
effects	O
of	O
stress	O
exposure	O
have	O
been	O
studied	O
extensively	O
,	O
little	O
is	O
known	O
about	O
the	O
long-lasting	O
effects	O
and	O
the	O
interaction	O
with	O
ageing	O
.	O

The	O
same	O
holds	O
true	O
for	O
the	O
treatment	O
with	O
selective	O
serotonin	CHEMICAL
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
,	O
which	O
have	O
been	O
shown	O
to	O
prevent	O
or	O
reverse	O
some	O
stress-induced	O
effects	O
.	O

Here	O
,	O
we	O
studied	O
the	O
direct	O
and	O
long-lasting	O
impact	O
of	O
chronic	O
social	O
stress	O
during	O
adolescence	O
and	O
the	O
impact	O
of	O
chronic	O
treatment	O
with	O
the	O
SSRI	O
paroxetine	CHEMICAL
in	O
adulthood	O
and	O
aged	O
animals	O
.	O

Therefore	O
,	O
male	O
CD1	O
mice	O
at	O
the	O
age	O
of	O
28	O
days	O
were	O
subjected	O
to	O
7	O
weeks	O
of	O
chronic	O
social	O
stress	O
.	O

Treatment	O
with	O
paroxetine	CHEMICAL
was	O
performed	O
per	O
os	O
with	O
a	O
dosage	O
of	O
20	O
mg	O
/	O
g	O
BW	O
.	O

We	O
were	O
able	O
to	O
reverse	O
most	O
of	O
the	O
effects	O
of	O
chronic	O
social	O
stress	O
in	O
adult	O
mice	O
(	O
4	O
months	O
old	O
)	O
and	O
to	O
some	O
extend	O
in	O
aged	O
animals	O
(	O
15	O
months	O
old	O
)	O
with	O
the	O
SSRI	O
treatment	O
.	O

Especially	O
the	O
regulation	O
of	O
the	O
HPA	O
axis	O
seems	O
to	O
be	O
affected	O
in	O
aged	O
mice	O
with	O
a	O
shift	O
to	O
the	O
use	O
of	O
vasopressin	GENE-Y
.	O

Our	O
results	O
demonstrate	O
that	O
chronic	O
stress	O
exposure	O
and	O
antidepressant	O
treatment	O
at	O
the	O
end	O
of	O
the	O
developmental	O
period	O
can	O
have	O
a	O
significant	O
and	O
long-lasting	O
impact	O
,	O
highly	O
relevant	O
for	O
healthy	O
ageing	O
.	O
Chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
is	O
a	O
major	O
cause	O
of	O
morbidity	O
and	O
mortality	O
worldwide	O
.	O

Oxidative	O
stress	O
is	O
an	O
important	O
mechanism	O
in	O
the	O
pathogenesis	O
of	O
this	O
disease	O
.	O

The	O
oxidant	O
/	O
antioxidant	O
imbalance	O
occurring	O
in	O
smokers	O
and	O
patients	O
with	O
COPD	O
is	O
well	O
established	O
.	O

Thus	O
,	O
therapeutic	O
strategies	O
targeting	O
oxidative	O
stress	O
with	O
pharmacological	O
antioxidant	O
agents	O
or	O
boosting	O
the	O
endogenous	O
levels	O
of	O
antioxidants	O
is	O
likely	O
to	O
be	O
beneficial	O
as	O
an	O
adjunctive	O
tool	O
in	O
the	O
treatment	O
of	O
COPD	O
patients	O
.	O

Thiol	CHEMICAL
compounts	O
such	O
as	O
N-acetyl-L-cysteine	CHEMICAL
(	O
NAC	CHEMICAL
)	O
,	O
carbocysteine	CHEMICAL
,	O
erdosteine	CHEMICAL
,	O
and	O
fudosteine	CHEMICAL
have	O
been	O
extensively	O
studied	O
.	O

Although	O
some	O
results	O
remain	O
controversial	O
,	O
NAC	CHEMICAL
and	O
carbocysteine	CHEMICAL
seem	O
to	O
have	O
beneficial	O
effect	O
in	O
patients	O
not	O
receiving	O
inhaled	O
corticosteroids	CHEMICAL
who	O
suffer	O
from	O
frequent	O
exacerbations	O
.	O

In	O
addition	O
,	O
other	O
antioxidants	O
like	O
superoxide	GENE-N
dismutase	O
(	O
SOD	GENE-N
)	O
mimetics	O
and	O
nuclear	GENE-Y
factor-erythroid	GENE-Y
2	GENE-Y
related	GENE-Y
factor	GENE-Y
2	GENE-Y
(	O
Nrf2	GENE-Y
)	O
are	O
shown	O
to	O
decrease	O
markers	O
of	O
oxidative	O
stress	O
in	O
patients	O
with	O
emphysema	O
,	O
while	O
others	O
like	O
glutathione	CHEMICAL
peroxidase	O
(	O
GPx	GENE-N
)	O
mimetics	O
and	O
NO	CHEMICAL
synthase	O
(	O
iNOS	GENE-Y
)	O
can	O
prevent	O
both	O
inflammation	O
and	O
oxidative	O
stress	O
in	O
clinical	O
trials	O
in	O
vivo	O
(	O
or	O
in	O
mouse	O
models	O
)	O
.	O

In	O
this	O
article	O
we	O
review	O
the	O
effectiveness	O
of	O
various	O
antioxidant	O
factors	O
in	O
COPD	O
and	O
their	O
potential	O
beneficial	O
effect	O
in	O
the	O
treatment	O
of	O
the	O
disease	O
.	O
Determinants	O
of	O
specificity	O
for	O
aflatoxin	CHEMICAL
B1-8	CHEMICAL
,	CHEMICAL
9-epoxide	CHEMICAL
in	O
alpha-class	GENE-N
glutathione	CHEMICAL
S-transferases	O
.	O
Structure-based	O
design	O
of	O
aliskiren	CHEMICAL
,	O
a	O
novel	O
orally	O
effective	O
renin	GENE-Y
inhibitor	O
.	O
RATIONALE	O
:	O
Social	O
defeat	O
stress	O
induces	O
physiological	O
and	O
behavioral	O
symptoms	O
,	O
including	O
anxiety	O
,	O
anhedonia	O
,	O
immune	O
deficits	O
,	O
and	O
altered	O
expression	O
of	O
key	O
brain	O
genes	O
.	O

OBJECTIVES	O
:	O
The	O
present	O
study	O
investigated	O
the	O
effects	O
of	O
social	O
defeat	O
stress	O
on	O
the	O
behaviors	O
and	O
expressions	O
of	O
Chat	GENE-Y
,	O
Grp78	GENE-Y
,	O
and	O
chop	GENE-Y
in	O
the	O
brains	O
of	O
adult	O
mice	O
.	O

METHODS	O
:	O
Adult	O
mice	O
were	O
divided	O
into	O
susceptible	O
and	O
unsusceptible	O
groups	O
after	O
10	O
days	O
of	O
social	O
defeat	O
stress	O
.	O

In	O
experiment	O
1	O
,	O
behavioral	O
tests	O
were	O
conducted	O
,	O
and	O
brains	O
were	O
processed	O
for	O
Western	O
blotting	O
at	O
day	O
27	O
after	O
stress	O
.	O

In	O
experiment	O
2	O
,	O
social	O
avoidance	O
tests	O
were	O
conducted	O
,	O
and	O
brains	O
were	O
processed	O
for	O
Western	O
blotting	O
at	O
day	O
12	O
after	O
stress	O
.	O

RESULTS	O
:	O
The	O
results	O
indicate	O
decreased	O
and	O
increased	O
locomotion	O
and	O
anxiety	O
behavior	O
in	O
all	O
defeated	O
mice	O
.	O

Decrease	O
in	O
social	O
interaction	O
,	O
increased	O
immobility	O
,	O
and	O
impaired	O
memory	O
performance	O
were	O
only	O
observed	O
in	O
susceptible	O
mice	O
.	O

A	O
decrease	O
in	O
the	O
Chat	O
level	O
at	O
days	O
12	O
and	O
27	O
was	O
noted	O
in	O
the	O
prefrontal	O
cortex	O
(	O
PFC	O
)	O
,	O
amygdala	O
(	O
Amyg	O
)	O
,	O
and	O
dorsal	O
hippocampus	O
(	O
HIP	O
)	O
in	O
defeated	O
mice	O
.	O

The	O
expression	O
levels	O
of	O
Grp78	GENE-Y
and	O
chop	GENE-Y
measured	O
on	O
days	O
12	O
and	O
27	O
were	O
significantly	O
greater	O
in	O
the	O
Amyg	O
of	O
susceptible	O
mice	O
.	O

In	O
the	O
PFC	O
and	O
HIP	O
,	O
defeated	O
mice	O
displayed	O
different	O
patterns	O
in	O
the	O
levels	O
of	O
Grp78	GENE-Y
and	O
chop	GENE-Y
expressions	O
measured	O
on	O
days	O
12	O
and	O
27	O
.	O

CONCLUSIONS	O
:	O
The	O
present	O
study	O
demonstrated	O
that	O
chronic	O
social	O
defeat	O
stress	O
in	O
mice	O
produces	O
stress-related	O
behaviors	O
.	O

Different	O
response	O
patterns	O
were	O
noted	O
for	O
Grp78	GENE-Y
and	O
chop	GENE-Y
expression	O
among	O
the	O
groups	O
in	O
terms	O
of	O
brain	O
regions	O
and	O
time-course	O
effects	O
.	O
Vitamin	CHEMICAL
A	CHEMICAL
deficiency	O
leads	O
to	O
focal	O
metaplasia	O
of	O
numerous	O
epithelial	O
tissues	O
with	O
altered	O
differentiation	O
from	O
columnar	O
(	O
in	O
general	O
)	O
to	O
stratified	O
squamous	O
cells	O
.	O

This	O
process	O
can	O
be	O
reversed	O
with	O
vitamin	CHEMICAL
A	CHEMICAL
repletion	O
.	O

Previously	O
,	O
we	O
described	O
a	O
system	O
of	O
retinoic	CHEMICAL
acid	CHEMICAL
(	O
RA	CHEMICAL
)	O
synthesis	O
in	O
the	O
cycling	O
rat	O
uterus	O
consisting	O
of	O
cellular	GENE-Y
retinol	GENE-Y
binding	GENE-Y
protein	GENE-Y
(	O
Crbp	GENE-Y
)	O
,	O
epithelial	GENE-Y
retinol	GENE-Y
dehydrogenase	GENE-Y
(	O
eRoldh	GENE-Y
)	O
,	O
retinal	GENE-Y
dehydrogenase	GENE-Y
2	GENE-Y
(	O
Aldh1a2	GENE-Y
)	O
,	O
and	O
cellular	GENE-Y
retinoic	CHEMICAL
acid	CHEMICAL
binding	O
protein	O
type	O
II	O
(	O
Crabp2	GENE-Y
)	O
.	O

Western	O
blot	O
analysis	O
,	O
RT-PCR	O
,	O
and	O
immunohistochemistry	O
were	O
performed	O
to	O
test	O
whether	O
this	O
retinoic	CHEMICAL
acid	CHEMICAL
synthesis	O
system	O
was	O
also	O
present	O
in	O
other	O
vitamin	CHEMICAL
A	CHEMICAL
sensitive	O
tissues	O
.	O

We	O
found	O
that	O
combinations	O
of	O
Crbp	GENE-Y
,	O
eRoldh	GENE-Y
,	O
Aldh1a2	GENE-Y
or	O
Aldh1a3	GENE-Y
,	O
and	O
Crabp2	GENE-Y
were	O
present	O
in	O
all	O
vitamin	CHEMICAL
A	CHEMICAL
sensitive	O
tissues	O
examined	O
.	O

In	O
the	O
ureter	O
,	O
while	O
eRoldh	GENE-Y
was	O
present	O
,	O
another	O
short	O
chain	O
alcohol	GENE-N
dehydrogenase	O
reductase	O
(	O
possibly	O
Roldh	GENE-N
1	GENE-N
,	GENE-N
2	GENE-N
,	GENE-N
or	GENE-N
3	GENE-N
)	O
was	O
in	O
higher	O
concentration	O
in	O
the	O
transitional	O
epithelia	O
.	O

In	O
several	O
tissues	O
,	O
Crbp	GENE-Y
,	O
Aldh1a2	GENE-Y
,	O
and	O
/	O
or	O
Aldh1a3	GENE-Y
localized	O
to	O
mesenchyme	O
and	O
/	O
or	O
epithelial	O
cells	O
,	O
while	O
eRoldh	GENE-Y
and	O
Crabp2	GENE-Y
were	O
expressed	O
only	O
in	O
epithelial	O
cells	O
.	O

This	O
suggests	O
that	O
mesenchymal-epithelial	O
interactions	O
may	O
be	O
as	O
important	O
in	O
the	O
adult	O
as	O
they	O
are	O
during	O
development	O
and	O
that	O
local	O
synthesis	O
of	O
RA	CHEMICAL
is	O
important	O
in	O
maintenance	O
of	O
these	O
tissues	O
.	O
The	O
toxicity	O
of	O
the	O
N-hydroxy	CHEMICAL
and	O
6-hydroxy	CHEMICAL
metabolites	O
of	O
3	CHEMICAL
,	CHEMICAL
4-dichloropropionanilide	CHEMICAL
does	O
not	O
depend	O
on	O
calcium	GENE-N
release-activated	O
calcium	CHEMICAL
channel	O
inhibition	O
.	O
Acetaminophen	CHEMICAL
(	O
APAP	CHEMICAL
)	O
overdose	O
is	O
a	O
classical	O
model	O
of	O
hepatocellular	O
necrosis;	O
however	O
,	O
the	O
involvement	O
of	O
the	O
Fas	GENE-Y
receptor	GENE-Y
in	O
the	O
pathophysiology	O
remains	O
controversial	O
.	O

Fas	GENE-Y
receptor-deficient	O
(	O
lpr	O
)	O
and	O
C57BL	O
/	O
6	O
mice	O
were	O
treated	O
with	O
APAP	CHEMICAL
to	O
compare	O
the	O
mechanisms	O
of	O
hepatotoxicity	O
.	O

Lpr	O
mice	O
were	O
partially	O
protected	O
against	O
APAP	CHEMICAL
hepatotoxicity	O
as	O
indicated	O
by	O
reduced	O
plasma	O
ALT	GENE-N
and	O
GDH	GENE-N
levels	O
and	O
liver	O
necrosis	O
.	O

Hepatic	O
Cyp2e1	GENE-Y
protein	O
,	O
adduct	O
formation	O
and	O
hepatic	O
glutathione	CHEMICAL
(	O
GSH	CHEMICAL
)	O
depletion	O
were	O
similar	O
,	O
demonstrating	O
equivalent	O
reactive	O
metabolite	O
generation	O
.	O

There	O
was	O
no	O
difference	O
in	O
cytokine	GENE-N
formation	O
or	O
hepatic	O
neutrophil	O
recruitment	O
.	O

Interestingly	O
,	O
hepatic	O
GSH	CHEMICAL
recovered	O
faster	O
in	O
lpr	O
mice	O
than	O
in	O
wild	O
type	O
animals	O
resulting	O
in	O
enhanced	O
detoxification	O
of	O
reactive	O
oxygen	CHEMICAL
species	O
.	O

Driving	O
the	O
increased	O
GSH	CHEMICAL
levels	O
,	O
mRNA	O
induction	O
and	O
protein	O
expression	O
of	O
glutamate-cysteine	CHEMICAL
ligase	O
(	O
gclc	GENE-Y
)	O
were	O
higher	O
in	O
lpr	O
mice	O
.	O

Inducible	GENE-Y
nitric	CHEMICAL
oxide	CHEMICAL
synthase	O
(	O
iNOS	GENE-Y
)	O
mRNA	O
and	O
protein	O
levels	O
at	O
6h	O
were	O
significantly	O
lower	O
in	O
lpr	O
mice	O
,	O
which	O
correlated	O
with	O
reduced	O
nitrotyrosine	CHEMICAL
staining	O
.	O

Heat	GENE-N
shock	GENE-N
protein	GENE-N
70	GENE-N
(	O
Hsp70	GENE-N
)	O
mRNA	O
levels	O
were	O
substantially	O
higher	O
in	O
lpr	O
mice	O
after	O
APAP	CHEMICAL
.	O

Conclusion	O
:	O
Our	O
data	O
suggest	O
that	O
the	O
faster	O
recovery	O
of	O
hepatic	O
GSH	CHEMICAL
levels	O
during	O
oxidant	O
stress	O
and	O
peroxynitrite	CHEMICAL
formation	O
,	O
reduced	O
iNOS	GENE-Y
expression	O
and	O
enhanced	O
induction	O
of	O
Hsp70	GENE-N
attenuated	O
the	O
susceptibility	O
to	O
APAP-induced	O
cell	O
death	O
in	O
lpr	O
mice	O
.	O
BACKGROUND	O
&	O
AIMS	O
:	O
Sensitization	O
of	O
Kupffer	O
cells	O
(	O
KCs	O
)	O
to	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
overproduction	O
of	O
tumor	GENE-Y
necrosis	GENE-Y
factor	GENE-Y
(	GENE-Y
TNF	GENE-Y
)	GENE-Y
alpha	GENE-Y
are	O
critical	O
for	O
progression	O
of	O
alcoholic	CHEMICAL
liver	O
injury	O
.	O

Thalidomide	CHEMICAL
has	O
been	O
shown	O
to	O
suppress	O
TNF-alpha	GENE-Y
production	O
from	O
macrophages	O
.	O

Accordingly	O
,	O
the	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
thalidomide	CHEMICAL
could	O
prevent	O
alcohol-induced	O
liver	O
injury	O
.	O

METHODS	O
:	O
Rats	O
were	O
given	O
ethanol	CHEMICAL
(	O
5	O
g	O
/	O
kg	O
body	O
wt	O
)	O
and	O
thalidomide	CHEMICAL
(	O
5	O
mg	O
/	O
kg	O
)	O
once	O
every	O
24	O
hours	O
intragastrically	O
.	O

To	O
assess	O
the	O
sensitization	O
of	O
Kupffer	O
cells	O
,	O
LPS	O
(	O
5	O
mg	O
/	O
kg	O
intravenously	O
)	O
was	O
administered	O
and	O
liver	O
histology	O
was	O
evaluated	O
24	O
hours	O
later	O
.	O

KCs	O
were	O
isolated	O
after	O
4	O
weeks	O
of	O
ethanol	CHEMICAL
treatment	O
and	O
intracellular	O
Ca2	CHEMICAL
+	CHEMICAL
(	O
[	O
Ca2	CHEMICAL
+	CHEMICAL
]	O
i	O
)	O
was	O
measured	O
using	O
fura-2	O
,	O
whereas	O
TNF-alpha	GENE-Y
was	O
evaluated	O
by	O
reverse-transcription	O
polymerase	O
chain	O
reaction	O
and	O
enzyme-linked	O
immunosorbent	O
assay	O
.	O

CD14	GENE-Y
was	O
determined	O
by	O
Western	O
and	O
fluorescence	O
staining	O
.	O

RESULTS	O
:	O
Treatment	O
with	O
ethanol	CHEMICAL
for	O
8	O
weeks	O
caused	O
marked	O
steatosis	O
,	O
necrosis	O
,	O
and	O
inflammation	O
in	O
the	O
liver	O
.	O

These	O
pathologic	O
parameters	O
were	O
diminished	O
markedly	O
by	O
treatment	O
with	O
thalidomide	CHEMICAL
.	O

In	O
the	O
4-week	O
ethanol	CHEMICAL
group	O
,	O
the	O
LPS-induced	O
liver	O
damage	O
was	O
aggravated	O
and	O
KCs	O
were	O
sensitized	O
to	O
LPS	O
.	O

Coadministration	O
of	O
thalidomide	CHEMICAL
with	O
ethanol	CHEMICAL
prevented	O
the	O
KC	O
sensitization	O
completely	O
.	O

Furthermore	O
,	O
thalidomide	CHEMICAL
abolished	O
the	O
LPS-induced	O
increase	O
in	O
CD14	GENE-Y
expression	O
and	O
[	O
Ca2	CHEMICAL
+	CHEMICAL
]	O
i	O
elevation	O
in	O
KCs	O
.	O

Gut	O
permeability	O
was	O
increased	O
about	O
10-fold	O
after	O
4	O
weeks	O
of	O
ethanol	CHEMICAL
exposure	O
,	O
which	O
was	O
not	O
affected	O
by	O
thalidomide	CHEMICAL
.	O

Moreover	O
,	O
thalidomide	CHEMICAL
reduced	O
the	O
LPS-induced	O
TNF-alpha	GENE-Y
production	O
by	O
KCs	O
by	O
decreasing	O
TNF-alpha	GENE-Y
messenger	O
RNA	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
collectively	O
indicate	O
that	O
thalidomide	CHEMICAL
prevents	O
alcoholic	O
liver	O
injury	O
through	O
suppression	O
of	O
TNF-alpha	GENE-Y
production	O
and	O
abolishment	O
of	O
KC	O
sensitization	O
.	O
Clinical	O
manifestations	O
of	O
genetic	O
defects	O
affecting	O
gonadotrophins	GENE-N
and	O
their	O
receptors	O
.	O
A	O
series	O
of	O
3-substituted	CHEMICAL
1	CHEMICAL
,	CHEMICAL
5-diarylpyrroles	CHEMICAL
bearing	O
a	O
nitrooxyalkyl	CHEMICAL
side	O
chain	O
linked	O
to	O
different	O
spacers	O
were	O
designed	O
.	O

New	O
classes	O
of	O
pyrrole-derived	O
nitrooxyalkyl	CHEMICAL
inverse	O
esters	CHEMICAL
,	O
carbonates	CHEMICAL
,	O
and	O
ethers	CHEMICAL
(	O
7-10	O
)	O
as	O
COX-2	GENE-Y
selective	O
inhibitors	O
and	O
NO	CHEMICAL
donors	O
were	O
synthesized	O
and	O
are	O
herein	O
reported	O
.	O

By	O
taking	O
into	O
account	O
the	O
metabolic	O
conversion	O
of	O
nitrooxyalkyl	CHEMICAL
ethers	CHEMICAL
(	O
9	O
,	O
10	O
)	O
into	O
corresponding	O
alcohols	CHEMICAL
,	O
derivatives	O
17	O
and	O
18	O
were	O
also	O
studied	O
.	O

Nitrooxy	CHEMICAL
derivatives	O
showed	O
NO-dependent	O
vasorelaxing	O
properties	O
,	O
while	O
most	O
of	O
the	O
compounds	O
proved	O
to	O
be	O
very	O
potent	O
and	O
selective	O
COX-2	GENE-Y
inhibitors	O
in	O
in	O
vitro	O
experimental	O
models	O
.	O

Further	O
in	O
vivo	O
studies	O
on	O
compounds	O
9a	O
,	O
c	O
and	O
17a	O
highlighted	O
good	O
anti-inflammatory	O
and	O
antinociceptive	O
activities	O
.	O

Compound	O
9c	O
was	O
able	O
to	O
inhibit	O
glycosaminoglycan	O
(	O
GAG	O
)	O
release	O
induced	O
by	O
interleukin-1β	GENE-Y
(	O
IL-1β	GENE-Y
)	O
,	O
showing	O
cartilage	O
protective	O
properties	O
.	O

Finally	O
,	O
molecular	O
modeling	O
and	O
(	CHEMICAL
1	CHEMICAL
)	CHEMICAL
H-	O
and	O
(	CHEMICAL
13	CHEMICAL
)	CHEMICAL
C-NMR	O
studies	O
performed	O
on	O
compounds	O
6c	O
,	O
d	O
,	O
9c	O
,	O
and	O
10b	O
allowed	O
the	O
right	O
conformation	O
of	O
nitrooxyalkyl	CHEMICAL
ester	CHEMICAL
and	CHEMICAL
ether	CHEMICAL
side	O
chain	O
of	O
these	O
molecules	O
within	O
the	O
COX-2	GENE-Y
active	O
site	O
to	O
be	O
assessed	O
.	O
Gabapentin	CHEMICAL
is	O
used	O
in	O
the	O
treatment	O
of	O
epilepsy	O
and	O
neuropathic	O
pain	O
.	O

Gabapentin	CHEMICAL
has	O
high	O
and	O
saturable	O
permeability	O
across	O
the	O
BBB	O
,	O
but	O
no	O
mechanistic	O
studies	O
underpinning	O
this	O
process	O
have	O
been	O
reported	O
.	O

The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
investigate	O
the	O
transport	O
of	O
gabapentin	CHEMICAL
in	O
a	O
model	O
of	O
the	O
BBB	O
,	O
identify	O
the	O
important	O
drug	O
transporter	O
(	O
s	O
)	O
and	O
to	O
use	O
mathematical	O
modelling	O
to	O
quantify	O
the	O
processes	O
involved	O
.	O

A	O
human	O
brain	O
endothelial	O
cell	O
line	O
(	O
hCMEC	O
/	O
D3	O
)	O
was	O
utilised	O
as	O
an	O
in-vitro	O
model	O
of	O
the	O
BBB	O
.	O

Uptake	O
of	O
radiolabeled	CHEMICAL
gabapentin	CHEMICAL
into	O
cells	O
in	O
the	O
presence	O
of	O
chemical	O
inhibitors	O
,	O
siRNA	O
or	O
overexpressed	O
drug	O
transporters	O
of	O
interest	O
was	O
investigated	O
.	O

Gabapentin	CHEMICAL
was	O
demonstrated	O
to	O
be	O
a	O
LAT1	GENE-Y
substrate	O
in	O
brain	O
endothelial	O
cells	O
(	O
LAT1-process;	O
Km	O
=	O
530μM	O
and	O
Vmax	O
=	O
7039pmoles	O
/	O
million	O
cells	O
/	O
min	O
versus	O
other-processes;	O
Km	O
=	O
923μM	O
and	O
Vmax	O
=	O
3656pmoles	O
/	O
million	O
cells	O
/	O
min	O
)	O
and	O
in	O
transfected	O
HEK	O
293	O
LAT1	GENE-Y
cells	O
(	O
LAT1-process;	O
Km	O
=	O
217μM	O
and	O
Vmax	O
=	O
5192pmoles	O
/	O
million	O
cells	O
/	O
min	O
versus	O
otherprocesses;	O
Km	O
=	O
1546μM	O
and	O
Vmax	O
=	O
3375pmoles	O
/	O
million	O
cells	O
/	O
min	O
)	O
.	O

At	O
physiological	O
concentrations	O
of	O
gabapentin	CHEMICAL
,	O
LAT1	GENE-Y
mediated	O
transport	O
was	O
3	O
or	O
~10-fold	O
higher	O
than	O
the	O
other	O
transport	O
processes	O
in	O
the	O
two	O
systems	O
,	O
respectively	O
,	O
demonstrating	O
clear	O
selectivity	O
for	O
gabapentin	CHEMICAL
.	O

In-silico	O
structural	O
homology	O
modelling	O
confirmed	O
that	O
LAT1	GENE-Y
could	O
have	O
the	O
LeuT	GENE-N
conserved	O
fold	O
and	O
functions	O
by	O
the	O
alternative	O
access	O
mechanism	O
.	O

Mathematical	O
modelling	O
of	O
this	O
mechanism	O
revealed	O
revised	O
significance	O
of	O
Vmax	O
and	O
Km	O
so	O
that	O
a	O
low	O
Km	O
may	O
not	O
necessarily	O
imply	O
a	O
high	O
affinity	O
transport	O
process	O
.	O

Gabapentin	CHEMICAL
was	O
negative	O
for	O
OCT	GENE-N
like	O
transport	O
and	O
LAT2	GENE-Y
activity	O
in	O
the	O
hCMEC	O
/	O
D3	O
and	O
OCT1	GENE-Y
transfected	O
cells	O
.	O

Our	O
data	O
shows	O
that	O
gabapentin	CHEMICAL
is	O
a	O
substrate	O
for	O
the	O
influx	O
transporter	O
LAT1	GENE-Y
at	O
therapeutic	O
concentrations	O
.	O
Comparison	O
of	O
the	O
novel	O
antipsychotic	O
ziprasidone	CHEMICAL
with	O
clozapine	CHEMICAL
and	O
olanzapine	CHEMICAL
:	O
inhibition	O
of	O
dorsal	O
raphe	O
cell	O
firing	O
and	O
the	O
role	O
of	O
5-HT1A	GENE-Y
receptor	GENE-Y
activation	O
.	O
Retinoic	CHEMICAL
acid	CHEMICAL
inhibits	O
HIV-1-induced	O
podocyte	O
proliferation	O
through	O
the	O
cAMP	CHEMICAL
pathway	O
.	O
Several	O
members	O
of	O
a	O
new	O
family	O
of	O
non-sugar-type	O
α-glycosidase	GENE-N
inhibitors	O
,	O
bearing	O
a	O
5-	CHEMICAL
(	CHEMICAL
p-toluenesulfonylamino	CHEMICAL
)	CHEMICAL
phthalimide	CHEMICAL
moiety	O
and	O
various	O
substituent	O
at	O
the	O
N2	O
position	O
,	O
were	O
synthesized	O
and	O
their	O
activities	O
were	O
investigated	O
.	O

The	O
newly	O
synthesized	O
compounds	O
displayed	O
different	O
inhibition	O
profile	O
towards	O
yeast	GENE-Y
α-glycosidase	GENE-Y
and	O
rat	GENE-N
intestinal	GENE-N
α-glycosidase	GENE-N
.	O

Almost	O
all	O
the	O
compounds	O
had	O
strong	O
inhibitory	O
activities	O
against	O
yeast	GENE-Y
α-glycosidase	GENE-Y
.	O

Regarding	O
rat	GENE-N
intestinal	GENE-N
α-glycosidase	GENE-N
,	O
only	O
analogs	O
with	O
N2-aromatic	O
substituents	O
displayed	O
varying	O
degrees	O
of	O
inhibitory	O
activities	O
on	O
rat	GENE-N
intestinal	GENE-N
maltase	GENE-N
and	O
lactase	GENE-N
and	O
nearly	O
all	O
compounds	O
showed	O
no	O
inhibition	O
against	O
rat	GENE-N
intestinal	GENE-N
α-amylase	GENE-N
.	O

Structure-activity	O
relationship	O
studies	O
indicated	O
that	O
5-	CHEMICAL
(	CHEMICAL
p-toluenesulfonylamino	CHEMICAL
)	CHEMICAL
phthalimide	CHEMICAL
moiety	O
is	O
a	O
favorable	O
scaffold	O
to	O
exert	O
the	O
α-glucosidase	GENE-N
inhibitory	O
activity	O
and	O
substituents	O
at	O
the	O
N2	O
position	O
have	O
considerable	O
influence	O
on	O
the	O
efficacy	O
of	O
the	O
inhibition	O
activities	O
.	O
Repeated	O
morphine	CHEMICAL
administration	O
leads	O
to	O
molecular	O
alterations	O
of	O
the	O
neural	O
circuitry	O
in	O
the	O
locus	O
coeruleus	O
and	O
nucleus	O
accumbens	O
.	O

These	O
changes	O
include	O
increased	O
activity	O
of	O
several	O
components	O
of	O
the	O
cAMP	CHEMICAL
signaling	O
pathway	O
that	O
are	O
thought	O
to	O
be	O
associated	O
with	O
psychological	O
and	O
somatic	O
signs	O
of	O
opiate	O
withdrawal	O
.	O

The	O
neuropeptide	O
galanin	GENE-Y
has	O
been	O
shown	O
to	O
attenuate	O
cAMP	CHEMICAL
signaling	O
in	O
multiple	O
cell	O
types	O
.	O

The	O
current	O
study	O
demonstrates	O
that	O
acute	O
galanin	GENE-Y
treatment	O
blocks	O
the	O
consequences	O
of	O
increased	O
cAMP	CHEMICAL
signaling	O
following	O
chronic	O
opiate	O
administration	O
and	O
withdrawal	O
in	O
Cath	O
.	O

a	O
cells	O
and	O
primary	O
cultures	O
of	O
striatal	O
neurons	O
as	O
measured	O
by	O
phosphorylation	O
of	O
the	O
transcription	O
factor	O
cAMP	GENE-N
regulatory	O
element-binding	O
protein	O
(	O
CREB	GENE-N
)	O
.	O

In	O
addition	O
,	O
galanin-mediated	O
attenuation	O
of	O
CREB	GENE-N
phosphorylation	O
is	O
independent	O
of	O
galanin-induced	O
extracellular	GENE-N
signal-regulated	GENE-N
kinase	GENE-N
(	GENE-N
ERK	GENE-N
)	GENE-N
1	GENE-N
/	GENE-N
2	GENE-N
phosphorylation	O
in	O
Cath	O
.	O

a	O
cells	O
.	O

These	O
data	O
suggest	O
that	O
galanin	GENE-N
receptors	GENE-N
may	O
serve	O
as	O
an	O
additional	O
potential	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
opiate	O
withdrawal	O
.	O
Prokinetic	O
effects	O
of	O
a	O
new	O
ghrelin	GENE-Y
receptor	GENE-Y
agonist	O
TZP-101	CHEMICAL
in	O
a	O
rat	O
model	O
of	O
postoperative	O
ileus	O
.	O
Our	O
previous	O
study	O
has	O
revealed	O
that	O
dioscin	CHEMICAL
,	O
a	O
compound	O
with	O
anti-inflammatory	O
,	O
lipid-lowering	O
,	O
anticancer	O
and	O
hepatoprotective	O
effects	O
,	O
may	O
induce	O
autophagy	O
in	O
hepatoma	O
cells	O
.	O

Autophagy	O
is	O
a	O
lysosomal	O
degradation	O
pathway	O
that	O
is	O
essential	O
for	O
cell	O
survival	O
and	O
tissue	O
homeostasis	O
.	O

In	O
this	O
study	O
,	O
the	O
role	O
of	O
autophagy	O
and	O
related	O
signaling	O
pathways	O
during	O
dioscin-induced	O
apoptosis	O
in	O
human	O
lung	O
cancer	O
cells	O
was	O
investigated	O
.	O

Results	O
from	O
4'-6-diamidino-2-phenylindole	CHEMICAL
and	O
annexin-V	O
/	O
PI	O
double-staining	O
assay	O
showed	O
that	O
caspase-3-	O
and	O
caspase-8-dependent	O
,	O
and	O
dose-dependent	O
apoptoses	O
were	O
detected	O
after	O
a	O
24-h	O
dioscin	CHEMICAL
treatment	O
.	O

Meanwhile	O
,	O
autophagy	O
was	O
detected	O
as	O
early	O
as	O
12	O
h	O
after	O
an	O
exposure	O
to	O
low-dose	O
dioscin	CHEMICAL
,	O
as	O
indicated	O
by	O
an	O
up-regulated	O
expression	O
of	O
LC3-II	GENE-Y
and	O
beclin-1	GENE-Y
proteins	O
.	O

Blockade	O
of	O
autophagy	O
with	O
bafilomycin	CHEMICAL
A1	CHEMICAL
or	O
3-methyladenine	CHEMICAL
sensitized	O
the	O
A549	O
and	O
H1299	O
cells	O
to	O
apoptosis	O
.	O

Treatment	O
of	O
A549	O
and	O
H1299	O
cells	O
with	O
dioscin	CHEMICAL
caused	O
a	O
dose-dependent	O
increase	O
in	O
ERK1	GENE-N
/	GENE-N
2	GENE-N
and	O
JNK1	GENE-N
/	GENE-N
2	GENE-N
activity	O
,	O
accompanied	O
with	O
a	O
decreased	O
PI3K	GENE-N
expression	O
and	O
decreased	O
phosphorylation	O
of	O
Akt	GENE-N
and	O
mTOR	GENE-N
.	O

Taken	O
together	O
,	O
this	O
study	O
demonstrated	O
for	O
the	O
first	O
time	O
that	O
autophagy	O
occurred	O
earlier	O
than	O
apoptosis	O
during	O
dioscin-induced	O
human	O
lung	O
cancer	O
cell	O
line	O
apoptosis	O
.	O

Dioscin-induced	O
autophagy	O
via	O
ERK1	GENE-N
/	GENE-N
2	GENE-N
and	O
JNK1	GENE-N
/	GENE-N
2	GENE-N
pathways	O
may	O
provide	O
a	O
protective	O
mechanism	O
for	O
cell	O
survival	O
against	O
dioscin-induced	O
apoptosis	O
to	O
act	O
as	O
a	O
cytoprotective	O
reaction	O
.	O
Bone	O
remodeling	O
is	O
affected	O
by	O
mechanical	O
loading	O
and	O
inflammatory	O
mediators	O
,	O
including	O
chemokines	GENE-N
.	O

The	O
chemokine	GENE-Y
(	GENE-Y
C-C	GENE-Y
motif	GENE-Y
)	GENE-Y
ligand	GENE-Y
3	GENE-Y
(	O
CCL3	GENE-Y
)	O
is	O
involved	O
in	O
bone	O
remodeling	O
by	O
binding	O
to	O
C-C	GENE-N
chemokine	GENE-N
receptors	GENE-N
1	GENE-N
and	GENE-N
5	GENE-N
(	O
CCR1	GENE-Y
and	O
CCR5	GENE-Y
)	O
expressed	O
on	O
osteoclasts	O
and	O
osteoblasts	O
.	O

Our	O
group	O
has	O
previously	O
demonstrated	O
that	O
CCR5	GENE-Y
down-regulates	O
mechanical	O
loading-induced	O
bone	O
resorption	O
.	O

Thus	O
,	O
the	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
role	O
of	O
CCR1	GENE-Y
and	O
CCL3	GENE-Y
in	O
bone	O
remodeling	O
induced	O
by	O
mechanical	O
loading	O
during	O
orthodontic	O
tooth	O
movement	O
in	O
mice	O
.	O

Our	O
results	O
showed	O
that	O
bone	O
remodeling	O
was	O
significantly	O
decreased	O
in	O
CCL3	GENE-Y
(	O
-	O
/	O
-	O
)	O
and	O
CCR1	GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
and	O
in	O
animals	O
treated	O
with	O
Met-RANTES	O
(	O
an	O
antagonist	O
of	O
CCR5	GENE-Y
and	O
CCR1	GENE-Y
)	O
.	O

mRNA	O
levels	O
of	O
receptor	GENE-Y
activator	GENE-Y
of	GENE-Y
nuclear	GENE-Y
factor	GENE-Y
kappa-B	GENE-Y
(	O
RANK	GENE-Y
)	O
,	O
its	O
ligand	O
RANKL	GENE-Y
,	O
tumor	GENE-Y
necrosis	GENE-Y
factor	GENE-Y
alpha	GENE-Y
(	O
TNF-α	GENE-Y
)	O
and	O
RANKL	GENE-Y
/	O
osteoprotegerin	GENE-Y
(	O
OPG	GENE-Y
)	O
ratio	O
were	O
diminished	O
in	O
the	O
periodontium	O
of	O
CCL3	GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
and	O
in	O
the	O
group	O
treated	O
with	O
Met-RANTES	O
.	O

Met-RANTES	O
treatment	O
also	O
reduced	O
the	O
levels	O
of	O
cathepsin	GENE-Y
K	GENE-Y
and	O
metalloproteinase	GENE-Y
13	GENE-Y
(	O
MMP13	GENE-Y
)	O
.	O

The	O
expression	O
of	O
the	O
osteoblast	O
markers	O
runt-related	GENE-Y
transcription	GENE-Y
factor	GENE-Y
2	GENE-Y
(	O
RUNX2	GENE-Y
)	O
and	O
periostin	GENE-Y
was	O
decreased	O
,	O
while	O
osteocalcin	GENE-Y
(	O
OCN	GENE-Y
)	O
was	O
augmented	O
in	O
CCL3	GENE-Y
(	O
-	O
/	O
-	O
)	O
and	O
Met-RANTES-treated	O
mice	O
.	O

Altogether	O
,	O
these	O
findings	O
show	O
that	O
CCR1	GENE-Y
is	O
pivotal	O
for	O
bone	O
remodeling	O
induced	O
by	O
mechanical	O
loading	O
during	O
orthodontic	O
tooth	O
movement	O
and	O
these	O
actions	O
depend	O
,	O
at	O
least	O
in	O
part	O
,	O
on	O
CCL3	GENE-Y
.	O
BACKGROUND	O
:	O
Recent	O
epidemiologic	O
and	O
laboratory	O
studies	O
have	O
suggested	O
that	O
non-steroidal	CHEMICAL
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
may	O
reduce	O
the	O
risk	O
of	O
breast	O
cancer	O
through	O
inhibition	O
of	O
cyclooxygenase-2	GENE-Y
(	O
COX-2	GENE-Y
)	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
case-control	O
study	O
to	O
measure	O
the	O
association	O
between	O
selective	O
cox-2	GENE-Y
inhibitors	O
,	O
particularly	O
celecoxib	CHEMICAL
,	O
rofecoxib	CHEMICAL
,	O
valdecoxib	CHEMICAL
and	O
non-specific	O
NSAID	O
subgroups	O
,	O
and	O
breast	O
cancer	O
risk	O
.	O

Between	O
2003	O
and	O
2006	O
,	O
a	O
total	O
of	O
18	O
,	O
368	O
incident	O
breast	O
cancer	O
cases	O
were	O
identified	O
in	O
the	O
Ingenix	O
/	O
Lab	O
Rx	O
insurance	O
database	O
,	O
which	O
contains	O
clinical	O
encounter	O
and	O
drug	O
prescription	O
data	O
.	O

Four	O
controls	O
per	O
case	O
were	O
randomly	O
selected	O
,	O
matched	O
on	O
age	O
and	O
time	O
in	O
database	O
.	O

Odds	O
ratios	O
(	O
OR	O
)	O
and	O
95%	O
confidence	O
intervals	O
(	O
CI	O
)	O
were	O
estimated	O
using	O
conditional	O
logistic	O
regression	O
.	O

RESULTS	O
:	O
Breast	O
cancer	O
risk	O
was	O
inversely	O
associated	O
with	O
both	O
non-specific	O
NSAID	O
and	O
selective	O
COX-2	GENE-Y
inhibitor	O
use	O
.	O

Greater	O
than	O
12	O
months'	O
duration	O
of	O
use	O
of	O
Celecoxib	CHEMICAL
at	O
a	O
standard	O
dose	O
(	O
200mg	O
/	O
day	O
)	O
was	O
associated	O
with	O
a	O
16%	O
decrease	O
in	O
breast	O
cancer	O
risk	O
(	O
OR	O
=	O
0	O
.	O
84	O
,	O
95%	O
CI	O
=	O
0	O
.	O
73	O
,	O
0	O
.	O
97	O
)	O
.	O

We	O
observed	O
the	O
greatest	O
risk	O
reduction	O
in	O
association	O
with	O
>2	O
years	O
of	O
rofecoxib	CHEMICAL
exposure	O
(	O
OR	O
=	O
0	O
.	O
54	O
,	O
95%	O
CI	O
=	O
0	O
.	O
37	O
,	O
0	O
.	O
80	O
)	O
.	O

Acetaminophen	CHEMICAL
,	O
a	O
compound	O
with	O
less	O
biological	O
plausibility	O
for	O
chemoprevention	O
,	O
showed	O
no	O
significant	O
association	O
with	O
the	O
risk	O
of	O
developing	O
breast	O
cancer	O
.	O

CONCLUSION	O
:	O
Consistent	O
with	O
animal	O
models	O
and	O
laboratory	O
investigations	O
,	O
higher	O
doses	O
of	O
selective	O
COX-2	GENE-Y
inhibitors	O
were	O
more	O
protective	O
against	O
breast	O
cancer	O
than	O
non-specific	O
NSAIDs	O
.	O

With	O
exposure	O
to	O
rofecoxib	CHEMICAL
,	O
a	O
selective	O
COX-2	GENE-Y
inhibitor	O
,	O
breast	O
cancer	O
risk	O
reduction	O
was	O
appreciable	O
(	O
46%	O
)	O
,	O
suggesting	O
a	O
possible	O
role	O
for	O
selective	O
COX-2	GENE-Y
inhibitors	O
in	O
breast	O
cancer	O
prophylaxis	O
.	O
Chronic	O
arsenic	CHEMICAL
ingestion	O
predisposes	O
to	O
vascular	O
disease	O
,	O
but	O
underlying	O
mechanisms	O
are	O
poorly	O
understood	O
.	O

In	O
the	O
present	O
study	O
we	O
have	O
analyzed	O
the	O
effects	O
of	O
short-term	O
arsenite	CHEMICAL
exposure	O
on	O
vascular	O
function	O
and	O
endothelium-dependent	O
relaxation	O
.	O

Endothelium-dependent	O
relaxations	O
,	O
nitric	CHEMICAL
oxide	CHEMICAL
(	O
NO	CHEMICAL
)	O
and	O
endothelium	O
derived	O
hyperpolarizing	O
factor	O
(	O
EDHF	O
)	O
-type	O
,	O
were	O
studied	O
in	O
rabbit	O
iliac	O
artery	O
and	O
aortic	O
rings	O
using	O
the	O
G	GENE-N
protein-coupled	GENE-N
receptor	GENE-N
agonist	O
acetylcholine	CHEMICAL
(	O
ACh	CHEMICAL
)	O
and	O
by	O
cyclopiazonic	CHEMICAL
acid	CHEMICAL
(	O
CPA	CHEMICAL
)	O
,	O
which	O
promotes	O
store-operated	O
Ca	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
entry	O
by	O
inhibiting	O
the	O
endothelial	O
SERCA	GENE-N
pump	O
.	O

Production	O
of	O
reactive	O
oxygen	CHEMICAL
species	O
(	O
ROS	O
)	O
in	O
the	O
endothelium	O
of	O
rabbit	O
aortic	O
valve	O
leaflets	O
and	O
endothelium-denuded	O
RIA	O
and	O
aortic	O
rings	O
was	O
assessed	O
by	O
imaging	O
of	O
dihydroethidium	CHEMICAL
.	O

In	O
the	O
iliac	O
artery	O
,	O
exposure	O
to	O
100μM	O
arsenite	CHEMICAL
for	O
30min	O
potentiated	O
EDHF-type	O
relaxations	O
evoked	O
by	O
both	O
CPA	CHEMICAL
and	O
ACh	CHEMICAL
.	O

Potentiation	O
was	O
prevented	O
by	O
catalase	GENE-Y
,	O
the	O
catalase	GENE-Y
/	O
superoxide	GENE-N
dismutase	O
mimetic	O
manganese	CHEMICAL
porphyrin	CHEMICAL
and	O
the	O
NADPH	GENE-N
oxidase	O
inhibitor	O
apocynin	CHEMICAL
.	O

By	O
contrast	O
in	O
aortic	O
rings	O
,	O
that	O
exhibited	O
negligible	O
EDHF-type	O
responses	O
,	O
endothelium-dependent	O
NO-mediated	O
relaxations	O
evoked	O
by	O
CPA	CHEMICAL
and	O
ACh	CHEMICAL
were	O
unaffected	O
by	O
arsenite	CHEMICAL
.	O

Arsenite	CHEMICAL
induced	O
apocynin-sensitive	O
increases	O
in	O
ROS	O
production	O
in	O
the	O
aortic	O
valve	O
endothelium	O
,	O
but	O
not	O
in	O
the	O
media	O
and	O
adventitia	O
of	O
the	O
iliac	O
artery	O
and	O
aorta	O
.	O

Our	O
results	O
suggest	O
that	O
arsenite	CHEMICAL
can	O
potentiate	O
EDHF-type	O
relaxations	O
via	O
a	O
mechanism	O
that	O
is	O
dependent	O
on	O
hydrogen	CHEMICAL
peroxide	CHEMICAL
,	O
thus	O
demonstrating	O
that	O
dismutation	O
of	O
the	O
superoxide	CHEMICAL
anion	O
generated	O
by	O
NADPH	GENE-N
oxidase	O
can	O
potentially	O
offset	O
loss	O
of	O
NO	CHEMICAL
bioavailability	O
under	O
conditions	O
of	O
reduced	O
eNOS	GENE-Y
activity	O
.	O

By	O
contrast	O
,	O
selective	O
increases	O
in	O
endothelial	O
ROS	O
production	O
following	O
exposure	O
to	O
arsenite	CHEMICAL
failed	O
to	O
modify	O
relaxations	O
mediated	O
by	O
endogenous	O
NO	CHEMICAL
.	O
This	O
study	O
aims	O
to	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
Rehmannia	O
glutinosa	O
acteosides	CHEMICAL
used	O
in	O
combination	O
with	O
the	O
angiotensin	GENE-N
receptor	GENE-N
blocker	O
irbesartan	CHEMICAL
to	O
treat	O
primary	O
chronic	O
glomerulonephritis	O
.	O

A	O
total	O
of	O
479	O
patients	O
diagnosed	O
with	O
primary	O
chronic	O
glomerulonephritis	O
were	O
recruited	O
from	O
outpatient	O
clinics	O
and	O
were	O
randomly	O
assigned	O
to	O
the	O
treatment	O
group	O
(	O
Rehmannia	O
glutinosa	O
acteosides	CHEMICAL
,	O
two	O
200-mg	O
capsules	O
,	O
bid;	O
and	O
irbesartan	CHEMICAL
,	O
one	O
150-mg	O
tablet	O
,	O
qd	O
)	O
or	O
the	O
control	O
group	O
(	O
irbesartan	CHEMICAL
,	O
one	O
150-mg	O
tablet	O
,	O
qd	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
24-h	O
urinary	O
protein	O
.	O

Secondary	O
outcome	O
measures	O
included	O
blood	O
pressure	O
,	O
estimated	O
glomerular	O
filtration	O
rate	O
,	O
erythrocyturia	O
,	O
serum	O
alanine	CHEMICAL
aminotransferase	O
,	O
aspartate	CHEMICAL
transaminase	O
and	O
electrolytes	O
.	O

After	O
8	O
weeks	O
of	O
treatment	O
,	O
the	O
treatment	O
group	O
showed	O
a	O
mean	O
reduction	O
in	O
24-h	O
proteinuria	O
of	O
36	O
.	O
42%	O
compared	O
to	O
baseline	O
,	O
which	O
was	O
significantly	O
higher	O
than	O
the	O
mean	O
reduction	O
from	O
baseline	O
of	O
27	O
.	O
97%	O
in	O
the	O
control	O
group	O
(	O
P	O
=	O
0	O
.	O
0278	O
)	O
.	O

Adverse	O
drug	O
reactions	O
occurred	O
at	O
a	O
similarly	O
low	O
rate	O
in	O
the	O
treatment	O
group	O
(	O
0	O
.	O
4%	O
)	O
and	O
control	O
group	O
(	O
1	O
.	O
2%	O
,	O
P	O
=	O
0	O
.	O
3724	O
)	O
.	O

In	O
the	O
treatment	O
of	O
chronic	O
glomerulonephritis	O
,	O
the	O
combination	O
of	O
Rehmannia	O
glutinosa	O
acteosides	CHEMICAL
and	O
irbesartan	CHEMICAL
can	O
reduce	O
proteinuria	O
more	O
effectively	O
than	O
irbesartan	CHEMICAL
alone	O
.	O

Copyright	O
©	O
2013	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O
Genentech	O
and	O
ImmunoGen	O
are	O
collaborating	O
on	O
the	O
development	O
of	O
trastuzumab	O
emtansine	O
,	O
a	O
HER2	GENE-Y
antibody-drug	O
conjugate	O
that	O
comprises	O
Genentech's	O
trastuzumab	O
antibody	O
linked	O
to	O
ImmunoGen's	O
anti-mitotic	O
agent	O
,	O
mertansine	CHEMICAL
(	O
a	O
maytansine	CHEMICAL
derivative;	O
also	O
known	O
as	O
DM1	CHEMICAL
)	O
.	O

The	O
conjugate	O
combines	O
two	O
strategies	O
:	O
the	O
anti-HER2	GENE-Y
activity	O
of	O
trastuzumab	O
,	O
and	O
the	O
targeted	O
intracellular	O
delivery	O
of	O
mertansine	CHEMICAL
,	O
a	O
tubulin	GENE-N
polymerisation	O
inhibitor	O
which	O
interferes	O
with	O
mitosis	O
and	O
promotes	O
apoptosis	O
.	O

The	O
linker	O
in	O
trastuzumab	O
emtansine	O
is	O
a	O
non-reducible	O
thioether	CHEMICAL
linker	O
,	O
N-succinimidyl-4-	CHEMICAL
(	CHEMICAL
N-maleimidomethyl	CHEMICAL
)	CHEMICAL
cyclohexane-1-carboxylate	CHEMICAL
(	O
SMCC	CHEMICAL
,	O
designated	O
MCC	CHEMICAL
after	O
conjugation	O
)	O
.	O

Trastuzumab	O
emtansine	O
(	O
Kadcyla™	O
)	O
has	O
been	O
launched	O
in	O
the	O
USA	O
as	O
second-line	O
monotherapy	O
for	O
HER2-positive	O
metastatic	O
breast	O
cancer	O
,	O
and	O
has	O
been	O
filed	O
for	O
approval	O
in	O
the	O
EU	O
and	O
Japan	O
in	O
this	O
indication	O
.	O

Trastuzumab	O
emtansine	O
is	O
in	O
phase	O
III	O
development	O
as	O
first-line	O
combination	O
therapy	O
or	O
monotherapy	O
for	O
metastatic	O
HER2-positive	O
breast	O
cancer	O
,	O
and	O
as	O
third-line	O
monotherapy	O
for	O
metastatic	O
HER2-positive	O
breast	O
cancer	O
.	O

Phase	O
II	O
development	O
is	O
underway	O
for	O
early-stage	O
breast	O
cancer	O
and	O
phase	O
II	O
/	O
III	O
development	O
is	O
underway	O
in	O
patients	O
with	O
HER2-positive	O
gastric	O
cancer	O
.	O

This	O
article	O
summarizes	O
the	O
milestones	O
in	O
the	O
development	O
of	O
trastuzumab	O
emtansine	O
leading	O
to	O
this	O
first	O
approval	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
HER2-positive	O
,	O
metastatic	O
breast	O
cancer	O
who	O
previously	O
received	O
trastuzumab	O
and	O
a	O
taxane	CHEMICAL
,	O
separately	O
or	O
in	O
combination	O
.	O
Complexity	O
in	O
influenza	O
virus	O
targeted	O
drug	O
design	O
:	O
interaction	O
with	O
human	GENE-N
sialidases	GENE-N
.	O
Titanium	CHEMICAL
dioxide	CHEMICAL
nanoparticles	O
increase	O
inflammatory	O
responses	O
in	O
vascular	O
endothelial	O
cells	O
.	O
In	O
many	O
renal	O
diseases	O
,	O
transforming	GENE-Y
growth	GENE-Y
factor	GENE-Y
β	GENE-Y
(	O
TGFβ	GENE-Y
)	O
-stimulated	O
canonical	O
Smad	GENE-Y
3	GENE-Y
and	O
noncanonical	O
mechanistic	GENE-Y
target	GENE-Y
of	GENE-Y
rapamycin	CHEMICAL
(	O
mTOR	GENE-Y
)	O
promote	O
increased	O
protein	O
synthesis	O
and	O
mesangial	O
cell	O
hypertrophy	O
.	O

The	O
cellular	O
underpinnings	O
involving	O
these	O
signaling	O
molecules	O
to	O
regulate	O
mesangial	O
cell	O
hypertrophy	O
are	O
not	O
fully	O
understood	O
.	O

Deptor	GENE-Y
has	O
recently	O
been	O
identified	O
as	O
an	O
mTOR	GENE-Y
interacting	O
protein	O
and	O
functions	O
as	O
an	O
endogenous	O
inhibitor	O
of	O
the	O
kinase	GENE-N
activity	O
for	O
both	O
TORC1	GENE-Y
and	O
TORC2	GENE-Y
.	O

Prolonged	O
incubation	O
of	O
mesangial	O
cells	O
with	O
TGFβ	GENE-Y
reduced	O
the	O
levels	O
of	O
deptor	GENE-Y
concomitant	O
with	O
an	O
increase	O
in	O
TORC1	GENE-Y
and	O
TORC2	GENE-Y
activity	O
.	O

Sustained	O
TGFβ	GENE-Y
activation	O
was	O
required	O
to	O
inhibit	O
association	O
of	O
deptor	GENE-Y
with	O
mTOR	GENE-N
,	O
whereas	O
rapid	O
activation	O
had	O
no	O
effect	O
.	O

Using	O
the	O
mTOR	GENE-Y
inhibitor	O
PP242	CHEMICAL
,	CHEMICAL
we	O
found	O
that	O
TGFβ-induced	O
both	O
early	O
and	O
sustained	O
activation	O
of	O
TORC1	GENE-Y
and	O
TORC2	GENE-Y
was	O
necessary	O
for	O
deptor	GENE-Y
suppression	O
.	O

PP242-induced	O
reversal	O
of	O
deptor	GENE-Y
suppression	O
by	O
TGFβ	GENE-Y
was	O
associated	O
with	O
a	O
significant	O
inhibition	O
of	O
TGFβ-stimulated	O
protein	O
synthesis	O
and	O
hypertrophy	O
.	O

Interestingly	O
,	O
expression	O
of	O
siRNA	O
against	O
Smad	GENE-Y
3	GENE-Y
or	O
Smad	GENE-Y
7	GENE-Y
,	O
which	O
blocks	O
TGFβ	GENE-N
receptor-specific	O
Smad	GENE-Y
3	GENE-Y
signaling	O
,	O
prevented	O
TGFβ-induced	O
suppression	O
of	O
deptor	GENE-Y
abundance	O
and	O
TORC1	GENE-N
/	GENE-N
2	GENE-N
activities	O
.	O

Furthermore	O
,	O
overexpression	O
of	O
Smad	GENE-Y
3	GENE-Y
decreased	O
deptor	GENE-Y
expression	O
similar	O
to	O
TGFβ	GENE-Y
stimulation	O
concomitant	O
with	O
increased	O
TORC1	GENE-Y
and	O
TORC2	GENE-Y
activities	O
.	O

Finally	O
,	O
knockdown	O
of	O
deptor	GENE-Y
reversed	O
Smad	GENE-Y
7-mediated	O
inhibition	O
of	O
protein	O
synthesis	O
and	O
mesangial	O
cell	O
hypertrophy	O
induced	O
by	O
TGFβ	GENE-Y
.	O

These	O
data	O
reveal	O
the	O
requirement	O
of	O
both	O
early	O
and	O
late	O
activation	O
of	O
mTOR	GENE-Y
for	O
TGFβ-induced	O
protein	O
synthesis	O
.	O

Our	O
results	O
support	O
that	O
TGFβ-stimulated	O
Smad	GENE-Y
3	GENE-Y
acts	O
as	O
a	O
key	O
node	O
to	O
instill	O
a	O
feedback	O
loop	O
between	O
deptor	GENE-Y
down-regulation	O
and	O
TORC1	GENE-N
/	GENE-N
2	GENE-N
activation	O
in	O
driving	O
mesangial	O
cell	O
hypertrophy	O
.	O
Layer-by-layer	O
(	O
LBL	O
)	O
assembly	O
is	O
an	O
attractive	O
platform	O
for	O
controlled	O
release	O
of	O
biologics	O
given	O
its	O
mild	O
fabrication	O
process	O
and	O
versatility	O
in	O
coating	O
substrates	O
of	O
any	O
shape	O
.	O

Proteins	O
can	O
be	O
incorporated	O
into	O
LBL	O
coatings	O
by	O
sequentially	O
depositing	O
oppositely	O
charged	O
polyelectrolytes	O
,	O
which	O
self-assemble	O
into	O
nanoscale	O
films	O
on	O
medical	O
devices	O
or	O
tissue	O
engineering	O
scaffolds	O
.	O

However	O
,	O
previously	O
reported	O
LBL	O
platforms	O
often	O
require	O
the	O
use	O
of	O
a	O
few	O
hundred	O
layers	O
to	O
avoid	O
burst	O
release	O
,	O
which	O
hinders	O
their	O
broad	O
translation	O
due	O
to	O
the	O
lengthy	O
fabrication	O
process	O
,	O
cost	O
,	O
and	O
batch-to-batch	O
variability	O
.	O

Here	O
we	O
report	O
a	O
biodegradable	O
LBL	O
platform	O
composed	O
of	O
only	O
10	O
layers	O
with	O
tunable	O
protein	O
release	O
kinetics	O
,	O
which	O
is	O
an	O
order	O
of	O
magnitude	O
less	O
than	O
previously	O
reported	O
LBL	O
platforms	O
.	O

We	O
performed	O
a	O
combinatorial	O
study	O
to	O
examine	O
the	O
effects	O
of	O
polymer	O
chemistry	O
and	O
order	O
of	O
deposition	O
of	O
poly	CHEMICAL
(	CHEMICAL
β-amino	CHEMICAL
)	CHEMICAL
esters	CHEMICAL
on	O
protein	O
release	O
kinetics	O
under	O
81	O
LBL	O
assembly	O
conditions	O
.	O

Using	O
the	O
optimal	O
"polyelectrolyte	O
couples"	O
for	O
constructing	O
the	O
LBL	O
film	O
,	O
basic	GENE-Y
fibroblast	GENE-Y
growth	GENE-Y
factor	GENE-Y
(	O
bFGF	GENE-Y
)	O
was	O
released	O
gradually	O
over	O
14	O
days	O
with	O
retained	O
biological	O
activity	O
to	O
stimulate	O
cell	O
proliferation	O
.	O

The	O
method	O
reported	O
herein	O
is	O
applicable	O
for	O
coating	O
various	O
substrates	O
including	O
metals	O
,	O
polymers	O
,	O
and	O
ceramics	O
and	O
may	O
be	O
used	O
for	O
a	O
broad	O
range	O
of	O
biomedical	O
and	O
tissue	O
engineering	O
applications	O
.	O
JAK	GENE-N
inhibitors	O
:	O
pharmacology	O
and	O
clinical	O
activity	O
in	O
chronic	O
myeloprolipherative	O
neoplasms	O
.	O
TMPRSS4	GENE-Y
is	O
a	O
novel	O
type	GENE-N
II	GENE-N
transmembrane	GENE-N
serine	GENE-N
protease	GENE-N
that	O
has	O
been	O
implicated	O
in	O
the	O
invasion	O
and	O
metastasis	O
of	O
colon	O
cancer	O
cells	O
.	O

In	O
this	O
study	O
,	O
a	O
novel	O
series	O
of	O
2-hydroxydiarylamide	CHEMICAL
derivatives	O
were	O
synthesized	O
and	O
evaluated	O
for	O
inhibiting	O
TMPRSS4	GENE-Y
serine	GENE-N
protease	O
activity	O
and	O
suppressing	O
cancer	O
cell	O
invasion	O
.	O

These	O
derivatives	O
demonstrated	O
good	O
inhibitory	O
activity	O
against	O
TMPRSS4	GENE-Y
serine	GENE-N
protease	O
,	O
which	O
correlated	O
with	O
the	O
promising	O
anti-invasive	O
activity	O
of	O
colon	O
cancer	O
cells	O
overexpressing	O
TMPRSS4	GENE-Y
.	O
Palmitate	CHEMICAL
and	O
lipopolysaccharide	O
trigger	O
synergistic	O
ceramide	CHEMICAL
production	O
in	O
primary	O
macrophages	O
.	O
This	O
work	O
reports	O
on	O
the	O
composition	O
and	O
bionutritional	O
value	O
of	O
organic	O
virgin	O
olive	O
oil	O
from	O
the	O
Nocellara	O
del	O
Belice	O
variety	O
,	O
one	O
cultivated	O
in	O
the	O
olive	O
areas	O
of	O
the	O
Sicily	O
region	O
,	O
Italy	O
.	O

Destoned	O
oils	O
obtained	O
by	O
processing	O
olives	O
with	O
a	O
destoning-based	O
procedure	O
were	O
compared	O
with	O
conventional	O
oils	O
.	O

This	O
innovative	O
technique	O
,	O
consisting	O
in	O
removing	O
the	O
stone	O
from	O
fruits	O
prior	O
to	O
processing	O
,	O
strongly	O
enhanced	O
the	O
already	O
high-quality	O
level	O
of	O
the	O
conventional	O
product	O
.	O

An	O
in-depth	O
analytical	O
investigation	O
from	O
2008	O
to	O
2010	O
showed	O
how	O
this	O
innovative	O
olive	O
extraction	O
process	O
led	O
to	O
an	O
excellent	O
peculiar	O
final	O
product	O
,	O
mainly	O
attributable	O
to	O
the	O
improved	O
biophenol	O
and	O
volatile	O
composition	O
,	O
as	O
well	O
as	O
higher	O
concentrations	O
of	O
the	O
lipophilic	O
and	O
vitamin	O
antioxidants	O
(	O
tocopherols	CHEMICAL
and	O
tocotrienols	CHEMICAL
)	O
.	O

It	O
had	O
higher	O
levels	O
of	O
oleocanthal	CHEMICAL
(	O
p-HPEA-EDA	CHEMICAL
)	O
,	O
a	O
nutraceutical	O
compound	O
exerting	O
actions	O
against	O
COX1	GENE-Y
and	O
COX2	GENE-Y
(	O
cycloxygenases	GENE-N
)	O
.	O

Its	O
head-space	O
aroma	O
displayed	O
new	O
volatile	O
phytomolecules	O
and	O
also	O
had	O
higher	O
levels	O
of	O
green	O
volatiles	O
from	O
the	O
lipoxygenase	GENE-N
(	O
LOX	GENE-N
)	O
-pathway	O
(	O
one	O
having	O
as	O
precursors	O
the	O
polyunsaturated	CHEMICAL
fatty	CHEMICAL
acids	CHEMICAL
containing	O
a	O
cis-cis-1	CHEMICAL
,	CHEMICAL
4-pentadiene	CHEMICAL
system	O
)	O
.	O

Among	O
the	O
other	O
bioactives	O
,	O
we	O
highlight	O
its	O
significant	O
levels	O
of	O
trans-β-carotene	CHEMICAL
and	O
xanthophylls	CHEMICAL
(	O
lutein	CHEMICAL
,	O
violaxanthin	CHEMICAL
,	O
neoxanthin	CHEMICAL
and	O
other	O
carotenoids	O
)	O
.	O

Its	O
enhanced	O
nutritional	O
value	O
was	O
also	O
attributable	O
to	O
the	O
increased	O
intensity	O
of	O
valuable	O
tasting	O
notes	O
.	O
The	O
α-hydroxy	CHEMICAL
ketones	CHEMICAL
are	O
used	O
as	O
building	O
blocks	O
for	O
compounds	O
of	O
pharmaceutical	O
interest	O
(	O
such	O
as	O
antidepressants	O
,	O
HIV-protease	GENE-N
inhibitors	O
and	O
antitumorals	O
)	O
.	O

They	O
can	O
be	O
obtained	O
by	O
the	O
action	O
of	O
enzymes	O
or	O
whole	O
cells	O
on	O
selected	O
substrates	O
,	O
such	O
as	O
diketones	CHEMICAL
.	O

We	O
have	O
studied	O
the	O
enantiospecificities	O
of	O
several	O
fungal	O
(	O
AKR3C1	GENE-N
,	O
AKR5F	GENE-N
and	O
AKR5G	GENE-N
)	O
and	O
human	O
(	O
AKR1B1	GENE-Y
and	O
AKR1B10	GENE-Y
)	O
aldo-keto	GENE-N
reductases	GENE-N
in	O
the	O
production	O
of	O
α-hydroxy	CHEMICAL
ketones	CHEMICAL
and	O
diols	CHEMICAL
from	O
vicinal	CHEMICAL
diketones	CHEMICAL
.	O

The	O
reactions	O
have	O
been	O
carried	O
out	O
with	O
pure	O
enzymes	O
and	O
with	O
an	O
NADPH-regenerating	O
system	O
consisting	O
of	O
glucose-6-phosphate	CHEMICAL
and	O
glucose-6-phosphate	GENE-Y
dehydrogenase	O
.	O

To	O
ascertain	O
the	O
regio	O
and	O
stereoselectivity	O
of	O
the	O
reduction	O
reactions	O
catalyzed	O
by	O
the	O
AKRs	GENE-N
,	O
we	O
have	O
separated	O
and	O
characterized	O
the	O
reaction	O
products	O
by	O
means	O
of	O
a	O
gas	O
chromatograph	O
equipped	O
with	O
a	O
chiral	O
column	O
and	O
coupled	O
to	O
a	O
mass	O
spectrometer	O
as	O
a	O
detector	O
.	O

According	O
to	O
the	O
regioselectivity	O
and	O
stereoselectivity	O
,	O
the	O
AKRs	GENE-N
studied	O
can	O
be	O
divided	O
in	O
two	O
groups	O
:	O
one	O
of	O
them	O
showed	O
preference	O
for	O
the	O
reduction	O
of	O
the	O
proximal	O
keto	CHEMICAL
group	O
,	O
resulting	O
in	O
the	O
S-enantiomer	O
of	O
the	O
corresponding	O
α-hydroxy	CHEMICAL
ketones	CHEMICAL
.	O

The	O
other	O
group	O
favored	O
the	O
reduction	O
of	O
the	O
distal	O
keto	CHEMICAL
group	O
and	O
yielded	O
the	O
corresponding	O
R-enantiomer	O
.	O

Three	O
of	O
the	O
AKRs	GENE-N
used	O
(	O
AKR1B1	GENE-Y
,	O
AKR1B10	GENE-Y
and	O
AKR3C1	GENE-N
)	O
could	O
produce	O
2	CHEMICAL
,	CHEMICAL
3-butanediol	CHEMICAL
from	O
acetoin	CHEMICAL
.	O

We	O
have	O
explored	O
the	O
structure	O
/	O
function	O
relationships	O
in	O
the	O
reactivity	O
between	O
several	O
yeast	GENE-N
and	GENE-N
human	GENE-N
AKRs	GENE-N
and	O
various	O
diketones	CHEMICAL
and	O
acetoin	CHEMICAL
.	O

In	O
addition	O
,	O
we	O
have	O
demonstrated	O
the	O
utility	O
of	O
these	O
AKRs	GENE-N
in	O
the	O
synthesis	O
of	O
selected	O
α-hydroxy	CHEMICAL
ketones	CHEMICAL
and	O
diols	CHEMICAL
.	O
Tissues	O
distribution	O
of	O
heavy	O
metals	O
and	O
erythrocytes	O
antioxidant	O
status	O
in	O
rats	O
exposed	O
to	O
Nigerian	O
bonny	O
light	O
crude	O
oil	O
.	O
(	CHEMICAL
-	CHEMICAL
)	CHEMICAL
-Galanthamine	CHEMICAL
(	O
GAL	CHEMICAL
)	O
,	O
an	O
alkaloid	O
from	O
the	O
flower	O
,	O
the	O
common	O
snowdrop	O
(	O
Galanthus	O
nivalis	O
)	O
,	O
shows	O
anticholinesterase	O
activity	O
.	O

This	O
property	O
has	O
made	O
GAL	O
the	O
target	O
of	O
research	O
as	O
to	O
its	O
effectiveness	O
in	O
the	O
treatment	O
of	O
Alzheimer's	O
disease	O
.	O

We	O
have	O
solved	O
the	O
X-ray	O
crystal	O
structure	O
of	O
GAL	O
bound	O
in	O
the	O
active	O
site	O
of	O
Torpedo	GENE-Y
californica	GENE-Y
acetylcholinesterase	GENE-Y
(	O
TcAChE	GENE-Y
)	O
to	O
2	O
.	O
3	O
A	O
resolution	O
.	O

The	O
inhibitor	O
binds	O
at	O
the	O
base	O
of	O
the	O
active	O
site	O
gorge	O
of	O
TcAChE	GENE-Y
,	O
interacting	O
with	O
both	O
the	O
choline-binding	O
site	O
(	O
Trp-84	O
)	O
and	O
the	O
acyl-binding	O
pocket	O
(	O
Phe-288	O
,	O
Phe-290	O
)	O
.	O

The	O
tertiary	CHEMICAL
amine	CHEMICAL
group	O
of	O
GAL	O
does	O
not	O
interact	O
closely	O
with	O
Trp-84;	O
rather	O
,	O
the	O
double	O
bond	O
of	O
its	O
cyclohexene	CHEMICAL
ring	O
stacks	O
against	O
the	O
indole	CHEMICAL
ring	O
.	O

The	O
tertiary	O
amine	O
appears	O
to	O
make	O
a	O
non-conventional	O
hydrogen	CHEMICAL
bond	O
,	O
via	O
its	O
N-methyl	CHEMICAL
group	O
,	O
to	O
Asp-72	O
,	O
near	O
the	O
top	O
of	O
the	O
gorge	O
.	O

The	O
hydroxyl	CHEMICAL
group	O
of	O
the	O
inhibitor	O
makes	O
a	O
strong	O
hydrogen	CHEMICAL
bond	O
(	O
2	O
.	O
7	O
A	O
)	O
with	O
Glu-199	O
.	O

The	O
relatively	O
tight	O
binding	O
of	O
GAL	O
to	O
TcAChE	GENE-Y
appears	O
to	O
arise	O
from	O
a	O
number	O
of	O
moderate	O
to	O
weak	O
interactions	O
with	O
the	O
protein	O
,	O
coupled	O
to	O
a	O
low	O
entropy	O
cost	O
for	O
binding	O
due	O
to	O
the	O
rigid	O
nature	O
of	O
the	O
inhibitor	O
.	O
Perfluorooctane	CHEMICAL
sulfonate	CHEMICAL
(	O
PFOS	CHEMICAL
)	O
affects	O
hormone	O
receptor	O
activity	O
,	O
steroidogenesis	O
,	O
and	O
expression	O
of	O
endocrine-related	O
genes	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
Dopamine	GENE-Y
transporter	O
gene	O
associated	O
with	O
diminished	O
subjective	O
response	O
to	O
amphetamine	CHEMICAL
.	O
A	O
membrane	O
vesicle-based	O
assay	O
to	O
enable	O
prediction	O
of	O
human	O
biliary	O
excretion	O
.	O
Cholinergic	O
fibers	O
from	O
the	O
brainstem	O
and	O
basal	O
forebrain	O
innervate	O
the	O
medial	O
prefrontal	O
cortex	O
(	O
mPFC	O
)	O
modulating	O
neuronal	O
activity	O
and	O
synaptic	O
plasticity	O
responses	O
to	O
hippocampal	O
inputs	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
muscarinic	O
and	O
glutamatergic	O
modulation	O
of	O
long-term	O
depression	O
(	O
LTD	O
)	O
in	O
the	O
intact	O
projections	O
from	O
CA1	O
to	O
mPFC	O
in	O
vivo	O
.	O

Cortical-evoked	O
responses	O
were	O
recorded	O
in	O
urethane-anesthetized	O
rats	O
for	O
30	O
min	O
during	O
baseline	O
and	O
4	O
h	O
following	O
LTD	O
.	O

In	O
order	O
to	O
test	O
the	O
potentiating	O
effects	O
of	O
pilocarpine	CHEMICAL
(	O
PILO	CHEMICAL
)	O
,	O
independent	O
groups	O
of	O
rats	O
received	O
either	O
a	O
microinjection	O
of	O
PILO	CHEMICAL
(	O
40	O
nmol;	O
i	O
.	O

c	O
.	O

v	O
.	O

)	O
or	O
vehicle	O
,	O
immediately	O
before	O
or	O
20	O
min	O
after	O
a	O
sub-threshold	O
LTD	O
protocol	O
(	O
600	O
pulses	O
,	O
1	O
Hz;	O
LFS600	O
)	O
.	O

Other	O
groups	O
received	O
either	O
an	O
infusion	O
of	O
the	O
selective	O
NMDA	GENE-N
receptor	O
antagonist	O
(	O
AP7;	O
10	O
nmol;	O
intra-mPFC	O
)	O
or	O
vehicle	O
,	O
10	O
min	O
prior	O
to	O
PILO	CHEMICAL
preceding	O
LFS600	O
,	O
or	O
prior	O
to	O
a	O
supra-threshold	O
LTD	O
protocol	O
(	O
900	O
pulses	O
,	O
1	O
Hz;	O
LFS900	O
)	O
.	O

Our	O
results	O
show	O
that	O
PILO	CHEMICAL
converts	O
a	O
transient	O
cortical	O
depression	O
induced	O
by	O
LFS600	O
into	O
a	O
robust	O
LTD	O
,	O
stable	O
for	O
at	O
least	O
4	O
h	O
.	O

When	O
applied	O
after	O
LFS600	O
,	O
PILO	CHEMICAL
does	O
not	O
change	O
either	O
mPFC	O
basal	O
neurotransmission	O
or	O
late	O
LTD	O
.	O

Our	O
data	O
also	O
indicate	O
that	O
NMDA	CHEMICAL
receptor	O
pre-activation	O
is	O
essential	O
to	O
the	O
muscarinic	O
enhancement	O
of	O
mPFC	O
synaptic	O
depression	O
,	O
since	O
AP7	CHEMICAL
microinjection	O
into	O
the	O
mPFC	O
blocked	O
the	O
conversion	O
of	O
transient	O
depression	O
into	O
long-lasting	O
LTD	O
produced	O
by	O
PILO	CHEMICAL
.	O

In	O
addition	O
,	O
AP7	CHEMICAL
effectively	O
blocked	O
the	O
long-lasting	O
LTD	O
induced	O
by	O
LFS900	O
.	O

Therefore	O
,	O
our	O
findings	O
suggest	O
that	O
the	O
glutamatergic	O
co-activation	O
of	O
prefrontal	O
neurons	O
is	O
important	O
for	O
the	O
effects	O
of	O
PILO	CHEMICAL
on	O
mPFC	O
synaptic	O
depression	O
,	O
which	O
could	O
play	O
an	O
important	O
role	O
in	O
the	O
control	O
of	O
executive	O
and	O
emotional	O
functions	O
.	O
Cyclooxygenase	GENE-N
inhibition	O
attenuates	O
3-nitropropionic	CHEMICAL
acid-induced	O
neurotoxicity	O
in	O
rats	O
:	O
possible	O
antioxidant	O
mechanisms	O
.	O
Decrease	O
in	O
interstitial	O
pH	O
of	O
the	O
tumor	O
stroma	O
and	O
over-expression	O
of	O
low	GENE-Y
density	GENE-Y
lipoprotein	GENE-Y
(	GENE-Y
LDL	GENE-Y
)	GENE-Y
receptors	GENE-Y
by	O
several	O
types	O
of	O
neoplastic	O
cells	O
have	O
been	O
suggested	O
to	O
be	O
important	O
determinants	O
of	O
selective	O
retention	O
of	O
photosensitizers	O
by	O
proliferative	O
tissues	O
.	O

The	O
interactions	O
of	O
chlorin	CHEMICAL
e6	CHEMICAL
(	O
Ce6	CHEMICAL
)	O
,	O
a	O
photosensitizer	O
bearing	O
three	O
carboxylic	CHEMICAL
groups	O
,	O
with	O
plasma	O
proteins	O
and	O
DOPC	O
unilamellar	O
vesicles	O
are	O
investigated	O
by	O
fluorescence	O
spectroscopy	O
.	O

The	O
binding	O
constant	O
to	O
liposomes	O
,	O
with	O
reference	O
to	O
the	O
DOPC	O
concentration	O
,	O
is	O
6	O
x	O
10	O
(	O
3	O
)	O
M	O
(	O
-1	O
)	O
at	O
pH	O
7	O
.	O
4	O
.	O

Binding	O
of	O
Ce6	CHEMICAL
to	O
LDL	GENE-N
involves	O
about	O
ten	O
high	O
affinity	O
sites	O
close	O
to	O
the	O
apoprotein	O
and	O
some	O
solubilization	O
in	O
the	O
lipid	O
compartment	O
.	O

The	O
overall	O
association	O
constant	O
is	O
5	O
.	O
7	O
x	O
10	O
(	O
7	O
)	O
M	O
(	O
-1	O
)	O
at	O
pH	O
7	O
.	O
4	O
.	O

Human	GENE-Y
serum	GENE-Y
albumin	GENE-Y
(	O
HSA	GENE-Y
)	O
is	O
the	O
major	O
carrier	O
(	O
association	O
constant	O
1	O
.	O
8	O
x	O
10	O
(	O
8	O
)	O
M	O
(	O
-1	O
)	O
at	O
pH	O
7	O
.	O
4	O
)	O
.	O

Whereas	O
the	O
affinity	O
of	O
Ce6	CHEMICAL
for	O
LDL	GENE-N
and	O
liposomes	O
increases	O
at	O
lower	O
pH	O
,	O
it	O
decreases	O
for	O
albumin	GENE-Y
.	O

Between	O
pH	O
7	O
.	O
4	O
and	O
6	O
.	O
5	O
,	O
the	O
relative	O
affinities	O
of	O
Ce6	CHEMICAL
for	O
LDL	GENE-N
versus	O
HSA	GENE-Y
,	O
and	O
for	O
membranes	O
versus	O
HSA	GENE-Y
,	O
are	O
multiplied	O
by	O
4	O
.	O
6	O
and	O
3	O
.	O
5	O
,	O
respectively	O
.	O

These	O
effects	O
are	O
likely	O
driven	O
by	O
the	O
ionization	O
equilibria	O
of	O
the	O
photosensitizer	O
carboxylic	CHEMICAL
chains	O
.	O

Then	O
,	O
the	O
cellular	O
uptake	O
of	O
chlorin	CHEMICAL
e6	CHEMICAL
may	O
be	O
facilitated	O
by	O
its	O
pH-mediated	O
redistribution	O
within	O
the	O
tumor	O
stroma	O
.	O
Mechanisms	O
of	O
agonist-induced	O
down-regulation	O
of	O
the	O
human	GENE-Y
kappa-opioid	GENE-Y
receptor	GENE-Y
:	O
internalization	O
is	O
required	O
for	O
down-regulation	O
.	O
Recent	O
studies	O
have	O
shed	O
new	O
light	O
on	O
a	O
possible	O
link	O
between	O
the	O
innate	O
activation	O
of	O
plasmocytoid	O
dendritic	O
cells	O
and	O
marginal	O
zone	O
B	O
cells	O
and	O
the	O
pathogenesis	O
of	O
systemic	O
lupus	O
erythematosus	O
.	O

Animal	O
studies	O
have	O
identified	O
that	O
this	O
response	O
requires	O
the	O
Toll-like	GENE-Y
receptor	GENE-Y
9	GENE-Y
(	O
TLR9	GENE-Y
)	O
.	O

Engagement	O
of	O
the	O
TLR9	GENE-Y
by	O
various	O
ligands	O
,	O
including	O
non-canonical	O
CpG-motifs	GENE-N
,	O
can	O
cause	O
or	O
aggravate	O
pathogenic	O
autoantibody	O
production	O
and	O
cytokine	GENE-N
secretion	O
in	O
lupus	O
.	O

Attempts	O
to	O
neutralize	O
this	O
activity	O
either	O
by	O
blocking	O
the	O
acidification	O
of	O
the	O
endosomal	O
compartment	O
with	O
chloroquine	O
and	O
related	O
compounds	O
,	O
or	O
by	O
preventing	O
the	O
interaction	O
between	O
the	O
CpG-DNA	O
sequences	O
and	O
TLR9	GENE-Y
using	O
inhibitory	O
oligonucleotides	O
could	O
be	O
a	O
promising	O
therapeutic	O
option	O
for	O
lupus	O
.	O
1	O
.	O

The	O
interactions	O
between	O
herbal	O
dietary	O
supplements	O
and	O
therapeutic	O
drugs	O
have	O
emerged	O
as	O
an	O
important	O
issue	O
and	O
P-glycoprotein	GENE-Y
(	O
P-gp	GENE-Y
)	O
has	O
been	O
reported	O
as	O
one	O
of	O
the	O
significant	O
factors	O
of	O
these	O
interactions	O
.	O

2	O
.	O

The	O
objective	O
of	O
this	O
article	O
is	O
to	O
examine	O
the	O
effects	O
of	O
single	O
and	O
repeated	O
administrations	O
of	O
silymarin	O
on	O
pharmacokinetics	O
of	O
a	O
P-gp	GENE-Y
substrate	O
,	O
risperidone	CHEMICAL
,	O
and	O
its	O
major	O
metabolite	O
,	O
9-hydroxyrisperidone	CHEMICAL
,	O
in	O
rats	O
.	O

3	O
.	O

To	O
determine	O
the	O
plasma	O
levels	O
of	O
risperidone	CHEMICAL
and	O
9-hydroxyrisperidone	CHEMICAL
in	O
rats	O
,	O
a	O
HPLC	O
method	O
was	O
developed	O
using	O
a	O
liquid-liquid	O
acid	O
back	O
extraction	O
.	O

When	O
risperidone	CHEMICAL
(	O
6	O
mg	O
/	O
kg	O
)	O
was	O
co-administered	O
with	O
silymarin	O
(	O
40	O
mg	O
/	O
kg	O
)	O
to	O
rats	O
orally	O
,	O
the	O
C	O
(	O
max	O
)	O
of	O
9-hydroxyrisperidone	CHEMICAL
was	O
significantly	O
increased	O
to1	O
.	O
3-fold	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
while	O
the	O
other	O
pharmacokinetic	O
parameters	O
did	O
not	O
show	O
any	O
significant	O
differences	O
.	O

Expanding	O
the	O
experiment	O
where	O
rats	O
were	O
repeatedly	O
administered	O
with	O
silymarin	O
for	O
5	O
days	O
prior	O
to	O
giving	O
risperidone	CHEMICAL
,	O
the	O
C	O
(	O
max	O
)	O
of	O
risperidone	CHEMICAL
and	O
9-hydroxyrisperidone	CHEMICAL
were	O
significantly	O
increased	O
to	O
2	O
.	O
4-fold	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
1	O
.	O
7-fold	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
respectively	O
,	O
and	O
the	O
AUC	O
(	O
0-t	O
)	O
,	O
as	O
well	O
to	O
1	O
.	O
7-fold	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
2	O
.	O
1-fold	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
respectively	O
.	O

4	O
.	O

The	O
repeated	O
exposures	O
of	O
silymarin	O
,	O
compared	O
to	O
single	O
administration	O
of	O
silymarin	O
,	O
increased	O
oral	O
bioavailability	O
and	O
affected	O
the	O
pharmacokinetics	O
of	O
risperidone	CHEMICAL
and	O
9-hydroxyrisperidone	CHEMICAL
,	O
by	O
inhibiting	O
P-gp	GENE-Y
.	O
OBJECTIVES	O
:	O
Medical	O
treatment	O
of	O
tyrosinemia	CHEMICAL
I	CHEMICAL
relies	O
on	O
the	O
herbicide	O
NTBC	CHEMICAL
[	O
Orfadin	CHEMICAL
2-	CHEMICAL
(	CHEMICAL
2-nitro-4-trifluoromethylbenzoyl	CHEMICAL
)	CHEMICAL
-cyclohexane-1	CHEMICAL
,	CHEMICAL
3-dione	CHEMICAL
]	O
,	O
an	O
inhibitor	O
of	O
plant	O
and	O
mammalian	O
2-oxoacid-utilizing	O
dioxygenases	GENE-N
with	O
a	O
collective	O
catalytic	O
cycle	O
(	O
'HAG'	O
mechanism	O
)	O
.	O

We	O
hypothesize	O
that	O
NTBC-treated	O
tyrosinemia	O
I	O
is	O
a	O
human	O
model	O
for	O
the	O
pathogenic	O
role	O
of	O
two	O
major	O
enzymes	O
in	O
this	O
class	O
,	O
4-hydroxyphenylpyruvate	CHEMICAL
dioxygenase	O
(	O
4-HPPD;	O
EC	GENE-Y
1	GENE-Y
.	GENE-Y
13	GENE-Y
.	GENE-Y
11	GENE-Y
.	GENE-Y
27	GENE-Y
)	O
and	O
prolyl	CHEMICAL
4-hydroxylase	O
(	O
P4-H;	O
E	GENE-Y
.	GENE-Y

C	GENE-Y
.	GENE-Y

1	GENE-Y
.	GENE-Y
14	GENE-Y
.	GENE-Y
11	GENE-Y
.	GENE-Y
2	GENE-Y
)	O
,	O
essential	O
for	O
tyrosine	CHEMICAL
and	O
collagen	GENE-N
metabolism	O
,	O
respectively	O
.	O

METHODS	O
:	O
In	O
a	O
patient	O
with	O
established	O
tyrosinemia	O
I	O
,	O
we	O
monitored	O
the	O
in	O
vivo	O
activities	O
of	O
4-HPPD	GENE-Y
and	O
P4-H	GENE-N
via	O
five	O
biomarkers	O
before	O
and	O
during	O
NTBC	CHEMICAL
medication	O
.	O

Hypothesis	O
testing	O
at	O
the	O
molecular	O
level	O
was	O
performed	O
by	O
computational	O
modeling	O
of	O
NTBC	CHEMICAL
binding	O
to	O
the	O
crystal	O
structure-derived	O
active	O
site	O
of	O
4-HPPD	O
,	O
and	O
then	O
relating	O
these	O
findings	O
to	O
our	O
experimental	O
results	O
and	O
to	O
known	O
P4-H	GENE-N
data	O
.	O

RESULTS	O
:	O
NTBC	O
rapidly	O
normalized	O
the	O
biomarkers	O
for	O
4-HPPD	GENE-Y
activity	O
.	O

However	O
,	O
those	O
for	O
P4-H	GENE-N
activity	O
remained	O
uniformly	O
elevated	O
after	O
one	O
hundred	O
days	O
on	O
NTBC	CHEMICAL
,	O
the	O
PIIINP	GENE-Y
biomarker	O
even	O
increasing	O
above	O
its	O
grossly	O
abnormal	O
,	O
initial	O
level	O
.	O

This	O
selective	O
enzyme	O
inhibition	O
despite	O
a	O
collective	O
catalytic	O
cycle	O
is	O
attributed	O
to	O
the	O
conformation	O
of	O
NTBC	CHEMICAL
,	O
which	O
only	O
fits	O
the	O
active	O
site	O
of	O
4-HPPD	GENE-Y
,	O
as	O
confirmed	O
by	O
its	O
crystal	O
structure	O
.	O

CONCLUSIONS	O
:	O
Normalization	O
of	O
hepatic	O
collagen	GENE-N
formation	O
,	O
highly	O
desirable	O
in	O
all	O
fibrotic	O
liver	O
diseases	O
,	O
is	O
not	O
achieved	O
by	O
NTBC	CHEMICAL
in	O
tyrosinemia	O
I	O
.	O

By	O
establishing	O
the	O
molecular	O
cause	O
for	O
this	O
failure	O
,	O
our	O
results	O
also	O
establish	O
a	O
rational	O
approach	O
to	O
identify	O
inhibitors	O
that	O
achieve	O
that	O
goal	O
,	O
either	O
by	O
joint	O
4-HPPD	GENE-Y
/	O
P-4H	GENE-N
inhibition	O
,	O
or	O
by	O
inhibition	O
of	O
only	O
P-4H	GENE-N
.	O
Mapping	O
the	O
block	O
of	O
a	O
cloned	O
human	GENE-N
inward	GENE-N
rectifier	GENE-N
potassium	CHEMICAL
channel	O
by	O
dofetilide	CHEMICAL
.	O
GLP-1	GENE-Y
receptor	GENE-Y
activated	O
insulin	GENE-Y
secretion	O
from	O
pancreatic	O
β-cells	O
:	O
mechanism	O
and	O
glucose	CHEMICAL
dependence	O
.	O
Benzodiazepines	CHEMICAL
(	O
BDZs	CHEMICAL
)	O
depress	O
neuronal	O
excitability	O
via	O
positive	O
allosteric	O
modulation	O
of	O
inhibitory	O
GABA	GENE-N
(	GENE-N
A	GENE-N
)	GENE-N
receptors	GENE-N
(	O
GABA	GENE-N
(	GENE-N
A	GENE-N
)	GENE-N
R	GENE-N
)	O
.	O

BDZs	CHEMICAL
and	O
other	O
positive	O
GABA	GENE-N
(	GENE-N
A	GENE-N
)	GENE-N
R	GENE-N
modulators	O
,	O
including	O
barbiturates	CHEMICAL
,	O
ethanol	CHEMICAL
,	O
and	O
neurosteroids	CHEMICAL
,	O
can	O
also	O
inhibit	O
L-type	GENE-N
voltage-gated	GENE-N
calcium	CHEMICAL
channels	O
(	O
L-VGCCs	GENE-N
)	O
,	O
which	O
could	O
contribute	O
to	O
reduced	O
neuronal	O
excitability	O
.	O

Because	O
neuronal	O
L-VGCC	GENE-N
function	O
is	O
up-regulated	O
after	O
long-term	O
GABA	GENE-N
(	GENE-N
A	GENE-N
)	GENE-N
R	GENE-N
modulator	O
exposure	O
,	O
an	O
interaction	O
with	O
L-VGCCs	GENE-N
may	O
also	O
play	O
a	O
role	O
in	O
physical	O
dependence	O
.	O

The	O
current	O
studies	O
assessed	O
the	O
effects	O
of	O
BDZs	CHEMICAL
(	O
diazepam	CHEMICAL
,	O
flurazepam	CHEMICAL
,	O
and	O
desalkylflurazepam	CHEMICAL
)	O
,	O
allopregnanolone	CHEMICAL
,	O
pentobarbital	CHEMICAL
,	O
and	O
ethanol	CHEMICAL
on	O
whole-cell	O
Ba	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
currents	O
through	O
recombinant	O
neuronal	O
Ca	GENE-Y
(	GENE-Y
v	GENE-Y
)	GENE-Y
1	GENE-Y
.	GENE-Y
2	GENE-Y
and	O
Ca	GENE-Y
(	GENE-Y
v	GENE-Y
)	GENE-Y
1	GENE-Y
.	GENE-Y
3	GENE-Y
L-VGCCs	GENE-N
expressed	O
with	O
beta	O
(	O
3	O
)	O
and	O
alpha	O
(	O
2	O
)	O
delta-1	O
in	O
HEK293T	O
cells	O
.	O

Allopregnanolone	CHEMICAL
was	O
the	O
most	O
potent	O
inhibitor	O
(	O
IC	O
(	O
50	O
)	O
,	O
approximately	O
10	O
muM	O
)	O
,	O
followed	O
by	O
BDZs	CHEMICAL
(	O
IC	O
(	O
50	O
)	O
,	O
approximately	O
50	O
muM	O
)	O
,	O
pentobarbital	CHEMICAL
(	O
IC	O
(	O
50	O
)	O
,	O
0	O
.	O
3-1	O
mM	O
)	O
,	O
and	O
ethanol	CHEMICAL
(	O
IC	O
(	O
50	O
)	O
,	O
approximately	O
300	O
mM	O
)	O
.	O

Ca	GENE-Y
(	GENE-Y
v	GENE-Y
)	GENE-Y
1	GENE-Y
.	GENE-Y
3	GENE-Y
channels	O
were	O
less	O
sensitive	O
to	O
pentobarbital	CHEMICAL
inhibition	O
than	O
Ca	GENE-Y
(	GENE-Y
v	GENE-Y
)	GENE-Y
1	GENE-Y
.	GENE-Y
2	GENE-Y
channels	O
,	O
similar	O
to	O
dihydropyridine	CHEMICAL
(	O
DHP	CHEMICAL
)	O
L-VGCC	GENE-N
antagonists	O
.	O

All	O
GABA	GENE-N
(	GENE-N
A	GENE-N
)	GENE-N
R	GENE-N
modulators	O
induced	O
a	O
negative	O
shift	O
in	O
the	O
steady-state	O
inactivation	O
curve	O
of	O
Ca	GENE-Y
(	GENE-Y
v	GENE-Y
)	GENE-Y
1	GENE-Y
.	GENE-Y
3	GENE-Y
channels	O
,	O
but	O
only	O
BDZs	CHEMICAL
and	O
pentobarbital	CHEMICAL
induced	O
a	O
negative	O
shift	O
in	O
Ca	GENE-Y
(	GENE-Y
v	GENE-Y
)	GENE-Y
1	GENE-Y
.	GENE-Y
2	GENE-Y
channel	O
inactivation	O
.	O

Mutation	O
of	O
the	O
high-affinity	GENE-N
DHP	CHEMICAL
binding	O
site	O
(	O
T1039Y	GENE-N
and	O
Q1043M	GENE-N
)	O
in	O
Ca	GENE-Y
(	GENE-Y
v	GENE-Y
)	GENE-Y
1	GENE-Y
.	GENE-Y
2	GENE-Y
channels	O
reduced	O
pentobarbital	CHEMICAL
potency	O
.	O

Despite	O
the	O
structural	O
similarity	O
between	O
benzothiazepines	CHEMICAL
and	O
BDZs	CHEMICAL
,	O
mutation	O
of	O
an	O
amino	CHEMICAL
acid	CHEMICAL
important	O
for	O
diltiazem	CHEMICAL
potency	O
(	O
I1150A	GENE-N
)	O
did	O
not	O
affect	O
diazepam	CHEMICAL
potency	O
.	O

Although	O
L-VGCC	GENE-N
inhibition	O
by	O
BDZs	CHEMICAL
occurred	O
at	O
concentrations	O
that	O
are	O
possibly	O
too	O
high	O
to	O
be	O
clinically	O
relevant	O
and	O
is	O
not	O
likely	O
to	O
play	O
a	O
role	O
in	O
the	O
up-regulation	O
of	O
L-VGCCs	GENE-N
during	O
long-term	O
treatment	O
,	O
pentobarbital	CHEMICAL
and	O
ethanol	O
inhibited	O
L-VGCCs	GENE-N
at	O
clinically	O
relevant	O
concentrations	O
.	O
1	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
relative	O
beta	O
1	O
/	O
beta	O
2	O
antagonist	O
selectivity	O
of	O
the	O
beta-adrenoceptor	GENE-N
blocker	O
nadolol	CHEMICAL
,	O
in	O
lower	O
than	O
conventional	O
clinical	O
doses	O
.	O

2	O
.	O

Eight	O
normal	O
volunteers	O
received	O
single	O
oral	O
doses	O
of	O
either	O
placebo	O
(	O
PL	O
)	O
,	O
nadolol	CHEMICAL
5	O
mg	O
(	O
N5	O
)	O
,	O
20	O
mg	O
(	O
N20	O
)	O
or	O
80	O
mg	O
(	O
N80	O
)	O
in	O
a	O
single-blind	O
,	O
randomised	O
crossover	O
design	O
.	O

beta	GENE-Y
1-adrenoceptor	GENE-Y
antagonism	O
was	O
assessed	O
by	O
attenuation	O
of	O
exercise	O
tachycardia	O
,	O
and	O
beta	GENE-Y
2-adrenoceptor	GENE-Y
blockade	O
by	O
effects	O
on	O
salbutamol-induced	O
chronotropic	O
,	O
hypokalaemic	O
and	O
finger	O
tremor	O
responses	O
.	O

The	O
relative	O
percentage	O
attenuation	O
of	O
beta	O
2	O
and	O
beta	O
1-mediated	O
responses	O
was	O
calculated	O
and	O
expressed	O
as	O
beta	O
2	O
:	O
beta	O
1	O
selectivity	O
ratios	O
.	O

3	O
.	O

Nadolol	CHEMICAL
produced	O
dose-related	O
reductions	O
in	O
exercise	O
tachycardia	O
in	O
keeping	O
with	O
increasing	O
beta	GENE-Y
1-adrenoceptor	GENE-Y
blockade;	O
mean	O
%	O
reduction	O
(	O
95%	O
CI	O
)	O
compared	O
with	O
placebo	O
:	O
N5	O
10	O
.	O
7	O
(	O
6	O
.	O
6	O
to	O
14	O
.	O
8	O
)	O
,	O
N20	O
21	O
.	O
4	O
(	O
17	O
.	O
3	O
to	O
25	O
.	O
4	O
)	O
,	O
N80	O
38	O
.	O
9	O
(	O
34	O
.	O
8	O
to	O
42	O
.	O
9	O
)	O
.	O

However	O
,	O
even	O
the	O
lowest	O
dose	O
of	O
nadolol	CHEMICAL
(	O
5	O
mg	O
)	O
produced	O
almost	O
complete	O
blunting	O
of	O
beta	O
2-mediated	O
effects	O
and	O
significantly	O
increase	O
exercise	O
hyperkalaemia;	O
peak	O
exercise	O
hyperkalaemia	O
(	O
mmol	O
l-1	O
)	O
(	O
means	O
and	O
95%	O
CI	O
)	O
:	O
PL	O
4	O
.	O
88	O
(	O
4	O
.	O
68	O
to	O
5	O
.	O
07	O
)	O
,	O
N5	O
5	O
.	O
36	O
(	O
5	O
.	O
17	O
to	O
5	O
.	O
55	O
)	O
,	O
N20	O
5	O
.	O
48	O
(	O
5	O
.	O
28	O
to	O
5	O
.	O
67	O
)	O
,	O
N80	O
5	O
.	O
42	O
(	O
5	O
.	O
22	O
to	O
5	O
.	O
61	O
)	O
.	O

beta	O
2	O
:	O
beta	O
1	O
selectivity	O
ratios	O
significantly	O
increased	O
as	O
the	O
dose	O
of	O
nadolol	CHEMICAL
was	O
reduced	O
.	O

4	O
.	O

These	O
data	O
suggest	O
that	O
whereas	O
in	O
the	O
clinical	O
dose	O
range	O
nadolol	CHEMICAL
behaves	O
as	O
a	O
non-selective	O
beta-adrenoceptor	GENE-N
antagonist	O
,	O
as	O
the	O
dose	O
is	O
reduced	O
this	O
drug	O
demonstrates	O
an	O
increasing	O
degree	O
of	O
selectivity	O
for	O
the	O
beta	GENE-Y
2-adrenoceptor	GENE-Y
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
The	O
aim	O
of	O
this	O
work	O
was	O
to	O
examine	O
the	O
chemical	O
constituents	O
and	O
antioxidant	O
potential	O
of	O
water-soluble	O
fractions	O
from	O
the	O
commonly	O
consumed	O
vegetable	O
,	O
Allium	O
vineale	O
.	O

The	O
water-soluble	O
fraction	O
,	O
containing	O
phenolic	O
compounds	O
,	O
was	O
extracted	O
with	O
ethyl	CHEMICAL
acetate	CHEMICAL
to	O
obtain	O
flavonoids	CHEMICAL
which	O
were	O
separated	O
and	O
purified	O
by	O
repeated	O
column	O
chromatography	O
over	O
Sephadex	O
LH-20	O
,	O
RP	O
C18	O
and	O
silica	CHEMICAL
gel	CHEMICAL
.	O

The	O
isolated	O
compounds	O
were	O
identified	O
according	O
to	O
their	O
physicochemical	O
properties	O
and	O
spectral	O
data	O
(	O
UV	O
,	O
HPLC-TOF	O
/	O
MS	O
,	O
(	CHEMICAL
1	CHEMICAL
)	CHEMICAL
H	CHEMICAL
NMR	O
,	O
(	CHEMICAL
13	CHEMICAL
)	CHEMICAL
C	CHEMICAL
NMR	O
and	O
2D	O
NMR	O
)	O
.	O

Three	O
flavonoids	O
were	O
isolated	O
and	O
identified	O
as	O
chrysoeriol-7-O-	CHEMICAL
[	CHEMICAL
2″-O-E-feruloyl	CHEMICAL
]	CHEMICAL
-β-d-glucoside	CHEMICAL
(	O
1	O
)	O
,	O
chrysoeriol	CHEMICAL
(	O
2	O
)	O
,	O
and	O
isorhamnetin-3-β-d-glucoside	CHEMICAL
(	O
3	O
)	O
.	O

Antioxidant	O
studies	O
of	O
the	O
aqueous	O
extract	O
and	O
three	O
isolated	O
compounds	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
were	O
undertaken	O
and	O
they	O
were	O
found	O
to	O
have	O
significant	O
antioxidant	O
activity	O
.	O

Antioxidant	O
activities	O
were	O
evaluated	O
for	O
total	O
antioxidant	O
activity	O
by	O
the	O
ferric	CHEMICAL
thiocyanate	CHEMICAL
method	O
,	O
ferric	CHEMICAL
ion	O
(	O
Fe	CHEMICAL
(	CHEMICAL
3	CHEMICAL
+	CHEMICAL
)	CHEMICAL
)	O
reducing	O
antioxidant	O
power	O
assay	O
(	O
FRAP	O
)	O
,	O
ferrous	CHEMICAL
ion	O
(	O
Fe	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
)	O
metal	O
chelating	O
activity	O
,	O
and	O
DPPH	CHEMICAL
free	O
radical-scavenging	O
activity	O
.	O

The	O
water-soluble	O
ethyl	CHEMICAL
acetate	CHEMICAL
and	O
methanol	CHEMICAL
extraction	O
methods	O
were	O
also	O
compared	O
using	O
HPLC-TOF	O
/	O
MS	O
.	O
Tumor-suppressive	O
Maspin	GENE-Y
Functions	O
as	O
a	O
Reactive	O
Oxygen	CHEMICAL
Species	O
Scavenger	O
:	O
IMPORTANCE	O
OF	O
CYSTEINE	CHEMICAL
RESIDUES	O
.	O
Virus-sized	O
particulate	O
adjuvants	O
such	O
as	O
ISCOMs	O
,	O
polystyrene	CHEMICAL
nanoparticles	O
and	O
virus-like	O
particles	O
have	O
been	O
shown	O
to	O
target	O
dendritic	O
cells	O
,	O
resulting	O
in	O
the	O
activation	O
of	O
T	O
and	O
B	O
cells	O
in	O
vivo	O
.	O

Using	O
an	O
ovine	O
pseudo-afferent	O
lymph	O
cannulation	O
model	O
to	O
capture	O
APC	O
that	O
traffic	O
from	O
the	O
site	O
of	O
injection	O
to	O
the	O
local	O
lymph	O
node	O
,	O
we	O
show	O
that	O
40-50nm	O
nanoparticles	O
are	O
taken	O
up	O
at	O
the	O
site	O
of	O
injection	O
by	O
dendritic	O
cells	O
(	O
DCs	O
)	O
migrating	O
to	O
the	O
draining	O
lymph	O
node	O
.	O

These	O
DCs	O
can	O
express	O
CD11c	GENE-Y
,	O
CD1b	GENE-Y
,	O
CD5	GENE-Y
,	O
MHC	GENE-N
class	GENE-N
II	GENE-N
and	O
CD8	GENE-N
.	O

Nanoparticles	O
transported	O
by	O
DCs	O
migrating	O
from	O
the	O
site	O
of	O
injection	O
to	O
the	O
local	O
lymph	O
node	O
therefore	O
needs	O
to	O
be	O
considered	O
as	O
a	O
new	O
mechanism	O
underlying	O
the	O
immunogenicity	O
of	O
virus-sized	O
vaccine	O
delivery	O
systems	O
.	O
Novel	O
mutations	O
of	O
androgen	GENE-Y
receptor	O
:	O
a	O
possible	O
mechanism	O
of	O
bicalutamide	CHEMICAL
withdrawal	O
syndrome	O
.	O
Chemoprevention	O
for	O
high-risk	O
women	O
:	O
tamoxifen	CHEMICAL
and	O
beyond	O
.	O
PURPOSE	O
:	O
We	O
provide	O
a	O
comprehensive	O
overview	O
of	O
the	O
role	O
of	O
alpha1-adrenergic	GENE-N
receptors	O
(	O
alpha1ARs	GENE-N
)	O
as	O
critical	O
mediators	O
of	O
lower	O
urinary	O
tract	O
symptoms	O
(	O
LUTS	O
)	O
and	O
pathophysiology	O
in	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
)	O
,	O
and	O
we	O
review	O
the	O
pharmacological	O
antagonists	O
of	O
alpha1ARs	GENE-N
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
A	O
review	O
was	O
performed	O
of	O
pertinent	O
studies	O
in	O
the	O
literature	O
relating	O
to	O
the	O
pathophysiology	O
of	O
LUTS	O
and	O
BPH	O
,	O
focusing	O
on	O
the	O
role	O
of	O
alpha1ARs	GENE-N
,	O
and	O
of	O
clinical	O
trial	O
and	O
practice	O
data	O
evaluating	O
the	O
different	O
agents	O
that	O
inhibit	O
these	O
receptors	O
.	O

RESULTS	O
:	O
Further	O
characterization	O
of	O
the	O
alpha1AR	GENE-N
gene	O
family	O
indicates	O
that	O
3	O
receptor	O
subtypes	O
exist	O
in	O
humans	O
.	O

Their	O
different	O
distribution	O
between	O
urinary	O
tract	O
and	O
cardiovascular	O
tissues	O
has	O
provided	O
a	O
strategy	O
for	O
the	O
development	O
of	O
improved	O
therapeutic	O
agents	O
.	O

Since	O
excessive	O
activity	O
of	O
the	O
alpha1aAR	GENE-Y
and	O
alpha1dAR	GENE-Y
subtypes	O
appears	O
to	O
be	O
a	O
common	O
feature	O
in	O
symptomatic	O
BPH	O
and	O
alpha1aARs	GENE-Y
are	O
enriched	O
in	O
prostatic	O
tissue	O
,	O
drugs	O
that	O
demonstrate	O
high	O
alpha1aAR	GENE-Y
selectivity	O
have	O
attracted	O
attention	O
.	O

Tamsulosin	CHEMICAL
,	O
which	O
has	O
high	O
affinity	O
for	O
alpha1aAR	GENE-Y
and	O
alpha1dAR	GENE-Y
subtypes	O
but	O
not	O
for	O
alpha1bAR	GENE-Y
,	O
shows	O
efficacy	O
similar	O
to	O
the	O
nonsubtype	O
selective	O
agents	O
terazosin	CHEMICAL
and	O
doxazosin	CHEMICAL
.	O

It	O
is	O
associated	O
with	O
fewer	O
cardiovascular	O
side	O
effects	O
,	O
although	O
it	O
has	O
some	O
ejaculatory	O
side	O
effects	O
.	O

The	O
nonsubtype	O
selective	O
agent	O
alfuzosin	CHEMICAL
also	O
demonstrates	O
efficacy	O
and	O
offers	O
an	O
enhanced	O
side	O
effect	O
profile	O
,	O
particularly	O
minimizing	O
hypotension	O
.	O

Other	O
agents	O
with	O
super	O
selective	O
specificity	O
for	O
the	O
alpha1aAR	GENE-Y
subtype	O
are	O
under	O
investigation	O
.	O

CONCLUSIONS	O
:	O
Further	O
advances	O
in	O
the	O
treatment	O
of	O
LUTS	O
associated	O
with	O
BPH	O
may	O
depend	O
not	O
only	O
on	O
receptor	O
subtype	O
selectivity	O
,	O
but	O
also	O
on	O
other	O
pharmacokinetic	O
and	O
pharmacodynamic	O
factors	O
.	O
The	O
topology	O
of	O
the	O
second	O
extracellular	O
loop	O
(	O
ECL2	O
)	O
and	O
its	O
interaction	O
with	O
ligands	O
is	O
unique	O
in	O
each	O
G	GENE-N
protein-coupled	GENE-N
receptor	GENE-N
.	O

When	O
the	O
orthosteric	O
ligand	O
pocket	O
located	O
in	O
the	O
transmembrane	O
(	O
TM	O
)	O
domain	O
is	O
occupied	O
,	O
ligand-specific	O
conformational	O
changes	O
occur	O
in	O
the	O
ECL2	O
.	O

In	O
more	O
than	O
90%	O
of	O
G	GENE-N
protein-coupled	GENE-N
receptors	GENE-N
,	O
ECL2	O
is	O
tethered	O
to	O
the	O
third	O
TM	O
helix	O
via	O
a	O
disulfide	O
bond	O
.	O

Therefore	O
,	O
understanding	O
the	O
extent	O
to	O
which	O
the	O
TM	O
domain	O
and	O
ECL2	O
conformations	O
are	O
coupled	O
is	O
useful	O
.	O

To	O
investigate	O
this	O
,	O
we	O
examined	O
conformational	O
changes	O
in	O
ECL2	O
of	O
the	O
angiotensin	GENE-Y
II	GENE-Y
type	GENE-Y
1	GENE-Y
receptor	GENE-Y
(	O
AT1R	GENE-Y
)	O
by	O
introducing	O
mutations	O
in	O
distant	O
sites	O
that	O
alter	O
the	O
activation	O
state	O
equilibrium	O
of	O
the	O
AT1R	GENE-Y
.	O

Differential	O
accessibility	O
of	O
reporter	O
cysteines	CHEMICAL
introduced	O
at	O
four	O
conformation-sensitive	O
sites	O
in	O
ECL2	O
of	O
these	O
mutants	O
was	O
measured	O
.	O

Binding	O
of	O
the	O
agonist	O
angiotensin	GENE-Y
II	GENE-Y
(	O
AngII	GENE-Y
)	O
and	O
inverse	O
agonist	O
losartan	CHEMICAL
in	O
wild-type	O
AT1R	GENE-Y
changed	O
the	O
accessibility	O
of	O
reporter	O
cysteines	CHEMICAL
,	O
and	O
the	O
pattern	O
was	O
consistent	O
with	O
ligand-specific	O
"lid"	O
conformations	O
of	O
ECL2	O
.	O

Without	O
agonist	O
stimulation	O
,	O
the	O
ECL2	O
in	O
the	O
gain	O
of	O
function	O
mutant	O
N111G	GENE-N
assumed	O
a	O
lid	O
conformation	O
similar	O
to	O
AngII-bound	O
wild-type	O
AT1R	GENE-Y
.	O

In	O
the	O
presence	O
of	O
inverse	O
agonists	O
,	O
the	O
conformation	O
of	O
ECL2	O
in	O
the	O
N111G	GENE-N
mutant	O
was	O
similar	O
to	O
the	O
inactive	O
state	O
of	O
wild-type	O
AT1R	GENE-Y
.	O

In	O
contrast	O
,	O
AngII	GENE-Y
did	O
not	O
induce	O
a	O
lid	O
conformation	O
in	O
ECL2	O
in	O
the	O
loss	O
of	O
function	O
D281A	GENE-N
mutant	O
,	O
which	O
is	O
consistent	O
with	O
the	O
reduced	O
AngII	GENE-Y
binding	O
affinity	O
in	O
this	O
mutant	O
.	O

However	O
,	O
a	O
lid	O
conformation	O
was	O
induced	O
by	O
[	O
Sar	CHEMICAL
(	O
1	O
)	O
,	O
Gln	CHEMICAL
(	O
2	O
)	O
,	O
Ile	CHEMICAL
(	O
8	O
)	O
]	O
AngII	GENE-Y
,	O
a	O
specific	O
analog	O
that	O
binds	O
to	O
the	O
D281A	GENE-N
mutant	O
with	O
better	O
affinity	O
than	O
AngII	GENE-Y
.	O

These	O
results	O
provide	O
evidence	O
for	O
the	O
emerging	O
paradigm	O
of	O
domain	O
coupling	O
facilitated	O
by	O
long	O
range	O
interactions	O
at	O
distant	O
sites	O
on	O
the	O
same	O
receptor	O
.	O
Carnosine	CHEMICAL
inhibits	O
Aβ	GENE-Y
(	GENE-Y
42	GENE-Y
)	GENE-Y
aggregation	O
by	O
perturbing	O
the	O
H-bond	O
network	O
in	O
and	O
around	O
the	O
central	O
hydrophobic	O
cluster	O
.	O
Microglial	O
disruption	O
in	O
young	O
mice	O
with	O
early	O
chronic	O
lead	O
exposure	O
.	O
For	O
many	O
years	O
,	O
dietary	O
arginine	CHEMICAL
supplementation	O
,	O
often	O
combined	O
with	O
other	O
substances	O
,	O
has	O
been	O
used	O
as	O
a	O
mechanism	O
to	O
boost	O
the	O
immune	O
system	O
.	O

Considerable	O
controversy	O
,	O
however	O
,	O
exists	O
as	O
to	O
the	O
benefits	O
and	O
indications	O
of	O
dietary	O
arginine	CHEMICAL
due	O
in	O
part	O
to	O
a	O
poor	O
understanding	O
of	O
the	O
role	O
played	O
by	O
this	O
amino	CHEMICAL
acid	CHEMICAL
in	O
maintaining	O
immune	O
function	O
.	O

Emerging	O
knowledge	O
promises	O
to	O
clear	O
this	O
controversy	O
and	O
allow	O
for	O
arginine's	O
safe	O
use	O
.	O

In	O
myeloid	O
cells	O
,	O
arginine	CHEMICAL
is	O
mainly	O
metabolized	O
either	O
by	O
inducible	GENE-Y
nitric	CHEMICAL
oxide	CHEMICAL
(	O
NO	CHEMICAL
)	O
synthases	O
(	O
iNOS	GENE-Y
)	O
or	O
by	O
arginase	GENE-Y
1	GENE-Y
,	O
enzymes	O
that	O
are	O
stimulated	O
by	O
T	O
helper	O
1	O
or	O
2	O
cytokines	GENE-N
,	O
respectively	O
.	O

Thus	O
,	O
activation	O
of	O
iNOS	GENE-Y
or	O
arginase	GENE-N
(	O
or	O
both	O
)	O
reflects	O
the	O
type	O
of	O
inflammatory	O
response	O
in	O
a	O
specific	O
disease	O
process	O
.	O

Myeloid	O
suppressor	O
cells	O
(	O
MSC	O
)	O
expressing	O
arginase	GENE-N
have	O
been	O
described	O
in	O
trauma	O
(	O
in	O
both	O
mice	O
and	O
humans	O
)	O
,	O
intra-abdominal	O
sepsis	O
,	O
certain	O
infections	O
,	O
and	O
prominently	O
,	O
cancer	O
.	O

Myeloid	O
cells	O
expressing	O
arginase	GENE-N
have	O
been	O
shown	O
to	O
accumulate	O
in	O
patients	O
with	O
cancer	O
.	O

Arginase	GENE-Y
1	GENE-Y
expression	O
is	O
also	O
detected	O
in	O
mononuclear	O
cells	O
after	O
trauma	O
or	O
surgery	O
.	O

MSC	O
efficiently	O
deplete	O
arginine	CHEMICAL
and	O
generate	O
ornithine	CHEMICAL
.	O

Through	O
arginine	CHEMICAL
depletion	O
,	O
MSC	O
may	O
control	O
NO	CHEMICAL
production	O
and	O
regulate	O
other	O
arginine-dependent	O
biological	O
processes	O
.	O

Low	O
circulating	O
arginine	CHEMICAL
has	O
been	O
documented	O
in	O
trauma	O
and	O
cancer	O
,	O
suggesting	O
that	O
MSC	O
may	O
exert	O
a	O
systemic	O
effect	O
and	O
cause	O
a	O
state	O
of	O
arginine	CHEMICAL
deficiency	O
.	O

Simultaneously	O
,	O
T	O
lymphocytes	O
depend	O
on	O
arginine	CHEMICAL
for	O
proliferation	O
,	O
zeta-chain	GENE-Y
peptide	GENE-Y
and	O
T-cell	GENE-N
receptor	GENE-N
complex	O
expression	O
,	O
and	O
the	O
development	O
of	O
memory	O
.	O

T-cells	O
cocultured	O
with	O
MSC	O
exhibit	O
the	O
molecular	O
and	O
functional	O
effects	O
associated	O
with	O
arginine	CHEMICAL
deficiency	O
.	O

Not	O
surprisingly	O
,	O
T-cell	O
abnormalities	O
,	O
including	O
decreased	O
proliferation	O
and	O
loss	O
of	O
the	O
zeta-chain	GENE-Y
,	O
are	O
observed	O
in	O
cancer	O
and	O
after	O
trauma	O
.	O
Atypical	O
teratoid	O
/	O
rhabdoid	O
tumor	O
of	O
the	O
CNS	O
:	O
cytopathology	O
and	O
immunohistochemistry	O
of	O
insulin-like	GENE-Y
growth	GENE-Y
factor-II	GENE-Y
,	O
insulin-like	GENE-Y
growth	GENE-Y
factor	GENE-Y
receptor	GENE-Y
type	GENE-Y
1	GENE-Y
,	O
cathepsin	GENE-Y
D	GENE-Y
,	O
and	O
Ki-67	GENE-Y
.	O
Phenytoin	CHEMICAL
and	O
carbamazepine	CHEMICAL
are	O
effective	O
and	O
inexpensive	O
anti-epileptic	O
drugs	O
(	O
AEDs	O
)	O
.	O

As	O
with	O
many	O
AEDs	O
,	O
a	O
broad	O
range	O
of	O
doses	O
is	O
used	O
,	O
with	O
the	O
final	O
"maintenance"	O
dose	O
normally	O
determined	O
by	O
trial	O
and	O
error	O
.	O

Although	O
many	O
genes	O
could	O
influence	O
response	O
to	O
these	O
medicines	O
,	O
there	O
are	O
obvious	O
candidates	O
.	O

Both	O
drugs	O
target	O
the	O
alpha-subunit	GENE-N
of	GENE-N
the	GENE-N
sodium	CHEMICAL
channel	O
,	O
encoded	O
by	O
the	O
SCN	GENE-N
family	O
of	O
genes	O
.	O

Phenytoin	CHEMICAL
is	O
principally	O
metabolized	O
by	O
CYP2C9	GENE-Y
,	O
and	O
both	O
are	O
probable	O
substrates	O
of	O
the	O
drug	GENE-N
transporter	GENE-N
P-glycoprotein	GENE-N
.	O

We	O
therefore	O
assessed	O
whether	O
variation	O
in	O
these	O
genes	O
associates	O
with	O
the	O
clinical	O
use	O
of	O
carbamazepine	CHEMICAL
and	O
phenytoin	CHEMICAL
in	O
cohorts	O
of	O
425	O
and	O
281	O
patients	O
,	O
respectively	O
.	O

We	O
report	O
that	O
a	O
known	O
functional	O
polymorphism	O
in	O
CYP2C9	GENE-Y
is	O
highly	O
associated	O
with	O
the	O
maximum	O
dose	O
of	O
phenytoin	CHEMICAL
(	O
P	O
=	O
0	O
.	O
0066	O
)	O
.	O

We	O
also	O
show	O
that	O
an	O
intronic	O
polymorphism	O
in	O
the	O
SCN1A	GENE-Y
gene	O
shows	O
significant	O
association	O
with	O
maximum	O
doses	O
in	O
regular	O
usage	O
of	O
both	O
carbamazepine	CHEMICAL
and	O
phenytoin	CHEMICAL
(	O
P	O
=	O
0	O
.	O
0051	O
and	O
P	O
=	O
0	O
.	O
014	O
,	O
respectively	O
)	O
.	O

This	O
polymorphism	O
disrupts	O
the	O
consensus	O
sequence	O
of	O
the	O
5'	O
splice	O
donor	O
site	O
of	O
a	O
highly	O
conserved	O
alternative	O
exon	O
(	O
5N	O
)	O
,	O
and	O
it	O
significantly	O
affects	O
the	O
proportions	O
of	O
the	O
alternative	O
transcripts	O
in	O
individuals	O
with	O
a	O
history	O
of	O
epilepsy	O
.	O

These	O
results	O
provide	O
evidence	O
of	O
a	O
drug	O
target	O
polymorphism	O
associated	O
with	O
the	O
clinical	O
use	O
of	O
AEDs	O
and	O
set	O
the	O
stage	O
for	O
a	O
prospective	O
evaluation	O
of	O
how	O
pharmacogenetic	O
diagnostics	O
can	O
be	O
used	O
to	O
improve	O
dosing	O
decisions	O
in	O
the	O
use	O
of	O
phenytoin	CHEMICAL
and	O
carbamazepine	CHEMICAL
.	O

Although	O
the	O
case	O
made	O
here	O
is	O
compelling	O
,	O
our	O
results	O
cannot	O
be	O
considered	O
definitive	O
or	O
ready	O
for	O
clinical	O
application	O
until	O
they	O
are	O
confirmed	O
by	O
independent	O
replication	O
.	O
An	O
optimized	O
RAD51	GENE-Y
inhibitor	O
that	O
disrupts	O
homologous	O
recombination	O
without	O
requiring	O
Michael	O
acceptor	O
reactivity	O
.	O
Selective	O
COX-2	GENE-Y
inhibitors	O
(	O
COXib	O
)	O
belonging	O
to	O
the	O
class	O
of	O
diaryl	CHEMICAL
heterocycles	CHEMICAL
(	O
e	O
.	O

g	O
.	O

,	O
celecoxib	CHEMICAL
,	O
rofecoxib	CHEMICAL
,	O
etc	O
.	O

)	O
,	O
are	O
devoid	O
of	O
the	O
undesirable	O
effects	O
due	O
to	O
their	O
capacity	O
to	O
inhibit	O
selectively	O
inducible	O
(	O
COX-2	GENE-Y
)	O
,	O
responsible	O
for	O
inflammatory	O
effects	O
but	O
not	O
constitutive	O
cyclooxygenase-1	GENE-Y
(	O
COX-1	GENE-Y
)	O
(	O
COX	GENE-N
)	O
;	O
responsible	O
for	O
cytoprotective	O
effects	O
on	O
gastric	O
mucosa	O
.	O

In	O
addition	O
,	O
several	O
reports	O
have	O
identified	O
an	O
increased	O
risk	O
of	O
cardiovascular	O
events	O
associated	O
with	O
the	O
use	O
of	O
COXib	O
.	O

We	O
have	O
developed	O
a	O
new	O
series	O
of	O
anti-inflammatory	O
agents	O
(	O
1	CHEMICAL
,	CHEMICAL
5-diarylpyrrole-3-alkoxyethyl	CHEMICAL
esters	CHEMICAL
and	CHEMICAL
ethers	CHEMICAL
)	O
.	O

To	O
evaluate	O
the	O
effect	O
of	O
two	O
1	CHEMICAL
,	CHEMICAL
5-diarylpyrrole-3-alkoxyethyl	CHEMICAL
ethers	CHEMICAL
,	O
VA441	CHEMICAL
and	O
VA428	CHEMICAL
(	O
up	O
to	O
100μM	O
)	O
,	O
respectively	O
,	O
in	O
comparison	O
with	O
two	O
well	O
known	O
COXib	O
,	O
celecoxib	CHEMICAL
and	O
rofecoxib	CHEMICAL
,	O
on	O
HaCaT	O
cell	O
(	O
keratinocytes	O
)	O
proliferation	O
and	O
toxicity	O
.	O

Crucial	O
molecules	O
in	O
cell	O
cycle	O
progression	O
,	O
i	O
.	O

e	O
.	O

NFκB	GENE-N
and	O
ERK	GENE-N
as	O
targets	O
/	O
mediators	O
and	O
cyclin	GENE-Y
D1	GENE-Y
and	O
p21	GENE-Y
Cip1	GENE-Y
/	O
Kip	GENE-Y
as	O
final	O
effectors	O
were	O
evaluated	O
by	O
Western	O
blot	O
,	O
immunohystochemistry	O
and	O
q-PCR	O
analysis	O
.	O

Both	O
compounds	O
,	O
VA441	CHEMICAL
and	O
VA428	CHEMICAL
,	O
showed	O
a	O
strong	O
inhibition	O
of	O
cell	O
proliferation	O
,	O
and	O
did	O
not	O
exhibit	O
cytotoxicity	O
.	O

The	O
anti-proliferative	O
effect	O
was	O
accompanied	O
by	O
a	O
strong	O
activation	O
of	O
ERK	GENE-N
and	O
induction	O
of	O
the	O
cell	O
cycle	O
inhibitor	O
p21	GENE-Y
.	O

In	O
addition	O
,	O
there	O
was	O
a	O
clear	O
inhibition	O
of	O
the	O
transcription	O
factor	O
NF-κB	GENE-N
and	O
downregulation	O
of	O
cyclin	GENE-Y
D1	GENE-Y
,	O
with	O
enforced	O
inhibition	O
of	O
the	O
HaCaT	O
cell	O
cycle	O
progression	O
.	O

These	O
data	O
suggest	O
that	O
compounds	O
VA441	CHEMICAL
and	O
VA428	CHEMICAL
,	O
along	O
with	O
their	O
role	O
in	O
inhibiting	O
COX-2	GENE-Y
and	O
inflammation	O
,	O
could	O
have	O
a	O
possible	O
therapeutic	O
(	O
topical	O
and	O
systemic	O
)	O
use	O
against	O
skin	O
proliferative	O
disorders	O
,	O
such	O
as	O
psoriasis	O
.	O
Natural	O
(	O
all	CHEMICAL
trans-retinoic	CHEMICAL
acid	CHEMICAL
,	O
RA	CHEMICAL
)	O
and	O
synthetic	O
retinoids	CHEMICAL
exhibit	O
potent	O
anti-proliferative	O
,	O
normalization	O
of	O
differentiation	O
and	O
anti-inflammatory	O
activities	O
which	O
appear	O
to	O
account	O
for	O
their	O
therapeutic	O
effects	O
in	O
acne	O
,	O
psoriasis	O
,	O
photoaging	O
,	O
precancerous	O
lesions	O
and	O
established	O
cancers	O
.	O

Although	O
RA	CHEMICAL
has	O
shown	O
considerable	O
promise	O
in	O
dermatologic	O
indications	O
,	O
certain	O
side	O
effects	O
have	O
restricted	O
its	O
use	O
as	O
a	O
choice	O
of	O
agent	O
for	O
chronic	O
administration	O
.	O

Systematic	O
synthesis	O
of	O
receptor-selective	O
retinoids	CHEMICAL
has	O
resulted	O
in	O
two	O
topical	O
drugs	O
,	O
Tazorac	CHEMICAL
/	O
Zorac	CHEMICAL
(	O
tazarotene	CHEMICAL
)	O
and	O
Differin	CHEMICAL
(	O
adapalene	CHEMICAL
)	O
.	O

Tazorac	CHEMICAL
is	O
indicated	O
for	O
psoriasis	O
and	O
acne	O
and	O
Differin	CHEMICAL
gel	O
for	O
the	O
treatment	O
of	O
acne	O
.	O

These	O
drugs	O
bind	O
to	O
the	O
retinoic	GENE-N
acid	GENE-N
receptor	O
(	O
RAR	GENE-N
)	O
family	O
members	O
.	O

Various	O
RAR	GENE-N
subtype-specific	O
and	O
function-selective	O
retinoids	CHEMICAL
have	O
been	O
synthesized	O
.	O

These	O
retinoids	CHEMICAL
,	O
which	O
are	O
in	O
various	O
stages	O
of	O
pre-clinical	O
development	O
for	O
the	O
treatment	O
of	O
cancers	O
,	O
psoriasis	O
and	O
as	O
an	O
antidote	O
to	O
Accutane-mediated	O
mucocutaneous	O
toxicity	O
,	O
will	O
also	O
be	O
discussed	O
in	O
this	O
review	O
.	O

Discovery	O
of	O
another	O
retinoid	GENE-N
receptor	O
,	O
retinoid	CHEMICAL
X	O
receptor	O
(	O
RXR	GENE-N
)	O
,	O
revealed	O
that	O
RXR-specific	O
retinoids	CHEMICAL
already	O
existed	O
in	O
retinoid	CHEMICAL
chemical	O
libraries	O
.	O

Structure	O
activity	O
relationship	O
studies	O
based	O
upon	O
binding	O
and	O
transactivation	O
assays	O
led	O
to	O
the	O
synthesis	O
of	O
RXR-specific	O
ligands	O
with	O
high	O
affinities	O
for	O
RXR	GENE-N
subtypes	O
.	O

These	O
compounds	O
were	O
found	O
to	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
hyperglycemia	O
in	O
animal	O
models	O
of	O
type	O
II	O
diabetes	O
.	O

The	O
discovery	O
of	O
novel	O
retinoids	CHEMICAL
along	O
with	O
an	O
increased	O
understanding	O
of	O
the	O
biological	O
functions	O
and	O
mechanisms	O
of	O
action	O
of	O
retinoid	CHEMICAL
receptors	O
are	O
likely	O
to	O
result	O
in	O
improved	O
treatments	O
for	O
existing	O
responsive	O
indications	O
and	O
identification	O
of	O
new	O
retinoid	CHEMICAL
therapeutic	O
targets	O
.	O
Numerous	O
studies	O
have	O
shown	O
that	O
resveratrol	CHEMICAL
(	O
RES	CHEMICAL
)	O
exerts	O
anti-inflammatory	O
effects	O
but	O
human	O
trials	O
evidencing	O
these	O
effects	O
in	O
vivo	O
are	O
limited	O
.	O

Furthermore	O
,	O
the	O
molecular	O
mechanisms	O
triggered	O
in	O
humans	O
following	O
the	O
oral	O
intake	O
of	O
RES	CHEMICAL
are	O
not	O
yet	O
understood	O
.	O

Therefore	O
,	O
the	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
molecular	O
changes	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
associated	O
to	O
the	O
one-year	O
daily	O
intake	O
of	O
a	O
RES	CHEMICAL
enriched	O
(	O
8mg	O
)	O
grape	O
extract	O
(	O
GE-RES	CHEMICAL
)	O
in	O
hypertensive	O
male	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
.	O

We	O
used	O
microarrays	O
and	O
RT-PCR	O
to	O
analyze	O
expression	O
changes	O
in	O
genes	O
and	O
microRNAs	O
(	O
miRs	O
)	O
involved	O
in	O
the	O
inflammatory	O
response	O
modulated	O
by	O
the	O
consumption	O
of	O
GE-RES	CHEMICAL
in	O
comparison	O
to	O
a	O
placebo	O
and	O
GE	O
lacking	O
RES	CHEMICAL
.	O

We	O
also	O
examined	O
the	O
changes	O
in	O
several	O
serobiochemical	O
variables	O
,	O
inflammatory	O
and	O
fibrinolytic	O
markers	O
.	O

Our	O
results	O
showed	O
that	O
supplementation	O
with	O
GE	O
or	O
GE-RES	CHEMICAL
did	O
not	O
affect	O
body	O
weight	O
,	O
blood	O
pressure	O
,	O
glucose	CHEMICAL
,	O
HbA1c	GENE-Y
or	O
lipids	O
,	O
beyond	O
the	O
values	O
regulated	O
by	O
gold	O
standard	O
medication	O
in	O
these	O
patients	O
.	O

We	O
did	O
not	O
find	O
either	O
any	O
significant	O
change	O
on	O
serum	O
inflammatory	O
markers	O
except	O
for	O
a	O
significant	O
reduction	O
of	O
ALP	GENE-N
and	O
IL-6	GENE-Y
levels	O
.	O

The	O
expression	O
of	O
the	O
pro-inflammatory	O
cytokines	GENE-N
CCL3	GENE-Y
,	O
IL-1β	GENE-Y
and	O
TNF-α	GENE-Y
was	O
significantly	O
reduced	O
and	O
that	O
of	O
the	O
transcriptional	O
repressor	O
LRRFIP-1	GENE-Y
increased	O
in	O
PBMCs	O
from	O
patients	O
taking	O
the	O
GE-RES	CHEMICAL
extract	O
.	O

Also	O
,	O
a	O
group	O
of	O
miRs	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
inflammatory	O
response	O
:	O
miR-21	GENE-Y
,	O
miR-181b	GENE-N
,	O
miR-663	GENE-Y
,	O
miR-30c2	GENE-Y
,	O
miR-155	GENE-Y
and	O
miR-34a	GENE-Y
were	O
found	O
to	O
be	O
highly	O
correlated	O
and	O
altered	O
in	O
the	O
group	O
consuming	O
the	O
GE-RES	CHEMICAL
for	O
12	O
months	O
.	O

Our	O
results	O
provide	O
preliminary	O
evidence	O
that	O
long-term	O
supplementation	O
with	O
a	O
grape	O
extract	O
containing	O
RES	CHEMICAL
downregulates	O
the	O
expression	O
of	O
key	O
pro-inflammatory	O
cytokines	GENE-N
with	O
the	O
involvement	O
of	O
inflammation-related	O
miRs	O
in	O
circulating	O
immune	O
cells	O
of	O
T2DM	O
hypertensive	O
medicated	O
patients	O
and	O
support	O
a	O
beneficial	O
immunomodulatory	O
effect	O
in	O
these	O
patients	O
.	O
OBJECTIVES	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
continuous	O
infusion	O
of	O
ritodrine	CHEMICAL
could	O
prevent	O
preterm	O
delivery	O
in	O
sheep	O
.	O

STUDY	O
DESIGN	O
:	O
Sheep	O
in	O
preterm	O
labor	O
induced	O
by	O
RU	CHEMICAL
486	CHEMICAL
(	O
mifepristone	CHEMICAL
)	O
received	O
infusions	O
of	O
either	O
ritodrine	CHEMICAL
(	O
n	O
=	O
5	O
)	O
or	O
saline	O
solution	O
(	O
n	O
=	O
5	O
)	O
,	O
and	O
the	O
progress	O
of	O
labor	O
was	O
monitored	O
.	O

beta	GENE-Y
2-Adrenergic	GENE-Y
receptor	GENE-Y
density	O
and	O
function	O
(	O
agonist-induced	O
cyclic	CHEMICAL
adenosine	CHEMICAL
monophosphate	CHEMICAL
production	O
)	O
was	O
measured	O
in	O
myometrial	O
samples	O
from	O
both	O
groups	O
.	O

RESULTS	O
:	O
Ritodrine	CHEMICAL
initially	O
inhibited	O
labor	O
contractions	O
.	O

This	O
inhibition	O
was	O
only	O
maintained	O
for	O
16	O
hours	O
,	O
after	O
which	O
both	O
the	O
amplitude	O
and	O
frequency	O
of	O
electromyographic	O
bursts	O
and	O
contractions	O
returned	O
.	O

The	O
failure	O
of	O
the	O
myometrium	O
to	O
respond	O
to	O
ritodrine	CHEMICAL
(	O
desensitization	O
)	O
was	O
associated	O
with	O
significant	O
reductions	O
in	O
agonist-induced	O
cyclic	CHEMICAL
adenosine	CHEMICAL
monophosphate	CHEMICAL
production	O
and	O
beta	GENE-Y
2-adrenergic	GENE-Y
receptor	GENE-Y
concentration	O
in	O
myometrial	O
tissue	O
collected	O
from	O
these	O
animals	O
compared	O
with	O
the	O
saline	O
solution-treated	O
controls	O
.	O

CONCLUSIONS	O
:	O
Continuous	O
infusion	O
of	O
ritodrine	CHEMICAL
to	O
sheep	O
in	O
preterm	O
labor	O
produces	O
only	O
a	O
transient	O
inhibition	O
of	O
contractions	O
.	O

This	O
desensitization	O
is	O
caused	O
by	O
a	O
down-regulation	O
of	O
myometrial	O
beta	GENE-Y
2-adrenergic	GENE-Y
receptors	GENE-Y
.	O
Frovatriptan	CHEMICAL
succinate	CHEMICAL
,	O
a	O
5-HT1B	GENE-N
/	GENE-N
1D	GENE-N
receptor	O
agonist	O
for	O
migraine	O
.	O
Synthesis	O
and	O
Biological	O
Evaluation	O
of	O
Urea	CHEMICAL
Derivatives	O
as	O
Highly	O
Potent	O
and	O
Selective	O
Rho	GENE-N
Kinase	GENE-N
Inhibitors	O
.	O
Metabolic	O
derangement	O
of	O
methionine	CHEMICAL
and	O
folate	CHEMICAL
metabolism	O
in	O
mice	O
deficient	O
in	O
methionine	GENE-Y
synthase	O
reductase	O
.	O
BACKGROUND	O
&	O
AIMS	O
:	O
Of	O
the	O
2	O
genes	O
(	O
MAT1A	GENE-Y
,	O
MAT2A	GENE-Y
)	O
encoding	O
methionine	GENE-N
adenosyltransferase	O
,	O
the	O
enzyme	O
that	O
synthesizes	O
S-adenosylmethionine	CHEMICAL
,	O
MAT1A	GENE-Y
,	O
is	O
expressed	O
in	O
liver	O
,	O
whereas	O
MAT2A	GENE-Y
is	O
expressed	O
in	O
extrahepatic	O
tissues	O
.	O

In	O
liver	O
,	O
MAT2A	GENE-Y
expression	O
associates	O
with	O
growth	O
,	O
dedifferentiation	O
,	O
and	O
cancer	O
.	O

Here	O
,	O
we	O
identified	O
the	O
beta	O
subunit	O
as	O
a	O
regulator	O
of	O
proliferation	O
in	O
human	O
hepatoma	O
cell	O
lines	O
.	O

The	O
beta	O
subunit	O
has	O
been	O
cloned	O
and	O
shown	O
to	O
lower	O
the	O
K	O
(	O
m	O
)	O
of	O
methionine	GENE-Y
adenosyltransferase	O
II	O
alpha2	O
(	O
the	O
MAT2A	GENE-Y
product	O
)	O
for	O
methionine	CHEMICAL
and	O
to	O
render	O
the	O
enzyme	O
more	O
susceptible	O
to	O
S-adenosylmethionine	CHEMICAL
inhibition	O
.	O

METHODS	O
:	O
Methionine	GENE-N
adenosyltransferase	O
II	O
alpha2	O
and	O
beta	O
subunit	O
expression	O
was	O
analyzed	O
in	O
human	O
and	O
rat	O
liver	O
and	O
hepatoma	O
cell	O
lines	O
and	O
their	O
interaction	O
studied	O
in	O
HuH7	O
cells	O
.	O

beta	O
Subunit	O
expression	O
was	O
up-	O
and	O
down-regulated	O
in	O
human	O
hepatoma	O
cell	O
lines	O
and	O
the	O
effect	O
on	O
DNA	O
synthesis	O
determined	O
.	O

RESULTS	O
:	O
We	O
found	O
that	O
beta	O
subunit	O
is	O
expressed	O
in	O
rat	O
extrahepatic	O
tissues	O
but	O
not	O
in	O
normal	O
liver	O
.	O

In	O
human	O
liver	O
,	O
beta	O
subunit	O
expression	O
associates	O
with	O
cirrhosis	O
and	O
hepatoma	O
.	O

beta	O
Subunit	O
is	O
expressed	O
in	O
most	O
(	O
HepG2	O
,	O
PLC	O
,	O
and	O
Hep3B	O
)	O
but	O
not	O
all	O
(	O
HuH7	O
)	O
hepatoma	O
cell	O
lines	O
.	O

Transfection	O
of	O
beta	O
subunit	O
reduced	O
S-adenosylmethionine	CHEMICAL
content	O
and	O
stimulated	O
DNA	O
synthesis	O
in	O
HuH7	O
cells	O
,	O
whereas	O
down-regulation	O
of	O
beta	O
subunit	O
expression	O
diminished	O
DNA	O
synthesis	O
in	O
HepG2	O
.	O

The	O
interaction	O
between	O
methionine	GENE-N
adenosyltransferase	O
II	O
alpha2	O
and	O
beta	O
subunit	O
was	O
demonstrated	O
in	O
HuH7	O
cells	O
.	O

CONCLUSIONS	O
:	O
Our	O
findings	O
indicate	O
that	O
beta	O
subunit	O
associates	O
with	O
cirrhosis	O
and	O
cancer	O
providing	O
a	O
proliferative	O
advantage	O
in	O
hepatoma	O
cells	O
through	O
its	O
interaction	O
with	O
methionine	GENE-Y
adenosyltransferase	O
II	O
alpha2	O
and	O
down-regulation	O
of	O
S-adenosylmethionine	CHEMICAL
levels	O
.	O
The	O
enzymatic	O
basis	O
for	O
the	O
metabolism	O
and	O
inhibitory	O
effects	O
of	O
valproic	CHEMICAL
acid	CHEMICAL
:	O
dehydrogenation	O
of	O
valproyl-CoA	CHEMICAL
by	O
2-methyl-branched-chain	GENE-Y
acyl-CoA	GENE-Y
dehydrogenase	O
.	O
Time-specific	O
effects	O
of	O
perinatal	O
glucocorticoid	O
treatment	O
on	O
anterior	O
pituitary	O
morphology	O
,	O
annexin	GENE-Y
1	GENE-Y
expression	O
and	O
adrenocorticotrophic	GENE-Y
hormone	GENE-Y
secretion	O
in	O
the	O
adult	O
female	O
rat	O
.	O
The	O
M6P	CHEMICAL
(	O
mannose	CHEMICAL
6-phosphate	CHEMICAL
)	O
/	O
IGF2R	GENE-Y
(	O
insulin-like	GENE-Y
growth	GENE-Y
factor	GENE-Y
II	GENE-Y
receptor	GENE-Y
)	O
interacts	O
with	O
a	O
variety	O
of	O
factors	O
that	O
impinge	O
on	O
tumour	O
invasion	O
and	O
metastasis	O
.	O

It	O
has	O
been	O
shown	O
that	O
expression	O
of	O
wild-type	O
M6P	CHEMICAL
/	O
IGF2R	GENE-Y
reduces	O
the	O
tumorigenic	O
and	O
invasive	O
properties	O
of	O
receptor-deficient	O
SCC-VII	O
squamous	O
cell	O
carcinoma	O
cells	O
.	O

We	O
have	O
now	O
used	O
mutant	O
forms	O
of	O
M6P	CHEMICAL
/	O
IGF2R	GENE-Y
to	O
assess	O
the	O
relevance	O
of	O
the	O
different	O
ligand-binding	O
sites	O
of	O
the	O
receptor	O
for	O
its	O
biological	O
activities	O
in	O
this	O
cellular	O
system	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
demonstrate	O
that	O
M6P	CHEMICAL
/	O
IGF2R	GENE-Y
does	O
not	O
require	O
a	O
functional	O
binding	O
site	O
for	O
insulin-like	GENE-Y
growth	GENE-Y
factor	GENE-Y
II	GENE-Y
for	O
inhibition	O
of	O
anchorage-independent	O
growth	O
and	O
matrix	O
invasion	O
by	O
SCC-VII	O
cells	O
.	O

In	O
contrast	O
,	O
the	O
simultaneous	O
mutation	O
of	O
both	O
M6P-binding	O
sites	O
is	O
sufficient	O
to	O
impair	O
all	O
cellular	O
functions	O
of	O
the	O
receptor	O
tested	O
.	O

These	O
findings	O
highlight	O
that	O
the	O
interaction	O
between	O
M6P	CHEMICAL
/	O
IGF2R	GENE-Y
and	O
M6P-modified	O
ligands	O
is	O
not	O
only	O
important	O
for	O
intracellular	O
accumulation	O
of	O
lysosomal	O
enzymes	O
and	O
formation	O
of	O
dense	O
lysosomes	O
,	O
but	O
is	O
also	O
crucial	O
for	O
the	O
ability	O
of	O
the	O
receptor	O
to	O
suppress	O
SCC-VII	O
growth	O
and	O
invasion	O
.	O

The	O
present	O
study	O
also	O
shows	O
that	O
some	O
of	O
the	O
biological	O
activities	O
of	O
M6P	CHEMICAL
/	O
IGF2R	GENE-Y
in	O
SCC-VII	O
cells	O
strongly	O
depend	O
on	O
a	O
functional	O
M6P-binding	O
site	O
within	O
domain	O
3	O
,	O
thus	O
providing	O
further	O
evidence	O
for	O
the	O
non-redundant	O
cellular	O
functions	O
of	O
the	O
individual	O
carbohydrate-binding	O
domains	O
of	O
the	O
receptor	O
.	O
OBJECTIVE	O
:	O
Tricyclic	CHEMICAL
antidepressants	O
(	O
TCAs	O
)	O
are	O
one	O
of	O
the	O
first-line	O
pharmacological	O
treatments	O
against	O
neuropathic	O
pain	O
.	O

TCAs	O
increase	O
the	O
extracellular	O
concentrations	O
of	O
noradrenaline	CHEMICAL
and	O
serotonin	CHEMICAL
by	O
blocking	O
the	O
reuptake	O
transporters	O
of	O
these	O
amines	CHEMICAL
.	O

However	O
,	O
the	O
precise	O
downstream	O
mechanism	O
leading	O
to	O
the	O
therapeutic	O
action	O
remains	O
identified	O
.	O

In	O
this	O
work	O
,	O
we	O
evaluated	O
the	O
role	O
of	O
adrenergic	GENE-N
receptors	GENE-N
(	O
ARs	GENE-N
)	O
in	O
the	O
action	O
of	O
TCAs	O
.	O

METHODS	O
:	O
We	O
used	O
pharmacological	O
and	O
genetic	O
approaches	O
in	O
mice	O
to	O
study	O
the	O
role	O
of	O
ARs	GENE-N
in	O
the	O
antiallodynic	O
action	O
of	O
the	O
TCA	O
nortriptyline	CHEMICAL
.	O

Peripheral	O
neuropathy	O
was	O
induced	O
by	O
the	O
insertion	O
of	O
a	O
polyethylene	O
cuff	O
around	O
the	O
main	O
branch	O
of	O
the	O
sciatic	O
nerve	O
.	O

The	O
specific	O
role	O
of	O
beta	GENE-Y
(	GENE-Y
2	GENE-Y
)	GENE-Y
-AR	GENE-Y
was	O
evaluated	O
by	O
studying	O
beta	GENE-Y
(	GENE-Y
2	GENE-Y
)	GENE-Y
-AR	GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

We	O
used	O
von	O
Frey	O
filaments	O
to	O
assess	O
mechanical	O
allodynia	O
.	O

RESULTS	O
:	O
The	O
antiallodynic	O
action	O
of	O
nortriptyline	CHEMICAL
was	O
not	O
affected	O
by	O
cotreatment	O
with	O
the	O
alpha	GENE-Y
(	GENE-Y
2	GENE-Y
)	GENE-Y
-AR	GENE-Y
antagonist	O
yohimbine	CHEMICAL
,	O
the	O
beta	GENE-Y
(	GENE-Y
1	GENE-Y
)	GENE-Y
-AR	GENE-Y
antagonists	O
atenolol	CHEMICAL
or	O
metoprolol	CHEMICAL
,	O
or	O
the	O
beta	GENE-Y
(	GENE-Y
3	GENE-Y
)	GENE-Y
-AR	GENE-Y
antagonist	O
SR	CHEMICAL
59230A	CHEMICAL
.	O

On	O
the	O
contrary	O
,	O
the	O
beta-AR	GENE-N
antagonists	O
propranolol	CHEMICAL
or	O
sotalol	CHEMICAL
,	O
the	O
beta	GENE-N
(	GENE-N
1	GENE-N
)	GENE-N
/	GENE-N
beta	GENE-N
(	GENE-N
2	GENE-N
)	GENE-N
-AR	GENE-N
antagonists	O
alprenolol	CHEMICAL
or	O
pindolol	CHEMICAL
,	O
or	O
the	O
specific	O
beta	GENE-Y
(	GENE-Y
2	GENE-Y
)	GENE-Y
-AR	GENE-Y
antagonist	O
ICI	CHEMICAL
118	CHEMICAL
,	CHEMICAL
551	CHEMICAL
blocked	O
the	O
action	O
of	O
nortriptyline	CHEMICAL
.	O

The	O
effect	O
of	O
nortriptyline	CHEMICAL
was	O
also	O
totally	O
absent	O
in	O
beta	GENE-Y
(	GENE-Y
2	GENE-Y
)	GENE-Y
-AR-deficient	O
mice	O
.	O

INTERPRETATION	O
:	O
Stimulation	O
of	O
beta	GENE-Y
(	GENE-Y
2	GENE-Y
)	GENE-Y
-AR	GENE-Y
is	O
necessary	O
for	O
nortriptyline	CHEMICAL
to	O
exert	O
its	O
antiallodynic	O
action	O
against	O
neuropathic	O
pain	O
.	O

These	O
findings	O
provide	O
new	O
insight	O
into	O
the	O
mechanism	O
by	O
which	O
antidepressants	O
alleviate	O
neuropathic	O
pain	O
.	O

Our	O
results	O
also	O
raise	O
the	O
question	O
of	O
a	O
potential	O
incompatibility	O
between	O
beta-blockers	O
that	O
affect	O
beta	GENE-Y
(	GENE-Y
2	GENE-Y
)	GENE-Y
-AR	GENE-Y
and	O
antidepressant	O
drugs	O
in	O
patients	O
treated	O
for	O
neuropathic	O
pain	O
.	O
Effects	O
of	O
the	O
inhibition	O
of	O
cyclo-oxygenase	GENE-N
1	GENE-N
or	GENE-N
2	GENE-N
or	O
5-lipoxygenase	GENE-Y
on	O
the	O
activation	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
axis	O
induced	O
by	O
interleukin-1beta	GENE-Y
in	O
the	O
male	O
Rat	O
.	O
Increased	O
responsiveness	O
of	O
rat	O
colonic	O
splanchnic	O
afferents	O
to	O
5-HT	CHEMICAL
after	O
inflammation	O
and	O
recovery	O
.	O
2-Phenyl-4-piperidinyl-6	CHEMICAL
,	CHEMICAL
7-dihydrothieno	CHEMICAL
[	CHEMICAL
3	CHEMICAL
,	CHEMICAL
4-d	CHEMICAL
]	CHEMICAL
pyrimidine	CHEMICAL
derivative	O
(	O
2	O
)	O
was	O
found	O
to	O
be	O
a	O
new	O
PDE4	GENE-N
inhibitor	O
with	O
moderate	O
PDE4B	GENE-Y
activity	O
(	O
IC50	O
=	O
150nM	O
)	O
.	O

A	O
number	O
of	O
derivatives	O
with	O
a	O
variety	O
of	O
4-amino	CHEMICAL
substituents	O
and	O
fused	O
bicyclic	O
pyrimidines	CHEMICAL
were	O
synthesized	O
.	O

Among	O
these	O
,	O
5	CHEMICAL
,	CHEMICAL
5-dioxo-7	CHEMICAL
,	CHEMICAL
8-dihydro-6H-thiopyrano	CHEMICAL
[	CHEMICAL
3	CHEMICAL
,	CHEMICAL
2-d	CHEMICAL
]	CHEMICAL
pyrimidine	CHEMICAL
derivative	O
(	O
18	O
)	O
showed	O
potent	O
PDE4B	GENE-Y
inhibitory	O
activity	O
(	O
IC50	O
=	O
25	O
nM	O
)	O
.	O

Finally	O
,	O
N-propylacetamide	CHEMICAL
derivative	O
(	O
31b	O
)	O
was	O
determined	O
as	O
a	O
potent	O
inhibitor	O
for	O
both	O
PDE4B	GENE-Y
(	O
IC50	O
=	O
7	O
.	O
5nM	O
)	O
and	O
TNF-α	GENE-Y
production	O
in	O
mouse	O
splenocytes	O
(	O
IC50	O
=	O
9	O
.	O
8nM	O
)	O
and	O
showed	O
good	O
in	O
vivo	O
anti-inflammatory	O
activity	O
in	O
the	O
LPS-induced	O
lung	O
inflammation	O
model	O
in	O
mice	O
(	O
ID50	O
=	O
18mg	O
/	O
kg	O
)	O
.	O

The	O
binding	O
mode	O
of	O
the	O
new	O
inhibitor	O
(	O
31e	O
)	O
in	O
the	O
catalytic	O
site	O
of	O
PDE4B	GENE-Y
is	O
presented	O
based	O
on	O
an	O
X-ray	O
crystal	O
structure	O
of	O
the	O
ligand-enzyme	O
complex	O
.	O
Topiramate	CHEMICAL
is	O
a	O
widely	O
used	O
antiepileptic	O
agent	O
whose	O
mechanism	O
of	O
action	O
is	O
poorly	O
understood	O
.	O

The	O
drug	O
has	O
been	O
reported	O
to	O
interact	O
with	O
various	O
ion	GENE-N
channel	GENE-N
types	O
,	O
including	O
AMPA	GENE-N
/	O
kainate	CHEMICAL
receptors	O
.	O

In	O
whole-cell	O
voltage-clamp	O
recordings	O
from	O
principal	O
neurons	O
of	O
the	O
rat	O
basolateral	O
amygdala	O
,	O
topiramate	CHEMICAL
at	O
low	O
concentrations	O
(	O
IC50	O
,	O
approximately	O
0	O
.	O
5	O
microm	O
)	O
selectively	O
inhibited	O
pharmacologically	O
isolated	O
excitatory	O
synaptic	O
currents	O
mediated	O
by	O
kainate	GENE-N
receptors	O
containing	O
the	O
GluR5	GENE-Y
subunit	O
.	O

Topiramate	CHEMICAL
also	O
partially	O
depressed	O
predominantly	O
AMPA-receptor-mediated	O
EPSCs	O
,	O
but	O
with	O
lower	O
efficacy	O
.	O

Topiramate	CHEMICAL
did	O
not	O
alter	O
the	O
degree	O
of	O
facilitation	O
in	O
paired-pulse	O
experiments	O
,	O
and	O
it	O
reduced	O
the	O
amplitude	O
of	O
miniature	O
EPSCs	O
without	O
affecting	O
their	O
frequency	O
,	O
demonstrating	O
that	O
the	O
block	O
of	O
synaptic	O
responses	O
occurs	O
postsynaptically	O
.	O

Inhibition	O
of	O
GluR5	GENE-Y
kainate	GENE-N
receptors	O
could	O
represent	O
a	O
key	O
mechanism	O
underlying	O
the	O
anticonvulsant	O
activity	O
of	O
topiramate	CHEMICAL
.	O

Moreover	O
,	O
these	O
results	O
support	O
the	O
concept	O
that	O
GluR5	GENE-Y
kainate	GENE-N
receptors	O
represent	O
a	O
novel	O
target	O
for	O
antiepileptic	O
drug	O
development	O
.	O
Antithrombotic	O
activity	O
of	O
a	O
newly	O
synthesized	O
coumarin	CHEMICAL
derivative	O
3-	CHEMICAL
(	CHEMICAL
5-hydroxy-2	CHEMICAL
,	CHEMICAL
2-dimethyl-chroman-6-yl	CHEMICAL
)	CHEMICAL
-N-{2-	CHEMICAL
[	CHEMICAL
3-	CHEMICAL
(	CHEMICAL
5-hydroxy-2	CHEMICAL
,	CHEMICAL
2-dimethyl-chroman-6-yl	CHEMICAL
)	CHEMICAL
-propionylamino	CHEMICAL
]	CHEMICAL
-ethyl}-propionamide	CHEMICAL
.	O
The	O
possibility	O
of	O
using	O
freshwater	O
Ulva	O
(	O
Chlorophyta	O
)	O
as	O
a	O
bioaccumulator	O
of	O
metals	O
(	O
Co	CHEMICAL
,	O
Cr	CHEMICAL
,	O
Cu	CHEMICAL
,	O
Mn	CHEMICAL
and	O
Zn	CHEMICAL
)	O
in	O
lake	O
and	O
river	O
water	O
was	O
examined	O
weekly	O
in	O
the	O
summer	O
of	O
2010	O
in	O
three	O
types	O
of	O
samples	O
:	O
the	O
water	O
,	O
the	O
sediment	O
and	O
the	O
thalli	O
of	O
Ulva	O
.	O

Samples	O
of	O
freshwater	O
Ulva	O
were	O
collected	O
from	O
two	O
aqueous	O
ecosystems	O
lie	O
250	O
km	O
away	O
from	O
the	O
basin	O
of	O
the	O
Baltic	O
Sea	O
and	O
53	O
km	O
from	O
each	O
other	O
.	O

A	O
flow	O
lake	O
located	O
in	O
the	O
centre	O
of	O
the	O
big	O
city	O
was	O
the	O
first	O
water	O
reservoir	O
(	O
ten	O
sites	O
)	O
and	O
second	O
,	O
the	O
suburban	O
river	O
(	O
six	O
sites	O
)	O
.	O

The	O
mean	O
metal	O
concentrations	O
in	O
the	O
Ulva	O
tissue	O
from	O
the	O
river	O
and	O
the	O
lake	O
decreased	O
in	O
the	O
following	O
order	O
:	O
Mn	CHEMICAL
>	O
Zn	CHEMICAL
>	O
Cr	CHEMICAL
>	O
Cu	CHEMICAL
>	O
Co	CHEMICAL
and	O
Mn	CHEMICAL
>	O
Cr	CHEMICAL
>	O
Zn	CHEMICAL
>	O
Cu	CHEMICAL
>	O
Co	CHEMICAL
,	O
respectively	O
.	O

Moreover	O
,	O
a	O
negative	O
and	O
statistically	O
significant	O
correlation	O
between	O
Mn	CHEMICAL
concentrations	O
in	O
the	O
Ulva	O
thalli	O
and	O
the	O
river	O
water	O
was	O
observed	O
.	O

Additionally	O
,	O
numerous	O
correlations	O
were	O
noted	O
between	O
the	O
different	O
concentrations	O
of	O
metals	O
within	O
the	O
Ulva	O
thalli	O
,	O
in	O
the	O
water	O
and	O
in	O
the	O
sediment	O
.	O

The	O
great	O
concentrations	O
of	O
Mn	CHEMICAL
and	O
Zn	CHEMICAL
and	O
the	O
smallest	O
of	O
Co	CHEMICAL
were	O
found	O
in	O
thalli	O
of	O
Ulva	O
,	O
irrespective	O
of	O
the	O
type	O
of	O
the	O
ecosystem	O
from	O
which	O
samples	O
of	O
algal	O
thalli	O
originated	O
.	O

Freshwater	O
Ulva	O
populations	O
examined	O
in	O
this	O
study	O
were	O
clearly	O
characterized	O
a	O
dozen	O
or	O
so	O
times	O
by	O
the	O
higher	O
Mn	CHEMICAL
and	O
Cr	CHEMICAL
accumulation	O
than	O
taxa	O
from	O
that	O
genera	O
coming	O
from	O
sea	O
ecosystems	O
.	O

The	O
calculated	O
bioconcentration	O
factor	O
confirm	O
the	O
high	O
potential	O
for	O
freshwater	O
Ulva	O
to	O
be	O
a	O
bioaccumulator	O
of	O
trace	O
metals	O
in	O
freshwater	O
ecosystems	O
.	O
The	O
phosphoramidate	CHEMICAL
nerve	O
agent	O
tabun	CHEMICAL
inhibits	O
butyrylcholinesterase	GENE-Y
(	O
BChE	GENE-Y
)	O
and	O
acetylcholinesterase	GENE-Y
by	O
making	O
a	O
covalent	O
bond	O
on	O
the	O
active	O
site	O
serine	CHEMICAL
.	O

The	O
adduct	O
loses	O
an	O
alkyl	CHEMICAL
group	O
in	O
a	O
process	O
called	O
aging	O
.	O

The	O
mechanism	O
of	O
aging	O
of	O
the	O
tabun	CHEMICAL
adduct	O
is	O
controversial	O
.	O

Some	O
studies	O
claim	O
that	O
aging	O
proceeds	O
through	O
deamination	O
,	O
whereas	O
crystal	O
structure	O
studies	O
show	O
aging	O
by	O
O-dealkylation	O
.	O

Our	O
goal	O
was	O
to	O
develop	O
a	O
method	O
that	O
clearly	O
distinguishes	O
between	O
deamination	O
and	O
O-dealkylation	O
.	O

We	O
began	O
by	O
studying	O
the	O
tetraisopropyl	CHEMICAL
pyrophosphoramide	CHEMICAL
adduct	O
of	O
BChE	GENE-Y
because	O
this	O
adduct	O
has	O
two	O
P-N	CHEMICAL
bonds	O
.	O

Mass	O
spectra	O
showed	O
that	O
the	O
P-N	CHEMICAL
bonds	O
were	O
stable	O
during	O
trypsin	GENE-N
digestion	O
at	O
pH	O
8	O
but	O
were	O
cleaved	O
during	O
pepsin	GENE-N
digestion	O
at	O
pH	O
2	O
.	O

The	O
P-N	CHEMICAL
bond	O
in	O
tabun	CHEMICAL
was	O
also	O
acid	O
labile	O
,	O
whereas	O
the	O
P-O	CHEMICAL
bond	O
was	O
stable	O
.	O

A	O
scheme	O
to	O
distinguish	O
aging	O
by	O
deamination	O
from	O
aging	O
by	O
O-dealkylation	O
was	O
based	O
on	O
the	O
acid	O
labile	O
P-N	CHEMICAL
bond	O
.	O

BChE	GENE-Y
was	O
inhibited	O
with	O
Sp-	CHEMICAL
and	CHEMICAL
Rp-tabun	CHEMICAL
thiocholine	CHEMICAL
nerve	O
agent	O
model	O
compounds	O
to	O
make	O
adducts	O
identical	O
to	O
those	O
of	O
tabun	CHEMICAL
with	O
known	O
stereochemistry	O
.	O

After	O
aging	O
and	O
digestion	O
with	O
pepsin	GENE-N
at	O
pH	O
2	O
,	O
peptide	O
FGES198AGAAS	GENE-N
from	O
Sp-tabun	CHEMICAL
thiocholine	CHEMICAL
had	O
a	O
mass	O
of	O
902	O
.	O
2	O
m	O
/	O
z	O
in	O
negative	O
mode	O
,	O
indicating	O
that	O
it	O
had	O
aged	O
by	O
deamination	O
,	O
whereas	O
peptide	O
FGES198AGAAS	GENE-N
from	O
Rp-tabun	CHEMICAL
thiocholine	CHEMICAL
had	O
a	O
mass	O
of	O
874	O
.	O
2	O
m	O
/	O
z	O
in	O
negative	O
mode	O
,	O
indicating	O
that	O
it	O
had	O
aged	O
by	O
O-dealkylation	O
.	O

BChE	GENE-Y
inhibited	O
by	O
authentic	O
,	O
racemic	CHEMICAL
tabun	CHEMICAL
yielded	O
both	O
902	O
.	O
2	O
and	O
874	O
.	O
2	O
m	O
/	O
z	O
peptides	O
,	O
indicating	O
that	O
both	O
stereoisomers	O
reacted	O
with	O
BChE	GENE-Y
and	O
aged	O
either	O
by	O
deamination	O
or	O
dealkylation	O
.	O
Fluoxetine	CHEMICAL
,	O
as	O
a	O
serotonin	CHEMICAL
re-uptake	O
inhibitor	O
augments	O
serotonin	CHEMICAL
concentration	O
within	O
the	O
synapse	O
by	O
inhibiting	O
the	O
serotonin	CHEMICAL
transporter	O
.	O

The	O
contribution	O
of	O
amino	CHEMICAL
acids	CHEMICAL
has	O
also	O
been	O
shown	O
in	O
depression	O
.	O

We	O
hypothesized	O
that	O
fluoxetine	CHEMICAL
exerts	O
its	O
actions	O
at	O
least	O
in	O
part	O
by	O
intervening	O
brain	O
signaling	O
operated	O
by	O
amino	CHEMICAL
acid	CHEMICAL
transmitters	O
.	O

Therefore	O
the	O
aim	O
of	O
this	O
study	O
is	O
to	O
supply	O
neurochemical	O
evidence	O
that	O
fluoxetine	CHEMICAL
produces	O
changes	O
in	O
amino	CHEMICAL
acids	CHEMICAL
in	O
cerebrospinal	O
fluid	O
of	O
rats	O
.	O

Sprague-Dawley	O
rats	O
were	O
anesthetized	O
and	O
concentric	O
microdialysis	O
probes	O
were	O
implanted	O
stereotaxically	O
into	O
the	O
right	O
lateral	O
ventricle	O
.	O

Intraperitoneal	O
fluoxetine	CHEMICAL
(	O
2	O
.	O
5	O
or	O
5	O
mg	O
/	O
kg	O
)	O
or	O
physiological	O
saline	O
was	O
administered	O
and	O
the	O
probes	O
were	O
perfused	O
with	O
artificial	O
cerebrospinal	O
fluid	O
at	O
a	O
rate	O
of	O
1	O
mul	O
/	O
min	O
.	O

In	O
the	O
chronic	O
fluoxetine	CHEMICAL
group	O
,	O
the	O
rats	O
were	O
treated	O
daily	O
with	O
oral	O
fluoxetine	CHEMICAL
solution	O
or	O
inert	O
syrup	O
for	O
3	O
weeks	O
.	O

The	O
microdialysis	O
probes	O
were	O
placed	O
on	O
the	O
21st	O
day	O
and	O
perfused	O
the	O
next	O
day	O
.	O

Fluoxetine	CHEMICAL
was	O
ineffective	O
in	O
changing	O
the	O
cerebrospinal	O
fluid	O
GABA	CHEMICAL
levels	O
at	O
the	O
dose	O
of	O
2	O
.	O
5	O
mg	O
/	O
kg	O
but	O
produced	O
a	O
significant	O
increase	O
in	O
the	O
perfusates	O
following	O
injection	O
of	O
5	O
mg	O
/	O
kg	O
of	O
fluoxetine	CHEMICAL
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Oral	O
fluoxetine	CHEMICAL
administration	O
(	O
5	O
mg	O
/	O
kg	O
)	O
for	O
21	O
days	O
also	O
elevated	O
the	O
CSF	O
GABA	CHEMICAL
levels	O
by	O
approximately	O
2-fold	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

L	CHEMICAL
:	CHEMICAL
-glutamic	CHEMICAL
acid	CHEMICAL
levels	O
were	O
not	O
affected	O
in	O
all	O
groups	O
.	O

These	O
neurochemical	O
findings	O
show	O
that	O
fluoxetine	CHEMICAL
,	O
a	O
selective	O
serotonin	CHEMICAL
re-uptake	O
inhibitor	O
affects	O
brain	O
GABA	CHEMICAL
levels	O
indirectly	O
,	O
and	O
our	O
results	O
suggest	O
that	O
acute	O
or	O
chronic	O
effects	O
may	O
be	O
involved	O
in	O
beneficial	O
and	O
/	O
or	O
adverse	O
effects	O
of	O
the	O
drug	O
.	O
1	O
.	O

Eight	O
types	O
and	O
subtypes	O
of	O
the	O
mouse	GENE-N
prostanoid	CHEMICAL
receptor	O
,	O
the	O
prostaglandin	CHEMICAL
D	CHEMICAL
(	O
DP	CHEMICAL
)	O
receptor	O
,	O
the	O
prostaglandin	GENE-Y
F	GENE-Y
(	O
FP	CHEMICAL
)	O
receptor	O
,	O
the	O
prostaglandin	GENE-Y
I	GENE-Y
(	O
IP	CHEMICAL
)	O
receptor	O
,	O
the	O
thromboxane	GENE-Y
A	GENE-Y
(	O
TP	CHEMICAL
)	O
receptor	O
and	O
the	O
EP1	GENE-Y
,	O
EP2	GENE-Y
,	O
EP3	GENE-Y
and	O
EP4	GENE-Y
subtypes	O
of	O
the	O
prostaglandin	CHEMICAL
E	CHEMICAL
receptor	O
,	O
were	O
stably	O
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
.	O

Their	O
ligand	O
binding	O
characteristics	O
were	O
examined	O
with	O
thirty	O
two	O
prostanoids	CHEMICAL
and	O
their	O
analogues	O
by	O
determining	O
the	O
Ki	O
values	O
from	O
the	O
displacement	O
curves	O
of	O
radioligand	O
binding	O
to	O
the	O
respective	O
receptors	O
.	O

2	O
.	O

The	O
DP	CHEMICAL
,	O
IP	CHEMICAL
and	O
TP	CHEMICAL
receptors	O
showed	O
high	O
ligand	O
binding	O
specificity	O
and	O
only	O
bound	O
their	O
own	O
putative	O
ligands	O
with	O
high	O
affinity	O
such	O
as	O
PGD2	CHEMICAL
,	O
BW245C	CHEMICAL
and	O
BW868C	CHEMICAL
for	O
DP	CHEMICAL
,	O
cicaprost	CHEMICAL
,	O
iloprost	CHEMICAL
and	O
isocabacyclin	CHEMICAL
for	O
IP	CHEMICAL
,	O
and	O
S-145	CHEMICAL
,	O
I-BOP	CHEMICAL
and	O
GR	CHEMICAL
32191	CHEMICAL
for	O
TP	CHEMICAL
.	O

3	O
.	O

The	O
FP	CHEMICAL
receptor	O
bound	O
PGF2	CHEMICAL
alpha	O
and	O
fluprostenol	CHEMICAL
with	O
Ki	O
values	O
of	O
3-4	O
nM	O
.	O

In	O
addition	O
,	O
PGD2	CHEMICAL
,	O
17-phenyl-PGE2	CHEMICAL
,	O
STA2	CHEMICAL
,	O
I-BOP	CHEMICAL
,	O
PGE2	CHEMICAL
and	O
M&B-28767	CHEMICAL
bound	O
to	O
this	O
receptor	O
with	O
Ki	O
values	O
less	O
than	O
100	O
nM	O
.	O

4	O
.	O

The	O
EP1	GENE-Y
receptor	O
bound	O
17-phenyl-PGE2	CHEMICAL
,	O
sulprostone	CHEMICAL
and	O
iloprost	CHEMICAL
in	O
addition	O
to	O
PGE2	CHEMICAL
and	O
PGE1	CHEMICAL
,	O
with	O
Ki	O
values	O
of	O
14-36	O
nM	O
.	O

16	CHEMICAL
,	CHEMICAL
16-dimethyl-PGE2	CHEMICAL
and	O
two	O
putative	O
EP1	GENE-Y
antagonists	O
,	O
AH6809	CHEMICAL
and	O
SC-19220	CHEMICAL
,	O
did	O
not	O
show	O
any	O
significant	O
binding	O
to	O
this	O
receptor	O
.	O

M&B-28767	CHEMICAL
,	O
a	O
putative	O
EP3	GENE-Y
agonist	O
,	O
and	O
misoprostol	CHEMICAL
,	O
a	O
putative	O
EP2	GENE-Y
/	O
EP3	GENE-Y
agonist	O
,	O
also	O
bound	O
to	O
this	O
receptor	O
with	O
Ki	O
values	O
of	O
120	O
nM	O
.	O

5	O
.	O

The	O
EP2	GENE-Y
and	O
EP4	GENE-Y
receptors	O
showed	O
similar	O
binding	O
profiles	O
.	O

They	O
bound	O
16	CHEMICAL
,	CHEMICAL
16-dimethyl	CHEMICAL
PGE2	CHEMICAL
and	O
11-deoxy-PGE1	CHEMICAL
in	O
addition	O
to	O
PGE2	CHEMICAL
and	O
PGE1	CHEMICAL
.	O

The	O
two	O
receptors	O
were	O
discriminated	O
by	O
butaprost	CHEMICAL
,	O
AH-13205	CHEMICAL
and	O
AH-6809	CHEMICAL
that	O
bound	O
to	O
the	O
EP2	GENE-Y
receptor	O
but	O
not	O
to	O
the	O
EP4	GENE-Y
receptor	O
,	O
and	O
by	O
1-OH-PGE1	CHEMICAL
that	O
bound	O
to	O
the	O
EP4	GENE-Y
but	O
not	O
to	O
the	O
EP2	GENE-Y
receptor	O
.	O

6	O
.	O

The	O
EP3	GENE-Y
receptor	O
showed	O
the	O
broadest	O
binding	O
profile	O
,	O
and	O
bound	O
sulprostone	CHEMICAL
,	O
M&B-28767	CHEMICAL
,	O
GR63799X	CHEMICAL
,	O
11-deoxy-PGE1	CHEMICAL
,	O
16	CHEMICAL
,	CHEMICAL
16-dimethyl-PGE2	CHEMICAL
and	O
17-phenyl-PGE2	CHEMICAL
,	O
in	O
addition	O
to	O
PGE2	CHEMICAL
and	O
PGE1	CHEMICAL
,	O
with	O
Ki	O
values	O
of	O
0	O
.	O
6-3	O
.	O
7	O
nM	O
.	O

In	O
addition	O
,	O
three	O
IP	GENE-Y
ligands	O
,	O
iloprost	CHEMICAL
,	O
carbacyclin	CHEMICAL
and	O
isocarbacyclin	CHEMICAL
,	O
and	O
one	O
TP	GENE-Y
ligand	O
,	O
STA2	CHEMICAL
,	O
bound	O
to	O
this	O
receptor	O
with	O
Ki	O
values	O
comparable	O
to	O
the	O
Ki	O
values	O
of	O
these	O
compounds	O
for	O
the	O
IP	GENE-Y
and	O
TP	GENE-Y
receptors	O
,	O
respectively	O
.	O

7	CHEMICAL
.	CHEMICAL

8-Epi-PGF2	CHEMICAL
alpha	O
showed	O
only	O
weak	O
binding	O
to	O
the	O
IP	GENE-Y
,	O
TP	GENE-Y
,	O
FP	GENE-Y
,	O
EP2	GENE-Y
and	O
EP3	GENE-Y
receptor	O
at	O
10	O
microM	O
concentration	O
.	O
[	O
Phospholipase	GENE-N
D	GENE-N
in	O
mammalian	O
cells	O
:	O
structure	O
,	O
properties	O
,	O
physiological	O
and	O
pathological	O
role	O
]	O
.	O
Structural	O
optimization	O
of	O
2	CHEMICAL
,	CHEMICAL
5-thiophene	CHEMICAL
amides	CHEMICAL
as	O
highly	O
potent	O
and	O
selective	O
17β-hydroxysteroid	GENE-Y
dehydrogenase	O
type	O
2	O
inhibitors	O
for	O
the	O
treatment	O
of	O
osteoporosis	O
.	O
DRD2	GENE-N
promoter	GENE-N
region	O
variation	O
as	O
a	O
predictor	O
of	O
sustained	O
response	O
to	O
antipsychotic	O
medication	O
in	O
first-episode	O
schizophrenia	O
patients	O
.	O
Discriminative	O
stimulus	O
effects	O
of	O
esteratic	O
local	O
anesthetics	O
in	O
squirrel	O
monkeys	O
.	O
The	O
effects	O
of	O
catecholamines	CHEMICAL
on	O
ciliary	O
motility	O
of	O
canine	O
bronchial	O
epithelium	O
was	O
studied	O
by	O
a	O
photoelectric	O
method	O
in	O
vitro	O
.	O

Addition	O
of	O
beta-adrenoceptor	GENE-N
agonists	O
increased	O
ciliary	O
beat	O
frequency	O
,	O
a	O
rank	O
order	O
of	O
potency	O
being	O
salbutamol	CHEMICAL
>	O
or	O
=	O
BRL	CHEMICAL
37344	CHEMICAL
,	O
a	O
selective	O
beta	GENE-Y
3-adrenoceptor	GENE-Y
agonist	O
>	O
norepinephrine	CHEMICAL
.	O

The	O
response	O
to	O
BRL	CHEMICAL
37344	CHEMICAL
was	O
relatively	O
resistant	O
to	O
the	O
blockade	O
of	O
beta	GENE-N
1-	GENE-N
and	GENE-N
beta	GENE-N
2-adrenoceptors	GENE-N
but	O
was	O
competitively	O
antagonized	O
by	O
the	O
beta	GENE-Y
3-adrenoceptor	GENE-Y
antagonist	O
cyanopindolol	CHEMICAL
,	O
with	O
the	O
pA2	O
value	O
being	O
lower	O
than	O
that	O
when	O
salbutamol	CHEMICAL
was	O
used	O
as	O
an	O
agonist	O
.	O

These	O
results	O
suggest	O
that	O
beta	GENE-Y
3-adrenoceptors	GENE-Y
exist	O
in	O
canine	O
bronchial	O
epithelium	O
and	O
that	O
stimulation	O
of	O
this	O
receptor	O
subtype	O
may	O
enhance	O
ciliary	O
motility	O
and	O
,	O
hence	O
,	O
mucociliary	O
transport	O
in	O
the	O
airway	O
.	O
Losartan	CHEMICAL
:	O
a	O
selective	O
angiotensin	GENE-Y
II	GENE-Y
type	O
1	O
(	O
AT1	O
)	O
receptor	O
antagonist	O
for	O
the	O
treatment	O
of	O
heart	O
failure	O
.	O
A	O
consistent	O
effect	O
of	O
repeated	O
exposure	O
to	O
3	CHEMICAL
,	CHEMICAL
4	CHEMICAL
methylenedioxymethamphetamine	CHEMICAL
(	O
MDMA	CHEMICAL
)	O
is	O
a	O
decrease	O
in	O
the	O
tissue	O
levels	O
of	O
serotonin	CHEMICAL
(	O
5-HT	CHEMICAL
)	O
.	O

A	O
variety	O
of	O
behavioural	O
and	O
neurochemical	O
tests	O
were	O
conducted	O
to	O
determine	O
whether	O
the	O
tissue	O
deficits	O
were	O
accompanied	O
by	O
an	O
increased	O
sensitivity	O
of	O
the	O
5-HT1a	GENE-Y
autoreceptor	O
.	O

Tests	O
were	O
conducted	O
2	O
weeks	O
following	O
MDMA	CHEMICAL
exposure	O
(	O
four	O
injections	O
of	O
10	O
.	O
0	O
mg	O
/	O
kg	O
,	O
IP	O
,	O
administered	O
at	O
2-h	O
intervals	O
in	O
a	O
single	O
day	O
)	O
.	O

The	O
response	O
to	O
the	O
5-HT1a	GENE-Y
agonist	O
,	O
8-OHDPAT	CHEMICAL
(	O
0	O
.	O
003-0	O
.	O
5	O
mg	O
/	O
kg	O
,	O
SC	O
)	O
,	O
was	O
assessed	O
using	O
lower	O
lip	O
retraction	O
(	O
LLR	O
)	O
,	O
hypoactivity	O
,	O
and	O
5-hydroxytryptophan	CHEMICAL
(	O
5-HTP	CHEMICAL
)	O
accumulation	O
following	O
decarboxylase	GENE-N
inhibition	O
.	O

The	O
8-OHDPAT	CHEMICAL
produced	O
a	O
dose-dependent	O
increase	O
in	O
LLR	O
and	O
hypoactivity	O
,	O
but	O
these	O
effects	O
were	O
comparable	O
for	O
MDMA	CHEMICAL
and	O
saline	O
pretreated	O
groups	O
.	O

MDMA	CHEMICAL
decreased	O
tissue	O
levels	O
of	O
5-HT	CHEMICAL
and	O
the	O
accumulation	O
of	O
5-HTP	CHEMICAL
,	O
but	O
these	O
effects	O
were	O
not	O
reflected	O
in	O
the	O
changes	O
in	O
autoreceptor	O
sensitivity	O
.	O

The	O
data	O
suggest	O
that	O
the	O
decrease	O
in	O
tissue	O
levels	O
of	O
5-HT	CHEMICAL
produced	O
by	O
MDMA	CHEMICAL
is	O
accompanied	O
by	O
a	O
decrease	O
in	O
tryptophan	CHEMICAL
hydroxylase	O
activity	O
but	O
cannot	O
be	O
explained	O
by	O
supersensitivity	O
of	O
the	O
5-HT1a	GENE-Y
autoreceptor	O
.	O
BACKGROUND	O
:	O
Clinical	O
trial	O
data	O
have	O
shown	O
that	O
among	O
breast	O
cancer	O
patients	O
who	O
were	O
disease	O
free	O
after	O
5	O
years	O
of	O
adjuvant	O
treatment	O
with	O
tamoxifen	CHEMICAL
,	O
further	O
extended	O
treatment	O
with	O
the	O
nonsteroidal	O
aromatase	GENE-Y
inhibitor	O
letrozole	CHEMICAL
reduces	O
breast	O
cancer	O
recurrence	O
.	O

We	O
examined	O
the	O
efficacy	O
and	O
tolerability	O
of	O
extended	O
adjuvant	O
therapy	O
with	O
another	O
aromatase	GENE-Y
inhibitor	O
,	O
anastrozole	CHEMICAL
,	O
for	O
3	O
years	O
among	O
women	O
who	O
had	O
completed	O
5	O
years	O
of	O
adjuvant	O
therapy	O
.	O

METHODS	O
:	O
Austrian	O
Breast	O
and	O
Colorectal	O
Cancer	O
Study	O
Group	O
(	O
ABCSG	O
)	O
Trial	O
6a	O
is	O
an	O
extension	O
of	O
ABCSG	O
Trial	O
6	O
,	O
in	O
which	O
hormone	GENE-N
receptor-positive	O
postmenopausal	O
patients	O
received	O
5	O
years	O
of	O
adjuvant	O
tamoxifen	CHEMICAL
,	O
with	O
or	O
without	O
the	O
aromatase	GENE-Y
inhibitor	O
aminoglutethimide	CHEMICAL
,	O
for	O
the	O
first	O
2	O
years	O
of	O
therapy	O
.	O

For	O
ABCSG	O
Trial	O
6a	O
,	O
patients	O
who	O
were	O
disease	O
free	O
at	O
the	O
end	O
of	O
Trial	O
6	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
3	O
years	O
of	O
anastrozole	CHEMICAL
or	O
no	O
further	O
treatment	O
.	O

Efficacy	O
data	O
were	O
analyzed	O
with	O
the	O
use	O
of	O
a	O
Cox	O
proportional	O
hazards	O
regression	O
model	O
with	O
two-sided	O
P	O
values	O
and	O
Kaplan-Meier	O
curves	O
,	O
and	O
tolerability	O
data	O
were	O
estimated	O
using	O
logistic	O
regression	O
analysis	O
with	O
odds	O
ratios	O
and	O
95%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
.	O

RESULTS	O
:	O
ABCSG	O
Trial	O
6a	O
included	O
856	O
patients	O
.	O

At	O
a	O
median	O
follow-up	O
of	O
62	O
.	O
3	O
months	O
,	O
women	O
who	O
received	O
anastrozole	CHEMICAL
(	O
n	O
=	O
387	O
)	O
had	O
a	O
statistically	O
significantly	O
reduced	O
risk	O
of	O
recurrence	O
(	O
locoregional	O
recurrence	O
,	O
contralateral	O
breast	O
cancer	O
,	O
or	O
distant	O
metastasis	O
)	O
compared	O
with	O
women	O
who	O
received	O
no	O
further	O
treatment	O
(	O
n	O
=	O
469;	O
hazard	O
ratio	O
=	O
0	O
.	O
62;	O
95%	O
CI	O
=	O
0	O
.	O
40	O
to	O
0	O
.	O
96	O
,	O
P	O
=	O
.	O
031	O
)	O
.	O

Anastrozole	CHEMICAL
was	O
well	O
tolerated	O
,	O
and	O
no	O
unexpected	O
adverse	O
events	O
were	O
reported	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
confirm	O
the	O
benefit	O
of	O
extending	O
adjuvant	O
tamoxifen	CHEMICAL
therapy	O
beyond	O
5	O
years	O
with	O
anastrozole	CHEMICAL
compared	O
with	O
no	O
further	O
treatment	O
.	O

Further	O
research	O
is	O
required	O
to	O
define	O
the	O
optimum	O
length	O
of	O
extended	O
adjuvant	O
therapy	O
and	O
to	O
investigate	O
the	O
possibility	O
of	O
tailoring	O
this	O
period	O
to	O
suit	O
different	O
disease	O
types	O
.	O
Catalpol	CHEMICAL
inhibits	O
LPS	O
plus	O
IFN-γ-induced	O
inflammatory	O
response	O
in	O
astrocytes	O
primary	O
cultures	O
.	O
OBJECTIVEIn	O
adults	O
,	O
1-h	O
glucose	CHEMICAL
during	O
an	O
oral	O
glucose	CHEMICAL
tolerance	O
test	O
(	O
OGTT	O
)	O
predicts	O
the	O
development	O
of	O
type	O
2	O
diabetes	O
independent	O
of	O
fasting	O
and	O
2-h	O
glucose	CHEMICAL
concentrations	O
.	O

The	O
purpose	O
of	O
the	O
current	O
investigation	O
was	O
to	O
examine	O
the	O
utility	O
of	O
elevated	O
1-h	O
glucose	CHEMICAL
levels	O
to	O
prospectively	O
predict	O
deterioration	O
in	O
β-cell	O
function	O
and	O
the	O
development	O
of	O
prediabetes	O
in	O
high-risk	O
youth	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODSObese	O
Latino	O
youth	O
with	O
a	O
family	O
history	O
of	O
type	O
2	O
diabetes	O
(	O
133	O
male	O
and	O
100	O
female;	O
age	O
11	O
.	O
1	O
±	O
1	O
.	O
7	O
years	O
)	O
completed	O
a	O
baseline	O
OGTT	O
and	O
were	O
divided	O
into	O
two	O
groups	O
based	O
upon	O
a	O
1-h	O
glucose	CHEMICAL
threshold	O
of	O
155	O
mg	O
/	O
dL	O
(	O
<155	O
mg	O
/	O
dL	O
,	O
n	O
=	O
151	O
,	O
or	O
≥155	O
mg	O
/	O
dL	O
,	O
n	O
=	O
82	O
)	O
.	O

Youth	O
were	O
followed	O
annually	O
for	O
up	O
to	O
8	O
years	O
for	O
assessment	O
of	O
glucose	CHEMICAL
tolerance	O
,	O
body	O
composition	O
by	O
dual-energy	O
X-ray	O
absorptiometry	O
,	O
and	O
insulin	GENE-Y
sensitivity	O
,	O
insulin	GENE-Y
secretion	O
,	O
and	O
the	O
disposition	O
index	O
by	O
the	O
frequently	O
sampled	O
intravenous	O
glucose	CHEMICAL
tolerance	O
test	O
.	O

RESULTSOver	O
time	O
,	O
the	O
≥155	O
mg	O
/	O
dL	O
group	O
exhibited	O
a	O
significantly	O
greater	O
decline	O
in	O
β-cell	O
function	O
compared	O
with	O
youth	O
with	O
a	O
1-h	O
glucose	CHEMICAL
<155	O
mg	O
/	O
dL	O
(	O
β	O
=	O
-327	O
.	O
8	O
±	O
126	O
.	O
2	O
,	O
P	O
=	O
0	O
.	O
01	O
)	O
.	O

Moreover	O
,	O
this	O
decline	O
was	O
independent	O
of	O
fasting	O
or	O
2-h	O
glucose	CHEMICAL
and	O
body	O
composition	O
.	O

When	O
the	O
data	O
were	O
restricted	O
to	O
only	O
participants	O
with	O
normal	O
glucose	CHEMICAL
tolerance	O
at	O
baseline	O
,	O
a	O
1-h	O
glucose	CHEMICAL
≥155	O
mg	O
/	O
dL	O
was	O
independently	O
associated	O
with	O
a	O
2	O
.	O
5	O
times	O
greater	O
likelihood	O
of	O
developing	O
prediabetes	O
during	O
follow-up	O
(	O
95%	O
CI	O
1	O
.	O
6-4	O
.	O
1	O
,	O
P	O
=	O
0	O
.	O
0001	O
)	O
.	O

CONCLUSIONSThese	O
data	O
suggest	O
that	O
a	O
1-h	O
glucose	CHEMICAL
≥155	O
mg	O
/	O
dL	O
during	O
an	O
OGTT	O
is	O
an	O
independent	O
predictor	O
of	O
β-cell	O
deterioration	O
and	O
progression	O
to	O
prediabetes	O
among	O
obese	O
Latino	O
youth	O
.	O
The	O
effect	O
of	O
a	O
21-day	O
treatment	O
with	O
the	O
dual	O
5-HT	CHEMICAL
and	O
NE	CHEMICAL
reuptake	O
blocker	O
venlafaxine	CHEMICAL
(	O
delivered	O
s	O
.	O

c	O
.	O

by	O
osmotic	O
minipumps	O
)	O
was	O
assessed	O
on	O
the	O
time	O
required	O
for	O
a	O
50%	O
recovery	O
(	O
RT	O
(	O
50	O
)	O
)	O
of	O
the	O
firing	O
activity	O
of	O
dorsal	O
hippocampus	O
CA	O
(	O
3	O
)	O
pyramidal	O
neurons	O
from	O
the	O
suppression	O
induced	O
by	O
microiontophoretic	O
applications	O
of	O
5-HT	CHEMICAL
and	O
NE	CHEMICAL
.	O

The	O
RT	O
(	O
50	O
)	O
values	O
for	O
5-HT	CHEMICAL
were	O
increased	O
by	O
both	O
10	O
and	O
40	O
mg	O
/	O
kg	O
/	O
day	O
regimens	O
of	O
venlafaxine	CHEMICAL
,	O
whereas	O
those	O
for	O
NE	CHEMICAL
were	O
increased	O
only	O
by	O
the	O
40	O
mg	O
/	O
kg	O
/	O
day	O
regimen	O
,	O
indicative	O
of	O
a	O
greater	O
potency	O
of	O
venlafaxine	CHEMICAL
in	O
blocking	O
5-HT	CHEMICAL
reuptake	O
.	O

The	O
sensitivity	O
of	O
the	O
postsynaptic	O
5-HT	GENE-Y
(	GENE-Y
1A	GENE-Y
)	GENE-Y
and	O
alpha	GENE-N
(	GENE-N
2	GENE-N
)	GENE-N
-adrenergic	GENE-N
receptors	GENE-N
was	O
altered	O
by	O
neither	O
regimen	O
of	O
venlafaxine	CHEMICAL
.	O

Using	O
a	O
paradigm	O
by	O
which	O
the	O
5-HT	GENE-Y
(	GENE-Y
1A	GENE-Y
)	GENE-Y
antagonist	O
WAY	CHEMICAL
100635	CHEMICAL
can	O
induce	O
a	O
disinhibition	O
of	O
firing	O
activity	O
of	O
CA	O
(	O
3	O
)	O
pyramidal	O
neurons	O
,	O
it	O
was	O
demonstrated	O
that	O
the	O
high	O
,	O
but	O
not	O
the	O
low	O
,	O
dose	O
of	O
venlafaxine	CHEMICAL
led	O
to	O
an	O
enhanced	O
tonic	O
activation	O
of	O
postsynaptic	O
5-HT	GENE-Y
(	GENE-Y
1A	GENE-Y
)	GENE-Y
receptors	O
in	O
the	O
dorsal	O
hippocampus	O
.	O

The	O
duration	O
of	O
the	O
suppressant	O
effect	O
of	O
the	O
firing	O
activity	O
of	O
CA	O
(	O
3	O
)	O
hippocampus	O
pyramidal	O
neurons	O
produced	O
by	O
the	O
electrical	O
stimulation	O
of	O
the	O
ascending	O
5-HT	CHEMICAL
pathway	O
was	O
significantly	O
reduced	O
when	O
the	O
frequency	O
of	O
the	O
stimulation	O
was	O
enhanced	O
from	O
1	O
Hz	O
to	O
5	O
Hz	O
in	O
control	O
rats	O
and	O
in	O
rats	O
treated	O
with	O
10	O
mg	O
/	O
kg	O
/	O
day	O
,	O
but	O
not	O
with	O
40	O
mg	O
/	O
kg	O
/	O
day	O
of	O
venlafaxine	CHEMICAL
.	O

Hence	O
,	O
venlafaxine	CHEMICAL
induced	O
a	O
desensitization	O
of	O
the	O
terminal	O
5-HT	GENE-Y
(	GENE-Y
1B	GENE-Y
)	GENE-Y
autoreceptor	O
only	O
at	O
the	O
high	O
dose	O
.	O

A	O
2-day	O
treatment	O
with	O
10	O
mg	O
/	O
kg	O
/	O
day	O
of	O
venlafaxine	CHEMICAL
induced	O
a	O
suppression	O
of	O
the	O
firing	O
activity	O
of	O
5-HT	CHEMICAL
neurons	O
of	O
the	O
dorsal	O
raphe	O
.	O

The	O
firing	O
activity	O
of	O
these	O
neurons	O
was	O
back	O
to	O
control	O
level	O
in	O
rats	O
that	O
had	O
been	O
treated	O
for	O
21	O
days	O
with	O
the	O
same	O
dose	O
of	O
venlafaxine	CHEMICAL
.	O

The	O
suppressant	O
effect	O
of	O
the	O
i	O
.	O

v	O
.	O

administration	O
of	O
the	O
5-HT	CHEMICAL
autoreceptor	O
agonist	O
LSD	O
on	O
the	O
firing	O
activity	O
of	O
dorsal	O
raphe	O
5-HT	CHEMICAL
neurons	O
was	O
reduced	O
in	O
rats	O
that	O
had	O
been	O
treated	O
for	O
21	O
days	O
with	O
10	O
mg	O
/	O
kg	O
/	O
day	O
of	O
venlafaxine	CHEMICAL
.	O

A	O
2-day	O
treatment	O
with	O
40	O
mg	O
/	O
kg	O
/	O
day	O
of	O
venlafaxine	CHEMICAL
,	O
unlike	O
the	O
10	O
mg	O
/	O
kg	O
/	O
day	O
regimen	O
,	O
induced	O
a	O
marked	O
suppression	O
of	O
the	O
firing	O
activity	O
of	O
locus	O
coeruleus	O
NE	CHEMICAL
neurons	O
.	O

However	O
,	O
in	O
contrast	O
to	O
5-HT	CHEMICAL
neurons	O
,	O
NE	CHEMICAL
neurons	O
did	O
not	O
recover	O
their	O
firing	O
activity	O
after	O
a	O
21-day	O
treatment	O
.	O

Taken	O
together	O
,	O
the	O
results	O
from	O
this	O
study	O
indicate	O
that	O
the	O
low	O
dose	O
of	O
venlafaxine	CHEMICAL
blocked	O
selectively	O
the	O
reuptake	O
of	O
5-HT	CHEMICAL
,	O
whereas	O
the	O
high	O
dose	O
blocked	O
the	O
reuptake	O
of	O
both	O
5-HT	CHEMICAL
and	O
NE	CHEMICAL
.	O

Moreover	O
,	O
an	O
enhancement	O
of	O
serotonergic	O
neurotransmission	O
by	O
venlafaxine	CHEMICAL
was	O
only	O
achieved	O
under	O
conditions	O
whereby	O
the	O
desensitization	O
of	O
the	O
terminal	O
5-HT	GENE-Y
(	GENE-Y
1B	GENE-Y
)	GENE-Y
autoreceptor	O
is	O
appended	O
to	O
that	O
of	O
the	O
somatodendritic	O
5-HT	GENE-Y
(	GENE-Y
1A	GENE-Y
)	GENE-Y
receptor	O
.	O
Plant	GENE-N
homeodomain	GENE-N
(	GENE-N
PHD	GENE-N
)	GENE-N
-type	GENE-N
zinc	CHEMICAL
fingers	O
play	O
an	O
important	O
role	O
in	O
recognizing	O
chromatin	O
modifications	O
and	O
recruiting	O
regulatory	O
proteins	O
to	O
specific	O
genes	O
.	O

A	O
specific	O
module	O
containing	O
a	O
conventional	O
PHD	GENE-N
finger	GENE-N
followed	O
by	O
an	O
extended	O
PHD	GENE-N
finger	GENE-N
exists	O
in	O
the	O
mammalian	O
AF10	GENE-N
protein	O
,	O
among	O
a	O
few	O
others	O
.	O

AF10	GENE-Y
has	O
mostly	O
been	O
studied	O
in	O
the	O
context	O
of	O
the	O
leukemic	O
MLL-AF10	GENE-Y
fusion	O
protein	O
,	O
which	O
lacks	O
the	O
N-terminal	O
PHD	O
fingers	O
of	O
AF10	GENE-Y
.	O

Although	O
this	O
domain	O
of	O
AF10	GENE-Y
is	O
the	O
most	O
conserved	O
region	O
of	O
the	O
protein	O
,	O
its	O
biological	O
significance	O
has	O
not	O
been	O
elucidated	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
genetic	O
and	O
biochemical	O
approaches	O
to	O
examine	O
the	O
PHD1-PHD2	GENE-N
region	O
of	O
the	O
Caenorhabditis	O
elegans	O
ortholog	O
of	O
AF10	GENE-Y
,	O
zinc	CHEMICAL
finger	O
protein	O
1	O
(	O
ZFP-1	GENE-Y
)	O
.	O

We	O
demonstrate	O
that	O
the	O
PHD1-PHD2	GENE-N
region	O
is	O
essential	O
for	O
viability	O
and	O
that	O
the	O
first	O
PHD	GENE-N
finger	GENE-N
contributes	O
to	O
the	O
preferred	O
binding	O
of	O
PHD1-PHD2	GENE-N
to	O
lysine	CHEMICAL
4-methylated	O
histone	O
H3	O
tails	O
.	O

Moreover	O
,	O
we	O
show	O
that	O
ZFP-1	GENE-Y
localization	O
peaks	O
overlap	O
with	O
H3K4	O
methylation-enriched	O
promoters	O
of	O
actively	O
expressed	O
genes	O
genomewide	O
and	O
that	O
H3K4	O
methylation	O
is	O
important	O
for	O
ZFP-1	GENE-Y
localization	O
to	O
promoters	O
in	O
the	O
embryo	O
.	O

We	O
predict	O
that	O
the	O
essential	O
biological	O
role	O
of	O
the	O
PHD1-PHD2	GENE-N
module	O
of	O
ZFP-1	GENE-Y
/	O
AF10	GENE-Y
is	O
connected	O
to	O
the	O
regulation	O
of	O
actively	O
expressed	O
genes	O
during	O
early	O
development	O
.	O
HR-MAS	O
NMR	O
Spectroscopy	O
of	O
Reconstructed	O
Human	O
Epidermis	O
:	O
Potential	O
for	O
the	O
in	O
Situ	O
Investigation	O
of	O
the	O
Chemical	O
Interactions	O
between	O
Skin	O
Allergens	O
and	O
Nucleophilic	O
Amino	CHEMICAL
Acids	CHEMICAL
.	O
Synthesis	O
of	O
C17-OH-north	O
unit	O
of	O
ritterazine	CHEMICAL
G	CHEMICAL
via	O
"Red-Ox"	O
modifications	O
of	O
hecogenin	CHEMICAL
acetate	CHEMICAL
.	O
In	O
this	O
study	O
,	O
the	O
in	O
vivo	O
effects	O
of	O
a	O
purified	O
saponin	CHEMICAL
mixture	O
(	O
PSM	O
)	O
,	O
obtained	O
from	O
Astragalus	O
corniculatus	O
Bieb	O
.	O

,	O
were	O
investigated	O
using	O
two	O
in	O
vivo	O
hepatotoxicity	O
models	O
based	O
on	O
liver	O
damage	O
caused	O
by	O
paracetamol	CHEMICAL
(	O
PC	O
)	O
and	O
carbon	CHEMICAL
tetrachloride	CHEMICAL
(	O
CCl4	CHEMICAL
)	O
.	O

The	O
effects	O
of	O
PSM	O
were	O
compared	O
with	O
silymarin	CHEMICAL
.	O

Male	O
Wistar	O
rats	O
were	O
challenged	O
orally	O
with	O
20%	O
CCl4	CHEMICAL
or	O
PC	O
(	O
2	O
g	O
/	O
kg	O
)	O
four	O
days	O
after	O
being	O
pre-treated	O
with	O
PSM	O
(	O
100	O
mg	O
/	O
kg	O
)	O
or	O
silymarin	CHEMICAL
(	O
200	O
mg	O
/	O
kg	O
)	O
.	O

A	O
significant	O
decrease	O
of	O
aspartate	GENE-Y
aminotransferase	O
,	O
alanine	GENE-N
aminotransferase	O
,	O
lactate	GENE-N
dehydrogenase	O
(	O
LDH	GENE-N
)	O
activities	O
and	O
glutathione	CHEMICAL
(	O
GSH	CHEMICAL
)	O
levels	O
and	O
an	O
increase	O
of	O
malondialdehyde	CHEMICAL
(	O
MDA	CHEMICAL
)	O
quantity	O
was	O
observed	O
after	O
CCl4	CHEMICAL
and	O
PC	O
administration	O
alone	O
.	O

PSM	O
pre-treatment	O
decreased	O
serum	GENE-N
transaminases	GENE-N
and	O
LDH	GENE-N
activities	O
and	O
MDA	CHEMICAL
levels	O
and	O
increased	O
the	O
levels	O
of	O
cell	O
protector	O
GSH	CHEMICAL
.	O

Biotransformation	O
phase	O
I	O
enzymes	O
were	O
also	O
assessed	O
in	O
both	O
models	O
.	O

In	O
the	O
CCl4	CHEMICAL
hepatotoxicity	O
model	O
,	O
pre-treatment	O
with	O
PSM	O
or	O
silymarin	CHEMICAL
resulted	O
in	O
significantly	O
increased	O
activities	O
of	O
ethylmorphine-N-demethylase	O
and	O
aniline	GENE-N
4-hydroxylase	O
activity	O
and	O
cytochrome	GENE-N
P450	GENE-N
,	O
compared	O
to	O
the	O
CCl4	CHEMICAL
only	O
group	O
.	O

Neither	O
silymarin	CHEMICAL
nor	O
PSM	O
influenced	O
PC	O
biotransformation	O
.	O

Our	O
results	O
suggest	O
that	O
PSM	O
,	O
obtained	O
from	O
A	O
.	O

corniculatus	O
,	O
Bieb	O
.	O

showed	O
in	O
vivo	O
hepatoprotective	O
and	O
antioxidant	O
activities	O
against	O
CCl4	CHEMICAL
and	O
PC-induced	O
liver	O
damage	O
comparable	O
to	O
that	O
of	O
silymarin	CHEMICAL
.	O

Copyright	O
©	O
2012	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O
The	O
mechanism	O
(	O
s	O
)	O
responsible	O
for	O
arterial	O
vasodilation	O
observed	O
following	O
acute	O
administration	O
of	O
racemic	CHEMICAL
carvedilol	CHEMICAL
,	O
a	O
novel	O
vasodilator	O
/	O
beta	GENE-N
adrenoceptor	GENE-N
antagonist	O
,	O
has	O
been	O
investigated	O
in	O
rats	O
.	O

In	O
conscious	O
spontaneously	O
hypertensive	O
rats	O
,	O
carvedilol	CHEMICAL
(	O
0	O
.	O
03-3	O
.	O
0	O
mg	O
/	O
kg	O
,	O
iv	O
)	O
produced	O
a	O
dose-dependent	O
reduction	O
in	O
blood	O
pressure	O
with	O
no	O
significant	O
effect	O
on	O
heart	O
rate	O
.	O

Because	O
cardiac	O
output	O
was	O
relatively	O
unaffected	O
,	O
the	O
antihypertensive	O
response	O
of	O
carvedilol	CHEMICAL
was	O
associated	O
with	O
a	O
dose-dependent	O
reduction	O
in	O
total	O
peripheral	O
vascular	O
resistance	O
.	O

Submaximal	O
antihypertensive	O
doses	O
of	O
carvedilol	CHEMICAL
were	O
chosen	O
for	O
mechanism	O
of	O
action	O
studies	O
in	O
pithed	O
rats	O
.	O

Carvedilol	CHEMICAL
(	O
0	O
.	O
3	O
mg	O
/	O
kg	O
,	O
iv	O
)	O
produced	O
a	O
significant	O
inhibition	O
of	O
the	O
beta	GENE-Y
1	GENE-Y
adrenoceptor	GENE-Y
mediated	O
positive	O
chronotropic	O
response	O
to	O
isoproterenol	CHEMICAL
.	O

This	O
same	O
dose	O
of	O
carvedilol	CHEMICAL
also	O
inhibited	O
,	O
but	O
to	O
a	O
lesser	O
degree	O
,	O
the	O
beta	GENE-Y
2	GENE-Y
adrenoceptor	GENE-Y
mediated	O
vasodepressor	O
response	O
to	O
salbutamol	CHEMICAL
in	O
pithed	O
rats	O
whose	O
blood	O
pressure	O
was	O
elevated	O
by	O
a	O
constant	O
intravenous	O
infusion	O
of	O
angiotensin	GENE-Y
II	GENE-Y
.	O

Thus	O
,	O
carvedilol	CHEMICAL
blocks	O
both	O
beta	GENE-N
1	GENE-N
and	GENE-N
beta	GENE-N
2	GENE-N
adrenoceptors	GENE-N
at	O
antihypertensive	O
doses	O
,	O
with	O
modest	O
selectivity	O
being	O
observed	O
for	O
the	O
beta	GENE-Y
1	GENE-Y
adrenoceptor	GENE-Y
subtype	O
.	O

Carvedilol	CHEMICAL
produced	O
significant	O
inhibition	O
of	O
the	O
alpha	GENE-N
1	GENE-N
adrenoceptor	GENE-N
mediated	O
pressor	O
response	O
to	O
cirazoline	CHEMICAL
in	O
the	O
pithed	O
rat	O
,	O
but	O
had	O
no	O
effect	O
on	O
the	O
alpha	GENE-Y
2	GENE-Y
adrenoceptor	GENE-Y
mediated	O
pressor	O
response	O
to	O
B-HT	CHEMICAL
933	CHEMICAL
,	O
suggesting	O
that	O
carvedilol	CHEMICAL
is	O
also	O
an	O
alpha	GENE-N
1	GENE-N
adrenoceptor	GENE-N
antagonist	O
at	O
antihypertensive	O
doses	O
.	O

Carvedilol	CHEMICAL
had	O
no	O
effect	O
on	O
the	O
pressor	O
response	O
elicited	O
by	O
angiotensin	GENE-Y
II	GENE-Y
,	O
indicating	O
a	O
lack	O
of	O
nonspecific	O
vasodilator	O
activity	O
.	O

The	O
vasopressor	O
response	O
to	O
the	O
calcium	CHEMICAL
channel	O
activator	O
,	O
BAY-K-8644	CHEMICAL
,	O
which	O
is	O
mediated	O
through	O
the	O
opening	O
of	O
voltage	GENE-N
dependent	GENE-N
calcium	CHEMICAL
channels	O
and	O
the	O
subsequent	O
translocation	O
of	O
extracellular	O
calcium	CHEMICAL
,	O
was	O
significantly	O
inhibited	O
by	O
carvedilol	CHEMICAL
(	O
1	O
mg	O
/	O
kg	O
,	O
iv	O
)	O
,	O
suggesting	O
that	O
carvedilol	CHEMICAL
is	O
also	O
a	O
calcium	GENE-N
channel	O
antagonist	O
,	O
consistent	O
with	O
our	O
previous	O
in	O
vitro	O
studies	O
.	O

In	O
anesthetized	O
spontaneously	O
hypertensive	O
rats	O
,	O
the	O
antihypertensive	O
activity	O
of	O
carvedilol	CHEMICAL
was	O
nearly	O
abolished	O
by	O
combined	O
pretreatment	O
of	O
the	O
rats	O
with	O
high	O
doses	O
of	O
the	O
alpha	GENE-N
1	GENE-N
adrenoceptor	GENE-N
antagonist	O
,	O
prazosin	CHEMICAL
(	O
1	O
mg	O
/	O
kg	O
,	O
iv	O
)	O
,	O
and	O
the	O
nonselective	O
beta	GENE-N
adrenoceptor	GENE-N
antagonist	O
,	O
propranolol	CHEMICAL
(	O
3	O
mg	O
/	O
kg	O
,	O
iv	O
)	O
,	O
suggesting	O
that	O
the	O
majority	O
of	O
the	O
antihypertensive	O
response	O
produced	O
by	O
carvedilol	CHEMICAL
may	O
be	O
accounted	O
for	O
by	O
blockade	O
of	O
beta	GENE-N
and	GENE-N
alpha	GENE-N
1	GENE-N
adrenoceptors	GENE-N
.	O

We	O
therefore	O
conclude	O
that	O
carvedilol	CHEMICAL
,	O
at	O
antihypertensive	O
doses	O
,	O
is	O
an	O
antagonist	O
of	O
beta	GENE-N
1	GENE-N
,	GENE-N
beta	GENE-N
2	GENE-N
,	GENE-N
and	GENE-N
alpha	GENE-N
1	GENE-N
adrenoceptors	GENE-N
,	O
and	O
also	O
of	O
calcium	GENE-N
channels	O
in	O
vascular	O
smooth	O
muscle	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O
Drug-protein	O
interactions	O
:	O
isolation	O
and	O
characterization	O
of	O
covalent	O
adducts	O
of	O
phenoxybenzamine	CHEMICAL
and	O
calmodulin	GENE-Y
.	O
Lipoxin	CHEMICAL
A4	CHEMICAL
(	O
LXA4	CHEMICAL
)	O
has	O
been	O
described	O
as	O
an	O
anti-inflammatory	O
mediator	O
,	O
which	O
exerts	O
its	O
effects	O
through	O
the	O
formyl	GENE-N
peptide	GENE-N
receptor	GENE-N
FPR2	GENE-Y
,	O
also	O
known	O
as	O
ALX	GENE-Y
.	O

However	O
,	O
there	O
has	O
been	O
a	O
controversy	O
whether	O
or	O
not	O
cells	O
expressing	O
FPR2	GENE-Y
/	O
ALX	GENE-Y
,	O
such	O
as	O
neutrophils	O
,	O
respond	O
to	O
LXA4	CHEMICAL
.	O

We	O
,	O
therefore	O
,	O
systematically	O
examined	O
the	O
ability	O
of	O
the	O
human	O
and	O
murine	O
forms	O
of	O
the	O
receptor	O
to	O
respond	O
to	O
LXA4	CHEMICAL
.	O

We	O
show	O
that	O
both	O
receptor	O
orthologues	O
responded	O
to	O
the	O
FPR2	GENE-Y
/	O
ALX	GENE-Y
peptide	O
agonist	O
WKYMVM	GENE-N
when	O
expressed	O
heterologously	O
.	O

In	O
contrast	O
,	O
LXA4	CHEMICAL
from	O
different	O
sources	O
neither	O
increased	O
[	O
Ca	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
]	O
i	O
and	O
extracellular-signal-regulated	GENE-N
kinase	GENE-N
(	O
ERK	GENE-N
)	O
phosphorylation	O
,	O
nor	O
did	O
it	O
induce	O
a	O
decrease	O
in	O
cAMP	CHEMICAL
levels	O
or	O
a	O
translocation	O
of	O
β-arrestin	GENE-N
.	O

Also	O
,	O
several	O
LXA4	CHEMICAL
analogues	O
were	O
found	O
to	O
be	O
unable	O
to	O
signal	O
through	O
FPR2	GENE-Y
/	O
ALX	GENE-Y
.	O

We	O
conclude	O
that	O
FPR2	GENE-Y
/	O
ALX	GENE-Y
is	O
not	O
activated	O
by	O
LXA4	CHEMICAL
and	O
that	O
the	O
molecular	O
mechanism	O
by	O
which	O
LXA4	CHEMICAL
functions	O
still	O
needs	O
to	O
be	O
identified	O
.	O
Non-steroidal	CHEMICAL
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
are	O
competitive	O
inhibitors	O
of	O
cyclooxygenase	GENE-N
(	O
COX	GENE-N
)	O
,	O
the	O
enzyme	O
that	O
mediates	O
biosynthesis	O
of	O
prostaglandins	CHEMICAL
and	O
thromboxanes	CHEMICAL
from	O
arachidonic	CHEMICAL
acid	CHEMICAL
.	O

There	O
are	O
at	O
least	O
two	O
different	O
isoforms	O
of	O
the	O
enzyme	O
known	O
as	O
COX-1	GENE-N
and	GENE-N
-2	GENE-N
.	O

Site	O
directed	O
mutagenesis	O
studies	O
suggest	O
that	O
non-selective	O
COX	GENE-N
inhibitors	O
of	O
diverse	O
chemical	O
families	O
exhibit	O
differential	O
binding	O
modes	O
to	O
the	O
two	O
isozymes	O
.	O

These	O
results	O
cannot	O
clearly	O
be	O
explained	O
from	O
the	O
sole	O
analysis	O
of	O
the	O
crystal	O
structures	O
of	O
COX	GENE-N
available	O
from	O
X-ray	O
diffraction	O
studies	O
.	O

With	O
the	O
aim	O
to	O
elucidate	O
the	O
structural	O
features	O
governing	O
the	O
differential	O
inhibitory	O
binding	O
behavior	O
of	O
these	O
inhibitors	O
,	O
molecular	O
modeling	O
studies	O
were	O
undertaken	O
to	O
generate	O
atomic	O
models	O
compatible	O
with	O
the	O
experimental	O
data	O
available	O
.	O

Accordingly	O
,	O
docking	O
of	O
different	O
COX	GENE-N
inhibitors	O
,	O
including	O
selective	O
and	O
non-selective	O
ligands	O
:	O
rofecoxib	CHEMICAL
,	O
ketoprofen	CHEMICAL
,	O
suprofen	CHEMICAL
,	O
carprofen	CHEMICAL
,	O
zomepirac	CHEMICAL
,	O
indomethacin	CHEMICAL
,	O
diclofenac	CHEMICAL
and	O
meclofenamic	CHEMICAL
acid	CHEMICAL
were	O
undertaken	O
using	O
the	O
AMBER	O
program	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
provide	O
new	O
insights	O
into	O
a	O
better	O
understanding	O
of	O
the	O
differential	O
binding	O
mode	O
of	O
diverse	O
families	O
of	O
COX	GENE-N
inhibitors	O
,	O
and	O
are	O
expected	O
to	O
contribute	O
to	O
the	O
design	O
of	O
new	O
selective	O
compounds	O
.	O
Neuronal	GENE-N
nicotinic	GENE-N
receptors	GENE-N
are	O
ligand-gated	GENE-N
ion	GENE-N
channels	GENE-N
of	O
the	O
central	O
and	O
peripheral	O
central	O
nervous	O
system	O
that	O
regulate	O
synaptic	O
activity	O
from	O
both	O
pre-	O
and	O
postsynaptic	O
sites	O
.	O

The	O
present	O
study	O
establishes	O
the	O
acute	O
interaction	O
of	O
bupropion	CHEMICAL
,	O
an	O
antidepressant	O
agent	O
that	O
is	O
also	O
effective	O
in	O
nicotine	O
dependence	O
,	O
with	O
nicotine	CHEMICAL
and	O
nicotinic	O
receptors	O
using	O
different	O
in	O
vivo	O
and	O
in	O
vitro	O
tests	O
.	O

Bupropion	CHEMICAL
was	O
found	O
to	O
block	O
nicotine's	O
antinociception	O
(	O
in	O
two	O
tests	O
)	O
,	O
motor	O
effects	O
,	O
hypothermia	O
,	O
and	O
convulsive	O
effects	O
with	O
different	O
potencies	O
in	O
the	O
present	O
investigation	O
,	O
suggesting	O
that	O
bupropion	CHEMICAL
possesses	O
some	O
selectivity	O
for	O
neuronal	O
nicotinic	O
receptors	O
underlying	O
these	O
various	O
nicotinic	O
effects	O
.	O

In	O
addition	O
,	O
bupropion	CHEMICAL
blocks	O
nicotine	CHEMICAL
activation	O
of	O
alpha	GENE-N
(	GENE-N
3	GENE-N
)	GENE-N
beta	GENE-N
(	GENE-N
2	GENE-N
)	GENE-N
,	GENE-N
alpha	GENE-N
(	GENE-N
4	GENE-N
)	GENE-N
beta	GENE-N
(	GENE-N
2	GENE-N
)	GENE-N
,	GENE-N
and	GENE-N
alpha	GENE-N
(	GENE-N
7	GENE-N
)	GENE-N
neuronal	GENE-N
acetylcholine	GENE-N
nicotinic	GENE-N
receptors	GENE-N
(	O
nAChRs	GENE-N
)	O
with	O
some	O
degree	O
of	O
selectivity	O
.	O

It	O
was	O
approximately	O
50	O
and	O
12	O
times	O
more	O
effective	O
in	O
blocking	O
alpha	O
(	O
3	O
)	O
beta	O
(	O
2	O
)	O
and	O
alpha	O
(	O
4	O
)	O
beta	O
(	O
2	O
)	O
than	O
alpha	O
(	O
7	O
.	O

)	O
This	O
functional	O
blockade	O
was	O
noncompetitive	O
,	O
because	O
it	O
was	O
insurmountable	O
by	O
increasing	O
concentration	O
of	O
ACh	O
in	O
the	O
nAChRs	GENE-N
subtypes	O
tested	O
.	O

Furthermore	O
,	O
bupropion	CHEMICAL
at	O
high	O
concentration	O
failed	O
to	O
displace	O
brain	O
[	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
H	CHEMICAL
]	CHEMICAL
nicotine	CHEMICAL
binding	O
sites	O
,	O
a	O
site	O
largely	O
composed	O
of	O
alpha	O
(	O
4	O
)	O
beta	O
(	O
2	O
)	O
subunit	O
combination	O
.	O

Given	O
the	O
observation	O
that	O
bupropion	CHEMICAL
inhibition	O
of	O
alpha	GENE-N
(	GENE-N
3	GENE-N
)	GENE-N
beta	GENE-N
(	GENE-N
2	GENE-N
)	GENE-N
and	GENE-N
alpha	GENE-N
(	GENE-N
4	GENE-N
)	GENE-N
beta	GENE-N
(	GENE-N
2	GENE-N
)	GENE-N
receptors	GENE-N
exhibits	O
voltage-independence	O
properties	O
,	O
bupropion	CHEMICAL
may	O
not	O
be	O
acting	O
as	O
an	O
open	O
channel	O
blocker	O
.	O

These	O
effects	O
may	O
explain	O
in	O
part	O
bupropion's	O
efficacy	O
in	O
nicotine	O
dependence	O
.	O

Our	O
present	O
findings	O
suggest	O
that	O
functional	O
blockade	O
of	O
neuronal	GENE-N
nAChRs	GENE-N
are	O
useful	O
in	O
nicotine	CHEMICAL
dependence	O
treatment	O
.	O
Saturable	O
active	O
efflux	O
by	O
p-glycoprotein	GENE-N
and	O
breast	GENE-Y
cancer	GENE-Y
resistance	GENE-Y
protein	GENE-Y
at	O
the	O
blood-brain	O
barrier	O
leads	O
to	O
nonlinear	O
distribution	O
of	O
elacridar	CHEMICAL
to	O
the	O
central	O
nervous	O
system	O
.	O
Pharmacodynamic	O
profile	O
of	O
the	O
direct	O
thrombin	GENE-Y
antagonist	O
bivalirudin	O
given	O
in	O
combination	O
with	O
the	O
glycoprotein	GENE-N
IIb	GENE-N
/	GENE-N
IIIa	GENE-N
antagonist	O
eptifibatide	O
.	O
Systematic	O
identification	O
of	O
functional	O
residues	O
in	O
mammalian	GENE-N
histone	GENE-N
H2AX	GENE-N
.	O
2	CHEMICAL
,	CHEMICAL
3	CHEMICAL
,	CHEMICAL
7	CHEMICAL
,	CHEMICAL
8-TCDD	CHEMICAL
induces	O
neurotoxicity	O
and	O
neuronal	O
apoptosis	O
in	O
the	O
rat	O
brain	O
cortex	O
and	O
PC12	O
cell	O
line	O
through	O
the	O
down-regulation	O
of	O
the	O
Wnt	GENE-N
/	O
β-catenin	GENE-Y
signaling	O
pathway	O
.	O
Marine	O
algae	O
are	O
popular	O
and	O
abundant	O
food	O
ingredients	O
mainly	O
in	O
Asian	O
countries	O
,	O
and	O
also	O
well	O
known	O
for	O
their	O
health	O
beneficial	O
effects	O
due	O
to	O
the	O
presence	O
of	O
biologically	O
active	O
components	O
.	O

The	O
marine	O
algae	O
have	O
been	O
studied	O
for	O
biologically	O
active	O
components	O
and	O
phlorotannins	CHEMICAL
,	O
marine	O
polyphenols	CHEMICAL
are	O
among	O
them	O
.	O

Among	O
marine	O
algae	O
,	O
brown	O
algae	O
have	O
extensively	O
studied	O
for	O
their	O
potential	O
anti-diabetic	O
activities	O
.	O

Majority	O
of	O
the	O
investigations	O
on	O
phlorotannins	CHEMICAL
derived	O
from	O
brown	O
algae	O
have	O
exhibited	O
their	O
various	O
anti-diabetic	O
mechanisms	O
such	O
as	O
α-glucosidase	GENE-N
and	O
α-amylase	GENE-N
inhibitory	O
effect	O
,	O
glucose	CHEMICAL
uptake	O
effect	O
in	O
skeletal	O
muscle	O
,	O
protein	GENE-Y
tyrosine	CHEMICAL
phosphatase	O
1B	O
(	O
PTP	GENE-Y
1B	GENE-Y
)	O
enzyme	O
inhibition	O
,	O
improvement	O
of	O
insulin	GENE-N
sensitivity	O
in	O
type	O
2	O
diabetic	O
db	O
/	O
db	O
mice	O
,	O
and	O
protective	O
effect	O
against	O
diabetes	O
complication	O
.	O

In	O
this	O
review	O
,	O
we	O
have	O
made	O
an	O
attempt	O
to	O
discuss	O
the	O
various	O
anti-diabetic	O
mechanisms	O
associated	O
with	O
phlorotannins	CHEMICAL
from	O
brown	O
algae	O
that	O
are	O
confined	O
to	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
Adverse	O
respiratory	O
reactions	O
to	O
aspirin	CHEMICAL
and	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
.	O
A	O
novel	O
class	O
of	O
3-	CHEMICAL
(	CHEMICAL
phenoxy-phenyl-methyl	CHEMICAL
)	CHEMICAL
-pyrrolidines	CHEMICAL
as	O
potent	O
and	O
balanced	O
norepinephrine	CHEMICAL
and	O
serotonin	CHEMICAL
reuptake	O
inhibitors	O
:	O
synthesis	O
and	O
structure-activity	O
relationships	O
.	O
Zinc	CHEMICAL
sulphate	CHEMICAL
and	O
vitamin	CHEMICAL
E	CHEMICAL
alleviate	O
reproductive	O
toxicity	O
caused	O
by	O
aluminium	CHEMICAL
sulphate	CHEMICAL
in	O
male	O
albino	O
rats	O
.	O
Effects	O
of	O
dopamine	GENE-N
receptor	O
agonists	O
and	O
antagonists	O
on	O
catecholamine	CHEMICAL
release	O
in	O
bovine	O
chromaffin	O
cells	O
.	O
Plasmacytoid	O
dendritic	O
cells	O
produce	O
cytokines	GENE-N
and	O
mature	O
in	O
response	O
to	O
the	O
TLR7	GENE-Y
agonists	O
,	O
imiquimod	CHEMICAL
and	O
resiquimod	CHEMICAL
.	O
In	O
the	O
present	O
study	O
,	O
six	O
cyanobacteria	O
isolates	O
were	O
evaluated	O
for	O
the	O
PAL	GENE-N
enzyme	O
activity	O
,	O
and	O
their	O
methanol	CHEMICAL
extracts	O
were	O
assessed	O
for	O
the	O
total	O
phenolic	CHEMICAL
amount	O
and	O
other	O
antioxidant	O
parameters	O
.	O

Synechocystis	O
sp	O
.	O

BASO444	O
and	O
Synechocystis	O
sp	O
.	O

BASO673	O
isolates	O
with	O
high	O
levels	O
of	O
total	O
phenols	CHEMICAL
(	O
66	O
.	O
0±1	O
.	O
2μg	O
/	O
mg	O
,	O
78	O
.	O
1±1	O
.	O
8μg	O
/	O
mg	O
,	O
respectively	O
)	O
also	O
showed	O
high	O
levels	O
of	O
PAL	GENE-N
activities	O
(	O
20	O
.	O
5±3	O
.	O
1U	O
/	O
mg	O
protein	O
,	O
17	O
.	O
2±2	O
.	O
3U	O
/	O
mg	O
protein	O
,	O
respectively	O
)	O
and	O
strong	O
antioxidant	O
activities	O
.	O

To	O
understand	O
the	O
effect	O
of	O
l-phenylalanine	CHEMICAL
(	O
l-phe	CHEMICAL
)	O
on	O
the	O
PAL	GENE-N
activity	O
,	O
total	O
phenolic	CHEMICAL
amount	O
,	O
and	O
phenolic	CHEMICAL
constituents	O
,	O
isolates	O
were	O
evaluated	O
with	O
100mg	O
/	O
l	O
l-phe	CHEMICAL
.	O

While	O
PAL	GENE-N
activities	O
exhibited	O
no	O
significant	O
change	O
with	O
l-phe	CHEMICAL
addition	O
,	O
total	O
phenolic	CHEMICAL
amount	O
of	O
the	O
isolates	O
significantly	O
increased	O
.	O

HPLC	O
analysis	O
revealed	O
gallic	CHEMICAL
acid	CHEMICAL
,	O
trans-cinnamic	CHEMICAL
acid	CHEMICAL
,	O
p-coumaric	CHEMICAL
acid	CHEMICAL
,	O
and	O
ferulic	CHEMICAL
acid	CHEMICAL
as	O
the	O
main	O
compounds	O
.	O

Results	O
suggested	O
that	O
the	O
two	O
isolate	O
mights	O
be	O
an	O
important	O
source	O
for	O
the	O
l-phe	CHEMICAL
inducible	O
phenolic	CHEMICAL
compounds	O
.	O
Minocycline	CHEMICAL
protects	O
against	O
permanent	O
cerebral	O
ischemia	O
in	O
wild	O
type	O
but	O
not	O
in	O
matrix	GENE-Y
metalloprotease-9-deficient	O
mice	O
.	O
Several	O
types	O
of	O
human	O
tumors	O
overexpress	O
cyclooxygenase	GENE-Y
(	GENE-Y
COX	GENE-Y
)	GENE-Y
-2	GENE-Y
but	O
not	O
COX-1	GENE-Y
,	O
and	O
gene	O
knockout	O
transfection	O
experiments	O
demonstrate	O
a	O
central	O
role	O
of	O
COX-2	GENE-Y
in	O
experimental	O
tumorigenesis	O
.	O

COX-2	GENE-Y
produces	O
prostaglandins	CHEMICAL
that	O
inhibit	O
apoptosis	O
and	O
stimulate	O
angiogenesis	O
and	O
invasiveness	O
.	O

Selective	O
COX-2	GENE-Y
inhibitors	O
reduce	O
prostaglandin	CHEMICAL
synthesis	O
,	O
restore	O
apoptosis	O
,	O
and	O
inhibit	O
cancer	O
cell	O
proliferation	O
.	O

In	O
animal	O
studies	O
they	O
limit	O
carcinogen-induced	O
tumorigenesis	O
.	O

In	O
contrast	O
,	O
aspirin-like	O
nonselective	O
NSAIDs	O
such	O
as	O
sulindac	CHEMICAL
and	O
indomethacin	CHEMICAL
inhibit	O
not	O
only	O
the	O
enzymatic	O
action	O
of	O
the	O
highly	O
inducible	O
,	O
proinflammatory	O
COX-2	GENE-Y
but	O
the	O
constitutively	O
expressed	O
,	O
cytoprotective	O
COX-1	GENE-Y
as	O
well	O
.	O

Consequently	O
,	O
nonselective	O
NSAIDs	O
can	O
cause	O
platelet	O
dysfunction	O
,	O
gastrointestinal	O
ulceration	O
,	O
and	O
kidney	O
damage	O
.	O

For	O
that	O
reason	O
,	O
selective	O
inhibition	O
of	O
COX-2	GENE-Y
to	O
treat	O
neoplastic	O
proliferation	O
is	O
preferable	O
to	O
nonselective	O
inhibition	O
.	O

Selective	O
COX-2	GENE-Y
inhibitors	O
,	O
such	O
as	O
meloxicam	CHEMICAL
,	O
celecoxib	CHEMICAL
(	O
SC-58635	CHEMICAL
)	O
,	O
and	O
rofecoxib	CHEMICAL
(	O
MK-0966	CHEMICAL
)	O
,	O
are	O
NSAIDs	O
that	O
have	O
been	O
modified	O
chemically	O
to	O
preferentially	O
inhibit	O
COX-2	GENE-Y
but	O
not	O
COX-1	GENE-Y
.	O

For	O
instance	O
,	O
meloxicam	CHEMICAL
inhibits	O
the	O
growth	O
of	O
cultured	O
colon	O
cancer	O
cells	O
(	O
HCA-7	O
and	O
Moser-S	O
)	O
that	O
express	O
COX-2	GENE-Y
but	O
has	O
no	O
effect	O
on	O
HCT-116	O
tumor	O
cells	O
that	O
do	O
not	O
express	O
COX-2	GENE-Y
.	O

NS-398	CHEMICAL
induces	O
apoptosis	O
in	O
COX-2	GENE-Y
expressing	O
LNCaP	O
prostate	O
cancer	O
cells	O
and	O
,	O
surprisingly	O
,	O
in	O
colon	O
cancer	O
S	O
/	O
KS	O
cells	O
that	O
does	O
not	O
express	O
COX-2	GENE-Y
.	O

This	O
effect	O
may	O
due	O
to	O
induction	O
of	O
apoptosis	O
through	O
uncoupling	O
of	O
oxidative	O
phosphorylation	O
and	O
down-regulation	O
of	O
Bcl-2	GENE-Y
,	O
as	O
has	O
been	O
demonstrated	O
for	O
some	O
nonselective	O
NSAIDs	O
,	O
for	O
instance	O
,	O
flurbiprofen	CHEMICAL
.	O

COX-2	GENE-Y
mRNA	O
and	O
COX-2	GENE-Y
protein	O
is	O
constitutively	O
expressed	O
in	O
the	O
kidney	O
,	O
brain	O
,	O
spinal	O
cord	O
,	O
and	O
ductus	O
deferens	O
,	O
and	O
in	O
the	O
uterus	O
during	O
implantation	O
.	O

In	O
addition	O
,	O
COX-2	GENE-Y
is	O
constitutively	O
and	O
dominantly	O
expressed	O
in	O
the	O
pancreatic	O
islet	O
cells	O
.	O

These	O
findings	O
might	O
somewhat	O
limit	O
the	O
use	O
of	O
presently	O
available	O
selective	O
COX-2	GENE-Y
inhibitors	O
in	O
cancer	O
prevention	O
but	O
will	O
probably	O
not	O
deter	O
their	O
successful	O
application	O
for	O
the	O
treatment	O
of	O
human	O
cancers	O
.	O
Role	O
of	O
nitric	CHEMICAL
oxide	CHEMICAL
in	O
the	O
chemistry	O
and	O
anticancer	O
activity	O
of	O
etoposide	CHEMICAL
(	O
VP-16	CHEMICAL
,	CHEMICAL
213	CHEMICAL
)	O
.	O
All	O
DNA	GENE-N
(	GENE-N
cytosine-5	O
)	O
-methyltransferases	O
contain	O
a	O
single	O
conserved	O
cysteine	CHEMICAL
.	O

It	O
has	O
been	O
proposed	O
that	O
this	O
cysteine	CHEMICAL
initiates	O
catalysis	O
by	O
attacking	O
the	O
C6	O
of	O
cytosine	CHEMICAL
and	O
thereby	O
activating	O
the	O
normally	O
inert	O
C5	O
position	O
.	O

We	O
show	O
here	O
that	O
substitutions	O
of	O
this	O
cysteine	CHEMICAL
in	O
the	O
E	O
.	O

coli	O
methylase	O
M	O
.	O

EcoRII	O
with	O
either	O
serine	CHEMICAL
or	O
tryptophan	CHEMICAL
results	O
in	O
a	O
complete	O
loss	O
of	O
ability	O
to	O
transfer	O
methyl	CHEMICAL
groups	O
to	O
DNA	O
.	O

Interestingly	O
,	O
mutants	O
with	O
either	O
serine	CHEMICAL
or	O
glycine	CHEMICAL
substitution	O
bind	O
tightly	O
to	O
substrate	O
DNA	O
.	O

These	O
mutants	O
resemble	O
the	O
wild-type	O
enzyme	O
in	O
that	O
their	O
binding	O
to	O
substrate	O
is	O
not	O
eliminated	O
by	O
the	O
presence	O
of	O
non-specific	O
DNA	O
in	O
the	O
reaction	O
,	O
it	O
is	O
sensitive	O
to	O
methylation	O
status	O
of	O
the	O
substrate	O
and	O
is	O
stimulated	O
by	O
an	O
analog	O
of	O
the	O
methyl	CHEMICAL
donor	O
.	O

Hence	O
the	O
conserved	O
cysteine	CHEMICAL
is	O
not	O
essential	O
for	O
the	O
specific	O
stable	O
binding	O
of	O
the	O
enzyme	O
to	O
its	O
substrate	O
.	O

However	O
,	O
substitution	O
of	O
the	O
cysteine	CHEMICAL
with	O
the	O
bulkier	O
tryptophan	CHEMICAL
does	O
reduce	O
DNA	O
binding	O
.	O

We	O
also	O
report	O
here	O
a	O
novel	O
procedure	O
for	O
the	O
synthesis	O
of	O
DNA	O
containing	O
5-fluorocytosine	CHEMICAL
.	O

Further	O
,	O
we	O
show	O
that	O
a	O
DNA	O
substrate	O
for	O
M	O
.	O

EcoRII	O
in	O
which	O
the	O
target	O
cytosine	CHEMICAL
is	O
replaced	O
by	O
5-fluorocytosine	CHEMICAL
is	O
a	O
mechanism-based	O
inhibitor	O
of	O
the	O
enzyme	O
and	O
that	O
it	O
forms	O
an	O
irreversible	O
complex	O
with	O
the	O
enzyme	O
.	O

As	O
expected	O
,	O
this	O
modified	O
substrate	O
does	O
not	O
form	O
irreversible	O
complexes	O
with	O
the	O
mutants	O
.	O
Effect	O
of	O
L-arginine-nitric	CHEMICAL
oxide	CHEMICAL
system	O
on	O
the	O
metabolism	O
of	O
essential	CHEMICAL
fatty	CHEMICAL
acids	CHEMICAL
in	O
chemical-induced	O
diabetes	O
mellitus	O
.	O
Recent	O
data	O
suggest	O
that	O
the	O
role	O
of	O
CYP3A4	GENE-Y
in	O
imatinib	CHEMICAL
metabolism	O
is	O
smaller	O
than	O
presumed	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
the	O
quantitative	O
importance	O
of	O
different	O
cytochrome	GENE-N
P450	GENE-N
(	O
P450	GENE-N
)	O
enzymes	O
in	O
imatinib	CHEMICAL
pharmacokinetics	O
.	O

First	O
,	O
the	O
metabolism	O
of	O
imatinib	CHEMICAL
was	O
investigated	O
using	O
recombinant	O
P450	GENE-N
enzymes	O
and	O
human	O
liver	O
microsomes	O
with	O
P450	GENE-N
isoform-selective	O
inhibitors	O
.	O

Thereafter	O
,	O
an	O
in	O
silico	O
model	O
for	O
imatinib	CHEMICAL
was	O
constructed	O
to	O
perform	O
pharmacokinetic	O
simulations	O
to	O
assess	O
the	O
roles	O
of	O
P450	GENE-N
enzymes	O
in	O
imatinib	CHEMICAL
elimination	O
at	O
clinically	O
used	O
imatinib	CHEMICAL
doses	O
.	O

In	O
vitro	O
,	O
CYP2C8	GENE-Y
inhibitors	O
and	O
CYP3A4	GENE-Y
inhibitors	O
inhibited	O
the	O
depletion	O
of	O
0	O
.	O
1	O
µM	O
imatinib	CHEMICAL
by	O
45	O
and	O
80%	O
,	O
respectively	O
,	O
and	O
the	O
formation	O
of	O
the	O
main	O
metabolite	O
of	O
imatinib	CHEMICAL
,	O
N-desmethylimatinib	CHEMICAL
,	O
by	O
>50%	O
.	O

Likewise	O
,	O
recombinant	O
CYP2C8	GENE-Y
and	O
CYP3A4	GENE-Y
metabolized	O
imatinib	CHEMICAL
extensively	O
,	O
whereas	O
other	O
isoforms	O
had	O
minor	O
effect	O
on	O
imatinib	CHEMICAL
concentrations	O
.	O

In	O
the	O
beginning	O
of	O
imatinib	CHEMICAL
treatment	O
,	O
the	O
fractions	O
of	O
its	O
hepatic	O
clearance	O
mediated	O
by	O
CYP2C8	GENE-Y
and	O
CYP3A4	GENE-Y
were	O
predicted	O
to	O
approximate	O
40	O
and	O
60%	O
,	O
respectively	O
.	O

During	O
long-term	O
treatment	O
with	O
imatinib	CHEMICAL
400	O
mg	O
once	O
or	O
twice	O
daily	O
,	O
up	O
to	O
65	O
or	O
75%	O
of	O
its	O
hepatic	O
elimination	O
was	O
predicted	O
to	O
occur	O
via	O
CYP2C8	GENE-Y
,	O
and	O
only	O
about	O
35	O
or	O
25%	O
by	O
CYP3A4	GENE-Y
,	O
due	O
to	O
dose-	O
and	O
time-dependent	O
autoinactivation	O
of	O
CYP3A4	GENE-Y
by	O
imatinib	CHEMICAL
.	O

Thus	O
,	O
although	O
CYP2C8	GENE-Y
and	O
CYP3A4	GENE-Y
are	O
the	O
main	O
enzymes	O
in	O
imatinib	CHEMICAL
metabolism	O
in	O
vitro	O
,	O
in	O
silico	O
predictions	O
indicate	O
that	O
imatinib	CHEMICAL
inhibits	O
its	O
own	O
CYP3A4-mediated	O
metabolism	O
,	O
assigning	O
a	O
key	O
role	O
for	O
CYP2C8	GENE-Y
.	O

During	O
multiple	O
dosing	O
,	O
pharmacogenetic	O
polymorphisms	O
and	O
drug	O
interactions	O
affecting	O
CYP2C8	GENE-Y
activity	O
may	O
cause	O
marked	O
interindividual	O
variation	O
in	O
the	O
exposure	O
and	O
response	O
to	O
imatinib	CHEMICAL
.	O
IGF-I	GENE-Y
signaling	O
is	O
essential	O
for	O
FSH	GENE-N
stimulation	O
of	O
AKT	GENE-N
and	O
steroidogenic	O
genes	O
in	O
granulosa	O
cells	O
.	O
Effects	O
of	O
zonisamide	CHEMICAL
on	O
dopaminergic	O
system	O
.	O
D2	GENE-Y
dopamine	CHEMICAL
receptors	O
colocalize	O
regulator	GENE-Y
of	GENE-Y
G-protein	GENE-Y
signaling	GENE-Y
9-2	GENE-Y
(	O
RGS9-2	GENE-Y
)	O
via	O
the	O
RGS9	GENE-Y
DEP	GENE-N
domain	GENE-N
,	O
and	O
RGS9	GENE-Y
knock-out	O
mice	O
develop	O
dyskinesias	O
associated	O
with	O
dopamine	CHEMICAL
pathways	O
.	O
Aripiprazole	CHEMICAL
,	O
7-	CHEMICAL
[	CHEMICAL
4-	CHEMICAL
[	CHEMICAL
4-	CHEMICAL
(	CHEMICAL
2	CHEMICAL
,	CHEMICAL
3-dichlorophenyl	CHEMICAL
)	CHEMICAL
-1-piperazinyl	CHEMICAL
]	CHEMICAL
butyloxy	CHEMICAL
]	CHEMICAL
-3	CHEMICAL
,	CHEMICAL
4-dihydro-2	CHEMICAL
(	CHEMICAL
1H	CHEMICAL
)	CHEMICAL
-quinolinon	CHEMICAL
e	CHEMICAL
,	O
a	O
novel	O
antipsychotic	O
with	O
partial	O
agonist	O
activity	O
at	O
dopamine	CHEMICAL
D2	O
receptors	O
,	O
bound	O
with	O
high	O
affinity	O
to	O
recombinant	O
human	GENE-Y
5-HT	GENE-Y
(	GENE-Y
1A	GENE-Y
)	GENE-Y
receptors	GENE-Y
(	O
h5-HT	GENE-Y
(	GENE-Y
1A	GENE-Y
)	GENE-Y
)	O
in	O
Chinese	O
hamster	O
ovary	O
cell	O
membranes	O
and	O
displayed	O
potent	O
,	O
partial	O
agonism	O
at	O
5-HT	GENE-Y
(	GENE-Y
1A	GENE-Y
)	GENE-Y
receptors	O
in	O
a	O
guanosine-5'-O-	CHEMICAL
(	CHEMICAL
3-	CHEMICAL
[	CHEMICAL
(	CHEMICAL
35	CHEMICAL
)	CHEMICAL
S	CHEMICAL
]	CHEMICAL
thio	CHEMICAL
)	CHEMICAL
-triphosphate	CHEMICAL
(	O
[	CHEMICAL
(	CHEMICAL
35	CHEMICAL
)	CHEMICAL
S	CHEMICAL
]	CHEMICAL
GTP	CHEMICAL
gamma	CHEMICAL
S	CHEMICAL
)	O
-binding	O
assay	O
that	O
was	O
blocked	O
completely	O
by	O
a	O
selective	O
5-HT	GENE-Y
(	GENE-Y
1A	GENE-Y
)	GENE-Y
receptor	O
antagonist	O
.	O

An	O
interaction	O
with	O
5-HT	GENE-Y
(	GENE-Y
1A	GENE-Y
)	GENE-Y
receptors	O
may	O
contribute	O
to	O
the	O
overall	O
efficacy	O
of	O
aripiprazole	O
against	O
symptoms	O
of	O
schizophrenia	O
,	O
including	O
anxiety	O
,	O
depression	O
,	O
cognitive	O
and	O
negative	O
symptoms	O
,	O
and	O
to	O
its	O
favorable	O
side-effect	O
profile	O
.	O

Combined	O
with	O
previous	O
studies	O
demonstrating	O
the	O
potent	O
partial	O
agonism	O
of	O
aripiprazole	CHEMICAL
at	O
dopamine	CHEMICAL
D2	O
receptors	O
,	O
this	O
study	O
suggests	O
aripiprazole	CHEMICAL
is	O
the	O
first	O
dopamine-serotonin	CHEMICAL
system	O
stabilizer	O
.	O
Biosynthetic	O
regulation	O
and	O
intracellular	O
transport	O
of	O
phosphatidylserine	CHEMICAL
in	O
mammalian	O
cells	O
.	O
Prenatal	O
exposure	O
to	O
bisphenol	CHEMICAL
A	CHEMICAL
impacts	O
midbrain	O
dopamine	CHEMICAL
neurons	O
and	O
hippocampal	O
spine	O
synapses	O
in	O
non-human	O
primates	O
.	O
Normal	O
growth	O
and	O
function	O
of	O
the	O
prostate	O
are	O
contingent	O
on	O
the	O
reduction	O
of	O
testosterone	CHEMICAL
to	O
dihydrotestosterone	CHEMICAL
(	O
DHT	CHEMICAL
)	O
by	O
5-alpha	GENE-N
reductase	GENE-N
(	GENE-N
5-AR	GENE-N
)	GENE-N
enzymes	GENE-N
types	GENE-N
1	GENE-N
and	GENE-N
2	GENE-N
.	O

It	O
has	O
been	O
theorized	O
that	O
an	O
overabundance	O
of	O
DHT	CHEMICAL
may	O
be	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
both	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
)	O
and	O
prostate	O
cancer	O
.	O

Inhibitors	O
of	O
5-AR	GENE-N
such	O
as	O
dutasteride	CHEMICAL
and	O
finasteride	CHEMICAL
may	O
therefore	O
have	O
an	O
important	O
role	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
BPH	O
and	O
prostate	O
cancer	O
.	O

Dutasteride	CHEMICAL
provides	O
greater	O
suppression	O
of	O
DHT	CHEMICAL
than	O
finasteride	CHEMICAL
,	O
thereby	O
underlying	O
the	O
hypothesis	O
that	O
inhibition	O
of	O
both	O
type	O
1	O
and	O
type	O
2	O
would	O
provide	O
correspondingly	O
greater	O
protection	O
than	O
inhibition	O
of	O
type	O
2	O
alone	O
.	O

We	O
review	O
the	O
potential	O
significance	O
of	O
the	O
5-AR	GENE-N
inhibitors	O
in	O
reducing	O
the	O
risk	O
of	O
prostate	O
cancer	O
according	O
to	O
the	O
basic	O
biology	O
of	O
prostate	O
disease	O
.	O
The	O
synthesis	O
and	O
pharmacological	O
evaluation	O
of	O
new	O
water-soluble	O
phosphoramidate	CHEMICAL
derivatives	O
of	O
the	O
COX-2	GENE-Y
selective	O
inhibitor	O
cimicoxib	CHEMICAL
(	O
4	O
)	O
are	O
described	O
.	O

The	O
sulfonylphosphoramidic	CHEMICAL
acid	CHEMICAL
derivative	O
10	O
was	O
converted	O
to	O
4	O
in	O
human	O
plasma	O
and	O
showed	O
excellent	O
in	O
vivo	O
activity	O
in	O
the	O
rat	O
carrageenan-edema	O
test	O
.	O

Pharmacokinetic	O
evaluation	O
in	O
dogs	O
indicated	O
that	O
10	O
behaved	O
as	O
a	O
prodrug	O
,	O
immediately	O
converting	O
to	O
4	O
and	O
giving	O
an	O
identical	O
profile	O
to	O
that	O
of	O
the	O
parent	O
compound	O
.	O

These	O
results	O
represent	O
the	O
first	O
description	O
of	O
phosphoramidic	CHEMICAL
acids	CHEMICAL
as	O
prodrugs	O
for	O
the	O
sulfonamido	CHEMICAL
group	O
.	O

Compound	O
10	O
also	O
exhibited	O
an	O
important	O
and	O
sustained	O
analgesic	O
effect	O
in	O
the	O
hyperalgesia	O
test	O
in	O
rats	O
and	O
a	O
high	O
aqueous	O
solubility	O
at	O
pH	O
higher	O
than	O
7	O
.	O

This	O
profile	O
led	O
to	O
the	O
selection	O
of	O
10	O
(	O
UR-14048	CHEMICAL
)	O
for	O
further	O
development	O
in	O
the	O
parenteral	O
treatment	O
of	O
acute	O
pain	O
.	O
Suppression	O
of	O
Src	GENE-Y
/	O
ERK	GENE-N
and	O
GSK-3	GENE-N
/	O
β-catenin	GENE-Y
signaling	O
by	O
pinosylvin	CHEMICAL
inhibits	O
the	O
growth	O
of	O
human	O
colorectal	O
cancer	O
cells	O
.	O
Hyperornithinemia	O
,	O
hyperammonemia	O
,	O
and	O
homocitrullinuria	O
(	O
HHH	O
)	O
syndrome	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
SLC25A15	GENE-Y
(	O
ORNT1	GENE-Y
)	O
gene	O
encoding	O
the	O
mitochondrial	O
ornithine	GENE-N
transporter	O
,	O
but	O
the	O
mechanism	O
of	O
pathogenesis	O
of	O
the	O
encephalopathy	O
,	O
spastic	O
paraparesis	O
and	O
hepatopathy	O
remains	O
undetermined	O
.	O

HHH	O
syndrome	O
was	O
diagnosed	O
in	O
a	O
2-year-old	O
Palestinian	O
boy	O
with	O
developmental	O
delay	O
and	O
seizures	O
,	O
and	O
subsequently	O
in	O
his	O
13-year-old	O
brother	O
with	O
developmental	O
delay	O
.	O

Direct	O
sequencing	O
of	O
the	O
PCR	O
products	O
of	O
SLC25A15	GENE-Y
exon	O
amplifications	O
revealed	O
that	O
both	O
brothers	O
were	O
homozygous	O
for	O
a	O
novel	O
446G	O
deletion	O
in	O
exon	O
3	O
as	O
well	O
as	O
for	O
a	O
760A>T	GENE-N
(	O
I254L	GENE-N
)	O
polymorphism	O
in	O
exon	O
5	O
,	O
which	O
is	O
downstream	O
of	O
a	O
premature	O
termination	O
codon	O
produced	O
by	O
the	O
frameshift	O
resulting	O
from	O
the	O
446G	O
deletion	O
.	O

The	O
index	O
patient	O
had	O
elevated	O
liver	O
enzymes	O
as	O
well	O
as	O
hyperalaninemia	O
,	O
lactic	CHEMICAL
acidemia	O
with	O
an	O
elevated	O
lactate	CHEMICAL
to	O
pyruvate	CHEMICAL
ratio	O
,	O
and	O
increased	O
urinary	O
excretion	O
of	O
lactate	CHEMICAL
,	O
glutarate	CHEMICAL
and	O
Krebs	O
cycle	O
intermediates	O
.	O

These	O
findings	O
are	O
indicative	O
of	O
mitochondrial	O
dysfunction	O
and	O
are	O
in	O
accordance	O
with	O
ultrastructural	O
studies	O
showing	O
increased	O
numbers	O
of	O
large	O
and	O
bizarre	O
mitochondria	O
in	O
liver	O
,	O
muscle	O
,	O
leukocytes	O
and	O
fibroblasts	O
of	O
some	O
HHH	O
patients	O
.	O

Neurologic	O
and	O
hepatic	O
manifestations	O
are	O
characteristic	O
of	O
some	O
primary	O
mitochondrial	O
disorders	O
.	O

Secondary	O
mitochondrial	O
dysfunction	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
these	O
same	O
features	O
in	O
HHH	O
syndrome	O
.	O
Within	O
the	O
past	O
decade	O
,	O
gonadotrophin-releasing	CHEMICAL
hormone	CHEMICAL
(	O
GnRH	CHEMICAL
)	O
agonists	O
have	O
contributed	O
greatly	O
to	O
the	O
success	O
of	O
cycles	O
programmed	O
for	O
in-vitro	O
fertilization	O
and	O
embryo	O
transfer	O
.	O

However	O
,	O
apart	O
from	O
a	O
preventive	O
effect	O
on	O
the	O
luteinizing	GENE-N
hormone	GENE-N
(	O
LH	GENE-N
)	O
surge	O
,	O
most	O
of	O
the	O
beneficial	O
effects	O
of	O
these	O
molecules	O
are	O
still	O
only	O
partly	O
known	O
.	O

A	O
precise	O
analysis	O
of	O
regimens	O
using	O
GnRH	CHEMICAL
agonists	O
for	O
ovarian	O
stimulation	O
shows	O
that	O
many	O
parameters	O
may	O
interfere	O
with	O
the	O
outcome	O
of	O
long-term	O
and	O
short-term	O
protocols	O
.	O

The	O
great	O
variability	O
between	O
these	O
protocols	O
hampers	O
our	O
comprehension	O
of	O
the	O
mechanisms	O
involved	O
in	O
the	O
overall	O
clinical	O
improvement	O
seen	O
with	O
this	O
therapy	O
.	O

The	O
hypophyseal	O
desensitization	O
induced	O
by	O
GnRH	CHEMICAL
agonists	O
is	O
greatly	O
dependent	O
on	O
the	O
dose	O
and	O
duration	O
of	O
their	O
administration	O
,	O
but	O
the	O
residual	O
gonadotrophin	GENE-N
secretion	O
is	O
imperfectly	O
estimated	O
by	O
hormonal	O
measurements	O
using	O
radioimmunometric	O
assays	O
.	O

Moreover	O
,	O
the	O
specific	O
role	O
of	O
GnRH	CHEMICAL
agonist-induced	O
ovarian	O
quiescence	O
on	O
subsequent	O
ovarian	O
responsiveness	O
to	O
gonadotrophins	GENE-N
and	O
on	O
endometrial	O
receptivity	O
deserves	O
further	O
investigation	O
.	O

Finally	O
,	O
a	O
direct	O
ovarian	O
action	O
of	O
GnRH	CHEMICAL
agonists	O
on	O
steroidogenesis	O
,	O
folliculogenesis	O
and	O
embryo	O
quality	O
is	O
still	O
controversial	O
in	O
humans	O
.	O

These	O
putative	O
deleterious	O
effects	O
of	O
GnRH	CHEMICAL
agonists	O
have	O
led	O
some	O
authors	O
to	O
recommend	O
a	O
reduction	O
of	O
both	O
dose	O
and	O
duration	O
of	O
GnRH	CHEMICAL
agonist	O
administration	O
for	O
women	O
identified	O
by	O
a	O
poor	O
response	O
to	O
gonadotrophins	GENE-N
.	O

Using	O
this	O
approach	O
,	O
a	O
few	O
reports	O
have	O
recently	O
shown	O
some	O
clinical	O
advantages	O
for	O
ovarian	O
responsiveness	O
but	O
no	O
convincing	O
evidence	O
for	O
any	O
improvement	O
in	O
pregnancy	O
rate	O
.	O

It	O
thus	O
appears	O
that	O
the	O
overall	O
impact	O
of	O
GnRH	CHEMICAL
agonists	O
on	O
reproductive	O
function	O
is	O
still	O
partly	O
misunderstood	O
.	O
Rapid	O
cortical	O
bone	O
loss	O
in	O
patients	O
with	O
chronic	O
kidney	O
disease	O
.	O
Sesamin	CHEMICAL
(	O
a	O
non-fat	O
portion	O
of	O
sesame	O
seed	O
oil	O
)	O
inhibits	O
delta-5	GENE-Y
desaturase	GENE-Y
activity	O
resulting	O
in	O
an	O
accumulation	O
of	O
dihomo-gamma-linolenic	CHEMICAL
acid	CHEMICAL
(	O
DGLA	CHEMICAL
)	O
which	O
can	O
displace	O
arachidonic	CHEMICAL
acid	CHEMICAL
(	O
AA	CHEMICAL
)	O
and	O
decrease	O
the	O
formation	O
of	O
pro-inflammatory	O
mediators	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
consumption	O
of	O
diets	O
containing	O
0	O
.	O
25wt%	O
sesamin	O
and	O
15	O
wt%	O
safflower	O
oil	O
(	O
SO	O
)	O
(	O
providing	O
12%	O
of	O
the	O
added	O
fat	O
as	O
linoleic	CHEMICAL
acid	CHEMICAL
)	O
or	O
a	O
15	O
wt%	O
2	O
:	O
1	O
mixture	O
of	O
linseed	O
oil	O
and	O
SO	O
(	O
LOSO	O
)	O
(	O
providing	O
6%	O
alpha-linolenic	CHEMICAL
acid	CHEMICAL
and	O
6%	O
linoleic	CHEMICAL
acid	CHEMICAL
)	O
for	O
3	O
weeks	O
on	O
the	O
liver	O
membrane	O
fatty	CHEMICAL
acid	CHEMICAL
composition	O
and	O
on	O
the	O
production	O
of	O
prostaglandin	CHEMICAL
(	CHEMICAL
PG	CHEMICAL
)	CHEMICAL
E2	CHEMICAL
,	O
TNF-alpha	GENE-Y
,	O
IL-6	GENE-Y
and	O
IL10	GENE-Y
in	O
mice	O
.	O

Consumption	O
of	O
sesamin-supplemented	O
SO	O
and	O
LOSO	O
diets	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
the	O
levels	O
of	O
20	O
:	O
3omega6	O
(	O
DGLA	CHEMICAL
)	O
,	O
suggesting	O
that	O
sesamin	CHEMICAL
inhibited	O
delta-5	O
desaturation	O
of	O
omega6	CHEMICAL
fatty	CHEMICAL
acids	CHEMICAL
.	O

In	O
animals	O
fed	O
LOSO	O
diets	O
,	O
the	O
levels	O
of	O
alpha-linolenic	CHEMICAL
acid	CHEMICAL
,	O
eicosapentaenoic	CHEMICAL
acid	CHEMICAL
(	O
EPA	CHEMICAL
)	O
and	O
of	O
docosahexaenoic	CHEMICAL
acid	CHEMICAL
(	O
DHA	CHEMICAL
)	O
were	O
elevated	O
with	O
a	O
concomitant	O
decrease	O
of	O
arachidonic	CHEMICAL
acid	CHEMICAL
(	O
AA	CHEMICAL
)	O
in	O
the	O
liver	O
membrane	O
phospholipids	O
.	O

Further	O
,	O
in	O
animals	O
fed	O
LOSO	O
diets	O
with	O
or	O
without	O
sesamin	CHEMICAL
,	O
an	O
increase	O
in	O
the	O
circulating	O
levels	O
of	O
TNF-alpha	GENE-Y
was	O
associated	O
with	O
a	O
concomitant	O
decrease	O
in	O
PGE2	CHEMICAL
.	O

Despite	O
a	O
lack	O
of	O
differences	O
in	O
the	O
levels	O
of	O
AA	CHEMICAL
,	O
the	O
PGE2	CHEMICAL
levels	O
were	O
significantly	O
lower	O
in	O
mice	O
fed	O
sesamin-supplemented	O
SO	O
compared	O
to	O
those	O
fed	O
SO	O
alone	O
.	O

Thus	O
,	O
these	O
data	O
suggest	O
that	O
irrespective	O
of	O
the	O
availability	O
of	O
a	O
specific	O
fatty	CHEMICAL
acid	CHEMICAL
as	O
a	O
substrate	O
,	O
through	O
regulating	O
the	O
PGE2	CHEMICAL
synthesis	O
,	O
the	O
production	O
of	O
TNF-alpha	GENE-Y
could	O
be	O
modulated	O
.	O
Inhibitory	O
effect	O
of	O
dihydroartemisinin	CHEMICAL
against	O
phorbol	CHEMICAL
ester-induced	O
cyclooxygenase-2	GENE-Y
expression	O
in	O
macrophages	O
.	O
Proximal	O
tubule	O
cells	O
extract	O
dicarboxylates	O
from	O
filtrate	O
and	O
blood	O
,	O
using	O
cotransporters	O
located	O
in	O
the	O
brush	O
border	O
[	O
sodium	GENE-N
dicarboxylate	O
cotransporter	O
(	O
NaDC-1	GENE-Y
)	O
]	O
and	O
basolateral	O
cell	O
membrane	O
(	O
NaDC-3	GENE-Y
)	O
.	O

We	O
expressed	O
the	O
human	GENE-Y
NaDC-3	GENE-Y
(	O
hNaDC-3	GENE-Y
)	O
in	O
Xenopus	O
laevis	O
oocytes	O
and	O
characterized	O
it	O
by	O
the	O
two-electrode	O
voltage-clamp	O
technique	O
.	O

At	O
-60	O
mV	O
,	O
succinate	CHEMICAL
(	O
4	O
carbons	CHEMICAL
)	O
and	O
glutarate	CHEMICAL
(	O
5	O
carbons	CHEMICAL
)	O
generated	O
inward	O
currents	O
due	O
to	O
translocation	O
of	O
three	O
sodium	CHEMICAL
ions	O
and	O
one	O
divalent	O
dicarboxylate	O
,	O
whereas	O
oxalate	CHEMICAL
(	O
2	O
carbons	CHEMICAL
)	O
and	O
malonate	CHEMICAL
(	O
3	O
carbons	CHEMICAL
)	O
did	O
not	O
.	O

The	O
cis-dicarboxylate	CHEMICAL
maleate	CHEMICAL
produced	O
currents	O
smaller	O
in	O
magnitude	O
,	O
whereas	O
the	O
trans-dicarboxylate	CHEMICAL
fumarate	CHEMICAL
generated	O
currents	O
similar	O
to	O
succinate	CHEMICAL
.	O

The	O
substituted	O
succinate	CHEMICAL
derivatives	O
,	O
malate	CHEMICAL
,	O
2	CHEMICAL
,	CHEMICAL
2-	CHEMICAL
and	CHEMICAL
2	CHEMICAL
,	CHEMICAL
3-dimethylsuccinate	CHEMICAL
,	O
and	O
2	CHEMICAL
,	CHEMICAL
3-dimercaptosuccinate	CHEMICAL
elicited	O
inward	O
currents	O
,	O
whereas	O
aspartate	CHEMICAL
and	O
guanidinosuccinate	CHEMICAL
showed	O
hardly	O
detectable	O
currents	O
.	O

The	O
C-5	CHEMICAL
dicarboxylates	CHEMICAL
glutarate	CHEMICAL
and	O
alpha-ketoglutarate	CHEMICAL
produced	O
larger	O
currents	O
than	O
succinate;	O
glutamate	CHEMICAL
and	O
folate	CHEMICAL
failed	O
to	O
cause	O
inward	O
currents	O
.	O

Kinetic	O
analysis	O
revealed	O
,	O
at	O
-60	O
mV	O
,	O
K	O
(	O
0	O
.	O
5	O
)	O
values	O
of	O
25	O
+	O
/	O
-	O
12	O
microM	O
for	O
succinate	CHEMICAL
and	O
45	O
+	O
/	O
-	O
13	O
microM	O
for	O
alpha-ketoglutarate	CHEMICAL
,	O
values	O
close	O
to	O
the	O
plasma	O
concentration	O
of	O
these	O
compounds	O
.	O

For	O
both	O
compounds	O
,	O
the	O
K	O
(	O
0	O
.	O
5	O
)	O
was	O
independent	O
of	O
voltage	O
,	O
whereas	O
the	O
maximal	O
current	O
increased	O
with	O
hyperpolarization	O
.	O

As	O
opposed	O
to	O
the	O
rat	O
and	O
flounder	O
orthologs	O
,	O
hNaDC-3	GENE-Y
was	O
hardly	O
inhibited	O
by	O
lithium	CHEMICAL
concentrations	O
up	O
to	O
5	O
mM	O
.	O

In	O
the	O
absence	O
of	O
sodium	CHEMICAL
,	O
however	O
,	O
lithium	CHEMICAL
can	O
mediate	O
succinate-dependent	O
currents	O
.	O

The	O
narrow	O
substrate	O
specificity	O
prevents	O
interaction	O
of	O
drugs	O
with	O
dicarboxylate-like	O
structure	O
with	O
hNaDC-3	GENE-Y
and	O
ensures	O
sufficient	O
support	O
of	O
the	O
proximal	O
tubule	O
cells	O
with	O
alpha-ketoglutarate	CHEMICAL
for	O
anion	O
secretion	O
via	O
organic	GENE-N
anion	GENE-N
transporter	GENE-N
1	GENE-N
or	GENE-N
3	GENE-N
.	O
Phenformin	CHEMICAL
has	O
a	O
direct	O
inhibitory	O
effect	O
on	O
the	O
ATP-sensitive	O
potassium	CHEMICAL
channel	O
.	O
Changes	O
in	O
intestinal	O
permeability	O
and	O
lactose	CHEMICAL
hydrolysis	O
have	O
been	O
investigated	O
in	O
three	O
adults	O
and	O
fifteen	O
infants	O
with	O
acute	O
rotaviral	O
gastroenteritis	O
by	O
differential	O
sugar	O
absorption	O
.	O

The	O
method	O
involves	O
chromatographic	O
measurement	O
of	O
urinary	O
lactose	CHEMICAL
,	O
lactulose	CHEMICAL
and	O
L-rhamnose	CHEMICAL
excretion	O
following	O
combined	O
ingestion	O
in	O
an	O
iso-osmolar	O
test	O
solution	O
.	O

All	O
patients	O
had	O
abnormal	O
intestinal	O
permeability	O
indicated	O
by	O
raised	O
urine	O
lactulose	CHEMICAL
/	O
L-rhamnose	CHEMICAL
excretion	O
,	O
ratio	O
of	O
percentages	O
recovered	O
in	O
5	O
h	O
,	O
of	O
0	O
.	O
462	O
(	O
0	O
.	O
100-1	O
.	O
227	O
)	O
mean	O
and	O
range	O
,	O
compared	O
with	O
0	O
.	O
027	O
(	O
0	O
.	O
008-0	O
.	O
052	O
)	O
for	O
healthy	O
controls	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Ten	O
patients	O
also	O
had	O
urinary	O
lactose	CHEMICAL
/	O
lactulose	CHEMICAL
excretion	O
ratios	O
raised	O
above	O
the	O
normal	O
range	O
(	O
0	O
.	O
014-0	O
.	O
41	O
,	O
mean	O
0	O
.	O
258	O
)	O
during	O
their	O
acute	O
illness	O
,	O
indicating	O
impaired	O
intestinal	O
lactose	CHEMICAL
hydrolysis	O
.	O

Both	O
indices	O
had	O
become	O
normal	O
4	O
weeks	O
after	O
the	O
acute	O
illness	O
,	O
serial	O
investigation	O
of	O
five	O
patients	O
showing	O
that	O
improvement	O
was	O
complete	O
much	O
earlier	O
.	O

Except	O
for	O
the	O
short	O
duration	O
these	O
changes	O
are	O
similar	O
to	O
those	O
associated	O
with	O
villous	O
atrophy	O
in	O
coeliac	O
disease	O
.	O

The	O
test	O
procedure	O
was	O
verified	O
with	O
respect	O
to	O
intestinal	O
lactose	CHEMICAL
hydrolysis	O
by	O
demonstrating	O
a	O
linear	O
relationship	O
between	O
lactose	CHEMICAL
/	O
lactulose	CHEMICAL
excretion	O
and	O
log	O
jejunal	O
mucosal	O
lactase	GENE-Y
activity	O
by	O
in	O
vitro	O
assay	O
(	O
R2	O
=	O
0	O
.	O
95	O
)	O
in	O
a	O
further	O
group	O
of	O
subjects	O
.	O

Differential	O
lactose	CHEMICAL
/	O
lactulose	CHEMICAL
/	O
L-rhamnose	CHEMICAL
absorption	O
provides	O
a	O
non-invasive	O
and	O
sensitive	O
index	O
of	O
small	O
intestinal	O
integrity	O
of	O
value	O
for	O
the	O
interpretation	O
of	O
prolonged	O
or	O
otherwise	O
complicated	O
enteritis	O
and	O
the	O
distinction	O
of	O
primary	O
secondary	O
intestinal	O
lactase	GENE-Y
deficiency	O
.	O
The	O
human	GENE-Y
telomeric	GENE-Y
protein	GENE-Y
TRF2	GENE-Y
is	O
required	O
to	O
protect	O
chromosome	O
ends	O
by	O
facilitating	O
their	O
organization	O
into	O
the	O
protective	O
capping	O
structure	O
.	O

Post-translational	O
modifications	O
of	O
TRF2	GENE-Y
such	O
as	O
phosphorylation	O
,	O
ubiquitination	O
,	O
SUMOylation	O
,	O
methylation	O
and	O
poly	O
(	O
ADP-ribosyl	O
)	O
ation	O
have	O
been	O
shown	O
to	O
play	O
important	O
roles	O
in	O
telomere	O
function	O
.	O

Here	O
we	O
show	O
that	O
TRF2	GENE-Y
specifically	O
interacts	O
with	O
the	O
histone	GENE-Y
acetyltransferase	GENE-Y
p300	GENE-Y
,	O
and	O
that	O
p300	GENE-Y
acetylates	O
the	O
lysine	CHEMICAL
residue	O
at	O
position	O
293	O
of	O
TRF2	GENE-Y
.	O

We	O
also	O
report	O
that	O
p300-mediated	O
acetylation	O
stabilizes	O
the	O
TRF2	GENE-Y
protein	O
by	O
inhibiting	O
its	O
ubiquitin-dependent	O
proteolysis	O
and	O
is	O
required	O
for	O
efficient	O
telomere	O
binding	O
of	O
TRF2	GENE-Y
.	O

Furthermore	O
,	O
overexpression	O
of	O
the	O
acetylation-deficient	O
mutant	O
,	O
K293R	GENE-N
,	O
induces	O
DNA-damage	O
response	O
foci	O
at	O
telomeres	O
,	O
thereby	O
leading	O
to	O
induction	O
of	O
impaired	O
cell	O
growth	O
,	O
cellular	O
senescence	O
and	O
altered	O
cell	O
cycle	O
distribution	O
.	O

A	O
small	O
but	O
significant	O
number	O
of	O
metaphase	O
chromosomes	O
show	O
no	O
telomeric	O
signals	O
at	O
chromatid	O
ends	O
,	O
suggesting	O
an	O
aberrant	O
telomere	O
structure	O
.	O

These	O
findings	O
demonstrate	O
that	O
acetylation	O
of	O
TRF2	GENE-Y
by	O
p300	GENE-Y
plays	O
a	O
crucial	O
role	O
in	O
the	O
maintenance	O
of	O
functional	O
telomeres	O
as	O
well	O
as	O
in	O
the	O
regulation	O
of	O
the	O
telomere-associated	O
DNA-damage	O
response	O
,	O
thus	O
providing	O
a	O
new	O
route	O
for	O
modulating	O
telomere	O
protection	O
function	O
.	O
OBJECTIVE	O
:	O
To	O
determine	O
the	O
type	O
of	O
mutation	O
in	O
a	O
patient	O
with	O
clinical	O
diagnosis	O
of	O
suspected	O
APRT	GENE-Y
deficiency	O
.	O

DESIGN	O
AND	O
METHODS	O
:	O
A	O
51-year-old	O
male	O
patient	O
,	O
with	O
a	O
clinical	O
history	O
of	O
two	O
prior	O
episodes	O
of	O
renal	O
colic	O
with	O
urinary	O
stone	O
excretion	O
(	O
reported	O
as	O
uric	CHEMICAL
acid	CHEMICAL
stones	O
in	O
the	O
first	O
episode	O
and	O
as	O
calcium	CHEMICAL
oxalate	CHEMICAL
stones	O
in	O
the	O
second	O
)	O
,	O
was	O
admitted	O
to	O
the	O
hospital	O
with	O
severe	O
non-oliguric	O
renal	O
failure	O
(	O
1	O
.	O
06	O
mmol	O
/	O
L	O
serum	O
creatinine	CHEMICAL
)	O
,	O
severe	O
hyponatremia	O
(	O
114	O
mmol	O
/	O
L	O
Na	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
)	O
,	O
metabolic	O
acidosis	O
(	O
14	O
mmol	O
/	O
L	O
HCO	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
(	CHEMICAL
-	CHEMICAL
)	CHEMICAL
)	O
and	O
uricemia	O
in	O
the	O
normal	O
range	O
.	O

Abnormalities	O
at	O
renal	O
scan	O
and	O
persistency	O
of	O
severe	O
renal	O
failure	O
required	O
to	O
start	O
haemodialysis	O
.	O

Results	O
of	O
renal	O
biopsy	O
prompted	O
us	O
to	O
undertake	O
a	O
biochemical	O
and	O
molecular	O
biological	O
evaluation	O
of	O
the	O
patient	O
for	O
suspected	O
adenine	CHEMICAL
phosphoribosyltransferase	O
(	O
APRT	GENE-Y
)	O
deficiency	O
.	O

RESULTS	O
:	O
HPLC	O
analysis	O
of	O
serum	O
and	O
urine	O
,	O
for	O
determining	O
purine	CHEMICAL
derivative	O
profile	O
,	O
showed	O
the	O
pathological	O
presence	O
of	O
adenine	CHEMICAL
in	O
both	O
biological	O
fluids	O
(	O
3	O
.	O
57	O
micromol	O
/	O
L	O
and	O
7	O
.	O
11	O
micromol	O
/	O
mmol	O
creatinine	CHEMICAL
in	O
serum	O
and	O
urine	O
,	O
respectively;	O
not	O
detectable	O
in	O
both	O
fluids	O
in	O
healthy	O
controls	O
)	O
.	O

APRT	GENE-Y
assay	O
in	O
a	O
sample	O
of	O
patient	O
hemolysate	O
showed	O
no	O
detectable	O
activity	O
of	O
the	O
enzyme	O
(	O
25	O
.	O
56	O
+	O
/	O
-9	O
.	O
55	O
U	O
/	O
L	O
red	O
blood	O
cells	O
in	O
control	O
healthy	O
subjects	O
)	O
.	O

Molecular	O
biological	O
analysis	O
of	O
the	O
amplified	O
APRT	GENE-Y
gene	O
revealed	O
that	O
the	O
patient	O
harboured	O
in	O
exon	O
3	O
a	O
homozygous	O
254	O
bp	O
deletion-8	O
bp	O
insertion	O
,	O
previously	O
described	O
only	O
once	O
in	O
a	O
compound	O
heterozygote	O
.	O

Analysis	O
of	O
the	O
patient	O
family	O
showed	O
that	O
heterozygotes	O
for	O
this	O
APRT	GENE-Y
gene	O
mutation	O
,	O
in	O
spite	O
of	O
a	O
69%	O
lower	O
APRT	GENE-Y
enzymatic	O
activity	O
than	O
that	O
of	O
healthy	O
subjects	O
,	O
had	O
no	O
detectable	O
adenine	CHEMICAL
concentrations	O
in	O
both	O
serum	O
and	O
urine	O
.	O

CONCLUSIONS	O
:	O
Results	O
of	O
the	O
first	O
patient	O
harbouring	O
the	O
homozygous	O
254	O
bp	O
deletion-8	O
bp	O
insertion	O
of	O
the	O
APRT	GENE-Y
gene	O
strongly	O
indicated	O
that	O
definitive	O
diagnosis	O
of	O
APRT	GENE-Y
deficiency	O
(	O
often	O
under	O
or	O
misdiagnosed	O
)	O
would	O
require	O
a	O
combined	O
clinical	O
,	O
biochemical	O
and	O
molecular	O
biological	O
evaluation	O
.	O
Polyethylenimine	CHEMICAL
(	O
PEI	CHEMICAL
)	O
is	O
one	O
of	O
the	O
most	O
broadly	O
used	O
polycations	O
for	O
gene	O
delivery	O
due	O
to	O
its	O
high	O
transfection	O
efficiency	O
and	O
commercial	O
availability	O
but	O
materials	O
are	O
cytotoxic	O
and	O
often	O
polydisperse	O
.	O

The	O
goal	O
of	O
current	O
work	O
is	O
to	O
develop	O
an	O
alternative	O
family	O
of	O
polycations	O
based	O
on	O
controlled	O
living	O
radical	O
polymerization	O
(	O
CLRP	O
)	O
and	O
to	O
optimize	O
the	O
polymer	O
structure	O
for	O
efficient	O
gene	O
delivery	O
.	O

In	O
this	O
study	O
,	O
well-defined	O
poly	CHEMICAL
(	CHEMICAL
glycidyl	CHEMICAL
methacrylate	CHEMICAL
)	CHEMICAL
(	O
P	CHEMICAL
(	CHEMICAL
GMA	CHEMICAL
)	CHEMICAL
)	O
homopolymers	O
were	O
synthesized	O
using	O
reversible	O
addition-fragmentation	O
chain	O
transfer	O
(	O
RAFT	O
)	O
polymerization	O
followed	O
by	O
decoration	O
using	O
three	O
different	O
types	O
of	O
oligoamines	CHEMICAL
,	O
i	O
.	O

e	O
.	O

,	O
tetraethylenepentamine	CHEMICAL
(	O
TEPA	CHEMICAL
)	O
,	O
pentaethylenehexamine	CHEMICAL
(	O
PEHA	CHEMICAL
)	O
,	O
and	O
tris	CHEMICAL
(	CHEMICAL
2-aminoethyl	CHEMICAL
)	CHEMICAL
amine	CHEMICAL
(	O
TREN	CHEMICAL
)	O
,	O
respectively	O
,	O
to	O
generate	O
various	O
P	CHEMICAL
(	CHEMICAL
GMA-oligoamine	CHEMICAL
)	CHEMICAL
homopolycations	O
.	O

The	O
effect	O
of	O
P	CHEMICAL
(	CHEMICAL
GMA	CHEMICAL
)	CHEMICAL
backbone	O
length	O
and	O
structure	O
of	O
oligoamine	CHEMICAL
on	O
gene	O
transfer	O
efficiency	O
was	O
then	O
determined	O
.	O

The	O
optimal	O
polymer	O
,	O
P	CHEMICAL
(	CHEMICAL
GMA-TEPA	CHEMICAL
)	CHEMICAL
(	CHEMICAL
50	CHEMICAL
)	CHEMICAL
,	O
provided	O
comparable	O
transfection	O
efficiency	O
but	O
lower	O
cytotoxicity	O
than	O
PEI	CHEMICAL
.	O

P	CHEMICAL
(	CHEMICAL
GMA-TEPA	CHEMICAL
)	CHEMICAL
(	CHEMICAL
50	CHEMICAL
)	CHEMICAL
was	O
then	O
used	O
as	O
the	O
cationic	O
block	O
in	O
diblock	O
copolymers	O
containing	O
hydrophilic	O
N-	CHEMICAL
(	CHEMICAL
2-hydroxypropyl	CHEMICAL
)	CHEMICAL
methacrylamide	CHEMICAL
(	O
HPMA	CHEMICAL
)	O
and	O
oligo	CHEMICAL
(	CHEMICAL
ethylene	CHEMICAL
glycol	CHEMICAL
)	CHEMICAL
monomethyl	CHEMICAL
ether	CHEMICAL
methacrylate	CHEMICAL
(	O
OEGMA	CHEMICAL
)	O
.	O

Polyplexes	O
of	O
block	O
copolymers	O
were	O
stable	O
against	O
aggregation	O
in	O
physiological	O
salt	O
condition	O
and	O
in	O
Opti-MEM	O
due	O
to	O
the	O
shielding	O
effect	O
of	O
P	CHEMICAL
(	CHEMICAL
HPMA	CHEMICAL
)	CHEMICAL
and	O
P	CHEMICAL
(	CHEMICAL
OEGMA	CHEMICAL
)	CHEMICAL
.	O

However	O
,	O
the	O
presence	O
of	O
the	O
HPMA	CHEMICAL
/	O
OEGMA	CHEMICAL
block	O
significantly	O
decreased	O
the	O
transfection	O
efficacy	O
of	O
P	CHEMICAL
(	CHEMICAL
GMA-TEPA	CHEMICAL
)	CHEMICAL
(	CHEMICAL
50	CHEMICAL
)	CHEMICAL
homopolycation	O
.	O

To	O
compensate	O
for	O
reduced	O
cell	O
uptake	O
caused	O
by	O
the	O
hydrophilic	O
shell	O
of	O
polyplex	O
,	O
the	O
integrin-binding	O
peptide	O
,	O
RGD	O
,	O
was	O
conjugated	O
to	O
the	O
hydrophilic	O
chain	O
end	O
of	O
P	CHEMICAL
(	CHEMICAL
OEGMA	CHEMICAL
)	CHEMICAL
(	CHEMICAL
15	CHEMICAL
)	CHEMICAL
-b-P	CHEMICAL
(	CHEMICAL
GMA-TEPA	CHEMICAL
)	CHEMICAL
(	CHEMICAL
50	CHEMICAL
)	CHEMICAL
copolymer	O
by	O
Michael-type	O
addition	O
reaction	O
.	O

At	O
low	O
polymer	O
to	O
DNA	O
ratios	O
,	O
the	O
RGD-functionalized	O
polymer	O
showed	O
increased	O
gene	O
delivery	O
efficiency	O
to	O
HeLa	O
cells	O
compared	O
to	O
analogous	O
polymers	O
lacking	O
RGD	O
.	O
Differential	O
interaction	O
of	O
glimepiride	CHEMICAL
and	O
glibenclamide	CHEMICAL
with	O
the	O
beta-cell	O
sulfonylurea	GENE-N
receptor	O
.	O

I	O
.	O

Binding	O
characteristics	O
.	O
Alkaloid	O
homoharringtonine	CHEMICAL
inhibits	O
polypeptide	O
chain	O
elongation	O
on	O
human	O
ribosomes	O
on	O
the	O
step	O
of	O
peptide	O
bond	O
formation	O
.	O
Tocopherols	CHEMICAL
and	O
tocotrienols	CHEMICAL
represent	O
the	O
two	O
subclasses	O
within	O
the	O
vitamin	CHEMICAL
E	CHEMICAL
family	O
of	O
compounds	O
.	O

However	O
,	O
tocotrienols	CHEMICAL
are	O
significantly	O
more	O
potent	O
than	O
tocopherols	CHEMICAL
in	O
suppressing	O
epidermal	GENE-Y
growth	GENE-Y
factor	GENE-Y
(	O
EGF	GENE-Y
)	O
-dependent	O
normal	O
mammary	O
epithelial	O
cell	O
growth	O
.	O

EGF	GENE-Y
is	O
a	O
potent	O
mitogen	O
for	O
normal	O
mammary	O
epithelial	O
cells	O
and	O
an	O
initial	O
event	O
in	O
EGF-receptor	GENE-Y
mitogenic-signalling	O
is	O
protein	GENE-N
kinase	GENE-N
C	GENE-N
(	O
PKC	GENE-N
)	O
activation	O
.	O

Studies	O
were	O
conducted	O
to	O
determine	O
if	O
the	O
antiproliferative	O
effects	O
of	O
specific	O
tocopherol	CHEMICAL
and	O
tocotrienol	CHEMICAL
isoforms	O
are	O
associated	O
with	O
a	O
reduction	O
in	O
EGF-receptor	GENE-Y
mitogenic	O
signalling	O
and	O
/	O
or	O
PKC	GENE-N
activation	O
.	O

Normal	O
mammary	O
epithelial	O
cells	O
isolated	O
from	O
midpregnant	O
BALB	O
/	O
c	O
mice	O
were	O
grown	O
in	O
primary	O
culture	O
,	O
and	O
maintained	O
on	O
serum-free	O
media	O
containing	O
10	O
ng	O
/	O
mL	O
EGF	GENE-Y
as	O
a	O
mitogen	O
,	O
and	O
treated	O
with	O
various	O
doses	O
(	O
0-250	O
microm	O
)	O
of	O
alpha-	CHEMICAL
,	CHEMICAL
gamma-	CHEMICAL
,	CHEMICAL
or	CHEMICAL
delta-tocopherol	CHEMICAL
or	O
alpha-	CHEMICAL
,	CHEMICAL
gamma-	CHEMICAL
,	CHEMICAL
or	CHEMICAL
delta-tocotrienol	CHEMICAL
.	O

Treatment	O
with	O
growth	O
inhibitory	O
doses	O
of	O
delta-tocopherol	CHEMICAL
(	O
100	O
microm	O
)	O
,	O
alpha-tocotrienol	CHEMICAL
(	O
50	O
microm	O
)	O
,	O
or	O
gamma-	CHEMICAL
or	CHEMICAL
delta-tocotrienol	CHEMICAL
(	O
10	O
microm	O
)	O
did	O
not	O
affect	O
EGF-receptor	GENE-Y
levels	O
,	O
EGF-induced	O
EGF-receptor	GENE-Y
tyrosine	CHEMICAL
kinase	O
activity	O
,	O
or	O
total	O
intracellular	O
levels	O
of	O
PKC	GENE-Y
(	GENE-Y
alpha	GENE-Y
)	GENE-Y
.	O

However	O
,	O
these	O
treatments	O
were	O
found	O
to	O
inhibit	O
EGF-induced	O
PKC	GENE-Y
(	GENE-Y
alpha	GENE-Y
)	GENE-Y
activation	O
as	O
determined	O
by	O
its	O
translocation	O
from	O
the	O
cytosolic	O
to	O
membrane	O
fraction	O
.	O

Treatment	O
with	O
250	O
microm	O
alpha-	CHEMICAL
or	CHEMICAL
gamma-tocopherol	CHEMICAL
had	O
no	O
affect	O
on	O
EGF-receptor	GENE-Y
mitogenic	O
signalling	O
or	O
cell	O
growth	O
.	O

These	O
findings	O
demonstrate	O
that	O
the	O
inhibitory	O
effects	O
of	O
specific	O
tocopherol	CHEMICAL
and	O
tocotrienol	CHEMICAL
isoforms	O
on	O
EGF-dependent	O
normal	O
mammary	O
epithelial	O
cell	O
mitogenesis	O
occurs	O
downstream	O
from	O
the	O
EGF-receptor	GENE-Y
and	O
appears	O
to	O
be	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
a	O
reduction	O
in	O
PKC	GENE-Y
(	GENE-Y
alpha	GENE-Y
)	GENE-Y
activation	O
.	O
RATIONALE	O
:	O
Induction	O
of	O
heme	GENE-Y
oxygenase-1	GENE-Y
(	O
HO-1	GENE-Y
)	O
protects	O
the	O
liver	O
against	O
reperfusion	O
injury	O
after	O
hemorrhagic	O
shock	O
.	O

Previous	O
data	O
suggest	O
that	O
the	O
beta	GENE-Y
(	GENE-Y
1	GENE-Y
)	GENE-Y
-adrenoceptor	GENE-Y
agonist	O
dobutamine	CHEMICAL
induces	O
HO-1	GENE-Y
in	O
hepatocytes	O
.	O

OBJECTIVES	O
:	O
To	O
investigate	O
the	O
functional	O
significance	O
of	O
dobutamine	CHEMICAL
pretreatment	O
for	O
liver	O
function	O
after	O
hemorrhagic	O
shock	O
in	O
vivo	O
.	O

METHODS	O
:	O
Anesthetized	O
rats	O
received	O
either	O
Ringer's	O
(	O
Vehicle	O
/	O
Shock	O
)	O
,	O
10	O
microg	O
/	O
kg	O
/	O
min	O
of	O
the	O
beta	GENE-Y
(	GENE-Y
1	GENE-Y
)	GENE-Y
-adrenoceptor	GENE-Y
agonist	O
dobutamine	CHEMICAL
(	O
Dob	CHEMICAL
/	O
Shock	O
)	O
,	O
or	O
10	O
microg	O
/	O
kg	O
/	O
min	O
dobutamine	CHEMICAL
and	O
500	O
microg	O
/	O
kg	O
/	O
min	O
of	O
the	O
beta	GENE-Y
(	GENE-Y
1	GENE-Y
)	GENE-Y
-adrenoceptor	GENE-Y
antagonist	O
esmolol	CHEMICAL
(	O
Dob	CHEMICAL
/	O
Esmolol	CHEMICAL
/	O
Shock	O
)	O
for	O
6	O
h	O
.	O

Hemorrhagic	O
shock	O
was	O
induced	O
thereafter	O
(	O
mean	O
arterial	O
pressure	O
,	O
35	O
mm	O
Hg	O
for	O
90	O
min	O
)	O
.	O

Animals	O
were	O
resuscitated	O
with	O
shed	O
blood	O
and	O
Ringer's	O
.	O

In	O
addition	O
,	O
the	O
HO	GENE-N
pathway	O
was	O
blocked	O
after	O
dobutamine	CHEMICAL
pretreatment	O
with	O
10	O
micromol	O
/	O
kg	O
tin-mesoporphyrin-IX	CHEMICAL
(	O
Dob	CHEMICAL
/	O
SnMP	CHEMICAL
/	O
Shock	O
)	O
or	O
animals	O
received	O
100	O
mg	O
/	O
kg	O
of	O
the	O
carbon	CHEMICAL
monoxide	CHEMICAL
donor	O
dichloromethane	CHEMICAL
(	O
DCM	CHEMICAL
/	O
Shock	O
)	O
.	O

MEASUREMENTS	O
:	O
Hepatocellular	O
metabolism	O
and	O
liver	O
blood	O
flow	O
were	O
measured	O
by	O
plasma	O
disappearance	O
rate	O
of	O
indocyanine	CHEMICAL
green	CHEMICAL
(	O
PDR	O
(	O
ICG	CHEMICAL
)	O
)	O
as	O
a	O
sensitive	O
marker	O
of	O
liver	O
function	O
.	O

MAIN	O
RESULTS	O
:	O
Pretreatment	O
with	O
dobutamine	CHEMICAL
induced	O
HO-1	GENE-Y
in	O
pericentral	O
hepatocytes	O
and	O
improved	O
PDR	O
(	O
ICG	O
)	O
(	O
Vehicle	O
/	O
Shock	O
:	O
11	O
.	O
7	O
+	O
/	O
-	O
8	O
.	O
12%	O
/	O
min	O
vs	O
.	O

Dob	CHEMICAL
/	O
Shock	O
:	O
19	O
.	O
7	O
+	O
/	O
-	O
2	O
.	O
46%	O
/	O
min	O
,	O
p	O
=	O
0	O
.	O
006	O
)	O
.	O

Blockade	O
of	O
the	O
HO	GENE-N
pathway	O
after	O
preconditioning	O
and	O
the	O
combined	O
pretreatment	O
with	O
dobutamine	CHEMICAL
and	O
esmolol	O
decreased	O
PDR	O
(	O
ICG	CHEMICAL
)	O
(	O
Dob	CHEMICAL
/	O
SnMP	CHEMICAL
/	O
Shock	O
:	O
12	O
.	O
6	O
+	O
/	O
-	O
4	O
.	O
24%	O
/	O
min	O
,	O
p	O
=	O
0	O
.	O
011;	O
Dob	CHEMICAL
/	O
Esmolol	CHEMICAL
/	O
Shock	O
:	O
10	O
.	O
2	O
+	O
/	O
-	O
4	O
.	O
34%	O
/	O
min	O
,	O
p	O
=	O
0	O
.	O
008	O
)	O
.	O

Pretreatment	O
with	O
a	O
carbon	CHEMICAL
monoxide	CHEMICAL
donor	O
improved	O
PDR	O
(	O
ICG	CHEMICAL
)	O
(	O
DCM	CHEMICAL
/	O
Shock	O
:	O
18	O
+	O
/	O
-	O
3	O
.	O
19%	O
/	O
min	O
,	O
p	O
=	O
0	O
.	O
022	O
)	O
compared	O
with	O
Vehicle	O
/	O
Shock	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
a	O
beta	GENE-Y
(	GENE-Y
1	GENE-Y
)	GENE-Y
-adrenoceptor-dependent	O
hepatic	O
up-regulation	O
of	O
HO-1	GENE-Y
and	O
a	O
better	O
maintained	O
hepatocellular	O
function	O
after	O
hemorrhagic	O
shock	O
in	O
animals	O
pretreated	O
with	O
dobutamine	CHEMICAL
.	O

The	O
improved	O
hepatocellular	O
function	O
may	O
be	O
in	O
part	O
mediated	O
by	O
carbon	CHEMICAL
monoxide	CHEMICAL
because	O
of	O
up-regulation	O
of	O
HO-1	GENE-Y
.	O

Pretreatment	O
with	O
dobutamine	CHEMICAL
might	O
be	O
a	O
potential	O
means	O
of	O
pharmacologic	O
preconditioning	O
before	O
ischemia-reperfusion	O
of	O
the	O
liver	O
.	O
β-Galactosidase	GENE-N
(	O
lacZ	GENE-N
)	O
has	O
bifunctional	O
activity	O
.	O

It	O
hydrolyzes	O
lactose	CHEMICAL
to	O
galactose	CHEMICAL
and	O
glucose	CHEMICAL
and	O
catalyzes	O
the	O
intramolecular	O
isomerization	O
of	O
lactose	CHEMICAL
to	O
allolactose	CHEMICAL
,	O
the	O
lac	O
operon	O
inducer	O
.	O

β-Galactosidase	GENE-N
promotes	O
the	O
isomerization	O
by	O
means	O
of	O
an	O
acceptor	O
site	O
that	O
binds	O
glucose	CHEMICAL
after	O
its	O
cleavage	O
from	O
lactose	CHEMICAL
and	O
thus	O
delays	O
its	O
exit	O
from	O
the	O
site	O
.	O

However	O
,	O
because	O
of	O
its	O
relatively	O
low	O
affinity	O
for	O
glucose	CHEMICAL
,	O
details	O
of	O
this	O
site	O
have	O
remained	O
elusive	O
.	O

We	O
present	O
structural	O
data	O
mapping	O
the	O
glucose	CHEMICAL
site	O
based	O
on	O
a	O
substituted	O
enzyme	O
(	O
G794A-β-galactosidase	GENE-N
)	O
that	O
traps	O
allolactose	CHEMICAL
.	O

Various	O
lines	O
of	O
evidence	O
indicate	O
that	O
the	O
glucose	CHEMICAL
of	O
the	O
trapped	O
allolactose	CHEMICAL
is	O
in	O
the	O
acceptor	O
position	O
.	O

The	O
evidence	O
includes	O
structures	O
with	O
Bis-Tris	CHEMICAL
(	CHEMICAL
2	CHEMICAL
,	CHEMICAL
2-bis	CHEMICAL
(	CHEMICAL
hydroxymethyl	CHEMICAL
)	CHEMICAL
-2	CHEMICAL
,	CHEMICAL
2'	CHEMICAL
,	CHEMICAL
2″-nitrilotriethanol	CHEMICAL
)	CHEMICAL
and	O
l-ribose	CHEMICAL
in	O
the	O
site	O
and	O
kinetic	O
binding	O
studies	O
with	O
substituted	O
β-galactosidases	GENE-N
.	O

The	O
site	O
is	O
composed	O
of	O
Asn-102	O
,	O
His-418	O
,	O
Lys-517	O
,	O
Ser-796	O
,	O
Glu-797	O
,	O
and	O
Trp-999	O
.	O

Ser-796	O
and	O
Glu-797	O
are	O
part	O
of	O
a	O
loop	O
(	O
residues	O
795-803	O
)	O
that	O
closes	O
over	O
the	O
active	O
site	O
.	O

This	O
loop	O
appears	O
essential	O
for	O
the	O
bifunctional	O
nature	O
of	O
the	O
enzyme	O
because	O
it	O
helps	O
form	O
the	O
glucose	CHEMICAL
binding	O
site	O
.	O

In	O
addition	O
,	O
because	O
the	O
loop	O
is	O
mobile	O
,	O
glucose	CHEMICAL
binding	O
is	O
transient	O
,	O
allowing	O
the	O
release	O
of	O
some	O
glucose	CHEMICAL
.	O

Bioinformatics	O
studies	O
showed	O
that	O
the	O
residues	O
important	O
for	O
interacting	O
with	O
glucose	CHEMICAL
are	O
only	O
conserved	O
in	O
a	O
subset	O
of	O
related	O
enzymes	O
.	O

Thus	O
,	O
intramolecular	O
isomerization	O
is	O
not	O
a	O
universal	O
feature	O
of	O
β-galactosidases	GENE-N
.	O

Genomic	O
analyses	O
indicated	O
that	O
lac	O
repressors	O
were	O
co-selected	O
only	O
within	O
the	O
conserved	O
subset	O
.	O

This	O
shows	O
that	O
the	O
glucose	CHEMICAL
binding	O
site	O
of	O
β-galactosidase	GENE-N
played	O
an	O
important	O
role	O
in	O
lac	O
operon	O
evolution	O
.	O
Design	O
and	O
synthesis	O
of	O
2-substituted	CHEMICAL
benzoxazoles	CHEMICAL
as	O
novel	O
PTP1B	GENE-Y
inhibitors	O
.	O
SU11248	CHEMICAL
is	O
a	O
novel	O
FLT3	GENE-Y
tyrosine	GENE-N
kinase	O
inhibitor	O
with	O
potent	O
activity	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
Allopurinol	CHEMICAL
is	O
an	O
inhibitor	O
of	O
xanthine	CHEMICAL
oxidoreductase	O
(	O
XOR	GENE-Y
)	O
and	O
inhibits	O
the	O
generation	O
of	O
uric	CHEMICAL
acid	CHEMICAL
(	O
UA	CHEMICAL
)	O
as	O
the	O
final	O
product	O
of	O
purine	CHEMICAL
catabolism	O
,	O
as	O
well	O
as	O
the	O
resulting	O
generation	O
of	O
superoxide	CHEMICAL
(	O
O2	CHEMICAL
(	CHEMICAL
-	CHEMICAL
)	CHEMICAL
)	O
,	O
in	O
humans	O
.	O

Elevation	O
of	O
the	O
serum	O
UA	CHEMICAL
(	O
SUA	O
)	O
level	O
,	O
referred	O
to	O
as	O
hyperuricemia	O
(	O
HU	O
)	O
,	O
eventually	O
leads	O
to	O
gout	O
and	O
allopurinol	CHEMICAL
has	O
been	O
used	O
for	O
the	O
treatment	O
of	O
HU	O
and	O
gout	O
.	O

Studies	O
have	O
revealed	O
the	O
role	O
of	O
elevated	O
SUA	O
levels	O
and	O
the	O
associated	O
oxidative	O
stress	O
(	O
OS	O
)	O
in	O
a	O
broad	O
spectrum	O
of	O
pathological	O
conditions	O
and	O
it	O
is	O
anticipated	O
that	O
these	O
findings	O
would	O
also	O
expand	O
the	O
use	O
of	O
allopurinol	CHEMICAL
as	O
a	O
therapeutic	O
drug	O
.	O

This	O
article	O
presents	O
a	O
review	O
of	O
reports	O
,	O
mainly	O
of	O
recent	O
studies	O
,	O
on	O
the	O
efficacy	O
of	O
allopurinol	CHEMICAL
in	O
various	O
diseases	O
and	O
explores	O
novel	O
potential	O
uses	O
of	O
the	O
drug	O
.	O

Important	O
novel	O
and	O
potential	O
uses	O
of	O
great	O
interest	O
include	O
metabolic	O
syndrome	O
(	O
MetS	O
)	O
and	O
related	O
disorders	O
,	O
chronic	O
kidney	O
disease	O
(	O
CKD	O
)	O
,	O
nonalcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFLD	O
)	O
and	O
nonalcoholic	O
steatohepatitis	O
(	O
NASH	O
)	O
.	O

Ischemia-reperfusion	O
injury	O
and	O
mucositis	O
,	O
encountered	O
as	O
adverse	O
effects	O
of	O
cancer	O
treatment	O
,	O
have	O
also	O
been	O
under	O
investigation	O
as	O
potential	O
targets	O
for	O
allopurinol	CHEMICAL
.	O
Endosulfan	CHEMICAL
(	O
ES	O
)	O
,	O
a	O
persistent	O
organochlorine	CHEMICAL
pesticide	O
,	O
is	O
widely	O
used	O
despite	O
its	O
toxicity	O
to	O
non-target	O
animals	O
.	O

Upon	O
reaching	O
water	O
bodies	O
,	O
ES	O
can	O
cause	O
negative	O
effects	O
on	O
aquatic	O
animals	O
,	O
including	O
disruption	O
of	O
hormonal	O
systems	O
.	O

However	O
,	O
the	O
action	O
of	O
ES	O
on	O
fish	O
reproductive	O
axis	O
has	O
been	O
hardly	O
studied	O
thus	O
far	O
.	O

The	O
aim	O
of	O
the	O
present	O
work	O
was	O
to	O
assess	O
the	O
endocrine	O
disruptive	O
potential	O
of	O
endosulfan	CHEMICAL
on	O
the	O
pituitary	O
gonadotropins	GENE-N
levels	O
and	O
on	O
the	O
testes	O
function	O
due	O
to	O
ES	O
in	O
the	O
South	O
American	O
freshwater	O
fish	O
Cichlasoma	O
dimerus	O
,	O
using	O
in	O
vitro	O
and	O
in	O
vivo	O
approaches	O
.	O

In	O
vitro	O
experiments	O
showed	O
that	O
ES	O
inhibited	O
the	O
LH-stimulated	O
steroidogenesis	O
in	O
gonads;	O
no	O
change	O
was	O
observed	O
in	O
gonadotropins	GENE-N
release	O
from	O
pituitaries	O
in	O
culture	O
.	O

Laboratory	O
waterborne	O
ES	O
(	O
0	O
.	O
1	O
,	O
0	O
.	O
3	O
and	O
1	O
μg	O
/	O
L	O
)	O
exposure	O
for	O
two	O
months	O
caused	O
decrease	O
in	O
βFSH	GENE-Y
pituitary	O
content	O
and	O
γGT	GENE-N
activity	O
in	O
the	O
testes	O
(	O
Sertoli	O
cell	O
function	O
marker	O
)	O
.	O

Testicular	O
histology	O
revealed	O
pathologies	O
such	O
as	O
scarce	O
intermediate	O
stages	O
of	O
spermatogenesis	O
,	O
release	O
of	O
immature	O
germ	O
cells	O
into	O
the	O
lobular	O
lumen	O
,	O
presence	O
of	O
foam	O
cells	O
and	O
interstitial	O
fibrosis	O
.	O

As	O
FSH	GENE-N
and	O
FSH-mediated	O
steroidogenesis	O
regulate	O
spermatogenesis	O
and	O
Sertoli	O
cell	O
function	O
,	O
the	O
effect	O
of	O
ES	O
on	O
FSH	GENE-N
could	O
be	O
responsible	O
for	O
the	O
morphological	O
alterations	O
observed	O
in	O
testes	O
.	O

In	O
vitro	O
,	O
ES	O
disrupted	O
steroidogenesis	O
in	O
gonads	O
,	O
therefore	O
similar	O
effects	O
in	O
vivo	O
cannot	O
be	O
ruled	O
out	O
.	O

Based	O
on	O
this	O
evidence	O
,	O
ES	O
exhibits	O
an	O
endocrine	O
disruptive	O
action	O
on	O
the	O
reproductive	O
axis	O
of	O
C	O
.	O

dimerus	O
,	O
causing	O
disruption	O
at	O
the	O
pituitary	O
and	O
/	O
or	O
at	O
the	O
gonad	O
level	O
.	O

These	O
effects	O
could	O
acquire	O
ecological	O
significance	O
under	O
prolonged	O
exposure	O
to	O
the	O
pesticide	O
in	O
nature	O
.	O
A	O
"clickable"	O
MTX	CHEMICAL
reagent	O
as	O
a	O
practical	O
tool	O
for	O
profiling	O
small-molecule-intracellular	O
target	O
interactions	O
via	O
MASPIT	O
.	O
Pseudohypoaldosteronism	O
type	O
1	O
(	O
PHA1	O
)	O
,	O
a	O
rare	O
disorder	O
of	O
infancy	O
,	O
presents	O
with	O
potential	O
life-threatening	O
salt	O
wasting	O
and	O
failure	O
to	O
thrive	O
.	O

Thus	O
far	O
,	O
PHA1	O
has	O
been	O
attributed	O
to	O
mutations	O
affecting	O
the	O
mineralocorticoid	GENE-Y
receptor	GENE-Y
or	O
any	O
of	O
the	O
three	O
subunits	O
assembling	O
the	O
amiloride-sensitive	O
epithelial	O
sodium	CHEMICAL
channel	O
(	O
ENaC	GENE-N
)	O
.	O

However	O
,	O
a	O
lot	O
of	O
patients	O
with	O
a	O
phenotype	O
resembling	O
PHA1	O
,	O
show	O
no	O
defects	O
in	O
these	O
proteins	O
,	O
making	O
it	O
likely	O
that	O
further	O
genes	O
are	O
involved	O
in	O
the	O
aetiology	O
of	O
this	O
disease	O
.	O

Recent	O
studies	O
have	O
elucidated	O
additional	O
participants	O
(	O
alpha-spectrin	GENE-Y
and	O
members	O
of	O
the	O
families	O
of	O
transmembrane	GENE-N
serine	CHEMICAL
proteases	O
,	O
ubiquitin-protein	GENE-N
ligases	GENE-N
,	O
and	O
serum-	GENE-N
and	GENE-N
glucocorticoid-regulated	GENE-N
kinases	GENE-N
,	O
respectively	O
)	O
regulating	O
and	O
/	O
or	O
interacting	O
in	O
the	O
complex	O
pathway	O
of	O
sodium	CHEMICAL
retention	O
in	O
the	O
amiloride-sensitive	O
distal	O
nephron	O
.	O

This	O
led	O
us	O
to	O
investigate	O
whether	O
PHA1	O
can	O
also	O
be	O
associated	O
with	O
mutations	O
in	O
some	O
of	O
these	O
genes	O
.	O

Our	O
data	O
suggest	O
that	O
at	O
least	O
the	O
prostasin	GENE-Y
gene	O
might	O
be	O
excluded	O
as	O
a	O
causative	O
locus	O
.	O
Recent	O
observations	O
point	O
to	O
the	O
role	O
played	O
by	O
Zn2	CHEMICAL
+	CHEMICAL
as	O
an	O
inducer	O
of	O
neuronal	O
death	O
.	O

Two	O
Zn2	CHEMICAL
+	CHEMICAL
targets	O
have	O
been	O
identified	O
that	O
result	O
in	O
inhibition	O
of	O
mitochondrial	O
respiration	O
:	O
the	O
bc1	GENE-N
center	O
and	O
,	O
more	O
recently	O
,	O
alpha-ketoglutarate	GENE-Y
dehydrogenase	O
.	O

Zn2	CHEMICAL
+	CHEMICAL
is	O
also	O
a	O
mediator	O
of	O
oxidative	O
stress	O
,	O
leading	O
to	O
mitochondrial	O
failure	O
,	O
release	O
of	O
apoptotic	O
peptides	O
,	O
and	O
neuronal	O
death	O
.	O

We	O
now	O
present	O
evidence	O
,	O
by	O
means	O
of	O
direct	O
biochemical	O
assays	O
,	O
that	O
Zn2	CHEMICAL
+	CHEMICAL
is	O
imported	O
through	O
the	O
Ca2	GENE-Y
+	GENE-Y
uniporter	O
and	O
directly	O
targets	O
major	O
enzymes	O
of	O
energy	O
production	O
(	O
lipoamide	GENE-Y
dehydrogenase	O
)	O
and	O
antioxidant	O
defense	O
(	O
thioredoxin	GENE-Y
reductase	GENE-Y
and	O
glutathione	GENE-Y
reductase	O
)	O
.	O

We	O
demonstrate	O
the	O
following	O
.	O

(	O
a	O
)	O
These	O
matrix	O
enzymes	O
are	O
rapidly	O
inhibited	O
by	O
application	O
of	O
Zn2	CHEMICAL
+	CHEMICAL
to	O
intact	O
mitochondria	O
.	O

(	O
b	O
)	O
Delayed	O
treatment	O
with	O
membrane-impermeable	O
chelators	O
has	O
no	O
effect	O
,	O
indicating	O
rapid	O
transport	O
of	O
biologically	O
relevant	O
quantities	O
of	O
Zn2	CHEMICAL
+	CHEMICAL
into	O
the	O
matrix	O
.	O

(	O
c	O
)	O
Membrane-permeable	O
chelators	O
stop	O
but	O
do	O
not	O
reverse	O
enzyme	O
inactivation	O
.	O

(	O
d	O
)	O
Enzyme	O
inhibition	O
is	O
rapid	O
and	O
irreversible	O
and	O
precedes	O
the	O
major	O
changes	O
associated	O
with	O
the	O
mitochondrial	O
permeability	O
transition	O
(	O
MPT	O
)	O
.	O

(	O
e	O
)	O
The	O
extent	O
and	O
rate	O
of	O
enzyme	O
inactivation	O
linearly	O
correlates	O
with	O
the	O
MPT	O
onset	O
and	O
propagation	O
.	O

(	O
f	O
)	O
The	O
Ca2	GENE-Y
+	GENE-Y
uniporter	O
blocker	O
,	O
Ruthenium	CHEMICAL
Red	CHEMICAL
,	O
protects	O
enzyme	O
activities	O
and	O
delays	O
pore	O
opening	O
up	O
to	O
2	O
microm	O
Zn2	CHEMICAL
+	CHEMICAL
.	O

An	O
additional	O
,	O
unidentified	O
import	O
route	O
functions	O
at	O
higher	O
Zn2	CHEMICAL
+	CHEMICAL
concentrations	O
.	O

(	O
g	O
)	O
No	O
enzyme	O
inactivation	O
is	O
observed	O
for	O
Ca2	CHEMICAL
+	CHEMICAL
-induced	O
MPT	O
.	O

These	O
observations	O
strongly	O
suggest	O
that	O
,	O
unlike	O
Ca2	CHEMICAL
+	CHEMICAL
,	O
exogenous	O
Zn2	CHEMICAL
+	CHEMICAL
interferes	O
with	O
mitochondrial	O
NADH	CHEMICAL
production	O
and	O
directly	O
alters	O
redox	O
protection	O
in	O
the	O
matrix	O
,	O
contributing	O
to	O
mitochondrial	O
dysfunction	O
.	O

Inactivation	O
of	O
these	O
enzymes	O
by	O
Zn2	CHEMICAL
+	CHEMICAL
is	O
irreversible	O
,	O
and	O
thus	O
only	O
their	O
de	O
novo	O
synthesis	O
can	O
restore	O
function	O
,	O
which	O
may	O
underlie	O
persistent	O
loss	O
of	O
oxidative	O
carbohydrate	CHEMICAL
metabolism	O
following	O
transient	O
ischemia	O
.	O
Fatty	CHEMICAL
acid	CHEMICAL
biosynthesis	O
is	O
an	O
emerging	O
target	O
for	O
the	O
development	O
of	O
novel	O
antibacterial	O
chemotherapeutics	O
.	O

The	O
dissociated	O
bacterial	O
system	O
is	O
substantially	O
different	O
from	O
the	O
large	O
,	O
multifunctional	O
protein	O
of	O
mammals	O
,	O
and	O
many	O
possibilities	O
exist	O
for	O
type-selective	O
drugs	O
.	O

Several	O
compounds	O
,	O
both	O
synthetic	O
and	O
natural	O
,	O
target	O
bacterial	O
fatty	CHEMICAL
acid	CHEMICAL
synthesis	O
.	O

Three	O
compounds	O
target	O
the	O
FabI	GENE-N
enoyl-ACP	O
reductase	O
step;	O
isoniazid	CHEMICAL
,	O
a	O
clinically	O
used	O
antituberculosis	O
drug	O
,	O
triclosan	CHEMICAL
,	O
a	O
widely	O
used	O
consumer	O
antimicrobial	O
,	O
and	O
diazaborines	CHEMICAL
.	O

In	O
addition	O
,	O
cerulenin	CHEMICAL
and	O
thiolactomycin	CHEMICAL
,	O
two	O
fungal	O
products	O
,	O
inhibit	O
the	O
FabH	GENE-N
,	O
FabB	GENE-N
and	O
FabF	GENE-N
condensation	O
enzymes	O
.	O

Finally	O
,	O
the	O
synthetic	O
reaction	O
intermediates	O
BP1	O
and	O
decynoyl-	CHEMICAL
N-acetyl	CHEMICAL
cysteamine	CHEMICAL
inhibit	O
the	O
acetyl-CoA	GENE-N
carboxylase	O
and	O
dehydratase	GENE-N
isomerase	GENE-N
steps	O
,	O
respectively	O
.	O

The	O
mechanisms	O
of	O
action	O
of	O
these	O
compounds	O
,	O
as	O
well	O
as	O
the	O
potential	O
development	O
of	O
new	O
drugs	O
targeted	O
against	O
this	O
pathway	O
,	O
are	O
discussed	O
.	O
Atherogenesis	O
in	O
the	O
vasculature	O
is	O
accelerated	O
by	O
changes	O
in	O
the	O
dynamic	O
equilibrium	O
between	O
endogenous	O
tissue	GENE-Y
plasminogen	GENE-Y
activator	GENE-Y
and	O
plasminogen	GENE-Y
activator	GENE-Y
inhibitor-1	GENE-Y
(	O
PAI-1	GENE-Y
)	O
.	O

Increased	O
expression	O
of	O
PAI-1	GENE-Y
,	O
decreased	O
expression	O
of	O
tissue	GENE-N
plasminogen	GENE-N
activator	GENE-N
,	O
or	O
both	O
can	O
lead	O
to	O
decreased	O
fibrinolytic	O
activity	O
and	O
predispose	O
to	O
thrombosis	O
.	O

Increased	O
concentrations	O
of	O
insulin	GENE-Y
(	O
and	O
proinsulin	GENE-Y
)	O
in	O
the	O
plasma	O
increase	O
plasma	O
PAI-1	GENE-Y
,	O
although	O
the	O
mechanisms	O
of	O
this	O
effect	O
are	O
not	O
known	O
.	O

In	O
addition	O
,	O
it	O
has	O
been	O
observed	O
that	O
basal	O
fibrinolytic	O
activity	O
is	O
decreased	O
in	O
patients	O
with	O
type	O
2	O
diabetes;	O
this	O
may	O
accelerate	O
atherosclerosis	O
by	O
exposing	O
vascular	O
luminal	O
wall	O
surfaces	O
to	O
persistent	O
and	O
recurrent	O
thrombi	O
.	O

Abnormalities	O
in	O
the	O
vessel	O
wall	O
appear	O
to	O
contribute	O
to	O
the	O
increased	O
risk	O
.	O

There	O
is	O
also	O
evidence	O
that	O
PAI-1	GENE-Y
content	O
is	O
increased	O
in	O
atherosclerotic	O
lesions	O
of	O
patients	O
with	O
type	O
2	O
diabetes	O
,	O
suggesting	O
that	O
interventions	O
to	O
reduce	O
insulin	GENE-Y
resistance	O
and	O
improve	O
glycemic	O
control	O
may	O
improve	O
the	O
fibrinolytic	O
response	O
.	O

Clinical	O
studies	O
in	O
patients	O
with	O
polycystic	O
ovary	O
syndrome	O
(	O
characterized	O
by	O
insulin	GENE-Y
resistance	O
,	O
hyperinsulinemia	O
,	O
ovarian	O
androgen	O
overproduction	O
,	O
and	O
impaired	O
fibrinolytic	O
capacity	O
)	O
demonstrated	O
that	O
treatment	O
with	O
troglitazone	CHEMICAL
,	O
an	O
insulin-sensitizing	O
agent	O
,	O
can	O
markedly	O
reduce	O
blood	O
levels	O
of	O
PAI-1	GENE-Y
.	O

There	O
is	O
also	O
clinical	O
evidence	O
that	O
these	O
agents	O
may	O
contribute	O
to	O
regression	O
of	O
intimal	O
medial	O
thickness	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
,	O
providing	O
further	O
indication	O
that	O
antidiabetic	O
interventions	O
may	O
help	O
inhibit	O
the	O
progression	O
of	O
early	O
atherosclerotic	O
lesions	O
.	O
Triethylenetetramine	CHEMICAL
(	O
TETA;	O
Syprine;	O
Merck	O
Rahway	O
,	O
NJ	O
)	O
,	O
a	O
drug	O
for	O
Wilson's	O
disease	O
,	O
is	O
a	O
copper	CHEMICAL
chelator	O
and	O
a	O
charge-deficient	O
analog	O
of	O
polyamine	CHEMICAL
spermidine	CHEMICAL
.	O

We	O
recently	O
showed	O
that	O
TETA	CHEMICAL
is	O
metabolized	O
in	O
vitro	O
by	O
polyamine	CHEMICAL
catabolic	O
enzyme	O
spermidine	GENE-Y
/	O
spermine-N	O
(	O
1	O
)	O
-acetyltransferase	O
(	O
SSAT1	GENE-Y
)	O
and	O
by	O
thialysine	GENE-Y
acetyltransferase	O
(	O
SSAT2	GENE-Y
)	O
to	O
its	O
monoacetylated	O
derivative	O
(	O
MAT	O
)	O
.	O

The	O
acetylation	O
of	O
TETA	CHEMICAL
is	O
increased	O
in	O
SSAT1-overexpressing	O
mice	O
compared	O
with	O
wild-type	O
mice	O
.	O

However	O
,	O
SSAT1-deficient	O
mice	O
metabolize	O
TETA	CHEMICAL
at	O
the	O
same	O
rate	O
as	O
the	O
wild-type	O
mice	O
,	O
indicating	O
the	O
existence	O
of	O
another	O
N-acetylase	GENE-N
respons	O
2ible	O
for	O
its	O
metabolism	O
in	O
mice	O
.	O

Here	O
,	O
we	O
show	O
that	O
siRNA-mediated	O
knockdown	O
of	O
SSAT2	GENE-Y
in	O
HEPG2	O
cells	O
and	O
in	O
primary	O
hepatocytes	O
from	O
the	O
SSAT1-deficient	O
or	O
wild-type	O
mice	O
reduced	O
the	O
metabolism	O
of	O
TETA	CHEMICAL
to	O
MAT	O
.	O

By	O
contrast	O
,	O
1	CHEMICAL
,	CHEMICAL
12-diamino-3	CHEMICAL
,	CHEMICAL
6	CHEMICAL
,	CHEMICAL
9-triazadodecane	CHEMICAL
(	O
SpmTrien	CHEMICAL
)	O
,	O
a	O
charge-deficient	O
spermine	CHEMICAL
analog	O
,	O
was	O
an	O
extremely	O
poor	O
substrate	O
of	O
human	GENE-Y
recombinant	GENE-Y
SSAT2	GENE-Y
and	O
was	O
metabolized	O
by	O
SSAT1	GENE-Y
in	O
HEPG2	O
cells	O
and	O
in	O
wild-type	O
primary	O
hepatocytes	O
.	O

Thus	O
,	O
despite	O
the	O
similar	O
structures	O
of	O
TETA	CHEMICAL
and	O
SpmTrien	CHEMICAL
,	O
SSAT2	GENE-Y
is	O
the	O
main	O
acetylator	O
of	O
TETA	CHEMICAL
,	O
whereas	O
SpmTrien	CHEMICAL
is	O
primarily	O
acetylated	O
by	O
SSAT1	GENE-Y
.	O
A	O
substantial	O
proportion	O
of	O
women	O
with	O
the	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
are	O
obese	O
and	O
obesity	O
is	O
considered	O
as	O
a	O
prothrombotic	O
state	O
.	O

Platelet-derived	O
microparticles	O
(	O
PMPs	O
)	O
might	O
be	O
implicated	O
in	O
the	O
activation	O
of	O
the	O
coagulation	O
cascade	O
.	O

We	O
aimed	O
to	O
assess	O
plasma	O
PMPs	O
in	O
overweight	O
/	O
obese	O
women	O
with	O
PCOS	O
.	O

We	O
measured	O
plasma	O
PMPs	O
and	O
determined	O
anthropometric	O
,	O
metabolic	O
,	O
hormonal	O
and	O
ultrasonographic	O
features	O
of	O
PCOS	O
in	O
67	O
overweight	O
/	O
obese	O
women	O
with	O
PCOS	O
(	O
with	O
body	O
mass	O
index	O
[	O
BMI	O
]	O
>25	O
.	O
0	O
kg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
in	O
21	O
BMI-matched	O
healthy	O
women	O
.	O

Circulating	O
androgens	CHEMICAL
and	O
markers	O
of	O
insulin	GENE-Y
resistance	O
(	O
IR	O
)	O
were	O
higher	O
in	O
women	O
with	O
PCOS	O
than	O
in	O
controls	O
.	O

Plasma	O
PMPs	O
were	O
also	O
higher	O
in	O
women	O
with	O
PCOS	O
than	O
in	O
controls	O
(	O
p	O
=	O
0	O
.	O
046	O
)	O
.	O

In	O
women	O
with	O
PCOS	O
,	O
plasma	O
PMPs	O
correlated	O
with	O
the	O
mean	O
number	O
of	O
follicles	O
in	O
the	O
ovaries	O
(	O
r	O
=	O
0	O
.	O
343;	O
p	O
=	O
0	O
.	O
006	O
)	O
.	O

In	O
controls	O
,	O
plasma	O
PMPs	O
did	O
not	O
correlate	O
with	O
any	O
of	O
the	O
studied	O
parameters	O
.	O

In	O
conclusion	O
,	O
plasma	O
PMPs	O
are	O
elevated	O
in	O
overweight	O
/	O
obese	O
women	O
with	O
PCOS	O
compared	O
with	O
BMI-matched	O
controls	O
.	O

The	O
cause	O
of	O
this	O
increase	O
is	O
unclear	O
but	O
both	O
IR	O
and	O
hyperandrogenemia	O
might	O
be	O
implicated	O
.	O

More	O
studies	O
are	O
required	O
to	O
elucidate	O
the	O
pathogenesis	O
of	O
the	O
elevation	O
of	O
PMPs	O
in	O
PCOS	O
and	O
to	O
assess	O
its	O
implications	O
on	O
the	O
cardiovascular	O
risk	O
of	O
these	O
patients	O
.	O
Effects	O
of	O
felodipine	CHEMICAL
(	O
a	O
dihydropyridine	CHEMICAL
calcium	GENE-N
channel	O
blocker	O
)	O
and	O
analogues	O
on	O
calmodulin-dependent	GENE-N
enzymes	GENE-N
.	O
DCPIB	CHEMICAL
,	O
the	O
proposed	O
selective	O
blocker	O
of	O
volume-regulated	GENE-N
anion	GENE-N
channels	GENE-N
,	O
inhibits	O
several	O
glutamate	CHEMICAL
transport	O
pathways	O
in	O
glial	O
cells	O
.	O
Functional	O
evidence	O
that	O
gastroprotection	O
can	O
be	O
induced	O
by	O
activation	O
of	O
central	O
alpha	GENE-Y
(	GENE-Y
2B	GENE-Y
)	GENE-Y
-adrenoceptor	GENE-Y
subtypes	O
in	O
the	O
rat	O
.	O
Role	O
of	O
acetylcholinesterase	O
(	O
AChE	O
)	O
secreted	O
by	O
parasitic	O
nematodes	O
on	O
the	O
growth	O
of	O
the	O
cell	O
line	O
from	O
epithelial	O
origin	O
HT29-D4	O
.	O
The	O
impact	O
of	O
the	O
synthetic	O
glucocorticoid	O
prednisone	CHEMICAL
on	O
adrenal	O
steroid	CHEMICAL
hormone	O
production	O
was	O
examined	O
using	O
24-hour	O
urinary	O
steroid	CHEMICAL
hormone	O
profiling	O
.	O

Five	O
women	O
,	O
who	O
were	O
chronically	O
taking	O
low-dose	O
prednisone	CHEMICAL
,	O
were	O
tested	O
,	O
and	O
the	O
relevant	O
literature	O
was	O
reviewed	O
.	O

As	O
expected	O
,	O
adrenal	O
glucocorticoid	O
production	O
,	O
measured	O
by	O
urinary	O
terminal	O
cortisol	CHEMICAL
and	O
cortisone	CHEMICAL
metabolites	O
,	O
was	O
markedly	O
suppressed	O
compared	O
to	O
reference	O
range	O
values	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
.	O

Urinary	O
cortisol	CHEMICAL
and	O
cortisone	CHEMICAL
,	O
reflecting	O
circulating	O
glucocorticoids	O
,	O
were	O
decreased	O
to	O
a	O
lesser	O
extent	O
than	O
their	O
terminal	O
metabolites	O
.	O

Urinary	O
dehydroepiandrosterone	CHEMICAL
(	O
DHEA	CHEMICAL
)	O
excretion	O
was	O
dramatically	O
suppressed	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
,	O
while	O
the	O
downstream	O
androgen	CHEMICAL
metabolites	O
androsterone	CHEMICAL
and	O
etiocholanolone	CHEMICAL
were	O
suppressed	O
to	O
a	O
lesser	O
extent	O
.	O

Aldosterone	CHEMICAL
and	O
tetrahydrocorticosterone	CHEMICAL
production	O
demonstrated	O
modest	O
suppression	O
after	O
prednisone	CHEMICAL
administration	O
,	O
but	O
allo-tetrahydrocorticosterone	CHEMICAL
,	O
which	O
is	O
highly	O
sensitive	O
to	O
adrenocorticotropic	GENE-Y
hormone	GENE-Y
(	O
ACTH	GENE-Y
)	O
secretion	O
,	O
was	O
suppressed	O
to	O
a	O
greater	O
extent	O
.	O

Prednisone	CHEMICAL
administration	O
results	O
in	O
a	O
decrease	O
in	O
ACTH	GENE-Y
secretion	O
by	O
the	O
anterior	O
pituitary	O
,	O
suppressing	O
synthesis	O
of	O
glucocorticoids	O
,	O
DHEA	CHEMICAL
,	O
and	O
DHEA	CHEMICAL
metabolites	O
.	O

Decreased	O
glucocorticoid	O
synthesis	O
is	O
adaptive	O
,	O
because	O
prednisone	CHEMICAL
is	O
active	O
at	O
the	O
glucocorticoid	GENE-Y
receptor	GENE-Y
,	O
but	O
suppression	O
of	O
DHEA	CHEMICAL
synthesis	O
is	O
not	O
mitigated	O
by	O
prednisone	CHEMICAL
.	O

DHEA	CHEMICAL
is	O
an	O
important	O
sex	O
hormone	O
precursor	O
,	O
neurosteroid	CHEMICAL
,	O
and	O
endocrine	O
and	O
immune	O
modulator;	O
therefore	O
,	O
DHEA	CHEMICAL
depletion	O
may	O
have	O
significant	O
adverse	O
consequences	O
in	O
terms	O
of	O
sex	O
hormone	O
production	O
,	O
bone	O
health	O
,	O
endocrine	O
and	O
immune	O
system	O
function	O
,	O
and	O
neuropsychiatric	O
status	O
.	O

Studies	O
of	O
DHEA	CHEMICAL
replacement	O
in	O
patients	O
taking	O
prednisone	CHEMICAL
for	O
lupus	O
demonstrate	O
amelioration	O
of	O
some	O
of	O
these	O
adverse	O
effects	O
.	O
Graphene	CHEMICAL
oxide	CHEMICAL
nanoribbons	O
(	O
GONRs	O
)	O
and	O
chemically	O
reduced	CHEMICAL
graphene	CHEMICAL
nanoribbons	O
(	O
crGNRs	O
)	O
were	O
dispersed	O
at	O
high	O
concentrations	O
in	O
chlorosulfonic	CHEMICAL
acid	CHEMICAL
to	O
form	O
anisotropic	O
liquid	O
crystal	O
phases	O
.	O

The	O
liquid	O
crystal	O
solutions	O
were	O
spun	O
directly	O
into	O
hundreds	O
of	O
meters	O
of	O
continuous	O
macroscopic	O
fibers	O
.	O

The	O
relationship	O
of	O
fiber	O
morphology	O
to	O
coagulation	O
bath	O
conditions	O
was	O
studied	O
.	O

The	O
effects	O
of	O
colloid	O
concentration	O
,	O
annealing	O
temperature	O
,	O
spinning	O
air	O
gap	O
,	O
and	O
pretension	O
during	O
annealing	O
on	O
the	O
fibers'	O
performance	O
were	O
also	O
investigated	O
.	O

Heat	O
treatment	O
of	O
the	O
as-spun	O
GONR	O
fibers	O
at	O
1500	O
°C	O
produced	O
thermally	O
reduced	CHEMICAL
graphene	CHEMICAL
nanoribbon	O
(	O
trGNR	O
)	O
fibers	O
with	O
a	O
tensile	O
strength	O
of	O
378	O
MPa	O
,	O
Young's	O
modulus	O
of	O
36	O
.	O
2	O
GPa	O
,	O
and	O
electrical	O
conductivity	O
of	O
285	O
S	O
/	O
cm	O
,	O
which	O
is	O
considerably	O
higher	O
than	O
that	O
in	O
other	O
reported	O
graphene-derived	O
fibers	O
.	O

This	O
better	O
trGNR	O
fiber	O
performance	O
was	O
due	O
to	O
the	O
air	O
gap	O
spinning	O
and	O
annealing	O
with	O
pretension	O
that	O
produced	O
higher	O
molecular	O
alignment	O
within	O
the	O
fibers	O
,	O
as	O
determined	O
by	O
X-ray	O
diffraction	O
and	O
scanning	O
electron	O
microscopy	O
.	O

The	O
specific	O
modulus	O
of	O
trGNR	O
fibers	O
is	O
higher	O
than	O
that	O
of	O
the	O
commercial	O
general	O
purpose	O
carbon	CHEMICAL
fibers	O
and	O
commonly	O
used	O
metals	O
such	O
as	O
Al	CHEMICAL
,	O
Cu	CHEMICAL
,	O
and	O
steel	CHEMICAL
.	O

The	O
properties	O
of	O
trGNR	O
fibers	O
can	O
be	O
further	O
improved	O
by	O
optimizing	O
the	O
spinning	O
conditions	O
with	O
higher	O
draw	O
ratio	O
,	O
annealing	O
conditions	O
with	O
higher	O
pretensions	O
,	O
and	O
using	O
longer	O
flake	O
GONRs	O
.	O

This	O
technique	O
is	O
a	O
new	O
high-carbon-yield	O
approach	O
to	O
make	O
the	O
next	O
generation	O
carbon	CHEMICAL
fibers	O
based	O
on	O
solution-based	O
liquid	O
crystal	O
phase	O
spinning	O
.	O
Active	O
Hexose	CHEMICAL
Correlated	O
Compound	O
(	O
AHCC	O
)	O
is	O
an	O
immunostimulatory	O
nutritional	O
supplement	O
.	O

AHCC	O
effects	O
and	O
mechanism	O
of	O
action	O
on	O
intestinal	O
epithelial	O
cells	O
or	O
monocytes	O
are	O
poorly	O
described	O
.	O

AHCC	O
was	O
added	O
to	O
the	O
culture	O
medium	O
of	O
intestinal	O
epithelial	O
cells	O
(	O
IEC18	O
and	O
HT29	O
cells	O
)	O
and	O
monocytes	O
(	O
THP-1	O
cells	O
)	O
and	O
assessed	O
the	O
secretion	O
of	O
proinflammatory	O
cytokines	GENE-N
by	O
ELISA	O
.	O

Inhibitors	O
of	O
NFκB	GENE-N
and	O
MAPKs	GENE-N
were	O
used	O
to	O
study	O
signal	O
transduction	O
pathways	O
while	O
TLR4	GENE-Y
and	O
MyD88	GENE-Y
were	O
silenced	O
in	O
IEC18	O
cells	O
using	O
shRNA	O
.	O

It	O
was	O
found	O
that	O
AHCC	O
induced	O
GROα	GENE-Y
and	O
MCP1	GENE-Y
secretion	O
in	O
IEC18	O
and	O
IL-8	GENE-Y
in	O
HT29	O
cells	O
.	O

These	O
effects	O
depended	O
on	O
NFκB	GENE-N
activation	O
,	O
and	O
partly	O
on	O
MAPKs	GENE-N
activation	O
and	O
on	O
the	O
presence	O
of	O
MyD88	GENE-Y
and	O
TLR4	GENE-Y
.	O

In	O
THP-1	O
cells	O
AHCC	O
evoked	O
IL-8	GENE-Y
,	O
IL-1β	GENE-Y
and	O
TNF-α	GENE-Y
secretion	O
.	O

The	O
induction	O
of	O
IL-8	GENE-Y
depended	O
on	O
JNK	GENE-N
and	O
NFκB	GENE-N
activation	O
.	O

Therefore	O
,	O
AHCC	O
exerts	O
immunostimulatory	O
effects	O
on	O
intestinal	O
epithelial	O
cells	O
and	O
monocytes	O
involving	O
TLR4	GENE-Y
/	O
MyD88	GENE-Y
and	O
NFκB	GENE-N
/	O
MAPK	GENE-N
signal	O
transduction	O
pathways	O
.	O
The	O
cellular	O
action	O
of	O
steroid	CHEMICAL
hormones	O
is	O
mediated	O
by	O
specific	O
receptors	O
.	O

Recently	O
,	O
two	O
different	O
estrogen	GENE-N
receptors	O
(	O
ER	O
)	O
,	O
alpha	O
and	O
beta	O
,	O
have	O
been	O
cloned	O
with	O
a	O
specific	O
tissue	O
distribution	O
.	O

Active	O
estrogen	CHEMICAL
as	O
well	O
as	O
active	O
progestin	CHEMICAL
are	O
compounds	O
of	O
oral	O
hormonal	O
contraceptives	O
and	O
hormone	O
replacement	O
therapy	O
.	O

To	O
examine	O
the	O
regulation	O
of	O
ER-alpha	GENE-N
and	GENE-N
-beta	GENE-N
activities	O
after	O
treatment	O
with	O
synthetic	O
progestins	CHEMICAL
and	O
synthetic	O
and	O
natural	O
estrogens	CHEMICAL
,	O
COS	O
7	O
cells	O
were	O
transfected	O
with	O
the	O
vector	O
expressing	O
ER-alpha	GENE-N
and	GENE-N
-beta	GENE-N
in	O
combination	O
with	O
a	O
luciferase	O
reporter	O
vector	O
.	O

ER-alpha	GENE-Y
activity	O
was	O
upregulated	O
in	O
the	O
presence	O
of	O
synthetic	O
progestins	CHEMICAL
in	O
a	O
dose-dependent	O
manner	O
.	O

Norethisterone	CHEMICAL
,	O
norethynodrel	CHEMICAL
and	O
desogestrel	CHEMICAL
proved	O
to	O
be	O
the	O
most	O
potent	O
stimulatory	O
agents	O
of	O
ER-alpha	GENE-Y
expression	O
.	O

On	O
the	O
other	O
hand	O
,	O
not	O
all	O
progestins	CHEMICAL
exhibited	O
a	O
stimulatory	O
action	O
on	O
ER-beta	GENE-Y
activity	O
.	O

Only	O
norgestrel	CHEMICAL
,	O
levonorgestrel	CHEMICAL
,	O
norethynodrel	CHEMICAL
and	O
norethisterone	CHEMICAL
induced	O
ER-beta-activating	O
functions	O
in	O
a	O
dose-dependent	O
manner	O
.	O

Luciferase	O
activity	O
due	O
to	O
estrogen	CHEMICAL
stimulation	O
served	O
as	O
a	O
positive	O
control	O
.	O

Our	O
results	O
indicate	O
that	O
progestins	CHEMICAL
have	O
different	O
effects	O
on	O
the	O
activities	O
of	O
ER-alpha	GENE-N
and	GENE-N
-beta	GENE-N
.	O
Characterization	O
of	O
cytosolic	GENE-Y
glutathione	CHEMICAL
peroxidase	O
and	O
phospholipid-hydroperoxide	CHEMICAL
glutathione	CHEMICAL
peroxidase	O
genes	O
in	O
rainbow	O
trout	O
(	O
Oncorhynchus	O
mykiss	O
)	O
and	O
their	O
modulation	O
by	O
in	O
vitro	O
selenium	CHEMICAL
exposure	O
.	O
beta-Adrenoceptor	GENE-N
binding	O
of	O
cardioselective	O
drugs	O
to	O
intact	O
ventricular	O
myocytes	O
was	O
performed	O
using	O
[	CHEMICAL
3H	CHEMICAL
]	CHEMICAL
CGP-12177	CHEMICAL
,	O
a	O
hydrophilic	O
non-beta	O
1	O
/	O
beta	O
2-selective	O
antagonist	O
radioligand	O
.	O

The	O
beta-adrenoceptor	GENE-N
density	O
on	O
the	O
intact	O
cardiomyocytes	O
was	O
about	O
2	O
x	O
10	O
(	O
5	O
)	O
molecules	O
/	O
cell	O
.	O

The	O
beta	O
1-selective	O
antagonists	O
H-I	O
42	O
BS	O
and	O
HX-CH	O
44	O
BS	O
competed	O
for	O
[	CHEMICAL
3H	CHEMICAL
]	CHEMICAL
CGP-12177	CHEMICAL
binding	O
sites	O
on	O
the	O
ventricular	O
myocytes	O
in	O
an	O
essentially	O
monophasic	O
manner	O
with	O
Ki	O
=	O
72	O
.	O
6	O
nM	O
and	O
Ki	O
=	O
76	O
.	O
7	O
nM	O
,	O
respectively	O
.	O

This	O
is	O
in	O
contrast	O
to	O
the	O
results	O
of	O
binding	O
data	O
from	O
heart	O
membranes	O
,	O
where	O
these	O
beta	O
1-antagonists	O
bind	O
in	O
a	O
biphasic	O
manner	O
with	O
about	O
30%	O
of	O
an	O
additional	O
low	O
affinity	O
site	O
,	O
presumably	O
corresponding	O
to	O
the	O
beta	GENE-Y
2-adrenoceptor	GENE-Y
.	O

The	O
beta	O
1-selective	O
antagonist	O
bisoprolol	CHEMICAL
revealed	O
two	O
binding	O
sites	O
at	O
the	O
heart	O
membranes	O
and	O
at	O
the	O
myocytes	O
as	O
well	O
with	O
Ki	O
(	O
1	O
)	O
=	O
34	O
.	O
2	O
and	O
20	O
.	O
0	O
nM	O
and	O
Ki	O
(	O
2	O
)	O
=	O
3	O
,	O
014	O
and	O
918	O
nM	O
,	O
respectively	O
.	O

Our	O
results	O
suggest	O
that	O
viable	O
adult	O
rat	O
ventricular	O
myocytes	O
may	O
contain	O
two	O
beta	GENE-N
1-adrenoceptor	GENE-N
binding	GENE-N
sites	GENE-N
exhibiting	O
different	O
affinities	O
for	O
bisoprolol	CHEMICAL
,	O
whereas	O
beta	GENE-Y
2-adrenergic	GENE-Y
receptors	GENE-Y
are	O
completely	O
absent	O
.	O
P21-activated	GENE-Y
kinase	GENE-Y
4	GENE-Y
(	O
PAK4	GENE-Y
)	O
is	O
required	O
for	O
metaphase	O
spindle	O
positioning	O
and	O
anchoring	O
.	O
BACKGROUND	O
:	O
Sunitinib	CHEMICAL
malate	CHEMICAL
(	O
SUTENT	CHEMICAL
)	O
is	O
an	O
oral	O
,	O
multitargeted	O
tyrosine	CHEMICAL
kinase	O
inhibitor	O
,	O
approved	O
multinationally	O
for	O
the	O
treatment	O
of	O
advanced	O
RCC	O
and	O
of	O
imatinib-resistant	O
or	O
-	O
intolerant	O
GIST	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
explore	O
potential	O
biomarkers	O
of	O
sunitinib	CHEMICAL
pharmacological	O
activity	O
via	O
serial	O
assessment	O
of	O
plasma	O
levels	O
of	O
four	O
soluble	O
proteins	O
from	O
patients	O
in	O
a	O
phase	O
II	O
study	O
of	O
advanced	O
RCC	O
:	O
VEGF	GENE-Y
,	O
soluble	GENE-Y
VEGFR-2	GENE-Y
(	O
sVEGFR-2	GENE-Y
)	O
,	O
placenta	GENE-Y
growth	GENE-Y
factor	GENE-Y
(	O
PlGF	GENE-Y
)	O
,	O
and	O
a	O
novel	O
soluble	GENE-Y
variant	GENE-Y
of	GENE-Y
VEGFR-3	GENE-Y
(	O
sVEGFR-3	GENE-Y
)	O
.	O

METHODS	O
:	O
Sunitinib	CHEMICAL
was	O
administered	O
at	O
50	O
mg	O
/	O
day	O
on	O
a	O
4	O
/	O
2	O
schedule	O
(	O
4	O
weeks	O
on	O
treatment	O
,	O
2	O
weeks	O
off	O
treatment	O
)	O
to	O
63	O
patients	O
with	O
metastatic	O
RCC	O
after	O
failure	O
of	O
first-line	O
cytokine	GENE-N
therapy	O
.	O

Predose	O
plasma	O
samples	O
were	O
collected	O
on	O
days	O
1	O
and	O
28	O
of	O
each	O
cycle	O
and	O
analyzed	O
via	O
ELISA	O
.	O

RESULTS	O
:	O
At	O
the	O
end	O
of	O
cycle	O
1	O
,	O
VEGF	GENE-Y
and	O
PlGF	GENE-Y
levels	O
increased	O
>3-fold	O
(	O
relative	O
to	O
baseline	O
)	O
in	O
24	O
/	O
54	O
(	O
44%	O
)	O
and	O
22	O
/	O
55	O
(	O
40%	O
)	O
cases	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

sVEGFR-2	GENE-Y
levels	O
decreased	O
>or	O
=	O
30%	O
in	O
50	O
/	O
55	O
(	O
91%	O
)	O
cases	O
and	O
>or	O
=	O
20%	O
in	O
all	O
cases	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
during	O
cycle	O
1	O
,	O
while	O
sVEGFR-3	GENE-Y
levels	O
were	O
decreased	O
>or	O
=	O
30%	O
in	O
48	O
of	O
55	O
cases	O
(	O
87%	O
)	O
,	O
and	O
>or	O
=	O
20%	O
in	O
all	O
but	O
2	O
cases	O
.	O

These	O
levels	O
tended	O
to	O
return	O
to	O
near-baseline	O
after	O
2	O
weeks	O
off	O
treatment	O
,	O
indicating	O
that	O
these	O
effects	O
were	O
dependent	O
on	O
drug	O
exposure	O
.	O

Overall	O
,	O
significantly	O
larger	O
changes	O
in	O
VEGF	GENE-Y
,	O
sVEGFR-2	GENE-Y
,	O
and	O
sVEGFR-3	GENE-Y
levels	O
were	O
observed	O
in	O
patients	O
exhibiting	O
objective	O
tumor	O
response	O
compared	O
with	O
those	O
exhibiting	O
stable	O
disease	O
or	O
disease	O
progression	O
(	O
P	O
<	O
0	O
.	O
05	O
for	O
each	O
analyte;	O
analysis	O
not	O
done	O
for	O
PlGF	GENE-Y
)	O
.	O

CONCLUSION	O
:	O
Sunitinib	CHEMICAL
treatment	O
in	O
advanced	O
RCC	O
patients	O
leads	O
to	O
modulation	O
of	O
plasma	O
levels	O
of	O
circulating	O
proteins	O
involved	O
in	O
VEGF	GENE-Y
signaling	O
,	O
including	O
soluble	O
forms	O
of	O
two	O
VEGF	GENE-N
receptors	GENE-N
.	O

This	O
panel	O
of	O
proteins	O
may	O
be	O
of	O
value	O
as	O
biomarkers	O
of	O
the	O
pharmacological	O
and	O
clinical	O
activity	O
of	O
sunitinib	CHEMICAL
in	O
RCC	O
,	O
and	O
of	O
angiogenic	O
processes	O
in	O
cancer	O
and	O
other	O
diseases	O
.	O
We	O
previously	O
characterized	O
1-ethyl-2-benzimidazolinone	CHEMICAL
(	O
1-EBIO	CHEMICAL
)	O
,	O
as	O
well	O
as	O
the	O
clinically	O
useful	O
benzoxazoles	CHEMICAL
,	O
chlorzoxazone	CHEMICAL
(	O
CZ	CHEMICAL
)	O
,	O
and	O
zoxazolamine	CHEMICAL
(	O
ZOX	CHEMICAL
)	O
,	O
as	O
pharmacological	O
activators	O
of	O
the	O
intermediate-conductance	GENE-N
Ca	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-activated	O
K	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
channel	O
,	O
hIK1	GENE-Y
.	O

The	O
mechanism	O
of	O
activation	O
of	O
hIK1	GENE-Y
,	O
as	O
well	O
as	O
the	O
highly	O
homologous	O
small-conductance	GENE-N
,	GENE-N
Ca	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-dependent	O
K	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
channel	O
,	O
rSK2	GENE-Y
,	O
was	O
determined	O
following	O
heterologous	O
expression	O
in	O
Xenopus	O
oocytes	O
using	O
two-electrode	O
voltage	O
clamp	O
(	O
TEVC	O
)	O
and	O
excised	O
,	O
inside-out	O
patch-clamp	O
techniques	O
.	O

1-EBIO	CHEMICAL
,	O
CZ	CHEMICAL
,	O
and	O
ZOX	CHEMICAL
activated	O
both	O
hIK1	GENE-Y
and	O
rSK2	GENE-Y
in	O
TEVC	O
and	O
excised	O
inside-out	O
patch-clamp	O
experiments	O
.	O

In	O
excised	O
,	O
inside-out	O
patches	O
,	O
1-EBIO	CHEMICAL
and	O
CZ	CHEMICAL
induced	O
a	O
concentration-dependent	O
activation	O
of	O
hIK1	GENE-Y
,	O
with	O
half-maximal	O
(	O
K	O
(	O
1	O
/	O
2	O
)	O
)	O
values	O
of	O
84	O
microM	O
and	O
98	O
microM	O
,	O
respectively	O
.	O

Similarly	O
,	O
CZ	CHEMICAL
activated	O
rSK2	GENE-Y
with	O
a	O
K	O
(	O
1	O
/	O
2	O
)	O
of	O
87	O
microM	O
.	O

In	O
the	O
absence	O
of	O
CZ	CHEMICAL
,	O
the	O
Ca	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-dependent	O
activation	O
of	O
hIK1	GENE-Y
was	O
best	O
fit	O
with	O
a	O
K	O
(	O
1	O
/	O
2	O
)	O
of	O
700	O
nM	O
and	O
a	O
Hill	O
coefficient	O
(	O
n	O
)	O
of	O
2	O
.	O
0	O
.	O

rSK2	GENE-Y
was	O
activated	O
by	O
Ca	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
with	O
a	O
K	O
(	O
1	O
/	O
2	O
)	O
of	O
700	O
nM	O
and	O
an	O
n	O
of	O
2	O
.	O
5	O
.	O

Addition	O
of	O
CZ	CHEMICAL
had	O
no	O
effect	O
on	O
either	O
the	O
K	O
(	O
1	O
/	O
2	O
)	O
or	O
n	O
for	O
Ca	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-dependent	O
activation	O
of	O
either	O
hIK1	GENE-Y
or	O
rSK2	GENE-Y
.	O

Rather	O
,	O
CZ	CHEMICAL
increased	O
channel	O
activity	O
at	O
all	O
Ca	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
concentrations	O
(	O
V	O
(	O
max	O
)	O
)	O
.	O

Event-duration	O
analysis	O
revealed	O
hIK1	GENE-Y
was	O
minimally	O
described	O
by	O
two	O
open	O
and	O
three	O
closed	O
times	O
.	O

Activation	O
by	O
1-EBIO	CHEMICAL
had	O
no	O
effect	O
on	O
tau	O
(	O
o1	O
)	O
,	O
tau	O
(	O
o2	O
)	O
,	O
or	O
tau	O
(	O
c1	O
)	O
,	O
whereas	O
tau	O
(	O
c2	O
)	O
and	O
tau	O
(	O
c3	O
)	O
were	O
reduced	O
from	O
9	O
.	O
0	O
and	O
92	O
.	O
6	O
ms	O
to	O
5	O
.	O
0	O
and	O
44	O
.	O
1	O
ms	O
,	O
respectively	O
.	O

In	O
conclusion	O
,	O
we	O
define	O
1-EBIO	CHEMICAL
,	O
CZ	CHEMICAL
,	O
and	O
ZOX	CHEMICAL
as	O
the	O
first	O
known	O
activators	O
of	O
hIK1	GENE-Y
and	O
rSK2	GENE-Y
.	O

Openers	O
of	O
IK	GENE-N
and	O
SK	GENE-N
channels	GENE-N
may	O
be	O
therapeutically	O
beneficial	O
in	O
cystic	O
fibrosis	O
and	O
vascular	O
diseases	O
.	O
Abstract	O
We	O
performed	O
this	O
study	O
to	O
investigate	O
the	O
effect	O
of	O
ketorolac	CHEMICAL
(	O
a	O
non-steroidal	O
anti-inflammatory	O
drug	O
)	O
administration	O
around	O
ovarian	O
stimulation	O
on	O
in	O
vivo	O
and	O
in	O
vitro	O
fertilization	O
process	O
.	O

Sixty-four	O
female	O
mice	O
(	O
ICR	O
)	O
were	O
injected	O
with	O
ketorolac	CHEMICAL
(	O
0	O
,	O
7	O
.	O
5	O
,	O
15	O
and	O
30	O
µg	O
/	O
d	O
)	O
for	O
3	O
d	O
starting	O
from	O
the	O
day	O
of	O
eCG	GENE-N
treatment	O
.	O

In	O
experiment	O
1	O
,	O
41	O
mice	O
were	O
triggered	O
by	O
hCG	GENE-N
and	O
then	O
mated;	O
two-cell	O
embryos	O
were	O
obtained	O
and	O
in	O
vitro	O
development	O
up	O
to	O
blastocyst	O
was	O
observed	O
.	O

In	O
experiment	O
2	O
,	O
23	O
mice	O
were	O
triggered	O
by	O
hCG	GENE-N
and	O
mature	O
oocytes	O
were	O
collected;	O
in	O
vitro	O
fertilization	O
rate	O
and	O
subsequent	O
embryo	O
development	O
up	O
to	O
blastocyst	O
was	O
recorded	O
.	O

In	O
experiment	O
1	O
,	O
the	O
blastocyst-forming	O
rates	O
per	O
in	O
vivo	O
fertilized	O
two-cell	O
embryo	O
showed	O
an	O
inverse	O
relationship	O
with	O
a	O
dosage	O
of	O
ketorolac	CHEMICAL
(	O
97	O
.	O
6%	O
,	O
64	O
.	O
2%	O
,	O
35	O
.	O
4%	O
and	O
25	O
.	O
9%	O
)	O
.	O

In	O
experiment	O
2	O
,	O
degenerated	O
oocytes	O
were	O
frequently	O
observed	O
in	O
a	O
dose-dependent	O
manner	O
(	O
4	O
.	O
3%	O
,	O
22	O
.	O
9%	O
,	O
22	O
.	O
4%	O
and	O
75	O
.	O
0%	O
)	O
.	O

Lower	O
fertilization	O
rates	O
were	O
noted	O
in	O
all	O
the	O
three	O
ketorolac-treating	O
groups;	O
blastocyst-forming	O
rate	O
was	O
significantly	O
lower	O
in	O
30-µg-treating	O
group	O
when	O
compared	O
with	O
the	O
control	O
group	O
.	O

Administration	O
of	O
ketorolac	CHEMICAL
around	O
ovarian	O
stimulation	O
significantly	O
affects	O
the	O
development	O
of	O
in	O
vivo	O
fertilized	O
embryo	O
in	O
a	O
dose-dependent	O
manner	O
.	O

High-dose	O
ketorolac	CHEMICAL
could	O
result	O
in	O
a	O
poor	O
oocyte	O
quality	O
and	O
decreased	O
embryo	O
developmental	O
competence	O
.	O
Functional	O
characteristics	O
of	O
H	CHEMICAL
+	CHEMICAL
-dependent	O
nicotinate	CHEMICAL
transport	O
in	O
primary	O
cultures	O
of	O
astrocytes	O
from	O
rat	O
cerebral	O
cortex	O
.	O
Model	O
for	O
a	O
factor	GENE-Y
IX	GENE-Y
activation	O
complex	O
on	O
blood	O
platelets	O
:	O
dimeric	O
conformation	O
of	O
factor	GENE-Y
XIa	GENE-Y
is	O
essential	O
.	O
Import	O
of	O
acylcarnitine	CHEMICAL
into	O
mitochondrial	O
matrix	O
through	O
carnitine	GENE-Y
/	O
acylcarnitine-translocase	O
(	O
CACT	GENE-Y
)	O
is	O
fundamental	O
for	O
lipid	O
catabolism	O
.	O

To	O
probe	O
the	O
effect	O
of	O
CACT	GENE-Y
down-expression	O
on	O
lipid	O
metabolism	O
in	O
muscle	O
,	O
human	O
myocytes	O
were	O
stably	O
transfected	O
with	O
CACT-antisense	O
construct	O
.	O

In	O
presence	O
of	O
low	O
concentration	O
of	O
palmitate	CHEMICAL
,	O
transfected	O
cells	O
showed	O
decreased	O
palmitate	O
oxidation	O
and	O
acetyl-carnitine	CHEMICAL
content	O
,	O
increased	O
palmitoyl-carnitine	CHEMICAL
level	O
,	O
and	O
reduced	O
insulin-dependent	O
decrease	O
of	O
fatty	O
acylcarnitine-to-fatty	O
acyl-CoA	O
ratio	O
.	O

The	O
augmented	O
palmitoyl-carnitine	CHEMICAL
synthesis	O
,	O
also	O
in	O
the	O
presence	O
of	O
insulin	GENE-Y
,	O
could	O
be	O
related	O
to	O
an	O
altered	O
regulation	O
of	O
carnitine-palmitoyl-transferase	O
1	O
(	O
CPT	GENE-Y
1	GENE-Y
)	O
by	O
malonyl-CoA	CHEMICAL
,	O
whose	O
synthesis	O
is	O
dependent	O
by	O
the	O
availability	O
of	O
cytosolic	O
acetyl-groups	O
.	O

Indeed	O
,	O
all	O
the	O
described	O
effects	O
were	O
completely	O
overcome	O
by	O
CACT	GENE-Y
neo-expression	O
by	O
recombinant	O
adenovirus	O
vector	O
or	O
by	O
addition	O
of	O
acetyl-carnitine	CHEMICAL
to	O
cultures	O
.	O

Acetyl-carnitine	CHEMICAL
effect	O
was	O
related	O
to	O
an	O
increase	O
of	O
malonyl-CoA	CHEMICAL
and	O
was	O
abolished	O
by	O
down-expression	O
,	O
via	O
antisense	O
RNA	O
strategy	O
,	O
of	O
acetyl-CoA	CHEMICAL
carboxylase-beta	O
,	O
the	O
mitochondrial	O
membrane	O
enzyme	O
involved	O
in	O
the	O
direct	O
CPT	GENE-Y
1	GENE-Y
inhibition	O
via	O
malonyl-CoA	CHEMICAL
synthesis	O
.	O

Thus	O
,	O
in	O
our	O
experimental	O
model	O
the	O
modulation	O
of	O
CACT	GENE-Y
expression	O
has	O
consequences	O
for	O
CPT	GENE-Y
1	GENE-Y
activity	O
,	O
while	O
the	O
biologic	O
effects	O
of	O
acetyl-carnitine	CHEMICAL
are	O
not	O
associated	O
with	O
a	O
generic	O
supply	O
of	O
energy	O
compounds	O
but	O
to	O
the	O
anaplerotic	O
property	O
of	O
the	O
molecule	O
.	O
Three-finger	GENE-N
toxins	GENE-N
,	O
a	O
deadly	O
weapon	O
of	O
elapid	O
venom--milestones	O
of	O
discovery	O
.	O
The	O
molecular	O
bases	O
for	O
phosphodiesterase	GENE-Y
5	GENE-Y
(	O
PDE5	GENE-Y
)	O
catalytic-site	O
affinity	O
for	O
cyclic	CHEMICAL
guanosine	CHEMICAL
monophosphate	CHEMICAL
(	O
cGMP	CHEMICAL
)	O
and	O
potency	O
of	O
inhibitors	O
are	O
poorly	O
understood	O
.	O

Cocrystal	O
structures	O
of	O
PDE5	GENE-N
catalytic	GENE-N
(	GENE-N
C	GENE-N
)	GENE-N
domain	GENE-N
with	O
inhibitors	O
reveal	O
a	O
hydrogen	CHEMICAL
bond	O
and	O
hydrophobic	O
interactions	O
with	O
Tyr-612	O
,	O
hydrogen	CHEMICAL
bonds	O
with	O
Gln-817	O
,	O
a	O
hydrophobic	O
clamp	O
formed	O
by	O
Phe-820	O
and	O
Val-782	O
,	O
and	O
contacts	O
with	O
His-613	O
,	O
Leu-765	O
,	O
and	O
Phe-786	O
[	O
Sung	O
et	O
al	O
.	O

(	O
2003	O
)	O
Nature	O
425	O
,	O
98-102;	O
Huai	O
et	O
al	O
.	O

(	O
2004	O
)	O
J	O
.	O

Biol	O
.	O

Chem	O
.	O

279	O
,	O
13095-13101	O
]	O
.	O

Present	O
results	O
of	O
point	O
mutations	O
of	O
full-length	O
PDE5	GENE-Y
showed	O
that	O
maximum	O
catalysis	O
was	O
decreased	O
2650-fold	O
in	O
H613A	GENE-N
and	O
55-fold	O
in	O
F820A	GENE-N
.	O

Catalytic-site	O
affinities	O
for	O
cGMP	CHEMICAL
,	O
vardenafil	CHEMICAL
,	O
sildenafil	CHEMICAL
,	O
tadalafil	CHEMICAL
,	O
or	O
3-isobutyl-1-methylxanthine	CHEMICAL
(	O
IBMX	CHEMICAL
)	O
were	O
respectively	O
weakened	O
14-	O
,	O
123-	O
,	O
30-	O
,	O
51-	O
,	O
and	O
43-fold	O
for	O
Y612A;	O
63-	O
,	O
511-	O
,	O
43-	O
,	O
95-	O
and	O
61-fold	O
for	O
Q817A;	O
and	O
59-	O
,	O
448-	O
,	O
71-	O
,	O
137-	O
,	O
and	O
93-fold	O
for	O
F820A	GENE-N
.	O

The	O
data	O
indicate	O
that	O
these	O
three	O
amino	CHEMICAL
acids	CHEMICAL
are	O
major	O
determinants	O
of	O
affinity	O
for	O
cGMP	CHEMICAL
and	O
potency	O
of	O
selective	O
and	O
nonselective	O
inhibitors	O
,	O
and	O
that	O
higher	O
vardenafil	CHEMICAL
potency	O
over	O
sildenafil	CHEMICAL
and	O
tadalafil	CHEMICAL
results	O
from	O
stronger	O
contacts	O
with	O
Tyr-612	O
,	O
Gln-817	O
,	O
and	O
Phe-820	O
.	O

Affinity	O
of	O
V782A	GENE-N
for	O
cGMP	CHEMICAL
,	O
vardenafil	CHEMICAL
,	O
sildenafil	CHEMICAL
,	O
tadalafil	CHEMICAL
,	O
or	O
IBMX	CHEMICAL
was	O
reduced	O
5	O
.	O
5-	O
,	O
23-	O
,	O
10-	O
,	O
3-	O
,	O
and	O
12-fold	O
,	O
respectively	O
.	O

Change	O
in	O
affinity	O
for	O
cGMP	CHEMICAL
,	O
vardenafil	CHEMICAL
,	O
sildenafil	CHEMICAL
,	O
or	O
IBMX	CHEMICAL
in	O
Y612F	GENE-N
,	O
H613A	GENE-N
,	O
L765A	GENE-N
,	O
or	O
F786A	GENE-N
was	O
less	O
,	O
but	O
affinity	O
of	O
H613A	GENE-N
or	O
F786A	GENE-N
for	O
tadalafil	CHEMICAL
was	O
weakened	O
37-	O
and	O
17-fold	O
,	O
respectively	O
.	O

The	O
results	O
quantify	O
the	O
role	O
of	O
PDE5	GENE-Y
catalytic-site	O
residues	O
for	O
cGMP	CHEMICAL
and	O
inhibitors	O
,	O
indicate	O
that	O
Tyr-612	O
,	O
Gln-817	O
,	O
and	O
Phe-820	O
are	O
the	O
most	O
important	O
cGMP	CHEMICAL
or	O
inhibitor	O
contacts	O
studied	O
,	O
and	O
identify	O
residues	O
that	O
contribute	O
to	O
selectivity	O
among	O
different	O
classes	O
of	O
inhibitors	O
.	O
Folate	CHEMICAL
Conjugation	O
to	O
Polymeric	O
Micelles	O
via	O
Boronic	CHEMICAL
Acid	CHEMICAL
Ester	CHEMICAL
to	O
Deliver	O
Platinum	CHEMICAL
Drugs	O
to	O
Ovarian	O
Cancer	O
Cell	O
Lines	O
.	O
Phosphodiesterase	GENE-Y
type	GENE-Y
5	GENE-Y
as	O
a	O
pharmacologic	O
target	O
in	O
erectile	O
dysfunction	O
.	O
Extracts	O
of	O
Scutellaria	O
baicalensis	O
reduced	O
body	O
weight	O
and	O
blood	O
triglyceride	CHEMICAL
in	O
db	O
/	O
db	O
Mice	O
.	O
A	O
series	O
of	O
imidazopyridazines	CHEMICAL
which	O
are	O
potent	O
inhibitors	O
of	O
Plasmodium	GENE-Y
falciparum	GENE-Y
calcium-dependent	O
protein	O
kinase	O
1	O
(	O
PfCDPK1	GENE-Y
)	O
was	O
identified	O
from	O
a	O
high-throughput	O
screen	O
against	O
the	O
isolated	O
enzyme	O
.	O

Subsequent	O
exploration	O
of	O
the	O
SAR	O
and	O
optimisation	O
has	O
yielded	O
leading	O
members	O
which	O
show	O
promising	O
in	O
vitro	O
anti-parasite	O
activity	O
along	O
with	O
good	O
in	O
vitro	O
ADME	O
and	O
selectivity	O
against	O
human	O
kinases	O
.	O

Initial	O
in	O
vivo	O
testing	O
has	O
revealed	O
good	O
oral	O
bioavailability	O
in	O
a	O
mouse	O
PK	O
study	O
and	O
modest	O
in	O
vivo	O
efficacy	O
in	O
a	O
Plasmodium	O
berghei	O
mouse	O
model	O
of	O
malaria	O
.	O
A	O
series	O
of	O
substituted	O
ortho-carboranylphenoxyacetanilides	CHEMICAL
were	O
synthesized	O
and	O
evaluated	O
for	O
their	O
ability	O
to	O
inhibit	O
hypoxia-induced	O
HIF-1	GENE-N
transcriptional	O
activity	O
using	O
a	O
cell-based	O
reporter	O
assay	O
in	O
HeLa	O
cells	O
expressing	O
the	O
HRE-dependent	O
firefly	O
luciferase	O
reporter	O
construct	O
(	O
HRE-Luc	O
)	O
and	O
constitutively	O
expressing	O
CMV-driven	O
Renilla	O
luciferase	O
reporter	O
,	O
and	O
their	O
ability	O
to	O
inhibit	O
cell	O
growth	O
(	O
GI	O
(	O
50	O
)	O
)	O
using	O
the	O
MTT	CHEMICAL
assay	O
.	O

Among	O
the	O
compounds	O
synthesized	O
,	O
1g	O
and	O
1l	O
showed	O
significant	O
inhibition	O
of	O
hypoxia-induced	O
HIF-1	GENE-N
transcriptional	O
activity	O
(	O
IC	O
(	O
50	O
)	O
:	O
1	O
.	O
9	O
±	O
0	O
.	O
4	O
and	O
1	O
.	O
4	O
±	O
0	O
.	O
2	O
μM	O
,	O
respectively	O
)	O
.	O

Both	O
compounds	O
suppressed	O
HIF-1α	GENE-Y
accumulation	O
in	O
a	O
concentration-dependent	O
manner	O
.	O

The	O
porcine	GENE-N
heart	GENE-N
malate	CHEMICAL
dehydrogenase	O
(	O
MDH	GENE-N
)	O
refolding	O
assay	O
revealed	O
that	O
compound	O
1l	O
inhibited	O
human	GENE-Y
Hsp60	GENE-Y
chaperone	O
activity	O
(	O
IC	O
(	O
50	O
)	O
:	O
6	O
.	O
80	O
±	O
0	O
.	O
25	O
μM	O
)	O
and	O
this	O
inhibition	O
activity	O
was	O
higher	O
than	O
that	O
of	O
ETB	CHEMICAL
(	O
IC	O
(	O
50	O
)	O
:	O
10	O
.	O
9	O
±	O
0	O
.	O
63	O
μM	O
)	O
.	O
Desipramine	CHEMICAL
administration	O
in	O
the	O
olfactory	O
bulbectomized	O
rat	O
:	O
changes	O
in	O
brain	O
beta-adrenoceptor	GENE-N
and	O
5-HT2A	GENE-Y
binding	O
sites	O
and	O
their	O
relationship	O
to	O
behaviour	O
.	O
Inhibition	O
of	O
vascular	GENE-Y
endothelial	GENE-Y
growth	GENE-Y
factor-A	GENE-Y
(	O
VEGF	GENE-Y
)	O
signaling	O
is	O
a	O
promising	O
therapeutic	O
approach	O
that	O
aims	O
to	O
stabilize	O
the	O
progression	O
of	O
solid	O
malignancies	O
by	O
abrogating	O
tumor-induced	O
angiogenesis	O
.	O

This	O
may	O
be	O
accomplished	O
by	O
inhibiting	O
the	O
kinase	GENE-N
activity	O
of	O
VEGF	GENE-Y
receptor-2	GENE-Y
(	O
KDR	GENE-Y
)	O
,	O
which	O
has	O
a	O
key	O
role	O
in	O
mediating	O
VEGF-induced	O
responses	O
.	O

The	O
novel	O
indole-ether	CHEMICAL
quinazoline	CHEMICAL
AZD2171	CHEMICAL
is	O
a	O
highly	O
potent	O
(	O
IC50	O
<	O
1	O
nmol	O
/	O
L	O
)	O
ATP-competitive	O
inhibitor	O
of	O
recombinant	O
KDR	GENE-Y
tyrosine	CHEMICAL
kinase	O
in	O
vitro	O
.	O

Concordant	O
with	O
this	O
activity	O
,	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
,	O
AZD2171	CHEMICAL
inhibited	O
VEGF-stimulated	O
proliferation	O
and	O
KDR	GENE-Y
phosphorylation	O
with	O
IC50	O
values	O
of	O
0	O
.	O
4	O
and	O
0	O
.	O
5	O
nmol	O
/	O
L	O
,	O
respectively	O
.	O

In	O
a	O
fibroblast	O
/	O
endothelial	O
cell	O
coculture	O
model	O
of	O
vessel	O
sprouting	O
,	O
AZD2171	CHEMICAL
also	O
reduced	O
vessel	O
area	O
,	O
length	O
,	O
and	O
branching	O
at	O
subnanomolar	O
concentrations	O
.	O

Once-daily	O
oral	O
administration	O
of	O
AZD2171	CHEMICAL
ablated	O
experimental	O
(	O
VEGF-induced	O
)	O
angiogenesis	O
in	O
vivo	O
and	O
inhibited	O
endochondral	O
ossification	O
in	O
bone	O
or	O
corpora	O
luteal	O
development	O
in	O
ovary;	O
physiologic	O
processes	O
that	O
are	O
highly	O
dependent	O
upon	O
neovascularization	O
.	O

The	O
growth	O
of	O
established	O
human	O
tumor	O
xenografts	O
(	O
colon	O
,	O
lung	O
,	O
prostate	O
,	O
breast	O
,	O
and	O
ovary	O
)	O
in	O
athymic	O
mice	O
was	O
inhibited	O
dose-dependently	O
by	O
AZD2171	CHEMICAL
,	O
with	O
chronic	O
administration	O
of	O
1	O
.	O
5	O
mg	O
per	O
kg	O
per	O
day	O
producing	O
statistically	O
significant	O
inhibition	O
in	O
all	O
models	O
.	O

A	O
histologic	O
analysis	O
of	O
Calu-6	O
lung	O
tumors	O
treated	O
with	O
AZD2171	CHEMICAL
revealed	O
a	O
reduction	O
in	O
microvessel	O
density	O
within	O
52	O
hours	O
that	O
became	O
progressively	O
greater	O
with	O
the	O
duration	O
of	O
treatment	O
.	O

These	O
changes	O
are	O
indicative	O
of	O
vascular	O
regression	O
within	O
tumors	O
.	O

Collectively	O
,	O
the	O
data	O
obtained	O
with	O
AZD2171	CHEMICAL
are	O
consistent	O
with	O
potent	O
inhibition	O
of	O
VEGF	GENE-Y
signaling	O
,	O
angiogenesis	O
,	O
neovascular	O
survival	O
,	O
and	O
tumor	O
growth	O
.	O

AZD2171	CHEMICAL
is	O
being	O
developed	O
clinically	O
as	O
a	O
once-daily	O
oral	O
therapy	O
for	O
the	O
treatment	O
of	O
cancer	O
.	O
The	O
role	O
of	O
platelet	O
/	O
lymphocyte	O
serotonin	GENE-Y
transporter	O
in	O
depression	O
and	O
beyond	O
.	O
Murine	O
prostaglandin	GENE-Y
endoperoxide	O
(	O
PGH	O
)	O
synthase-1	O
and	O
PGH	GENE-Y
synthase-2	GENE-Y
expressed	O
in	O
cos-1	O
cells	O
were	O
found	O
to	O
be	O
differentially	O
sensitive	O
to	O
inhibition	O
by	O
common	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
.	O

Aspirin	CHEMICAL
completely	O
inhibited	O
bis-oxygenation	O
of	O
arachidonate	O
by	O
PGH	GENE-Y
synthase-1;	O
in	O
contrast	O
,	O
aspirin-treated	O
PGH	GENE-Y
synthase-2	GENE-Y
metabolized	O
arachidonate	O
primarily	O
to	O
15-hydroxyeicosatetraenoic	CHEMICAL
acid	CHEMICAL
(	O
15-HETE	CHEMICAL
)	O
instead	O
of	O
PGH2	O
.	O

ID50	O
values	O
were	O
determined	O
for	O
a	O
panel	O
of	O
common	O
NSAIDs	O
by	O
measuring	O
instantaneous	O
inhibition	O
of	O
cyclooxygenase	GENE-N
activity	O
using	O
an	O
oxygen	CHEMICAL
electrode	O
.	O

Among	O
common	O
NSAIDs	O
tested	O
,	O
indomethacin	CHEMICAL
,	O
sulindac	CHEMICAL
sulfide	CHEMICAL
,	O
and	O
piroxicam	CHEMICAL
preferentially	O
inhibited	O
PGH	GENE-Y
synthase-1;	O
ibuprofen	CHEMICAL
,	O
flurbiprofen	CHEMICAL
,	O
and	O
meclofenamate	CHEMICAL
inhibited	O
both	O
enzymes	O
with	O
comparable	O
potencies;	O
and	O
6-methoxy-2-naphthylacetic	CHEMICAL
acid	CHEMICAL
preferentially	O
inhibited	O
PGH	GENE-Y
synthase-2	GENE-Y
.	O

These	O
results	O
demonstrate	O
that	O
the	O
two	O
PGH	GENE-N
synthases	GENE-N
are	O
pharmacologically	O
distinct	O
and	O
indicate	O
that	O
it	O
may	O
be	O
possible	O
to	O
develop	O
isozyme-specific	O
cyclooxygenase	GENE-N
inhibitors	O
useful	O
both	O
for	O
anti-inflammatory	O
therapy	O
and	O
for	O
delineating	O
between	O
the	O
biological	O
roles	O
of	O
the	O
PGH	GENE-N
synthase	GENE-N
isozymes	O
.	O
The	O
cardiomyocyte	O
apoptosis	O
plays	O
a	O
critical	O
role	O
in	O
the	O
development	O
of	O
myocardial	O
injury	O
after	O
ischemia	O
and	O
reperfusion	O
.	O

Thus	O
,	O
alteration	O
of	O
the	O
major	O
apoptosis-regulatory	O
factors	O
during	O
myocardial	O
ischemia-reperfusion	O
is	O
expected	O
to	O
have	O
favorable	O
cardioprotective	O
effects	O
.	O

Herein	O
,	O
we	O
report	O
ischemic-reperfused	O
myocardial	O
infarction	O
(	O
MI	O
)	O
repair	O
with	O
siRNA	O
against	O
Src	GENE-Y
homology	GENE-Y
region	GENE-Y
2	GENE-Y
domain-containing	GENE-Y
tyrosine	CHEMICAL
phosphatase-1	O
(	O
SHP-1	GENE-Y
)	O
,	O
which	O
is	O
known	O
as	O
a	O
key	O
factor	O
involved	O
in	O
regulating	O
the	O
progress	O
of	O
apoptosis	O
in	O
many	O
cell	O
types	O
.	O

A	O
low	O
molecular	O
weight	O
polyethyleneimine	CHEMICAL
modified	O
with	O
deoxycholic	CHEMICAL
acid	CHEMICAL
(	O
PEI1	O
.	O
8-DA	O
)	O
-based	O
delivery	O
strategy	O
was	O
suggested	O
for	O
the	O
cardiac	O
application	O
of	O
SHP-1	GENE-Y
siRNA	O
to	O
overcome	O
the	O
poor	O
gene	O
delivery	O
efficiency	O
to	O
myocardium	O
due	O
to	O
the	O
highly	O
charged	O
structures	O
of	O
the	O
compact	O
cardiac	O
muscles	O
.	O

The	O
PEI1	O
.	O
8-DA	O
conjugates	O
formed	O
stable	O
nanocomplexes	O
with	O
SHP-1	GENE-Y
siRNA	O
via	O
electrostatic	O
and	O
hydrophobic	O
interactions	O
.	O

The	O
PEI1	O
.	O
8-DA	O
/	O
SHP-1	GENE-Y
siRNA	O
polyplexes	O
effectively	O
silenced	O
SHP-1	GENE-Y
gene	O
expression	O
in	O
cardiomyocytes	O
,	O
leading	O
to	O
a	O
significant	O
inhibition	O
of	O
cardiomyocyte	O
apoptosis	O
under	O
hypoxia	O
.	O

In	O
comparison	O
to	O
conventional	O
gene	O
carriers	O
,	O
relatively	O
large	O
amounts	O
of	O
siRNA	O
molecules	O
remained	O
after	O
treatment	O
with	O
the	O
PEI1	O
.	O
8-DA	O
/	O
SHP-1	GENE-Y
siRNA	O
polyplexes	O
.	O

Cardiac	O
administration	O
of	O
the	O
PEI1	O
.	O
8-DA	O
/	O
SHP-1	GENE-Y
siRNA	O
polyplexes	O
resulted	O
in	O
substantial	O
improvement	O
in	O
SHP-1	GENE-Y
gene	O
silencing	O
,	O
which	O
can	O
be	O
explained	O
by	O
the	O
enhancement	O
of	O
cardiac	O
delivery	O
efficiency	O
of	O
the	O
PEI1	O
.	O
8-DA	O
conjugates	O
.	O

In	O
addition	O
,	O
in	O
vivo	O
treatment	O
with	O
the	O
PEI1	O
.	O
8-DA	O
/	O
SHP-1	GENE-Y
siRNA	O
polyplexes	O
induced	O
a	O
highly	O
significant	O
reduction	O
in	O
myocardial	O
apoptosis	O
and	O
infarct	O
size	O
in	O
rat	O
MI	O
models	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
PEI1	O
.	O
8-DA	O
/	O
SHP-1	GENE-Y
siRNA	O
polyplex	O
formulation	O
is	O
a	O
useful	O
system	O
for	O
efficient	O
gene	O
delivery	O
into	O
the	O
compact	O
myocardium	O
that	O
provides	O
a	O
fundamental	O
advantage	O
in	O
treating	O
ischemic-reperfused	O
MI	O
.	O
A	O
simple	O
in	O
vitro	O
test	O
system	O
based	O
on	O
the	O
use	O
of	O
peroxide-eliminating	O
oxidoreductases	O
(	O
glutathione	CHEMICAL
reductase	O
,	O
glutathione	GENE-N
peroxidase	O
)	O
is	O
described	O
.	O

The	O
system	O
allows	O
detection	O
of	O
antioxidant	O
properties	O
of	O
aqueous	O
extracts	O
from	O
raw	O
medicinal	O
plants	O
.	O

The	O
system	O
was	O
used	O
for	O
testing	O
water	O
extract	O
of	O
Baikalskii-6	O
tea	O
.	O

Antioxidant	O
and	O
,	O
presumably	O
,	O
adaptogenic	O
activity	O
of	O
this	O
tea	O
was	O
detected	O
.	O

In	O
addition	O
to	O
activation	O
of	O
glutathione	GENE-N
reductase	O
and	O
glutathione	GENE-N
peroxidase	O
,	O
the	O
preparation	O
inhibits	O
erythrocyte	O
catalase	GENE-Y
and	O
therefore	O
should	O
not	O
be	O
used	O
for	O
detection	O
of	O
antioxidant	O
activity	O
in	O
in	O
vitro	O
screening	O
tests	O
.	O
Role	O
of	O
Asp104	O
in	O
the	O
SHV	GENE-N
beta-lactamase	GENE-N
.	O
A	O
method	O
has	O
been	O
developed	O
for	O
the	O
measurement	O
of	O
transport	O
activities	O
in	O
membrane	O
vesicles	O
obtained	O
from	O
Sf9	O
cells	O
for	O
3β-hydroxy-Δ	CHEMICAL
(	CHEMICAL
5	CHEMICAL
)	CHEMICAL
-bile	CHEMICAL
acids	CHEMICAL
by	O
high-performance	O
liquid	O
chromatography-electrospray	O
ionization-tandem	O
mass	O
spectrometry	O
.	O

Calibration	O
curves	O
for	O
the	O
bile	CHEMICAL
acids	CHEMICAL
were	O
linear	O
over	O
the	O
range	O
of	O
10	O
to	O
2000	O
pmol	O
/	O
mL	O
,	O
and	O
the	O
detection	O
limit	O
was	O
less	O
than	O
1	O
pmol	O
/	O
mL	O
for	O
3β-hydroxy-Δ	CHEMICAL
(	CHEMICAL
5	CHEMICAL
)	CHEMICAL
-bile	CHEMICAL
acids	CHEMICAL
using	O
selected	O
reaction	O
monitoring	O
analysis	O
.	O

The	O
analytical	O
method	O
was	O
applied	O
to	O
measurements	O
of	O
transport	O
activities	O
in	O
membrane	O
vesicles	O
obtained	O
from	O
human	GENE-N
multidrug	GENE-N
resistance-associated	GENE-N
protein	GENE-N
2-	GENE-N
,	GENE-N
3-	O
,	O
and	O
human	GENE-Y
bile	CHEMICAL
salt	CHEMICAL
export	O
pump-expressing	O
Sf9	O
cells	O
for	O
conjugated	O
3β-hydroxy-Δ	CHEMICAL
(	CHEMICAL
5	CHEMICAL
)	CHEMICAL
-bile	CHEMICAL
acids	CHEMICAL
.	O

The	O
present	O
study	O
demonstrated	O
that	O
human	GENE-Y
multidrug	GENE-Y
resistance-associated	GENE-Y
protein	GENE-Y
3	GENE-Y
vesicles	O
accepted	O
conjugated	O
3β-hydroxy-Δ	CHEMICAL
(	CHEMICAL
5	CHEMICAL
)	CHEMICAL
-bile	CHEMICAL
acids	CHEMICAL
along	O
with	O
common	O
bile	CHEMICAL
acids	CHEMICAL
such	O
as	O
glycocholic	CHEMICAL
acid	CHEMICAL
and	O
taurolithocholic	CHEMICAL
acid	CHEMICAL
3-sulfate	CHEMICAL
.	O
A	O
positive	O
association	O
between	O
air	O
pollution	O
exposure	O
and	O
increased	O
human	O
risk	O
of	O
chronic	O
heart	O
disease	O
progression	O
is	O
well	O
established	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
test	O
two	O
hypotheses	O
:	O
(	O
1	O
)	O
the	O
cardiac	O
compensatory	O
changes	O
in	O
response	O
to	O
air	O
pollution	O
are	O
dependent	O
on	O
its	O
composition	O
and	O
(	O
2	O
)	O
specific	O
cardiac	O
adaptations	O
are	O
regulated	O
by	O
atrial	GENE-Y
natriuretic	GENE-Y
peptide	GENE-Y
(	O
ANP	GENE-Y
)	O
.	O

We	O
address	O
these	O
hypotheses	O
by	O
initially	O
examining	O
the	O
exposure	O
effects	O
of	O
ozone	CHEMICAL
(	O
O	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
)	O
and	O
/	O
or	O
particulate	O
matter	O
(	O
PM	O
)	O
on	O
cardiac	O
function	O
in	O
C57Bl	O
/	O
6J	O
(	O
B6	O
)	O
mice	O
.	O

Subsequently	O
,	O
the	O
results	O
are	O
compared	O
with	O
cardiac	O
functional	O
changes	O
to	O
the	O
same	O
exposures	O
in	O
Nppa	GENE-Y
(	O
the	O
precursor	O
gene	O
for	O
ANP	GENE-Y
)	O
knockout	O
(	O
KO	O
)	O
mice	O
.	O

Separate	O
groups	O
of	O
mice	O
underwent	O
3	O
consecutive	O
days	O
of	O
the	O
same	O
exposure	O
sequence	O
for	O
3h	O
each	O
consisting	O
of	O
the	O
following	O
:	O
(	O
1	O
)	O
6h	O
of	O
filtered	O
air	O
(	O
FAFA	O
)	O
,	O
(	O
2	O
)	O
O	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
then	O
FA	O
(	O
O	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
FA	O
)	O
,	O
(	O
3	O
)	O
FA	O
then	O
carbon	CHEMICAL
black	CHEMICAL
(	O
FACB	O
)	O
,	O
or	O
(	O
4	O
)	O
O	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
then	O
CB	O
.	O

Cardiac	O
function	O
was	O
assessed	O
using	O
a	O
conductance	O
catheter	O
to	O
generate	O
cardiac	O
pressure-volume	O
loops	O
8-10h	O
following	O
each	O
exposure	O
sequence	O
.	O

As	O
compared	O
with	O
FAFA	O
,	O
each	O
sequence	O
led	O
to	O
a	O
substantial	O
drop	O
(	O
as	O
much	O
as	O
33%	O
)	O
in	O
stroke	O
volume	O
and	O
cardiac	O
output	O
.	O

However	O
,	O
these	O
losses	O
of	O
cardiac	O
function	O
occurred	O
by	O
different	O
compensatory	O
mechanisms	O
dependent	O
on	O
the	O
pollutant	O
composition	O
.	O

For	O
example	O
,	O
O	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
FA	O
exposure	O
led	O
to	O
reductions	O
in	O
both	O
end-systolic	O
and	O
end-diastolic	O
left	O
ventricular	O
(	O
LV	O
)	O
volumes	O
,	O
whereas	O
FACB	O
exposure	O
led	O
an	O
increase	O
in	O
end-diastolic	O
LV	O
volume	O
.	O

These	O
same	O
cardiac	O
compensatory	O
changes	O
were	O
largely	O
abolished	O
in	O
Nppa	GENE-Y
KO	O
mice	O
following	O
O	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
FA	O
or	O
FACB	O
exposure	O
.	O

These	O
results	O
suggest	O
that	O
cardiac	O
functional	O
changes	O
in	O
response	O
to	O
air	O
pollution	O
exposure	O
are	O
strongly	O
dependent	O
on	O
the	O
pollutant	O
constituents	O
,	O
especially	O
related	O
to	O
O	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
and	O
/	O
or	O
PM	O
.	O

Furthermore	O
,	O
ANP	GENE-Y
regulation	O
appears	O
to	O
be	O
crucial	O
to	O
these	O
cardiac	O
compensatory	O
mechanisms	O
induced	O
by	O
air	O
pollution	O
.	O
Understanding	O
the	O
molecular	O
evolution	O
of	O
genes	O
that	O
underlie	O
intraspecific	O
polymorphisms	O
can	O
provide	O
insights	O
into	O
the	O
process	O
of	O
adaptive	O
evolution	O
.	O

For	O
adaptive	O
polymorphisms	O
characterized	O
by	O
gene	O
presence	O
/	O
absence	O
(	O
P	O
/	O
A	O
)	O
variation	O
,	O
underlying	O
loci	O
commonly	O
show	O
signatures	O
of	O
long-term	O
balancing	O
selection	O
,	O
with	O
gene-presence	O
and	O
gene-absence	O
alleles	O
maintained	O
as	O
two	O
divergent	O
lineages	O
.	O

We	O
examined	O
the	O
molecular	O
evolution	O
of	O
two	O
unlinked	O
P	O
/	O
A	O
polymorphisms	O
that	O
underlie	O
a	O
well-documented	O
adaptive	O
polymorphism	O
for	O
cyanogenesis	O
(	O
hydrogen	CHEMICAL
cyanide	CHEMICAL
release	O
with	O
tissue	O
damage	O
)	O
in	O
white	O
clover	O
.	O

Both	O
cyanogenic	O
and	O
acyanogenic	O
plants	O
occur	O
in	O
this	O
species	O
,	O
and	O
the	O
ecological	O
forces	O
that	O
maintain	O
this	O
chemical	O
defence	O
polymorphism	O
have	O
been	O
studied	O
for	O
several	O
decades	O
.	O

Using	O
a	O
sample	O
of	O
65	O
plants	O
,	O
we	O
investigated	O
the	O
molecular	O
evolution	O
of	O
sequences	O
flanking	O
the	O
two	O
underlying	O
cyanogenesis	O
genes	O
:	O
Ac	GENE-N
/	GENE-N
ac	GENE-N
(	O
controlling	O
the	O
presence	O
/	O
absence	O
of	O
cyanogenic	CHEMICAL
glucosides	CHEMICAL
)	O
and	O
Li	GENE-N
/	GENE-N
li	GENE-N
(	O
controlling	O
the	O
presence	O
/	O
absence	O
of	O
their	O
hydrolysing	O
enzyme	O
,	O
linamarase	GENE-N
)	O
.	O

A	O
combination	O
of	O
genome	O
walking	O
,	O
PCR	O
assays	O
,	O
DNA	O
sequence	O
analysis	O
and	O
Southern	O
blotting	O
was	O
used	O
to	O
test	O
whether	O
these	O
adaptive	O
P	O
/	O
A	O
polymorphisms	O
show	O
evidence	O
of	O
long-term	O
balancing	O
selection	O
,	O
or	O
whether	O
gene-absence	O
alleles	O
have	O
evolved	O
repeatedly	O
through	O
independent	O
deletion	O
events	O
.	O

For	O
both	O
loci	O
,	O
we	O
detect	O
no	O
signatures	O
of	O
balancing	O
selection	O
in	O
the	O
closest	O
flanking	O
genomic	O
sequences	O
.	O

Instead	O
,	O
we	O
find	O
evidence	O
for	O
variation	O
in	O
the	O
size	O
of	O
the	O
deletions	O
characterizing	O
gene-absence	O
alleles	O
.	O

These	O
observations	O
strongly	O
suggest	O
that	O
both	O
of	O
these	O
polymorphisms	O
have	O
been	O
evolving	O
through	O
recurrent	O
gene	O
deletions	O
over	O
time	O
.	O

We	O
discuss	O
the	O
genetic	O
mechanisms	O
that	O
could	O
account	O
for	O
this	O
surprising	O
pattern	O
and	O
the	O
implications	O
of	O
these	O
findings	O
for	O
mechanisms	O
of	O
rapid	O
adaptive	O
evolution	O
in	O
white	O
clover	O
.	O
Preparation	O
of	O
functionalized	O
alkynyl	CHEMICAL
magnetic	O
microspheres	O
for	O
the	O
selective	O
enrichment	O
of	O
cell	O
glycoproteins	O
based	O
on	O
click	O
chemistry	O
.	O
Serotonin	GENE-Y
transporter	O
gene	O
regulatory	O
region	O
polymorphism	O
(	O
5-HTTLPR	GENE-Y
)	O
,	O
[	CHEMICAL
3H	CHEMICAL
]	CHEMICAL
paroxetine	CHEMICAL
binding	O
in	O
healthy	O
control	O
subjects	O
and	O
alcohol-dependent	O
patients	O
and	O
their	O
relationships	O
to	O
impulsivity	O
.	O
Binding	O
of	O
Diverse	O
Environmental	O
Chemicals	O
with	O
Human	GENE-N
Cytochromes	GENE-N
P450	GENE-N
2A13	GENE-N
,	GENE-N
2A6	GENE-N
,	GENE-N
and	GENE-N
1B1	GENE-N
and	O
Enzyme	O
Inhibition	O
.	O
Effects	O
of	O
Crataegus	O
microphylla	O
on	O
vascular	O
dysfunction	O
in	O
streptozotocin-induced	O
diabetic	O
rats	O
.	O
Lipid	O
raft	O
modulation	O
by	O
Rp1	CHEMICAL
reverses	O
multidrug	O
resistance	O
via	O
inactivating	O
MDR-1	GENE-Y
and	O
Src	GENE-Y
inhibition	O
.	O
Triptans	CHEMICAL
are	O
commonly	O
used	O
anti-migraine	O
drugs	O
and	O
show	O
agonist	O
action	O
mainly	O
at	O
serotonin	GENE-N
5-HT	O
(	O
1B	O
/	O
1D	O
/	O
1F	O
)	O
receptors	O
.	O

It	O
is	O
not	O
known	O
whether	O
frequent	O
or	O
long-term	O
treatment	O
with	O
these	O
drugs	O
would	O
alter	O
5-HT	CHEMICAL
receptor	O
function	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
protracted	O
(	O
14-18	O
days	O
)	O
sumatriptan	CHEMICAL
and	O
zolmitriptan	CHEMICAL
treatment	O
in	O
rats	O
on	O
5-HT	GENE-N
(	GENE-N
1	GENE-N
)	GENE-N
receptor	GENE-N
mRNA	O
expression	O
and	O
function	O
in	O
tissues	O
related	O
to	O
migraine	O
pathophysiology	O
.	O

RT-PCR	O
analysis	O
revealed	O
that	O
5-HT	GENE-N
(	GENE-N
1B	GENE-N
/	GENE-N
1D	GENE-N
/	GENE-N
1F	GENE-N
)	GENE-N
receptor	GENE-N
mRNA	O
was	O
reduced	O
in	O
the	O
trigeminal	O
ganglion	O
after	O
treatment	O
with	O
either	O
triptan	CHEMICAL
(	O
reduction	O
by	O
:	O
sumatriptan	CHEMICAL
39%	O
and	O
zolmitriptan	CHEMICAL
61%	O
for	O
5-HT	GENE-Y
(	GENE-Y
1B	GENE-Y
)	GENE-Y
;	O
60%vs	O
41%	O
for	O
5-HT	GENE-Y
(	GENE-Y
1D	GENE-Y
)	GENE-Y
;	O
32%vs	O
68%	O
for	O
5-HT	GENE-Y
(	GENE-Y
1F	GENE-Y
)	GENE-Y
)	O
.	O

Sumatriptan	CHEMICAL
attenuated	O
5-HT	GENE-Y
(	GENE-Y
1D	GENE-Y
)	GENE-Y
receptor	O
mRNA	O
by	O
49%	O
in	O
the	O
basilar	O
artery	O
,	O
whereas	O
zolmitriptan	CHEMICAL
reduced	O
5-HT	GENE-Y
(	GENE-Y
1B	GENE-Y
)	GENE-Y
mRNA	O
in	O
this	O
tissue	O
by	O
70%	O
.	O

No	O
change	O
in	O
5-HT	GENE-N
(	GENE-N
1	GENE-N
)	GENE-N
receptor	GENE-N
mRNA	O
expression	O
was	O
observed	O
in	O
coronary	O
artery	O
and	O
dura	O
mater	O
.	O

Chronic	O
triptan	CHEMICAL
treatment	O
had	O
no	O
effect	O
in	O
two	O
functional	O
assays	O
[	O
sumatriptan	CHEMICAL
mediated	O
inhibition	O
(	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O

p	O
.	O

)	O
of	O
electrically	O
induced	O
plasma	O
protein	O
extravasation	O
in	O
dura	O
mater	O
and	O
5-nonyloxytryptamine-stimulated	O
[	CHEMICAL
(	CHEMICAL
35	CHEMICAL
)	CHEMICAL
S	CHEMICAL
]	CHEMICAL
guanosine-5'-O-	CHEMICAL
(	CHEMICAL
3-thio	CHEMICAL
)	CHEMICAL
triphosphate	CHEMICAL
binding	O
in	O
substantia	O
nigra	O
]	O
.	O

Furthermore	O
,	O
vasoconstriction	O
to	O
5-HT	CHEMICAL
in	O
isolated	O
basilar	O
artery	O
was	O
not	O
affected	O
by	O
chronic	O
triptan	O
treatment	O
,	O
while	O
it	O
was	O
slightly	O
reduced	O
in	O
coronary	O
artery	O
.	O

We	O
conclude	O
that	O
,	O
although	O
our	O
treatment	O
protocol	O
altered	O
mRNA	O
receptor	O
expression	O
in	O
several	O
tissues	O
relevant	O
to	O
migraine	O
pathophysiology	O
,	O
it	O
did	O
not	O
attenuate	O
5-HT	GENE-N
(	GENE-N
1	GENE-N
)	GENE-N
receptor-dependent	O
functions	O
in	O
rats	O
.	O
Although	O
osteoclasts	O
incorporate	O
bisphosphonates	CHEMICAL
during	O
bone	O
resorption	O
,	O
the	O
mechanism	O
of	O
this	O
incorporation	O
by	O
osteoclasts	O
is	O
not	O
known	O
.	O

We	O
previously	O
reported	O
that	O
bisphosphonates	CHEMICAL
disrupt	O
the	O
actin	GENE-N
rings	O
(	O
clear	O
zones	O
)	O
formed	O
in	O
normal	O
osteoclasts	O
,	O
but	O
did	O
not	O
disrupt	O
actin	GENE-N
rings	O
in	O
osteoclasts	O
derived	O
from	O
osteosclerotic	O
oc	O
/	O
oc	O
mice	O
,	O
which	O
have	O
a	O
defect	O
in	O
the	O
gene	O
encoding	O
vacuolar	GENE-N
H	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-ATPase	O
(	O
V-ATPase	GENE-N
)	O
.	O

The	O
present	O
study	O
showed	O
that	O
V-ATPase	GENE-N
is	O
directly	O
involved	O
in	O
the	O
incorporation	O
of	O
risedronate	CHEMICAL
,	O
a	O
nitrogen	CHEMICAL
containing	CHEMICAL
bisphosphonate	CHEMICAL
,	O
into	O
osteoclasts	O
.	O

Treatment	O
of	O
osteoclasts	O
with	O
risedronate	CHEMICAL
disrupted	O
actin	O
rings	O
and	O
inhibited	O
pit	O
formation	O
by	O
osteoclasts	O
on	O
dentine	O
slices	O
.	O

Bafilomycin	CHEMICAL
A	CHEMICAL
(	CHEMICAL
1	CHEMICAL
)	CHEMICAL
,	O
a	O
V-ATPase	GENE-N
inhibitor	O
,	O
inhibited	O
the	O
pit-forming	O
activity	O
of	O
osteoclasts	O
but	O
did	O
not	O
disrupt	O
actin	GENE-N
rings	O
.	O

Risedronate	CHEMICAL
failed	O
to	O
disrupt	O
actin	GENE-N
rings	O
in	O
the	O
presence	O
of	O
bafilomycin	CHEMICAL
A	CHEMICAL
(	CHEMICAL
1	CHEMICAL
)	CHEMICAL
.	O

E-64	CHEMICAL
,	O
a	O
lysosomal	O
cysteine	CHEMICAL
proteinase	GENE-N
inhibitor	O
,	O
showed	O
no	O
inhibitory	O
effect	O
on	O
the	O
demineralization	O
of	O
dentine	O
by	O
osteoclasts	O
but	O
inhibited	O
the	O
digestion	O
of	O
dentine	O
matrix	O
proteins	O
without	O
disrupting	O
actin	GENE-N
rings	O
.	O

Risedronate	CHEMICAL
disrupted	O
actin	GENE-N
rings	O
even	O
in	O
the	O
presence	O
of	O
E-64	CHEMICAL
.	O

Treatment	O
of	O
osteoclasts	O
placed	O
on	O
plastic	O
plates	O
with	O
risedronate	CHEMICAL
also	O
disrupted	O
actin	GENE-N
rings	O
.	O

Bafilomycin	CHEMICAL
A	CHEMICAL
(	CHEMICAL
1	CHEMICAL
)	CHEMICAL
but	O
not	O
E64	CHEMICAL
prevented	O
the	O
disruption	O
of	O
actin	GENE-N
rings	O
in	O
osteoclasts	O
treated	O
with	O
risedronate	CHEMICAL
on	O
plastic	O
plates	O
.	O

Inhibition	O
of	O
V-ATPase	GENE-N
with	O
bafilomycin	CHEMICAL
A	CHEMICAL
(	CHEMICAL
1	CHEMICAL
)	CHEMICAL
also	O
prevented	O
disruption	O
of	O
actin	GENE-N
rings	O
by	O
etidronate	CHEMICAL
,	O
a	O
non-nitrogen-containing	CHEMICAL
bisphosphonate	CHEMICAL
.	O

These	O
results	O
suggest	O
that	O
V-ATPase	GENE-N
induced	O
acidification	O
beneath	O
the	O
ruffled	O
borders	O
of	O
osteoclasts	O
and	O
subsequent	O
bone	O
demineralization	O
triggers	O
the	O
incorporation	O
of	O
both	O
nitrogen-containing	O
and	O
non-nitrogen-containing	CHEMICAL
bisphosphonates	CHEMICAL
into	O
osteoclasts	O
.	O
The	O
expression	O
and	O
activity	O
of	O
Fatty	CHEMICAL
Acid	CHEMICAL
Synthase	O
(	O
FASN;	O
the	O
sole	O
enzyme	O
capable	O
of	O
the	O
reductive	O
de	O
novo	O
synthesis	O
of	O
long-chain	CHEMICAL
fatty	CHEMICAL
acids	CHEMICAL
from	O
acetyl-CoA	CHEMICAL
,	O
malonyl-CoA	CHEMICAL
,	O
and	O
nicotinamide	CHEMICAL
adenine	CHEMICAL
dinucleotide	CHEMICAL
phosphate	CHEMICAL
-NADPH-	O
)	O
is	O
extremely	O
low	O
in	O
nearly	O
all	O
nonmalignant	O
adult	O
tissues	O
,	O
whereas	O
it	O
is	O
significantly	O
up-regulated	O
or	O
activated	O
in	O
many	O
cancer	O
types	O
,	O
thus	O
creating	O
the	O
potential	O
for	O
a	O
large	O
therapeutic	O
index	O
.	O

Since	O
the	O
pioneering	O
observation	O
that	O
inhibition	O
of	O
FASN	GENE-Y
activity	O
by	O
the	O
mycotoxin	O
cerulenin	CHEMICAL
preferentially	O
kills	O
cancer	O
cells	O
and	O
retards	O
the	O
growth	O
of	O
tumors	O
in	O
xenografts	O
models	O
,	O
numerous	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
have	O
confirmed	O
the	O
potential	O
of	O
FASN	GENE-Y
as	O
a	O
target	O
for	O
antineoplastic	O
intervention	O
.	O

Other	O
FASN	GENE-Y
inhibitors	O
such	O
as	O
the	O
cerulenin	CHEMICAL
derivative	O
C75	O
,	O
the	O
beta-lactone	CHEMICAL
orlistat	CHEMICAL
,	O
the	O
green	O
tea	O
polyphenol	CHEMICAL
epigallocatechin-3-gallate	CHEMICAL
(	O
EGCG	CHEMICAL
)	O
and	O
other	O
naturally	O
occurring	O
flavonoids	CHEMICAL
(	O
i	O
.	O

e	O
.	O

,	O
luteolin	CHEMICAL
,	O
quercetin	CHEMICAL
,	O
and	O
kaempferol	CHEMICAL
)	O
,	O
as	O
well	O
as	O
the	O
antibiotic	O
triclosan	CHEMICAL
,	O
have	O
been	O
identified	O
and	O
have	O
been	O
shown	O
to	O
limit	O
cancer	O
cell	O
growth	O
by	O
inducing	O
apoptotic	O
cell	O
death	O
.	O

Though	O
the	O
exact	O
mode	O
of	O
action	O
of	O
these	O
FASN	GENE-Y
inhibitors	O
is	O
under	O
discussion	O
,	O
it	O
has	O
been	O
revealed	O
that	O
depletion	O
of	O
end-product	O
fatty	CHEMICAL
acids	CHEMICAL
,	O
toxic	O
intracellular	O
accumulation	O
of	O
supra-physiological	O
concentrations	O
of	O
the	O
FASN	GENE-Y
substrate	O
malonyl-CoA	CHEMICAL
and	O
/	O
or	O
limited	O
membrane	O
synthesis	O
and	O
/	O
or	O
functioning	O
by	O
altered	O
production	O
of	O
phospholipids	O
partitioning	O
into	O
detergent-resistant	O
membrane	O
microdomains	O
(	O
lipid	O
raft-aggregates	O
)	O
,	O
can	O
explain	O
,	O
at	O
least	O
in	O
part	O
,	O
the	O
cytostatic	O
,	O
cytotoxic	O
as	O
well	O
as	O
the	O
apoptotic	O
effects	O
occurring	O
upon	O
pharmacological	O
inhibition	O
of	O
FASN	GENE-Y
activity	O
in	O
cancer	O
cells	O
.	O

Moreover	O
,	O
several	O
cancer-associated	O
molecular	O
features	O
including	O
nonfunctioning	O
p53	GENE-Y
,	O
overexpression	O
of	O
the	O
Her-2	GENE-Y
/	O
neu	GENE-Y
(	O
erbB-2	GENE-Y
)	O
oncogene	O
,	O
and	O
hyperactivation	O
of	O
the	O
PI-3'K	GENE-N
down-stream	O
effector	O
protein	GENE-Y
kinase	GENE-Y
B	GENE-Y
(	O
AKT	GENE-Y
)	O
,	O
appear	O
to	O
determine	O
an	O
exacerbated	O
sensitivity	O
to	O
FASN	GENE-Y
inhibition-induced	O
cancer	O
cell	O
death	O
.	O

Although	O
few	O
of	O
these	O
inhibitors	O
are	O
expected	O
to	O
be	O
"exclusively"	O
selective	O
for	O
FASN	GENE-Y
,	O
the	O
potential	O
of	O
FASN	GENE-Y
as	O
a	O
target	O
for	O
antineoplastic	O
intervention	O
has	O
eventually	O
been	O
confirmed	O
by	O
RNA	O
interference	O
(	O
RNAi	O
)	O
-knockdown	O
of	O
FASN	GENE-Y
.	O

Certainly	O
,	O
future	O
studies	O
should	O
definitely	O
elucidate	O
the	O
ultimate	O
biochemical	O
link	O
between	O
FASN	GENE-Y
inhibition	O
and	O
cancer	O
cell	O
death	O
.	O

Although	O
the	O
combination	O
of	O
FASN	GENE-Y
structural	O
complexity	O
and	O
until	O
recently	O
the	O
lack	O
of	O
X-ray	O
crystallography	O
data	O
of	O
mammalian	GENE-N
FASN	GENE-N
created	O
a	O
significant	O
challenge	O
in	O
the	O
exploitation	O
of	O
FASN	GENE-Y
as	O
a	O
valuable	O
target	O
for	O
drug	O
development	O
,	O
it	O
is	O
hoped	O
that	O
the	O
improvement	O
in	O
the	O
selectivity	O
and	O
potency	O
of	O
forthcoming	O
novel	O
FASN-targeted	O
small	O
molecule	O
inhibitors	O
by	O
taking	O
advantage	O
,	O
for	O
instance	O
,	O
of	O
the	O
recent	O
4	O
.	O
5	O
A	O
resolution	O
X-ray	O
crystallographic	O
map	O
of	O
mammalian	GENE-N
FASN	GENE-N
,	O
will	O
direct	O
the	O
foundation	O
of	O
a	O
new	O
family	O
of	O
chemotherapeutic	O
agents	O
in	O
cancer	O
history	O
.	O
Full	O
agonists	O
to	O
the	O
peroxisome	GENE-Y
proliferator-activated	GENE-Y
receptor	GENE-Y
(	GENE-Y
PPAR	GENE-Y
)	GENE-Y
γ	GENE-Y
,	O
such	O
as	O
Rosiglitazone	CHEMICAL
,	O
have	O
been	O
associated	O
with	O
a	O
series	O
of	O
undesired	O
side	O
effects	O
,	O
such	O
as	O
weight	O
gain	O
,	O
fluid	O
retention	O
,	O
cardiac	O
hypertrophy	O
,	O
and	O
hepatotoxicity	O
.	O

Nevertheless	O
,	O
PPARγ	GENE-Y
is	O
involved	O
in	O
the	O
expression	O
of	O
genes	O
that	O
control	O
glucose	CHEMICAL
and	O
lipid	O
metabolism	O
and	O
is	O
an	O
important	O
target	O
for	O
drugs	O
against	O
type	O
2	O
diabetes	O
,	O
dyslipidemia	O
,	O
atherosclerosis	O
,	O
and	O
cardiovascular	O
disease	O
.	O

In	O
an	O
effort	O
to	O
identify	O
novel	O
PPARγ	GENE-Y
ligands	O
with	O
an	O
improved	O
pharmacological	O
profile	O
,	O
emphasis	O
has	O
shifted	O
to	O
selective	O
ligands	O
with	O
partial	O
agonist	O
binding	O
properties	O
.	O

Toward	O
this	O
end	O
we	O
applied	O
an	O
integrated	O
in	O
silico	O
/	O
in	O
vitro	O
workflow	O
,	O
based	O
on	O
pharmacophore-	O
and	O
structure-based	O
virtual	O
screening	O
of	O
the	O
ZINC	O
library	O
,	O
coupled	O
with	O
competitive	O
binding	O
and	O
transactivation	O
assays	O
,	O
and	O
adipocyte	O
differentiation	O
and	O
gene	O
expression	O
studies	O
.	O

Hit	O
compound	O
9	O
was	O
identified	O
as	O
the	O
most	O
potent	O
ligand	O
(	O
IC50	O
=	O
0	O
.	O
3	O
μM	O
)	O
and	O
a	O
relatively	O
poor	O
inducer	O
of	O
adipocyte	O
differentiation	O
.	O

The	O
binding	O
mode	O
of	O
compound	O
9	O
was	O
confirmed	O
by	O
molecular	O
dynamics	O
simulation	O
,	O
and	O
the	O
calculated	O
free	O
energy	O
of	O
binding	O
was	O
-8	O
.	O
4	O
kcal	O
/	O
mol	O
.	O

A	O
novel	O
functional	O
group	O
,	O
the	O
carbonitrile	CHEMICAL
group	O
,	O
was	O
identified	O
to	O
be	O
a	O
key	O
substituent	O
in	O
the	O
ligand-protein	O
interactions	O
.	O

Further	O
studies	O
on	O
the	O
transcriptional	O
regulation	O
properties	O
of	O
compound	O
9	O
revealed	O
a	O
gene	O
regulatory	O
profile	O
that	O
was	O
to	O
a	O
large	O
extent	O
unique	O
,	O
however	O
functionally	O
closer	O
to	O
that	O
of	O
a	O
partial	O
agonist	O
.	O
Externalization	O
of	O
phosphatidylserine	CHEMICAL
during	O
apoptosis	O
does	O
not	O
specifically	O
require	O
either	O
isoform	O
of	O
phosphatidylserine	GENE-N
synthase	O
.	O
The	O
propeptides	O
of	O
VEGF-D	GENE-Y
determine	O
heparin	O
binding	O
,	O
receptor	O
heterodimerization	O
,	O
and	O
effects	O
on	O
tumor	O
biology	O
.	O
Ginseng	O
has	O
shown	O
an	O
efficacy	O
in	O
preventing	O
and	O
managing	O
various	O
health	O
conditions	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
the	O
effect	O
of	O
the	O
fermented	O
ginseng	O
extract	O
(	O
FGE	O
)	O
in	O
type	O
2	O
diabetes	O
mellitus	O
murine	O
model	O
.	O

FGE	O
was	O
provided	O
to	O
male	O
C57BL	O
/	O
ksJ-db	O
/	O
db	O
mice	O
for	O
8	O
weeks	O
at	O
0	O
.	O
1%	O
(	O
w	O
/	O
w	O
)	O
dose	O
in	O
contrast	O
to	O
water	O
for	O
the	O
control	O
group	O
.	O

Potential	O
anti-diabetic	O
mechanisms	O
were	O
investigated	O
with	O
blood	O
glucose	O
,	O
serum	GENE-N
insulin	GENE-N
,	O
serum	GENE-Y
adiponectin	GENE-Y
,	O
hemoglobin	GENE-N
A1c	GENE-N
(	O
HbA1c	GENE-N
)	O
,	O
glucose	CHEMICAL
tolerance	O
,	O
insulin	GENE-N
secretion	O
assay	O
,	O
quantitative	O
real-time	O
polymerase	O
chain	O
reaction	O
,	O
and	O
hematoxylin-eosin	CHEMICAL
staining	O
.	O

Compared	O
with	O
the	O
control	O
group	O
,	O
the	O
FGE	O
group	O
had	O
lower	O
levels	O
of	O
blood	O
glucose	CHEMICAL
after	O
6	O
and	O
9	O
h	O
fasting	O
,	O
HbA1c	GENE-N
,	O
and	O
the	O
area	O
under	O
the	O
curve	O
in	O
an	O
oral	O
glucose	CHEMICAL
tolerance	O
test	O
and	O
higher	O
levels	O
of	O
adiponectin	GENE-Y
and	O
serum	GENE-N
insulin	GENE-N
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
FGE	O
group	O
had	O
higher	O
levels	O
of	O
peroxisome	GENE-Y
proliferator-activated	GENE-Y
receptor	GENE-Y
gamma	GENE-Y
2	GENE-Y
and	O
glucose	CHEMICAL
transporter	O
protein	O
2	O
mRNAs	O
,	O
a	O
lower	O
level	O
of	O
tumor	GENE-Y
necrosis	GENE-Y
factor-α	GENE-Y
(	O
TNF-α	GENE-Y
)	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
less	O
lymphocytes	O
in	O
pancreas	O
than	O
the	O
control	O
group	O
had	O
.	O

The	O
FGE	O
exerted	O
anti-diabetic	O
effects	O
in	O
type	O
2	O
diabetic	O
mice	O
.	O
Fragment-based	O
drug	O
design	O
and	O
identification	O
of	O
HJC0123	CHEMICAL
,	O
a	O
novel	O
orally	O
bioavailable	O
STAT3	GENE-Y
inhibitor	O
for	O
cancer	O
therapy	O
.	O
Low-operating-voltage	O
flexible	O
organic	O
thin-film	O
transistors	O
with	O
high	O
thermal	O
stability	O
using	O
DPh-DNTT	CHEMICAL
and	O
SAM	O
gate	O
dielectrics	O
are	O
reported	O
.	O

The	O
mobility	O
of	O
the	O
transistors	O
are	O
decreased	O
by	O
23%	O
after	O
heating	O
to	O
250	O
°C	O
for	O
30	O
min	O
.	O

Furthermore	O
,	O
flexible	O
organic	O
pseudo-CMOS	O
inverter	O
circuits	O
,	O
which	O
are	O
functional	O
after	O
heating	O
to	O
200	O
°C	O
.	O
Histidine	GENE-N
triad	O
nucleotide	CHEMICAL
binding	O
proteins	O
(	O
Hints	GENE-N
)	O
are	O
the	O
most	O
ancient	O
members	O
of	O
the	O
histidine	GENE-N
triad	O
protein	O
superfamily	O
of	O
nucleotidyltransferases	GENE-N
and	O
hydrolyases	GENE-N
.	O

Protein-protein	O
interaction	O
studies	O
have	O
found	O
that	O
complexes	O
of	O
the	O
transcription	O
factors	O
MITF	GENE-Y
or	O
USF2	GENE-Y
and	O
lysyl-tRNA	O
synthetase	O
(	O
LysRS	GENE-Y
)	O
are	O
associated	O
with	O
human	GENE-Y
Hint1	GENE-Y
.	O

Therefore	O
,	O
we	O
hypothesized	O
that	O
lysyl-AMP	CHEMICAL
or	O
the	O
LysRS	GENE-Y
.	O

lysyl-AMP	CHEMICAL
may	O
be	O
a	O
native	O
substrate	O
for	O
Hints	GENE-N
.	O

To	O
explore	O
the	O
biochemical	O
relationship	O
between	O
Hint1	GENE-Y
and	O
LysRS	GENE-Y
,	O
a	O
series	O
of	O
catalytic	O
radiolabeling	O
,	O
mutagenesis	O
,	O
and	O
kinetic	O
experiments	O
was	O
conducted	O
with	O
purified	O
LysRSs	GENE-N
and	O
Hints	GENE-N
from	O
human	O
and	O
Escherichia	O
coli	O
.	O

After	O
incubation	O
of	O
the	O
E	GENE-N
.	GENE-N

coli	GENE-N
or	GENE-N
human	GENE-N
LysRS	GENE-N
with	O
Hints	GENE-N
and	O
[	CHEMICAL
alpha-	CHEMICAL
(	CHEMICAL
32	CHEMICAL
)	CHEMICAL
P	CHEMICAL
]	CHEMICAL
ATP	CHEMICAL
,	O
but	O
not	O
[	CHEMICAL
alpha-	CHEMICAL
(	CHEMICAL
32	CHEMICAL
)	CHEMICAL
P	CHEMICAL
]	CHEMICAL
GTP	CHEMICAL
,	O
(	CHEMICAL
32	CHEMICAL
)	CHEMICAL
P-labeled	O
Hints	GENE-N
were	O
observed	O
.	O

By	O
varying	O
time	O
and	O
the	O
concentrations	O
of	O
lysine	CHEMICAL
,	O
Mg	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
,	O
or	O
LysRS	GENE-Y
,	O
the	O
adenylation	O
of	O
Hint	GENE-N
was	O
found	O
to	O
be	O
dependent	O
on	O
the	O
formation	O
of	O
lysyl-AMP	CHEMICAL
.	O

Site-directed	O
mutagenesis	O
studies	O
of	O
the	O
active	O
site	O
histidine	GENE-N
triad	O
revealed	O
that	O
Hint	GENE-N
labeling	O
could	O
be	O
abolished	O
by	O
substitution	O
of	O
either	O
His-101	O
of	O
E	GENE-Y
.	GENE-Y

coli	GENE-Y
hinT	GENE-Y
or	O
His-112	O
of	O
human	GENE-Y
Hint1	GENE-Y
by	O
either	O
alanine	CHEMICAL
or	O
glycine	CHEMICAL
.	O

Ap	O
(	O
4	O
)	O
A	O
,	O
believed	O
to	O
be	O
synthesized	O
by	O
LysRS	GENE-Y
in	O
vivo	O
,	O
and	O
Zn	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
were	O
shown	O
to	O
inhibit	O
the	O
formation	O
of	O
Hint-AMP	CHEMICAL
with	O
an	O
IC	O
(	O
50	O
)	O
value	O
in	O
the	O
low	O
micromolar	O
range	O
.	O

Consistent	O
with	O
pyrophosphate	CHEMICAL
being	O
an	O
inhibitor	O
for	O
aminoacyl-tRNA	O
synthetase	O
,	O
incubations	O
in	O
the	O
presence	O
of	O
pyrophosphatase	GENE-N
resulted	O
in	O
enhanced	O
formation	O
of	O
Hint-AMP	CHEMICAL
.	O

These	O
results	O
demonstrate	O
that	O
the	O
lysyl-AMP	CHEMICAL
intermediate	O
formed	O
by	O
LysRS	GENE-Y
is	O
a	O
natural	O
substrate	O
for	O
Hints	GENE-N
and	O
suggests	O
a	O
potential	O
highly	O
conserved	O
regulatory	O
role	O
for	O
Hints	GENE-N
on	O
LysRS	GENE-Y
and	O
possibly	O
other	O
aminoacyl-tRNA	O
synthetases	O
.	O
BACKGROUND	O
:	O
Voltage-gated	GENE-N
sodium	CHEMICAL
channels	O
dysregulation	O
is	O
important	O
for	O
hyperexcitability	O
leading	O
to	O
pain	O
persistence	O
.	O

Sodium	GENE-N
channel	O
blockers	O
currently	O
used	O
to	O
treat	O
neuropathic	O
pain	O
are	O
poorly	O
tolerated	O
.	O

Getting	O
new	O
molecules	O
to	O
clinical	O
use	O
is	O
laborious	O
.	O

We	O
here	O
propose	O
a	O
drug	O
already	O
marketed	O
as	O
anticonvulsant	O
,	O
rufinamide	CHEMICAL
.	O

METHODS	O
:	O
We	O
compared	O
the	O
behavioral	O
effect	O
of	O
rufinamide	CHEMICAL
to	O
amitriptyline	CHEMICAL
using	O
the	O
Spared	O
Nerve	O
Injury	O
neuropathic	O
pain	O
model	O
in	O
mice	O
.	O

We	O
compared	O
the	O
effect	O
of	O
rufinamide	CHEMICAL
on	O
sodium	CHEMICAL
currents	O
using	O
in	O
vitro	O
patch	O
clamp	O
in	O
cells	O
expressing	O
the	O
voltage-gated	GENE-N
sodium	CHEMICAL
channel	O
Nav1	GENE-Y
.	GENE-Y
7	GENE-Y
isoform	O
and	O
on	O
dissociated	O
dorsal	O
root	O
ganglion	O
neurons	O
to	O
amitriptyline	CHEMICAL
and	O
mexiletine	CHEMICAL
.	O

RESULTS	O
:	O
In	O
naive	O
mice	O
,	O
amitriptyline	CHEMICAL
(	O
20	O
mg	O
/	O
kg	O
)	O
increased	O
withdrawal	O
threshold	O
to	O
mechanical	O
stimulation	O
from	O
1	O
.	O
3	O
(	O
0	O
.	O
6-1	O
.	O
9	O
)	O
(	O
median	O
[	O
95%	O
CI	O
]	O
)	O
to	O
2	O
.	O
3	O
g	O
(	O
2	O
.	O
2-2	O
.	O
5	O
)	O
and	O
latency	O
of	O
withdrawal	O
to	O
heat	O
stimulation	O
from	O
13	O
.	O
1	O
(	O
10	O
.	O
4-15	O
.	O
5	O
)	O
to	O
30	O
.	O
0	O
s	O
(	O
21	O
.	O
8-31	O
.	O
9	O
)	O
,	O
whereas	O
rufinamide	CHEMICAL
had	O
no	O
effect	O
.	O

Rufinamide	CHEMICAL
and	O
amitriptyline	CHEMICAL
alleviated	O
injury-induced	O
mechanical	O
allodynia	O
for	O
4	O
h	O
(	O
maximal	O
effect	O
:	O
0	O
.	O
10	O
+	O
/	O
-	O
0	O
.	O
03	O
g	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
to	O
1	O
.	O
99	O
+	O
/	O
-	O
0	O
.	O
26	O
g	O
for	O
rufinamide	CHEMICAL
and	O
0	O
.	O
25	O
+	O
/	O
-	O
0	O
.	O
22	O
g	O
to	O
1	O
.	O
92	O
+	O
/	O
-	O
0	O
.	O
85	O
g	O
for	O
amitriptyline	CHEMICAL
)	O
.	O

All	O
drugs	O
reduced	O
peak	O
current	O
and	O
stabilized	O
the	O
inactivated	O
state	O
of	O
voltage-gated	GENE-N
sodium	CHEMICAL
channel	O
Nav1	GENE-Y
.	GENE-Y
7	GENE-Y
,	O
with	O
similar	O
effects	O
in	O
dorsal	O
root	O
ganglion	O
neurons	O
.	O

CONCLUSIONS	O
:	O
At	O
doses	O
alleviating	O
neuropathic	O
pain	O
,	O
amitriptyline	CHEMICAL
showed	O
alteration	O
of	O
behavioral	O
response	O
possibly	O
related	O
to	O
either	O
alteration	O
of	O
basal	O
pain	O
sensitivity	O
or	O
sedative	O
effect	O
or	O
both	O
.	O

Side-effects	O
and	O
drug	O
tolerance	O
/	O
compliance	O
are	O
major	O
problems	O
with	O
drugs	O
such	O
as	O
amitriptyline	CHEMICAL
.	O

Rufinamide	CHEMICAL
seems	O
to	O
have	O
a	O
better	O
tolerability	O
profile	O
and	O
could	O
be	O
a	O
new	O
alternative	O
to	O
explore	O
for	O
the	O
treatment	O
of	O
neuropathic	O
pain	O
.	O
Nutrients	O
and	O
bioactive	O
compounds	O
of	O
Thai	O
indigenous	O
fruits	O
.	O
Epigenetic	O
Regulation	O
Is	O
a	O
Crucial	O
Factor	O
in	O
the	O
Repression	O
of	O
UGT1A1	GENE-Y
Expression	O
in	O
the	O
Human	O
Kidney	O
.	O
A	O
cDNA	O
encoding	O
the	O
mouse	GENE-Y
carbonic	GENE-Y
anhydrase	GENE-Y
V	GENE-Y
gene	O
was	O
isolated	O
by	O
reverse	O
transcription	O
and	O
polymerase	O
chain	O
reaction	O
from	O
BALB	O
/	O
c	O
mouse	O
liver	O
mRNA	O
.	O

Vectors	O
containing	O
the	O
full	O
coding	O
sequence	O
as	O
well	O
as	O
two	O
different	O
NH2-terminal	O
truncated	O
genes	O
expressed	O
enzymatically	O
active	O
protein	O
in	O
Escherichia	O
coli	O
.	O

The	GENE-Y
carbonic	GENE-Y
anhydrase	GENE-Y
V	GENE-Y
produced	O
by	O
a	O
vector	O
containing	O
the	O
full	O
coding	O
sequence	O
,	O
which	O
includes	O
a	O
possible	O
NH2-terminal	O
mitochondrial	O
targeting	O
signal	O
,	O
was	O
proteolytically	O
processed	O
by	O
E	O
.	O

coli	O
and	O
contained	O
several	O
amino-terminal	O
ends	O
.	O

The	O
two	O
NH2-terminal	O
truncated	O
vectors	O
deleted	O
,	O
respectively	O
,	O
1	O
)	O
the	O
29-amino	CHEMICAL
acid	CHEMICAL
putative	O
targeting	O
sequence	O
and	O
2	O
)	O
51	O
amino	CHEMICAL
acids	CHEMICAL
,	O
yielding	O
a	O
protein	O
equivalent	O
to	O
a	O
carbonic	GENE-Y
anhydrase	GENE-Y
(	GENE-Y
CA	GENE-Y
)	GENE-Y
V	GENE-Y
isolated	O
from	O
mouse	O
liver	O
mitochondria;	O
and	O
both	O
vectors	O
produced	O
homogeneous	O
protein	O
fractions	O
.	O

These	O
latter	O
two	O
forms	O
of	O
CA	GENE-Y
V	GENE-Y
had	O
identical	O
steady-state	O
constants	O
for	O
the	O
hydration	O
of	O
CO2	CHEMICAL
,	O
with	O
maximal	O
values	O
of	O
kcat	O
/	O
Km	O
at	O
3	O
x	O
10	O
(	O
7	O
)	O
M-1	O
s-1	O
and	O
kcat	O
at	O
3	O
x	O
10	O
(	O
5	O
)	O
s-1	O
with	O
an	O
apparent	O
pKa	O
for	O
catalysis	O
of	O
7	O
.	O
4	O
determined	O
from	O
kcat	O
/	O
Km	O
.	O

In	O
catalytic	O
properties	O
,	O
mouse	GENE-Y
CA	GENE-Y
V	GENE-Y
is	O
closest	O
to	O
CA	GENE-Y
I;	O
however	O
,	O
in	O
inhibition	O
by	O
acetazolamide	CHEMICAL
,	O
ethoxzolamide	CHEMICAL
,	O
and	O
cyanate	CHEMICAL
,	O
CA	GENE-Y
V	GENE-Y
is	O
very	O
similar	O
to	O
CA	GENE-Y
II	GENE-Y
.	O

Mouse	GENE-Y
CA	GENE-Y
V	GENE-Y
has	O
a	O
tyrosine	O
at	O
position	O
64	O
,	O
where	O
the	O
highly	O
active	O
isozyme	O
II	O
has	O
histidine	CHEMICAL
serving	O
as	O
a	O
proton	O
shuttle	O
in	O
the	O
catalytic	O
pathway	O
.	O

Investigation	O
of	O
a	O
site-specific	O
mutant	O
of	O
CA	GENE-Y
V	GENE-Y
containing	O
the	O
replacement	O
Tyr64-->His	CHEMICAL
showed	O
that	O
the	O
unique	O
kinetic	O
properties	O
of	O
CA	GENE-Y
V	GENE-Y
are	O
not	O
due	O
to	O
the	O
presence	O
of	O
tyrosine	CHEMICAL
at	O
position	O
64	O
.	O
An	O
overview	O
of	O
transcriptional	O
regulation	O
in	O
response	O
to	O
toxicological	O
insult	O
.	O
Novel	O
N-indolylmethyl	CHEMICAL
substituted	CHEMICAL
spiroindoline-3	CHEMICAL
,	CHEMICAL
2'-quinazolines	CHEMICAL
were	O
designed	O
as	O
potential	O
inhibitiors	O
of	O
SIRT1	GENE-Y
.	O

These	O
compounds	O
were	O
synthesized	O
in	O
good	O
yields	O
by	O
using	O
Pd	CHEMICAL
/	O
C-Cu	CHEMICAL
mediated	O
coupling-cyclization	O
strategy	O
as	O
a	O
key	O
step	O
involving	O
the	O
reaction	O
of	O
1-	CHEMICAL
(	CHEMICAL
prop-2-ynyl	CHEMICAL
)	CHEMICAL
-1'H-spiro	CHEMICAL
[	CHEMICAL
indoline-3	CHEMICAL
,	CHEMICAL
2'-quinazoline	CHEMICAL
]	CHEMICAL
-2	CHEMICAL
,	CHEMICAL
4'	CHEMICAL
(	CHEMICAL
3'H	CHEMICAL
)	CHEMICAL
-dione	CHEMICAL
with	O
2-iodoanilides	CHEMICAL
.	O

Some	O
of	O
the	O
compounds	O
synthesized	O
have	O
shown	O
encouraging	O
inhibition	O
of	O
Sir	GENE-Y
2	GENE-Y
protein	O
(	O
a	O
yeast	O
homologue	O
of	O
mammalian	GENE-N
SIRT1	GENE-N
)	O
in	O
vitro	O
and	O
three	O
of	O
them	O
showed	O
dose	O
dependent	O
inhibition	O
of	O
Sir	GENE-Y
2	GENE-Y
.	O

The	O
docking	O
results	O
suggested	O
that	O
the	O
benzene	CHEMICAL
ring	O
of	O
1	CHEMICAL
,	CHEMICAL
2	CHEMICAL
,	CHEMICAL
3	CHEMICAL
,	CHEMICAL
4-tetrahydroquinazolin	CHEMICAL
ring	O
system	O
of	O
these	O
molecules	O
occupied	O
the	O
deep	O
hydrophobic	O
pocket	O
of	O
the	O
protein	O
and	O
one	O
of	O
the	O
NH	CHEMICAL
along	O
with	O
the	O
sulfonyl	CHEMICAL
group	O
participated	O
in	O
strong	O
H-bonding	O
interaction	O
with	O
the	O
amino	CHEMICAL
acid	CHEMICAL
residues	O
.	O
This	O
study	O
aims	O
to	O
investigate	O
potential	O
diabetic	O
retinopathy	O
(	O
DR	O
)	O
risk	O
factors	O
by	O
evaluating	O
the	O
circulating	O
levels	O
of	O
pentosidine	CHEMICAL
,	O
soluble	GENE-Y
receptor	GENE-Y
for	GENE-Y
advanced	GENE-Y
glycation	GENE-Y
end-product	GENE-Y
(	O
sRAGE	GENE-Y
)	O
,	O
advanced	O
oxidation	O
protein	O
product	O
(	O
AOPP	O
)	O
as	O
well	O
as	O
glutathione	CHEMICAL
peroxidase	O
(	O
GPx	GENE-N
)	O
and	O
superoxide	CHEMICAL
dismutase	O
(	O
SOD	GENE-N
)	O
activities	O
in	O
DR	O
patients	O
.	O

A	O
total	O
of	O
235	O
healthy	O
controls	O
,	O
171	O
type	O
2	O
diabetic	O
without	O
retinopathy	O
(	O
DNR	O
)	O
and	O
200	O
diabetic	O
retinopathy	O
(	O
DR	O
)	O
patients	O
were	O
recruited	O
.	O

Plasma	O
was	O
extracted	O
for	O
the	O
estimation	O
of	O
pentosidine	CHEMICAL
,	O
sRAGE	GENE-Y
,	O
AOPP	O
levels	O
and	O
GPx	GENE-N
activity	O
whereas	O
peripheral	O
blood	O
mononuclear	O
cells	O
were	O
disrupted	O
for	O
SOD	GENE-N
activity	O
measurement	O
.	O

DNR	O
and	O
DR	O
patients	O
showed	O
significantly	O
higher	O
levels	O
of	O
plasma	O
pentosidine	CHEMICAL
,	O
sRAGE	GENE-Y
and	O
AOPP	O
but	O
lower	O
GPx	GENE-N
and	O
SOD	GENE-N
activities	O
when	O
compared	O
to	O
healthy	O
controls	O
.	O

The	O
sRAGE	GENE-Y
/	O
pentosidine	CHEMICAL
ratio	O
in	O
DR	O
patients	O
was	O
significantly	O
lower	O
than	O
the	O
ratio	O
detected	O
in	O
DNR	O
patients	O
.	O

Proliferative	O
DR	O
patients	O
had	O
significantly	O
higher	O
levels	O
of	O
plasma	O
pentosidine	CHEMICAL
,	O
sRAGE	GENE-Y
,	O
AOPP	O
and	O
sRAGE	GENE-Y
/	O
pentosidine	CHEMICAL
ratio	O
than	O
non-proliferative	O
DR	O
patients	O
.	O

High	O
HbA1c	GENE-Y
level	O
,	O
long	O
duration	O
of	O
diabetes	O
and	O
low	O
sRAGE	GENE-Y
/	O
pentosidine	CHEMICAL
ratio	O
were	O
determined	O
as	O
the	O
risk	O
factors	O
for	O
DR	O
.	O

This	O
study	O
suggests	O
that	O
sRAGE	GENE-Y
/	O
pentosidine	CHEMICAL
ratio	O
could	O
serve	O
as	O
a	O
risk	O
factor	O
determinant	O
for	O
type	O
2	O
DR	O
as	O
it	O
has	O
a	O
positive	O
correlation	O
with	O
the	O
severity	O
of	O
DR	O
.	O
[	O
Effects	O
of	O
thrombolysis	O
and	O
anticoagulation	O
on	O
the	O
functions	O
of	O
vascular	O
endothelial	O
cells	O
and	O
coagulation	O
and	O
fibrinolysis	O
in	O
patients	O
with	O
pulmonary	O
thromboembolism	O
]	O
.	O
The	O
prostaglandin	CHEMICAL
F	CHEMICAL
(	CHEMICAL
2alpha	CHEMICAL
)	CHEMICAL
receptor	O
(	O
PTGFR	GENE-Y
)	O
is	O
believed	O
to	O
play	O
a	O
role	O
in	O
the	O
process	O
of	O
parturition	O
.	O

The	O
main	O
support	O
for	O
this	O
comes	O
from	O
animal	O
studies;	O
however	O
,	O
in	O
humans	O
,	O
the	O
evidence	O
is	O
less	O
clear	O
.	O

The	O
gene	O
coding	O
for	O
PTGFR	GENE-Y
may	O
be	O
subject	O
to	O
alternative	O
splicing	O
to	O
generate	O
alternate	O
variants	O
with	O
different	O
signalling	O
pathways	O
.	O

We	O
have	O
determined	O
regional	O
(	O
upper	O
versus	O
lower	O
segment	O
)	O
and	O
labour-associated	O
expression	O
of	O
PTGFR	GENE-Y
mRNA	O
and	O
a	O
recently	O
identified	O
splice	O
variant	O
of	O
PTGFR	GENE-Y
in	O
human	O
myometrium	O
and	O
decidua	O
.	O

We	O
also	O
examined	O
the	O
effect	O
of	O
the	O
inflammatory	O
cytokine	GENE-N
interleukin-1beta	GENE-Y
(	O
IL-1beta	GENE-Y
)	O
on	O
PTGFR	GENE-Y
mRNA	O
expression	O
in	O
a	O
model	O
of	O
cultured	O
human	O
myometrial	O
smooth	O
muscle	O
cells	O
.	O

We	O
identified	O
a	O
PTGFR	GENE-Y
transcript	GENE-Y
variant	GENE-Y
2	GENE-Y
(	O
PTGFR-v2	GENE-Y
)	O
generated	O
by	O
alternate	O
splicing	O
in	O
human	O
myometrium	O
and	O
decidua	O
.	O

The	O
PTGFR-v2	GENE-Y
contains	O
an	O
additional	O
71	O
base	O
pair	O
exon	O
,	O
which	O
results	O
in	O
a	O
truncated	O
protein	O
at	O
297	O
amino	CHEMICAL
acids	CHEMICAL
compared	O
with	O
the	O
PTGFR	GENE-Y
transcript	GENE-Y
variant	GENE-Y
1	GENE-Y
(	O
PTGFR-v1	GENE-Y
)	O
at	O
359	O
amino	CHEMICAL
acids	CHEMICAL
.	O

In	O
contrast	O
to	O
our	O
hypothesis	O
,	O
we	O
demonstrate	O
that	O
PTGFR-v1	GENE-Y
and	O
PTGFR-v2	GENE-Y
mRNA	O
expression	O
is	O
not	O
significantly	O
higher	O
in	O
upper	O
segment	O
compared	O
with	O
lower	O
segment	O
paired	O
samples	O
.	O

We	O
also	O
show	O
a	O
labour-associated	O
decrease	O
in	O
PTGFR-v1	GENE-Y
and	O
PTGFR-v2	GENE-Y
mRNA	O
expression	O
in	O
lower	O
segment	O
myometrial	O
samples	O
.	O

IL-1beta-stimulated	O
mRNA	O
expression	O
of	O
both	O
PTGFR	GENE-Y
variants	O
in	O
a	O
distinct	O
time-dependent	O
manner	O
in	O
myometrial	O
cell	O
cultures	O
.	O

We	O
suggest	O
that	O
the	O
role	O
of	O
the	O
PTGFR	GENE-Y
in	O
the	O
human	O
uterus	O
requires	O
further	O
validation	O
prior	O
to	O
pursuing	O
it	O
as	O
a	O
target	O
for	O
the	O
treatment	O
of	O
preterm	O
labour	O
.	O

In	O
addition	O
,	O
the	O
presence	O
of	O
distinct	O
variants	O
suggests	O
further	O
levels	O
of	O
gene	O
regulation	O
within	O
the	O
pregnant	O
uterus	O
.	O
OBJECTIVE	O
:	O
The	O
activity	O
of	O
the	O
antitumoral	O
agent	O
bexarotene	CHEMICAL
(	O
Targretin	CHEMICAL
,	O
Bexarotene	CHEMICAL
)	O
depends	O
on	O
its	O
binding	O
to	O
the	O
nuclear	O
retinoid-X	O
receptor	O
(	O
RXR	GENE-N
)	O
and	O
subsequent	O
transcriptional	O
regulation	O
of	O
target	O
genes	O
.	O

Through	O
RXR	GENE-N
activation	O
,	O
bexarotene	CHEMICAL
may	O
modulate	O
numerous	O
metabolic	O
pathways	O
involved	O
in	O
atherosclerosis	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
bexarotene	CHEMICAL
on	O
atherosclerosis	O
progression	O
in	O
a	O
dyslipidemic	O
murine	O
model	O
,	O
the	O
human	GENE-Y
apolipoprotein	GENE-Y
E2	GENE-Y
knockin	O
mouse	O
,	O
that	O
develops	O
essentially	O
macrophage-laden	O
lesions	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Atherosclerotic	O
lesions	O
together	O
with	O
different	O
metabolic	O
pathways	O
involved	O
in	O
atherosclerosis	O
were	O
investigated	O
in	O
mice	O
treated	O
or	O
not	O
with	O
bexarotene	CHEMICAL
.	O

Bexarotene	CHEMICAL
protects	O
from	O
atherosclerosis	O
development	O
in	O
mice	O
,	O
at	O
least	O
in	O
part	O
by	O
improving	O
the	O
circulating	O
cholesterol	CHEMICAL
distribution	O
profile	O
likely	O
via	O
a	O
marked	O
decrease	O
of	O
dietary	O
cholesterol	CHEMICAL
absorption	O
caused	O
by	O
modulation	O
of	O
intestinal	O
expression	O
of	O
genes	O
recently	O
identified	O
as	O
major	O
players	O
in	O
this	O
process	O
,	O
Niemann-Pick-C1-Like1	GENE-Y
(	O
NPC1L1	GENE-Y
)	O
and	O
CD13	GENE-Y
.	O

This	O
atheroprotection	O
appears	O
despite	O
a	O
strong	O
hypertriglyceridemia	O
.	O

Moreover	O
,	O
bexarotene	CHEMICAL
treatment	O
only	O
modestly	O
modulates	O
inflammatory	O
gene	O
expression	O
in	O
the	O
vascular	O
wall	O
,	O
but	O
markedly	O
enhanced	O
the	O
capacity	O
of	O
macrophages	O
to	O
efflux	O
cellular	O
lipids	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
provide	O
evidence	O
of	O
a	O
favorable	O
pharmacological	O
effect	O
of	O
bexarotene	CHEMICAL
on	O
atherosclerosis	O
despite	O
the	O
induction	O
of	O
hypertriglyceridemia	O
,	O
likely	O
via	O
a	O
beneficial	O
action	O
on	O
intestinal	O
absorption	O
and	O
macrophage	O
efflux	O
.	O
GABA-induced	O
currents	O
have	O
been	O
characterized	O
in	O
isolated	O
horizontal	O
cells	O
from	O
lower	O
vertebrates	O
but	O
not	O
in	O
mammalian	O
horizontal	O
cells	O
.	O

Therefore	O
horizontal	O
cells	O
were	O
isolated	O
after	O
enzymatical	O
and	O
mechanical	O
dissociation	O
of	O
the	O
adult	O
mouse	O
retina	O
and	O
visually	O
identified	O
.	O

We	O
recorded	O
from	O
horizontal	O
cell	O
bodies	O
using	O
the	O
whole	O
cell	O
and	O
outside-out	O
configuration	O
of	O
the	O
patch-clamp	O
technique	O
.	O

Extracellular	O
application	O
of	O
GABA	CHEMICAL
induced	O
inward	O
currents	O
carried	O
by	O
chloride	CHEMICAL
ions	O
.	O

GABA-evoked	O
currents	O
were	O
completely	O
and	O
reversibly	O
blocked	O
by	O
the	O
competitive	O
GABAA	GENE-N
receptor	GENE-N
antagonist	O
bicuculline	CHEMICAL
(	O
IC50	O
=	O
1	O
.	O
7	O
microM	O
)	O
,	O
indicating	O
expression	O
of	O
GABAA	GENE-N
but	O
not	O
GABAC	GENE-N
receptors	GENE-N
.	O

Their	O
affinity	O
for	O
GABA	CHEMICAL
was	O
moderate	O
(	O
EC50	O
=	O
30	O
microM	O
)	O
,	O
and	O
the	O
Hill	O
coefficient	O
was	O
1	O
.	O
3	O
,	O
corresponding	O
to	O
two	O
GABA	GENE-N
binding	O
sites	O
.	O

GABA	CHEMICAL
responses	O
were	O
partially	O
reduced	O
by	O
picrotoxin	CHEMICAL
with	O
differential	O
effects	O
on	O
peak	O
and	O
steady-state	O
current	O
values	O
.	O

Zinc	CHEMICAL
blocked	O
the	O
GABA	CHEMICAL
response	O
with	O
an	O
IC50	O
value	O
of	O
7	O
.	O
3	O
microM	O
in	O
a	O
noncompetitive	O
manner	O
.	O

Furthermore	O
,	O
GABA	CHEMICAL
receptors	O
of	O
horizontal	O
cells	O
were	O
modulated	O
by	O
extracellular	O
application	O
of	O
diazepam	CHEMICAL
,	O
zolpidem	CHEMICAL
,	O
methyl	CHEMICAL
6	CHEMICAL
,	CHEMICAL
7-dimethoxy-4-ethyl-beta-carboxylate	CHEMICAL
,	O
pentobarbital	CHEMICAL
,	O
and	O
alphaxalone	CHEMICAL
,	O
thus	O
showing	O
typical	O
pharmacological	O
properties	O
of	O
CNS	O
GABAA	GENE-N
receptors	GENE-N
.	O

GABA-evoked	O
single-channel	O
currents	O
were	O
characterized	O
by	O
a	O
main	O
conductance	O
state	O
of	O
29	O
.	O
8	O
pS	O
and	O
two	O
subconductance	O
states	O
(	O
20	O
.	O
2	O
and	O
10	O
.	O
8	O
pS	O
,	O
respectively	O
)	O
.	O

Kinetic	O
analysis	O
of	O
single-channel	O
events	O
within	O
bursts	O
revealed	O
similar	O
mean	O
open	O
and	O
closed	O
times	O
for	O
the	O
main	O
conductance	O
and	O
the	O
20	O
.	O
2-pS	O
subconductance	O
state	O
,	O
resulting	O
in	O
open	O
probabilities	O
of	O
44	O
.	O
6	O
and	O
42	O
.	O
7%	O
,	O
respectively	O
.	O

The	O
ratio	O
of	O
open	O
to	O
closed	O
times	O
,	O
however	O
,	O
was	O
significantly	O
different	O
for	O
the	O
10	O
.	O
8-pS	O
subconductance	O
state	O
with	O
an	O
open	O
probability	O
of	O
57	O
.	O
2%	O
.	O
Catecholamine	CHEMICAL
mimetic	O
EDTA-bis	CHEMICAL
(	CHEMICAL
tyramide	CHEMICAL
)	CHEMICAL
was	O
synthesized	O
and	O
characterized	O
by	O
various	O
spectroscopic	O
techniques	O
(	O
NMR	O
,	O
Mass	O
spectroscopy	O
)	O
and	O
λem	O
310	O
nm	O
for	O
the	O
excitation	O
at	O
270	O
nm	O
.	O

Molecular	O
docking	O
studies	O
were	O
performed	O
with	O
Human	GENE-Y
Serum	GENE-Y
Albumin	GENE-Y
(	O
HSA	GENE-Y
:	O
PDB	O
1E78	O
)	O
,	O
showing	O
binding	O
pattern	O
with	O
amino	CHEMICAL
acid	CHEMICAL
residues	O
Arg218	O
,	O
Arg222	O
and	O
Lys444	O
,	O
identifies	O
the	O
ligand-HSA	GENE-Y
interaction	O
for	O
the	O
transportation	O
affinity	O
of	O
the	O
ligand	O
at	O
the	O
specific	O
site	O
of	O
the	O
target	O
.	O

Subsequently	O
binding	O
study	O
with	O
HSA	O
at	O
λex	O
=	O
350	O
nm	O
found	O
to	O
be	O
5	O
.	O
847x10	O
(	O
4	O
)	O
M	O
(	O
-1	O
)	O
shows	O
effective	O
quenching	O
effect	O
.	O

Additionally	O
to	O
go	O
more	O
insight	O
AChE	O
binding	O
affinity	O
was	O
investigated	O
,	O
which	O
shows	O
90%	O
binding	O
affinity	O
for	O
the	O
10	O
mM	O
concentration	O
.	O

IC50	O
value	O
was	O
was	O
found	O
18	O
.	O
60	O
μM	O
for	O
MAO-B	GENE-Y
inhibition	O
.	O

Finally	O
,	O
EDTA-bis	CHEMICAL
(	CHEMICAL
tyramide	CHEMICAL
)	CHEMICAL
labeled	O
with	O
(	CHEMICAL
99m	CHEMICAL
)	CHEMICAL
Tc	CHEMICAL
to	O
investigate	O
its	O
in-vivo	O
radiopharmaceutical	O
efficiency	O
,	O
having	O
97%	O
binding	O
affinity	O
with	O
98%	O
radiochemical	O
purity	O
.	O

In-vivo	O
studies	O
were	O
carried	O
out	O
for	O
(	CHEMICAL
99m	CHEMICAL
)	CHEMICAL
Tc-	CHEMICAL
EDTA-bis	CHEMICAL
(	CHEMICAL
tyramide	CHEMICAL
)	CHEMICAL
included	O
blood	O
kinetics	O
showed	O
a	O
quick	O
wash	O
out	O
from	O
the	O
circulation	O
via	O
renal	O
route	O
and	O
biodistribution	O
revealed	O
that	O
maximum%ID	O
/	O
g	O
was	O
found	O
in	O
kidney	O
at	O
1h	O
and	O
its	O
scintigraphy	O
image	O
shows	O
3	O
.	O
96%	O
brain	O
uptake	O
with	O
respect	O
to	O
whole	O
body	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O
Pyridinium	CHEMICAL
oximes	CHEMICAL
as	O
cholinesterase	GENE-Y
reactivators	O
.	O

Structure-activity	O
relationship	O
and	O
efficacy	O
in	O
the	O
treatment	O
of	O
poisoning	O
with	O
organophosphorus	CHEMICAL
compounds	O
.	O
Thymidylate	CHEMICAL
kinase	O
(	O
TMPK	GENE-Y
)	O
is	O
a	O
key	O
enzyme	O
for	O
pyrimidine	CHEMICAL
synthesis	O
that	O
catalyzes	O
the	O
phosphorylation	O
of	O
thymidine	CHEMICAL
5'-monophosphate	CHEMICAL
(	O
dTMP	CHEMICAL
)	O
in	O
the	O
presence	O
of	O
ATP	CHEMICAL
and	O
Mg	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
to	O
form	O
thymidine	CHEMICAL
5'-diphosphate	CHEMICAL
(	O
dTDP	CHEMICAL
)	O
,	O
which	O
is	O
then	O
converted	O
to	O
thymidine	CHEMICAL
5'-triphosphate	CHEMICAL
(	O
dTTP	CHEMICAL
)	O
by	O
nucleoside-diphosphate	CHEMICAL
kinase	O
(	O
NDK	O
)	O
.	O

TMPK	GENE-Y
has	O
an	O
important	O
function	O
in	O
cell	O
proliferation	O
and	O
its	O
enzyme	O
kinetics	O
and	O
related	O
structures	O
have	O
been	O
determined	O
in	O
various	O
organisms	O
.	O

TMPK	GENE-Y
is	O
well	O
recognized	O
as	O
a	O
potential	O
drug	O
target	O
,	O
with	O
the	O
most	O
notable	O
function	O
being	O
in	O
the	O
activation	O
of	O
anti-HIV	O
nucleoside	CHEMICAL
prodrugs	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
TMPK	GENE-Y
is	O
a	O
validated	O
target	O
for	O
antibiotic	O
development	O
against	O
gram-positive	O
bacterium	O
of	O
Staphylococcus	O
aureus	O
.	O

In	O
addition	O
,	O
inhibition	O
of	O
human	GENE-Y
TMPK	GENE-Y
increases	O
the	O
potential	O
of	O
anticancer	O
agent	O
doxorubicin	CHEMICAL
toward	O
colon	O
cancer	O
cells	O
regardless	O
of	O
p53	GENE-Y
status	O
.	O

Following	O
the	O
rapid	O
expanding	O
knowledge	O
on	O
TMPKs	GENE-Y
and	O
the	O
rising	O
interests	O
in	O
TMPKs	GENE-Y
as	O
a	O
drug	O
target	O
,	O
in	O
this	O
review	O
we	O
try	O
to	O
describe	O
current	O
research	O
on	O
TMPKs	GENE-Y
in	O
various	O
organisms	O
of	O
eukaryotes	O
,	O
prokaryotes	O
and	O
viruses	O
and	O
to	O
provide	O
information	O
for	O
designing	O
new	O
potential	O
inhibitors	O
against	O
TMPKs	GENE-Y
.	O
Alteration	O
of	O
α-tocopherol-associated	O
protein	O
(	O
TAP	GENE-Y
)	O
expression	O
in	O
human	O
breast	O
epithelial	O
cells	O
during	O
breast	O
cancer	O
development	O
.	O
D4	GENE-Y
dopamine	CHEMICAL
receptor	O
binding	O
affinity	O
does	O
not	O
distinguish	O
between	O
typical	O
and	O
atypical	O
antipsychotic	O
drugs	O
.	O
We	O
investigated	O
the	O
effects	O
of	O
resveratrol	CHEMICAL
on	O
rat	O
portal	O
vein	O
(	O
RPV	O
)	O
contractility	O
without	O
endothelium	O
.	O

Contractions	O
were	O
produced	O
by	O
electrical	O
field	O
stimulation	O
of	O
perivascular	O
nerves	O
(	O
EFS	O
)	O
,	O
norepinephrine	CHEMICAL
(	O
NE	O
)	O
,	O
adenosine	CHEMICAL
5'-triphosphate	CHEMICAL
(	O
ATP	CHEMICAL
)	O
,	O
high	O
K	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
solution	O
and	O
by	O
calcium	CHEMICAL
chloride	CHEMICAL
(	O
CaCl	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
)	O
in	O
Ca	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-free	O
and	O
high	O
K	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
,	O
Ca	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-free	O
solution	O
.	O

The	O
EFS-evoked	O
contractions	O
were	O
more	O
sensitive	O
to	O
resveratrol	CHEMICAL
and	O
to	O
NS1619-selective	O
openers	O
of	O
big	O
calcium-sensitive	O
(	GENE-N
BK	GENE-N
(	GENE-N
Ca	CHEMICAL
)	O
)	O
channels	O
,	O
than	O
NE-evoked	O
contractions	O
.	O

Effects	O
of	O
resveratrol	CHEMICAL
on	O
the	O
ATP-evoked	O
contractions	O
were	O
weak	O
.	O

Blockers	O
of	O
BK	GENE-N
(	GENE-N
Ca	CHEMICAL
)	O
channels	O
partly	O
inhibited	O
the	O
effect	O
of	O
resveratrol	CHEMICAL
only	O
in	O
EFS-contracted	O
preparations	O
.	O

Western	O
blotting	O
showed	O
that	O
RPV	O
expressed	O
K	GENE-Y
(	O
Ca	CHEMICAL
)	O
1	O
.	O
1	O
protein	O
.	O

Inhibitors	O
of	O
ATP-	O
and	O
voltage-sensitive	O
K	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
channels	O
did	O
not	O
modify	O
the	O
effects	O
of	O
resveratrol	CHEMICAL
.	O

None	O
of	O
the	O
antagonists	O
of	O
K	GENE-N
(	GENE-N
+	GENE-N
)	GENE-N
channels	O
affected	O
the	O
resveratrol	CHEMICAL
inhibition	O
of	O
NE-evoked	O
contractions	O
and	O
effect	O
of	O
high	O
concentrations	O
of	O
resveratrol	CHEMICAL
on	O
the	O
EFS-evoked	O
contractions	O
.	O

Resveratrol	CHEMICAL
more	O
potently	O
inhibited	O
CaCl	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
than	O
potassium	CHEMICAL
chloride	CHEMICAL
contractions	O
of	O
RPV	O
.	O

Thus	O
,	O
BK	GENE-N
(	GENE-N
Ca	CHEMICAL
)	O
channels	O
partly	O
mediate	O
the	O
inhibitory	O
effect	O
of	O
resveratrol	CHEMICAL
on	O
the	O
neurogenic	O
contractions	O
of	O
RPV	O
.	O

The	O
smooth	O
muscle	O
Ca	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
channels	O
and	O
/	O
or	O
Ca	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
mobilizing	O
through	O
cells	O
might	O
be	O
involved	O
in	O
the	O
effects	O
of	O
resveratrol	CHEMICAL
on	O
the	O
contractility	O
of	O
RPV	O
.	O

Our	O
results	O
are	O
important	O
for	O
better	O
understanding	O
the	O
impact	O
of	O
resveratrol	CHEMICAL
on	O
the	O
portal	O
circulation	O
.	O

Copyright	O
©	O
2013	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O
OAT1	GENE-Y
and	O
OAT3	GENE-Y
:	O
targets	O
of	O
drug-drug	O
interaction	O
between	O
entecavir	CHEMICAL
and	O
JBP485	CHEMICAL
.	O
β-Cell	O
lipotoxicity	O
is	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
type	O
2	O
diabetes	O
.	O

However	O
,	O
no	O
study	O
has	O
examined	O
its	O
role	O
in	O
type	O
1	O
diabetes	O
,	O
which	O
could	O
be	O
clinically	O
relevant	O
for	O
slow-onset	O
type	O
1	O
diabetes	O
.	O

Reports	O
of	O
enhanced	O
cytokine	GENE-N
toxicity	O
in	O
fat-laden	O
islets	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
lipid	O
and	O
cytokine	GENE-N
toxicity	O
may	O
be	O
synergistic	O
.	O

Thus	O
,	O
β-cell	O
lipotoxicity	O
could	O
be	O
enhanced	O
in	O
models	O
of	O
autoimmune	O
diabetes	O
.	O

To	O
determine	O
this	O
,	O
we	O
examined	O
the	O
effects	O
of	O
prolonged	O
free	O
fatty	CHEMICAL
acids	CHEMICAL
elevation	O
on	O
β-cell	O
secretory	O
function	O
in	O
the	O
prediabetic	O
diabetes-prone	O
BioBreeding	O
(	O
dp-BB	O
)	O
rat	O
,	O
its	O
diabetes-resistant	O
BioBreeding	O
(	O
dr-BB	O
)	O
control	O
,	O
and	O
normal	O
Wistar-Furth	O
(	O
WF	O
)	O
rats	O
.	O

Rats	O
received	O
a	O
48-h	O
iv	O
infusion	O
of	O
saline	O
or	O
Intralipid	O
plus	O
heparin	O
(	O
IH	O
)	O
(	O
to	O
elevate	O
free	O
fatty	CHEMICAL
acid	CHEMICAL
levels	O
~2-fold	O
)	O
followed	O
by	O
hyperglycemic	O
clamp	O
or	O
islet	O
secretion	O
studies	O
ex	O
vivo	O
.	O

IH	O
significantly	O
decreased	O
β-cell	O
function	O
,	O
assessed	O
both	O
by	O
the	O
disposition	O
index	O
(	O
insulin	GENE-N
secretion	O
corrected	O
for	O
IH-induced	O
insulin	GENE-N
resistance	O
)	O
and	O
in	O
isolated	O
islets	O
,	O
in	O
dp-BB	O
,	O
but	O
not	O
in	O
dr-BB	O
or	O
WF	O
,	O
rats	O
,	O
and	O
the	O
effect	O
of	O
IH	O
was	O
inhibited	O
by	O
the	O
antioxidant	O
N-acetylcysteine	CHEMICAL
.	O

Furthermore	O
,	O
IH	O
significantly	O
increased	O
islet	O
cytokine	GENE-N
mRNA	O
and	O
plasma	O
cytokine	GENE-N
levels	O
(	O
monocyte	GENE-Y
chemoattractant	GENE-Y
protein-1	GENE-Y
and	O
IL-10	GENE-Y
)	O
in	O
dp-BB	O
,	O
but	O
not	O
in	O
dr-BB	O
or	O
WF	O
,	O
rats	O
.	O

All	O
dp-BB	O
rats	O
had	O
mononuclear	O
infiltration	O
of	O
islets	O
,	O
which	O
was	O
absent	O
in	O
dr-BB	O
and	O
WF	O
rats	O
.	O

In	O
conclusion	O
,	O
the	O
presence	O
of	O
insulitis	O
was	O
permissive	O
for	O
IH-induced	O
β-cell	O
dysfunction	O
in	O
the	O
BB	O
rat	O
,	O
which	O
suggests	O
a	O
link	O
between	O
β-cell	O
lipotoxicity	O
and	O
islet	O
inflammation	O
.	O
Low	O
levels	O
of	O
serotonin	CHEMICAL
may	O
reduce	O
the	O
density	O
of	O
the	O
serotonin	GENE-Y
transporter	O
(	O
SERT	GENE-Y
)	O
by	O
either	O
increasing	O
trafficking	O
or	O
reducing	O
synthesis;	O
a	O
"neuroadaptive	O
response"	O
.	O

To	O
determine	O
whether	O
3	CHEMICAL
,	CHEMICAL
4-methylenedioxymethamphetamine	CHEMICAL
(	O
MDMA	CHEMICAL
)	O
-induced	O
reductions	O
in	O
SERT	GENE-Y
density	O
could	O
be	O
related	O
to	O
such	O
a	O
mechanism	O
,	O
p-chlorophenylalanine	CHEMICAL
or	O
MDMA	CHEMICAL
was	O
administered	O
to	O
rats	O
,	O
and	O
brain	O
serotonin	CHEMICAL
and	O
SERT	GENE-Y
density	O
were	O
measured	O
.	O

As	O
expected	O
,	O
both	O
treatments	O
led	O
to	O
serotonin	CHEMICAL
depletion	O
1	O
,	O
7	O
and	O
14	O
days	O
later	O
.	O

However	O
,	O
only	O
MDMA	CHEMICAL
reduced	O
SERT	GENE-Y
density	O
.	O

This	O
observation	O
suggests	O
that	O
MDMA-induced	O
reductions	O
in	O
SERT	GENE-Y
density	O
do	O
not	O
represent	O
neuroadaptive	O
responses	O
to	O
decreased	O
levels	O
of	O
brain	O
serotonin	CHEMICAL
,	O
but	O
may	O
occur	O
in	O
response	O
to	O
some	O
other	O
stimulus	O
or	O
to	O
the	O
neurotoxic	O
effects	O
of	O
MDMA	CHEMICAL
.	O
Hibiscus	O
sabdariffa	O
L	O
.	O

in	O
the	O
treatment	O
of	O
hypertension	O
and	O
hyperlipidemia	O
:	O
a	O
comprehensive	O
review	O
of	O
animal	O
and	O
human	O
studies	O
.	O
The	O
Drosophila	O
fat	O
body	O
is	O
a	O
liver-	O
and	O
adipose-like	O
tissue	O
that	O
stores	O
fat	O
and	O
serves	O
as	O
a	O
detoxifying	O
and	O
immune	O
responsive	O
organ	O
.	O

We	O
have	O
previously	O
shown	O
that	O
a	O
high	O
sugar	CHEMICAL
diet	O
leads	O
to	O
elevated	O
hemolymph	O
glucose	CHEMICAL
and	O
systemic	O
insulin	GENE-N
resistance	O
in	O
developing	O
larvae	O
and	O
adults	O
.	O

Here	O
,	O
we	O
used	O
stable	O
isotope	O
tracer	O
feeding	O
to	O
demonstrate	O
that	O
rearing	O
larvae	O
on	O
high	O
sugar	CHEMICAL
diets	O
impaired	O
the	O
synthesis	O
of	O
esterified	O
fatty	CHEMICAL
acids	CHEMICAL
from	O
dietary	O
glucose	CHEMICAL
.	O

Fat	O
body	O
lipid	O
profiling	O
revealed	O
changes	O
in	O
both	O
carbon	CHEMICAL
chain	O
length	O
and	O
degree	O
of	O
unsaturation	O
of	O
fatty	CHEMICAL
acid	CHEMICAL
substituents	O
,	O
particularly	O
in	O
stored	O
triglycerides	CHEMICAL
.	O

We	O
tested	O
the	O
role	O
of	O
the	O
fat	O
body	O
in	O
larval	O
tolerance	O
of	O
caloric	O
excess	O
.	O

Our	O
experiments	O
demonstrated	O
that	O
lipogenesis	O
was	O
necessary	O
for	O
animals	O
to	O
tolerate	O
high	O
sugar	CHEMICAL
feeding	O
as	O
tissue-specific	O
loss	O
of	O
orthologs	O
of	O
carbohydrate	GENE-N
response	O
element-binding	O
protein	O
or	O
stearoyl-CoA	GENE-Y
desaturase	O
1	O
resulted	O
in	O
lethality	O
on	O
high	O
sugar	CHEMICAL
diets	O
.	O

By	O
contrast	O
,	O
increasing	O
the	O
fat	O
content	O
of	O
the	O
fat	O
body	O
by	O
knockdown	O
of	O
king-tubby	GENE-Y
was	O
associated	O
with	O
reduced	O
hyperglycemia	O
and	O
improved	O
growth	O
and	O
tolerance	O
of	O
high	O
sugar	CHEMICAL
diets	O
.	O

Our	O
work	O
supports	O
a	O
critical	O
role	O
for	O
the	O
fat	O
body	O
and	O
the	O
Drosophila	GENE-N
carbohydrate	CHEMICAL
response	O
element-binding	O
protein	O
ortholog	O
in	O
metabolic	O
homeostasis	O
in	O
Drosophila	O
.	O
Activating	O
internal	O
tandem	O
duplication	O
(	O
ITD	O
)	O
insertions	O
in	O
the	O
juxtamembrane	GENE-N
domain	GENE-N
of	O
the	O
FLT3	GENE-Y
tyrosine	GENE-N
kinase	O
are	O
found	O
in	O
about	O
one	O
fourth	O
of	O
patients	O
with	O
acute	O
myeloid	O
leukemia	O
and	O
have	O
been	O
shown	O
to	O
be	O
an	O
independent	O
negative	O
prognostic	O
factor	O
for	O
survival	O
.	O

We	O
show	O
that	O
sorafenib	CHEMICAL
(	O
BAY	CHEMICAL
43-9006	CHEMICAL
,	O
Nexavar	CHEMICAL
)	O
potently	O
inhibits	O
FLT3	GENE-Y
enzymatic	O
and	O
signaling	O
activities	O
.	O

In	O
HEK293	O
cells	O
stably	O
transfected	O
with	O
FLT3-WT	O
or	O
FLT3-ITD	O
,	O
sorafenib	CHEMICAL
blocked	O
basal	O
and	O
ligand	O
dependent	O
FLT3-mediated	O
tyrosine	CHEMICAL
autophosphorylation	O
as	O
well	O
as	O
extracellular	GENE-N
signal-regulated	GENE-N
kinase1	GENE-N
/	GENE-N
2	GENE-N
and	O
Stat5	GENE-Y
phosphorylation	O
.	O

In	O
leukemia	O
cell	O
lines	O
MV4-11	O
and	O
EOL-1	O
,	O
sorafenib	CHEMICAL
treatment	O
resulted	O
in	O
decreased	O
cell	O
proliferation	O
and	O
inhibition	O
of	O
FLT3	GENE-Y
signaling	O
.	O

The	O
growth	O
of	O
the	O
FLT3-independent	O
RS4-11	O
cell	O
line	O
was	O
only	O
weakly	O
inhibited	O
by	O
sorafenib	CHEMICAL
.	O

Cell	O
cycle	O
arrest	O
and	O
induction	O
of	O
apoptosis	O
were	O
observed	O
upon	O
treatment	O
with	O
sorafenib	CHEMICAL
in	O
MV4-11	O
and	O
EOL-1	O
cells	O
.	O

The	O
antitumor	O
efficacy	O
of	O
sorafenib	CHEMICAL
was	O
evaluated	O
against	O
the	O
MV4-11	O
leukemia	O
grown	O
subcutaneously	O
in	O
NCr	O
nu	O
/	O
nu	O
mice	O
.	O

Doses	O
of	O
3	O
and	O
10	O
mg	O
/	O
kg	O
administered	O
orally	O
for	O
14	O
days	O
resulted	O
in	O
six	O
and	O
nine	O
out	O
of	O
10	O
animals	O
with	O
complete	O
responses	O
,	O
respectively	O
.	O

The	O
demonstration	O
that	O
sorafenib	CHEMICAL
exhibits	O
potent	O
target	O
inhibition	O
and	O
efficacy	O
in	O
FLT3-driven	O
models	O
suggests	O
that	O
this	O
compound	O
may	O
have	O
a	O
therapeutic	O
benefit	O
for	O
patients	O
with	O
FLT3-driven	O
leukemias	O
.	O
Molecular	O
recognition	O
of	O
histidine	CHEMICAL
tRNA	O
by	O
histidyl-tRNA	GENE-Y
synthetase	GENE-Y
from	O
hyperthermophilic	O
archaeon	O
,	O
Aeropyrum	O
pernix	O
K1	O
.	O
BACKGROUND	O
:	O
Inhibitors	O
of	O
monoamine	GENE-N
oxidase	O
(	O
MAO	GENE-N
)	O
with	O
selectivity	O
and	O
specificity	O
for	O
MAO	GENE-Y
type	GENE-Y
B	GENE-Y
(	O
MAO-B	GENE-Y
)	O
prolong	O
the	O
duration	O
of	O
action	O
of	O
both	O
endogenously	O
and	O
exogenously	O
derived	O
dopamine	CHEMICAL
.	O

Rasagiline	CHEMICAL
[	O
N-propargyl-l	CHEMICAL
(	CHEMICAL
R	CHEMICAL
)	CHEMICAL
-aminoindan	CHEMICAL
]	O
is	O
a	O
second-generation	O
propargylamine	CHEMICAL
pharmacophore	O
that	O
selectively	O
and	O
irreversibly	O
inhibits	O
brain	O
MAO-B	GENE-Y
and	O
is	O
specifically	O
designed	O
for	O
the	O
treatment	O
of	O
Parkinson's	O
disease	O
(	O
PD	O
)	O
.	O

OBJECTIVE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
review	O
the	O
pharmacology	O
,	O
tolerability	O
,	O
and	O
clinical	O
efficacy	O
of	O
rasagiline	CHEMICAL
in	O
the	O
treatment	O
of	O
PD	O
.	O

METHODS	O
:	O
MEDLINE	O
(	O
1966-April	O
2007	O
)	O
,	O
the	O
Cochrane	O
Database	O
of	O
Systematic	O
Reviews	O
,	O
and	O
International	O
Pharmaceutical	O
Abstracts	O
(	O
1970-April	O
2007	O
)	O
were	O
searched	O
for	O
original	O
research	O
and	O
review	O
articles	O
published	O
in	O
English	O
.	O

The	O
search	O
terms	O
were	O
monoamine	GENE-N
oxidase	O
,	O
neuroprotection	O
,	O
Parkinson	O
disease	O
,	O
propargylamine	CHEMICAL
,	O
rasagiline	CHEMICAL
,	O
and	O
selegiline	CHEMICAL
.	O

The	O
reference	O
lists	O
of	O
articles	O
were	O
also	O
consulted	O
,	O
as	O
was	O
information	O
provided	O
by	O
the	O
manufacturer	O
of	O
rasagiline	CHEMICAL
.	O

RESULTS	O
:	O
Data	O
from	O
63	O
clinical	O
and	O
laboratory	O
studies	O
were	O
analyzed	O
.	O

Based	O
on	O
the	O
results	O
from	O
those	O
studies	O
,	O
we	O
concluded	O
that	O
rasagiline	CHEMICAL
PO	O
QD	O
,	O
at	O
the	O
therapeutic	O
dosage	O
range	O
of	O
0	O
.	O
5	O
to	O
1	O
rag	O
/	O
d	O
,	O
is	O
effective	O
and	O
well	O
tolerated	O
and	O
completely	O
,	O
selectively	O
,	O
and	O
specifically	O
inhibited	O
MAO-B	GENE-Y
.	O

Pharmacologically	O
,	O
rasagiline	CHEMICAL
was	O
found	O
to	O
be	O
<	O
or	O
=	O
10-fold	O
more	O
potent	O
than	O
selegiline	CHEMICAL
and	O
was	O
not	O
metabolized	O
to	O
amphetamine	CHEMICAL
derivatives	O
.	O

Rasagiline	CHEMICAL
was	O
effective	O
both	O
as	O
monotherapy	O
in	O
early	O
PD	O
and	O
as	O
adjunctive	O
treatment	O
in	O
patients	O
with	O
advancing	O
PD	O
and	O
motor	O
fluctuations	O
.	O

As	O
monotherapy	O
,	O
rasagiline	CHEMICAL
provided	O
modest	O
yet	O
clinically	O
meaningful	O
benefit	O
.	O

A	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
found	O
that	O
,	O
after	O
26	O
weeks	O
of	O
treatment	O
,	O
the	O
adjusted	O
effect	O
size	O
for	O
total	O
Unified	O
Parkinson's	O
Disease	O
Rating	O
Scale	O
score	O
was	O
-4	O
.	O
20	O
(	O
95%	O
CI	O
,	O
-5	O
.	O
66	O
to	O
-2	O
.	O
73	O
)	O
for	O
rasagiline	O
1	O
mg	O
/	O
d	O
versus	O
placebo	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Preliminary	O
long-term	O
data	O
from	O
an	O
open-label	O
study	O
suggest	O
a	O
sustained	O
therapeutic	O
advantage	O
when	O
rasagiline	O
is	O
initiated	O
early	O
(	O
before	O
the	O
need	O
for	O
dopaminergic	O
agents	O
)	O
rather	O
than	O
later	O
.	O

In	O
patients	O
with	O
more	O
advanced	O
disease	O
who	O
received	O
treatment	O
with	O
dopaminergic	O
agents	O
,	O
rasagiline	CHEMICAL
and	O
entacapone	CHEMICAL
were	O
associated	O
with	O
reductions	O
of	O
"off"	O
time	O
significantly	O
greater	O
than	O
placebo	O
(	O
-1	O
.	O
18	O
and	O
-1	O
.	O
2	O
vs	O
0	O
.	O
4	O
hour;	O
both	O
,	O
P	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Rasagiline	CHEMICAL
was	O
well	O
tolerated	O
in	O
younger	O
(	O
aged	O
<;70	O
years	O
)	O
and	O
older	O
(	O
aged	O
>	O
or	O
=	O
70	O
years	O
)	O
patients	O
with	O
early	O
or	O
advanced	O
PD	O
.	O

Pharmacologically	O
,	O
rasagiline	O
has	O
the	O
potential	O
to	O
augment	O
the	O
vasopressor	O
effects	O
of	O
diet-derived	O
tyramine	CHEMICAL
(	O
ie	O
,	O
the	O
"cheese	O
reaction"	O
)	O
.	O

However	O
,	O
clinical	O
challenge	O
studies	O
of	O
tyramine	CHEMICAL
have	O
found	O
this	O
unlikely	O
to	O
occur	O
even	O
with	O
ingestion	O
of	O
supraphysiologic	O
amounts	O
of	O
tyramine	CHEMICAL
.	O

In	O
experimental	O
models	O
,	O
rasagiline	CHEMICAL
has	O
been	O
found	O
to	O
have	O
neuroprotective	O
properties	O
that	O
may	O
be	O
independent	O
of	O
MAO-B	GENE-Y
inhibition	O
.	O

CONCLUSIONS	O
:	O
Based	O
on	O
this	O
review	O
,	O
rasagiline	CHEMICAL
has	O
been	O
found	O
to	O
be	O
well	O
tolerated	O
and	O
effective	O
in	O
the	O
treatment	O
of	O
early	O
PD	O
and	O
as	O
adjunctive	O
treatment	O
in	O
motor	O
fluctuations	O
.	O

Whether	O
rasagiline	O
is	O
associated	O
with	O
clinically	O
significant	O
neuroprotection	O
(	O
ie	O
,	O
disease	O
modification	O
)	O
in	O
PD	O
is	O
the	O
subject	O
of	O
ongoing	O
clinical	O
trials	O
.	O
Trichostatin	CHEMICAL
A	CHEMICAL
(	O
TSA	CHEMICAL
)	O
has	O
been	O
shown	O
to	O
prevent	O
fibrosis	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
present	O
study	O
aimed	O
at	O
investigating	O
the	O
role	O
of	O
reactive	O
oxygen	CHEMICAL
species	O
(	O
ROS	O
)	O
scavenging	O
by	O
TSA	CHEMICAL
on	O
transforming	GENE-Y
growth	GENE-Y
factor-β	GENE-Y
(	O
TGF-β	GENE-Y
)	GENE-Y
-induced	O
myofibroblast	O
differentiation	O
of	O
corneal	O
fibroblasts	O
in	O
vitro	O
.	O

Human	O
immortalized	O
corneal	O
fibroblasts	O
were	O
treated	O
with	O
TGF-β	GENE-Y
in	O
the	O
presence	O
of	O
TSA	CHEMICAL
,	O
the	O
NAD	GENE-N
(	GENE-N
P	GENE-N
)	GENE-N
H	GENE-N
oxidase	O
inhibitor	O
diphenyleneiodonium	CHEMICAL
(	O
DPI	CHEMICAL
)	O
,	O
the	O
antioxidant	O
N-acetyl-cysteine	CHEMICAL
(	O
NAC	CHEMICAL
)	O
,	O
the	O
NF-E2-related	GENE-Y
factor	GENE-Y
2-antioxidant	GENE-N
response	GENE-N
element	GENE-N
(	O
Nrf2-ARE	GENE-N
)	O
activator	O
sulforaphane	CHEMICAL
,	O
or	O
small	O
interfering	O
RNA	O
.	O

Myofibroblast	O
differentiation	O
was	O
assessed	O
by	O
α-smooth	GENE-Y
muscle	GENE-Y
actin	GENE-Y
(	O
α-SMA	GENE-Y
)	O
expression	O
,	O
F-actin	GENE-N
bundle	O
formation	O
,	O
and	O
collagen	GENE-N
gel	O
contraction	O
.	O

ROS	O
,	O
H	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
O	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
,	O
intracellular	O
glutathione	CHEMICAL
(	O
GSH	CHEMICAL
)	O
level	O
,	O
cellular	O
total	O
antioxidant	O
capacity	O
,	O
and	O
the	O
activation	O
of	O
Nrf2-ARE	GENE-N
signaling	O
were	O
determined	O
with	O
various	O
assays	O
.	O

Treatment	O
with	O
TSA	CHEMICAL
and	O
the	O
Nrf2-ARE	GENE-N
activator	O
resulted	O
in	O
increased	O
inhibition	O
of	O
the	O
TGF-β-induced	O
myofibroblast	O
differentiation	O
as	O
compared	O
with	O
treatment	O
with	O
DPI	CHEMICAL
or	O
NAC	CHEMICAL
.	O

Furthermore	O
,	O
TSA	CHEMICAL
also	O
decreased	O
cellular	O
ROS	O
and	O
H	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
O	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
accumulation	O
induced	O
by	O
TGF-β	GENE-Y
,	O
whereas	O
it	O
elevated	O
intracellular	O
GSH	CHEMICAL
level	O
and	O
cellular	O
total	O
antioxidant	O
capacity	O
.	O

In	O
addition	O
,	O
TSA	CHEMICAL
induced	O
Nrf2	GENE-Y
nuclear	O
translocation	O
and	O
up-regulated	O
the	O
expression	O
of	O
Nrf2-ARE	GENE-N
downstream	O
antioxidant	O
genes	O
,	O
whereas	O
Nrf2	GENE-Y
knockdown	O
by	O
RNA	O
interference	O
blocked	O
the	O
inhibition	O
of	O
TSA	CHEMICAL
on	O
myofibroblast	O
differentiation	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
provides	O
the	O
first	O
evidence	O
implicating	O
that	O
TSA	CHEMICAL
inhibits	O
TGF-β-induced	O
ROS	O
accumulation	O
and	O
myofibroblast	O
differentiation	O
via	O
enhanced	O
Nrf2-ARE	GENE-N
signaling	O
.	O
Desipramine	CHEMICAL
treatment	O
decreases	O
3H-nisoxetine	CHEMICAL
binding	O
and	O
norepinephrine	CHEMICAL
transporter	O
mRNA	O
in	O
SK-N-SHSY5Y	O
cells	O
.	O
Glycine	CHEMICAL
and	O
gamma-aminobutyric	CHEMICAL
acid	CHEMICAL
(	O
GABA	CHEMICAL
)	O
are	O
the	O
major	O
inhibitory	O
neurotransmitters	O
in	O
the	O
retina	O
.	O

Approximately	O
half	O
of	O
the	O
amacrine	O
cells	O
release	O
glycine	CHEMICAL
at	O
their	O
synapses	O
with	O
bipolar	O
,	O
other	O
amacrine	O
,	O
and	O
ganglion	O
cells	O
.	O

Whereas	O
the	O
retinal	CHEMICAL
distributions	O
of	O
glycine	CHEMICAL
receptor	O
(	GENE-N
GlyR	GENE-N
)	GENE-N
subunits	GENE-N
alpha1	GENE-N
,	GENE-N
alpha2	GENE-N
,	GENE-N
and	GENE-N
alpha3	GENE-N
have	O
been	O
mapped	O
,	O
the	O
role	O
of	O
the	O
alpha4	O
subunit	O
in	O
retinal	CHEMICAL
circuitry	O
remains	O
unclear	O
.	O

A	O
rabbit	O
polyclonal	O
antiserum	O
was	O
raised	O
against	O
a	O
peptide	O
that	O
comprises	O
the	O
C-terminal	O
14	O
amino	CHEMICAL
acids	CHEMICAL
of	O
the	O
mouse	GENE-Y
GlyR	GENE-Y
alpha4	GENE-Y
subunit	O
.	O

Using	O
immunocytochemistry	O
,	O
we	O
localized	O
the	O
alpha4	O
subunit	O
in	O
the	O
inner	O
plexiform	O
layer	O
(	O
IPL	O
)	O
in	O
brightly	O
fluorescent	O
puncta	O
,	O
which	O
represent	O
postsynaptically	O
clustered	O
GlyRs	GENE-N
.	O

This	O
was	O
shown	O
by	O
double-labeling	O
sections	O
for	O
GlyR	GENE-Y
alpha4	GENE-Y
and	O
synaptic	O
markers	O
(	O
bassoon	GENE-Y
,	O
gephyrin	GENE-Y
)	O
.	O

Double-labeling	O
sections	O
for	O
GlyR	GENE-Y
alpha4	GENE-Y
and	O
the	O
other	O
GlyR	GENE-N
alpha	GENE-N
subunits	O
shows	O
that	O
they	O
are	O
mostly	O
clustered	O
at	O
different	O
synapses;	O
however	O
,	O
approximately	O
30%	O
of	O
the	O
alpha4-containing	O
synapses	O
also	O
express	O
the	O
alpha2	O
subunit	O
.	O

We	O
also	O
studied	O
the	O
pre-	O
and	O
postsynaptic	O
partners	O
at	O
GlyR	GENE-Y
alpha4-containing	O
synapses	O
and	O
found	O
that	O
displaced	O
(	O
ON-	O
)	O
cholinergic	O
amacrine	O
cells	O
prominently	O
expressed	O
the	O
alpha4	O
subunit	O
.	O

The	O
density	O
of	O
GlyR	GENE-Y
alpha4-expressing	O
synapses	O
in	O
wildtype	O
,	O
Glra1	GENE-Y
(	O
ot	O
/	O
ot	O
)	O
,	O
and	O
Glra3	GENE-Y
(	O
-	O
/	O
-	O
)	O
mouse	O
retinas	O
did	O
not	O
differ	O
significantly	O
.	O

Thus	O
,	O
there	O
is	O
no	O
apparent	O
compensation	O
of	O
the	O
loss	O
of	O
alpha1	O
or	O
alpha3	O
subunits	O
by	O
an	O
upregulation	O
of	O
alpha4	O
subunit	O
gene	O
expression;	O
however	O
,	O
the	O
alpha2	O
subunit	O
is	O
moderately	O
upregulated	O
.	O
PURPOSE	O
:	O
Talampanel	CHEMICAL
(	O
LY300164	CHEMICAL
)	O
,	O
a	O
potent	O
and	O
selective	O
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate	GENE-N
(	O
AMPA	CHEMICAL
)	O
-receptor	O
antagonist	O
,	O
is	O
a	O
potential	O
new	O
antiepileptic	O
drug	O
(	O
AED	O
)	O
.	O

This	O
study	O
examines	O
the	O
single-	O
and	O
multiple-dose	O
pharmacokinetics	O
,	O
safety	O
,	O
and	O
tolerability	O
of	O
talampanel	CHEMICAL
in	O
patients	O
with	O
intractable	O
epilepsy	O
and	O
assesses	O
the	O
potential	O
for	O
pharmacokinetic	O
interaction	O
.	O

METHODS	O
:	O
Eleven	O
of	O
14	O
patients	O
entered	O
into	O
the	O
study	O
completed	O
.	O

Fourteen	O
patients	O
were	O
evaluated	O
for	O
safety	O
,	O
13	O
patients	O
were	O
used	O
in	O
the	O
single-dose	O
,	O
and	O
11	O
patients	O
in	O
the	O
multiple-dose	O
pharmacokinetic	O
analysis	O
.	O

Each	O
patient	O
initially	O
received	O
a	O
single	O
35-mg	O
dose	O
of	O
talampanel	CHEMICAL
followed	O
by	O
the	O
measurement	O
of	O
pharmacokinetic	O
profiles	O
.	O

A	O
21-day	O
t	O
.	O

i	O
.	O

d	O
.	O

dosing	O
regimen	O
was	O
then	O
determined	O
for	O
each	O
patient	O
based	O
on	O
his	O
or	O
her	O
initial	O
pharmacokinetic	O
profile	O
.	O

Adverse	O
events	O
were	O
recorded	O
by	O
patients	O
or	O
their	O
carers	O
.	O

RESULTS	O
:	O
After	O
oral	O
ingestion	O
,	O
talampanel	CHEMICAL
was	O
rapidly	O
absorbed	O
,	O
with	O
maximal	O
plasma	O
concentrations	O
achieved	O
within	O
1-3	O
h	O
.	O

Talampanel	CHEMICAL
concentrations	O
in	O
patients	O
taking	O
enzyme-inducing	O
AEDs	O
were	O
50%	O
lower	O
than	O
those	O
seen	O
in	O
healthy	O
volunteers	O
.	O

Mean	O
talampanel	CHEMICAL
t1	O
/	O
2	O
values	O
were	O
3	O
.	O
0	O
h	O
compared	O
with	O
4	O
.	O
2	O
h	O
in	O
healthy	O
volunteers	O
.	O

After	O
multiple-dose	O
and	O
steady-state	O
,	O
talampanel	CHEMICAL
t1	O
/	O
2	O
values	O
were	O
increased	O
to	O
5	O
.	O
6	O
h	O
Talampanel	CHEMICAL
and	O
valproic	CHEMICAL
acid	CHEMICAL
(	O
VPA	CHEMICAL
)	O
appear	O
to	O
inhibit	O
each	O
other's	O
metabolism	O
mutually	O
.	O

Talampanel	CHEMICAL
had	O
no	O
effect	O
on	O
plasma	O
concentrations	O
of	O
other	O
AEDs	O
.	O

Multiple-dose	O
talampanel	CHEMICAL
administration	O
was	O
associated	O
with	O
nonlinear	O
pharmacokinetics	O
.	O

No	O
serious	O
adverse	O
events	O
were	O
reported;	O
the	O
most	O
frequently	O
reported	O
being	O
dizziness	O
,	O
ataxia	O
,	O
drowsiness	O
,	O
and	O
headaches	O
CONCLUSIONS	O
:	O
Talampanel	CHEMICAL
dosing	O
strategies	O
may	O
be	O
reliant	O
on	O
concomitant	O
AED	O
medication	O
,	O
as	O
enzyme-inducing	O
AEDs	O
enhance	O
,	O
whereas	O
VPA	CHEMICAL
inhibits	O
its	O
metabolism	O
.	O

Talampanel	CHEMICAL
was	O
well	O
tolerated	O
,	O
although	O
adverse	O
events	O
occurred	O
at	O
lower	O
doses	O
compared	O
with	O
those	O
in	O
healthy	O
subjects	O
,	O
probably	O
because	O
of	O
the	O
additive	O
effect	O
of	O
concomitant	O
AEDs	O
.	O
Silent	GENE-Y
information	GENE-Y
regulator	GENE-Y
2	GENE-Y
(	O
Sir2	GENE-Y
)	O
enzymes	O
or	O
sirtuins	GENE-N
are	O
a	O
family	O
of	O
evolutionarily	O
conserved	O
intracellular	GENE-N
protein	GENE-N
deacetylases	GENE-N
that	O
can	O
catalyze	O
the	O
acetyl	CHEMICAL
group	O
removal	O
from	O
the	O
specific	O
Nε-acetyl-lysine	CHEMICAL
(	O
AcK	O
)	O
side	O
chains	O
on	O
a	O
variety	O
of	O
proteins	O
from	O
all	O
kingdoms	O
of	O
life	O
.	O

Yeast	GENE-Y
Sir2	GENE-Y
was	O
the	O
first	O
sirtuin	GENE-N
identified	O
,	O
and	O
so	O
far	O
seven	O
sirtuins	GENE-N
(	O
i	O
.	O

e	O
.	O

SIRT1-7	GENE-N
)	O
have	O
been	O
found	O
in	O
mammals	O
including	O
humans	O
.	O

The	O
sirtuin-catalyzed	O
deacetylation	O
reaction	O
has	O
captured	O
tremendous	O
interest	O
during	O
the	O
past	O
a	O
few	O
years	O
because	O
of	O
(	O
i	O
)	O
its	O
increasingly	O
demonstrated	O
importance	O
in	O
many	O
crucial	O
biological	O
processes	O
such	O
as	O
gene	O
transcription	O
,	O
metabolism	O
,	O
and	O
aging	O
,	O
and	O
thus	O
its	O
therapeutic	O
potential	O
for	O
metabolic	O
and	O
age-related	O
diseases	O
and	O
cancer	O
,	O
and	O
(	O
ii	O
)	O
its	O
unique	O
deacetylation	O
chemistry	O
.	O

Specifically	O
,	O
the	O
sirtuin-catalyzed	O
AcK	O
side	O
chain	O
deacetylation	O
is	O
not	O
merely	O
an	O
amide	CHEMICAL
hydrolysis	O
reaction	O
,	O
instead	O
is	O
coupled	O
to	O
the	O
nicotinamide	CHEMICAL
cleavage	O
from	O
β-nicotinamide	CHEMICAL
adenine	CHEMICAL
dinucleotide	CHEMICAL
(	O
β-NAD	CHEMICAL
+	O
or	O
NAD	CHEMICAL
+	O
)	O
with	O
the	O
generation	O
of	O
three	O
enzymatic	O
products	O
,	O
i	O
.	O

e	O
.	O

the	O
deacetylated	O
protein	O
species	O
,	O
nicotinamide	O
,	O
and	O
2'-O-acetyl-ADP-ribose	CHEMICAL
(	O
2'-O-AADPR	CHEMICAL
)	O
.	O

Here	O
the	O
author	O
would	O
like	O
to	O
review	O
the	O
past	O
endeavors	O
on	O
developing	O
mechanism-based	O
sirtuin	GENE-N
modulators	O
(	O
inhibitors	O
and	O
activators	O
)	O
.	O

The	O
first	O
part	O
of	O
this	O
article	O
will	O
provide	O
an	O
updated	O
mechanistic	O
picture	O
of	O
the	O
sirtuin-catalyzed	O
deacetylation	O
reaction	O
.	O

The	O
second	O
part	O
will	O
be	O
focused	O
on	O
how	O
the	O
mechanistic	O
knowledge	O
has	O
been	O
exploited	O
for	O
the	O
design	O
of	O
effective	O
sirtuin	GENE-N
modulators	O
.	O
Identification	O
of	O
a	O
nuclear	GENE-N
receptor	GENE-N
for	O
bile	CHEMICAL
acids	CHEMICAL
.	O
Levels	O
of	O
ATP	CHEMICAL
and	O
other	O
nucleotides	CHEMICAL
increased	O
in	O
wounded	O
potato	O
tuber	O
slices	O
,	O
maintained	O
on	O
moist	O
paper	O
for	O
24	O
h	O
after	O
preparation	O
.	O

The	O
relative	O
expression	O
intensity	O
of	O
genes	O
encoding	O
adenosine	CHEMICAL
kinase	O
(	O
AK	GENE-Y
)	O
and	O
adenine	CHEMICAL
phosphoribosyltransferase	O
(	O
APRT	GENE-N
)	O
in	O
wounded	O
slices	O
was	O
greater	O
than	O
the	O
intensity	O
of	O
genes	O
of	O
the	O
de	O
novo	O
pathway	O
,	O
glycineamide	CHEMICAL
ribonucleotide	O
formyltransferase	O
(	O
GART	GENE-Y
)	O
and	O
5-aminoimidazole	CHEMICAL
ribonucleotide	O
synthetase	O
(	O
AIRS	GENE-Y
)	O
.	O

In	O
vitro	O
activities	O
of	O
adenosine	CHEMICAL
kinase	O
(	O
ATP	GENE-Y
:	O
adenosine	CHEMICAL
5'-phosphotransferase;	O
EC	GENE-N
2	GENE-N
.	GENE-N
7	GENE-N
.	GENE-N
1	GENE-N
.	GENE-N
20	GENE-N
)	O
and	O
adenine	GENE-Y
phosphoribosyltransferase	O
(	O
AMP	GENE-N
:	O
pyrophosphate	CHEMICAL
phospho-d-ribosyltransferase;	O
EC	GENE-N
2	GENE-N
.	GENE-N
4	GENE-N
.	GENE-N
2	GENE-N
.	GENE-N
7	GENE-N
)	O
increased	O
during	O
wounding	O
.	O

Adenosine	GENE-N
nucleosidase	O
(	O
adenosine	GENE-N
ribohydrolase;	O
EC	GENE-N
3	GENE-N
.	GENE-N
2	GENE-N
.	GENE-N
2	GENE-N
.	GENE-N
7	GENE-N
)	O
activity	O
was	O
negligible	O
in	O
freshly	O
prepared	O
slices	O
,	O
but	O
its	O
activity	O
is	O
dramatically	O
enhanced	O
in	O
wounded	O
slices	O
.	O

In	O
situ	O
adenosine	CHEMICAL
salvage	O
activity	O
,	O
estimated	O
from	O
the	O
incorporation	O
of	O
radioactivity	O
from	O
exogenously	O
supplied	O
[	CHEMICAL
8-	CHEMICAL
(	CHEMICAL
14	CHEMICAL
)	CHEMICAL
C	CHEMICAL
]	CHEMICAL
adenosine	CHEMICAL
into	O
nucleotides	CHEMICAL
and	O
RNA	O
,	O
increased	O
more	O
than	O
five	O
times	O
in	O
the	O
wounded	O
slices	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
greater	O
expression	O
of	O
the	O
genes	O
encoding	O
enzymes	O
of	O
adenosine	CHEMICAL
salvage	O
during	O
wounding	O
is	O
closely	O
related	O
to	O
the	O
increased	O
supply	O
of	O
adenine	CHEMICAL
nucleotides	O
in	O
the	O
wounded	O
slices	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
alterations	O
of	O
the	O
redox	O
balance	O
induced	O
by	O
the	O
lipid	O
fraction	O
of	O
oxLDL	GENE-N
in	O
Caco-2	O
intestinal	O
cells	O
,	O
and	O
the	O
effects	O
of	O
tyrosol	CHEMICAL
and	O
protocatechuic	CHEMICAL
acid	CHEMICAL
,	O
two	O
dietary	O
phenolic	CHEMICAL
compounds	O
.	O

We	O
found	O
that	O
oxidized	O
lipids	O
extracted	O
from	O
oxLDL	GENE-N
(	O
LipE	GENE-Y
)	O
induced	O
oxidative	O
stress	O
by	O
determining	O
,	O
6	O
h	O
after	O
treatment	O
,	O
ROS	O
overproduction	O
(	O
about	O
a	O
100%	O
and	O
a	O
43%	O
increase	O
of	O
O*2	CHEMICAL
and	O
H2O2	CHEMICAL
production	O
,	O
respectively	O
,	O
P<	O
.	O
05	O
:	O
LipE	GENE-Y
vs	O
.	O

control	O
)	O
and	O
,	O
12	O
h	O
after	O
treatment	O
,	O
GSH	O
depletion	O
(	O
about	O
a	O
26%	O
decrease	O
,	O
P<	O
.	O
05	O
:	O
LipE	GENE-Y
vs	O
.	O

control	O
)	O
,	O
and	O
by	O
impairing	O
the	O
activities	O
of	O
superoxide	GENE-N
dismutase	O
,	O
catalase	GENE-Y
and	O
glutathione	GENE-N
peroxidase	O
.	O

In	O
response	O
to	O
the	O
induced	O
oxidative	O
stress	O
,	O
we	O
observed	O
significant	O
overexpression	O
of	O
glutathione	GENE-N
peroxidase	O
(	O
6	O
h	O
after	O
treatment	O
:	O
P<	O
.	O
05	O
)	O
,	O
glutathione	GENE-N
reductase	O
and	O
gamma-glutamylcysteine	GENE-Y
synthetase	O
(	O
12	O
h	O
after	O
treatment	O
:	O
P<	O
.	O
05	O
)	O
.	O

Notably	O
,	O
when	O
GSH	O
depletion	O
occurred	O
,	O
p66Shc	GENE-Y
protein	O
expression	O
increased	O
by	O
about	O
300%	O
with	O
respect	O
to	O
control	O
(	O
P<	O
.	O
001;	O
LipE	GENE-Y
vs	O
.	O

control	O
)	O
.	O

These	O
effects	O
were	O
fully	O
counteracted	O
by	O
dietary	O
phenolics	CHEMICAL
which	O
inhibited	O
ROS	O
overproduction	O
and	O
GSH	O
consumption	O
,	O
rendered	O
the	O
reactive	O
transcription	O
of	O
glutathione-associated	O
enzymes	O
unnecessary	O
and	O
blocked	O
the	O
intracellular	O
signals	O
leading	O
to	O
the	O
overexpression	O
and	O
rearrangement	O
of	O
p66Shc	GENE-Y
signalling	O
molecule	O
.	O

Altogether	O
,	O
these	O
results	O
suggest	O
that	O
the	O
impairment	O
of	O
the	O
antioxidant	O
system	O
hijacks	O
intestinal	O
cells	O
towards	O
an	O
apoptotic-prone	O
phenotype	O
via	O
the	O
activation	O
of	O
p66Shc	GENE-Y
molecule	O
.	O

They	O
also	O
propose	O
a	O
reappraisal	O
of	O
dietary	O
polyphenols	CHEMICAL
as	O
intestinal	O
protecting	O
agents	O
,	O
indicating	O
the	O
antiapoptotic	O
effect	O
as	O
a	O
further	O
mechanism	O
of	O
action	O
of	O
these	O
antioxidant	O
compounds	O
.	O
Puerarin	CHEMICAL
stimulates	O
proliferation	O
and	O
differentiation	O
and	O
protects	O
against	O
cell	O
death	O
in	O
human	O
osteoblastic	O
MG-63	O
cells	O
via	O
ER-dependent	O
MEK	GENE-N
/	O
ERK	GENE-N
and	O
PI3K	GENE-N
/	O
Akt	GENE-N
activation	O
.	O
3-Amido	CHEMICAL
pyrrolopyrazine	CHEMICAL
JAK	GENE-N
kinase	GENE-N
inhibitors	O
:	O
development	O
of	O
a	O
JAK3	GENE-Y
vs	O
JAK1	GENE-Y
selective	O
inhibitor	O
and	O
evaluation	O
in	O
cellular	O
and	O
in	O
vivo	O
models	O
.	O
Tailorable	O
cell	O
culture	O
platforms	O
from	O
enzymatically	O
cross-linked	O
multifunctional	O
poly	CHEMICAL
(	CHEMICAL
ethylene	CHEMICAL
glycol	CHEMICAL
)	CHEMICAL
-based	O
hydrogels	O
.	O
Discovery	O
of	O
oxysterol-derived	O
pharmacological	O
chaperones	O
for	O
NPC1	GENE-Y
:	O
implication	O
for	O
the	O
existence	O
of	O
second	O
sterol-binding	O
site	O
.	O
Role	O
of	O
metabotropic	GENE-Y
glutamate	CHEMICAL
receptor	O
1	O
in	O
the	O
basolateral	O
amygdala-driven	O
prefrontal	O
cortical	O
deactivation	O
in	O
inflammatory	O
pain	O
in	O
the	O
rat	O
.	O
The	O
biological	O
effects	O
of	O
dose-dependent	O
inhibition	O
of	O
renin	GENE-Y
have	O
rarely	O
been	O
extensively	O
studied	O
after	O
oral	O
(	O
p	O
.	O

o	O
.	O

)	O
dosing	O
in	O
humans	O
.	O

We	O
studied	O
remikiren	CHEMICAL
(	O
Ro42-4892	CHEMICAL
)	O
,	O
a	O
selective	O
renin	GENE-Y
inhibitor	O
,	O
in	O
normal	O
volunteers	O
after	O
activation	O
of	O
the	O
renin-angiotensin	GENE-Y
system	O
(	O
RAS	O
)	O
based	O
on	O
salt	O
depletion	O
.	O

Twelve	O
normal	O
men	O
(	O
28	O
+	O
/	O
-	O
9	O
years	O
,	O
77	O
+	O
/	O
-	O
10	O
kg	O
)	O
,	O
comprising	O
three	O
consecutive	O
dose	O
panels	O
of	O
4	O
subjects	O
,	O
received	O
four	O
treatments	O
,	O
double-blind	O
and	O
randomised	O
2	O
weeks	O
apart	O
:	O
panel	O
I	O
,	O
placebo	O
(	O
P	O
)	O
,	O
or	O
30	O
,	O
100	O
,	O
and	O
300	O
mg	O
,	O
remikiren;	O
panel	O
II	O
,	O
placebo	O
or	O
300	O
,	O
600	O
mg	O
,	O
1	O
,	O
000;	O
panel	O
III	O
,	O
placebo	O
or	O
30	O
,	O
600	O
,	O
and	O
1	O
,	O
000	O
mg	O
.	O

The	O
RAS	O
was	O
activated	O
by	O
40	O
mmol	O
/	O
day	O
sodium	O
diet	O
plus	O
frusemide	O
(	O
40	O
mg	O
BDS	O
)	O
,	O
for	O
3	O
days	O
before	O
each	O
study	O
day	O
.	O

Data	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
were	O
examined	O
by	O
repeated-measures	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
.	O

RAS	O
activation	O
was	O
confirmed	O
by	O
24-h	O
urinary	O
sodium	CHEMICAL
excretion	O
(	O
screen	O
,	O
142	O
+	O
/	O
-	O
74	O
mmol	O
/	O
24	O
h;	O
prestudy	O
,	O
66	O
+	O
/	O
-	O
33	O
,	O
59	O
+	O
/	O
-	O
41	O
,	O
78	O
+	O
/	O
-	O
4	O
,	O
73	O
+	O
/	O
-	O
30	O
mmol	O
/	O
24	O
h	O
)	O
and	O
increase	O
in	O
plasma	O
renin	GENE-Y
activity	O
(	O
PRA	O
)	O
(	O
screen	O
,	O
0	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
3	O
ng	O
AI	O
/	O
ml	O
/	O
h;	O
before	O
dosing	O
,	O
P	O
,	O
6	O
.	O
5	O
+	O
/	O
-	O
3	O
.	O
1;	O
30	O
mg	O
,	O
8	O
.	O
2	O
+	O
/	O
-	O
3;	O
100	O
mg	O
,	O
9	O
.	O
4	O
+	O
/	O
-	O
5	O
.	O
7;	O
300	O
mg	O
,	O
6	O
.	O
5	O
+	O
/	O
-	O
2	O
.	O
4;	O
600	O
mg	O
,	O
5	O
.	O
2	O
+	O
/	O
-	O
2;	O
1	O
,	O
000	O
mg	O
,	O
6	O
.	O
2	O
+	O
/	O
-	O
4	O
.	O
4	O
ng	O
AI	O
/	O
ml	O
/	O
h	O
)	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
crocin	CHEMICAL
,	O
main	O
component	O
of	O
Crocus	O
sativus	O
L	O
.	O

(	O
Saffron	O
)	O
against	O
subchronic	O
diazinon	CHEMICAL
(	O
DZN	CHEMICAL
)	O
induced	O
cardiotoxicity	O
in	O
rats	O
.	O

METHODS	O
:	O
Rats	O
were	O
divided	O
into	O
7	O
groups;	O
control	O
(	O
corn	O
oil	O
,	O
gavage	O
)	O
,	O
DZN	O
(	O
15mg	O
/	O
kg	O
/	O
day	O
,	O
gavage	O
,	O
)	O
,	O
crocin	CHEMICAL
(	O
12	O
.	O
5	O
,	O
25	O
or	O
50mg	O
/	O
kg	O
/	O
day	O
,	O
i	O
.	O

p	O
)	O
plus	O
DZN	CHEMICAL
,	O
vitamin	CHEMICAL
E	CHEMICAL
(	O
200IU	O
/	O
kg	O
,	O
i	O
.	O

p	O
,	O
three	O
times	O
per	O
week	O
)	O
plus	O
DZN	CHEMICAL
and	O
crocin	CHEMICAL
(	O
50mg	O
/	O
kg	O
/	O
day	O
,	O
i	O
.	O

p	O
)	O
groups	O
.	O

Treatments	O
were	O
continued	O
for	O
4weeks	O
.	O

Creatine	GENE-N
phosphokinase	O
MB	O
(	O
CK-MB	GENE-N
)	O
,	O
malondealdehyde	CHEMICAL
(	O
MDA	CHEMICAL
)	O
and	O
glutathione	CHEMICAL
(	O
GSH	CHEMICAL
)	O
levels	O
were	O
evaluated	O
in	O
heart	O
tissue	O
at	O
the	O
end	O
of	O
treatments	O
.	O

Levels	O
of	O
apoptotic	O
proteins	O
(	O
Bax	GENE-Y
,	O
Bcl2	GENE-Y
,	O
caspase	GENE-Y
3	GENE-Y
)	O
and	O
cytosolic	GENE-Y
cytochrome	GENE-Y
c	GENE-Y
were	O
analyzed	O
by	O
Western	O
blotting	O
.	O

Transcript	O
levels	O
of	O
Bax	GENE-Y
and	O
Bcl2	GENE-Y
were	O
also	O
determined	O
using	O
qRT	O
PCR	O
.	O

RESULTS	O
:	O
DZN	CHEMICAL
induced	O
histophatological	O
damages	O
and	O
elevated	O
the	O
level	O
of	O
cardiac	O
marker	O
CK-MB	GENE-N
.	O

These	O
effects	O
were	O
associated	O
with	O
increased	O
MDA	CHEMICAL
level	O
,	O
lower	O
level	O
of	O
reduced	O
GSH	CHEMICAL
and	O
induction	O
of	O
apoptosis	O
through	O
elevation	O
of	O
Bax	GENE-Y
/	O
Bcl2	GENE-Y
ratio	O
(	O
both	O
protein	O
and	O
mRNA	O
levels	O
)	O
,	O
cytochrome	GENE-Y
c	GENE-Y
release	O
to	O
the	O
cytosol	O
and	O
activation	O
caspase	GENE-Y
3	GENE-Y
in	O
cardiac	O
tissue	O
.	O

Crocin	CHEMICAL
(	O
25	O
and	O
50mg	O
/	O
kg	O
)	O
or	O
vitamin	CHEMICAL
E	CHEMICAL
improved	O
histopathological	O
damages	O
,	O
decreased	O
MDA	CHEMICAL
and	O
CK-MB	GENE-N
,	O
increased	O
GSH	CHEMICAL
content	O
and	O
attenuated	O
the	O
increase	O
of	O
Bax	GENE-Y
/	O
Bcl2	GENE-Y
ratio	O
,	O
activation	O
of	O
caspase	GENE-Y
3	GENE-Y
and	O
release	O
of	O
cytochrome	GENE-Y
c	GENE-Y
to	O
the	O
cytosol	O
induced	O
by	O
DZN	CHEMICAL
.	O

In	O
summary	O
,	O
DZN	CHEMICAL
induced	O
mitochondrial-mediated	O
apoptosis	O
in	O
heart	O
tissue	O
of	O
rat	O
following	O
subchronic	O
exposure	O
.	O

Crocin	CHEMICAL
,	O
as	O
an	O
antioxidant	O
,	O
showed	O
protective	O
effects	O
against	O
DZN	CHEMICAL
cardiotoxicity	O
by	O
reducing	O
lipid	O
peroxidation	O
and	O
alleviating	O
apoptosis	O
.	O
The	O
present	O
study	O
investigates	O
enzyme	O
activities	O
of	O
the	O
urea	O
cycle	O
,	O
transamidinase	GENE-Y
and	O
ornithine-proline	CHEMICAL
inter-conversion	O
in	O
the	O
hypertrophied	O
kidney	O
after	O
unilateral	O
nephrectomy	O
in	O
mice	O
.	O

Surgical	O
removal	O
of	O
the	O
left	O
kidney	O
in	O
mice	O
led	O
to	O
compensatory	O
enlargement	O
of	O
the	O
right	O
kidney	O
after	O
1	O
and	O
14	O
days	O
.	O

This	O
renal	O
growth	O
was	O
associated	O
with	O
an	O
increase	O
in	O
glomerular	O
volume	O
(	O
but	O
not	O
number	O
)	O
and	O
enlargement	O
of	O
the	O
proximal	O
convoluted	O
tubules	O
.	O

The	O
total	O
renal	O
protein	O
content	O
increased	O
in	O
proportion	O
to	O
the	O
increase	O
in	O
kidney	O
weight	O
,	O
but	O
the	O
protein	O
per	O
gram	O
weight	O
of	O
kidney	O
did	O
not	O
change	O
.	O

The	O
specific	O
activity	O
of	O
only	O
ornithine	GENE-Y
aminotransferase	O
(	O
OAT	GENE-Y
)	O
,	O
the	O
rate-limiting	O
enzyme	O
in	O
the	O
conversion	O
of	O
ornithine	CHEMICAL
to	O
proline	CHEMICAL
,	O
increased	O
in	O
2	O
weeks	O
of	O
hypertrophy	O
.	O

The	O
specific	O
activity	O
of	O
all	O
other	O
enzymes	O
was	O
unchanged	O
.	O

However	O
,	O
the	O
total	O
enzyme	O
activity	O
per	O
kidney	O
of	O
all	O
the	O
enzymes	O
,	O
without	O
exception	O
,	O
was	O
elevated	O
in	O
the	O
hypertrophied	O
kidney	O
.	O

While	O
the	O
increase	O
in	O
total	O
OAT	GENE-Y
activity	O
was	O
much	O
more	O
than	O
the	O
increase	O
in	O
kidney	O
weight	O
,	O
all	O
other	O
enzymes	O
increased	O
more	O
or	O
less	O
in	O
proportion	O
to	O
the	O
increase	O
in	O
renal	O
mass	O
.	O

The	O
results	O
suggest	O
that	O
compensation	O
in	O
OAT	GENE-Y
activity	O
to	O
chronic	O
reduction	O
in	O
renal	O
mass	O
was	O
complete	O
,	O
but	O
only	O
partial	O
in	O
the	O
case	O
of	O
other	O
enzymes	O
.	O
Ethanol	CHEMICAL
extract	O
of	O
Adiantum	O
capillus-veneris	O
L	O
.	O

suppresses	O
the	O
production	O
of	O
inflammatory	O
mediators	O
by	O
inhibiting	O
NF-κB	GENE-N
activation	O
.	O
Fungicide	O
prochloraz	CHEMICAL
and	O
environmental	O
pollutant	O
dioxin	CHEMICAL
induce	O
the	O
ABCG2	GENE-Y
transporter	O
in	O
bovine	O
mammary	O
epithelial	O
cells	O
by	O
the	O
arylhydrocarbon	GENE-Y
receptor	O
signaling	O
pathway	O
.	O
In	O
the	O
present	O
investigation	O
,	O
16	O
new	O
rotundic	CHEMICAL
acid	CHEMICAL
(	O
RA	O
)	O
derivatives	O
modified	O
at	O
the	O
C-3	O
,	O
C-23	O
and	O
C-28	O
positions	O
were	O
synthesized	O
.	O

The	O
cytotoxicities	O
of	O
the	O
derivatives	O
were	O
evaluated	O
against	O
HeLa	O
,	O
A375	O
,	O
HepG2	O
,	O
SPC-A1	O
and	O
NCI-H446	O
human	O
tumor	O
cell	O
lines	O
by	O
MTT	CHEMICAL
assay	O
.	O

Among	O
these	O
derivatives	O
,	O
compounds	O
4-7	O
exhibited	O
stronger	O
cell	O
growth	O
inhibitory	O
than	O
RA	O
and	O
compound	O
4	O
was	O
found	O
to	O
be	O
the	O
best	O
inhibition	O
activity	O
on	O
five	O
human	O
tumor	O
cell	O
lines	O
with	O
IC50	O
<10μM	O
.	O

The	O
apoptosis	O
mechanism	O
of	O
compound	O
4	O
in	O
HeLa	O
cells	O
was	O
investigated	O
by	O
western	O
blot	O
analysis	O
.	O

The	O
results	O
indicated	O
that	O
compound	O
4	O
could	O
induce	O
apoptosis	O
through	O
increasing	O
protein	O
expression	O
of	O
cleaved	O
caspase-3	GENE-Y
and	O
Bax	GENE-Y
,	O
and	O
decreasing	O
protein	O
expression	O
of	O
Bcl-2	GENE-Y
.	O

In	O
summary	O
,	O
the	O
present	O
work	O
suggests	O
that	O
compound	O
4	O
might	O
serve	O
as	O
an	O
effective	O
chemotherapeutic	O
candidate	O
.	O
Arsenic	CHEMICAL
trioxide	CHEMICAL
(	O
ATO	CHEMICAL
)	O
is	O
widely	O
used	O
in	O
tumor	O
treatment	O
,	O
but	O
excessive	O
arsenic	CHEMICAL
exposure	O
can	O
have	O
adverse	O
effects	O
.	O

We	O
recently	O
found	O
that	O
,	O
in	O
primary	O
osteoblasts	O
,	O
ATO	CHEMICAL
produces	O
oxidative	O
stress	O
and	O
causes	O
DNA	O
tailing	O
,	O
but	O
does	O
not	O
induce	O
apoptosis	O
.	O

We	O
further	O
examined	O
the	O
signaling	O
pathway	O
by	O
which	O
osteoblasts	O
survive	O
ATO	CHEMICAL
treatment	O
,	O
and	O
found	O
that	O
they	O
were	O
arrested	O
at	O
G2	O
/	O
M	O
phase	O
of	O
the	O
cell	O
cycle	O
at	O
30h	O
and	O
overrode	O
the	O
G2	O
/	O
M	O
boundary	O
at	O
48h	O
.	O

After	O
treatment	O
for	O
30h	O
,	O
there	O
was	O
increased	O
Cdc2	GENE-Y
phosphorylation	O
and	O
expression	O
of	O
Wee1	GENE-Y
,	O
a	O
Cdc2	GENE-Y
kinase	GENE-N
,	O
and	O
expression	O
of	O
the	O
cell	O
cycle	O
inhibitor	O
,	O
p21	GENE-Y
(	O
waf1	GENE-Y
/	O
cip1	GENE-Y
)	O
,	O
which	O
interacts	O
with	O
Cdc2	GENE-Y
.	O

Furthermore	O
,	O
levels	O
of	O
the	O
phosphatase	GENE-Y
Cdc25C	GENE-Y
,	O
which	O
activates	O
Cdc2	GENE-Y
,	O
were	O
decreased	O
,	O
while	O
the	O
ratio	O
of	O
its	O
phosphorylated	O
/	O
inactivated	O
form	O
to	O
the	O
total	O
amount	O
was	O
increased	O
.	O

Moreover	O
,	O
phosphorylation	O
/	O
activation	O
of	O
the	O
checkpoint	O
kinases	O
Chk1	GENE-Y
,	O
Chk2	GENE-Y
and	O
p53	GENE-Y
levels	O
were	O
increased	O
,	O
as	O
were	O
levels	O
of	O
activated	O
ATM	GENE-Y
and	O
γ-H2AX	GENE-Y
.	O

The	O
cell	O
viability	O
was	O
decreased	O
as	O
an	O
ATM	GENE-Y
inhibitor	O
was	O
added	O
.	O

Additionally	O
,	O
these	O
effects	O
of	O
ATO	CHEMICAL
on	O
γ-H2AX	GENE-Y
,	O
Chk1	GENE-Y
,	O
Chk2	GENE-Y
,	O
p53	GENE-Y
,	O
and	O
p21	GENE-Y
(	O
waf1	GENE-Y
/	O
cip1	GENE-Y
)	O
were	O
reduced	O
by	O
an	O
ATM	GENE-Y
inhibitor	O
.	O

These	O
findings	O
suggest	O
that	O
G2	O
/	O
M	O
phase	O
arrest	O
of	O
osteoblasts	O
is	O
mediated	O
by	O
Chk1	GENE-Y
/	O
Chk2	GENE-Y
activation	O
via	O
an	O
ATM-dependent	O
pathway	O
by	O
which	O
osteoblasts	O
survive	O
.	O
Prototypic	GENE-N
G	GENE-N
protein-coupled	GENE-N
receptor	GENE-N
for	O
the	O
intestinotrophic	GENE-Y
factor	GENE-Y
glucagon-like	GENE-Y
peptide	GENE-Y
2	GENE-Y
.	O
Benzodiazepine	GENE-N
receptor	O
binding	O
of	O
triazolobenzodiazepines	CHEMICAL
in	O
vivo	O
:	O
increased	O
receptor	O
number	O
with	O
low-dose	O
alprazolam	CHEMICAL
.	O
Arsenic	CHEMICAL
geochemistry	O
in	O
a	O
biostimulated	O
aquifer	O
:	O
An	O
aqueous	O
speciation	O
study	O
.	O
Persistent	O
hyperglycemia	O
is	O
associated	O
with	O
chronic	O
oxidative	O
stress	O
which	O
contributes	O
to	O
the	O
development	O
and	O
progression	O
of	O
diabetes-associated	O
complications	O
.	O

The	O
sensitivity	O
of	O
pancreatic	O
β-cells	O
to	O
oxidative	O
stress	O
has	O
been	O
attributed	O
to	O
their	O
low	O
content	O
of	O
antioxidants	O
compared	O
with	O
other	O
tissues	O
.	O

Bioactive	O
compounds	O
with	O
potent	O
antidiabetic	O
properties	O
have	O
been	O
shown	O
to	O
ameliorate	O
hyperglycemia	O
mediated	O
oxidative	O
stress	O
.	O

Recently	O
,	O
we	O
have	O
reported	O
that	O
oral	O
administration	O
of	O
fisetin	CHEMICAL
(	O
10	O
mg	O
/	O
Kg	O
b	O
.	O

w	O
.	O

)	O
,	O
a	O
bioflavonoid	CHEMICAL
found	O
to	O
be	O
present	O
in	O
strawberries	O
,	O
persimmon	O
,	O
to	O
STZ-induced	O
experimental	O
diabetic	O
rats	O
significantly	O
improved	O
normoglycemia	O
.	O

The	O
present	O
study	O
was	O
aimed	O
to	O
evaluate	O
the	O
antioxidant	O
potential	O
of	O
fisetin	CHEMICAL
in	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Diabetes	O
was	O
induced	O
by	O
single	O
intraperitoneal	O
injection	O
of	O
streptozotocin	CHEMICAL
(	O
50	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
.	O

Fisetin	CHEMICAL
was	O
administered	O
orally	O
for	O
30	O
days	O
.	O

At	O
the	O
end	O
of	O
the	O
study	O
,	O
all	O
animals	O
were	O
killed	O
.	O

Blood	O
samples	O
were	O
collected	O
for	O
the	O
biochemical	O
estimations	O
.	O

The	O
antioxidant	O
status	O
was	O
evaluated	O
.	O

Histological	O
examinations	O
were	O
performed	O
on	O
pancreatic	O
tissues	O
.	O

Fisetin	CHEMICAL
treatment	O
showed	O
a	O
significant	O
decline	O
in	O
the	O
levels	O
of	O
blood	O
glucose	CHEMICAL
,	O
glycosylated	GENE-N
hemoglobin	GENE-N
(	O
HbA1c	GENE-N
)	O
,	O
NF-kB	GENE-N
p65	GENE-Y
unit	O
(	O
in	O
pancreas	O
)	O
and	O
IL-1β	GENE-Y
(	O
plasma	O
)	O
,	O
serum	O
nitric	CHEMICAL
oxide	CHEMICAL
(	O
NO	CHEMICAL
)	O
with	O
an	O
elevation	O
in	O
plasma	O
insulin	GENE-N
.	O

The	O
treatment	O
also	O
improved	O
the	O
antioxidant	O
status	O
in	O
pancreas	O
as	O
well	O
as	O
plasma	O
of	O
diabetic	O
rats	O
indicating	O
the	O
antioxidant	O
potential	O
of	O
fisetin	CHEMICAL
.	O

In	O
addition	O
,	O
the	O
results	O
of	O
DPPH	CHEMICAL
and	O
ABTS	CHEMICAL
assays	O
substantiate	O
the	O
free	O
radical	O
scavenging	O
activity	O
of	O
fisetin	CHEMICAL
.	O

Histological	O
studies	O
of	O
the	O
pancreas	O
also	O
evidenced	O
the	O
tissue	O
protective	O
nature	O
of	O
fisetin	CHEMICAL
.	O

It	O
is	O
concluded	O
that	O
,	O
fisetin	CHEMICAL
possesses	O
antioxidant	O
and	O
anti-inflammatory	O
property	O
and	O
may	O
be	O
considered	O
as	O
an	O
adjunct	O
for	O
the	O
treatment	O
of	O
diabetes	O
.	O
The	O
serotonin	GENE-N
(	O
5-HT	CHEMICAL
)	O
receptors	O
of	O
type	O
6	O
(	O
5-HT6	GENE-Y
)	O
are	O
quite	O
different	O
from	O
all	O
other	O
5-HT	CHEMICAL
receptors	O
,	O
as	O
they	O
include	O
a	O
short	O
third	O
cytoplasmatic	O
loop	O
and	O
a	O
long	O
C-terminal	O
tail	O
,	O
and	O
one	O
intron	O
located	O
in	O
the	O
middle	O
of	O
the	O
third	O
cytoplasmatic	O
loop	O
.	O

A	O
lot	O
of	O
controversies	O
still	O
exist	O
regarding	O
their	O
binding	O
affinity	O
,	O
effects	O
of	O
5-HT6	GENE-Y
ligands	O
on	O
brain	O
catecholamines	CHEMICAL
,	O
behavioral	O
syndromes	O
regulated	O
by	O
them	O
,	O
and	O
brain	O
distribution	O
.	O

In	O
spite	O
of	O
the	O
lack	O
of	O
information	O
on	O
metabolic	O
pattern	O
of	O
the	O
various	O
compounds	O
,	O
some	O
of	O
5-HT6	GENE-Y
receptor	O
ligands	O
entered	O
the	O
clinical	O
development	O
as	O
potential	O
anti-dementia	O
,	O
antipsychotic	O
,	O
antidepressant	O
and	O
anti-obese	O
drugs	O
.	O

The	O
present	O
paper	O
is	O
a	O
comprehensive	O
review	O
on	O
the	O
state	O
of	O
art	O
of	O
the	O
5-HT6	GENE-Y
receptors	O
,	O
while	O
highlighting	O
the	O
potential	O
clinical	O
applications	O
of	O
5-HT6	GENE-Y
receptor	O
agonists	O
/	O
antagonists	O
.	O
A	O
series	O
of	O
compounds	O
based	O
on	O
a	O
4-phenyl-2-phenylaminopyridine	CHEMICAL
scaffold	O
that	O
are	O
potent	O
and	O
selective	O
inhibitors	O
of	O
Traf2-	GENE-Y
and	GENE-Y
Nck-interacting	GENE-Y
kinase	GENE-Y
(	O
TNIK	GENE-Y
)	O
activity	O
are	O
described	O
.	O

These	O
compounds	O
were	O
used	O
as	O
tools	O
to	O
test	O
the	O
importance	O
of	O
TNIK	GENE-Y
kinase	GENE-N
activity	O
in	O
signaling	O
and	O
proliferation	O
in	O
Wnt-activated	O
colorectal	O
cancer	O
cells	O
.	O

The	O
results	O
indicate	O
that	O
pharmacological	O
inhibition	O
of	O
TNIK	GENE-Y
kinase	GENE-N
activity	O
has	O
minimal	O
effects	O
on	O
either	O
Wnt	GENE-N
/	O
TCF4	GENE-Y
/	O
β-catenin-driven	O
transcription	O
or	O
viability	O
.	O

The	O
findings	O
suggest	O
that	O
the	O
kinase	GENE-N
activity	O
of	O
TNIK	GENE-Y
may	O
be	O
less	O
important	O
to	O
Wnt	GENE-N
signaling	O
than	O
other	O
aspects	O
of	O
TNIK	GENE-Y
function	O
,	O
such	O
as	O
its	O
putative	O
role	O
in	O
stabilizing	O
the	O
TCF4	GENE-Y
/	O
β-catenin	GENE-Y
transcriptional	O
complex	O
.	O
A	O
series	O
of	O
N-substituted	O
lobelane	CHEMICAL
analogues	O
was	O
synthesized	O
and	O
evaluated	O
for	O
their	O
[	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
H	CHEMICAL
]	CHEMICAL
dihydrotetrabenazine	CHEMICAL
binding	O
affinity	O
at	O
the	O
vesicular	GENE-N
monoamine	CHEMICAL
transporter	O
and	O
for	O
their	O
inhibition	O
of	O
vesicular	O
[	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
H	CHEMICAL
]	CHEMICAL
dopamine	CHEMICAL
uptake	O
.	O

Compound	O
19a	O
,	O
which	O
contains	O
an	O
N-1	CHEMICAL
,	CHEMICAL
2	CHEMICAL
(	CHEMICAL
R	CHEMICAL
)	CHEMICAL
-dihydroxypropyl	CHEMICAL
group	O
,	O
had	O
been	O
identified	O
as	O
a	O
potential	O
clinical	O
candidate	O
for	O
the	O
treatment	O
of	O
methamphetamine	CHEMICAL
abuse	O
.	O
[	O
Proliferation	O
inhibition	O
effect	O
of	O
indomethacin	CHEMICAL
on	O
CML	O
cells	O
associated	O
with	O
down-regulation	O
of	O
phosphorylated	O
STAT1	GENE-Y
/	O
STAT5	GENE-Y
and	O
inhibition	O
of	O
COX-2	GENE-Y
expression	O
]	O
.	O
Recent	O
findings	O
have	O
implicated	O
the	O
5-hydroxytryptamine	GENE-Y
2B	O
(	O
5-HT2B	O
)	O
serotonin	CHEMICAL
receptor	O
in	O
mediating	O
the	O
heart	O
valve	O
fibroplasia	O
[	O
valvular	O
heart	O
disease	O
(	O
VHD	O
)	O
]	O
and	O
primary	O
pulmonary	O
hypertension	O
observed	O
in	O
patients	O
taking	O
the	O
now-banned	O
appetite	O
suppressant	O
fenfluramine	CHEMICAL
(	O
Pondimin	CHEMICAL
,	O
Redux	CHEMICAL
)	O
.	O

Via	O
large-scale	O
,	O
random	O
screening	O
of	O
a	O
portion	O
of	O
the	O
receptorome	O
,	O
we	O
have	O
discovered	O
that	O
the	O
amphetamine	CHEMICAL
derivative	O
3	CHEMICAL
,	CHEMICAL
4-methylenedioxymethamphetamine	CHEMICAL
(	O
MDMA	CHEMICAL
,	O
"Ecstasy"	O
)	O
and	O
its	O
N-demethylated	O
metabolite	O
3	CHEMICAL
,	CHEMICAL
4-methylenedioxyamphetamine	CHEMICAL
(	O
MDA	CHEMICAL
)	O
each	O
preferentially	O
bind	O
to	O
and	O
activate	O
human	GENE-Y
recombinant	GENE-Y
5-HT2B	GENE-Y
receptors	GENE-Y
.	O

We	O
also	O
demonstrate	O
that	O
MDMA	CHEMICAL
and	O
MDA	CHEMICAL
,	O
like	O
fenfluramine	CHEMICAL
and	O
its	O
N-deethylated	O
metabolite	O
norfenfluramine	CHEMICAL
,	O
elicit	O
prolonged	O
mitogenic	O
responses	O
in	O
human	O
valvular	O
interstitial	O
cells	O
via	O
activation	O
of	O
5-HT2B	GENE-Y
receptors	O
.	O

We	O
also	O
report	O
that	O
pergolide	CHEMICAL
and	O
dihydroergotamine	CHEMICAL
,	O
two	O
drugs	O
recently	O
demonstrated	O
to	O
induce	O
VHD	O
in	O
humans	O
,	O
potently	O
activate	O
5-HT2B	GENE-Y
receptors	O
,	O
thus	O
validating	O
this	O
assay	O
system	O
for	O
its	O
ability	O
to	O
predict	O
medications	O
that	O
might	O
induce	O
VHD	O
.	O

Our	O
discovery	O
that	O
MDMA	CHEMICAL
and	O
a	O
major	O
metabolite	O
,	O
MDA	CHEMICAL
,	O
induce	O
prolonged	O
mitogenic	O
responses	O
in	O
vitro	O
similar	O
to	O
those	O
induced	O
by	O
fenfluramine	CHEMICAL
and	O
norfenfluramine	CHEMICAL
in	O
vivo	O
(	O
i	O
.	O

e	O
.	O

,	O
valvular	O
interstitial	O
cell	O
fibroplasia	O
)	O
predict	O
that	O
long-term	O
MDMA	CHEMICAL
use	O
could	O
lead	O
to	O
the	O
development	O
of	O
fenfluramine-like	O
VHD	O
.	O

Because	O
of	O
the	O
widespread	O
abuse	O
of	O
MDMA	CHEMICAL
,	O
these	O
findings	O
have	O
major	O
public	O
health	O
implications	O
.	O

These	O
findings	O
also	O
underscore	O
the	O
necessity	O
of	O
screening	O
current	O
and	O
future	O
drugs	O
at	O
h5-HT2B	GENE-Y
receptors	O
for	O
agonist	O
actions	O
before	O
their	O
use	O
in	O
humans	O
.	O
Chemical	O
characterization	O
of	O
chicken	GENE-N
and	GENE-N
rat	GENE-N
lipoprotein	GENE-N
lipase	GENE-N
(	O
LPL	GENE-N
)	O
was	O
carried	O
out	O
following	O
purification	O
of	O
LPL	GENE-N
.	O

Molecular	O
weight	O
and	O
isoelectric	O
point	O
of	O
both	O
purified	O
enzymes	O
were	O
determined	O
to	O
be	O
60	O
KDa	O
and	O
pH	O
4	O
,	O
while	O
optimum	O
temperature	O
and	O
pH	O
to	O
yield	O
the	O
maximal	O
activity	O
were	O
about	O
37	O
degrees	O
C	O
and	O
pH	O
8	O
.	O
5	O
.	O

Metallic	O
ions	O
,	O
NaCl	CHEMICAL
and	O
protamine	O
sulfate	CHEMICAL
reduced	O
,	O
and	O
heparin	O
increased	O
,	O
both	O
LPL	GENE-N
activities	O
.	O

Michaelis	O
constants	O
for	O
LPLs	GENE-N
determined	O
with	O
triolein	CHEMICAL
emulsion	O
as	O
the	O
substrate	O
were	O
0	O
.	O
98	O
and	O
1	O
.	O
57	O
,	O
and	O
those	O
of	O
Vmax	O
were	O
379	O
.	O
2	O
and	O
181	O
.	O
3	O
,	O
in	O
chickens	O
and	O
rats	O
,	O
respectively	O
.	O

Triton	O
WR-1339	O
caused	O
mixed-type	O
inhibition	O
in	O
rat	O
,	O
but	O
inhibited	O
chicken	GENE-Y
LPL	GENE-Y
noncompetitively	O
.	O

In	O
LPLs	GENE-N
of	O
chickens	O
and	O
rats	O
,	O
values	O
of	O
Ki	O
were	O
66	O
.	O
7	O
and	O
36	O
.	O
4	O
with	O
triolein	CHEMICAL
emulsion	O
as	O
the	O
substrate	O
,	O
and	O
832	O
.	O
4	O
and	O
66	O
.	O
0	O
with	O
respective	O
VLDL	GENE-N
as	O
the	O
substrate	O
.	O

These	O
results	O
show	O
species	O
difference	O
between	O
chickens	O
and	O
rats	O
in	O
the	O
affinity	O
to	O
lipoproteins	GENE-N
of	O
LPL	GENE-N
and	O
inhibition	O
of	O
LPL	GENE-N
by	O
Triton	O
WR-1339	O
.	O
Nuclear	GENE-N
factor-κB	GENE-N
(	O
NF-κB	GENE-N
)	O
is	O
a	O
transcription	O
factor	O
that	O
mediates	O
the	O
inducible	O
expression	O
of	O
a	O
variety	O
of	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

NF-κB	GENE-N
activation	O
induces	O
numerous	O
proinflammatory	O
gene	O
products	O
including	O
cytokines	GENE-N
,	O
cyclooxygenase-2	GENE-Y
(	O
COX-2	GENE-Y
)	O
,	O
and	O
inducible	GENE-Y
nitric	CHEMICAL
oxide	CHEMICAL
synthase	O
(	O
iNOS	GENE-Y
)	O
.	O

The	O
divalent	O
heavy	O
metal	O
mercury	CHEMICAL
has	O
been	O
used	O
for	O
thousands	O
of	O
years	O
.	O

Although	O
mercury	CHEMICAL
is	O
clearly	O
toxic	O
to	O
most	O
mammalian	O
organ	O
systems	O
,	O
especially	O
the	O
immune	O
system	O
,	O
exposure	O
has	O
still	O
increased	O
in	O
some	O
areas	O
of	O
the	O
world	O
.	O

However	O
,	O
the	O
underlying	O
toxic	O
mechanism	O
is	O
not	O
clearly	O
identified	O
.	O

Here	O
,	O
we	O
report	O
biochemical	O
evidence	O
that	O
mercury	CHEMICAL
alone	O
induces	O
NF-κB	GENE-N
activation	O
,	O
resulting	O
in	O
the	O
induced	O
expression	O
of	O
COX-2	GENE-Y
and	O
iNOS	GENE-Y
.	O

The	O
results	O
suggest	O
that	O
mercury	CHEMICAL
can	O
induce	O
inflammatory	O
diseases	O
by	O
lowering	O
host	O
defense	O
.	O
We	O
investigated	O
the	O
effects	O
of	O
transforming	GENE-Y
growth	GENE-Y
factor	GENE-Y
alpha	GENE-Y
(	O
TGF-alpha	GENE-Y
)	O
on	O
DNA	O
synthesis	O
and	O
proliferation	O
in	O
primary	O
cultures	O
of	O
adult	O
rat	O
hepatocytes	O
and	O
examined	O
the	O
influence	O
of	O
alpha	GENE-N
and	GENE-N
beta	GENE-N
adrenoceptor	GENE-N
agonists	O
on	O
the	O
TGF-alpha-induced	O
responses	O
.	O

TGF-alpha	GENE-Y
(	O
1	O
.	O
0	O
ng	O
/	O
ml	O
)	O
produced	O
a	O
4	O
.	O
1-fold	O
elevation	O
of	O
DNA	O
synthesis	O
during	O
3	O
h	O
of	O
culture	O
and	O
a	O
1	O
.	O
2-fold	O
increase	O
in	O
the	O
nucleus	O
number	O
(	O
proliferation	O
)	O
during	O
4	O
h	O
of	O
culture	O
at	O
a	O
cell	O
density	O
of	O
3	O
.	O
3	O
x	O
10	O
(	O
4	O
)	O
cells	O
/	O
cm	O
(	O
2	O
)	O
.	O

The	O
TGF-alpha-induced	O
hepatocyte	O
DNA	O
synthesis	O
and	O
proliferation	O
were	O
dose-dependent	O
at	O
EC	O
(	O
50	O
)	O
values	O
of	O
0	O
.	O
36	O
ng	O
/	O
ml	O
and	O
0	O
.	O
45	O
ng	O
/	O
ml	O
,	O
respectively	O
.	O

Hepatocyte	O
DNA	O
synthesis	O
and	O
proliferation	O
induced	O
by	O
1	O
.	O
0	O
ng	O
/	O
ml	O
TGF-alpha	GENE-Y
did	O
not	O
reduce	O
even	O
at	O
higher	O
initial	O
plating	O
densities	O
(	O
5	O
.	O
0	O
x	O
10	O
(	O
4	O
)	O
and	O
1	O
.	O
0	O
x	O
10	O
(	O
5	O
)	O
cells	O
/	O
cm	O
(	O
2	O
)	O
)	O
.	O

Increasing	O
concentrations	O
of	O
the	O
beta	GENE-Y
(	GENE-Y
2	GENE-Y
)	GENE-Y
adrenoceptor	GENE-Y
agonist	O
metaproterenol	CHEMICAL
(	O
10	O
(	O
-7	O
)	O
-10	O
(	O
-6	O
)	O
M	O
)	O
markedly	O
reduced	O
the	O
proliferative	O
effects	O
of	O
TGF-alpha	GENE-Y
,	O
whereas	O
those	O
of	O
the	O
alpha	GENE-N
(	GENE-N
2	GENE-N
)	GENE-N
adrenoceptor	GENE-N
agonist	O
5-bromo-6-	CHEMICAL
[	CHEMICAL
2-imidazolin-2-yl-amino	CHEMICAL
]	CHEMICAL
-quinoxaline	CHEMICAL
(	O
UK-14304;	O
10	O
(	O
-6	O
)	O
-10	O
(	O
-5	O
)	O
M	O
)	O
and	O
the	O
alpha	GENE-N
(	GENE-N
1	GENE-N
)	GENE-N
adrenoceptor	GENE-N
agonist	O
phenylephrine	CHEMICAL
(	O
10	O
(	O
-7	O
)	O
-10	O
(	O
-6	O
)	O
M	O
)	O
significantly	O
potentiated	O
the	O
TGF-alpha	GENE-Y
action	O
.	O

The	O
proliferative	O
effects	O
of	O
TGF-alpha	GENE-Y
(	O
1	O
.	O
0	O
ng	O
/	O
ml	O
)	O
were	O
not	O
affected	O
significantly	O
by	O
a	O
monoclonal	O
antiepidermal	GENE-Y
growth	GENE-Y
factor	GENE-Y
receptor	GENE-Y
antibody	O
(	O
1-100	O
ng	O
/	O
ml	O
)	O
and	O
were	O
almost	O
completely	O
blocked	O
by	O
specific	O
inhibitors	O
of	O
signal	O
transducers	O
such	O
as	O
genistein	CHEMICAL
(	O
10	O
(	O
-5	O
)	O
M	O
)	O
,	O
1-6	CHEMICAL
[	CHEMICAL
[	CHEMICAL
17beta-3methoxyestra-1	CHEMICAL
,	CHEMICAL
3	CHEMICAL
,	CHEMICAL
5	CHEMICAL
(	CHEMICAL
10	CHEMICAL
)	CHEMICAL
-trien-17-yl	CHEMICAL
]	CHEMICAL
amino	CHEMICAL
]	CHEMICAL
hexyl	CHEMICAL
]	CHEMICAL
-1H-pyrrol2	CHEMICAL
,	CHEMICAL
5-dione	CHEMICAL
(	O
U-73122;	O
0	O
(	O
-5	O
)	O
M	O
)	O
,	O
wortmannin	CHEMICAL
(	O
5	O
x	O
10	O
(	O
-7	O
)	O
M	O
)	O
,	O
sphingosine	CHEMICAL
(	O
5	O
x	O
10	O
(	O
-6	O
)	O
M	O
)	O
,	O
2'-amino-3'-methoxyflavone	CHEMICAL
(	O
PD98059;	O
5	O
x	O
10	O
(	O
-5	O
)	O
M	O
)	O
,	O
and	O
rapamycin	CHEMICAL
(	O
10	O
ng	O
/	O
ml	O
)	O
.	O

These	O
results	O
suggest	O
that	O
among	O
the	O
elements	O
that	O
link	O
signals	O
of	O
cell	O
surface	O
receptor	O
to	O
the	O
nucleus	O
,	O
the	O
proliferative	O
action	O
of	O
TGF-alpha	GENE-Y
is	O
mediated	O
,	O
at	O
least	O
,	O
by	O
tyrosine	GENE-N
kinase	O
,	O
phospholipase	GENE-N
C	GENE-N
,	O
phosphatidylinositol	GENE-N
3-kinase	GENE-N
,	O
protein	GENE-N
kinase	GENE-N
C	GENE-N
,	O
mitogen-activated	GENE-N
protein	GENE-N
kinase	GENE-N
kinase	GENE-N
,	O
and	O
ribosomal	GENE-N
protein	O
p70	O
S6	O
kinase	O
.	O
Oncolytic	O
activity	O
and	O
mechanism	O
of	O
action	O
of	O
a	O
novel	O
L-cysteine	CHEMICAL
derivative	O
,	O
L-cysteine	CHEMICAL
,	CHEMICAL
ethyl	CHEMICAL
ester	CHEMICAL
,	CHEMICAL
S-	CHEMICAL
(	CHEMICAL
N-methylcarbamate	CHEMICAL
)	CHEMICAL
monohydrochloride	CHEMICAL
.	O
[	O
Acetylsalicylic	CHEMICAL
acid	CHEMICAL
resistance--clinical	O
diagnosis	O
with	O
unclear	O
mechanism	O
]	O
.	O
In	O
recent	O
years	O
the	O
use	O
of	O
the	O
opioid	O
oxycodone	CHEMICAL
has	O
increased	O
markedly	O
and	O
replacing	O
morphine	CHEMICAL
as	O
the	O
first-line	O
choice	O
of	O
opioid	O
in	O
several	O
countries	O
.	O

There	O
are	O
formulations	O
for	O
oral	O
immediate	O
,	O
oral	O
extended	O
release	O
and	O
intravenous	O
use	O
.	O

The	O
bioavailability	O
is	O
higher	O
than	O
for	O
morphine	CHEMICAL
and	O
less	O
variable	O
.	O

Oxycodone	CHEMICAL
is	O
primarily	O
metabolized	O
in	O
the	O
liver	O
by	O
the	O
cytochrome	GENE-N
P450	GENE-N
(	O
CYP	GENE-N
)	O
enzymes	O
with	O
CYP3A	GENE-N
as	O
the	O
major	O
metabolic	O
pathway	O
and	O
CYP2D6	GENE-Y
as	O
the	O
minor	O
metabolic	O
pathway	O
to	O
noroxycodone	CHEMICAL
,	O
oxymorphone	CHEMICAL
and	O
noroxymorphone	CHEMICAL
.	O

Oxycodone	CHEMICAL
exerts	O
its	O
analgesic	O
effect	O
via	O
the	O
µ-opioid	GENE-N
receptor	GENE-N
.	O

The	O
metabolism	O
of	O
CYP2D6	GENE-Y
substrates	O
varies	O
to	O
a	O
large	O
degree	O
between	O
individuals	O
as	O
a	O
result	O
of	O
allele	O
functionality	O
.	O

Poor	O
metabolizers	O
(	O
PM	O
)	O
have	O
two	O
non-functional	O
alleles	O
,	O
extensive	O
metabolizers	O
(	O
EM	O
)	O
are	O
homozygous	O
with	O
two	O
functional	O
alleles	O
or	O
heterozygous	O
with	O
one	O
functional	O
allele	O
and	O
ultrarapid	O
metabolizers	O
(	O
UM	O
)	O
have	O
more	O
than	O
two	O
functional	O
alleles	O
.	O

There	O
are	O
pronounced	O
interethnic	O
differences	O
in	O
the	O
allele	O
distribution	O
.	O

On	O
the	O
basis	O
of	O
studies	O
performed	O
thus	O
far	O
,	O
oxycodone	CHEMICAL
concentrations	O
in	O
comparison	O
with	O
EM	O
are	O
similar	O
in	O
PM	O
and	O
reduced	O
in	O
UM	O
.	O

The	O
pharmacokinetics	O
in	O
UM	O
are	O
insufficiently	O
investigated	O
.	O

Simultaneous	O
inhibition	O
of	O
both	O
CYP3A	GENE-N
and	O
CYP2D6	GENE-Y
results	O
in	O
increased	O
oxycodone	CHEMICAL
concentrations	O
and	O
such	O
a	O
combination	O
should	O
be	O
avoided	O
.	O

A	O
similar	O
effect	O
is	O
to	O
be	O
expected	O
with	O
use	O
of	O
a	O
CYP3A	GENE-N
inhibitor	O
in	O
CYP2D6	GENE-Y
PM	O
.	O

Concomitant	O
use	O
of	O
enzyme	O
inducers	O
such	O
as	O
rifampicin	CHEMICAL
,	O
St	O
John's	O
wort	O
and	O
carbamazepine	CHEMICAL
should	O
be	O
avoided	O
because	O
of	O
the	O
risk	O
of	O
subtherapeutic	O
concentrations	O
of	O
oxycodone	CHEMICAL
.	O

When	O
the	O
dosage	O
of	O
morphine	CHEMICAL
may	O
result	O
in	O
unpredictable	O
bioavailability	O
,	O
like	O
in	O
patients	O
with	O
severe	O
hepatic	O
cirrhosis	O
,	O
oxycodone	CHEMICAL
might	O
be	O
beneficial	O
because	O
it	O
has	O
higher	O
and	O
less	O
variability	O
in	O
bioavailability	O
between	O
patients	O
than	O
morphine	CHEMICAL
.	O
5-aminosalicylic	CHEMICAL
acid	CHEMICAL
(	O
5-ASA	CHEMICAL
)	O
preparations	O
(	O
eg	O
,	O
mesalazine	CHEMICAL
,	O
mesalamine	CHEMICAL
)	O
are	O
well-established	O
preparations	O
used	O
in	O
the	O
management	O
of	O
inflammatory	O
bowel	O
disease	O
.	O

These	O
drugs	O
are	O
most	O
useful	O
for	O
the	O
treatment	O
of	O
mild	O
to	O
moderate	O
flares	O
of	O
ulcerative	O
colitis	O
and	O
,	O
especially	O
,	O
for	O
maintenance	O
of	O
remission	O
.	O

Although	O
most	O
gastroenterologists	O
are	O
very	O
familiar	O
with	O
these	O
drugs	O
,	O
the	O
interest	O
in	O
these	O
drugs	O
has	O
undergone	O
a	O
resurgence	O
,	O
with	O
new	O
preparations	O
offering	O
convenience	O
and	O
high	O
dosage	O
,	O
while	O
preserving	O
their	O
customary	O
safety	O
.	O

New	O
dosage	O
regimens	O
are	O
likely	O
to	O
become	O
standard	O
practice	O
in	O
the	O
near	O
future	O
.	O

There	O
is	O
also	O
considerable	O
interest	O
in	O
chemoprevention	O
of	O
colorectal	O
cancer	O
in	O
the	O
context	O
of	O
inflammatory	O
bowel	O
disease	O
,	O
and	O
the	O
role	O
of	O
long-term	O
maintenance	O
therapy	O
with	O
5-ASAs	CHEMICAL
in	O
achieving	O
such	O
chemoprevention	O
.	O

A	O
mechanism	O
of	O
action	O
for	O
such	O
chemoprevention	O
has	O
been	O
provided	O
by	O
the	O
agonism	O
of	O
the	O
peroxisome	GENE-Y
proliferator-activated	GENE-Y
receptor-gamma	GENE-Y
by	O
5-ASA	CHEMICAL
,	O
which	O
unifies	O
its	O
efficacy	O
as	O
an	O
anti-inflammatory	O
and	O
chemopreventive	O
agent	O
.	O

In	O
the	O
future	O
,	O
even	O
more	O
effective	O
agents	O
based	O
on	O
5-ASA	CHEMICAL
are	O
expected	O
,	O
based	O
on	O
more	O
powerful	O
agonism	O
of	O
peroxisome	GENE-Y
proliferator-activated	GENE-Y
receptor-gamma;	O
5-ASA	CHEMICAL
preparations	O
have	O
become	O
'trendy'	O
again	O
.	O
Interleukin	GENE-Y
2	GENE-Y
toxin	O
:	O
a	O
step	O
toward	O
selective	O
immunomodulation	O
.	O
Hepatic	O
very-low-density	GENE-N
lipoprotein	GENE-N
and	O
apolipoprotein	GENE-Y
B	GENE-Y
production	O
are	O
increased	O
following	O
in	O
vivo	O
induction	O
of	O
betaine-homocysteine	CHEMICAL
S-methyltransferase	O
.	O
Versatile	O
conjugation	O
of	O
octreotide	CHEMICAL
to	O
dendrimers	O
by	O
cycloaddition	O
(	O
"click"	O
)	O
chemistry	O
to	O
yield	O
high-affinity	O
multivalent	O
cyclic	O
Peptide	O
dendrimers	O
.	O
The	O
feasibility	O
of	O
administering	O
a	O
relatively	O
high	O
dose	O
of	O
the	O
gonadotrophin-releasing	CHEMICAL
hormone	CHEMICAL
(	O
GnRH	GENE-Y
)	O
antagonist	O
ganirelix	CHEMICAL
by	O
means	O
of	O
a	O
needle-free	O
injection	O
device	O
,	O
which	O
could	O
be	O
useful	O
in	O
the	O
long-term	O
treatment	O
of	O
sex-steroid-dependent	O
disorders	O
,	O
was	O
evaluated	O
in	O
a	O
randomized	O
,	O
crossover	O
study	O
in	O
16	O
healthy	O
females	O
.	O

Local	O
tolerance	O
and	O
pharmacokinetics	O
of	O
ganirelix	CHEMICAL
administered	O
by	O
MediJector	O
versus	O
conventional	O
needle	O
injections	O
were	O
compared	O
.	O

Additionally	O
,	O
the	O
pharmacodynamic	O
effect	O
was	O
evaluated	O
.	O

Two	O
milligrams	O
of	O
ganirelix	CHEMICAL
was	O
administered	O
s	O
.	O

c	O
.	O

once	O
daily	O
for	O
7	O
days	O
by	O
Medi-Jector	O
or	O
conventional	O
needle	O
in	O
a	O
randomized	O
sequence	O
,	O
without	O
a	O
washout	O
period	O
.	O

No	O
apparent	O
differences	O
in	O
local	O
tolerance	O
were	O
observed	O
.	O

Most	O
injections	O
(	O
87	O
.	O
5%	O
)	O
gave	O
either	O
no	O
or	O
only	O
a	O
mild	O
reaction	O
.	O

Of	O
the	O
moderate	O
reactions	O
,	O
swelling	O
and	O
redness	O
were	O
reported	O
most	O
frequently	O
(	O
overall	O
4	O
.	O
9	O
and	O
8	O
.	O
5%	O
per	O
injection	O
,	O
respectively	O
)	O
.	O

Administration	O
by	O
Medi-Jector	O
was	O
bioequivalent	O
to	O
conventional	O
needle	O
injection	O
with	O
respect	O
to	O
the	O
peak	O
concentration	O
and	O
area	O
under	O
the	O
curve	O
.	O

A	O
profound	O
suppression	O
of	O
luteinizing	GENE-N
hormone	GENE-N
and	O
follicle	GENE-N
stimulating	GENE-N
hormone	GENE-N
was	O
observed	O
.	O

Serum	O
oestradiol	CHEMICAL
and	O
progesterone	CHEMICAL
concentrations	O
were	O
relatively	O
low	O
prior	O
to	O
treatment	O
and	O
remained	O
low	O
during	O
the	O
entire	O
study	O
period	O
.	O

In	O
conclusion	O
,	O
administration	O
of	O
a	O
relatively	O
high	O
dose	O
of	O
ganirelix	CHEMICAL
by	O
Medi-Jector	O
might	O
be	O
useful	O
for	O
long-term	O
treatment	O
of	O
sex-steroid	CHEMICAL
dependent	O
disorders	O
.	O
In	O
order	O
for	O
a	O
protein	O
to	O
elicit	O
a	O
systemic	O
allergic	O
response	O
it	O
must	O
reach	O
the	O
circulatory	O
system	O
through	O
the	O
intestinal	O
mucosa	O
as	O
a	O
sufficiently	O
large	O
fragment	O
with	O
adequate	O
structural	O
integrity	O
.	O

Sunflower	GENE-Y
LTP	GENE-Y
and	O
2S	GENE-Y
albumins	GENE-Y
(	O
SFA8	GENE-Y
and	O
three	O
mixed	O
fractions	O
of	O
Alb1	GENE-N
and	O
Alb2	GENE-N
)	O
were	O
digested	O
in	O
simulated	O
gastric	O
fluid	O
(	O
SGF	O
)	O
for	O
2h	O
and	O
the	O
conditions	O
were	O
then	O
changed	O
to	O
mimic	O
the	O
intestinal	O
environment	O
for	O
a	O
further	O
2h	O
digestion	O
.	O

The	O
effects	O
of	O
phosphatidylcholine	CHEMICAL
(	O
PC	O
)	O
and	O
emulsification	O
on	O
the	O
digestibility	O
of	O
the	O
proteins	O
were	O
investigated	O
.	O

PC	O
protected	O
all	O
of	O
the	O
proteins	O
studied	O
against	O
both	O
gastric	O
and	O
intestinal	O
digestive	O
enzymes	O
but	O
to	O
different	O
extents	O
.	O

Emulsification	O
of	O
SFA8	GENE-Y
resulted	O
in	O
strong	O
protection	O
against	O
digestion	O
,	O
which	O
was	O
further	O
enhanced	O
by	O
the	O
presence	O
of	O
PC	O
in	O
the	O
SGF	O
.	O

These	O
results	O
highlight	O
the	O
importance	O
of	O
considering	O
real	O
food	O
structures	O
such	O
as	O
emulsified	O
systems	O
and	O
also	O
the	O
gastrointestinal	O
environment	O
that	O
proteins	O
are	O
exposed	O
to	O
once	O
consumed	O
when	O
assessing	O
allergenicity	O
.	O
Fluorescent	O
sensing	O
layer	O
for	O
the	O
determination	O
of	O
L-malic	CHEMICAL
acid	CHEMICAL
in	O
wine	O
.	O
Over	O
expression	O
of	O
lipoxygenase	GENE-N
(	O
LOX	GENE-N
)	O
and	O
urease	GENE-N
has	O
already	O
contributed	O
to	O
the	O
pathology	O
of	O
different	O
human	O
disease	O
.	O

Targeting	O
the	O
inhibition	O
of	O
these	O
enzymes	O
has	O
proved	O
great	O
clinical	O
utility	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
scrutinised	O
the	O
inhibitory	O
profile	O
of	O
the	O
aerial	O
parts	O
of	O
the	O
Polygonatum	O
verticillatum	O
enzyme	O
against	O
LOX	GENE-N
,	O
urease	GENE-N
,	O
acetylcholinesterase	GENE-Y
(	O
AChE	GENE-Y
)	O
and	O
butyrylcholinesterase	GENE-Y
(	O
BChE	GENE-Y
)	O
using	O
standard	O
experimental	O
protocols	O
.	O

When	O
checked	O
against	O
lipoxygenase	GENE-N
,	O
the	O
extracts	O
revealed	O
significant	O
attenuation	O
.	O

Of	O
the	O
tested	O
extracts	O
,	O
the	O
ethyl	CHEMICAL
acetate	CHEMICAL
fraction	O
was	O
the	O
most	O
potent	O
(	O
half-maximal	O
inhibitory	O
concentration	O
(	O
IC50	O
)	O
:	O
97	O
µg	O
/	O
mL	O
)	O
followed	O
by	O
aqueous	O
fraction	O
IC50	O
:	O
109	O
µg	O
/	O
mL	O
)	O
.	O

Regarding	O
urease	GENE-N
inhibition	O
,	O
n-butanol	CHEMICAL
was	O
the	O
most	O
potent	O
fraction	O
(	O
IC50	O
:	O
97	O
µg	O
/	O
mL	O
)	O
.	O

However	O
,	O
the	O
extracts	O
did	O
not	O
show	O
significant	O
inhibition	O
on	O
AChE	GENE-Y
and	O
BChE	GENE-Y
.	O

In	O
the	O
preliminary	O
phytochemical	O
tests	O
,	O
the	O
aerial	O
parts	O
of	O
the	O
plant	O
showed	O
the	O
presence	O
of	O
saponins	CHEMICAL
,	O
alkaloids	O
,	O
flavonoids	CHEMICAL
,	O
phenols	CHEMICAL
,	O
tannins	CHEMICAL
and	O
terpenoids	CHEMICAL
.	O

The	O
current	O
findings	O
could	O
be	O
attributed	O
to	O
these	O
groups	O
of	O
compounds	O
.	O
Serotonin	GENE-Y
1A	O
receptor	O
(	O
5-HT	GENE-Y
(	GENE-Y
1A	GENE-Y
)	GENE-Y
R	GENE-Y
)	O
agonists	O
have	O
emerged	O
as	O
valuable	O
supplements	O
to	O
l-DOPA	CHEMICAL
therapy	O
,	O
demonstrating	O
that	O
they	O
can	O
decrease	O
side	O
effects	O
and	O
enhance	O
motor	O
function	O
in	O
animal	O
models	O
of	O
Parkinson's	O
disease	O
(	O
PD	O
)	O
and	O
human	O
PD	O
patients	O
.	O

The	O
precise	O
mechanism	O
by	O
which	O
these	O
receptors	O
act	O
remains	O
unknown	O
and	O
there	O
is	O
limited	O
information	O
on	O
how	O
5-HT	GENE-Y
(	GENE-Y
1A	GENE-Y
)	GENE-Y
R	GENE-Y
stimulation	O
impacts	O
striatal	O
dopamine	CHEMICAL
(	O
DA	CHEMICAL
)	O
D1	O
receptor	O
(	O
D1R	GENE-Y
)	O
and	O
D2	GENE-Y
receptor	GENE-Y
(	O
D2R	GENE-Y
)	O
function	O
.	O

The	O
current	O
study	O
examined	O
the	O
effects	O
of	O
5-HT	GENE-Y
(	GENE-Y
1A	GENE-Y
)	GENE-Y
R	GENE-Y
stimulation	O
on	O
DA	GENE-N
receptor-mediated	O
behaviors	O
.	O

Male	O
Sprague-Dawley	O
rats	O
were	O
rendered	O
hemiparkinsonian	O
by	O
unilateral	O
6-OHDA	CHEMICAL
lesions	O
and	O
primed	O
with	O
the	O
D1R	GENE-Y
agonist	O
SKF81297	CHEMICAL
(	O
0	O
.	O
8	O
mg	O
/	O
kg	O
,	O
i	O
.	O

p	O
.	O

)	O
in	O
order	O
to	O
sensitize	O
DA	GENE-N
receptors	O
.	O

Using	O
a	O
randomized	O
within	O
subjects	O
design	O
,	O
rats	O
received	O
a	O
first	O
injection	O
of	O
:	O
Vehicle	O
(	O
dH	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
O	CHEMICAL
)	O
or	O
the	O
5-HT	GENE-Y
(	GENE-Y
1A	GENE-Y
)	GENE-Y
R	GENE-Y
agonist	O
+	CHEMICAL
/	CHEMICAL
-8-OH-DPAT	CHEMICAL
(	O
0	O
.	O
1	O
or	O
1	O
.	O
0	O
mg	O
/	O
kg	O
,	O
i	O
.	O

p	O
.	O

)	O
,	O
followed	O
by	O
a	O
second	O
injection	O
of	O
:	O
Vehicle	O
(	O
dimethyl	CHEMICAL
sulfoxide	CHEMICAL
)	O
,	O
the	O
D1R	GENE-Y
agonist	O
SKF81297	CHEMICAL
(	O
0	O
.	O
8	O
mg	O
/	O
kg	O
,	O
i	O
.	O

p	O
.	O

)	O
,	O
the	O
D2R	GENE-Y
agonist	O
quinpirole	CHEMICAL
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
,	O
i	O
.	O

p	O
.	O

)	O
,	O
or	O
l-DOPA	CHEMICAL
(	O
12	O
mg	O
/	O
kg	O
+	O
benserazide	CHEMICAL
,	O
15	O
mg	O
/	O
kg	O
,	O
i	O
.	O

p	O
.	O

)	O
.	O

On	O
test	O
days	O
,	O
rats	O
were	O
monitored	O
over	O
a	O
2-h	O
period	O
immediately	O
following	O
the	O
second	O
injection	O
for	O
abnormal	O
involuntary	O
movements	O
(	O
AIMs	O
)	O
,	O
analogous	O
to	O
dyskinesia	O
observed	O
in	O
PD	O
patients	O
,	O
and	O
contralateral	O
rotations	O
.	O

The	O
present	O
findings	O
indicate	O
that	O
5-HT	GENE-Y
(	GENE-Y
1A	GENE-Y
)	GENE-Y
R	GENE-Y
stimulation	O
reduces	O
AIMs	O
induced	O
by	O
D1R	GENE-Y
,	O
D2R	GENE-Y
and	O
l-DOPA	CHEMICAL
administration	O
while	O
its	O
effects	O
on	O
DA	CHEMICAL
agonist-induced	O
rotations	O
were	O
receptor-dependent	O
,	O
suggesting	O
that	O
direct	O
5-HT	GENE-Y
(	GENE-Y
1A	GENE-Y
)	GENE-Y
R	GENE-Y
and	O
DA	CHEMICAL
receptor	O
interactions	O
may	O
contribute	O
to	O
the	O
unique	O
profile	O
of	O
5-HT	GENE-Y
(	GENE-Y
1A	GENE-Y
)	GENE-Y
R	GENE-Y
agonists	O
for	O
the	O
improvement	O
of	O
PD	O
treatment	O
.	O
Ebastine	CHEMICAL
is	O
a	O
long-acting	O
nonsedating	O
second	O
generation	O
histamine	GENE-Y
H1	GENE-Y
receptor	GENE-Y
antagonist	O
which	O
binds	O
preferentially	O
to	O
peripheral	O
H1	GENE-Y
receptors	GENE-Y
in	O
vivo	O
.	O

It	O
has	O
shown	O
antihistamine	O
and	O
antiallergic	O
activity	O
in	O
healthy	O
volunteers	O
and	O
patients	O
with	O
allergies	O
,	O
and	O
protected	O
against	O
histamine-induced	O
bronchoconstriction	O
in	O
patients	O
with	O
asthma	O
.	O

Significant	O
symptom	O
improvement	O
is	O
observed	O
in	O
patients	O
with	O
seasonal	O
or	O
perennial	O
allergic	O
rhinitis	O
or	O
chronic	O
idiopathic	O
urticaria	O
following	O
administration	O
of	O
ebastine	CHEMICAL
10	O
mg	O
/	O
day	O
,	O
or	O
20	O
mg	O
/	O
day	O
in	O
severe	O
rhinitis	O
.	O

In	O
clinical	O
trials	O
,	O
the	O
efficacy	O
of	O
ebastine	CHEMICAL
10	O
or	O
20	O
mg	O
/	O
day	O
was	O
generally	O
similar	O
to	O
standard	O
dosages	O
of	O
terfenadine	CHEMICAL
,	O
cetirizine	CHEMICAL
,	O
astemizole	CHEMICAL
and	O
loratadine	CHEMICAL
in	O
patients	O
with	O
seasonal	O
allergic	O
rhinitis	O
,	O
astemizole	CHEMICAL
,	O
terfenadine	CHEMICAL
and	O
ketotifen	CHEMICAL
in	O
patients	O
with	O
chronic	O
idiopathic	O
urticaria	O
,	O
and	O
ketotifen	CHEMICAL
,	O
terfenadine	CHEMICAL
,	O
chlorpheniramine	CHEMICAL
and	O
mequitazine	CHEMICAL
in	O
patients	O
with	O
perennial	O
allergic	O
rhinitis	O
.	O

The	O
most	O
frequent	O
adverse	O
events	O
reported	O
during	O
ebastine	CHEMICAL
therapy	O
are	O
drowsiness	O
,	O
headache	O
and	O
dry	O
mouth	O
,	O
the	O
incidence	O
being	O
similar	O
to	O
that	O
reported	O
in	O
placebo	O
recipients	O
.	O

Serious	O
adverse	O
cardiac	O
events	O
,	O
observed	O
on	O
rare	O
occasions	O
with	O
some	O
other	O
histamine	CHEMICAL
H1	O
receptor	O
antagonists	O
,	O
have	O
not	O
been	O
reported	O
with	O
ebastine	CHEMICAL
,	O
and	O
there	O
has	O
been	O
no	O
evidence	O
of	O
QTc	O
interval	O
prolongation	O
related	O
to	O
ebastine	CHEMICAL
therapy	O
.	O

Thus	O
,	O
once-daily	O
ebastine	O
offers	O
an	O
effective	O
and	O
well-tolerated	O
alternative	O
to	O
other	O
second	O
generation	O
antihistamines	O
in	O
current	O
use	O
for	O
the	O
first-line	O
treatment	O
of	O
seasonal	O
and	O
perennial	O
allergic	O
rhinitis	O
and	O
chronic	O
idiopathic	O
urticaria	O
.	O
Nonalcoholic	O
fatty	O
liver	O
disease	O
:	O
current	O
issues	O
and	O
novel	O
treatment	O
approaches	O
.	O
2-Amino-3-	CHEMICAL
[	CHEMICAL
3-hydroxy-5-	CHEMICAL
(	CHEMICAL
2-thiazolyl	CHEMICAL
)	CHEMICAL
-4-isoxazolyl	CHEMICAL
]	CHEMICAL
propionic	CHEMICAL
acid	CHEMICAL
(	O
1	O
)	O
is	O
a	O
potent	O
AMPA	GENE-N
receptor	O
agonist	O
with	O
moderate	O
affinity	O
for	O
native	O
kainic	GENE-N
acid	GENE-N
(	O
KA	CHEMICAL
)	O
receptors	O
,	O
whereas	O
(	CHEMICAL
S	CHEMICAL
)	CHEMICAL
-E-4-	CHEMICAL
(	CHEMICAL
2	CHEMICAL
,	CHEMICAL
2-dimethylpropylidene	CHEMICAL
)	CHEMICAL
glutamic	CHEMICAL
acid	CHEMICAL
(	O
3	O
)	O
show	O
high	O
affinity	O
for	O
the	O
GluR5	GENE-Y
subtype	O
of	O
KA	GENE-N
receptors	O
and	O
much	O
lower	O
affinity	O
for	O
the	O
GluR2	GENE-Y
subtype	O
of	O
AMPA	GENE-N
receptors	O
.	O

As	O
an	O
attempt	O
to	O
develop	O
new	O
pharmacological	O
tools	O
for	O
studies	O
of	O
GluR5	GENE-Y
receptors	O
,	O
(	CHEMICAL
S	CHEMICAL
)	CHEMICAL
-E-4-	CHEMICAL
(	CHEMICAL
2-thiazolylmethylene	CHEMICAL
)	CHEMICAL
glutamic	CHEMICAL
acid	CHEMICAL
(	O
4a	O
)	O
was	O
designed	O
as	O
a	O
structural	O
hybrid	O
between	O
1	O
and	O
3	O
.	O

4a	O
was	O
shown	O
to	O
be	O
a	O
potent	O
GluR5	GENE-Y
agonist	O
and	O
a	O
high	O
affinity	O
ligand	O
and	O
to	O
indiscriminately	O
bind	O
to	O
the	O
AMPA	GENE-N
receptor	O
subtypes	O
GluR1-4	GENE-N
with	O
lower	O
affinities	O
.	O

Compounds	O
4b-h	O
,	O
in	O
which	O
the	O
2-thiazolyl	CHEMICAL
substituent	O
of	O
4a	O
was	O
replaced	O
by	O
other	O
heterocyclic	CHEMICAL
rings	O
,	O
which	O
have	O
previously	O
been	O
incorporated	O
as	O
5-substituents	O
in	O
AMPA	CHEMICAL
analogues	O
,	O
as	O
exemplified	O
by	O
1	O
were	O
also	O
synthesized	O
.	O

Compounds	O
4b-h	O
were	O
either	O
inactive	O
(	O
4e	O
,	O
f	O
)	O
or	O
weaker	O
than	O
4a	O
as	O
affinity	O
ligands	O
for	O
GluR1-4	GENE-N
and	O
GluR5	GENE-Y
with	O
relative	O
potencies	O
comparable	O
with	O
those	O
of	O
the	O
corresponding	O
AMPA	CHEMICAL
analogues	O
as	O
AMPA	GENE-N
receptor	O
agonists	O
.	O

Compounds	O
4a-h	O
may	O
be	O
useful	O
tools	O
for	O
the	O
progressing	O
pharmacophore	O
mapping	O
of	O
the	O
GluR5	GENE-Y
agonist	O
binding	O
site	O
.	O
Treatment-related	O
osteoporosis	O
in	O
men	O
with	O
prostate	O
cancer	O
.	O
A	O
novel	O
series	O
of	O
substituted	O
(	CHEMICAL
E	CHEMICAL
)	CHEMICAL
-3-	CHEMICAL
(	CHEMICAL
Benzo	CHEMICAL
[	CHEMICAL
d	CHEMICAL
]	CHEMICAL
thiazol-2-ylamino	CHEMICAL
)	CHEMICAL
phenylprop-2-en-1-onewere	O
synthesized	O
starting	O
from	O
2-aminobenzothiazole	CHEMICAL
and	O
1-aryl-3	CHEMICAL
,	CHEMICAL
3-bis-	CHEMICAL
(	CHEMICAL
methylsulfanyl	CHEMICAL
)	CHEMICAL
-2-propen-1-onesin	O
the	O
presence	O
of	O
a	O
catalytic	O
amount	O
of	O
sodium	CHEMICAL
hydride	CHEMICAL
in	O
THF	CHEMICAL
.	O

The	O
synthesised	O
compounds'	O
structures	O
were	O
confirmed	O
by	O
IR	O
,	O
Mass	O
spectrometry	O
,	O
(	CHEMICAL
1	CHEMICAL
)	CHEMICAL
H	CHEMICAL
NMR	O
,	O
(	CHEMICAL
13	CHEMICAL
)	CHEMICAL
C	CHEMICAL
NMR	O
and	O
HRMS	O
spectral	O
data	O
.	O

These	O
compounds	O
were	O
evaluated	O
for	O
their	O
antidiabetic	O
activity	O
,	O
and	O
most	O
of	O
the	O
derivatives	O
of	O
(	CHEMICAL
E	CHEMICAL
)	CHEMICAL
-3-	CHEMICAL
(	CHEMICAL
Benzo	CHEMICAL
[	CHEMICAL
d	CHEMICAL
]	CHEMICAL
thiazol-2-ylamino	CHEMICAL
)	CHEMICAL
phenylprop-2-en-1-one	CHEMICAL
displayed	O
significant	O
antidiabetic	O
activity	O
.	O
Effects	O
of	O
DMSA-coated	O
Fe3O4	CHEMICAL
nanoparticles	O
on	O
the	O
transcription	O
of	O
genes	O
related	O
to	O
iron	CHEMICAL
and	O
osmosis	O
homeostasis	O
.	O
Toxic	O
,	O
halogenated	O
cysteine	CHEMICAL
S-conjugates	CHEMICAL
and	O
targeting	O
of	O
mitochondrial	O
enzymes	O
of	O
energy	O
metabolism	O
.	O
The	O
purpose	O
of	O
this	O
transverse	O
prospective	O
study	O
was	O
to	O
determine	O
blood	O
nutritional	O
,	O
immunity	O
and	O
inflammatory	O
proteins	O
change	O
in	O
vitamin	CHEMICAL
A	CHEMICAL
deficiency	O
in	O
children	O
of	O
school-age	O
(	O
262	O
children	O
,	O
aged	O
7	O
to	O
15	O
years	O
)	O
.	O

Blood	O
vitamin	CHEMICAL
A	CHEMICAL
has	O
been	O
determined	O
by	O
HPLC	O
with	O
UV	O
detection	O
.	O

Proteins	O
have	O
been	O
measured	O
by	O
radial	O
immunodiffusion	O
according	O
to	O
Mancini	O
.	O

Results	O
showed	O
that	O
96	O
children	O
(	O
36	O
.	O
6%	O
)	O
presented	O
a	O
vitamin	CHEMICAL
A	CHEMICAL
deficiency	O
(	O
vitamin	CHEMICAL
A	CHEMICAL
<	O
200	O
microg	O
/	O
L	O
with	O
a	O
retinol	GENE-N
binding	GENE-N
protein	GENE-N
/	O
transthyretin	GENE-Y
molar	O
ratio	O
=	O
0	O
.	O
29	O
+	O
/	O
-	O
0	O
.	O
06	O
)	O
while	O
166	O
(	O
63	O
.	O
3%	O
)	O
children	O
presented	O
normal	O
blood	O
concentrations	O
of	O
vitamin	CHEMICAL
A	CHEMICAL
(	O
vitamin	CHEMICAL
A	CHEMICAL
>	O
or	O
=	O
200	O
microg	O
/	O
L	O
with	O
a	O
Retinol	GENE-N
Binding	O
Protein	O
/	O
Transthyretin	GENE-Y
molar	O
ratio	O
=	O
0	O
.	O
40	O
+	O
/	O
-	O
0	O
.	O
08	O
)	O
.	O

This	O
study	O
showed	O
that	O
the	O
retinol	GENE-N
binding	O
protein	O
and	O
the	O
immunoglobulin	GENE-N
A	GENE-N
are	O
lower	O
in	O
children	O
with	O
vitamin	CHEMICAL
A	CHEMICAL
deficiency	O
.	O

On	O
the	O
other	O
hand	O
,	O
an	O
isolated	O
increase	O
of	O
alpha-1	GENE-Y
glycoprotein	GENE-Y
acid	GENE-Y
has	O
been	O
observed	O
in	O
boys	O
with	O
vitamin	CHEMICAL
A	CHEMICAL
deficiency	O
.	O

The	O
vitamin	CHEMICAL
A	CHEMICAL
deficiency	O
observed	O
in	O
this	O
survey	O
is	O
due	O
to	O
a	O
micronutrients	O
deficiency	O
in	O
the	O
diet	O
which	O
is	O
essentially	O
based	O
on	O
glucides	O
.	O

The	O
positive	O
correlation	O
between	O
vitamin	CHEMICAL
A	CHEMICAL
and	O
immunoglobulin	GENE-N
A	GENE-N
concentrations	O
might	O
be	O
the	O
result	O
of	O
the	O
vitamin	CHEMICAL
A	CHEMICAL
inductive	O
effect	O
during	O
immunoglobulins	GENE-N
A	GENE-N
synthesis	O
.	O

The	O
isolated	O
increasing	O
of	O
alpha-1	GENE-Y
glycoprotein	GENE-Y
acid	GENE-Y
in	O
boys	O
with	O
vitamin	CHEMICAL
A	CHEMICAL
deficiency	O
has	O
been	O
assigned	O
to	O
the	O
ecosensitiveness	O
of	O
the	O
unfavourable	O
environment	O
.	O

We	O
therefore	O
concluded	O
that	O
,	O
in	O
Ivorian	O
primary-school-aged	O
children	O
with	O
vitamin	CHEMICAL
A	CHEMICAL
deficiency	O
,	O
nutritional	O
,	O
immunity	O
and	O
inflammatory	O
proteins	O
which	O
are	O
modified	O
are	O
respectively	O
retinol	GENE-N
binding	O
protein	O
,	O
immunoglobulin	GENE-N
A	GENE-N
and	O
alpha-1	GENE-Y
glycoprotein	GENE-Y
acid	GENE-Y
.	O
Phenylalanine	CHEMICAL
hydroxylase	O
,	O
tyrosine	CHEMICAL
hydroxylase	O
,	O
and	O
tryptophan	GENE-Y
hydroxylase	O
constitute	O
a	O
small	O
family	O
of	O
monooxygenases	GENE-N
that	O
utilize	O
tetrahydropterins	CHEMICAL
as	O
substrates	O
.	O

When	O
from	O
eukaryotic	O
sources	O
,	O
these	O
enzymes	O
are	O
composed	O
of	O
a	O
homologous	O
catalytic	O
domain	O
to	O
which	O
are	O
attached	O
discrete	O
N-terminal	O
regulatory	O
domains	O
and	O
short	O
C-terminal	O
tetramerization	O
domains	O
,	O
whereas	O
the	O
bacterial	O
enzymes	O
lack	O
the	O
N-terminal	O
and	O
C-terminal	O
domains	O
.	O

Each	O
enzyme	O
contains	O
a	O
single	O
ferrous	CHEMICAL
iron	CHEMICAL
atom	O
bound	O
to	O
two	O
histidines	CHEMICAL
and	O
a	O
glutamate	CHEMICAL
.	O

Recent	O
mechanistic	O
studies	O
have	O
begun	O
to	O
provide	O
insights	O
into	O
the	O
mechanisms	O
of	O
oxygen	CHEMICAL
activation	O
and	O
hydroxylation	O
.	O

Although	O
the	O
hydroxylating	O
intermediate	O
in	O
these	O
enzymes	O
has	O
not	O
been	O
identified	O
,	O
the	O
iron	O
is	O
likely	O
to	O
be	O
involved	O
.	O

Reversible	O
phosphorylation	O
of	O
serine	CHEMICAL
residues	O
in	O
the	O
regulatory	O
domains	O
affects	O
the	O
activities	O
of	O
all	O
three	O
enzymes	O
.	O

In	O
addition	O
,	O
phenylalanine	GENE-Y
hydroxylase	O
is	O
allosterically	O
regulated	O
by	O
its	O
substrates	O
,	O
phenylalanine	CHEMICAL
and	O
tetrahydrobiopterin	CHEMICAL
.	O
Syzygium	O
aqueum	O
leaf	O
extract	O
and	O
its	O
bioactive	O
compounds	O
enhances	O
pre-adipocyte	O
differentiation	O
and	O
2-NBDG	CHEMICAL
uptake	O
in	O
3T3-L1	O
cells	O
.	O
OBJECTIVE	O
:	O
Ziprasidone	CHEMICAL
is	O
an	O
atypical	O
antipsychotic	O
drug	O
that	O
shows	O
a	O
higher	O
affinity	O
for	O
serotonin	CHEMICAL
5-HT	GENE-Y
(	O
2	O
)	O
receptors	O
compared	O
with	O
dopamine	GENE-Y
D	O
(	O
2	O
)	O
receptors	O
in	O
vitro	O
.	O

The	O
affinity	O
of	O
ziprasidone	CHEMICAL
for	O
these	O
receptors	O
in	O
vivo	O
in	O
patients	O
was	O
examined	O
in	O
a	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
study	O
.	O

METHOD	O
:	O
The	O
authors	O
conducted	O
a	O
PET	O
study	O
to	O
evaluate	O
D	GENE-Y
(	GENE-Y
2	GENE-Y
)	GENE-Y
occupancy	O
(	O
using	O
[	CHEMICAL
(	CHEMICAL
11	CHEMICAL
)	CHEMICAL
C	CHEMICAL
]	CHEMICAL
raclopride	CHEMICAL
)	O
and	O
5-HT	GENE-Y
(	O
2	O
)	O
occupancy	O
(	O
using	O
[	CHEMICAL
(	CHEMICAL
18	CHEMICAL
)	CHEMICAL
F	CHEMICAL
]	CHEMICAL
setoperone	CHEMICAL
)	O
in	O
brain	O
regions	O
of	O
interest	O
in	O
16	O
patients	O
with	O
schizophrenia	O
or	O
schizoaffective	O
disorder	O
randomly	O
assigned	O
to	O
receive	O
40	O
,	O
80	O
,	O
120	O
,	O
or	O
160	O
mg	O
/	O
day	O
of	O
ziprasidone	CHEMICAL
,	O
which	O
reflected	O
the	O
recommended	O
dose	O
range	O
.	O

PET	O
scanning	O
was	O
done	O
after	O
3	O
weeks	O
of	O
administration	O
and	O
at	O
trough	O
plasma	O
levels	O
,	O
i	O
.	O

e	O
.	O

,	O
12-16	O
hours	O
after	O
the	O
last	O
dose	O
.	O

RESULTS	O
:	O
The	O
mean	O
5-HT	GENE-Y
(	O
2	O
)	O
receptor	O
occupancy	O
was	O
significantly	O
higher	O
than	O
the	O
mean	O
D	GENE-Y
(	GENE-Y
2	GENE-Y
)	GENE-Y
receptor	GENE-Y
occupancy	O
(	O
mean	O
=	O
76%	O
,	O
SD	O
=	O
15%	O
,	O
and	O
mean	O
=	O
56%	O
,	O
SD	O
=	O
18%	O
,	O
respectively	O
)	O
.	O

The	O
estimated	O
plasma	O
ziprasidone	CHEMICAL
concentration	O
associated	O
with	O
50%	O
maximal	O
5-HT	GENE-Y
(	GENE-Y
2	GENE-Y
)	GENE-Y
receptor	O
occupancy	O
was	O
almost	O
four	O
times	O
lower	O
than	O
that	O
for	O
D	GENE-Y
(	GENE-Y
2	GENE-Y
)	GENE-Y
receptor	GENE-Y
occupancy	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
affirm	O
that	O
ziprasidone	CHEMICAL
is	O
similar	O
to	O
other	O
novel	O
antipsychotics	O
in	O
having	O
greater	O
5-HT	GENE-Y
(	GENE-Y
2	GENE-Y
)	GENE-Y
than	O
D	GENE-N
(	GENE-N
2	GENE-N
)	GENE-N
receptor	GENE-N
occupancy	O
at	O
therapeutic	O
doses	O
and	O
suggest	O
that	O
the	O
optimal	O
effective	O
dose	O
of	O
ziprasidone	CHEMICAL
is	O
closer	O
to	O
120	O
mg	O
/	O
day	O
than	O
to	O
the	O
lower	O
doses	O
suggested	O
by	O
previous	O
PET	O
studies	O
.	O

The	O
relatively	O
high	O
D	GENE-Y
(	GENE-Y
2	GENE-Y
)	GENE-Y
receptor	GENE-Y
occupancy	O
,	O
even	O
at	O
trough	O
plasma	O
levels	O
,	O
suggests	O
that	O
ziprasidone	CHEMICAL
is	O
more	O
similar	O
to	O
risperidone	CHEMICAL
and	O
olanzapine	O
in	O
receptor	O
occupancy	O
profile	O
than	O
to	O
clozapine	CHEMICAL
and	O
quetiapine	CHEMICAL
.	O

Since	O
ziprasidone	CHEMICAL
plasma	O
levels	O
show	O
significant	O
(	O
more	O
than	O
twofold	O
)	O
variation	O
within	O
a	O
single	O
dose	O
cycle	O
,	O
studies	O
that	O
are	O
aimed	O
at	O
peak	O
plasma	O
levels	O
(	O
6	O
hours	O
after	O
the	O
last	O
dose	O
)	O
and	O
that	O
examine	O
extrastriatal	O
regions	O
are	O
required	O
to	O
fully	O
characterize	O
the	O
in	O
vivo	O
occupancy	O
profile	O
of	O
ziprasidone	CHEMICAL
.	O
Inspired	O
by	O
the	O
water-enhanced	O
mechanical	O
gradient	O
character	O
of	O
the	O
squid	O
beak	O
,	O
we	O
herein	O
report	O
a	O
nanocomposite	O
that	O
mimics	O
both	O
the	O
architecture	O
and	O
properties	O
of	O
this	O
interesting	O
natural	O
material	O
.	O

Similar	O
to	O
the	O
squid	O
beak	O
,	O
we	O
have	O
developed	O
nanocomposites	O
where	O
the	O
degree	O
of	O
cross-linking	O
is	O
controlled	O
along	O
the	O
length	O
of	O
the	O
film	O
.	O

In	O
this	O
study	O
,	O
we	O
utilized	O
tunicate	O
cellulose	O
nanocrystals	O
as	O
the	O
nanofiller	O
that	O
are	O
functionalized	O
with	O
allyl	CHEMICAL
moieties	O
.	O

Using	O
photoinduced	O
thiol-ene	O
chemistry	O
,	O
we	O
have	O
been	O
able	O
to	O
cross-link	O
the	O
CNC	O
nanofiller	O
.	O

In	O
the	O
dry	O
state	O
where	O
strong	O
CNC	O
interactions	O
can	O
occur	O
,	O
only	O
a	O
small	O
mechanical	O
contrast	O
is	O
observed	O
between	O
the	O
cross-linked	O
and	O
uncross-linked	O
samples	O
.	O

However	O
,	O
when	O
the	O
films	O
are	O
exposed	O
to	O
water	O
,	O
which	O
"switches	O
off"	O
the	O
noncovalent	O
CNC	O
interactions	O
,	O
a	O
significant	O
mechanical	O
contrast	O
is	O
observed	O
between	O
the	O
same	O
films	O
.	O

For	O
example	O
,	O
at	O
20	O
wt	O
%	O
CNC	O
(	O
in	O
the	O
dry	O
film	O
)	O
,	O
an	O
increase	O
in	O
wet	O
modulus	O
from	O
60	O
to	O
300	O
MPa	O
(	O
∼500%	O
increase	O
)	O
is	O
observed	O
after	O
photoirradiation	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
the	O
wet	O
modulus	O
can	O
be	O
controlled	O
by	O
altering	O
the	O
UV	O
exposure	O
time	O
which	O
allows	O
access	O
to	O
mechanical	O
gradient	O
films	O
.	O
Recent	O
work	O
has	O
revealed	O
cAMP-dependent	O
phosphorylation	O
of	O
the	O
18-kDa	O
IP	O
subunit	O
of	O
the	O
mammalian	GENE-N
complex	GENE-N
I	GENE-N
of	O
the	O
respiratory	O
chain	O
,	O
encoded	O
by	O
the	O
nuclear	O
NDUFS4	GENE-Y
gene	O
(	O
chromosome	O
5	O
)	O
.	O

Phosphorylation	O
of	O
this	O
protein	O
has	O
been	O
shown	O
to	O
take	O
place	O
in	O
fibroblast	O
cultures	O
in	O
vivo	O
,	O
as	O
well	O
as	O
in	O
isolated	O
mitochondria	O
,	O
which	O
in	O
addition	O
to	O
the	O
cytosol	O
also	O
contain	O
,	O
in	O
the	O
inner-membrane	O
matrix	O
fraction	O
,	O
a	O
cAMP-dependent	O
protein	O
kinase	O
.	O

Mitochondria	O
appear	O
to	O
have	O
a	O
Ca2	CHEMICAL
+	CHEMICAL
-inhibited	O
phosphatase	GENE-N
,	O
which	O
dephosphorylates	O
the	O
18-kDa	O
phosphoprotein	O
.	O

In	O
fibroblast	O
and	O
myoblast	O
cultures	O
cAMP-dependent	O
phosphorylation	O
of	O
the	O
18-kDa	O
protein	O
is	O
associated	O
with	O
potent	O
stimulation	O
of	O
complex	GENE-N
I	GENE-N
and	O
overall	O
respiratory	O
activity	O
with	O
NAD-linked	O
substrates	O
.	O

Mutations	O
in	O
the	O
human	GENE-Y
NDUFS4	GENE-Y
gene	O
have	O
been	O
found	O
,	O
which	O
in	O
the	O
homozygous	O
state	O
are	O
associated	O
with	O
deficiency	O
of	O
complex	GENE-N
I	GENE-N
and	O
fatal	O
neurological	O
syndrome	O
.	O

In	O
one	O
case	O
consisting	O
of	O
a	O
5	O
bp	O
duplication	O
,	O
which	O
destroyed	O
the	O
phosphorylation	O
site	O
,	O
cAMP-dependent	O
activation	O
of	O
complex	GENE-N
I	GENE-N
was	O
abolished	O
in	O
the	O
patient's	O
fibroblast	O
cultures	O
.	O

In	O
another	O
case	O
consisting	O
of	O
a	O
nonsense	O
mutation	O
,	O
leading	O
to	O
termination	O
of	O
the	O
protein	O
after	O
only	O
14	O
residues	O
of	O
the	O
putative	O
mitochondria	O
targeting	O
peptide	O
,	O
a	O
defect	O
in	O
the	O
assembly	O
of	O
complex	GENE-N
I	GENE-N
was	O
found	O
in	O
fibroblast	O
cultures	O
.	O
The	O
TGF-β	GENE-N
signaling	O
pathway	O
is	O
involved	O
with	O
multiple	O
processes	O
in	O
the	O
mammalian	O
ovary	O
,	O
including	O
primordial	O
follicle	O
formation	O
,	O
granulosa	O
cell	O
(	O
GC	O
)	O
proliferation	O
,	O
follicle	O
atresia	O
,	O
ovulation	O
,	O
and	O
feedback	O
regulation	O
between	O
the	O
pituitary	O
and	O
ovary	O
.	O

The	O
transcriptional	O
factor	O
SMAD4	GENE-Y
is	O
the	O
central	O
component	O
of	O
the	O
canonical	O
TGF-β	GENE-Y
signaling	O
pathway	O
.	O

Smad4	GENE-Y
knockout	O
using	O
Amhr2-Cre	O
,	O
which	O
is	O
expressed	O
in	O
GCs	O
of	O
immature	O
developing	O
follicles	O
,	O
causes	O
premature	O
luteinization	O
.	O

In	O
this	O
study	O
,	O
we	O
specifically	O
depleted	O
Smad4	GENE-Y
in	O
GCs	O
of	O
preovulatory	O
follicles	O
using	O
Cyp19-Cre	O
mice	O
.	O

As	O
different	O
from	O
results	O
with	O
Smad4	GENE-Y
(	O
fl	O
/	O
fl	O
)	O
;Amhr2-Cre	O
mice	O
,	O
Smad4	GENE-Y
depletion	O
in	O
preovulatory	O
follicles	O
did	O
not	O
cause	O
premature	O
luteinization	O
or	O
suppress	O
GC	O
proliferation;	O
rather	O
,	O
it	O
increased	O
follicle	O
atresia	O
.	O

In	O
addition	O
,	O
Nppc	GENE-Y
and	O
Npr2	GENE-Y
expressions	O
were	O
reduced	O
by	O
Smad4	GENE-Y
depletion;	O
thus	O
,	O
their	O
effect	O
of	O
maintaining	O
oocyte	O
meiotic	O
arrest	O
was	O
weakened	O
in	O
Smad4	GENE-Y
conditional	O
knockout	O
mice	O
.	O

Smad4	GENE-Y
(	O
fl	O
/	O
fl	O
)	O
;Cyp19-Cre	O
female	O
mice	O
were	O
subfertile	O
and	O
had	O
irregular	O
estrous	O
cycles	O
and	O
ovulation	O
defects	O
.	O

Smad4	GENE-Y
knockout	O
also	O
blocked	O
luteinizing	GENE-N
hormone	GENE-N
(	O
LH	GENE-N
)	O
-induced	O
cumulus	O
expansion	O
and	O
follicle	O
rupture	O
,	O
but	O
not	O
oocyte	O
meiotic	O
resumption	O
.	O

Our	O
results	O
also	O
indicated	O
that	O
SMAD4	GENE-Y
was	O
required	O
for	O
LH-stimulated	O
activation	O
of	O
ERK1	GENE-N
/	GENE-N
2	GENE-N
and	O
the	O
expressions	O
of	O
ovulation-related	O
genes	O
.	O

The	O
defects	O
arising	O
from	O
SMAD4	GENE-Y
depletion	O
could	O
not	O
be	O
rescued	O
by	O
intra-ovarian	O
mediators	O
of	O
LH	GENE-N
actions	O
,	O
such	O
as	O
EGF-like	O
factors	O
and	O
prostaglandin	CHEMICAL
E2	CHEMICAL
.	O

Furthermore	O
,	O
corpus	O
lutea	O
did	O
not	O
form	O
in	O
Smad4	GENE-Y
(	O
fl	O
/	O
fl	O
)	O
;Cyp19-Cre	O
female	O
mice	O
,	O
indicating	O
that	O
SMAD4	GENE-Y
was	O
crucial	O
for	O
GCs	O
terminal	O
differentiation	O
.	O

Thus	O
,	O
by	O
characterizing	O
the	O
ovarian	O
phenotypes	O
of	O
preovulatory	O
follicle-specific	O
Smad4	GENE-Y
knockout	O
mice	O
,	O
we	O
identified	O
the	O
developmental	O
stage-specific	O
functions	O
of	O
the	O
canonical	O
TGF-β	GENE-Y
signaling	O
pathway	O
in	O
ovulation	O
and	O
luteinization	O
.	O
Effects	O
of	O
biotin	CHEMICAL
supplementation	O
in	O
the	O
diet	O
on	O
insulin	GENE-N
secretion	O
,	O
islet	GENE-N
gene	O
expression	O
,	O
glucose	CHEMICAL
homeostasis	O
and	O
beta-cell	O
proportion	O
.	O
We	O
have	O
demonstrated	O
that	O
the	O
complementary	O
combination	O
of	O
grazing	O
incidence	O
X-ray	O
fluorescence	O
(	O
GIXF	O
)	O
with	O
specular	O
X-ray	O
reflectivity	O
(	O
XRR	O
)	O
can	O
be	O
used	O
to	O
quantitatively	O
determine	O
the	O
density	O
profiles	O
of	O
Ni	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
ions	O
complexed	O
with	O
chelator	O
headgroups	O
as	O
well	O
as	O
S	CHEMICAL
atoms	O
in	O
recombinant	O
proteins	O
anchored	O
to	O
lipid	O
monolayers	O
at	O
the	O
air	O
/	O
water	O
interface	O
.	O

First	O
,	O
we	O
prepared	O
phospholipid	O
monolayers	O
incorporating	O
chelator	O
lipid	O
anchors	O
at	O
different	O
molar	O
fractions	O
at	O
the	O
air	O
/	O
water	O
interface	O
.	O

The	O
fine-structures	O
perpendicular	O
to	O
the	O
global	O
plane	O
of	O
monolayers	O
were	O
characterized	O
by	O
XRR	O
in	O
the	O
presence	O
of	O
Ni	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
ions	O
,	O
yielding	O
the	O
thickness	O
,	O
roughness	O
,	O
and	O
electron	O
density	O
of	O
the	O
stratified	O
lipid	O
monolayers	O
.	O

X-ray	O
fluorescence	O
intensities	O
from	O
Ni	CHEMICAL
Kα	O
core	O
levels	O
recorded	O
at	O
the	O
incidence	O
angles	O
below	O
and	O
above	O
the	O
critical	O
angle	O
of	O
total	O
reflection	O
allow	O
for	O
the	O
determination	O
of	O
the	O
position	O
and	O
lateral	O
density	O
of	O
Ni	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
ions	O
associated	O
with	O
chelator	O
headgroups	O
with	O
a	O
high	O
spatial	O
accuracy	O
(	O
±5	O
Å	O
)	O
.	O

The	O
coupling	O
of	O
histidine-tagged	O
Xenopus	GENE-Y
cadherin	GENE-Y
11	GENE-Y
(	O
Xcad-11	GENE-Y
)	O
can	O
also	O
be	O
identified	O
by	O
changes	O
in	O
the	O
fines-structures	O
using	O
XRR	O
.	O

Although	O
fluorescence	O
intensities	O
from	O
S	CHEMICAL
Kα	O
level	O
were	O
much	O
weaker	O
than	O
Ni	CHEMICAL
Kα	O
signals	O
,	O
we	O
could	O
detect	O
the	O
location	O
of	O
S	CHEMICAL
atoms	O
in	O
recombinant	O
Xcad-11	GENE-Y
proteins	O
.	O
Tris	CHEMICAL
(	CHEMICAL
1-chloro-2-propyl	CHEMICAL
)	CHEMICAL
phosphate	CHEMICAL
(	O
TCPP	CHEMICAL
)	O
and	O
tris	CHEMICAL
(	CHEMICAL
1	CHEMICAL
,	CHEMICAL
3-dichloro-2-propyl	CHEMICAL
)	CHEMICAL
phosphate	CHEMICAL
(	O
TDCPP	CHEMICAL
)	O
are	O
organic	O
flame	O
retardants	O
detected	O
in	O
the	O
environment	O
and	O
biota	O
for	O
which	O
toxicological	O
data	O
for	O
avian	O
species	O
are	O
limited	O
.	O

In	O
this	O
study	O
,	O
domestic	O
chicken	O
eggs	O
were	O
injected	O
with	O
TCPP	CHEMICAL
or	O
TDCPP	CHEMICAL
(	O
maximum	O
dose	O
=	O
51600	O
and	O
45000	O
ng	O
/	O
g	O
egg	O
,	O
respectively	O
)	O
to	O
determine	O
dose-dependent	O
effects	O
on	O
pipping	O
success	O
,	O
development	O
,	O
hepatic	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
expression	O
levels	O
of	O
genes	O
associated	O
with	O
xenobiotic	O
metabolism	O
and	O
the	O
thyroid	O
hormone	O
(	O
TH	O
)	O
pathway	O
,	O
and	O
TH	O
levels	O
following	O
20-22	O
days	O
of	O
incubation	O
.	O

Neither	O
compound	O
reduced	O
pipping	O
success;	O
however	O
,	O
TCPP	CHEMICAL
significantly	O
delayed	O
pipping	O
at	O
9240	O
and	O
51600	O
ng	O
/	O
g	O
and	O
reduced	O
tarsus	O
length	O
at	O
51600	O
ng	O
/	O
g	O
.	O

TDCPP	CHEMICAL
exposure	O
resulted	O
in	O
significant	O
decreases	O
in	O
head	O
plus	O
bill	O
length	O
,	O
embryo	O
mass	O
and	O
gallbladder	O
size	O
at	O
45000	O
ng	O
/	O
g	O
and	O
reduced	O
plasma	O
free	O
T4	O
levels	O
at	O
7640	O
ng	O
/	O
g	O
.	O

Type	GENE-Y
I	GENE-Y
deiodinase	GENE-Y
,	O
liver	GENE-Y
fatty-acid	GENE-Y
binding	GENE-Y
protein	GENE-Y
and	O
cytochrome	GENE-Y
P450	GENE-Y
(	GENE-Y
CYP	GENE-Y
)	GENE-Y
3A37	GENE-Y
mRNA	O
levels	O
were	O
significantly	O
induced	O
by	O
TCPP	CHEMICAL
,	O
while	O
TDCPP	CHEMICAL
induced	O
CYP3A37	GENE-Y
and	O
CYP2H1	GENE-Y
.	O

Chemical	O
analysis	O
of	O
egg	O
contents	O
at	O
incubation	O
days	O
0	O
,	O
5	O
,	O
11	O
,	O
18	O
,	O
and	O
19	O
revealed	O
that	O
>92%	O
of	O
the	O
injected	O
TCPP	CHEMICAL
or	O
TDCPP	CHEMICAL
concentration	O
was	O
detectable	O
up	O
to	O
day	O
5;	O
however	O
,	O
<1%	O
was	O
detected	O
by	O
day	O
19	O
.	O

The	O
observed	O
phenotypic	O
responses	O
to	O
TCPP	CHEMICAL
and	O
TDCPP	CHEMICAL
exposure	O
may	O
be	O
associated	O
with	O
disruption	O
of	O
the	O
TH-axis	O
,	O
which	O
is	O
critical	O
for	O
normal	O
growth	O
and	O
development	O
in	O
birds	O
.	O

The	O
effects	O
of	O
TDCPP	CHEMICAL
on	O
the	O
gallbladder	O
indicate	O
that	O
the	O
disturbance	O
of	O
lipid	O
metabolism	O
is	O
a	O
likely	O
target	O
in	O
its	O
mechanism	O
of	O
toxicity	O
.	O
Anti-Ulcerative	O
Colitis	O
Activity	O
of	O
Compounds	O
from	O
Euphorbia	O
granuleta	O
Forssk	O
.	O
Selective	O
inhibition	O
of	O
cyclooxygenase	GENE-Y
2	GENE-Y
spares	O
renal	O
function	O
and	O
prostaglandin	CHEMICAL
synthesis	O
in	O
cirrhotic	O
rats	O
with	O
ascites	O
.	O
Over	O
the	O
last	O
years	O
,	O
considerable	O
progress	O
has	O
been	O
made	O
for	O
the	O
identification	O
and	O
characterization	O
of	O
drug	O
transporters	O
,	O
and	O
several	O
modeling	O
studies	O
have	O
been	O
undertaken	O
to	O
predict	O
their	O
effects	O
on	O
ADME	O
profiling	O
.	O

Thus	O
,	O
this	O
study	O
was	O
focused	O
on	O
the	O
peptide	O
transporter	O
hPepT2	GENE-Y
,	O
which	O
influences	O
the	O
regional	O
pharmacokinetics	O
in	O
brain	O
,	O
the	O
reabsorption	O
from	O
renal	O
tubular	O
fluid	O
and	O
the	O
pulmonary	O
delivery	O
.	O

A	O
reliable	O
model	O
for	O
hPepT2	GENE-Y
was	O
generated	O
by	O
fragments	O
based	O
on	O
the	O
resolved	O
structure	O
of	O
the	O
homologue	O
lactose	GENE-N
permease	O
LacY	GENE-N
and	O
the	O
structure	O
is	O
made	O
available	O
as	O
Supplementary	O
data	O
.	O

The	O
interaction	O
capacities	O
of	O
such	O
a	O
model	O
were	O
explored	O
by	O
docking	O
a	O
set	O
of	O
75	O
known	O
ligands	O
.	O

Docking	O
results	O
underlined	O
the	O
predilection	O
of	O
hPepT2	GENE-Y
for	O
highly	O
hydrophobic	O
ligands	O
and	O
the	O
key	O
role	O
of	O
ionic	O
interactions	O
elicited	O
by	O
both	O
charged	O
termini	O
.	O

The	O
docking	O
results	O
were	O
further	O
verified	O
developing	O
a	O
pharmacophore	O
model	O
which	O
clarified	O
the	O
key	O
features	O
required	O
for	O
an	O
optimal	O
hPepT2	GENE-Y
affinity	O
and	O
confirmed	O
the	O
main	O
factors	O
governing	O
the	O
hPepT2	GENE-Y
/	O
hPepT1	GENE-Y
selectivity	O
.	O

The	O
soundness	O
of	O
the	O
docking	O
results	O
and	O
the	O
agreement	O
with	O
the	O
pharmacophore	O
mapping	O
afford	O
an	O
encouraging	O
validation	O
for	O
the	O
proposed	O
hPepT2	GENE-Y
model	O
and	O
suggest	O
that	O
it	O
can	O
be	O
conveniently	O
exploited	O
to	O
design	O
peptide-like	O
molecules	O
with	O
an	O
improved	O
affinity	O
for	O
this	O
transporter	O
.	O
Cellular	O
assessment	O
of	O
the	O
extract	O
of	O
bambangan	O
(	O
Mangifera	O
pajang	O
)	O
as	O
a	O
potential	O
cytoprotective	O
agent	O
for	O
the	O
human	O
hepatocellular	O
HepG2	O
cell	O
line	O
.	O
Aldosterone	CHEMICAL
induces	O
elastin	GENE-Y
production	O
in	O
cardiac	O
fibroblasts	O
through	O
activation	O
of	O
insulin-like	GENE-Y
growth	GENE-Y
factor-I	GENE-Y
receptors	GENE-Y
in	O
a	O
mineralocorticoid	GENE-Y
receptor-independent	O
manner	O
.	O
Candesartan	CHEMICAL
is	O
an	O
angiotensin	GENE-Y
II	GENE-Y
type	GENE-Y
1	GENE-Y
receptor	GENE-Y
blocker	O
(	O
ARB	O
)	O
that	O
has	O
been	O
to	O
shown	O
to	O
limit	O
ischemic	O
stroke	O
and	O
improve	O
stroke	O
outcome	O
.	O

In	O
experimental	O
stroke	O
,	O
candesartan	CHEMICAL
induces	O
a	O
proangiogenic	O
effect	O
that	O
is	O
partly	O
attributable	O
to	O
vascular	GENE-Y
endothelial	GENE-Y
growth	GENE-Y
factor	GENE-Y
.	O

Brain-derived	GENE-Y
neurotrophic	GENE-Y
factor	GENE-Y
(	O
BDNF	GENE-Y
)	O
is	O
a	O
member	O
of	O
the	O
neurotrophin	GENE-N
family	O
that	O
has	O
been	O
reported	O
to	O
have	O
angiogenic	O
effects	O
and	O
play	O
an	O
important	O
role	O
in	O
recovery	O
after	O
stroke	O
.	O

The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
determine	O
the	O
role	O
of	O
BDNF	GENE-Y
in	O
the	O
proangiogenic	O
effect	O
of	O
candesartan	O
in	O
the	O
brain	O
under	O
hypertensive	O
conditions	O
.	O

Accordingly	O
,	O
spontaneously	O
hypertensive	O
rats	O
were	O
treated	O
with	O
candesartan	CHEMICAL
,	O
and	O
brain	O
tissue	O
samples	O
were	O
collected	O
for	O
quantification	O
of	O
BDNF	GENE-Y
expression	O
.	O

In	O
addition	O
,	O
human	O
cerebromicrovascular	O
endothelial	O
cells	O
were	O
treated	O
with	O
either	O
low-dose	O
(	O
1	O
ƒM	O
)	O
or	O
high-dose	O
(	O
1	O
µM	O
)	O
angiotensin	GENE-Y
II	GENE-Y
alone	O
or	O
in	O
combination	O
with	O
candesartan	CHEMICAL
(	O
0	O
.	O
16	O
µM	O
)	O
to	O
assess	O
the	O
effect	O
of	O
candesartan	CHEMICAL
treatment	O
and	O
BDNF	GENE-Y
involvement	O
in	O
the	O
behavior	O
of	O
endothelial	O
cells	O
.	O

Candesartan	CHEMICAL
significantly	O
increased	O
the	O
expression	O
of	O
BDNF	GENE-Y
in	O
the	O
SHR	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
addition	O
,	O
candesartan	CHEMICAL
reversed	O
the	O
antiangiogenic	O
effect	O
of	O
the	O
1-µM	O
dose	O
of	O
AngII	GENE-Y
(	O
P	O
=	O
0	O
.	O
0001	O
)	O
.	O

The	O
observed	O
effects	O
of	O
candesartan	CHEMICAL
were	O
ablated	O
by	O
neutralizing	O
the	O
effects	O
of	O
BDNF	GENE-Y
.	O

Treatment	O
with	O
the	O
AT2	GENE-Y
antagonist	O
PD-123319	CHEMICAL
significantly	O
reduced	O
tube-like	O
formation	O
in	O
endothelial	O
cells	O
.	O

AT2	GENE-Y
stimulation	O
induced	O
the	O
BDNF	GENE-Y
expression	O
and	O
migration	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
conclusion	O
,	O
candesartan	CHEMICAL
exerts	O
a	O
proangiogenic	O
effect	O
on	O
brain	O
microvascular	O
endothelial	O
cells	O
treated	O
with	O
angiotensin	GENE-Y
II	GENE-Y
.	O

This	O
response	O
is	O
attributable	O
to	O
increased	O
BDNF	GENE-Y
expression	O
and	O
is	O
mediated	O
through	O
stimulation	O
of	O
the	O
AT2	GENE-Y
receptor	GENE-Y
.	O
First-Line	O
Management	O
of	O
EGFR-Mutated	O
Advanced	O
Lung	O
Adenocarcinoma	O
:	O
Recent	O
Developments	O
.	O
Pathophysiological	O
roles	O
of	O
aldo-keto	GENE-N
reductases	GENE-N
(	O
AKR1C1	GENE-Y
and	O
AKR1C3	GENE-Y
)	O
in	O
development	O
of	O
cisplatin	CHEMICAL
resistance	O
in	O
human	O
colon	O
cancers	O
.	O
Posttranslational	O
modification	O
of	O
the	O
neural	GENE-Y
cell	GENE-Y
adhesion	GENE-Y
molecule	GENE-Y
(	O
NCAM	GENE-Y
)	O
by	O
polysialic	CHEMICAL
acid	CHEMICAL
(	O
polySia	CHEMICAL
)	O
is	O
well	O
studied	O
in	O
the	O
nervous	O
system	O
and	O
described	O
as	O
a	O
dynamic	O
modulator	O
of	O
plastic	O
processes	O
like	O
precursor	O
cell	O
migration	O
,	O
axon	O
fasciculation	O
,	O
and	O
synaptic	O
plasticity	O
.	O

Here	O
,	O
we	O
describe	O
a	O
novel	O
function	O
of	O
polysialylated	GENE-Y
NCAM	GENE-Y
(	O
polySia-NCAM	O
)	O
in	O
innate	O
immunity	O
of	O
the	O
lung	O
.	O

In	O
mature	O
lung	O
tissue	O
of	O
healthy	O
donors	O
,	O
polySia	CHEMICAL
was	O
exclusively	O
attached	O
to	O
the	O
transmembrane	O
isoform	O
NCAM-140	GENE-Y
and	O
located	O
to	O
intracellular	O
compartments	O
of	O
epithelial	O
cells	O
.	O

In	O
patients	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
however	O
,	O
increased	O
polySia	CHEMICAL
levels	O
and	O
processing	O
of	O
the	O
NCAM	GENE-Y
carrier	O
were	O
observed	O
.	O

Processing	O
of	O
polysialylated	GENE-Y
NCAM	GENE-Y
was	O
reproduced	O
in	O
a	O
mouse	O
model	O
by	O
bleomycin	CHEMICAL
administration	O
leading	O
to	O
an	O
activation	O
of	O
the	O
inflammasome	O
and	O
secretion	O
of	O
interleukin	GENE-Y
(	GENE-Y
IL	GENE-Y
)	GENE-Y
-1β	GENE-Y
.	O

As	O
shown	O
in	O
a	O
cell	O
culture	O
model	O
,	O
polySia-NCAM-140	GENE-Y
was	O
kept	O
in	O
the	O
late	O
trans-Golgi	O
apparatus	O
of	O
lung	O
epithelial	O
cells	O
and	O
stimulation	O
by	O
IL-1β	GENE-Y
or	O
lipopolysaccharide	O
induced	O
metalloprotease-mediated	O
ectodomain	GENE-N
shedding	O
,	O
resulting	O
in	O
the	O
secretion	O
of	O
soluble	O
polySia-NCAM	O
.	O

Interestingly	O
,	O
polySia	CHEMICAL
chains	O
of	O
secreted	O
NCAM	GENE-Y
neutralized	O
the	O
cytotoxic	O
activity	O
of	O
extracellular	O
histones	GENE-N
as	O
well	O
as	O
DNA	O
/	O
histone-network-containing	O
"neutrophil	O
extracellular	O
traps"	O
,	O
which	O
are	O
formed	O
during	O
invasion	O
of	O
microorganisms	O
.	O

Thus	O
,	O
shedding	O
of	O
polySia-NCAM	O
by	O
lung	O
epithelial	O
cells	O
may	O
provide	O
a	O
host-protective	O
mechanism	O
to	O
reduce	O
tissue	O
damage	O
during	O
inflammatory	O
processes	O
.	O
RATIONALE	O
:	O
Prepulse	O
inhibition	O
(	O
PPI	O
)	O
is	O
an	O
operational	O
measure	O
of	O
sensorimotor	O
gating	O
that	O
is	O
deficient	O
in	O
schizophrenia	O
patients	O
.	O

In	O
rats	O
,	O
PPI	O
deficits	O
induced	O
by	O
dopamine	CHEMICAL
(	O
DA	CHEMICAL
)	O
agonists	O
are	O
reversed	O
by	O
antipsychotics	O
.	O

Inhibition	O
of	O
the	O
striatum-rich	O
phosphodiesterase	GENE-Y
(	GENE-Y
PDE	GENE-Y
)	GENE-Y
10A	GENE-Y
may	O
represent	O
a	O
novel	O
antipsychotic	O
mechanism	O
.	O

Previous	O
studies	O
were	O
controversial	O
,	O
showing	O
antipsychotic-like	O
profiles	O
in	O
measures	O
of	O
PPI	O
for	O
the	O
preferential	O
PDE10A	GENE-Y
inhibitor	O
papaverine	CHEMICAL
(	O
PAP	O
)	O
but	O
not	O
the	O
novel	O
PDE10A	GENE-Y
inhibitor	O
TP-10	O
.	O

OBJECTIVE	O
:	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
the	O
antipsychotic	O
profile	O
of	O
PAP	O
in	O
rats	O
using	O
PPI	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
PPI	O
deficits	O
were	O
induced	O
in	O
rats	O
by	O
apomorphine	CHEMICAL
(	O
APO;	O
0	O
.	O
1	O
,	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
or	O
D	O
:	O
-amphetamine	CHEMICAL
(	O
AMPH;	O
4	O
mg	O
/	O
kg	O
)	O
.	O

PAP	O
(	O
3	O
,	O
10	O
,	O
30	O
mg	O
/	O
kg	O
)	O
or	O
haloperidol	CHEMICAL
(	O
HAL;	O
0	O
.	O
1	O
mg	O
/	O
kg	O
)	O
was	O
tested	O
against	O
these	O
agonists	O
in	O
Sprague-Dawley	O
(	O
SD	O
)	O
or	O
Wistar	O
(	O
WI	O
)	O
rats	O
.	O

Prepulse	O
intervals	O
ranged	O
from	O
10	O
to	O
120	O
ms	O
.	O

Further	O
tests	O
evaluated	O
the	O
effects	O
of	O
PAP	O
on	O
spontaneous	O
locomotion	O
,	O
AMPH	CHEMICAL
(	O
1	O
mg	O
/	O
kg	O
)	O
-induced	O
hyperlocomotion	O
,	O
and	O
core	O
body	O
temperature	O
(	O
T	O
degrees	O
)	O
.	O

RESULTS	O
:	O
HAL	CHEMICAL
reversed	O
APO-induced	O
PPI	O
deficits	O
but	O
PAP	O
failed	O
to	O
reverse	O
APO-	O
and	O
AMPH-induced	O
PPI	O
deficits	O
at	O
all	O
doses	O
,	O
strains	O
,	O
pretreatment	O
times	O
,	O
and	O
prepulse	O
intervals	O
.	O

PAP	O
(	O
30	O
mg	O
/	O
kg	O
)	O
significantly	O
reduced	O
AMPH	CHEMICAL
hyperlocomotion	O
in	O
SD	O
rats	O
,	O
and	O
a	O
similar	O
pattern	O
was	O
detected	O
in	O
WI	O
rats	O
.	O

This	O
PAP	O
dose	O
also	O
strongly	O
reduced	O
spontaneous	O
locomotion	O
and	O
T	O
degrees	O
in	O
SD	O
rats	O
.	O

CONCLUSION	O
:	O
Our	O
study	O
does	O
not	O
support	O
an	O
antipsychotic-like	O
profile	O
of	O
PAP	O
in	O
dopaminergic	O
PPI	O
models	O
.	O
Norepinephrine	CHEMICAL
(	O
10	O
microM	O
)	O
,	O
methoxamine	CHEMICAL
(	O
100	O
microM	O
)	O
and	O
clonidine	CHEMICAL
(	O
100	O
microM	O
)	O
with	O
guanosine	CHEMICAL
5'-triphosphate	CHEMICAL
(	O
GTP	O
,	O
50	O
microM	O
)	O
or	O
guanosine	CHEMICAL
5'-O-	CHEMICAL
(	CHEMICAL
3-thiotriphosphate	CHEMICAL
)	CHEMICAL
(	O
GTP	CHEMICAL
gamma-S	CHEMICAL
,	O
10	O
microM	O
)	O
all	O
significantly	O
enhanced	O
the	O
contraction	O
induced	O
by	O
0	O
.	O
3	O
microM	O
Ca2	CHEMICAL
+	CHEMICAL
(	O
pCa6	O
.	O
5	O
)	O
in	O
beta-escin-skinned	O
smooth	O
muscle	O
of	O
rabbit	O
thoracic	O
aorta	O
.	O

The	O
enhancement	O
of	O
Ca2	CHEMICAL
+	CHEMICAL
contraction	O
produced	O
by	O
norepinephrine	CHEMICAL
was	O
greater	O
than	O
that	O
produced	O
by	O
methoxamine	CHEMICAL
or	O
clonidine	CHEMICAL
.	O

In	O
beta-escin-skinned	O
strips	O
of	O
chloroethylclonidine-pretreated	O
smooth	O
muscle	O
,	O
the	O
enhancement	O
of	O
Ca2	CHEMICAL
+	CHEMICAL
contraction	O
produced	O
by	O
norepinephrine	CHEMICAL
was	O
significantly	O
decreased	O
,	O
whereas	O
the	O
amplitude	O
was	O
the	O
same	O
as	O
that	O
produced	O
by	O
methoxamine	CHEMICAL
or	O
clonidine;	O
this	O
enhancement	O
was	O
inhibited	O
by	O
the	O
selective	O
alpha	GENE-Y
1A-adrenoceptor	GENE-Y
antagonist	O
WB	CHEMICAL
4101	CHEMICAL
(	O
100	O
nM	O
)	O
.	O

The	O
enhancement	O
of	O
Ca2	CHEMICAL
+	CHEMICAL
contraction	O
produced	O
by	O
methoxamine	CHEMICAL
and	O
clonidine	CHEMICAL
was	O
not	O
affected	O
by	O
chloroethylclonidine	CHEMICAL
pretreatment	O
.	O

The	O
effects	O
of	O
methoxamine	CHEMICAL
,	O
clonidine	CHEMICAL
and	O
norepinephrine	CHEMICAL
in	O
the	O
chloroethylclonidine-pretreated	O
tissue	O
were	O
all	O
inhibited	O
by	O
guanosine	CHEMICAL
5'-O-	CHEMICAL
(	CHEMICAL
2-thiodiphosphate	CHEMICAL
)	CHEMICAL
(	O
GDP	CHEMICAL
beta-S	CHEMICAL
,	O
1	O
mM	O
)	O
and	O
1-	CHEMICAL
(	CHEMICAL
5-isoquinolinylsulfonyl	CHEMICAL
)	CHEMICAL
-methylpiperazine	CHEMICAL
(	O
H-7	O
,	O
20	O
microM	O
)	O
.	O

Furthermore	O
,	O
the	O
phosphorylation	O
of	O
myosin	GENE-N
light	GENE-N
chain	GENE-N
produced	O
by	O
norepinephrine	CHEMICAL
was	O
greater	O
than	O
that	O
produced	O
by	O
clonidine	CHEMICAL
.	O

These	O
results	O
suggest	O
that	O
both	O
alpha	GENE-N
1-adrenoceptor	GENE-N
subtypes	GENE-N
(	GENE-N
alpha	GENE-N
1A	GENE-N
and	GENE-N
alpha	GENE-N
1B	GENE-N
)	O
increase	O
the	O
Ca2	CHEMICAL
+	CHEMICAL
sensitivity	O
of	O
contractile	O
elements	O
,	O
and	O
that	O
the	O
Ca2	CHEMICAL
+	CHEMICAL
sensitization	O
produced	O
by	O
alpha	GENE-Y
1A-subtype	GENE-Y
receptors	GENE-Y
is	O
mediated	O
through	O
G-protein	GENE-N
and	O
protein	GENE-N
kinase	GENE-N
C	GENE-N
,	O
and	O
plays	O
an	O
important	O
role	O
in	O
contraction	O
of	O
smooth	O
muscle	O
of	O
rabbit	O
thoracic	O
aorta	O
.	O
Although	O
agonist	O
binding	O
in	O
adrenergic	GENE-N
receptors	GENE-N
is	O
fairly	O
well	O
understood	O
and	O
involves	O
residues	O
located	O
in	O
transmembrane	O
domains	O
3	O
through	O
6	O
,	O
there	O
are	O
few	O
residues	O
reported	O
that	O
are	O
involved	O
in	O
antagonist	O
binding	O
.	O

In	O
fact	O
,	O
a	O
major	O
docking	O
site	O
for	O
antagonists	O
has	O
never	O
been	O
reported	O
in	O
any	O
G-protein	GENE-N
coupled	GENE-N
receptor	GENE-N
.	O

It	O
has	O
been	O
speculated	O
that	O
antagonist	O
binding	O
is	O
quite	O
diverse	O
depending	O
upon	O
the	O
chemical	O
structure	O
of	O
the	O
antagonist	O
,	O
which	O
can	O
be	O
quite	O
different	O
from	O
agonists	O
.	O

We	O
now	O
report	O
the	O
identification	O
of	O
two	O
phenylalanine	CHEMICAL
residues	O
in	O
transmembrane	O
domain	O
7	O
of	O
the	O
alpha	GENE-Y
(	GENE-Y
1a	GENE-Y
)	GENE-Y
-adrenergic	GENE-Y
receptor	GENE-Y
(	O
Phe-312	O
and	O
Phe-308	O
)	O
that	O
are	O
a	O
major	O
site	O
of	O
antagonist	O
affinity	O
.	O

Mutation	O
of	O
either	O
Phe-308	O
or	O
Phe-312	O
resulted	O
in	O
significant	O
losses	O
of	O
affinity	O
(	O
4-1200-fold	O
)	O
for	O
the	O
antagonists	O
prazosin	CHEMICAL
,	O
WB4101	CHEMICAL
,	O
BMY7378	CHEMICAL
,	O
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
niguldipine	CHEMICAL
,	O
and	O
5-methylurapidil	CHEMICAL
,	O
with	O
no	O
changes	O
in	O
affinity	O
for	O
phenethylamine-type	O
agonists	O
such	O
as	O
epinephrine	CHEMICAL
,	O
methoxamine	CHEMICAL
,	O
or	O
phenylephrine	CHEMICAL
.	O

Interestingly	O
,	O
both	O
residues	O
are	O
involved	O
in	O
the	O
binding	O
of	O
all	O
imidazoline-type	O
agonists	O
such	O
as	O
oxymetazoline	CHEMICAL
,	O
cirazoline	CHEMICAL
,	O
and	O
clonidine	CHEMICAL
,	O
confirming	O
previous	O
evidence	O
that	O
this	O
class	O
of	O
ligand	O
binds	O
differently	O
than	O
phenethylamine-type	O
agonists	O
and	O
may	O
be	O
more	O
antagonist-like	O
,	O
which	O
may	O
explain	O
their	O
partial	O
agonist	O
properties	O
.	O

In	O
modeling	O
these	O
interactions	O
with	O
previous	O
mutagenesis	O
studies	O
and	O
using	O
the	O
current	O
backbone	O
structure	O
of	O
rhodopsin	GENE-Y
,	O
we	O
conclude	O
that	O
antagonist	O
binding	O
is	O
docked	O
higher	O
in	O
the	O
pocket	O
closer	O
to	O
the	O
extracellular	O
surface	O
than	O
agonist	O
binding	O
and	O
appears	O
skewed	O
toward	O
transmembrane	O
domain	O
7	O
.	O
BACKGROUND	O
:	O
(	CHEMICAL
+	CHEMICAL
/	CHEMICAL
-	CHEMICAL
)	CHEMICAL
-Modafinil	CHEMICAL
has	O
piqued	O
interest	O
as	O
a	O
treatment	O
for	O
attention-deficit	O
/	O
hyperactivity	O
disorder	O
and	O
stimulant	O
dependence	O
.	O

The	O
R-enantiomer	CHEMICAL
of	CHEMICAL
modafinil	CHEMICAL
might	O
have	O
unique	O
pharmacological	O
properties	O
that	O
should	O
be	O
further	O
investigated	O
.	O

METHODS	O
:	O
(	CHEMICAL
+	CHEMICAL
/	CHEMICAL
-	CHEMICAL
)	CHEMICAL
-Modafinil	CHEMICAL
and	O
its	O
R-	O
(	O
-	O
)	O
-	O
and	O
S-	O
(	O
+	O
)	O
-enantiomers	O
were	O
synthesized	O
and	O
tested	O
for	O
inhibition	O
of	O
[	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
H	CHEMICAL
]	CHEMICAL
dopamine	CHEMICAL
(	O
DA	CHEMICAL
)	O
uptake	O
and	O
[	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
H	CHEMICAL
]	CHEMICAL
WIN	CHEMICAL
35428	CHEMICAL
binding	O
in	O
human	GENE-Y
dopamine	CHEMICAL
transporter	O
(	O
DAT	GENE-Y
)	O
wild-type	O
and	O
mutants	O
with	O
altered	O
conformational	O
equilibria	O
.	O

Data	O
were	O
compared	O
with	O
cocaine	CHEMICAL
and	O
the	O
atypical	O
DA	CHEMICAL
uptake	O
inhibitor	O
,	O
JHW	CHEMICAL
007	CHEMICAL
.	O

R-	CHEMICAL
and	CHEMICAL
S-modafinil	CHEMICAL
were	O
also	O
evaluated	O
in	O
microdialysis	O
studies	O
in	O
the	O
mouse	O
nucleus	O
accumbens	O
shell	O
and	O
in	O
a	O
cocaine	CHEMICAL
discrimination	O
procedure	O
.	O

RESULTS	O
:	O
(	CHEMICAL
+	CHEMICAL
/	CHEMICAL
-	CHEMICAL
)	CHEMICAL
-	CHEMICAL
,	CHEMICAL
R-	CHEMICAL
,	CHEMICAL
and	CHEMICAL
S-modafinil	CHEMICAL
bind	O
to	O
the	O
DAT	GENE-Y
and	O
inhibit	O
DA	CHEMICAL
uptake	O
less	O
potently	O
than	O
cocaine	CHEMICAL
,	O
with	O
R-modafinil	CHEMICAL
having	O
approximately	O
threefold	O
higher	O
affinity	O
than	O
its	O
S-enantiomer	O
.	O

Molecular	O
docking	O
studies	O
revealed	O
subtle	O
differences	O
in	O
binding	O
modes	O
for	O
the	O
enantiomers	O
.	O

R-modafinil	CHEMICAL
was	O
significantly	O
less	O
potent	O
in	O
the	O
DAT	GENE-Y
Y156F	GENE-N
mutant	O
compared	O
with	O
wild-type	O
DAT	GENE-Y
,	O
whereas	O
S-modafinil	CHEMICAL
was	O
affected	O
less	O
.	O

Studies	O
with	O
the	O
Y335A	GENE-N
DAT	GENE-Y
mutant	O
showed	O
that	O
the	O
R-	O
and	O
S-enantiomers	O
tolerated	O
the	O
inward-facing	O
conformation	O
better	O
than	O
cocaine	CHEMICAL
,	O
which	O
was	O
further	O
supported	O
by	O
[	CHEMICAL
2-	CHEMICAL
(	CHEMICAL
trimethylammonium	CHEMICAL
)	CHEMICAL
ethyl	CHEMICAL
]	CHEMICAL
-methanethiosulfonate	CHEMICAL
reactivity	O
on	O
the	O
DAT	GENE-Y
E2C	GENE-N
I159C	GENE-N
.	O

Microdialysis	O
studies	O
demonstrated	O
that	O
both	O
R-	CHEMICAL
and	CHEMICAL
S-modafinil	CHEMICAL
produced	O
increases	O
in	O
extracellular	O
DA	CHEMICAL
concentrations	O
in	O
the	O
nucleus	O
accumbens	O
shell	O
less	O
efficaciously	O
than	O
cocaine	CHEMICAL
and	O
with	O
a	O
longer	O
duration	O
of	O
action	O
.	O

Both	O
enantiomers	O
fully	O
substituted	O
in	O
mice	O
trained	O
to	O
discriminate	O
cocaine	CHEMICAL
from	O
saline	O
.	O

CONCLUSIONS	O
:	O
R-modafinil	CHEMICAL
displays	O
an	O
in	O
vitro	O
profile	O
different	O
from	O
cocaine	CHEMICAL
.	O

Future	O
trials	O
with	O
R-modafinil	CHEMICAL
as	O
a	O
substitute	O
therapy	O
with	O
the	O
potential	O
benefit	O
of	O
cognitive	O
enhancement	O
for	O
psychostimulant	O
addiction	O
are	O
warranted	O
.	O
Cinobufagin	CHEMICAL
,	O
a	O
major	O
component	O
of	O
cinobufacini	O
(	O
huachansu	O
)	O
,	O
is	O
an	O
important	O
cardenolidal	CHEMICAL
steroid	CHEMICAL
.	O

Several	O
studies	O
have	O
suggested	O
that	O
cinobufagin	CHEMICAL
has	O
potent	O
anti-cancer	O
effects	O
.	O

The	O
present	O
study	O
examines	O
the	O
apoptosis-inducing	O
activity	O
and	O
the	O
underlying	O
mechanism	O
of	O
action	O
of	O
cinobufagin	CHEMICAL
in	O
osteosarcoma	O
(	O
OS	O
)	O
cells	O
.	O

Our	O
results	O
showed	O
that	O
cinobufagin	CHEMICAL
potently	O
inhibited	O
the	O
proliferation	O
of	O
U2OS	O
,	O
MG63	O
and	O
SaOS-2	O
cells	O
.	O

Significant	O
increases	O
in	O
G2	O
/	O
M	O
cell-cycle	O
arrest	O
and	O
apoptosis	O
in	O
OS	O
cells	O
were	O
also	O
observed	O
.	O

The	O
expression	O
levels	O
of	O
several	O
apoptotic	O
proteins	O
were	O
assessed	O
after	O
cinobufagin	CHEMICAL
treatment	O
in	O
U2OS	O
cells	O
.	O

Among	O
them	O
,	O
xIAP	GENE-Y
,	O
cIAP-1	GENE-Y
,	O
survivin	GENE-Y
and	O
Bcl-2	GENE-Y
levels	O
decreased	O
remarkably	O
,	O
while	O
the	O
levels	O
of	O
Bax	GENE-Y
and	O
cleaved-PARP	GENE-N
increased	O
.	O

Furthermore	O
,	O
we	O
validated	O
the	O
inhibition	O
of	O
GSK-3β	GENE-Y
/	O
NF-κB	GENE-N
signaling	O
following	O
cinobufagin	CHEMICAL
treatment	O
.	O

Western	O
blots	O
showed	O
a	O
decrease	O
in	O
nuclear	O
p65	GENE-Y
protein	O
expression	O
after	O
exposure	O
to	O
different	O
concentrations	O
of	O
cinobufagin	CHEMICAL
,	O
while	O
the	O
phosphorylation	O
of	O
GSK-3β	GENE-Y
was	O
simultaneously	O
increased	O
.	O

Transduction	O
with	O
constitutively	O
active	O
forms	O
of	O
GSK-3β	GENE-Y
could	O
protect	O
against	O
the	O
downregulation	O
of	O
p65	GENE-Y
and	O
upregulation	O
of	O
cleaved-PARP	GENE-N
that	O
are	O
induced	O
by	O
cinobufagin	CHEMICAL
treatment	O
.	O

However	O
,	O
combined	O
treatment	O
with	O
cinobufagin	CHEMICAL
and	O
SB216367	CHEMICAL
resulted	O
in	O
a	O
significant	O
reduction	O
in	O
p65	GENE-Y
and	O
an	O
increase	O
in	O
cleaved-PARP	GENE-N
in	O
U2OS	O
cells	O
.	O

Altogether	O
,	O
these	O
results	O
show	O
that	O
cinobufagin	CHEMICAL
is	O
a	O
promising	O
agent	O
for	O
the	O
treatment	O
of	O
OS	O
.	O

These	O
studies	O
are	O
the	O
first	O
to	O
reveal	O
the	O
involvement	O
of	O
the	O
GSK-3β	GENE-Y
/	O
NF-κB	GENE-N
pathway	O
in	O
cinobufagin-induced	O
apoptosis	O
.	O
Exploring	O
the	O
Interplay	O
Between	O
Ligand	O
Derivatisation	O
and	O
Cation	O
Type	O
in	O
the	O
Assembly	O
of	O
Hybrid	O
Polyoxometalate	CHEMICAL
Mn-Andersons	O
.	O
BACKGROUND	O
AND	O
RATIONALE	O
:	O
We	O
previously	O
found	O
that	O
the	O
intronic	O
norepinephrine	CHEMICAL
transporter	O
gene	O
(	O
SLC6A2	GENE-Y
)	O
polymorphism	O
rs36017	O
modulates	O
feelings	O
of	O
elation	O
after	O
administration	O
of	O
20	O
mg	O
D-amphetamine	CHEMICAL
in	O
healthy	O
volunteers	O
.	O

OBJECTIVES	O
:	O
In	O
this	O
study	O
,	O
we	O
further	O
investigated	O
the	O
association	O
between	O
D-amphetamine	CHEMICAL
response	O
and	O
11	O
SLC6A2	GENE-Y
single-nucleotide	CHEMICAL
polymorphisms	O
(	O
SNPs	O
)	O
,	O
including	O
rs36017	O
,	O
in	O
an	O
extended	O
sample	O
of	O
Caucasian	O
young	O
adults	O
.	O

METHODS	O
:	O
One	O
hundred	O
fifty-nine	O
healthy	O
volunteers	O
participated	O
in	O
a	O
three-session	O
double-blind	O
crossover	O
design	O
receiving	O
either	O
placebo	O
or	O
oral	O
D-amphetamine	CHEMICAL
(	O
10	O
and	O
20	O
mg	O
)	O
.	O

Based	O
on	O
our	O
previous	O
results	O
,	O
we	O
examined	O
the	O
associations	O
between	O
levels	O
of	O
self-reported	O
elation	O
and	O
vigor	O
after	O
D-amphetamine	CHEMICAL
administration	O
and	O
SNPs	O
and	O
SNP	O
haplotypes	O
in	O
SLC6A2	GENE-Y
.	O

RESULTS	O
:	O
Consistent	O
with	O
our	O
previous	O
findings	O
,	O
SNPs	O
rs36017	O
and	O
rs1861647	O
were	O
associated	O
with	O
significantly	O
higher	O
ratings	O
of	O
elation	O
and	O
vigor	O
after	O
20	O
mg	O
Damphetamine	CHEMICAL
.	O

Ratings	O
of	O
vigor	O
after	O
20	O
mg	O
D-amphetamine	CHEMICAL
were	O
also	O
associated	O
with	O
a	O
two-SNP	O
haplotype	O
formed	O
with	O
rs1861647	O
and	O
rs5569	O
and	O
a	O
three-SNP	O
haplotype	O
formed	O
with	O
rs36017	O
,	O
rs10521329	O
,	O
and	O
rs3785155	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
provide	O
further	O
evidence	O
that	O
genetic	O
variants	O
in	O
the	O
SLC6A2	GENE-Y
gene	O
are	O
involved	O
in	O
acute	O
response	O
to	O
D-amphetamine	CHEMICAL
,	O
which	O
may	O
influence	O
progression	O
to	O
amphetamine	CHEMICAL
abuse	O
.	O

Identifying	O
sources	O
of	O
variation	O
in	O
acute	O
drug	O
responses	O
could	O
lead	O
to	O
better	O
prevention	O
and	O
treatment	O
of	O
psychostimulant	O
abuse	O
and	O
may	O
be	O
valuable	O
in	O
the	O
therapeutic	O
use	O
of	O
stimulants	O
.	O
Effects	O
of	O
the	O
serine	GENE-Y
/	O
threonine	CHEMICAL
kinase	O
SGK1	O
on	O
the	O
epithelial	GENE-N
Na	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
channel	O
(	O
ENaC	GENE-N
)	O
and	O
CFTR	GENE-Y
:	O
implications	O
for	O
cystic	O
fibrosis	O
.	O
In	O
the	O
present	O
study	O
,	O
age-related	O
changes	O
of	O
pyridoxal	CHEMICAL
5'-phosphate	CHEMICAL
(	O
PLP	CHEMICAL
)	O
synthesizing	O
enzymes	O
,	O
pyridoxal	CHEMICAL
kinase	O
(	O
PLK	GENE-N
)	O
and	O
pyridoxine	CHEMICAL
5'-phosphate	CHEMICAL
oxidase	O
(	O
PNPO	GENE-N
)	O
,	O
their	O
protein	O
contents	O
and	O
activities	O
were	O
examined	O
in	O
the	O
gerbil	O
hippocampus	O
proper	O
.	O

Significant	O
age-dependent	O
changes	O
in	O
PLK	GENE-N
and	O
PNPO	GENE-N
immunoreactivities	O
were	O
found	O
in	O
the	O
CA1	O
region	O
,	O
but	O
not	O
in	O
the	O
CA2	O
/	O
3	O
region	O
.	O

In	O
the	O
postnatal	O
month	O
1	O
(	O
PM	O
1	O
)	O
group	O
,	O
PLK	GENE-N
and	O
PNPO	GENE-N
immunoreactivities	O
were	O
detected	O
mainly	O
in	O
the	O
stratum	O
pyramidale	O
of	O
the	O
CA1	O
region	O
.	O

PLK	GENE-N
and	O
PNPO	GENE-N
immunoreactivities	O
and	O
their	O
protein	O
contents	O
were	O
highest	O
in	O
the	O
PM	O
6	O
group	O
,	O
showing	O
that	O
many	O
CA1	O
pyramidal	O
cells	O
had	O
strong	O
PLK	GENE-N
and	O
PNPO	GENE-N
immunoreactivities	O
.	O

Thereafter	O
,	O
PLK	GENE-N
and	O
PNPO	GENE-N
immunoreactivities	O
started	O
to	O
decrease	O
and	O
were	O
very	O
low	O
at	O
PM	O
24	O
.	O

Alterations	O
in	O
the	O
change	O
patterns	O
in	O
protein	O
contents	O
and	O
total	O
activities	O
of	O
PLK	GENE-N
and	O
PNPO	GENE-N
corresponded	O
to	O
the	O
immunohistochemical	O
data	O
,	O
but	O
their	O
specific	O
activities	O
were	O
not	O
altered	O
in	O
any	O
experimental	O
group	O
.	O

Based	O
on	O
double	O
immunofluorescence	O
study	O
,	O
PLK	GENE-N
and	O
PNPO	GENE-N
immunoreactive	O
cells	O
in	O
the	O
strata	O
oriens	O
and	O
radiatum	O
were	O
identified	O
as	O
GABAergic	O
cells	O
.	O

Therefore	O
,	O
decreases	O
of	O
PLK	GENE-N
and	O
PNPO	GENE-N
in	O
the	O
hippocampal	O
CA1	O
region	O
of	O
aged	O
brains	O
may	O
be	O
involved	O
in	O
aging	O
processes	O
related	O
with	O
gamma-aminobutyric	CHEMICAL
acid	CHEMICAL
(	O
GABA	CHEMICAL
)	O
function	O
.	O
Ergovaline	CHEMICAL
binding	O
and	O
activation	O
of	O
D2	GENE-Y
dopamine	CHEMICAL
receptors	O
in	O
GH4ZR7	O
cells	O
.	O
Cyclooxygenase	GENE-N
isozymes	O
(	O
COX-1	GENE-Y
and	O
COX-2	GENE-Y
)	O
are	O
found	O
to	O
be	O
constitutively	O
expressed	O
in	O
brain	O
,	O
with	O
neuronal	O
expression	O
of	O
COX-2	GENE-Y
being	O
rapidly	O
induced	O
after	O
numerous	O
insults	O
,	O
including	O
cerebral	O
ischemia	O
.	O

Because	O
overactivation	O
of	O
N-methyl-D-aspartate	GENE-N
(	O
NMDA	CHEMICAL
)	O
receptors	O
has	O
been	O
implicated	O
in	O
the	O
cell	O
loss	O
associated	O
with	O
ischemia	O
,	O
we	O
characterized	O
the	O
expression	O
of	O
the	O
COX	GENE-N
isozymes	O
in	O
murine	O
mixed	O
cortical	O
cell	O
cultures	O
and	O
used	O
isozyme-selective	O
inhibitors	O
to	O
determine	O
their	O
relative	O
contribution	O
to	O
NMDA	GENE-N
receptor-stimulated	O
prostaglandin	CHEMICAL
(	O
PG	CHEMICAL
)	O
production	O
and	O
excitotoxic	O
neuronal	O
cell	O
death	O
.	O

Immunocytochemical	O
analysis	O
of	O
mixed	O
cortical	O
cell	O
cultures	O
revealed	O
that	O
COX-2	GENE-Y
expression	O
was	O
restricted	O
to	O
neurons	O
,	O
whereas	O
COX-1	GENE-Y
was	O
expressed	O
in	O
both	O
neurons	O
and	O
astrocytes	O
.	O

Brief	O
exposure	O
to	O
NMDA	CHEMICAL
(	O
5	O
min;	O
100	O
microM	O
)	O
elicited	O
a	O
time-dependent	O
accumulation	O
of	O
PGs	O
in	O
the	O
culture	O
medium	O
that	O
preceded	O
neuronal	O
cell	O
death	O
and	O
correlated	O
with	O
the	O
induction	O
of	O
COX-2	GENE-Y
mRNA	O
.	O

COX-1	GENE-Y
expression	O
remained	O
unchanged	O
.	O

Flurbiprofen	CHEMICAL
,	O
a	O
nonselective	O
COX-1	GENE-Y
/	O
COX-2	GENE-Y
inhibitor	O
,	O
blocked	O
NMDA-stimulated	O
PG	CHEMICAL
production	O
and	O
attenuated	O
neuronal	O
death	O
in	O
a	O
concentration-dependent	O
manner	O
.	O

Similar	O
results	O
were	O
obtained	O
with	O
the	O
specific	O
COX-2	GENE-Y
inhibitor	O
NS-398	CHEMICAL
(	O
10-30	O
microM	O
)	O
but	O
not	O
with	O
the	O
selective	O
COX-1	GENE-Y
inhibitor	O
valeryl	CHEMICAL
salicylate	CHEMICAL
(	O
10-300	O
microM	O
)	O
.	O

Inhibition	O
of	O
total	O
constitutive	O
COX	GENE-N
activity	O
with	O
aspirin	CHEMICAL
(	O
100	O
microM	O
,	O
1	O
.	O
5	O
h	O
)	O
before	O
NMDA	CHEMICAL
exposure	O
did	O
not	O
prevent	O
subsequent	O
NMDA-mediated	O
neuronal	O
cell	O
death	O
.	O

However	O
,	O
neuronal	O
injury	O
in	O
aspirin-pretreated	O
cultures	O
was	O
attenuated	O
by	O
flurbiprofen	CHEMICAL
administration	O
after	O
NMDA	CHEMICAL
exposure	O
.	O

Finally	O
,	O
the	O
protection	O
afforded	O
by	O
COX-2	GENE-Y
inhibition	O
was	O
specific	O
for	O
NMDA	CHEMICAL
because	O
neither	O
flurbiprofen	CHEMICAL
nor	O
NS-398	CHEMICAL
protected	O
neurons	O
against	O
kainate-mediated	O
neurotoxicity	O
.	O

Together	O
,	O
these	O
results	O
support	O
the	O
conclusion	O
that	O
newly	O
synthesized	O
COX-2	GENE-Y
protein	O
contributes	O
to	O
NMDA-induced	O
neuronal	O
injury	O
.	O
Excess	O
activation	O
of	O
glutamatergic	O
neurotransmission	O
in	O
the	O
cerebral	O
cortex	O
following	O
ethanol	CHEMICAL
withdrawal	O
is	O
considered	O
to	O
contribute	O
to	O
significant	O
behavioural	O
disturbances	O
,	O
and	O
to	O
alcohol	CHEMICAL
craving	O
.	O

Astrocytes	O
may	O
play	O
a	O
role	O
in	O
these	O
manifestations	O
because	O
astrocytes	O
are	O
essential	O
in	O
the	O
regulation	O
of	O
released	O
glutamate	CHEMICAL
and	O
its	O
conversion	O
to	O
glutamine	CHEMICAL
through	O
the	O
enzyme	O
glutamine	GENE-Y
synthetase	O
(	O
GS	GENE-Y
)	O
.	O

However	O
,	O
it	O
is	O
unclear	O
if	O
withdrawal	O
from	O
free-choice	O
ethanol	CHEMICAL
drinking	O
causes	O
changes	O
in	O
the	O
numbers	O
of	O
astrocytes	O
expressing	O
GS	GENE-Y
or	O
the	O
cytoskeletal	O
protein	O
of	O
astrocytes	O
glial	GENE-Y
fibrillary	GENE-Y
acidic	GENE-Y
protein	GENE-Y
(	O
GFAP	GENE-Y
)	O
.	O

Alcohol-preferring	O
(	O
P	O
)	O
rats	O
exposed	O
to	O
free-choice	O
ethanol	CHEMICAL
drinking	O
were	O
either	O
maintained	O
without	O
forced	O
interruption	O
of	O
ethanol	CHEMICAL
drinking	O
,	O
subjected	O
to	O
a	O
3-day	O
withdrawal	O
period	O
at	O
the	O
end	O
of	O
2	O
months	O
,	O
or	O
subjected	O
to	O
three	O
3-day	O
withdrawal	O
periods	O
along	O
6	O
months	O
.	O

At	O
2	O
months	O
,	O
P	O
rats	O
were	O
also	O
compared	O
with	O
alcohol-naive	O
alcohol	CHEMICAL
non-preferring	O
rats	O
(	O
NP	O
)	O
rats	O
.	O

Packing	O
density	O
of	O
GS	GENE-Y
and	O
GFAP-immunoreactive	O
(	O
IR	O
)	O
astrocytes	O
was	O
measured	O
in	O
sections	O
from	O
the	O
prelimbic	O
cortex	O
(	O
PLC	O
)	O
using	O
the	O
optical	O
disector	O
probe	O
.	O

An	O
alcohol	CHEMICAL
deprivation	O
effect	O
was	O
observed	O
in	O
P	O
rats	O
with	O
withdrawals	O
during	O
a	O
6-month	O
ethanol	O
drinking	O
period	O
.	O

Ethanol	CHEMICAL
withdrawal	O
significantly	O
increased	O
the	O
packing	O
density	O
of	O
GS-	O
and	O
GFAP-IR	O
astrocytes	O
in	O
the	O
PLC	O
of	O
P	O
rats	O
as	O
compared	O
with	O
P	O
rats	O
with	O
continuous	O
access	O
to	O
ethanol	O
.	O

In	O
addition	O
,	O
there	O
was	O
a	O
positive	O
correlation	O
between	O
the	O
pre-withdrawal	O
ethanol	CHEMICAL
consumption	O
and	O
the	O
packing	O
density	O
of	O
GS-IR	O
astrocytes	O
.	O

The	O
present	O
results	O
suggest	O
the	O
involvement	O
of	O
astrocytes	O
in	O
the	O
regulation	O
of	O
the	O
glutamatergic	O
activation	O
associated	O
with	O
withdrawal	O
from	O
free-choice	O
ethanol	CHEMICAL
consumption	O
and	O
point	O
to	O
differential	O
adaptations	O
of	O
GS	GENE-Y
and	O
GFAP	GENE-Y
to	O
prolonged	O
alcohol	CHEMICAL
drinking	O
in	O
the	O
PLC	O
of	O
P	O
rats	O
.	O
Novel	O
pentablock	O
copolymer	O
(	O
PLA-PCL-PEG-PCL-PLA	CHEMICAL
)	O
based	O
nanoparticles	O
for	O
controlled	O
drug	O
delivery	O
:	O
Effect	O
of	O
copolymer	O
compositions	O
on	O
the	O
crystallinity	O
of	O
copolymers	O
and	O
in	O
vitro	O
drug	O
release	O
profile	O
from	O
nanoparticles	O
.	O
Botulinum	GENE-Y
toxin	GENE-Y
type	GENE-Y
A	GENE-Y
(	O
BoNT	GENE-Y
/	GENE-Y
A	GENE-Y
)	O
produced	O
by	O
Clostridium	O
botulinum	O
inhibits	O
Ca2	CHEMICAL
+	CHEMICAL
-dependent	O
acetylcholine	CHEMICAL
(	O
ACh	CHEMICAL
)	O
release	O
(	O
neuroexocytosis	O
)	O
at	O
peripheral	O
neuromuscular	O
junctions	O
,	O
sometimes	O
causing	O
neuromuscular	O
paralysis	O
.	O

This	O
inhibitory	O
effect	O
is	O
attributed	O
to	O
its	O
metalloprotease	GENE-N
activity	O
to	O
cleave	O
the	O
25-kDa	GENE-Y
synaptosomal-associated	GENE-Y
protein	GENE-Y
,	O
which	O
is	O
essential	O
for	O
the	O
exocytotic	O
machinery	O
.	O

However	O
,	O
deletion	O
of	O
this	O
protein	O
does	O
not	O
result	O
in	O
a	O
complete	O
block	O
of	O
neuroexocytosis	O
,	O
suggesting	O
that	O
botulinum-mediated	O
inhibition	O
may	O
occur	O
via	O
another	O
mechanism	O
.	O

Rho	GENE-N
GTPases	GENE-N
,	O
a	O
class	O
of	O
small	O
GTP-binding	O
proteins	O
(	O
G	GENE-N
proteins	GENE-N
)	O
,	O
control	O
actin	GENE-N
cytoskeletal	O
organization	O
,	O
thereby	O
regulating	O
a	O
variety	O
of	O
cellular	O
functions	O
in	O
various	O
cells	O
,	O
including	O
neuronal	O
cells	O
.	O

We	O
have	O
shown	O
that	O
the	O
G	GENE-N
protein	GENE-N
activator	O
lysophosphatidic	CHEMICAL
acid	CHEMICAL
(	O
LPA	CHEMICAL
)	O
triggered	O
actin	O
reorganization	O
followed	O
by	O
Ca2	CHEMICAL
+	CHEMICAL
-dependent	O
ACh	CHEMICAL
release	O
in	O
nerve	GENE-Y
growth	GENE-Y
factor-treated	O
PC12	O
cells	O
and	O
that	O
BoNT	GENE-Y
/	GENE-Y
A	GENE-Y
blocked	O
both	O
events	O
through	O
degradation	O
of	O
RhoB	GENE-Y
by	O
the	O
proteasome	GENE-N
.	O

Overexpression	O
of	O
wild-type	O
RhoB	GENE-Y
caused	O
actin	O
reorganization	O
and	O
enhanced	O
the	O
release	O
of	O
ACh	CHEMICAL
by	O
LPA	CHEMICAL
to	O
overcome	O
toxin's	O
inhibitory	O
effect	O
on	O
actin	GENE-N
reorganization	O
/	O
exocytosis	O
stimulated	O
by	O
LPA	CHEMICAL
,	O
whereas	O
overexpression	O
of	O
a	O
dominant	O
negative	O
RhoB	GENE-Y
inhibited	O
ACh	CHEMICAL
release	O
,	O
regardless	O
of	O
LPA	CHEMICAL
and	O
/	O
or	O
toxin	O
treatment	O
.	O

Finally	O
,	O
a	O
knockdown	O
of	O
the	O
RhoB	GENE-Y
gene	O
via	O
sequence-specific	O
,	O
post-transcriptional	O
gene	O
silencing	O
reduced	O
RhoB	GENE-Y
expression	O
in	O
PC12	O
cells	O
,	O
resulting	O
in	O
total	O
inhibition	O
of	O
both	O
actin	GENE-N
reorganization	O
and	O
ACh	CHEMICAL
release	O
induced	O
by	O
LPA	CHEMICAL
.	O

We	O
conclude	O
that	O
the	O
RhoB	GENE-Y
signaling	O
pathway	O
regulates	O
ACh	CHEMICAL
release	O
via	O
actin	GENE-N
cytoskeletal	O
reorganization	O
and	O
that	O
botulinum	GENE-N
toxin	GENE-N
inhibits	O
neuroexocytosis	O
by	O
targeting	O
RhoB	GENE-Y
pathway	O
.	O
Insulin-	O
and	O
glucagon-like	GENE-Y
peptide-1-induced	O
changes	O
in	O
heart	O
rate	O
and	O
vagosympathetic	O
activity	O
:	O
why	O
they	O
matter	O
.	O
Expression	O
and	O
1	CHEMICAL
,	CHEMICAL
4-dihydropyridine-binding	O
properties	O
of	O
brain	O
L-type	GENE-N
calcium	CHEMICAL
channel	O
isoforms	O
.	O
Gastrodin	CHEMICAL
attenuation	O
of	O
the	O
inflammatory	O
response	O
in	O
H9c2	O
cardiomyocytes	O
involves	O
inhibition	O
of	O
NF-κB	GENE-N
and	O
MAPKs	GENE-N
activation	O
via	O
the	O
phosphatidylinositol	GENE-N
3-kinase	O
signaling	O
.	O
Chalcogenopyrylium	CHEMICAL
Dyes	O
as	O
Differential	O
Modulators	O
of	O
Organic	O
Anion	O
Transport	O
by	O
MRP1	GENE-Y
,	O
MRP2	GENE-Y
and	O
MRP4	GENE-Y
.	O
Olopatadine	CHEMICAL
hydrochloride	CHEMICAL
(	O
olopatadine	CHEMICAL
)	O
is	O
an	O
antiallergic	O
drug	O
with	O
histamine	CHEMICAL
H	O
(	O
1	O
)	O
receptor	O
antagonistic	O
activity	O
.	O

Recently	O
,	O
olopatadine	CHEMICAL
has	O
been	O
shown	O
to	O
bind	O
to	O
S100A12	GENE-Y
which	O
is	O
a	O
member	O
of	O
the	O
S100	GENE-N
family	O
of	O
calcium-binding	O
proteins	O
,	O
and	O
exerts	O
multiple	O
proinflammatory	O
activities	O
including	O
chemotaxis	O
for	O
monocytes	O
and	O
neutrophils	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
possibility	O
that	O
the	O
interaction	O
of	O
olopatadine	O
with	O
S100A12	GENE-Y
inhibits	O
the	O
proinflammatory	O
effects	O
of	O
S100A12	GENE-Y
.	O

Pretreatment	O
of	O
olopatadine	CHEMICAL
with	O
S100A12	GENE-Y
reduced	O
migration	O
of	O
THP-1	O
,	O
a	O
monocyte	O
cell	O
line	O
,	O
induced	O
by	O
S100A12	GENE-Y
alone	O
,	O
but	O
did	O
not	O
affect	O
recombinant	O
human	O
regulated	O
upon	O
activation	O
,	O
normal	O
T	O
cell	O
expressed	O
and	O
secreted	O
(	O
RANTES	O
)	O
-induced	O
migration	O
.	O

Amlexanox	CHEMICAL
,	O
which	O
also	O
binds	O
to	O
S100A12	GENE-Y
,	O
inhibited	O
the	O
THP-1	O
migration	O
induced	O
by	O
S100A12	GENE-Y
.	O

However	O
,	O
ketotifen	O
,	O
another	O
histamine	CHEMICAL
H	O
(	O
1	O
)	O
receptor	O
antagonist	O
,	O
had	O
little	O
effect	O
on	O
the	O
activity	O
of	O
S100A12	GENE-Y
.	O

These	O
results	O
suggest	O
that	O
olopatadine	O
has	O
a	O
new	O
mechanism	O
of	O
action	O
,	O
that	O
is	O
,	O
suppression	O
of	O
the	O
function	O
of	O
S100A12	GENE-Y
,	O
in	O
addition	O
to	O
histamine	CHEMICAL
H	O
(	O
1	O
)	O
receptor	O
antagonistic	O
activity	O
.	O
Current	O
and	O
future	O
prospects	O
for	O
anticoagulant	O
therapy	O
:	O
inhibitors	O
of	O
factor	GENE-Y
Xa	GENE-Y
and	O
factor	GENE-Y
IIa	GENE-Y
.	O
Neuromuscular	O
blocking	O
drugs	O
produce	O
muscle	O
weakness	O
by	O
interaction	O
with	O
nicotinic-acetylcholine	CHEMICAL
receptors	O
.	O

Cardiovascular	O
side	O
effects	O
have	O
been	O
reported	O
.	O

In	O
this	O
study	O
the	O
neuromuscular	O
blocking	O
drug	O
vecuronium	CHEMICAL
and	O
the	O
controls	O
gallamine	CHEMICAL
and	O
pancuronium	CHEMICAL
slowed	O
the	O
rate	O
of	O
atropine	CHEMICAL
induced	O
[	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
H	CHEMICAL
]	CHEMICAL
N-methylscopolamine	CHEMICAL
dissociation	O
from	O
Chinese	O
hamster	O
ovary	O
cells	O
expressing	O
recombinant	O
human	GENE-Y
muscarinic	GENE-Y
M2	GENE-Y
receptors	GENE-Y
K	O
(	O
off	O
)	O
values	O
min	O
(	O
-1	O
)	O
;	O
vecuronium	CHEMICAL
(	O
125	O
nM	O
)	O
,	O
atropine	CHEMICAL
0	O
.	O
45	O
+	O
/	O
-0	O
.	O
07	O
+	O
blocker	O
0	O
.	O
04	O
+	O
/	O
-0	O
.	O
02;	O
gallamine	CHEMICAL
(	O
21	O
nM	O
)	O
,	O
atropine	CHEMICAL
0	O
.	O
42	O
+	O
/	O
-0	O
.	O
05	O
+	O
blocker	O
0	O
.	O
15	O
+	O
/	O
-0	O
.	O
04;	O
pancuronium	CHEMICAL
(	O
21	O
nM	O
)	O
,	O
atropine	CHEMICAL
0	O
.	O
36	O
+	O
/	O
-0	O
.	O
03	O
+	O
blocker	O
0	O
.	O
03	O
+	O
/	O
-0	O
.	O
01	O
)	O
.	O

These	O
data	O
indicate	O
that	O
vecuronium	CHEMICAL
,	O
gallamine	CHEMICAL
and	O
pancuronium	CHEMICAL
interact	O
with	O
an	O
allosteric	O
site	O
on	O
the	O
muscarinic	GENE-Y
M2	GENE-Y
receptor	GENE-Y
(	O
located	O
on	O
the	O
heart	O
)	O
and	O
this	O
may	O
explain	O
some	O
of	O
their	O
cardiac	O
side	O
effects	O
.	O
Bimodal	O
occurrence	O
of	O
aspartoacylase	GENE-Y
in	O
myelin	O
and	O
cytosol	O
of	O
brain	O
.	O
A	O
noncatalytic	O
tetrahydrofolate	GENE-N
tight	O
binding	O
site	O
is	O
on	O
the	O
small	O
domain	O
of	O
10-formyltetrahydrofolate	GENE-Y
dehydrogenase	O
.	O
Multifunctional	O
targets	O
of	O
dietary	O
polyphenols	CHEMICAL
in	O
disease	O
:	O
a	O
case	O
for	O
the	O
chemokine	GENE-N
network	O
and	O
energy	O
metabolism	O
.	O
Cocaine	CHEMICAL
modulates	O
serum	O
levels	O
of	O
progesterone	CHEMICAL
in	O
intact	O
female	O
and	O
male	O
rats	O
,	O
as	O
well	O
as	O
in	O
pregnant	O
dams	O
,	O
and	O
progesterone	CHEMICAL
decreases	O
or	O
attenuates	O
cocaine-induced	O
behavioral	O
and	O
reward	O
responses	O
.	O

It	O
has	O
been	O
postulated	O
that	O
cocaine's	O
modulation	O
of	O
serum	O
progesterone	CHEMICAL
levels	O
may	O
in	O
turn	O
alter	O
progesterone	CHEMICAL
receptor	O
activity	O
,	O
thereby	O
contributing	O
to	O
cocaine-induced	O
alterations	O
of	O
neuronal	O
functions	O
and	O
genomic	O
regulations	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
intact	O
male	O
rats	O
received	O
acute	O
injections	O
of	O
saline	O
or	O
cocaine	CHEMICAL
(	O
15	O
or	O
30	O
mg	O
/	O
kg	O
,	O
dissolved	O
in	O
0	O
.	O
9%	O
saline	O
,	O
intraperitoneal	O
)	O
.	O

Progesterone	CHEMICAL
serum	O
levels	O
,	O
progesterone	GENE-Y
receptor	O
(	O
PR	GENE-Y
)	O
protein	O
levels	O
,	O
and	O
PR-DNA	O
binding	O
complexes	O
were	O
measured	O
in	O
the	O
striatum	O
by	O
radioimmunoassay	O
,	O
Western	O
blot	O
,	O
and	O
gel	O
shift	O
analyses	O
,	O
respectively	O
.	O

After	O
injection	O
of	O
15	O
mg	O
/	O
kg	O
of	O
cocaine	CHEMICAL
,	O
induction	O
of	O
progesterone	CHEMICAL
serum	O
levels	O
was	O
closely	O
followed	O
by	O
an	O
increase	O
in	O
receptor	O
protein	O
levels	O
and	O
DNA	O
binding	O
complexes	O
.	O

After	O
injection	O
of	O
30	O
mg	O
/	O
kg	O
of	O
cocaine	CHEMICAL
,	O
similar	O
effects	O
were	O
observed	O
along	O
with	O
an	O
attenuation	O
of	O
receptor	O
protein	O
levels	O
and	O
DNA	O
binding	O
complexes	O
at	O
60	O
min	O
.	O

Our	O
results	O
suggest	O
that	O
activation	O
of	O
progesterone	CHEMICAL
receptors	O
may	O
be	O
a	O
mechanism	O
by	O
which	O
cocaine	CHEMICAL
mediates	O
behavior	O
through	O
molecular	O
alterations	O
in	O
the	O
central	O
nervous	O
system	O
.	O
The	O
high	O
potential	O
of	O
quinazolinone	CHEMICAL
containing	O
natural	O
products	O
and	O
their	O
derivatives	O
in	O
medicinal	O
chemistry	O
led	O
us	O
to	O
discover	O
four	O
novel	O
series	O
of	O
53	O
compounds	O
of	O
quinazolinone	CHEMICAL
based	O
on	O
the	O
concept	O
of	O
molecular	O
hybridization	O
.	O

Most	O
of	O
the	O
synthesized	O
analogues	O
exhibited	O
potent	O
leishmanicidal	O
activity	O
against	O
intracellular	O
amastigotes	O
(	O
IC50	O
from	O
0	O
.	O
65	O
±	O
0	O
.	O
2	O
to	O
7	O
.	O
76	O
±	O
2	O
.	O
1	O
μM	O
)	O
as	O
compared	O
to	O
miltefosine	CHEMICAL
(	O
IC50	O
=	O
8	O
.	O
4	O
±	O
2	O
.	O
1	O
μM	O
)	O
and	O
nontoxic	O
toward	O
the	O
J-774A	O
.	O
1	O
cell	O
line	O
and	O
Vero	O
cells	O
.	O

Moreover	O
,	O
activation	O
of	O
Th1	O
type	O
and	O
suppression	O
of	O
Th2	O
type	O
immune	O
responses	O
and	O
induction	O
in	O
nitric	CHEMICAL
oxide	CHEMICAL
generation	O
proved	O
that	O
8a	O
and	O
8g	O
induce	O
murine	O
macrophages	O
to	O
prevent	O
survival	O
of	O
parasites	O
.	O

Compounds	O
8a	O
and	O
8g	O
exhibited	O
significant	O
in	O
vivo	O
inhibition	O
of	O
parasite	O
73	O
.	O
15	O
±	O
12	O
.	O
69%	O
and	O
80	O
.	O
93	O
±	O
10	O
.	O
50%	O
against	O
Leishmania	O
donovani	O
/	O
hamster	O
model	O
.	O

Our	O
results	O
indicate	O
that	O
compounds	O
8a	O
,	O
8g	O
,	O
and	O
9f	O
represent	O
a	O
new	O
structural	O
lead	O
for	O
this	O
serious	O
and	O
neglected	O
disease	O
.	O
The	O
options	O
for	O
migraine	O
treatment	O
have	O
increased	O
in	O
the	O
recent	O
years	O
and	O
will	O
expand	O
in	O
the	O
near	O
future	O
.	O

In	O
this	O
work	O
both	O
recent	O
and	O
future	O
options	O
for	O
migraine	O
treatment	O
are	O
critically	O
reviewed	O
.	O

Firstly	O
the	O
late	O
advances	O
in	O
the	O
symptomatic	O
treatment	O
of	O
migraine	O
,	O
including	O
the	O
new	O
5-HT1B	GENE-N
/	GENE-N
D	GENE-N
agonists	O
"triptans"	O
appeared	O
after	O
sumatriptan	CHEMICAL
,	O
are	O
reviewed	O
.	O

Possible	O
alternative	O
,	O
such	O
as	O
selective	O
5-HT1D	GENE-Y
and	O
5-HT1F	GENE-Y
agonists	O
,	O
are	O
also	O
discussed	O
.	O

In	O
the	O
second	O
part	O
of	O
this	O
manuscript	O
the	O
new	O
,	O
possible	O
options	O
for	O
the	O
preventive	O
treatment	O
of	O
migraine	O
comprising	O
"antiepileptics"	O
,	O
such	O
as	O
valproic	CHEMICAL
acid	CHEMICAL
,	O
gabapentin	CHEMICAL
and	O
topiramate	CHEMICAL
,	O
calcium-antagonists	O
,	O
such	O
as	O
cyclandelate	CHEMICAL
and	O
dotarizin	CHEMICAL
,	O
and	O
a	O
miscellany	O
,	O
including	O
riboflavin	CHEMICAL
,	O
are	O
analysed	O
.	O

Finally	O
,	O
possible	O
compounds	O
for	O
the	O
future	O
,	O
such	O
as	O
the	O
selective	O
inhibitors	O
of	O
neurokinin	GENE-N
receptors	GENE-N
or	O
drugs	O
acting	O
upon	O
neuronal	GENE-N
calcium	CHEMICAL
channels	O
,	O
are	O
commented	O
.	O

From	O
this	O
review	O
we	O
conclude	O
that	O
while	O
there	O
have	O
been	O
relevant	O
advances	O
in	O
the	O
symptomatic	O
treatment	O
of	O
migraine	O
,	O
there	O
is	O
a	O
need	O
for	O
the	O
development	O
of	O
better	O
preventive	O
compounds	O
.	O
Adenylosuccinate	CHEMICAL
synthetase	O
(	O
AdSS	GENE-Y
)	O
catalyses	O
the	O
Mg	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
dependent	O
formation	O
of	O
adenylosuccinate	CHEMICAL
from	O
IMP	CHEMICAL
and	O
aspartate	CHEMICAL
,	O
the	O
reaction	O
being	O
driven	O
by	O
the	O
hydrolysis	O
of	O
GTP	CHEMICAL
to	O
GDP	CHEMICAL
.	O

All	O
characterized	O
AdSS	GENE-Y
thus	O
far	O
exhibit	O
a	O
random	O
kinetic	O
mechanism	O
.	O

We	O
present	O
here	O
kinetic	O
evidence	O
that	O
unlike	O
all	O
other	O
AdSS	GENE-Y
,	O
Plasmodium	GENE-Y
falciparum	GENE-Y
AdSS	GENE-Y
(	O
PfAdSS	GENE-Y
)	O
has	O
ordered	O
substrate	O
binding	O
.	O

Inhibition	O
studies	O
show	O
that	O
binding	O
of	O
GTP	CHEMICAL
requires	O
IMP	CHEMICAL
binding	O
while	O
aspartate	O
binds	O
to	O
the	O
enzyme-IMP-GTP	CHEMICAL
complex	O
.	O

A	O
structural	O
basis	O
for	O
this	O
difference	O
in	O
mechanism	O
is	O
presented	O
.	O

Kinetically	O
,	O
PfAdSS	GENE-Y
is	O
closer	O
to	O
the	O
mouse	O
acidic	O
isozyme	O
rather	O
than	O
to	O
the	O
mouse	O
basic	O
isozyme	O
.	O

The	O
mouse	O
acidic	O
isozyme	O
is	O
thought	O
to	O
play	O
a	O
role	O
in	O
the	O
purine	CHEMICAL
nucleotide	CHEMICAL
biosynthetic	O
pathway	O
.	O

Regulation	O
of	O
PfAdSS	GENE-Y
in	O
vivo	O
can	O
therefore	O
,	O
be	O
expected	O
to	O
be	O
similar	O
to	O
the	O
mouse	O
acidic	O
isozyme	O
,	O
in	O
agreement	O
with	O
the	O
role	O
of	O
PfAdSS	GENE-Y
as	O
the	O
only	O
pathway	O
for	O
the	O
synthesis	O
of	O
adenine	CHEMICAL
nucleotides	CHEMICAL
in	O
the	O
parasite	O
.	O

However	O
,	O
PfAdSS	GENE-Y
differs	O
from	O
both	O
the	O
mammalian	O
homologs	O
in	O
that	O
fructose-1	CHEMICAL
,	CHEMICAL
6-bisphosphate	CHEMICAL
,	O
a	O
potent	O
inhibitor	O
of	O
the	O
mammalian	O
enzyme	O
,	O
is	O
an	O
activator	O
of	O
PfAdSS	GENE-Y
.	O

The	O
differences	O
highlighted	O
here	O
are	O
promising	O
in	O
terms	O
of	O
species-specific	O
drug	O
design	O
,	O
targeting	O
this	O
essential	O
enzyme	O
in	O
the	O
parasite	O
.	O
Electronic	O
transitions	O
of	O
protonated	O
and	O
deprotonated	O
amino	CHEMICAL
acids	CHEMICAL
in	O
aqueous	O
solution	O
in	O
the	O
region	O
145-300	O
nm	O
studied	O
by	O
attenuated	O
total	O
reflection	O
far-ultraviolet	O
spectroscopy	O
.	O
Progesterone	CHEMICAL
receptor	O
(	O
PR	GENE-Y
)	O
plays	O
a	O
key	O
role	O
in	O
reproductive	O
functions	O
,	O
and	O
compounds	O
that	O
inhibit	O
progesterone	CHEMICAL
action	O
(	O
antiprogestins	CHEMICAL
)	O
have	O
potential	O
use	O
in	O
the	O
treatment	O
of	O
estrogen-	O
and	O
progesterone-dependent	O
diseases	O
,	O
including	O
uterine	O
leiomyomas	O
and	O
breast	O
cancer	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
chemically	O
synthesized	O
novel	O
17-fluorinated	CHEMICAL
steroids	CHEMICAL
and	O
evaluated	O
the	O
cytotoxicity	O
profiles	O
of	O
these	O
compounds	O
in	O
T47D	O
breast	O
cancer	O
cells	O
compared	O
to	O
the	O
activity	O
of	O
known	O
antiprogestins	CHEMICAL
,	O
including	O
ZK230	CHEMICAL
211	CHEMICAL
,	O
RU-486	CHEMICAL
,	O
CDB2914	CHEMICAL
,	O
CDB4124	CHEMICAL
and	O
ORG33628	CHEMICAL
.	O

We	O
analyzed	O
in	O
vitro	O
receptor-binding	O
assays	O
and	O
PR-transactivation	O
assays	O
to	O
establish	O
the	O
antiprogestational	O
activity	O
of	O
these	O
molecules	O
.	O

The	O
representative	O
antiprogestin	O
EC304	CHEMICAL
was	O
found	O
to	O
inhibit	O
in	O
vitro	O
tumorigenicity	O
in	O
a	O
dose-dependent	O
fashion	O
in	O
T47D	O
cells	O
by	O
a	O
colony	O
formation	O
assay	O
at	O
1	O
and	O
10nM	O
concentrations	O
.	O

The	O
potent	O
in	O
vivo	O
antiprogestational	O
activity	O
of	O
EC304	CHEMICAL
was	O
also	O
demonstrated	O
in	O
an	O
antinidation	O
assay	O
for	O
the	O
interruption	O
of	O
early	O
pregnancy	O
in	O
rats	O
.	O

The	O
strong	O
antiprogestational	O
activity	O
and	O
absence	O
of	O
antiglucocorticoid	O
activity	O
in	O
EC	O
compounds	O
may	O
demonstrate	O
their	O
utility	O
in	O
the	O
treatment	O
of	O
leiomyoma	O
,	O
endometriosis	O
and	O
breast	O
cancer	O
.	O
Permanent	O
Neonatal	O
Diabetes	O
in	O
INSC94Y	GENE-N
Transgenic	O
Pigs	O
.	O
Theoretical	O
Characterization	O
of	O
Galanin	GENE-Y
Receptor	GENE-Y
Type	GENE-Y
3	GENE-Y
(	O
Gal3	GENE-Y
)	O
and	O
Its	O
Interaction	O
with	O
Agonist	O
(	O
GALANIN	GENE-Y
)	O
and	O
Antagonists	O
(	O
SNAP	O
37889	O
and	O
SNAP	O
398299	O
)	O
:	O
An	O
In	O
Silico	O
Analysis	O
.	O
Cocaine-	O
and	O
amphetamine-regulated	O
transcript	O
(	O
CART	GENE-Y
)	O
is	O
widely	O
expressed	O
in	O
the	O
rat	O
central	O
nervous	O
system	O
,	O
notably	O
in	O
areas	O
involved	O
in	O
control	O
of	O
autonomic	O
and	O
neuroendocrine	O
functions	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
CART	GENE-Y
peptide	GENE-Y
fragment	O
55-102	O
,	O
referred	O
to	O
herein	O
as	O
CARTp	GENE-Y
,	O
by	O
intrathecal	O
injection	O
on	O
blood	O
pressure	O
(	O
BP	O
)	O
and	O
heart	O
rate	O
(	O
HR	O
)	O
before	O
and	O
after	O
intrathecal	O
glutamate	CHEMICAL
in	O
urethane-anesthetized	O
male	O
Sprague-Dawley	O
rats	O
.	O

CARTp	GENE-Y
(	O
0	O
.	O
1-10	O
nmol	O
)	O
administered	O
intrathecally	O
caused	O
no	O
or	O
a	O
small	O
,	O
statistically	O
insignificant	O
increase	O
of	O
blood	O
pressure	O
and	O
heart	O
rate	O
,	O
except	O
at	O
the	O
concentration	O
of	O
10	O
nmol	O
,	O
which	O
caused	O
a	O
significant	O
increase	O
of	O
blood	O
pressure	O
and	O
heart	O
rate	O
.	O

Intrathecal	O
glutamate	CHEMICAL
(	O
0	O
.	O
1-10	O
nmol	O
)	O
produced	O
a	O
dose-dependent	O
increase	O
in	O
arterial	O
pressure	O
and	O
heart	O
rate	O
.	O

Pretreatment	O
with	O
CARTp	GENE-Y
dose-dependently	O
potentiated	O
the	O
pressor	O
effects	O
of	O
glutamate	CHEMICAL
(	O
1	O
nmol	O
)	O
,	O
which	O
by	O
itself	O
elicited	O
a	O
moderate	O
increase	O
of	O
blood	O
pressure	O
and	O
heart	O
rate	O
.	O

Further	O
,	O
CARTp	GENE-Y
significantly	O
potentiated	O
the	O
tachycardic	O
effect	O
of	O
glutamate	CHEMICAL
at	O
1	O
and	O
5	O
nmol	O
,	O
but	O
attenuated	O
the	O
response	O
at	O
10	O
nmol	O
.	O

The	O
effect	O
of	O
CARTp	GENE-Y
was	O
long-lasting	O
,	O
as	O
it	O
enhanced	O
glutamatergic	O
responses	O
up	O
to	O
90	O
min	O
after	O
administration	O
.	O

Prior	O
injection	O
of	O
CARTp	GENE-Y
antiserum	O
(	O
1	O
:	O
500	O
)	O
but	O
not	O
normal	O
rabbit	O
serum	O
nullified	O
the	O
potentiating	O
effect	O
of	O
CARTp	GENE-Y
on	O
glutamatergic	O
responses	O
.	O

The	O
result	O
suggests	O
that	O
CARTp	GENE-Y
,	O
whose	O
immunoreactivity	O
is	O
detectable	O
in	O
sympathetic	O
preganglionic	O
neurons	O
as	O
well	O
as	O
in	O
fibers	O
projecting	O
into	O
the	O
intermediolateral	O
cell	O
column	O
,	O
augments	O
spinal	O
sympathetic	O
outflow	O
elicited	O
by	O
glutamate	CHEMICAL
at	O
lower	O
concentrations	O
and	O
may	O
directly	O
excite	O
neurons	O
in	O
the	O
intermediolateral	O
cell	O
column	O
at	O
higher	O
concentrations	O
.	O
3-Methylcholanthrene	CHEMICAL
(	O
MC	O
)	O
is	O
a	O
readily	O
metabolized	O
aryl	CHEMICAL
hydrocarbon	CHEMICAL
receptor	O
(	O
AHR	GENE-Y
)	O
agonist	O
.	O

MC	O
disrupts	O
expression	O
of	O
mouse	GENE-Y
hepatic	GENE-Y
growth	GENE-Y
hormone	GENE-Y
(	O
GH	GENE-Y
)	O
signaling	O
components	O
and	O
suppresses	O
cytochrome	GENE-Y
P450	GENE-Y
2D9	GENE-Y
(	O
Cyp2d9	GENE-Y
)	O
,	O
a	O
male-specific	O
gene	O
controlled	O
by	O
pulsatile	O
GH	GENE-Y
via	O
signal	GENE-Y
transducer	GENE-Y
and	GENE-Y
activator	GENE-Y
of	GENE-Y
transcription	GENE-Y
5b	GENE-Y
(	O
STAT5b	GENE-Y
)	O
.	O

To	O
determine	O
if	O
these	O
effects	O
of	O
MC	O
depend	O
on	O
hepatic	GENE-N
microsomal	GENE-N
P450-mediated	O
activity	O
,	O
we	O
examined	O
biologic	O
responses	O
to	O
MC	O
treatment	O
in	O
liver	O
Cpr-null	O
(	O
LCN	O
)	O
mice	O
with	O
hepatocyte-specific	O
conditional	O
deletion	O
of	O
NADPH-cytochrome	O
P450	O
oxidoreductase	O
(	O
POR	GENE-Y
)	O
.	O

MC	O
caused	O
mild	O
induction	O
of	O
Por	GENE-Y
and	O
a	O
hepatic	O
inflammatory	O
marker	O
in	O
wild-type	O
mice	O
,	O
whereas	O
MC	O
caused	O
strong	O
induction	O
of	O
AHR	GENE-Y
target	O
genes	O
,	O
Cyp1a1	GENE-Y
,	O
Cyp1a2	GENE-Y
,	O
and	O
Cyp1b1	GENE-Y
in	O
wild-type	O
and	O
LCN	O
mice	O
.	O

Two	O
mouse	GENE-Y
hepatic	GENE-Y
STAT5b	GENE-Y
target	O
genes	O
,	O
Cyp2d9	GENE-Y
and	O
major	GENE-Y
urinary	GENE-Y
protein	GENE-Y
2	GENE-Y
(	O
Mup2	GENE-Y
)	O
,	O
were	O
suppressed	O
by	O
MC	O
in	O
wild-type	O
mice	O
,	O
and	O
the	O
CYP2D9	GENE-Y
mRNA	O
response	O
was	O
maintained	O
in	O
LCN	O
mice	O
.	O

In	O
wild-type	O
mice	O
only	O
,	O
MC	O
decreased	O
hepatic	O
GH	GENE-Y
receptor	GENE-Y
(	O
GHR	GENE-Y
)	O
mRNA	O
but	O
increased	O
GHR	GENE-Y
protein	O
levels	O
.	O

There	O
was	O
an	O
apparent	O
impairment	O
of	O
STAT5	GENE-Y
phosphorylation	O
by	O
MC	O
in	O
wild-type	O
and	O
LCN	O
mice	O
,	O
but	O
large	O
interanimal	O
variation	O
prevented	O
achievement	O
of	O
statistical	O
significance	O
.	O

In	O
vehicle-treated	O
mice	O
,	O
basal	O
levels	O
of	O
MUP2	GENE-Y
mRNA	O
,	O
GHR	GENE-Y
mRNA	O
,	O
GHR	O
protein	O
,	O
and	O
the	O
activation	O
status	O
of	O
extracellular	GENE-Y
signal-regulated	GENE-Y
kinase	GENE-Y
2	GENE-Y
and	O
Akt	GENE-Y
were	O
influenced	O
by	O
hepatic	O
Por	GENE-Y
genetic	O
status	O
.	O

These	O
results	O
indicate	O
that	O
the	O
effects	O
of	O
MC	O
on	O
hepatic	GENE-Y
GH	GENE-Y
signaling	O
components	O
and	O
target	O
genes	O
are	O
complex	O
,	O
involving	O
aspects	O
that	O
are	O
both	O
dependent	O
and	O
independent	O
of	O
hepatic	GENE-N
microsomal	GENE-N
P450-mediated	O
activity	O
.	O
24R	CHEMICAL
,	CHEMICAL
25-	CHEMICAL
(	CHEMICAL
OH	CHEMICAL
)	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
D	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
mediates	O
its	O
membrane	O
receptor-dependent	O
effects	O
on	O
protein	GENE-N
kinase	GENE-N
C	GENE-N
and	O
alkaline	GENE-N
phosphatase	GENE-N
via	O
phospholipase	GENE-N
A	GENE-N
(	GENE-N
2	GENE-N
)	GENE-N
and	O
cyclooxygenase-1	GENE-Y
but	O
not	O
cyclooxygenase-2	GENE-Y
in	O
growth	O
plate	O
chondrocytes	O
.	O
Novel	O
signaling	O
pathways	O
promote	O
a	O
paracrine	O
wave	O
of	O
prostacyclin-induced	O
vascular	O
smooth	O
muscle	O
differentiation	O
.	O
Krüppel-like	GENE-Y
Factor	GENE-Y
3	GENE-Y
(	O
KLF3	GENE-Y
)	O
is	O
a	O
transcriptional	O
regulator	O
that	O
we	O
have	O
shown	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
adipogenesis	O
in	O
vitro	O
.	O

Here	O
we	O
report	O
that	O
KLF3	GENE-Y
null	O
mice	O
are	O
lean	O
and	O
protected	O
from	O
diet-induced	O
obesity	O
and	O
glucose	CHEMICAL
intolerance	O
.	O

On	O
a	O
chow	O
diet	O
,	O
plasma	O
levels	O
of	O
leptin	GENE-Y
are	O
decreased	O
,	O
and	O
adiponectin	GENE-Y
is	O
increased	O
.	O

Despite	O
significant	O
reductions	O
in	O
body	O
weight	O
and	O
adiposity	O
,	O
wildtype	O
and	O
knockout	O
animals	O
show	O
equivalent	O
energy	O
intake	O
,	O
expenditure	O
and	O
excretion	O
.	O

To	O
investigate	O
the	O
molecular	O
events	O
underlying	O
these	O
observations	O
,	O
we	O
used	O
microarray	O
analysis	O
to	O
compare	O
gene	O
expression	O
in	O
Klf3	GENE-Y
(	O
+	O
/	O
+	O
)	O
and	O
Klf3	GENE-Y
(	O
-	O
/	O
-	O
)	O
tissues	O
.	O

We	O
found	O
that	O
mRNA	O
expression	O
of	O
Fam132a	GENE-Y
,	O
which	O
encodes	O
a	O
newly	O
identified	O
insulin-sensitizing	O
adipokine	GENE-N
,	O
adipolin	GENE-Y
,	O
is	O
significantly	O
upregulated	O
in	O
the	O
absence	O
of	O
KLF3	GENE-Y
.	O

We	O
confirmed	O
that	O
KLF3	GENE-Y
binds	O
the	O
Fam132a	GENE-N
promoter	GENE-N
in	O
vitro	O
and	O
in	O
vivo	O
and	O
that	O
this	O
leads	O
to	O
repression	O
of	O
promoter	O
activity	O
.	O

Further	O
,	O
plasma	O
adipolin	GENE-Y
levels	O
were	O
significantly	O
increased	O
in	O
Klf3	GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
compared	O
to	O
wild-type	O
littermates	O
.	O

Boosting	O
levels	O
of	O
adipolin	GENE-Y
via	O
targeting	O
of	O
KLF3	GENE-Y
offers	O
a	O
novel	O
potential	O
therapeutic	O
strategy	O
for	O
the	O
treatment	O
of	O
insulin	GENE-N
resistance	O
.	O
At	O
present	O
the	O
only	O
FDA-approved	O
therapy	O
for	O
Alzheimer's	O
disease	O
involves	O
the	O
administration	O
of	O
acetylcholinesterase	GENE-Y
inhibitors	O
,	O
to	O
alleviate	O
the	O
cholinergic	O
deficit	O
associated	O
with	O
this	O
disease	O
.	O

However	O
,	O
none	O
of	O
the	O
approved	O
drugs	O
is	O
ideal	O
in	O
efficacy	O
or	O
tolerability	O
.	O

One	O
possible	O
strategy	O
to	O
improve	O
selectivity	O
and	O
potency	O
is	O
to	O
design	O
drugs	O
that	O
can	O
simultaneously	O
bind	O
to	O
the	O
catalytic	O
and	O
peripheral	O
anionic	O
sites	O
of	O
AChE	GENE-Y
.	O

In	O
this	O
review	O
we	O
will	O
describe	O
the	O
development	O
of	O
dimeric	O
AChE	GENE-Y
inhibitors	O
,	O
from	O
the	O
early	O
observations	O
of	O
high	O
inhibition	O
potency	O
by	O
bis-quaternary	O
inhibitors	O
,	O
to	O
the	O
structure-based	O
design	O
of	O
dimers	O
based	O
on	O
tacrine	CHEMICAL
,	O
huperzine	CHEMICAL
A	CHEMICAL
,	O
galanthamine	CHEMICAL
,	O
and	O
polyamines	CHEMICAL
.	O
Human	GENE-Y
polymerase	GENE-Y
kappa	GENE-Y
uses	O
a	O
template-slippage	O
deletion	O
mechanism	O
,	O
but	O
can	O
realign	O
the	O
slipped	O
strands	O
to	O
favour	O
base	O
substitution	O
mutations	O
over	O
deletions	O
.	O
Eosinophilic	O
oesophagitis	O
:	O
a	O
common	O
cause	O
of	O
dysphagia	O
in	O
young	O
The	O
anticonvulsant	O
activity	O
of	O
inhibitors	O
of	O
monoamine	GENE-N
oxidase	O
(	O
MAO	GENE-N
)	O
was	O
reported	O
early	O
after	O
the	O
development	O
of	O
irreversible	O
MAO	GENE-N
inhibitors	O
such	O
as	O
tranylcypromine	CHEMICAL
,	O
but	O
was	O
never	O
clinically	O
used	O
because	O
of	O
the	O
adverse	O
effects	O
of	O
these	O
compounds	O
.	O

The	O
more	O
recently	O
developed	O
reversible	O
MAO	GENE-N
inhibitors	O
with	O
selectivity	O
for	O
either	O
the	O
MAO-A	GENE-Y
or	O
MAO-B	GENE-Y
isoenzyme	O
forms	O
have	O
not	O
been	O
studied	O
extensively	O
in	O
animal	O
models	O
of	O
epilepsy	O
,	O
so	O
it	O
is	O
not	O
known	O
which	O
type	O
of	O
MAO	GENE-N
inhibitor	O
is	O
particularly	O
effective	O
in	O
this	O
respect	O
.	O

We	O
compared	O
the	O
following	O
drugs	O
in	O
the	O
kindling	O
model	O
of	O
epilepsy	O
:	O
1	O
)	O
L-deprenyl	CHEMICAL
(	O
selegiline	CHEMICAL
)	O
,	O
i	O
.	O

e	O
.	O

,	O
an	O
irreversible	O
inhibitor	O
of	O
MAO-B	GENE-Y
,	O
which	O
,	O
however	O
,	O
also	O
inhibits	O
MAO-A	GENE-Y
at	O
higher	O
doses	O
,	O
2	O
)	O
the	O
novel	O
reversible	O
MAO-B	GENE-Y
inhibitor	O
LU	CHEMICAL
53439	CHEMICAL
(	O
3	CHEMICAL
,	CHEMICAL
4-dimethyl-7-	CHEMICAL
(	CHEMICAL
2-isopropyl-1	CHEMICAL
,	CHEMICAL
3	CHEMICAL
,	CHEMICAL
4-thiadiazol-5-yl	CHEMICAL
)	CHEMICAL
-methoxy-coumarin	CHEMICAL
)	O
,	O
which	O
is	O
much	O
more	O
selective	O
for	O
MAO-B	GENE-Y
than	O
L-deprenyl	CHEMICAL
,	O
3	O
)	O
the	O
novel	O
reversible	O
and	O
highly	O
selective	O
MAO-A	GENE-Y
inhibitor	O
LU	CHEMICAL
43839	CHEMICAL
(	O
esuprone;	O
7-hydroxy-3	CHEMICAL
,	CHEMICAL
4-dimethylcoumarin	CHEMICAL
ethanesulfonate	CHEMICAL
)	O
,	O
and	O
4	O
)	O
the	O
irreversible	O
nonselective	O
MAO	GENE-N
inhibitor	O
tranylcypromine	CHEMICAL
.	O

Esuprone	CHEMICAL
proved	O
to	O
be	O
an	O
effective	O
anticonvulsant	O
in	O
the	O
kindling	O
model	O
with	O
a	O
similar	O
potency	O
as	O
L-deprenyl	CHEMICAL
.	O

In	O
contrast	O
to	O
esuprone	CHEMICAL
and	O
L-deprenyl	CHEMICAL
,	O
the	O
selective	O
MAO-B	GENE-Y
inhibitor	O
LU	CHEMICAL
53439	CHEMICAL
was	O
not	O
effective	O
in	O
the	O
kindling	O
model;	O
this	O
substantiates	O
the	O
previous	O
notion	O
that	O
the	O
anticonvulsant	O
activity	O
of	O
L-deprenyl	CHEMICAL
is	O
not	O
related	O
to	O
MAO-B	GENE-Y
inhibition	O
,	O
but	O
to	O
other	O
effects	O
of	O
this	O
drug	O
,	O
such	O
as	O
inhibition	O
of	O
MAO-A	GENE-Y
.	O

Drugs	O
inhibiting	O
both	O
MAO-A	GENE-Y
and	O
MAO-B	GENE-Y
to	O
a	O
similar	O
extent	O
(	O
tranylcypromine	CHEMICAL
)	O
or	O
combinations	O
of	O
selective	O
MAO-A	GENE-Y
and	O
MAO-B	GENE-Y
inhibitors	O
(	O
esuprone	CHEMICAL
plus	O
LU	CHEMICAL
53439	CHEMICAL
)	O
had	O
no	O
advantage	O
over	O
MAO-A	GENE-Y
inhibition	O
alone	O
,	O
but	O
were	O
less	O
well	O
tolerated	O
.	O

The	O
data	O
thus	O
suggest	O
that	O
selective	O
MAO-A	GENE-Y
inhibitors	O
such	O
as	O
esuprone	CHEMICAL
may	O
be	O
an	O
interesting	O
new	O
approach	O
for	O
the	O
treatment	O
of	O
epilepsy	O
.	O
Cyprodinil	CHEMICAL
as	O
an	O
activator	O
of	O
aryl	GENE-Y
hydrocarbon	GENE-Y
receptor	O
.	O
1	O
.	O

The	O
effects	O
of	O
10	O
mg	O
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-	CHEMICAL
and	CHEMICAL
(	CHEMICAL
-	CHEMICAL
)	CHEMICAL
-chlorpheniramine	CHEMICAL
and	O
5	O
mg	O
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-	CHEMICAL
and	CHEMICAL
(	CHEMICAL
-	CHEMICAL
)	CHEMICAL
-dimethindene	CHEMICAL
on	O
daytime	O
sleep	O
latencies	O
,	O
digit	O
symbol	O
substitution	O
and	O
subjective	O
assessments	O
of	O
mood	O
and	O
well-being	O
were	O
studied	O
in	O
6	O
healthy	O
young	O
adult	O
humans	O
.	O

Each	O
subject	O
also	O
took	O
5	O
mg	O
triprolidine	CHEMICAL
hydrochloride	CHEMICAL
as	O
an	O
active	O
control	O
and	O
two	O
placebos	O
.	O

2	O
.	O

Daytime	O
sleep	O
latencies	O
were	O
reduced	O
with	O
triprolidine	CHEMICAL
,	O
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-chlorpheniramine	CHEMICAL
and	O
(	CHEMICAL
-	CHEMICAL
)	CHEMICAL
-dimethindene	CHEMICAL
,	O
and	O
subjects	O
also	O
reported	O
that	O
they	O
felt	O
more	O
sleepy	O
after	O
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-chlorpheniramine	CHEMICAL
and	O
(	CHEMICAL
-	CHEMICAL
)	CHEMICAL
-dimethindene	CHEMICAL
.	O

Performance	O
on	O
digit	O
symbol	O
substitution	O
was	O
impaired	O
with	O
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-chlorpheniramine	CHEMICAL
.	O

3	O
.	O

Changes	O
in	O
measures	O
with	O
(	CHEMICAL
-	CHEMICAL
)	CHEMICAL
-chlorpheniramine	CHEMICAL
and	O
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-dimethindene	CHEMICAL
were	O
not	O
different	O
from	O
changes	O
with	O
placebo	O
.	O

4	O
.	O

In	O
the	O
present	O
study	O
,	O
changes	O
in	O
measures	O
of	O
drowsiness	O
and	O
performance	O
were	O
limited	O
to	O
the	O
enantiomers	O
with	O
high	O
affinity	O
for	O
the	O
histamine	GENE-Y
H1-receptor	O
.	O

These	O
findings	O
strongly	O
suggest	O
that	O
sedation	O
can	O
arise	O
from	O
H1-receptor	GENE-Y
antagonism	O
alone	O
,	O
and	O
provide	O
further	O
support	O
for	O
the	O
belief	O
that	O
the	O
histaminergic	O
system	O
is	O
concerned	O
with	O
the	O
regulation	O
of	O
alertness	O
in	O
man	O
.	O
ERP	O
evidence	O
suggests	O
executive	O
dysfunction	O
in	O
ecstasy	CHEMICAL
polydrug	O
users	O
.	O
The	O
comparative	O
formation	O
of	O
the	O
heterocyclic	O
aromatic	O
amine	O
2-amino-1-methyl-6-phenylimidazo	CHEMICAL
[	CHEMICAL
4	CHEMICAL
,	CHEMICAL
5-b	CHEMICAL
]	CHEMICAL
pyridine	CHEMICAL
(	O
PhIP	CHEMICAL
)	O
in	O
both	O
creatinine	CHEMICAL
/	O
phenylalanine	CHEMICAL
(	O
CRN	CHEMICAL
/	O
Phe	CHEMICAL
)	O
and	O
creatinine	CHEMICAL
/	O
phenylalanine	CHEMICAL
/	O
4-oxo-2-nonenal	CHEMICAL
(	O
CRN	CHEMICAL
/	O
Phe	CHEMICAL
/	O
ON	O
)	O
systems	O
was	O
studied	O
to	O
analyse	O
the	O
ability	O
of	O
lipid-derived	O
reactive	O
carbonyls	CHEMICAL
to	O
promote	O
PhIP	CHEMICAL
formation	O
.	O

Although	O
PhIP	CHEMICAL
was	O
produced	O
to	O
some	O
extent	O
in	O
the	O
CRN	CHEMICAL
/	O
Phe	CHEMICAL
system	O
,	O
the	O
presence	O
of	O
the	O
oxidized	O
lipid	O
increased	O
considerably	O
the	O
amount	O
of	O
PhIP	CHEMICAL
produced	O
.	O

This	O
increase	O
seemed	O
to	O
be	O
a	O
consequence	O
of	O
the	O
decrease	O
in	O
the	O
E	O
(	O
a	O
)	O
of	O
the	O
reaction	O
when	O
the	O
lipid	O
was	O
present	O
,	O
which	O
diminished	O
from	O
112	O
.	O
9	O
to	O
80	O
.	O
9	O
kJ	O
/	O
mol	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
addition	O
of	O
the	O
lipid	O
did	O
not	O
seem	O
to	O
produce	O
PhIP	CHEMICAL
by	O
an	O
alternative	O
mechanism	O
because	O
PhIP	CHEMICAL
was	O
formed	O
analogously	O
in	O
both	O
CRN	CHEMICAL
/	O
Phe	CHEMICAL
and	O
CRN	CHEMICAL
/	O
Phe	CHEMICAL
/	O
ON	O
systems	O
as	O
a	O
function	O
of	O
pH	O
,	O
creatinine	CHEMICAL
concentration	O
,	O
phenylalanine	CHEMICAL
concentration	O
,	O
time	O
,	O
temperature	O
,	O
oxygen	CHEMICAL
concentration	O
in	O
the	O
reaction	O
atmosphere	O
,	O
and	O
the	O
addition	O
of	O
different	O
amounts	O
of	O
ammonia	CHEMICAL
.	O

All	O
these	O
results	O
suggest	O
that	O
the	O
ability	O
of	O
lipid	O
oxidation	O
products	O
to	O
produce	O
PhIP	CHEMICAL
is	O
related	O
to	O
their	O
capacity	O
to	O
induce	O
the	O
Strecker	O
degradation	O
of	O
phenylalanine	CHEMICAL
to	O
phenylacetaldehyde	CHEMICAL
.	O

Therefore	O
,	O
any	O
other	O
reactive	O
carbonyl	CHEMICAL
compound	O
that	O
can	O
produce	O
the	O
Strecker	O
degradation	O
of	O
phenylalanine	CHEMICAL
should	O
also	O
be	O
considered	O
as	O
a	O
potential	O
inducer	O
of	O
PhIP	CHEMICAL
formation	O
under	O
appropriate	O
conditions	O
.	O
Adenylosuccinate	CHEMICAL
synthetase	O
(	O
AdSS	GENE-Y
)	O
catalyses	O
the	O
Mg	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
dependent	O
formation	O
of	O
adenylosuccinate	CHEMICAL
from	O
IMP	CHEMICAL
and	O
aspartate	CHEMICAL
,	O
the	O
reaction	O
being	O
driven	O
by	O
the	O
hydrolysis	O
of	O
GTP	CHEMICAL
to	O
GDP	CHEMICAL
.	O

All	O
characterized	O
AdSS	GENE-Y
thus	O
far	O
exhibit	O
a	O
random	O
kinetic	O
mechanism	O
.	O

We	O
present	O
here	O
kinetic	O
evidence	O
that	O
unlike	O
all	O
other	O
AdSS	GENE-Y
,	O
Plasmodium	GENE-Y
falciparum	GENE-Y
AdSS	GENE-Y
(	O
PfAdSS	GENE-Y
)	O
has	O
ordered	O
substrate	O
binding	O
.	O

Inhibition	O
studies	O
show	O
that	O
binding	O
of	O
GTP	CHEMICAL
requires	O
IMP	CHEMICAL
binding	O
while	O
aspartate	O
binds	O
to	O
the	O
enzyme-IMP-GTP	CHEMICAL
complex	O
.	O

A	O
structural	O
basis	O
for	O
this	O
difference	O
in	O
mechanism	O
is	O
presented	O
.	O

Kinetically	O
,	O
PfAdSS	GENE-Y
is	O
closer	O
to	O
the	O
mouse	O
acidic	O
isozyme	O
rather	O
than	O
to	O
the	O
mouse	O
basic	O
isozyme	O
.	O

The	O
mouse	O
acidic	O
isozyme	O
is	O
thought	O
to	O
play	O
a	O
role	O
in	O
the	O
purine	CHEMICAL
nucleotide	CHEMICAL
biosynthetic	O
pathway	O
.	O

Regulation	O
of	O
PfAdSS	GENE-Y
in	O
vivo	O
can	O
therefore	O
,	O
be	O
expected	O
to	O
be	O
similar	O
to	O
the	O
mouse	O
acidic	O
isozyme	O
,	O
in	O
agreement	O
with	O
the	O
role	O
of	O
PfAdSS	GENE-Y
as	O
the	O
only	O
pathway	O
for	O
the	O
synthesis	O
of	O
adenine	CHEMICAL
nucleotides	CHEMICAL
in	O
the	O
parasite	O
.	O

However	O
,	O
PfAdSS	GENE-Y
differs	O
from	O
both	O
the	O
mammalian	O
homologs	O
in	O
that	O
fructose-1	CHEMICAL
,	CHEMICAL
6-bisphosphate	CHEMICAL
,	O
a	O
potent	O
inhibitor	O
of	O
the	O
mammalian	O
enzyme	O
,	O
is	O
an	O
activator	O
of	O
PfAdSS	GENE-Y
.	O

The	O
differences	O
highlighted	O
here	O
are	O
promising	O
in	O
terms	O
of	O
species-specific	O
drug	O
design	O
,	O
targeting	O
this	O
essential	O
enzyme	O
in	O
the	O
parasite	O
.	O
QT	O
prolongation	O
,	O
a	O
risk	O
factor	O
for	O
arrhythmias	O
,	O
can	O
result	O
from	O
genetic	O
variants	O
in	O
one	O
(	O
or	O
more	O
)	O
of	O
the	O
genes	O
governing	O
cardiac	O
repolarization	O
as	O
well	O
as	O
intake	O
of	O
drugs	O
known	O
to	O
affect	O
a	O
cardiac	O
K	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
channel	O
encoded	O
by	O
human	GENE-Y
ether-a-go-go-related	O
gene	O
(	O
HERG	GENE-Y
)	O
.	O

In	O
this	O
paper	O
,	O
we	O
will	O
report	O
a	O
case	O
of	O
drug-induced	O
long	O
QT	O
syndrome	O
associated	O
with	O
an	O
H	GENE-Y
(	GENE-Y
1	GENE-Y
)	GENE-Y
-receptor	GENE-Y
antagonist	O
,	O
hydroxyzine	CHEMICAL
,	O
in	O
which	O
a	O
mutation	O
was	O
identified	O
in	O
the	O
HERG	GENE-Y
gene	O
.	O

After	O
taking	O
75	O
mg	O
of	O
hydroxyzine	CHEMICAL
for	O
several	O
days	O
,	O
a	O
34-year-old	O
female	O
began	O
to	O
experience	O
repetitive	O
syncope	O
.	O

The	O
deleterious	O
effect	O
of	O
hydroxyzine	CHEMICAL
was	O
suspected	O
because	O
QTc	O
interval	O
shortened	O
from	O
630	O
to	O
464	O
ms	O
after	O
cessation	O
of	O
the	O
drug	O
.	O

Later	O
on	O
,	O
the	O
patient	O
was	O
found	O
to	O
harbor	O
an	O
A614V-HERG	GENE-Y
mutation	O
.	O

By	O
using	O
the	O
patch-clamp	O
technique	O
in	O
the	O
heterologous	O
expression	O
system	O
,	O
we	O
examined	O
the	O
functional	O
outcome	O
of	O
the	O
A614V	GENE-N
mutation	O
and	O
confirmed	O
a	O
dominant-negative	O
effect	O
on	O
HERG	GENE-Y
expression	O
.	O

Hydroxyzine	CHEMICAL
concentration-dependently	O
inhibited	O
both	O
wild-type	O
(	O
WT	O
)	O
and	O
WT	O
/	O
A614V-HERG	GENE-Y
K	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
currents	O
.	O

Half-maximum	O
block	O
concentrations	O
of	O
WT	O
and	O
WT	O
/	O
A614V-HERG	GENE-Y
K	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
currents	O
were	O
0	O
.	O
62	O
and	O
0	O
.	O
52	O
microM	O
,	O
respectively	O
.	O

Thus	O
,	O
accidental	O
combination	O
of	O
genetic	O
mutation	O
and	O
intake	O
of	O
hydroxyzine	CHEMICAL
appeared	O
to	O
have	O
led	O
to	O
a	O
severe	O
phenotype	O
,	O
probably	O
,	O
syncope	O
due	O
to	O
torsade	O
de	O
pointes	O
.	O
An	O
extract	O
procedure	O
for	O
studying	O
the	O
free	O
and	O
glycosilated	O
aroma	O
compounds	O
in	O
grapes	O
.	O
The	O
GABA	GENE-N
A	O
receptor	O
subunits	O
heterologously	O
expressed	O
in	O
Xenopus	O
oocytes	O
.	O
Optimization	O
of	O
Non-ATP	CHEMICAL
Competitive	O
CDK	GENE-N
/	O
Cyclin	GENE-N
Groove	O
Inhibitors	O
through	O
REPLACE-Mediated	O
Fragment	O
Assembly	O
.	O
Polybrominated	CHEMICAL
diphenyl	CHEMICAL
ethers	CHEMICAL
(	O
PBDEs	CHEMICAL
)	O
were	O
widely	O
used	O
flame	O
retardants	O
that	O
have	O
become	O
persistent	O
environmental	O
pollutants	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
in	O
vitro	O
oxidative	O
metabolism	O
of	O
2	CHEMICAL
,	CHEMICAL
2'	CHEMICAL
,	CHEMICAL
4	CHEMICAL
,	CHEMICAL
4'-tetrabromodiphenyl	CHEMICAL
ether	CHEMICAL
(	O
BDE-47	CHEMICAL
)	O
,	O
a	O
major	O
PBDE	CHEMICAL
detected	O
in	O
human	O
tissue	O
and	O
environmental	O
samples	O
.	O

Biotransformation	O
of	O
BDE-47	CHEMICAL
by	O
pooled	O
and	O
individual	O
human	O
liver	O
microsomes	O
and	O
by	O
human	GENE-N
recombinant	GENE-N
cytochrome	GENE-N
P450	GENE-N
(	O
P450	GENE-N
)	O
enzymes	O
was	O
assessed	O
using	O
a	O
liquid	O
chromatography	O
/	O
tandem	O
mass	O
spectrometry-based	O
method	O
.	O

Of	O
the	O
nine	O
hydroxylated	O
metabolites	O
of	O
BDE-47	CHEMICAL
produced	O
by	O
human	O
liver	O
microsomes	O
,	O
seven	O
metabolites	O
were	O
identified	O
using	O
authentic	O
standards	O
.	O

A	O
monohydroxy-tetrabrominated	O
and	O
a	O
dihydroxy-tetrabrominated	O
metabolite	O
remain	O
unidentified	O
.	O

Kinetic	O
analysis	O
of	O
the	O
rates	O
of	O
metabolite	O
formation	O
revealed	O
that	O
the	O
major	O
metabolites	O
were	O
5-hydroxy-2	CHEMICAL
,	CHEMICAL
2'	CHEMICAL
,	CHEMICAL
4	CHEMICAL
,	CHEMICAL
4'-tetrabromodiphenyl	CHEMICAL
ether	CHEMICAL
(	O
5-OH-BDE-47	CHEMICAL
)	O
,	O
6-hydroxy-2	CHEMICAL
,	CHEMICAL
2'	CHEMICAL
,	CHEMICAL
4	CHEMICAL
,	CHEMICAL
4'-tetrabromodiphenyl	CHEMICAL
ether	CHEMICAL
(	O
6-OH-BDE-47	CHEMICAL
)	O
,	O
and	O
possibly	O
the	O
unidentified	O
monohydroxy-tetrabrominated	O
metabolite	O
.	O

Among	O
the	O
human	GENE-N
recombinant	GENE-N
P450	GENE-N
enzymes	O
tested	O
,	O
P450	GENE-Y
2B6	GENE-Y
was	O
the	O
most	O
active	O
enzyme	O
in	O
the	O
formation	O
of	O
the	O
hydroxylated	O
metabolites	O
of	O
BDE-47	CHEMICAL
.	O

Moreover	O
,	O
the	O
formation	O
of	O
all	O
metabolites	O
of	O
BDE-47	CHEMICAL
by	O
pooled	O
human	O
liver	O
microsomes	O
was	O
inhibited	O
by	O
a	O
P450	GENE-Y
2B6-specific	O
antibody	O
and	O
was	O
highly	O
correlated	O
with	O
P450	GENE-Y
2B6-mediated	O
activity	O
in	O
single	O
donor	O
liver	O
microsomes	O
indicating	O
that	O
P450	GENE-Y
2B6	GENE-Y
was	O
the	O
major	O
P450	GENE-N
responsible	O
for	O
the	O
biotransformation	O
of	O
BDE-47	CHEMICAL
.	O

Additional	O
experiments	O
involving	O
the	O
incubation	O
of	O
liver	O
microsomes	O
with	O
individual	O
monohydroxy-tetrabrominated	O
metabolites	O
in	O
place	O
of	O
BDE-47	CHEMICAL
demonstrated	O
that	O
2	CHEMICAL
,	CHEMICAL
4-dibromophenol	CHEMICAL
was	O
a	O
product	O
of	O
BDE-47	CHEMICAL
and	O
several	O
primary	O
metabolites	O
,	O
but	O
the	O
dihydroxy-tetrabrominated	O
metabolite	O
was	O
not	O
formed	O
by	O
sequential	O
hydroxylation	O
of	O
any	O
of	O
the	O
monohydroxy-tetrabrominated	O
metabolites	O
tested	O
.	O

The	O
present	O
study	O
provides	O
a	O
comprehensive	O
characterization	O
of	O
the	O
oxidative	O
metabolism	O
of	O
BDE-47	CHEMICAL
by	O
human	O
liver	O
microsomes	O
and	O
P450	GENE-Y
2B6	GENE-Y
.	O
Species-specific	O
differences	O
in	O
the	O
glucocorticoid	GENE-Y
receptor	GENE-Y
transactivation	O
function	O
upon	O
binding	O
with	O
betamethasone-esters	CHEMICAL
.	O
Characterization	O
of	O
the	O
substrate	O
mimic	O
bound	O
to	O
engineered	O
prostacyclin	GENE-Y
synthase	O
in	O
solution	O
using	O
high-resolution	O
NMR	O
spectroscopy	O
and	O
mutagenesis	O
:	O
implication	O
of	O
the	O
molecular	O
mechanism	O
in	O
biosynthesis	O
of	O
prostacyclin	CHEMICAL
.	O
The	O
functions	O
of	O
microRNAs	O
(	O
miRNAs	O
)	O
as	O
either	O
oncogenes	O
or	O
tumor	O
suppressors	O
in	O
regulating	O
cancer-related	O
events	O
have	O
been	O
established	O
.	O

We	O
analyzed	O
the	O
alterations	O
in	O
the	O
miRNA	O
expression	O
profile	O
of	O
the	O
glioma	O
cell	O
line	O
U-251	O
caused	O
by	O
ionizing	O
radiation	O
(	O
IR	O
)	O
by	O
using	O
an	O
miRNA	O
array	O
and	O
identified	O
several	O
miRNAs	O
whose	O
expression	O
was	O
significantly	O
affected	O
by	O
IR	O
.	O

Among	O
the	O
IR-responsive	O
miRNAs	O
,	O
we	O
further	O
examined	O
the	O
function	O
of	O
miR-193a-3p	GENE-Y
,	O
which	O
exhibited	O
the	O
most	O
significant	O
growth-inhibiting	O
effect	O
.	O

miR-193a-3p	GENE-Y
was	O
observed	O
to	O
induce	O
apoptosis	O
in	O
both	O
U-251	O
and	O
HeLa	O
cells	O
.	O

We	O
also	O
demonstrated	O
that	O
miR-193a-3p	GENE-Y
induces	O
the	O
accumulation	O
of	O
intracellular	O
reactive	O
oxygen	CHEMICAL
species	O
(	O
ROS	O
)	O
and	O
DNA	O
damage	O
as	O
determined	O
by	O
the	O
level	O
of	O
γH2AX	GENE-Y
and	O
by	O
performing	O
the	O
comet	O
assay	O
.	O

The	O
induction	O
of	O
both	O
apoptosis	O
and	O
DNA	O
damage	O
by	O
miR-193a-3p	GENE-Y
was	O
blocked	O
by	O
antioxidant	O
treatment	O
,	O
indicating	O
the	O
crucial	O
role	O
of	O
ROS	O
in	O
the	O
action	O
of	O
miR-193a-3p	GENE-Y
.	O

Among	O
the	O
putative	O
target	O
proteins	O
,	O
the	O
expression	O
of	O
Mcl-1	GENE-Y
,	O
an	O
anti-apoptotic	O
Bcl-2	GENE-Y
family	O
member	O
,	O
decreased	O
because	O
of	O
miR-193a-3p	GENE-Y
transfection	O
.	O

A	O
reporter	O
assay	O
using	O
a	O
luciferase	O
construct	O
containing	O
the	O
3'-untranslated	O
region	O
of	O
Mcl-1	GENE-Y
confirmed	O
that	O
Mcl-1	GENE-Y
is	O
a	O
direct	O
target	O
of	O
miR-193a-3p	GENE-Y
.	O

Down-regulation	O
of	O
Mcl-1	GENE-Y
by	O
siRNA	O
transfection	O
closely	O
mimicked	O
the	O
outcome	O
of	O
miR-193a-3p	GENE-Y
transfection	O
showing	O
increased	O
ROS	O
,	O
DNA	O
damage	O
,	O
cytochrome	GENE-Y
c	GENE-Y
release	O
,	O
and	O
apoptosis	O
.	O

Ectopic	O
expression	O
of	O
Mcl-1	GENE-Y
suppressed	O
the	O
pro-apoptotic	O
action	O
of	O
miR-193a-3p	GENE-Y
,	O
suggesting	O
that	O
Mcl-1	GENE-Y
depletion	O
is	O
critical	O
for	O
miR-193a-3p	GENE-Y
induced	O
apoptosis	O
.	O

Collectively	O
,	O
our	O
results	O
suggest	O
a	O
novel	O
function	O
for	O
miR-193a-3p	GENE-Y
and	O
its	O
potential	O
application	O
in	O
cancer	O
therapy	O
.	O
Binding	O
of	O
factor	GENE-Y
Xa	GENE-Y
to	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
is	O
contributed	O
by	O
effector	GENE-Y
cell	GENE-Y
protease	GENE-Y
receptor-1	GENE-Y
(	O
EPR-1	GENE-Y
)	O
.	O

The	O
structural	O
requirements	O
of	O
this	O
recognition	O
were	O
investigated	O
.	O

Factor	GENE-Y
Xa	GENE-Y
or	O
catalytically	O
inactive	O
5-dimethylaminonaphthalene-1sulfonyl	CHEMICAL
(	CHEMICAL
dansyl	CHEMICAL
)	CHEMICAL
Glu-Gly-Arg-	CHEMICAL
(	CHEMICAL
DEGR	CHEMICAL
)	CHEMICAL
-chloromethylketone-factor	GENE-Y
Xa	GENE-Y
bound	O
indistinguishably	O
to	O
HUVEC	O
and	O
EPR-1	GENE-Y
transfectants	O
,	O
and	O
inhibited	O
equally	O
well	O
the	O
binding	O
of	O
125I-factor	GENE-Y
Xa	GENE-Y
to	O
these	O
cells	O
.	O

Similarly	O
,	O
factor	GENE-Y
Xa	GENE-Y
active	O
site	O
inhibitors	O
TAP	O
or	O
NAP5	O
did	O
not	O
reduce	O
ligand	O
binding	O
to	O
EPR-1	GENE-Y
.	O

A	O
factor	GENE-Y
X	GENE-Y
peptide	O
duplicating	O
the	O
inter-EGF	GENE-N
sequence	GENE-N
Leu83-Phe84-Thr85-Arg86-Lys87-Leu88-	GENE-N
(	GENE-N
Gly	CHEMICAL
)	O
inhibited	O
factor	GENE-Y
V	GENE-Y
/	GENE-Y
Va-independent	O
prothrombin	GENE-Y
activation	O
by	O
HUVEC	O
and	O
blocked	O
binding	O
of	O
125I-factor	GENE-Y
Xa	GENE-Y
to	O
these	O
cells	O
in	O
a	O
dose-dependent	O
manner	O
(	O
IC50	O
approximately	O
20-40	O
microM	O
)	O
.	O

In	O
contrast	O
,	O
none	O
of	O
the	O
other	O
factor	GENE-Y
X	GENE-Y
peptides	O
tested	O
or	O
a	O
control	O
peptide	O
with	O
the	O
inter-EGF	GENE-N
sequence	GENE-N
in	O
scrambled	O
order	O
was	O
effective	O
.	O

A	O
recombinant	O
chimeric	O
molecule	O
expressing	O
the	O
factor	GENE-Y
X	GENE-Y
sequence	O
Leu83-Leu88	GENE-N
within	O
a	O
factor	GENE-Y
IX	GENE-Y
backbone	O
inhibited	O
binding	O
of	O
125I-factor	GENE-Y
Xa	GENE-Y
to	O
HUVEC	O
and	O
EPR-1	GENE-Y
transfectants	O
in	O
a	O
dose-dependent	O
fashion	O
,	O
while	O
recombinant	O
factor	GENE-Y
IX	GENE-Y
or	O
plasma	O
IXa	GENE-Y
had	O
no	O
effect	O
.	O

An	O
antibody	O
generated	O
against	O
the	O
factor	GENE-Y
X	GENE-Y
peptide	O
83-88	O
,	O
and	O
designated	O
JC15	O
,	O
inhibited	O
125I-factor	GENE-Y
Xa	GENE-Y
binding	O
to	O
HUVEC	O
.	O

The	O
JC15	O
antibody	O
bound	O
to	O
factor	GENE-Y
Xa	GENE-Y
and	O
the	O
recombinant	O
IX	O
/	O
X83-88	O
chimera	O
in	O
a	O
concentration	O
dependent	O
manner	O
,	O
while	O
no	O
specific	O
reactivity	O
with	O
factors	GENE-N
X	GENE-N
or	GENE-N
IXa	GENE-N
was	O
observed	O
.	O

Furthermore	O
,	O
binding	O
of	O
125I-factor	GENE-Y
Xa	GENE-Y
to	O
immobilized	O
JC15	O
was	O
inhibited	O
by	O
molar	O
excess	O
of	O
unlabeled	O
factor	GENE-Y
Xa	GENE-Y
,	O
but	O
not	O
by	O
comparable	O
concentrations	O
of	O
factors	GENE-N
X	GENE-N
or	GENE-N
IXa	GENE-N
.	O

These	O
findings	O
identify	O
the	O
inter-EGF	GENE-N
sequence	GENE-N
Leu83-Leu88	GENE-N
in	O
factor	GENE-Y
Xa	GENE-Y
as	O
a	O
novel	O
recognition	O
site	O
for	O
EPR-1	GENE-Y
,	O
and	O
suggest	O
its	O
potential	O
role	O
as	O
a	O
protease	O
activation-dependent	O
neo-epitope	O
.	O

This	O
interacting	O
motif	O
may	O
help	O
elucidate	O
the	O
contribution	O
of	O
factor	GENE-Y
Xa	GENE-Y
to	O
cellular	O
assembly	O
of	O
coagulation	O
and	O
vascular	O
injury	O
.	O
Demonstration	O
of	O
histamine	CHEMICAL
receptors	O
on	O
human	O
platelets	O
by	O
flow	O
cytometry	O
.	O
Nerve	O
Terminal	O
GABAA	GENE-N
Receptors	GENE-N
Activate	O
Ca2	CHEMICAL
+	CHEMICAL
/	O
Calmodulin-dependent	O
Signaling	O
to	O
Inhibit	O
Voltage-gated	O
Ca2	CHEMICAL
+	CHEMICAL
Influx	O
and	O
Glutamate	CHEMICAL
Release	O
.	O
Mechanisms	O
of	O
Pharmacokinetic	O
Enhancement	O
Between	O
Ritonavir	CHEMICAL
and	O
Saquinavir;	O
Micro	O
/	O
Small	O
Dosing	O
Tests	O
Using	O
Midazolam	CHEMICAL
(	O
CYP3A4	GENE-Y
)	O
,	O
Fexofenadine	CHEMICAL
(	O
p-Glycoprotein	GENE-N
)	O
,	O
and	O
Pravastatin	CHEMICAL
(	O
OATP1B1	GENE-Y
)	O
as	O
Probe	O
Drugs	O
.	O
Herbicidal	O
inhibitors	O
of	O
amino	CHEMICAL
acid	CHEMICAL
biosynthesis	O
and	O
herbicide-tolerant	O
crops	O
.	O
Anti-inflammatory	O
effects	O
of	O
a	O
special	O
carbohydrate-whey	O
protein	O
cake	O
after	O
exhaustive	O
cycling	O
in	O
humans	O
.	O
Alteration	O
of	O
gastric	O
functions	O
and	O
candidate	O
genes	O
associated	O
with	O
weight	O
reduction	O
in	O
response	O
to	O
sibutramine	CHEMICAL
.	O
Antioxidant	O
capacity	O
,	O
polyphenolic	CHEMICAL
content	O
and	O
tandem	O
HPLC-DAD-ESI	O
/	O
MS	O
profiling	O
of	O
phenolic	CHEMICAL
compounds	O
from	O
the	O
South	O
American	O
berries	O
Luma	O
apiculata	O
and	O
L	O
.	O

chequén	O
.	O
Characterization	O
of	O
efflux	GENE-N
transporters	GENE-N
involved	O
in	O
distribution	O
and	O
disposition	O
of	O
apixaban	CHEMICAL
.	O
NLRP3	GENE-Y
inflammasome	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
various	O
kinds	O
of	O
immunological	O
diseases	O
including	O
colitis	O
.	O

However	O
,	O
there	O
are	O
few	O
drug	O
candidates	O
targeting	O
inflammasomes	O
for	O
the	O
treatment	O
of	O
colitis	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
aimed	O
at	O
examining	O
the	O
effect	O
of	O
1-ethyl-5-methyl-2-phenyl-1H-benzo	CHEMICAL
[	CHEMICAL
d	CHEMICAL
]	CHEMICAL
imidazole	CHEMICAL
,	O
a	O
synthetic	O
small	O
molecular	O
compound	O
also	O
named	O
Fc11a-2	CHEMICAL
,	O
for	O
the	O
treatment	O
of	O
dextran	O
sulfate	CHEMICAL
sodium	CHEMICAL
(	O
DSS	O
)	O
-induced	O
experimental	O
colitis	O
in	O
mice	O
via	O
targeting	O
NLRP3	GENE-Y
inflammasome	O
.	O

Treatment	O
with	O
Fc11a-2	O
dose-dependently	O
attenuated	O
the	O
loss	O
of	O
body	O
weight	O
and	O
shortening	O
of	O
colon	O
length	O
induced	O
by	O
DSS	O
.	O

In	O
addition	O
,	O
the	O
disease	O
activity	O
index	O
,	O
histopathologic	O
scores	O
and	O
myeloperoxidase	GENE-N
activity	O
were	O
also	O
significantly	O
reduced	O
by	O
Fc11a-2	CHEMICAL
treatment	O
.	O

Moreover	O
,	O
protein	O
and	O
mRNA	O
levels	O
of	O
DSS-induced	O
proinflammatory	O
cytokines	GENE-N
in	O
colon	O
,	O
including	O
TNF-α	GENE-Y
,	O
IL-1β	GENE-Y
,	O
IL-18	GENE-Y
,	O
IL-17A	GENE-Y
and	O
IFN-γ	GENE-Y
,	O
were	O
markedly	O
suppressed	O
by	O
Fc11a-2	CHEMICAL
.	O

Furthermore	O
,	O
a	O
decreased	O
CD11c	O
(	O
+	O
)	O
macrophage	O
infiltration	O
in	O
colons	O
and	O
inactivation	O
of	O
caspase-1	GENE-Y
in	O
peritoneal	O
macrophages	O
were	O
detected	O
in	O
Fc11a-2-treated	O
mice	O
.	O

The	O
mechanism	O
of	O
action	O
of	O
Fc11a-2	CHEMICAL
was	O
related	O
to	O
the	O
inhibition	O
of	O
the	O
cleavage	O
of	O
pro-caspase-1	GENE-Y
,	O
pro-IL-1β	GENE-Y
and	O
pro-IL-18	GENE-Y
which	O
in	O
turn	O
suppressed	O
the	O
activation	O
of	O
NLRP3	GENE-Y
inflammasome	O
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrate	O
the	O
ability	O
of	O
Fc11a-2	CHEMICAL
to	O
inhibit	O
NLRP3	GENE-Y
inflammasome	O
activation	O
and	O
its	O
potential	O
use	O
in	O
the	O
treatment	O
of	O
inflammatory	O
bowel	O
diseases	O
.	O
Abstract	O
Context	O
:	O
Near-Infrared	O
(	O
NIR	O
)	O
spectroscopy	O
is	O
an	O
important	O
component	O
of	O
a	O
Process	O
Analytical	O
Technology	O
(	O
PAT	O
)	O
toolbox	O
and	O
is	O
a	O
key	O
technology	O
for	O
enabling	O
the	O
rapid	O
analysis	O
of	O
pharmaceutical	O
tablets	O
.	O

Objective	O
:	O
The	O
aim	O
of	O
this	O
research	O
work	O
was	O
to	O
develop	O
and	O
validate	O
NIR-chemometric	O
methods	O
not	O
only	O
for	O
the	O
determination	O
of	O
active	O
pharmaceutical	O
ingredients	O
content	O
but	O
also	O
pharmaceutical	O
properties	O
(	O
crushing	O
strength	O
,	O
disintegration	O
time	O
)	O
of	O
meloxicam	CHEMICAL
tablets	O
.	O

Materials	O
and	O
methods	O
:	O
The	O
development	O
of	O
the	O
method	O
for	O
active	O
content	O
assay	O
was	O
performed	O
on	O
samples	O
corresponding	O
to	O
80%	O
,	O
90%	O
,	O
100%	O
,	O
110%	O
and	O
120%	O
of	O
meloxicam	CHEMICAL
content	O
and	O
the	O
development	O
of	O
the	O
methods	O
for	O
pharmaceutical	O
characterization	O
was	O
performed	O
on	O
samples	O
prepared	O
at	O
seven	O
different	O
compression	O
forces	O
(	O
ranging	O
from	O
7	O
to	O
45	O
kN	O
)	O
using	O
NIR	O
transmission	O
spectra	O
of	O
intact	O
tablets	O
and	O
PLS	O
as	O
a	O
regression	O
method	O
.	O

Results	O
:	O
The	O
results	O
show	O
that	O
the	O
developed	O
methods	O
have	O
good	O
trueness	O
,	O
precision	O
and	O
accuracy	O
and	O
are	O
appropriate	O
for	O
direct	O
active	O
content	O
assay	O
in	O
tablets	O
(	O
ranging	O
from	O
12	O
to	O
18	O
mg	O
/	O
tablet	O
)	O
and	O
also	O
for	O
predicting	O
crushing	O
strength	O
and	O
disintegration	O
time	O
of	O
intact	O
meloxicam	CHEMICAL
tablets	O
.	O

Discussion	O
:	O
The	O
comparative	O
data	O
show	O
that	O
the	O
proposed	O
methods	O
are	O
in	O
good	O
agreement	O
with	O
the	O
reference	O
methods	O
currently	O
used	O
for	O
the	O
characterization	O
of	O
meloxicam	CHEMICAL
tablets	O
(	O
HPLC-UV	O
methods	O
for	O
the	O
assay	O
and	O
European	O
Pharmacopeia	O
methods	O
for	O
determining	O
the	O
crushing	O
strength	O
and	O
disintegration	O
time	O
)	O
.	O

Conclusion	O
:	O
The	O
results	O
show	O
the	O
possibility	O
to	O
predict	O
both	O
chemical	O
properties	O
(	O
active	O
content	O
)	O
and	O
physical	O
/	O
pharmaceutical	O
properties	O
(	O
crushing	O
strength	O
and	O
disintegration	O
time	O
)	O
directly	O
,	O
without	O
any	O
sample	O
preparation	O
,	O
from	O
the	O
same	O
NIR	O
transmission	O
spectrum	O
of	O
meloxicam	CHEMICAL
tablets	O
.	O
The	O
aryl	GENE-Y
hydrocarbon	GENE-Y
receptor	O
is	O
a	O
member	O
of	O
the	O
basic-helix-loop-helix	GENE-N
family	GENE-N
of	O
transcription	O
factors	O
.	O

AhR	GENE-Y
mediates	O
the	O
biochemical	O
and	O
toxic	O
effects	O
of	O
a	O
number	O
of	O
polyaromatic	CHEMICAL
hydrocarbons	CHEMICAL
such	O
as	O
2	CHEMICAL
,	CHEMICAL
3	CHEMICAL
,	CHEMICAL
7	CHEMICAL
,	CHEMICAL
8	CHEMICAL
,	CHEMICAL
-tetrachloro-dibenzo-p-dioxin	CHEMICAL
(	O
TCDD	CHEMICAL
)	O
.	O

AhR	GENE-Y
is	O
widely	O
known	O
for	O
regulating	O
the	O
transcription	O
of	O
drug	O
metabolizing	O
enzymes	O
involved	O
in	O
the	O
xenobiotic	O
metabolism	O
of	O
carcinogens	O
and	O
therapeutic	O
agents	O
,	O
such	O
as	O
cytochrome	GENE-Y
P450-1B1	GENE-Y
(	O
CYP1B1	GENE-Y
)	O
.	O

Additionally	O
,	O
AhR	GENE-Y
has	O
also	O
been	O
reported	O
to	O
interact	O
with	O
multiple	O
signaling	O
pathways	O
during	O
prostate	O
development	O
.	O

Here	O
we	O
investigate	O
the	O
effect	O
of	O
sustained	O
AhR	GENE-Y
signaling	O
on	O
androgen	GENE-Y
receptor	O
function	O
in	O
prostate	O
cancer	O
cells	O
.	O

Immunoblot	O
analysis	O
shows	O
that	O
AhR	GENE-Y
expression	O
is	O
increased	O
in	O
androgen	CHEMICAL
independent	O
(	O
C4-2	O
)	O
prostate	O
cancer	O
cells	O
when	O
compared	O
to	O
androgen	CHEMICAL
sensitive	O
(	O
LNCaP	O
)	O
cells	O
.	O

RT-PCR	O
studies	O
revealed	O
constitutive	O
AhR	GENE-Y
signaling	O
in	O
C4-2	O
cells	O
without	O
the	O
ligand	O
induced	O
activation	O
required	O
in	O
LNCaP	O
cells	O
.	O

A	O
reduction	O
of	O
AhR	GENE-Y
activity	O
by	O
short	O
RNA	O
mediated	O
silencing	O
in	O
C4-2	O
cells	O
reduced	O
expression	O
of	O
both	O
AhR	GENE-Y
and	O
androgen	CHEMICAL
responsive	O
genes	O
.	O

The	O
decrease	O
in	O
androgen	CHEMICAL
responsive	O
genes	O
correlates	O
to	O
a	O
decrease	O
in	O
phosphorylated	GENE-Y
androgen	CHEMICAL
receptor	O
and	O
androgen	CHEMICAL
receptor	O
expression	O
in	O
the	O
nucleus	O
.	O

Furthermore	O
,	O
the	O
forced	O
decrease	O
in	O
AhR	GENE-Y
expression	O
resulted	O
in	O
a	O
50%	O
decline	O
in	O
the	O
growth	O
rate	O
of	O
C4-2	O
cells	O
.	O

These	O
data	O
indicates	O
that	O
AhR	GENE-Y
is	O
required	O
to	O
maintain	O
hormone	O
independent	O
signaling	O
and	O
growth	O
by	O
the	O
androgen	CHEMICAL
receptor	O
in	O
C4-2	O
cells	O
.	O

Collectively	O
,	O
these	O
data	O
provide	O
evidence	O
of	O
a	O
direct	O
role	O
for	O
AhR	GENE-Y
in	O
androgen	CHEMICAL
independent	O
signaling	O
and	O
provides	O
insight	O
into	O
the	O
molecular	O
mechanisms	O
responsible	O
for	O
sustained	O
androgen	CHEMICAL
receptor	O
signaling	O
in	O
hormone	O
refractory	O
prostate	O
cancer	O
.	O
Claudin-3	GENE-Y
and	O
claudin-4	GENE-Y
regulate	O
sensitivity	O
to	O
cisplatin	CHEMICAL
by	O
controlling	O
expression	O
of	O
the	O
copper	GENE-N
and	O
cisplatin	CHEMICAL
influx	O
transporter	O
CTR1	GENE-Y
.	O
Juglone	CHEMICAL
,	O
isolated	O
from	O
Juglans	O
mandshurica	O
Maxim	O
,	O
induces	O
apoptosis	O
via	O
down-regulation	O
of	O
AR	GENE-Y
expression	O
in	O
human	O
prostate	O
cancer	O
LNCaP	O
cells	O
.	O
A	O
convective	O
replica-exchange	O
method	O
for	O
sampling	O
new	O
energy	O
basins	O
.	O
Comparative	O
efficacy	O
and	O
safety	O
of	O
the	O
novel	O
oral	O
anticoagulants	O
dabigatran	CHEMICAL
,	O
rivaroxaban	CHEMICAL
and	O
apixaban	CHEMICAL
in	O
preclinical	O
and	O
clinical	O
development	O
.	O
The	O
tricyclic	CHEMICAL
antidepressant	O
clomipramine	CHEMICAL
increases	O
plasma	O
glucose	CHEMICAL
levels	O
of	O
mice	O
.	O
OBJECTIVE	O
:	O
The	O
following	O
study	O
was	O
performed	O
to	O
evaluate	O
the	O
importance	O
of	O
phosphodiesterases	GENE-Y
3A	GENE-Y
(	O
PDE3A	GENE-Y
)	O
and	O
5A	O
(	O
PDE5A	GENE-Y
)	O
for	O
the	O
regulation	O
of	O
penile	O
smooth	O
muscle	O
tone	O
.	O

Furthermore	O
,	O
indications	O
of	O
side	O
effects	O
of	O
specific	O
inhibitors	O
in	O
certain	O
tissues	O
as	O
well	O
as	O
of	O
a	O
possible	O
relation	O
between	O
the	O
level	O
of	O
PDE3A	GENE-Y
and	O
PDE5A	GENE-Y
gene	O
expression	O
and	O
erectile	O
dysfunction	O
should	O
have	O
been	O
deduced	O
from	O
the	O
results	O
obtained	O
.	O

METHODS	O
:	O
Total	O
ribonucleic	O
acid	O
was	O
isolated	O
from	O
different	O
human	O
tissues	O
(	O
urogenital	O
tract	O
,	O
gastrointestinal	O
tract	O
,	O
cardiovascular	O
system	O
and	O
central	O
nervous	O
system	O
)	O
and	O
subjected	O
to	O
RTPCR	O
analysis	O
and	O
Northern	O
blotting	O
using	O
primers	O
and	O
probes	O
specific	O
for	O
PDE3A	GENE-Y
and	O
PDE5A	GENE-Y
.	O

RESULTS	O
:	O
As	O
shown	O
by	O
RT-PCR	O
and	O
Northern	O
blotting	O
,	O
PDE3A	GENE-Y
and	O
PDE5A	GENE-Y
mRNAs	O
exhibit	O
a	O
distinct	O
distribution	O
throughout	O
the	O
tissues	O
examined	O
but	O
were	O
2-fold	O
higher	O
in	O
cavernous	O
tissue	O
than	O
in	O
all	O
other	O
tissues	O
investigated	O
.	O

However	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
levels	O
of	O
gene	O
expression	O
between	O
the	O
two	O
subgroups	O
of	O
patients	O
.	O

CONCLUSIONS	O
:	O
Very	O
high	O
expression	O
levels	O
of	O
PDE3A	GENE-Y
and	O
PDE5A	GENE-Y
in	O
human	O
cavernous	O
tissue	O
underscore	O
the	O
physiological	O
importance	O
of	O
these	O
enzymes	O
for	O
the	O
regulation	O
of	O
penile	O
erection	O
,	O
emphasizing	O
their	O
therapeutical	O
and	O
pharmacological	O
relevance	O
.	O

The	O
distribution	O
pattern	O
of	O
the	O
mRNA	O
for	O
the	O
isoenzymes	O
PDE3A	GENE-Y
and	O
PDE5A	GENE-Y
may	O
explain	O
the	O
pharmacological	O
effects	O
as	O
well	O
as	O
the	O
side	O
effects	O
of	O
milrinone	CHEMICAL
and	O
sidenafil	CHEMICAL
.	O
Alpha	GENE-Y
2u-globulin	GENE-Y
mediated	O
hyaline	O
droplet	O
nephropathy	O
(	O
HDN	O
)	O
is	O
a	O
male	O
rat	O
specific	O
lesion	O
induced	O
when	O
a	O
compound	O
or	O
metabolite	O
binds	O
to	O
alpha	GENE-Y
2u-globulin	GENE-Y
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
if	O
the	O
newer	O
and	O
more	O
sensitive	O
renal	O
biomarkers	O
would	O
be	O
altered	O
with	O
HDN	O
as	O
well	O
as	O
be	O
able	O
to	O
distinguish	O
between	O
HDN	O
and	O
oxidative	O
stress-induced	O
kidney	O
injury	O
.	O

Rats	O
were	O
dosed	O
orally	O
for	O
7	O
days	O
to	O
determine	O
(	O
1	O
)	O
if	O
HDN	O
(	O
induced	O
by	O
2-propanol	CHEMICAL
or	O
D-limonene	CHEMICAL
)	O
altered	O
the	O
newer	O
renal	O
biomarkers	O
and	O
not	O
BUN	O
or	O
creatinine	CHEMICAL
,	O
(	O
2	O
)	O
if	O
renal	O
biomarkers	O
could	O
distinguish	O
between	O
HDN	O
and	O
oxidative	O
stress-induced	O
kidney	O
injury	O
(	O
induced	O
by	O
potassium	CHEMICAL
bromate	CHEMICAL
)	O
,	O
(	O
3	O
)	O
sensitivity	O
of	O
HDN-induced	O
renal	O
biomarker	O
changes	O
relative	O
to	O
D-limonene	CHEMICAL
dose	O
,	O
and	O
(	O
4	O
)	O
reversibility	O
of	O
HDN	O
and	O
renal	O
biomarkers	O
,	O
using	O
vehicle	O
or	O
300	O
mg	O
/	O
kg	O
/	O
day	O
D-limonene	CHEMICAL
with	O
7	O
days	O
of	O
dosing	O
and	O
necropsies	O
scheduled	O
over	O
the	O
period	O
of	O
Days	O
8-85	O
.	O

HDN-induced	O
renal	O
biomarker	O
changes	O
in	O
male	O
rats	O
were	O
potentially	O
compound	O
specific	O
:	O
(	O
1	O
)	O
2-propanol	CHEMICAL
induced	O
mild	O
HDN	O
without	O
increased	O
renal	O
biomarkers	O
,	O
(	O
2	O
)	O
potassium	CHEMICAL
bromate	CHEMICAL
induced	O
moderate	O
HDN	O
with	O
increased	O
clusterin	GENE-Y
,	O
and	O
(	O
3	O
)	O
D-limonene	CHEMICAL
induced	O
marked	O
HDN	O
with	O
increased	O
αGST	GENE-N
,	O
μGST	GENE-N
and	O
albumin	GENE-Y
.	O

Administration	O
of	O
potassium	CHEMICAL
bromate	CHEMICAL
did	O
not	O
result	O
in	O
oxidative	O
stress-induced	O
kidney	O
injury	O
,	O
based	O
on	O
histopathology	O
and	O
renal	O
biomarkers	O
creatinine	O
and	O
BUN	O
.	O

The	O
compound	O
D-limonene	CHEMICAL
induced	O
a	O
dose	O
dependent	O
increase	O
in	O
HDN	O
severity	O
and	O
renal	O
biomarker	O
changes	O
without	O
altering	O
BUN	O
,	O
creatinine	CHEMICAL
or	O
NAG	GENE-Y
:	O
(	O
1	O
)	O
minimal	O
induction	O
of	O
HDN	O
and	O
no	O
altered	O
biomarkers	O
at	O
10	O
mg	O
/	O
kg	O
/	O
day	O
,	O
(	O
2	O
)	O
mild	O
induction	O
of	O
HDN	O
with	O
increased	O
αGST	GENE-N
and	O
μGST	GENE-N
at	O
50	O
mg	O
/	O
kg	O
/	O
day	O
and	O
(	O
3	O
)	O
marked	O
induction	O
of	O
HDN	O
with	O
increased	O
αGST	GENE-N
,	O
μGST	GENE-N
and	O
albumin	GENE-Y
at	O
300	O
mg	O
/	O
kg	O
/	O
day	O
.	O

HDN	O
induced	O
by	O
D-limonene	CHEMICAL
was	O
reversible	O
,	O
but	O
with	O
a	O
variable	O
renal	O
biomarker	O
pattern	O
over	O
time	O
:	O
Day	O
8	O
there	O
was	O
increased	O
αGST	GENE-N
,	O
μGST	GENE-N
and	O
albumin;	O
on	O
Day	O
15	O
increased	O
clusterin	GENE-Y
,	O
albumin	GENE-Y
and	O
Kim-1	GENE-Y
.	O

In	O
summary	O
,	O
HDN	O
altered	O
the	O
newer	O
and	O
more	O
sensitive	O
renal	O
biomarkers	O
in	O
a	O
time	O
and	O
possibly	O
compound	O
dependent	O
manner	O
.	O
Late-onset	O
cobalamin-C	O
disorder	O
:	O
a	O
challenging	O
diagnosis	O
.	O
Pemetrexed	CHEMICAL
in	O
pancreatic	O
cancer	O
.	O
Thiazinotrienomycin	CHEMICAL
B	CHEMICAL
(	O
TT-B	CHEMICAL
)	O
,	O
an	O
ansamycin	CHEMICAL
isolated	O
from	O
fermentation	O
broths	O
of	O
Streptomyces	O
sp	O
.	O

MJ672-m3	O
,	O
inhibited	O
the	O
growth	O
in	O
vitro	O
of	O
human	O
stomach	O
tumor	O
SC-6	O
cells	O
over	O
10	O
times	O
more	O
strongly	O
than	O
the	O
growth	O
of	O
other	O
human	O
tumor	O
cells	O
,	O
such	O
as	O
HeLa	O
(	O
cervix	O
)	O
,	O
T24	O
(	O
bladder	O
)	O
and	O
LX-1	O
(	O
lung	O
)	O
.	O

The	O
extent	O
of	O
growth	O
inhibition	O
by	O
TT-B	O
of	O
SC-6	O
,	O
but	O
not	O
of	O
LX-1	O
nor	O
T24	O
,	O
was	O
lowered	O
in	O
a	O
competitive	O
manner	O
by	O
raising	O
serum	O
concentrations	O
in	O
the	O
culture	O
medium	O
.	O

TT-B	CHEMICAL
inhibited	O
the	O
cell	O
cycle	O
progression	O
of	O
SC-6	O
at	O
an	O
early	O
stage	O
of	O
the	O
progression	O
from	O
G0	O
/	O
G1	O
to	O
S	O
.	O

The	O
inhibition	O
was	O
again	O
competitive	O
with	O
serum	O
concentrations	O
in	O
the	O
culture	O
medium	O
.	O

No	O
direct	O
inhibition	O
of	O
DNA	O
synthesis	O
was	O
observed	O
at	O
the	O
concentration	O
range	O
which	O
caused	O
the	O
cell	O
cycle	O
arrest	O
.	O

TT-B	CHEMICAL
and	O
anti-epidermal	GENE-Y
growth	GENE-Y
factor	GENE-Y
receptor	GENE-Y
(	O
anti-EGFR	GENE-Y
)	O
were	O
antagonistic	O
to	O
each	O
other	O
in	O
inhibiting	O
the	O
cell	O
cycle	O
progression	O
of	O
SC-6	O
from	O
G0	O
/	O
G1	O
to	O
S	O
,	O
suggesting	O
that	O
the	O
two	O
compounds	O
share	O
the	O
same	O
target	O
,	O
EGFR	GENE-Y
.	O

The	O
kinase	GENE-N
activity	O
of	O
EGFR	GENE-Y
was	O
little	O
inhibited	O
by	O
TT-B	CHEMICAL
in	O
a	O
cell-free	O
system	O
.	O
Abstract	O
1	O
.	O

IPI-926	CHEMICAL
is	O
a	O
novel	O
semisynthetic	O
cyclopamine	CHEMICAL
derivative	O
that	O
is	O
a	O
potent	O
and	O
selective	O
Smoothened	O
inhibitor	O
that	O
blocks	O
the	O
hedgehog	O
signal	O
transduction	O
pathway	O
.	O

2	O
.	O

The	O
in	O
vivo	O
clearance	O
of	O
IPI-926	CHEMICAL
is	O
low	O
in	O
mouse	O
and	O
dog	O
and	O
moderate	O
in	O
monkey	O
.	O

The	O
volume	O
of	O
distribution	O
is	O
high	O
across	O
species	O
.	O

Oral	O
bioavailability	O
ranges	O
from	O
moderate	O
in	O
monkey	O
to	O
high	O
in	O
mouse	O
and	O
dog	O
.	O

Predicted	O
human	O
clearance	O
using	O
simple	O
allometry	O
is	O
low	O
(	O
24	O
L	O
h	O
(	O
-1	O
)	O
)	O
,	O
predicted	O
volume	O
of	O
distribution	O
is	O
high	O
(	O
469	O
L	O
)	O
and	O
predicted	O
half-life	O
is	O
long	O
(	O
20	O
h	O
)	O
.	O

3	O
.	O

IPI-926	CHEMICAL
is	O
highly	O
bound	O
to	O
plasma	O
proteins	O
and	O
has	O
minimal	O
interaction	O
with	O
human	GENE-N
α-1-acid	GENE-N
glycoprotein	GENE-N
.	O

4	O
.	O

In	O
vitro	O
metabolic	O
stability	O
ranges	O
from	O
stable	O
to	O
moderately	O
stable	O
.	O

Twelve	O
oxidative	O
metabolites	O
were	O
detected	O
in	O
mouse	O
,	O
rat	O
,	O
dog	O
,	O
monkey	O
and	O
human	O
liver	O
microsome	O
incubations	O
and	O
none	O
were	O
unique	O
to	O
human	O
.	O

5	O
.	O

IPI-926	CHEMICAL
is	O
not	O
a	O
potent	O
reversible	O
inhibitor	O
of	O
CYP1A2	GENE-N
,	GENE-N
2C8	GENE-N
,	GENE-N
2C9	GENE-N
or	GENE-N
3A4	GENE-N
(	O
testosterone	CHEMICAL
)	O
.	O

IPI-926	CHEMICAL
is	O
a	O
moderate	O
inhibitor	O
of	O
CYP2C19	GENE-N
,	GENE-N
2D6	GENE-N
and	GENE-N
3A4	GENE-N
(	O
midazolam	CHEMICAL
)	O
with	O
KI	O
values	O
of	O
19	O
,	O
16	O
and	O
4	O
.	O
5	O
µM	O
,	O
respectively	O
.	O

IPI-926	CHEMICAL
is	O
both	O
a	O
substrate	O
and	O
inhibitor	O
(	O
IC50	O
=	O
1	O
.	O
9	O
µM	O
)	O
of	O
P-glycoprotein	GENE-N
.	O

6	O
.	O

In	O
summary	O
,	O
IPI-926	CHEMICAL
has	O
desirable	O
pre-clinical	O
absorption	O
,	O
distribution	O
,	O
metabolism	O
and	O
excretion	O
properties	O
.	O
Palbinone	CHEMICAL
from	O
Paeonia	O
suffruticosa	O
Protects	O
Hepatic	O
Cells	O
via	O
Up-regulation	O
of	O
Heme	CHEMICAL
Oxygenase-1	O
.	O
Group	GENE-N
III	GENE-N
metabotropic	GENE-N
glutamate	CHEMICAL
(	O
mGlu	O
)	O
receptors	O
are	O
localized	O
in	O
presynaptic	O
terminals	O
within	O
basal	O
ganglia	O
(	O
BG	O
)	O
circuitry	O
that	O
become	O
hyperactive	O
due	O
to	O
dopamine	CHEMICAL
depletion	O
in	O
Parkinson's	O
disease	O
(	O
PD	O
)	O
.	O

For	O
this	O
reason	O
,	O
group	GENE-N
III	GENE-N
mGlu	GENE-N
receptors	GENE-N
,	O
in	O
particular	O
mGlu4	GENE-Y
,	O
have	O
been	O
considered	O
as	O
key	O
strategic	O
targets	O
for	O
non-dopaminergic	O
pharmacological	O
treatments	O
aimed	O
at	O
modulating	O
these	O
synapses	O
,	O
without	O
producing	O
the	O
well	O
known	O
side-effects	O
of	O
l-DOPA	CHEMICAL
,	O
in	O
particular	O
the	O
highly	O
disabling	O
l-DOPA-induced	O
dyskinesia	O
(	O
LID	O
)	O
.	O

Herein	O
we	O
add	O
physiological	O
and	O
functional	O
support	O
to	O
this	O
hypothesis	O
using	O
Lu	CHEMICAL
AF21934	CHEMICAL
,	O
a	O
novel	O
selective	O
and	O
brain-penetrant	O
mGlu4	GENE-Y
receptor	O
positive	O
allosteric	O
modulator	O
(	O
PAM	O
)	O
tool	O
compound	O
.	O

By	O
in	O
vitro	O
electrophysiological	O
recordings	O
we	O
demonstrate	O
that	O
Lu	CHEMICAL
AF21934	CHEMICAL
inhibits	O
corticostriatal	O
synaptic	O
transmission	O
and	O
enhances	O
the	O
effect	O
of	O
the	O
orthosteric	O
mGlu4	GENE-Y
receptor-preferred	O
agonist	O
LSP1-2111	CHEMICAL
.	O

In	O
naïve	O
rats	O
,	O
Lu	CHEMICAL
AF21934	CHEMICAL
dose-dependently	O
(	O
10	O
and	O
30	O
mg	O
/	O
kg	O
)	O
alleviated	O
haloperidol-induced	O
catalepsy	O
.	O

In	O
hemiparkinsonian	O
rats	O
(	O
unilateral	O
6-hydroxydopamine	CHEMICAL
lesion	O
of	O
the	O
substantia	O
nigra	O
pars	O
compacta	O
)	O
,	O
Lu	CHEMICAL
AF21934	CHEMICAL
alone	O
did	O
not	O
affect	O
akinesia	O
at	O
the	O
doses	O
tested	O
(	O
10	O
and	O
30	O
mg	O
/	O
kg	O
)	O
.	O

However	O
,	O
when	O
Lu	CHEMICAL
AF21934	CHEMICAL
was	O
combined	O
with	O
sub-threshold	O
doses	O
of	O
l-DOPA	CHEMICAL
(	O
1	O
and	O
5	O
mg	O
/	O
kg	O
)	O
,	O
it	O
acted	O
synergistically	O
in	O
alleviating	O
akinesia	O
in	O
a	O
dose-dependent	O
manner	O
and	O
,	O
notably	O
,	O
also	O
reduced	O
the	O
incidence	O
of	O
LID	O
but	O
not	O
its	O
severity	O
.	O

Interestingly	O
,	O
these	O
effects	O
occurred	O
at	O
Lu	CHEMICAL
AF21934	CHEMICAL
brain	O
free	O
concentrations	O
that	O
showed	O
functional	O
activity	O
in	O
in	O
vitro	O
screens	O
(	O
calcium	CHEMICAL
flux	O
and	O
electrophysiology	O
assays	O
)	O
.	O

These	O
results	O
support	O
the	O
potential	O
for	O
antiparkinsonian	O
clinical	O
use	O
of	O
a	O
combined	O
treatment	O
consisting	O
in	O
l-DOPA	CHEMICAL
and	O
a	O
mGlu4	GENE-Y
receptor	O
PAM	O
to	O
reduce	O
efficacious	O
l-DOPA	CHEMICAL
doses	O
(	O
generally	O
known	O
as	O
l-DOPA	CHEMICAL
sparing	O
)	O
,	O
while	O
maintaining	O
the	O
same	O
benefit	O
on	O
PD	O
motor	O
troubles	O
,	O
and	O
at	O
the	O
same	O
time	O
minimizing	O
the	O
development	O
of	O
LID	O
.	O

This	O
article	O
is	O
part	O
of	O
a	O
Special	O
Issue	O
entitled	O
'Metabotropic	GENE-N
Glutamate	CHEMICAL
Receptors'	O
.	O
The	O
putative	O
JAK-STAT	GENE-N
inhibitor	O
AG490	CHEMICAL
exacerbates	O
LPS-fever	O
,	O
reduces	O
sickness	O
behavior	O
,	O
and	O
alters	O
the	O
expression	O
of	O
pro-	O
and	O
anti-inflammatory	O
genes	O
in	O
the	O
rat	O
brain	O
.	O
3-Methylglutaconic	CHEMICAL
aciduria-lessons	O
from	O
50	O
genes	O
and	O
977	O
patients	O
.	O
Medulloblastoma	O
(	O
MB	O
)	O
is	O
the	O
most	O
common	O
malignant	O
neuroepithelial	O
tumor	O
of	O
childhood	O
.	O

The	O
DNA	GENE-Y
topoisomerase	GENE-Y
II	GENE-Y
(	O
Topo	GENE-Y
II	GENE-Y
)	O
inhibitor	O
etoposide	CHEMICAL
has	O
been	O
widely	O
used	O
for	O
the	O
treatment	O
of	O
MBs;	O
however	O
,	O
it	O
remains	O
unknown	O
whether	O
MB	O
cells	O
are	O
more	O
sensitive	O
to	O
etoposide	CHEMICAL
than	O
other	O
malignant	O
neuroepithelial	O
tumor	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
tested	O
the	O
chemosensitivities	O
of	O
malignant	O
neuroepithelial	O
tumors	O
(	O
26	O
glioblastomas	O
,	O
9	O
anaplastic	O
astrocytomas	O
,	O
and	O
5	O
MBs	O
)	O
to	O
etoposide	CHEMICAL
and	O
vincristine	CHEMICAL
using	O
the	O
succinate	CHEMICAL
dehydrogenase	O
inhibition	O
test	O
and	O
found	O
that	O
MB	O
cells	O
are	O
more	O
sensitive	O
to	O
etoposide	CHEMICAL
and	O
more	O
resistant	O
to	O
vincristine	CHEMICAL
than	O
other	O
tumor	O
cells	O
.	O

We	O
performed	O
quantitative	O
reverse-transcription	O
polymerase	O
chain	O
reaction	O
to	O
evaluate	O
the	O
expression	O
of	O
genes	O
related	O
to	O
etoposide	CHEMICAL
sensitivity	O
,	O
and	O
found	O
co-overexpression	O
of	O
DNA	GENE-N
topoisomerase	GENE-N
II	GENE-N
(	GENE-N
Topo	GENE-N
II	GENE-N
)	GENE-N
alpha	GENE-N
and	GENE-N
beta	GENE-N
mRNA	O
in	O
MBs	O
.	O

In	O
addition	O
,	O
the	O
levels	O
of	O
Topo	GENE-N
IIalpha	GENE-N
and	GENE-N
beta	GENE-N
mRNA	O
in	O
these	O
tumors	O
correlated	O
with	O
etoposide	CHEMICAL
sensitivity	O
.	O

Immunohistochemical	O
studies	O
using	O
surgical	O
samples	O
of	O
these	O
tumors	O
demonstrated	O
that	O
the	O
percentages	O
of	O
Topo	GENE-Y
IIalpha	GENE-Y
immunopositive	O
cells	O
(	O
Topo	GENE-Y
IIalpha	GENE-Y
labeling	O
index	O
)	O
correlated	O
with	O
those	O
of	O
Ki-67	O
immunopositive	O
cells	O
(	O
MIB-1	GENE-Y
labeling	O
index	O
)	O
;	O
however	O
,	O
neither	O
the	O
Topo	GENE-Y
IIalpha	GENE-Y
nor	O
the	O
MIB-1	GENE-Y
labeling	O
index	O
correlated	O
with	O
the	O
levels	O
of	O
Topo	GENE-Y
IIalpha	GENE-Y
mRNA	O
or	O
etoposide	CHEMICAL
sensitivity	O
.	O

Based	O
on	O
these	O
observations	O
,	O
Topo	GENE-N
IIalpha	GENE-N
and	GENE-N
beta	GENE-N
mRNA	O
expression	O
,	O
but	O
not	O
the	O
Topo	GENE-Y
IIalpha	GENE-Y
labeling	O
index	O
,	O
might	O
be	O
a	O
useful	O
marker	O
for	O
sensitivity	O
to	O
etoposide	CHEMICAL
in	O
human	O
malignant	O
neuroepithelial	O
tumors	O
.	O
The	O
detailed	O
molecular	O
mechanism	O
of	O
action	O
of	O
second-generation	O
BCR-ABL	GENE-Y
tyrosine	GENE-N
kinase	GENE-N
inhibitors	O
,	O
including	O
perturbed	O
targets	O
and	O
pathways	O
,	O
should	O
contribute	O
to	O
rationalized	O
therapy	O
in	O
chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
or	O
in	O
other	O
affected	O
diseases	O
.	O

Here	O
,	O
we	O
characterized	O
the	O
target	O
profile	O
of	O
the	O
dual	O
SRC	GENE-Y
/	O
ABL	GENE-Y
inhibitor	O
bosutinib	CHEMICAL
employing	O
a	O
two-tiered	O
approach	O
using	O
chemical	O
proteomics	O
to	O
identify	O
natural	O
binders	O
in	O
whole	O
cell	O
lysates	O
of	O
primary	O
CML	O
and	O
K562	O
cells	O
in	O
parallel	O
to	O
in	O
vitro	O
kinase	GENE-N
assays	O
against	O
a	O
large	O
recombinant	O
kinase	GENE-N
panel	O
.	O

The	O
combined	O
strategy	O
resulted	O
in	O
a	O
global	O
survey	O
of	O
bosutinib	CHEMICAL
targets	O
comprised	O
of	O
over	O
45	O
novel	O
tyrosine	CHEMICAL
and	O
serine	CHEMICAL
/	O
threonine	CHEMICAL
kinases	O
.	O

We	O
have	O
found	O
clear	O
differences	O
in	O
the	O
target	O
patterns	O
of	O
bosutinib	CHEMICAL
in	O
primary	O
CML	O
cells	O
versus	O
the	O
K562	O
cell	O
line	O
.	O

A	O
comparison	O
of	O
bosutinib	CHEMICAL
with	O
dasatinib	CHEMICAL
across	O
the	O
whole	O
kinase	GENE-N
panel	O
revealed	O
overlapping	O
,	O
but	O
distinct	O
,	O
inhibition	O
profiles	O
.	O

Common	O
among	O
those	O
were	O
the	O
SRC	GENE-Y
,	O
ABL	GENE-Y
and	O
TEC	GENE-Y
family	O
kinases	GENE-N
.	O

Bosutinib	CHEMICAL
did	O
not	O
inhibit	O
KIT	GENE-Y
or	O
platelet-derived	GENE-N
growth	GENE-N
factor	GENE-N
receptor	GENE-N
,	O
but	O
prominently	O
targeted	O
the	O
apoptosis-linked	O
STE20	GENE-N
kinases	GENE-N
.	O

Although	O
in	O
vivo	O
bosutinib	CHEMICAL
is	O
inactive	O
against	O
ABL	GENE-Y
T315I	GENE-N
,	O
we	O
found	O
this	O
clinically	O
important	O
mutant	O
to	O
be	O
enzymatically	O
inhibited	O
in	O
the	O
mid-nanomolar	O
range	O
.	O

Finally	O
,	O
bosutinib	CHEMICAL
is	O
the	O
first	O
kinase	GENE-N
inhibitor	O
shown	O
to	O
target	O
CAMK2G	GENE-Y
,	O
recently	O
implicated	O
in	O
myeloid	O
leukemia	O
cell	O
proliferation	O
.	O
Reabsorption	O
of	O
amino	CHEMICAL
acids	CHEMICAL
is	O
an	O
important	O
function	O
of	O
the	O
renal	O
proximal	O
tubule	O
.	O

pH-dependent	O
amino	CHEMICAL
acid	CHEMICAL
transport	O
has	O
been	O
measured	O
previously	O
using	O
rabbit	O
renal	O
brush-border	O
membrane	O
vesicles	O
(	O
BBMV	O
)	O
.	O

The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
determine	O
whether	O
this	O
pH-dependent	O
uptake	O
represents	O
H	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
/	O
amino	CHEMICAL
acid	CHEMICAL
cotransport	O
via	O
a	O
PAT1-like	O
transport	O
system	O
.	O

The	O
rabbit	GENE-Y
PAT1	GENE-Y
cDNA	O
was	O
isolated	O
(	O
2296bp	O
including	O
both	O
5'	O
and	O
3'	O
untranslated	O
regions	O
and	O
poly	GENE-N
(	GENE-N
A	GENE-N
)	GENE-N
tail	GENE-N
)	GENE-N
and	O
the	O
open	GENE-N
reading	GENE-N
frame	GENE-N
codes	O
for	O
a	O
protein	O
of	O
475	O
amino	CHEMICAL
acids	CHEMICAL
(	O
92%	O
identity	O
to	O
human	GENE-Y
PAT1	GENE-Y
)	O
.	O

Rabbit	GENE-Y
PAT1	GENE-Y
mRNA	O
was	O
found	O
in	O
all	O
tissues	O
investigated	O
including	O
kidney	O
.	O

When	O
expressed	O
heterologously	O
in	O
a	O
mammalian	O
cell	O
line	O
,	O
rabbit	GENE-Y
PAT1	GENE-Y
mediates	O
pH-dependent	O
,	O
Na	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-independent	O
uptake	O
of	O
proline	CHEMICAL
,	O
glycine	CHEMICAL
,	O
l-alanine	CHEMICAL
and	O
alpha-	CHEMICAL
(	CHEMICAL
methylamino	CHEMICAL
)	CHEMICAL
isobutyric	CHEMICAL
acid	CHEMICAL
.	O

Proline	CHEMICAL
uptake	O
was	O
maximal	O
at	O
pH	O
5	O
.	O
0	O
(	O
K	O
(	O
m	O
)	O
2	O
.	O
2	O
+	O
/	O
-0	O
.	O
7	O
mM	O
)	O
.	O

A	O
transport	O
system	O
with	O
identical	O
characteristics	O
(	O
ion	O
dependency	O
,	O
substrate	O
specificity	O
)	O
was	O
detected	O
in	O
rabbit	O
renal	O
BBMV	O
where	O
an	O
overshoot	O
was	O
observed	O
in	O
the	O
absence	O
of	O
Na	CHEMICAL
+	CHEMICAL
but	O
in	O
the	O
presence	O
of	O
an	O
inwardly	O
directed	O
H	CHEMICAL
+	CHEMICAL
gradient	O
.	O

In	O
the	O
presence	O
of	O
Na	CHEMICAL
+	CHEMICAL
and	O
under	O
conditions	O
in	O
which	O
PAT1	GENE-Y
transport	O
function	O
was	O
suppressed	O
,	O
a	O
second	O
proline	CHEMICAL
uptake	O
system	O
was	O
detected	O
that	O
exhibited	O
functional	O
characteristics	O
similar	O
to	O
those	O
of	O
the	O
IMINO	GENE-N
system	GENE-N
.	O

The	O
functional	O
characteristics	O
of	O
rabbit	GENE-Y
PAT1	GENE-Y
in	O
either	O
mammalian	O
cells	O
or	O
renal	O
BBMV	O
suggest	O
that	O
PAT1	GENE-Y
is	O
the	O
low-affinity	O
transporter	O
of	O
proline	CHEMICAL
,	O
glycine	CHEMICAL
and	O
hydroxyproline	CHEMICAL
believed	O
to	O
be	O
defective	O
in	O
patients	O
with	O
iminoglycinuria	O
.	O
The	O
aim	O
of	O
this	O
work	O
was	O
to	O
develop	O
by	O
means	O
of	O
co-extrusion	O
a	O
multilayered	O
dosage	O
form	O
characterized	O
by	O
a	O
dual	O
release	O
profile	O
of	O
the	O
same	O
drug	O
.	O

Co-extrudates	O
consisted	O
of	O
two	O
concentric	O
polymer	O
matrices	O
:	O
a	O
core	O
having	O
a	O
lipophilic	O
character	O
and	O
a	O
coat	O
with	O
a	O
hydrophilic	O
character	O
.	O

Diclofenac	CHEMICAL
sodium	CHEMICAL
(	O
DS	O
)	O
was	O
incorporated	O
as	O
model	O
drug	O
in	O
both	O
layers	O
.	O

Several	O
polymers	O
were	O
screened	O
on	O
the	O
basis	O
of	O
their	O
processability	O
via	O
hot	O
melt	O
extrusion	O
(	O
HME	O
)	O
and	O
in	O
vitro	O
drug	O
release	O
.	O

Polymer	O
combinations	O
with	O
suitable	O
properties	O
(	O
i	O
.	O

e	O
.	O

,	O
similar	O
extrusion	O
temperature	O
,	O
appropriate	O
drug	O
release	O
profile	O
)	O
were	O
processed	O
via	O
co-extrusion	O
.	O

(	O
Co-	O
)	O
extruded	O
samples	O
were	O
characterized	O
in	O
terms	O
of	O
solid	O
state	O
(	O
XRD	O
,	O
SEM	O
)	O
,	O
in	O
vitro	O
drug	O
release	O
,	O
core	O
/	O
coat	O
adhesion	O
,	O
and	O
bioavailability	O
.	O

Based	O
on	O
the	O
polymer	O
screening	O
,	O
two	O
polymer	O
combinations	O
were	O
selected	O
for	O
co-extrusion	O
:	O
ethylcellulose	O
(	O
core	O
)	O
combined	O
with	O
Soluplus®	O
(	O
coat	O
)	O
and	O
polycaprolactone	CHEMICAL
(	O
core	O
)	O
with	O
PEO	CHEMICAL
(	O
coat	O
)	O
.	O

These	O
combinations	O
were	O
successfully	O
co-extruded	O
.	O

XRD	O
revealed	O
that	O
DS	O
remained	O
crystalline	O
during	O
extrusion	O
in	O
ethylcellulose	O
,	O
Soluplus®	O
,	O
polycaprolactone	CHEMICAL
,	O
and	O
PEO	CHEMICAL
.	O

The	O
polycaprolactone	CHEMICAL
/	O
PEO	CHEMICAL
combination	O
could	O
be	O
processed	O
at	O
a	O
lower	O
temperature	O
(	O
70°C	O
)	O
,	O
vs	O
.	O

140°C	O
for	O
ethylcellulose	O
/	O
Soluplus®	O
.	O

The	O
maximum	O
drug	O
load	O
in	O
core	O
and	O
coat	O
depended	O
on	O
the	O
extrusion	O
temperature	O
and	O
the	O
die	O
dimensions	O
,	O
while	O
adhesion	O
between	O
core	O
and	O
coat	O
was	O
mainly	O
determined	O
by	O
the	O
drug	O
load	O
and	O
by	O
the	O
extrusion	O
temperature	O
.	O

In	O
vitro	O
drug	O
release	O
from	O
the	O
co-extruded	O
formulations	O
was	O
reflected	O
in	O
the	O
in	O
vivo	O
behavior	O
:	O
formulations	O
with	O
a	O
higher	O
DS	O
content	O
in	O
the	O
coat	O
(	O
i	O
.	O

e	O
.	O

,	O
faster	O
drug	O
release	O
)	O
resulted	O
in	O
higher	O
Cmax	O
and	O
higher	O
AUC	O
values	O
.	O

Co-extrusion	O
is	O
a	O
viable	O
method	O
to	O
produce	O
in	O
a	O
single	O
step	O
a	O
multilayer	O
dosage	O
form	O
with	O
dual	O
drug	O
release	O
.	O
Steatotic	O
grafts	O
are	O
excluded	O
for	O
use	O
in	O
partial	O
liver	O
transplantation	O
(	O
LT	O
)	O
because	O
of	O
the	O
increased	O
risk	O
of	O
primary	O
nonfunction	O
.	O

This	O
study	O
investigated	O
the	O
effects	O
of	O
suramin	CHEMICAL
,	O
a	O
polysulfonated	CHEMICAL
naphthylurea	CHEMICAL
,	O
on	O
the	O
outcome	O
of	O
steatotic	O
partial	O
LT	O
.	O

Rat	O
livers	O
were	O
harvested	O
after	O
acute	O
ethanol	CHEMICAL
treatment	O
(	O
6	O
g	O
/	O
kg	O
,	O
intragastric	O
administration	O
)	O
,	O
reduced	O
in	O
size	O
to	O
≈	O
1	O
/	O
3	O
,	O
and	O
transplanted	O
.	O

Serum	O
alanine	CHEMICAL
aminotransferase	O
(	O
ALT	GENE-N
)	O
and	O
total	O
bilirubin	CHEMICAL
levels	O
as	O
well	O
as	O
hepatic	O
necrosis	O
and	O
apoptosis	O
were	O
significantly	O
higher	O
after	O
transplantation	O
of	O
fatty	O
partial	O
grafts	O
(	O
FPG	O
)	O
than	O
lean	O
partial	O
grafts	O
(	O
LPG	O
)	O
.	O

Suramin	CHEMICAL
(	O
5	O
mg	O
/	O
kg	O
,	O
i	O
.	O

p	O
.	O

)	O
decreased	O
ALT	GENE-N
by	O
≈	O
60%	O
,	O
hyperbilirubinemia	O
by	O
75%	O
,	O
necrosis	O
by	O
83%	O
,	O
and	O
apoptosis	O
by	O
70%	O
after	O
FPG	O
transplantation	O
.	O

Hepatic	O
cellular	O
5-bromo-2'-deoxyuridine	CHEMICAL
(	O
BrdU	CHEMICAL
)	O
incorporation	O
increased	O
to	O
28%	O
in	O
LPG	O
but	O
was	O
only	O
2%	O
in	O
FPG	O
at	O
48	O
hours	O
,	O
and	O
the	O
mitotic	O
index	O
increased	O
to	O
7%	O
in	O
LPG	O
but	O
was	O
only	O
0	O
.	O
2%	O
in	O
FPG	O
,	O
indicating	O
suppressed	O
regeneration	O
in	O
FPG	O
.	O

Suramin	CHEMICAL
increased	O
BrdU	CHEMICAL
incorporation	O
and	O
the	O
mitotic	O
index	O
to	O
43%	O
and	O
9%	O
,	O
respectively	O
,	O
in	O
FPG	O
.	O

All	O
FPG	O
recipients	O
died	O
within	O
5	O
days	O
.	O

Suramin	CHEMICAL
recovered	O
survival	O
of	O
FPG	O
to	O
62%	O
.	O

Tumor	GENE-Y
necrosis	GENE-Y
factor-α	GENE-Y
(	O
TNF-α	GENE-Y
)	GENE-Y
mRNA	O
was	O
2	O
.	O
2-fold	O
higher	O
in	O
FPG	O
than	O
in	O
LPG	O
and	O
was	O
associated	O
with	O
activation	O
of	O
caspase-8	GENE-Y
and	O
caspase-3	GENE-Y
in	O
FPG	O
.	O

Suramin	CHEMICAL
decreased	O
TNF-α	GENE-Y
and	O
caspase	GENE-N
activation	O
in	O
FPG	O
.	O

Transforming	GENE-N
growth	GENE-N
factor-β	GENE-N
(	O
TGF-β	GENE-N
)	O
,	O
phospho-Smad2	O
/	O
3	O
and	O
p21Cip1	GENE-Y
were	O
significantly	O
higher	O
in	O
FPG	O
than	O
in	O
LPG	O
and	O
suramin	CHEMICAL
blocked	O
TGF-β	GENE-N
formation	O
and	O
its	O
down-stream	O
signaling	O
pathway	O
.	O

Taken	O
together	O
,	O
suramin	CHEMICAL
improves	O
the	O
outcome	O
of	O
FPG	O
transplantation	O
,	O
most	O
likely	O
by	O
inhibition	O
of	O
TNF-α	GENE-Y
and	O
TGF-β	GENE-N
formation	O
.	O
It	O
has	O
recently	O
been	O
shown	O
that	O
high-fat	O
diets	O
induce	O
the	O
expression	O
of	O
peroxisome	GENE-Y
proliferator-activated	GENE-Y
receptor	GENE-Y
(	O
PPAR	GENE-Y
)	O
with	O
a	O
concomitant	O
decrease	O
in	O
expression	O
of	O
retinoic	CHEMICAL
acid	CHEMICAL
(	O
RAR	GENE-N
)	O
and	O
triiodothyronine	CHEMICAL
(	O
TR	O
)	O
receptors	O
in	O
rat	O
liver	O
.	O

The	O
authors	O
have	O
suggested	O
that	O
PPAR	GENE-Y
activation	O
may	O
be	O
responsible	O
for	O
these	O
modifications	O
in	O
nuclear	GENE-N
receptor	GENE-N
expression	O
.	O

With	O
the	O
aim	O
of	O
gaining	O
further	O
insight	O
into	O
a	O
possible	O
relationship	O
between	O
the	O
patterns	O
of	O
expression	O
of	O
these	O
receptors	O
,	O
we	O
have	O
examined	O
,	O
using	O
a	O
pharmacological	O
model	O
,	O
the	O
effect	O
of	O
a	O
strong	O
and	O
specific	O
PPAR	GENE-Y
activation	O
induced	O
by	O
bezafibrate	CHEMICAL
,	O
a	O
peroxisome	O
proliferator	O
agent	O
.	O

Activation	O
of	O
PPAR	GENE-Y
was	O
evaluated	O
by	O
quantifying	O
PPAR	GENE-Y
alpha	GENE-Y
mRNA	O
and	O
acyl-CoA	CHEMICAL
oxidase	O
mRNA	O
.	O

The	O
expression	O
of	O
RAR	GENE-N
and	O
TR	GENE-N
was	O
determined	O
by	O
assaying	O
the	O
binding	O
properties	O
of	O
these	O
nuclear	GENE-N
receptors	GENE-N
and	O
by	O
quantifying	O
the	O
mRNA	O
level	O
of	O
RAR	GENE-Y
beta	GENE-Y
and	O
TR	GENE-N
alpha1	GENE-N
,	GENE-N
beta1	GENE-N
isoforms	O
.	O

After	O
a	O
10	O
day	O
treatment	O
of	O
young	O
rats	O
,	O
induction	O
of	O
PPAR	GENE-Y
(	O
PPAR	GENE-Y
alpha	GENE-Y
mRNA	O
was	O
increased	O
by	O
40%	O
[	O
P<	O
0	O
.	O
05	O
and	O
acyl-CoA	GENE-Y
oxidase	O
mRNA	O
by	O
411%	O
[	O
P<0	O
.	O
001	O
]	O
)	O
and	O
a	O
concomitant	O
decrease	O
of	O
RAR	GENE-N
and	O
TR	GENE-N
expression	O
(	O
Maximal	O
Binding	O
Capacity	O
was	O
decreased	O
by	O
21	O
and	O
26%	O
,	O
respectively	O
[	O
P<0	O
.	O
05	O
]	O
)	O
in	O
the	O
liver	O
was	O
observed	O
.	O

RXR	GENE-Y
alpha	GENE-Y
mRNA	O
expression	O
was	O
unchanged	O
by	O
treatment	O
.	O

Cross-talk	O
between	O
RAR	GENE-N
,	O
TR	GENE-N
and	O
PPAR	GENE-Y
signalling	O
pathways	O
may	O
be	O
implicated	O
in	O
the	O
new	O
patterns	O
of	O
nuclear	GENE-N
receptor	GENE-N
expression	O
observed	O
.	O

The	O
decreased	O
expression	O
of	O
RAR	GENE-N
and	O
TR	GENE-N
reported	O
here	O
could	O
provide	O
a	O
novel	O
element	O
for	O
the	O
understanding	O
of	O
the	O
link	O
between	O
PPAR	GENE-Y
and	O
tumorigenesis	O
in	O
rat	O
liver	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
dexamethasone	CHEMICAL
on	O
the	O
synthesis	O
of	O
steroidogenic	GENE-Y
acute	GENE-Y
regulatory	GENE-Y
protein	GENE-Y
(	O
StAR	GENE-Y
)	O
and	O
the	O
expression	O
of	O
DAX-1	GENE-Y
(	O
dosage	GENE-Y
sensitive	GENE-Y
sex	GENE-Y
reversal	GENE-Y
adrenal	GENE-Y
hypoplasia	GENE-Y
congenita	GENE-Y
critical	GENE-Y
region	GENE-Y
on	GENE-Y
the	GENE-Y
X	GENE-Y
chromosome	GENE-Y
,	GENE-Y
gene	GENE-Y
1	GENE-Y
)	O
and	O
SF-1	GENE-Y
(	O
steroidogenic	GENE-Y
factor-1	GENE-Y
)	O
in	O
vivo	O
.	O

Male	O
rats	O
were	O
treated	O
with	O
dexamethasone	CHEMICAL
(	O
0	O
.	O
4	O
and	O
4	O
mg	O
/	O
kg	O
body	O
wt	O
per	O
day	O
)	O
by	O
intraperitoneal	O
injections	O
using	O
phosphate-buffered	O
saline	O
as	O
the	O
vehicle	O
for	O
7	O
d	O
.	O

At	O
the	O
end	O
of	O
7	O
d	O
,	O
serum	O
testosterone	CHEMICAL
levels	O
were	O
decreased	O
.	O

Response	O
to	O
luteinizing	GENE-N
hormone	GENE-N
(	O
LH	GENE-N
)	O
and	O
8-bromo-cyclic-AMP	CHEMICAL
(	O
8-Br-cAMP	CHEMICAL
)	O
in	O
vitro	O
was	O
reduced	O
in	O
testicular	O
cells	O
isolated	O
from	O
dexamethasone-treated	O
rat	O
testes	O
.	O

Dexamethasone	CHEMICAL
decreased	O
LH-stimulated	O
cAMP	CHEMICAL
production	O
.	O

The	O
conversion	O
of	O
22	CHEMICAL
(	CHEMICAL
R	CHEMICAL
)	CHEMICAL
-hydroxycholesterol	CHEMICAL
,	O
pregnenolone	CHEMICAL
,	O
17-hydroxypregnenolone	CHEMICAL
,	O
dehydroepiandrosterone	CHEMICAL
,	O
and	O
androstenedione	CHEMICAL
to	O
testosterone	CHEMICAL
was	O
not	O
affected	O
by	O
dexamethasone	CHEMICAL
.	O

Dexamethasone	CHEMICAL
increased	O
DAX-1	GENE-Y
expression	O
and	O
concordantly	O
decreased	O
StAR	GENE-Y
protein	O
and	O
mRNA	O
in	O
testicular	O
cells	O
.	O

The	O
increase	O
in	O
DAX-1	GENE-Y
protein	O
corresponded	O
to	O
a	O
57%	O
reduction	O
in	O
StAR	GENE-Y
mRNA	O
levels	O
concomitant	O
with	O
a	O
79%	O
reduction	O
in	O
serum	O
testosterone	CHEMICAL
levels	O
.	O

Dexamethasone	CHEMICAL
had	O
no	O
effect	O
on	O
the	O
level	O
of	O
SF-1	GENE-Y
,	O
but	O
increased	O
the	O
amount	O
of	O
complexed	O
DAX-1-SF-1	GENE-Y
.	O

Dexamethasone	CHEMICAL
in	O
vitro	O
suppressed	O
StAR	GENE-N
promoter	GENE-N
activity	O
when	O
an	O
increasing	O
amount	O
of	O
DAX-1	GENE-Y
cDNA	O
was	O
transfected	O
.	O

These	O
results	O
demonstrate	O
that	O
dexamethasone	CHEMICAL
increases	O
expression	O
of	O
DAX-1	GENE-Y
,	O
which	O
results	O
in	O
increased	O
amounts	O
of	O
complexed	O
DAX-1-SF-1	GENE-Y
,	O
in	O
the	O
absence	O
of	O
any	O
change	O
in	O
the	O
expression	O
of	O
SF-1	GENE-Y
.	O

These	O
observations	O
strongly	O
support	O
the	O
concept	O
that	O
dexamethasone	CHEMICAL
suppresses	O
rat	O
testicular	O
testosterone	CHEMICAL
production	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
increasing	O
the	O
amount	O
of	O
complexed	O
DAX-1-SF-1	GENE-Y
in	O
these	O
cells	O
,	O
which	O
leads	O
directly	O
to	O
decreased	O
availability	O
of	O
free	O
SF-1	GENE-Y
and	O
,	O
therefore	O
,	O
decreased	O
activation	O
of	O
transcription	O
of	O
the	O
rat	GENE-Y
StAR	GENE-Y
gene	O
.	O
A	O
series	O
of	O
phenolic	CHEMICAL
acids	CHEMICAL
and	O
phenol	CHEMICAL
natural	O
products	O
,	O
such	O
as	O
p-hydroxybenzoic	CHEMICAL
acid	CHEMICAL
,	O
p-coumaric	CHEMICAL
acid	CHEMICAL
,	O
caffeic	CHEMICAL
acid	CHEMICAL
,	O
ferulic	CHEMICAL
acid	CHEMICAL
,	O
gallic	CHEMICAL
acid	CHEMICAL
,	O
syringic	CHEMICAL
acid	CHEMICAL
,	O
quercetin	CHEMICAL
,	O
and	O
ellagic	CHEMICAL
acid	CHEMICAL
,	O
were	O
investigated	O
for	O
their	O
inhibitory	O
effects	O
against	O
the	O
metalloenzyme	GENE-N
carbonic	GENE-N
anhydrase	GENE-N
(	O
CA	GENE-N
,	O
EC	GENE-Y
4	GENE-Y
.	GENE-Y
2	GENE-Y
.	GENE-Y
1	GENE-Y
.	GENE-Y
1	GENE-Y
)	O
.	O

All	O
mammalian	O
isozymes	O
of	O
human	O
(	O
h	O
)	O
or	O
murine	O
(	O
m	O
)	O
origin	O
hCA	GENE-Y
I-hCA	GENE-Y
XII	GENE-Y
,	O
mCA	GENE-Y
XIII	GENE-Y
and	O
hCA	GENE-Y
XIV	GENE-Y
were	O
inhibited	O
in	O
the	O
low	O
micromolar	O
or	O
submicromolar	O
range	O
by	O
these	O
(	O
poly	O
)	O
phenols	O
(	O
K	O
(	O
I	O
)	O
s	O
in	O
the	O
range	O
of	O
0	O
.	O
87-7	O
.	O
79	O
microM	O
)	O
.	O

p-Hydroxybenzoic	CHEMICAL
acid	CHEMICAL
was	O
the	O
best	O
inhibitor	O
of	O
all	O
isozymes	O
(	O
K	O
(	O
I	O
)	O
s	O
of	O
0	O
.	O
87-35	O
.	O
4	O
microM	O
)	O
and	O
the	O
different	O
isozymes	O
showed	O
very	O
variable	O
inhibition	O
profiles	O
with	O
these	O
derivatives	O
.	O

Phenols	CHEMICAL
like	O
the	O
ones	O
investigated	O
here	O
possess	O
a	O
CA	GENE-N
inhibition	O
mechanism	O
distinct	O
of	O
that	O
of	O
the	O
sulfonamides	CHEMICAL
/	O
sulfamates	CHEMICAL
used	O
clinically	O
or	O
the	O
coumarins	CHEMICAL
.	O

Unlike	O
the	O
sulfonamides	CHEMICAL
,	O
which	O
bind	O
to	O
the	O
catalytic	O
zinc	CHEMICAL
ion	O
,	O
phenols	CHEMICAL
are	O
anchored	O
at	O
the	O
Zn	CHEMICAL
(	CHEMICAL
II	CHEMICAL
)	CHEMICAL
-coordinated	O
water	O
molecule	O
and	O
bind	O
more	O
externally	O
within	O
the	O
active	O
site	O
cavity	O
,	O
making	O
contacts	O
with	O
various	O
amino	CHEMICAL
acid	CHEMICAL
residues	O
.	O

As	O
this	O
is	O
the	O
region	O
with	O
the	O
highest	O
variability	O
between	O
the	O
many	O
CA	GENE-N
isozymes	O
found	O
in	O
mammals	O
,	O
this	O
class	O
of	O
compounds	O
may	O
lead	O
to	O
isoform-selective	O
inhibitors	O
targeting	O
just	O
one	O
or	O
few	O
of	O
the	O
medicinally	O
relevant	O
CAs	GENE-N
.	O
Enzymatic	O
characterization	O
of	O
a	O
recombinant	O
isoform	O
hybrid	O
of	O
glutamic	GENE-N
acid	GENE-N
decarboxylase	O
(	O
rGAD67	GENE-N
/	GENE-N
65	GENE-N
)	O
expressed	O
in	O
yeast	O
.	O
We	O
have	O
investigated	O
the	O
effects	O
of	O
volatile	O
anaesthetics	O
on	O
electron	O
transport	O
chain	O
activity	O
in	O
the	O
mammalian	O
heart	O
.	O

Halothane	CHEMICAL
,	O
isoflurane	CHEMICAL
and	O
sevoflurane	CHEMICAL
reversibly	O
increased	O
NADH	CHEMICAL
fluorescence	O
(	O
autofluorescence	O
)	O
in	O
intact	O
ventricular	O
myocytes	O
of	O
guinea-pig	O
,	O
suggesting	O
that	O
NADH	CHEMICAL
oxidation	O
was	O
impaired	O
.	O

Using	O
pig	O
heart	O
submitochondrial	O
particles	O
we	O
found	O
that	O
the	O
anaesthetics	O
dose-dependently	O
inhibited	O
NADH	CHEMICAL
oxidation	O
in	O
the	O
order	O
:	O
halothane	CHEMICAL
>	O
isoflurane	CHEMICAL
=	O
sevoflurane	CHEMICAL
.	O

Succinate	CHEMICAL
oxidation	O
was	O
unaffected	O
by	O
either	O
isoflurane	CHEMICAL
or	O
sevoflurane	CHEMICAL
,	O
indicating	O
that	O
these	O
agents	O
selectively	O
inhibit	O
complex	GENE-N
I	GENE-N
(	O
NADH	GENE-N
:	O
ubiquinone	CHEMICAL
oxidoreductase	O
)	O
.	O

In	O
addition	O
to	O
inhibiting	O
NADH	CHEMICAL
oxidation	O
,	O
halothane	CHEMICAL
also	O
inhibited	O
succinate	CHEMICAL
oxidation	O
(	O
and	O
succinate	GENE-N
dehydrogenase	O
)	O
,	O
albeit	O
to	O
a	O
lesser	O
extent	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
complex	GENE-N
I	GENE-N
is	O
a	O
target	O
of	O
volatile	O
anaesthetics	O
,	O
we	O
examined	O
the	O
effects	O
of	O
these	O
agents	O
on	O
NADH	GENE-N
:	O
ubiquinone	CHEMICAL
oxidoreductase	O
(	O
EC	GENE-N
1	GENE-N
.	GENE-N
6	GENE-N
.	GENE-N
99	GENE-N
.	GENE-N
3	GENE-N
)	O
activity	O
using	O
the	O
ubiquinone	CHEMICAL
analogue	O
DBQ	CHEMICAL
(	O
decylubiquinone	CHEMICAL
)	O
as	O
substrate	O
.	O

Halothane	CHEMICAL
,	O
isoflurane	CHEMICAL
and	O
sevoflurane	CHEMICAL
dose-dependently	O
inhibited	O
NADH	CHEMICAL
:	O
DBQ	CHEMICAL
oxidoreductase	O
activity	O
.	O

Unlike	O
the	O
classical	O
inhibitor	O
rotenone	CHEMICAL
,	O
none	O
of	O
the	O
anaesthetics	O
completely	O
inhibited	O
enzyme	O
activity	O
at	O
high	O
concentration	O
,	O
suggesting	O
that	O
these	O
agents	O
bind	O
weakly	O
to	O
the	O
'hydrophobic	O
inhibitory	O
site'	O
of	O
complex	GENE-N
I	GENE-N
.	O

In	O
conclusion	O
,	O
halothane	CHEMICAL
,	O
isoflurane	CHEMICAL
and	O
sevoflurane	CHEMICAL
inhibit	O
complex	GENE-N
I	GENE-N
(	O
NADH	GENE-N
:	O
ubiquinone	CHEMICAL
oxidoreductase	O
)	O
of	O
the	O
electron	O
transport	O
chain	O
.	O

At	O
concentrations	O
of	O
approximately	O
2	O
MAC	O
(	O
minimal	O
alveolar	O
concentration	O
)	O
,	O
the	O
activity	O
of	O
NADH	GENE-N
:	O
ubiquinone	CHEMICAL
oxidoreductase	O
was	O
reduced	O
by	O
about	O
20	O
%	O
in	O
the	O
presence	O
of	O
halothane	CHEMICAL
or	O
isoflurane	CHEMICAL
,	O
and	O
by	O
about	O
10	O
%	O
in	O
the	O
presence	O
of	O
sevoflurane	CHEMICAL
.	O

These	O
inhibitory	O
effects	O
are	O
unlikely	O
to	O
compromise	O
cardiac	O
performance	O
at	O
usual	O
clinical	O
concentrations	O
,	O
but	O
may	O
contribute	O
to	O
the	O
mechanism	O
by	O
which	O
volatile	O
anaesthetics	O
induce	O
pharmacological	O
preconditioning	O
.	O
ETHNOPHARMACOLOGICAL	O
RELEVANCE	O
:	O
Licorice	O
(	O
Glycyrrhiza	O
uralensis	O
Fisch	O
.	O

,	O
Leguminosae	O
)	O
has	O
been	O
used	O
in	O
herbal	O
medicine	O
and	O
food	O
supplement	O
worldwide	O
for	O
centuries	O
.	O

Licorice	O
is	O
a	O
common	O
ingredient	O
of	O
several	O
prescriptions	O
of	O
traditional	O
Chinese	O
medicine	O
which	O
have	O
been	O
proved	O
to	O
inhibit	O
infection	O
of	O
human	O
respiratory	O
syncytial	O
virus	O
(	O
HRSV	O
)	O
.	O

There	O
are	O
two	O
preparations	O
of	O
licorice	O
,	O
Radix	O
Glycyrrhizae	O
and	O
Radix	O
Glycyrrhizae	O
Preparata	O
.	O

However	O
,	O
it	O
is	O
unknown	O
whether	O
licorice	O
or	O
which	O
preparation	O
of	O
licorice	O
is	O
effective	O
against	O
HRSV	O
,	O
nor	O
is	O
its	O
active	O
constituent	O
.	O

AIM	O
OF	O
THE	O
STUDY	O
:	O
We	O
tested	O
the	O
hypothesis	O
that	O
Radix	O
Glycyrrhizae	O
can	O
effectively	O
decrease	O
HRSV-induced	O
plaque	O
formation	O
in	O
respiratory	O
mucosal	O
cell	O
lines	O
.	O

We	O
also	O
tried	O
to	O
find	O
out	O
the	O
active	O
constituent	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Anti-HRSV	O
activities	O
of	O
hot	O
water	O
extracts	O
of	O
preparations	O
of	O
licorice	O
,	O
glycyrrhizin	CHEMICAL
and	O
18β-glycyrrhetinic	CHEMICAL
acid	CHEMICAL
(	O
18β-GA	CHEMICAL
)	O
,	O
the	O
active	O
constituents	O
of	O
licorice	O
,	O
were	O
examined	O
by	O
plaque	O
reduction	O
assay	O
in	O
both	O
human	O
upper	O
(	O
HEp-2	O
)	O
and	O
low	O
(	O
A549	O
)	O
respiratory	O
tract	O
cell	O
lines	O
.	O

Abilities	O
of	O
crude	O
licorice	O
to	O
inhibit	O
viral	O
replication	O
and	O
to	O
stimulate	O
IFN-β	GENE-Y
were	O
evaluated	O
by	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
and	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
,	O
respectively	O
.	O

RESULTS	O
:	O
Radix	O
Glycyrrhizae	O
and	O
Radix	O
Glycyrrhizae	O
Preparata	O
dose-dependently	O
inhibited	O
HRSV-induced	O
plaque	O
formation	O
in	O
both	O
HEp-2	O
and	O
A549	O
cell	O
lines	O
(	O
p<0	O
.	O
0001	O
)	O
.	O

The	O
effect	O
of	O
Radix	O
Glycyrrhizae	O
was	O
better	O
than	O
that	O
of	O
Radix	O
Glycyrrhizae	O
Preparata	O
on	O
HEp-2	O
cells	O
.	O

However	O
,	O
there	O
was	O
no	O
difference	O
of	O
their	O
anti-HRSV	O
effects	O
on	O
A549	O
cells	O
.	O

Besides	O
,	O
glycyrrhizin	CHEMICAL
was	O
ineffective	O
at	O
all	O
.	O

Nevertheless	O
,	O
18β-GA	CHEMICAL
showed	O
a	O
potent	O
anti-HRSV	O
activity	O
.	O

Radix	O
Glycyrrhizae	O
was	O
more	O
effective	O
when	O
given	O
before	O
viral	O
inoculation	O
(	O
p<0	O
.	O
0001	O
)	O
which	O
may	O
be	O
due	O
to	O
its	O
inhibition	O
of	O
viral	O
attachment	O
on	O
(	O
p<0	O
.	O
0001	O
)	O
and	O
penetration	O
(	O
p<0	O
.	O
0001	O
)	O
into	O
the	O
host	O
cells	O
.	O

The	O
anti-HRSV	O
activity	O
of	O
Radix	O
Glycyrrhizae	O
was	O
further	O
confirmed	O
by	O
RT-PCR	O
and	O
qRT-PCR	O
.	O

300μg	O
/	O
ml	O
Radix	O
Glycyrrhizae	O
markedly	O
decreased	O
the	O
viral	O
amounts	O
within	O
the	O
cells	O
and	O
in	O
the	O
suspension	O
.	O

Radix	O
Glycyrrhizae	O
might	O
further	O
stimulate	O
mucosal	O
cells	O
to	O
secrete	O
IFN-β	GENE-Y
to	O
counteract	O
viral	O
infection	O
.	O

CONCLUSIONS	O
:	O
Both	O
Radix	O
Glycyrrhizae	O
and	O
Radix	O
Glycyrrhizae	O
Preparata	O
are	O
effective	O
against	O
HRSV	O
infection	O
on	O
airway	O
epithelial	O
cells	O
.	O

Radix	O
Glycyrrhizae	O
inhibited	O
HRSV	O
mainly	O
by	O
preventing	O
viral	O
attachment	O
,	O
internalization	O
,	O
and	O
by	O
stimulating	O
IFN	GENE-N
secretion	O
.	O

18β-GA	CHEMICAL
may	O
be	O
one	O
of	O
its	O
active	O
constituents	O
.	O
Felbamate	CHEMICAL
block	O
of	O
recombinant	O
N-methyl-D-aspartate	GENE-N
receptors	O
:	O
selectivity	O
for	O
the	O
NR2B	GENE-Y
subunit	O
.	O
Rivastigmine	CHEMICAL
for	O
Alzheimer's	O
disease	O
.	O
Promoter	O
polymorphisms	O
regulating	O
corticotrophin-releasing	GENE-Y
hormone	GENE-Y
transcription	O
in	O
vitro	O
.	O
Nucleos	CHEMICAL
(	CHEMICAL
t	CHEMICAL
)	CHEMICAL
ide	CHEMICAL
analogues	O
have	O
proven	O
useful	O
in	O
the	O
treatment	O
of	O
viral	O
infections	O
.	O

Ribavirin	CHEMICAL
is	O
a	O
nucleoside	O
,	O
guanosine	CHEMICAL
analogue	O
,	O
whose	O
mechanisms	O
of	O
action	O
include	O
inhibition	O
of	O
inosine	CHEMICAL
monophosphate	CHEMICAL
dehydrogenase	O
(	O
IMPDH	GENE-N
)	O
,	O
which	O
is	O
the	O
key	O
step	O
in	O
de	O
novo	O
guanine	CHEMICAL
synthesis	O
,	O
a	O
requirement	O
for	O
viral	O
replication	O
.	O

In	O
combination	O
with	O
pegylated	GENE-N
interferon	GENE-N
alfa	GENE-N
,	O
ribavirin	CHEMICAL
is	O
the	O
standard	O
of	O
care	O
for	O
the	O
treatment	O
of	O
chronic	O
hepatitis	O
C	O
today	O
.	O

However	O
,	O
the	O
medication	O
is	O
associated	O
with	O
significant	O
haemolytic	O
anaemia	O
,	O
which	O
may	O
require	O
dose	O
reduction	O
,	O
discontinuation	O
or	O
treatment	O
with	O
recombinant	O
human	GENE-Y
erythropoietin	GENE-Y
.	O

Dose	O
reduction	O
also	O
appears	O
to	O
decrease	O
sustained	O
viral	O
clearance	O
rates	O
.	O

Newer	O
IMPDH	GENE-N
inhibitors	O
are	O
in	O
various	O
stages	O
of	O
development	O
.	O

Viramidine	CHEMICAL
,	O
a	O
liver-targeting	O
prodrug	O
of	O
ribavirin	CHEMICAL
,	O
has	O
demonstrated	O
significant	O
antiviral	O
activity	O
and	O
erythrocyte-sparing	O
properties	O
.	O

It	O
is	O
currently	O
in	O
Phase	O
3	O
trials	O
.	O

Clinical	O
trials	O
of	O
merimepodib	CHEMICAL
,	O
another	O
investigational	O
IMPDH	GENE-N
inhibitor	O
,	O
have	O
completed	O
enrolment	O
for	O
a	O
Phase	O
2b	O
study	O
as	O
a	O
third	O
medication	O
for	O
administration	O
with	O
pegylated	GENE-N
interferon	GENE-N
plus	O
ribavirin	CHEMICAL
.	O

Although	O
other	O
IMDPH	GENE-N
inhibitors	O
also	O
have	O
antiviral	O
activity	O
,	O
these	O
medications	O
appear	O
best	O
suited	O
as	O
immunosuppressive	O
medications	O
at	O
this	O
time	O
.	O
Minor	O
Compensatory	O
Changes	O
in	O
SAGE	O
Mdr1a	GENE-Y
(	O
P-gp	GENE-N
)	O
,	O
Bcrp	GENE-Y
,	O
and	O
Mrp2	GENE-Y
Knockout	O
Rats	O
do	O
not	O
Detract	O
from	O
their	O
General	O
Utility	O
in	O
the	O
Study	O
of	O
Transporter-mediated	O
Pharmacokinetics	O
.	O
Thymidylate	GENE-Y
kinase	O
:	O
an	O
old	O
topic	O
brings	O
new	O
perspectives	O
.	O
Biosynthesis	O
of	O
highly	O
enriched	O
(	CHEMICAL
13	CHEMICAL
)	CHEMICAL
C-lycopene	CHEMICAL
for	O
human	O
metabolic	O
studies	O
using	O
repeated	O
batch	O
tomato	O
cell	O
culturing	O
with	O
(	CHEMICAL
13	CHEMICAL
)	CHEMICAL
C-glucose	CHEMICAL
.	O
Localization	O
of	O
the	O
ammonium	CHEMICAL
transporter	O
proteins	O
RhBG	GENE-Y
and	O
RhCG	GENE-Y
in	O
mouse	O
kidney	O
.	O
Antidepressant-like	O
effect	O
of	O
oleanolic	CHEMICAL
acid	CHEMICAL
in	O
mice	O
exposed	O
to	O
the	O
repeated	O
forced	O
swimming	O
test	O
.	O
9-Methoxycamptothecin	CHEMICAL
(	O
MCPT	CHEMICAL
)	O
has	O
been	O
recently	O
reported	O
to	O
have	O
a	O
strong	O
anticancer	O
activity	O
.	O

However	O
,	O
its	O
detailed	O
mechanism	O
of	O
action	O
in	O
human	O
cancer	O
cells	O
has	O
not	O
been	O
well	O
clarified	O
.	O

The	O
results	O
showed	O
that	O
MCPT	CHEMICAL
induced	O
cytotoxicity	O
in	O
seven	O
human	O
cancer	O
cell	O
lines	O
in	O
a	O
dose	O
dependent	O
manner	O
after	O
72h	O
,	O
with	O
A2780	O
and	O
Hela	O
cell	O
lines	O
more	O
sensitive	O
,	O
so	O
the	O
two	O
cell	O
lines	O
were	O
chosen	O
to	O
do	O
further	O
studies	O
.	O

MCPT	CHEMICAL
induced	O
strong	O
G2	O
/	O
M	O
arrest	O
in	O
both	O
A2780	O
cells	O
and	O
Hela	O
cells	O
after	O
24h	O
,	O
following	O
by	O
substantial	O
sub-G1	O
arrest	O
(	O
indicating	O
apoptosis	O
)	O
.	O

The	O
apoptosis	O
was	O
verified	O
by	O
staining	O
with	O
Annexin	O
V-FITC	CHEMICAL
and	O
propidium	CHEMICAL
iodide	CHEMICAL
.	O

ROS	O
generation	O
increased	O
significantly	O
in	O
MCPT-induced	O
apoptosis	O
.	O

Meanwhile	O
,	O
the	O
apoptosis	O
appeared	O
to	O
be	O
dependent	O
on	O
caspase-3	GENE-N
,	GENE-N
-8	GENE-N
and	GENE-N
-9	GENE-N
in	O
A2780	O
cells	O
,	O
and	O
caspase-3	GENE-Y
in	O
Hela	O
cells	O
.	O

In	O
addition	O
,	O
MCPT	CHEMICAL
induced	O
up-regulation	O
expression	O
of	O
most	O
of	O
seventeen	O
genes	O
in	O
both	O
cell	O
lines	O
.	O

Western	O
blot	O
verified	O
that	O
changes	O
of	O
TNFα	GENE-Y
,	O
Fas	GENE-Y
,	O
P53	GENE-Y
and	O
P27	GENE-Y
protein	O
level	O
were	O
consistent	O
with	O
their	O
gene	O
expression	O
changes	O
.	O

Taken	O
together	O
,	O
MCPT	CHEMICAL
plays	O
an	O
important	O
role	O
in	O
tumor	O
growth	O
suppression	O
by	O
inducing	O
apoptosis	O
in	O
both	O
cell	O
lines	O
via	O
extrinsic	O
and	O
intrinsic	O
apoptotic	O
pathways	O
,	O
and	O
has	O
the	O
potential	O
to	O
be	O
developed	O
into	O
an	O
antitumor	O
agent	O
.	O
A	O
series	O
of	O
GPR119	GENE-Y
agonists	O
based	O
on	O
a	O
2	CHEMICAL
,	CHEMICAL
6-diazatricyclo	CHEMICAL
[	CHEMICAL
3	CHEMICAL
.	CHEMICAL
3	CHEMICAL
.	CHEMICAL
1	CHEMICAL
.	CHEMICAL
1∼3	CHEMICAL
,	CHEMICAL
7∼	CHEMICAL
]	CHEMICAL
decane	CHEMICAL
ring	O
system	O
is	O
described	O
.	O

Also	O
provided	O
is	O
a	O
detailed	O
account	O
of	O
the	O
development	O
of	O
a	O
multigram	O
scale	O
synthesis	O
of	O
the	O
diazatricyclic	CHEMICAL
ring	O
system	O
,	O
which	O
was	O
achieved	O
using	O
a	O
Hofmann-Löffler-Freytag	O
reaction	O
as	O
the	O
key	O
step	O
.	O

The	O
basis	O
for	O
the	O
use	O
of	O
this	O
complex	O
framework	O
lies	O
in	O
an	O
attempt	O
to	O
constrain	O
one	O
end	O
of	O
the	O
molecule	O
in	O
the	O
"agonist	O
conformation"	O
as	O
was	O
previously	O
described	O
for	O
3-oxa-7-aza-bicyclo	CHEMICAL
[	CHEMICAL
3	CHEMICAL
.	CHEMICAL
3	CHEMICAL
.	CHEMICAL
1	CHEMICAL
]	CHEMICAL
nonanes	CHEMICAL
.	O

Optimization	O
of	O
carbamate	CHEMICAL
analogues	O
of	O
the	O
diazatricylic	CHEMICAL
compounds	O
led	O
to	O
the	O
identification	O
of	O
32i	O
as	O
a	O
potent	O
agonist	O
of	O
the	O
GPR119	GENE-Y
receptor	O
with	O
low	O
unbound	O
human	O
liver	O
microsomal	O
clearance	O
.	O

The	O
use	O
of	O
an	O
agonist	O
response	O
weighted	O
ligand	O
lipophilic	O
efficiency	O
(	O
LLE	O
)	O
termed	O
AgLLE	O
is	O
discussed	O
along	O
with	O
the	O
issues	O
of	O
applying	O
efficiency	O
measures	O
to	O
agonist	O
programs	O
.	O

Ultimately	O
,	O
solubility	O
limited	O
absorption	O
and	O
poor	O
exposure	O
reduced	O
further	O
interest	O
in	O
these	O
molecules	O
.	O
The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
design	O
novel	O
pentablock	O
copolymers	O
(	O
polylatide-polycaprolactone-polyethylene	CHEMICAL
glycol-	O
polycaprolactone-polylatide	CHEMICAL
)	O
(	O
PLA-PCL-PEG-PCL-PLA	CHEMICAL
)	O
to	O
prepare	O
nanoparticle	O
formulations	O
which	O
provide	O
continuous	O
delivery	O
of	O
steroids	CHEMICAL
over	O
a	O
longer	O
duration	O
with	O
minimal	O
burst	O
effect	O
.	O

Another	O
purpose	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
poly	CHEMICAL
(	CHEMICAL
L-lactide	CHEMICAL
)	CHEMICAL
(	O
PLLA	CHEMICAL
)	O
or	O
poly	CHEMICAL
(	CHEMICAL
D	CHEMICAL
,	CHEMICAL
L-lactide	CHEMICAL
)	CHEMICAL
(	O
PDLLA	CHEMICAL
)	O
incorporation	O
on	O
crystallinity	O
of	O
pentablock	O
copolymers	O
and	O
in	O
vitro	O
release	O
profile	O
of	O
triamcinolone	CHEMICAL
acetonide	CHEMICAL
(	O
selected	O
as	O
model	O
drug	O
)	O
from	O
nanoparticles	O
.	O

PLA-PCL-PEG-PCL-PLA	CHEMICAL
copolymers	O
with	O
different	O
block	O
ratio	O
of	O
PCL	CHEMICAL
/	O
PLA	CHEMICAL
segment	O
were	O
synthesized	O
.	O

Release	O
of	O
triamcinolone	CHEMICAL
acetonide	CHEMICAL
from	O
nanoparticles	O
was	O
significantly	O
affected	O
by	O
crystallinity	O
of	O
the	O
copolymers	O
.	O

Burst	O
release	O
of	O
triamcinolone	CHEMICAL
acetonide	CHEMICAL
from	O
nanoparticles	O
was	O
significantly	O
minimized	O
with	O
incorporation	O
of	O
proper	O
ratio	O
of	O
PDLLA	CHEMICAL
in	O
the	O
existing	O
triblock	O
(	O
PCL-PEG-PCL	CHEMICAL
)	O
copolymer	O
.	O

Moreover	O
,	O
pentablock	O
copolymer	O
based	O
nanoparticles	O
exhibited	O
continuous	O
release	O
of	O
triamcinolone	CHEMICAL
acetonide	CHEMICAL
.	O

Pentablock	O
copolymer	O
based	O
nanoparticles	O
can	O
be	O
utilized	O
to	O
achieve	O
continuous	O
near	O
zero-order	O
delivery	O
of	O
corticosteroids	O
from	O
nanoparticles	O
without	O
any	O
burst	O
effect	O
.	O
Genome-wide	O
screen	O
for	O
modulation	O
of	O
hepatic	O
apolipoprotein	GENE-Y
A-I	GENE-Y
(	O
ApoA-I	GENE-Y
)	O
secretion	O
.	O
Neurochemical	O
effects	O
of	O
the	O
monoamine	GENE-N
oxidase	O
inhibitor	O
phenelzine	CHEMICAL
on	O
brain	O
GABA	CHEMICAL
and	O
alanine	CHEMICAL
:	O
A	O
comparison	O
with	O
vigabatrin	CHEMICAL
.	O
DNA	GENE-Y
topoisomerase	GENE-Y
IIalpha	GENE-Y
(	O
TOP2A	GENE-Y
)	O
inhibitors	O
up-regulate	O
fatty	CHEMICAL
acid	CHEMICAL
synthase	O
gene	O
expression	O
in	O
SK-Br3	O
breast	O
cancer	O
cells	O
:	O
in	O
vitro	O
evidence	O
for	O
a	O
'functional	O
amplicon'	O
involving	O
FAS	GENE-Y
,	O
Her-2	GENE-Y
/	O
neu	GENE-Y
and	O
TOP2A	GENE-Y
genes	O
.	O
Estrogens	CHEMICAL
,	O
and	O
particularly	O
glucuronides	O
such	O
as	O
ethinylestradiol	CHEMICAL
(	O
EE	O
)	O
,	O
have	O
been	O
shown	O
to	O
cause	O
cholestasis	O
in	O
animal	O
studies	O
,	O
by	O
reducing	O
bile	CHEMICAL
acid	CHEMICAL
uptake	O
by	O
hepatocytes	O
.	O

The	O
aim	O
of	O
the	O
present	O
article	O
was	O
to	O
investigate	O
anticholestatic	O
activity	O
of	O
resveratrol	CHEMICAL
(	O
RES	CHEMICAL
)	O
against	O
liver	O
cholestasis	O
induced	O
by	O
EE	O
in	O
adult	O
female	O
rats	O
.	O

The	O
daily	O
oral	O
administration	O
of	O
the	O
RES	CHEMICAL
at	O
a	O
concentration	O
of	O
25	O
mg	O
/	O
kg	O
body	O
weight	O
for	O
15	O
days	O
to	O
rats	O
treated	O
with	O
EE	O
(	O
100	O
μg	O
/	O
kg	O
body	O
weight	O
for	O
5	O
days	O
)	O
resulted	O
in	O
a	O
significant	O
protection	O
against	O
EE-induced	O
decrease	O
in	O
both	O
serum	O
cholesterol	O
and	O
bile	CHEMICAL
acid	CHEMICAL
levels	O
as	O
well	O
as	O
against	O
an	O
increase	O
of	O
serum	O
bilirubin	CHEMICAL
concentration	O
.	O

The	O
treatment	O
also	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
hepatic	O
superoxide	GENE-N
dismutase	O
,	O
glutathione	GENE-N
peroxidase	O
,	O
glutathione	GENE-Y
reductase	O
,	O
and	O
catalase	GENE-Y
activities	O
as	O
well	O
as	O
hepatic	O
protein-bound	O
and	O
nonprotein	O
sulfhydryl	CHEMICAL
groups	O
.	O

RES	CHEMICAL
inhibited	O
serum	O
alkaline	GENE-N
phosphatase	GENE-N
,	O
alanine	GENE-N
aminotransferase	O
,	O
pi-glutathione-S-transferase	O
,	O
gamma-glutamyl	CHEMICAL
transpeptidase	O
,	O
and	O
alpha-glutathione-S-transferase	O
activities	O
,	O
as	O
well	O
as	O
reduced	O
serum	O
tumor	GENE-Y
necrosis	GENE-Y
factor-alpha	GENE-Y
,	O
nitric	CHEMICAL
oxide	CHEMICAL
,	O
and	O
hepatic	O
malondialdehyde	CHEMICAL
as	O
compared	O
to	O
EE-treated	O
rats	O
.	O

The	O
results	O
clearly	O
suggest	O
that	O
RES	CHEMICAL
has	O
a	O
powerful	O
prophylactic	O
action	O
in	O
cholestasis	O
induced	O
by	O
EE	O
.	O

Taken	O
together	O
,	O
RES	CHEMICAL
has	O
potential	O
as	O
a	O
preventive	O
and	O
therapeutic	O
agent	O
for	O
cholestasis	O
and	O
deserves	O
clinical	O
trial	O
in	O
the	O
near	O
future	O
as	O
an	O
adjuvant	O
therapy	O
in	O
women	O
treated	O
with	O
estrogen	CHEMICAL
.	O
Deduced	O
amino	CHEMICAL
acid	CHEMICAL
sequence	O
from	O
the	O
bovine	GENE-Y
oxytocin-neurophysin	O
I	O
precursor	O
cDNA	O
.	O
Ghrelin	GENE-Y
is	O
a	O
stomach-derived	O
orexigenic	O
peptide	O
.	O

The	O
goal	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
roles	O
of	O
mu	GENE-N
and	GENE-N
kappa	GENE-N
opioid	GENE-N
receptors	GENE-N
in	O
systemic	O
ghrelin-mediated	O
regulation	O
of	O
the	O
mesolimbic	O
dopamine	CHEMICAL
system	O
.	O

To	O
evaluate	O
the	O
interaction	O
of	O
systemic	O
ghrelin	GENE-Y
with	O
values	O
of	O
food	O
reward	O
,	O
rats	O
were	O
exposed	O
to	O
food	O
removal	O
,	O
regular	O
food	O
or	O
palatable	O
food	O
after	O
systemic	O
ghrelin	GENE-Y
administration	O
.	O

Extracellular	O
dopamine	CHEMICAL
levels	O
were	O
quantified	O
in	O
the	O
nucleus	O
accumbens	O
(	O
NAc	O
)	O
and	O
receptor-specific	O
compounds	O
were	O
infused	O
into	O
the	O
ventral	O
tegmental	O
area	O
(	O
VTA	O
)	O
using	O
dual-probe	O
microdialysis	O
.	O

Consumption	O
of	O
regular	O
or	O
palatable	O
food	O
without	O
systemic	O
ghrelin	GENE-Y
administration	O
induced	O
an	O
increase	O
in	O
dopamine	CHEMICAL
levels	O
in	O
the	O
NAc	O
via	O
activation	O
of	O
mu	GENE-Y
opioid	GENE-Y
receptors	GENE-Y
in	O
the	O
VTA	O
.	O

Systemic	O
ghrelin	GENE-Y
administration	O
(	O
3	O
nmol	O
,	O
i	O
.	O

v	O
.	O

)	O
followed	O
by	O
no	O
food	O
induced	O
a	O
decrease	O
in	O
dopamine	CHEMICAL
levels	O
via	O
activation	O
of	O
kappa	GENE-Y
opioid	GENE-Y
receptors	GENE-Y
in	O
the	O
VTA	O
.	O

Systemic	O
ghrelin	GENE-Y
administration	O
followed	O
by	O
consumption	O
of	O
regular	O
food	O
induced	O
an	O
increase	O
in	O
dopamine	CHEMICAL
levels	O
via	O
preferential	O
activation	O
of	O
mu	GENE-Y
opioid	GENE-Y
receptors	GENE-Y
,	O
whereas	O
systemic	O
ghrelin	GENE-Y
administration	O
followed	O
by	O
consumption	O
of	O
palatable	O
food	O
suppressed	O
the	O
increase	O
in	O
dopamine	CHEMICAL
levels	O
via	O
preferential	O
activation	O
of	O
kappa	GENE-Y
opioid	GENE-Y
receptors	GENE-Y
.	O

Thus	O
,	O
natural	O
food	O
reward	O
and	O
systemic	O
ghrelin	GENE-Y
activate	O
mu	GENE-N
and	GENE-N
kappa	GENE-N
opioid	GENE-N
receptor	GENE-N
pathways	O
in	O
the	O
VTA	O
,	O
respectively	O
,	O
resulting	O
in	O
opposite	O
influences	O
on	O
dopamine	CHEMICAL
release	O
in	O
the	O
NAc	O
.	O

Furthermore	O
,	O
systemic	O
ghrelin	GENE-Y
induces	O
switching	O
of	O
the	O
dominant	O
opioid	GENE-N
receptor	GENE-N
pathway	O
for	O
highly	O
rewarding	O
food	O
from	O
mu	O
to	O
kappa	O
,	O
resulting	O
in	O
suppression	O
of	O
the	O
mesolimbic	O
dopamine	CHEMICAL
system	O
.	O

These	O
novel	O
findings	O
might	O
provide	O
insights	O
into	O
the	O
neural	O
pathways	O
involved	O
in	O
eating	O
disorders	O
.	O
Liver	GENE-N
X	GENE-N
receptors	GENE-N
:	O
Emerging	O
therapeutic	O
targets	O
for	O
Alzheimer's	O
disease	O
.	O
Anti-diabetic	O
Activity	O
of	O
Swertiamarin	CHEMICAL
is	O
due	O
to	O
an	O
Active	O
Metabolite	O
,	O
Gentianine	CHEMICAL
,	O
that	O
Upregulates	O
PPAR-γ	GENE-Y
Gene	O
Expression	O
in	O
3T3-L1	O
cells	O
.	O
Serotonin	GENE-Y
transporter	O
function	O
in	O
vivo	O
:	O
assessment	O
by	O
chronoamperometry	O
.	O
Distinct	O
patterns	O
of	O
mutations	O
occurring	O
in	O
de	O
novo	O
AML	O
versus	O
AML	O
arising	O
in	O
the	O
setting	O
of	O
severe	O
congenital	O
neutropenia	O
.	O
UNLABELLED	O
:	O
Long	O
standing	O
confusion	O
exists	O
in	O
the	O
terminology	O
of	O
hypokalaemic	O
salt-losing	O
tubulopathies	O
(	O
SLTs	O
)	O
.	O

SLTs	O
are	O
autosomal	O
recessively	O
transmitted	O
and	O
characterized	O
by	O
normotensive	O
secondary	O
hyperreninism	O
/	O
hyperaldosteronism	O
with	O
hypokalaemic	O
metabolic	O
alkalosis	O
.	O

Historically	O
,	O
four	O
phenotypical	O
variants	O
have	O
been	O
described	O
:	O
(	O
1	O
)	O
the	O
(	O
classic	O
)	O
Bartter	O
syndrome	O
(	O
cBS	O
)	O
,	O
(	O
2	O
)	O
the	O
hypomagnesaemic	O
hypocalciuric	O
Gitelman	O
syndrome	O
(	O
GS	O
)	O
,	O
(	O
3	O
)	O
the	O
hypercalciuric	O
hyperprostaglandin-E-syndrome	O
(	O
HPS	O
)	O
or	O
antenatal	O
Bartter	O
syndrome	O
(	O
aBS	O
)	O
and	O
(	O
4	O
)	O
the	O
hyperprostaglandin-E-syndrome	O
with	O
sensorineural	O
deafness	O
(	O
HPS	O
+	O
SND	O
)	O
.	O

The	O
latter	O
two	O
syndromes	O
are	O
the	O
most	O
severe	O
variants	O
with	O
antenatal	O
manifestation	O
with	O
polyhydramnios	O
and	O
life-threatening	O
course	O
of	O
salt-	O
and	O
water-loss	O
.	O

Defects	O
in	O
five	O
renal	O
membrane	O
proteins	O
involved	O
in	O
electrolyte	O
reabsorption	O
have	O
been	O
identified	O
:	O
In	O
HPS-patients	O
mutations	O
in	O
(	O
1	O
)	O
either	O
the	O
furosemide-sensitive	O
sodium-potassium-chloride	CHEMICAL
cotransporter	O
NKCC2	GENE-Y
,	O
or	O
(	O
2	O
)	O
in	O
the	O
potassium	GENE-N
channel	O
ROMK	GENE-Y
have	O
been	O
identified	O
,	O
and	O
(	O
3	O
)	O
HPS	O
+	O
SND	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
beta-subunit	GENE-Y
of	GENE-Y
the	GENE-Y
chloride	CHEMICAL
channels	O
ClC-Kb	O
and	O
-Ka	O
(	O
named	O
barttin	GENE-Y
)	O
,	O
all	O
mimicking	O
the	O
major	O
pharmacological	O
effects	O
of	O
furosemide	CHEMICAL
with	O
minor	O
potassium-wasting	O
in	O
ROMK-patients	O
as	O
seen	O
in	O
patients	O
treated	O
with	O
simultaneous	O
furosemide	CHEMICAL
and	O
amiloride	CHEMICAL
,	O
and	O
minor	O
calcium-wasting	O
in	O
Barttin-patients	O
resembling	O
the	O
combination	O
of	O
furosemide	CHEMICAL
and	O
thiazides	CHEMICAL
.	O

(	O
4	O
)	O
cBS	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
chloride	CHEMICAL
channel	O
ClC-Kb	GENE-Y
with	O
similar	O
clinical	O
characteristics	O
as	O
seen	O
under	O
combination	O
of	O
thiazides	CHEMICAL
and	O
furosemide	CHEMICAL
,	O
(	O
5	O
)	O
GS	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
thiazide-sensitive	O
sodium-chloride	CHEMICAL
cotransporter	O
NCCT	GENE-Y
resembling	O
the	O
effect	O
of	O
long-term	O
thiazide	CHEMICAL
administration	O
.	O

CONCLUSION	O
:	O
The	O
combination	O
of	O
pharmacology	O
and	O
genetics	O
suggests	O
a	O
new	O
terminology	O
for	O
the	O
above	O
described	O
SLTs	O
:	O
Furosemide-like-SLT	O
for	O
HPS	O
caused	O
by	O
NKCC2-mutations	O
,	O
furosemide	CHEMICAL
/	O
amiloride-like-SLT	O
for	O
HPS	O
caused	O
by	O
ROMK-mutations	O
,	O
furosemide	CHEMICAL
/	O
thiazide-like-SLT	O
for	O
HPS	O
+	O
SND	O
,	O
thiazide	CHEMICAL
/	O
furosemide-like-SLT	O
for	O
cBS	O
,	O
and	O
thiazide-like-SLT	O
for	O
GS	O
.	O
Vitamin	CHEMICAL
A	CHEMICAL
or	O
retinol	CHEMICAL
is	O
arguably	O
the	O
most	O
multifunctional	O
vitamin	CHEMICAL
in	O
the	O
human	O
body	O
as	O
it	O
is	O
essential	O
from	O
embryogenesis	O
to	O
adulthood	O
.	O

The	O
pleiotropic	O
effects	O
of	O
vitamin	CHEMICAL
A	CHEMICAL
are	O
exerted	O
mainly	O
by	O
one	O
active	O
metabolite	O
,	O
all-trans	CHEMICAL
retinoic	CHEMICAL
acid	CHEMICAL
(	O
atRA	CHEMICAL
)	O
,	O
which	O
regulates	O
the	O
expression	O
of	O
a	O
battery	O
of	O
target	O
genes	O
through	O
several	O
families	O
of	O
nuclear	GENE-N
receptors	GENE-N
(	O
RARs	GENE-N
,	O
RXRs	GENE-N
and	O
PPARβ	GENE-N
/	GENE-N
δ	GENE-N
)	O
,	O
polymorphic	GENE-N
retinoic	CHEMICAL
acid	CHEMICAL
(	O
RA	O
)	O
response	O
elements	O
and	O
multiple	O
coregulators	O
.	O

It	O
also	O
involves	O
extra	O
nuclear	O
and	O
non-transcriptional	O
effects	O
such	O
as	O
the	O
activation	O
of	O
kinase	GENE-N
cascades	O
,	O
which	O
are	O
integrated	O
in	O
the	O
nucleus	O
via	O
the	O
phosphorylation	O
of	O
several	O
actors	O
of	O
RA	O
signaling	O
.	O

However	O
,	O
vitamin	CHEMICAL
A	CHEMICAL
itself	O
proved	O
recently	O
to	O
be	O
active	O
and	O
RARs	GENE-N
to	O
be	O
present	O
in	O
the	O
cytosol	O
to	O
regulate	O
translation	O
and	O
cell	O
plasticity	O
.	O

All	O
these	O
new	O
concepts	O
expand	O
the	O
scope	O
of	O
the	O
biologic	O
functions	O
of	O
vitamin	CHEMICAL
A	CHEMICAL
and	O
RA	O
.	O
Using	O
the	O
alpha	GENE-N
1-adrenoceptor	GENE-N
subtype-selective	O
antagonists	O
chlorethylclonidine	CHEMICAL
(	O
CEC	CHEMICAL
)	O
,	O
WB4101	CHEMICAL
,	O
and	O
5-methyl-urapidil	CHEMICAL
,	O
we	O
have	O
examined	O
the	O
possible	O
heterogeneity	O
in	O
the	O
alpha	GENE-N
1-adrenoceptor	GENE-N
populations	O
in	O
rabbit	O
aorta	O
.	O

The	O
alpha	GENE-N
1-adrenoceptor	GENE-N
alkylating	O
agent	O
CEC	O
selectively	O
inhibited	O
the	O
phasic	O
component	O
of	O
the	O
norepinephrine-induced	O
contractile	O
response	O
,	O
with	O
little	O
effect	O
on	O
the	O
tonic	O
component	O
.	O

The	O
alpha	GENE-N
1-adrenoceptor	GENE-N
occupancy-response	O
relationship	O
defined	O
by	O
the	O
phenoxybenzamine	CHEMICAL
inactivation	O
method	O
was	O
rectangular	O
hyperbolic	O
for	O
the	O
tonic	O
response	O
,	O
whereas	O
that	O
for	O
the	O
phasic	O
response	O
was	O
linear	O
,	O
indicating	O
the	O
different	O
degree	O
of	O
receptor	O
reserve	O
for	O
the	O
two	O
responses	O
.	O

Radioligand	O
binding	O
studies	O
with	O
the	O
nonselective	O
alpha	GENE-N
1-adrenoceptor	GENE-N
antagonist	O
radioligand	O
125I-BE2254	CHEMICAL
showed	O
that	O
73-87%	O
of	O
the	O
binding	O
sites	O
in	O
rabbit	O
aorta	O
are	O
CEC	CHEMICAL
sensitive	O
and	O
they	O
are	O
predominantly	O
low	O
affinity	O
sites	O
both	O
for	O
WB4101	CHEMICAL
(	O
pKd	O
=	O
8	O
.	O
1	O
)	O
and	O
for	O
5-methylurapidil	CHEMICAL
(	O
pKd	O
=	O
7	O
.	O
1	O
)	O
.	O

Moreover	O
,	O
alpha	GENE-N
1-adrenoceptor-mediated	O
phosphatidylinositol	CHEMICAL
(	O
PI	CHEMICAL
)	O
hydrolysis	O
was	O
CEC	CHEMICAL
sensitive	O
,	O
and	O
fractional	O
inactivation	O
of	O
alpha	GENE-N
1	GENE-N
receptors	GENE-N
with	O
CEC	CHEMICAL
showed	O
equivalent	O
increments	O
in	O
the	O
reduction	O
of	O
PI	CHEMICAL
hydrolysis	O
and	O
phasic	O
contractile	O
response	O
,	O
suggesting	O
that	O
both	O
responses	O
are	O
linearly	O
related	O
to	O
the	O
CEC-sensitive	O
receptor	O
sites	O
.	O

The	O
Schild	O
plots	O
for	O
the	O
competitive	O
antagonists	O
WB4101	CHEMICAL
and	O
5-methyl-urapidil	CHEMICAL
against	O
alpha	GENE-Y
1a-adrenoceptor-selective	O
agonist	O
methoxamine-induced	O
contraction	O
were	O
linear	O
and	O
had	O
slopes	O
not	O
significantly	O
different	O
from	O
unity	O
,	O
with	O
a	O
pA2	O
of	O
9	O
.	O
07	O
+	O
/	O
-	O
0	O
.	O
07	O
(	O
n	O
=	O
5	O
)	O
for	O
WB4101	CHEMICAL
and	O
9	O
.	O
09	O
+	O
/	O
-	O
0	O
.	O
05	O
(	O
n	O
=	O
3	O
)	O
for	O
5-methyl-urapidil	CHEMICAL
.	O

However	O
,	O
the	O
Schilod	O
plots	O
for	O
these	O
antagonists	O
against	O
norepinephrine	CHEMICAL
were	O
curvilinear	O
.	O

Computer-assisted	O
analysis	O
of	O
these	O
curvilinear	O
Schild	O
plots	O
in	O
a	O
two-receptor	O
system	O
indicated	O
that	O
alpha	GENE-N
1-adrenoceptor	GENE-N
populations	O
responsible	O
for	O
the	O
constrictive	O
response	O
are	O
predominantly	O
(	O
approximately	O
80-90%	O
)	O
low	O
affinity	O
sites	O
for	O
the	O
two	O
antagonists	O
(	O
pKd	O
approximately	O
8	O
.	O
1	O
for	O
WB4101	CHEMICAL
and	O
pKd	O
approximately	O
7	O
.	O
1	O
for	O
5-methyl-urapidil	CHEMICAL
)	O
and	O
a	O
small	O
population	O
(	O
approximately	O
10-20%	O
)	O
are	O
high	O
affinity	O
sites	O
(	O
pKd	O
approximately	O
9	O
.	O
1	O
for	O
both	O
WB4101	CHEMICAL
and	O
5-methyl-urapidil	CHEMICAL
)	O
,	O
which	O
was	O
in	O
good	O
agreement	O
with	O
radioligand	O
binding	O
studies	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O
UNLABELLED	O
:	O
Trifluorothymidine	CHEMICAL
(	O
TFT	CHEMICAL
)	O
can	O
be	O
phosphorylated	O
by	O
thymidine	GENE-N
kinase	O
(	O
TK	GENE-N
)	O
to	O
TFTMP	O
which	O
can	O
inhibit	O
thymidylate	GENE-Y
synthase	O
(	O
TS	GENE-Y
)	O
,	O
resulting	O
in	O
depletion	O
of	O
thymidine	CHEMICAL
nucleotides	CHEMICAL
.	O

TFT	CHEMICAL
can	O
be	O
degraded	O
by	O
thymidine	CHEMICAL
phosphorylase	O
(	O
TP	GENE-Y
)	O
which	O
can	O
be	O
inhibited	O
by	O
thymidine	CHEMICAL
phosphorylase	O
inhibitor	O
(	O
TPI	O
)	O
.	O

Using	O
the	O
TS	GENE-Y
in	O
situ	O
Inhibition	O
Assay	O
(	O
TSIA	O
)	O
FM3A	O
breast	O
cancer	O
cells	O
were	O
exposed	O
4	O
h	O
or	O
24	O
h	O
to	O
TFT	CHEMICAL
and	O
5-Fluorouracil	CHEMICAL
(	O
5FU	CHEMICAL
)	O
.	O

TS	GENE-Y
activity	O
reduced	O
to	O
9%	O
(	O
0	O
.	O
1	O
microM	O
TFT	CHEMICAL
)	O
and	O
58%	O
(	O
1	O
microM	O
5FU	CHEMICAL
)	O
after	O
4	O
h	O
exposure	O
and	O
to	O
6%	O
(	O
TFT	CHEMICAL
)	O
and	O
21%	O
(	O
5FU	CHEMICAL
)	O
after	O
24	O
h	O
exposure	O
.	O

TPI	O
did	O
not	O
affect	O
TS	GENE-Y
inhibition	O
by	O
TFT	CHEMICAL
.	O

FM3A	O
cells	O
lacking	O
TK	GENE-N
or	O
TS	GENE-Y
activity	O
(	O
FM3A	O
/	O
TK-	O
)	O
were	O
far	O
less	O
sensitive	O
to	O
TFT	CHEMICAL
compared	O
to	O
FM3A	O
cells	O
.	O

CONCLUSION	O
:	O
TFT	CHEMICAL
can	O
be	O
taken	O
up	O
and	O
activated	O
very	O
rapidly	O
by	O
FM3A	O
cancer	O
cells	O
,	O
probably	O
due	O
to	O
favourable	O
TK	O
enzyme	O
properties	O
,	O
and	O
TPI	O
did	O
not	O
influence	O
this	O
.	O
Follicle-stimulating	GENE-N
hormone	GENE-N
(	O
FSH	GENE-N
)	O
,	O
a	O
dimeric	O
glycoprotein	O
synthesized	O
in	O
the	O
anterior	O
pituitary	O
gland	O
,	O
is	O
important	O
for	O
the	O
production	O
of	O
sex	O
steroids	CHEMICAL
and	O
gametes	O
.	O

FSH-beta	GENE-Y
(	O
FSH	GENE-Y
beta	GENE-Y
)	O
and	O
FSH	GENE-Y
receptor	GENE-Y
(	O
FSHR	GENE-Y
)	O
knockout	O
mice	O
display	O
impaired	O
ovarian	O
follicular	O
development	O
and	O
infertility	O
in	O
females	O
and	O
small	O
testes	O
,	O
oligospermia	O
,	O
and	O
fertility	O
in	O
males	O
.	O

Humans	O
with	O
FSH	GENE-Y
beta	GENE-Y
gene	O
mutations	O
tend	O
to	O
have	O
a	O
more	O
severe	O
phenotype	O
than	O
those	O
with	O
FSHR	GENE-Y
gene	O
mutations	O
,	O
although	O
infertility	O
and	O
varying	O
degrees	O
of	O
impaired	O
sex	O
steroid	CHEMICAL
production	O
occur	O
in	O
both	O
types	O
of	O
mutations	O
.	O

Data	O
from	O
human	O
and	O
mouse	O
mutations	O
in	O
the	O
FSH	GENE-N
beta	GENE-N
and	O
FSHR	GENE-N
genes	O
suggest	O
that	O
FSH	GENE-N
is	O
necessary	O
for	O
normal	O
pubertal	O
development	O
and	O
fertility	O
in	O
males	O
and	O
females	O
.	O
The	O
ATP	CHEMICAL
required	O
for	O
potentiation	O
of	O
skeletal	O
muscle	O
contraction	O
is	O
released	O
via	O
pannexin	GENE-N
hemichannels	O
.	O
Wide-ranging	O
exploration	O
of	O
analogues	O
of	O
an	O
ATP-competitive	O
pyrrolopyrimidine	O
inhibitor	O
of	O
Akt	GENE-N
led	O
to	O
the	O
discovery	O
of	O
clinical	O
candidate	O
AZD5363	CHEMICAL
,	O
which	O
showed	O
increased	O
potency	O
,	O
reduced	O
hERG	GENE-Y
affinity	O
,	O
and	O
higher	O
selectivity	O
against	O
the	O
closely	O
related	O
AGC	GENE-N
kinase	GENE-N
ROCK	GENE-N
.	O

This	O
compound	O
demonstrated	O
good	O
preclinical	O
drug	O
metabolism	O
and	O
pharmacokinetics	O
(	O
DMPK	O
)	O
properties	O
and	O
,	O
after	O
oral	O
dosing	O
,	O
showed	O
pharmacodynamic	O
knockdown	O
of	O
phosphorylation	O
of	O
Akt	GENE-N
and	O
downstream	O
biomarkers	O
in	O
vivo	O
,	O
and	O
inhibition	O
of	O
tumor	O
growth	O
in	O
a	O
breast	O
cancer	O
xenograft	O
model	O
.	O
Neurotrophins	GENE-N
,	O
the	O
cognate	O
ligands	O
for	O
the	O
Trk	GENE-N
receptors	GENE-N
,	O
are	O
homodimers	O
and	O
induce	O
Trk	GENE-N
dimerization	O
through	O
a	O
symmetric	O
bivalent	O
mechanism	O
.	O

We	O
report	O
here	O
that	O
amitriptyline	CHEMICAL
,	O
an	O
antidepressant	O
drug	O
,	O
directly	O
binds	O
TrkA	GENE-Y
and	O
TrkB	GENE-Y
and	O
triggers	O
their	O
dimerization	O
and	O
activation	O
.	O

Amitriptyline	CHEMICAL
,	O
but	O
not	O
any	O
other	O
tricyclic	CHEMICAL
or	O
selective	O
serotonin	CHEMICAL
reuptake	O
inhibitor	O
antidepressants	O
,	O
promotes	O
TrkA	GENE-Y
autophosphorylation	O
in	O
primary	O
neurons	O
and	O
induces	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
.	O

Amitriptyline	CHEMICAL
binds	O
the	O
extracellular	O
domain	O
of	O
both	O
TrkA	GENE-Y
and	O
TrkB	GENE-Y
and	O
promotes	O
TrkA-TrkB	GENE-Y
receptor	O
heterodimerization	O
.	O

Truncation	O
of	O
amitriptyline	CHEMICAL
binding	O
motif	O
on	O
TrkA	GENE-Y
abrogates	O
the	O
receptor	O
dimerization	O
by	O
amitriptyline	CHEMICAL
.	O

Administration	O
of	O
amitriptyline	CHEMICAL
to	O
mice	O
activates	O
both	O
receptors	O
and	O
significantly	O
reduces	O
kainic	CHEMICAL
acid-triggered	O
neuronal	O
cell	O
death	O
.	O

Inhibition	O
of	O
TrkA	GENE-Y
,	O
but	O
not	O
TrkB	GENE-Y
,	O
abolishes	O
amitriptyline's	O
neuroprotective	O
effect	O
without	O
impairing	O
its	O
antidepressant	O
activity	O
.	O

Thus	O
,	O
amitriptyline	CHEMICAL
acts	O
as	O
a	O
TrkA	GENE-Y
and	O
TrkB	GENE-Y
agonist	O
and	O
possesses	O
marked	O
neurotrophic	O
activity	O
.	O
Polybrominated	CHEMICAL
diphenyl	CHEMICAL
ethers	CHEMICAL
(	O
PBDEs	CHEMICAL
)	O
were	O
widely	O
used	O
flame	O
retardants	O
that	O
have	O
become	O
persistent	O
environmental	O
pollutants	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
in	O
vitro	O
oxidative	O
metabolism	O
of	O
2	CHEMICAL
,	CHEMICAL
2'	CHEMICAL
,	CHEMICAL
4	CHEMICAL
,	CHEMICAL
4'-tetrabromodiphenyl	CHEMICAL
ether	CHEMICAL
(	O
BDE-47	CHEMICAL
)	O
,	O
a	O
major	O
PBDE	CHEMICAL
detected	O
in	O
human	O
tissue	O
and	O
environmental	O
samples	O
.	O

Biotransformation	O
of	O
BDE-47	CHEMICAL
by	O
pooled	O
and	O
individual	O
human	O
liver	O
microsomes	O
and	O
by	O
human	GENE-N
recombinant	GENE-N
cytochrome	GENE-N
P450	GENE-N
(	O
P450	GENE-N
)	O
enzymes	O
was	O
assessed	O
using	O
a	O
liquid	O
chromatography	O
/	O
tandem	O
mass	O
spectrometry-based	O
method	O
.	O

Of	O
the	O
nine	O
hydroxylated	O
metabolites	O
of	O
BDE-47	CHEMICAL
produced	O
by	O
human	O
liver	O
microsomes	O
,	O
seven	O
metabolites	O
were	O
identified	O
using	O
authentic	O
standards	O
.	O

A	O
monohydroxy-tetrabrominated	O
and	O
a	O
dihydroxy-tetrabrominated	O
metabolite	O
remain	O
unidentified	O
.	O

Kinetic	O
analysis	O
of	O
the	O
rates	O
of	O
metabolite	O
formation	O
revealed	O
that	O
the	O
major	O
metabolites	O
were	O
5-hydroxy-2	CHEMICAL
,	CHEMICAL
2'	CHEMICAL
,	CHEMICAL
4	CHEMICAL
,	CHEMICAL
4'-tetrabromodiphenyl	CHEMICAL
ether	CHEMICAL
(	O
5-OH-BDE-47	CHEMICAL
)	O
,	O
6-hydroxy-2	CHEMICAL
,	CHEMICAL
2'	CHEMICAL
,	CHEMICAL
4	CHEMICAL
,	CHEMICAL
4'-tetrabromodiphenyl	CHEMICAL
ether	CHEMICAL
(	O
6-OH-BDE-47	CHEMICAL
)	O
,	O
and	O
possibly	O
the	O
unidentified	O
monohydroxy-tetrabrominated	O
metabolite	O
.	O

Among	O
the	O
human	GENE-N
recombinant	GENE-N
P450	GENE-N
enzymes	O
tested	O
,	O
P450	GENE-Y
2B6	GENE-Y
was	O
the	O
most	O
active	O
enzyme	O
in	O
the	O
formation	O
of	O
the	O
hydroxylated	O
metabolites	O
of	O
BDE-47	CHEMICAL
.	O

Moreover	O
,	O
the	O
formation	O
of	O
all	O
metabolites	O
of	O
BDE-47	CHEMICAL
by	O
pooled	O
human	O
liver	O
microsomes	O
was	O
inhibited	O
by	O
a	O
P450	GENE-Y
2B6-specific	O
antibody	O
and	O
was	O
highly	O
correlated	O
with	O
P450	GENE-Y
2B6-mediated	O
activity	O
in	O
single	O
donor	O
liver	O
microsomes	O
indicating	O
that	O
P450	GENE-Y
2B6	GENE-Y
was	O
the	O
major	O
P450	GENE-N
responsible	O
for	O
the	O
biotransformation	O
of	O
BDE-47	CHEMICAL
.	O

Additional	O
experiments	O
involving	O
the	O
incubation	O
of	O
liver	O
microsomes	O
with	O
individual	O
monohydroxy-tetrabrominated	O
metabolites	O
in	O
place	O
of	O
BDE-47	CHEMICAL
demonstrated	O
that	O
2	CHEMICAL
,	CHEMICAL
4-dibromophenol	CHEMICAL
was	O
a	O
product	O
of	O
BDE-47	CHEMICAL
and	O
several	O
primary	O
metabolites	O
,	O
but	O
the	O
dihydroxy-tetrabrominated	O
metabolite	O
was	O
not	O
formed	O
by	O
sequential	O
hydroxylation	O
of	O
any	O
of	O
the	O
monohydroxy-tetrabrominated	O
metabolites	O
tested	O
.	O

The	O
present	O
study	O
provides	O
a	O
comprehensive	O
characterization	O
of	O
the	O
oxidative	O
metabolism	O
of	O
BDE-47	CHEMICAL
by	O
human	O
liver	O
microsomes	O
and	O
P450	GENE-Y
2B6	GENE-Y
.	O
ETHNOPHARMACOLOGICAL	O
RELEVANCE	O
:	O
Cyperi	O
Rhizoma	O
has	O
commonly	O
been	O
used	O
for	O
the	O
treatment	O
of	O
gynecological	O
and	O
neuropsychiatric	O
disorders	O
in	O
traditional	O
medicine	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
estrogenic	O
properties	O
and	O
neuroprotective	O
effects	O
of	O
Cyperi	O
Rhizoma	O
under	O
estrogen-deprived	O
condition	O
in	O
female	O
mice	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
To	O
determine	O
the	O
estrogen-like	O
effect	O
of	O
Cyperi	O
Rhizoma	O
extract	O
(	O
CRE	O
)	O
,	O
we	O
measured	O
luciferase	O
expression	O
after	O
transfection	O
of	O
a	O
promoter	O
construct	O
containing	O
an	O
estrogen	GENE-N
response	O
element	O
(	O
ERE	GENE-N
)	O
and	O
treatment	O
of	O
CRE	O
.	O

To	O
evaluate	O
the	O
neuroprotective	O
effect	O
of	O
CRE	O
,	O
we	O
measured	O
striatal	O
dopamine	CHEMICAL
,	O
movement	O
ability	O
,	O
tyrosine	GENE-Y
hydroxylase	O
(	O
TH	GENE-Y
)	O
immunoreactivity	O
,	O
and	O
apoptosis-related	O
protein	O
expression	O
levels	O
after	O
treatment	O
of	O
CRE	O
either	O
with	O
or	O
without	O
1-methyl-4-phenyl-1	CHEMICAL
,	CHEMICAL
2	CHEMICAL
,	CHEMICAL
3	CHEMICAL
,	CHEMICAL
6-tetrahydropyridine	CHEMICAL
(	O
MPTP	CHEMICAL
)	O
in	O
ovariectomized	O
female	O
mice	O
.	O

RESULTS	O
:	O
CRE	O
significantly	O
induced	O
the	O
luciferase	O
expression	O
driven	O
by	O
an	O
ERE	GENE-N
in	O
PC12	O
cells	O
,	O
a	O
dopaminergic	O
cell	O
line	O
,	O
in	O
a	O
dose-dependent	O
manner	O
.	O

In	O
mice	O
,	O
MPTP	CHEMICAL
significantly	O
decreased	O
the	O
levels	O
of	O
dopamine	CHEMICAL
in	O
the	O
striatum	O
and	O
behavior	O
performance;	O
in	O
contrast	O
,	O
both	O
CRE	O
and	O
17β-estradiol	CHEMICAL
benzoate	CHEMICAL
(	O
EB	O
)	O
recovered	O
these	O
parameters	O
to	O
normal	O
levels	O
.	O

CRE	O
and	O
EB	O
treatment	O
also	O
recovered	O
TH	GENE-Y
immunopositive	O
fibers	O
and	O
cells	O
,	O
respectively	O
,	O
from	O
MPTP	CHEMICAL
toxicity	O
.	O

Additionally	O
,	O
MPTP	CHEMICAL
significantly	O
down-regulated	O
Bcl-2	GENE-Y
expression	O
in	O
the	O
mitochondria	O
of	O
dopaminergic	O
cells	O
in	O
the	O
SN	O
,	O
followed	O
by	O
an	O
increase	O
in	O
Bax	GENE-Y
expression	O
,	O
cytochrome	GENE-Y
C	GENE-Y
translocation	O
to	O
the	O
cytosol	O
,	O
andcleaved-caspase-3	GENE-Y
expression	O
,	O
whereas	O
these	O
were	O
inhibited	O
by	O
CRE	O
or	O
EB	O
treatment	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
provide	O
the	O
first	O
evidence	O
that	O
CRE	O
has	O
estrogen-like	O
and	O
neuroprotective	O
effects	O
on	O
dopaminergic	O
neurons	O
in	O
estrogen-deprived	O
mice	O
treated	O
with	O
MPTP-toxin	O
.	O
Serotonin	GENE-Y
transporters	O
(	O
SERT	GENE-Y
)	O
play	O
an	O
essential	O
role	O
in	O
the	O
termination	O
and	O
regulation	O
of	O
serotonin	CHEMICAL
signaling	O
in	O
the	O
brain	O
.	O

SERT	GENE-Y
is	O
also	O
the	O
target	O
of	O
antidepressants	O
and	O
psychostimulants	O
.	O

Molecules	O
with	O
novel	O
activities	O
and	O
modes	O
of	O
interaction	O
with	O
regard	O
to	O
SERT	GENE-Y
function	O
are	O
of	O
great	O
scientific	O
and	O
clinical	O
interest	O
.	O

We	O
explored	O
structural	O
regions	O
outside	O
the	O
putative	O
serotonin	CHEMICAL
translocation	O
pathway	O
to	O
identify	O
potential	O
binding	O
sites	O
for	O
allosteric	O
transporter	O
modulators	O
(	O
ATMs	O
)	O
.	O

Mutational	O
studies	O
revealed	O
a	O
pocket	O
of	O
amino	CHEMICAL
acids	CHEMICAL
outside	O
the	O
orthosteric	O
substrate	O
binding	O
sites	O
located	O
in	O
the	O
interface	O
between	O
extracellular	O
loops	O
1	O
and	O
3	O
that	O
when	O
mutated	O
affect	O
transporter	O
function	O
.	O

Using	O
the	O
structure	O
of	O
the	O
bacterial	O
transporter	O
homologue	O
leucine	GENE-N
transporter	O
as	O
a	O
template	O
,	O
we	O
developed	O
a	O
structural	O
model	O
of	O
SERT	GENE-Y
.	O

We	O
performed	O
molecular	O
dynamics	O
simulations	O
to	O
further	O
characterize	O
the	O
allosteric	O
pocket	O
that	O
was	O
identified	O
by	O
site-directed	O
mutagenesis	O
studies	O
and	O
employed	O
this	O
pocket	O
in	O
a	O
virtual	O
screen	O
for	O
small-molecule	O
modulators	O
of	O
SERT	GENE-Y
function	O
.	O

In	O
functional	O
transport	O
assays	O
,	O
we	O
found	O
that	O
one	O
of	O
the	O
identified	O
molecules	O
,	O
ATM7	O
,	O
increased	O
the	O
reuptake	O
of	O
serotonin	CHEMICAL
,	O
possibly	O
by	O
facilitating	O
the	O
interaction	O
of	O
serotonin	CHEMICAL
with	O
transport-ready	O
conformations	O
of	O
SERT	GENE-Y
when	O
concentrations	O
of	O
serotonin	CHEMICAL
were	O
low	O
and	O
rate	O
limiting	O
.	O

In	O
addition	O
,	O
ATM7	O
potentiates	O
3	CHEMICAL
,	CHEMICAL
4-methylenedioxy-N-methylamphetamine	CHEMICAL
(	O
MDMA	CHEMICAL
,	O
"Ecstasy"	O
)	O
-induced	O
reversed	O
transport	O
by	O
SERT	GENE-Y
.	O

Taking	O
advantage	O
of	O
a	O
conformationally	O
sensitive	O
residue	O
in	O
transmembrane	O
domain	O
6	O
,	O
we	O
demonstrate	O
that	O
ATM7	O
mechanistically	O
stabilizes	O
an	O
outward-facing	O
conformation	O
of	O
SERT	GENE-Y
.	O

Taken	O
together	O
these	O
observations	O
demonstrate	O
that	O
ATM7	O
acts	O
through	O
a	O
novel	O
mechanism	O
that	O
involves	O
allosteric	O
modulation	O
of	O
SERT	GENE-Y
function	O
.	O
RIF1	GENE-Y
is	O
essential	O
for	O
53BP1-dependent	O
nonhomologous	O
end	O
joining	O
and	O
suppression	O
of	O
DNA	O
double-strand	O
break	O
resection	O
.	O
Derivatives	O
of	O
5-	CHEMICAL
(	CHEMICAL
dipentylamino	CHEMICAL
)	CHEMICAL
-5-oxo-pentanoic	CHEMICAL
acid	CHEMICAL
are	O
a	O
new	O
class	O
of	O
non-peptide	O
cholecystokinin	GENE-Y
(	O
CCK	GENE-Y
)	O
antagonists	O
.	O

The	O
most	O
potent	O
compound	O
,	O
D	CHEMICAL
,	CHEMICAL
L-4-	CHEMICAL
(	CHEMICAL
3	CHEMICAL
,	CHEMICAL
4-dichlorobenzoylamino	CHEMICAL
)	CHEMICAL
-5-	CHEMICAL
(	CHEMICAL
dipentylamino	CHEMICAL
)	CHEMICAL
-5-oxo-pen	CHEMICAL
tanoic	CHEMICAL
acid	CHEMICAL
(	O
lorglumide	CHEMICAL
,	O
CR	CHEMICAL
1409	CHEMICAL
)	O
,	O
has	O
a	O
great	O
affinity	O
for	O
the	O
pancreatic	O
CCK	GENE-N
receptors	GENE-N
and	O
is	O
a	O
competitive	O
,	O
specific	O
and	O
potent	O
CCK	GENE-Y
antagonist	O
on	O
the	O
smooth	O
muscles	O
of	O
the	O
gall	O
bladder	O
and	O
ileum	O
of	O
the	O
guinea	O
pig	O
and	O
on	O
the	O
CCK-induced	O
amylase	GENE-N
secretion	O
of	O
isolated	O
pancreatic	O
acini	O
.	O

In	O
vivo	O
lorglumide	CHEMICAL
antagonizes	O
the	O
contraction	O
of	O
the	O
gall	O
bladder	O
of	O
the	O
guinea	O
pig	O
and	O
of	O
the	O
dog	O
provoked	O
by	O
i	O
.	O

v	O
.	O

CCK-8	GENE-N
or	O
ceruletide	CHEMICAL
(	O
caerulein	CHEMICAL
)	O
.	O

It	O
antagonizes	O
the	O
satiety	O
effect	O
of	O
CCK-8	GENE-Y
in	O
the	O
rat	O
and	O
is	O
protective	O
against	O
ceruletide-	O
,	O
taurocholate-	O
and	O
diet-induced	O
pancreatitis	O
.	O

Lorglumide	CHEMICAL
is	O
therefore	O
a	O
useful	O
pharmacological	O
tool	O
to	O
study	O
the	O
functions	O
of	O
CCK	GENE-Y
.	O

For	O
its	O
pharmacological	O
properties	O
,	O
its	O
relatively	O
low	O
toxicity	O
and	O
because	O
it	O
is	O
active	O
also	O
after	O
oral	O
administration	O
,	O
lorglumide	CHEMICAL
is	O
a	O
candidate	O
for	O
diagnostic	O
or	O
therapeutic	O
use	O
in	O
man	O
when	O
an	O
involvement	O
of	O
CCK	GENE-Y
is	O
suspected	O
.	O
Alkyl	CHEMICAL
substituted	CHEMICAL
2'-benzoylpyridine	CHEMICAL
thiosemicarbazone	CHEMICAL
chelators	O
with	O
potent	O
and	O
selective	O
anti-neoplastic	O
activity	O
:	O
novel	O
ligands	O
that	O
limit	O
methemoglobin	GENE-N
formation	O
.	O
Cysteamine-induced	O
reduction	O
in	O
gastrointestinal	O
somatostatin	GENE-Y
:	O
evidence	O
for	O
a	O
region-specific	O
loss	O
in	O
immunoreactivity	O
.	O
Inhibition	O
of	O
human	GENE-N
alcohol	CHEMICAL
and	O
aldehyde	CHEMICAL
dehydrogenases	O
by	O
cimetidine	CHEMICAL
and	O
assessment	O
of	O
its	O
effects	O
on	O
ethanol	CHEMICAL
metabolism	O
.	O
Presence	O
of	O
cyclic	GENE-N
nucleotide	CHEMICAL
phosphodiesterases	O
PDE1A	GENE-Y
,	O
existing	O
as	O
a	O
stable	O
complex	O
with	O
calmodulin	GENE-N
,	O
and	O
PDE3A	GENE-Y
in	O
human	O
spermatozoa	O
.	O
Trim24-repressed	O
VL30	GENE-N
retrotransposons	GENE-N
regulate	O
gene	O
expression	O
by	O
producing	O
noncoding	O
RNA	O
.	O
Effects	O
of	O
the	O
herbal	O
medicine	O
composition	O
"Saiko-ka-ryukotsu-borei-To"	O
on	O
the	O
function	O
of	O
endothelial	O
progenitor	O
cells	O
in	O
hypertensive	O
rats	O
.	O
Cisplatin-induced	O
nephrotoxicity	O
is	O
an	O
important	O
limiting	O
factor	O
for	O
cisplatin	CHEMICAL
use	O
.	O

Tumor	GENE-Y
necrosis	GENE-Y
factor-α	GENE-Y
(	O
TNF-α	GENE-Y
)	O
is	O
known	O
to	O
contribute	O
to	O
cisplatin-induced	O
nephrotoxicity	O
by	O
inducing	O
an	O
inflammatory	O
process	O
aggravating	O
the	O
primary	O
injury	O
,	O
thereby	O
resulting	O
in	O
acute	O
kidney	O
injury	O
(	O
AKI	O
)	O
.	O

The	O
present	O
study	O
investigates	O
the	O
pathways	O
synergistically	O
activated	O
by	O
cisplatin	CHEMICAL
and	O
TNF-α	GENE-Y
responsible	O
for	O
TNF-α-enhanced	O
cisplatin-induced	O
renal	O
cell	O
injury	O
.	O

To	O
do	O
so	O
,	O
immortalized	O
renal	O
proximal	O
tubular	O
epithelial	O
cells	O
(	O
IM-PTECs	O
)	O
were	O
co-treated	O
with	O
TNF-α	GENE-Y
and	O
cisplatin	CHEMICAL
.	O

Under	O
these	O
conditions	O
,	O
cisplatin	CHEMICAL
induced	O
dose-dependent	O
apoptosis	O
in	O
IM-PTECs	O
,	O
which	O
was	O
significantly	O
enhanced	O
by	O
TNF-α	GENE-Y
.	O

Transcriptomic	O
analysis	O
revealed	O
that	O
cisplatin	CHEMICAL
inhibited	O
the	O
typical	O
TNF-α	GENE-Y
response	O
and	O
cisplatin	CHEMICAL
/	O
TNF-α	GENE-Y
treatment	O
up-regulated	O
cell	O
death	O
pathways	O
while	O
it	O
down-regulated	O
survival	O
pathways	O
compared	O
to	O
cisplatin	CHEMICAL
alone	O
.	O

In	O
concordance	O
,	O
the	O
gene	O
expression	O
levels	O
of	O
kidney	O
injury	O
markers	O
combined	O
with	O
activation	O
of	O
specific	O
inflammatory	O
mediators	O
were	O
enhanced	O
by	O
cisplatin	CHEMICAL
/	O
TNF-α	GENE-Y
treatment	O
,	O
resembling	O
the	O
in	O
vivo	O
cisplatin-induced	O
nephrotoxicity	O
response	O
.	O

Furthermore	O
,	O
combined	O
cisplatin	CHEMICAL
/	O
TNF-α	GENE-Y
treatment	O
inhibited	O
NF-κB	GENE-N
nuclear	O
translocation	O
and	O
NF-κB-mediated	O
gene	O
transcription	O
leading	O
to	O
enhanced	O
and	O
prolonged	O
JNK	GENE-N
and	O
c-Jun	GENE-Y
phosphorylation	O
.	O

JNK	GENE-N
sustained	O
activation	O
further	O
inhibited	O
NF-κB	GENE-N
signaling	O
via	O
a	O
feedback	O
loop	O
mechanism	O
.	O

This	O
led	O
to	O
an	O
alteration	O
in	O
the	O
transcription	O
of	O
the	O
NF-κB-induced	O
anti-apoptotic	O
genes	O
c-IAP2	GENE-Y
,	O
Bcl-XL	GENE-Y
,	O
Bruce	GENE-Y
and	O
Bcl2	GENE-Y
and	O
pro-apoptotic	O
genes	O
Bfk	GENE-Y
and	O
Xaf1	GENE-Y
and	O
consequently	O
to	O
sensitization	O
of	O
the	O
IM-PTECs	O
toward	O
cisplatin	CHEMICAL
/	O
TNF-α-induced	O
toxicity	O
.	O

In	O
conclusion	O
,	O
our	O
findings	O
support	O
a	O
model	O
whereby	O
renal	O
cells	O
exposed	O
to	O
both	O
cisplatin	CHEMICAL
and	O
TNF-α	GENE-Y
switch	O
into	O
a	O
more	O
pro-apoptotic	O
and	O
inflammatory	O
program	O
by	O
altering	O
their	O
NF-κB	GENE-N
/	O
JNK	GENE-N
/	O
c-Jun	GENE-Y
balance	O
.	O
Inhibition	O
of	O
ATM	GENE-Y
and	O
ATR	GENE-Y
kinase	GENE-N
activities	O
by	O
the	O
radiosensitizing	O
agent	O
,	O
caffeine	CHEMICAL
.	O
Potential	O
of	O
endogenous	O
estrogen	GENE-Y
receptor	O
beta	O
to	O
influence	O
the	O
selective	O
ER	GENE-Y
modulator	O
ERbeta	GENE-Y
complex	O
.	O
Contribution	O
of	O
Leydig	O
and	O
Sertoli	O
cells	O
to	O
testosterone	CHEMICAL
production	O
in	O
mouse	O
fetal	O
testes	O
.	O
OBJECTIVE	O
:	O
ADP	CHEMICAL
plays	O
an	O
important	O
role	O
in	O
platelet	O
aggregation	O
by	O
activating	O
P2Y12	GENE-Y
receptors	O
.	O

We	O
assessed	O
the	O
hypothesis	O
that	O
P2Y12	GENE-Y
receptors	O
are	O
expressed	O
in	O
vascular	O
smooth	O
muscle	O
cells	O
(	O
VSMC	O
)	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
P2Y12	GENE-Y
receptor	O
mRNA	O
was	O
found	O
to	O
have	O
a	O
high	O
expression	O
among	O
the	O
P2	GENE-N
receptors	GENE-N
in	O
human	O
VSMC	O
,	O
significantly	O
higher	O
than	O
the	O
other	O
2	O
ADP	CHEMICAL
receptors	O
(	O
P2Y1	GENE-Y
and	O
P2Y13	GENE-Y
,	O
real-time	O
polymerase	O
chain	O
reaction	O
)	O
.	O

Western	O
blots	O
gave	O
a	O
band	O
of	O
50	O
kD	O
,	O
similar	O
to	O
that	O
in	O
platelets	O
.	O

To	O
unmask	O
a	O
P2Y12	GENE-Y
receptor-mediated	O
vasoconstriction	O
by	O
simulating	O
the	O
in	O
vivo	O
situation	O
,	O
vessels	O
were	O
precontracted	O
to	O
a	O
submaximal	O
level	O
.	O

2-MeSADP	CHEMICAL
stimulated	O
contractions	O
in	O
vessel	O
segments	O
from	O
internal	O
mammary	O
artery	O
(	O
IM	O
)	O
,	O
IM	O
branches	O
and	O
small	O
veins	O
(	O
Emax	O
=	O
15	O
+	O
/	O
-6%	O
of	O
60	O
mmol	O
/	O
L	O
K	CHEMICAL
+	CHEMICAL
contraction	O
,	O
pEC50	O
=	O
5	O
.	O
6	O
+	O
/	O
-0	O
.	O
6	O
,	O
Emax	O
=	O
21	O
+	O
/	O
-1%	O
,	O
pEC50	O
=	O
6	O
.	O
8	O
+	O
/	O
-0	O
.	O
1	O
,	O
and	O
Emax	O
=	O
48	O
+	O
/	O
-9%	O
,	O
pEC50	O
=	O
6	O
.	O
6	O
+	O
/	O
-0	O
.	O
4	O
)	O
.	O

The	O
selective	O
P2Y12	GENE-Y
antagonist	O
AR-C67085	CHEMICAL
blocked	O
2-MeSADP	CHEMICAL
contractions	O
.	O

The	O
contraction	O
was	O
not	O
reduced	O
in	O
patients	O
using	O
clopidogrel	CHEMICAL
,	O
a	O
drug	O
inhibiting	O
ADP-induced	O
platelet	O
aggregation	O
by	O
blocking	O
the	O
P2Y12	GENE-Y
receptor	O
.	O

This	O
may	O
be	O
explained	O
by	O
the	O
high	O
instability	O
of	O
the	O
active	O
clopidogrel	CHEMICAL
metabolite	O
that	O
never	O
reaches	O
the	O
systemic	O
circulation	O
.	O

CONCLUSIONS	O
:	O
ADP	CHEMICAL
acting	O
on	O
P2Y12	GENE-Y
receptors	O
not	O
only	O
is	O
important	O
for	O
platelet	O
activation	O
but	O
also	O
stimulates	O
vasoconstriction	O
.	O

Stable	O
drugs	O
with	O
antagonistic	O
effects	O
on	O
P2Y12	GENE-Y
receptors	O
,	O
affecting	O
both	O
platelets	O
and	O
VSMC	O
,	O
could	O
be	O
of	O
double	O
therapeutic	O
benefit	O
in	O
their	O
prevention	O
of	O
both	O
thrombosis	O
and	O
vasospasm	O
.	O
Tadalafil	CHEMICAL
(	O
Cialis	CHEMICAL
)	O
for	O
men	O
with	O
erectile	O
dysfunction	O
.	O
Human	GENE-N
CYP3A	GENE-N
is	O
the	O
most	O
abundant	O
P450	GENE-N
isozyme	O
present	O
in	O
the	O
human	O
liver	O
and	O
small	O
intestine	O
,	O
and	O
metabolizes	O
around	O
50%	O
of	O
medical	O
drugs	O
on	O
the	O
market	O
.	O

The	O
human	GENE-N
CYP3A	GENE-N
subfamily	O
comprises	O
four	O
members	O
(	O
CYP3A4	GENE-Y
,	O
CYP3A5	GENE-Y
,	O
CYP3A7	GENE-Y
,	O
CYP3A43	GENE-Y
)	O
encoded	O
on	O
human	O
chromosome	O
7	O
.	O

However	O
,	O
transgenic	O
mouse	O
lines	O
carrying	O
the	O
entire	O
human	GENE-N
CYP3A	GENE-N
cluster	O
have	O
not	O
been	O
constructed	O
because	O
of	O
limitations	O
in	O
conventional	O
cloning	O
techniques	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
introduction	O
of	O
a	O
human	O
artificial	O
chromosome	O
(	O
HAC	O
)	O
containing	O
the	O
entire	O
genomic	O
human	GENE-N
CYP3A	GENE-N
locus	O
recapitulates	O
tissue-	O
and	O
stage-specific	O
expression	O
of	O
human	GENE-N
CYP3A	GENE-N
genes	O
and	O
xenobiotic	O
metabolism	O
in	O
mice	O
.	O

About	O
700	O
kb	O
of	O
the	O
entire	O
CYP3A	GENE-N
genomic	O
segment	O
was	O
cloned	O
into	O
a	O
HAC	O
(	O
CYP3A-HAC	O
)	O
,	O
and	O
trans-chromosomic	O
(	O
Tc	O
)	O
mice	O
carrying	O
a	O
single	O
copy	O
of	O
germline-transmittable	O
CYP3A-HAC	O
were	O
generated	O
via	O
a	O
chromosome-engineering	O
technique	O
.	O

The	O
tissue-	O
and	O
stage-specific	O
expression	O
profiles	O
of	O
CYP3A	GENE-N
genes	O
were	O
consistent	O
with	O
those	O
seen	O
in	O
humans	O
.	O

We	O
further	O
generated	O
mice	O
carrying	O
the	O
CYP3A-HAC	O
in	O
the	O
background	O
homozygous	O
for	O
targeted	O
deletion	O
of	O
most	O
endogenous	O
Cyp3a	GENE-N
genes	O
.	O

In	O
this	O
mouse	O
strain	O
with	O
'fully	O
humanized'	GENE-N
CYP3A	GENE-N
genes	O
,	O
the	O
kinetics	O
of	O
triazolam	CHEMICAL
metabolism	O
,	O
CYP3A-mediated	O
mechanism-based	O
inactivation	O
effects	O
and	O
formation	O
of	O
fetal-specific	O
metabolites	O
of	O
dehydroepiandrosterone	CHEMICAL
observed	O
in	O
humans	O
were	O
well	O
reproduced	O
.	O

Thus	O
,	O
these	O
mice	O
are	O
likely	O
to	O
be	O
valuable	O
in	O
evaluating	O
novel	O
drugs	O
metabolized	O
by	O
CYP3A	GENE-N
enzymes	O
and	O
in	O
studying	O
the	O
regulation	O
of	O
human	GENE-N
CYP3A	GENE-N
gene	O
expression	O
.	O

Furthermore	O
,	O
this	O
system	O
can	O
also	O
be	O
used	O
for	O
generating	O
Tc	O
mice	O
carrying	O
other	O
human	O
metabolic	O
genes	O
.	O
Neural	O
stem	O
/	O
progenitor	O
cells	O
display	O
a	O
low	O
requirement	O
for	O
oxidative	O
metabolism	O
independent	O
of	O
hypoxia	GENE-Y
inducible	GENE-Y
factor-1alpha	GENE-Y
expression	O
.	O
Helicobacter	O
pylori	O
induces	O
macrophage	O
apoptosis	O
by	O
activation	O
of	O
arginase	GENE-Y
II	GENE-Y
.	O
Adenylosuccinate	GENE-Y
synthetase	O
(	O
AdSS	GENE-Y
)	O
catalyzes	O
the	O
Mg2	CHEMICAL
+	CHEMICAL
dependent	O
condensation	O
of	O
a	O
molecule	O
of	O
IMP	O
with	O
aspartate	CHEMICAL
to	O
form	O
adenylosuccinate	CHEMICAL
,	O
in	O
a	O
reaction	O
driven	O
by	O
the	O
hydrolysis	O
of	O
GTP	CHEMICAL
to	O
GDP	CHEMICAL
.	O

AdSS	GENE-Y
from	O
the	O
thermophilic	O
archaea	O
,	O
Methanocaldococcus	O
jannaschii	O
(	O
MjAdSS	GENE-Y
)	O
is	O
345	O
amino	CHEMICAL
acids	CHEMICAL
long	O
against	O
an	O
average	O
length	O
of	O
430-457	O
amino	CHEMICAL
acids	CHEMICAL
for	O
most	O
mesophilic	O
AdSS	GENE-Y
.	O

This	O
short	O
AdSS	GENE-Y
has	O
two	O
large	O
deletions	O
that	O
map	O
to	O
the	O
middle	O
and	O
C-terminus	O
of	O
the	O
protein	O
.	O

This	O
article	O
discusses	O
the	O
detailed	O
kinetic	O
characterization	O
of	O
MjAdSS	GENE-Y
.	O

Initial	O
velocity	O
and	O
product	O
inhibition	O
studies	O
,	O
carried	O
out	O
at	O
70	O
degrees	O
C	O
,	O
suggest	O
a	O
rapid	O
equilibrium	O
random	O
AB	O
steady-state	O
ordered	O
C	O
kinetic	O
mechanism	O
for	O
the	O
MjAdSS	GENE-Y
catalyzed	O
reaction	O
.	O

AdSS	GENE-Y
are	O
known	O
to	O
exhibit	O
monomer-dimer	O
equilibrium	O
with	O
the	O
dimer	O
being	O
implicated	O
in	O
catalysis	O
.	O

In	O
contrast	O
,	O
our	O
studies	O
show	O
that	O
MjAdSS	GENE-Y
is	O
an	O
equilibrium	O
mixture	O
of	O
dimers	O
and	O
tetramers	O
with	O
the	O
tetramer	O
being	O
the	O
catalytically	O
active	O
form	O
.	O

The	O
tetramer	O
dissociates	O
into	O
dimers	O
with	O
a	O
minor	O
increase	O
in	O
ionic	O
strength	O
of	O
the	O
buffer	O
,	O
while	O
the	O
dimer	O
is	O
extremely	O
stable	O
and	O
does	O
not	O
dissociate	O
even	O
at	O
1	O
.	O
2	O
M	O
NaCl	CHEMICAL
.	O

Phosphate	CHEMICAL
,	O
a	O
product	O
of	O
the	O
reaction	O
,	O
was	O
found	O
to	O
be	O
a	O
potent	O
inhibitor	O
of	O
MjAdSS	GENE-Y
showing	O
biphasic	O
inhibition	O
of	O
enzyme	O
activity	O
.	O

The	O
inhibition	O
was	O
competitive	O
with	O
IMP	O
and	O
noncompetitive	O
with	O
GTP	CHEMICAL
.	O

MjAdSS	GENE-Y
,	O
like	O
the	O
mouse	GENE-N
acidic	CHEMICAL
isozyme	O
,	O
exhibits	O
substrate	O
inhibition	O
,	O
with	O
IMP	O
inhibiting	O
enzyme	O
activity	O
at	O
subsaturating	O
GTP	CHEMICAL
concentrations	O
.	O

Regulation	O
of	O
enzyme	O
activity	O
by	O
the	O
glycolytic	O
intermediate	O
,	O
fructose	CHEMICAL
1	CHEMICAL
,	CHEMICAL
6	CHEMICAL
bisphosphate	CHEMICAL
,	O
was	O
also	O
observed	O
with	O
the	O
inhibition	O
being	O
competitive	O
with	O
IMP	O
and	O
noncompetitive	O
against	O
GTP	CHEMICAL
.	O
Sorafenib	CHEMICAL
:	O
recent	O
update	O
on	O
activity	O
as	O
a	O
single	O
agent	O
and	O
in	O
combination	O
with	O
interferon-alpha2	GENE-Y
in	O
patients	O
with	O
advanced-stage	O
renal	O
cell	O
carcinoma	O
.	O
PPARgamma	GENE-Y
controls	O
CD1d	GENE-Y
expression	O
by	O
turning	O
on	O
retinoic	CHEMICAL
acid	CHEMICAL
synthesis	O
in	O
developing	O
human	O
dendritic	O
cells	O
.	O
Hydrogen	CHEMICAL
sulfide	CHEMICAL
increases	O
nitric	CHEMICAL
oxide	CHEMICAL
production	O
with	O
calcium-dependent	O
activation	O
of	O
endothelial	GENE-Y
nitric	CHEMICAL
oxide	CHEMICAL
synthase	O
in	O
endothelial	O
cells	O
.	O
KCC	GENE-N
isoforms	O
in	O
a	O
human	O
lens	O
epithelial	O
cell	O
line	O
(	O
B3	O
)	O
and	O
lens	O
tissue	O
extracts	O
.	O
The	O
medial	O
prefrontal	O
cortex	O
(	O
mPFC	O
)	O
has	O
been	O
implicated	O
in	O
modulating	O
anxiety	O
.	O

However	O
,	O
it	O
is	O
unknown	O
whether	O
excitatory	O
or	O
inhibitory	O
neurotransmission	O
in	O
the	O
infralimbic	O
(	O
IL	O
)	O
subregion	O
of	O
the	O
mPFC	O
underlies	O
the	O
pathology	O
of	O
anxiety-related	O
behavior	O
.	O

To	O
address	O
this	O
issue	O
,	O
we	O
infused	O
the	O
GABAA	GENE-N
receptor	GENE-N
(	O
GABAAR	GENE-N
)	O
antagonist	O
bicuculline	CHEMICAL
to	O
temporarily	O
activate	O
the	O
IL	O
cortex	O
.	O

IL	O
cortex	O
activation	O
decreased	O
the	O
time	O
spent	O
in	O
the	O
center	O
area	O
in	O
the	O
open	O
field	O
test	O
,	O
decreased	O
exploration	O
of	O
the	O
open-arms	O
in	O
the	O
elevated	O
plus	O
maze	O
test	O
,	O
and	O
increased	O
the	O
latency	O
to	O
bite	O
food	O
in	O
the	O
novelty-suppressed	O
feeding	O
test	O
.	O

These	O
findings	O
substantiate	O
the	O
GABAergic	O
system's	O
role	O
in	O
anxiety-related	O
behaviors	O
.	O

IL	O
cortex	O
inactivation	O
with	O
the	O
AMPA	GENE-N
receptor	O
(	O
AMPAR	GENE-N
)	O
antagonist	O
CNQX	O
produced	O
opposite	O
,	O
anxiolytic	O
effects	O
.	O

However	O
,	O
infusion	O
of	O
the	O
NMDA	CHEMICAL
receptor	O
(	O
NMDAR	GENE-N
)	O
antagonist	O
AP5	O
into	O
the	O
IL	O
cortex	O
had	O
no	O
significant	O
effect	O
.	O

Additionally	O
,	O
we	O
did	O
not	O
observe	O
motor	O
activity	O
deficits	O
or	O
appetite	O
deficits	O
following	O
inhibition	O
of	O
GABAergic	O
or	O
glutamatergic	O
neurotransmission	O
.	O

Interestingly	O
,	O
we	O
found	O
parallel	O
and	O
corresponding	O
electrophysiological	O
changes	O
in	O
anxious	O
mice;	O
compared	O
to	O
mice	O
with	O
relatively	O
low	O
anxiety	O
,	O
the	O
relatively	O
high	O
anxiety	O
mice	O
exhibited	O
smaller	O
evoked	O
inhibitory	O
postsynaptic	O
currents	O
(	O
eIPSCs	O
)	O
and	O
larger	O
AMPA-mediated	O
evoked	O
excitatory	O
postsynaptic	O
currents	O
(	O
eEPSCs	O
)	O
in	O
pyramidal	O
neurons	O
in	O
the	O
IL	O
cortex	O
.	O

The	O
changes	O
of	O
eIPSCs	O
and	O
eEPSCs	O
were	O
due	O
to	O
presynaptic	O
mechanisms	O
.	O

Our	O
results	O
suggest	O
that	O
imbalances	O
of	O
neurotransmission	O
in	O
the	O
IL	O
cortex	O
may	O
cause	O
a	O
net	O
increase	O
in	O
excitatory	O
inputs	O
onto	O
pyramidal	O
neurons	O
,	O
which	O
may	O
underlie	O
the	O
pathogenic	O
mechanism	O
of	O
anxiety	O
disorders	O
.	O
Factor	GENE-Y
VIII	GENE-Y
(	O
FVIII	GENE-Y
)	O
and	O
factor	GENE-Y
V	GENE-Y
(	O
FV	GENE-Y
)	O
are	O
homologous	O
coagulation	GENE-N
cofactors	GENE-N
sharing	O
a	O
similar	O
domain	O
organization	O
(	O
A1-A2-B-A3-C1-C2	GENE-N
)	O
and	O
are	O
both	O
extensively	O
glycosylated	O
within	O
their	O
B-domains	GENE-N
.	O

In	O
mammalian	O
cell	O
expression	O
systems	O
,	O
compared	O
with	O
FV	GENE-Y
,	O
the	O
FVIII	GENE-Y
primary	O
translation	O
product	O
is	O
inefficiently	O
transported	O
out	O
of	O
the	O
endoplasmic	O
reticulum	O
.	O

Here	O
we	O
show	O
that	O
FVIII	GENE-Y
is	O
degraded	O
within	O
the	O
cell	O
by	O
a	O
lactacystin-inhibitable	O
pathway	O
,	O
implicating	O
the	O
cytosolic	O
20	GENE-N
S	GENE-N
proteasome	GENE-N
machinery	O
.	O

Protein	GENE-N
chaperones	GENE-N
calnexin	GENE-Y
(	O
CNX	GENE-Y
)	O
and	O
calreticulin	GENE-Y
(	O
CRT	GENE-Y
)	O
preferentially	O
interact	O
with	O
glycoproteins	O
containing	O
monoglucosylated	O
N-linked	O
oligosaccharides	O
and	O
are	O
proposed	O
to	O
traffic	O
proteins	O
through	O
degradative	O
and	O
/	O
or	O
secretory	O
pathways	O
.	O

Utilizing	O
co-immunoprecipitation	O
assays	O
,	O
intracellular	O
FVIII	GENE-Y
was	O
detected	O
in	O
association	O
with	O
CNX	GENE-Y
maximally	O
within	O
30	O
min	O
to	O
1	O
h	O
following	O
synthesis	O
,	O
whereas	O
FV	GENE-Y
could	O
not	O
be	O
detected	O
in	O
association	O
with	O
CNX	GENE-Y
.	O

In	O
contrast	O
,	O
both	O
FVIII	GENE-Y
and	O
FV	GENE-Y
displayed	O
interaction	O
with	O
CRT	GENE-Y
during	O
transit	O
through	O
the	O
secretory	O
pathway	O
.	O

B-domain	GENE-N
deleted	O
FVIII	GENE-Y
significantly	O
reduced	O
the	O
CNX	GENE-Y
and	O
CRT	GENE-Y
interaction	O
,	O
indicating	O
the	O
B-domain	GENE-N
may	O
represent	O
a	O
primary	O
CNX	GENE-Y
and	O
CRT	GENE-Y
interaction	O
site	O
.	O

In	O
the	O
presence	O
of	O
inhibitors	O
of	O
glucose	O
trimming	O
,	O
the	O
interactions	O
of	O
FVIII	GENE-Y
with	O
CNX	GENE-Y
,	O
and	O
of	O
FVIII	GENE-Y
and	O
FV	GENE-Y
with	O
CRT	GENE-Y
,	O
were	O
significantly	O
reduced	O
whereas	O
the	O
secretion	O
of	O
FVIII	GENE-Y
,	O
and	O
not	O
FV	GENE-Y
,	O
was	O
inhibited	O
.	O

In	O
addition	O
,	O
transfection	O
in	O
a	O
glucosidase	GENE-Y
I-deficient	O
Chinese	O
hamster	O
ovary	O
cell	O
line	O
(	O
Lec23	O
)	O
demonstrated	O
that	O
both	O
degradation	O
and	O
secretion	O
of	O
FVIII	GENE-Y
were	O
inhibited	O
,	O
with	O
little	O
effect	O
on	O
the	O
secretion	O
of	O
FV	GENE-Y
.	O

These	O
results	O
support	O
that	O
CNX	GENE-Y
and	O
CRT	GENE-Y
binding	O
,	O
mediated	O
at	O
least	O
in	O
part	O
by	O
the	O
B-domain	GENE-N
of	O
FVIII	GENE-Y
,	O
is	O
required	O
for	O
efficient	O
FVIII	GENE-Y
degradation	O
and	O
secretion	O
.	O

In	O
contrast	O
,	O
FV	GENE-Y
does	O
not	O
require	O
CNX	GENE-Y
interaction	O
for	O
efficient	O
secretion	O
.	O

The	O
results	O
suggest	O
a	O
unique	O
requirement	O
for	O
carbohydrate	CHEMICAL
processing	O
and	O
molecular	O
chaperone	O
interactions	O
that	O
may	O
limit	O
the	O
productive	O
secretion	O
of	O
FVIII	GENE-Y
.	O
Cis-silencing	O
of	O
PIP5K1B	GENE-Y
evidenced	O
in	O
Friedreich's	O
ataxia	O
patient	O
cells	O
results	O
in	O
cytoskeleton	O
anomalies	O
.	O
Combined	O
targeting	O
of	O
FGFR2	GENE-Y
and	O
mTOR	GENE-Y
by	O
ponatinib	CHEMICAL
and	O
ridaforolimus	CHEMICAL
results	O
in	O
synergistic	O
antitumor	O
activity	O
in	O
FGFR2	GENE-Y
mutant	O
endometrial	O
cancer	O
models	O
.	O
Growth	GENE-Y
factor	GENE-Y
receptor-bound	GENE-Y
protein	GENE-Y
10	GENE-Y
(	O
Grb10	GENE-Y
)	O
is	O
a	O
Src	GENE-N
homology	GENE-N
2	GENE-N
(	GENE-N
SH2	GENE-N
)	GENE-N
domain-containing	O
protein	O
and	O
one	O
of	O
the	O
binding	O
partners	O
for	O
several	O
trans-membrane	O
tyrosine-kinase	O
receptors	O
,	O
including	O
insulin	GENE-Y
receptor	GENE-Y
(	O
IR	GENE-Y
)	O
and	O
insulin-like	GENE-Y
growth	GENE-Y
factor-1	GENE-Y
receptor	GENE-Y
(	O
IGF1-R	GENE-Y
)	O
.	O

The	O
hippocampus	O
,	O
which	O
is	O
critical	O
for	O
cognitive	O
functions	O
,	O
is	O
one	O
of	O
the	O
main	O
distribution	O
areas	O
of	O
Grb10	GENE-Y
in	O
the	O
central	O
nervous	O
system	O
.	O

In	O
recent	O
years	O
,	O
diabetic	O
encephalopathy	O
has	O
been	O
defined	O
as	O
a	O
third	O
type	O
of	O
diabetes	O
and	O
the	O
IGF1-IR	GENE-Y
pathway	O
has	O
been	O
shown	O
to	O
be	O
critical	O
for	O
the	O
neuropathogenic	O
process	O
of	O
cognitive	O
disorder	O
in	O
diabetes	O
.	O

However	O
,	O
the	O
role	O
of	O
endogenous	O
Grb10	GENE-Y
in	O
regulating	O
the	O
IGF1-IR	GENE-Y
pathway	O
and	O
neurobehavioral	O
changes	O
is	O
not	O
explicit	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
in	O
vivo	O
function	O
of	O
endogenous	O
Grb10	GENE-Y
in	O
diabetic	O
encephalopathy	O
and	O
the	O
underlying	O
mechanisms	O
.	O

Using	O
stereotaxic	O
surgical	O
techniques	O
and	O
lentiviral	O
vectors	O
expressing	O
specific	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
,	O
we	O
could	O
steadily	O
knock	O
down	O
Grb10	GENE-Y
expression	O
in	O
the	O
hippocampus	O
.	O

More	O
importantly	O
,	O
we	O
demonstrated	O
that	O
hippocampus-specific	O
modulation	O
of	O
Grb10	GENE-Y
protein	O
levels	O
led	O
to	O
a	O
prominent	O
remission	O
of	O
cognitive	O
disorder	O
,	O
including	O
improvements	O
in	O
both	O
ultrastructural	O
pathology	O
and	O
abnormal	O
neurobehavioural	O
changes	O
.	O

Our	O
findings	O
indicate	O
that	O
endogenous	O
overexpression	O
of	O
Grb10	GENE-Y
functions	O
as	O
a	O
suppressor	O
of	O
the	O
IGF1-IR	GENE-Y
pathway	O
,	O
which	O
may	O
represent	O
an	O
important	O
mechanism	O
that	O
regulates	O
cognitive	O
disorder	O
in	O
diabetes	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O
Salidroside	CHEMICAL
attenuates	O
myocardial	O
ischemia-reperfusion	O
injury	O
via	O
PI3K	GENE-N
/	O
Akt	GENE-N
signaling	O
pathway	O
.	O
Identification	O
of	O
nuclear	GENE-N
factor-κB	GENE-N
sites	O
in	O
the	O
Slc2a4	GENE-N
gene	GENE-N
promoter	GENE-N
.	O
Many	O
members	O
of	O
the	O
nudix	GENE-N
hydrolase	GENE-N
family	O
exhibit	O
considerable	O
substrate	O
multispecificity	O
and	O
ambiguity	O
,	O
which	O
raises	O
significant	O
issues	O
when	O
assessing	O
their	O
functions	O
in	O
vivo	O
and	O
gives	O
rise	O
to	O
errors	O
in	O
database	O
annotation	O
.	O

Several	O
display	O
low	O
antimutator	O
activity	O
when	O
expressed	O
in	O
bacterial	O
tester	O
strains	O
as	O
well	O
as	O
some	O
degree	O
of	O
activity	O
in	O
vitro	O
towards	O
mutagenic	O
,	O
oxidized	CHEMICAL
nucleotides	CHEMICAL
such	O
as	O
8-oxo-dGTP	CHEMICAL
.	O

However	O
,	O
many	O
of	O
these	O
show	O
greater	O
activity	O
towards	O
other	O
nucleotides	CHEMICAL
such	O
as	O
ADP-ribose	CHEMICAL
or	O
diadenosine	CHEMICAL
tetraphosphate	CHEMICAL
(	O
Ap	CHEMICAL
(	CHEMICAL
4	CHEMICAL
)	CHEMICAL
A	CHEMICAL
)	O
.	O

The	O
antimutator	O
activities	O
have	O
tended	O
to	O
gain	O
prominence	O
in	O
the	O
literature	O
,	O
whereas	O
they	O
may	O
in	O
fact	O
represent	O
the	O
residual	O
activity	O
of	O
an	O
ancestral	O
antimutator	O
enzyme	O
that	O
has	O
become	O
secondary	O
to	O
the	O
more	O
recently	O
evolved	O
major	O
activity	O
after	O
gene	O
duplication	O
.	O

Whether	O
any	O
meaningful	O
antimutagenic	O
function	O
has	O
also	O
been	O
retained	O
in	O
vivo	O
requires	O
very	O
careful	O
assessment	O
.	O

Then	O
again	O
,	O
other	O
examples	O
of	O
substrate	O
ambiguity	O
may	O
indicate	O
as	O
yet	O
unexplored	O
regulatory	O
systems	O
.	O

For	O
example	O
,	O
bacterial	O
Ap	CHEMICAL
(	CHEMICAL
4	CHEMICAL
)	CHEMICAL
A	CHEMICAL
hydrolases	O
also	O
efficiently	O
remove	O
pyrophosphate	CHEMICAL
from	O
the	O
5'	O
termini	O
of	O
mRNAs	O
,	O
suggesting	O
a	O
potential	O
role	O
for	O
Ap	CHEMICAL
(	CHEMICAL
4	CHEMICAL
)	CHEMICAL
A	CHEMICAL
in	O
the	O
control	O
of	O
bacterial	O
mRNA	O
turnover	O
,	O
while	O
the	O
ability	O
of	O
some	O
eukaryotic	O
mRNA	O
decapping	O
enzymes	O
to	O
degrade	O
IDP	CHEMICAL
and	O
dIDP	CHEMICAL
or	O
diphosphoinositol	CHEMICAL
polyphosphates	CHEMICAL
(	O
DIPs	CHEMICAL
)	O
may	O
also	O
be	O
indicative	O
of	O
new	O
regulatory	O
networks	O
in	O
RNA	O
metabolism	O
.	O

DIP	CHEMICAL
phosphohydrolases	O
also	O
degrade	O
diadenosine	CHEMICAL
polyphosphates	CHEMICAL
and	O
inorganic	O
polyphosphates	CHEMICAL
,	O
suggesting	O
further	O
avenues	O
for	O
investigation	O
.	O

This	O
article	O
uses	O
these	O
and	O
other	O
examples	O
to	O
highlight	O
the	O
need	O
for	O
a	O
greater	O
awareness	O
of	O
the	O
possible	O
significance	O
of	O
substrate	O
ambiguity	O
among	O
the	O
nudix	GENE-N
hydrolases	GENE-N
as	O
well	O
as	O
the	O
need	O
to	O
exert	O
caution	O
when	O
interpreting	O
incomplete	O
analyses	O
.	O
Spatial	O
memory	O
deficits	O
in	O
maternal	O
iron	CHEMICAL
deficiency	O
paradigms	O
are	O
associated	O
with	O
altered	O
glucocorticoid	O
levels	O
.	O
The	O
anticholinesterase	O
effects	O
of	O
bis	CHEMICAL
(	CHEMICAL
7	CHEMICAL
)	CHEMICAL
-tacrine	CHEMICAL
were	O
compared	O
with	O
tacrine	CHEMICAL
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Based	O
on	O
IC50	O
ratios	O
,	O
the	O
dimeric	O
analog	O
bis	CHEMICAL
(	CHEMICAL
7	CHEMICAL
)	CHEMICAL
-tacrine	CHEMICAL
was	O
,	O
in	O
a	O
reversible	O
manner	O
,	O
up	O
to	O
150-fold	O
more	O
potent	O
and	O
250-fold	O
more	O
selective	O
than	O
tacrine	CHEMICAL
for	O
acetylcholinesterase	GENE-Y
(	O
AChE	GENE-Y
)	O
over	O
butyrylcholinesterase	GENE-Y
(	O
BChE	GENE-Y
)	O
.	O

Following	O
a	O
single	O
oral	O
administration	O
,	O
both	O
bis	CHEMICAL
(	CHEMICAL
7	CHEMICAL
)	CHEMICAL
-tacrine	CHEMICAL
and	O
tacrine	CHEMICAL
produced	O
dose-dependent	O
inhibitions	O
of	O
AChE	GENE-Y
in	O
rat	O
brain	O
,	O
but	O
bis	CHEMICAL
(	CHEMICAL
7	CHEMICAL
)	CHEMICAL
-tacrine	CHEMICAL
exhibited	O
higher	O
efficacy	O
and	O
AChE	GENE-Y
/	O
BChE	GENE-Y
selectivity	O
than	O
tacrine	CHEMICAL
.	O

The	O
anti-AChE	GENE-Y
efficacy	O
of	O
bis	CHEMICAL
(	CHEMICAL
7	CHEMICAL
)	CHEMICAL
-tacrine	CHEMICAL
was	O
quite	O
similar	O
following	O
an	O
oral	O
or	O
i	O
.	O

p	O
.	O

administration	O
,	O
but	O
tacrine	CHEMICAL
showed	O
much	O
lower	O
efficacy	O
when	O
administered	O
orally	O
than	O
when	O
given	O
i	O
.	O

p	O
.	O

These	O
findings	O
suggest	O
bis	CHEMICAL
(	CHEMICAL
7	CHEMICAL
)	CHEMICAL
-tacrine	CHEMICAL
,	O
a	O
highly	O
potent	O
and	O
selective	O
inhibitor	O
of	O
AChE	GENE-Y
,	O
can	O
probably	O
be	O
used	O
as	O
an	O
improved	O
drug	O
in	O
the	O
palliative	O
treatment	O
of	O
AD	O
.	O
A	O
comparison	O
of	O
the	O
signalling	O
properties	O
of	O
two	O
tyramine	GENE-Y
receptors	O
from	O
Drosophila	O
.	O
1	O
.	O

The	O
affinities	O
of	O
a	O
number	O
of	O
alpha	GENE-N
1-adrenoceptor	GENE-N
antagonists	O
were	O
determined	O
by	O
displacement	O
of	O
[	CHEMICAL
3H	CHEMICAL
]	CHEMICAL
-prazosin	CHEMICAL
binding	O
from	O
cloned	O
human	GENE-Y
alpha	GENE-Y
1A-adrenoceptors	GENE-Y
(	O
previously	O
designated	O
cloned	O
alpha	O
1c	O
subtype	O
)	O
,	O
alpha	O
1B	O
alpha	O
1D	O
and	O
rat	GENE-Y
alpha	GENE-Y
1D-adrenoceptors	GENE-Y
,	O
stably	O
expressed	O
in	O
rat-1	O
fibroblasts	O
.	O

Functional	O
affinity	O
estimates	O
for	O
these	O
compounds	O
were	O
also	O
determined	O
from	O
noradrenaline-mediated	O
contractions	O
of	O
rat	O
aorta	O
.	O

2	O
.	O

BMY	CHEMICAL
7378	CHEMICAL
displayed	O
high	O
affinity	O
for	O
cloned	O
human	GENE-Y
alpha	GENE-Y
1D-adrenoceptors	GENE-Y
(	O
pKi	O
=	O
8	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
10	O
)	O
and	O
was	O
selective	O
over	O
alpha	O
1A	O
(	O
pKi	O
=	O
6	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
10	O
)	O
and	O
alpha	O
1B	O
subtypes	O
(	O
6	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
11	O
)	O
.	O

WB	O
4101	O
,	O
benoxathian	CHEMICAL
and	O
phentolamine	CHEMICAL
displayed	O
high	O
affinity	O
for	O
alpha	GENE-N
1A	GENE-N
and	GENE-N
alpha	GENE-N
1D	GENE-N
adrenoceptors	GENE-N
compared	O
to	O
the	O
alpha	O
1B	O
subtype	O
.	O

Spiperone	CHEMICAL
displayed	O
high	O
affinity	O
and	O
selectivity	O
for	O
alpha	GENE-Y
1B	GENE-Y
adrenoceptors	GENE-Y
(	O
pKi	O
8	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
16	O
)	O
.	O

5-Methyl-urapidil	CHEMICAL
was	O
selective	O
for	O
cloned	O
alpha	GENE-Y
1A	GENE-Y
adrenoceptors	GENE-Y
.	O

3	O
.	O

Comparative	O
binding	O
affinities	O
(	O
pKi	O
)	O
for	O
compounds	O
at	O
cloned	O
human	GENE-N
and	GENE-N
rat1D	GENE-N
adrenoceptors	GENE-N
were	O
almost	O
identical	O
(	O
r	O
=	O
0	O
.	O
99	O
,	O
slope	O
=	O
1	O
.	O
08	O
)	O
.	O

4	O
.	O

Prazosin	CHEMICAL
,	O
doxazosin	CHEMICAL
and	O
5-methyl-urapidil	CHEMICAL
were	O
potent	O
,	O
competitive	O
antagonists	O
of	O
noradrenaline-mediated	O
contractions	O
of	O
rat	O
aorta	O
(	O
pA2	O
values	O
of	O
9	O
.	O
8	O
,	O
8	O
.	O
8	O
and	O
7	O
.	O
8	O
respectively	O
)	O
.	O

The	O
selective	O
alpha	O
1D	O
antagonist	O
BMY	CHEMICAL
7378	CHEMICAL
was	O
also	O
a	O
potent	O
antagonist	O
on	O
rat	O
aorta	O
(	O
pKB	O
=	O
8	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
1	O
)	O
but	O
the	O
interaction	O
of	O
this	O
compound	O
was	O
not	O
consistent	O
with	O
competitive	O
antagonism	O
at	O
a	O
single	O
population	O
of	O
receptors	O
.	O

5	O
.	O

Functional	O
affinities	O
for	O
compounds	O
determined	O
against	O
noradrenaline-mediated	O
contractions	O
of	O
rat	O
aorta	O
correlated	O
well	O
with	O
binding	O
affinities	O
at	O
cloned	O
alpha	GENE-Y
1D-adrenoceptors	GENE-Y
(	O
r	O
=	O
0	O
.	O
96	O
)	O
,	O
but	O
not	O
with	O
alpha	O
1A	O
(	O
r	O
=	O
0	O
.	O
61	O
)	O
or	O
alpha	O
1B	O
(	O
r	O
=	O
0	O
.	O
46	O
)	O
subtypes	O
.	O

6	O
.	O

Noradrenaline-mediated	O
contractions	O
of	O
rat	O
aorta	O
were	O
sensitive	O
to	O
the	O
alkylating	O
effects	O
of	O
chlorethylclonidine	CHEMICAL
(	O
CEC	CHEMICAL
)	O
.	O

CEC	O
(	O
10	O
microM	O
)	O
caused	O
a	O
small	O
rightward	O
shift	O
in	O
the	O
noradrenaline	CHEMICAL
concentration-response	O
curve	O
.	O

CEC	CHEMICAL
at	O
100	O
microM	O
caused	O
a	O
further	O
shift	O
and	O
suppression	O
of	O
the	O
maximum	O
response	O
to	O
noradrenaline	CHEMICAL
.	O
7	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
noradrenaline	CHEMICAL
predominantly	O
,	O
but	O
not	O
exclusively	O
,	O
mediates	O
contraction	O
of	O
rat	O
aorta	O
through	O
the	O
activation	O
of	O
an	O
alphalD-adrenoceptor	GENE-Y
.	O
Thiazolidinediones	CHEMICAL
(	O
TZDs	CHEMICAL
)	O
affect	O
osteoblast	O
viability	O
and	O
biomarkers	O
independently	O
of	O
the	O
TZD	CHEMICAL
effects	O
on	O
aromatase	GENE-Y
.	O
Tissue-type	GENE-Y
plasminogen	GENE-Y
activator	GENE-Y
(	O
tPA	GENE-Y
)	O
,	O
a	O
serine	GENE-N
protease	O
well	O
known	O
for	O
generating	O
plasmin	GENE-Y
,	O
has	O
been	O
demonstrated	O
to	O
induce	O
matrix	GENE-Y
metalloproteinase-9	GENE-Y
(	O
MMP-9	GENE-Y
)	O
gene	O
expression	O
and	O
protein	O
secretion	O
in	O
renal	O
interstitial	O
fibroblasts	O
.	O

However	O
,	O
exactly	O
how	O
tPA	GENE-Y
transduces	O
its	O
signal	O
into	O
the	O
nucleus	O
to	O
control	O
gene	O
expression	O
is	O
unknown	O
.	O

This	O
study	O
investigated	O
the	O
mechanism	O
by	O
which	O
tPA	GENE-Y
induces	O
MMP-9	GENE-Y
gene	O
expression	O
.	O

Both	O
wild-type	O
and	O
non-enzymatic	O
mutant	O
tPA	GENE-Y
were	O
found	O
to	O
induce	O
MMP-9	GENE-Y
expression	O
in	O
rat	O
kidney	O
interstitial	O
fibroblasts	O
(	O
NRK-49F	O
)	O
,	O
indicating	O
that	O
the	O
actions	O
of	O
tPA	GENE-Y
are	O
independent	O
of	O
its	O
proteolytic	O
activity	O
.	O

tPA	GENE-Y
bound	O
to	O
the	O
low	GENE-Y
density	GENE-Y
lipoprotein	GENE-Y
receptor-related	GENE-Y
protein-1	GENE-Y
(	O
LRP-1	GENE-Y
)	O
in	O
NRK-49F	O
cells	O
,	O
and	O
this	O
binding	O
was	O
competitively	O
abrogated	O
by	O
the	O
LRP-1	GENE-Y
antagonist	O
,	O
the	O
receptor-associated	O
protein	O
.	O

In	O
mouse	O
embryonic	O
fibroblasts	O
(	O
PEA-13	O
)	O
lacking	O
LRP-1	GENE-Y
,	O
tPA	GENE-Y
failed	O
to	O
induce	O
MMP-9	GENE-Y
expression	O
.	O

Furthermore	O
,	O
tPA	GENE-Y
induced	O
rapid	O
tyrosine	CHEMICAL
phosphorylation	O
on	O
the	O
beta	O
subunit	O
of	O
LRP-1	GENE-Y
,	O
which	O
was	O
followed	O
by	O
the	O
activation	O
of	O
Mek1	GENE-Y
and	O
its	O
downstream	O
Erk-1	GENE-N
and	GENE-N
-2	GENE-N
.	O

Blockade	O
of	O
Erk-1	GENE-N
/	GENE-N
2	GENE-N
activation	O
by	O
the	O
Mek1	GENE-Y
inhibitor	O
abolished	O
MMP-9	GENE-Y
induction	O
by	O
tPA	GENE-Y
in	O
NRK-49F	O
cells	O
.	O

Conversely	O
,	O
overexpression	O
of	O
constitutively	GENE-Y
activated	GENE-Y
Mek1	GENE-Y
induced	O
Erk-1	GENE-N
/	GENE-N
2	GENE-N
phosphorylation	O
and	O
MMP-9	GENE-Y
expression	O
.	O

In	O
mouse	O
obstructed	O
kidney	O
,	O
tPA	GENE-Y
,	O
LRP-1	GENE-Y
,	O
and	O
MMP-9	GENE-Y
were	O
concomitantly	O
induced	O
in	O
the	O
renal	O
interstitium	O
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
besides	O
its	O
classical	O
proteolytic	O
activity	O
,	O
tPA	GENE-Y
acts	O
as	O
a	O
cytokine	GENE-N
that	O
binds	O
to	O
the	O
cell	O
membrane	O
receptor	O
LRP-1	GENE-Y
,	O
induces	O
its	O
tyrosine	CHEMICAL
phosphorylation	O
,	O
and	O
triggers	O
intracellular	O
signal	O
transduction	O
,	O
thereby	O
inducing	O
specific	O
gene	O
expression	O
in	O
renal	O
interstitial	O
fibroblasts	O
.	O
Tyrosinase	GENE-Y
inhibitors	O
from	O
Rhododendron	O
collettianum	O
and	O
their	O
structure-activity	O
relationship	O
(	O
SAR	O
)	O
studies	O
.	O
mTOR	GENE-Y
Regulates	O
Nox4-Mediated	O
Podocyte	O
Depletion	O
in	O
Diabetic	O
Renal	O
Injury	O
.	O
Leydig	O
cell	O
hyperplasia	O
and	O
Leydig	O
cell	O
tumours	O
of	O
the	O
ovary	O
are	O
rare	O
.	O

We	O
present	O
two	O
cases	O
in	O
which	O
patients	O
had	O
increased	O
blood	O
levels	O
of	O
testosterone	CHEMICAL
and	O
frank	O
hirsutism	O
.	O

Imaging	O
showed	O
minimal	O
abnormalities	O
.	O

After	O
adrenal	O
disease	O
had	O
been	O
ruled	O
out	O
,	O
they	O
underwent	O
a	O
bilateral	O
oophorectomy	O
.	O

One	O
case	O
showed	O
a	O
Leydig	O
cell	O
hyperplasia	O
,	O
the	O
other	O
a	O
Leydig	O
cell	O
tumour	O
.	O

An	O
androgen	CHEMICAL
producing	O
tumour	O
should	O
be	O
excluded	O
in	O
every	O
woman	O
with	O
evidence	O
of	O
hirsutism	O
or	O
frank	O
virilization	O
and	O
markedly	O
elevated	O
testosterone	CHEMICAL
levels	O
.	O

Adrenal	O
disease	O
with	O
androgen	CHEMICAL
hypersecretion	O
can	O
be	O
suspected	O
by	O
detailed	O
clinical	O
,	O
laboratory	O
and	O
radiologic	O
imaging	O
.	O

Although	O
DHEAS	CHEMICAL
has	O
a	O
good	O
sensitivity	O
in	O
the	O
detection	O
of	O
adrenal	O
origin	O
of	O
hyperandrogenism	O
(	O
and	O
hence	O
a	O
good	O
negative	O
predictive	O
value	O
)	O
it	O
is	O
not	O
specific	O
(	O
specificity	O
ranging	O
from	O
85	O
to	O
98%	O
)	O
.	O

Imaging	O
of	O
the	O
ovaries	O
can	O
be	O
helpful	O
but	O
does	O
not	O
rule	O
out	O
ovarian	O
disease	O
if	O
normal	O
.	O

Indeed	O
,	O
diffuse	O
stromal	O
Leydig	O
cell	O
hyperplasia	O
and	O
Leydig	O
cell	O
tumours	O
(	O
usually	O
small	O
)	O
may	O
escape	O
imaging	O
and	O
in	O
some	O
cases	O
diagnosis	O
can	O
only	O
be	O
made	O
on	O
pathology	O
.	O

As	O
these	O
clinical	O
entities	O
represent	O
a	O
diagnostic	O
and	O
therapeutic	O
challenge	O
,	O
oophorectomy	O
should	O
be	O
considered	O
in	O
postmenopausal	O
women	O
with	O
hirsutism	O
and	O
elevated	O
testosterone	CHEMICAL
levels	O
,	O
after	O
the	O
exclusion	O
of	O
adrenal	O
causes	O
.	O

The	O
procedure	O
is	O
relatively	O
safe	O
and	O
effective	O
.	O

Follow-up	O
remains	O
indicated	O
.	O
Components	O
of	O
the	O
Interleukin-6	GENE-Y
transsignalling	O
system	O
are	O
associated	O
with	O
the	O
metabolic	O
syndrome	O
,	O
endothelial	O
dysfunction	O
and	O
arterial	O
stiffness	O
.	O
Pharmacological	O
therapy	O
of	O
Cushing's	O
syndrome	O
:	O
drugs	O
and	O
indications	O
.	O
Mutations	O
in	O
the	O
alanine-glyoxylate	CHEMICAL
amino	O
transferase	O
gene	O
(	O
AGXT	GENE-Y
)	O
are	O
responsible	O
for	O
primary	O
hyperoxaluria	O
type	O
I	O
,	O
a	O
rare	O
disease	O
characterized	O
by	O
excessive	O
hepatic	O
oxalate	O
production	O
that	O
leads	O
to	O
renal	O
failure	O
.	O

We	O
generated	O
a	O
null	O
mutant	O
mouse	O
by	O
targeted	O
mutagenesis	O
of	O
the	O
homologous	O
gene	O
,	O
Agxt	GENE-Y
,	O
in	O
embryonic	O
stem	O
cells	O
.	O

Mutant	O
mice	O
developed	O
normally	O
,	O
and	O
they	O
exhibited	O
hyperoxaluria	O
and	O
crystalluria	O
.	O

Approximately	O
half	O
of	O
the	O
male	O
mice	O
in	O
mixed	O
genetic	O
background	O
developed	O
calcium	CHEMICAL
oxalate	CHEMICAL
urinary	O
stones	O
.	O

Severe	O
nephrocalcinosis	O
and	O
renal	O
failure	O
developed	O
after	O
enhancement	O
of	O
oxalate	CHEMICAL
production	O
by	O
ethylene	CHEMICAL
glycol	CHEMICAL
administration	O
.	O

Hepatic	O
expression	O
of	O
human	GENE-Y
AGT1	GENE-Y
,	O
the	O
protein	O
encoded	O
by	O
AGXT	GENE-Y
,	O
by	O
adenoviral	O
vector-mediated	O
gene	O
transfer	O
in	O
Agxt	GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
normalized	O
urinary	O
oxalate	CHEMICAL
excretion	O
and	O
prevented	O
oxalate	CHEMICAL
crystalluria	O
.	O

Subcellular	O
fractionation	O
and	O
immunofluorescence	O
studies	O
revealed	O
that	O
,	O
as	O
in	O
the	O
human	O
liver	O
,	O
the	O
expressed	O
wild-type	O
human	GENE-Y
AGT1	GENE-Y
was	O
predominantly	O
localized	O
in	O
mouse	O
hepatocellular	O
peroxisomes	O
,	O
whereas	O
the	O
most	O
common	O
mutant	O
form	O
of	O
AGT1	GENE-Y
(	O
G170R	GENE-N
)	O
was	O
localized	O
predominantly	O
in	O
the	O
mitochondria	O
.	O
Due	O
to	O
its	O
production	O
of	O
potent	O
antimicrobial	O
oxidants	O
including	O
hypochlorous	CHEMICAL
acid	CHEMICAL
,	O
human	GENE-Y
myeloperoxidase	GENE-Y
(	O
MPO	GENE-Y
)	O
plays	O
a	O
critical	O
role	O
in	O
innate	O
immunity	O
and	O
inflammatory	O
diseases	O
.	O

Thus	O
MPO	GENE-Y
is	O
an	O
attractive	O
target	O
in	O
drug	O
design	O
.	O

(	CHEMICAL
Aminoalkyl	CHEMICAL
)	CHEMICAL
fluoroindole	CHEMICAL
derivatives	O
were	O
detected	O
to	O
be	O
very	O
potent	O
MPO	GENE-Y
inhibitors;	O
however	O
,	O
they	O
also	O
promote	O
inhibition	O
of	O
the	O
serotonin	CHEMICAL
reuptake	O
transporter	O
(	O
SERT	GENE-Y
)	O
at	O
the	O
same	O
concentration	O
range	O
.	O

Via	O
structure-based	O
drug	O
design	O
,	O
a	O
new	O
series	O
of	O
MPO	GENE-Y
inhibitors	O
derived	O
from	O
3-alkylindole	CHEMICAL
were	O
synthesized	O
and	O
their	O
effects	O
were	O
assessed	O
on	O
MPO-mediated	O
taurine	CHEMICAL
chlorination	O
and	O
low-density	GENE-N
lipoprotein	GENE-N
oxidation	O
as	O
well	O
as	O
on	O
inhibition	O
of	O
SERT	GENE-Y
.	O

The	O
fluoroindole	CHEMICAL
compound	O
with	O
three	O
carbons	CHEMICAL
in	O
the	O
side	O
chain	O
and	O
one	O
amide	CHEMICAL
group	O
exhibited	O
a	O
selectivity	O
index	O
of	O
35	O
(	O
Ki	O
/	O
IC50	O
)	O
with	O
high	O
inhibition	O
of	O
MPO	GENE-Y
activity	O
(	O
IC50	O
=	O
18	O
nM	O
)	O
,	O
whereas	O
its	O
effect	O
on	O
SERT	GENE-Y
was	O
in	O
the	O
micromolar	O
range	O
.	O

Structure-function	O
relationships	O
,	O
mechanism	O
of	O
action	O
,	O
and	O
safety	O
of	O
the	O
molecule	O
are	O
discussed	O
.	O
X-chromosomal	O
dystonia	O
parkinsonism	O
syndrome	O
(	O
XDP	O
,	O
'lubag'	O
)	O
is	O
associated	O
with	O
sequence	O
changes	O
within	O
the	O
TAF1	GENE-N
/	O
DYT3	GENE-N
multiple	O
transcript	O
system	O
.	O

Although	O
most	O
sequence	O
changes	O
are	O
intronic	O
,	O
one	O
,	O
disease-specific	O
single-nucleotide	CHEMICAL
change	O
3	O
(	O
DSC3	O
)	O
,	O
is	O
located	O
within	O
an	O
exon	O
(	O
d4	O
)	O
.	O

Transcribed	O
exon	O
d4	O
occurs	O
as	O
part	O
of	O
multiple	O
splice	O
variants	O
.	O

These	O
variants	O
include	O
exons	O
d3	O
and	O
d4	O
spliced	O
to	O
exons	O
of	O
TAF1	GENE-Y
,	O
and	O
an	O
independent	O
transcript	O
composed	O
of	O
exons	O
d2-d4	O
.	O

Location	O
of	O
DSC3	O
in	O
exon	O
d4	O
and	O
utilization	O
of	O
this	O
exon	O
in	O
multiple	O
splice	O
variants	O
suggest	O
an	O
important	O
role	O
of	O
DSC3	O
in	O
the	O
XDP	O
pathogenesis	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
transfected	O
neuroblastoma	O
cells	O
with	O
four	O
expression	O
constructs	O
,	O
including	O
exons	O
d2-d4	O
[	O
d2-d4	O
/	O
wild-type	O
(	O
wt	O
)	O
and	O
d2-d4	O
/	O
DSC3	O
]	O
and	O
d3-d4	O
(	O
d3-d4	O
/	O
wt	O
and	O
d3-d4	O
/	O
DSC3	O
)	O
.	O

Expression	O
profiling	O
revealed	O
a	O
dramatic	O
effect	O
of	O
DSC3	O
on	O
overall	O
gene	O
expression	O
.	O

Three	O
hundred	O
and	O
sixty-two	O
genes	O
differed	O
between	O
cells	O
containing	O
d2-d4	O
/	O
wt	O
and	O
d2-d4	O
/	O
DSC3	O
.	O

Annotation	O
clustering	O
revealed	O
enrichment	O
of	O
genes	O
related	O
to	O
vesicular	O
transport	O
,	O
dopamine	CHEMICAL
metabolism	O
,	O
synapse	O
function	O
,	O
Ca	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
metabolism	O
and	O
oxidative	O
stress	O
.	O

Two	O
hundred	O
and	O
eleven	O
genes	O
were	O
differentially	O
expressed	O
in	O
d3-d4	O
/	O
wt	O
versus	O
d3-d4	O
/	O
DSC3	O
.	O

Annotation	O
clustering	O
highlighted	O
genes	O
in	O
signal	O
transduction	O
and	O
cell-cell	O
interaction	O
.	O

The	O
data	O
show	O
an	O
important	O
role	O
of	O
physiologically	O
occurring	O
transcript	O
d2-d4	O
in	O
normal	O
brain	O
function	O
.	O

Interference	O
with	O
this	O
role	O
by	O
DSC3	O
is	O
a	O
likely	O
pathological	O
mechanism	O
in	O
XDP	O
.	O

Disturbance	O
of	O
dopamine	O
function	O
and	O
of	O
Ca	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
metabolism	O
can	O
explain	O
abnormal	O
movement;	O
loss	O
of	O
protection	O
against	O
reactive	O
oxygen	CHEMICAL
species	O
may	O
account	O
for	O
the	O
neurodegenerative	O
changes	O
in	O
XDP	O
.	O

Although	O
d3-d4	O
also	O
affect	O
genes	O
potentially	O
related	O
to	O
neurodegenerative	O
processes	O
,	O
their	O
physiologic	O
role	O
as	O
splice	O
variants	O
of	O
TAF1	GENE-Y
awaits	O
further	O
exploration	O
.	O
Hypoxia-response	GENE-N
element	GENE-N
(	O
HRE	GENE-N
)	O
-directed	O
transcriptional	O
regulation	O
of	O
the	O
rat	GENE-Y
lysyl	CHEMICAL
oxidase	O
gene	O
in	O
response	O
to	O
cobalt	CHEMICAL
and	O
cadmium	CHEMICAL
.	O
Lead	O
is	O
a	O
heavy	O
metal	O
widely	O
distributed	O
in	O
the	O
environment	O
.	O

Lead	O
is	O
a	O
ubiquitous	O
environmental	O
toxin	O
that	O
is	O
capable	O
of	O
causing	O
numerous	O
acute	O
and	O
chronic	O
illnesses	O
.	O

Human	O
and	O
animal	O
exposure	O
demonstrates	O
that	O
lead	O
is	O
nephrotoxic	O
.	O

However	O
,	O
attempts	O
to	O
reduce	O
lead-induced	O
nephrotoxicity	O
were	O
not	O
found	O
suitable	O
for	O
clinical	O
use	O
.	O

Recently	O
,	O
flaxseed	O
oil	O
(	O
FXO	O
)	O
,	O
a	O
rich	O
source	O
of	O
ω-3	CHEMICAL
fatty	CHEMICAL
acids	CHEMICAL
and	O
lignans	CHEMICAL
,	O
has	O
been	O
shown	O
to	O
prevent	O
/	O
reduce	O
the	O
progression	O
of	O
certain	O
types	O
of	O
cardiovascular	O
and	O
renal	O
disorders	O
.	O

In	O
view	O
of	O
this	O
,	O
the	O
present	O
study	O
investigates	O
the	O
protective	O
effect	O
of	O
FXO	O
on	O
lead	CHEMICAL
acetate	CHEMICAL
(	O
PbAc	CHEMICAL
)	O
-induced	O
renal	O
damage	O
.	O

Rats	O
were	O
pre-fed	O
normal	O
diet	O
and	O
the	O
diet	O
rich	O
in	O
FXO	O
for	O
14	O
days	O
,	O
and	O
then	O
,	O
four	O
doses	O
of	O
lead	CHEMICAL
acetate	CHEMICAL
(	O
25	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
were	O
administered	O
intraperitoneally	O
while	O
still	O
on	O
diet	O
.	O

Various	O
serum	O
parameters	O
,	O
enzymes	O
of	O
carbohydrate	CHEMICAL
metabolism	O
,	O
brush	O
border	O
membrane	O
(	O
BBM	O
)	O
,	O
and	O
oxidative	O
stress	O
were	O
analyzed	O
in	O
rat	O
kidney	O
.	O

PbAc	CHEMICAL
nephrotoxicity	O
was	O
characterized	O
by	O
increased	O
serum	O
creatinine	CHEMICAL
and	O
blood	O
urea	CHEMICAL
nitrogen	CHEMICAL
.	O

PbAc	CHEMICAL
increased	O
the	O
activities	O
of	O
lactate	CHEMICAL
dehydrogenase	O
and	O
NADP-malic	O
enzyme	O
,	O
whereas	O
it	O
decreased	O
malate	CHEMICAL
and	O
glucose-6-phosphate	CHEMICAL
dehydrogenase	O
,	O
glucose-6-phosphatase	O
,	O
fructose-1	O
,	O
6-bisphosphatase	O
,	O
and	O
BBM	O
enzyme	O
activities	O
.	O

PbAc	CHEMICAL
caused	O
oxidant	O
/	O
antioxidant	O
imbalances	O
as	O
reflected	O
by	O
increased	O
lipid	O
peroxidation	O
and	O
decreased	O
activities	O
of	O
superoxide	GENE-N
dismutase	O
,	O
glutathione	GENE-N
peroxidase	O
,	O
and	O
catalase	GENE-Y
.	O

In	O
contrast	O
,	O
FXO	O
alone	O
enhanced	O
the	O
enzyme	O
activities	O
of	O
carbohydrate	CHEMICAL
metabolism	O
,	O
BBM	O
,	O
and	O
antioxidant	O
defense	O
system	O
.	O

FXO	O
feeding	O
to	O
PbAc-treated	O
rats	O
markedly	O
enhanced	O
resistance	O
to	O
PbAc-elicited	O
deleterious	O
effects	O
.	O

In	O
conclusion	O
,	O
dietary	O
FXO	O
supplementation	O
ameliorated	O
PbAc-induced	O
specific	O
metabolic	O
alterations	O
and	O
oxidative	O
damage	O
by	O
empowering	O
antioxidant	O
defense	O
mechanism	O
and	O
improving	O
BBM	O
integrity	O
and	O
energy	O
metabolism	O
.	O
[	O
The	O
relation	O
between	O
metabolism	O
of	O
biopterin	CHEMICAL
and	O
dystonia-parkinsonism	O
]	O
.	O
In	O
this	O
study	O
,	O
the	O
stabilization	O
effects	O
of	O
three	O
polymers	O
on	O
four	O
model	O
drugs	O
(	O
felodipine	CHEMICAL
,	O
fenofibrate	CHEMICAL
,	O
carbamazepine	CHEMICAL
,	O
and	O
celecoxib	CHEMICAL
)	O
under	O
saturated	O
humidity	O
were	O
investigated	O
.	O

Three	O
different	O
types	O
of	O
thin	O
films	O
(	O
solid	O
dispersions	O
,	O
drug	O
films	O
with	O
a	O
polymer	O
film	O
coating	O
and	O
drug	O
films	O
laid	O
on	O
top	O
of	O
polymer	O
coated	O
surfaces	O
)	O
were	O
prepared	O
and	O
compared	O
with	O
films	O
containing	O
the	O
drug	O
alone	O
.	O

ATR-FTIR	O
spectroscopy	O
,	O
polarised	O
light	O
microscopy	O
(	O
PLM	O
)	O
,	O
scanning	O
electron	O
microscopy	O
(	O
SEM	O
)	O
and	O
nano-thermal	O
analysis	O
(	O
nano-TA	O
)	O
were	O
performed	O
on	O
the	O
model	O
systems	O
after	O
storage	O
under	O
saturated	O
humidity	O
.	O

The	O
recrystallisation	O
tendency	O
of	O
the	O
drug	O
in	O
the	O
drug	O
containing	O
thin	O
films	O
was	O
found	O
to	O
be	O
strongly	O
related	O
to	O
the	O
intrinsic	O
crystallization	O
tendency	O
of	O
the	O
drug	O
film	O
alone	O
and	O
the	O
strength	O
of	O
drug-polymer	O
interactions	O
.	O

Additionally	O
,	O
under	O
high	O
humidity	O
,	O
the	O
glass	O
transition	O
temperature	O
of	O
the	O
polymer	O
is	O
no	O
longer	O
an	O
indicator	O
of	O
its	O
drug	O
stabilization	O
capability	O
.	O

Instead	O
,	O
it	O
is	O
the	O
hygroscobicity	O
of	O
the	O
polymer	O
that	O
appears	O
to	O
be	O
the	O
most	O
important	O
parameter	O
.	O

Amongst	O
the	O
polymers	O
tested	O
in	O
this	O
study	O
,	O
EUDRAGIT	CHEMICAL
E	CHEMICAL
PO	CHEMICAL
was	O
found	O
to	O
have	O
the	O
greatest	O
inhibitory	O
effect	O
on	O
crystallization	O
,	O
whilst	O
PVP	CHEMICAL
K30	CHEMICAL
was	O
found	O
to	O
have	O
the	O
least	O
protective	O
effect;	O
presumably	O
because	O
of	O
its	O
hygroscopic	O
nature	O
.	O
6-Hydroxydopamine	CHEMICAL
(	O
6-OHDA	CHEMICAL
)	O
is	O
a	O
neurotoxin	O
that	O
generates	O
an	O
experimental	O
model	O
of	O
Parkinson's	O
disease	O
in	O
rodents	O
and	O
is	O
commonly	O
employed	O
to	O
induce	O
a	O
lesion	O
in	O
dopaminergic	O
pathways	O
.	O

The	O
characterization	O
of	O
those	O
molecular	O
mechanisms	O
linked	O
to	O
6-OHDA-induced	O
early	O
toxicity	O
is	O
needed	O
to	O
better	O
understand	O
the	O
cellular	O
events	O
further	O
leading	O
to	O
neurodegeneration	O
.	O

The	O
present	O
work	O
explored	O
how	O
6-OHDA	CHEMICAL
triggers	O
early	O
downstream	O
signaling	O
pathways	O
that	O
activate	O
neurotoxicity	O
in	O
the	O
rat	O
striatum	O
.	O

Mitochondrial	O
function	O
,	O
caspases-dependent	O
apoptosis	O
,	O
kinases	GENE-N
signaling	O
(	O
Akt	GENE-N
,	O
ERK	GENE-N
1	GENE-N
/	GENE-N
2	GENE-N
,	O
SAP	GENE-N
/	O
JNK	GENE-N
and	O
p38	GENE-N
)	O
and	O
crosstalk	O
between	O
nuclear	GENE-N
factor	GENE-N
kappa	GENE-N
B	GENE-N
(	O
NF-κB	GENE-N
)	O
and	O
nuclear	GENE-Y
factor-erythroid-2-related	GENE-Y
factor	GENE-Y
2	GENE-Y
(	O
Nrf2	GENE-Y
)	O
were	O
evaluated	O
at	O
early	O
times	O
post-lesion	O
.	O

We	O
found	O
that	O
6-OHDA	CHEMICAL
initiates	O
cell	O
damage	O
via	O
mitochondrial	GENE-N
complex	GENE-N
I	GENE-N
inhibition	O
,	O
cytochrome	GENE-Y
c	GENE-Y
and	O
apoptosis-inducing	GENE-N
factor	GENE-N
(	O
AIF	GENE-N
)	O
release	O
,	O
as	O
well	O
as	O
activation	O
of	O
caspases	GENE-N
9	GENE-N
and	GENE-N
3	GENE-N
to	O
induce	O
apoptosis	O
,	O
kinase	GENE-N
signaling	O
modulation	O
and	O
NF-κB-mediated	O
inflammatory	O
responses	O
,	O
accompanied	O
by	O
inhibition	O
of	O
antioxidant	O
systems	O
regulated	O
by	O
the	O
Nrf2	GENE-Y
pathway	O
.	O

Our	O
results	O
suggest	O
that	O
kinases	O
SAP	GENE-N
/	O
JNK	GENE-N
and	O
p38	GENE-N
up-regulation	O
may	O
play	O
a	O
role	O
in	O
the	O
early	O
stages	O
of	O
6-OHDA	CHEMICAL
toxicity	O
to	O
trigger	O
intrinsic	O
pathways	O
for	O
apoptosis	O
and	O
enhanced	O
NF-κB	GENE-N
activation	O
.	O

In	O
turn	O
,	O
these	O
cellular	O
events	O
inhibit	O
the	O
activation	O
of	O
cytoprotective	O
mechanisms	O
,	O
thereby	O
leading	O
to	O
a	O
condition	O
of	O
general	O
damage	O
.	O
The	O
effects	O
of	O
mitiglinide	CHEMICAL
(	O
KAD-1229	CHEMICAL
)	O
,	O
a	O
new	O
anti-diabetic	O
drug	O
,	O
on	O
ATP-sensitive	GENE-N
K	GENE-N
+	GENE-N
channels	GENE-N
and	O
insulin	GENE-Y
secretion	O
:	O
comparison	O
with	O
the	O
sulfonylureas	CHEMICAL
and	O
nateglinide	CHEMICAL
.	O
Androgen	CHEMICAL
receptors	O
are	O
present	O
in	O
numerous	O
tissues	O
throughout	O
the	O
female	O
body	O
,	O
and	O
knowledge	O
of	O
the	O
specific	O
actions	O
of	O
androgens	CHEMICAL
at	O
different	O
sites	O
is	O
increasing	O
,	O
along	O
with	O
the	O
understanding	O
of	O
their	O
contribution	O
to	O
various	O
pathophysiological	O
states	O
.	O

This	O
article	O
reviews	O
the	O
physiology	O
of	O
androgens	CHEMICAL
(	O
testosterone	CHEMICAL
and	O
dihydrotestosterone	CHEMICAL
)	O
and	O
immediate	O
androgen	CHEMICAL
precursors	O
(	O
dehydroepiandrosterone	CHEMICAL
[	O
DHEA	CHEMICAL
]	O
,	O
dehydroepiandrosterone	CHEMICAL
sulfate	CHEMICAL
[	O
DHEAS	CHEMICAL
]	O
,	O
and	O
androstenedione	CHEMICAL
)	O
,	O
with	O
specific	O
reference	O
to	O
the	O
androgen	GENE-Y
receptor	O
,	O
production	O
and	O
metabolism	O
of	O
C-	CHEMICAL
(	CHEMICAL
19	CHEMICAL
)	CHEMICAL
steroids	CHEMICAL
,	O
circulating	O
androgen	CHEMICAL
concentrations	O
,	O
and	O
androgen	CHEMICAL
actions	O
.	O

In	O
addition	O
,	O
the	O
evidence	O
for	O
physiological	O
modulation	O
of	O
androgens	CHEMICAL
including	O
circadian	O
variation	O
,	O
cyclical	O
variation	O
,	O
age	O
,	O
and	O
natural	O
menopause	O
is	O
reviewed	O
.	O
Tetrahydrobiopterin	CHEMICAL
[	O
(	CHEMICAL
6R	CHEMICAL
)	CHEMICAL
-5	CHEMICAL
,	CHEMICAL
6	CHEMICAL
,	CHEMICAL
7	CHEMICAL
,	CHEMICAL
8-tetrahydro-L-biopterin	CHEMICAL
,	O
H	CHEMICAL
(	CHEMICAL
4	CHEMICAL
)	CHEMICAL
biopterin	CHEMICAL
]	O
is	O
one	O
of	O
several	O
cofactors	O
of	O
nitric	GENE-N
oxide	GENE-N
synthases	O
(	O
EC	GENE-Y
1	GENE-Y
.	GENE-Y
14	GENE-Y
.	GENE-Y
13	GENE-Y
.	GENE-Y
39	GENE-Y
)	O
.	O

Here	O
we	O
compared	O
the	O
action	O
of	O
N	CHEMICAL
(	CHEMICAL
5	CHEMICAL
)	CHEMICAL
-substituted	O
derivatives	O
on	O
recombinant	O
rat	GENE-Y
neuronal	GENE-Y
nitric	CHEMICAL
oxide	CHEMICAL
synthase	O
with	O
their	O
effects	O
on	O
dihydropteridine	GENE-Y
reductase	O
(	O
EC	GENE-Y
1	GENE-Y
.	GENE-Y
6	GENE-Y
.	GENE-Y
99	GENE-Y
.	GENE-Y
7	GENE-Y
)	O
and	O
phenylalanine	GENE-Y
hydroxylase	O
(	O
EC	GENE-Y
1	GENE-Y
.	GENE-Y
14	GENE-Y
.	GENE-Y
16	GENE-Y
.	GENE-Y
1	GENE-Y
)	O
,	O
the	O
well-studied	O
classical	O
H	CHEMICAL
(	CHEMICAL
4	CHEMICAL
)	CHEMICAL
biopterin-dependent	O
reactions	O
.	O

H	CHEMICAL
(	CHEMICAL
4	CHEMICAL
)	CHEMICAL
biopterin	CHEMICAL
substituted	O
at	O
N	CHEMICAL
(	CHEMICAL
5	CHEMICAL
)	CHEMICAL
with	O
methyl	CHEMICAL
,	O
hydroxymethyl	CHEMICAL
,	O
formyl	CHEMICAL
and	O
acetyl	CHEMICAL
groups	O
were	O
used	O
.	O

Substitution	O
at	O
N	CHEMICAL
(	CHEMICAL
5	CHEMICAL
)	CHEMICAL
occurs	O
at	O
a	O
position	O
critical	O
to	O
the	O
redox	O
cycle	O
of	O
the	O
cofactor	O
in	O
phenylalanine	GENE-Y
hydroxylase	O
/	O
dihydropteridine	GENE-Y
reductase	O
.	O

We	O
also	O
included	O
N	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
'-methyl	CHEMICAL
H	CHEMICAL
(	CHEMICAL
4	CHEMICAL
)	CHEMICAL
biopterin	CHEMICAL
,	O
a	O
derivative	O
substituted	O
at	O
a	O
position	O
not	O
directly	O
involved	O
in	O
redox	O
cycling	O
,	O
as	O
a	O
control	O
.	O

As	O
compared	O
with	O
N	CHEMICAL
(	CHEMICAL
5	CHEMICAL
)	CHEMICAL
-methyl	CHEMICAL
H	CHEMICAL
(	CHEMICAL
4	CHEMICAL
)	CHEMICAL
biopterin	CHEMICAL
,	O
N	CHEMICAL
(	CHEMICAL
5	CHEMICAL
)	CHEMICAL
-formyl	CHEMICAL
H	CHEMICAL
(	CHEMICAL
4	CHEMICAL
)	CHEMICAL
biopterin	CHEMICAL
bound	O
with	O
twice	O
the	O
capacity	O
but	O
stimulated	O
nitric	GENE-N
oxide	GENE-N
synthase	O
to	O
a	O
lesser	O
extent	O
.	O

Depending	O
on	O
the	O
substituent	O
used	O
,	O
N	CHEMICAL
(	CHEMICAL
5	CHEMICAL
)	CHEMICAL
-substituted	O
derivatives	O
were	O
redox-active	O
:	O
N	CHEMICAL
(	CHEMICAL
5	CHEMICAL
)	CHEMICAL
-methyl-	O
and	O
N	CHEMICAL
(	CHEMICAL
5	CHEMICAL
)	CHEMICAL
-hydroxyl	CHEMICAL
methyl	CHEMICAL
H	CHEMICAL
(	CHEMICAL
4	CHEMICAL
)	CHEMICAL
biopterin	CHEMICAL
,	O
but	O
not	O
N	CHEMICAL
(	CHEMICAL
5	CHEMICAL
)	CHEMICAL
-formyl-	O
and	O
N	CHEMICAL
(	CHEMICAL
5	CHEMICAL
)	CHEMICAL
-acetyl	CHEMICAL
H	CHEMICAL
(	CHEMICAL
4	CHEMICAL
)	CHEMICAL
biopterin	CHEMICAL
,	O
reduced	O
2	CHEMICAL
,	CHEMICAL
6-dichlorophenol	CHEMICAL
indophenol	CHEMICAL
.	O

N	CHEMICAL
(	CHEMICAL
5	CHEMICAL
)	CHEMICAL
-Substituted	CHEMICAL
H	CHEMICAL
(	CHEMICAL
4	CHEMICAL
)	CHEMICAL
biopterin	CHEMICAL
derivatives	O
were	O
not	O
oxidized	O
to	O
products	O
serving	O
as	O
substrates	O
for	O
dihydropteridine	GENE-Y
reductase	O
and	O
,	O
depending	O
on	O
the	O
substituent	O
,	O
were	O
competitive	O
inhibitors	O
of	O
phenylalanine	GENE-Y
hydroxylase	O
:	O
N	CHEMICAL
(	CHEMICAL
5	CHEMICAL
)	CHEMICAL
-methyl-	O
and	O
N	CHEMICAL
(	CHEMICAL
5	CHEMICAL
)	CHEMICAL
-hydroxymethyl	CHEMICAL
H	CHEMICAL
(	CHEMICAL
4	CHEMICAL
)	CHEMICAL
biopterin	CHEMICAL
inhibited	O
phenylalanine	GENE-Y
hydroxylase	O
,	O
whereas	O
N	CHEMICAL
(	CHEMICAL
5	CHEMICAL
)	CHEMICAL
-formyl-	O
and	O
N	CHEMICAL
(	CHEMICAL
5	CHEMICAL
)	CHEMICAL
-acetyl	CHEMICAL
H	CHEMICAL
(	CHEMICAL
4	CHEMICAL
)	CHEMICAL
biopterin	CHEMICAL
had	O
no	O
effect	O
.	O

Our	O
data	O
demonstrate	O
differences	O
in	O
the	O
mechanism	O
of	O
stimulation	O
of	O
phenylalanine	GENE-Y
hydroxylase	O
and	O
nitric	GENE-N
oxide	GENE-N
synthase	O
by	O
H	CHEMICAL
(	CHEMICAL
4	CHEMICAL
)	CHEMICAL
biopterin	CHEMICAL
.	O

They	O
are	O
compatible	O
with	O
a	O
novel	O
,	O
non-classical	O
,	O
redox-active	O
contribution	O
of	O
H	CHEMICAL
(	CHEMICAL
4	CHEMICAL
)	CHEMICAL
biopterin	CHEMICAL
to	O
the	O
catalysis	O
of	O
the	O
nitric	GENE-N
oxide	GENE-N
synthase	O
reaction	O
.	O
Safrole-2'	CHEMICAL
,	CHEMICAL
3'-oxide	CHEMICAL
induces	O
atherosclerotic	O
plaque	O
vulnerability	O
in	O
apolipoprotein	GENE-Y
E-knockout	O
mice	O
.	O
Pharmacological	O
and	O
genetic	O
evidence	O
for	O
pre-	O
and	O
postsynaptic	O
D2	GENE-Y
receptor	GENE-Y
involvement	O
in	O
motor	O
responses	O
to	O
nociceptin	GENE-Y
/	GENE-Y
orphanin	GENE-Y
FQ	GENE-Y
receptor	GENE-Y
ligands	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
fenoterol-induced	O
constitutive	O
beta	GENE-Y
(	GENE-Y
2	GENE-Y
)	GENE-Y
-adrenoceptor	GENE-Y
activity	O
on	O
muscarinic	GENE-N
receptor	GENE-N
agonist-	O
and	O
histamine-induced	O
bovine	O
tracheal	O
smooth	O
muscle	O
contractions	O
.	O

Bovine	O
tracheal	O
smooth	O
muscle	O
strips	O
were	O
incubated	O
with	O
10	O
microM	O
fenoterol	CHEMICAL
or	O
vehicle	O
for	O
various	O
periods	O
of	O
time	O
(	O
5	O
,	O
30	O
min	O
,	O
18	O
h	O
)	O
at	O
37	O
degrees	O
C	O
.	O

After	O
extensive	O
washout	O
(	O
3	O
h	O
,	O
37	O
degrees	O
C	O
)	O
,	O
isometric	O
contractions	O
were	O
measured	O
to	O
the	O
full	O
muscarinic	GENE-N
receptor	GENE-N
agonist	O
methacholine	CHEMICAL
,	O
the	O
partial	O
muscarinic	GENE-N
receptor	GENE-N
agonist	O
4-	CHEMICAL
(	CHEMICAL
m-chlorophenyl-carbamoyloxy	CHEMICAL
)	CHEMICAL
-2-butynyltrimethylammonium	CHEMICAL
(	O
McN-A-343	CHEMICAL
)	O
and	O
histamine	CHEMICAL
.	O

Fenoterol	CHEMICAL
treatment	O
significantly	O
reduced	O
the	O
sensitivity	O
(	O
pEC	O
(	O
50	O
)	O
)	O
to	O
methacholine	CHEMICAL
in	O
a	O
time-dependent	O
manner	O
,	O
without	O
affecting	O
maximal	O
contraction	O
(	O
E	O
(	O
max	O
)	O
)	O
.	O

Fenoterol	CHEMICAL
treatment	O
similarly	O
reduced	O
the	O
pEC	O
(	O
50	O
)	O
of	O
McN-A-343	CHEMICAL
and	O
histamine;	O
however	O
,	O
E	O
(	O
max	O
)	O
values	O
were	O
also	O
reduced	O
,	O
to	O
approximately	O
70%	O
of	O
control	O
after	O
18-h	O
treatment	O
.	O

The	O
inverse	O
agonist	O
timolol	CHEMICAL
,	O
having	O
no	O
effect	O
on	O
control	O
preparations	O
,	O
consistently	O
restored	O
the	O
reduced	O
pEC	O
(	O
50	O
)	O
and	O
E	O
(	O
max	O
)	O
values	O
of	O
the	O
contractile	O
agonists	O
.	O

Remarkably	O
,	O
in	O
the	O
presence	O
of	O
timolol	O
the	O
pEC	O
(	O
50	O
)	O
values	O
of	O
McN-A-343	CHEMICAL
and	O
histamine	CHEMICAL
in	O
fenoterol-treated	O
airways	O
were	O
significantly	O
enhanced	O
compared	O
to	O
controls	O
.	O

In	O
conclusion	O
,	O
fenoterol-induced	O
constitutive	O
beta	GENE-Y
(	GENE-Y
2	GENE-Y
)	GENE-Y
-adrenoceptor	GENE-Y
activity	O
reduces	O
muscarinic	GENE-N
receptor	GENE-N
agonist-	O
and	O
histamine-induced	O
contractions	O
of	O
bovine	O
tracheal	O
smooth	O
muscle	O
,	O
which	O
can	O
be	O
reversed	O
by	O
the	O
inverse	O
agonist	O
timolol	CHEMICAL
.	O

Moreover	O
,	O
after	O
beta	GENE-Y
(	GENE-Y
2	GENE-Y
)	GENE-Y
-adrenoceptor	GENE-Y
agonist	O
treatment	O
,	O
inverse	O
agonism	O
by	O
beta-adrenoceptor	GENE-N
antagonists	O
may	O
cause	O
enhanced	O
airway	O
reactivity	O
to	O
contractile	O
mediators	O
.	O
Activation	O
of	O
beta2-	GENE-N
and	GENE-N
beta3-adrenergic	GENE-N
receptors	GENE-N
increases	O
brain	O
tryptophan	CHEMICAL
.	O
Enhanced	O
beta	O
cell	O
function	O
and	O
anti-inflammatory	O
effect	O
after	O
chronic	O
treatment	O
with	O
the	O
dipeptidyl	GENE-Y
peptidase-4	GENE-Y
inhibitor	O
vildagliptin	CHEMICAL
in	O
an	O
advanced-aged	O
diet-induced	O
obesity	O
mouse	O
model	O
.	O
3-Hydroxypyridin-2-thione	CHEMICAL
as	O
Novel	O
Zinc	CHEMICAL
Binding	O
Group	O
for	O
Selective	O
Histone	GENE-N
Deacetylase	GENE-N
Inhibition	O
.	O
We	O
obtained	O
a	O
full-length	O
cDNA	O
based	O
on	O
a	O
sequence	O
deposited	O
in	O
GenBank	GENE-Y
(	GENE-Y
accession	GENE-Y
No	GENE-Y
.	GENE-Y

AB045133	GENE-Y
)	GENE-Y
,	O
annotated	O
as	O
rabbit	GENE-Y
peroxisomal	GENE-Y
NADP	CHEMICAL
(	CHEMICAL
H	CHEMICAL
)	CHEMICAL
-dependent	O
retinol	CHEMICAL
dehydrogenase-reductase	O
(	O
NDRD	GENE-Y
)	O
.	O

The	O
rabbit	O
NDRD	GENE-Y
gene	O
,	O
like	O
its	O
mouse	O
and	O
human	O
homologs	O
,	O
harbors	O
2	O
initiation	O
sites	O
,	O
one	O
of	O
which	O
theoretically	O
encodes	O
a	O
29	O
.	O
6	O
kDa	O
protein	O
with	O
279	O
amino	CHEMICAL
acids	CHEMICAL
,	O
and	O
the	O
other	O
encodes	O
a	O
27	O
.	O
4	O
kDa	O
protein	O
with	O
260	O
amino	CHEMICAL
acids	CHEMICAL
.	O

The	O
purification	O
of	O
a	O
rabbit	GENE-N
cytosolic	GENE-N
retinol	CHEMICAL
oxidoreductase	O
with	O
a	O
subunit	O
molecular	O
mass	O
of	O
34	O
kDa	O
and	O
an	O
N	CHEMICAL
terminus	O
that	O
is	O
not	O
completely	O
identical	O
to	O
that	O
of	O
NDRD	GENE-Y
,	O
has	O
been	O
reported	O
.	O

An	O
enzyme	O
responsible	O
for	O
the	O
all-trans	CHEMICAL
retinal	CHEMICAL
reductase	O
activity	O
in	O
the	O
liver	O
cytosol	O
of	O
New	O
Zealand	O
white	O
rabbit	O
was	O
purified	O
to	O
homogeneity	O
using	O
differential	O
centrifugation	O
and	O
successive	O
chromatographic	O
analyses	O
.	O

The	O
subunit	O
molecular	O
mass	O
of	O
the	O
purified	O
enzyme	O
,	O
revealed	O
by	O
SDS-PAGE	O
,	O
was	O
approximately	O
27	O
kDa	O
.	O

The	O
intact	O
molecular	O
mass	O
,	O
measured	O
by	O
MALDI-TOF	O
mass	O
spectrometry	O
,	O
was	O
27	O
.	O
368	O
kDa	O
.	O

The	O
60	O
kDa	O
relative	O
mobility	O
observed	O
in	O
size-exclusion	O
chromatography	O
indicates	O
that	O
the	O
native	O
protein	O
probably	O
exists	O
as	O
a	O
dimer	O
.	O

The	O
purified	O
enzyme	O
was	O
positively	O
confirmed	O
to	O
be	O
the	O
product	O
of	O
NDRD	GENE-Y
by	O
peptide	O
mass	O
fingerprinting	O
,	O
tandem	O
mass	O
spectrometry	O
,	O
and	O
N-terminal	O
sequencing	O
.	O

Taken	O
together	O
,	O
the	O
results	O
suggested	O
that	O
the	O
native	O
protein	O
is	O
truncated	O
at	O
the	O
N	CHEMICAL
terminus	O
.	O
Apolipoprotein	GENE-Y
E3	GENE-Y
(	O
apoE3	GENE-Y
)	O
safeguards	O
pig	O
proximal	O
tubular	O
LLC-PK1	O
cells	O
against	O
reduction	O
in	O
SGLT1	GENE-Y
activity	O
induced	O
by	O
gentamicin	CHEMICAL
C	CHEMICAL
.	O
Integrated	O
chemical	O
and	O
biological	O
analysis	O
to	O
explain	O
estrogenic	O
potency	O
in	O
bile	O
extracts	O
of	O
red	O
mullet	O
(	O
Mullus	O
barbatus	O
)	O
.	O
Dietary	O
alpha-linolenic	CHEMICAL
acid	CHEMICAL
increases	O
TNF-alpha	GENE-Y
,	O
and	O
decreases	O
IL-6	GENE-Y
,	O
IL-10	GENE-Y
in	O
response	O
to	O
LPS	O
:	O
effects	O
of	O
sesamin	CHEMICAL
on	O
the	O
delta-5	O
desaturation	O
of	O
omega6	CHEMICAL
and	CHEMICAL
omega3	CHEMICAL
fatty	CHEMICAL
acids	CHEMICAL
in	O
mice	O
.	O
Gliomas	O
are	O
primary	O
brain	O
tumors	O
with	O
a	O
complex	O
biology	O
characterized	O
by	O
antigenic	O
and	O
genomic	O
heterogeneity	O
and	O
a	O
propensity	O
for	O
invasion	O
into	O
normal	O
brain	O
tissue	O
.	O

High	O
grade	O
glioma	O
cells	O
possess	O
a	O
voltage-independent	O
,	O
amiloride-inhibitable	O
,	O
inward	O
Na	CHEMICAL
+	CHEMICAL
current	O
.	O

This	O
current	O
does	O
not	O
exist	O
in	O
normal	O
astrocytes	O
or	O
low	O
grade	O
tumor	O
cells	O
.	O

Inhibition	O
of	O
this	O
conductance	O
decreases	O
glioma	O
growth	O
and	O
cell	O
migration	O
making	O
it	O
a	O
potential	O
therapeutic	O
target	O
.	O

Our	O
previous	O
results	O
have	O
shown	O
that	O
the	O
acid-sensing	GENE-N
ion	GENE-N
channels	GENE-N
(	O
ASICs	GENE-N
)	O
,	O
members	O
of	O
the	O
epithelial	GENE-N
Na	CHEMICAL
+	CHEMICAL
channel	O
(	O
ENaC	GENE-N
)	O
/	O
degenerin	GENE-N
(	O
DEG	GENE-N
)	O
family	O
of	O
ion	GENE-N
channels	GENE-N
are	O
part	O
of	O
this	O
current	O
pathway	O
.	O

We	O
hypothesized	O
that	O
one	O
member	O
of	O
the	O
ENaC	GENE-N
/	O
DEG	GENE-N
family	O
,	O
ASIC2	GENE-Y
,	O
is	O
retained	O
intracellularly	O
and	O
that	O
it	O
is	O
the	O
lack	O
of	O
functional	O
expression	O
of	O
ASIC2	GENE-Y
at	O
the	O
cell	O
surface	O
that	O
results	O
in	O
hyperactivity	O
of	O
this	O
conductance	O
in	O
high	O
grade	O
gliomas	O
.	O

In	O
this	O
study	O
we	O
show	O
that	O
the	O
chemical	O
chaperone	O
,	O
glycerol	CHEMICAL
,	O
and	O
the	O
transcriptional	O
regulator	O
,	O
sodium	CHEMICAL
4-phenylbutyrate	CHEMICAL
,	O
inhibit	O
the	O
constitutively	O
activated	O
inward	O
current	O
and	O
reduce	O
cell	O
growth	O
and	O
migration	O
in	O
glioblastoma	O
multiforme	O
.	O

The	O
results	O
suggest	O
that	O
these	O
compounds	O
induce	O
the	O
movement	O
of	O
ASIC2	GENE-Y
to	O
the	O
plasma	O
membrane	O
,	O
and	O
once	O
there	O
,	O
the	O
basally	O
active	O
inward	O
current	O
characteristic	O
of	O
glioma	O
cells	O
is	O
abolished	O
by	O
inherent	O
negative	O
regulatory	O
mechanisms	O
.	O

This	O
in	O
turn	O
compromises	O
the	O
ability	O
of	O
the	O
glioma	O
cell	O
to	O
migrate	O
and	O
proliferate	O
.	O

These	O
results	O
support	O
the	O
hypothesis	O
that	O
the	O
conductance	O
pathway	O
in	O
high	O
grade	O
glioma	O
cells	O
is	O
comprised	O
of	O
ENaC	GENE-N
/	O
DEG	GENE-N
subunits	O
and	O
that	O
abolishing	O
this	O
channel	O
activity	O
promotes	O
a	O
reversion	O
of	O
a	O
high	O
grade	O
glioma	O
cell	O
to	O
a	O
phenotype	O
resembling	O
that	O
of	O
normal	O
astrocytes	O
.	O
Assignment	O
of	O
anabolic-androgenic	O
and	O
antiandrogenic	O
properties	O
to	O
some	O
chlorine-substituted	O
steroids	CHEMICAL
on	O
the	O
basis	O
of	O
their	O
binding	O
characteristics	O
to	O
the	O
androgen	GENE-Y
receptor	O
of	O
the	O
rat	O
seminal	O
vesicle	O
.	O
Alzheimer's	O
disease	O
(	O
AD	O
)	O
is	O
a	O
progressive	O
neurodegenerative	O
disorder	O
that	O
is	O
characterized	O
by	O
progressive	O
loss	O
of	O
memory	O
and	O
cognitive	O
impairment	O
.	O

Aggregation	O
of	O
amyloid-β	GENE-Y
(	GENE-Y
Aβ	GENE-Y
)	GENE-Y
peptides	GENE-Y
is	O
the	O
crucial	O
factor	O
in	O
the	O
onset	O
of	O
AD	O
.	O

The	O
toxic	O
Aβ	GENE-Y
peptides	O
Aβ40	GENE-Y
and	O
Aβ42	GENE-Y
are	O
produced	O
from	O
the	O
Aβ	GENE-Y
precursor	GENE-Y
protein	GENE-Y
(	O
APP	GENE-Y
)	O
,	O
a	O
transmembrane	O
protein	O
which	O
is	O
folded	O
and	O
modified	O
in	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
.	O

ER	O
is	O
the	O
main	O
organelle	O
for	O
the	O
synthesis	O
and	O
processing	O
of	O
nearly	O
all	O
proteins	O
as	O
well	O
as	O
the	O
main	O
cellular	O
source	O
of	O
Ca2	CHEMICAL
+	CHEMICAL
.	O

Under	O
stress	O
conditions	O
,	O
three	O
main	O
ER	O
pathways	O
including	O
inositol-requiring	O
enzyme	O
1	O
,	O
protein	GENE-Y
kinase	GENE-Y
RNA-like	GENE-Y
ER	GENE-Y
kinase	GENE-Y
,	O
and	O
activating	GENE-Y
transcription	GENE-Y
factor	GENE-Y
6	GENE-Y
become	O
activated	O
causing	O
the	O
accumulation	O
of	O
unfolded	O
or	O
misfolded	O
proteins	O
within	O
ER	O
lumen	O
.	O

These	O
pathways	O
manage	O
the	O
stress	O
by	O
regulating	O
the	O
expression	O
of	O
chaperones	O
and	O
enzymes	O
involved	O
in	O
protein	O
folding	O
.	O

Several	O
studies	O
have	O
reported	O
the	O
dysfunction	O
of	O
these	O
stress-sensing	O
pathways	O
in	O
pathological	O
conditions	O
,	O
including	O
neurodegenerative	O
diseases	O
.	O

Recent	O
studies	O
have	O
proposed	O
that	O
neuronal	O
death	O
in	O
AD	O
arises	O
from	O
dysfunction	O
of	O
the	O
ER	O
.	O

Here	O
,	O
we	O
will	O
review	O
recent	O
research	O
findings	O
on	O
the	O
interaction	O
between	O
ER	O
and	O
mitochondria	O
,	O
and	O
its	O
effect	O
on	O
apoptotic	O
pathways	O
.	O

We	O
further	O
provide	O
insights	O
into	O
studies	O
which	O
suggest	O
the	O
role	O
of	O
ER	O
in	O
animal	O
and	O
/	O
or	O
cellular	O
models	O
of	O
AD	O
.	O

Therapeutic	O
strategies	O
that	O
modulate	O
ER	O
could	O
represent	O
a	O
promising	O
approach	O
for	O
prevention	O
or	O
treatment	O
of	O
AD	O
.	O
Fat	O
infiltration	O
within	O
muscle	O
is	O
one	O
of	O
a	O
number	O
of	O
features	O
of	O
vitamin	CHEMICAL
D	CHEMICAL
deficiency	O
,	O
which	O
leads	O
to	O
a	O
decline	O
in	O
muscle	O
functionality	O
.	O

The	O
origin	O
of	O
this	O
fat	O
is	O
unclear	O
,	O
but	O
one	O
possibility	O
is	O
that	O
it	O
forms	O
from	O
myogenic	O
precursor	O
cells	O
present	O
in	O
the	O
muscle	O
,	O
which	O
transdifferentiate	O
into	O
mature	O
adipocytes	O
.	O

The	O
current	O
study	O
examined	O
the	O
effect	O
of	O
the	O
active	O
form	O
of	O
vitamin	CHEMICAL
D₃	CHEMICAL
,	O
1	CHEMICAL
,	CHEMICAL
25-dihydroxyvitamin	CHEMICAL
D₃	CHEMICAL
(	O
1	CHEMICAL
,	CHEMICAL
25	CHEMICAL
(	CHEMICAL
OH	CHEMICAL
)	CHEMICAL
₂D₃	CHEMICAL
)	O
,	O
on	O
the	O
capacity	O
of	O
the	O
C2C12	O
muscle	O
cell	O
line	O
to	O
differentiate	O
towards	O
the	O
myogenic	O
and	O
adipogenic	O
lineages	O
.	O

Cells	O
were	O
cultured	O
in	O
myogenic	O
or	O
adipogenic	O
differentiation	O
media	O
containing	O
increasing	O
concentrations	O
(	O
0	O
,	O
10⁻¹³	O
,	O
10⁻¹¹	O
,	O
10⁻⁹	O
,	O
10⁻⁷	O
or	O
10⁻⁵	O
M	O
)	O
of	O
1	CHEMICAL
,	CHEMICAL
25	CHEMICAL
(	CHEMICAL
OH	CHEMICAL
)	CHEMICAL
₂D₃	CHEMICAL
for	O
up	O
to	O
6	O
days	O
and	O
markers	O
of	O
muscle	O
and	O
fat	O
development	O
measured	O
.	O

Mature	O
myofibres	O
were	O
formed	O
in	O
both	O
adipogenic	O
and	O
myogenic	O
media	O
,	O
but	O
fat	O
droplets	O
were	O
only	O
observed	O
in	O
adipogenic	O
media	O
.	O

Relative	O
to	O
controls	O
,	O
low	O
physiological	O
concentrations	O
(	O
10⁻¹³	O
and	O
10⁻¹¹	O
M	O
)	O
of	O
1	CHEMICAL
,	CHEMICAL
25	CHEMICAL
(	CHEMICAL
OH	CHEMICAL
)	CHEMICAL
₂D3	CHEMICAL
increased	O
fat	O
droplet	O
accumulation	O
,	O
whereas	O
high	O
physiological	O
(	O
10⁻⁹	O
M	O
)	O
and	O
supraphysiological	O
concentrations	O
(	O
≥10⁻⁷	O
M	O
)	O
inhibited	O
fat	O
accumulation	O
.	O

This	O
increased	O
accumulation	O
of	O
fat	O
with	O
low	O
physiological	O
concentrations	O
(	O
10⁻¹³	O
and	O
10⁻¹¹	O
M	O
)	O
was	O
associated	O
with	O
a	O
sequential	O
up-regulation	O
of	O
PPARγ2	GENE-Y
(	O
PPARG	GENE-Y
)	O
and	O
FABP4	GENE-Y
mRNA	O
,	O
indicating	O
formation	O
of	O
adipocytes	O
,	O
whereas	O
higher	O
concentrations	O
(	O
≥10⁻⁹	O
M	O
)	O
reduced	O
all	O
these	O
effects	O
,	O
and	O
the	O
highest	O
concentration	O
(	O
10⁻⁵	O
M	O
)	O
appeared	O
to	O
have	O
toxic	O
effects	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
demonstrate	O
dose-dependent	O
effects	O
of	O
1	CHEMICAL
,	CHEMICAL
25	CHEMICAL
(	CHEMICAL
OH	CHEMICAL
)	CHEMICAL
₂D₃	CHEMICAL
on	O
the	O
transdifferentiation	O
of	O
muscle	O
cells	O
into	O
adipose	O
cells	O
.	O

Low	O
physiological	O
concentrations	O
(	O
possibly	O
mimicking	O
a	O
deficient	O
state	O
)	O
induced	O
adipogenesis	O
,	O
whereas	O
higher	O
(	O
physiological	O
and	O
supraphysiological	O
)	O
concentrations	O
attenuated	O
this	O
effect	O
.	O
Vitamin	CHEMICAL
E	CHEMICAL
(	O
alpha-tocopherol	CHEMICAL
)	O
is	O
an	O
essential	O
fat-soluble	O
nutrient	O
with	O
antioxidant	O
properties	O
.	O

alpha-Tocopherol	GENE-Y
transfer	O
protein	O
(	O
alpha-TTP	GENE-Y
)	O
,	O
the	O
product	O
of	O
the	O
gene	O
responsible	O
for	O
familial	O
isolated	O
vitamin	CHEMICAL
E	CHEMICAL
deficiency	O
,	O
plays	O
an	O
important	O
role	O
in	O
maintaining	O
the	O
plasma	O
alpha-tocopherol	CHEMICAL
level	O
by	O
mediating	O
the	O
secretion	O
of	O
alpha-tocopherol	CHEMICAL
by	O
the	O
liver	O
.	O

However	O
,	O
the	O
mechanisms	O
underlying	O
hepatic	O
alpha-tocopherol	CHEMICAL
secretion	O
are	O
not	O
fully	O
understood	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
elucidate	O
the	O
mechanism	O
of	O
alpha-tocopherol	CHEMICAL
re-efflux	O
from	O
hepatocytes	O
,	O
the	O
cells	O
that	O
have	O
the	O
most	O
important	O
role	O
in	O
regulating	O
plasma-alpha-tocopherol	CHEMICAL
concentrations	O
.	O

From	O
in	O
vitro	O
experiments	O
using	O
[	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
H	CHEMICAL
]	CHEMICAL
alpha-tocopheryl	CHEMICAL
acetate	CHEMICAL
and	O
McARH7777	O
cells	O
that	O
stably	O
express	O
alpha-tocopherol	GENE-Y
transfer	O
protein	O
(	O
alpha-TTP	GENE-Y
)	O
,	O
the	O
following	O
results	O
were	O
obtained	O
.	O

First	O
,	O
addition	O
of	O
apolipoprotein	GENE-Y
A-I	GENE-Y
(	O
apoA-I	GENE-Y
)	O
,	O
a	O
direct	O
acceptor	O
of	O
the	O
ATP-binding	O
cassette	O
transporter	O
A1	O
(	O
ABCA1	GENE-Y
)	O
-secreted	O
lipids	O
,	O
increased	O
alpha-tocopherol	CHEMICAL
secretion	O
in	O
a	O
dose-dependent	O
manner	O
.	O

Second	O
,	O
probucol	CHEMICAL
,	O
an	O
antiatherogenic	O
compound	O
reported	O
to	O
be	O
an	O
inactivator	O
of	O
ABCA1	GENE-Y
reduced	O
hepatic	O
alpha-tocopherol	CHEMICAL
secretion	O
.	O

Third	O
,	O
ABCA1-RNAi	O
suppressed	O
hepatic	O
alpha-tocopherol	CHEMICAL
secretion	O
.	O

In	O
a	O
mouse	O
in	O
vivo	O
experiment	O
,	O
addition	O
of	O
1%	O
probucol	CHEMICAL
to	O
the	O
diet	O
decreased	O
plasma	O
alpha-tocopherol	CHEMICAL
concentrations	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
ABCA1	GENE-Y
is	O
substantially	O
involved	O
in	O
hepatic	O
alpha-tocopherol	CHEMICAL
secretion	O
.	O
2-Amino-1-methyl-6-phenylimidazo	CHEMICAL
[	CHEMICAL
4	CHEMICAL
,	CHEMICAL
5-b	CHEMICAL
]	CHEMICAL
pyridine	CHEMICAL
(	O
PhIP	CHEMICAL
)	O
is	O
one	O
of	O
the	O
most	O
abundant	O
heterocyclic	CHEMICAL
amines	CHEMICAL
(	O
HCAs	CHEMICAL
)	O
generated	O
from	O
overcooking	O
meat	O
at	O
high	O
temperatures	O
.	O

To	O
understand	O
the	O
possible	O
mechanism	O
of	O
PhIP-associated	O
stomach	O
cancer	O
,	O
the	O
effects	O
of	O
PhIP	CHEMICAL
on	O
morphology	O
,	O
oxidative	O
stress	O
,	O
gene	O
expression	O
of	O
c-fos	GENE-Y
,	O
c-jun	GENE-Y
and	O
p16	GENE-Y
in	O
rat	O
stomachs	O
were	O
investigated	O
.	O

The	O
results	O
showed	O
that	O
(	O
1	O
)	O
15mg	O
/	O
kg	O
body	O
weight	O
PhIP	CHEMICAL
induced	O
obvious	O
histopathological	O
changes	O
in	O
gastric	O
mucosa;	O
(	O
2	O
)	O
PhIP	CHEMICAL
(	O
10	O
and	O
/	O
or	O
15mg	O
/	O
kg	O
)	O
significantly	O
decreased	O
superoxide	GENE-N
dismutase	O
(	O
SOD	GENE-N
)	O
and	O
glutathioneperoxidase	GENE-N
(	O
GPx	GENE-N
)	O
activities	O
,	O
while	O
increased	O
catalase	GENE-Y
(	O
CAT	GENE-Y
)	O
activity	O
compared	O
with	O
the	O
control	O
.	O

With	O
the	O
elevated	O
doses	O
of	O
PhIP	CHEMICAL
,	O
malondialdehyde	CHEMICAL
(	O
MDA	CHEMICAL
)	O
contents	O
,	O
protein	O
carbonyl	CHEMICAL
(	O
PCO	O
)	O
contents	O
and	O
DNA-protein	O
crosslinks	O
(	O
DPC	O
)	O
coefficients	O
were	O
significantly	O
raised	O
in	O
a	O
dose-dependent	O
manner;	O
(	O
3	O
)	O
PhIP	CHEMICAL
at	O
the	O
doses	O
of	O
10mg	O
/	O
kg	O
and	O
/	O
or	O
15mg	O
/	O
kg	O
significantly	O
inhibited	O
p16	GENE-Y
mRNA	O
and	O
protein	O
expression	O
,	O
whereas	O
enhanced	O
c-fos	GENE-Y
and	O
c-jun	GENE-Y
expression	O
relative	O
to	O
control	O
.	O

The	O
data	O
indicated	O
that	O
PhIP	CHEMICAL
could	O
cause	O
stomach	O
injury	O
,	O
oxidative	O
stress	O
in	O
rat	O
stomachs	O
as	O
well	O
as	O
the	O
activation	O
of	O
c-fos	GENE-Y
and	O
c-jun	GENE-Y
and	O
inactivation	O
of	O
p16	GENE-Y
,	O
which	O
may	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
PhIP-associated	O
stomach	O
cancer	O
.	O
In	O
vitro	O
antiprogestational	O
/	O
antiglucocorticoid	O
activity	O
and	O
progestin	GENE-N
and	O
glucocorticoid	GENE-Y
receptor	GENE-Y
binding	O
of	O
the	O
putative	O
metabolites	O
and	O
synthetic	O
derivatives	O
of	O
CDB-2914	CHEMICAL
,	O
CDB-4124	CHEMICAL
,	O
and	O
mifepristone	CHEMICAL
.	O
Non-targeted	O
metabolomic	O
approach	O
reveals	O
urinary	O
metabolites	O
linked	O
to	O
steroid	CHEMICAL
biosynthesis	O
pathway	O
after	O
ingestion	O
of	O
citrus	O
juice	O
.	O
Based	O
on	O
detailed	O
,	O
high	O
level	O
ab	O
initio	O
calculations	O
on	O
a	O
number	O
of	O
halogenated	O
compounds	O
of	O
second	O
row	O
,	O
late	O
p-block	O
elements	O
,	O
the	O
SFn	CHEMICAL
,	O
ClFn	CHEMICAL
,	O
PFn	CHEMICAL
,	O
SCln	CHEMICAL
,	O
and	O
SFnCl	CHEMICAL
families	O
,	O
we	O
found	O
that	O
a	O
new	O
type	O
of	O
bond	O
-	O
the	O
recoupled	O
pair	O
bond	O
-	O
accounts	O
for	O
the	O
ability	O
of	O
these	O
elements	O
to	O
form	O
hypervalent	O
,	O
or	O
hypercoordinated	O
,	O
compounds	O
.	O

Hypervalent	O
molecules	O
are	O
formed	O
when	O
it	O
is	O
energetically	O
favorable	O
for	O
the	O
electrons	O
in	O
a	O
lone	O
pair	O
orbital	O
to	O
be	O
recoupled	O
,	O
allowing	O
each	O
of	O
the	O
electrons	O
to	O
form	O
chemical	O
bonds	O
with	O
ligands	O
.	O

In	O
this	O
paper	O
,	O
we	O
characterize	O
the	O
structures	O
and	O
energetics	O
of	O
the	O
ground	O
and	O
low-lying	O
excited	O
states	O
of	O
the	O
ClFn	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
(	O
n	O
=	O
1-6	O
)	O
ions	O
,	O
using	O
high	O
level	O
ab	O
initio	O
methods	O
[	O
MRCI	O
,	O
CCSD	O
(	O
T	O
)	O
/	O
RCCSD	O
(	O
T	O
)	O
]	O
with	O
large	O
correlation	O
consistent	O
basis	O
sets	O
.	O

We	O
computed	O
a	O
number	O
of	O
quantities	O
,	O
including	O
ClFn	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
structures	O
,	O
bond	O
dissociation	O
energies	O
and	O
ClFn	CHEMICAL
ionization	O
energies	O
,	O
and	O
compare	O
our	O
results	O
with	O
the	O
available	O
experimental	O
data	O
.	O

Both	O
the	O
bond	O
dissociation	O
energies	O
and	O
ionization	O
energies	O
oscillate	O
,	O
variations	O
that	O
are	O
readily	O
explained	O
using	O
the	O
recoupled	O
pair	O
bonding	O
model	O
.	O

Comparisons	O
are	O
drawn	O
between	O
the	O
ClFn	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
cations	O
and	O
their	O
counterparts	O
in	O
the	O
isoelectronic	O
SFn	CHEMICAL
series	O
,	O
which	O
possess	O
many	O
similarities	O
.	O

We	O
found	O
two	O
significant	O
differences	O
between	O
the	O
ClFn	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
and	O
SFn	CHEMICAL
series	O
:	O
(	O
i	O
)	O
the	O
bond	O
dissociation	O
energies	O
of	O
ClFn	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
are	O
much	O
weaker	O
than	O
those	O
of	O
the	O
corresponding	O
SFn	CHEMICAL
species	O
,	O
and	O
(	O
ii	O
)	O
there	O
is	O
no	O
stable	O
(	O
3	O
)	O
A2	O
state	O
in	O
ClF2	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
corresponding	O
to	O
the	O
stable	O
state	O
found	O
in	O
SF2	CHEMICAL
.	O

Examination	O
of	O
the	O
Mulliken	O
populations	O
at	O
the	O
HF	CHEMICAL
/	O
AVTZ	O
level	O
for	O
ClFn	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
and	O
SFn	CHEMICAL
species	O
predicts	O
that	O
the	O
F	CHEMICAL
atom	O
in	O
the	O
axial	O
(	O
recoupled	O
pair	O
bonding	O
)	O
position	O
is	O
more	O
highly	O
charged	O
than	O
the	O
F	CHEMICAL
atom	O
in	O
the	O
equatorial	O
(	O
covalent	O
bonding	O
)	O
position;	O
there	O
is	O
also	O
less	O
change	O
transfer	O
to	O
the	O
F	CHEMICAL
atoms	O
in	O
ClFn	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
than	O
in	O
SFn	CHEMICAL
.	O

The	O
positive	O
charge	O
on	O
Cl	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
makes	O
it	O
more	O
difficult	O
for	O
an	O
F	CHEMICAL
atom	O
to	O
attract	O
electrons	O
from	O
Cl	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
than	O
from	O
S	CHEMICAL
and	O
correspondingly	O
less	O
favorable	O
to	O
recouple	O
the	O
electrons	O
in	O
the	O
lone	O
pair	O
orbitals	O
in	O
the	O
ClFn	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
species	O
.	O
Cooperation	O
of	O
the	O
conserved	O
aspartate	CHEMICAL
439	O
and	O
bound	O
amino	CHEMICAL
acid	CHEMICAL
substrate	O
is	O
important	O
for	O
high-affinity	O
Na	CHEMICAL
+	CHEMICAL
binding	O
to	O
the	O
glutamate	GENE-N
transporter	O
EAAC1	GENE-Y
.	O
Using	O
chimeric	O
mice	O
with	O
humanized	O
livers	O
to	O
predict	O
human	O
drug	O
metabolism	O
and	O
a	O
drug-drug	O
interaction	O
.	O
The	O
role	O
of	O
adenosine	GENE-N
receptors	O
in	O
regulating	O
production	O
of	O
tumour	GENE-Y
necrosis	GENE-Y
factor-alpha	GENE-Y
and	O
chemokines	GENE-N
by	O
human	O
lung	O
macrophages	O
.	O
Anion	O
inhibition	O
studies	O
of	O
the	O
α-carbonic	GENE-Y
anhydrase	GENE-Y
from	O
the	O
pathogenic	O
bacterium	O
Vibrio	O
cholerae	O
.	O
In	O
the	O
last	O
couple	O
of	O
decades	O
fungal	O
infections	O
have	O
become	O
a	O
significant	O
clinical	O
problem	O
.	O

A	O
major	O
interest	O
into	O
fungal	O
steroid	CHEMICAL
action	O
has	O
been	O
provoked	O
since	O
research	O
has	O
proven	O
that	O
steroid	CHEMICAL
hormones	O
are	O
toxic	O
to	O
fungi	O
and	O
affect	O
the	O
host	O
/	O
fungus	O
relationship	O
.	O

Steroid	CHEMICAL
hormones	O
were	O
found	O
to	O
differ	O
in	O
their	O
antifungal	O
activity	O
in	O
ascomycetous	O
fungi	O
Hortaea	O
werneckii	O
,	O
Saccharomyces	O
cerevisiae	O
and	O
Aspergillus	O
oryzae	O
.	O

Dehydroepiandrosterone	O
was	O
shown	O
to	O
be	O
the	O
strongest	O
inhibitor	O
of	O
growth	O
in	O
all	O
three	O
varieties	O
of	O
fungi	O
followed	O
by	O
androstenedione	CHEMICAL
and	O
testosterone	CHEMICAL
.	O

For	O
their	O
protection	O
,	O
fungi	O
use	O
several	O
mechanisms	O
to	O
lower	O
the	O
toxic	O
effects	O
of	O
steroids	CHEMICAL
.	O

The	O
efficiency	O
of	O
biotransformation	O
in	O
detoxification	O
depended	O
on	O
the	O
microorganism	O
and	O
steroid	CHEMICAL
substrate	O
used	O
.	O

Biotransformation	O
was	O
a	O
relatively	O
slow	O
process	O
as	O
it	O
also	O
depended	O
on	O
the	O
growth	O
phase	O
of	O
the	O
fungus	O
.	O

In	O
addition	O
to	O
biotransformation	O
,	O
steroid	CHEMICAL
extrusion	O
out	O
of	O
the	O
cells	O
contributed	O
to	O
the	O
lowering	O
of	O
the	O
active	O
intracellular	O
steroid	CHEMICAL
concentration	O
.	O

Plasma	O
membrane	O
Pdr5	GENE-N
transporter	O
was	O
found	O
to	O
be	O
the	O
most	O
effective	O
,	O
followed	O
by	O
Snq2	GENE-N
transporter	O
and	O
vacuolar	O
transporters	O
Ybt1	GENE-N
and	O
Ycf1	GENE-N
.	O

Proteins	O
Aus1	GENE-N
and	O
Dan1	GENE-N
were	O
not	O
found	O
to	O
be	O
involved	O
in	O
steroid	CHEMICAL
import	O
.	O

The	O
research	O
of	O
possible	O
targets	O
of	O
steroid	CHEMICAL
hormone	O
action	O
in	O
fungi	O
suggests	O
that	O
steroid	CHEMICAL
hormones	O
inhibit	O
ergosterol	CHEMICAL
biosynthesis	O
in	O
S	O
.	O

cerevisiae	O
and	O
H	O
.	O

werneckii	O
.	O

Results	O
of	O
this	O
inhibition	O
caused	O
changes	O
in	O
the	O
sterol	CHEMICAL
content	O
of	O
the	O
cellular	O
membrane	O
.	O

The	O
presence	O
of	O
steroid	CHEMICAL
hormones	O
most	O
probably	O
causes	O
the	O
degradation	O
of	O
the	O
Tat2	GENE-N
permease	O
and	O
impairment	O
of	O
tryptophan	CHEMICAL
import	O
.	O
Effect	O
of	O
serum	O
withdrawal	O
on	O
the	O
contribution	O
of	O
L-type	GENE-N
calcium	CHEMICAL
channels	O
(	O
CaV1	GENE-Y
.	GENE-Y
2	GENE-Y
)	O
to	O
intracellular	O
Ca2	CHEMICAL
+	CHEMICAL
responses	O
and	O
chemotaxis	O
in	O
cultured	O
human	O
vascular	O
smooth	O
muscle	O
cells	O
.	O
Catalytic	O
mechanism	O
of	O
guanidinoacetate	GENE-Y
methyltransferase	O
:	O
crystal	O
structures	O
of	O
guanidinoacetate	GENE-Y
methyltransferase	O
ternary	O
complexes	O
.	O
Mesenchymal	O
stem	O
cells	O
(	O
MSC	O
)	O
have	O
shown	O
considerable	O
promise	O
for	O
the	O
regeneration	O
and	O
repair	O
of	O
damaged	O
tissue	O
.	O

However	O
,	O
the	O
electrophysiological	O
properties	O
of	O
K	CHEMICAL
+	CHEMICAL
channels	O
in	O
MSC	O
are	O
not	O
well	O
established	O
and	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
K	CHEMICAL
+	CHEMICAL
channels	O
in	O
the	O
regulation	O
of	O
MSC	O
proliferation	O
.	O

We	O
detected	O
three	O
distinct	O
outward	O
currents	O
in	O
MSC	O
:	O
(	O
i	O
)	O
a	O
delayed	O
rectifier	O
current	O
(	O
IK	O
(	O
DR	O
)	O
)	O
;	O
(	O
ii	O
)	O
a	O
Ca2	CHEMICAL
+	CHEMICAL
-activated	O
K	CHEMICAL
+	CHEMICAL
current	O
(	O
IK	O
(	O
Ca	O
)	O
)	O
;	O
and	O
(	O
iii	O
)	O
a	O
transient	O
outward	O
K	CHEMICAL
+	CHEMICAL
current	O
(	O
Ito	O
)	O
.	O

All	O
three	O
were	O
present	O
either	O
alone	O
or	O
in	O
combination	O
in	O
almost	O
all	O
cells	O
(	O
90%	O
)	O
investigated	O
.	O

However	O
,	O
10%	O
of	O
cells	O
did	O
not	O
express	O
a	O
functional	O
current	O
within	O
physiological	O
potentials	O
.	O

Reverse	O
transcription-polymerase	O
chain	O
reaction	O
was	O
used	O
to	O
identify	O
mRNA	O
associated	O
with	O
functional	O
ionic	O
currents	O
.	O

Kv1	GENE-Y
.	GENE-Y
2	GENE-Y
and	O
Kv2	GENE-Y
.	GENE-Y
1	GENE-Y
were	O
associated	O
with	O
IK	O
(	O
DR	O
)	O
;	O
Slo	GENE-Y
and	O
KCNN4	GENE-Y
were	O
associated	O
with	O
IK	O
(	O
Ca	O
)	O
;	O
and	O
Kv1	GENE-Y
.	GENE-Y
4	GENE-Y
and	O
Kv4	GENE-Y
.	GENE-Y
3	GENE-Y
were	O
associated	O
with	O
Ito	O
.	O

The	O
Kv	GENE-N
channel	GENE-N
blockers	O
amiodarone	CHEMICAL
,	O
tetraethylammonium	CHEMICAL
and	O
verapamil	CHEMICAL
,	O
as	O
well	O
as	O
increased	O
extracellular	O
K	CHEMICAL
+	CHEMICAL
levels	O
,	O
inhibited	O
proliferation	O
of	O
cultured	O
MSC	O
.	O

In	O
MSC	O
treated	O
with	O
Kv	GENE-N
channel	GENE-N
blockers	O
or	O
an	O
increased	O
extracellular	O
concentration	O
of	O
K	CHEMICAL
+	CHEMICAL
,	O
the	O
proportion	O
of	O
cells	O
in	O
the	O
S	O
phase	O
decreased	O
significantly	O
and	O
the	O
proportion	O
of	O
cells	O
in	O
the	O
G	O
(	O
0	O
)	O
/	O
G	O
(	O
1	O
)	O
phase	O
tended	O
to	O
increase	O
,	O
indicating	O
that	O
the	O
cells	O
were	O
prevented	O
from	O
entering	O
the	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

Our	O
findings	O
suggest	O
that	O
rat	O
MSC	O
heterogeneously	O
express	O
distinct	O
types	O
of	O
K	CHEMICAL
+	CHEMICAL
current	O
,	O
of	O
which	O
the	O
voltage-gated	O
IK	O
(	O
DR	O
)	O
-like	O
K	CHEMICAL
+	CHEMICAL
current	O
is	O
most	O
common	O
.	O

Kv	GENE-N
channel	GENE-N
activity	O
modulates	O
the	O
progression	O
of	O
the	O
cell	O
cycle	O
,	O
affecting	O
the	O
proliferation	O
of	O
MSC	O
.	O
The	O
chemoattractant	GENE-Y
receptor-homologous	GENE-Y
molecule	GENE-Y
expressed	GENE-Y
on	GENE-Y
Th2	GENE-Y
cells	GENE-Y
(	O
CRTH2	GENE-Y
)	O
receptor	O
,	O
a	O
G	GENE-N
protein-coupled	GENE-N
receptor	GENE-N
that	O
mediates	O
chemotaxis	O
of	O
inflammatory	O
cells	O
in	O
response	O
to	O
prostaglandin	CHEMICAL
D2	CHEMICAL
(	O
PGD2	CHEMICAL
)	O
,	O
is	O
hypothesized	O
to	O
play	O
a	O
role	O
in	O
Th2-mediated	O
allergic	O
disease	O
.	O

In	O
addition	O
to	O
PGD2	CHEMICAL
,	O
CRTH2	GENE-Y
can	O
be	O
activated	O
by	O
indomethacin	CHEMICAL
,	O
a	O
nonselective	O
cyclooxygenase	GENE-N
inhibitor	O
and	O
widely	O
used	O
nonsteroidal	O
anti-inflammatory	O
drug	O
(	O
NSAID	O
)	O
.	O

To	O
evaluate	O
the	O
structural	O
features	O
that	O
confer	O
CRTH2	GENE-Y
binding	O
selectivity	O
,	O
structure-activity	O
relationship	O
analysis	O
of	O
arylacetic	CHEMICAL
acid	CHEMICAL
class	O
NSAIDs	O
as	O
CRTH2	GENE-Y
receptor	O
ligands	O
was	O
performed	O
.	O

Indomethacin	CHEMICAL
,	O
sulindac	CHEMICAL
sulfide	CHEMICAL
,	O
and	O
zomepirac	CHEMICAL
displaced	O
[	CHEMICAL
3H	CHEMICAL
]	CHEMICAL
PGD2	CHEMICAL
binding	O
at	O
the	O
mouse	GENE-Y
CRTH2	GENE-Y
receptor	GENE-Y
(	O
mCRTH2	GENE-Y
)	O
with	O
comparable	O
affinity	O
(	O
Ki	O
=	O
1	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
1	O
,	O
2	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
4	O
,	O
and	O
3	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
3	O
microM	O
,	O
respectively	O
)	O
.	O

The	O
indomethacin	CHEMICAL
metabolite	O
5'-O-desmethyl	CHEMICAL
indomethacin	CHEMICAL
(	O
5'-DMI	CHEMICAL
)	O
possessed	O
binding	O
affinity	O
similar	O
to	O
indomethacin;	O
however	O
,	O
elimination	O
of	O
the	O
2-methyl	CHEMICAL
substituent	O
on	O
the	O
indole	CHEMICAL
ring	O
resulted	O
in	O
a	O
10-fold	O
decrease	O
in	O
binding	O
affinity	O
.	O

No	O
binding	O
was	O
detected	O
for	O
indole	CHEMICAL
acetic	CHEMICAL
acid	CHEMICAL
and	O
indole	CHEMICAL
derivatives	O
such	O
as	O
tryptophan	CHEMICAL
,	O
serotonin	CHEMICAL
,	O
and	O
5-hydroxy	CHEMICAL
indole	CHEMICAL
acetic	CHEMICAL
acid	CHEMICAL
,	O
demonstrating	O
the	O
importance	O
of	O
the	O
N-acyl	CHEMICAL
moiety	O
of	O
indomethacin	CHEMICAL
.	O

Neutral	O
derivatives	O
of	O
indomethacin	CHEMICAL
also	O
failed	O
to	O
bind	O
to	O
mCRTH2	GENE-Y
,	O
suggesting	O
that	O
the	O
negatively	O
charged	O
carboxylate	CHEMICAL
moiety	O
participates	O
in	O
a	O
key	O
ligand-receptor	O
interaction	O
.	O

Despite	O
similar	O
binding	O
affinities	O
,	O
NSAID-type	O
mCRTH2	GENE-Y
ligands	O
exhibited	O
variable	O
potencies	O
as	O
mCRTH2	GENE-Y
agonists	O
.	O

Sulindac	CHEMICAL
sulfide	CHEMICAL
and	O
5'-DMI	CHEMICAL
inhibited	O
intracellular	O
cyclic	CHEMICAL
AMP	CHEMICAL
(	O
[	O
cAMP	CHEMICAL
]	O
i	O
)	O
generation	O
and	O
stimulated	O
cell	O
migration	O
comparable	O
with	O
indomethacin	CHEMICAL
.	O

In	O
contrast	O
,	O
zomepirac	CHEMICAL
did	O
not	O
inhibit	O
[	O
cAMP	CHEMICAL
]	O
i	O
generation	O
or	O
stimulate	O
cell	O
migration	O
but	O
weakly	O
antagonized	O
the	O
effects	O
of	O
indomethacin	CHEMICAL
on	O
[	O
cAMP	CHEMICAL
]	O
i	O
.	O

Together	O
,	O
these	O
results	O
reveal	O
structural	O
features	O
of	O
arylacetic	CHEMICAL
acid	CHEMICAL
NSAIDs	O
that	O
may	O
be	O
exploited	O
for	O
the	O
development	O
of	O
selective	O
CRTH2	GENE-Y
ligands	O
.	O
A	O
study	O
of	O
parabens	CHEMICAL
and	O
bisphenol	CHEMICAL
A	CHEMICAL
in	O
surface	O
water	O
and	O
fish	O
brain	O
tissue	O
from	O
the	O
Greater	O
Pittsburgh	O
Area	O
.	O
Synthesis	O
and	O
micellar	O
mimic	O
properties	O
of	O
bile	CHEMICAL
acid	CHEMICAL
trimers	O
.	O
Antitumor	O
agents	O
,	O
130	O
,	O
Novel	O
4	O
beta-arylamino	CHEMICAL
derivatives	O
of	O
3'	CHEMICAL
,	CHEMICAL
4'-didemethoxy-3'	CHEMICAL
,	CHEMICAL
4'-dioxo-4-deoxypodophyllotoxin	CHEMICAL
as	O
potent	O
inhibitors	O
of	O
human	GENE-Y
DNA	GENE-Y
topoisomerase	GENE-Y
II	GENE-Y
.	O
Multiple	O
protective	O
effects	O
of	O
melatonin	CHEMICAL
against	O
maternal	O
cholestasis-induced	O
oxidative	O
stress	O
and	O
apoptosis	O
in	O
the	O
rat	O
fetal	O
liver-placenta-maternal	O
liver	O
trio	O
.	O
Recent	O
studies	O
have	O
indicated	O
that	O
the	O
basic	O
residues	O
Arg	CHEMICAL
(	O
93	O
)	O
,	O
Lys	CHEMICAL
(	O
96	O
)	O
,	O
Arg	CHEMICAL
(	O
125	O
)	O
,	O
Arg	CHEMICAL
(	O
165	O
)	O
,	O
Lys	CHEMICAL
(	O
169	O
)	O
,	O
Lys	CHEMICAL
(	O
236	O
)	O
,	O
and	O
Arg	CHEMICAL
(	O
240	O
)	O
(	O
chymotrypsin	GENE-N
numbering	O
)	O
constitute	O
an	O
exosite	O
in	O
the	O
catalytic	O
domain	O
of	O
factor	GENE-Y
Xa	GENE-Y
that	O
can	O
effectively	O
bind	O
heparin	O
only	O
if	O
the	O
acidic	O
N-terminal	O
Gla	O
domain	O
of	O
the	O
proteinase	GENE-N
was	O
neutralized	O
by	O
physiological	O
levels	O
of	O
calcium	CHEMICAL
.	O

Binding	O
of	O
a	O
full-length	O
heparin	O
chain	O
to	O
this	O
site	O
of	O
factor	GENE-Y
Xa	GENE-Y
in	O
the	O
presence	O
of	O
calcium	CHEMICAL
makes	O
a	O
significant	O
contribution	O
to	O
acceleration	O
of	O
the	O
proteinase	GENE-N
inhibition	O
by	O
antithrombin	GENE-Y
through	O
a	O
ternary	O
complex	O
bridging	O
or	O
template	O
mechanism	O
.	O

Moreover	O
,	O
certain	O
basic	O
residues	O
of	O
this	O
site	O
,	O
particularly	O
Arg	CHEMICAL
(	O
165	O
)	O
and	O
Lys	CHEMICAL
(	O
169	O
)	O
,	O
play	O
a	O
key	O
role	O
in	O
factor	GENE-Y
Va	GENE-Y
and	O
/	O
or	O
prothrombin	GENE-Y
recognition	O
by	O
factor	GENE-Y
Xa	GENE-Y
in	O
the	O
prothrombinase	O
complex	O
.	O

This	O
article	O
reviews	O
recent	O
structural	O
,	O
mutagenesis	O
and	O
kinetic	O
data	O
that	O
lead	O
to	O
identification	O
of	O
this	O
exosite	O
and	O
discusses	O
how	O
the	O
binding	O
of	O
protein	O
or	O
polysaccharide	O
cofactors	O
to	O
this	O
site	O
of	O
factor	GENE-Y
Xa	GENE-Y
can	O
modulate	O
the	O
specificity	O
and	O
physiological	O
function	O
of	O
this	O
key	O
coagulant	O
enzyme	O
in	O
plasma	O
.	O
Small	O
molecule	O
chloropyramine	CHEMICAL
hydrochloride	CHEMICAL
(	O
C4	O
)	O
targets	O
the	O
binding	O
site	O
of	O
focal	GENE-Y
adhesion	GENE-Y
kinase	GENE-Y
and	O
vascular	GENE-Y
endothelial	GENE-Y
growth	GENE-Y
factor	GENE-Y
receptor	GENE-Y
3	GENE-Y
and	O
suppresses	O
breast	O
cancer	O
growth	O
in	O
vivo	O
.	O
Inflammatory	O
bowel	O
disease	O
is	O
an	O
urgent	O
public	O
health	O
problem	O
with	O
a	O
high	O
incidence	O
in	O
developed	O
countries	O
.	O

Alterations	O
of	O
lifestyle	O
or	O
dietary	O
interventions	O
may	O
attenuate	O
the	O
disease	O
progression	O
and	O
increase	O
the	O
efficacy	O
of	O
current	O
therapies	O
.	O

Here	O
we	O
tested	O
the	O
effect	O
of	O
chronic	O
supplementation	O
with	O
a	O
mineral	O
extract	O
from	O
red	O
marine	O
algae	O
-	O
rich	O
in	O
calcium	CHEMICAL
(	O
34%	O
)	O
,	O
magnesium	CHEMICAL
,	O
phosphorus	CHEMICAL
,	O
selenium	CHEMICAL
and	O
other	O
trace	O
minerals	O
-	O
in	O
a	O
clinically	O
relevant	O
model	O
of	O
spontaneous	O
enterocolitis	O
,	O
interleukin	GENE-Y
(	GENE-Y
IL	GENE-Y
)	GENE-Y
-10	GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

The	O
mineral	O
extract	O
was	O
administered	O
in	O
the	O
drinking	O
water	O
of	O
Il10	GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
on	O
C57BL	O
/	O
6	O
J	O
and	O
BALB	O
/	O
c	O
strain	O
backgrounds	O
for	O
25	O
weeks	O
commencing	O
from	O
3	O
to	O
4	O
weeks	O
of	O
age	O
.	O

The	O
mineral	O
extract	O
ameliorated	O
the	O
spontaneous	O
development	O
of	O
colitis	O
and	O
severity	O
of	O
disease	O
in	O
Il10	GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
on	O
a	O
C57BL	O
/	O
6	O
J	O
background	O
.	O

Mineral	O
extract-treated	O
Il10	GENE-Y
(	O
-	O
/	O
-	O
)	O
C57BL	O
/	O
6	O
J	O
strain	O
mice	O
had	O
significantly	O
reduced	O
mortality	O
,	O
circulating	O
levels	O
of	O
serum	GENE-N
Amyloid	GENE-N
A	GENE-N
and	O
reduced	O
colonic	O
tissue	O
damage	O
.	O

In	O
contrast	O
,	O
comparable	O
treatment	O
of	O
Il10	GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
on	O
a	O
BALB	O
/	O
c	O
background	O
with	O
the	O
mineral	O
extract	O
did	O
not	O
alter	O
the	O
course	O
of	O
colitis	O
.	O

These	O
data	O
demonstrate	O
that	O
chronic	O
supplementation	O
with	O
a	O
natural	O
mineral	O
extract	O
selectively	O
ameliorates	O
spontaneous	O
mild-moderate	O
colitis	O
in	O
Il10	GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
on	O
a	O
C57BL	O
/	O
6	O
J	O
,	O
but	O
does	O
not	O
attenuate	O
more	O
moderate-severe	O
colitis	O
in	O
BALB	O
/	O
c	O
strain	O
animals	O
.	O

Copyright	O
©	O
2013	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O
Mammalian	GENE-Y
cysteine	CHEMICAL
dioxygenase	O
(	O
CDO	GENE-Y
)	O
is	O
a	O
non-heme	O
iron	CHEMICAL
metalloenzyme	O
that	O
catalyzes	O
the	O
first	O
committed	O
step	O
in	O
oxidative	O
cysteine	CHEMICAL
catabolism	O
.	O

The	O
active	O
site	O
coordination	O
of	O
CDO	GENE-Y
comprises	O
a	O
mononuclear	O
iron	CHEMICAL
ligated	O
by	O
the	O
Nepsilon	O
atoms	O
of	O
three	O
protein-derived	O
histidines	CHEMICAL
,	O
thus	O
representing	O
a	O
new	O
variant	O
on	O
the	O
2-histidine-1-carboxylate	GENE-N
(	O
2H1C	CHEMICAL
)	O
facial	O
triad	O
motif	O
.	O

Nitric	CHEMICAL
oxide	CHEMICAL
was	O
used	O
as	O
a	O
spectroscopic	O
probe	O
in	O
investigating	O
the	O
order	O
of	O
substrate-O2	CHEMICAL
binding	O
by	O
EPR	O
spectroscopy	O
.	O

In	O
these	O
experiments	O
,	O
CDO	GENE-Y
exhibits	O
an	O
ordered	O
binding	O
of	O
l-cysteine	CHEMICAL
prior	O
to	O
NO	CHEMICAL
(	O
and	O
presumably	O
O2	CHEMICAL
)	O
similar	O
to	O
that	O
observed	O
for	O
the	O
2H1C	GENE-N
class	O
of	O
non-heme	O
iron	CHEMICAL
enzymes	O
.	O

Moreover	O
,	O
the	O
CDO	GENE-Y
active	O
site	O
is	O
essentially	O
unreactive	O
toward	O
NO	CHEMICAL
in	O
the	O
absence	O
of	O
substrate	O
,	O
suggesting	O
an	O
obligate	O
ordered	O
binding	O
of	O
l-cysteine	CHEMICAL
prior	O
to	O
NO	CHEMICAL
.	O

Typically	O
,	O
addition	O
of	O
NO	CHEMICAL
to	O
a	O
mononuclear	O
non-heme	O
iron	CHEMICAL
center	O
results	O
in	O
the	O
formation	O
of	O
an	O
{FeNO}7	O
(	O
S	O
=	O
3	O
/	O
2	O
)	O
species	O
characterized	O
by	O
an	O
axial	O
EPR	O
spectrum	O
with	O
gx	O
,	O
gy	O
,	O
and	O
gz	O
values	O
of	O
approximately	O
4	O
,	O
approximately	O
4	O
,	O
and	O
approximately	O
2	O
,	O
respectively	O
.	O

However	O
,	O
upon	O
addition	O
of	O
NO	CHEMICAL
to	O
CDO	GENE-Y
in	O
the	O
presence	O
of	O
substrate	O
l-cysteine	CHEMICAL
,	O
a	O
low-spin	O
{FeNO}7	O
(	O
S	O
=	O
1	O
/	O
2	O
)	O
signal	O
that	O
accounts	O
for	O
approximately	O
85%	O
of	O
the	O
iron	CHEMICAL
within	O
the	O
enzyme	O
develops	O
.	O

Similar	O
{FeNO}7	O
(	O
S	O
=	O
1	O
/	O
2	O
)	O
EPR	O
signals	O
have	O
been	O
observed	O
for	O
a	O
variety	O
of	O
octahedral	O
mononuclear	O
iron-nitrosyl	CHEMICAL
synthetic	O
complexes;	O
however	O
,	O
this	O
type	O
of	O
iron-nitrosyl	CHEMICAL
species	O
is	O
not	O
commonly	O
observed	O
for	O
non-heme	O
iron	CHEMICAL
enzymes	O
.	O

Substitution	O
of	O
l-cysteine	CHEMICAL
with	O
isosteric	O
substrate	O
analogues	O
cysteamine	CHEMICAL
,	O
3-mercaptopropionic	CHEMICAL
acid	CHEMICAL
,	O
and	O
propane	CHEMICAL
thiol	CHEMICAL
did	O
not	O
produce	O
any	O
analogous	O
{FeNO}7	O
signals	O
(	O
S	O
=	O
1	O
/	O
2	O
or	O
3	O
/	O
2	O
)	O
,	O
thus	O
reflecting	O
the	O
high	O
substrate	O
specificity	O
of	O
the	O
enzyme	O
observed	O
by	O
a	O
number	O
of	O
researchers	O
.	O

The	O
unusual	O
{FeNO}7	O
(	O
S	O
=	O
1	O
/	O
2	O
)	O
electronic	O
configuration	O
adopted	O
by	O
the	O
substrate-bound	O
iron-nitrosyl	CHEMICAL
CDO	GENE-Y
(	O
termed	O
{ES-NO}7	O
)	O
is	O
a	O
result	O
of	O
the	O
bidentate	CHEMICAL
thiol	CHEMICAL
/	CHEMICAL
amine	CHEMICAL
coordination	O
of	O
l-cysteine	CHEMICAL
in	O
the	O
NO-bound	O
CDO	GENE-Y
active	O
site	O
.	O

DFT	O
computations	O
were	O
performed	O
to	O
further	O
characterize	O
this	O
species	O
.	O

The	O
DFT-predicted	O
geometric	O
parameters	O
for	O
{ES-NO}7	O
are	O
in	O
good	O
agreement	O
with	O
the	O
crystallographically	O
determined	O
substrate-bound	O
active	O
site	O
configuration	O
of	O
CDO	GENE-Y
and	O
are	O
consistent	O
with	O
known	O
iron-nitrosyl	CHEMICAL
model	O
complexes	O
.	O

Moreover	O
,	O
the	O
computed	O
EPR	O
parameters	O
(	O
g	O
and	O
A	O
values	O
)	O
are	O
in	O
excellent	O
agreement	O
with	O
experimental	O
results	O
for	O
this	O
CDO	GENE-Y
species	O
and	O
those	O
obtained	O
from	O
comparable	O
synthetic	O
{FeNO}7	O
(	O
S	O
=	O
1	O
/	O
2	O
)	O
iron-nitrosyl	CHEMICAL
complexes	O
.	O
CD74	GENE-N
is	O
a	O
type	O
II	O
transmembrane	O
protein	O
that	O
can	O
act	O
as	O
a	O
receptor	O
for	O
macrophage	GENE-Y
migration	GENE-Y
inhibitory	GENE-Y
factor	GENE-Y
(	O
MIF	GENE-Y
)	O
and	O
plays	O
a	O
role	O
in	O
MIF-regulated	O
responses	O
.	O

We	O
reported	O
that	O
MIF	GENE-Y
inhibited	O
osteoclast	O
formation	O
and	O
MIF	GENE-Y
knockout	O
(	O
KO	O
)	O
mice	O
had	O
decreased	O
bone	O
mass	O
.	O

We	O
therefore	O
examined	O
if	O
CD74	GENE-Y
was	O
involved	O
in	O
the	O
ability	O
of	O
MIF	GENE-Y
to	O
alter	O
osteoclastogenesis	O
in	O
cultured	O
bone	O
marrow	O
(	O
BM	O
)	O
from	O
wild-type	O
(	O
WT	O
)	O
and	O
CD74-deficient	O
(	O
KO	O
)	O
male	O
mice	O
.	O

We	O
also	O
measured	O
the	O
bone	O
phenotype	O
of	O
CD74	GENE-Y
KO	O
male	O
mice	O
.	O

Bone	O
mass	O
in	O
the	O
femur	O
of	O
8-week-old	O
mice	O
was	O
measured	O
by	O
micro-computed	O
tomography	O
and	O
histomorphometry	O
.	O

Bone	O
marrow	O
cells	O
from	O
CD74	GENE-Y
KO	O
mice	O
formed	O
15%	O
more	O
osteoclast-like	O
cells	O
(	O
OCLs	O
)	O
with	O
macrophage	GENE-Y
colony-stimulating	GENE-Y
factor	GENE-Y
(	O
M-CSF	GENE-Y
)	O
and	O
receptor	O
activator	O
of	O
NF-κB	GENE-N
ligand	O
(	O
RANKL	GENE-Y
)	O
(	O
both	O
at	O
30	O
ng	O
/	O
mL	O
)	O
compared	O
to	O
WT	O
.	O

Addition	O
of	O
MIF	GENE-Y
to	O
WT	O
cultures	O
inhibited	O
OCL	O
formation	O
by	O
16%	O
but	O
had	O
no	O
effect	O
on	O
CD74KO	O
cultures	O
.	O

The	O
number	O
of	O
colony	O
forming	O
unit	O
granulocyte-macrophage	O
(	O
CFU-GM	O
)	O
in	O
the	O
bone	O
marrow	O
of	O
CD74	GENE-Y
KO	O
mice	O
was	O
26%	O
greater	O
than	O
in	O
WT	O
controls	O
.	O

Trabecular	O
bone	O
volume	O
(	O
TBV	O
)	O
in	O
the	O
femurs	O
of	O
CD74	GENE-Y
KO	O
male	O
mice	O
was	O
decreased	O
by	O
26%	O
compared	O
to	O
WT	O
.	O

In	O
addition	O
,	O
cortical	O
area	O
and	O
thickness	O
were	O
decreased	O
by	O
14%	O
and	O
11%	O
,	O
respectively	O
.	O

Histomorphometric	O
analysis	O
demonstrated	O
that	O
tartrate-resistant	O
acid	O
phosphatase	O
(	O
TRAP	GENE-Y
)	O
(	O
+	O
)	O
osteoclast	O
number	O
and	O
area	O
were	O
significantly	O
increased	O
in	O
CD74	GENE-Y
KO	O
by	O
35%	O
and	O
43%	O
,	O
respectively	O
compared	O
to	O
WT	O
.	O

Finally	O
,	O
we	O
examined	O
the	O
effect	O
of	O
MIF	GENE-Y
on	O
RANKL-induced-signaling	O
pathways	O
in	O
bone	O
marrow	O
macrophage	O
(	O
BMM	O
)	O
cultures	O
.	O

MIF	GENE-Y
treatment	O
decreased	O
RANKL-induced	O
nuclear	GENE-Y
factor	GENE-Y
of	GENE-Y
activated	GENE-Y
T	GENE-Y
cells	GENE-Y
,	GENE-Y
cytoplasmic	GENE-Y
1	GENE-Y
(	O
NFATc1	GENE-Y
)	O
and	O
c-Fos	GENE-Y
protein	O
in	O
BMM	O
cultures	O
by	O
70%	O
and	O
41%	O
,	O
respectively	O
.	O

Our	O
data	O
demonstrate	O
that	O
CD74	GENE-Y
is	O
required	O
for	O
MIF	GENE-Y
to	O
affect	O
in	O
vitro	O
osteoclastogenesis	O
.	O

Further	O
,	O
the	O
bone	O
phenotype	O
of	O
CD74	GENE-Y
KO	O
mice	O
is	O
similar	O
to	O
that	O
of	O
MIF	GENE-Y
KO	O
mice	O
.	O

MIF	GENE-Y
treatment	O
of	O
WT	O
cultures	O
suppressed	O
RANKL-induced	O
activator	GENE-Y
protein	GENE-Y
1	GENE-Y
(	O
AP-1	GENE-Y
)	O
expression	O
,	O
which	O
resulted	O
in	O
decreased	O
osteoclast	O
differentiation	O
in	O
vitro	O
.	O

We	O
propose	O
that	O
CD74	GENE-Y
plays	O
a	O
critical	O
role	O
in	O
the	O
MIF	GENE-Y
inhibition	O
of	O
osteoclastogenesis	O
.	O
BACKGROUND	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
utility	O
of	O
remnant	O
uptake	O
on	O
postoperative	O
radioiodine	CHEMICAL
scans	O
as	O
an	O
oncologic	O
indicator	O
after	O
thyroidectomy	O
for	O
differentiated	O
thyroid	O
cancer	O
(	O
DTC	O
)	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
retrospective	O
review	O
of	O
patients	O
undergoing	O
total	O
thyroidectomy	O
for	O
DTC	O
and	O
subsequent	O
radioactive	O
iodine	CHEMICAL
(	O
RAI	O
)	O
treatment	O
.	O

Of	O
the	O
eight	O
surgeons	O
included	O
,	O
three	O
were	O
considered	O
high	O
volume	O
,	O
performing	O
at	O
least	O
20	O
thyroidectomies	O
per	O
year	O
.	O

Patients	O
with	O
distant	O
metastases	O
at	O
diagnosis	O
or	O
poorly	O
differentiated	O
variants	O
were	O
excluded	O
.	O

To	O
control	O
for	O
the	O
effect	O
of	O
varying	O
RAI	O
doses	O
,	O
the	O
remnant	O
uptake	O
was	O
analyzed	O
as	O
a	O
ratio	O
of	O
the	O
percentage	O
uptake	O
to	O
the	O
dose	O
received	O
(	O
uptake	O
to	O
dose	O
ratio	O
,	O
UDR	O
)	O
.	O

Multivariate	O
logistic	O
regression	O
was	O
used	O
to	O
determine	O
the	O
influence	O
of	O
UDR	O
on	O
recurrence	O
.	O

RESULTS	O
:	O
Of	O
the	O
223	O
patients	O
who	O
met	O
inclusion	O
criteria	O
,	O
21	O
patients	O
(	O
9	O
.	O
42%	O
)	O
experienced	O
a	O
recurrence	O
.	O

Those	O
who	O
recurred	O
had	O
a	O
ten-fold	O
higher	O
UDR	O
compared	O
to	O
those	O
who	O
did	O
not	O
recur	O
(	O
0	O
.	O
030	O
vs	O
.	O

0	O
.	O
003	O
,	O
p	O
=	O
0	O
.	O
001	O
)	O
.	O

Similarly	O
,	O
patients	O
with	O
increasing	O
postoperative	O
thyroglobulin	GENE-Y
measurements	O
(	O
0	O
.	O
339	O
vs	O
.	O

0	O
.	O
003	O
,	O
p<0	O
.	O
001	O
)	O
also	O
had	O
significantly	O
greater	O
UDRs	O
compared	O
to	O
those	O
with	O
stable	O
thyroglobulin	GENE-Y
.	O

The	O
UDRs	O
of	O
high	O
volume	O
surgeons	O
were	O
significantly	O
smaller	O
than	O
low	O
volume	O
surgeons	O
(	O
0	O
.	O
003	O
vs	O
.	O

0	O
.	O
025	O
,	O
p	O
=	O
0	O
.	O
002	O
)	O
.	O

When	O
combined	O
with	O
other	O
known	O
predictors	O
for	O
recurrence	O
,	O
UDR	O
(	O
OR	O
3	O
.	O
71	O
,	O
C	O
.	O

I	O
1	O
.	O
05	O
-	O
13	O
.	O
10	O
,	O
p	O
=	O
0	O
.	O
041	O
)	O
was	O
significantly	O
associated	O
with	O
recurrence	O
.	O

High	O
volume	O
surgeons	O
maintained	O
a	O
low	O
level	O
of	O
permanent	O
complications	O
across	O
all	O
UDRs	O
whereas	O
low	O
volume	O
surgeons	O
had	O
greater	O
permanent	O
complications	O
associated	O
with	O
higher	O
uptake	O
.	O
Dehydroepiandrosterone	CHEMICAL
post-transcriptionally	O
modifies	O
CYP1A2	GENE-Y
induction	O
involving	O
androgen	GENE-Y
receptor	O
.	O
Thyroid	O
cancers	O
arising	O
from	O
a	O
thyroglossal	O
duct	O
cyst	O
(	O
TGDC	O
)	O
are	O
rarely	O
reported	O
.	O

No	O
clear	O
consensus	O
exists	O
regarding	O
optimal	O
management	O
.	O

In	O
this	O
light	O
,	O
TGDC	O
carcinomas	O
recently	O
treated	O
at	O
Asan	O
Medical	O
Center	O
,	O
as	O
well	O
as	O
previously	O
reported	O
cases	O
in	O
the	O
literature	O
,	O
were	O
reviewed	O
.	O

There	O
were	O
ten	O
patients	O
who	O
were	O
diagnosed	O
with	O
TGDC	O
carcinoma	O
at	O
our	O
institution	O
.	O

All	O
patients	O
underwent	O
pre-operative	O
fine-needle	O
aspiration	O
biopsy	O
(	O
FNAB	O
)	O
.	O

Nine	O
patients	O
were	O
suspected	O
of	O
having	O
papillary	O
carcinoma	O
following	O
cytology	O
.	O

The	O
Sistrunk	O
operation	O
(	O
SO	O
)	O
was	O
performed	O
in	O
four	O
patients	O
,	O
SO	O
with	O
total	O
thyroidectomy	O
(	O
SO	O
/	O
TT	O
)	O
was	O
performed	O
in	O
three	O
patients	O
,	O
and	O
SO	O
/	O
TT	O
with	O
neck	O
dissection	O
was	O
performed	O
in	O
three	O
patients	O
.	O

Six	O
patients	O
who	O
received	O
total	O
thyroidectomy	O
underwent	O
radioactive	O
iodine	CHEMICAL
(	O
RAI	O
)	O
therapy	O
and	O
T4	O
suppression	O
.	O

With	O
a	O
median	O
follow-up	O
period	O
of	O
28	O
.	O
5	O
months	O
,	O
two	O
patients	O
showed	O
recurrence	O
and	O
one	O
of	O
them	O
died	O
of	O
the	O
disease	O
.	O

We	O
analyzed	O
163	O
cases	O
from	O
1990	O
to	O
2012	O
with	O
three	O
or	O
more	O
cases	O
TGDC	O
carcinoma	O
,	O
including	O
the	O
present	O
study	O
.	O

Among	O
48	O
patients	O
who	O
underwent	O
FNAB	O
,	O
75%	O
had	O
papillary	O
thyroid	O
carcinoma	O
(	O
PTC	O
)	O
.	O

SO	O
,	O
SO	O
/	O
TT	O
,	O
or	O
SO	O
/	O
TT	O
with	O
neck	O
dissection	O
was	O
performed	O
in	O
27%	O
,	O
41%	O
,	O
and	O
32%	O
of	O
patients	O
,	O
respectively	O
.	O

Among	O
119	O
patients	O
who	O
received	O
total	O
thyroidectomy	O
,	O
36%	O
had	O
concomitant	O
PTC	O
in	O
the	O
thyroid	O
.	O

Among	O
52	O
patients	O
who	O
received	O
neck	O
dissection	O
,	O
69%	O
had	O
cervical	O
nodal	O
involvement	O
.	O

The	O
results	O
of	O
our	O
review	O
suggest	O
that	O
when	O
TGDC	O
carcinoma	O
is	O
suspected	O
,	O
ultrasonography	O
and	O
,	O
if	O
necessary	O
,	O
FNAB	O
should	O
be	O
performed	O
.	O

If	O
these	O
tests	O
reveal	O
a	O
suspected	O
lesion	O
in	O
the	O
thyroid	O
or	O
lymph	O
node	O
,	O
SO	O
/	O
TT	O
and	O
lymph	O
node	O
dissection	O
should	O
be	O
performed	O
.	O
Arsenic	CHEMICAL
is	O
one	O
of	O
the	O
most	O
hazardous	O
substances	O
in	O
the	O
environment	O
known	O
to	O
cause	O
toxicity	O
in	O
multiple	O
organs	O
.	O

Cell	O
adhesion	O
,	O
morphological	O
alterations	O
,	O
cell	O
proliferation	O
,	O
terminal	O
deoxyuridine	CHEMICAL
triphosphate	CHEMICAL
nick-end	O
labeling	O
(	O
TUNEL	O
)	O
and	O
caspase-3	O
/	O
CPP32	O
fluorometric	O
protease	O
assay	O
were	O
important	O
biomarkers	O
to	O
assess	O
apoptosis	O
in	O
cells	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
arsenic-induced	O
apoptosis	O
in	O
the	O
hepatocytes	O
of	O
rat	O
and	O
its	O
protective	O
efficacy	O
with	O
coadministration	O
of	O
ascorbic	CHEMICAL
acid	CHEMICAL
(	O
AA	O
)	O
and	O
Pleurotus	GENE-N
florida	GENE-N
lectin	GENE-N
(	O
PFL	GENE-N
)	O
individually	O
.	O

Results	O
of	O
the	O
present	O
study	O
also	O
showed	O
that	O
arsenic	CHEMICAL
caused	O
cytotoxicity	O
by	O
elevating	O
morphological	O
alterations	O
,	O
TUNEL-positive	O
nuclei	O
,	O
caspase-3	GENE-Y
activity	O
and	O
DNA	O
damage	O
and	O
reducing	O
cell	O
adhesion	O
and	O
cell	O
proliferation	O
in	O
a	O
time-dependent	O
manner	O
.	O

The	O
apoptosis	O
in	O
hepatocytes	O
was	O
reverted	O
to	O
normal	O
value	O
after	O
coadministration	O
of	O
mushroom	GENE-N
lectin	GENE-N
in	O
arsenic-exposed	O
rat	O
.	O

The	O
study	O
provided	O
significant	O
evidence	O
that	O
PFL	GENE-N
has	O
antiapoptotic	O
property	O
against	O
arsenic-induced	O
toxicity	O
.	O

The	O
beneficial	O
effect	O
of	O
PFL	GENE-N
was	O
proportional	O
to	O
its	O
duration	O
of	O
exposure	O
.	O

Retard	O
activities	O
of	O
superoxide	CHEMICAL
dismutase	O
and	O
catalase	GENE-Y
,	O
enhanced	O
lipid	O
peroxidation	O
as	O
well	O
as	O
protein	O
carbonyl	CHEMICAL
in	O
erythrocytes	O
caused	O
by	O
arsenic	CHEMICAL
could	O
also	O
be	O
maintained	O
toward	O
normalcy	O
by	O
supplementation	O
of	O
AA	O
and	O
PFL	GENE-N
.	O

These	O
antioxidative	O
effects	O
were	O
exhibited	O
in	O
a	O
time-dependant	O
manner	O
.	O

In	O
rat	O
,	O
treatment	O
with	O
AA	O
and	O
PFL	GENE-N
prevented	O
alteration	O
of	O
plasma	O
enzyme	O
activities	O
caused	O
by	O
arsenic	CHEMICAL
.	O

The	O
results	O
concluded	O
that	O
treatment	O
with	O
PFL	GENE-N
has	O
significant	O
role	O
in	O
protecting	O
animals	O
from	O
arsenic-induced	O
erythrocytic	O
damage	O
.	O

This	O
finding	O
might	O
be	O
of	O
therapeutic	O
benefit	O
in	O
people	O
suffering	O
from	O
chronic	O
exposure	O
to	O
arsenic	CHEMICAL
from	O
natural	O
sources	O
,	O
a	O
global	O
problem	O
especially	O
relevant	O
to	O
millions	O
of	O
people	O
on	O
the	O
Indian	O
subcontinent	O
.	O
Humans	O
are	O
commonly	O
exposed	O
to	O
nicotine	CHEMICAL
,	O
one	O
of	O
the	O
most	O
important	O
lifestyle	O
chemicals	O
.	O

The	O
occurrence	O
of	O
high	O
levels	O
of	O
arsenic	CHEMICAL
in	O
the	O
groundwater	O
of	O
the	O
southeast	O
region	O
of	O
Asia	O
has	O
received	O
much	O
attention	O
in	O
the	O
past	O
decade	O
and	O
has	O
become	O
a	O
global	O
health	O
concern	O
.	O

Predominant	O
occurrence	O
of	O
both	O
these	O
chemicals	O
and	O
ease	O
of	O
their	O
human	O
exposure	O
led	O
us	O
to	O
investigate	O
the	O
effect	O
of	O
nicotine	CHEMICAL
,	O
a	O
major	O
tobacco	O
alkaloid	O
,	O
on	O
arsenic	CHEMICAL
toxicity	O
.	O

Adult	O
male	O
rats	O
were	O
pre-exposed	O
to	O
two	O
different	O
doses	O
of	O
nicotine	CHEMICAL
(	O
0	O
.	O
75	O
and	O
3	O
mg	O
/	O
kg	O
,	O
intraperitoneally	O
)	O
for	O
7	O
days	O
followed	O
by	O
30	O
days	O
of	O
arsenic	CHEMICAL
exposure	O
(	O
50	O
ppm	O
sodium	CHEMICAL
arsenite	CHEMICAL
in	O
drinking	O
water	O
)	O
.	O

Nicotine	CHEMICAL
pre-exposure	O
resulted	O
in	O
an	O
increased	O
brain	O
arsenic	CHEMICAL
accumulation	O
and	O
a	O
decreased	O
liver	O
arsenic	CHEMICAL
concentration	O
.	O

Arsenic	CHEMICAL
also	O
caused	O
a	O
significant	O
oxidative	O
stress	O
in	O
the	O
blood	O
,	O
brain	O
and	O
liver	O
of	O
the	O
exposed	O
rats	O
.	O

Glutathione-S-transferase	O
,	O
a	O
phase	O
II	O
enzyme	O
,	O
was	O
inhibited	O
by	O
both	O
arsenic	CHEMICAL
and	O
nicotine	CHEMICAL
but	O
no	O
such	O
inhibition	O
was	O
noted	O
in	O
arsenic-treated	O
animals	O
pre-exposed	O
to	O
nicotine	CHEMICAL
.	O

Upon	O
nicotine	CHEMICAL
pre-exposure	O
,	O
brain	O
acetylcholinesterase	GENE-Y
increased	O
,	O
while	O
monoamine	GENE-N
oxidase	GENE-N
(	O
MAO	GENE-N
)	O
decreased	O
.	O

The	O
toxic	O
effects	O
of	O
MAO	GENE-N
significantly	O
attenuated	O
with	O
nicotine	CHEMICAL
pre-exposure	O
.	O

The	O
present	O
study	O
suggests	O
that	O
nicotine	CHEMICAL
may	O
not	O
be	O
the	O
major	O
contributing	O
factor	O
for	O
the	O
previously	O
reported	O
synergistic	O
toxic	O
interaction	O
between	O
tobacco	O
and	O
arsenic	CHEMICAL
.	O

Nicotine	CHEMICAL
pre-exposure	O
in	O
arsenic-exposed	O
animals	O
revealed	O
interesting	O
toxicokinetics	O
and	O
oxidative	O
stress	O
modulating	O
interactions	O
in	O
the	O
brain	O
and	O
liver	O
of	O
rats	O
,	O
which	O
requires	O
further	O
exploration	O
.	O
Acetylcholinesterase	GENE-Y
(	O
AChE	GENE-Y
)	O
at	O
the	O
neuromuscular	O
junction	O
(	O
NMJ	O
)	O
is	O
anchored	O
to	O
the	O
synaptic	O
basal	O
lamina	O
via	O
a	O
triple	O
helical	O
collagen	GENE-Y
Q	GENE-Y
(	O
ColQ	GENE-Y
)	O
in	O
the	O
form	O
of	O
asymmetric	O
AChE	GENE-Y
(	O
AChE	GENE-Y
/	O
ColQ	GENE-Y
)	O
.	O

The	O
C-terminal	O
domain	O
of	O
ColQ	GENE-Y
binds	O
to	O
MuSK	GENE-Y
,	O
the	O
muscle-specific	O
receptor	GENE-N
tyrosine	CHEMICAL
kinase	O
,	O
that	O
mediates	O
a	O
signal	O
for	O
acetylcholine	CHEMICAL
receptor	O
(	O
AChR	GENE-N
)	O
clustering	O
at	O
the	O
NMJ	O
.	O

ColQ	GENE-Y
also	O
binds	O
to	O
heparan	GENE-N
sulfate	GENE-N
proteoglycans	GENE-N
including	O
perlecan	GENE-Y
.	O

Congenital	O
defects	O
of	O
ColQ	GENE-Y
cause	O
endplate	O
AChE	GENE-Y
deficiency	O
.	O

A	O
single	O
intravenous	O
administration	O
of	O
adeno-associated	O
virus	O
serotype	O
8	O
(	O
AAV8	O
)	O
-COLQ	GENE-Y
to	O
Colq-	O
/	O
-	O
mice	O
rescued	O
motor	O
functions	O
,	O
synaptic	O
transmission	O
,	O
and	O
the	O
ultrastructure	O
of	O
NMJ	O
.	O

We	O
also	O
injected	O
AAV1-COLQ-IRES-EGFP	O
to	O
the	O
left	O
tibialis	O
anterior	O
and	O
observed	O
colocalization	O
of	O
AChE	GENE-Y
/	O
ColQ	GENE-Y
at	O
all	O
the	O
examined	O
NMJs	O
of	O
the	O
non-injected	O
limbs	O
.	O

Additionally	O
,	O
injection	O
of	O
purified	O
recombinant	O
AChE	GENE-Y
/	O
ColQ	GENE-Y
protein	O
complex	O
into	O
gluteus	O
maximus	O
accumulated	O
AChE	GENE-Y
in	O
non-injected	O
forelimbs	O
.	O

These	O
observations	O
suggest	O
that	O
the	O
tissue-targeting	O
signal	O
of	O
ColQ	GENE-Y
can	O
be	O
exploited	O
to	O
specifically	O
deliver	O
the	O
transgene	O
product	O
to	O
the	O
target	O
tissue	O
.	O

MuSK	GENE-Y
antibody-positive	O
myasthenia	O
gravis	O
(	O
MG	O
)	O
accounts	O
for	O
5-15%	O
of	O
autoimmune	O
MG	O
.	O

As	O
AChR	GENE-N
deficiency	O
is	O
typically	O
mild	O
and	O
as	O
cholinesterase	GENE-Y
inhibitors	O
are	O
generally	O
ineffective	O
or	O
worsen	O
myasthenic	O
symptoms	O
,	O
we	O
asked	O
if	O
the	O
patient's	O
MuSK-IgG	O
interferes	O
with	O
binding	O
of	O
ColQ	GENE-Y
to	O
MuSK	GENE-Y
.	O

In	O
vitro	O
overlay	O
of	O
AChE	O
/	O
ColQ	GENE-Y
to	O
muscle	O
sections	O
of	O
Colq-	O
/	O
-	O
mice	O
revealed	O
that	O
MuSK-IgG	O
blocks	O
binding	O
of	O
ColQ	GENE-Y
to	O
the	O
NMJ	O
.	O

In	O
vitro	O
plate-binding	O
of	O
MuSK	O
to	O
ColQ	GENE-Y
disclosed	O
that	O
MuSK-IgG	GENE-N
exerts	O
a	O
dose-dependent	O
block	O
of	O
MuSK-ColQ	GENE-Y
interaction	O
.	O

In	O
addition	O
,	O
passive	O
transfer	O
of	O
MuSK-IgG	GENE-N
to	O
mice	O
reduced	O
the	O
size	O
and	O
density	O
of	O
ColQ	GENE-Y
to	O
∼10%	O
of	O
controls	O
and	O
had	O
a	O
lesser	O
effect	O
on	O
the	O
sizes	O
and	O
densities	O
of	O
AChR	GENE-N
and	O
MuSK	GENE-Y
.	O

Elucidation	O
of	O
molecular	O
mechanisms	O
of	O
specific	O
binding	O
of	O
ColQ	GENE-Y
to	O
the	O
NMJ	O
enabled	O
us	O
to	O
ameliorate	O
devastating	O
myasthenic	O
symptoms	O
of	O
Colq-	O
/	O
-	O
mice	O
and	O
to	O
reveal	O
bases	O
of	O
anti-MuSK	GENE-Y
MG	O
.	O
Introduction	O
:	O
The	O
pharmacological	O
profile	O
of	O
eprosartan--implications	O
for	O
cerebrovascular	O
and	O
cardiovascular	O
risk	O
reduction	O
.	O
Mechanistic	O
Aspects	O
of	O
hSOD1	GENE-Y
Maturation	O
from	O
the	O
Solution	O
Structure	O
of	O
Cu	CHEMICAL
(	CHEMICAL
I	CHEMICAL
)	CHEMICAL
-Loaded	O
hCCS	GENE-N
Domain	GENE-N
1	GENE-N
and	O
Analysis	O
of	O
Disulfide-Free	O
hSOD1	GENE-Y
Mutants	O
.	O
Serum	O
carvedilol	CHEMICAL
concentration	O
and	O
its	O
relation	O
to	O
change	O
in	O
plasma	O
brain	GENE-Y
natriuretic	GENE-Y
peptide	GENE-Y
level	O
in	O
the	O
treatment	O
of	O
heart	O
failure	O
:	O
a	O
preliminary	O
study	O
.	O
It	O
was	O
investigated	O
whether	O
ethanol	CHEMICAL
(	O
Et	O
)	O
modifies	O
the	O
damaging	O
impact	O
of	O
lead	O
(	O
Pb	CHEMICAL
)	O
on	O
bone	O
metabolism	O
in	O
a	O
rat	O
model	O
reflecting	O
excessive	O
alcohol	CHEMICAL
consumption	O
by	O
humans	O
exposed	O
to	O
relatively	O
high	O
levels	O
of	O
this	O
metal	O
.	O

For	O
this	O
purpose	O
,	O
markers	O
of	O
bone	O
formation	O
(	O
osteocalcin	GENE-Y
,	O
procollagen	GENE-N
I	GENE-N
,	O
osteoprotegerin	GENE-Y
,	O
alkaline	GENE-Y
phosphatase	GENE-Y
)	O
and	O
resorption	O
(	O
telopeptides	O
of	O
collagen	GENE-N
I	GENE-N
,	O
soluble	O
receptor	GENE-Y
activator	GENE-Y
of	GENE-Y
nuclear	GENE-Y
factor-κB	GENE-Y
ligand	GENE-Y
)	O
,	O
calciotropic	O
hormones	O
(	O
parathormone	GENE-Y
,	O
calcitonin	GENE-Y
,	O
25-hydroxyvitamin	CHEMICAL
D	CHEMICAL
and	O
1	CHEMICAL
,	CHEMICAL
25-dihydroxyvitamin	CHEMICAL
D	CHEMICAL
)	O
in	O
the	O
serum	O
,	O
and	O
the	O
femur	O
content	O
of	O
mineral	O
(	O
including	O
calcium	CHEMICAL
-	O
Ca	CHEMICAL
and	O
inorganic	O
phosphorus	CHEMICAL
-	O
Pi	O
)	O
and	O
organic	O
components	O
were	O
estimated	O
in	O
the	O
rats	O
exposed	O
to	O
500mg	O
Pb	CHEMICAL
/	O
l	O
(	O
in	O
drinking	O
water	O
)	O
or	O
/	O
and	O
Et	O
(	O
5g	O
/	O
kg	O
b	O
.	O

wt	O
.	O

/	O
24h	O
,	O
by	O
oral	O
gavage	O
)	O
for	O
12weeks	O
.	O

Moreover	O
,	O
Ca	CHEMICAL
and	O
Pi	O
in	O
the	O
serum	O
and	O
urine	O
,	O
alkaline	GENE-Y
phosphatase	GENE-Y
in	O
the	O
bone	O
tissue	O
and	O
Pb	CHEMICAL
in	O
the	O
blood	O
and	O
femur	O
were	O
determined	O
.	O

The	O
exposure	O
to	O
Pb	CHEMICAL
or	O
/	O
and	O
Et	O
decreased	O
bone	O
formation	O
and	O
increased	O
its	O
resorption	O
resulting	O
in	O
the	O
bone	O
demineralization	O
.	O

These	O
effects	O
were	O
accompanied	O
by	O
destroying	O
the	O
hormonal	O
regulation	O
of	O
mineral	O
metabolism	O
,	O
and	O
Ca	CHEMICAL
and	O
Pi	O
imbalance	O
.	O

The	O
co-exposure	O
to	O
Pb	CHEMICAL
and	O
Et-induced	O
disorders	O
in	O
bone	O
metabolism	O
were	O
more	O
advanced	O
than	O
those	O
caused	O
by	O
Pb	CHEMICAL
alone	O
.	O

Et	O
co-administration	O
increased	O
Pb	CHEMICAL
concentration	O
in	O
the	O
blood	O
and	O
decreased	O
its	O
accumulation	O
in	O
the	O
bone	O
.	O

This	O
paper	O
is	O
the	O
first	O
report	O
providing	O
evidence	O
that	O
consumption	O
of	O
Et	O
under	O
exposure	O
to	O
Pb	CHEMICAL
intensifies	O
disorders	O
in	O
bone	O
metabolism	O
and	O
that	O
destroying	O
of	O
the	O
receptor	GENE-Y
activator	GENE-Y
nuclear	GENE-Y
factor-κB	GENE-Y
(	O
RANK	GENE-Y
)	O
/	O
RANK	GENE-Y
ligand	GENE-Y
/	O
osteoprotegerin	GENE-Y
system	O
is	O
involved	O
in	O
the	O
mechanisms	O
of	O
interactive	O
action	O
of	O
these	O
xenobiotics	O
on	O
the	O
skeleton	O
.	O

The	O
modifying	O
impact	O
of	O
Et	O
may	O
be	O
an	O
effect	O
of	O
its	O
independent	O
osteotropic	O
action	O
and	O
interaction	O
with	O
Pb	CHEMICAL
.	O

Based	O
on	O
the	O
results	O
it	O
can	O
be	O
concluded	O
that	O
alcohol	CHEMICAL
abuse	O
by	O
subjects	O
excessively	O
exposed	O
to	O
Pb	CHEMICAL
considerably	O
increases	O
the	O
risk	O
of	O
bone	O
damage	O
.	O
Mutations	O
in	O
the	O
insulin	GENE-Y
(	O
INS	GENE-Y
)	O
gene	O
may	O
cause	O
permanent	O
neonatal	O
diabetes	O
mellitus	O
(	O
PNDM	O
)	O
.	O

Ins2	GENE-Y
mutant	O
mouse	O
models	O
provided	O
important	O
insights	O
into	O
the	O
disease	O
mechanisms	O
of	O
PNDM	O
but	O
have	O
limitations	O
for	O
translational	O
research	O
.	O

To	O
establish	O
a	O
large	O
animal	O
model	O
of	O
PNDM	O
,	O
we	O
generated	O
INS	GENE-Y
(	O
C94Y	GENE-N
)	O
transgenic	O
pigs	O
.	O

A	O
line	O
expressing	O
high	O
levels	O
of	O
INS	GENE-Y
(	O
C94Y	GENE-N
)	O
mRNA	O
(	O
70-86%	O
of	O
wild-type	O
INS	GENE-Y
transcripts	O
)	O
exhibited	O
elevated	O
blood	O
glucose	CHEMICAL
soon	O
after	O
birth	O
but	O
unaltered	O
β-cell	O
mass	O
at	O
the	O
age	O
of	O
8	O
days	O
.	O

At	O
4	O
.	O
5	O
months	O
,	O
INS	GENE-Y
(	O
C94Y	GENE-N
)	O
transgenic	O
pigs	O
exhibited	O
41%	O
reduced	O
body	O
weight	O
,	O
72%	O
decreased	O
β-cell	O
mass	O
(	O
-53%	O
relative	O
to	O
body	O
weight	O
)	O
,	O
and	O
60%	O
lower	O
fasting	O
insulin	GENE-Y
levels	O
compared	O
with	O
littermate	O
controls	O
.	O

β-cells	O
of	O
INS	GENE-Y
(	O
C94Y	GENE-N
)	O
transgenic	O
pigs	O
showed	O
a	O
marked	O
reduction	O
of	O
insulin	GENE-Y
secretory	O
granules	O
and	O
severe	O
dilation	O
of	O
the	O
endoplasmic	O
reticulum	O
.	O

Cataract	O
development	O
was	O
already	O
visible	O
in	O
8-day-old	O
INS	GENE-Y
(	O
C94Y	GENE-N
)	O
transgenic	O
pigs	O
and	O
became	O
more	O
severe	O
with	O
increasing	O
age	O
.	O

Diabetes-associated	O
pathological	O
alterations	O
of	O
kidney	O
and	O
nervous	O
tissue	O
were	O
not	O
detected	O
during	O
the	O
observation	O
period	O
of	O
1	O
year	O
.	O

The	O
stable	O
diabetic	O
phenotype	O
and	O
its	O
rescue	O
by	O
insulin	GENE-Y
treatment	O
make	O
the	O
INS	GENE-Y
(	O
C94Y	GENE-N
)	O
transgenic	O
pig	O
an	O
attractive	O
model	O
for	O
insulin	GENE-Y
supplementation	O
and	O
islet	O
transplantation	O
trials	O
,	O
and	O
for	O
studying	O
developmental	O
consequences	O
of	O
maternal	O
diabetes	O
mellitus	O
.	O
Sorafenib	CHEMICAL
inhibits	O
the	O
angiogenesis	O
and	O
growth	O
of	O
orthotopic	O
anaplastic	O
thyroid	O
carcinoma	O
xenografts	O
in	O
nude	O
mice	O
.	O
The	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
cholesterol-lowering	O
effect	O
of	O
two	O
novel	O
plant	O
stanol	CHEMICAL
derivatives	O
and	O
its	O
potential	O
molecular	O
mechanism	O
in	O
hyper-cholesterol	CHEMICAL
mice	O
induced	O
by	O
a	O
high-cholesterol	CHEMICAL
diet	O
.	O

Results	O
showed	O
that	O
oral	O
administration	O
of	O
plant	O
stanyl	CHEMICAL
hemisuccinate	CHEMICAL
(	O
2×	O
,	O
5×	O
)	O
and	O
plant	O
stanyl	CHEMICAL
sorbitol	CHEMICAL
succinate	CHEMICAL
(	O
2×	O
,	O
5×	O
)	O
effectively	O
attenuated	O
the	O
serum	O
total	O
cholesterol	CHEMICAL
and	O
low	GENE-N
density	GENE-N
lipoprotein	GENE-N
cholesterol	CHEMICAL
levels	O
,	O
while	O
had	O
no	O
effect	O
on	O
the	O
serum	O
triacylglycerol	CHEMICAL
and	O
high	GENE-N
density	GENE-N
lipoprotein	GENE-N
cholesterol	CHEMICAL
.	O

And	O
plant	O
stanol	CHEMICAL
derivatives	O
decreased	O
liver	O
cholesterol	CHEMICAL
concentration	O
and	O
increased	O
faecal	O
cholesterol	CHEMICAL
output	O
.	O

Meanwhile	O
,	O
both	O
plant	O
stanyl	CHEMICAL
hemisuccinate	CHEMICAL
and	O
plant	O
stanyl	CHEMICAL
sorbitol	CHEMICAL
succinate	CHEMICAL
could	O
remarkably	O
promote	O
liver	GENE-Y
X	GENE-Y
receptor	GENE-Y
alpha	GENE-Y
(	O
LXRα	GENE-Y
)	O
expression	O
,	O
and	O
increased	O
cholesterol	GENE-Y
7α-hydroxylase	O
(	O
CYP7A1	GENE-Y
)	O
expression	O
and	O
faecal	O
total	O
bile	CHEMICAL
acid	CHEMICAL
output	O
to	O
varying	O
degrees	O
.	O

These	O
results	O
suggested	O
two	O
novel	O
plant	O
stanol	CHEMICAL
derivatives	O
possessed	O
hypocholesterolemic	O
effect	O
,	O
and	O
the	O
cholesterol-lowering	O
action	O
of	O
plant	O
stanol	CHEMICAL
derivatives	O
may	O
be	O
through	O
activating	O
the	O
potential	O
LXRα-CYP7A1-bile	CHEMICAL
acid	CHEMICAL
excretion	O
pathway	O
.	O
Molecular	O
cloning	O
and	O
expression	O
of	O
the	O
rat	GENE-Y
EAAT4	GENE-Y
glutamate	GENE-N
transporter	O
subtype	O
.	O
Gastric	GENE-N
mucin	GENE-N
secretion	O
in	O
response	O
to	O
beta-adrenergic	GENE-N
G	GENE-N
protein-coupled	GENE-N
receptor	GENE-N
activation	O
is	O
mediated	O
by	O
SRC	GENE-Y
kinase-dependent	O
epidermal	GENE-Y
growth	GENE-Y
factor	GENE-Y
receptor	GENE-Y
transactivation	O
.	O
An	O
intestinal	O
immune	O
system	O
modulating	O
polysaccharide	O
(	O
CUI-3IIb-3-2	O
,	O
18kDa	O
)	O
was	O
purified	O
from	O
Citrus	O
unshiu	O
peel	O
.	O

CUI-3IIb-3-2	O
mainly	O
comprised	O
GalA	CHEMICAL
,	O
GlcA	CHEMICAL
,	O
Ara	CHEMICAL
,	O
Gal	CHEMICAL
and	O
Rha	CHEMICAL
,	O
and	O
it	O
consisted	O
of	O
4-linked	O
GalA	CHEMICAL
,	O
terminal	O
Araf	CHEMICAL
,	O
4-	O
or	O
5-linked	O
/	O
3	O
,	O
4-	O
or	O
3	O
,	O
5-branched	O
Ara	CHEMICAL
,	O
terminal	O
Gal	CHEMICAL
,	O
and	O
2-linked	O
/	O
2	O
,	O
4-branched	O
Rha	CHEMICAL
.	O

After	O
CUI-3IIb-3-2	O
digestion	O
by	O
endo-α-d-	O
(	O
1→4	O
)	O
-polygalacturonase	GENE-N
,	O
its	O
hydrolysate	O
was	O
fractionated	O
into	O
PG-1	O
and	O
PG-2	O
.	O

Methylation	O
analyses	O
of	O
PG-1	O
and	O
PG-2	O
using	O
base-catalysed	O
β-elimination	O
suggested	O
that	O
CUI-3IIb-3-2	O
be	O
assumed	O
as	O
pectic-type	O
polysaccharide	O
.	O

Since	O
the	O
activities	O
of	O
PG-1	O
and	O
PG-2	O
were	O
potently	O
decreased	O
,	O
the	O
whole	O
polysaccharide	O
structure	O
of	O
CUI-3IIb-3-2	O
would	O
be	O
essential	O
to	O
maintain	O
the	O
activity	O
.	O

Meanwhile	O
,	O
when	O
CUI-3IIb	O
was	O
orally	O
administered	O
in	O
mice	O
,	O
bone	O
marrow	O
cell	O
proliferation	O
and	O
GM-CSF	O
/	O
IL-6	GENE-Y
production	O
from	O
Peyer's	O
patch	O
cell	O
were	O
significantly	O
higher	O
(	O
1	O
.	O
76-	O
and	O
2	O
.	O
03	O
/	O
2	O
.	O
51-fold	O
,	O
respectively	O
)	O
than	O
a	O
saline	O
.	O

Therefore	O
,	O
a	O
pectic-type	O
polysaccharide	O
from	O
citrus	O
peel	O
could	O
stimulate	O
Peyer's	O
patches	O
and	O
produce	O
hematopoietic	O
growth	O
factors	O
resulted	O
in	O
bone	O
marrow	O
cell	O
proliferation	O
.	O
The	O
insulin	GENE-N
/	O
IGF-1	GENE-N
pathway	O
controls	O
a	O
number	O
of	O
physiological	O
processes	O
in	O
the	O
nematode	O
worm	O
Caenorhabditis	O
elegans	O
,	O
including	O
development	O
,	O
aging	O
and	O
stress	O
response	O
.	O

We	O
previously	O
found	O
that	O
the	O
Akt	GENE-Y
/	O
PKB	GENE-Y
ortholog	O
AKT-1	GENE-Y
dampens	O
the	O
apoptotic	O
response	O
to	O
genotoxic	O
stress	O
in	O
the	O
germline	O
by	O
negatively	O
regulating	O
the	O
p53-like	GENE-Y
transcription	GENE-Y
factor	GENE-Y
CEP-1	GENE-Y
.	O

Here	O
,	O
we	O
report	O
unexpected	O
rearrangements	O
to	O
the	O
insulin	GENE-N
/	O
IGF-1	GENE-N
pathway	O
,	O
whereby	O
the	O
insulin-like	GENE-Y
receptor	GENE-Y
DAF-2	GENE-Y
and	O
3-phosphoinositide-dependent	O
protein	O
kinase	O
PDK-1	O
oppose	O
AKT-1	GENE-Y
to	O
promote	O
DNA	O
damage-induced	O
apoptosis	O
.	O

While	O
DNA	O
damage	O
does	O
not	O
affect	O
phosphorylation	O
at	O
the	O
PDK-1	GENE-Y
site	O
Thr350	GENE-N
/	GENE-N
Thr308	GENE-N
of	O
AKT-1	GENE-Y
,	O
it	O
increased	O
phosphorylation	O
at	O
Ser517	O
/	O
Ser473	O
.	O

Although	O
ablation	O
of	O
daf-2	GENE-Y
or	O
pdk-1	GENE-Y
completely	O
suppressed	O
akt-1-dependent	O
apoptosis	O
,	O
the	O
transcriptional	O
activation	O
of	O
CEP-1	GENE-Y
was	O
unaffected	O
,	O
suggesting	O
that	O
daf-2	GENE-Y
and	O
pdk-1	GENE-Y
act	O
independently	O
or	O
downstream	O
of	O
cep-1	GENE-Y
and	O
akt-1	GENE-Y
.	O

Ablation	O
of	O
the	O
akt-1	GENE-Y
paralog	O
akt-2	GENE-Y
or	O
the	O
downstream	O
target	O
of	O
the	O
insulin	GENE-N
/	O
IGF-1	GENE-N
pathway	O
daf-16	GENE-Y
(	O
a	O
FOXO	GENE-Y
transcription	O
factor	O
)	O
restored	O
sensitivity	O
to	O
damage-induced	O
apoptosis	O
in	O
daf-2	GENE-Y
and	O
pdk-1	GENE-Y
mutants	O
.	O

In	O
addition	O
,	O
daf-2	GENE-Y
and	O
pdk-1	GENE-Y
mutants	O
have	O
reduced	O
levels	O
of	O
phospho-MPK-1	O
/	O
ERK	GENE-N
in	O
their	O
germ	O
cells	O
,	O
indicating	O
that	O
the	O
insulin	GENE-N
/	O
IGF-1	GENE-N
pathway	O
promotes	O
Ras	GENE-N
signaling	O
in	O
the	O
germline	O
.	O

Ablation	O
of	O
the	O
Ras	GENE-N
effector	O
gla-3	GENE-Y
,	O
a	O
negative	O
regulator	O
of	O
mpk-1	GENE-Y
,	O
restored	O
sensitivity	O
to	O
apoptosis	O
in	O
daf-2	GENE-Y
mutants	O
,	O
suggesting	O
that	O
gla-3	GENE-Y
acts	O
downstream	O
of	O
daf-2	GENE-Y
.	O

In	O
addition	O
,	O
the	O
hypersensitivity	O
of	O
let-60	GENE-Y
/	O
Ras	GENE-N
gain-of-function	O
mutants	O
to	O
damage-induced	O
apoptosis	O
was	O
suppressed	O
to	O
wild-type	O
levels	O
by	O
ablation	O
of	O
daf-2	GENE-Y
.	O

Thus	O
,	O
insulin	GENE-N
/	O
IGF-1	GENE-N
signaling	O
selectively	O
engages	O
AKT-2	GENE-Y
/	O
DAF-16	GENE-Y
to	O
promote	O
DNA	O
damage-induced	O
germ	O
cell	O
apoptosis	O
downstream	O
of	O
CEP-1	GENE-Y
through	O
the	O
Ras	GENE-N
pathway	O
.	O
Inhibition	O
of	O
cardiac	O
voltage-gated	GENE-N
sodium	CHEMICAL
channels	O
by	O
grape	O
polyphenols	O
.	O
GnRH	GENE-Y
I	GENE-Y
regulates	O
reproduction	O
.	O

A	O
second	O
form	O
,	O
designated	O
GnRH	GENE-Y
II	GENE-Y
,	O
selectively	O
binds	O
type	O
II	O
GnRH	CHEMICAL
receptors	O
.	O

Amino	CHEMICAL
acids	CHEMICAL
of	O
the	O
type	GENE-Y
I	GENE-Y
GnRH	CHEMICAL
receptor	O
required	O
for	O
binding	O
of	O
GnRH	GENE-Y
I	GENE-Y
(	O
Asp2	O
.	O
61	O
(	O
98	O
)	O
,	O
Asn2	O
.	O
65	O
(	O
102	O
)	O
,	O
and	O
Lys3	O
.	O
32	O
(	O
121	O
)	O
)	O
are	O
conserved	O
in	O
the	O
type	GENE-Y
II	GENE-Y
GnRH	CHEMICAL
receptor	O
,	O
but	O
their	O
roles	O
in	O
receptor	O
function	O
are	O
unknown	O
.	O

We	O
have	O
delineated	O
their	O
functions	O
using	O
mutagenesis	O
,	O
signaling	O
and	O
binding	O
assays	O
,	O
immunoblotting	O
,	O
and	O
computational	O
modeling	O
.	O

Mutating	O
Asp2	GENE-N
.	GENE-N
61	GENE-N
(	GENE-N
97	GENE-N
)	GENE-N
to	GENE-N
Glu	CHEMICAL
or	O
Ala	CHEMICAL
,	O
Asn2	GENE-N
.	GENE-N
65	GENE-N
(	GENE-N
101	GENE-N
)	GENE-N
to	GENE-N
Ala	CHEMICAL
,	O
or	O
Lys3	GENE-N
.	GENE-N
32	GENE-N
(	GENE-N
120	GENE-N
)	GENE-N
to	GENE-N
Gln	CHEMICAL
decreased	O
potency	O
of	O
GnRH	GENE-Y
II-stimulated	O
inositol	CHEMICAL
phosphate	CHEMICAL
production	O
.	O

Consistent	O
with	O
proposed	O
roles	O
in	O
ligand	O
recognition	O
,	O
mutations	O
eliminated	O
measurable	O
binding	O
of	O
GnRH	GENE-Y
II	GENE-Y
,	O
whereas	O
expression	O
of	O
mutant	O
receptors	O
was	O
not	O
decreased	O
.	O

In	O
detailed	O
analysis	O
of	O
how	O
these	O
residues	O
affect	O
ligand-dependent	O
signaling	O
,	O
[	GENE-Y
Trp2	GENE-Y
]	GENE-Y
-GnRH	GENE-Y
I	GENE-Y
showed	O
lesser	O
decreases	O
in	O
potency	O
than	O
GnRH	GENE-Y
I	GENE-Y
at	O
the	O
Asp2	GENE-N
.	GENE-N
61	GENE-N
(	GENE-N
97	GENE-N
)	GENE-N
Glu	GENE-N
mutant	O
.	O

In	O
contrast	O
,	O
[	GENE-Y
Trp2	GENE-Y
]	GENE-Y
-GnRH	GENE-Y
II	GENE-Y
showed	O
the	O
same	O
loss	O
of	O
potency	O
as	O
GnRH	GENE-Y
II	GENE-Y
at	O
this	O
mutant	O
.	O

This	O
suggests	O
that	O
Asp2	O
.	O
61	O
(	O
97	O
)	O
contributes	O
to	O
recognition	O
of	O
His2	CHEMICAL
of	O
GnRH	CHEMICAL
I	CHEMICAL
,	O
but	O
not	O
of	O
GnRH	CHEMICAL
II	CHEMICAL
.	O

GnRH	CHEMICAL
II	CHEMICAL
showed	O
a	O
large	O
decrease	O
in	O
potency	O
at	O
the	O
Asn2	GENE-N
.	GENE-N
65	GENE-N
(	GENE-N
101	GENE-N
)	GENE-N
Ala	GENE-N
mutant	O
compared	O
with	O
analogs	O
lacking	O
the	O
CO	CHEMICAL
group	O
of	O
Gly10NH2	CHEMICAL
.	O

This	O
suggests	O
that	O
Asn2	O
.	O
65	O
(	O
101	O
)	O
recognizes	O
Gly10NH2	CHEMICAL
of	O
GnRH	GENE-Y
II	GENE-Y
.	O

GnRH	GENE-N
agonists	O
showed	O
large	O
decreases	O
in	O
potency	O
at	O
the	O
Lys3	GENE-N
.	GENE-N
32	GENE-N
(	GENE-N
120	GENE-N
)	GENE-N
Gln	GENE-N
mutant	O
,	O
but	O
antagonist	O
activity	O
was	O
unaffected	O
.	O

This	O
suggests	O
that	O
Lys3	O
.	O
32	O
(	O
120	O
)	O
recognizes	O
agonists	O
,	O
but	O
not	O
antagonists	O
,	O
as	O
in	O
the	O
type	O
I	O
receptor	O
.	O

These	O
data	O
indicate	O
that	O
roles	O
of	O
conserved	O
residues	O
are	O
similar	O
,	O
but	O
not	O
identical	O
,	O
in	O
the	O
type	GENE-N
I	GENE-N
and	GENE-N
II	GENE-N
GnRH	CHEMICAL
receptors	O
.	O
Beta	GENE-N
1-	GENE-N
and	GENE-N
beta	GENE-N
2-adrenoceptor	GENE-N
binding	O
and	O
functional	O
response	O
in	O
right	O
and	O
left	O
atria	O
of	O
rat	O
heart	O
.	O
Exenatide	O
,	O
the	O
active	O
ingredient	O
of	O
BYETTA	O
(	O
exenatide	O
injection	O
)	O
,	O
is	O
an	O
incretin	GENE-Y
mimetic	O
that	O
has	O
been	O
developed	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
type	O
2	O
diabetes	O
.	O

Exenatide	O
binds	O
to	O
and	O
activates	O
the	O
known	O
GLP-1	GENE-Y
receptor	GENE-Y
with	O
a	O
potency	O
comparable	O
to	O
that	O
of	O
the	O
mammalian	O
incretin	GENE-N
GLP-1	GENE-N
(	GENE-N
7-36	GENE-N
)	GENE-N
,	O
thereby	O
acting	O
as	O
a	O
glucoregulatory	O
agent	O
.	O

AC3174	O
is	O
an	O
analog	O
of	O
exenatide	O
with	O
leucine	CHEMICAL
substituted	O
for	O
methionine	CHEMICAL
at	O
position	O
14	O
,	O
[	O
Leu	O
(	O
14	O
)	O
]	O
exendin-4	O
.	O

The	O
purpose	O
of	O
these	O
studies	O
was	O
to	O
evaluate	O
the	O
glucoregulatory	O
activity	O
and	O
pharmacokinetics	O
of	O
AC3174	O
.	O

In	O
RINm5f	O
cell	O
membranes	O
,	O
the	O
potency	O
of	O
AC3174	O
for	O
the	O
displacement	O
of	O
[	O
(	CHEMICAL
125	CHEMICAL
)	CHEMICAL
I	CHEMICAL
]	O
GLP-1	GENE-Y
and	O
activation	O
of	O
adenylate	CHEMICAL
cyclase	O
was	O
similar	O
to	O
that	O
of	O
exenatide	O
and	O
GLP-1	GENE-Y
.	O

In	O
vivo	O
,	O
AC3174	O
,	O
administered	O
as	O
a	O
single	O
IP	O
injection	O
,	O
significantly	O
decreased	O
plasma	O
glucose	CHEMICAL
concentration	O
and	O
glucose	CHEMICAL
excursion	O
following	O
the	O
administration	O
of	O
an	O
oral	O
glucose	CHEMICAL
challenge	O
in	O
both	O
non-diabetic	O
(	O
C57BL	O
/	O
6	O
)	O
and	O
diabetic	O
db	O
/	O
db	O
mice	O
(	O
P<0	O
.	O
05	O
vs	O
.	O

vehicle-treated	O
)	O
.	O

The	O
magnitude	O
of	O
glucose	CHEMICAL
lowering	O
of	O
AC3174	O
was	O
comparable	O
to	O
exenatide	O
.	O

The	O
ED	O
(	O
50	O
)	O
values	O
of	O
AC3174	O
for	O
glucose	CHEMICAL
lowering	O
(	O
60	O
minute	O
post-dose	O
)	O
were	O
1	O
.	O
2	O
microg	O
/	O
kg	O
in	O
db	O
/	O
db	O
mice	O
and	O
1	O
.	O
3	O
microg	O
/	O
kg	O
in	O
C57BL	O
/	O
6	O
mice	O
.	O

AC3174	O
has	O
insulinotropic	O
activity	O
in	O
vivo	O
.	O

Administration	O
of	O
AC3174	O
resulted	O
in	O
a	O
4-fold	O
increase	O
in	O
insulin	GENE-N
concentrations	O
in	O
normal	O
mice	O
following	O
an	O
IP	O
glucose	CHEMICAL
challenge	O
.	O

AC3174	O
was	O
also	O
shown	O
to	O
inhibit	O
food	O
intake	O
and	O
decrease	O
gastric	O
emptying	O
in	O
rodent	O
models	O
.	O

AC3174	O
was	O
stable	O
in	O
human	O
plasma	O
(	O
>90%	O
of	O
parent	O
peptide	O
was	O
present	O
after	O
5	O
h	O
of	O
incubation	O
)	O
.	O

In	O
rats	O
,	O
the	O
in	O
vivo	O
half-life	O
of	O
AC3174	O
was	O
42-43	O
min	O
following	O
SC	O
administration	O
.	O

In	O
summary	O
,	O
AC3174	O
is	O
an	O
analog	O
of	O
exenatide	O
that	O
binds	O
to	O
the	O
GLP-1	GENE-Y
receptor	GENE-Y
in	O
vitro	O
and	O
shares	O
many	O
of	O
the	O
biological	O
and	O
glucoregulatory	O
activities	O
of	O
exenatide	O
and	O
GLP-1	GENE-Y
in	O
vivo	O
.	O
Considering	O
the	O
prevalence	O
of	O
cardiovascular	O
disease	O
in	O
public	O
health	O
and	O
the	O
limited	O
validated	O
therapeutic	O
options	O
,	O
this	O
study	O
aimed	O
to	O
find	O
novel	O
compounds	O
targeting	O
the	O
angiotensin	GENE-Y
II	GENE-Y
type	GENE-Y
1	GENE-Y
receptor	GENE-Y
,	O
accepted	O
as	O
a	O
therapeutic	O
target	O
in	O
cardiovascular	O
disease	O
.	O

A	O
small	O
library	O
consisting	O
of	O
89	O
compounds	O
from	O
39	O
Chinese	O
herbs	O
was	O
profiled	O
using	O
a	O
cell-based	O
calcium	O
mobilization	O
assay	O
which	O
was	O
developed	O
and	O
characterized	O
for	O
high-throughput	O
screening	O
.	O

[	CHEMICAL
6	CHEMICAL
]	CHEMICAL
-Gingerol	CHEMICAL
derived	O
from	O
Zingiber	O
officinale	O
Roscoe	O
(	O
ginger	O
)	O
was	O
identified	O
as	O
a	O
novel	O
angiotensin	GENE-Y
II	GENE-Y
type	GENE-Y
1	GENE-Y
receptor	GENE-Y
antagonist	O
,	O
with	O
an	O
IC50	O
value	O
of	O
8	O
.	O
173	O
µM	O
.	O

The	O
hit	O
was	O
further	O
tested	O
by	O
a	O
specificity	O
assay	O
indicating	O
that	O
it	O
had	O
no	O
antagonistic	O
effects	O
on	O
other	O
evaluated	O
GPCRs	GENE-N
,	O
such	O
as	O
endothelin	GENE-N
receptors	GENE-N
.	O

The	O
major	O
ingredient	O
of	O
ginger	O
,	O
[	CHEMICAL
6	CHEMICAL
]	CHEMICAL
-gingerol	CHEMICAL
,	O
could	O
inhibit	O
angiotensin	GENE-Y
II	GENE-Y
type	GENE-Y
1	GENE-Y
receptor	GENE-Y
activation	O
,	O
which	O
partially	O
clarified	O
the	O
mechanism	O
of	O
ginger	O
regulating	O
blood	O
pressure	O
and	O
strengthening	O
heart	O
in	O
the	O
cardiovascular	O
system	O
.	O
P21-activated	GENE-Y
protein	GENE-Y
kinase	GENE-Y
1	GENE-Y
(	O
Pak1	GENE-Y
)	O
mediates	O
the	O
cross	O
talk	O
between	O
insulin	GENE-N
and	O
β-catenin	GENE-Y
on	O
proglucagon	GENE-N
gene	O
expression	O
and	O
its	O
ablation	O
affects	O
glucose	CHEMICAL
homeostasis	O
in	O
male	O
C57BL	O
/	O
6	O
mice	O
.	O
Evaluation	O
of	O
histamine	GENE-N
H1-	O
,	O
H2-	O
,	O
and	O
H3-receptor	O
ligands	O
at	O
the	O
human	GENE-Y
histamine	CHEMICAL
H4	O
receptor	O
:	O
identification	O
of	O
4-methylhistamine	CHEMICAL
as	O
the	O
first	O
potent	O
and	O
selective	O
H4	GENE-Y
receptor	GENE-Y
agonist	O
.	O
Intracerebroventricular	O
administration	O
of	O
SMS	CHEMICAL
201-995	CHEMICAL
(	O
5	O
micrograms	O
/	O
rat	O
)	O
,	O
a	O
somatostatin	GENE-Y
analogue	O
,	O
induced	O
barrel	O
rotation	O
in	O
rats	O
.	O

Pretreatment	O
with	O
ceruletide	CHEMICAL
(	O
40	O
micrograms	O
/	O
100	O
g	O
b	O
.	O

wt	O
.	O

,	O
IP	O
)	O
3	O
days	O
or	O
7	O
days	O
prior	O
to	O
the	O
injection	O
of	O
SMS	CHEMICAL
201-995	CHEMICAL
significantly	O
inhibited	O
the	O
response	O
rate	O
of	O
barrel	O
rotation	O
induced	O
by	O
SMS	CHEMICAL
201-995	CHEMICAL
,	O
but	O
not	O
that	O
induced	O
by	O
arginine-vasopressin	CHEMICAL
(	O
1	O
microgram	O
/	O
rat	O
,	O
ICV	O
)	O
.	O

The	O
suppressive	O
effect	O
of	O
ceruletide	CHEMICAL
on	O
barrel	O
rotation	O
could	O
be	O
partially	O
countered	O
by	O
MK-329	CHEMICAL
,	O
a	O
selective	O
peripheral	O
CCK	GENE-Y
(	GENE-Y
CCK-A	GENE-Y
)	GENE-Y
receptor	GENE-Y
antagonist	O
.	O

Desulfated	O
cerulein	O
did	O
not	O
affect	O
the	O
barrel	O
rotation	O
induced	O
by	O
SMS	CHEMICAL
201-995	CHEMICAL
.	O

These	O
findings	O
suggest	O
that	O
ceruletide	CHEMICAL
specifically	O
suppresses	O
the	O
barrel	O
rotation	O
evoked	O
by	O
SMS	CHEMICAL
201-995	CHEMICAL
in	O
a	O
long-lasting	O
manner	O
possibly	O
acting	O
through	O
CCK-A	GENE-Y
receptor	GENE-Y
.	O
Lysyl	CHEMICAL
oxidase	O
(	O
LO	GENE-Y
)	O
catalyzes	O
crosslink	O
of	O
collagen	GENE-N
,	O
elastin	GENE-Y
,	O
and	O
histone	GENE-N
H1	GENE-N
,	O
stabilizing	O
the	O
extracellular	O
matrix	O
and	O
cell	O
nucleus	O
.	O

This	O
enzyme	O
displays	O
dual	O
functions	O
for	O
tumorigenesis	O
,	O
i	O
.	O

e	O
.	O

,	O
as	O
a	O
tumor	O
suppressor	O
inactivating	O
the	O
ras	GENE-N
oncogene	O
and	O
as	O
a	O
tumor	O
promoter	O
enhancing	O
malignant	O
cell	O
metastasis	O
.	O

To	O
elucidate	O
LO	GENE-Y
transcriptional	O
regulation	O
,	O
we	O
have	O
cloned	O
the	O
804	O
base	O
pair	O
region	O
upstream	O
of	O
the	O
translation	GENE-N
start	GENE-N
site	GENE-N
(	O
ATG	GENE-N
)	O
of	O
the	O
rat	GENE-Y
LO	GENE-Y
gene	O
with	O
the	O
maximal	O
promoter	O
activity	O
.	O

Computer	O
analysis	O
indicated	O
that	O
at	O
least	O
four	O
hypoxia-response	GENE-N
element	GENE-N
(	O
HRE	GENE-N
)	O
consensuses	O
(	O
5'-ACGTG-3'	GENE-N
)	O
exist	O
in	O
the	O
cloned	O
LO	GENE-N
promoter	GENE-N
.	O

Treatment	O
of	O
rat	O
lung	O
fibroblasts	O
(	O
RFL6	O
)	O
with	O
CoCl2	CHEMICAL
(	O
Co	CHEMICAL
,	O
10-100	O
μM	O
)	O
,	O
a	O
chemical	O
hypoxia	O
reagent	O
,	O
enhanced	O
LO	GENE-Y
mRNA	O
expression	O
and	O
promoter	O
activities	O
.	O

Overexpression	O
of	O
LO	GENE-Y
was	O
associated	O
with	O
upregulation	O
of	O
hypoxia-inducible	GENE-Y
factor	GENE-Y
(	GENE-Y
HIF	GENE-Y
)	GENE-Y
-1α	GENE-Y
at	O
mRNA	O
levels	O
in	O
cobalt	CHEMICAL
(	O
Co	CHEMICAL
)	O
-treated	O
cells	O
.	O

Thus	O
,	O
LO	GENE-Y
is	O
a	O
hypoxia-responsive	O
gene	O
.	O

Dominant	GENE-Y
negative-HIF-1α	GENE-Y
inhibited	O
LO	GENE-N
promoter	GENE-N
activities	O
stimulated	O
by	O
Co	CHEMICAL
.	O

Electrophoretic	O
mobility	O
shift	O
,	O
oligonucleotide	O
competition	O
,	O
and	O
in	O
vitro	O
translated	O
HIF-1α	GENE-Y
binding	O
assays	O
indicated	O
that	O
only	O
one	O
HRE	GENE-N
mapped	O
at	O
-387	O
/	O
-383	O
relative	O
to	O
ATG	GENE-N
was	O
functionally	O
active	O
among	O
four	O
consensuses	O
.	O

Site-directed	O
mutation	O
of	O
this	O
HRE	GENE-N
significantly	O
diminished	O
the	O
Co-induced	O
and	O
LO	GENE-N
promoter-directed	O
expression	O
of	O
the	O
reporter	O
gene	O
.	O

Cadmium	CHEMICAL
(	O
Cd	CHEMICAL
)	O
,	O
an	O
inducer	O
of	O
reactive	O
oxygen	CHEMICAL
species	O
,	O
inhibited	O
HIF-1α	GENE-Y
mRNA	O
expression	O
and	O
HIF-1α	GENE-Y
binding	O
to	O
the	O
LO	GENE-Y
gene	O
in	O
Co-treated	O
cells	O
as	O
revealed	O
by	O
RT-PCR	O
and	O
ChIP	O
assays	O
,	O
respectively	O
.	O

Thus	O
,	O
modulation	O
of	O
the	O
HRE	GENE-N
activity	O
by	O
Co	CHEMICAL
and	O
Cd	CHEMICAL
plays	O
a	O
critical	O
role	O
in	O
LO	GENE-Y
gene	O
transactivation	O
.	O
Characterization	O
of	O
insulin-like	GENE-N
growth	GENE-N
factor-binding	GENE-N
protein-related	GENE-N
proteins	GENE-N
(	GENE-N
IGFBP-rPs	GENE-N
)	GENE-N
1	GENE-N
,	GENE-N
2	GENE-N
,	GENE-N
and	GENE-N
3	GENE-N
in	O
human	O
prostate	O
epithelial	O
cells	O
:	O
potential	O
roles	O
for	O
IGFBP-rP1	GENE-N
and	GENE-N
2	GENE-N
in	O
senescence	O
of	O
the	O
prostatic	O
epithelium	O
.	O
Does	O
the	O
expression	O
of	O
c-kit	GENE-Y
(	O
CD117	GENE-Y
)	O
in	O
neuroendocrine	O
tumors	O
represent	O
a	O
target	O
for	O
Aim	O
:	O
A	O
number	O
of	O
studies	O
have	O
demonstrated	O
that	O
ABCB1	GENE-Y
and	O
BCRP	GENE-Y
(	O
ABCG2	GENE-Y
)	O
actively	O
transport	O
Aβ	GENE-Y
.	O

We	O
aimed	O
to	O
investigate	O
the	O
association	O
of	O
genetic	O
variants	O
of	O
selected	O
multidrug	GENE-N
transporters	GENE-N
with	O
Alzheimer's	O
disease	O
(	O
AD	O
)	O
in	O
histopathologically	O
confirmed	O
AD	O
cases	O
and	O
controls	O
.	O

Materials	O
&	O
methods	O
:	O
DNA	O
from	O
brain	O
tissue	O
of	O
71	O
AD	O
cases	O
with	O
Consortium	O
to	O
Establish	O
a	O
Registry	O
for	O
Alzheimer's	O
Disease	O
(	O
CERAD	O
)	O
neuropathological	O
stages	O
B	O
/	O
C	O
and	O
81	O
controls	O
was	O
genotyped	O
for	O
selected	O
variants	O
in	O
ABCA1	GENE-Y
,	O
ABCA7	GENE-Y
,	O
ABCB1	GENE-Y
,	O
ABCC2	GENE-Y
and	O
ABCG2	GENE-Y
.	O

In	O
addition	O
,	O
the	O
APOE4	GENE-Y
status	O
was	O
analyzed	O
.	O

Results	O
:	O
The	O
novel	O
ABCA7	GENE-Y
SNP	O
,	O
rs3752246	O
,	O
tended	O
to	O
be	O
associated	O
with	O
AD	O
in	O
our	O
study	O
.	O

Variants	O
in	O
ABCB1	GENE-Y
were	O
significantly	O
less	O
frequent	O
in	O
AD	O
cases	O
older	O
than	O
65	O
years	O
of	O
age	O
and	O
among	O
females	O
.	O

This	O
association	O
of	O
ABCB1	GENE-Y
2677G>T	GENE-N
(	O
rs2032582	O
)	O
was	O
more	O
pronounced	O
in	O
APOE4-negative	O
cases	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
.	O

However	O
,	O
only	O
ABCC2	GENE-Y
3972C>T	GENE-N
(	O
rs3740066	O
)	O
was	O
significantly	O
associated	O
with	O
AD	O
risk	O
after	O
logistic	O
regression	O
analysis	O
including	O
all	O
variants	O
.	O

Other	O
transporters	O
showed	O
a	O
lack	O
of	O
association	O
.	O

Conclusion	O
:	O
Our	O
results	O
support	O
the	O
hypothesis	O
that	O
ABCB1	GENE-Y
and	O
possibly	O
other	O
ABC-transporters	GENE-N
are	O
involved	O
in	O
the	O
process	O
of	O
Aβ	GENE-Y
accumulation	O
in	O
the	O
aging	O
brain	O
and	O
may	O
modulate	O
the	O
risk	O
for	O
AD	O
in	O
an	O
allele-specific	O
manner	O
,	O
and	O
thus	O
might	O
represent	O
a	O
new	O
target	O
for	O
prevention	O
and	O
treatment	O
of	O
AD	O
.	O

Original	O
submitted	O
8	O
October	O
2012;	O
Revision	O
submitted	O
22	O
January	O
2013	O
.	O
β-Ionone	CHEMICAL
is	O
an	O
end	O
ring	O
analog	O
of	O
β-carotenoid	O
which	O
has	O
been	O
shown	O
to	O
possess	O
potent	O
anti-proliferative	O
activity	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

To	O
investigate	O
the	O
possible	O
inhibitory	O
effects	O
of	O
β-ionone	CHEMICAL
,	O
we	O
studied	O
cell	O
growth	O
characteristics	O
,	O
DNA	O
synthesis	O
,	O
cell	O
cycle	O
progression	O
,	O
as	O
well	O
as	O
mitogen-activated	GENE-N
protein	GENE-N
kinases	GENE-N
(	O
MAPKs	GENE-N
)	O
pathways	O
in	O
the	O
human	O
gastric	O
adenocarcinoma	O
cancer	O
cell	O
line	O
(	O
SGC-7901	O
)	O
.	O

Our	O
results	O
show	O
that	O
cell	O
growth	O
and	O
DNA	O
synthesis	O
were	O
inhibited	O
,	O
and	O
the	O
cell	O
cycle	O
was	O
arrested	O
at	O
the	O
G0	O
/	O
G1	O
phase	O
in	O
a	O
dose-dependent	O
manner	O
in	O
cells	O
treated	O
with	O
β-ionone	CHEMICAL
(	O
25	O
,	O
50	O
,	O
100	O
and	O
200	O
μmol	O
/	O
L	O
)	O
for	O
24	O
h	O
.	O

We	O
found	O
that	O
the	O
β-ionone	CHEMICAL
significantly	O
decreased	O
the	O
extracellular	GENE-N
signal-regulated	GENE-N
kinase	GENE-N
protein	O
expression	O
and	O
significantly	O
increased	O
the	O
levels	O
of	O
p38	GENE-N
and	O
Jun-amino-terminal	O
kinase	O
protein	O
expression	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

β-Ionone	CHEMICAL
also	O
inhibited	O
cell	GENE-N
cycle-related	GENE-N
proteins	GENE-N
of	O
Cdk4	GENE-Y
,	O
Cyclin	GENE-N
B1	GENE-N
,	GENE-N
D1	GENE-N
and	O
increased	O
p27	GENE-Y
protein	O
expression	O
in	O
SGC-7901	O
cells	O
.	O

These	O
results	O
suggested	O
that	O
the	O
cell	O
cycle	O
arrest	O
observed	O
may	O
be	O
regulated	O
through	O
a	O
MAPK	GENE-N
pathway	O
by	O
transcriptional	O
down-regulation	O
of	O
cell	O
cycle	O
proteins	O
.	O

These	O
results	O
demonstrate	O
potent	O
ability	O
of	O
β-ionone	CHEMICAL
to	O
arrest	O
cell	O
cycle	O
of	O
SGC-7901	O
cells	O
and	O
decrease	O
proliferation	O
.	O
Herein	O
a	O
library	O
of	O
hybrid	O
Mn-Anderson	O
polyoxometalates	CHEMICAL
anions	O
are	O
presented	O
:	O
1	O
,	O
[	CHEMICAL
(	CHEMICAL
MnMo	CHEMICAL
(	CHEMICAL
6	CHEMICAL
)	CHEMICAL
O	CHEMICAL
(	CHEMICAL
18	CHEMICAL
)	CHEMICAL
)	CHEMICAL
(	CHEMICAL
(	CHEMICAL
OCH	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
)	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
-C-	CHEMICAL
(	CHEMICAL
CH	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
)	CHEMICAL
(	CHEMICAL
7	CHEMICAL
)	CHEMICAL
CHCH	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
)	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
]	CHEMICAL
(	CHEMICAL
3-	CHEMICAL
)	CHEMICAL
;	O
compound	O
2	O
,	O
[	CHEMICAL
(	CHEMICAL
MnMo	CHEMICAL
(	CHEMICAL
6	CHEMICAL
)	CHEMICAL
O	CHEMICAL
(	CHEMICAL
18	CHEMICAL
)	CHEMICAL
)	CHEMICAL
(	CHEMICAL
(	CHEMICAL
OCH	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
)	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
C-NHCH	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
C	CHEMICAL
(	CHEMICAL
16	CHEMICAL
)	CHEMICAL
H	CHEMICAL
(	CHEMICAL
9	CHEMICAL
)	CHEMICAL
)	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
]	CHEMICAL
(	CHEMICAL
3-	CHEMICAL
)	CHEMICAL
;	O
compound	O
3	O
,	O
[	CHEMICAL
(	CHEMICAL
MnMo	CHEMICAL
(	CHEMICAL
6	CHEMICAL
)	CHEMICAL
O	CHEMICAL
(	CHEMICAL
18	CHEMICAL
)	CHEMICAL
)	CHEMICAL
(	CHEMICAL
(	CHEMICAL
OCH	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
)	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
C-	CHEMICAL
(	CHEMICAL
CH	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
)	CHEMICAL
(	CHEMICAL
7	CHEMICAL
)	CHEMICAL
CHCH	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
)	CHEMICAL
(	CHEMICAL
1	CHEMICAL
)	CHEMICAL
(	CHEMICAL
(	CHEMICAL
OCH	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
)	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
C-NHCH	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
C	CHEMICAL
(	CHEMICAL
16	CHEMICAL
)	CHEMICAL
H	CHEMICAL
(	CHEMICAL
9	CHEMICAL
)	CHEMICAL
)	CHEMICAL
(	CHEMICAL
1	CHEMICAL
)	CHEMICAL
]	CHEMICAL
(	CHEMICAL
3-	CHEMICAL
)	CHEMICAL
;	O
compound	O
4	O
,	O
[	CHEMICAL
(	CHEMICAL
MnMo	CHEMICAL
(	CHEMICAL
6	CHEMICAL
)	CHEMICAL
O	CHEMICAL
(	CHEMICAL
18	CHEMICAL
)	CHEMICAL
)	CHEMICAL
(	CHEMICAL
(	CHEMICAL
OCH	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
)	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
C-NHC	CHEMICAL
(	CHEMICAL
O	CHEMICAL
)	CHEMICAL
CH	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
CHCH	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
)	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
]	CHEMICAL
(	CHEMICAL
3-	CHEMICAL
)	CHEMICAL
and	O
compounds	O
5-9	O
,	O
[	CHEMICAL
(	CHEMICAL
MnMo	CHEMICAL
(	CHEMICAL
6	CHEMICAL
)	CHEMICAL
O	CHEMICAL
(	CHEMICAL
18	CHEMICAL
)	CHEMICAL
)	CHEMICAL
(	CHEMICAL
(	CHEMICAL
OCH	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
)	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
C-NHC	CHEMICAL
(	CHEMICAL
O	CHEMICAL
)	CHEMICAL
(	CHEMICAL
CH	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
)	CHEMICAL
(	CHEMICAL
x	CHEMICAL
)	CHEMICAL
CH	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
)	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
]	CHEMICAL
)	O
,	O
where	O
x	O
=	O
4	O
,	O
10	O
,	O
12	O
,	O
14	O
,	O
and	O
18	O
respectively	O
.	O

The	O
compounds	O
resulting	O
from	O
the	O
cation	O
exchange	O
of	O
the	O
anions	O
1-9	O
to	O
give	O
TBA	CHEMICAL
(	O
a	O
)	O
and	O
DMDOA	CHEMICAL
(	O
b	O
)	O
salts	O
,	O
and	O
additionally	O
for	O
compounds	O
1	O
,	O
2	O
and	O
3	O
,	O
tetraphenylphosphonium	CHEMICAL
(	O
PPh	CHEMICAL
(	CHEMICAL
4	CHEMICAL
)	CHEMICAL
)	O
(	O
c	O
)	O
salts	O
,	O
are	O
explored	O
at	O
the	O
air	O
/	O
water	O
interface	O
using	O
scanning	O
force	O
microscopy	O
,	O
showing	O
a	O
range	O
of	O
architectures	O
including	O
hexagonal	O
structures	O
,	O
nanofibers	O
and	O
other	O
supramolecular	O
forms	O
.	O

Additionally	O
the	O
solid-state	O
structures	O
for	O
compounds	O
1c	O
,	O
2c	O
,	O
4a	O
,	O
6a	O
,	O
9a	O
,	O
are	O
presented	O
for	O
the	O
first	O
time	O
and	O
these	O
investigations	O
demonstrate	O
the	O
delicate	O
interplay	O
between	O
the	O
structure	O
of	O
the	O
covalently	O
derivatised	O
hybrid	O
organo-clusters	O
as	O
well	O
as	O
the	O
ion-exchange	O
cation	O
types	O
.	O
Species-specific	O
pharmacological	O
properties	O
of	O
human	GENE-Y
alpha	GENE-Y
(	GENE-Y
2A	GENE-Y
)	GENE-Y
-adrenoceptors	GENE-Y
.	O
HRG1	GENE-Y
is	O
essential	O
for	O
heme	CHEMICAL
transport	O
from	O
the	O
phagolysosome	O
of	O
macrophages	O
during	O
erythrophagocytosis	O
.	O
The	O
selective	O
SYK	GENE-Y
inhibitor	O
P505-15	CHEMICAL
(	O
PRT062607	CHEMICAL
)	O
inhibits	O
B	O
cell	O
signaling	O
and	O
function	O
in	O
vitro	O
and	O
in	O
vivo	O
and	O
augments	O
the	O
activity	O
of	O
fludarabine	CHEMICAL
in	O
chronic	O
lymphocytic	O
leukemia	O
.	O
Heparin-binding	O
exosite	O
of	O
factor	GENE-Y
Xa	GENE-Y
.	O
Cell	O
penetrating	O
peptide	O
tethered	O
bi-ligand	O
liposomes	O
for	O
delivery	O
to	O
brain	O
in	O
vivo	O
:	O
Biodistribution	O
and	O
transfection	O
.	O
Reversal	O
of	O
P-glycoprotein-mediated	O
multidrug	O
resistance	O
is	O
induced	O
by	O
mollugin	CHEMICAL
in	O
MCF-7	O
/	O
adriamycin	O
cells	O
.	O
Aurora	GENE-N
kinases	GENE-N
play	O
an	O
essential	O
role	O
in	O
mitotic	O
progression	O
and	O
are	O
potentially	O
druggable	O
targets	O
in	O
cancer	O
therapy	O
.	O

We	O
identified	O
benzo	CHEMICAL
[	CHEMICAL
e	CHEMICAL
]	CHEMICAL
pyridoindoles	CHEMICAL
(	O
BePI	CHEMICAL
)	O
as	O
powerful	O
aurora	GENE-N
kinase	GENE-N
inhibitors	O
.	O

Their	O
efficiency	O
was	O
demonstrated	O
both	O
in	O
enzymatic	O
inhibition	O
studies	O
and	O
in	O
cell	O
culture	O
assays	O
.	O

New	O
BePI	CHEMICAL
molecules	O
were	O
synthesized	O
,	O
and	O
a	O
structure-activity	O
relationship	O
study	O
was	O
conducted	O
with	O
the	O
aim	O
of	O
improving	O
the	O
activity	O
and	O
solubility	O
of	O
the	O
lead	O
compound	O
.	O

Tetracyclic	CHEMICAL
BePI	CHEMICAL
derivatives	O
are	O
characterized	O
by	O
a	O
particular	O
curved	O
shape	O
,	O
and	O
the	O
presence	O
of	O
an	O
oxo	CHEMICAL
group	O
on	O
the	O
pyridine	CHEMICAL
ring	O
was	O
found	O
to	O
be	O
required	O
for	O
aurora	GENE-Y
kinase	GENE-Y
B	GENE-Y
inhibition	O
.	O

New	O
hydrosoluble	O
benzo	CHEMICAL
[	CHEMICAL
e	CHEMICAL
]	CHEMICAL
pyridoindolones	CHEMICAL
were	O
subsequently	O
designed	O
,	O
and	O
their	O
efficacy	O
was	O
tested	O
by	O
a	O
combination	O
of	O
cell-cycle	O
analysis	O
and	O
time-lapse	O
experiments	O
in	O
live	O
cells	O
.	O

The	O
most	O
active	O
BePI	CHEMICAL
derivative	O
,	O
13	O
b	O
,	O
inhibited	O
the	O
cell	O
cycle	O
,	O
drove	O
cells	O
to	O
polyploidy	O
,	O
and	O
eventually	O
induced	O
apoptosis	O
.	O

It	O
exhibited	O
high	O
antiproliferative	O
activity	O
in	O
HeLa	O
cells	O
with	O
an	O
IC	O
(	O
50	O
)	O
value	O
of	O
63	O
nM	O
.	O

Relative	O
to	O
compounds	O
tested	O
in	O
clinical	O
trials	O
,	O
this	O
antiproliferative	O
potency	O
places	O
13	O
b	O
among	O
the	O
top	O
10	O
aurora	GENE-N
kinase	GENE-N
inhibitors	O
.	O

Our	O
results	O
justify	O
further	O
in	O
vivo	O
evaluation	O
in	O
preclinical	O
animal	O
models	O
of	O
cancer	O
.	O
TGIF	GENE-N
inhibits	O
retinoid	CHEMICAL
signaling	O
.	O
Modulation	O
of	O
epidermal	GENE-Y
growth	GENE-Y
factor	GENE-Y
receptor	GENE-Y
in	O
endocrine-resistant	O
,	O
oestrogen	CHEMICAL
receptor-positive	O
breast	O
cancer	O
.	O
Cotrimoxazole	O
,	O
an	O
association	O
of	O
trimethoprim	CHEMICAL
and	O
sulfamethoxazole	CHEMICAL
,	O
and	O
dapsone	CHEMICAL
,	O
are	O
mainstays	O
for	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
Pneumocystis	O
pneumonia	O
(	O
PcP	O
)	O
.	O

The	O
inability	O
to	O
culture	O
Pneumocystis	O
prevents	O
routine	O
susceptibility	O
testing	O
and	O
detection	O
of	O
drug	O
resistance	O
.	O

Instead	O
,	O
molecular	O
techniques	O
have	O
been	O
used	O
to	O
detect	O
Pneumocystis	GENE-Y
jiroveci	GENE-Y
dihydropteroate	CHEMICAL
synthase	O
(	O
DHPS	GENE-Y
)	O
mutations	O
that	O
cause	O
sulfa	CHEMICAL
resistance	O
in	O
other	O
microorganisms	O
.	O

The	O
most	O
frequent	O
DHPS	GENE-Y
mutations	O
occur	O
at	O
nucleotide	CHEMICAL
positions	O
165	O
and	O
171	O
,	O
which	O
lead	O
to	O
an	O
amino	CHEMICAL
acid	CHEMICAL
change	O
at	O
positions	O
55	O
and	O
57	O
.	O

Several	O
studies	O
suggest	O
that	O
these	O
mutations	O
are	O
associated	O
with	O
the	O
failure	O
of	O
chemoprophylaxis	O
for	O
PcP	O
.	O

The	O
aim	O
was	O
to	O
establish	O
the	O
frequency	O
and	O
characteristics	O
of	O
P	GENE-Y
jiroveci	GENE-Y
DHPS	GENE-Y
mutations	O
among	O
colonized	O
individuals	O
and	O
PcP	O
patients	O
from	O
Spain	O
.	O

A	O
total	O
of	O
50	O
colonized	O
individuals	O
and	O
25	O
PcP	O
patients	O
were	O
studied	O
.	O

DHPS	GENE-Y
polymorphisms	O
were	O
identified	O
by	O
restriction	O
fragment	O
length	O
polymorphism	O
assay	O
.	O

The	O
analysis	O
provided	O
a	O
rate	O
of	O
28%	O
of	O
DHPS	GENE-Y
gene	O
mutations	O
in	O
our	O
population	O
,	O
with	O
the	O
presence	O
of	O
all	O
possible	O
polymorphisms	O
described	O
.	O

The	O
presence	O
of	O
mutations	O
was	O
higher	O
in	O
PcP	O
patients	O
than	O
in	O
colonized	O
subjects	O
(	O
40%	O
vs	O
22%	O
)	O
,	O
probably	O
because	O
of	O
the	O
chemoprophylaxis	O
used	O
in	O
PcP	O
patients	O
.	O

The	O
comparison	O
between	O
patients	O
with	O
and	O
without	O
DHPS	GENE-Y
mutations	O
did	O
not	O
show	O
statistical	O
differences	O
due	O
to	O
age	O
,	O
sex	O
,	O
steroid	O
use	O
,	O
sulfa	CHEMICAL
drug	CHEMICAL
exposure	O
,	O
or	O
smoking	O
.	O

A	O
high	O
rate	O
of	O
DHPS	GENE-Y
mutations	O
in	O
our	O
area	O
of	O
Spain	O
,	O
not	O
only	O
confined	O
to	O
patients	O
previously	O
exposed	O
to	O
sulfa	CHEMICAL
drugs	CHEMICAL
,	O
is	O
shown	O
in	O
this	O
study	O
.	O

As	O
well	O
as	O
PcP	O
patients	O
,	O
colonized	O
individuals	O
who	O
harbor	O
P	O
jiroveci	O
strains	O
with	O
DHPS	GENE-Y
mutations	O
could	O
play	O
a	O
major	O
role	O
in	O
the	O
transmission	O
cycle	O
of	O
these	O
mutations	O
,	O
representing	O
a	O
reservoir	O
and	O
source	O
of	O
infection	O
for	O
susceptible	O
individuals	O
.	O

Further	O
research	O
is	O
thus	O
warranted	O
to	O
assess	O
the	O
true	O
scope	O
of	O
the	O
problem	O
and	O
to	O
design	O
rational	O
preventive	O
strategies	O
.	O
The	O
ATP-sensitive	O
potassium	CHEMICAL
(	O
KATP	O
)	O
channels	O
in	O
pancreatic	O
beta	O
cells	O
are	O
critical	O
in	O
the	O
regulation	O
of	O
glucose-induced	O
insulin	GENE-Y
secretion	O
.	O

Although	O
electrophysiological	O
studies	O
provide	O
clues	O
to	O
the	O
complex	O
control	O
of	O
KATP	GENE-N
channels	GENE-N
by	O
ATP	CHEMICAL
,	O
MgADP	CHEMICAL
,	O
and	O
pharmacological	O
agents	O
,	O
the	O
molecular	O
mechanism	O
of	O
KATP-channel	GENE-N
regulation	O
remains	O
unclear	O
.	O

The	O
KATP	GENE-N
channel	GENE-N
is	O
a	O
heterooligomeric	O
complex	O
of	O
SUR1	GENE-Y
subunits	O
of	O
the	O
ATP-binding-cassette	O
superfamily	O
with	O
two	O
nucleotide-binding	O
folds	O
(	O
NBF1	GENE-N
and	O
NBF2	GENE-N
)	O
and	O
the	O
pore-forming	O
Kir6	GENE-Y
.	GENE-Y
2	GENE-Y
subunits	O
.	O

Here	O
,	O
we	O
report	O
that	O
MgATP	CHEMICAL
and	O
MgADP	CHEMICAL
,	O
but	O
not	O
the	O
Mg	CHEMICAL
salt	O
of	O
gamma-thio-ATP	CHEMICAL
,	O
stabilize	O
the	O
binding	O
of	O
prebound	O
8-azido-	CHEMICAL
[	CHEMICAL
alpha-32P	CHEMICAL
]	CHEMICAL
ATP	CHEMICAL
to	O
SUR1	GENE-Y
.	O

Mutation	O
in	O
the	O
Walker	GENE-N
A	GENE-N
and	GENE-N
B	GENE-N
motifs	GENE-N
of	O
NBF2	GENE-N
of	O
SUR1	GENE-Y
abolished	O
this	O
stabilizing	O
effect	O
of	O
MgADP	CHEMICAL
.	O

These	O
results	O
suggest	O
that	O
SUR1	GENE-Y
binds	O
8-azido-ATP	CHEMICAL
strongly	O
at	O
NBF1	GENE-N
and	O
that	O
MgADP	CHEMICAL
,	O
either	O
by	O
direct	O
binding	O
to	O
NBF2	GENE-N
or	O
by	O
hydrolysis	O
of	O
bound	O
MgATP	CHEMICAL
at	O
NBF2	GENE-N
,	O
stabilizes	O
prebound	O
8-azido-ATP	CHEMICAL
binding	O
at	O
NBF1	GENE-N
.	O

The	O
sulfonylurea	CHEMICAL
glibenclamide	CHEMICAL
caused	O
release	O
of	O
prebound	O
8-azido-	CHEMICAL
[	CHEMICAL
alpha-32P	CHEMICAL
]	CHEMICAL
ATP	CHEMICAL
from	O
SUR1	GENE-Y
in	O
the	O
presence	O
of	O
MgADP	CHEMICAL
or	O
MgATP	CHEMICAL
in	O
a	O
concentration-dependent	O
manner	O
.	O

This	O
direct	O
biochemical	O
evidence	O
of	O
cooperative	O
interaction	O
in	O
nucleotide	CHEMICAL
binding	O
of	O
the	O
two	O
NBFs	GENE-N
of	O
SUR1	GENE-Y
suggests	O
that	O
glibenclamide	CHEMICAL
both	O
blocks	O
this	O
cooperative	O
binding	O
of	O
ATP	CHEMICAL
and	O
MgADP	CHEMICAL
and	O
,	O
in	O
cooperation	O
with	O
the	O
MgADP	CHEMICAL
bound	O
at	O
NBF2	GENE-N
,	O
causes	O
ATP	CHEMICAL
to	O
be	O
released	O
from	O
NBF1	GENE-N
.	O
OBJECTIVETo	O
assess	O
glucose-lowering	O
mechanisms	O
of	O
sitagliptin	CHEMICAL
(	O
S	O
)	O
,	O
metformin	CHEMICAL
(	O
M	O
)	O
,	O
and	O
the	O
two	O
combined	O
(	O
M	O
+	O
S	O
)	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODSWe	O
randomized	O
16	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
to	O
four	O
6-week	O
treatments	O
with	O
placebo	O
(	O
P	O
)	O
,	O
M	O
,	O
S	O
,	O
and	O
M	O
+	O
S	O
.	O

After	O
each	O
period	O
,	O
subjects	O
received	O
a	O
6-h	O
meal	O
tolerance	O
test	O
(	O
MTT	CHEMICAL
)	O
with	O
[	CHEMICAL
(	CHEMICAL
14	CHEMICAL
)	CHEMICAL
C	CHEMICAL
]	CHEMICAL
glucose	CHEMICAL
to	O
calculate	O
glucose	CHEMICAL
kinetics	O
.	O

Fasting	O
plasma	O
glucose	CHEMICAL
(	O
FPG	O
)	O
,	O
fasting	O
plasma	O
insulin	GENE-Y
,	O
C-peptide	O
(	O
insulin	GENE-Y
secretory	O
rate	O
[	O
ISR	O
]	O
)	O
,	O
fasting	O
plasma	O
glucagon	GENE-Y
,	O
and	O
bioactive	O
glucagon-like	GENE-Y
peptide	GENE-Y
(	O
GLP-1	GENE-Y
)	O
and	O
gastrointestinal	GENE-Y
insulinotropic	GENE-Y
peptide	GENE-Y
(	O
GIP	GENE-Y
)	O
was	O
measured	O
.	O

RESULTSFPG	O
decreased	O
from	O
P	O
,	O
160	O
±	O
4	O
to	O
M	O
,	O
150	O
±	O
4;	O
S	O
,	O
154	O
±	O
4;	O
and	O
M	O
+	O
S	O
,	O
125	O
±	O
3	O
mg	O
/	O
dL	O
.	O

Mean	O
post-MTT	CHEMICAL
PG	O
decreased	O
from	O
P	O
,	O
207	O
±	O
5	O
to	O
M	O
,	O
191	O
±	O
4;	O
S	O
,	O
195	O
±	O
4;	O
and	O
M	O
+	O
S	O
,	O
161	O
±	O
3	O
mg	O
/	O
dL	O
(	O
P	O
<	O
0	O
.	O
01	O
]	O
.	O

The	O
increase	O
in	O
mean	O
post-MTT	CHEMICAL
plasma	O
insulin	GENE-Y
and	O
in	O
ISR	O
was	O
similar	O
in	O
P	O
,	O
M	O
,	O
and	O
S	O
and	O
slightly	O
greater	O
in	O
M	O
+	O
S	O
.	O

Fasting	O
plasma	O
glucagon	GENE-Y
was	O
equal	O
(	O
∼65-75	O
pg	O
/	O
mL	O
)	O
with	O
all	O
treatments	O
,	O
but	O
there	O
was	O
a	O
significant	O
drop	O
during	O
the	O
initial	O
120	O
min	O
with	O
S	O
24%	O
and	O
M	O
+	O
S	O
34%	O
(	O
both	O
P	O
<	O
0	O
.	O
05	O
)	O
vs	O
.	O

P	O
17%	O
and	O
M	O
16%	O
.	O

Fasting	O
and	O
mean	O
post-MTT	CHEMICAL
plasma	O
bioactive	O
GLP-1	GENE-Y
were	O
higher	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
after	O
S	O
and	O
M	O
+	O
S	O
vs	O
.	O

M	O
and	O
P	O
.	O

Basal	O
endogenous	O
glucose	CHEMICAL
production	O
(	O
EGP	O
)	O
fell	O
from	O
P	O
2	O
.	O
0	O
±	O
0	O
.	O
1	O
to	O
S	O
1	O
.	O
8	O
±	O
0	O
.	O
1	O
mg	O
/	O
kg	O
⋅	O
min	O
,	O
M	O
1	O
.	O
8	O
±	O
0	O
.	O
2	O
mg	O
/	O
kg	O
⋅	O
min	O
[	O
both	O
P	O
<	O
0	O
.	O
05	O
vs	O
.	O

P	O
)	O
,	O
and	O
M	O
+	O
S	O
1	O
.	O
5	O
±	O
0	O
.	O
1	O
mg	O
/	O
kg	O
⋅	O
min	O
(	O
P	O
<	O
0	O
.	O
01	O
vs	O
.	O

P	O
)	O
.	O

Although	O
the	O
EGP	O
slope	O
of	O
decline	O
was	O
faster	O
in	O
M	O
and	O
M	O
+	O
S	O
vs	O
.	O

S	O
,	O
all	O
had	O
comparable	O
greater	O
post-MTT	O
EGP	O
inhibition	O
vs	O
.	O

P	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONSM	O
+	O
S	O
combined	O
produce	O
additive	O
effects	O
to	O
1	O
)	O
reduce	O
FPG	O
and	O
postmeal	O
PG	O
,	O
2	O
)	O
augment	O
GLP-1	GENE-Y
secretion	O
and	O
β-cell	O
function	O
,	O
3	O
)	O
decrease	O
plasma	O
glucagon	GENE-Y
,	O
and	O
4	O
)	O
inhibit	O
fasting	O
and	O
postmeal	O
EGP	O
compared	O
with	O
M	O
or	O
S	O
monotherapy	O
.	O
Circulating	O
protein	O
biomarkers	O
of	O
pharmacodynamic	O
activity	O
of	O
sunitinib	CHEMICAL
in	O
patients	O
with	O
metastatic	O
renal	O
cell	O
carcinoma	O
:	O
modulation	O
of	O
VEGF	GENE-Y
and	O
VEGF-related	O
proteins	O
.	O
Molecular	O
identification	O
of	O
high	O
and	O
low	O
affinity	O
receptors	O
for	O
nicotinic	CHEMICAL
acid	CHEMICAL
.	O
Conformation	O
Guides	O
Molecular	O
Efficacy	O
in	O
Docking	O
Screens	O
of	O
Activated	O
β-2	GENE-Y
Adrenergic	GENE-Y
G	GENE-Y
Protein	GENE-Y
Coupled	GENE-Y
Receptor	GENE-Y
.	O
It	O
is	O
well	O
known	O
that	O
UVB	O
(	O
290-320	O
nm	O
)	O
induces	O
inflammation	O
in	O
skin	O
by	O
the	O
transcription	O
and	O
release	O
of	O
cytokines	GENE-N
and	O
chemokines	GENE-N
from	O
skin	O
keratinocytes	O
.	O

In	O
addition	O
,	O
it	O
is	O
considered	O
that	O
intracellular	O
reactive	O
oxygen	CHEMICAL
species	O
(	O
ROS	O
)	O
plays	O
an	O
important	O
role	O
in	O
UVB-induced	O
inflammatory	O
response	O
in	O
the	O
skin	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
vitamin	CHEMICAL
C	CHEMICAL
,	O
a	O
potent	O
antioxidant	O
,	O
on	O
the	O
regulation	O
of	O
UVB-induced	O
skin	O
inflammation	O
via	O
the	O
modulation	O
of	O
chemokines	GENE-N
production	O
.	O

Vitamin	CHEMICAL
C	CHEMICAL
uptake	O
into	O
keratinocytes	O
is	O
increased	O
by	O
UVB	O
irradiation	O
in	O
a	O
time-	O
and	O
dose-dependent	O
manner	O
through	O
the	O
translocation	O
of	O
sodium-dependent	O
vitamin	CHEMICAL
C	CHEMICAL
transporter-1	O
(	O
SVCT-1	GENE-Y
)	O
,	O
a	O
vitamin	CHEMICAL
C-specific	O
transporter	O
,	O
from	O
the	O
cytosol	O
to	O
the	O
membrane	O
.	O

To	O
evaluate	O
the	O
effect	O
of	O
vitamin	CHEMICAL
C	CHEMICAL
on	O
the	O
chemokine	GENE-N
mRNA	O
expression	O
,	O
we	O
performed	O
RNase	O
protection	O
assay	O
.	O

As	O
a	O
result	O
,	O
there	O
was	O
a	O
remarkable	O
change	O
in	O
chemokine	GENE-N
mRNA	O
expression	O
,	O
especially	O
IL-8	GENE-Y
and	O
monocyte	GENE-Y
chemoattractant	GENE-Y
protein	GENE-Y
(	GENE-Y
MCP	GENE-Y
)	GENE-Y
-1	GENE-Y
expression	O
.	O

In	O
addition	O
,	O
increased	O
IL-8	GENE-Y
and	O
MCP-1	GENE-Y
mRNA	O
expressions	O
were	O
suppressed	O
by	O
vitamin	CHEMICAL
C	CHEMICAL
treatment	O
.	O

We	O
also	O
confirmed	O
the	O
results	O
of	O
protein	O
levels	O
measured	O
by	O
ELISA	O
.	O

Taken	O
together	O
,	O
vitamin	CHEMICAL
C	CHEMICAL
uptake	O
is	O
increased	O
in	O
UVB-irradiated	O
keratinocytes	O
through	O
the	O
translocation	O
of	O
SVCT-1	GENE-Y
and	O
regulates	O
inflammatory	O
response	O
in	O
the	O
skin	O
via	O
the	O
downregulation	O
of	O
IL-8	GENE-Y
and	O
MCP-1	GENE-Y
production	O
.	O
The	O
use	O
of	O
leflunomide	CHEMICAL
in	O
the	O
treatment	O
of	O
rheumatoid	O
arthritis	O
:	O
an	O
experimental	O
and	O
clinical	O
review	O
.	O
We	O
investigated	O
the	O
basis	O
for	O
the	O
difference	O
in	O
the	O
cardiotonic	O
effects	O
of	O
the	O
PDE3	GENE-N
inhibitors	O
cilostazol	CHEMICAL
and	O
milrinone	CHEMICAL
in	O
the	O
rabbit	O
heart	O
.	O

Cilostazol	CHEMICAL
displayed	O
greater	O
selectivity	O
than	O
milrinone	CHEMICAL
for	O
inhibition	O
of	O
cAMP-PDE	O
activity	O
in	O
microsomal	O
vs	O
cytosolic	O
fractions	O
from	O
rabbit	O
heart	O
.	O

This	O
difference	O
was	O
due	O
to	O
the	O
inhibition	O
of	O
significantly	O
less	O
cytosolic	O
cAMP-PDE	O
activity	O
by	O
cilostazol	CHEMICAL
compared	O
to	O
milrinone	CHEMICAL
.	O

A	O
combination	O
of	O
cilostazol	CHEMICAL
(	O
>15	O
microM	O
)	O
and	O
the	O
PDE4	GENE-N
selective	O
inhibitor	O
,	O
rolipram	CHEMICAL
(	O
5	O
microM	O
)	O
,	O
inhibited	O
levels	O
of	O
cytosolic	O
cAMP-PDE	O
activity	O
similar	O
to	O
those	O
inhibited	O
by	O
milrinone	CHEMICAL
on	O
its	O
own	O
.	O

This	O
suggested	O
that	O
milrinone	CHEMICAL
inhibited	O
PDE4	GENE-N
in	O
addition	O
to	O
PDE3	GENE-N
activity	O
.	O

In	O
isolated	O
rabbit	O
cardiomyocytes	O
,	O
milrinone	CHEMICAL
(	O
>10	O
microM	O
)	O
caused	O
greater	O
elevations	O
in	O
intracellular	O
cAMP	CHEMICAL
and	O
calcium	CHEMICAL
than	O
cilostazol	CHEMICAL
.	O

In	O
the	O
presence	O
of	O
rolipram	CHEMICAL
,	O
however	O
,	O
the	O
cAMP	CHEMICAL
and	O
calcium	CHEMICAL
elevating	O
effects	O
of	O
cilostazol	CHEMICAL
and	O
milrinone	CHEMICAL
were	O
similar	O
.	O

Therefore	O
,	O
in	O
rabbit	O
heart	O
,	O
partial	O
inhibition	O
of	O
PDE4	GENE-N
by	O
milrinone	CHEMICAL
contributed	O
to	O
greater	O
increases	O
in	O
cardiomyocyte	O
cAMP	CHEMICAL
and	O
calcium	CHEMICAL
levels	O
than	O
cilostazol	CHEMICAL
.	O

PDE4	GENE-N
activity	O
in	O
failing	O
human	O
heart	O
was	O
lower	O
than	O
in	O
rabbit	O
heart	O
and	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
inhibition	O
of	O
human	GENE-N
cytosolic	GENE-N
cAMP-PDE	O
by	O
cilostazol	CHEMICAL
and	O
milrinone	CHEMICAL
.	O

Our	O
results	O
suggest	O
that	O
in	O
normal	O
rabbit	O
heart	O
inhibition	O
of	O
PDE4	GENE-N
by	O
milrinone	CHEMICAL
may	O
partly	O
contribute	O
to	O
the	O
greater	O
cardiotonic	O
effect	O
of	O
milrinone	CHEMICAL
when	O
compared	O
to	O
cilostazol	CHEMICAL
.	O

However	O
,	O
the	O
lower	O
level	O
of	O
PDE4	GENE-N
activity	O
in	O
failing	O
human	O
heart	O
suggests	O
that	O
factors	O
other	O
than	O
inhibition	O
of	O
PDE4	GENE-N
by	O
milrinone	CHEMICAL
may	O
contribute	O
to	O
differences	O
in	O
cardiotonic	O
action	O
when	O
compared	O
to	O
cilostazol	CHEMICAL
.	O
Highly	O
oriented	O
pyrolytic	O
graphite	CHEMICAL
characterized	O
by	O
a	O
low	O
misorientation	O
of	O
crystallites	O
is	O
fluorinated	O
using	O
a	O
gaseous	O
mixture	O
of	O
BrF	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
with	O
Br	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
at	O
room	O
temperature	O
.	O

The	O
golden-colored	O
product	O
,	O
easily	O
delaminating	O
into	O
micrometer-size	O
transparent	O
flakes	O
,	O
is	O
an	O
intercalation	O
compound	O
where	O
Br	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
molecules	O
are	O
hosted	O
between	O
fluorinated	O
graphene	CHEMICAL
layers	O
of	O
approximate	O
C	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
F	CHEMICAL
composition	O
.	O

To	O
unravel	O
the	O
chemical	O
bonding	O
in	O
semifluorinated	O
graphite	CHEMICAL
,	O
we	O
apply	O
angle-resolved	O
near-edge	O
X-ray	O
absorption	O
fine	O
structure	O
(	O
NEXAFS	O
)	O
spectroscopy	O
and	O
quantum-chemical	O
modeling	O
.	O

The	O
strong	O
angular	O
dependence	O
of	O
the	O
CK	O
and	O
FK	O
edge	O
NEXAFS	O
spectra	O
on	O
the	O
incident	O
radiation	O
indicates	O
that	O
room-temperature-produced	O
graphite	CHEMICAL
fluoride	CHEMICAL
is	O
a	O
highly	O
anisotropic	O
material	O
,	O
where	O
half	O
of	O
the	O
carbon	CHEMICAL
atoms	O
are	O
covalently	O
bonded	O
with	O
fluorine	CHEMICAL
,	O
while	O
the	O
rest	O
of	O
the	O
carbon	O
atoms	O
preserve	O
π	O
electrons	O
.	O

Comparison	O
of	O
the	O
experimental	O
CK	O
edge	O
spectrum	O
with	O
theoretical	O
spectra	O
plotted	O
for	O
C	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
F	CHEMICAL
models	O
reveals	O
that	O
fluorine	CHEMICAL
atoms	O
are	O
more	O
likely	O
to	O
form	O
chains	O
.	O

This	O
conclusion	O
agrees	O
with	O
the	O
atomic	O
force	O
microscopy	O
observation	O
of	O
a	O
chain-like	O
pattern	O
on	O
the	O
surface	O
of	O
graphite	CHEMICAL
fluoride	CHEMICAL
layers	O
.	O
The	O
active	O
metabolite	O
of	O
Clopidogrel	CHEMICAL
disrupts	O
P2Y12	GENE-Y
receptor	O
oligomers	O
and	O
partitions	O
them	O
out	O
of	O
lipid	O
rafts	O
.	O
Antihypertensive	O
and	O
metabolic	O
effects	O
of	O
high-dose	O
olmesartan	CHEMICAL
and	O
telmisartan	CHEMICAL
in	O
type	O
2	O
diabetes	O
patients	O
with	O
hypertension	O
.	O
Thionamides	CHEMICAL
,	O
inhibitors	O
of	O
the	O
thyroid	GENE-Y
peroxidase-mediated	O
iodination	O
,	O
are	O
clinically	O
used	O
in	O
the	O
treatment	O
of	O
hyperthyroidism	O
.	O

However	O
,	O
the	O
use	O
of	O
antithyroid	O
drugs	O
is	O
associated	O
with	O
immunomodulatory	O
effects	O
,	O
and	O
recent	O
studies	O
with	O
thionamide-related	O
heterocyclic	CHEMICAL
thioderivates	CHEMICAL
demonstrated	O
direct	O
anti-inflammatory	O
and	O
immunosuppressive	O
properties	O
.	O

Using	O
primary	O
human	O
T-lymphocytes	O
,	O
we	O
show	O
that	O
the	O
heterocyclic	CHEMICAL
thionamides	CHEMICAL
carbimazole	CHEMICAL
and	O
propylthiouracil	CHEMICAL
inhibit	O
synthesis	O
of	O
the	O
proinflammatory	O
cytokines	GENE-N
tumor	GENE-Y
necrosis	GENE-Y
factor	GENE-Y
(	GENE-Y
TNF	GENE-Y
)	GENE-Y
alpha	GENE-Y
and	O
interferon	GENE-Y
(	GENE-Y
IFN	GENE-Y
)	GENE-Y
gamma	GENE-Y
.	O

In	O
addition	O
,	O
DNA	O
binding	O
of	O
nuclear	GENE-N
factor	GENE-N
(	GENE-N
NF	GENE-N
)	GENE-N
-kappaB	GENE-N
,	O
a	O
proinflammatory	O
transcription	O
factor	O
that	O
regulates	O
both	O
TNFalpha	GENE-Y
and	O
IFNgamma	GENE-Y
synthesis	O
,	O
and	O
NF-kappaB-dependent	O
reporter	O
gene	O
expression	O
were	O
reduced	O
.	O

Abrogation	O
of	O
NF-kappaB	GENE-N
activity	O
was	O
accompanied	O
by	O
reduced	O
phosphorylation	O
and	O
proteolytic	O
degradation	O
of	O
inhibitor	GENE-Y
of	GENE-Y
kappaB	GENE-Y
(	GENE-Y
IkappaB	GENE-Y
)	GENE-Y
alpha	GENE-Y
,	O
the	O
inhibitory	O
subunit	O
of	O
the	O
NF-kappaB	GENE-N
complex	O
.	O

Carbimazole	CHEMICAL
inhibited	O
NF-kappaB	GENE-N
via	O
the	O
small	O
GTPase	GENE-N
Rac-1	GENE-Y
,	O
whereas	O
propylthiouracil	CHEMICAL
inhibited	O
the	O
phosphorylation	O
of	O
IkappaBalpha	GENE-Y
by	O
its	O
kinase	GENE-N
inhibitor	GENE-Y
of	GENE-Y
kappaB	GENE-Y
kinase	GENE-Y
alpha	GENE-Y
.	O

Methimazole	O
had	O
no	O
effect	O
on	O
NF-kappaB	GENE-N
induction	O
,	O
demonstrating	O
that	O
drug	O
potency	O
correlated	O
with	O
the	O
chemical	O
reactivity	O
of	O
the	O
thionamide-associated	O
sulfur	CHEMICAL
group	O
.	O

Taken	O
together	O
,	O
our	O
data	O
demonstrate	O
that	O
thioureylenes	CHEMICAL
with	O
a	O
common	O
,	O
heterocyclic	CHEMICAL
structure	O
inhibit	O
inflammation	O
and	O
immune	O
function	O
via	O
the	O
NF-kappaB	GENE-N
pathway	O
.	O

Our	O
results	O
may	O
explain	O
the	O
observed	O
remission	O
of	O
proinflammatory	O
diseases	O
upon	O
antithyroid	O
therapy	O
in	O
hyperthyroid	O
patients	O
.	O

The	O
use	O
of	O
related	O
thioureylenes	CHEMICAL
may	O
provide	O
a	O
new	O
therapeutic	O
basis	O
for	O
the	O
development	O
and	O
application	O
of	O
anti-inflammatory	O
compounds	O
.	O
Chemical	O
constituents	O
of	O
Euphorbia	O
hyberna	O
L	O
.	O

(	O
Euphorbiaceae	O
)	O
.	O
Reduced	O
amplitude	O
of	O
the	O
cortical	O
P300	GENE-Y
event-related	O
potential	O
(	O
ERP	O
)	O
component	O
during	O
response	O
inhibition	O
is	O
associated	O
with	O
vulnerability	O
to	O
alcohol	CHEMICAL
use	O
disorders	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
an	O
experimental	O
manipulation	O
of	O
response	O
conflict	O
on	O
the	O
amplitude	O
of	O
the	O
P300	GENE-Y
component	O
during	O
response	O
inhibition	O
,	O
and	O
examined	O
whether	O
individual	O
differences	O
in	O
the	O
amplitude	O
of	O
this	O
P300	GENE-Y
component	O
would	O
predict	O
voluntary	O
ad-lib	O
alcohol	CHEMICAL
consumption	O
,	O
in	O
social	O
drinkers	O
.	O

Using	O
a	O
repeated	O
measures	O
design	O
,	O
16	O
participants	O
performed	O
a	O
stop-signal	O
task	O
after	O
receiving	O
instructions	O
that	O
either	O
emphasised	O
or	O
de-emphasised	O
response	O
conflict	O
while	O
their	O
electroencephalogram	O
(	O
EEG	O
)	O
was	O
concurrently	O
recorded	O
,	O
before	O
their	O
ad-lib	O
drinking	O
was	O
assessed	O
.	O

Results	O
revealed	O
that	O
task	O
instructions	O
had	O
the	O
predicted	O
effects	O
on	O
behavioural	O
indices	O
of	O
response	O
inhibition	O
and	O
the	O
associated	O
P300	GENE-Y
components	O
.	O

Most	O
importantly	O
,	O
individual	O
differences	O
in	O
the	O
amplitude	O
of	O
P300	GENE-Y
subcomponents	O
during	O
response	O
inhibition	O
were	O
negatively	O
correlated	O
with	O
ad-lib	O
alcohol	CHEMICAL
consumption	O
.	O

Results	O
provide	O
the	O
first	O
experimental	O
support	O
for	O
theoretical	O
models	O
that	O
posit	O
that	O
reduced	O
amplitude	O
of	O
the	O
P300	GENE-Y
during	O
response	O
inhibition	O
is	O
associated	O
with	O
alcohol-seeking	O
behaviour	O
in	O
humans	O
.	O
Maturation	O
of	O
neuromuscular	O
transmission	O
during	O
early	O
development	O
in	O
zebrafish	O
.	O
Male	O
and	O
female	O
Sprague-Dawley	O
rats	O
were	O
administered	O
quinpirole	CHEMICAL
(	O
1	O
mg	O
/	O
kg	O
,	O
i	O
.	O

p	O
.	O

)	O
or	O
saline	O
once	O
daily	O
from	O
postnatal	O
day	O
(	O
P	O
)	O
1	O
to	O
P21	O
.	O

This	O
drug	O
treatment	O
has	O
been	O
shown	O
to	O
produce	O
long-term	O
priming	O
of	O
the	O
D2	GENE-Y
receptor	GENE-Y
.	O

Beginning	O
on	O
P62	O
,	O
rats	O
were	O
administered	O
the	O
atypical	O
antipsychotic	O
olanzapine	CHEMICAL
(	O
2	O
.	O
5	O
mg	O
/	O
kg	O
)	O
or	O
saline	O
twice	O
daily	O
(	O
i	O
.	O

p	O
.	O

)	O
for	O
28	O
days	O
.	O

One	O
day	O
after	O
olanzapine	CHEMICAL
treatment	O
ceased	O
,	O
rats	O
were	O
tested	O
on	O
the	O
place	O
and	O
match-to-place	O
versions	O
of	O
the	O
Morris	O
water	O
maze	O
(	O
MWM	O
)	O
for	O
seven	O
consecutive	O
days	O
.	O

Dopamine	GENE-Y
D2	O
receptor	O
priming	O
was	O
verified	O
through	O
a	O
yawning	O
behavioural	O
test	O
,	O
a	O
D2	GENE-Y
receptor-mediated	O
event	O
,	O
before	O
olanzapine	CHEMICAL
was	O
administered	O
as	O
well	O
as	O
after	O
olanzapine	CHEMICAL
treatment	O
and	O
behavioural	O
testing	O
were	O
complete	O
.	O

Results	O
showed	O
that	O
neonatal	O
quinpirole	CHEMICAL
treatment	O
induced	O
D2	GENE-Y
priming	O
that	O
was	O
eliminated	O
by	O
olanzapine	CHEMICAL
treatment	O
.	O

On	O
the	O
MWM	O
place	O
version	O
,	O
D2-primed	O
rats	O
demonstrated	O
a	O
significant	O
impairment	O
that	O
was	O
eliminated	O
by	O
olanzapine	CHEMICAL
treatment	O
,	O
but	O
olanzapine	CHEMICAL
treatment	O
to	O
animals	O
neonatally	O
treated	O
with	O
saline	O
produced	O
a	O
significant	O
deficit	O
on	O
the	O
place	O
version	O
of	O
the	O
MWM	O
.	O

There	O
were	O
no	O
significant	O
deficits	O
on	O
the	O
match-to-place	O
version	O
.	O

Brain	O
tissue	O
analyses	O
revealed	O
that	O
neonatal	O
quinpirole	CHEMICAL
treatment	O
produced	O
a	O
significant	O
decrease	O
in	O
hippocampal	O
NGF	GENE-Y
,	O
BDNF	GENE-Y
and	O
ChAT	GENE-Y
that	O
was	O
eliminated	O
by	O
olanzapine	CHEMICAL
treatment	O
.	O

Neonatal	O
quinpirole	CHEMICAL
treatment	O
produced	O
a	O
significant	O
decrease	O
in	O
BDNF	GENE-Y
and	O
ChAT	GENE-Y
in	O
the	O
frontal	O
cortex	O
that	O
was	O
unaffected	O
by	O
olanzapine	CHEMICAL
treatment	O
.	O

These	O
results	O
show	O
that	O
olanzapine	CHEMICAL
eliminates	O
D2	GENE-Y
receptor	GENE-Y
priming	O
and	O
cognitive	O
impairment	O
and	O
also	O
alleviates	O
decreases	O
in	O
neurotrophins	O
and	O
acetylcholinergic	O
markers	O
produced	O
by	O
D2	GENE-Y
priming	O
in	O
the	O
hippocampus	O
.	O
Cigarette	O
smoking	O
causes	O
cellular	O
oxidative	O
stress	O
resulting	O
in	O
inflammatory	O
diseases	O
of	O
lung	O
wherein	O
transcription	O
factor	O
NF-κB	GENE-N
plays	O
an	O
important	O
role	O
.	O

It	O
is	O
possible	O
that	O
vitamin	CHEMICAL
C	CHEMICAL
,	O
an	O
antioxidant	O
,	O
may	O
prevent	O
cigarette	O
smoke	O
(	O
CS	O
)	O
-induced	O
NF-κB	GENE-N
activation	O
that	O
involves	O
degradation	O
of	O
I-κBε	GENE-Y
and	O
nuclear	O
translocation	O
of	O
c-Rel	GENE-Y
/	O
p50	GENE-Y
in	O
alveolar	O
epithelial	O
cells	O
.	O

Therefore	O
,	O
to	O
examine	O
the	O
hypothesis	O
,	O
we	O
verified	O
the	O
effect	O
of	O
vitamin	CHEMICAL
C	CHEMICAL
on	O
CS-induced	O
expression	O
of	O
NF-κB	GENE-N
driven	O
luciferase	O
reporter	O
and	O
NF-κB	GENE-N
binding	O
at	O
its	O
target	O
DNA	O
by	O
EMSA	O
in	O
alveolar	O
epithelial	O
A549	O
cells	O
.	O

We	O
also	O
examined	O
the	O
level	O
of	O
I-κBε	GENE-Y
and	O
sub-cellular	O
distribution	O
of	O
c-Rel	GENE-Y
by	O
western	O
blotting	O
and	O
immunofluorescence	O
respectively	O
in	O
CSE-treated	O
A549	O
cells	O
with	O
or	O
without	O
vitamin	CHEMICAL
C	CHEMICAL
pretreatment	O
.	O

We	O
observed	O
a	O
significant	O
reduction	O
in	O
CSE	O
induced	O
luciferase	O
expression	O
,	O
NF-κB	GENE-N
DNA	O
binding	O
,	O
I-κBε	GENE-Y
degradation	O
and	O
c-Rel	GENE-Y
nuclear	O
translocation	O
in	O
cells	O
pretreated	O
with	O
vitamin	CHEMICAL
C	CHEMICAL
.	O

To	O
further	O
validate	O
the	O
result	O
,	O
we	O
examined	O
sub-cellular	O
distribution	O
of	O
c-Rel	GENE-Y
in	O
lungs	O
of	O
CS-exposed	O
guinea	O
pigs	O
treated	O
or	O
untreated	O
with	O
vitamin	CHEMICAL
C	CHEMICAL
.	O

Result	O
showed	O
that	O
vitamin	CHEMICAL
C	CHEMICAL
treatment	O
resulted	O
in	O
markedly	O
reduced	O
c-Rel	GENE-Y
nuclear	O
translocation	O
.	O

All	O
these	O
results	O
demonstrate	O
that	O
vitamin	CHEMICAL
C	CHEMICAL
prevents	O
CS	O
(	O
E	O
)	O
-induced	O
NF-κB	GENE-N
activation	O
and	O
thus	O
it	O
could	O
be	O
used	O
for	O
the	O
prevention	O
of	O
CS-induced	O
inflammatory	O
diseases	O
.	O
Phillyrin	CHEMICAL
attenuates	O
high	O
glucose-induced	O
lipid	O
accumulation	O
in	O
human	O
HepG2	O
hepatocytes	O
through	O
the	O
activation	O
of	O
LKB1	GENE-Y
/	O
AMP-activated	O
protein	O
kinase-dependent	O
signalling	O
.	O
[	O
Heteologous	O
expression	O
of	O
Mortierella	GENE-Y
isabellina	GENE-Y
delta6	GENE-Y
-fatty	CHEMICAL
acid	CHEMICAL
desaturase	O
gene	O
in	O
soybean	O
]	O
.	O
Carbonic	GENE-N
anhydrase	GENE-N
inhibitors	O
.	O

Inhibition	O
of	O
mammalian	GENE-N
isoforms	GENE-N
I-XIV	GENE-N
with	O
a	O
series	O
of	O
natural	O
product	O
polyphenols	CHEMICAL
and	O
phenolic	CHEMICAL
acids	CHEMICAL
.	O
The	O
increased	O
number	O
of	O
Leydig	O
cells	O
by	O
di	CHEMICAL
(	CHEMICAL
2-ethylhexyl	CHEMICAL
)	CHEMICAL
phthalate	CHEMICAL
comes	O
from	O
the	O
differentiation	O
of	O
stem	O
cells	O
into	O
Leydig	O
cell	O
lineage	O
in	O
the	O
adult	O
rat	O
testis	O
.	O
Development	O
of	O
hypoxia-inducible	GENE-Y
factor	GENE-Y
(	GENE-Y
HIF	GENE-Y
)	GENE-Y
-1α	GENE-Y
inhibitors	O
:	O
effect	O
of	O
ortho-carborane	CHEMICAL
substituents	O
on	O
HIF	GENE-N
transcriptional	O
activity	O
under	O
hypoxia	O
.	O
Effects	O
of	O
labor	O
and	O
delivery	O
on	O
fibrinolysis	O
.	O
Blockade	O
of	O
LTC4	CHEMICAL
synthesis	O
caused	O
by	O
additive	O
inhibition	O
of	O
gIV-PLA2	GENE-N
phosphorylation	O
:	O
Effect	O
of	O
salmeterol	CHEMICAL
and	O
PDE4	GENE-N
inhibition	O
in	O
human	O
eosinophils	O
.	O
To	O
evaluate	O
the	O
cytokine	GENE-N
balance	O
and	O
enzymatic	O
alterations	O
induced	O
by	O
environmental	O
pesticide	O
exposure	O
during	O
pregnancy	O
,	O
this	O
transversal	O
study	O
explored	O
placentas	O
derived	O
from	O
non-exposed	O
women	O
(	O
control	O
group-CG	O
)	O
,	O
and	O
from	O
women	O
living	O
in	O
a	O
rural	O
area	O
(	O
rural	O
group-RG	O
)	O
,	O
collected	O
during	O
intensive	O
organophosphate	CHEMICAL
(	O
OP	O
)	O
pesticide	O
spraying	O
season	O
(	O
RG-SS	O
)	O
and	O
during	O
non-spraying	O
season	O
(	O
RG-NSS	O
)	O
.	O

The	O
exposure	O
biomarkers	O
blood	O
cholinesterase	GENE-Y
and	O
placental	O
carboxylesterase	GENE-N
(	O
CaE	GENE-N
)	O
were	O
significantly	O
decreased	O
in	O
RG-SS	O
.	O

Among	O
the	O
cytokines	GENE-N
studied	O
IL-8	GENE-Y
,	O
IL-6	GENE-Y
,	O
TNFα	GENE-Y
,	O
IL-10	GENE-Y
,	O
TGFβ	GENE-Y
and	O
IL-13	GENE-Y
,	O
the	O
expression	O
frequency	O
of	O
IL-13	GENE-Y
increased	O
in	O
RG-SS	O
.	O

Arginase	GENE-N
and	O
ornithine	CHEMICAL
decarboxylase	O
(	O
ODC	GENE-Y
)	O
enzymes	O
were	O
induced	O
in	O
syncytiotrophoblast	O
and	O
endothelial	O
cells	O
.	O

Interestingly	O
,	O
the	O
decrease	O
in	O
CaE	GENE-N
activity	O
was	O
associated	O
with	O
arginase	O
and	O
ODC	GENE-Y
activity	O
induction	O
.	O

These	O
findings	O
suggest	O
that	O
environmental	O
pesticide	O
exposure	O
impacts	O
the	O
placenta	O
by	O
increasing	O
the	O
expression	O
frequency	O
of	O
the	O
anti-inflammatory	O
cytokine	GENE-N
IL-13	GENE-Y
,	O
which	O
may	O
be	O
related	O
to	O
the	O
up-regulation	O
of	O
enzymes	O
implicated	O
in	O
tissue	O
repair	O
.	O
3D	O
ligand-based	O
virtual	O
screening	O
was	O
employed	O
to	O
identify	O
novel	O
scaffolds	O
for	O
cannabinoid	GENE-N
receptor	GENE-N
ligand	O
development	O
.	O

A	O
total	O
of	O
112	O
compounds	O
with	O
diverse	O
structures	O
were	O
purchased	O
from	O
commercial	O
vendors	O
.	O

12	O
CB1	GENE-Y
receptor	O
antagonists	O
/	O
inverse	O
agonists	O
and	O
10	O
CB2	GENE-Y
receptor	O
agonists	O
were	O
identified	O
in	O
vitro	O
.	O

One	O
of	O
the	O
CB2	GENE-Y
agonists	O
,	O
N-cyclopentyl-4-ethoxy-6-	CHEMICAL
(	CHEMICAL
4-methylpiperidin-1-yl	CHEMICAL
)	CHEMICAL
-1	CHEMICAL
,	CHEMICAL
3	CHEMICAL
,	CHEMICAL
5-triazin-2-amine	CHEMICAL
(	O
19	O
,	O
-logEC	O
(	O
50	O
)	O
=	O
7	O
.	O
5	O
,	O
E	O
(	O
max	O
)	O
=	O
255%	O
)	O
was	O
selected	O
for	O
further	O
development	O
.	O

As	O
far	O
as	O
we	O
are	O
aware	O
,	O
the	O
compound's	O
1	CHEMICAL
,	CHEMICAL
3	CHEMICAL
,	CHEMICAL
5-triazine	CHEMICAL
scaffold	O
represents	O
a	O
new	O
core	O
structure	O
for	O
CB2	GENE-Y
agonists	O
.	O

A	O
library	O
of	O
fifty-seven	O
2	CHEMICAL
,	CHEMICAL
4	CHEMICAL
,	CHEMICAL
6-trisubstituted-1	CHEMICAL
,	CHEMICAL
3	CHEMICAL
,	CHEMICAL
5-triazines	CHEMICAL
was	O
created	O
to	O
clarify	O
the	O
structure-activity	O
relationship	O
study	O
of	O
the	O
analogs	O
.	O
We	O
have	O
previously	O
reported	O
that	O
NADPH	CHEMICAL
oxidase	O
2	O
(	O
Nox2	GENE-Y
)	O
is	O
up-regulated	O
in	O
spinal	O
cord	O
microglia	O
after	O
spinal	O
nerve	O
injury	O
,	O
demonstrating	O
that	O
it	O
is	O
critical	O
for	O
microglia	O
activation	O
and	O
subsequent	O
pain	O
hypersensitivity	O
.	O

However	O
,	O
the	O
mechanisms	O
and	O
molecules	O
involved	O
in	O
Nox2	GENE-Y
induction	O
have	O
not	O
been	O
elucidated	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
Toll-like	GENE-N
receptors	GENE-N
(	O
TLRs	GENE-N
)	O
are	O
involved	O
in	O
nerve	O
injury-induced	O
spinal	O
cord	O
microglia	O
activation	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
role	O
of	O
TLR	GENE-N
in	O
Nox2	GENE-Y
expression	O
in	O
spinal	O
cord	O
microglia	O
after	O
peripheral	O
nerve	O
injury	O
.	O

Studies	O
using	O
TLR	GENE-N
knock-out	O
mice	O
have	O
shown	O
that	O
nerve	O
injury-induced	O
microglial	O
Nox2	GENE-Y
up-regulation	O
is	O
abrogated	O
in	O
TLR2	GENE-Y
but	O
not	O
in	O
TLR3	GENE-N
or	GENE-N
-4	GENE-N
knock-out	O
mice	O
.	O

Intrathecal	O
injection	O
of	O
lipoteichoic	O
acid	O
,	O
a	O
TLR2	GENE-Y
agonist	O
,	O
induced	O
Nox2	GENE-Y
expression	O
in	O
spinal	O
cord	O
microglia	O
both	O
at	O
the	O
mRNA	O
and	O
protein	O
levels	O
.	O

Similarly	O
,	O
lipoteichoic	O
acid	O
stimulation	O
induced	O
Nox2	GENE-Y
expression	O
and	O
reactive	O
oxygen	CHEMICAL
species	O
production	O
in	O
primary	O
spinal	O
cord	O
glial	O
cells	O
in	O
vitro	O
.	O

Studies	O
on	O
intracellular	O
signaling	O
pathways	O
indicate	O
that	O
NF-κB	GENE-N
and	O
p38	GENE-N
MAP	GENE-N
kinase	GENE-N
activation	O
is	O
required	O
for	O
TLR2-induced	O
Nox2	GENE-Y
expression	O
in	O
glial	O
cells	O
.	O

Conclusively	O
,	O
our	O
data	O
show	O
that	O
TLR2	GENE-Y
mediates	O
nerve	O
injury-induced	O
Nox2	GENE-Y
gene	O
expression	O
in	O
spinal	O
cord	O
microglia	O
via	O
NF-κB	GENE-N
and	O
p38	GENE-N
activation	O
and	O
thereby	O
may	O
contribute	O
to	O
spinal	O
cord	O
microglia	O
activation	O
.	O
Substrates	O
of	O
IAP	GENE-N
ubiquitin	GENE-N
ligases	GENE-N
identified	O
with	O
a	O
designed	O
orthogonal	O
E3	GENE-N
ligase	GENE-N
,	O
the	O
NEDDylator	O
.	O
A	O
dose-ranging	O
study	O
was	O
performed	O
to	O
compare	O
the	O
beta	GENE-Y
1-adrenoceptor	GENE-Y
selectivity	O
of	O
bisoprolol	CHEMICAL
with	O
that	O
of	O
atenolol	CHEMICAL
and	O
nadolol	CHEMICAL
.	O

Seven	O
normal	O
subjects	O
(	O
mean	O
age	O
26	O
y	O
)	O
were	O
given	O
single	O
oral	O
doses	O
of	O
bisoprolol	CHEMICAL
5	O
mg	O
(	O
B5	O
)	O
,	O
10	O
mg	O
(	O
B10	O
)	O
,	O
20	O
mg	O
(	O
B20	O
)	O
;	O
atenolol	CHEMICAL
50	O
mg	O
(	O
A50	O
)	O
,	O
100	O
mg	O
(	O
A100	O
)	O
;	O
nadolol	CHEMICAL
40	O
mg	O
(	O
N40	O
)	O
;	O
and	O
placebo	O
(	O
PL	O
)	O
,	O
in	O
a	O
single	O
blind	O
randomised	O
cross-over	O
design	O
.	O

Beta	GENE-Y
2-adrenoceptor	GENE-Y
responses	O
were	O
assessed	O
by	O
attenuation	O
of	O
finger	O
tremor	O
and	O
cardiovascular	O
responses	O
to	O
graded	O
isoprenaline	CHEMICAL
infusions	O
.	O

Dose-response	O
curves	O
were	O
constructed	O
,	O
and	O
doses	O
of	O
isoprenaline	CHEMICAL
required	O
to	O
increase	O
finger	O
tremor	O
by	O
100%	O
(	O
IT100	O
)	O
,	O
heart	O
rate	O
by	O
25	O
beats	O
/	O
min	O
(	O
IH25	O
)	O
,	O
SBP	O
by	O
25	O
mmHg	O
(	O
IS25	O
)	O
,	O
cardiac	O
output	O
by	O
35%	O
(	O
IC35	O
)	O
,	O
and	O
decrease	O
DBP	O
by	O
10	O
mmHg	O
(	O
ID10	O
)	O
,	O
after	O
each	O
treatment	O
were	O
calculated	O
.	O

These	O
indices	O
were	O
compared	O
with	O
placebo	O
response	O
and	O
expressed	O
as	O
dose-ratios	O
.	O

Exercise	O
heart	O
rate	O
(	O
EHR	O
)	O
was	O
used	O
to	O
assess	O
beta	GENE-Y
1-adrenoceptor	GENE-Y
blockade	O
.	O

There	O
were	O
dose-related	O
increases	O
in	O
plasma	O
concentrations	O
of	O
bisoprolol	CHEMICAL
and	O
atenolol	CHEMICAL
.	O

Reduction	O
of	O
EHR	O
was	O
significantly	O
less	O
with	O
B5	O
(	O
16	O
.	O
8%	O
)	O
in	O
comparison	O
with	O
all	O
other	O
treatments	O
:	O
B10	O
21	O
.	O
9%	O
,	O
B20	O
23	O
.	O
1%;	O
A50	O
22	O
.	O
5%	O
,	O
A100	O
22	O
.	O
6%;	O
N40	O
22	O
.	O
9%	O
.	O

There	O
were	O
small	O
but	O
significant	O
reductions	O
in	O
isoprenaline-induced	O
tachycardia	O
with	O
bisoprolol	CHEMICAL
and	O
atenolol	CHEMICAL
,	O
although	O
mean	O
dose-ratios	O
were	O
considerably	O
less	O
in	O
comparison	O
with	O
N40	O
(	O
IH25	O
dose-ratios	O
)	O
:	O
B5	O
2	O
.	O
55	O
,	O
B10	O
3	O
.	O
18	O
,	O
B20	O
3	O
.	O
93	O
,	O
A50	O
2	O
.	O
91	O
,	O
A100	O
4	O
.	O
89	O
,	O
N40	O
17	O
.	O
23	O
.	O

There	O
were	O
similar	O
patterns	O
for	O
the	O
other	O
isoprenaline	CHEMICAL
responses	O
.	O

These	O
results	O
show	O
that	O
conventional	O
doses	O
of	O
bisoprolol	CHEMICAL
(	O
10	O
mg	O
)	O
and	O
atenolol	CHEMICAL
(	O
50	O
mg	O
)	O
produced	O
equal	O
antagonism	O
of	O
beta	GENE-N
1	GENE-N
and	GENE-N
beta	GENE-N
2-adrenoceptors	GENE-N
,	O
and	O
therefore	O
possess	O
equal	O
degrees	O
of	O
beta	GENE-Y
1-adrenoceptor	GENE-Y
selectivity	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Hypertrophic	O
effect	O
of	O
selective	O
beta	GENE-Y
(	GENE-Y
1	GENE-Y
)	GENE-Y
-adrenoceptor	GENE-Y
stimulation	O
on	O
ventricular	O
cardiomyocytes	O
from	O
adult	O
rat	O
.	O
Regulation	O
of	O
adenosine	CHEMICAL
levels	O
during	O
cerebral	O
ischemia	O
.	O
Cyclooxygenase	GENE-N
and	O
5-lipoxygenase	GENE-Y
inhibitors	O
protect	O
against	O
mononuclear	O
phagocyte	O
neurotoxicity	O
.	O
The	O
L-type	GENE-N
calcium	CHEMICAL
channel	O
(	O
LTCC	GENE-N
)	O
isoforms	O
Ca	GENE-Y
(	GENE-Y
v	GENE-Y
)	GENE-Y
1	GENE-Y
.	GENE-Y
2	GENE-Y
and	O
Ca	GENE-Y
(	GENE-Y
v	GENE-Y
)	GENE-Y
1	GENE-Y
.	GENE-Y
3	GENE-Y
display	O
similar	O
1	CHEMICAL
,	CHEMICAL
4-dihydropyridine	CHEMICAL
(	O
DHP	CHEMICAL
)	O
binding	O
properties	O
and	O
are	O
both	O
expressed	O
in	O
mammalian	O
brain	O
.	O

Recent	O
work	O
implicates	O
Ca	GENE-Y
(	GENE-Y
v	GENE-Y
)	GENE-Y
1	GENE-Y
.	GENE-Y
3	GENE-Y
channels	O
as	O
interesting	O
drug	O
targets	O
,	O
but	O
no	O
isoform-selective	O
modulators	O
exist	O
.	O

It	O
is	O
also	O
unknown	O
to	O
what	O
extent	O
Ca	GENE-Y
(	GENE-Y
v	GENE-Y
)	GENE-Y
1	GENE-Y
.	GENE-Y
1	GENE-Y
and	O
Ca	GENE-Y
(	GENE-Y
v	GENE-Y
)	GENE-Y
1	GENE-Y
.	GENE-Y
4	GENE-Y
contribute	O
to	O
L-type-specific	O
DHP	CHEMICAL
binding	O
activity	O
in	O
brain	O
.	O

To	O
address	O
this	O
question	O
and	O
to	O
determine	O
whether	O
DHPs	O
can	O
discriminate	O
between	O
Ca	GENE-Y
(	GENE-Y
v	GENE-Y
)	GENE-Y
1	GENE-Y
.	GENE-Y
2	GENE-Y
and	O
Ca	GENE-Y
(	GENE-Y
v	GENE-Y
)	GENE-Y
1	GENE-Y
.	GENE-Y
3	GENE-Y
binding	O
pockets	O
,	O
we	O
combined	O
radioreceptor	O
assays	O
and	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
qPCR	O
)	O
.	O

We	O
bred	O
double	O
mutants	O
(	O
Ca	GENE-N
(	GENE-N
v	GENE-N
)	GENE-N
-DM	O
)	O
from	O
mice	O
expressing	O
mutant	O
Ca	GENE-Y
(	GENE-Y
v	GENE-Y
)	GENE-Y
1	GENE-Y
.	GENE-Y
2	GENE-Y
channels	O
[	O
Ca	GENE-Y
(	GENE-Y
v	GENE-Y
)	GENE-Y
1	GENE-Y
.	GENE-Y
2DHP	O
(	O
-	O
/	O
-	O
)	O
]	O
lacking	O
high	O
affinity	O
for	O
DHPs	O
and	O
from	O
Ca	GENE-Y
(	GENE-Y
v	GENE-Y
)	GENE-Y
1	GENE-Y
.	GENE-Y
3	GENE-Y
knockouts	O
[	O
Ca	GENE-Y
(	GENE-Y
v	GENE-Y
)	GENE-Y
1	GENE-Y
.	GENE-Y
3	GENE-Y
(	O
-	O
/	O
-	O
)	O
]	O
.	O

(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-	CHEMICAL
[	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
H	CHEMICAL
]	CHEMICAL
isradipine	CHEMICAL
binding	O
to	O
Ca	GENE-Y
(	GENE-Y
v	GENE-Y
)	GENE-Y
1	GENE-Y
.	GENE-Y
2DHP	O
(	O
-	O
/	O
-	O
)	O
and	O
Ca	GENE-N
(	GENE-N
v	GENE-N
)	GENE-N
-DM	O
brains	O
was	O
reduced	O
to	O
15	O
.	O
1	O
and	O
4	O
.	O
4%	O
of	O
wild	O
type	O
,	O
respectively	O
,	O
indicating	O
that	O
Ca	GENE-Y
(	GENE-Y
v	GENE-Y
)	GENE-Y
1	GENE-Y
.	GENE-Y
3	GENE-Y
accounts	O
for	O
10	O
.	O
7%	O
of	O
brain	O
LTCCs	GENE-N
.	O

qPCR	O
revealed	O
that	O
Ca	GENE-Y
(	GENE-Y
v	GENE-Y
)	GENE-Y
1	GENE-Y
.	GENE-Y
1	GENE-Y
and	O
Ca	GENE-Y
(	GENE-Y
v	GENE-Y
)	GENE-Y
1	GENE-Y
.	GENE-Y
4	GENE-Y
alpha	GENE-Y
(	GENE-Y
1	GENE-Y
)	GENE-Y
subunits	O
comprised	O
0	O
.	O
08%	O
of	O
the	O
LTCC	GENE-N
transcripts	O
in	O
mouse	O
whole	O
brain	O
,	O
suggesting	O
that	O
they	O
cannot	O
account	O
for	O
the	O
residual	O
binding	O
.	O

Instead	O
,	O
this	O
could	O
be	O
explained	O
by	O
low-affinity	O
binding	O
(	O
127-fold	O
K	O
(	O
d	O
)	O
increase	O
)	O
to	O
the	O
mutated	O
Ca	GENE-Y
(	GENE-Y
v	GENE-Y
)	GENE-Y
1	GENE-Y
.	GENE-Y
2	GENE-Y
channels	O
.	O

Inhibition	O
of	O
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-	CHEMICAL
[	CHEMICAL
(	CHEMICAL
3	CHEMICAL
)	CHEMICAL
H	CHEMICAL
]	CHEMICAL
isradipine	CHEMICAL
binding	O
to	O
Ca	GENE-Y
(	GENE-Y
v	GENE-Y
)	GENE-Y
1	GENE-Y
.	GENE-Y
2DHP	O
(	O
-	O
/	O
-	O
)	O
(	O
predominantly	O
Ca	GENE-Y
(	GENE-Y
v	GENE-Y
)	GENE-Y
1	GENE-Y
.	GENE-Y
3	GENE-Y
)	O
and	O
wild-type	O
(	O
predominantly	O
Ca	GENE-Y
(	GENE-Y
v	GENE-Y
)	GENE-Y
1	GENE-Y
.	GENE-Y
2	GENE-Y
)	O
brain	O
membranes	O
by	O
unlabeled	O
DHPs	O
revealed	O
a	O
3-	O
to	O
4-fold	O
selectivity	O
of	O
nitrendipine	CHEMICAL
and	O
nifedipine	CHEMICAL
for	O
the	O
Ca	GENE-Y
(	GENE-Y
v	GENE-Y
)	GENE-Y
1	GENE-Y
.	GENE-Y
2	GENE-Y
binding	O
pocket	O
,	O
a	O
finding	O
further	O
confirmed	O
with	O
heterologously	O
expressed	O
channels	O
.	O

This	O
suggests	O
that	O
small	O
differences	O
in	O
their	O
binding	O
pockets	O
may	O
allow	O
development	O
of	O
isoform-selective	O
modulators	O
for	O
LTCCs	GENE-N
and	O
that	O
,	O
because	O
of	O
their	O
very	O
low	O
expression	O
,	O
Ca	GENE-Y
(	GENE-Y
v	GENE-Y
)	GENE-Y
1	GENE-Y
.	GENE-Y
1	GENE-Y
and	O
Ca	GENE-Y
(	GENE-Y
v	GENE-Y
)	GENE-Y
1	GENE-Y
.	GENE-Y
4	GENE-Y
are	O
unlikely	O
to	O
serve	O
as	O
drug	O
targets	O
to	O
treat	O
CNS	O
diseases	O
.	O
PURPOSE	O
:	O
To	O
determine	O
whether	O
the	O
temperature-sensitive	O
rat	O
retinal	CHEMICAL
pigment	O
epithelial	O
cell	O
line	O
(	O
RPE-J	O
)	O
express	O
mRNA	O
transcripts	O
for	O
apolipoprotein	GENE-N
(	O
apo	GENE-N
)	O
and	O
microsomal	GENE-Y
triglyceride	CHEMICAL
transfer	O
protein	O
(	O
MTP	GENE-Y
)	O
and	O
whether	O
it	O
can	O
synthesize	O
and	O
secrete	O
neutral	O
lipids	O
.	O

METHODS	O
:	O
RPE-J	O
cells	O
were	O
cultured	O
in	O
plastic	O
tissue	O
culture	O
flasks	O
and	O
on	O
Transwell	O
filters	O
.	O

RT-PCR	O
was	O
used	O
to	O
check	O
mRNA	O
expression	O
.	O

Phagocytosis	O
was	O
checked	O
by	O
adding	O
FITC-labeled	O
beads	O
and	O
measuring	O
the	O
intensity	O
of	O
the	O
fluorescence	O
.	O

Lipids	O
were	O
extracted	O
from	O
cultured	O
cells	O
that	O
were	O
fed	O
photoreceptor	O
outer	O
segments	O
(	O
OS	O
)	O
for	O
24h;	O
thin	O
layer	O
chromatography	O
and	O
enzymatic	O
fluorimetry	O
were	O
used	O
to	O
assay	O
lipid	O
content	O
.	O

Cells	O
were	O
supplemented	O
with	O
[	CHEMICAL
3H	CHEMICAL
]	CHEMICAL
-oleate	CHEMICAL
(	O
5000	O
dpm	O
/	O
nmole	O
)	O
bound	O
to	O
1	O
.	O
5%	O
fatty	CHEMICAL
acid	CHEMICAL
free	O
bovine	GENE-Y
serum	GENE-Y
albumin	GENE-Y
in	O
order	O
to	O
permit	O
detection	O
of	O
the	O
new	O
synthesis	O
and	O
secretion	O
of	O
neutral	O
lipids	O
.	O

RESULTS	O
:	O
RPE-J	O
cells	O
express	O
mRNA	O
for	O
apoA-I	GENE-Y
,	O
apoA-II	GENE-Y
,	O
apoB	GENE-Y
,	O
apoC-I	GENE-N
,	GENE-N
II	GENE-N
,	GENE-N
III	GENE-N
,	O
and	O
apo	GENE-Y
E	GENE-Y
,	O
as	O
well	O
as	O
MTP	GENE-Y
.	O

RPE-J	O
cells	O
can	O
phagocytose	O
OS	O
and	O
beads	O
.	O

OS-fed	O
RPE-J	O
cells	O
,	O
relative	O
to	O
untreated	O
cells	O
,	O
have	O
5	O
.	O
8	O
times	O
more	O
triglyceride	CHEMICAL
,	O
2	O
.	O
6	O
times	O
more	O
phospholipid	O
,	O
1	O
.	O
5	O
times	O
more	O
unesterified	O
cholesterol	CHEMICAL
,	O
and	O
0	O
.	O
3	O
times	O
more	O
esterified	O
cholesterol	CHEMICAL
.	O

Radiolabeled	O
neutral	O
lipid	O
is	O
detected	O
in	O
cells	O
and	O
medium	O
.	O

All	O
lipids	O
increase	O
in	O
cells	O
with	O
time	O
but	O
only	O
phospholipid	O
increases	O
in	O
the	O
medium	O
with	O
time	O
.	O

CONCLUSIONS	O
:	O
RPE	O
cells	O
express	O
genes	O
encoding	O
apolipoproteins	GENE-N
and	O
MTP	GENE-Y
.	O

Following	O
the	O
ingestion	O
of	O
OS	O
,	O
RPE-J	O
cells	O
contain	O
abundant	O
lipid	O
.	O

Following	O
the	O
ingestion	O
of	O
long-chain	O
fatty	O
acids	O
,	O
RPE-J	O
cells	O
can	O
synthesize	O
neutral	O
lipids	O
.	O

Future	O
experiments	O
will	O
determine	O
if	O
RPE-J	O
cells	O
secrete	O
lipoprotein	GENE-N
particles	O
containing	O
these	O
proteins	O
.	O
Human	GENE-Y
follistatin	GENE-Y
is	O
a	O
regulatory	O
glycoprotein	O
with	O
widespread	O
biologic	O
functions	O
,	O
including	O
antiinflammatory	O
activities	O
,	O
wound-healing	O
properties	O
,	O
and	O
muscle-stimulating	O
effects	O
.	O

The	O
role	O
of	O
follistatin	GENE-Y
in	O
a	O
wide	O
range	O
of	O
biologic	O
activities	O
shows	O
promise	O
for	O
potential	O
clinical	O
application	O
,	O
which	O
has	O
prompted	O
considerable	O
interest	O
in	O
the	O
investigation	O
of	O
the	O
protein	O
as	O
a	O
potential	O
disease-modifying	O
agent	O
.	O

In	O
spite	O
of	O
this	O
potential	O
,	O
the	O
development	O
of	O
follistatin	GENE-Y
as	O
a	O
broad	O
use	O
biotherapeutic	O
has	O
been	O
severely	O
hindered	O
by	O
a	O
poor	O
understanding	O
and	O
characterization	O
of	O
its	O
pharmacokinetic	O
/	O
pharmacodynamic	O
(	O
PK	O
/	O
PD	O
)	O
relationships	O
.	O

Therefore	O
,	O
to	O
better	O
define	O
these	O
relationships	O
,	O
we	O
performed	O
in-depth	O
analyses	O
of	O
the	O
PK	O
/	O
PD	O
relationships	O
of	O
native	O
follistatin-315	GENE-Y
(	O
FST315	GENE-Y
)	O
.	O

Our	O
data	O
indicate	O
that	O
the	O
intrinsic	O
PK	O
/	O
PD	O
properties	O
of	O
native	O
FST315	GENE-Y
are	O
poorly	O
suited	O
for	O
acting	O
as	O
a	O
parentally	O
administered	O
biotherapeutic	O
with	O
broad	O
systemic	O
effects	O
.	O

Here	O
,	O
we	O
leveraged	O
protein	O
engineering	O
to	O
modify	O
the	O
PK	O
characteristics	O
of	O
the	O
native	O
molecule	O
by	O
fusing	O
FST315	GENE-Y
to	O
a	O
murine	GENE-N
IgG	GENE-N
(	GENE-N
1	GENE-N
)	GENE-N
Fc	GENE-N
and	O
removing	O
the	O
intrinsic	O
heparan	O
sulfate-binding	O
activity	O
of	O
follistatin	GENE-Y
.	O

The	O
engineered	O
variant	O
molecule	O
had	O
~100-	O
and	O
~1600-fold	O
improvements	O
in	O
terminal	O
half-life	O
and	O
exposure	O
,	O
respectively	O
.	O

In	O
contrast	O
to	O
the	O
native	O
FST315	GENE-Y
,	O
the	O
variant	O
showed	O
a	O
robust	O
,	O
dose-dependent	O
pharmacological	O
effect	O
when	O
administered	O
subcutaneously	O
on	O
a	O
weekly	O
basis	O
in	O
mouse	O
models	O
of	O
muscle	O
atrophy	O
and	O
degeneration	O
.	O

These	O
studies	O
highlight	O
the	O
underappreciated	O
and	O
critical	O
relationship	O
between	O
optimizing	O
multiple	O
physical	O
and	O
chemical	O
properties	O
of	O
follistatin	GENE-Y
on	O
its	O
overall	O
PK	O
/	O
PD	O
profile	O
.	O

Moreover	O
,	O
our	O
findings	O
provide	O
the	O
first	O
documented	O
strategy	O
toward	O
the	O
development	O
of	O
a	O
follistatin	GENE-Y
therapeutic	O
with	O
potential	O
use	O
in	O
patients	O
affected	O
with	O
skeletal	O
muscle	O
diseases	O
.	O
The	O
V600E	GENE-N
BRAF	GENE-Y
kinase	GENE-N
mutation	O
,	O
which	O
activates	O
the	O
downstream	O
MAPK	GENE-N
signaling	O
pathway	O
,	O
commonly	O
occurs	O
in	O
about	O
8%	O
of	O
all	O
human	O
malignancies	O
and	O
about	O
50%	O
of	O
all	O
melanomas	O
.	O

In	O
this	O
study	O
,	O
we	O
employed	O
virtual	O
screening	O
and	O
chemical	O
synthesis	O
to	O
identify	O
a	O
series	O
of	O
N-	CHEMICAL
(	CHEMICAL
thiophen-2-yl	CHEMICAL
)	CHEMICAL
benzamide	CHEMICAL
derivatives	O
as	O
potent	O
BRAF	GENE-Y
(	O
V600E	GENE-N
)	O
inhibitors	O
.	O

Structure-activity	O
relationship	O
studies	O
of	O
these	O
derivatives	O
revealed	O
that	O
compounds	O
b40	O
and	O
b47	O
are	O
the	O
two	O
most	O
potent	O
BRAF	GENE-Y
(	O
V600E	GENE-N
)	O
inhibitors	O
in	O
this	O
series	O
.	O
Sphingolipids	O
are	O
well	O
established	O
effectors	O
of	O
signal	O
transduction	O
downstream	O
of	O
the	O
tumor	GENE-N
necrosis	GENE-N
factor	GENE-N
(	GENE-N
TNF	GENE-N
)	GENE-N
receptor	GENE-N
.	O

In	O
a	O
previous	O
study	O
,	O
we	O
showed	O
that	O
the	O
sphingosine	GENE-Y
kinase	O
/	O
sphingosine	CHEMICAL
1-phosphate	CHEMICAL
(	O
S1P	CHEMICAL
)	O
pathway	O
couples	O
TNF	GENE-N
receptor	GENE-N
to	O
induction	O
of	O
the	O
cyclooxygenase	GENE-Y
2	GENE-Y
gene	O
and	O
prostaglandin	CHEMICAL
synthesis	O
(	O
Pettus	O
,	O
B	O
.	O

J	O
.	O

,	O
Bielawski	O
,	O
J	O
.	O

,	O
Porcelli	O
,	O
A	O
.	O

M	O
.	O

,	O
Reames	O
,	O
D	O
.	O

L	O
.	O

,	O
Johnson	O
,	O
K	O
.	O

R	O
.	O

,	O
Morrow	O
,	O
J	O
.	O

,	O
Chalfant	O
,	O
C	O
.	O

E	O
.	O

,	O
Obeid	O
,	O
L	O
.	O

M	O
.	O

,	O
and	O
Hannun	O
,	O
Y	O
.	O

A	O
.	O

(	O
2003	O
)	O
FASEB	O
J	O
.	O

17	O
,	O
1411-1421	O
)	O
.	O

In	O
this	O
study	O
,	O
the	O
requirement	O
for	O
acid	GENE-Y
sphingomyelinase	GENE-Y
and	O
sphingomyelin	O
metabolites	O
in	O
the	O
TNFalpha	GENE-Y
/	O
prostaglandin	CHEMICAL
E	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
(	O
PGE	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
)	O
pathway	O
was	O
investigated	O
.	O

The	O
amphiphilic	O
compound	O
desipramine	CHEMICAL
,	O
a	O
frequently	O
employed	O
inhibitor	O
of	O
acid	GENE-Y
sphingomyelinase	GENE-Y
(	O
ASMase	GENE-Y
)	O
,	O
blocked	O
PGE	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
production	O
.	O

However	O
,	O
the	O
action	O
of	O
desipramine	CHEMICAL
was	O
independent	O
of	O
its	O
action	O
on	O
ASMase	GENE-Y
,	O
since	O
neither	O
genetic	O
loss	O
of	O
ASMase	GENE-Y
(	O
Niemann-Pick	O
fibroblasts	O
)	O
nor	O
knockdown	O
of	O
ASMase	GENE-Y
using	O
RNA	O
interference	O
affected	O
TNFalpha-induced	O
PGE	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
synthesis	O
.	O

Further	O
investigations	O
revealed	O
that	O
desipramine	CHEMICAL
down-regulated	O
acid	GENE-Y
ceramidase	GENE-Y
(	O
AC	GENE-Y
)	O
,	O
but	O
not	O
sphingosine	CHEMICAL
kinase	O
,	O
at	O
the	O
protein	O
level	O
.	O

This	O
resulted	O
in	O
a	O
time-dependent	O
drop	O
in	O
sphingosine	CHEMICAL
and	O
S1P	CHEMICAL
levels	O
.	O

Moreover	O
,	O
exogenous	O
administration	O
of	O
either	O
sphingosine	CHEMICAL
or	O
S1P	CHEMICAL
rescued	O
PGE	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
biosynthesis	O
after	O
desipramine	CHEMICAL
treatment	O
.	O

Interestingly	O
,	O
knockdown	O
of	O
endogenous	O
AC	GENE-Y
by	O
RNA	O
interference	O
attenuated	O
cyclooxygenase	GENE-Y
2	GENE-Y
induction	O
by	O
TNFalpha	GENE-Y
and	O
subsequent	O
PGE	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
biosynthesis	O
.	O

Taken	O
together	O
,	O
these	O
results	O
define	O
a	O
novel	O
role	O
for	O
AC	GENE-Y
in	O
the	O
TNFalpha	GENE-Y
/	O
PGE	CHEMICAL
(	CHEMICAL
2	CHEMICAL
)	CHEMICAL
pathway	O
.	O

In	O
addition	O
,	O
the	O
results	O
of	O
this	O
study	O
warrant	O
careful	O
reconsideration	O
of	O
desipramine	CHEMICAL
as	O
a	O
specific	O
inhibitor	O
for	O
ASMase	GENE-Y
.	O
The	O
effects	O
of	O
aluminium	CHEMICAL
lactate	CHEMICAL
(	O
Al-lactate	CHEMICAL
)	O
on	O
the	O
rat	O
cerebral	O
synaptosome	O
integral	O
proteins	O
adenosinetriphosphatase	GENE-N
(	O
ATPase	GENE-N
)	O
and	O
acetylcholinesterase	GENE-Y
(	O
AChE	GENE-Y
)	O
were	O
studied	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Coexposure	O
with	O
ethanol	CHEMICAL
(	O
EtOH	CHEMICAL
)	O
was	O
studied	O
in	O
both	O
situations	O
.	O

Isolation	O
of	O
synaptosomes	O
was	O
carried	O
out	O
using	O
isoosmotic	O
Percoll	O
gradients	O
.	O

In	O
in	O
vitro	O
experiments	O
,	O
the	O
synaptosomes	O
were	O
exposed	O
to	O
different	O
concentrations	O
of	O
Al-lactate	CHEMICAL
in	O
the	O
incubation	O
mixture	O
.	O

Al-lactate	CHEMICAL
caused	O
decreases	O
in	O
total	O
ATPase	GENE-N
and	O
AChE	GENE-Y
activities	O
concentration	O
dependently	O
.	O

The	O
decrease	O
in	O
ATP	CHEMICAL
activity	O
started	O
at	O
0	O
.	O
2	O
mM	O
concentration	O
,	O
and	O
concentration	O
for	O
the	O
50%	O
decrease	O
of	O
the	O
enzyme	O
activity	O
(	O
EC50	O
)	O
was	O
1	O
.	O
1	O
mM	O
.	O

The	O
decrease	O
in	O
AChE	GENE-Y
activity	O
started	O
at	O
5-10	O
mM	O
concentration	O
,	O
and	O
the	O
EC50	O
value	O
was	O
15	O
.	O
8	O
mM	O
.	O

Coexposure	O
with	O
ethanol	CHEMICAL
(	O
2	O
mM	O
)	O
increased	O
the	O
EC50	O
values	O
similarly	O
in	O
both	O
cases	O
.	O

After	O
90-day	O
oral	O
exposure	O
of	O
rats	O
to	O
Al-lactate	CHEMICAL
(	O
91	O
.	O
8	O
mg	O
/	O
kg	O
/	O
day	O
)	O
,	O
the	O
serum	O
aluminium	CHEMICAL
level	O
was	O
0	O
.	O
9-1	O
.	O
3	O
ptM	O
/	O
l	O
.	O

Coexposure	O
with	O
EtOH	CHEMICAL
(	O
3	O
.	O
0	O
g	O
/	O
kg	O
/	O
day	O
)	O
did	O
not	O
significantly	O
increase	O
the	O
blood	O
Al	O
(	O
0	O
.	O
7	O
2	O
.	O
2	O
pM	O
/	O
l	O
)	O
.	O

Aluminium	CHEMICAL
exposure	O
caused	O
a	O
decrease	O
in	O
the	O
blood	O
EtOH	CHEMICAL
concentration	O
(	O
0	O
.	O
6	O
mM	O
/	O
1	O
)	O
compared	O
with	O
blood	O
EtOH	CHEMICAL
(	O
12	O
.	O
3	O
mM	O
/	O
1	O
)	O
in	O
the	O
rats	O
exposed	O
to	O
ethanol	CHEMICAL
only	O
.	O

In	O
the	O
rats	O
studied	O
2	O
weeks	O
after	O
the	O
Al	O
exposure	O
,	O
the	O
activities	O
of	O
ATPase	GENE-N
and	O
AChE	GENE-Y
were	O
significantly	O
lower	O
than	O
in	O
the	O
rats	O
studied	O
immediately	O
after	O
the	O
exposure	O
.	O

Correspondingly	O
,	O
a	O
significant	O
decrease	O
in	O
AChE	GENE-Y
activity	O
was	O
found	O
in	O
Al	O
and	O
EtOH-exposed	O
rats	O
,	O
but	O
in	O
the	O
control	O
rats	O
there	O
were	O
no	O
differences	O
between	O
the	O
study	O
groups	O
.	O

Immediately	O
after	O
the	O
90-day	O
dosing	O
,	O
the	O
exposed	O
rats	O
did	O
not	O
differ	O
significantly	O
from	O
the	O
control	O
rats	O
.	O

Based	O
on	O
the	O
in	O
vitro	O
results	O
,	O
the	O
neural	O
membrane	O
integral	O
proteins	O
ATPase	GENE-N
and	O
AChE	GENE-Y
may	O
be	O
considered	O
as	O
targets	O
for	O
the	O
effects	O
of	O
aluminium	CHEMICAL
and	O
ethanol	CHEMICAL
.	O

Ninety-day	O
in	O
vivo	O
exposure	O
of	O
rats	O
to	O
aluminium	CHEMICAL
caused	O
decrease	O
in	O
ATPase	GENE-N
and	O
AChE	GENE-Y
activities	O
,	O
detectable	O
2	O
weeks	O
after	O
the	O
exposure	O
.	O
The	O
neurospecific	O
cholesterol	CHEMICAL
24-hydroxylase	O
converts	O
excess	O
brain	O
cholesterol	CHEMICAL
into	O
24S-hydroxycholesterol	CHEMICAL
(	O
24OHC	CHEMICAL
)	O
which	O
,	O
via	O
the	O
liver	GENE-N
X	GENE-N
receptor	GENE-N
(	O
LXR	GENE-N
)	O
,	O
can	O
increase	O
the	O
expression	O
and	O
synthesis	O
of	O
astrocyte	O
ApoE	GENE-Y
.	O

24OHC	CHEMICAL
effluxes	O
directly	O
from	O
brain	O
into	O
plasma	O
where	O
it	O
is	O
considered	O
an	O
indicator	O
of	O
brain	O
cholesterol	CHEMICAL
turnover	O
.	O

It	O
is	O
reduced	O
in	O
neurodegenerative	O
disease	O
states	O
proportionally	O
to	O
the	O
severity	O
of	O
disease	O
and	O
the	O
degree	O
of	O
brain	O
atrophy	O
.	O

In	O
the	O
early	O
phases	O
of	O
active	O
disease	O
,	O
a	O
higher	O
rate	O
of	O
turnover	O
may	O
result	O
in	O
transitory	O
increases	O
in	O
plasma	O
24OHC	CHEMICAL
.	O

Less	O
than	O
1%	O
of	O
the	O
total	O
brain	O
excretion	O
of	O
24OHC	CHEMICAL
occurs	O
via	O
the	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
whereas	O
almost	O
all	O
27-hydroxycholesterol	CHEMICAL
(	O
27OHC	CHEMICAL
)	O
excretion	O
is	O
dependent	O
on	O
the	O
function	O
of	O
the	O
blood-cerebrospinal	O
fluid	O
barrier	O
.	O

Iincreased	O
CSF	O
oxysterols	CHEMICAL
were	O
found	O
in	O
patients	O
with	O
neurodegenerative	O
and	O
neuroinflammatory	O
diseases	O
in	O
the	O
presence	O
of	O
barrier	O
dysfunction	O
.	O

In	O
neurodegeneration	O
,	O
free	O
cholesterol	CHEMICAL
released	O
from	O
dying	O
cells	O
may	O
engulf	O
neurons	O
.	O

Cholesterol	CHEMICAL
also	O
increases	O
Amyloid	GENE-Y
β	GENE-Y
(	O
Aβ	GENE-Y
)	O
deposition	O
and	O
tau	GENE-Y
pathology	O
.	O

ApoE	GENE-Y
,	O
24OHC	CHEMICAL
,	O
tau	GENE-Y
and	O
soluble	GENE-Y
APP	GENE-Y
were	O
correlated	O
in	O
Alzheimer	O
disease	O
(	O
AD	O
)	O
samples	O
.	O

Excess	O
of	O
cholesterol	CHEMICAL
converted	O
into	O
24OHC	CHEMICAL
may	O
up-regulate	O
ApoE	GENE-Y
synthesis	O
which	O
is	O
a	O
scavenger	O
for	O
Aβ	GENE-Y
and	O
Tau	GENE-Y
.	O

In	O
AD	O
this	O
protective	O
mechanism	O
seems	O
to	O
be	O
inefficient	O
,	O
probably	O
due	O
to	O
the	O
presence	O
of	O
high	O
concentrations	O
of	O
27OHC	CHEMICAL
,	O
microvascular	O
dysfunction	O
and	O
the	O
decreased	O
efficiency	O
of	O
ApoE4	GENE-Y
as	O
lipid	O
transporter	O
and	O
Aβ	GENE-Y
scavenger	O
.	O

24OHC	CHEMICAL
itself	O
was	O
cytotoxic	O
.	O

Analysis	O
of	O
side	O
chain	O
oxysterols	CHEMICAL
in	O
the	O
CSF	O
is	O
likely	O
to	O
provided	O
useful	O
information	O
about	O
cholesterol	CHEMICAL
metabolism	O
and	O
ApoE	GENE-Y
function	O
in	O
the	O
pathogenesis	O
of	O
AD	O
.	O
Preincubation	O
(	O
30	O
min	O
)	O
of	O
bovine	O
tracheal	O
smooth	O
muscle	O
with	O
various	O
concentrations	O
(	O
0	O
.	O
1	O
,	O
1	O
and	O
10	O
microM	O
)	O
of	O
fenoterol	CHEMICAL
decreased	O
isoprenaline-induced	O
maximal	O
relaxation	O
(	O
E	O
(	O
max	O
)	O
)	O
of	O
methacholine-contracted	O
preparations	O
in	O
a	O
concentration	O
dependent	O
fashion	O
,	O
indicating	O
desensitization	O
of	O
the	O
beta	GENE-Y
(	GENE-Y
2	GENE-Y
)	GENE-Y
-adrenoceptor	GENE-Y
.	O

Preincubation	O
with	O
1	O
microM	O
of	O
the	O
protein	GENE-N
kinase	GENE-N
C	GENE-N
(	O
PKC	GENE-N
)	O
activator	O
phorbol	CHEMICAL
12-myristate	CHEMICAL
13-acetate	CHEMICAL
(	O
PMA	CHEMICAL
)	O
caused	O
a	O
small	O
but	O
significant	O
decrease	O
in	O
isoprenaline-induced	O
E	O
(	O
max	O
)	O
,	O
indicating	O
activated	O
PKC-mediated	O
heterologous	O
beta	GENE-Y
(	GENE-Y
2	GENE-Y
)	GENE-Y
-adrenoceptor	GENE-Y
desensitization	O
.	O

To	O
investigate	O
the	O
capacity	O
of	O
activated	O
PKC	GENE-N
to	O
regulate	O
homologous	O
desensitization	O
,	O
we	O
incubated	O
the	O
smooth	O
muscle	O
strips	O
with	O
the	O
combination	O
of	O
both	O
1	O
microM	O
PMA	O
and	O
1	O
microM	O
fenoterol	CHEMICAL
.	O

This	O
combined	O
treatment	O
synergistically	O
decreased	O
the	O
isoprenaline-induced	O
maximal	O
relaxation	O
,	O
as	O
compared	O
to	O
the	O
individual	O
effects	O
of	O
PMA	CHEMICAL
and	O
fenoterol	CHEMICAL
alone	O
,	O
indicating	O
a	O
common	O
pathway	O
for	O
heterologous	O
and	O
homologous	O
desensitization	O
.	O

Moreover	O
,	O
the	O
specific	O
PKC-inhibitor	O
2-	CHEMICAL
[	CHEMICAL
1-	CHEMICAL
(	CHEMICAL
3-dimethylaminopropyl	CHEMICAL
)	CHEMICAL
-1H-indol-3-yl	CHEMICAL
]	CHEMICAL
-3-	CHEMICAL
(	CHEMICAL
1H-indol-3-yl	CHEMICAL
)	CHEMICAL
maleimide	CHEMICAL
(	O
GF	CHEMICAL
109203X	CHEMICAL
)	O
markedly	O
increased	O
the	O
potency	O
and	O
E	O
(	O
max	O
)	O
of	O
isoprenaline	CHEMICAL
for	O
all	O
conditions	O
used	O
,	O
including	O
control	O
conditions	O
,	O
and	O
the	O
synergistic	O
effects	O
of	O
PMA	CHEMICAL
and	O
fenoterol	CHEMICAL
were	O
completely	O
prevented	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	O
demonstrates	O
that	O
homologous	O
desensitization	O
of	O
the	O
beta	GENE-Y
(	GENE-Y
2	GENE-Y
)	GENE-Y
-adrenergic	GENE-Y
receptor	GENE-Y
can	O
be	O
enhanced	O
by	O
PKC	GENE-N
activation	O
.	O

For	O
the	O
first	O
time	O
we	O
have	O
provided	O
evidence	O
that	O
this	O
concept	O
is	O
functionally	O
operative	O
in	O
airway	O
smooth	O
muscle	O
,	O
and	O
it	O
may	O
explain	O
the	O
reduced	O
bronchodilator	O
response	O
to	O
beta	GENE-Y
(	GENE-Y
2	GENE-Y
)	GENE-Y
-adrenoceptor	GENE-Y
agonists	O
in	O
patients	O
with	O
asthma	O
during	O
a	O
severe	O
exacerbation	O
.	O
Inhibition	O
pathways	O
of	O
the	O
potent	O
organophosphate	CHEMICAL
CBDP	CHEMICAL
with	O
cholinesterases	GENE-Y
revealed	O
by	O
X-ray	O
crystallographic	O
snapshots	O
and	O
mass	O
spectrometry	O
.	O
Disrupted	O
cytoskeletal	O
homeostasis	O
,	O
astrogliosis	O
and	O
apoptotic	O
cell	O
death	O
in	O
the	O
cerebellum	O
of	O
preweaning	O
rats	O
injected	O
with	O
diphenyl	CHEMICAL
ditelluride	CHEMICAL
.	O
Investigating	O
the	O
enteroenteric	O
recirculation	O
of	O
apixaban	CHEMICAL
,	O
a	O
factor	GENE-N
Xa	GENE-N
inhibitor	O
:	O
administration	O
of	O
activated	O
charcoal	O
to	O
bile	O
duct-cannulated	O
rats	O
and	O
dogs	O
receiving	O
an	O
intravenous	O
dose	O
and	O
use	O
of	O
drug	O
transporter	O
knockout	O
rats	O
.	O
Mutations	O
in	O
leucine-rich	O
repeat	O
kinase	O
2	O
(	O
LRRK2	GENE-Y
)	O
are	O
associated	O
with	O
familial	O
Parkinson's	O
disease	O
(	O
PD	O
)	O
.	O

The	O
kinase	O
activity	O
of	O
this	O
complex	O
protein	O
is	O
increased	O
by	O
pathogenic	O
mutations	O
.	O

Inhibition	O
of	O
LRRK2	GENE-Y
kinase	GENE-N
activity	O
has	O
therefore	O
emerged	O
as	O
a	O
promising	O
approach	O
for	O
the	O
treatment	O
of	O
PD	O
.	O

Herein	O
we	O
report	O
our	O
findings	O
on	O
a	O
series	O
of	O
4-alkylamino-7-aryl-3-cyanoquinolines	CHEMICAL
that	O
exhibit	O
kinase	GENE-N
inhibitory	O
activity	O
against	O
both	O
wild	O
type	O
and	O
G2019S	GENE-N
mutant	O
LRRK2	GENE-Y
.	O

Activity	O
was	O
determined	O
in	O
both	O
biochemical	O
and	O
cellular	O
assays	O
.	O

Compound	O
14	O
was	O
further	O
evaluated	O
in	O
an	O
in	O
vivo	O
pharmacodynamic	O
study	O
and	O
found	O
to	O
significantly	O
inhibit	O
Ser935	O
phosphorylation	O
after	O
oral	O
dosing	O
.	O
Endocrine	O
disrupting	O
effects	O
of	O
ochratoxin	CHEMICAL
A	CHEMICAL
at	O
the	O
level	O
of	O
nuclear	GENE-N
receptor	GENE-N
activation	O
and	O
steroidogenesis	O
.	O
Zolmitriptan	CHEMICAL
and	O
human	O
aggression	O
:	O
interaction	O
with	O
alcohol	CHEMICAL
.	O
The	O
fidelity	O
of	O
transcription	O
:	O
RPB1	GENE-Y
(	O
RPO21	GENE-Y
)	O
mutations	O
that	O
increase	O
transcriptional	O
slippage	O
in	O
S	O
.	O

cerevisiae	O
.	O
The	O
effects	O
of	O
kisspeptin	GENE-N
in	O
human	O
reproductive	O
function	O
-	O
therapeutic	O
implications	O
.	O
Carvedilol	CHEMICAL
selectively	O
inhibits	O
oscillatory	O
intracellular	O
calcium	CHEMICAL
changes	O
evoked	O
by	O
human	O
alpha1D-	GENE-N
and	GENE-N
alpha1B-adrenergic	GENE-N
receptors	GENE-N
.	O
Twelve	O
alkyl	CHEMICAL
analogues	O
(	O
1-12	O
)	O
of	O
the	O
high-affinity	O
serotonin	CHEMICAL
transporter	O
(	O
SERT	GENE-Y
)	O
inhibitor	O
6-nitroquipazine	CHEMICAL
(	O
6-NQ	CHEMICAL
)	O
were	O
synthesized	O
and	O
studied	O
using	O
in	O
vitro	O
radioligand	O
competition	O
binding	O
assays	O
to	O
determine	O
their	O
binding	O
affinity	O
(	O
Ki	O
)	O
.	O

The	O
putative	O
antidepressant	O
activity	O
of	O
five	O
of	O
the	O
binders	O
with	O
the	O
highest	O
SERT	GENE-Y
binding	O
affinities	O
was	O
studied	O
by	O
the	O
forced	O
swim	O
and	O
locomotor	O
activity	O
mouse	O
tests	O
.	O

The	O
three-dimensional	O
(	O
3D	O
)	O
structures	O
of	O
8	O
and	O
9	O
were	O
determined	O
using	O
NOE	O
NMR	O
technique	O
.	O

Flexible	O
docking	O
of	O
the	O
compounds	O
was	O
undertaken	O
to	O
illustrate	O
the	O
binding	O
of	O
the	O
compounds	O
in	O
the	O
SERT	GENE-Y
model	O
.	O

Our	O
results	O
showed	O
that	O
several	O
of	O
the	O
6-NQ	CHEMICAL
analogues	O
are	O
high-affinity	O
SERT	GENE-Y
inhibitors	O
and	O
indicated	O
that	O
the	O
octyl	CHEMICAL
(	O
8	O
)	O
,	O
decyl	CHEMICAL
(	O
10	O
)	O
and	O
dodecyl	CHEMICAL
(	O
12	O
)	O
6-NQ	CHEMICAL
analogues	O
exhibit	O
moderate	O
antidepressant	O
activity	O
.	O
Involvement	O
of	O
serotonin	CHEMICAL
5-HT3	GENE-Y
receptors	O
in	O
the	O
modulation	O
of	O
noradrenergic	O
transmission	O
by	O
serotonin	CHEMICAL
reuptake	O
inhibitors	O
:	O
a	O
microdialysis	O
study	O
in	O
rat	O
brain	O
.	O
A	O
base	O
substitution	O
at	O
a	O
splice	O
site	O
in	O
the	O
COL3A1	GENE-Y
gene	O
causes	O
exon	O
skipping	O
and	O
generates	O
abnormal	O
type	GENE-N
III	GENE-N
procollagen	GENE-N
in	O
a	O
patient	O
with	O
Ehlers-Danlos	O
syndrome	O
type	O
IV	O
.	O
ADEPT	O
:	O
Addition	O
of	O
the	O
AT1	GENE-Y
receptor	GENE-Y
antagonist	O
eprosartan	CHEMICAL
to	O
ACE	GENE-Y
inhibitor	O
therapy	O
in	O
chronic	O
heart	O
failure	O
trial	O
:	O
hemodynamic	O
and	O
neurohormonal	O
effects	O
.	O
Ntp	O
and	O
Ctp	O
,	O
synthetic	O
peptides	O
based	O
on	O
the	O
N-	O
and	O
C-terminal	O
sequences	O
of	O
K	GENE-Y
(	GENE-Y
IR	GENE-Y
)	GENE-Y
6	GENE-Y
.	GENE-Y
0	GENE-Y
,	O
respectively	O
,	O
were	O
used	O
to	O
probe	O
gating	O
of	O
K	GENE-Y
(	GENE-Y
IR	GENE-Y
)	GENE-Y
6	GENE-Y
.	GENE-Y
0	GENE-Y
/	O
SUR	GENE-Y
K	GENE-N
(	O
ATP	CHEMICAL
)	O
channels	O
.	O

Micromolar	O
Ntp	O
dose-dependently	O
increased	O
the	O
mean	O
open	O
channel	O
probability	O
in	O
ligand-free	O
solution	O
(	O
P	O
(	O
O	O
(	O
max	O
)	O
)	O
)	O
and	O
attenuated	O
the	O
ATP	CHEMICAL
inhibition	O
of	O
K	GENE-Y
(	GENE-Y
IR	GENE-Y
)	GENE-Y
6	GENE-Y
.	GENE-Y
2	GENE-Y
/	O
SUR1	GENE-Y
,	O
but	O
had	O
no	O
effect	O
on	O
homomeric	O
K	GENE-Y
(	GENE-Y
IR	GENE-Y
)	GENE-Y
6	GENE-Y
.	GENE-Y
2	GENE-Y
channels	O
.	O

Ntp	O
(	O
up	O
to	O
approximately	O
10	O
(	O
-4	O
)	O
m	O
)	O
did	O
not	O
affect	O
significantly	O
the	O
mean	O
open	O
or	O
"fast	O
,	O
"	O
K	CHEMICAL
(	CHEMICAL
+	CHEMICAL
)	CHEMICAL
driving	O
force-dependent	O
,	O
intraburst	O
closed	O
times	O
,	O
verifying	O
that	O
Ntp	O
selectively	O
modulates	O
the	O
ratio	O
of	O
mean	O
burst	O
to	O
interburst	O
times	O
.	O

Ctp	O
and	O
Rnp	O
,	O
a	O
randomized	O
Ntp	O
,	O
had	O
no	O
effect	O
,	O
indicating	O
that	O
the	O
effects	O
of	O
Ntp	O
are	O
structure	O
specific	O
.	O

Ntp	O
opened	O
K	GENE-Y
(	GENE-Y
IR	GENE-Y
)	GENE-Y
6	GENE-Y
.	GENE-Y
1	GENE-Y
/	O
SUR1	GENE-Y
channels	O
normally	O
silent	O
in	O
the	O
absence	O
of	O
stimulatory	O
Mg	O
(	O
-	O
)	O
nucleotide	CHEMICAL
(	CHEMICAL
s	CHEMICAL
)	CHEMICAL
and	O
attenuated	O
the	O
coupling	O
of	O
high-affinity	O
sulfonylurea	CHEMICAL
binding	O
with	O
K	GENE-N
(	O
ATP	CHEMICAL
)	O
pore	O
closure	O
.	O

These	O
effects	O
resemble	O
those	O
seen	O
with	O
N-terminal	O
deletions	O
(	O
DeltaN	O
)	O
of	O
K	GENE-Y
(	GENE-Y
IR	GENE-Y
)	GENE-Y
6	GENE-Y
.	GENE-Y
0	GENE-Y
,	O
and	O
application	O
of	O
Ntp	O
to	O
DeltaNK	GENE-N
(	GENE-N
ATP	CHEMICAL
)	O
channels	O
decreased	O
their	O
P	O
(	O
O	O
(	O
max	O
)	O
)	O
and	O
apparent	O
IC	O
(	O
50	O
)	O
for	O
ATP	CHEMICAL
in	O
the	O
absence	O
of	O
Mg	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
.	O

The	O
results	O
are	O
consistent	O
with	O
a	O
competition	O
between	O
Ntp	O
and	O
the	O
endogenous	O
N	CHEMICAL
terminus	O
for	O
a	O
site	O
of	O
interaction	O
on	O
the	O
cytoplasmic	O
face	O
of	O
the	O
channel	O
or	O
with	O
partial	O
replacement	O
of	O
the	O
deleted	O
N	CHEMICAL
terminus	O
by	O
Ntp	O
,	O
respectively	O
.	O

The	O
K	GENE-Y
(	GENE-Y
IR	GENE-Y
)	GENE-Y
N	CHEMICAL
terminus	O
and	O
the	O
TMD0-L0	O
segment	O
of	O
SUR1	GENE-Y
are	O
known	O
to	O
control	O
the	O
P	O
(	O
O	O
(	O
max	O
)	O
)	O
.	O

The	O
L0	O
linker	O
has	O
been	O
reported	O
to	O
be	O
required	O
for	O
glibenclamide	CHEMICAL
binding	O
,	O
and	O
DeltaNK	GENE-Y
(	GENE-Y
IR	GENE-Y
)	GENE-Y
6	GENE-Y
.	GENE-Y
2	GENE-Y
/	O
SUR1	GENE-Y
channels	O
exhibit	O
reduced	O
labeling	O
of	O
K	GENE-Y
(	GENE-Y
IR	GENE-Y
)	GENE-Y
with	O
(	CHEMICAL
125	CHEMICAL
)	CHEMICAL
I-azidoglibenclamide	CHEMICAL
,	O
implying	O
that	O
the	O
K	GENE-Y
(	GENE-Y
IR	GENE-Y
)	GENE-Y
N	CHEMICAL
terminus	O
and	O
L0	O
of	O
SUR1	GENE-Y
are	O
in	O
proximity	O
.	O

We	O
hypothesize	O
that	O
L0	O
interacts	O
with	O
the	O
K	GENE-Y
(	GENE-Y
IR	GENE-Y
)	GENE-Y
N	CHEMICAL
terminus	O
in	O
ligand-inhibited	O
K	GENE-N
(	O
ATP	CHEMICAL
)	O
channels	O
and	O
put	O
forward	O
a	O
model	O
,	O
based	O
on	O
the	O
architecture	O
of	O
BtuCD	GENE-N
,	O
MsbA	GENE-N
,	O
and	O
the	O
KcsA	GENE-N
channel	O
,	O
in	O
which	O
TMD0-L0	O
links	O
the	O
MDR-like	O
core	O
of	O
SUR	GENE-Y
with	O
the	O
K	GENE-Y
(	GENE-Y
IR	GENE-Y
)	GENE-Y
pore	O
.	O
Generation	O
and	O
analysis	O
of	O
constitutively	O
active	O
and	O
physically	O
destabilized	O
mutants	O
of	O
the	O
human	GENE-Y
beta	GENE-Y
(	GENE-Y
1	GENE-Y
)	GENE-Y
-adrenoceptor	GENE-Y
.	O
Amide	CHEMICAL
hydrolysis	O
of	O
a	O
novel	O
chemical	O
series	O
of	O
microsomal	GENE-Y
prostaglandin	CHEMICAL
E	CHEMICAL
synthase-1	O
inhibitors	O
induces	O
kidney	O
toxicity	O
in	O
the	O
rat	O
.	O
The	O
assembly	O
and	O
activation	O
of	O
oligomeric	O
complexes	O
of	O
FGF	GENE-N
,	O
the	O
transmembrane	GENE-N
receptor	GENE-N
kinase	GENE-N
(	O
FGFR	GENE-N
)	O
,	O
and	O
heparan	O
sulfate	CHEMICAL
transmit	O
intracellular	O
signals	O
regulating	O
growth	O
and	O
function	O
of	O
cells	O
.	O

An	O
understanding	O
of	O
the	O
structural	O
relationships	O
between	O
the	O
three	O
subunits	O
and	O
their	O
redundancy	O
and	O
specificity	O
is	O
essential	O
for	O
understanding	O
the	O
ubiquitous	O
FGF	GENE-N
signaling	O
system	O
in	O
health	O
and	O
disease	O
.	O

Previously	O
,	O
we	O
reported	O
that	O
a	O
primary	O
heparin	O
or	O
heparan	O
sulfate	CHEMICAL
binding	O
site	O
resides	O
in	O
a	O
distinct	O
sequence	O
in	O
immunoglobulin	GENE-N
(	GENE-N
Ig	GENE-N
)	GENE-N
-like	GENE-N
module	GENE-N
II	GENE-N
of	O
the	O
three	O
modules	O
of	O
FGFR	GENE-N
.	O

Here	O
we	O
report	O
that	O
in	O
the	O
absence	O
of	O
flanking	O
sequences	O
,	O
isolated	O
Ig	GENE-N
module	GENE-N
II	GENE-N
of	O
FGFR1	GENE-Y
supports	O
the	O
binding	O
of	O
FGF-1	GENE-Y
,	O
FGF-2	GENE-Y
,	O
and	O
FGF-7	GENE-Y
in	O
respective	O
order	O
of	O
affinity	O
.	O

None	O
of	O
the	O
three	O
FGFs	GENE-N
detectably	O
bind	O
Ig	GENE-N
module	GENE-N
I	GENE-N
or	GENE-N
the	GENE-N
IIIb	GENE-N
and	GENE-N
IIIc	GENE-N
splice	O
variants	O
of	O
Ig	GENE-N
module	GENE-N
III	GENE-N
in	O
the	O
absence	O
of	O
flanking	O
sequences	O
.	O

Ig	GENE-N
module	GENE-N
I	GENE-N
and	O
the	O
C-terminus	O
of	O
Ig	GENE-N
module	GENE-N
III	GENE-N
are	O
dispensable	O
for	O
high-affinity	O
binding	O
of	O
FGF-1	GENE-Y
,	O
FGF-2	GENE-Y
,	O
and	O
FGF-7	GENE-Y
.	O

Alterations	O
in	O
highly	O
conserved	O
Ig	GENE-N
module	GENE-N
II	GENE-N
in	O
the	O
heparin	O
binding	O
domain	O
and	O
substitution	O
of	O
individual	O
sequence	O
domains	O
spanning	O
the	O
entire	O
sequence	O
of	O
Ig	GENE-N
module	GENE-N
II	GENE-N
with	O
those	O
from	O
Ig	GENE-N
module	GENE-N
I	GENE-N
obliterated	O
FGF	GENE-N
binding	O
.	O

Addition	O
of	O
a	O
specific	O
number	O
of	O
FGFR	GENE-N
sequences	O
to	O
the	O
C-terminus	O
of	O
Ig	GENE-N
module	GENE-N
II	GENE-N
resulted	O
in	O
a	O
gain	O
in	O
affinity	O
for	O
FGF-7	GENE-Y
.	O

Several	O
site-specific	O
alterations	O
in	O
the	O
C-terminus	O
of	O
full-length	O
FGFR1IIIc	GENE-N
,	O
an	O
isoform	O
that	O
otherwise	O
absolutely	O
rejects	O
FGF-7	GENE-Y
,	O
resulted	O
in	O
gain	O
of	O
FGF-7	GENE-Y
binding	O
.	O

These	O
results	O
suggest	O
that	O
a	O
complex	O
of	O
Ig	GENE-N
module	GENE-N
II	GENE-N
and	O
heparan	O
sulfate	CHEMICAL
is	O
the	O
base	O
common	O
active	O
core	O
of	O
the	O
FGFR	GENE-N
ectodomain	GENE-N
and	O
that	O
flanking	O
structural	O
domains	O
modify	O
FGF	GENE-N
affinity	O
and	O
determine	O
specificity	O
.	O
Estramustine	CHEMICAL
,	O
and	O
derivatives	O
of	O
estramustine	CHEMICAL
with	O
a	O
charged	O
substituent	O
at	O
position	O
17	O
on	O
the	O
estrogen	CHEMICAL
moiety	O
,	O
have	O
been	O
investigated	O
for	O
their	O
effects	O
on	O
bovine	O
brain	O
microtubules	O
in	O
vitro	O
.	O

The	O
negatively	O
charged	O
estramustine	CHEMICAL
phosphate	CHEMICAL
has	O
been	O
found	O
previously	O
to	O
be	O
a	O
microtubule-associated	GENE-N
protein	GENE-N
(	O
MAP	GENE-N
)	O
-dependent	O
microtubule	O
inhibitor	O
[	O
Wallin	O
M	O
,	O
Deinum	O
J	O
and	O
Friden	O
B	O
,	O
FEBS	O
Lett	O
179	O
:	O
289-293	O
,	O
1985	O
]	O
.	O

In	O
the	O
present	O
study	O
the	O
binding	O
of	O
estramustine	CHEMICAL
phosphate	CHEMICAL
to	O
MAP2	GENE-Y
and	O
tau	GENE-Y
was	O
investigated	O
.	O

Both	O
these	O
MAPs	GENE-N
were	O
found	O
to	O
have	O
two	O
to	O
three	O
binding	O
sites	O
for	O
estramustine	CHEMICAL
phosphate	CHEMICAL
which	O
is	O
compatible	O
with	O
the	O
reported	O
number	O
of	O
basic	O
amino	CHEMICAL
acid	CHEMICAL
repeats	O
of	O
these	O
MAPs	GENE-N
,	O
considered	O
to	O
be	O
the	O
ultimate	O
tubulin	GENE-N
binding	O
domains	O
.	O

The	O
Kd	O
for	O
the	O
binding	O
of	O
estramustine	CHEMICAL
phosphate	CHEMICAL
to	O
MAP2	GENE-N
was	O
estimated	O
to	O
be	O
20	O
microM	O
at	O
4	O
degrees	O
,	O
and	O
for	O
the	O
binding	O
of	O
tau	O
,	O
200	O
microM	O
.	O

The	O
rate	O
of	O
dissociation	O
was	O
very	O
low	O
(	O
T1	O
/	O
2	O
greater	O
than	O
2	O
hr	O
)	O
,	O
which	O
indicates	O
that	O
the	O
binding	O
of	O
estramustine	CHEMICAL
phosphate	CHEMICAL
may	O
stabilize	O
the	O
protein-drug	O
complex	O
by	O
changing	O
the	O
protein	O
conformation	O
.	O

Two	O
new	O
negatively	O
charged	O
estramustine	CHEMICAL
derivatives	O
,	O
estramustine	CHEMICAL
sulphate	CHEMICAL
and	O
estramustine	CHEMICAL
glucuronide	CHEMICAL
,	O
were	O
found	O
to	O
be	O
similar	O
MAP-dependent	O
microtubule	O
inhibitors	O
.	O

The	O
concentration	O
for	O
50%	O
inhibition	O
of	O
assembly	O
was	O
100	O
microM	O
for	O
the	O
sulphate	CHEMICAL
derivative	O
,	O
the	O
same	O
as	O
found	O
previously	O
for	O
estramustine	CHEMICAL
phosphate	CHEMICAL
,	O
and	O
250	O
microM	O
for	O
the	O
more	O
bulky	O
estramustine	CHEMICAL
glucuronide	CHEMICAL
.	O

A	O
positively	O
charged	O
derivative	O
,	O
estramustine	CHEMICAL
sarcosinate	CHEMICAL
,	O
did	O
not	O
inhibit	O
microtubule	O
assembly	O
or	O
alter	O
the	O
composition	O
of	O
the	O
coassembled	O
MAPs	GENE-N
.	O

The	O
morphology	O
of	O
the	O
microtubules	O
was	O
,	O
however	O
,	O
affected	O
.	O

The	O
uncharged	O
estramustine	CHEMICAL
bound	O
to	O
both	O
tubulin	GENE-N
and	O
MAPs	GENE-N
,	O
but	O
no	O
effects	O
were	O
seen	O
on	O
microtubule	O
assembly	O
,	O
the	O
composition	O
of	O
coassembled	O
MAPs	GENE-N
or	O
the	O
microtubule	O
morphology	O
.	O

Our	O
results	O
suggest	O
that	O
only	O
negatively	O
charged	O
estramustine	CHEMICAL
derivatives	O
have	O
a	O
MAP-dependent	O
microtubule	O
inhibitory	O
effect	O
.	O

The	O
two	O
new	O
negatively	O
charged	O
derivatives	O
could	O
therefore	O
be	O
valuable	O
tools	O
in	O
the	O
study	O
of	O
tubulin-MAP	GENE-N
interactions	O
.	O

The	O
results	O
also	O
confirm	O
that	O
these	O
interactions	O
between	O
tubulin	GENE-N
and	O
MAPs	GENE-N
are	O
mainly	O
electrostatic	O
.	O
The	O
Tumor	O
Suppressor	O
Kruppel-Like	GENE-Y
Factor	GENE-Y
6	GENE-Y
is	O
a	O
Novel	O
Aryl	CHEMICAL
Hydrocarbon	CHEMICAL
Receptor	O
DNA	O
Binding	O
Partner	O
.	O
S100A4	GENE-Y
,	O
a	O
member	O
of	O
the	O
S100	GENE-N
family	O
of	O
Ca	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-binding	O
proteins	O
,	O
regulates	O
carcinoma	O
cell	O
motility	O
via	O
interactions	O
with	O
myosin-IIA	GENE-Y
.	O

Numerous	O
studies	O
indicate	O
that	O
S100A4	GENE-Y
is	O
not	O
simply	O
a	O
marker	O
for	O
metastatic	O
disease	O
,	O
but	O
rather	O
has	O
a	O
direct	O
role	O
in	O
metastatic	O
progression	O
.	O

These	O
observations	O
suggest	O
that	O
S100A4	GENE-Y
is	O
an	O
excellent	O
target	O
for	O
therapeutic	O
intervention	O
.	O

Using	O
a	O
unique	O
biosensor-based	O
assay	O
,	O
trifluoperazine	CHEMICAL
(	O
TFP	CHEMICAL
)	O
was	O
identified	O
as	O
an	O
inhibitor	O
that	O
disrupts	O
the	O
S100A4	GENE-Y
/	O
myosin-IIA	GENE-Y
interaction	O
.	O

To	O
examine	O
the	O
interaction	O
of	O
S100A4	GENE-Y
with	O
TFP	CHEMICAL
,	O
we	O
determined	O
the	O
2	O
.	O
3	O
A	O
crystal	O
structure	O
of	O
human	O
Ca	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-S100A4	GENE-Y
bound	O
to	O
TFP	CHEMICAL
.	O

Two	O
TFP	CHEMICAL
molecules	O
bind	O
within	O
the	O
hydrophobic	O
target	O
binding	O
pocket	O
of	O
Ca	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-S100A4	GENE-Y
with	O
no	O
significant	O
conformational	O
changes	O
observed	O
in	O
the	O
protein	O
upon	O
complex	O
formation	O
.	O

NMR	O
chemical	O
shift	O
perturbations	O
are	O
consistent	O
with	O
the	O
crystal	O
structure	O
and	O
demonstrate	O
that	O
TFP	CHEMICAL
binds	O
to	O
the	O
target	O
binding	O
cleft	O
of	O
S100A4	GENE-Y
in	O
solution	O
.	O

Remarkably	O
,	O
TFP	CHEMICAL
binding	O
results	O
in	O
the	O
assembly	O
of	O
five	O
Ca	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-S100A4	GENE-Y
/	O
TFP	O
dimers	O
into	O
a	O
tightly	O
packed	O
pentameric	O
ring	O
.	O

Within	O
each	O
pentamer	O
most	O
of	O
the	O
contacts	O
between	O
S100A4	GENE-Y
dimers	O
occurs	O
through	O
the	O
TFP	CHEMICAL
moieties	O
.	O

The	O
Ca	CHEMICAL
(	CHEMICAL
2	CHEMICAL
+	CHEMICAL
)	CHEMICAL
-S100A4	GENE-Y
/	O
prochlorperazine	CHEMICAL
(	O
PCP	CHEMICAL
)	O
complex	O
exhibits	O
a	O
similar	O
pentameric	O
assembly	O
.	O

Equilibrium	O
sedimentation	O
and	O
cross-linking	O
studies	O
demonstrate	O
the	O
cooperative	O
formation	O
of	O
a	O
similarly	O
sized	O
S100A4	GENE-Y
/	O
TFP	CHEMICAL
oligomer	O
in	O
solution	O
.	O

Assays	O
examining	O
the	O
ability	O
of	O
TFP	CHEMICAL
to	O
block	O
S100A4-mediated	O
disassembly	O
of	O
myosin-IIA	GENE-Y
filaments	O
demonstrate	O
that	O
significant	O
inhibition	O
of	O
S100A4	GENE-Y
function	O
occurs	O
only	O
at	O
TFP	CHEMICAL
concentrations	O
that	O
promote	O
S100A4	GENE-Y
oligomerization	O
.	O

Together	O
these	O
studies	O
support	O
a	O
unique	O
mode	O
of	O
inhibition	O
in	O
which	O
phenothiazines	CHEMICAL
disrupt	O
the	O
S100A4	GENE-Y
/	O
myosin-IIA	GENE-Y
interaction	O
by	O
sequestering	O
S100A4	GENE-Y
via	O
small	O
molecule-induced	O
oligomerization	O
.	O
A	O
series	O
of	O
epidemiological	O
,	O
experimental	O
and	O
preliminary	O
clinical	O
trials	O
strongly	O
suggest	O
that	O
mesalazine	CHEMICAL
or	O
5-aminosalicyclic	CHEMICAL
acid	CHEMICAL
(	O
5-ASA	CHEMICAL
)	O
may	O
have	O
antineoplastic	O
and	O
potentially	O
prophylactic	O
chemopreventive	O
properties	O
.	O

It	O
is	O
assumed	O
that	O
mesalazine	CHEMICAL
may	O
have	O
similar	O
genetic	O
and	O
molecular	O
targets	O
as	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
,	O
which	O
is	O
further	O
supported	O
by	O
its	O
close	O
similarity	O
with	O
aspirin	CHEMICAL
,	O
differing	O
only	O
in	O
its	O
structure	O
by	O
the	O
presence	O
of	O
an	O
amino	O
group	O
at	O
position	O
5	O
of	O
the	O
benzene	CHEMICAL
ring	O
.	O

The	O
putative	O
chemopreventive	O
actions	O
include	O
the	O
inhibition	O
of	O
inflammatory	O
cascades	O
and	O
/	O
or	O
reactions	O
involved	O
in	O
cell	O
growth	O
and	O
proliferation	O
,	O
such	O
as	O
cyclo-oxygenase	GENE-N
(	O
COX-1	GENE-Y
and	O
COX-2	GENE-Y
)	O
,	O
which	O
regulate	O
cell	O
proliferation	O
through	O
the	O
formation	O
of	O
prostaglandins;	O
lipoxygenase;	O
nuclear	GENE-N
factor	GENE-N
kappaB	GENE-N
(	O
NFkappaB	GENE-N
)	O
,	O
responsible	O
for	O
the	O
subsequent	O
expression	O
of	O
pro-inflammatory	O
molecules;	O
MAP	GENE-N
kinases	GENE-N
and	O
Bcl-2	GENE-Y
,	O
as	O
well	O
as	O
the	O
activation	O
of	O
apoptotic	O
processes	O
,	O
such	O
as	O
the	O
stimulation	O
of	O
intestinal	O
sphingomyelinase	GENE-N
.	O

The	O
peroxisome-proliferator-activated	GENE-Y
receptor	GENE-Y
delta	GENE-Y
(	O
PPARdelta	GENE-Y
)	O
,	O
which	O
also	O
regulates	O
gene	O
transcription	O
,	O
is	O
thought	O
to	O
play	O
a	O
role	O
in	O
both	O
inflammatory	O
and	O
non-inflammatory	O
driven	O
carcinogenesis	O
.	O

This	O
may	O
be	O
another	O
significant	O
target	O
.	O

It	O
is	O
hypothesized	O
that	O
5-ASAs	CHEMICAL
may	O
prevent	O
the	O
enhancing	O
effect	O
of	O
prostaglandins	CHEMICAL
on	O
PPARdelta	GENE-Y
binding	O
to	O
DNA	O
by	O
its	O
COX	GENE-N
inhibitory	O
properties	O
,	O
decreasing	O
proliferation	O
of	O
colorectal	O
mucosal	O
cells	O
in	O
non-inflammatory	O
bowel	O
disease	O
patients	O
with	O
sporadic	O
polyps	O
of	O
the	O
large	O
bowel	O
.	O
Antithrombin	O
binding	O
of	O
low	O
molecular	O
weight	O
heparins	O
and	O
inhibition	O
of	O
factor	GENE-Y
Xa	GENE-Y
.	O
Locally	O
administered	O
prostaglandin	CHEMICAL
E2	CHEMICAL
prevents	O
aeroallergen-induced	O
airway	O
sensitization	O
in	O
mice	O
through	O
immunomodulatory	O
mechanisms	O
.	O
Argininosuccinate	GENE-Y
synthetase	O
(	O
ASS	GENE-Y
,	O
EC	GENE-Y
6	GENE-Y
.	GENE-Y
3	GENE-Y
.	GENE-Y
4	GENE-Y
.	GENE-Y
5	GENE-Y
)	O
catalyses	O
the	O
condensation	O
of	O
citrulline	CHEMICAL
and	O
aspartate	O
to	O
form	O
argininosuccinate	CHEMICAL
,	O
the	O
immediate	O
precursor	O
of	O
arginine	CHEMICAL
.	O

First	O
identified	O
in	O
the	O
liver	O
as	O
the	O
limiting	O
enzyme	O
of	O
the	O
urea	CHEMICAL
cycle	O
,	O
ASS	GENE-N
is	O
now	O
recognized	O
as	O
a	O
ubiquitous	O
enzyme	O
in	O
mammalian	O
tissues	O
.	O

Indeed	O
,	O
discovery	O
of	O
the	O
citrulline-NO	CHEMICAL
cycle	O
has	O
increased	O
interest	O
in	O
this	O
enzyme	O
that	O
was	O
found	O
to	O
represent	O
a	O
potential	O
limiting	O
step	O
in	O
NO	CHEMICAL
synthesis	O
.	O

Depending	O
on	O
arginine	CHEMICAL
utilization	O
,	O
location	O
and	O
regulation	O
of	O
ASS	GENE-Y
are	O
quite	O
different	O
.	O

In	O
the	O
liver	O
,	O
where	O
arginine	O
is	O
hydrolyzed	O
to	O
form	O
urea	CHEMICAL
and	O
ornithine	CHEMICAL
,	O
the	O
ASS	GENE-Y
gene	O
is	O
highly	O
expressed	O
,	O
and	O
hormones	O
and	O
nutrients	O
constitute	O
the	O
major	O
regulating	O
factors	O
:	O
(	O
a	O
)	O
glucocorticoids	O
,	O
glucagon	GENE-Y
and	O
insulin	GENE-Y
,	O
particularly	O
,	O
control	O
the	O
expression	O
of	O
this	O
gene	O
both	O
during	O
development	O
and	O
adult	O
life;	O
(	O
b	O
)	O
dietary	O
protein	O
intake	O
stimulates	O
ASS	GENE-Y
gene	O
expression	O
,	O
with	O
a	O
particular	O
efficiency	O
of	O
specific	O
amino	CHEMICAL
acids	CHEMICAL
like	O
glutamine	CHEMICAL
.	O

In	O
contrast	O
,	O
in	O
NO-producing	O
cells	O
,	O
where	O
arginine	CHEMICAL
is	O
the	O
direct	O
substrate	O
in	O
the	O
NO	CHEMICAL
synthesis	O
,	O
ASS	GENE-Y
gene	O
is	O
expressed	O
at	O
a	O
low	O
level	O
and	O
in	O
this	O
way	O
,	O
proinflammatory	O
signals	O
constitute	O
the	O
main	O
factors	O
of	O
regulation	O
of	O
the	O
gene	O
expression	O
.	O

In	O
most	O
cases	O
,	O
regulation	O
of	O
ASS	GENE-Y
gene	O
expression	O
is	O
exerted	O
at	O
a	O
transcriptional	O
level	O
,	O
but	O
molecular	O
mechanisms	O
are	O
still	O
poorly	O
understood	O
.	O
The	O
2	CHEMICAL
,	CHEMICAL
2'	CHEMICAL
,	CHEMICAL
4	CHEMICAL
,	CHEMICAL
4'-tetrabromodiphenyl	CHEMICAL
ether	CHEMICAL
hydroxylated	O
metabolites	O
5-OH-BDE-47	CHEMICAL
and	O
6-OH-BDE-47	CHEMICAL
stimulate	O
estradiol	CHEMICAL
secretion	O
in	O
the	O
ovary	O
by	O
activating	O
aromatase	GENE-N
expression	O
.	O
Coronary	O
heart	O
disease	O
(	O
CHD	O
)	O
is	O
the	O
leading	O
cause	O
of	O
death	O
worldwide	O
,	O
and	O
effective	O
treatment	O
of	O
hyperlipidaemia	O
can	O
prevent	O
development	O
of	O
CHD	O
and	O
significantly	O
reduce	O
the	O
risk	O
for	O
cardiovascular	O
events	O
and	O
mortality	O
in	O
this	O
disease	O
.	O

The	O
advent	O
of	O
3-hydroxy-3-methylglutaryl	CHEMICAL
coenzyme	CHEMICAL
A	CHEMICAL
(	O
HMG-CoA	CHEMICAL
)	O
reductase	O
inhibitors	O
(	O
statins	CHEMICAL
)	O
has	O
revolutionised	O
the	O
treatment	O
of	O
hyperlipidaemia	O
,	O
but	O
many	O
patients	O
receiving	O
these	O
drugs	O
still	O
do	O
not	O
achieve	O
their	O
therapeutic	O
goals	O
.	O

Rosuvastatin	CHEMICAL
(	O
Crestor;	O
formerly	O
ZD4522	CHEMICAL
)	O
is	O
a	O
new	O
,	O
potent	O
and	O
long-lasting	O
inhibitor	O
of	O
HMG-CoA	GENE-Y
reductase	O
that	O
is	O
highly	O
selective	O
for	O
hepatocytes	O
.	O

Its	O
pharmacokinetics	O
permit	O
once-daily	O
dosing	O
,	O
and	O
a	O
lack	O
of	O
oxidative	O
hepatic	O
metabolism	O
results	O
in	O
a	O
reduced	O
potential	O
for	O
drug-drug	O
interactions	O
.	O

Preliminary	O
clinical	O
results	O
indicate	O
that	O
it	O
produces	O
rapid	O
dose-related	O
reductions	O
in	O
total	O
cholesterol	CHEMICAL
,	O
low-density	GENE-N
lipoprotein	GENE-N
cholesterol	CHEMICAL
,	O
triglycerides	CHEMICAL
,	O
and	O
apolipoprotein	GENE-Y
B	GENE-Y
that	O
may	O
exceed	O
those	O
achieved	O
with	O
other	O
currently	O
available	O
statins	O
.	O

Increases	O
in	O
high-density	GENE-N
lipoprotein	GENE-N
cholesterol	CHEMICAL
have	O
also	O
been	O
observed	O
.	O

Rosuvastatin	CHEMICAL
is	O
also	O
well	O
tolerated	O
,	O
with	O
no	O
evidence	O
of	O
either	O
hepato-	O
or	O
myotoxicity	O
.	O

It	O
is	O
hoped	O
that	O
new	O
agents	O
such	O
as	O
rosuvastatin	CHEMICAL
may	O
help	O
to	O
reduce	O
the	O
high	O
global	O
morbidity	O
,	O
mortality	O
and	O
associated	O
costs	O
of	O
CHD	O
and	O
related	O
vascular	O
disorders	O
.	O
Changes	O
of	O
phosphorylation	O
of	O
cAMP	GENE-N
response	O
element	O
binding	O
protein	O
in	O
rat	O
nucleus	O
accumbens	O
after	O
chronic	O
ethanol	CHEMICAL
intake	O
:	O
naloxone	CHEMICAL
reversal	O
.	O
Acute	O
alcohol	CHEMICAL
effects	O
on	O
subtypes	O
of	O
impulsivity	O
and	O
the	O
role	O
of	O
alcohol-outcome	O
expectancies	O
.	O
BACKGROUND	O
:	O
Motor	O
vehicle	O
accidents	O
(	O
MVAs	O
)	O
are	O
a	O
leading	O
cause	O
of	O
posttraumatic	O
stress	O
disorder	O
(	O
PTSD	O
)	O
in	O
the	O
general	O
population	O
.	O

Alterations	O
in	O
norepinephrine	CHEMICAL
and	O
serotonin	CHEMICAL
systems	O
have	O
been	O
proposed	O
as	O
mechanisms	O
involved	O
in	O
the	O
pathophysiology	O
of	O
the	O
condition	O
,	O
with	O
treatment	O
directed	O
at	O
these	O
neurotransmitter	O
systems	O
.	O

Reboxetine	CHEMICAL
,	O
a	O
selective	O
norepinephrine	CHEMICAL
reuptake	O
inhibitor	O
,	O
exhibits	O
high	O
affinity	O
and	O
selectivity	O
for	O
the	O
human	GENE-Y
norepinephrine	CHEMICAL
transporter	O
.	O

Inasmuch	O
as	O
PTSD	O
may	O
be	O
associated	O
with	O
dysregulation	O
of	O
noradrenergic	O
activity	O
,	O
the	O
present	O
double-blind	O
randomized	O
clinical	O
trial	O
intended	O
to	O
evaluate	O
reboxetine's	O
efficacy	O
in	O
the	O
management	O
of	O
MVA-related	O
PTSD	O
and	O
to	O
compare	O
its	O
efficacy	O
with	O
a	O
medication	O
commonly	O
used	O
in	O
PTSD	O
,	O
the	O
selective	O
serotonin	CHEMICAL
reuptake	O
inhibitor	O
fluvoxamine	CHEMICAL
.	O

METHODS	O
:	O
Forty	O
patients	O
with	O
MVA-related	O
PTSD	O
attending	O
a	O
local	O
community	O
mental	O
health	O
outpatient	O
clinic	O
were	O
randomized	O
to	O
receive	O
a	O
fixed	O
dose	O
of	O
either	O
reboxetine	CHEMICAL
(	O
8	O
mg	O
/	O
d	O
)	O
or	O
fluvoxamine	CHEMICAL
(	O
150	O
mg	O
/	O
d	O
)	O
in	O
a	O
double-blind	O
fashion	O
for	O
a	O
period	O
of	O
8	O
weeks	O
.	O

RESULTS	O
:	O
At	O
baseline	O
and	O
at	O
study	O
end	O
point	O
,	O
the	O
2	O
subgroups	O
demonstrated	O
no	O
statistical	O
differences	O
in	O
scores	O
on	O
PTSD	O
,	O
depression	O
,	O
and	O
anxiety	O
rating	O
scales	O
.	O

Both	O
medications	O
led	O
to	O
significant	O
improvements	O
in	O
all	O
clinical	O
scales	O
measured	O
.	O

Nine	O
patients	O
receiving	O
reboxetine	CHEMICAL
and	O
3	O
receiving	O
fluvoxamine	CHEMICAL
withdrew	O
from	O
the	O
study	O
because	O
of	O
side	O
effects	O
.	O

CONCLUSIONS	O
:	O
Study	O
observations	O
indicate	O
comparable	O
efficacy	O
of	O
reboxetine	CHEMICAL
and	O
fluvoxamine	CHEMICAL
in	O
the	O
management	O
of	O
MVA-related	O
PTSD	O
despite	O
reboxetine's	O
selective	O
noradrenergic	O
activity	O
.	O

Reboxetine	CHEMICAL
appears	O
to	O
be	O
at	O
least	O
as	O
effective	O
as	O
fluvoxamine	CHEMICAL
and	O
may	O
offer	O
an	O
alternative	O
management	O
option	O
in	O
this	O
often	O
difficult-to-treat	O
and	O
disabling	O
condition	O
.	O

A	O
lower	O
and	O
flexible	O
reboxetine	CHEMICAL
dosing	O
schedule	O
will	O
be	O
recommended	O
for	O
future	O
research	O
to	O
improve	O
its	O
tolerability	O
in	O
PTSD	O
patients	O
.	O
EphB1	GENE-Y
null	O
mice	O
exhibit	O
neuronal	O
loss	O
in	O
substantia	O
nigra	O
pars	O
reticulata	O
and	O
spontaneous	O
locomotor	O
hyperactivity	O
.	O
Two	O
alleles	O
of	O
the	O
HG1	GENE-Y
gene	O
,	O
which	O
encodes	O
a	O
putative	O
GABA	GENE-N
receptor	O
alpha	O
/	O
gamma	O
subunit	O
,	O
were	O
isolated	O
from	O
Haemonchus	O
contortus	O
.	O

These	O
two	O
alleles	O
were	O
shown	O
previously	O
to	O
be	O
associated	O
with	O
ivermectin	CHEMICAL
susceptibility	O
(	O
HG1A	GENE-Y
)	O
and	O
resistance	O
(	O
HG1E	GENE-Y
)	O
,	O
respectively	O
.	O

Sequence	O
analysis	O
indicates	O
that	O
they	O
differ	O
in	O
four	O
amino	CHEMICAL
acids	CHEMICAL
.	O

To	O
explore	O
the	O
functional	O
properties	O
of	O
the	O
two	O
alleles	O
,	O
a	O
full-length	O
cDNA	O
encoding	O
the	O
beta	O
subunit	O
,	O
a	O
key	O
functional	O
component	O
of	O
the	O
GABA	GENE-N
receptor	O
,	O
was	O
isolated	O
from	O
Caenorhabditis	O
elegans	O
(	O
gab-1	GENE-Y
,	O
corresponding	O
to	O
the	O
GenBank	GENE-Y
locus	GENE-Y
ZC482	GENE-Y
.	GENE-Y
1	GENE-Y
)	O
and	O
coexpressed	O
in	O
Xenopus	O
oocytes	O
with	O
the	O
HG1	GENE-Y
alleles	O
.	O

When	O
gab-1	GENE-Y
was	O
coexpressed	O
with	O
either	O
the	O
HG1A	GENE-Y
allele	O
or	O
the	O
HG1E	GENE-Y
allele	O
in	O
Xenopus	O
oocytes	O
,	O
gamma-aminobutyric	GENE-N
acid	GENE-N
(	O
GABA	CHEMICAL
)	O
-responsive	O
channels	O
with	O
different	O
sensitivity	O
to	O
the	O
agonist	O
were	O
formed	O
.	O

The	O
effects	O
of	O
ivermectin	CHEMICAL
on	O
the	O
hetero-oligomeric	O
receptors	O
were	O
determined	O
.	O

Application	O
of	O
ivermectin	CHEMICAL
alone	O
had	O
no	O
effect	O
on	O
the	O
receptors	O
.	O

However	O
,	O
when	O
coapplied	O
with	O
10	O
micro	O
m	O
GABA	CHEMICAL
,	O
ivermectin	CHEMICAL
potentiated	O
the	O
GABA-evoked	O
current	O
of	O
the	O
GAB-1	GENE-Y
/	O
HG1A	GENE-Y
receptor	O
,	O
but	O
attenuated	O
the	O
GABA	CHEMICAL
response	O
of	O
the	O
GAB-1	GENE-Y
/	O
HG1E	GENE-Y
receptor	O
.	O

We	O
demonstrated	O
that	O
the	O
coexpressed	O
HG1	GENE-Y
and	O
GAB-1	GENE-Y
receptors	O
are	O
GABA-responsive	O
,	O
and	O
provide	O
evidence	O
for	O
the	O
possible	O
involvement	O
of	O
GABA	CHEMICAL
receptors	O
in	O
the	O
mechanism	O
of	O
ivermectin	CHEMICAL
resistance	O
.	O
Late	O
in	O
an	O
adenovirus	O
infection	O
,	O
the	O
viral	GENE-N
proteinase	GENE-N
(	O
AVP	GENE-N
)	O
becomes	O
activated	O
to	O
process	O
virion	O
precursor	O
proteins	O
used	O
in	O
virus	O
assembly	O
.	O

AVP	GENE-N
is	O
activated	O
by	O
two	O
cofactors	O
,	O
the	O
viral	O
DNA	O
and	O
pVIc	CHEMICAL
,	O
an	O
11-amino	CHEMICAL
acid	CHEMICAL
peptide	O
originating	O
from	O
the	O
C	CHEMICAL
terminus	O
of	O
the	O
precursor	O
protein	O
pVI	GENE-N
.	O

There	O
is	O
a	O
conundrum	O
in	O
the	O
activation	O
of	O
AVP	GENE-N
in	O
that	O
AVP	GENE-N
and	O
pVI	GENE-N
are	O
sequence-independent	O
DNA-binding	O
proteins	O
with	O
nm	O
equilibrium	O
dissociation	O
constants	O
such	O
that	O
in	O
the	O
virus	O
particle	O
,	O
they	O
are	O
predicted	O
to	O
be	O
essentially	O
irreversibly	O
bound	O
to	O
the	O
viral	O
DNA	O
.	O

Here	O
,	O
we	O
resolve	O
that	O
conundrum	O
by	O
showing	O
that	O
activation	O
of	O
AVP	GENE-N
takes	O
place	O
on	O
the	O
one-dimensional	O
contour	O
of	O
DNA	O
.	O

In	O
vitro	O
,	O
pVI	GENE-N
,	O
a	O
substrate	O
,	O
slides	O
on	O
DNA	O
via	O
one-dimensional	O
diffusion	O
,	O
D	O
(	O
1	O
)	O
=	O
1	O
.	O
45	O
×	O
10	O
(	O
6	O
)	O
bp	O
(	O
2	O
)	O
/	O
s	O
,	O
until	O
it	O
binds	O
to	O
AVP	GENE-N
also	O
on	O
the	O
same	O
DNA	O
molecule	O
.	O

AVP	GENE-N
,	O
partially	O
activated	O
by	O
being	O
bound	O
to	O
DNA	O
,	O
excises	O
pVIc	CHEMICAL
,	O
which	O
binds	O
to	O
the	O
AVP	GENE-N
molecule	O
that	O
cut	O
it	O
out	O
.	O

pVIc	CHEMICAL
then	O
forms	O
a	O
disulfide	CHEMICAL
bond	O
with	O
AVP	GENE-N
forming	O
the	O
fully	O
active	O
AVP-pVIc	GENE-N
complex	O
bound	O
to	O
DNA	O
.	O

In	O
vivo	O
,	O
in	O
heat-disrupted	O
immature	O
virus	O
,	O
AVP	GENE-N
was	O
also	O
activated	O
by	O
pVI	GENE-N
in	O
DNA-dependent	O
reactions	O
.	O

This	O
activation	O
mechanism	O
illustrates	O
a	O
new	O
paradigm	O
for	O
virion	O
maturation	O
and	O
a	O
new	O
way	O
,	O
by	O
sliding	O
on	O
DNA	O
,	O
for	O
bimolecular	O
complexes	O
to	O
form	O
among	O
proteins	O
not	O
involved	O
in	O
DNA	O
metabolism	O
.	O
The	O
thiopurine	CHEMICAL
drugs-azathioprine	CHEMICAL
(	O
AZA	CHEMICAL
)	O
,	O
6-mercaptopurine	CHEMICAL
(	O
6-MP	CHEMICAL
)	O
,	O
and	O
thioguanine-are	O
widely	O
used	O
to	O
treat	O
malignancies	O
,	O
rheumatic	O
diseases	O
,	O
dermatologic	O
conditions	O
,	O
inflammatory	O
bowel	O
disease	O
,	O
and	O
solid	O
organ	O
transplant	O
rejection	O
.	O

However	O
,	O
thiopurine	CHEMICAL
drugs	O
have	O
a	O
relatively	O
narrow	O
therapeutic	O
index	O
and	O
are	O
capable	O
of	O
causing	O
life-threatening	O
toxicity	O
,	O
most	O
often	O
myelosuppression	O
.	O

Thiopurine	CHEMICAL
S-methyltransferase	O
(	O
TPMT;	O
EC	GENE-N
2	GENE-N
.	GENE-N
1	GENE-N
.	GENE-N
1	GENE-N
.	GENE-N
67	GENE-N
)	O
,	O
an	O
enzyme	O
that	O
catalyzes	O
S-methylation	O
of	O
these	O
drugs	O
,	O
exhibits	O
a	O
genetic	O
polymorphism	O
in	O
10%	O
of	O
Caucasians	O
,	O
with	O
1	O
/	O
300	O
individuals	O
having	O
complete	O
deficiency	O
.	O

Patients	O
with	O
intermediate	O
or	O
deficient	O
TPMT	GENE-Y
activity	O
are	O
at	O
risk	O
for	O
excessive	O
toxicity	O
after	O
receiving	O
standard	O
doses	O
of	O
thiopurine	CHEMICAL
medications	O
.	O

This	O
report	O
reviews	O
the	O
recent	O
advances	O
in	O
the	O
knowledge	O
of	O
the	O
mechanism	O
of	O
action	O
as	O
well	O
as	O
the	O
molecular	O
basis	O
and	O
interethnic	O
variations	O
of	O
TPMT	GENE-Y
and	O
inosine	GENE-Y
triphosphate	GENE-Y
pyrophosphatase	O
(	O
ITPase;	O
EC	GENE-N
3	GENE-N
.	GENE-N
6	GENE-N
.	GENE-N
1	GENE-N
.	GENE-N
19	GENE-N
)	O
,	O
another	O
enzyme	O
implicated	O
in	O
thiopurine	CHEMICAL
toxicity	O
.	O

In	O
addition	O
,	O
an	O
update	O
on	O
pharmacokinetics	O
,	O
metabolism	O
,	O
drug-drug	O
interactions	O
,	O
safety	O
,	O
and	O
tolerability	O
of	O
thiopurine	CHEMICAL
drugs	O
is	O
provided	O
.	O
Management	O
of	O
psoriasis	O
:	O
the	O
position	O
of	O
retinoid	CHEMICAL
drugs	O
.	O
Mortality	O
risk	O
in	O
men	O
is	O
associated	O
with	O
a	O
common	O
mutation	O
in	O
the	O
methylene-tetrahydrofolate	CHEMICAL
reductase	O
gene	O
(	O
MTHFR	GENE-Y
)	O
.	O
Hydroxysafflor	CHEMICAL
yellow	CHEMICAL
A	CHEMICAL
(	O
HSYA	CHEMICAL
)	O
is	O
an	O
active	O
ingredient	O
obtained	O
from	O
the	O
flower	O
of	O
Carthamus	O
tinctorius	O
L	O
.	O

The	O
present	O
study	O
investigated	O
the	O
effects	O
of	O
HSYA	CHEMICAL
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
inflammatory	O
signal	O
transduction	O
in	O
human	O
alveolar	O
epithelial	O
A549	O
cells	O
.	O

A549	O
cells	O
stimulated	O
with	O
LPS	O
were	O
incubated	O
with	O
three	O
doses	O
of	O
HSYA	CHEMICAL
(	O
1	O
,	O
4	O
and	O
16μmol	O
/	O
L	O
)	O
.	O

HSYA	CHEMICAL
suppressed	O
the	O
expression	O
of	O
TLR-4	GENE-Y
,	O
Myd88	GENE-Y
,	O
ICAM-1	GENE-Y
,	O
TNFα	GENE-Y
,	O
IL-1β	GENE-Y
and	O
IL-6	GENE-Y
at	O
the	O
mRNA	O
and	O
protein	O
level	O
,	O
and	O
inhibited	O
the	O
adhesion	O
of	O
leukocytes	O
to	O
A549	O
cells	O
.	O

HSYA	CHEMICAL
treatment	O
also	O
decreased	O
NF-κB	GENE-N
p65	GENE-Y
nuclear	O
translocation	O
and	O
inhibited	O
the	O
phosphorylation	O
of	O
p38	GENE-N
mitogen-activated	GENE-N
protein	GENE-N
kinase	GENE-N
(	O
p38	GENE-N
MAPK	GENE-N
)	O
.	O

These	O
findings	O
suggest	O
that	O
HSYA	CHEMICAL
effectively	O
inhibits	O
LPS-induced	O
inflammatory	O
signal	O
transduction	O
in	O
A549	O
cells	O
.	O
Charge	O
screening	O
between	O
anionic	O
and	O
cationic	O
surfactants	O
in	O
ionic	O
liquids	O
.	O
RATIONALE	O
:	O
A	O
substantial	O
body	O
of	O
research	O
suggests	O
that	O
the	O
neuropeptide	O
oxytocin	GENE-Y
promotes	O
social	O
affiliative	O
behaviors	O
in	O
a	O
wide	O
range	O
of	O
animals	O
including	O
humans	O
.	O

However	O
,	O
its	O
antiaggressive	O
action	O
has	O
not	O
been	O
unequivocally	O
demonstrated	O
in	O
male	O
laboratory	O
rodents	O
.	O

OBJECTIVE	O
:	O
Our	O
primary	O
goal	O
was	O
to	O
examine	O
the	O
putative	O
serenic	O
effect	O
of	O
oxytocin	GENE-Y
in	O
a	O
feral	O
strain	O
(	O
wild	O
type	O
Groningen	O
,	O
WTG	O
)	O
of	O
rats	O
that	O
generally	O
show	O
a	O
much	O
broader	O
variation	O
and	O
higher	O
levels	O
of	O
intermale	O
aggression	O
than	O
commonly	O
used	O
laboratory	O
strains	O
of	O
rats	O
.	O

METHODS	O
:	O
Resident	O
animals	O
were	O
intracerebroventricularly	O
(	O
icv	O
)	O
administered	O
with	O
different	O
doses	O
of	O
synthetic	O
oxytocin	GENE-Y
and	O
oxytocin	GENE-Y
receptor	O
antagonist	O
,	O
alone	O
and	O
in	O
combination	O
,	O
in	O
order	O
to	O
manipulate	O
brain	O
oxytocin	GENE-Y
functioning	O
and	O
to	O
assess	O
their	O
behavioral	O
response	O
to	O
an	O
intruder	O
.	O

RESULTS	O
:	O
Our	O
data	O
clearly	O
demonstrate	O
that	O
acute	O
icv	O
administered	O
oxytocin	GENE-Y
produces	O
dose-dependent	O
and	O
receptor-selective	O
changes	O
in	O
social	O
behavior	O
,	O
reducing	O
aggression	O
and	O
potentiating	O
social	O
exploration	O
.	O

These	O
antiaggressive	O
effects	O
are	O
stronger	O
in	O
the	O
more	O
offensive	O
rats	O
.	O

On	O
the	O
other	O
hand	O
,	O
administration	O
of	O
an	O
oxytocin	GENE-Y
receptor	O
antagonist	O
tends	O
to	O
increase	O
(	O
nonsignificantly	O
)	O
aggression	O
only	O
in	O
low-medium	O
aggressive	O
animals	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
transiently	O
enhancing	O
brain	O
oxytocin	GENE-Y
function	O
has	O
potent	O
antiaggressive	O
effects	O
,	O
whereas	O
its	O
attenuation	O
tends	O
to	O
enhance	O
aggressiveness	O
.	O

In	O
addition	O
,	O
a	O
possible	O
inverse	O
relationship	O
between	O
trait	O
aggression	O
and	O
endogenous	O
oxytocinergic	O
signaling	O
is	O
revealed	O
.	O

Overall	O
,	O
this	O
study	O
emphasizes	O
the	O
importance	O
of	O
brain	O
oxytocinergic	O
signaling	O
for	O
regulating	O
intermale	O
offensive	O
aggression	O
.	O

This	O
study	O
supports	O
the	O
suggestion	O
that	O
oxytocin	GENE-Y
receptor	O
agonists	O
could	O
clinically	O
be	O
useful	O
for	O
curbing	O
heightened	O
aggression	O
seen	O
in	O
a	O
range	O
of	O
neuropsychiatric	O
disorders	O
like	O
antisocial	O
personality	O
disorder	O
,	O
autism	O
,	O
and	O
addiction	O
.	O
Probing	O
the	O
Role	O
of	O
the	O
Vancomycin	CHEMICAL
E-Ring	O
Aryl	CHEMICAL
Chloride	CHEMICAL
:	O
Selective	O
Divergent	O
Synthesis	O
and	O
Evaluation	O
of	O
Alternatively	O
Substituted	O
E-Ring	O
Analogues	O
.	O
Podocyte	O
apoptosis	O
is	O
a	O
critical	O
mechanism	O
for	O
excessive	O
loss	O
of	O
urinary	O
albumin	GENE-Y
that	O
eventuates	O
in	O
kidney	O
fibrosis	O
.	O

Pharmacological	O
doses	O
of	O
the	O
mTOR	GENE-Y
inhibitor	O
rapamycin	CHEMICAL
reduce	O
albuminura	O
in	O
diabetes	O
.	O

We	O
explored	O
the	O
hypothesis	O
that	O
mTOR	GENE-Y
mediates	O
podocyte	O
injury	O
in	O
diabetes	O
.	O

High	O
glucose	CHEMICAL
(	O
HG	O
)	O
induces	O
apoptosis	O
of	O
podocytes	O
,	O
inhibits	O
AMPK	GENE-N
activation	O
,	O
inactivates	O
tuberin	GENE-Y
and	O
activates	O
mTOR	GENE-Y
.	O

HG	O
also	O
increases	O
the	O
levels	O
of	O
Nox4	GENE-Y
and	O
Nox1	GENE-Y
and	O
NADPH	GENE-N
oxidase	O
activity	O
.	O

Inhibition	O
of	O
mTOR	GENE-Y
by	O
low	O
dose	O
rapamycin	CHEMICAL
decreases	O
HG-induced	O
Nox4	GENE-Y
and	O
Nox1	GENE-Y
,	O
NADPH	GENE-N
oxidase	O
activity	O
and	O
podocyte	O
apoptosis	O
.	O

Inhibition	O
of	O
mTOR	GENE-Y
had	O
no	O
effect	O
on	O
AMPK	GENE-N
or	O
tuberin	GENE-Y
phosphorylation	O
indicating	O
that	O
mTOR	GENE-Y
is	O
downstream	O
of	O
these	O
signaling	O
molecules	O
.	O

In	O
isolated	O
glomeruli	O
of	O
OVE26	O
mice	O
,	O
there	O
is	O
similar	O
decrease	O
in	O
the	O
activation	O
of	O
AMPK	GENE-N
and	O
tuberin	GENE-Y
and	O
activation	O
of	O
mTOR	GENE-Y
with	O
increase	O
in	O
Nox4	GENE-Y
and	O
NADPH	GENE-N
oxidase	O
activity	O
.	O

Inhibition	O
of	O
mTOR	GENE-Y
by	O
small	O
dose	O
of	O
rapamycin	CHEMICAL
reduces	O
podocyte	O
apoptosis	O
,	O
attenuates	O
glomerular	O
injury	O
and	O
albuminuria	O
.	O

Our	O
data	O
provide	O
evidence	O
for	O
a	O
novel	O
function	O
of	O
mTOR	GENE-Y
in	O
Nox4-derived	O
ROS	O
generation	O
and	O
podocyte	O
apoptosis	O
that	O
contributes	O
to	O
urinary	O
albumin	GENE-Y
excretion	O
in	O
type	O
1	O
diabetes	O
.	O

Thus	O
mTOR	GENE-Y
and	O
or	O
NADPH	GENE-N
oxidase	O
inhibition	O
may	O
represent	O
a	O
therapeutic	O
modality	O
of	O
diabetic	O
kidney	O
disease	O
.	O
6-Chloro-3-alkylamino-4H-thieno	CHEMICAL
[	CHEMICAL
3	CHEMICAL
,	CHEMICAL
2-e	CHEMICAL
]	CHEMICAL
-1	CHEMICAL
,	CHEMICAL
2	CHEMICAL
,	CHEMICAL
4-thiadiazine	CHEMICAL
1	CHEMICAL
,	CHEMICAL
1-dioxide	CHEMICAL
derivatives	O
potently	O
and	O
selectively	O
activate	O
ATP	GENE-N
sensitive	O
potassium	CHEMICAL
channels	O
of	O
pancreatic	O
beta-cells	O
.	O
The	O
dermis	O
of	O
a	O
child	O
with	O
Ehlers-Danlos	O
syndrome	O
type	O
IV	O
(	O
EDS-IV	O
)	O
contained	O
about	O
11%	O
of	O
the	O
normal	O
amount	O
of	O
type	GENE-N
III	GENE-N
collagen	GENE-N
and	O
cultured	O
dermal	O
fibroblasts	O
produced	O
a	O
reduced	O
amount	O
of	O
type	GENE-N
III	GENE-N
procollagen	GENE-N
which	O
was	O
secreted	O
poorly	O
.	O

Type	GENE-N
III	GENE-N
collagen	GENE-N
produced	O
by	O
these	O
cells	O
contained	O
normal	O
and	O
abnormal	O
alpha-chains	O
and	O
cyanogen	CHEMICAL
bromide	CHEMICAL
peptides	O
.	O

The	O
site	O
of	O
the	O
structural	O
defect	O
in	O
the	O
abnormal	O
alpha	GENE-Y
1	GENE-Y
(	GENE-Y
III	GENE-Y
)	GENE-Y
chains	GENE-Y
was	O
localized	O
to	O
the	O
region	O
of	O
Met797	O
,	O
which	O
is	O
at	O
the	O
junction	O
of	O
the	O
two	O
carboxyl-terminal	O
CB5	GENE-N
and	GENE-N
CB9	GENE-N
cyanogen	CHEMICAL
bromide	CHEMICAL
peptides	O
.	O

Chemical	O
cleavage	O
of	O
heteroduplexes	O
formed	O
between	O
EDS-IV	O
mRNA	O
and	O
a	O
normal	O
cDNA	O
clone	O
covering	O
the	O
CB5	GENE-N
and	GENE-N
CB9	GENE-N
region	GENE-N
showed	O
that	O
about	O
100	O
nucleotides	CHEMICAL
were	O
mismatched	O
.	O

Sequencing	O
of	O
amplified	O
and	O
cloned	O
cDNA	O
spanning	O
the	O
mutant	O
region	O
revealed	O
a	O
108	O
nucleotide	CHEMICAL
deletion	O
corresponding	O
to	O
amino	CHEMICAL
acid	CHEMICAL
residues	O
Gly775	O
to	O
Lys810	O
.	O

The	O
deleted	O
nucleotide	CHEMICAL
sequence	O
corresponded	O
to	O
sequences	O
that	O
,	O
by	O
analogy	O
to	O
the	O
organization	O
of	O
the	O
type	GENE-N
I	GENE-N
collagen	GENE-N
genes	O
,	O
should	O
be	O
precisely	O
encoded	O
by	O
exon	O
41	O
of	O
the	O
COL3A1	GENE-Y
gene	O
.	O

Sequencing	O
of	O
amplified	O
genomic	O
DNA	O
,	O
prepared	O
using	O
disimilar	O
amounts	O
of	O
primers	O
specific	O
for	O
exons	O
41	O
and	O
42	O
,	O
displayed	O
a	O
base	O
substitution	O
(	O
G-to-A	O
)	O
in	O
the	O
highly	O
conserved	O
GT	O
dinucleotide	CHEMICAL
of	O
the	O
5'	O
splice	O
site	O
of	O
intron	O
41	O
.	O

Normal	O
sequences	O
were	O
also	O
obtained	O
from	O
the	O
normal	O
allele	O
.	O

It	O
is	O
likely	O
that	O
the	O
GT-to-AT	O
transition	O
at	O
the	O
splice	O
donor	O
site	O
of	O
intron	O
41	O
generated	O
an	O
abnormally	O
spliced	O
mRNA	O
in	O
which	O
sequences	O
of	O
exon	O
40	O
and	O
42	O
were	O
joined	O
together	O
with	O
maintenance	O
of	O
the	O
reading	O
frame	O
.	O

The	O
corresponding	O
peptide	O
deletion	O
included	O
the	O
cyanogen	CHEMICAL
bromide	CHEMICAL
cleavage	O
site	O
Met797-Pro798	O
and	O
the	O
mammalian	GENE-N
collagenase	GENE-N
cleavage	GENE-N
site	GENE-N
at	O
Gly781-Ile782	O
.	O

These	O
losses	O
account	O
for	O
the	O
resistance	O
of	O
EDS-IV	GENE-N
collagen	GENE-N
to	O
cyanogen	CHEMICAL
bromide	CHEMICAL
and	O
mammalian	GENE-N
collagenase	GENE-N
digestion	O
.	O

Cultured	O
fibroblasts	O
produced	O
normal	O
homotrimer	O
,	O
mutant	O
homotrimer	O
,	O
and	O
mixed	O
heterotrimer	O
type	GENE-N
III	GENE-N
collagen	GENE-N
molecules	O
.	O

The	O
mutant	O
homotrimer	O
molecules	O
were	O
the	O
major	O
pepsin-resistant	O
species	O
and	O
about	O
69%	O
of	O
the	O
alpha	GENE-Y
1	GENE-Y
(	GENE-Y
III	GENE-Y
)	GENE-Y
mRNA	O
was	O
in	O
the	O
mutant	O
form	O
.	O
Obesity	O
increases	O
prostanoid-mediated	O
vasoconstriction	O
and	O
vascular	GENE-Y
thromboxane	CHEMICAL
receptor	O
gene	O
expression	O
.	O
A	O
Re-evaluation	O
of	O
the	O
Role	O
of	O
hCTR1	GENE-Y
,	O
the	O
Human	GENE-N
High	GENE-N
Affinity	GENE-N
Cu	CHEMICAL
Transporter	O
in	O
Pt-Drug	O
Entry	O
into	O
Human	O
Cells	O
.	O
There	O
has	O
been	O
a	O
steep	O
increase	O
in	O
the	O
prevalence	O
of	O
dementia	O
in	O
recent	O
decades	O
,	O
which	O
has	O
roughly	O
followed	O
an	O
increase	O
in	O
pesticide	O
use	O
some	O
decades	O
earlier	O
,	O
a	O
time	O
when	O
it	O
is	O
probable	O
that	O
current	O
dementia	O
patients	O
could	O
have	O
been	O
exposed	O
to	O
pesticides	O
.	O

This	O
raises	O
the	O
question	O
whether	O
pesticides	O
contribute	O
to	O
dementia	O
pathogenesis	O
.	O

Indeed	O
,	O
many	O
studies	O
have	O
found	O
increased	O
prevalence	O
of	O
cognitive	O
,	O
behavioral	O
and	O
psychomotor	O
dysfunction	O
in	O
individuals	O
chronically	O
exposed	O
to	O
pesticides	O
.	O

Furthermore	O
,	O
evidence	O
from	O
recent	O
studies	O
shows	O
a	O
possible	O
association	O
between	O
chronic	O
pesticide	O
exposure	O
and	O
an	O
increased	O
prevalence	O
of	O
dementia	O
,	O
including	O
Alzheimer's	O
disease	O
(	O
AD	O
)	O
dementia	O
.	O

At	O
the	O
cellular	O
and	O
molecular	O
level	O
,	O
the	O
mechanism	O
of	O
action	O
of	O
many	O
classes	O
of	O
pesticides	O
suggests	O
that	O
these	O
compounds	O
could	O
be	O
,	O
at	O
least	O
partly	O
,	O
accountable	O
for	O
the	O
neurodegeneration	O
accompanying	O
AD	O
and	O
other	O
dementias	O
.	O

For	O
example	O
,	O
organophosphates	CHEMICAL
,	O
which	O
inhibit	O
acetylcholinesterase	GENE-Y
as	O
do	O
the	O
drugs	O
used	O
in	O
treating	O
AD	O
symptoms	O
,	O
have	O
also	O
been	O
shown	O
to	O
lead	O
to	O
microtubule	O
derangements	O
and	O
tau	GENE-Y
hyperphosphorylation	O
,	O
a	O
hallmark	O
of	O
AD	O
.	O

This	O
emerging	O
association	O
is	O
of	O
considerable	O
public	O
health	O
importance	O
,	O
given	O
the	O
increasing	O
dementia	O
prevalence	O
and	O
pesticide	O
use	O
.	O

Here	O
we	O
review	O
the	O
epidemiological	O
links	O
between	O
dementia	O
and	O
pesticide	O
exposure	O
and	O
discuss	O
the	O
possible	O
pathophysiological	O
mechanisms	O
and	O
clinical	O
implications	O
of	O
this	O
association	O
.	O
NMDA	GENE-N
Receptor	O
Activation	O
Down-Regulates	O
Expression	O
of	O
δ	GENE-Y
Subunit-Containing	GENE-Y
GABA-A	O
Receptors	O
in	O
Cultured	O
Hippocampal	O
Neurons	O
.	O
The	O
human	O
liver	O
cell	O
line	O
HepaRG	O
has	O
been	O
recognized	O
as	O
a	O
promising	O
source	O
for	O
in	O
vitro	O
testing	O
of	O
metabolism	O
and	O
toxicity	O
of	O
compounds	O
.	O

However	O
,	O
currently	O
the	O
hepatic	O
differentiation	O
of	O
these	O
cells	O
relies	O
on	O
exposure	O
to	O
dimethylsulfoxide	CHEMICAL
(	O
DMSO	CHEMICAL
)	O
,	O
which	O
,	O
as	O
a	O
side	O
effect	O
,	O
has	O
a	O
cytotoxic	O
effect	O
and	O
represses	O
an	O
all-round	O
hepatic	O
functionality	O
.	O

The	O
AMC-bioartificial	O
liver	O
(	O
AMC-BAL	O
)	O
is	O
a	O
three-dimensional	O
bioreactor	O
that	O
has	O
previously	O
been	O
shown	O
to	O
upregulate	O
various	O
liver	O
functions	O
of	O
cultured	O
cells	O
.	O

We	O
therefore	O
cultured	O
HepaRG	O
cells	O
in	O
the	O
AMC-BAL	O
without	O
DMSO	CHEMICAL
and	O
characterized	O
the	O
drug	O
metabolism	O
.	O

Within	O
14	O
days	O
of	O
culture	O
,	O
the	O
HepaRG-AMC-BALs	O
contained	O
highly	O
polarized	O
viable	O
liver-like	O
tissue	O
with	O
heterogeneous	O
expression	O
of	O
CYP3A4	GENE-Y
.	O

We	O
found	O
a	O
substantial	O
metabolism	O
of	O
the	O
tested	O
substrates	O
,	O
ranging	O
from	O
26%	O
(	O
UDP-glucuronosyltransferase	O
1A1	O
)	O
,	O
47%	O
(	O
CYP3A4	GENE-Y
)	O
,	O
to	O
240%	O
(	O
CYP2C9	GENE-Y
)	O
of	O
primary	O
human	O
hepatocytes	O
.	O

The	O
CYP3A4	GENE-Y
activity	O
could	O
be	O
induced	O
2-fold	O
by	O
rifampicin	CHEMICAL
,	O
whereas	O
CYP2C9	GENE-Y
activity	O
remained	O
equally	O
high	O
.	O

The	O
HepaRG-AMC-BAL	O
secreted	O
bile	CHEMICAL
acids	CHEMICAL
at	O
43%	O
the	O
rate	O
of	O
primary	O
human	O
hepatocytes	O
and	O
demonstrated	O
hydroxylation	O
,	O
conjugation	O
,	O
and	O
transport	O
of	O
bile	CHEMICAL
salts	CHEMICAL
.	O

Concluding	O
,	O
culturing	O
HepaRG	O
cells	O
in	O
the	O
AMC-BAL	O
yields	O
substantial	O
phase	O
1	O
and	O
phase	O
2	O
drug	O
metabolism	O
,	O
while	O
maintaining	O
high	O
viability	O
,	O
rendering	O
DMSO	CHEMICAL
addition	O
superfluous	O
for	O
the	O
promotion	O
of	O
drug	O
metabolism	O
.	O

Therefore	O
,	O
AMC-BAL	O
culturing	O
makes	O
the	O
HepaRG	O
cells	O
more	O
suitable	O
for	O
testing	O
metabolism	O
and	O
toxicity	O
of	O
drugs	O
.	O
Stimulatory	O
effect	O
of	O
insulin	GENE-Y
on	O
theca-interstitial	O
cell	O
proliferation	O
and	O
cell	O
cycle	O
regulatory	O
proteins	O
through	O
MTORC1	GENE-N
dependent	O
pathway	O
.	O
Higher	O
farnesyl	CHEMICAL
diphosphate	CHEMICAL
synthase	O
activity	O
in	O
human	O
colorectal	O
cancer	O
inhibition	O
of	O
cellular	O
apoptosis	O
.	O
Chloride	GENE-N
channels	O
in	O
renal	O
disease	O
.	O
Gonadotropin	GENE-Y
Regulated	GENE-Y
Testicular	GENE-Y
RNA	GENE-Y
Helicase	GENE-Y
(	O
GRTH	GENE-Y
/	O
Ddx25	GENE-Y
)	O
is	O
a	O
post-transcriptional	O
regulator	O
of	O
genes	O
that	O
are	O
essential	O
for	O
spermatid	O
elongation	O
and	O
completion	O
of	O
spermatogenesis	O
.	O

It	O
also	O
prevents	O
Leydig	O
cells	O
(	O
LC	O
)	O
from	O
gonadotropin	GENE-N
overstimulation	O
of	O
androgen	CHEMICAL
production	O
.	O

In	O
transgenic	O
(	O
Tg	O
)	O
mice	O
carrying	O
deletions	O
of	O
the	O
GRTH	GENE-Y
5'	O
flanking	O
regions	O
we	O
previously	O
demonstrated	O
that	O
the	O
-1085	O
bp	O
to	O
ATG	O
contains	O
the	O
elements	O
for	O
basal	O
and	O
androgen-induced	O
LC	O
specific	O
expression	O
.	O

No	O
expression	O
in	O
germ	O
cells	O
(	O
GC	O
)	O
was	O
found	O
with	O
sequences	O
extended	O
up	O
to	O
-3	O
.	O
6	O
Kb	O
.	O

To	O
define	O
regulatory	O
regions	O
of	O
GRTH	GENE-Y
required	O
for	O
expression	O
in	O
GC	O
,	O
Tg	O
mice	O
were	O
generated	O
with	O
5'	O
flanking	O
sequence	O
6	O
.	O
4	O
Kb	O
(	O
6	O
.	O
4	O
Kb-Tg	O
)	O
and	O
/	O
or	O
deletion	O
using	O
GFP	O
as	O
reporter	O
gene	O
in	O
the	O
present	O
study	O
.	O

GFP	O
was	O
expressed	O
in	O
all	O
lines	O
.	O

Immuno-histochemistry	O
analysis	O
showed	O
that	O
6	O
.	O
4Kb-Tg	O
directed	O
GFP	O
expression	O
in	O
both	O
GC	O
and	O
LC	O
.	O

Deletion	O
of	O
the	O
sequence	O
-205	O
bp	O
to	O
-3	O
.	O
6	O
Kb	O
(	O
6	O
.	O
4Kb	O
/	O
del-Tg	O
)	O
directs	O
GFP	O
expression	O
only	O
in	O
meiotic	O
and	O
haploid	O
GCs	O
.	O

This	O
indicated	O
that	O
the	O
distal	O
region	O
-6	O
.	O
4	O
Kb	O
/	O
-3	O
.	O
6	O
Kb	O
is	O
required	O
for	O
GRTH	GENE-Y
cell	O
specific	O
expression	O
in	O
GC	O
.	O

Also	O
,	O
it	O
inhibits	O
the	O
expression	O
of	O
GRTH	GENE-Y
in	O
LC	O
directed	O
by	O
the	O
205	GENE-N
bp	GENE-N
promoter	GENE-N
,	O
an	O
effect	O
that	O
is	O
neutralized	O
by	O
the	O
-3	O
.	O
6Kb	O
/	O
-205bp	O
sequence	O
.	O

Flutamide	O
treatment	O
prevents	O
GFP	O
/	O
GRTH	GENE-Y
expression	O
in	O
Tg	O
lines	O
demonstrating	O
in	O
vivo	O
direct	O
and	O
indirect	O
effects	O
of	O
endogenous	O
androgen	CHEMICAL
on	O
GC	O
and	O
LC	O
,	O
respectively	O
.	O

Our	O
studies	O
have	O
generated	O
and	O
characterized	O
transgenic	O
lines	O
that	O
can	O
be	O
utilized	O
to	O
define	O
requirements	O
for	O
cell	O
specific	O
expression	O
of	O
the	O
GRTH	GENE-Y
gene	O
and	O
to	O
further	O
advance	O
our	O
knowledge	O
on	O
the	O
regulation	O
of	O
GRTH	GENE-Y
by	O
androgen	CHEMICAL
in	O
germ	O
cells	O
.	O
Guided	O
by	O
the	O
acetylcholinesterase	GENE-Y
inhibiting	O
activity	O
,	O
the	O
bisindole	CHEMICAL
alkaloid	CHEMICAL
3'-R	CHEMICAL
/	CHEMICAL
S-hydroxyvoacamine	CHEMICAL
was	O
isolated	O
from	O
a	O
stem	O
extract	O
of	O
Tabernaemontana	O
divaricata	O
,	O
a	O
plant	O
used	O
in	O
Thailand	O
in	O
traditional	O
rejuvenation	O
remedies	O
for	O
improving	O
the	O
memory	O
.	O

The	O
structure	O
of	O
the	O
alkaloid	O
was	O
elucidated	O
by	O
extensive	O
use	O
of	O
NMR	O
spectroscopy	O
and	O
the	O
complete	O
assignment	O
of	O
the	O
(	CHEMICAL
1	CHEMICAL
)	CHEMICAL
H	CHEMICAL
and	O
(	CHEMICAL
13	CHEMICAL
)	CHEMICAL
C	CHEMICAL
NMR	O
spectra	O
is	O
reported	O
.	O

The	O
alkaloid	O
acted	O
as	O
a	O
non-competitive	O
inhibitor	O
against	O
AChE	GENE-Y
with	O
an	O
IC50	O
value	O
of	O
7	O
.	O
00±1	O
.	O
99μM	O
.	O

An	O
HPLC	O
method	O
was	O
developed	O
for	O
the	O
quantitative	O
analysis	O
of	O
the	O
AChE	GENE-Y
inhibitor	O
.	O

It	O
suggested	O
that	O
there	O
was	O
12	O
.	O
4%	O
(	O
w	O
/	O
w	O
)	O
of	O
3'-R	CHEMICAL
/	CHEMICAL
S-hydroxyvoacamine	CHEMICAL
in	O
the	O
alkaloid	O
enriched	O
fraction	O
of	O
T	O
.	O

divaricata	O
stem	O
.	O
Imiquimod	CHEMICAL
is	O
a	O
topical	O
immune	O
response	O
modifier	O
that	O
binds	O
to	O
Toll-like	GENE-N
receptor-7	GENE-N
and	GENE-N
-8	GENE-N
,	O
inducing	O
interferon-alpha	GENE-N
.	O

We	O
treated	O
superficial	O
basal	O
cell	O
carcinomas	O
(	O
BCC	O
)	O
with	O
imiquimod	CHEMICAL
5%	O
cream	O
daily	O
for	O
5-8	O
days	O
.	O

The	O
BCC	O
lesions	O
were	O
biopsied	O
before	O
treatment	O
and	O
following	O
imiquimod	CHEMICAL
treatment	O
,	O
when	O
the	O
lesion	O
showed	O
the	O
signs	O
of	O
erosion	O
.	O

We	O
applied	O
histology	O
,	O
immunohistochemistry	O
and	O
gene	O
array	O
technology	O
(	O
Affymetrix	O
)	O
to	O
gain	O
further	O
insight	O
into	O
the	O
mode	O
of	O
action	O
of	O
imiquimod	CHEMICAL
.	O

Our	O
findings	O
demonstrate	O
that	O
imiquimod-induced	O
BCC	O
regression	O
is	O
associated	O
with	O
a	O
strong	O
activity	O
of	O
the	O
innate	O
immune	O
response	O
,	O
mediated	O
by	O
cells	O
of	O
macrophage-monocyte	O
origin	O
and	O
is	O
associated	O
with	O
the	O
induction	O
of	O
apoptosis	O
.	O
Quercetin	CHEMICAL
suppressed	O
CYP2E1-dependent	O
ethanol	CHEMICAL
hepatotoxicity	O
via	O
depleting	O
heme	O
pool	O
and	O
releasing	O
CO	CHEMICAL
.	O
Non-selective	O
inhibition	O
of	O
monoamine	CHEMICAL
oxidase	O
(	O
MAO	GENE-N
)	O
enzymes	O
(	O
ie	O
,	O
isoforms	O
A	O
and	O
B	O
)	O
in	O
the	O
brain	O
are	O
associated	O
with	O
clinically	O
significant	O
antidepressant	O
effects	O
.	O

In	O
the	O
US	O
,	O
the	O
selegiline	CHEMICAL
transdermal	O
system	O
(	O
STS;	O
EMSAM	O
)	O
is	O
the	O
first	O
antidepressant	O
transdermal	O
delivery	O
system	O
to	O
receive	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
approved	O
labeling	O
for	O
the	O
treatment	O
of	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
.	O

Currently	O
,	O
the	O
use	O
of	O
orally	O
administered	O
MAO	GENE-N
inhibitor	O
antidepressants	O
(	O
eg	O
,	O
phenelzine	CHEMICAL
,	O
tranylcypromine	CHEMICAL
)	O
is	O
limited	O
by	O
the	O
risk	O
of	O
tyramine-provoked	O
events	O
(	O
eg	O
,	O
acute	O
hypertension	O
and	O
headache	O
,	O
also	O
known	O
as	O
the	O
"cheese	O
reaction"	O
)	O
when	O
combined	O
with	O
dietary	O
tyramine	CHEMICAL
.	O

The	O
selegiline	CHEMICAL
transdermal	O
system	O
is	O
the	O
only	O
MAOI	O
available	O
in	O
the	O
US	O
for	O
the	O
treatment	O
of	O
MDD	O
that	O
does	O
not	O
require	O
dietary	O
restriction	O
at	O
the	O
clinically	O
effective	O
dose	O
of	O
6	O
mg	O
/	O
24	O
hours	O
.	O

Delivery	O
of	O
selegiline	O
transdermally	O
(	O
EMSAM	O
(	O
(	O
R	O
)	O
)	O
)	O
bypasses	O
hepatic	O
first	O
pass	O
metabolism	O
,	O
thereby	O
avoiding	O
significant	O
inhibition	O
of	O
gastrointestinal	O
and	O
hepatic	O
MAO-A	GENE-Y
activity	O
(	O
ie	O
,	O
reduced	O
risk	O
of	O
tyramine-provoked	O
events	O
)	O
while	O
still	O
providing	O
sufficient	O
levels	O
of	O
selegiline	CHEMICAL
in	O
the	O
brain	O
to	O
produce	O
an	O
antidepressant	O
effect	O
.	O

At	O
dosages	O
of	O
6-12	O
mg	O
/	O
24	O
hours	O
,	O
EMSAM	O
has	O
been	O
shown	O
to	O
improve	O
symptoms	O
of	O
depression	O
,	O
have	O
good	O
tolerability	O
,	O
and	O
have	O
high	O
rates	O
of	O
medication	O
adherence	O
.	O

However	O
,	O
at	O
higher	O
doses	O
of	O
EMSAM	O
(	O
ie	O
,	O
9	O
mg	O
/	O
24	O
hours	O
or	O
more	O
)	O
,	O
dietary	O
restriction	O
of	O
tyramine	CHEMICAL
intake	O
is	O
recommended	O
.	O

The	O
introduction	O
of	O
EMSAM	O
overcomes	O
many	O
of	O
the	O
safety	O
concerns	O
affiliated	O
with	O
the	O
conventional	O
oral	O
MAO	GENE-N
inhibitors	O
and	O
EMSAM	O
may	O
be	O
considered	O
another	O
strategy	O
for	O
the	O
treatment	O
of	O
MDD	O
,	O
especially	O
in	O
patients	O
who	O
cannot	O
tolerate	O
oral	O
antidepressants	O
,	O
are	O
poorly	O
adherent	O
,	O
who	O
present	O
with	O
atypical	O
depressive	O
symptoms	O
,	O
or	O
have	O
failed	O
other	O
antidepressants	O
.	O
Aldehyde	GENE-N
oxidase	O
importance	O
in	O
vivo	O
in	O
xenobiotic	O
metabolism	O
:	O
imidacloprid	CHEMICAL
nitroreduction	O
in	O
mice	O
.	O
The	O
polyamines	CHEMICAL
spermidine	CHEMICAL
,	O
spermine	CHEMICAL
,	O
and	O
their	O
precursor	O
putrescine	CHEMICAL
are	O
essential	O
for	O
cell	O
growth	O
and	O
the	O
regulation	O
of	O
the	O
cell	O
cycle	O
.	O

Recent	O
studies	O
suggest	O
that	O
excessive	O
accumulation	O
of	O
polyamines	CHEMICAL
favors	O
either	O
malignant	O
transformation	O
or	O
apoptosis	O
,	O
depending	O
on	O
the	O
cell	O
type	O
and	O
the	O
stimulus	O
.	O

This	O
study	O
examines	O
the	O
involvement	O
of	O
polyamines	CHEMICAL
in	O
the	O
induction	O
of	O
apoptosis	O
by	O
the	O
DNA	GENE-Y
topoisomerase	GENE-Y
I	GENE-Y
inhibitor	O
,	O
camptothecin	O
.	O

In	O
IEC-6	O
cells	O
,	O
camptothecin	CHEMICAL
induced	O
apoptosis	O
within	O
6	O
h	O
,	O
accompanied	O
by	O
detachment	O
of	O
cells	O
.	O

Detached	O
cells	O
showed	O
DNA	O
laddering	O
and	O
caspase	GENE-Y
3	GENE-Y
induction	O
,	O
characteristic	O
features	O
of	O
apoptosis	O
.	O

Depletion	O
of	O
putrescine	CHEMICAL
,	O
spermidine	CHEMICAL
,	O
and	O
spermine	CHEMICAL
by	O
DL-alpha-difluoromethylornithine	CHEMICAL
(	O
DFMO	CHEMICAL
)	O
,	O
a	O
specific	O
inhibitor	O
of	O
ornithine	GENE-Y
decarboxylase	O
(	O
ODC	GENE-Y
)	O
that	O
is	O
the	O
first	O
rate-limiting	O
enzyme	O
for	O
polyamine	CHEMICAL
biosynthesis	O
,	O
decreased	O
the	O
apoptotic	O
index	O
.	O

Delayed	O
apoptosis	O
was	O
accompanied	O
by	O
a	O
decrease	O
in	O
caspase	GENE-Y
3	GENE-Y
activity	O
in	O
polyamine-depleted	O
cells	O
.	O

Addition	O
of	O
putrescine	CHEMICAL
restored	O
the	O
induction	O
of	O
apoptosis	O
as	O
indicated	O
by	O
an	O
increase	O
in	O
the	O
number	O
of	O
detached	O
cells	O
and	O
caspase	GENE-Y
3	GENE-Y
activity	O
.	O

Polyamine	CHEMICAL
depletion	O
did	O
not	O
change	O
the	O
level	O
of	O
caspase	GENE-Y
3	GENE-Y
protein	O
.	O

Inhibition	O
of	O
S-adenosylmethionine	GENE-Y
decarboxylase	O
by	O
a	O
specific	O
inhibitor	O
[	O
diethylglyoxal	CHEMICAL
bis-	CHEMICAL
(	CHEMICAL
guanylhydrazone	CHEMICAL
)	CHEMICAL
;	O
DEGBG	CHEMICAL
]	O
led	O
to	O
depletion	O
of	O
spermidine	CHEMICAL
and	O
spermine	CHEMICAL
with	O
a	O
significant	O
accumulation	O
of	O
putrescine	CHEMICAL
and	O
induction	O
of	O
ODC	GENE-Y
.	O

The	O
DEGBG-treated	O
cells	O
showed	O
an	O
increase	O
in	O
apoptosis	O
,	O
suggesting	O
the	O
importance	O
of	O
putrescine	CHEMICAL
in	O
the	O
apoptotic	O
process	O
.	O

Addition	O
of	O
putrescine	CHEMICAL
to	O
DFMO-treated	O
cell	O
extracts	O
did	O
not	O
increase	O
caspase	GENE-Y
3	GENE-Y
activity	O
.	O

The	O
above	O
results	O
indicate	O
that	O
polyamine	CHEMICAL
depletion	O
delays	O
the	O
onset	O
of	O
apoptosis	O
in	O
IEC-6	O
cells	O
and	O
confers	O
protection	O
against	O
DNA	O
damaging	O
agents	O
,	O
suggesting	O
that	O
polyamines	CHEMICAL
might	O
be	O
involved	O
in	O
the	O
caspase	GENE-N
activating	O
signal	O
cascade	O
.	O
Levothyroxine	CHEMICAL
replacement	O
therapy	O
with	O
vitamin	CHEMICAL
E	CHEMICAL
supplementation	O
prevents	O
oxidative	O
stress	O
and	O
cognitive	O
deficit	O
in	O
experimental	O
hypothyroidism	O
.	O
Iron	CHEMICAL
oxide	CHEMICAL
particles	O
modulate	O
the	O
ovalbumin-induced	O
Th2	O
immune	O
response	O
in	O
mice	O
.	O
Inhibition	O
of	O
monoamine	GENE-N
oxidase	O
by	O
phthalide	CHEMICAL
analogues	O
.	O
Ellagic	CHEMICAL
acid	CHEMICAL
attenuates	O
bleomycin	CHEMICAL
and	O
cyclophosphamide-induced	O
pulmonary	O
toxicity	O
in	O
Wistar	O
rats	O
.	O
Molecular	O
mechanism	O
of	O
terbinafine	CHEMICAL
resistance	O
in	O
Saccharomyces	O
cerevisiae	O
.	O
Acetylcholinesterase	GENE-Y
(	O
AChE	GENE-Y
)	O
is	O
a	O
most	O
remarkable	O
protein	O
,	O
not	O
only	O
because	O
it	O
is	O
one	O
of	O
the	O
fastest	O
enzymes	O
in	O
nature	O
,	O
but	O
also	O
since	O
it	O
appears	O
in	O
many	O
molecular	O
forms	O
and	O
is	O
regulated	O
by	O
elaborate	O
genetic	O
networks	O
.	O

AChE	GENE-Y
is	O
expressed	O
in	O
many	O
tissues	O
during	O
development	O
and	O
in	O
mature	O
organisms	O
,	O
as	O
well	O
as	O
in	O
healthy	O
and	O
diseased	O
states	O
.	O

In	O
search	O
for	O
alternative	O
,	O
"non-classical"	O
functions	O
of	O
cholinesterases	GENE-Y
(	O
ChEs	GENE-Y
)	O
,	O
AChE	GENE-Y
could	O
either	O
work	O
within	O
the	O
frame	O
of	O
classic	O
cholinergic	O
systems	O
,	O
but	O
in	O
non-neural	O
tissues	O
(	O
"non-synaptic	O
function"	O
)	O
,	O
or	O
act	O
non-enzymatically	O
.	O

Here	O
,	O
we	O
review	O
briefly	O
some	O
of	O
the	O
major	O
ideas	O
and	O
advances	O
of	O
this	O
field	O
,	O
and	O
report	O
on	O
some	O
recent	O
progress	O
from	O
our	O
own	O
experimental	O
work	O
,	O
e	O
.	O

g	O
.	O

that	O
(	O
i	O
)	O
non-neural	O
ChEs	GENE-N
have	O
pronounced	O
,	O
predominantly	O
enzymatic	O
effects	O
on	O
early	O
embryonic	O
(	O
limb	O
)	O
development	O
in	O
chick	O
and	O
mouse	O
,	O
that	O
(	O
ii	O
)	O
retinal	O
R28	O
cells	O
of	O
the	O
rat	O
overexpressing	O
synaptic	O
AChE	GENE-Y
present	O
a	O
significantly	O
decreased	O
cell	O
proliferation	O
,	O
and	O
that	O
(	O
iii	O
)	O
in	O
developing	O
chick	O
retina	O
ACh-synthesizing	O
and	O
ACh-degrading	O
cells	O
originate	O
from	O
the	O
same	O
postmitotic	O
precursor	O
cells	O
,	O
which	O
later	O
form	O
two	O
locally	O
opposing	O
cell	O
populations	O
.	O

We	O
suggest	O
that	O
such	O
distinct	O
distributions	O
of	O
ChAT	O
(	O
+	O
)	O
vs	O
.	O

AChE	GENE-Y
(	O
+	O
)	O
cells	O
in	O
the	O
inner	O
half	O
retina	O
provide	O
graded	O
distributions	O
of	O
ACh	CHEMICAL
,	O
which	O
can	O
direct	O
cell	O
differentiation	O
and	O
network	O
formation	O
.	O

Thus	O
,	O
as	O
corroborated	O
by	O
works	O
from	O
many	O
labs	O
,	O
AChE	GENE-Y
can	O
be	O
considered	O
a	O
highly	O
co-opting	O
protein	O
,	O
which	O
can	O
combine	O
enzymatic	O
and	O
non-enzymatic	O
functions	O
within	O
one	O
molecule	O
.	O
In	O
vitro	O
and	O
in	O
vivo	O
functional	O
characterization	O
of	O
bovine	GENE-Y
vitamin	CHEMICAL
K-dependent	O
gamma-carboxylase	O
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
.	O
Allosteric	O
interaction	O
of	O
the	O
neuromuscular	O
blockers	O
vecuronium	CHEMICAL
and	O
pancuronium	CHEMICAL
with	O
recombinant	O
human	GENE-Y
muscarinic	GENE-Y
M2	GENE-Y
receptors	GENE-Y
.	O
ETHNOPHARMACOLOGICAL	O
RELEVANCE	O
:	O
Antrodia	O
camphorata	O
(	O
AC	O
)	O
is	O
well	O
known	O
in	O
Taiwan	O
as	O
a	O
traditional	O
Chinese	O
medicinal	O
fungus	O
.	O

However	O
,	O
the	O
anticancer	O
activity	O
of	O
AC	O
against	O
human	GENE-Y
HER-2	GENE-Y
/	O
neu-overexpressing	O
ovarian	O
cancers	O
is	O
poorly	O
understood	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
whether	O
a	O
submerged	O
fermentation	O
culture	O
of	O
AC	O
can	O
inhibit	O
human	O
ovarian	O
carcinoma	O
cell	O
(	O
SKOV-3	O
)	O
proliferation	O
by	O
suppressing	O
the	O
HER-2	GENE-Y
/	O
neu	GENE-Y
signaling	O
pathway	O
.	O

Cell	O
viability	O
,	O
colony	O
formation	O
,	O
DCFH-DA	O
fluorescence	O
microscopy	O
,	O
western	O
blotting	O
,	O
HER-2	GENE-Y
/	O
neu	GENE-Y
immunofluorescence	O
imaging	O
,	O
flow	O
cytometry	O
,	O
and	O
TUNEL	O
assays	O
were	O
carried	O
out	O
to	O
determine	O
the	O
anti-cancer	O
effects	O
of	O
AC	O
.	O

RESULTS	O
:	O
MTT	CHEMICAL
and	O
colony	O
formation	O
assays	O
showed	O
that	O
AC	O
induced	O
a	O
dose-dependent	O
reduction	O
in	O
SKOV-3	O
cell	O
growth	O
.	O

Immunoblot	O
analysis	O
demonstrated	O
that	O
HER-2	GENE-Y
/	O
neu	GENE-Y
activity	O
and	O
tyrosine	CHEMICAL
phosphorylation	O
were	O
significantly	O
inhibited	O
by	O
AC	O
.	O

Furthermore	O
,	O
AC	O
treatment	O
significantly	O
inhibited	O
the	O
activation	O
of	O
PI3K	GENE-N
/	O
Akt	GENE-N
and	O
their	O
downstream	O
effector	O
β-catenin	GENE-Y
.	O

We	O
also	O
observed	O
that	O
AC	O
caused	O
G2	O
/	O
M	O
arrest	O
mediated	O
by	O
down-regulation	O
of	O
cyclin	GENE-Y
D1	GENE-Y
,	O
cyclin	GENE-Y
A	GENE-Y
,	O
cyclin	GENE-Y
B1	GENE-Y
,	O
and	O
Cdk1	GENE-Y
and	O
increased	O
p27	GENE-Y
expression	O
.	O

Notably	O
,	O
AC	O
induced	O
apoptosis	O
,	O
which	O
was	O
associated	O
with	O
DNA	O
fragmentation	O
,	O
cytochrome	GENE-Y
c	GENE-Y
release	O
,	O
caspase-9	GENE-N
/	GENE-N
-3	GENE-N
activation	O
,	O
PARP	GENE-N
degradation	O
,	O
and	O
Bcl-2	GENE-Y
/	O
Bax	GENE-Y
dysregulation	O
.	O

An	O
increase	O
in	O
intracellular	O
reactive	O
oxygen	CHEMICAL
species	O
(	O
ROS	O
)	O
was	O
observed	O
in	O
AC-treated	O
cells	O
,	O
whereas	O
the	O
antioxidant	O
N-acetylcysteine	CHEMICAL
(	O
NAC	CHEMICAL
)	O
prevented	O
AC-induced	O
cell	O
death	O
,	O
HER-2	GENE-Y
/	O
neu	GENE-Y
depletion	O
,	O
PI3K	GENE-N
/	O
Akt	GENE-N
inactivation	O
,	O
and	O
Bcl-2	GENE-Y
/	O
Bax	GENE-Y
dysregulation	O
,	O
indicating	O
that	O
AC-induced	O
cell	O
death	O
was	O
mediated	O
by	O
ROS	O
generation	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
AC	O
may	O
exert	O
anti-tumor	O
activity	O
against	O
human	O
ovarian	O
carcinoma	O
by	O
suppressing	O
HER-2	GENE-Y
/	O
neu	GENE-Y
signaling	O
pathways	O
.	O
BACKGROUND	O
&	O
AIMS	O
:	O
It	O
has	O
been	O
variably	O
suggested	O
that	O
nonselective	O
NSAIDs	O
and	O
cyclooxygenase	GENE-Y
(	GENE-Y
COX	GENE-Y
)	GENE-Y
-2	GENE-Y
selective	O
inhibitors	O
aggravate	O
or	O
ameliorate	O
clinical	O
disease	O
activity	O
in	O
patients	O
with	O
inflammatory	O
bowel	O
disease	O
.	O

We	O
assessed	O
the	O
effect	O
of	O
these	O
drugs	O
in	O
patients	O
with	O
inflammatory	O
bowel	O
disease	O
(	O
n	O
=	O
209	O
)	O
and	O
the	O
possible	O
mechanisms	O
.	O

METHODS	O
:	O
First	O
,	O
patients	O
with	O
quiescent	O
Crohn's	O
disease	O
and	O
ulcerative	O
colitis	O
received	O
the	O
non-NSAID	O
analgesic	O
acetaminophen	CHEMICAL
(	O
n	O
=	O
26	O
)	O
and	O
the	O
conventional	O
NSAIDs	O
naproxen	CHEMICAL
(	O
n	O
=	O
32	O
)	O
,	O
diclofenac	CHEMICAL
(	O
n	O
=	O
29	O
)	O
,	O
and	O
indomethacin	CHEMICAL
(	O
n	O
=	O
22	O
)	O
for	O
4	O
weeks	O
.	O

The	O
Harvey-Bradshaw	O
index	O
was	O
used	O
to	O
define	O
relapse	O
.	O

Second	O
,	O
to	O
assess	O
the	O
mechanism	O
of	O
relapse	O
,	O
intestinal	O
inflammation	O
was	O
quantitated	O
(	O
fecal	O
calprotectin	O
)	O
before	O
and	O
during	O
treatment	O
(	O
20	O
patients	O
/	O
group	O
)	O
with	O
acetaminophen	CHEMICAL
,	O
naproxen	CHEMICAL
(	O
topical	O
effect	O
,	O
COX-1	GENE-N
and	GENE-N
-2	GENE-N
inhibitor	O
)	O
,	O
nabumetone	CHEMICAL
(	O
COX-1	GENE-N
and	GENE-N
-2	GENE-N
inhibitor	O
)	O
,	O
nimesulide	CHEMICAL
(	O
selective	O
COX-2	GENE-Y
inhibitor	O
)	O
,	O
and	O
low-dose	O
aspirin	CHEMICAL
(	O
selective	O
COX-1	GENE-Y
inhibition	O
)	O
.	O

RESULTS	O
:	O
Nonselective	O
NSAIDs	O
were	O
associated	O
with	O
a	O
17%-28%	O
relapse	O
rate	O
within	O
9	O
days	O
of	O
ingestion	O
.	O

No	O
patient	O
had	O
an	O
early	O
relapse	O
on	O
acetaminophen	CHEMICAL
,	O
nimesulide	CHEMICAL
,	O
or	O
aspirin	CHEMICAL
,	O
whereas	O
those	O
on	O
naproxen	CHEMICAL
and	O
nabumetone	CHEMICAL
(	O
20%	O
)	O
experienced	O
relapse	O
.	O

These	O
clinical	O
relapses	O
were	O
associated	O
with	O
escalating	O
intestinal	O
inflammatory	O
activity	O
.	O

CONCLUSIONS	O
:	O
NSAID	O
ingestion	O
is	O
associated	O
with	O
frequent	O
and	O
early	O
clinical	O
relapse	O
of	O
quiescent	O
inflammatory	O
bowel	O
disease	O
,	O
and	O
the	O
mechanism	O
appears	O
to	O
be	O
due	O
to	O
dual	O
inhibition	O
of	O
the	O
COX	GENE-N
enzymes	O
.	O

Selective	O
COX-2	GENE-Y
inhibition	O
with	O
nimesulide	CHEMICAL
and	O
COX-1	GENE-Y
inhibition	O
with	O
low-dose	O
aspirin	CHEMICAL
appear	O
to	O
be	O
well-tolerated	O
in	O
the	O
short-term	O
.	O
Zearalenone	CHEMICAL
(	O
ZEA	CHEMICAL
,	O
F2	O
)	O
is	O
one	O
of	O
the	O
most	O
common	O
mycotoxins	O
and	O
the	O
only	O
known	O
mycoestrogen	CHEMICAL
.	O

It	O
enters	O
the	O
food	O
and	O
feed	O
chain	O
from	O
contaminated	O
cereals	O
and	O
infiltrates	O
into	O
sewage	O
or	O
natural	O
waters	O
posing	O
potential	O
threat	O
to	O
exposed	O
livestock	O
,	O
wildlife	O
and	O
humans	O
.	O

Therefore	O
evaluation	O
of	O
its	O
biological	O
effects	O
is	O
of	O
international	O
importance	O
.	O

We	O
performed	O
toxicological	O
tests	O
on	O
zebrafish	O
(	O
Danio	O
rerio	O
)	O
larvae	O
and	O
adults	O
.	O

Developmental	O
toxicity	O
was	O
assessed	O
by	O
an	O
extended	O
(	O
5	O
days	O
)	O
fish	O
embryo	O
toxicity	O
test	O
(	O
FET	O
)	O
.	O

Effects	O
of	O
early	O
ZEA	CHEMICAL
exposure	O
were	O
concentration-dependent	O
with	O
LC50	O
and	O
LC10	O
values	O
of	O
893	O
and	O
335μg	O
/	O
L	O
.	O

In	O
larvae	O
exposed	O
to	O
500μg	O
/	O
L	O
and	O
above	O
,	O
ZEA	CHEMICAL
induced	O
similar	O
phenotype	O
to	O
has	O
(	O
heart-and	O
soul	O
)	O
showing	O
defects	O
in	O
heart	O
and	O
eye	O
development	O
and	O
upward	O
curvature	O
of	O
the	O
body	O
axis	O
.	O

From	O
250μg	O
/	O
L	O
at	O
72hpf	O
the	O
gap	O
in	O
the	O
melanophore	O
streak	O
at	O
the	O
base	O
of	O
the	O
tail	O
fin	O
was	O
missing	O
and	O
the	O
fin	O
fold	O
was	O
abnormal	O
,	O
suggesting	O
disturbance	O
in	O
the	O
development	O
of	O
the	O
adult	O
tail	O
fin	O
primordium	O
.	O

Estrogenic	O
potency	O
was	O
measured	O
on	O
the	O
basis	O
of	O
Vitellogenin	GENE-N
(	O
Vtg	GENE-N
)	O
protein	O
(	O
adults	O
)	O
levels	O
and	O
relative	O
abundance	O
of	O
vitellogenin-1	GENE-Y
mRNA	O
(	O
vtg-1	GENE-Y
)	O
(	O
larvae	O
and	O
adults	O
)	O
.	O

qRT-PCR	O
in	O
larvae	O
proved	O
to	O
be	O
sufficient	O
substitute	O
to	O
adult	O
tests	O
and	O
sensitive	O
enough	O
to	O
detect	O
ZEA	CHEMICAL
in	O
0	O
.	O
1μg	O
/	O
L	O
concentrations	O
,	O
that	O
is	O
close	O
to	O
levels	O
observed	O
in	O
wastewaters	O
.	O

Developmental	O
defects	O
reveal	O
that	O
besides	O
direct	O
estrogenic	O
effects	O
,	O
zearalenone	CHEMICAL
might	O
interact	O
with	O
other	O
ontogenic	O
pathways	O
.	O
Identification	O
of	O
benzofuran	CHEMICAL
central	O
cores	O
for	O
the	O
inhibition	O
of	O
leukotriene	GENE-Y
A	GENE-Y
(	GENE-Y
4	GENE-Y
)	GENE-Y
hydrolase	O
.	O
Alendronate	CHEMICAL
(	O
4-amino-1-hydroxybutylidene-1	CHEMICAL
,	CHEMICAL
1-bisphosphonate	CHEMICAL
)	O
is	O
a	O
potent	O
bisphosphonate	CHEMICAL
that	O
inhibits	O
osteoclastic	O
bone	O
resorption	O
and	O
has	O
proven	O
effective	O
for	O
the	O
treatment	O
of	O
osteoporosis	O
.	O

Its	O
molecular	O
mechanism	O
of	O
action	O
,	O
however	O
,	O
has	O
not	O
been	O
defined	O
precisely	O
.	O

Here	O
we	O
report	O
that	O
alendronate	CHEMICAL
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
protein-tyrosine-phosphatase-meg1	O
(	O
PTPmeg1	GENE-Y
)	O
.	O

Two	O
substrates	O
were	O
employed	O
in	O
this	O
study	O
:	O
fluorescein	O
diphosphate	CHEMICAL
and	O
the	O
phosphotyrosyl	O
peptide	O
src-pY527	O
.	O

With	O
either	O
substrate	O
,	O
alendronate	CHEMICAL
was	O
a	O
slow	O
binding	O
inhibitor	O
of	O
PTPmeg1	GENE-Y
.	O

Among	O
the	O
other	O
bisphosphonates	CHEMICAL
studied	O
,	O
alendronate	CHEMICAL
was	O
more	O
potent	O
and	O
selective	O
for	O
PTPmeg1	GENE-Y
.	O

The	O
hydrolysis	O
of	O
fluorescein	O
diphosphate	CHEMICAL
by	O
PTP	GENE-Y
epsilon	GENE-Y
and	O
PTPmeg1	GENE-Y
was	O
sensitive	O
to	O
alendronate	CHEMICAL
,	O
with	O
IC50	O
values	O
of	O
less	O
than	O
1	O
microM;	O
PTPsigma	GENE-Y
,	O
however	O
,	O
under	O
the	O
same	O
conditions	O
,	O
was	O
inhibited	O
by	O
only	O
50%	O
with	O
141	O
microM	O
alendronate	CHEMICAL
.	O

Similarly	O
,	O
with	O
the	O
src-pY527	O
substrate	O
,	O
alendronate	CHEMICAL
inhibition	O
was	O
also	O
PTP	GENE-N
dependent	O
.	O

Alendronate	CHEMICAL
inhibited	O
PTPmeg1	GENE-Y
with	O
an	O
IC50	O
value	O
of	O
23	O
microM	O
,	O
PTPsigma	GENE-Y
with	O
an	O
IC50	O
value	O
of	O
2	O
microM	O
,	O
and	O
did	O
not	O
inhibit	O
PTP	GENE-Y
epsilon	GENE-Y
at	O
concentrations	O
up	O
to	O
1	O
mM	O
.	O

The	O
alendronate	CHEMICAL
inhibition	O
of	O
these	O
three	O
PTPs	GENE-N
and	O
two	O
substrates	O
is	O
consistent	O
with	O
the	O
formation	O
of	O
a	O
ternary	O
complex	O
comprised	O
of	O
enzyme	O
,	O
substrate	O
,	O
and	O
inhibitor	O
.	O

PTP	GENE-N
inhibition	O
by	O
hisphosphonates	CHEMICAL
or	O
vanadate	CHEMICAL
was	O
diminished	O
by	O
the	O
metal	O
chelating	O
agent	O
EDTA	CHEMICAL
,	O
or	O
by	O
the	O
reducing	O
agent	O
dithiothreitol	CHEMICAL
,	O
suggesting	O
that	O
a	O
metal	O
ion	O
and	O
the	O
oxidation	O
of	O
a	O
cysteine	CHEMICAL
residue	O
are	O
required	O
for	O
full	O
inhibition	O
.	O

These	O
observations	O
show	O
substrate-	O
and	O
enzyme-specific	O
PTP	GENE-N
inhibition	O
by	O
alendronate	CHEMICAL
and	O
support	O
the	O
possibility	O
that	O
a	O
certain	O
PTP	GENE-N
(	O
s	O
)	O
may	O
be	O
the	O
molecular	O
target	O
for	O
alendronate	CHEMICAL
action	O
.	O
The	O
bone	GENE-N
morphogenetic	GENE-N
protein	GENE-N
(	O
BMP	GENE-N
)	O
signaling	O
pathway	O
has	O
essential	O
functions	O
in	O
development	O
,	O
homeostasis	O
,	O
and	O
the	O
normal	O
and	O
pathophysiologic	O
remodeling	O
of	O
tissues	O
.	O

Small	O
molecule	O
inhibitors	O
of	O
the	O
BMP	GENE-N
receptor	GENE-N
kinase	GENE-N
family	O
have	O
been	O
useful	O
for	O
probing	O
physiologic	O
functions	O
of	O
BMP	GENE-N
signaling	O
in	O
vitro	O
and	O
in	O
vivo	O
and	O
may	O
have	O
roles	O
in	O
the	O
treatment	O
of	O
BMP-mediated	O
diseases	O
.	O

Here	O
we	O
describe	O
the	O
development	O
of	O
a	O
selective	O
and	O
potent	O
inhibitor	O
of	O
the	O
BMP	GENE-N
type	GENE-N
I	GENE-N
receptor	GENE-N
kinases	GENE-N
,	O
LDN-212854	CHEMICAL
,	O
which	O
in	O
contrast	O
to	O
previously	O
described	O
BMP	GENE-N
receptor	GENE-N
kinase	GENE-N
inhibitors	O
exhibits	O
nearly	O
4	O
orders	O
of	O
selectivity	O
for	O
BMP	GENE-N
versus	O
the	O
closely	O
related	O
TGF-β	GENE-N
and	O
Activin	GENE-Y
type	GENE-Y
I	GENE-Y
receptors	GENE-Y
.	O

In	O
vitro	O
,	O
LDN-212854	CHEMICAL
exhibits	O
some	O
selectivity	O
for	O
ALK2	GENE-Y
in	O
preference	O
to	O
other	O
BMP	GENE-N
type	GENE-N
I	GENE-N
receptors	GENE-N
,	O
ALK1	GENE-Y
and	O
ALK3	GENE-Y
,	O
which	O
may	O
permit	O
the	O
interrogation	O
of	O
ALK2-mediated	O
signaling	O
,	O
transcriptional	O
activity	O
,	O
and	O
function	O
.	O

LDN-212854	CHEMICAL
potently	O
inhibits	O
heterotopic	O
ossification	O
in	O
an	O
inducible	O
transgenic	O
mutant	O
ALK2	GENE-Y
mouse	O
model	O
of	O
fibrodysplasia	O
ossificans	O
progressiva	O
.	O

These	O
findings	O
represent	O
a	O
significant	O
step	O
toward	O
developing	O
selective	O
inhibitors	O
targeting	O
individual	O
members	O
of	O
the	O
highly	O
homologous	O
BMP	GENE-N
type	GENE-N
I	GENE-N
receptor	GENE-N
family	O
.	O

Such	O
inhibitors	O
would	O
provide	O
greater	O
resolution	O
as	O
probes	O
of	O
physiologic	O
function	O
and	O
improved	O
selectivity	O
against	O
therapeutic	O
targets	O
.	O
Our	O
purpose	O
was	O
to	O
test	O
the	O
impact	O
of	O
single	O
and	O
/	O
or	O
combined	O
treatment	O
with	O
the	O
AT	GENE-N
(	GENE-N
1	GENE-N
)	GENE-N
-receptor	O
blocker	O
candesartan	CHEMICAL
and	O
the	O
HMG-CoA	CHEMICAL
reductase	O
inhibitor	O
rosuvastatin	CHEMICAL
on	O
infarct	O
size	O
and	O
neuroscore	O
in	O
transient	O
cerebral	O
ischemia	O
in	O
rats	O
.	O

L-NAME	CHEMICAL
was	O
used	O
to	O
test	O
whether	O
any	O
potential	O
effect	O
was	O
due	O
to	O
activation	O
of	O
endothelial	GENE-Y
nitric	CHEMICAL
oxide	CHEMICAL
synthase	O
(	O
eNOS	GENE-Y
)	O
.	O

Therefore	O
,	O
the	O
middle	O
cerebral	O
artery	O
was	O
occluded	O
for	O
1	O
h	O
(	O
MCAO	O
)	O
followed	O
by	O
7	O
days	O
reperfusion	O
.	O

Rats	O
received	O
candesartan	CHEMICAL
2h	O
before	O
and	O
daily	O
after	O
MCAO	O
(	O
pretreatment	O
)	O
or	O
daily	O
after	O
MCAO	O
(	O
posttreatment	O
)	O
;	O
rosuvastatin	CHEMICAL
was	O
given	O
daily	O
for	O
7	O
days	O
before	O
MCAO	O
without	O
or	O
with	O
candesartan	CHEMICAL
pre-	O
and	O
posttreatment	O
.	O

In	O
addition	O
,	O
candesartan	CHEMICAL
and	O
rosuvastatin	CHEMICAL
were	O
combined	O
with	O
L-NAME	CHEMICAL
.	O

Infarct	O
size	O
and	O
neuroscore	O
at	O
day	O
7	O
were	O
compared	O
to	O
those	O
of	O
controls	O
.	O

As	O
result	O
,	O
compared	O
to	O
controls	O
(	O
109	O
+	O
/	O
-12	O
mm	O
(	O
3	O
)	O
)	O
infarct	O
size	O
with	O
candesartan	CHEMICAL
(	O
pretreatment	O
:	O
21	O
+	O
/	O
-5	O
mm	O
(	O
3	O
)	O
;	O
posttreatment	O
:	O
68	O
+	O
/	O
-29	O
mm	O
(	O
3	O
)	O
;	O
P<0	O
.	O
05	O
)	O
or	O
rosuvastatin	CHEMICAL
(	O
69	O
+	O
/	O
-14	O
mm	O
(	O
3	O
)	O
;	O
P<0	O
.	O
05	O
)	O
was	O
smaller	O
.	O

Combined	O
treatment	O
also	O
reduced	O
infarct	O
size	O
(	O
pretreatment	O
:	O
37	O
+	O
/	O
-15	O
mm	O
(	O
3	O
)	O
;	O
posttreatment	O
57	O
+	O
/	O
-20mm	O
(	O
3	O
)	O
;	O
P<0	O
.	O
05	O
)	O
;	O
but	O
there	O
was	O
no	O
benefit	O
of	O
combined	O
treatment	O
over	O
candesartan	CHEMICAL
pretreatment	O
alone	O
.	O

Compared	O
to	O
controls	O
(	O
2	O
.	O
08	O
+	O
/	O
-0	O
.	O
28	O
)	O
only	O
candesartan	CHEMICAL
pretreatment	O
and	O
combined	O
treatment	O
improved	O
the	O
neuroscore	O
(	O
0	O
.	O
97	O
+	O
/	O
-0	O
.	O
05	O
,	O
1	O
.	O
10	O
+	O
/	O
-0	O
.	O
33;	O
P<0	O
.	O
05	O
)	O
.	O

L-NAME	CHEMICAL
abolished	O
the	O
reduction	O
in	O
infarct	O
size	O
and	O
improvement	O
in	O
neuroscore	O
.	O

In	O
conclusion	O
,	O
both	O
,	O
candesartan	CHEMICAL
or	O
rosuvastatin	CHEMICAL
treatment	O
alone	O
reduced	O
infarct	O
size	O
in	O
transient	O
cerebral	O
ischemia	O
,	O
and	O
the	O
best	O
result	O
was	O
achieved	O
with	O
candesartan	CHEMICAL
pretreatment	O
.	O

Combined	O
treatment	O
was	O
superior	O
to	O
rosuvastatin	CHEMICAL
alone	O
,	O
but	O
not	O
to	O
candesartan	CHEMICAL
.	O

The	O
therapeutic	O
benefit	O
of	O
both	O
agents	O
was	O
at	O
least	O
in	O
parts	O
mediated	O
by	O
eNOS-activation	O
.	O
The	O
plasminogen	GENE-Y
binding	O
with	O
streptokinase	GENE-N
decapeptides	O
,	O
modeling	O
the	O
primary	O
structure	O
of	O
molecule	O
,	O
and	O
chymotryptic	O
fragments	O
of	O
streptokinase	GENE-N
have	O
been	O
investigated	O
.	O

The	O
immunoenzymatic	O
assay	O
has	O
shown	O
that	O
plasminogen	GENE-Y
binds	O
to	O
all	O
streptokinase	GENE-N
fragments	O
with	O
the	O
decreasing	O
affinity	O
in	O
the	O
set	O
of	O
fragments	O
:	O
36	O
>	O
30	O
>	O
17	O
>	O
7	O
>	O
11	O
kDa	O
.	O

Location	O
of	O
the	O
binding	O
sites	O
in	O
streptokinase	GENE-N
primary	O
structure	O
was	O
performed	O
using	O
the	O
immobilized	O
decapeptides	O
on	O
plastic	O
pins	O
adopted	O
to	O
IEA	O
.	O

In	O
the	O
presence	O
of	O
10	O
mM	O
6-aminohexanoic	CHEMICAL
acid	CHEMICAL
11	O
sites	O
for	O
human	GENE-N
Glu-	O
and	O
mini-plasminogens	O
,	O
pig	GENE-N
and	GENE-N
bovine	GENE-N
plasminogens	GENE-N
binding	O
have	O
been	O
found	O
.	O

They	O
were	O
of	O
the	O
same	O
location	O
for	O
human	GENE-N
,	GENE-N
bovine	GENE-N
and	GENE-N
pig	GENE-N
plasminogens	GENE-N
.	O

3	O
sites	O
were	O
located	O
in	O
plasminogen	GENE-N
alpha-domain--T43-A72	O
,	O
N113-T126	O
,	O
Q133-V158	O
,	O
5	O
sites	O
in	O
beta-domain--T163-L188	O
,	O
A203-S222	O
,	O
Q239-I264	O
,	O
Y275-L294	O
,	O
T315-L340	O
,	O
and	O
3	O
sites	O
in	O
gamma-domain--T361-R362	O
,	O
N377-E392	O
,	O
T397-N410	O
.	O

Participation	O
of	O
linear	O
part	O
of	O
streptokinase	GENE-N
polypeptide	O
chain	O
in	O
plasminogen--streptokinase	GENE-N
complex	O
formation	O
is	O
suggested	O
.	O
Although	O
interleukin	GENE-Y
2	GENE-Y
(	O
IL-2	GENE-Y
)	O
and	O
IL-15	GENE-Y
signal	O
through	O
the	O
common	O
gamma	O
chain	O
(	O
gammac	O
)	O
and	O
through	O
IL-2	GENE-Y
receptor	GENE-Y
beta-chain	GENE-Y
(	O
CD122	GENE-Y
)	O
subunits	O
,	O
they	O
direct	O
distinct	O
physiologic	O
and	O
immunotherapeutic	O
responses	O
in	O
T	O
cells	O
.	O

The	O
present	O
study	O
provides	O
some	O
insight	O
into	O
why	O
IL-2	GENE-Y
and	O
IL-15	GENE-Y
differentially	O
regulate	O
T-cell	O
function	O
by	O
revealing	O
that	O
these	O
cytokines	GENE-N
are	O
strikingly	O
distinct	O
in	O
their	O
ability	O
to	O
control	O
protein	O
synthesis	O
and	O
T-cell	O
mass	O
.	O

IL-2	GENE-Y
and	O
IL-15	GENE-Y
are	O
shown	O
to	O
be	O
equivalent	O
mitogens	O
for	O
antigen-stimulated	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
but	O
not	O
for	O
equivalent	O
growth	O
factors	O
.	O

Antigen-primed	O
T	O
cells	O
cannot	O
autonomously	O
maintain	O
amino	O
acid	O
incorporation	O
or	O
de	O
novo	O
protein	O
synthesis	O
without	O
exogenous	O
cytokine	GENE-N
stimulation	O
.	O

Both	O
IL-2	GENE-Y
and	O
IL-15	GENE-Y
induce	O
amino	CHEMICAL
acid	CHEMICAL
uptake	O
and	O
protein	O
synthesis	O
in	O
antigen-activated	O
T	O
cells;	O
however	O
,	O
the	O
IL-2	GENE-Y
response	O
is	O
strikingly	O
more	O
potent	O
than	O
the	O
IL-15	GENE-Y
response	O
.	O

The	O
differential	O
action	O
of	O
IL-2	GENE-Y
and	O
IL-15	GENE-N
on	O
amino	CHEMICAL
acid	CHEMICAL
uptake	O
and	O
protein	O
synthesis	O
is	O
explained	O
by	O
temporal	O
differences	O
in	O
signaling	O
induced	O
by	O
these	O
2	O
cytokines	GENE-N
.	O

Hence	O
,	O
the	O
present	O
results	O
show	O
that	O
cytokines	GENE-N
that	O
are	O
equivalent	O
mitogens	O
can	O
have	O
different	O
potency	O
in	O
terms	O
of	O
regulating	O
protein	O
synthesis	O
and	O
cell	O
growth	O
.	O
Association	O
of	O
DRD2	GENE-Y
polymorphisms	O
and	O
chlorpromazine-induced	O
extrapyramidal	O
syndrome	O
in	O
Chinese	O
schizophrenic	O
patients	O
.	O
Purification	O
and	O
characterization	O
of	O
membrane-bound	GENE-N
polyphenoloxidase	GENE-N
(	O
mPPO	GENE-N
)	O
from	O
Snake	O
fruit	O
[	O
Salacca	O
zalacca	O
(	O
Gaertn	O
.	O

)	O
Voss	O
]	O
.	O
OBJECTIVE	O
:	O
To	O
determine	O
the	O
efficacy	O
and	O
safety	O
of	O
the	O
cyclooxygenase	GENE-Y
2	GENE-Y
(	O
COX-2	GENE-Y
)	O
specific	O
inhibitor	O
,	O
rofecoxib	CHEMICAL
in	O
patients	O
with	O
osteoarthritis	O
(	O
OA	O
)	O
of	O
the	O
knee	O
.	O

METHODS	O
:	O
Rofecoxib	CHEMICAL
,	O
25	O
mg	O
or	O
125	O
mg	O
once	O
daily	O
,	O
was	O
compared	O
with	O
placebo	O
in	O
a	O
6	O
week	O
,	O
double	O
blind	O
,	O
parallel	O
group	O
,	O
randomized	O
,	O
multicenter	O
study	O
of	O
219	O
patients	O
with	O
knee	O
OA	O
.	O

RESULTS	O
:	O
Both	O
doses	O
of	O
rofecoxib	CHEMICAL
produced	O
clinically	O
significant	O
improvement	O
as	O
assessed	O
by	O
primary	O
(	O
e	O
.	O

g	O
.	O

,	O
WOMAC	O
Pain	O
Subscale	O
0-100	O
mm	O
,	O
decrease	O
from	O
baseline	O
:	O
placebo	O
:	O
7	O
.	O
1	O
mm;	O
rofecoxib	CHEMICAL
25	O
mg	O
:	O
28	O
.	O
1	O
mm	O
,	O
rofecoxib	CHEMICAL
125	O
mg	O
:	O
28	O
.	O
0	O
mm;	O
p	O
<	O
0	O
.	O
001	O
rofecoxib	CHEMICAL
vs	O
placebo	O
)	O
and	O
secondary	O
efficacy	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
criteria	O
compared	O
with	O
placebo	O
.	O

Clinical	O
improvement	O
with	O
the	O
25	O
mg	O
dose	O
was	O
similar	O
to	O
that	O
with	O
the	O
125	O
mg	O
dose	O
.	O

Both	O
rofecoxib	CHEMICAL
doses	O
were	O
generally	O
well	O
tolerated	O
.	O

CONCLUSION	O
:	O
Specific	O
inhibition	O
of	O
COX-2	GENE-Y
by	O
25	O
and	O
125	O
mg	O
rofecoxib	CHEMICAL
,	O
administered	O
once	O
daily	O
,	O
resulted	O
in	O
clinically	O
meaningful	O
improvements	O
in	O
patients	O
with	O
OA	O
.	O

This	O
study	O
confirms	O
that	O
COX-2	GENE-Y
derived	O
prostanoids	CHEMICAL
are	O
important	O
clinical	O
mediators	O
of	O
pain	O
and	O
other	O
symptoms	O
of	O
knee	O
OA	O
and	O
that	O
inhibition	O
of	O
COX-1	GENE-Y
is	O
not	O
required	O
to	O
provide	O
clinical	O
benefit	O
.	O
Neuroendocrine	O
tumors	O
are	O
very	O
heterogeneous	O
,	O
develop	O
from	O
a	O
variety	O
of	O
tissues	O
,	O
and	O
can	O
be	O
difficult	O
to	O
diagnose	O
.	O

Without	O
the	O
clinical	O
manifestation	O
of	O
metastases	O
,	O
it	O
is	O
often	O
difficult	O
to	O
characterize	O
them	O
as	O
malignant	O
.	O

Even	O
so-called	O
completely	O
(	O
R0	O
)	O
resected	O
tumors	O
can	O
spread	O
clinically	O
visible	O
metastases	O
within	O
a	O
few	O
months	O
after	O
initial	O
surgery	O
.	O

Treatment	O
options	O
for	O
neuroendocrine	O
tumors	O
including	O
pheochromocytoma	O
are	O
limited	O
.	O

Molecular	O
targeted	O
therapies	O
using	O
tyrosine	GENE-N
kinase	O
inhibitors	O
might	O
prove	O
to	O
be	O
helpful	O
in	O
patients	O
with	O
these	O
tumors	O
.	O

In	O
an	O
immunohistochemical	O
study	O
,	O
we	O
examined	O
KIT	GENE-Y
in	O
26	O
pheochromocytomas	O
,	O
8	O
of	O
which	O
were	O
malignant	O
(	O
3	O
adrenal	O
pheochromocytomas	O
,	O
5	O
paragangliomas	O
)	O
.	O

KIT	GENE-Y
expression	O
was	O
found	O
in	O
one	O
of	O
these	O
8	O
malignant	O
tumors	O
.	O

This	O
2	O
.	O
5-cm-large	O
adrenal	O
pheochromocytoma	O
originated	O
from	O
a	O
woman	O
with	O
neurofibromatosis	O
type	O
1	O
and	O
spread	O
into	O
spine	O
,	O
skull	O
,	O
and	O
lung	O
.	O

KIT	GENE-Y
expression	O
could	O
be	O
demonstrated	O
in	O
5%	O
of	O
tumor	O
cells	O
.	O

On	O
the	O
basis	O
of	O
KIT	GENE-Y
expression	O
immunohistochemically	O
,	O
we	O
treated	O
patients	O
with	O
neuroendocrine	O
(	O
i	O
.	O

e	O
.	O

,	O
medullary	O
thyroid	O
cancer	O
)	O
and	O
other	O
tumors	O
with	O
imatinib	CHEMICAL
400	O
mg	O
per	O
day	O
,	O
but	O
without	O
efficacy	O
after	O
2	O
months	O
of	O
therapy	O
.	O

Similar	O
results	O
were	O
shown	O
by	O
other	O
investigators	O
.	O

Therefore	O
,	O
monotherapy	O
with	O
imatinib	CHEMICAL
may	O
not	O
be	O
efficacious	O
in	O
patients	O
with	O
neuroendocrine	O
tumors	O
that	O
express	O
KIT	GENE-Y
.	O

Tyrosine	GENE-N
kinase	O
inhibitors	O
such	O
as	O
sorafenib	CHEMICAL
that	O
targets	O
several	O
receptors	O
in	O
addition	O
to	O
KIT	GENE-Y
may	O
be	O
more	O
efficacious	O
in	O
treating	O
patients	O
with	O
neuroendocrine	O
tumors	O
.	O
A	O
series	O
of	O
xanthine	CHEMICAL
derivatives	O
in	O
which	O
a	O
methylene	CHEMICAL
was	O
inserted	O
at	O
position	O
8	O
of	O
xanthine	CHEMICAL
scaffold	O
was	O
synthesized	O
and	O
evaluated	O
as	O
inhibitors	O
of	O
dipeptidyl	GENE-Y
peptidase	GENE-Y
4	GENE-Y
(	O
DPP-4	GENE-Y
)	O
for	O
the	O
treatment	O
of	O
type	O
2	O
diabetes	O
.	O

As	O
the	O
results	O
of	O
structure-activity	O
relationship	O
(	O
SAR	O
)	O
study	O
of	O
the	O
series	O
,	O
the	O
compounds	O
with	O
4-methyl-quinazoline-2-yl-methyl	CHEMICAL
group	O
at	O
N-1	O
position	O
and	O
2-aminoethylaminomethyl	CHEMICAL
group	O
gave	O
better	O
activities	O
.	O

Compounds	O
H4	O
and	O
H9	O
showed	O
good	O
DPP-4	GENE-Y
inhibition	O
and	O
more	O
than	O
100-fold	O
selectivity	O
over	O
DPP-7	GENE-Y
and	O
DPP-8	GENE-Y
.	O
Orlistat	CHEMICAL
,	O
a	O
new	O
lipase	GENE-N
inhibitor	O
for	O
the	O
management	O
of	O
obesity	O
.	O
Effects	O
of	O
the	O
tricyclic	CHEMICAL
antidepressant	O
clomipramine	CHEMICAL
on	O
plasma	O
glucose	CHEMICAL
levels	O
in	O
mice	O
were	O
studied	O
.	O

Clomipramine	CHEMICAL
at	O
doses	O
ranging	O
5	O
-	O
20	O
mg	O
/	O
kg	O
elicited	O
significant	O
hyperglycemia	O
in	O
mice	O
.	O

Hyperglycemia	O
elicited	O
by	O
clomipramine	CHEMICAL
was	O
not	O
reduced	O
by	O
pretreatment	O
with	O
the	O
5-hydroxytryptamine	CHEMICAL
(	O
5-HT	CHEMICAL
)	O
depleter	O
p-chlorophenylalanine	CHEMICAL
.	O

The	O
5-HT	GENE-N
(	GENE-N
1	GENE-N
/	GENE-N
2	GENE-N
/	GENE-N
5	GENE-N
/	GENE-N
7	GENE-N
)	GENE-N
-receptor	GENE-N
antagonist	O
methysergide	O
and	O
the	O
5-HT	GENE-N
(	GENE-N
2A	GENE-N
/	GENE-N
2B	GENE-N
/	GENE-N
2C	GENE-N
)	GENE-N
-receptor	GENE-N
antagonist	O
LY	CHEMICAL
53857	CHEMICAL
enhanced	O
clomipramine-induced	O
hyperglycemia	O
,	O
while	O
the	O
5-HT	GENE-N
(	GENE-N
1A	GENE-N
/	GENE-N
1B	GENE-N
)	GENE-N
-receptor	GENE-N
antagonist	O
(	CHEMICAL
-	CHEMICAL
)	CHEMICAL
-propranolol	CHEMICAL
and	O
the	O
5-HT	GENE-N
(	GENE-N
3	GENE-N
/	GENE-N
4	GENE-N
)	GENE-N
-receptor	GENE-N
antagonist	O
tropisetron	CHEMICAL
did	O
not	O
affect	O
it	O
.	O

The	O
5-HT	GENE-N
(	GENE-N
2B	GENE-N
/	GENE-N
2C	GENE-N
)	GENE-N
-receptor	GENE-N
antagonist	O
SB	CHEMICAL
206553	CHEMICAL
facilitated	O
hyperglycemia	O
induced	O
by	O
clomipramine	CHEMICAL
,	O
although	O
the	O
5-HT	GENE-Y
(	GENE-Y
2A	GENE-Y
)	GENE-Y
-receptor	O
antagonist	O
ketanserin	CHEMICAL
was	O
without	O
effect	O
.	O

Clomipramine-induced	O
hyperglycemia	O
was	O
reduced	O
by	O
prior	O
adrenalectomy	O
.	O

These	O
results	O
suggest	O
that	O
clomipramine	CHEMICAL
induces	O
hyperglycemia	O
in	O
mice	O
by	O
blocking	O
the	O
5-HT	GENE-Y
(	GENE-Y
2B	GENE-Y
)	GENE-Y
and	O
/	O
or	O
5-HT	GENE-Y
(	GENE-Y
2C	GENE-Y
)	GENE-Y
receptors	O
,	O
which	O
results	O
in	O
facilitation	O
of	O
adrenaline	CHEMICAL
release	O
.	O
